Références Inhibiteurs de Kinases - Advion Interchim Scientific

Une fois votre référence choisie, rendez-vous sur notre site www.interchim.com pour commander aisément vos besoins.

REFERENCE	DESCRIPTION	COND.	PURITE	DESCRIPTIF
10004412	Reversine	1 mg	≥98%	A purine derivative; induces differentiation or dedifferentiation, depending on cell type; inhibits the Aurora A, B, and C kinases with IC50 values of 98-876 nM; A3 receptor antagonist (Ki = 0.66 µM); inhibits MPS1 (IC50s = 6 and 2.8 nM for its kinase domain and full-length version, respectively); induces autophagy in WRO human follicular thyroid cancer cells; decreases Akt/mTOR signaling
10004412	Reversine	10 mg	≥98%	A purine derivative; induces differentiation or dedifferentiation, depending on cell type; inhibits the Aurora A, B, and C kinases with IC50 values of 98-876 nM; A3 receptor antagonist (Ki = 0.66 µM); inhibits MPS1 (IC50s = 6 and 2.8 nM for its kinase domain and full-length version, respectively); induces autophagy in WRO human follicular thyroid cancer cells; decreases Akt/mTOR signaling
10004412	Reversine	25 mg	≥98%	A purine derivative; induces differentiation or dedifferentiation, depending on cell type; inhibits the Aurora A, B, and C kinases with IC50 values of 98-876 nM; A3 receptor antagonist (Ki = 0.66 µM); inhibits MPS1 (IC50s = 6 and 2.8 nM for its kinase domain and full-length version, respectively); induces autophagy in WRO human follicular thyroid cancer cells; decreases Akt/mTOR signaling
10004412	Reversine	5 mg	≥98%	A purine derivative; induces differentiation or dedifferentiation, depending on cell type; inhibits the Aurora A, B, and C kinases with IC50 values of 98-876 nM; A3 receptor antagonist (Ki = 0.66 µM); inhibits MPS1 (IC50s = 6 and 2.8 nM for its kinase domain and full-length version, respectively); induces autophagy in WRO human follicular thyroid cancer cells; decreases Akt/mTOR signaling
10005167	Genistein	100 mg	≥98%	An isoflavonoid phytoestrogen with kinase inhibitory, anticancer, pro-cancer, hepatoprotective, and antiviral properties; inhibits EGFR, pp50v-Src, and pp110gag-fes (IC50s = 6, 7-8, and 6.5 µg/ml, respectively); reduces tumor invasion and angiogenesis in a Bel 7402 mouse subrenal capsule xenograft model at 50 mg/kg per day; increases the incidence of uterine adenocarcinoma in a mouse model of cancer induced by DES at 50 mg/kg per day administered on postnatal days 1-5; reduces lipid accumulation and inflammation in the liver of OVX and non-OVX female rats in a model of high-fat high-fructose diet-induced model of NASH at 16 mg/kg per day; inhibits HIV-1 DNA synthesis in resting CD4+ T cells at 10 µM
10005167	Genistein	1000 mg	≥98%	An isoflavonoid phytoestrogen with kinase inhibitory, anticancer, pro-cancer, hepatoprotective, and antiviral properties; inhibits EGFR, pp50v-Src, and pp110gag-fes (IC50s = 6, 7-8, and 6.5 µg/ml, respectively); reduces tumor invasion and angiogenesis in a Bel 7402 mouse subrenal capsule xenograft model at 50 mg/kg per day; increases the incidence of uterine adenocarcinoma in a mouse model of cancer induced by DES at 50 mg/kg per day administered on postnatal days 1-5; reduces lipid accumulation and inflammation in the liver of OVX and non-OVX female rats in a model of high-fat high-fructose diet-induced model of NASH at 16 mg/kg per day; inhibits HIV-1 DNA synthesis in resting CD4+ T cells at 10 µM
10005167	Genistein	250 mg	≥98%	An isoflavonoid phytoestrogen with kinase inhibitory, anticancer, pro-cancer, hepatoprotective, and antiviral properties; inhibits EGFR, pp50v-Src, and pp110gag-fes (IC50s = 6, 7-8, and 6.5 µg/ml, respectively); reduces tumor invasion and angiogenesis in a Bel 7402 mouse subrenal capsule xenograft model at 50 mg/kg per day; increases the incidence of uterine adenocarcinoma in a mouse model of cancer induced by DES at 50 mg/kg per day administered on postnatal days 1-5; reduces lipid accumulation and inflammation in the liver of OVX and non-OVX female rats in a model of high-fat high-fructose diet-induced model of NASH at 16 mg/kg per day; inhibits HIV-1 DNA synthesis in resting CD4+ T cells at 10 µM
10005167	Genistein	500 mg	≥98%	An isoflavonoid phytoestrogen with kinase inhibitory, anticancer, pro-cancer, hepatoprotective, and antiviral properties; inhibits EGFR, pp50v-Src, and pp110gag-fes (IC50s = 6, 7-8, and 6.5 µg/ml, respectively); reduces tumor invasion and angiogenesis in a Bel 7402 mouse subrenal capsule xenograft model at 50 mg/kg per day; increases the incidence of uterine adenocarcinoma in a mouse model of cancer induced by DES at 50 mg/kg per day administered on postnatal days 1-5; reduces lipid accumulation and inflammation in the liver of OVX and non-OVX female rats in a model of high-fat high-fructose diet-induced model of NASH at 16 mg/kg per day; inhibits HIV-1 DNA synthesis in resting CD4+ T cells at 10 µM
10005583	Y-27632 (hydrochlorid	1 mg	≥98%	A potent, ATP-competitive inhibitor of ROCKs including p160ROCK (Ki = 140 nM) and ROCK2 (IC50 = 800 nM); also inhibits PRK2 with an IC50 value of 600 nM
10005583	Y-27632 (hydrochlorid	10 mg	≥98%	A potent, ATP-competitive inhibitor of ROCKs including p160ROCK (Ki = 140 nM) and ROCK2 (IC50 = 800 nM); also inhibits PRK2 with an IC50 value of 600 nM

10005583	Y-27632 (hydrochloric	5 mg	≥98%	A potent, ATP-competitive inhibitor of ROCKs including p160ROCK (Ki = 140 nM) and ROCK2 (IC50 = 800 nM); also inhibits PRK2 with an IC50 value of 600 nM
10005583	Y-27632 (hydrochloric	50 mg	≥98%	A potent, ATP-competitive inhibitor of ROCKs including p160ROCK (Ki = 140 nM) and ROCK2 (IC50 = 800 nM); also inhibits PRK2 with an IC50 value of 600 nM
10006148	Leelamine	10 mg	≥98%	A pyruvate dehydrogenase kinase inhibitor (IC50 = 9.5 µM); exhibits 20% displacement of [3H]-CP55940 at the the human CB1 and CB2 receptors at 10 µM activity
10006148	Leelamine	25 mg	≥98%	A pyruvate dehydrogenase kinase inhibitor (IC50 = 9.5 µM); exhibits 20% displacement of [3H]-CP55940 at the the human CB1 and CB2 receptors at 10 µM activity
10006148	Leelamine	5 mg	≥98%	A pyruvate dehydrogenase kinase inhibitor (IC50 = 9.5 µM); exhibits 20% displacement of [3H]-CP55940 at the the human CB1 and CB2 receptors at 10 µM activity
10006148	Leelamine	50 mg	≥98%	A pyruvate dehydrogenase kinase inhibitor (IC50 = 9.5 µM); exhibits 20% displacement of [3H]-CP55940 at the the human CB1 and CB2 receptors at 10 µM activity
10006606	Retreversine	1 mg	≥98%	An inactive isomer of reversine; is inactive at 10-fold higher concentrations than reversine in the myoblast assay
10006606	Retreversine	10 mg	≥98%	An inactive isomer of reversine; is inactive at 10-fold higher concentrations than reversine in the myoblast assay
10006606	Retreversine	5 mg	≥98%	An inactive isomer of reversine; is inactive at 10-fold higher concentrations than reversine in the myoblast assay
10006606	Retreversine	500 µg	≥98%	An inactive isomer of reversine; is inactive at 10-fold higher concentrations than reversine in the myoblast assay
10006727	PD 169316	1 mg	>98%	A selective inhibitor of p38 MAPK (IC50 = 89 nM); >100-fold IC50 for ERK and >1,000-fold higher for PKA and PKCα; inhibits apoptosis of neuronal and non-neuronal cells deprived of specific trophic factors such as potassium or nerve growth factor
10006727	PD 169316	10 mg	>98%	A selective inhibitor of p38 MAPK (IC50 = 89 nM); >100-fold IC50 for ERK and >1,000-fold higher for PKA and PKCα; inhibits apoptosis of neuronal and non-neuronal cells deprived of specific trophic factors such as potassium or nerve growth factor
10006727	PD 169316	25 mg	>98%	A selective inhibitor of p38 MAPK (IC50 = 89 nM); >100-fold IC50 for ERK and >1,000-fold higher for PKA and PKCα; inhibits apoptosis of neuronal and non-neuronal cells deprived of specific trophic factors such as potassium or nerve growth factor
10006727	PD 169316	5 mg	>98%	A selective inhibitor of p38 MAPK (IC50 = 89 nM); >100-fold IC50 for ERK and >1,000-fold higher for PKA and PKCα; inhibits apoptosis of neuronal and non-neuronal cells deprived of specific trophic factors such as potassium or nerve growth factor
10007349	TGX-221	1 mg	≥98%	A potent, selective, and cell permable inhibitor of PI3K p110b; IC50 value increases from 5 to ~50 nM at ATP concentrations of 50 µM and 1 mM, respectively; inhibits PtdIns-(3,4)-P2 production in platelets with an IC50 value of 50 nM
10007349	TGX-221	10 mg	≥98%	A potent, selective, and cell permable inhibitor of PI3K p110b; IC50 value increases from 5 to ~50 nM at ATP concentrations of 50 µM and 1 mM, respectively; inhibits PtdIns-(3,4)-P2 production in platelets with an IC50 value of 50 nM
10007349	TGX-221	5 mg	≥98%	A potent, selective, and cell permable inhibitor of PI3K p110b; IC50 value increases from 5 to ~50 nM at ATP concentrations of 50 µM and 1 mM, respectively; inhibits PtdIns-(3,4)-P2 production in platelets with an IC50 value of 50 nM
10007349	TGX-221	500 µg	≥98%	A potent, selective, and cell permable inhibitor of PI3K p110b; IC50 value increases from 5 to ~50 nM at ATP concentrations of 50 µM and 1 mM, respectively; inhibits PtdIns-(3,4)-P2 production in platelets with an IC50 value of 50 nM
10007653	(S)-H-1152 (hydrochlo	1 mg	≥95%	A potent, specific, ATP-competitive, and cell permeable inhibitor of ROCK (Ki = 1.6 nM); more potent inhibitor of ROCK than either Y-27632 (Ki = 140 nM) or HA-1077 (Ki = 330 nM); poorly inhibits PKA, PKC, and MLCK
10007653	(S)-H-1152 (hydrochlo	10 mg	≥95%	A potent, specific, ATP-competitive, and cell permeable inhibitor of ROCK (Ki = 1.6 nM); more potent inhibitor of ROCK than either Y-27632 (Ki = 140 nM) or HA-1077 (Ki = 330 nM); poorly inhibits PKA, PKC, and MLCK
10007653	(S)-H-1152 (hydrochlo	5 mg	≥95%	A potent, specific, ATP-competitive, and cell permeable inhibitor of ROCK (Ki = 1.6 nM); more potent inhibitor of ROCK than either Y-27632 (Ki = 140 nM) or HA-1077 (Ki = 330 nM); poorly inhibits PKA, PKC, and MLCK
10007653	(S)-H-1152 (hydrochlo	500 µg	≥95%	A potent, specific, ATP-competitive, and cell permeable inhibitor of ROCK (Ki = 1.6 nM); more potent inhibitor of ROCK than either Y-27632 (Ki = 140 nM) or HA-1077 (Ki = 330 nM); poorly inhibits PKA, PKC, and MLCK

10007707	AS-605240	1 mg	≥98%	A potent inhibitor of PI3Kγ; inhibits human recombinant PI3Kγ, α, β, and δ in an ATP-competitive manner (IC50s = 8, 60, 270, and 300 nM, respectively); inhibits C5a-mediated phosphorylation of protein kinase B in RAW 264 cells (IC50 = 90 nM); suppresses joint inflammation in mouse models of rheumatoid arthritis; reduces RANTES-induced peritoneal neutrophil recruitment in a mouse model of leukocyte chemotaxis (ED50 = 9.1 mg/kg)
10007707	AS-605240	10 mg	≥98%	A potent inhibitor of PI3Kγ; inhibits human recombinant PI3Kγ, α, β, and δ in an ATP-competitive manner (IC50s = 8, 60, 270, and 300 nM, respectively); inhibits C5a-mediated phosphorylation of protein kinase B in RAW 264 cells (IC50 = 90 nM); suppresses joint inflammation in mouse models of rheumatoid arthritis; reduces RANTES-induced peritoneal neutrophil recruitment in a mouse model of leukocyte chemotaxis (ED50 = 9.1 mg/kg)
10007707	AS-605240	25 mg	≥98%	A potent inhibitor of PI3Kγ; inhibits human recombinant PI3Kγ, α, β, and δ in an ATP-competitive manner (IC50s = 8, 60, 270, and 300 nM, respectively); inhibits C5a-mediated phosphorylation of protein kinase B in RAW 264 cells (IC50 = 90 nM); suppresses joint inflammation in mouse models of rheumatoid arthritis; reduces RANTES-induced peritoneal neutrophil recruitment in a mouse model of leukocyte chemotaxis (ED50 = 9.1 mg/kg)
10007707	AS-605240	5 mg	≥98%	A potent inhibitor of PI3Kγ; inhibits human recombinant PI3Kγ, α, β, and δ in an ATP-competitive manner (IC50s = 8, 60, 270, and 300 nM, respectively); inhibits C5a-mediated phosphorylation of protein kinase B in RAW 264 cells (IC50 = 90 nM); suppresses joint inflammation in mouse models of rheumatoid arthritis; reduces RANTES-induced peritoneal neutrophil recruitment in a mouse model of leukocyte chemotaxis (ED50 = 9.1 mg/kg)
10007784	D-myo-Inositol-1,3,4,5	1 mg	≥98%	An anticancer inositol phosphate; inhibits the phosphorylation and kinase activity of Akt/PKB, inducing apoptosis in ovarian, lung, and breast cancer cells; exhibits antiangiogenic activity in vitro, blocking capillary tube formation of HUVECs, as well as antitumor effects against cancer xenografts in mice; binds to the PH domain of Grp1 (Kd = 590 nM)
10007784	D-myo-Inositol-1,3,4,5	100 µg	≥98%	An anticancer inositol phosphate; inhibits the phosphorylation and kinase activity of Akt/PKB, inducing apoptosis in ovarian, lung, and breast cancer cells; exhibits antiangiogenic activity in vitro, blocking capillary tube formation of HUVECs, as well as antitumor effects against cancer xenografts in mice; binds to the PH domain of Grp1 (Kd = 590 nM)
10007784	D-myo-Inositol-1,3,4,5	500 µg	≥98%	An anticancer inositol phosphate; inhibits the phosphorylation and kinase activity of Akt/PKB, inducing apoptosis in ovarian, lung, and breast cancer cells; exhibits antiangiogenic activity in vitro, blocking capillary tube formation of HUVECs, as well as antitumor effects against cancer xenografts in mice; binds to the PH domain of Grp1 (Kd = 590 nM)
10007907	Sphingosine (d18:1)	10 mg	≥98%	Sphingosine (d18:1) is formed primarily from the breakdown of ceramide. Sphingosine inhibits PKC and phosphatidic acid phosphohydrolase, whereas it activates PLD and DAG kinase. Phosphorylation of sphingosine by SPHK 1 and SPHK 2 produces sphingosine-1-phosphate, a potent bioactive lipid that exhibits a broad spectrum of biological activities including cell proliferation, survival, migration, cytoskeletal organization, and morphogenesis.
10007907	Sphingosine (d18:1)	100 mg	≥98%	Sphingosine (d18:1) is formed primarily from the breakdown of ceramide. Sphingosine inhibits PKC and phosphatidic acid phosphohydrolase, whereas it activates PLD and DAG kinase. Phosphorylation of sphingosine by SPHK 1 and SPHK 2 produces sphingosine-1-phosphate, a potent bioactive lipid that exhibits a broad spectrum of biological activities including cell proliferation, survival, migration, cytoskeletal organization, and morphogenesis.
10007907	Sphingosine (d18:1)	25 mg	≥98%	Sphingosine (d18:1) is formed primarily from the breakdown of ceramide. Sphingosine inhibits PKC and phosphatidic acid phosphohydrolase, whereas it activates PLD and DAG kinase. Phosphorylation of sphingosine by SPHK 1 and SPHK 2 produces sphingosine-1-phosphate, a potent bioactive lipid that exhibits a broad spectrum of biological activities including cell proliferation, survival, migration, cytoskeletal organization, and morphogenesis.
10007907	Sphingosine (d18:1)	50 mg	≥98%	Sphingosine (d18:1) is formed primarily from the breakdown of ceramide. Sphingosine inhibits PKC and phosphatidic acid phosphohydrolase, whereas it activates PLD and DAG kinase. Phosphorylation of sphingosine by SPHK 1 and SPHK 2 produces sphingosine-1-phosphate, a potent bioactive lipid that exhibits a broad spectrum of biological activities including cell proliferation, survival, migration, cytoskeletal organization, and morphogenesis.
10008131	JNJ-10198409	1 mg	≥98%	An inhibitor of PDGF-BB tyrosine kinase with an IC50 value of 4.2 nM when tested in human coronary artery smooth muscle cells
10008131	JNJ-10198409	10 mg	≥98%	An inhibitor of PDGF-BB tyrosine kinase with an IC50 value of 4.2 nM when tested in human coronary artery smooth muscle cells

10008131	JNJ-10198409	5 mg	≥98%	An inhibitor of PDGF-BB tyrosine kinase with an IC50 value of 4.2 nM when tested in human coronary artery smooth muscle cells
10008131	JNJ-10198409	50 mg	≥98%	An inhibitor of PDGF-BB tyrosine kinase with an IC50 value of 4.2 nM when tested in human coronary artery smooth muscle cells
10008614	Leelamine (hydrochlo	10 mg	≥98%	The hydrochloride of leelamine, an inhibitor of pyruvate dehydrogenase kinase.
10008614	Leelamine (hydrochlo	100 mg	≥98%	The hydrochloride of leelamine, an inhibitor of pyruvate dehydrogenase kinase.
10008614	Leelamine (hydrochlo	5 mg	≥98%	The hydrochloride of leelamine, an inhibitor of pyruvate dehydrogenase kinase.
10008614	Leelamine (hydrochlo	50 mg	≥98%	The hydrochloride of leelamine, an inhibitor of pyruvate dehydrogenase kinase.
10009052	AS-252424	1 mg	≥95%	A potent inhibitor of PI3K with selectivity for the g isoform; inhibits human recombinant PI3Kg, a, d, with IC50 values of 30, 940, 20,000, and 20,000 nM, respectively
10009052	AS-252424	10 mg	≥95%	A potent inhibitor of PI3K with selectivity for the g isoform; inhibits human recombinant PI3Kg, a, d, with IC50 values of 30, 940, 20,000, and 20,000 nM, respectively
10009052	AS-252424	25 mg	≥95%	A potent inhibitor of PI3K with selectivity for the g isoform; inhibits human recombinant PI3Kg, a, d, with IC50 values of 30, 940, 20,000, and 20,000 nM, respectively
10009052	AS-252424	5 mg	≥95%	A potent inhibitor of PI3K with selectivity for the g isoform; inhibits human recombinant PI3Kg, a, d, with IC50 values of 30, 940, 20,000, and 20,000 nM, respectively
10009078	CAY10505	10 mg	≥98%	A potent inhibitor of PI3Kγ, selectively inhibiting the γ isoform (IC50 = 30 nM) better than the α, β, and δ isoforms (IC50 = 0.94, 20, and 20 µM, respectively); inhibits phosphorylation of PKB/Akt in mouse macrophages (IC50 = 228 nM)
10009078	CAY10505	25 mg	≥98%	A potent inhibitor of PI3Kγ, selectively inhibiting the γ isoform (IC50 = 30 nM) better than the α, β, and δ isoforms (IC50 = 0.94, 20, and 20 µM, respectively); inhibits phosphorylation of PKB/Akt in mouse macrophages (IC50 = 228 nM)
10009078	CAY10505	5 mg	≥98%	A potent inhibitor of PI3Kγ, selectively inhibiting the γ isoform (IC50 = 30 nM) better than the α, β, and δ isoforms (IC50 = 0.94, 20, and 20 µM, respectively); inhibits phosphorylation of PKB/Akt in mouse macrophages (IC50 = 228 nM)
10009078	CAY10505	50 mg	≥98%	A potent inhibitor of PI3Kγ, selectively inhibiting the γ isoform (IC50 = 30 nM) better than the α, β, and δ isoforms (IC50 = 0.94, 20, and 20 µM, respectively); inhibits phosphorylation of PKB/Akt in mouse macrophages (IC50 = 228 nM)
10009197	Flavopiridol (hydrochl	10 mg	≥95%	An inhibitor of cyclin-dependent kinases (Cdks; IC50s = ~100, ~100, ~100, and 300 nM for Cdk1, Cdk2, Cdk4, and Cdk7, respectively); inhibits TEFb (Ki = 3 nM); inhibits transcription of a CMV promoter in HeLa nuclear extract (IC50 = 34 nM), Tat-stimulated transcription of an HIV-1 promotor (IC50 = 7 nM), and HIV-1 replication in HEK239T cells (IC50 = <10 nM); induces apoptosis and cyclin D1 depletion and delays tumor growth in an HN-12 head and neck carcinoma mouse xenograft model at 5 mg/kg; suppresses synovial hyperplasia and joint destruction in a mouse model of collagen-induced arthritis
10009197	Flavopiridol (hydrochl	25 mg	≥95%	An inhibitor of cyclin-dependent kinases (Cdks; IC50s = ~100, ~100, ~100, and 300 nM for Cdk1, Cdk2, Cdk4, and Cdk7, respectively); inhibits TEFb (Ki = 3 nM); inhibits transcription of a CMV promoter in HeLa nuclear extract (IC50 = 34 nM), Tat-stimulated transcription of an HIV-1 promotor (IC50 = 7 nM), and HIV-1 replication in HEK239T cells (IC50 = <10 nM); induces apoptosis and cyclin D1 depletion and delays tumor growth in an HN-12 head and neck carcinoma mouse xenograft model at 5 mg/kg; suppresses synovial hyperplasia and joint destruction in a mouse model of collagen-induced arthritis
10009197	Flavopiridol (hydrochl	5 mg	≥95%	An inhibitor of cyclin-dependent kinases (Cdks; IC50s = ~100, ~100, ~100, and 300 nM for Cdk1, Cdk2, Cdk4, and Cdk7, respectively); inhibits TEFb (Ki = 3 nM); inhibits transcription of a CMV promoter in HeLa nuclear extract (IC50 = 34 nM), Tat-stimulated transcription of an HIV-1 promotor (IC50 = 7 nM), and HIV-1 replication in HEK239T cells (IC50 = <10 nM); induces apoptosis and cyclin D1 depletion and delays tumor growth in an HN-12 head and neck carcinoma mouse xenograft model at 5 mg/kg; suppresses synovial hyperplasia and joint destruction in a mouse model of collagen-induced arthritis
10009197	Flavopiridol (hydrochl	50 mg	≥95%	An inhibitor of cyclin-dependent kinases (Cdks; IC50s = ~100, ~100, ~100, and 300 nM for Cdk1, Cdk2, Cdk4, and Cdk7, respectively); inhibits TEFb (Ki = 3 nM); inhibits transcription of a CMV promoter in HeLa nuclear extract (IC50 = 34 nM), Tat-stimulated transcription of an HIV-1 promotor (IC50 = 7 nM), and HIV-1 replication in HEK239T cells (IC50 = <10 nM); induces apoptosis and cyclin D1 depletion and delays tumor growth in an HN-12 head and neck carcinoma mouse xenograft model at 5 mg/kg; suppresses synovial hyperplasia and joint destruction in a mouse model of collagen-induced arthritis

10009209	PI-103	1 mg	≥98%	A potent, cell-permeable, ATP-competitive inhibitor of PI3K family members (IC50 = 2, 8, 20, 26 nM for DNA-PK, p110α, mTORC1, and PI3-KC2β, respectively)
10009209	PI-103	10 mg	≥98%	A potent, cell-permeable, ATP-competitive inhibitor of PI3K family members (IC50 = 2, 8, 20, 26 nM for DNA-PK, p110α, mTORC1, and PI3-KC2β, respectively)
10009209	PI-103	25 mg	≥98%	A potent, cell-permeable, ATP-competitive inhibitor of PI3K family members (IC50 = 2, 8, 20, 26 nM for DNA-PK, p110α, mTORC1, and PI3-KC2β, respectively)
10009209	PI-103	5 mg	≥98%	A potent, cell-permeable, ATP-competitive inhibitor of PI3K family members (IC50 = 2, 8, 20, 26 nM for DNA-PK, p110α, mTORC1, and PI3-KC2β, respectively)
10009210	PIK-75 (hydrochloride	1 mg	≥98%	A selective inhibitor of p110α with an IC50 value of 5.8 nM; inhibits p110γ and p110β with IC50 values of 0.076 µM and 1.3 µM, respectively
10009210	PIK-75 (hydrochloride	10 mg	≥98%	A selective inhibitor of p110α with an IC50 value of 5.8 nM; inhibits p110γ and p110β with IC50 values of 0.076 µM and 1.3 µM, respectively
10009210	PIK-75 (hydrochloride	25 mg	≥98%	A selective inhibitor of p110α with an IC50 value of 5.8 nM; inhibits p110γ and p110β with IC50 values of 0.076 µM and 1.3 µM, respectively
10009210	PIK-75 (hydrochloride	5 mg	≥98%	A selective inhibitor of p110α with an IC50 value of 5.8 nM; inhibits p110γ and p110β with IC50 values of 0.076 µM and 1.3 µM, respectively
10009212	PIK-93	1 mg	≥98%	A PI4KIIIβ inhibitor (IC50 = 19 nM); selective over PI4KIIIα and PI4KIIα; inhibits PI3K catalytic subunits (IC50s = 39, 590, 120, and 16 nM for p110α, p110β, p110δ, and p110γ, respectively); reduces enteroviral RNA replication when used at a concentration of 125 nM in HeLa cells; inhibits intracellular ceramide transport
10009212	PIK-93	10 mg	≥98%	A PI4KIIIβ inhibitor (IC50 = 19 nM); selective over PI4KIIIα and PI4KIIα; inhibits PI3K catalytic subunits (IC50s = 39, 590, 120, and 16 nM for p110α, p110β, p110δ, and p110γ, respectively); reduces enteroviral RNA replication when used at a concentration of 125 nM in HeLa cells; inhibits intracellular ceramide transport
10009212	PIK-93	25 mg	≥98%	A PI4KIIIβ inhibitor (IC50 = 19 nM); selective over PI4KIIIα and PI4KIIα; inhibits PI3K catalytic subunits (IC50s = 39, 590, 120, and 16 nM for p110α, p110β, p110δ, and p110γ, respectively); reduces enteroviral RNA replication when used at a concentration of 125 nM in HeLa cells; inhibits intracellular ceramide transport
10009212	PIK-93	5 mg	≥98%	A PI4KIIIβ inhibitor (IC50 = 19 nM); selective over PI4KIIIα and PI4KIIα; inhibits PI3K catalytic subunits (IC50s = 39, 590, 120, and 16 nM for p110α, p110β, p110δ, and p110γ, respectively); reduces enteroviral RNA replication when used at a concentration of 125 nM in HeLa cells; inhibits intracellular ceramide transport
10009222	Sphingosine Kinase In	10 mg	≥95%	An SPHK1 inhibitor (IC50 = 0.5 µM for non-ATP-competitive inhibition of human recombinant SPHK1); selective for SPHK1 over ERK2, PI3K, and PKCα at 50s = 0.9-4.6 µM)
10009222	Sphingosine Kinase In	25 mg	≥95%	An SPHK1 inhibitor (IC50 = 0.5 µM for non-ATP-competitive inhibition of human recombinant SPHK1); selective for SPHK1 over ERK2, PI3K, and PKCα at 50s = 0.9-4.6 µM)
10009222	Sphingosine Kinase In	5 mg	≥95%	An SPHK1 inhibitor (IC50 = 0.5 µM for non-ATP-competitive inhibition of human recombinant SPHK1); selective for SPHK1 over ERK2, PI3K, and PKCα at 50s = 0.9-4.6 µM)
10009222	Sphingosine Kinase In	50 mg	≥95%	An SPHK1 inhibitor (IC50 = 0.5 µM for non-ATP-competitive inhibition of human recombinant SPHK1); selective for SPHK1 over ERK2, PI3K, and PKCα at 50s = 0.9-4.6 µM)
10009366	Piceatannol	10 mg	>98%	A resveratrol analog that exhibits potent anticancer properties; induces apoptosis in BJAB Burkitt-like lymphoma cells with an ED50 value of 25 µM
10009366	Piceatannol	25 mg	>98%	A resveratrol analog that exhibits potent anticancer properties; induces apoptosis in BJAB Burkitt-like lymphoma cells with an ED50 value of 25 µM
10009366	Piceatannol	5 mg	>98%	A resveratrol analog that exhibits potent anticancer properties; induces apoptosis in BJAB Burkitt-like lymphoma cells with an ED50 value of 25 µM
10009366	Piceatannol	50 mg	>98%	A resveratrol analog that exhibits potent anticancer properties; induces apoptosis in BJAB Burkitt-like lymphoma cells with an ED50 value of 25 µM
10009557	SC-1	1 mg	≥98%	A small molecule activator of stem cell renewal that allows the propagation of OG2 mES cells for at least 10 passages in an undifferentiated state; activity is mediated by the combined inhibition of RasGAP and ERK1 with Kd values of 98 and 212 nM, respectively
10009557	SC-1	10 mg	≥98%	A small molecule activator of stem cell renewal that allows the propagation of OG2 mES cells for at least 10 passages in an undifferentiated state; activity is mediated by the combined inhibition of RasGAP and ERK1 with Kd values of 98 and 212 nM, respectively
10009557	SC-1	25 mg	≥98%	A small molecule activator of stem cell renewal that allows the propagation of OG2 mES cells for at least 10 passages in an undifferentiated state; activity is mediated by the combined inhibition of RasGAP and ERK1 with Kd values of 98 and 212 nM, respectively

10009557	SC-1	5 mg	≥98%	A small molecule activator of stem cell renewal that allows the propagation of OG2 mES cells for at least 10 passages in an undifferentiated state; activity is mediated by the combined inhibition of RasGAP and ERK1 with Kd values of 98 and 212 nM, respectively
10009569	(R)-Roscovitine	1 mg	≥98%	A potent inhibitor of Cdk2/cyclin E with an IC50 value of 0.1 µM; also inhibits Cdk7/cyclin H, Cdk5/p35, and cell division cycle (cdc)/cyclin B with IC50 values of 0.49, 0.16, and 0.65 µM, respectively
10009569	(R)-Roscovitine	10 mg	≥98%	A potent inhibitor of Cdk2/cyclin E with an IC50 value of 0.1 µM; also inhibits Cdk7/cyclin H, Cdk5/p35, and cell division cycle (cdc)/cyclin B with IC50 values of 0.49, 0.16, and 0.65 µM, respectively
10009569	(R)-Roscovitine	5 mg	≥98%	A potent inhibitor of Cdk2/cyclin E with an IC50 value of 0.1 µM; also inhibits Cdk7/cyclin H, Cdk5/p35, and cell division cycle (cdc)/cyclin B with IC50 values of 0.49, 0.16, and 0.65 µM, respectively
10009569	(R)-Roscovitine	500 µg	≥98%	A potent inhibitor of Cdk2/cyclin E with an IC50 value of 0.1 µM; also inhibits Cdk7/cyclin H, Cdk5/p35, and cell division cycle (cdc)/cyclin B with IC50 values of 0.49, 0.16, and 0.65 µM, respectively
10009644	Sorafenib	10 mg	≥98%	A multi-kinase inhibitor; inhibits Raf-1 and B-RAF (IC50s = 6 and 22 µM, respectively); inhibits VEGFR2, VEGFR3, PDGFRβ, FLT3, and c-Kit (IC50s = 90, 15, 20, 57, and 58 nM, respectively); selective for these kinases over 12 other kinases (IC50s = >10 µM for all); inhibits proliferation of PLC/PRF/5 and HepG2 cells (IC50s = 6.3 and 4.5 µM, respectively); inhibits tumor growth in a PLC/PRF/5 mouse xenograft model at 30 mg/kg; induces ferroptotic cell death in HT-1080 fibrosarcoma cells at 10 µM but not in a variety of other cancer cell lines; inhibits HCV replication in Huh7.5 cells (IC50 = 7.2 µM)
10009644	Sorafenib	25 mg	≥98%	A multi-kinase inhibitor; inhibits Raf-1 and B-RAF (IC50s = 6 and 22 µM, respectively); inhibits VEGFR2, VEGFR3, PDGFRβ, FLT3, and c-Kit (IC50s = 90, 15, 20, 57, and 58 nM, respectively); selective for these kinases over 12 other kinases (IC50s = >10 µM for all); inhibits proliferation of PLC/PRF/5 and HepG2 cells (IC50s = 6.3 and 4.5 µM, respectively); inhibits tumor growth in a PLC/PRF/5 mouse xenograft model at 30 mg/kg; induces ferroptotic cell death in HT-1080 fibrosarcoma cells at 10 µM but not in a variety of other cancer cell lines; inhibits HCV replication in Huh7.5 cells (IC50 = 7.2 µM)
10009644	Sorafenib	5 mg	≥98%	A multi-kinase inhibitor; inhibits Raf-1 and B-RAF (IC50s = 6 and 22 µM, respectively); inhibits VEGFR2, VEGFR3, PDGFRβ, FLT3, and c-Kit (IC50s = 90, 15, 20, 57, and 58 nM, respectively); selective for these kinases over 12 other kinases (IC50s = >10 µM for all); inhibits proliferation of PLC/PRF/5 and HepG2 cells (IC50s = 6.3 and 4.5 µM, respectively); inhibits tumor growth in a PLC/PRF/5 mouse xenograft model at 30 mg/kg; induces ferroptotic cell death in HT-1080 fibrosarcoma cells at 10 µM but not in a variety of other cancer cell lines; inhibits HCV replication in Huh7.5 cells (IC50 = 7.2 µM)
10009644	Sorafenib	50 mg	≥98%	A multi-kinase inhibitor; inhibits Raf-1 and B-RAF (IC50s = 6 and 22 µM, respectively); inhibits VEGFR2, VEGFR3, PDGFRβ, FLT3, and c-Kit (IC50s = 90, 15, 20, 57, and 58 nM, respectively); selective for these kinases over 12 other kinases (IC50s = >10 µM for all); inhibits proliferation of PLC/PRF/5 and HepG2 cells (IC50s = 6.3 and 4.5 µM, respectively); inhibits tumor growth in a PLC/PRF/5 mouse xenograft model at 30 mg/kg; induces ferroptotic cell death in HT-1080 fibrosarcoma cells at 10 µM but not in a variety of other cancer cell lines; inhibits HCV replication in Huh7.5 cells (IC50 = 7.2 µM)
10009851	D-myo-Inositol-1,3,4,5	1 mg	≥98%	A member of the inositol phosphate (InsP) family of small, soluble second messengers; inhibits the phosphorylation and kinase activity of Akt/PKB, inducing apoptosis in ovarian, lung, and breast cancer cells; exhibits antiangiogenic activity as well as antitumor effects; binds to the PH domain of Grp1 with a Kd of 590 nM.
10009851	D-myo-Inositol-1,3,4,5	100 µg	≥98%	A member of the inositol phosphate (InsP) family of small, soluble second messengers; inhibits the phosphorylation and kinase activity of Akt/PKB, inducing apoptosis in ovarian, lung, and breast cancer cells; exhibits antiangiogenic activity as well as antitumor effects; binds to the PH domain of Grp1 with a Kd of 590 nM.
10009851	D-myo-Inositol-1,3,4,5	500 µg	≥98%	A member of the inositol phosphate (InsP) family of small, soluble second messengers; inhibits the phosphorylation and kinase activity of Akt/PKB, inducing apoptosis in ovarian, lung, and breast cancer cells; exhibits antiangiogenic activity as well as antitumor effects; binds to the PH domain of Grp1 with a Kd of 590 nM.
10010043	CAY10561	1 mg	≥98%	A selective, potent inhibitor of ERK2 (Ki = 2 nM); inhibits proliferation of COLO 205 cells (IC50 = 0.54 µM)
10010043	CAY10561	10 mg	≥98%	A selective, potent inhibitor of ERK2 (Ki = 2 nM); inhibits proliferation of COLO 205 cells (IC50 = 0.54 µM)
10010043	CAY10561	5 mg	≥98%	A selective, potent inhibitor of ERK2 (Ki = 2 nM); inhibits proliferation of COLO 205 cells (IC50 = 0.54 µM)
10010043	CAY10561	500 µg	≥98%	A selective, potent inhibitor of ERK2 (Ki = 2 nM); inhibits proliferation of COLO 205 cells (IC50 = 0.54 µM)

10010175	AS-604850	1 mg	≥98%	AS-604850 is a selective, ATP-competitive inhibitor of PI3Kγ with IC50 values of 0.25, >20, >20, and 4.5 μM for the human recombinant γ, .delta., β, and α isoforms, respectively.{13338} AS-604850 inhibited MCP-1-mediated monocyte chemotaxis with an IC50 value of 21 μM and reduced RANTES-induced peritoneal neutrophil recruitment in a murine model of leukocyte chemotaxis with an ED50 value of 42.4 mg/kg.{13338}
10010175	AS-604850	10 mg	≥98%	AS-604850 is a selective, ATP-competitive inhibitor of PI3Kγ with IC50 values of 0.25, >20, >20, and 4.5 μM for the human recombinant γ, .delta., β, and α isoforms, respectively.{13338} AS-604850 inhibited MCP-1-mediated monocyte chemotaxis with an IC50 value of 21 μM and reduced RANTES-induced peritoneal neutrophil recruitment in a murine model of leukocyte chemotaxis with an ED50 value of 42.4 mg/kg.{13338}
10010175	AS-604850	25 mg	≥98%	AS-604850 is a selective, ATP-competitive inhibitor of PI3Kγ with IC50 values of 0.25, >20, >20, and 4.5 μM for the human recombinant γ, .delta., β, and α isoforms, respectively.{13338} AS-604850 inhibited MCP-1-mediated monocyte chemotaxis with an IC50 value of 21 μM and reduced RANTES-induced peritoneal neutrophil recruitment in a murine model of leukocyte chemotaxis with an ED50 value of 42.4 mg/kg.{13338}
10010175	AS-604850	5 mg	≥98%	AS-604850 is a selective, ATP-competitive inhibitor of PI3Kγ with IC50 values of 0.25, >20, >20, and 4.5 μM for the human recombinant γ, .delta., β, and α isoforms, respectively.{13338} AS-604850 inhibited MCP-1-mediated monocyte chemotaxis with an IC50 value of 21 μM and reduced RANTES-induced peritoneal neutrophil recruitment in a murine model of leukocyte chemotaxis with an ED50 value of 42.4 mg/kg.{13338}
10010177	PI3-Kinase α Inhibitor	1 mg	≥98%	An inhibitor of PI3K p110α (IC50 = 2 nM in an enzyme assay); selective for p110α over p110β, p110γ, and PI3K C2β (IC50s = 16, 660, and 220 nM, respectively); inhibits mTOR (IC50 = 49 nM); inhibits proliferation in A375 melanoma cells (IC50 = 0.58 μM)
10010177	PI3-Kinase α Inhibitor	10 mg	≥98%	An inhibitor of PI3K p110α (IC50 = 2 nM in an enzyme assay); selective for p110α over p110β, p110γ, and PI3K C2β (IC50s = 16, 660, and 220 nM, respectively); inhibits mTOR (IC50 = 49 nM); inhibits proliferation in A375 melanoma cells (IC50 = 0.58 μM)
10010177	PI3-Kinase α Inhibitor	5 mg	≥98%	An inhibitor of PI3K p110α (IC50 = 2 nM in an enzyme assay); selective for p110α over p110β, p110γ, and PI3K C2β (IC50s = 16, 660, and 220 nM, respectively); inhibits mTOR (IC50 = 49 nM); inhibits proliferation in A375 melanoma cells (IC50 = 0.58 μM)
10010177	PI3-Kinase α Inhibitor	500 μg	≥98%	An inhibitor of PI3K p110α (IC50 = 2 nM in an enzyme assay); selective for p110α over p110β, p110γ, and PI3K C2β (IC50s = 16, 660, and 220 nM, respectively); inhibits mTOR (IC50 = 49 nM); inhibits proliferation in A375 melanoma cells (IC50 = 0.58 μM)
10010235	Terreic Acid	1 mg	≥95%	A cell-permeable quinone epoxide that selectively inhibits BTK catalytic activity (BTK; IC50s = 10 and 3 μM for basal and activation levels, respectively); binds to BTK-PH and blocks the interaction between BTK-PH and PKC (IC50 = 100 μM in human mast cell lysates) without affecting PKC activity; minimal effect on Lyn, Syk, PKA, casein kinase I, ERK1, ERK2, and p38 kinase activities
10010235	Terreic Acid	5 mg	≥95%	A cell-permeable quinone epoxide that selectively inhibits BTK catalytic activity (BTK; IC50s = 10 and 3 μM for basal and activation levels, respectively); binds to BTK-PH and blocks the interaction between BTK-PH and PKC (IC50 = 100 μM in human mast cell lysates) without affecting PKC activity; minimal effect on Lyn, Syk, PKA, casein kinase I, ERK1, ERK2, and p38 kinase activities
10010236	ML-9	10 mg	≥98%	An inhibitor of PKB/Akt activity (IC50 = 10-50 μM) that inhibits insulin-stimulated glucose transport and intracellular protein translocation; inhibits additional serine/threonine kinases including PKA (IC50 = ~20 μM), p90 S6 (IC50 = ~50 μM), and MAP kinase (IC50 = ~35 μM)
10010236	ML-9	100 mg	≥98%	An inhibitor of PKB/Akt activity (IC50 = 10-50 μM) that inhibits insulin-stimulated glucose transport and intracellular protein translocation; inhibits additional serine/threonine kinases including PKA (IC50 = ~20 μM), p90 S6 (IC50 = ~50 μM), and MAP kinase (IC50 = ~35 μM)
10010236	ML-9	250 mg	≥98%	An inhibitor of PKB/Akt activity (IC50 = 10-50 μM) that inhibits insulin-stimulated glucose transport and intracellular protein translocation; inhibits additional serine/threonine kinases including PKA (IC50 = ~20 μM), p90 S6 (IC50 = ~50 μM), and MAP kinase (IC50 = ~35 μM)
10010236	ML-9	50 mg	≥98%	An inhibitor of PKB/Akt activity (IC50 = 10-50 μM) that inhibits insulin-stimulated glucose transport and intracellular protein translocation; inhibits additional serine/threonine kinases including PKA (IC50 = ~20 μM), p90 S6 (IC50 = ~50 μM), and MAP kinase (IC50 = ~35 μM)
10010237	Triciribine	1 mg	≥98%	A cell-permeable tricyclic nucleoside that inhibits the phosphorylation, activation, and signalling of Akt-1, -2, and -3
10010237	Triciribine	10 mg	≥98%	A cell-permeable tricyclic nucleoside that inhibits the phosphorylation, activation, and signalling of Akt-1, -2, and -3
10010237	Triciribine	5 mg	≥98%	A cell-permeable tricyclic nucleoside that inhibits the phosphorylation, activation, and signalling of Akt-1, -2, and -3
10010238	Erbstatin analog	1 mg	≥98%	A stable, potent analog of erbstatin; inhibits EGFR tyrosine kinase in vitro with an IC50 of 0.14 μg/ml; inhibits EGF-stimulated growth in NIH3T3 cells with an IC50 value of 0.5 μg/ml; delays onset of EGF-induced DNA synthesis
10010238	Erbstatin analog	10 mg	≥98%	A stable, potent analog of erbstatin; inhibits EGFR tyrosine kinase in vitro with an IC50 of 0.14 μg/ml; inhibits EGF-stimulated growth in NIH3T3 cells with an IC50 value of 0.5 μg/ml; delays onset of EGF-induced DNA synthesis
10010238	Erbstatin analog	5 mg	≥98%	A stable, potent analog of erbstatin; inhibits EGFR tyrosine kinase in vitro with an IC50 of 0.14 μg/ml; inhibits EGF-stimulated growth in NIH3T3 cells with an IC50 value of 0.5 μg/ml; delays onset of EGF-induced DNA synthesis

10010238	Erbstatin analog	50 mg	≥98%	A stable, potent analog of erbstatin; inhibits EGFR tyrosine kinase in vitro with an IC50 of 0.14 µg/ml; inhibits EGF-stimulated growth in NIH3T3 cells with an IC50 value of 0.5 µg/ml; delays onset of EGF-induced DNA synthesis
10010239	Kenpaullone	1 mg	≥98%	An ATP-competitive inhibitor of several CDKs as well as GSK3β
10010239	Kenpaullone	10 mg	≥98%	An ATP-competitive inhibitor of several CDKs as well as GSK3β
10010239	Kenpaullone	25 mg	≥98%	An ATP-competitive inhibitor of several CDKs as well as GSK3β
10010239	Kenpaullone	5 mg	≥98%	An ATP-competitive inhibitor of several CDKs as well as GSK3β
10010240	Olomoucine	1 mg	≥98%	An ATP-competitive CDK inhibitor; inhibits CDC2/cyclin B (IC50 = 7 µM), Cdk2/cyclin A (IC50 = 7 µM), Cdk2/cyclin E (IC50 = 7 µM, Cdk/p35 kinase (IC50 = 3 µM), and ERK1/p44 MAPK (IC50 = 25 µM)
10010240	Olomoucine	10 mg	≥98%	An ATP-competitive CDK inhibitor; inhibits CDC2/cyclin B (IC50 = 7 µM), Cdk2/cyclin A (IC50 = 7 µM), Cdk2/cyclin E (IC50 = 7 µM, Cdk/p35 kinase (IC50 = 3 µM), and ERK1/p44 MAPK (IC50 = 25 µM)
10010240	Olomoucine	25 mg	≥98%	An ATP-competitive CDK inhibitor; inhibits CDC2/cyclin B (IC50 = 7 µM), Cdk2/cyclin A (IC50 = 7 µM), Cdk2/cyclin E (IC50 = 7 µM, Cdk/p35 kinase (IC50 = 3 µM), and ERK1/p44 MAPK (IC50 = 25 µM)
10010240	Olomoucine	5 mg	≥98%	An ATP-competitive CDK inhibitor; inhibits CDC2/cyclin B (IC50 = 7 µM), Cdk2/cyclin A (IC50 = 7 µM), Cdk2/cyclin E (IC50 = 7 µM, Cdk/p35 kinase (IC50 = 3 µM), and ERK1/p44 MAPK (IC50 = 25 µM)
10010242	AG-494	10 mg	≥98%	An inhibitor of EGF receptor kinase with an IC50 value of 1 µM in HT-22 cells
10010242	AG-494	25 mg	≥98%	An inhibitor of EGF receptor kinase with an IC50 value of 1 µM in HT-22 cells
10010242	AG-494	5 mg	≥98%	An inhibitor of EGF receptor kinase with an IC50 value of 1 µM in HT-22 cells
10010242	AG-494	50 mg	≥98%	An inhibitor of EGF receptor kinase with an IC50 value of 1 µM in HT-22 cells
10010243	AG-825	1 mg	≥98%	A selective ATP-competitive inhibitor of the tyrosine kinase activity of HER2/neu (IC50 = 0.35 µM)
10010243	AG-825	10 mg	≥98%	A selective ATP-competitive inhibitor of the tyrosine kinase activity of HER2/neu (IC50 = 0.35 µM)
10010243	AG-825	5 mg	≥98%	A selective ATP-competitive inhibitor of the tyrosine kinase activity of HER2/neu (IC50 = 0.35 µM)
10010243	AG-825	50 mg	≥98%	A selective ATP-competitive inhibitor of the tyrosine kinase activity of HER2/neu (IC50 = 0.35 µM)
10010244	AG-1478	1 mg	≥98%	An inhibitor of EGFR kinase with an IC50 value of 3 nM
10010244	AG-1478	10 mg	≥98%	An inhibitor of EGFR kinase with an IC50 value of 3 nM
10010244	AG-1478	25 mg	≥98%	An inhibitor of EGFR kinase with an IC50 value of 3 nM
10010244	AG-1478	5 mg	≥98%	An inhibitor of EGFR kinase with an IC50 value of 3 nM
10010246	SB-216763	10 mg	≥98%	An inhibitor of GSK3α (IC50 = 34 nM, GSK3β similar) that stimulates glycogen synthesis in Chang human liver cells (EC50 = 3.6 µM); induces expression of β-catenin-LEF/Tcf regulated reporter genes HEK293 cells
10010246	SB-216763	100 mg	≥98%	An inhibitor of GSK3α (IC50 = 34 nM, GSK3β similar) that stimulates glycogen synthesis in Chang human liver cells (EC50 = 3.6 µM); induces expression of β-catenin-LEF/Tcf regulated reporter genes HEK293 cells
10010246	SB-216763	5 mg	≥98%	An inhibitor of GSK3α (IC50 = 34 nM, GSK3β similar) that stimulates glycogen synthesis in Chang human liver cells (EC50 = 3.6 µM); induces expression of β-catenin-LEF/Tcf regulated reporter genes HEK293 cells
10010246	SB-216763	50 mg	≥98%	An inhibitor of GSK3α (IC50 = 34 nM, GSK3β similar) that stimulates glycogen synthesis in Chang human liver cells (EC50 = 3.6 µM); induces expression of β-catenin-LEF/Tcf regulated reporter genes HEK293 cells
10010247	SB-415286	1 mg	≥98%	A potent and selective cell-permeable, ATP-competitive inhibitor of GSK3α (IC50 = 78 nM, Ki = 31 nM); similar potency for GSK3β
10010247	SB-415286	10 mg	≥98%	A potent and selective cell-permeable, ATP-competitive inhibitor of GSK3α (IC50 = 78 nM, Ki = 31 nM); similar potency for GSK3β
10010247	SB-415286	5 mg	≥98%	A potent and selective cell-permeable, ATP-competitive inhibitor of GSK3α (IC50 = 78 nM, Ki = 31 nM); similar potency for GSK3β
10010248	AG-17	10 mg	≥98%	An inhibitor of EGF receptor kinase with an IC50 value of 460 µM in the human epidermoid carcinoma cell line A431.
10010248	AG-17	25 mg	≥98%	An inhibitor of EGF receptor kinase with an IC50 value of 460 µM in the human epidermoid carcinoma cell line A431.
10010248	AG-17	5 mg	≥98%	An inhibitor of EGF receptor kinase with an IC50 value of 460 µM in the human epidermoid carcinoma cell line A431.
10010248	AG-17	50 mg	≥98%	An inhibitor of EGF receptor kinase with an IC50 value of 460 µM in the human epidermoid carcinoma cell line A431.
10010249	H-8 (hydrochloride)	10 mg	≥98%	A potent inhibitor of PKA and PKG that shows moderate inhibition for PKC and MLCK with Ki values of 1.2, 0.48, 15, and 68 µM, respectively
10010249	H-8 (hydrochloride)	25 mg	≥98%	A potent inhibitor of PKA and PKG that shows moderate inhibition for PKC and MLCK with Ki values of 1.2, 0.48, 15, and 68 µM, respectively

10010249	H-8 (hydrochloride)	5 mg	≥98%	A potent inhibitor of PKA and PKG that shows moderate inhibition for PKC and MLCK with Ki values of 1.2, 0.48, 15, and 68 μM, respectively
10010249	H-8 (hydrochloride)	50 mg	≥98%	A potent inhibitor of PKA and PKG that shows moderate inhibition for PKC and MLCK with Ki values of 1.2, 0.48, 15, and 68 μM, respectively
10010265	LFM-A13	10 mg	≥98%	A BTK inhibitor (IC50 = 2.5 μM); selective for BTK over JAK1, JAK3, IRK, EGFR, and HCK (IC50s = >278 μM for all), as well as a panel of seven serine/threonine, 10 tyrosine, and one lipid kinase (IC50s = >200-500 μM), but does inhibit PLK3 (Ki = 7.2 μM) and Plx1 (IC50 = 10 μM); increases anti-FAS antibody-induced apoptosis in NALM-6-UM-1 ALL cells; reduces tumor growth in an MMTV/neu transgenic mouse model of breast cancer at 50 mg/kg
10010265	LFM-A13	100 mg	≥98%	A BTK inhibitor (IC50 = 2.5 μM); selective for BTK over JAK1, JAK3, IRK, EGFR, and HCK (IC50s = >278 μM for all), as well as a panel of seven serine/threonine, 10 tyrosine, and one lipid kinase (IC50s = >200-500 μM), but does inhibit PLK3 (Ki = 7.2 μM) and Plx1 (IC50 = 10 μM); increases anti-FAS antibody-induced apoptosis in NALM-6-UM-1 ALL cells; reduces tumor growth in an MMTV/neu transgenic mouse model of breast cancer at 50 mg/kg
10010265	LFM-A13	5 mg	≥98%	A BTK inhibitor (IC50 = 2.5 μM); selective for BTK over JAK1, JAK3, IRK, EGFR, and HCK (IC50s = >278 μM for all), as well as a panel of seven serine/threonine, 10 tyrosine, and one lipid kinase (IC50s = >200-500 μM), but does inhibit PLK3 (Ki = 7.2 μM) and Plx1 (IC50 = 10 μM); increases anti-FAS antibody-induced apoptosis in NALM-6-UM-1 ALL cells; reduces tumor growth in an MMTV/neu transgenic mouse model of breast cancer at 50 mg/kg
10010265	LFM-A13	50 mg	≥98%	A BTK inhibitor (IC50 = 2.5 μM); selective for BTK over JAK1, JAK3, IRK, EGFR, and HCK (IC50s = >278 μM for all), as well as a panel of seven serine/threonine, 10 tyrosine, and one lipid kinase (IC50s = >200-500 μM), but does inhibit PLK3 (Ki = 7.2 μM) and Plx1 (IC50 = 10 μM); increases anti-FAS antibody-induced apoptosis in NALM-6-UM-1 ALL cells; reduces tumor growth in an MMTV/neu transgenic mouse model of breast cancer at 50 mg/kg
10010267	SC-514	10 mg	≥98%	A selective and reversible inhibitor of IKK2 (IC50 = 3-12 μM) that displays >10-fold selectivity over 28 other kinases; attenuates NF-κB-mediated gene expression in synovial fibroblasts, smooth muscle cells, and astrocytes
10010267	SC-514	25 mg	≥98%	A selective and reversible inhibitor of IKK2 (IC50 = 3-12 μM) that displays >10-fold selectivity over 28 other kinases; attenuates NF-κB-mediated gene expression in synovial fibroblasts, smooth muscle cells, and astrocytes
10010267	SC-514	5 mg	≥98%	A selective and reversible inhibitor of IKK2 (IC50 = 3-12 μM) that displays >10-fold selectivity over 28 other kinases; attenuates NF-κB-mediated gene expression in synovial fibroblasts, smooth muscle cells, and astrocytes
10010267	SC-514	50 mg	≥98%	A selective and reversible inhibitor of IKK2 (IC50 = 3-12 μM) that displays >10-fold selectivity over 28 other kinases; attenuates NF-κB-mediated gene expression in synovial fibroblasts, smooth muscle cells, and astrocytes
10010268	Lavendustin A	1 mg	≥95%	A selective inhibitor of EGF receptor-associated tyrosine kinase (IC50 = 11 nM); used to differentiate rat mesenchymal stem cells, to inhibit NMDA-stimulated cGMP production, and to inhibit VEGF-induced angiogenesis
10010268	Lavendustin A	10 mg	≥95%	A selective inhibitor of EGF receptor-associated tyrosine kinase (IC50 = 11 nM); used to differentiate rat mesenchymal stem cells, to inhibit NMDA-stimulated cGMP production, and to inhibit VEGF-induced angiogenesis
10010268	Lavendustin A	5 mg	≥95%	A selective inhibitor of EGF receptor-associated tyrosine kinase (IC50 = 11 nM); used to differentiate rat mesenchymal stem cells, to inhibit NMDA-stimulated cGMP production, and to inhibit VEGF-induced angiogenesis
10010275	Apigenin	100 mg	≥98%	Inhibits CK2 activity in the renal cortex with an IC50 value of 30 μM; potent inhibitor of NO and PGE2 biosynthesis by reducing iNOS and COX-2 expression
10010275	Apigenin	25 mg	≥98%	Inhibits CK2 activity in the renal cortex with an IC50 value of 30 μM; potent inhibitor of NO and PGE2 biosynthesis by reducing iNOS and COX-2 expression
10010275	Apigenin	50 mg	≥98%	Inhibits CK2 activity in the renal cortex with an IC50 value of 30 μM; potent inhibitor of NO and PGE2 biosynthesis by reducing iNOS and COX-2 expression
10010275	Apigenin	500 mg	≥98%	Inhibits CK2 activity in the renal cortex with an IC50 value of 30 μM; potent inhibitor of NO and PGE2 biosynthesis by reducing iNOS and COX-2 expression
10010300	AG-18	10 mg	>98%	AG-18 is an inhibitor of EGF receptor kinase with an IC50 value of 35 μM in the human epidermoid carcinoma cell line A431.{14963}
10010300	AG-18	25 mg	>98%	AG-18 is an inhibitor of EGF receptor kinase with an IC50 value of 35 μM in the human epidermoid carcinoma cell line A431.{14963}
10010300	AG-18	5 mg	>98%	AG-18 is an inhibitor of EGF receptor kinase with an IC50 value of 35 μM in the human epidermoid carcinoma cell line A431.{14963}

10010300	AG-18	50 mg	>98%	AG-18 is an inhibitor of EGF receptor kinase with an IC50 value of 35 µM in the human epidermoid carcinoma cell line A431.{14963}
10010301	CAY10554	10 mg	≥95%	A potent inhibitor of Cdk5 and Cdk2, with IC50 values of 64 and 98 nM, respectively
10010301	CAY10554	25 mg	≥95%	A potent inhibitor of Cdk5 and Cdk2, with IC50 values of 64 and 98 nM, respectively
10010301	CAY10554	5 mg	≥95%	A potent inhibitor of Cdk5 and Cdk2, with IC50 values of 64 and 98 nM, respectively
10010301	CAY10554	50 mg	≥95%	A potent inhibitor of Cdk5 and Cdk2, with IC50 values of 64 and 98 nM, respectively
10010302	DRB	10 mg	≥98%	Inhibits CKII (IC50 range of 4-10 µM), Cdk7 (IC50 = ~20 µM), Cdk8 (IC50 = ~20 µM), and Cdk9 (IC50 = 3 µM); inhibits elongation during RNA polymerase II transcription; triggers p53-dependent apoptosis of human colon adenocarcinoma cells; inhibits trans-activated transcription of the Tat protein of HIV-1 (IC50 = ~4 µM)
10010302	DRB	100 mg	≥98%	Inhibits CKII (IC50 range of 4-10 µM), Cdk7 (IC50 = ~20 µM), Cdk8 (IC50 = ~20 µM), and Cdk9 (IC50 = 3 µM); inhibits elongation during RNA polymerase II transcription; triggers p53-dependent apoptosis of human colon adenocarcinoma cells; inhibits trans-activated transcription of the Tat protein of HIV-1 (IC50 = ~4 µM)
10010302	DRB	250 mg	≥98%	Inhibits CKII (IC50 range of 4-10 µM), Cdk7 (IC50 = ~20 µM), Cdk8 (IC50 = ~20 µM), and Cdk9 (IC50 = 3 µM); inhibits elongation during RNA polymerase II transcription; triggers p53-dependent apoptosis of human colon adenocarcinoma cells; inhibits trans-activated transcription of the Tat protein of HIV-1 (IC50 = ~4 µM)
10010302	DRB	50 mg	≥98%	Inhibits CKII (IC50 range of 4-10 µM), Cdk7 (IC50 = ~20 µM), Cdk8 (IC50 = ~20 µM), and Cdk9 (IC50 = 3 µM); inhibits elongation during RNA polymerase II transcription; triggers p53-dependent apoptosis of human colon adenocarcinoma cells; inhibits trans-activated transcription of the Tat protein of HIV-1 (IC50 = ~4 µM)
10010309	RG-13022	10 mg	≥98%	An inhibitor of EGF receptor kinase (IC50 = 1 µM in HT-22 cells)
10010309	RG-13022	5 mg	≥98%	An inhibitor of EGF receptor kinase (IC50 = 1 µM in HT-22 cells)
10010309	RG-13022	50 mg	≥98%	An inhibitor of EGF receptor kinase (IC50 = 1 µM in HT-22 cells)
10010310	RG-14620	10 mg	≥98%	An inhibitor of EGF receptor kinase (IC50 = 3 µM in HT-22 cells)
10010310	RG-14620	5 mg	≥98%	An inhibitor of EGF receptor kinase (IC50 = 3 µM in HT-22 cells)
10010310	RG-14620	50 mg	≥98%	An inhibitor of EGF receptor kinase (IC50 = 3 µM in HT-22 cells)
10010311	AG-490	10 mg	≥98%	An selective inhibitor of JAK2 activity that blocks leukemic cell growth in vitro and in vivo by inducing programmed cell death; blocks growth of all pre-B acute leukemia cells at a concentration of 5 µM
10010311	AG-490	25 mg	≥98%	An selective inhibitor of JAK2 activity that blocks leukemic cell growth in vitro and in vivo by inducing programmed cell death; blocks growth of all pre-B acute leukemia cells at a concentration of 5 µM
10010311	AG-490	5 mg	≥98%	An selective inhibitor of JAK2 activity that blocks leukemic cell growth in vitro and in vivo by inducing programmed cell death; blocks growth of all pre-B acute leukemia cells at a concentration of 5 µM
10010311	AG-490	50 mg	≥98%	An selective inhibitor of JAK2 activity that blocks leukemic cell growth in vitro and in vivo by inducing programmed cell death; blocks growth of all pre-B acute leukemia cells at a concentration of 5 µM
10010312	AG-82	10 mg	≥95%	An inhibitor of EGF receptor kinase (IC50 = 3 µM in A431 cells)
10010312	AG-82	25 mg	≥95%	An inhibitor of EGF receptor kinase (IC50 = 3 µM in A431 cells)
10010312	AG-82	5 mg	≥95%	An inhibitor of EGF receptor kinase (IC50 = 3 µM in A431 cells)
10010312	AG-82	50 mg	≥95%	An inhibitor of EGF receptor kinase (IC50 = 3 µM in A431 cells)
10010313	AG-99	10 mg	≥98%	An inhibitor of EGF receptor kinase (IC50 = 10 µM in A431 cells)
10010313	AG-99	25 mg	≥98%	An inhibitor of EGF receptor kinase (IC50 = 10 µM in A431 cells)
10010313	AG-99	5 mg	≥98%	An inhibitor of EGF receptor kinase (IC50 = 10 µM in A431 cells)
10010313	AG-99	50 mg	≥98%	An inhibitor of EGF receptor kinase (IC50 = 10 µM in A431 cells)
10010314	AG-213	10 mg	≥97%	An inhibitor of EGF receptor kinase (IC50 = 2.4 µM in A431 cells)
10010314	AG-213	25 mg	≥97%	An inhibitor of EGF receptor kinase (IC50 = 2.4 µM in A431 cells)
10010314	AG-213	5 mg	≥97%	An inhibitor of EGF receptor kinase (IC50 = 2.4 µM in A431 cells)
10010314	AG-213	50 mg	≥97%	An inhibitor of EGF receptor kinase (IC50 = 2.4 µM in A431 cells)

10010315	AG-183	10 mg	≥98%	An inhibitor of EGF receptor kinase (IC50 = 0.8 μM in A431 cells)
10010315	AG-183	25 mg	≥98%	An inhibitor of EGF receptor kinase (IC50 = 0.8 μM in A431 cells)
10010315	AG-183	5 mg	≥98%	An inhibitor of EGF receptor kinase (IC50 = 0.8 μM in A431 cells)
10010315	AG-183	50 mg	≥98%	An inhibitor of EGF receptor kinase (IC50 = 0.8 μM in A431 cells)
10010329	Lavendustin C	1 mg	≥98%	A potent tyrosine kinase inhibitor; inhibits EGF receptor-associated tyrosine kinase, pp60c-src(+) kinase, and Ca2+ calmodulin-dependent kinase II (IC50s = 0.012, 0.5, and 0.2 μM, respectively); inhibits tyrosine kinase-associated neutrophil degranulation and superoxide generation at 10-150 μM
10010329	Lavendustin C	10 mg	≥98%	A potent tyrosine kinase inhibitor; inhibits EGF receptor-associated tyrosine kinase, pp60c-src(+) kinase, and Ca2+ calmodulin-dependent kinase II (IC50s = 0.012, 0.5, and 0.2 μM, respectively); inhibits tyrosine kinase-associated neutrophil degranulation and superoxide generation at 10-150 μM
10010329	Lavendustin C	5 mg	≥98%	A potent tyrosine kinase inhibitor; inhibits EGF receptor-associated tyrosine kinase, pp60c-src(+) kinase, and Ca2+ calmodulin-dependent kinase II (IC50s = 0.012, 0.5, and 0.2 μM, respectively); inhibits tyrosine kinase-associated neutrophil degranulation and superoxide generation at 10-150 μM
10010329	Lavendustin C	50 mg	≥98%	A potent tyrosine kinase inhibitor; inhibits EGF receptor-associated tyrosine kinase, pp60c-src(+) kinase, and Ca2+ calmodulin-dependent kinase II (IC50s = 0.012, 0.5, and 0.2 μM, respectively); inhibits tyrosine kinase-associated neutrophil degranulation and superoxide generation at 10-150 μM
10010367	ZM 336372	1 mg	≥98%	A potent ATP-competitive inhibitor of Raf-1 in vitro (IC50 = 70 nM) with the paradoxical effect of inducing >100-fold activation of Raf-1 in whole cells; activates the Raf-1 signaling pathway in human carcinoid tumor cells resulting in suppression of cellular proliferation
10010367	ZM 336372	10 mg	≥98%	A potent ATP-competitive inhibitor of Raf-1 in vitro (IC50 = 70 nM) with the paradoxical effect of inducing >100-fold activation of Raf-1 in whole cells; activates the Raf-1 signaling pathway in human carcinoid tumor cells resulting in suppression of cellular proliferation
10010367	ZM 336372	25 mg	≥98%	A potent ATP-competitive inhibitor of Raf-1 in vitro (IC50 = 70 nM) with the paradoxical effect of inducing >100-fold activation of Raf-1 in whole cells; activates the Raf-1 signaling pathway in human carcinoid tumor cells resulting in suppression of cellular proliferation
10010367	ZM 336372	5 mg	≥98%	A potent ATP-competitive inhibitor of Raf-1 in vitro (IC50 = 70 nM) with the paradoxical effect of inducing >100-fold activation of Raf-1 in whole cells; activates the Raf-1 signaling pathway in human carcinoid tumor cells resulting in suppression of cellular proliferation
10010368	GW 5074	1 mg	≥98% (mixture	A potent, selective, and cell-permeable inhibitor of Raf-1 (IC50 = 9 nM); blocks phosphorylation of ERK1/2 by 90% in cells stimulated with EGF when given at 5 μM; shows more than 100-fold selectivity for Raf-1 versus several related kinases
10010368	GW 5074	10 mg	≥98% (mixture	A potent, selective, and cell-permeable inhibitor of Raf-1 (IC50 = 9 nM); blocks phosphorylation of ERK1/2 by 90% in cells stimulated with EGF when given at 5 μM; shows more than 100-fold selectivity for Raf-1 versus several related kinases
10010368	GW 5074	25 mg	≥98% (mixture	A potent, selective, and cell-permeable inhibitor of Raf-1 (IC50 = 9 nM); blocks phosphorylation of ERK1/2 by 90% in cells stimulated with EGF when given at 5 μM; shows more than 100-fold selectivity for Raf-1 versus several related kinases
10010368	GW 5074	5 mg	≥98% (mixture	A potent, selective, and cell-permeable inhibitor of Raf-1 (IC50 = 9 nM); blocks phosphorylation of ERK1/2 by 90% in cells stimulated with EGF when given at 5 μM; shows more than 100-fold selectivity for Raf-1 versus several related kinases
10010375	5-Iodotubercidin	1 mg	≥95%	Initiates glycogen synthesis in hepatocytes by causing inactivation of phosphorylase a and activation of glycogen synthase a (maximal effects with ~20 μM Itu); potent inhibitor of ERK2 (Ki = 525 nM)
10010375	5-Iodotubercidin	100 μg	≥95%	Initiates glycogen synthesis in hepatocytes by causing inactivation of phosphorylase a and activation of glycogen synthase a (maximal effects with ~20 μM Itu); potent inhibitor of ERK2 (Ki = 525 nM)
10010375	5-Iodotubercidin	250 μg	≥95%	Initiates glycogen synthesis in hepatocytes by causing inactivation of phosphorylase a and activation of glycogen synthase a (maximal effects with ~20 μM Itu); potent inhibitor of ERK2 (Ki = 525 nM)
10010375	5-Iodotubercidin	5 mg	≥95%	Initiates glycogen synthesis in hepatocytes by causing inactivation of phosphorylase a and activation of glycogen synthase a (maximal effects with ~20 μM Itu); potent inhibitor of ERK2 (Ki = 525 nM)
10010399	SB 202190	10 mg	≥98%	A selective, potent, cell-permeable inhibitor of p38 MAP kinases, inhibiting p38α (SAPK2A, MAPK14) and p38β (SAPK2B, MAPK11) with IC50 values of 50 and 100 nM, respectively; at 10 μM, has negligible effects on a range of other kinases, including other MAP kinases (ERKs, JNKs)
10010399	SB 202190	100 mg	≥98%	A selective, potent, cell-permeable inhibitor of p38 MAP kinases, inhibiting p38α (SAPK2A, MAPK14) and p38β (SAPK2B, MAPK11) with IC50 values of 50 and 100 nM, respectively; at 10 μM, has negligible effects on a range of other kinases, including other MAP kinases (ERKs, JNKs)
10010399	SB 202190	25 mg	≥98%	A selective, potent, cell-permeable inhibitor of p38 MAP kinases, inhibiting p38α (SAPK2A, MAPK14) and p38β (SAPK2B, MAPK11) with IC50 values of 50 and 100 nM, respectively; at 10 μM, has negligible effects on a range of other kinases, including other MAP kinases (ERKs, JNKs)

10010399	SB 202190	50 mg	≥98%	A selective, potent, cell-permeable inhibitor of p38 MAP kinases, inhibiting p38α (SAPK2A, MAPK14) and p38β (SAPK2B, MAPK11) with IC50 values of 50 and 100 nM, respectively; at 10 μM, has negligible effects on a range of other kinases, including other MAP kinases (ERKs, JNKs)
10010400	CAY10571	10 mg	≥95%	An analog of SB203580, the highly specific pyridinylimidazole inhibitor of p38 MAPK; inhibits IL-1 production in the human monocytic cell line THP (IC50 = 0.20 μM) and binds CSAID binding protein, a serine/threonine kinase homologous to p38, inhibiting its kinase activity (IC50 = 0.03 μM)
10010400	CAY10571	25 mg	≥95%	An analog of SB203580, the highly specific pyridinylimidazole inhibitor of p38 MAPK; inhibits IL-1 production in the human monocytic cell line THP (IC50 = 0.20 μM) and binds CSAID binding protein, a serine/threonine kinase homologous to p38, inhibiting its kinase activity (IC50 = 0.03 μM)
10010400	CAY10571	5 mg	≥95%	An analog of SB203580, the highly specific pyridinylimidazole inhibitor of p38 MAPK; inhibits IL-1 production in the human monocytic cell line THP (IC50 = 0.20 μM) and binds CSAID binding protein, a serine/threonine kinase homologous to p38, inhibiting its kinase activity (IC50 = 0.03 μM)
10010422	Nilotinib	10 mg	≥95%	A tyrosine kinase inhibitor that potently inhibits Bcr/Abl tyrosine kinase and is effective in the treatment of certain leukemias; ~20-fold more potent than imatinib in inhibiting Bcr/Abl (e.g., IC50 = 15 versus 280 nM, respectively)
10010422	Nilotinib	25 mg	≥95%	A tyrosine kinase inhibitor that potently inhibits Bcr/Abl tyrosine kinase and is effective in the treatment of certain leukemias; ~20-fold more potent than imatinib in inhibiting Bcr/Abl (e.g., IC50 = 15 versus 280 nM, respectively)
10010422	Nilotinib	5 mg	≥95%	A tyrosine kinase inhibitor that potently inhibits Bcr/Abl tyrosine kinase and is effective in the treatment of certain leukemias; ~20-fold more potent than imatinib in inhibiting Bcr/Abl (e.g., IC50 = 15 versus 280 nM, respectively)
10010422	Nilotinib	50 mg	≥95%	A tyrosine kinase inhibitor that potently inhibits Bcr/Abl tyrosine kinase and is effective in the treatment of certain leukemias; ~20-fold more potent than imatinib in inhibiting Bcr/Abl (e.g., IC50 = 15 versus 280 nM, respectively)
10010466	SP 600125	10 mg	≥98%	Reversible inhibitor of JNK1, 2, and 3 (IC50 = 0.11 μM); is cell-permeable and inhibits c-Jun phosphorylation in cells; blocks the expression of COX-2 and TNF-α in monocytes and IL-10, TNF-α, and IFN-γ in T-cells; prevents apoptosis in B-cells; inhibits autophagy in HeLa cells
10010466	SP 600125	25 mg	≥98%	Reversible inhibitor of JNK1, 2, and 3 (IC50 = 0.11 μM); is cell-permeable and inhibits c-Jun phosphorylation in cells; blocks the expression of COX-2 and TNF-α in monocytes and IL-10, TNF-α, and IFN-γ in T-cells; prevents apoptosis in B-cells; inhibits autophagy in HeLa cells
10010466	SP 600125	5 mg	≥98%	Reversible inhibitor of JNK1, 2, and 3 (IC50 = 0.11 μM); is cell-permeable and inhibits c-Jun phosphorylation in cells; blocks the expression of COX-2 and TNF-α in monocytes and IL-10, TNF-α, and IFN-γ in T-cells; prevents apoptosis in B-cells; inhibits autophagy in HeLa cells
10010466	SP 600125	50 mg	≥98%	Reversible inhibitor of JNK1, 2, and 3 (IC50 = 0.11 μM); is cell-permeable and inhibits c-Jun phosphorylation in cells; blocks the expression of COX-2 and TNF-α in monocytes and IL-10, TNF-α, and IFN-γ in T-cells; prevents apoptosis in B-cells; inhibits autophagy in HeLa cells
10010497	Manumycin A	1 mg	≥98%	A potent and selective farnesyltransferase (FTase) inhibitor with anti-tumor activity: inhibits rat brain FTase with a Ki value of 1.2 μM, thereby preventing Ras activation; inhibits IKK in an number of cells types
10010497	Manumycin A	5 mg	≥98%	A potent and selective farnesyltransferase (FTase) inhibitor with anti-tumor activity: inhibits rat brain FTase with a Ki value of 1.2 μM, thereby preventing Ras activation; inhibits IKK in an number of cells types
10010541	L-threo-Sphingosine (	10 mg	>98%	An analog of D-erythro-sphingosine; inhibits PKC in mixed micelle assays with 50% inhibition at 2.2 mol % making it a more potent inhibitor compared to D-erythro-sphingosine or other analogs of shorter alkyl chain length
10010541	L-threo-Sphingosine (	100 mg	>98%	An analog of D-erythro-sphingosine; inhibits PKC in mixed micelle assays with 50% inhibition at 2.2 mol % making it a more potent inhibitor compared to D-erythro-sphingosine or other analogs of shorter alkyl chain length
10010541	L-threo-Sphingosine (	5 mg	>98%	An analog of D-erythro-sphingosine; inhibits PKC in mixed micelle assays with 50% inhibition at 2.2 mol % making it a more potent inhibitor compared to D-erythro-sphingosine or other analogs of shorter alkyl chain length
10010541	L-threo-Sphingosine (	50 mg	>98%	An analog of D-erythro-sphingosine; inhibits PKC in mixed micelle assays with 50% inhibition at 2.2 mol % making it a more potent inhibitor compared to D-erythro-sphingosine or other analogs of shorter alkyl chain length
10010556	H-89 (hydrochloride)	10 mg	≥98%	A potent, non-selective inhibitor of PKA with an IC50 value of 0.14 μM (Ki = 48 nM) that is widely used to disrupt PKA signaling; inhibits S6K1, MSK1, ROCK2, PKBa, and MAPKAP-K1b with IC50 values of 0.08, 0.12, 0.27, 2.6, and 2.8 μM, respectively
10010556	H-89 (hydrochloride)	25 mg	≥98%	A potent, non-selective inhibitor of PKA with an IC50 value of 0.14 μM (Ki = 48 nM) that is widely used to disrupt PKA signaling; inhibits S6K1, MSK1, ROCK2, PKBa, and MAPKAP-K1b with IC50 values of 0.08, 0.12, 0.27, 2.6, and 2.8 μM, respectively
10010556	H-89 (hydrochloride)	5 mg	≥98%	A potent, non-selective inhibitor of PKA with an IC50 value of 0.14 μM (Ki = 48 nM) that is widely used to disrupt PKA signaling; inhibits S6K1, MSK1, ROCK2, PKBa, and MAPKAP-K1b with IC50 values of 0.08, 0.12, 0.27, 2.6, and 2.8 μM, respectively

10010556	H-89 (hydrochloride)	50 mg	≥98%	A potent, non-selective inhibitor of PKA with an IC50 value of 0.14 µM (Ki = 48 nM) that is widely used to disrupt PKA signaling; inhibits S6K1, MSK1, ROCK2, PKBa, and MAPKAP-K1b with IC50 values of 0.08, 0.12, 0.27, 2.6, and 2.8 µM, respectively
10010558	HA-1004 (hydrochlori	10 mg	≥98%	An inhibitor of PKG and PKA (Kis = 1.4 and 2.3 µM, respectively); induces relaxation of isolated rabbit aortic strips precontracted with a variety of agonists (EC50s = 0.32-0.63 µM), as well as phenylephrine with or without calcium (EC50s = 2.3 and 0.5 µM, respectively); inhibits histamine-induced bronchoconstriction in guinea pigs without affecting blood pressure at 0.1 mg per animal
10010558	HA-1004 (hydrochlori	5 mg	≥98%	An inhibitor of PKG and PKA (Kis = 1.4 and 2.3 µM, respectively); induces relaxation of isolated rabbit aortic strips precontracted with a variety of agonists (EC50s = 0.32-0.63 µM), as well as phenylephrine with or without calcium (EC50s = 2.3 and 0.5 µM, respectively); inhibits histamine-induced bronchoconstriction in guinea pigs without affecting blood pressure at 0.1 mg per animal
10010559	HA-1077 (hydrochlori	10 mg	≥98%	A potent inhibitor of ROCK2, PRK-2, MSK1, and MAPKAP-K1b with IC50 values of 1.9, 4, 5, and 15 µM, respectively; has been shown to reduce blood vessel constriction, decreases pulmonary arterial pressure, inhibit tumor angiogenesis, and improve insulin signaling in a diabetic rat model; drug forms are marketed for the treatment of pulmonary arterial hypertension and stable angina
10010559	HA-1077 (hydrochlori	100 mg	≥98%	A potent inhibitor of ROCK2, PRK-2, MSK1, and MAPKAP-K1b with IC50 values of 1.9, 4, 5, and 15 µM, respectively; has been shown to reduce blood vessel constriction, decreases pulmonary arterial pressure, inhibit tumor angiogenesis, and improve insulin signaling in a diabetic rat model; drug forms are marketed for the treatment of pulmonary arterial hypertension and stable angina
10010559	HA-1077 (hydrochlori	50 mg	≥98%	A potent inhibitor of ROCK2, PRK-2, MSK1, and MAPKAP-K1b with IC50 values of 1.9, 4, 5, and 15 µM, respectively; has been shown to reduce blood vessel constriction, decreases pulmonary arterial pressure, inhibit tumor angiogenesis, and improve insulin signaling in a diabetic rat model; drug forms are marketed for the treatment of pulmonary arterial hypertension and stable angina
10010568	AG-370	1 mg	≥95% (cis/tran	A selective inhibitor of PDGF receptor kinase with an IC50 value of20 µM in human bone marrow; inhibits the EGF receptor with an IC50 value of 820 µM
10010568	AG-370	10 mg	≥95% (cis/tran	A selective inhibitor of PDGF receptor kinase with an IC50 value of20 µM in human bone marrow; inhibits the EGF receptor with an IC50 value of 820 µM
10010568	AG-370	25 mg	≥95% (cis/tran	A selective inhibitor of PDGF receptor kinase with an IC50 value of20 µM in human bone marrow; inhibits the EGF receptor with an IC50 value of 820 µM
10010568	AG-370	5 mg	≥95% (cis/tran	A selective inhibitor of PDGF receptor kinase with an IC50 value of20 µM in human bone marrow; inhibits the EGF receptor with an IC50 value of 820 µM
10010591	Wortmannin	1 mg	≥98%	An irreversible PI3K inhibitor (IC50 = 1-10 nM); inhibits Drosophila, murine, and human class II PI3Ks (IC50s = 5, 50, 450 nM, respectively); ~50-100-fold selective for PI3Ks over mTOR, DNA-PK, PI4K, MLCK, and p38 MAPK; inhibits polo-like kinase 1 (IC50 = 24 nM) and polo-like kinase 3 (IC50 = 49 nM)
10010591	Wortmannin	10 mg	≥98%	An irreversible PI3K inhibitor (IC50 = 1-10 nM); inhibits Drosophila, murine, and human class II PI3Ks (IC50s = 5, 50, 450 nM, respectively); ~50-100-fold selective for PI3Ks over mTOR, DNA-PK, PI4K, MLCK, and p38 MAPK; inhibits polo-like kinase 1 (IC50 = 24 nM) and polo-like kinase 3 (IC50 = 49 nM)
10010591	Wortmannin	5 mg	≥98%	An irreversible PI3K inhibitor (IC50 = 1-10 nM); inhibits Drosophila, murine, and human class II PI3Ks (IC50s = 5, 50, 450 nM, respectively); ~50-100-fold selective for PI3Ks over mTOR, DNA-PK, PI4K, MLCK, and p38 MAPK; inhibits polo-like kinase 1 (IC50 = 24 nM) and polo-like kinase 3 (IC50 = 49 nM)
10010592	AG-1296	1 mg	>98%	An inhibitor of PDGF receptor kinase (IC50 = ~0.4 µM in Swiss 3T3 cells); inhibits ligand-stimulated DNA synthesis in platelet-derived growth factor receptor and stem cell factor/kit receptor transfected cells (IC50s = 1.5 and 1.8 µM, respectively); reverses the transformed phenotype of sis oncogene transfected NIH3T3 cells
10010592	AG-1296	10 mg	>98%	An inhibitor of PDGF receptor kinase (IC50 = ~0.4 µM in Swiss 3T3 cells); inhibits ligand-stimulated DNA synthesis in platelet-derived growth factor receptor and stem cell factor/kit receptor transfected cells (IC50s = 1.5 and 1.8 µM, respectively); reverses the transformed phenotype of sis oncogene transfected NIH3T3 cells
10010592	AG-1296	25 mg	>98%	An inhibitor of PDGF receptor kinase (IC50 = ~0.4 µM in Swiss 3T3 cells); inhibits ligand-stimulated DNA synthesis in platelet-derived growth factor receptor and stem cell factor/kit receptor transfected cells (IC50s = 1.5 and 1.8 µM, respectively); reverses the transformed phenotype of sis oncogene transfected NIH3T3 cells

10010592	AG-1296	5 mg	>98%	An inhibitor of PDGF receptor kinase (IC50 = ~0.4 µM in Swiss 3T3 cells); inhibits ligand-stimulated DNA synthesis in platelet-derived growth factor receptor and stem cell factor/kit receptor transfected cells (IC50s = 1.5 and 1.8 µM, respectively); reverses the transformed phenotype of sis oncogene transfected NIH3T3 cells
10010749	PIK-90	1 mg	≥98%	A potent, cell permeable PI3K inhibitor (IC50 = 11, 350, 18, and 58 nM for p110 subunit isoforms α, β, γ, and δ, respectively); reduces chemotaxis and induces apoptosis in chronic lymphocytic leukemia B cells; blocks proliferation of glioma cells in vitro; blocks insulin-stimulated phosphorylation of Akt in L1 adipocytes and L6 myotubes; prevents activation of the mTORC1 pathway
10010749	PIK-90	10 mg	≥98%	A potent, cell permeable PI3K inhibitor (IC50 = 11, 350, 18, and 58 nM for p110 subunit isoforms α, β, γ, and δ, respectively); reduces chemotaxis and induces apoptosis in chronic lymphocytic leukemia B cells; blocks proliferation of glioma cells in vitro; blocks insulin-stimulated phosphorylation of Akt in L1 adipocytes and L6 myotubes; prevents activation of the mTORC1 pathway
10010749	PIK-90	5 mg	≥98%	A potent, cell permeable PI3K inhibitor (IC50 = 11, 350, 18, and 58 nM for p110 subunit isoforms α, β, γ, and δ, respectively); reduces chemotaxis and induces apoptosis in chronic lymphocytic leukemia B cells; blocks proliferation of glioma cells in vitro; blocks insulin-stimulated phosphorylation of Akt in L1 adipocytes and L6 myotubes; prevents activation of the mTORC1 pathway
10010965	KT 5823	100 µg	≥95%	A potent, selective inhibitor of PKG (in vitro IC50 = 234 nM); cell-permeable and often used in intact cells to assess the role of PKG in signaling
10010965	KT 5823	25 µg	≥95%	A potent, selective inhibitor of PKG (in vitro IC50 = 234 nM); cell-permeable and often used in intact cells to assess the role of PKG in signaling
10010965	KT 5823	50 µg	≥95%	A potent, selective inhibitor of PKG (in vitro IC50 = 234 nM); cell-permeable and often used in intact cells to assess the role of PKG in signaling
10010965	KT 5823	500 µg	≥95%	A potent, selective inhibitor of PKG (in vitro IC50 = 234 nM); cell-permeable and often used in intact cells to assess the role of PKG in signaling
10011011	KT 5720	100 µg	≥98%	A potent inhibitor of PKA; blocks PKA signaling through competitive inhibition of ATP (Ki = 60 nM); inhibits phosphorylase kinase, PDK1, MEK, MSK1, PKBα, and GSK3β
10011011	KT 5720	250 µg	≥98%	A potent inhibitor of PKA; blocks PKA signaling through competitive inhibition of ATP (Ki = 60 nM); inhibits phosphorylase kinase, PDK1, MEK, MSK1, PKBα, and GSK3β
10011011	KT 5720	50 µg	≥98%	A potent inhibitor of PKA; blocks PKA signaling through competitive inhibition of ATP (Ki = 60 nM); inhibits phosphorylase kinase, PDK1, MEK, MSK1, PKBα, and GSK3β
10011011	KT 5720	500 µg	≥98%	A potent inhibitor of PKA; blocks PKA signaling through competitive inhibition of ATP (Ki = 60 nM); inhibits phosphorylase kinase, PDK1, MEK, MSK1, PKBα, and GSK3β
10011056	3-O-methyl-N-acetyl-D	1 mg	≥95%	An inhibitor of N-acetylglucosamine and N-acetylmannosamine (Kis = 17 and 80 µM in rat liver in vitro)
10011056	3-O-methyl-N-acetyl-D	10 mg	≥95%	An inhibitor of N-acetylglucosamine and N-acetylmannosamine (Kis = 17 and 80 µM in rat liver in vitro)
10011056	3-O-methyl-N-acetyl-D	5 mg	≥95%	An inhibitor of N-acetylglucosamine and N-acetylmannosamine (Kis = 17 and 80 µM in rat liver in vitro)
10011246	WHI-P131	1 mg	≥98%	A selective inhibitor of JAK3 with an IC50 value of 78 µM that does not affect the enzymatic activity of JAK1, JAK2, or other protein tyrosine kinases (IC50 ≥350 µM); induces apoptosis in JAK3-expressing human leukemia cell lines NALM-6 and LC1;19, but not in melanoma or squamous carcinoma cell lines
10011246	WHI-P131	10 mg	≥98%	A selective inhibitor of JAK3 with an IC50 value of 78 µM that does not affect the enzymatic activity of JAK1, JAK2, or other protein tyrosine kinases (IC50 ≥350 µM); induces apoptosis in JAK3-expressing human leukemia cell lines NALM-6 and LC1;19, but not in melanoma or squamous carcinoma cell lines
10011246	WHI-P131	25 mg	≥98%	A selective inhibitor of JAK3 with an IC50 value of 78 µM that does not affect the enzymatic activity of JAK1, JAK2, or other protein tyrosine kinases (IC50 ≥350 µM); induces apoptosis in JAK3-expressing human leukemia cell lines NALM-6 and LC1;19, but not in melanoma or squamous carcinoma cell lines
10011246	WHI-P131	5 mg	≥98%	A selective inhibitor of JAK3 with an IC50 value of 78 µM that does not affect the enzymatic activity of JAK1, JAK2, or other protein tyrosine kinases (IC50 ≥350 µM); induces apoptosis in JAK3-expressing human leukemia cell lines NALM-6 and LC1;19, but not in melanoma or squamous carcinoma cell lines
10011247	CAY10574	1 mg	≥95%	A potent, selective inhibitor of Cdk9 in vitro (IC50 = 0.35 µM); a competitive inhibitor of Cdk2-cyclin E with respect to ATP, with Ki and IC50 values of 13.3 and 20 µM, respectively
10011247	CAY10574	10 mg	≥95%	A potent, selective inhibitor of Cdk9 in vitro (IC50 = 0.35 µM); a competitive inhibitor of Cdk2-cyclin E with respect to ATP, with Ki and IC50 values of 13.3 and 20 µM, respectively

10011247	CAY10574	5 mg	≥95%	A potent, selective inhibitor of Cdk9 in vitro (IC50 = 0.35 μM); a competitive inhibitor of Cdk2-cyclin E with respect to ATP, with Ki and IC50 values of 13.3 and 20 μM, respectively
10011247	CAY10574	50 mg	≥95%	A potent, selective inhibitor of Cdk9 in vitro (IC50 = 0.35 μM); a competitive inhibitor of Cdk2-cyclin E with respect to ATP, with Ki and IC50 values of 13.3 and 20 μM, respectively
10011248	CAY10575	1 mg	≥95%	An inhibitor of IKKε (IC50 = ~15.8 μM)
10011248	CAY10575	10 mg	≥95%	An inhibitor of IKKε (IC50 = ~15.8 μM)
10011248	CAY10575	25 mg	≥95%	An inhibitor of IKKε (IC50 = ~15.8 μM)
10011248	CAY10575	5 mg	≥95%	An inhibitor of IKKε (IC50 = ~15.8 μM)
10011249	CAY10576	1 mg	≥95%	A potent and selective inhibitor of IKKε (IC50 = 40 nM); inactive against IKKα and IKKβ
10011249	CAY10576	10 mg	≥95%	A potent and selective inhibitor of IKKε (IC50 = 40 nM); inactive against IKKα and IKKβ
10011249	CAY10576	5 mg	≥95%	A potent and selective inhibitor of IKKε (IC50 = 40 nM); inactive against IKKα and IKKβ
10011249	CAY10576	50 mg	≥95%	A potent and selective inhibitor of IKKε (IC50 = 40 nM); inactive against IKKα and IKKβ
10011250	NH125	1 mg	≥95%	An imidazole that has potent antibacterial properties in drug-resistant bacteria; in bacteria, inhibits several histidine kinases, inhibiting YycG with IC50 values ranging from 0.7-4.7 μM; decreases viability of several cancer cell lines with IC50 values ranging from 0.7-4.7 μM
10011250	NH125	10 mg	≥95%	An imidazole that has potent antibacterial properties in drug-resistant bacteria; in bacteria, inhibits several histidine kinases, inhibiting YycG with IC50 values ranging from 0.7-4.7 μM; decreases viability of several cancer cell lines with IC50 values ranging from 0.7-4.7 μM
10011250	NH125	25 mg	≥95%	An imidazole that has potent antibacterial properties in drug-resistant bacteria; in bacteria, inhibits several histidine kinases, inhibiting YycG with IC50 values ranging from 0.7-4.7 μM; decreases viability of several cancer cell lines with IC50 values ranging from 0.7-4.7 μM
10011250	NH125	5 mg	≥95%	An imidazole that has potent antibacterial properties in drug-resistant bacteria; in bacteria, inhibits several histidine kinases, inhibiting YycG with IC50 values ranging from 0.7-4.7 μM; decreases viability of several cancer cell lines with IC50 values ranging from 0.7-4.7 μM
10011251	TWS119	1 mg	≥90%	A GSK3β inhibitor (IC50 = 30 nM); induces neurogenesis in mouse embryonic stem cells 400 nM
10011251	TWS119	10 mg	≥90%	A GSK3β inhibitor (IC50 = 30 nM); induces neurogenesis in mouse embryonic stem cells 400 nM
10011251	TWS119	25 mg	≥90%	A GSK3β inhibitor (IC50 = 30 nM); induces neurogenesis in mouse embryonic stem cells 400 nM
10011251	TWS119	5 mg	≥90%	A GSK3β inhibitor (IC50 = 30 nM); induces neurogenesis in mouse embryonic stem cells 400 nM
10011255	NSC 210902	1 mg	≥95%	A selective CK2 inhibitor (IC50 = 1 μM); selective for CK2 over JNK3, GSK3, Cdk5, and MSK1; competitively inhibits binding of ATP (Ki = 0.28 μM)
10011255	NSC 210902	10 mg	≥95%	A selective CK2 inhibitor (IC50 = 1 μM); selective for CK2 over JNK3, GSK3, Cdk5, and MSK1; competitively inhibits binding of ATP (Ki = 0.28 μM)
10011255	NSC 210902	5 mg	≥95%	A selective CK2 inhibitor (IC50 = 1 μM); selective for CK2 over JNK3, GSK3, Cdk5, and MSK1; competitively inhibits binding of ATP (Ki = 0.28 μM)
10011255	NSC 210902	50 mg	≥95%	A selective CK2 inhibitor (IC50 = 1 μM); selective for CK2 over JNK3, GSK3, Cdk5, and MSK1; competitively inhibits binding of ATP (Ki = 0.28 μM)
10011256	CAY10577	1 mg	≥95%	A CK2 inhibitor (IC50 = 0.8 μM)
10011256	CAY10577	10 mg	≥95%	A CK2 inhibitor (IC50 = 0.8 μM)
10011256	CAY10577	5 mg	≥95%	A CK2 inhibitor (IC50 = 0.8 μM)
10011256	CAY10577	50 mg	≥95%	A CK2 inhibitor (IC50 = 0.8 μM)
10011264	CAY10578	1 mg	≥95%	A potent and selective CK2 inhibitor (IC50 = 0.3 μM); selective for CK2 over GSK3, Cdk5, and MSK1; is ATP competitive (Ki = 0.2 μM)
10011264	CAY10578	10 mg	≥95%	A potent and selective CK2 inhibitor (IC50 = 0.3 μM); selective for CK2 over GSK3, Cdk5, and MSK1; is ATP competitive (Ki = 0.2 μM)
10011264	CAY10578	25 mg	≥95%	A potent and selective CK2 inhibitor (IC50 = 0.3 μM); selective for CK2 over GSK3, Cdk5, and MSK1; is ATP competitive (Ki = 0.2 μM)
10011264	CAY10578	5 mg	≥95%	A potent and selective CK2 inhibitor (IC50 = 0.3 μM); selective for CK2 over GSK3, Cdk5, and MSK1; is ATP competitive (Ki = 0.2 μM)
10012431	PD 184161	1 mg	≥98%	A potent MEK1/2 inhibitor (IC50 = 10-100 nM); more effective at inhibiting phosphorylation of ERK1/2 than PD 098059 and U0126; inhibits proliferation, induces apoptosis, and possesses antitumor activity in MEK-dependent cancers
10012431	PD 184161	10 mg	≥98%	A potent MEK1/2 inhibitor (IC50 = 10-100 nM); more effective at inhibiting phosphorylation of ERK1/2 than PD 098059 and U0126; inhibits proliferation, induces apoptosis, and possesses antitumor activity in MEK-dependent cancers
10012431	PD 184161	25 mg	≥98%	A potent MEK1/2 inhibitor (IC50 = 10-100 nM); more effective at inhibiting phosphorylation of ERK1/2 than PD 098059 and U0126; inhibits proliferation, induces apoptosis, and possesses antitumor activity in MEK-dependent cancers

10012431	PD 184161	5 mg	≥98%	A potent MEK1/2 inhibitor (IC50 = 10-100 nM); more effective at inhibiting phosphorylation of ERK1/2 than PD 098059 and U0126; inhibits proliferation, induces apoptosis, and possesses antitumor activity in MEK-dependent cancers
10012600	Myricetin	10 mg	≥98%	A flavonoid compound that acts as a powerful antioxidant; inhibits TBARS formation with an IC50 value of 6.34 µM; blocks oxLDL uptake by U937-derived macrophages at 20 µM; demonstrates potent chemopreventative potential by binding JAK1/STAT3 to inhibit neoplastic transformation of murine JB6 Pt cells
10012600	Myricetin	100 mg	≥98%	A flavonoid compound that acts as a powerful antioxidant; inhibits TBARS formation with an IC50 value of 6.34 µM; blocks oxLDL uptake by U937-derived macrophages at 20 µM; demonstrates potent chemopreventative potential by binding JAK1/STAT3 to inhibit neoplastic transformation of murine JB6 Pt cells
10012600	Myricetin	25 mg	≥98%	A flavonoid compound that acts as a powerful antioxidant; inhibits TBARS formation with an IC50 value of 6.34 µM; blocks oxLDL uptake by U937-derived macrophages at 20 µM; demonstrates potent chemopreventative potential by binding JAK1/STAT3 to inhibit neoplastic transformation of murine JB6 Pt cells
10012600	Myricetin	50 mg	≥98%	A flavonoid compound that acts as a powerful antioxidant; inhibits TBARS formation with an IC50 value of 6.34 µM; blocks oxLDL uptake by U937-derived macrophages at 20 µM; demonstrates potent chemopreventative potential by binding JAK1/STAT3 to inhibit neoplastic transformation of murine JB6 Pt cells
10012605	Hispidin	1 mg	≥95%	A polyphenol with diverse biological activities; scavenges radicals at 14.47 equivalents of trolox in a TEAC assay; inhibits transcriptional activity of NF-κB, decreases iNOS expression, and decreases generation of ROS in LPS-induced macrophage RAW 264.7 cells; inhibits apoptosis and increases insulin secretion in hydrogen peroxide-treated RINm5F pancreatic β-cells.; inhibits PKCβ (IC50 = 2 µM); inhibits BACE1 (IC50 = 4.9 µM) and PE (IC50 = 16 µM) but not other serine proteases when used at a concentration of 40 µM (0.6, 0, 8.2, and 3.1% inhibition of chymotrypsin, trypsin, elastase, and TACE, respectively)
10012605	Hispidin	5 mg	≥95%	A polyphenol with diverse biological activities; scavenges radicals at 14.47 equivalents of trolox in a TEAC assay; inhibits transcriptional activity of NF-κB, decreases iNOS expression, and decreases generation of ROS in LPS-induced macrophage RAW 264.7 cells; inhibits apoptosis and increases insulin secretion in hydrogen peroxide-treated RINm5F pancreatic β-cells.; inhibits PKCβ (IC50 = 2 µM); inhibits BACE1 (IC50 = 4.9 µM) and PE (IC50 = 16 µM) but not other serine proteases when used at a concentration of 40 µM (0.6, 0, 8.2, and 3.1% inhibition of chymotrypsin, trypsin, elastase, and TACE, respectively)
10398	TG003	1 mg	≥95%	A novel benzothiazole compound that inhibits Clk1/Sty and Clk4 (IC50 = 20 and 15 nM, respectively); at 1 µM, suppresses Clk-mediated phosphorylation which inhibits SF2/ASF-dependent splicing of β-globin pre-mRNA in vitro
10398	TG003	10 mg	≥95%	A novel benzothiazole compound that inhibits Clk1/Sty and Clk4 (IC50 = 20 and 15 nM, respectively); at 1 µM, suppresses Clk-mediated phosphorylation which inhibits SF2/ASF-dependent splicing of β-globin pre-mRNA in vitro
10398	TG003	25 mg	≥95%	A novel benzothiazole compound that inhibits Clk1/Sty and Clk4 (IC50 = 20 and 15 nM, respectively); at 1 µM, suppresses Clk-mediated phosphorylation which inhibits SF2/ASF-dependent splicing of β-globin pre-mRNA in vitro
10398	TG003	5 mg	≥95%	A novel benzothiazole compound that inhibits Clk1/Sty and Clk4 (IC50 = 20 and 15 nM, respectively); at 1 µM, suppresses Clk-mediated phosphorylation which inhibits SF2/ASF-dependent splicing of β-globin pre-mRNA in vitro
10459	PKC 412	1 mg	≥98%	A cell-permeable, reversible inhibitor of several kinases, including PKCα, PKCβ, PKCγ, Syk, FLK1, Akt,PKA, c-Kit, C-Fgr, c-Src, FLT3, PDFRβ, VEGFR1, and VEGF2, with IC50 values ranging from 80-500 nM
10459	PKC 412	10 mg	≥98%	A cell-permeable, reversible inhibitor of several kinases, including PKCα, PKCβ, PKCγ, Syk, FLK1, Akt,PKA, c-Kit, C-Fgr, c-Src, FLT3, PDFRβ, VEGFR1, and VEGF2, with IC50 values ranging from 80-500 nM
10459	PKC 412	25 mg	≥98%	A cell-permeable, reversible inhibitor of several kinases, including PKCα, PKCβ, PKCγ, Syk, FLK1, Akt,PKA, c-Kit, C-Fgr, c-Src, FLT3, PDFRβ, VEGFR1, and VEGF2, with IC50 values ranging from 80-500 nM
10459	PKC 412	5 mg	≥98%	A cell-permeable, reversible inhibitor of several kinases, including PKCα, PKCβ, PKCγ, Syk, FLK1, Akt,PKA, c-Kit, C-Fgr, c-Src, FLT3, PDFRβ, VEGFR1, and VEGF2, with IC50 values ranging from 80-500 nM
10460	Doramapimod	1 mg	≥98%	A highly potent inhibitor of p38 MAPK (Kd = 0.1 nM) that blocks TNFα release in LPS-stimulated THP-1 cells with an IC50 value of 18 nM; At 10 µM, inhibits JNK2α2 in vitro

10460	Doramapimod	10 mg	≥98%	A highly potent inhibitor of p38 MAPK (Kd = 0.1 nM) that blocks TNFα release in LPS-stimulated THP-1 cells with an IC50 value of 18 nM; At 10 μM, inhibits JNK2α2 in vitro
10460	Doramapimod	25 mg	≥98%	A highly potent inhibitor of p38 MAPK (Kd = 0.1 nM) that blocks TNFα release in LPS-stimulated THP-1 cells with an IC50 value of 18 nM; At 10 μM, inhibits JNK2α2 in vitro
10460	Doramapimod	5 mg	≥98%	A highly potent inhibitor of p38 MAPK (Kd = 0.1 nM) that blocks TNFα release in LPS-stimulated THP-1 cells with an IC50 value of 18 nM; At 10 μM, inhibits JNK2α2 in vitro
10483	Erlotinib	1 g	≥98%	A tyrosine kinase inhibitor which inhibits EGFR-associated kinase activity (IC50 = 2.5 μM) and tumor growth in human HN5 tumor xenografts in mice with an ED50 value of 9 mg/kg; suppresses cyclin-dependent kinase 2 (Cdk2) activity in breast cancer cells (IC50 = 4.6 μM) and JAK2 mutant JAK2V617F positive hematopoietic progenitor cells (IC50 = 5 μM)
10483	Erlotinib	250 mg	≥98%	A tyrosine kinase inhibitor which inhibits EGFR-associated kinase activity (IC50 = 2.5 μM) and tumor growth in human HN5 tumor xenografts in mice with an ED50 value of 9 mg/kg; suppresses cyclin-dependent kinase 2 (Cdk2) activity in breast cancer cells (IC50 = 4.6 μM) and JAK2 mutant JAK2V617F positive hematopoietic progenitor cells (IC50 = 5 μM)
10483	Erlotinib	5 g	≥98%	A tyrosine kinase inhibitor which inhibits EGFR-associated kinase activity (IC50 = 2.5 μM) and tumor growth in human HN5 tumor xenografts in mice with an ED50 value of 9 mg/kg; suppresses cyclin-dependent kinase 2 (Cdk2) activity in breast cancer cells (IC50 = 4.6 μM) and JAK2 mutant JAK2V617F positive hematopoietic progenitor cells (IC50 = 5 μM)
10483	Erlotinib	500 mg	≥98%	A tyrosine kinase inhibitor which inhibits EGFR-associated kinase activity (IC50 = 2.5 μM) and tumor growth in human HN5 tumor xenografts in mice with an ED50 value of 9 mg/kg; suppresses cyclin-dependent kinase 2 (Cdk2) activity in breast cancer cells (IC50 = 4.6 μM) and JAK2 mutant JAK2V617F positive hematopoietic progenitor cells (IC50 = 5 μM)
10527	Necrostatin-5	25 mg	≥98%	A RIP1 kinase inhibitor; inhibits phosphorylation of RIP1 in Jurkat cells at 10 and 30 μM; inhibits TNF-α-induced necroptosis in FADD-deficient Jurkat cells (EC50 = 0.24 μM); reduces LDH release in S. marcescens-infected MH-S macrophages; improves survival in a mouse model of S. marcescens-induced pneumonia at 100 μM, i.p.
10527	Necrostatin-5	5 mg	≥98%	A RIP1 kinase inhibitor; inhibits phosphorylation of RIP1 in Jurkat cells at 10 and 30 μM; inhibits TNF-α-induced necroptosis in FADD-deficient Jurkat cells (EC50 = 0.24 μM); reduces LDH release in S. marcescens-infected MH-S macrophages; improves survival in a mouse model of S. marcescens-induced pneumonia at 100 μM, i.p.
10543	MK-8669	1 mg	≥95%	A rapamycin analog that selectively inhibits mTOR (IC50 = 0.2 nM); binds FKBP12 to form a complex that associates with the FKBP-rapamycin binding domain on mTOR and allosterically inhibits mTORC1 kinase activity
10543	MK-8669	10 mg	≥95%	A rapamycin analog that selectively inhibits mTOR (IC50 = 0.2 nM); binds FKBP12 to form a complex that associates with the FKBP-rapamycin binding domain on mTOR and allosterically inhibits mTORC1 kinase activity
10543	MK-8669	5 mg	≥95%	A rapamycin analog that selectively inhibits mTOR (IC50 = 0.2 nM); binds FKBP12 to form a complex that associates with the FKBP-rapamycin binding domain on mTOR and allosterically inhibits mTORC1 kinase activity
10565	NVP-BEZ235	100 mg	≥98%	A dual inhibitor of class I PI3Ks and mTOR (IC50s = 4, 75, 7, and 5 nM, for p110α, - β, -δ, and -γ, respectively) and mTOR (IC50 = 20 nM); selective for these enzymes over a panel of kinases (IC50s = >10 μM for all); inhibits proliferation of, and induces apoptosis in, MCF-7, MDA-MB-468, SK-BR-3, and MDA-MB-361 breast cancer cells at 0.1 or 1 μM; reduces tumor growth in a U87MG mouse xenograft model at 25, 35, or 45 mg/kg
10565	NVP-BEZ235	25 mg	≥98%	A dual inhibitor of class I PI3Ks and mTOR (IC50s = 4, 75, 7, and 5 nM, for p110α, - β, -δ, and -γ, respectively) and mTOR (IC50 = 20 nM); selective for these enzymes over a panel of kinases (IC50s = >10 μM for all); inhibits proliferation of, and induces apoptosis in, MCF-7, MDA-MB-468, SK-BR-3, and MDA-MB-361 breast cancer cells at 0.1 or 1 μM; reduces tumor growth in a U87MG mouse xenograft model at 25, 35, or 45 mg/kg
10565	NVP-BEZ235	250 mg	≥98%	A dual inhibitor of class I PI3Ks and mTOR (IC50s = 4, 75, 7, and 5 nM, for p110α, - β, -δ, and -γ, respectively) and mTOR (IC50 = 20 nM); selective for these enzymes over a panel of kinases (IC50s = >10 μM for all); inhibits proliferation of, and induces apoptosis in, MCF-7, MDA-MB-468, SK-BR-3, and MDA-MB-361 breast cancer cells at 0.1 or 1 μM; reduces tumor growth in a U87MG mouse xenograft model at 25, 35, or 45 mg/kg
10565	NVP-BEZ235	50 mg	≥98%	A dual inhibitor of class I PI3Ks and mTOR (IC50s = 4, 75, 7, and 5 nM, for p110α, - β, -δ, and -γ, respectively) and mTOR (IC50 = 20 nM); selective for these enzymes over a panel of kinases (IC50s = >10 μM for all); inhibits proliferation of, and induces apoptosis in, MCF-7, MDA-MB-468, SK-BR-3, and MDA-MB-361 breast cancer cells at 0.1 or 1 μM; reduces tumor growth in a U87MG mouse xenograft model at 25, 35, or 45 mg/kg

10587	ABC294640	1 mg	≥98%	An inhibitor of SPHK2 (Ki = 9.8 µM); inhibits SPHK2 (IC50 = 60 µM) without affecting SPHK1 activity up to 100 µM but does reduce SPHK1a protein levels in cells via an SPHK1-indirect proteasomal-dependent mechanism at 5-25 µM; inactive against a panel of 20 lipid-regulated kinases at 50 µM; inhibits proliferation of a variety of human cancer cell lines (IC50s = 6, 12.2, 32.8, and 48.1 µM, respectively); reduces tumor growth in a mouse syngeneic model of mammary adenocarcinoma at 35 and 100 mg/kg every other day; reduces colonic inflammation in mouse and rat models of Crohn's disease
10587	ABC294640	10 mg	≥98%	An inhibitor of SPHK2 (Ki = 9.8 µM); inhibits SPHK2 (IC50 = 60 µM) without affecting SPHK1 activity up to 100 µM but does reduce SPHK1a protein levels in cells via an SPHK1-indirect proteasomal-dependent mechanism at 5-25 µM; inactive against a panel of 20 lipid-regulated kinases at 50 µM; inhibits proliferation of a variety of human cancer cell lines (IC50s = 6, 12.2, 32.8, and 48.1 µM, respectively); reduces tumor growth in a mouse syngeneic model of mammary adenocarcinoma at 35 and 100 mg/kg every other day; reduces colonic inflammation in mouse and rat models of Crohn's disease
10587	ABC294640	25 mg	≥98%	An inhibitor of SPHK2 (Ki = 9.8 µM); inhibits SPHK2 (IC50 = 60 µM) without affecting SPHK1 activity up to 100 µM but does reduce SPHK1a protein levels in cells via an SPHK1-indirect proteasomal-dependent mechanism at 5-25 µM; inactive against a panel of 20 lipid-regulated kinases at 50 µM; inhibits proliferation of a variety of human cancer cell lines (IC50s = 6, 12.2, 32.8, and 48.1 µM, respectively); reduces tumor growth in a mouse syngeneic model of mammary adenocarcinoma at 35 and 100 mg/kg every other day; reduces colonic inflammation in mouse and rat models of Crohn's disease
10587	ABC294640	5 mg	≥98%	An inhibitor of SPHK2 (Ki = 9.8 µM); inhibits SPHK2 (IC50 = 60 µM) without affecting SPHK1 activity up to 100 µM but does reduce SPHK1a protein levels in cells via an SPHK1-indirect proteasomal-dependent mechanism at 5-25 µM; inactive against a panel of 20 lipid-regulated kinases at 50 µM; inhibits proliferation of a variety of human cancer cell lines (IC50s = 6, 12.2, 32.8, and 48.1 µM, respectively); reduces tumor growth in a mouse syngeneic model of mammary adenocarcinoma at 35 and 100 mg/kg every other day; reduces colonic inflammation in mouse and rat models of Crohn's disease
10618	PLX4032	10 mg	≥98%	An orally bioavailable, ATP-competitive inhibitor of mutant V600E and wild type B-Raf kinases (IC50s = 31 and 100 nM, respectively); inhibits cell proliferation in a variety of cell lines expressing B-RafV600E and is effective against the growth of tumors bearing the B-RafV600E mutation
10618	PLX4032	25 mg	≥98%	An orally bioavailable, ATP-competitive inhibitor of mutant V600E and wild type B-Raf kinases (IC50s = 31 and 100 nM, respectively); inhibits cell proliferation in a variety of cell lines expressing B-RafV600E and is effective against the growth of tumors bearing the B-RafV600E mutation
10618	PLX4032	5 mg	≥98%	An orally bioavailable, ATP-competitive inhibitor of mutant V600E and wild type B-Raf kinases (IC50s = 31 and 100 nM, respectively); inhibits cell proliferation in a variety of cell lines expressing B-RafV600E and is effective against the growth of tumors bearing the B-RafV600E mutation
10618	PLX4032	50 mg	≥98%	An orally bioavailable, ATP-competitive inhibitor of mutant V600E and wild type B-Raf kinases (IC50s = 31 and 100 nM, respectively); inhibits cell proliferation in a variety of cell lines expressing B-RafV600E and is effective against the growth of tumors bearing the B-RafV600E mutation
10638	FLLL32	1 mg	≥98%	An inhibitor of JAK2-mediated phosphorylation of STAT3 on Tyr705 in cancer cells (IC50 = ~5 µM); blocks signaling from IFN-α or IL-6 through JAK2/STAT3 and induces apoptosis in several types of cancer cells
10638	FLLL32	10 mg	≥98%	An inhibitor of JAK2-mediated phosphorylation of STAT3 on Tyr705 in cancer cells (IC50 = ~5 µM); blocks signaling from IFN-α or IL-6 through JAK2/STAT3 and induces apoptosis in several types of cancer cells
10638	FLLL32	25 mg	≥98%	An inhibitor of JAK2-mediated phosphorylation of STAT3 on Tyr705 in cancer cells (IC50 = ~5 µM); blocks signaling from IFN-α or IL-6 through JAK2/STAT3 and induces apoptosis in several types of cancer cells
10638	FLLL32	5 mg	≥98%	An inhibitor of JAK2-mediated phosphorylation of STAT3 on Tyr705 in cancer cells (IC50 = ~5 µM); blocks signaling from IFN-α or IL-6 through JAK2/STAT3 and induces apoptosis in several types of cancer cells
10702	AZD1480	1 mg	≥98%	A selective JAK2 inhibitor that blocks signaling (IC50 = 58 nM at 5 mM ATP) and proliferation of JAK2-expressing cell lines (GI50 = 60 nM); displays good pharmacokinetics in vivo, inhibits STAT3 and STAT5 activation in vivo, and suppresses tumorigenesis in mouse xenografts harboring constitutive STAT3 activity
10702	AZD1480	10 mg	≥98%	A selective JAK2 inhibitor that blocks signaling (IC50 = 58 nM at 5 mM ATP) and proliferation of JAK2-expressing cell lines (GI50 = 60 nM); displays good pharmacokinetics in vivo, inhibits STAT3 and STAT5 activation in vivo, and suppresses tumorigenesis in mouse xenografts harboring constitutive STAT3 activity

10702	AZD1480	5 mg	≥98%	A selective JAK2 inhibitor that blocks signaling (IC50 = 58 nM at 5 mM ATP) and proliferation of JAK2-expressing cell lines (GI50 = 60 nM); displays good pharmacokinetics in vivo, inhibits STAT3 and STAT5 activation in vivo, and suppresses tumorigenesis in mouse xenografts harboring constitutive STAT3 activity
10702	AZD1480	50 mg	≥98%	A selective JAK2 inhibitor that blocks signaling (IC50 = 58 nM at 5 mM ATP) and proliferation of JAK2-expressing cell lines (GI50 = 60 nM); displays good pharmacokinetics in vivo, inhibits STAT3 and STAT5 activation in vivo, and suppresses tumorigenesis in mouse xenografts harboring constitutive STAT3 activity
10735	Phthalazinone pyrazo	1 mg	≥98%	A potent inhibitor of Aurora A kinase (IC50 = 31 nM); does not inhibit Aurora B kinase at doses up to 100 µM; inhibits the proliferation of HCT116, COLO 205, and MCF-7 cells (IC50 = 7.8, 2.9, and 1.6 µM, respectively)
10735	Phthalazinone pyrazo	10 mg	≥98%	A potent inhibitor of Aurora A kinase (IC50 = 31 nM); does not inhibit Aurora B kinase at doses up to 100 µM; inhibits the proliferation of HCT116, COLO 205, and MCF-7 cells (IC50 = 7.8, 2.9, and 1.6 µM, respectively)
10735	Phthalazinone pyrazo	5 mg	≥98%	A potent inhibitor of Aurora A kinase (IC50 = 31 nM); does not inhibit Aurora B kinase at doses up to 100 µM; inhibits the proliferation of HCT116, COLO 205, and MCF-7 cells (IC50 = 7.8, 2.9, and 1.6 µM, respectively)
10793	AG-879	10 mg	≥95%	A tyrphostin compound that inhibits nerve growth factor (NGF)-dependent TrkA tyrosine phosphorylation in PC-12 cells (IC50 = ~40µM), HER2-ErbB2 kinase in several breast and ovarian cancer cell lines (IC50 = ~0.5 µM), and the VEGF receptor FLK1 (IC50 = ~1 µM)
10793	AG-879	25 mg	≥95%	A tyrphostin compound that inhibits nerve growth factor (NGF)-dependent TrkA tyrosine phosphorylation in PC-12 cells (IC50 = ~40µM), HER2-ErbB2 kinase in several breast and ovarian cancer cell lines (IC50 = ~0.5 µM), and the VEGF receptor FLK1 (IC50 = ~1 µM)
10793	AG-879	5 mg	≥95%	A tyrphostin compound that inhibits nerve growth factor (NGF)-dependent TrkA tyrosine phosphorylation in PC-12 cells (IC50 = ~40µM), HER2-ErbB2 kinase in several breast and ovarian cancer cell lines (IC50 = ~0.5 µM), and the VEGF receptor FLK1 (IC50 = ~1 µM)
10793	AG-879	50 mg	≥95%	A tyrphostin compound that inhibits nerve growth factor (NGF)-dependent TrkA tyrosine phosphorylation in PC-12 cells (IC50 = ~40µM), HER2-ErbB2 kinase in several breast and ovarian cancer cell lines (IC50 = ~0.5 µM), and the VEGF receptor FLK1 (IC50 = ~1 µM)
10876	SC-66	10 mg	≥98%	An allosteric inhibitor of Akt that facilitates both ubiquitination and deactivation of Akt; inhibits Akt activity in HEK293T cells, promoting cell death; suppresses tumor growth in mice
10876	SC-66	100 mg	≥98%	An allosteric inhibitor of Akt that facilitates both ubiquitination and deactivation of Akt; inhibits Akt activity in HEK293T cells, promoting cell death; suppresses tumor growth in mice
10876	SC-66	25 mg	≥98%	An allosteric inhibitor of Akt that facilitates both ubiquitination and deactivation of Akt; inhibits Akt activity in HEK293T cells, promoting cell death; suppresses tumor growth in mice
10876	SC-66	5 mg	≥98%	An allosteric inhibitor of Akt that facilitates both ubiquitination and deactivation of Akt; inhibits Akt activity in HEK293T cells, promoting cell death; suppresses tumor growth in mice
10954	1-NA-PP1	1 mg	≥98%	A reversible, cell-permeable inhibitor of Src-family tyrosine kinases that have been mutated, by a single base substitution, to become 'analog sensitive' (as), as compared to the wild-type kinase; inhibits v-Src-as1, with an I338G substitution, preferentially over v-Src (IC50 = 1.5 nM versus 1.0 µM, respectively); used to elucidate functions of several kinases in both mammalian and yeast systems
10954	1-NA-PP1	10 mg	≥98%	A reversible, cell-permeable inhibitor of Src-family tyrosine kinases that have been mutated, by a single base substitution, to become 'analog sensitive' (as), as compared to the wild-type kinase; inhibits v-Src-as1, with an I338G substitution, preferentially over v-Src (IC50 = 1.5 nM versus 1.0 µM, respectively); used to elucidate functions of several kinases in both mammalian and yeast systems
10954	1-NA-PP1	5 mg	≥98%	A reversible, cell-permeable inhibitor of Src-family tyrosine kinases that have been mutated, by a single base substitution, to become 'analog sensitive' (as), as compared to the wild-type kinase; inhibits v-Src-as1, with an I338G substitution, preferentially over v-Src (IC50 = 1.5 nM versus 1.0 µM, respectively); used to elucidate functions of several kinases in both mammalian and yeast systems
10954	1-NA-PP1	50 mg	≥98%	A reversible, cell-permeable inhibitor of Src-family tyrosine kinases that have been mutated, by a single base substitution, to become 'analog sensitive' (as), as compared to the wild-type kinase; inhibits v-Src-as1, with an I338G substitution, preferentially over v-Src (IC50 = 1.5 nM versus 1.0 µM, respectively); used to elucidate functions of several kinases in both mammalian and yeast systems
10997	Torin 1	10 mg	≥95%	A potent and selective inhibitor of mTOR (IC50 = 2 and 10 nM for mTORC1 and mTORC2, respectively); efficacious at a dose of 20 mg/kg in inhibiting downstream effectors of mTOR in mice

10997	Torin 1	25 mg	≥95%	A potent and selective inhibitor of mTOR (IC50 = 2 and 10 nM for mTORC1 and mTORC2, respectively); efficacious at a dose of 20 mg/kg in inhibiting downstream effectors of mTOR in mice
10997	Torin 1	50 mg	≥95%	A potent and selective inhibitor of mTOR (IC50 = 2 and 10 nM for mTORC1 and mTORC2, respectively); efficacious at a dose of 20 mg/kg in inhibiting downstream effectors of mTOR in mice
11020	Bisindolylmaleimide II	1 mg	≥97% (isomer	A general inhibitor of all PKC subtypes with structural similarity to the nonspecific PKC inhibitor staurosporine; inhibits PDK1 (IC50 = 14 µM) and PKA (IC50 = 2.94 µM)
11020	Bisindolylmaleimide II	5 mg	≥97% (isomer	A general inhibitor of all PKC subtypes with structural similarity to the nonspecific PKC inhibitor staurosporine; inhibits PDK1 (IC50 = 14 µM) and PKA (IC50 = 2.94 µM)
11022	BIBF 1120	10 mg	≥95%	A VEGFR, FGFR, and PDGFR inhibitor (IC50s = 13-34, 37-610, 59, and 65 nM for VEGFR1-3, FGFR1-4, PDGFRα, and PDGFRβ, respectively); selective for VEGFR, FGFR, and PDGFR over a panel of 33 kinases but does inhibit FLT3, LCK, LYN, and Src (IC50s = 16-156 nM); inhibits growth factor-dependent proliferation of HUVECs, HSMECs, HUASMCs, and BRPs (EC50s = 7-290 nM); reduces tumor microvessel density and the number of PDGFRβ-expressing perivascular cells in a FaDu head and neck small cell carcinoma mouse xenograft model at 100 mg/kg; inhibits tumor growth in a Caki-1 renal cancer mouse xenograft model
11022	BIBF 1120	100 mg	≥95%	A VEGFR, FGFR, and PDGFR inhibitor (IC50s = 13-34, 37-610, 59, and 65 nM for VEGFR1-3, FGFR1-4, PDGFRα, and PDGFRβ, respectively); selective for VEGFR, FGFR, and PDGFR over a panel of 33 kinases but does inhibit FLT3, LCK, LYN, and Src (IC50s = 16-156 nM); inhibits growth factor-dependent proliferation of HUVECs, HSMECs, HUASMCs, and BRPs (EC50s = 7-290 nM); reduces tumor microvessel density and the number of PDGFRβ-expressing perivascular cells in a FaDu head and neck small cell carcinoma mouse xenograft model at 100 mg/kg; inhibits tumor growth in a Caki-1 renal cancer mouse xenograft model
11022	BIBF 1120	250 mg	≥95%	A VEGFR, FGFR, and PDGFR inhibitor (IC50s = 13-34, 37-610, 59, and 65 nM for VEGFR1-3, FGFR1-4, PDGFRα, and PDGFRβ, respectively); selective for VEGFR, FGFR, and PDGFR over a panel of 33 kinases but does inhibit FLT3, LCK, LYN, and Src (IC50s = 16-156 nM); inhibits growth factor-dependent proliferation of HUVECs, HSMECs, HUASMCs, and BRPs (EC50s = 7-290 nM); reduces tumor microvessel density and the number of PDGFRβ-expressing perivascular cells in a FaDu head and neck small cell carcinoma mouse xenograft model at 100 mg/kg; inhibits tumor growth in a Caki-1 renal cancer mouse xenograft model
11022	BIBF 1120	50 mg	≥95%	A VEGFR, FGFR, and PDGFR inhibitor (IC50s = 13-34, 37-610, 59, and 65 nM for VEGFR1-3, FGFR1-4, PDGFRα, and PDGFRβ, respectively); selective for VEGFR, FGFR, and PDGFR over a panel of 33 kinases but does inhibit FLT3, LCK, LYN, and Src (IC50s = 16-156 nM); inhibits growth factor-dependent proliferation of HUVECs, HSMECs, HUASMCs, and BRPs (EC50s = 7-290 nM); reduces tumor microvessel density and the number of PDGFRβ-expressing perivascular cells in a FaDu head and neck small cell carcinoma mouse xenograft model at 100 mg/kg; inhibits tumor growth in a Caki-1 renal cancer mouse xenograft model
11029	SMI-4a	1 mg	≥98%	A Pim kinase inhibitor that blocks mTORC1 activity via activation of AMPK, killing a wide range of both myeloid and lymphoid cell lines (with IC50 values ranging from 0.8 to 40 µM); induces G1 phase cell-cycle arrest, dose-dependent induction of p27Kip1, apoptosis through the mitochondrial pathway, and inhibition of the mTORC1 pathway at 10 µM in pre–T-LBL cells
11029	SMI-4a	10 mg	≥98%	A Pim kinase inhibitor that blocks mTORC1 activity via activation of AMPK, killing a wide range of both myeloid and lymphoid cell lines (with IC50 values ranging from 0.8 to 40 µM); induces G1 phase cell-cycle arrest, dose-dependent induction of p27Kip1, apoptosis through the mitochondrial pathway, and inhibition of the mTORC1 pathway at 10 µM in pre–T-LBL cells
11029	SMI-4a	5 mg	≥98%	A Pim kinase inhibitor that blocks mTORC1 activity via activation of AMPK, killing a wide range of both myeloid and lymphoid cell lines (with IC50 values ranging from 0.8 to 40 µM); induces G1 phase cell-cycle arrest, dose-dependent induction of p27Kip1, apoptosis through the mitochondrial pathway, and inhibition of the mTORC1 pathway at 10 µM in pre–T-LBL cells
11029	SMI-4a	50 mg	≥98%	A Pim kinase inhibitor that blocks mTORC1 activity via activation of AMPK, killing a wide range of both myeloid and lymphoid cell lines (with IC50 values ranging from 0.8 to 40 µM); induces G1 phase cell-cycle arrest, dose-dependent induction of p27Kip1, apoptosis through the mitochondrial pathway, and inhibition of the mTORC1 pathway at 10 µM in pre–T-LBL cells
11072	Bisindolylmaleimide II	1 mg	≥98%	A protein kinase C inhibitor with structural similarity to staurosporine; inhibits PKCα (93% kinase activity inhibited at 1 µM), PDK1 (IC50 =3.8 µM), S6K1, MAPKAP-K1, RSK2 and MSK1

11072	Bisindolylmaleimide II	5 mg	≥98%	A protein kinase C inhibitor with structural similarity to staurosporine; inhibits PKCα (93% kinase activity inhibited at 1 µM), PDK1 (IC50 =3.8 µM), S6K1, MAPKAP-K1, RSK2 and MSK1
11073	Bisindolylmaleimide X	1 mg	≥98%	A selective, cell-permeable PKC inhibitor that displays 10-fold greater selectivity for PKCα (IC50 = 9 nM) and 4-fold greater selectivity for PKCβI (IC50 = 28 nM) over Ca2+-independent PKCε (IC50 = 108 nM); prevents T-cell activation and proliferation associated with chronic inflammatory responses in vivo
11073	Bisindolylmaleimide X	5 mg	≥98%	A selective, cell-permeable PKC inhibitor that displays 10-fold greater selectivity for PKCα (IC50 = 9 nM) and 4-fold greater selectivity for PKCβI (IC50 = 28 nM) over Ca2+-independent PKCε (IC50 = 108 nM); prevents T-cell activation and proliferation associated with chronic inflammatory responses in vivo
11226	AS-703026	1 mg	≥95%	Selectively inhibits MEK1/2; potently inhibits growth and survival of human INA-6 multiple myeloma cells and cytokine-induced osteoclast differentiation (IC50s = 10 and 18.2 nM, respectively); 30 mg/kg reduced tumor growth significantly in mice bearing H929 MM xenografts
11226	AS-703026	10 mg	≥95%	Selectively inhibits MEK1/2; potently inhibits growth and survival of human INA-6 multiple myeloma cells and cytokine-induced osteoclast differentiation (IC50s = 10 and 18.2 nM, respectively); 30 mg/kg reduced tumor growth significantly in mice bearing H929 MM xenografts
11226	AS-703026	25 mg	≥95%	Selectively inhibits MEK1/2; potently inhibits growth and survival of human INA-6 multiple myeloma cells and cytokine-induced osteoclast differentiation (IC50s = 10 and 18.2 nM, respectively); 30 mg/kg reduced tumor growth significantly in mice bearing H929 MM xenografts
11226	AS-703026	5 mg	≥95%	Selectively inhibits MEK1/2; potently inhibits growth and survival of human INA-6 multiple myeloma cells and cytokine-induced osteoclast differentiation (IC50s = 10 and 18.2 nM, respectively); 30 mg/kg reduced tumor growth significantly in mice bearing H929 MM xenografts
11314	Chelerythrine (chlorid	1 mg	≥98%	A potent, cell permeable inhibitor of PKC (IC50 = 660 nM); also inhibits Bcl-xL function (IC50 = 1.5 µM), inducing apoptosis in several cancer cell lines; can have PKC-independent effects, activate p38 and JUNK signaling pathways, and induce apoptosis in cancer cells both in vitro and in vivo
11314	Chelerythrine (chlorid	10 mg	≥98%	A potent, cell permeable inhibitor of PKC (IC50 = 660 nM); also inhibits Bcl-xL function (IC50 = 1.5 µM), inducing apoptosis in several cancer cell lines; can have PKC-independent effects, activate p38 and JUNK signaling pathways, and induce apoptosis in cancer cells both in vitro and in vivo
11314	Chelerythrine (chlorid	25 mg	≥98%	A potent, cell permeable inhibitor of PKC (IC50 = 660 nM); also inhibits Bcl-xL function (IC50 = 1.5 µM), inducing apoptosis in several cancer cell lines; can have PKC-independent effects, activate p38 and JUNK signaling pathways, and induce apoptosis in cancer cells both in vitro and in vivo
11314	Chelerythrine (chlorid	5 mg	≥98%	A potent, cell permeable inhibitor of PKC (IC50 = 660 nM); also inhibits Bcl-xL function (IC50 = 1.5 µM), inducing apoptosis in several cancer cell lines; can have PKC-independent effects, activate p38 and JUNK signaling pathways, and induce apoptosis in cancer cells both in vitro and in vivo
11338	K252a	1 mg	≥98%	A staurosporine analog that inhibits PKC, PKA, CaMKII, and phosphorylase kinase (IC50s = 470, 140, 270, and 1.7 nM, respectively); inhibits PRK1 (IC50 = 3.2 nM in vitro), a PKC-related kinase that phosphorylates histone H3 at threonine 11
11338	K252a	5 mg	≥98%	A staurosporine analog that inhibits PKC, PKA, CaMKII, and phosphorylase kinase (IC50s = 470, 140, 270, and 1.7 nM, respectively); inhibits PRK1 (IC50 = 3.2 nM in vitro), a PKC-related kinase that phosphorylates histone H3 at threonine 11
11339	K252b	1 mg	≥98%	A cell-impermeable kinase inhibitor, first described as an inhibitor of PKC; used to inhibit extracellular kinases (ectokinases) of cells in culture; inhibits receptor-mediated degranulation from RBL-2H3 cells (IC50 = 0.5 µg/ml); also used in comparison studies with the cell-permeable inhibitor K252a
11339	K252b	500 µg	≥98%	A cell-impermeable kinase inhibitor, first described as an inhibitor of PKC; used to inhibit extracellular kinases (ectokinases) of cells in culture; inhibits receptor-mediated degranulation from RBL-2H3 cells (IC50 = 0.5 µg/ml); also used in comparison studies with the cell-permeable inhibitor K252a
11422	R406	1 mg	≥95%	A potent orally available inhibitor of Syk (Ki = 30 nM); blocks FcεRI-dependent mast cell activation (EC50 = 43 nM) and, at 3 µM, reduces the release of IL-10, -12, and -13 by immune complex-pulsed dendritic cells
11422	R406	10 mg	≥95%	A potent orally available inhibitor of Syk (Ki = 30 nM); blocks FcεRI-dependent mast cell activation (EC50 = 43 nM) and, at 3 µM, reduces the release of IL-10, -12, and -13 by immune complex-pulsed dendritic cells
11422	R406	25 mg	≥95%	A potent orally available inhibitor of Syk (Ki = 30 nM); blocks FcεRI-dependent mast cell activation (EC50 = 43 nM) and, at 3 µM, reduces the release of IL-10, -12, and -13 by immune complex-pulsed dendritic cells
11422	R406	5 mg	≥95%	A potent orally available inhibitor of Syk (Ki = 30 nM); blocks FcεRI-dependent mast cell activation (EC50 = 43 nM) and, at 3 µM, reduces the release of IL-10, -12, and -13 by immune complex-pulsed dendritic cells

11423	BAY 61-3606 (hydroch	1 mg	≥98%	A Syk inhibitor (Ki = 7.5 nM); selective for Syk over Lyn, Fyn, Src, Itk, and BTK (Kis = >4.7 µM for all); inhibits anti-IgE-induced histamine release in isolated human mast cells sensitized with IgE (IC50 = 5.1 nM); reduces anti-IgM-induced proliferation of isolated mouse splenic B cells (IC50 = 58 nM); sensitizes MCF-7 human breast cancer cells to TRAIL-induced apoptosis from 0.31-2.5 µM; inhibits passive cutaneous anaphylaxis in rats (ED50 = 8 mg/kg); reduces tumor growth in an MCF-7 mouse xenograft model at 50 mg/kg alone or in combination with TRAIL
11423	BAY 61-3606 (hydroch	10 mg	≥98%	A Syk inhibitor (Ki = 7.5 nM); selective for Syk over Lyn, Fyn, Src, Itk, and BTK (Kis = >4.7 µM for all); inhibits anti-IgE-induced histamine release in isolated human mast cells sensitized with IgE (IC50 = 5.1 nM); reduces anti-IgM-induced proliferation of isolated mouse splenic B cells (IC50 = 58 nM); sensitizes MCF-7 human breast cancer cells to TRAIL-induced apoptosis from 0.31-2.5 µM; inhibits passive cutaneous anaphylaxis in rats (ED50 = 8 mg/kg); reduces tumor growth in an MCF-7 mouse xenograft model at 50 mg/kg alone or in combination with TRAIL
11423	BAY 61-3606 (hydroch	5 mg	≥98%	A Syk inhibitor (Ki = 7.5 nM); selective for Syk over Lyn, Fyn, Src, Itk, and BTK (Kis = >4.7 µM for all); inhibits anti-IgE-induced histamine release in isolated human mast cells sensitized with IgE (IC50 = 5.1 nM); reduces anti-IgM-induced proliferation of isolated mouse splenic B cells (IC50 = 58 nM); sensitizes MCF-7 human breast cancer cells to TRAIL-induced apoptosis from 0.31-2.5 µM; inhibits passive cutaneous anaphylaxis in rats (ED50 = 8 mg/kg); reduces tumor growth in an MCF-7 mouse xenograft model at 50 mg/kg alone or in combination with TRAIL
11478	CHR-6494	1 mg	≥98%	A selective Haspin protein kinase inhibitor (IC50 = 2 nM), selective over 27 other protein kinases, including Aurora B kinase (IC50 > 1 µM)
11478	CHR-6494	10 mg	≥98%	A selective Haspin protein kinase inhibitor (IC50 = 2 nM), selective over 27 other protein kinases, including Aurora B kinase (IC50 > 1 µM)
11478	CHR-6494	5 mg	≥98%	A selective Haspin protein kinase inhibitor (IC50 = 2 nM), selective over 27 other protein kinases, including Aurora B kinase (IC50 > 1 µM)
11491	AZD 7762	1 mg	≥98%	Selectively inhibits checkpoint kinases Chk1 and Chk2 (IC50s = 5 nM); abrogates DNA damage-induced S and G2 checkpoints (EC50 = 10 nM) and potentiates the efficacy of gemcitabine and topotecan by modulating downstream checkpoint pathway proteins
11491	AZD 7762	10 mg	≥98%	Selectively inhibits checkpoint kinases Chk1 and Chk2 (IC50s = 5 nM); abrogates DNA damage-induced S and G2 checkpoints (EC50 = 10 nM) and potentiates the efficacy of gemcitabine and topotecan by modulating downstream checkpoint pathway proteins
11491	AZD 7762	25 mg	≥98%	Selectively inhibits checkpoint kinases Chk1 and Chk2 (IC50s = 5 nM); abrogates DNA damage-induced S and G2 checkpoints (EC50 = 10 nM) and potentiates the efficacy of gemcitabine and topotecan by modulating downstream checkpoint pathway proteins
11491	AZD 7762	5 mg	≥98%	Selectively inhibits checkpoint kinases Chk1 and Chk2 (IC50s = 5 nM); abrogates DNA damage-induced S and G2 checkpoints (EC50 = 10 nM) and potentiates the efficacy of gemcitabine and topotecan by modulating downstream checkpoint pathway proteins
11492	Afatinib	1 mg	≥95%	Selective and irreversible dual inhibitor of EGFR and HER2 kinase activity (IC50s = 0.5 and 14 nM, respectively); suppresses transformation in isogenic cell-based assays, inhibits survival of cancer cell lines, and at 20 mg/kg, induces tumor regression in xenograft and transgenic lung cancer models
11492	Afatinib	10 mg	≥95%	Selective and irreversible dual inhibitor of EGFR and HER2 kinase activity (IC50s = 0.5 and 14 nM, respectively); suppresses transformation in isogenic cell-based assays, inhibits survival of cancer cell lines, and at 20 mg/kg, induces tumor regression in xenograft and transgenic lung cancer models
11492	Afatinib	5 mg	≥95%	Selective and irreversible dual inhibitor of EGFR and HER2 kinase activity (IC50s = 0.5 and 14 nM, respectively); suppresses transformation in isogenic cell-based assays, inhibits survival of cancer cell lines, and at 20 mg/kg, induces tumor regression in xenograft and transgenic lung cancer models
11492	Afatinib	50 mg	≥95%	Selective and irreversible dual inhibitor of EGFR and HER2 kinase activity (IC50s = 0.5 and 14 nM, respectively); suppresses transformation in isogenic cell-based assays, inhibits survival of cancer cell lines, and at 20 mg/kg, induces tumor regression in xenograft and transgenic lung cancer models
11493	Lapatinib	10 mg	≥98%	A dual inhibitor of EGFR and ErbB2 (IC50s = 19 and 3 nM, respectively); inhibits the growth of EGFR-overexpressing A431 skin cancer and ErbB2-overexpressing SK-BR-3 breast cancer cells (IC50s = 0.14 and 0.124 µM, respectively); inhibits the growth of ErbB2-amplified OD19 esophageal and NCI-N87 gastric cancer cells (IC50s = 0.09 and 0.01 µM, respectively); inhibits the growth of gastric cancer cells in which ErbB2 is not amplified (IC50s = 0.35-8.58 µM); induces apoptosis in NCI-N87 and OD19 cells at 1 µM; reduces tumor growth in a BT474 breast cancer mouse xenograft model at 50 mg/kg; reduces tumor growth in an NCI-N87 mouse xenograft model at 100 mg/kg and induces tumor regression when used in combination with trastuzumab

11493	Lapatinib	100 mg	≥98%	A dual inhibitor of EGFR and ErbB2 (IC50s = 19 and 3 nM, respectively); inhibits the growth of EGFR-overexpressing A431 skin cancer and ErbB2-overexpressing SK-BR-3 breast cancer cells (IC50s = 0.14 and 0.124 µM, respectively); inhibits the growth of ErbB2-amplified OD19 esophageal and NCI-N87 gastric cancer cells (IC50s = 0.09 and 0.01 µM, respectively); inhibits the growth of gastric cancer cells in which ErbB2 is not amplified (IC50s = 0.35-8.58 µM); induces apoptosis in NCI-N87 and OD19 cells at 1 µM; reduces tumor growth in a BT474 breast cancer mouse xenograft model at 50 mg/kg; reduces tumor growth in an NCI-N87 mouse xenograft model at 100 mg/kg and induces tumor regression when used in combination with trastuzumab
11493	Lapatinib	25 mg	≥98%	A dual inhibitor of EGFR and ErbB2 (IC50s = 19 and 3 nM, respectively); inhibits the growth of EGFR-overexpressing A431 skin cancer and ErbB2-overexpressing SK-BR-3 breast cancer cells (IC50s = 0.14 and 0.124 µM, respectively); inhibits the growth of ErbB2-amplified OD19 esophageal and NCI-N87 gastric cancer cells (IC50s = 0.09 and 0.01 µM, respectively); inhibits the growth of gastric cancer cells in which ErbB2 is not amplified (IC50s = 0.35-8.58 µM); induces apoptosis in NCI-N87 and OD19 cells at 1 µM; reduces tumor growth in a BT474 breast cancer mouse xenograft model at 50 mg/kg; reduces tumor growth in an NCI-N87 mouse xenograft model at 100 mg/kg and induces tumor regression when used in combination with trastuzumab
11493	Lapatinib	5 mg	≥98%	A dual inhibitor of EGFR and ErbB2 (IC50s = 19 and 3 nM, respectively); inhibits the growth of EGFR-overexpressing A431 skin cancer and ErbB2-overexpressing SK-BR-3 breast cancer cells (IC50s = 0.14 and 0.124 µM, respectively); inhibits the growth of ErbB2-amplified OD19 esophageal and NCI-N87 gastric cancer cells (IC50s = 0.09 and 0.01 µM, respectively); inhibits the growth of gastric cancer cells in which ErbB2 is not amplified (IC50s = 0.35-8.58 µM); induces apoptosis in NCI-N87 and OD19 cells at 1 µM; reduces tumor growth in a BT474 breast cancer mouse xenograft model at 50 mg/kg; reduces tumor growth in an NCI-N87 mouse xenograft model at 100 mg/kg and induces tumor regression when used in combination with trastuzumab
11494	Ponatinib	1 mg	≥98%	An inhibitor of native (IC50 = 0.37 nM) and mutant Bcr-Abl; inhibits the tyrosine kinase inhibitor-resistant mutant Bcr-AblT315I (IC50 = 2 nM), as well as Bcr-AblQ252H, Bcr-AblY253F, Bcr-AblM351T, and Bcr-AblH396P mutants (IC50s = 0.44, 0.3, 0.3, and 0.34 nM, respectively); selective for Bcr-Abl and these mutants over the insulin receptor, IGF-1R, Aurora A kinase, and Cdk2/cyclin E but does inhibit c-Src, VEGFR2, FGFR1, and PDGFRα (IC50s = 5.4, 1.5, 2.2, and 1.1 nM, respectively); inhibits proliferation of Ba/F3 cells expressing native (IC50 = 0.5 nM) or mutant Bcr-Abl (IC50s = 0.5-36 nM); reduces tumor growth in a Ba/F3 Bcr-AblT315I mouse xenograft model at 10-30 mg/kg
11494	Ponatinib	10 mg	≥98%	An inhibitor of native (IC50 = 0.37 nM) and mutant Bcr-Abl; inhibits the tyrosine kinase inhibitor-resistant mutant Bcr-AblT315I (IC50 = 2 nM), as well as Bcr-AblQ252H, Bcr-AblY253F, Bcr-AblM351T, and Bcr-AblH396P mutants (IC50s = 0.44, 0.3, 0.3, and 0.34 nM, respectively); selective for Bcr-Abl and these mutants over the insulin receptor, IGF-1R, Aurora A kinase, and Cdk2/cyclin E but does inhibit c-Src, VEGFR2, FGFR1, and PDGFRα (IC50s = 5.4, 1.5, 2.2, and 1.1 nM, respectively); inhibits proliferation of Ba/F3 cells expressing native (IC50 = 0.5 nM) or mutant Bcr-Abl (IC50s = 0.5-36 nM); reduces tumor growth in a Ba/F3 Bcr-AblT315I mouse xenograft model at 10-30 mg/kg
11494	Ponatinib	5 mg	≥98%	An inhibitor of native (IC50 = 0.37 nM) and mutant Bcr-Abl; inhibits the tyrosine kinase inhibitor-resistant mutant Bcr-AblT315I (IC50 = 2 nM), as well as Bcr-AblQ252H, Bcr-AblY253F, Bcr-AblM351T, and Bcr-AblH396P mutants (IC50s = 0.44, 0.3, 0.3, and 0.34 nM, respectively); selective for Bcr-Abl and these mutants over the insulin receptor, IGF-1R, Aurora A kinase, and Cdk2/cyclin E but does inhibit c-Src, VEGFR2, FGFR1, and PDGFRα (IC50s = 5.4, 1.5, 2.2, and 1.1 nM, respectively); inhibits proliferation of Ba/F3 cells expressing native (IC50 = 0.5 nM) or mutant Bcr-Abl (IC50s = 0.5-36 nM); reduces tumor growth in a Ba/F3 Bcr-AblT315I mouse xenograft model at 10-30 mg/kg
11494	Ponatinib	50 mg	≥98%	An inhibitor of native (IC50 = 0.37 nM) and mutant Bcr-Abl; inhibits the tyrosine kinase inhibitor-resistant mutant Bcr-AblT315I (IC50 = 2 nM), as well as Bcr-AblQ252H, Bcr-AblY253F, Bcr-AblM351T, and Bcr-AblH396P mutants (IC50s = 0.44, 0.3, 0.3, and 0.34 nM, respectively); selective for Bcr-Abl and these mutants over the insulin receptor, IGF-1R, Aurora A kinase, and Cdk2/cyclin E but does inhibit c-Src, VEGFR2, FGFR1, and PDGFRα (IC50s = 5.4, 1.5, 2.2, and 1.1 nM, respectively); inhibits proliferation of Ba/F3 cells expressing native (IC50 = 0.5 nM) or mutant Bcr-Abl (IC50s = 0.5-36 nM); reduces tumor growth in a Ba/F3 Bcr-AblT315I mouse xenograft model at 10-30 mg/kg
11495	Cediranib	10 mg	≥98%	A potent inhibitor of VEGFR1, 2, and 3 (IC50s = 5, 1, and 3 nM, respectively); also potently inhibits a variety of other receptor and non-receptor tyrosine kinases; blocks tubule formation by HUVECs in vitro and prevents angiogenesis as well as xenograft tumor growth in vivo
11495	Cediranib	25 mg	≥98%	A potent inhibitor of VEGFR1, 2, and 3 (IC50s = 5, 1, and 3 nM, respectively); also potently inhibits a variety of other receptor and non-receptor tyrosine kinases; blocks tubule formation by HUVECs in vitro and prevents angiogenesis as well as xenograft tumor growth in vivo

11495	Cediranib	5 mg	≥98%	A potent inhibitor of VEGFR1, 2, and 3 (IC50s = 5, 1, and 3 nM, respectively); also potently inhibits a variety of other receptor and non-receptor tyrosine kinases; blocks tubule formation by HUVECs in vitro and prevents angiogenesis as well as xenograft tumor growth in vivo
11496	AT-9283	10 mg	≥98%	A broad spectrum kinase inhibitor that potently inhibits Aurora A, Aurora B, JAK2, JAK3, and c-ABL (IC50s = 3, 3, 1.2, 1.1, and 4 nM, respectively); potently (IC50 = receptor tyrosine kinases
11496	AT-9283	25 mg	≥98%	A broad spectrum kinase inhibitor that potently inhibits Aurora A, Aurora B, JAK2, JAK3, and c-ABL (IC50s = 3, 3, 1.2, 1.1, and 4 nM, respectively); potently (IC50 = receptor tyrosine kinases
11496	AT-9283	5 mg	≥98%	A broad spectrum kinase inhibitor that potently inhibits Aurora A, Aurora B, JAK2, JAK3, and c-ABL (IC50s = 3, 3, 1.2, 1.1, and 4 nM, respectively); potently (IC50 = receptor tyrosine kinases
11496	AT-9283	50 mg	≥98%	A broad spectrum kinase inhibitor that potently inhibits Aurora A, Aurora B, JAK2, JAK3, and c-ABL (IC50s = 3, 3, 1.2, 1.1, and 4 nM, respectively); potently (IC50 = receptor tyrosine kinases
11497	Saracatinib	10 mg	≥90%	A dual inhibitor of c-Src and Abl (IC50 = 2.7 and 30 nM, respectively); less effectively inhibits other kinases; blocks cell motility, migration, adhesion, invasion, proliferation, differentiation, and survival; reduces osteoclast bone resorption
11497	Saracatinib	25 mg	≥90%	A dual inhibitor of c-Src and Abl (IC50 = 2.7 and 30 nM, respectively); less effectively inhibits other kinases; blocks cell motility, migration, adhesion, invasion, proliferation, differentiation, and survival; reduces osteoclast bone resorption
11497	Saracatinib	5 mg	≥90%	A dual inhibitor of c-Src and Abl (IC50 = 2.7 and 30 nM, respectively); less effectively inhibits other kinases; blocks cell motility, migration, adhesion, invasion, proliferation, differentiation, and survival; reduces osteoclast bone resorption
11497	Saracatinib	50 mg	≥90%	A dual inhibitor of c-Src and Abl (IC50 = 2.7 and 30 nM, respectively); less effectively inhibits other kinases; blocks cell motility, migration, adhesion, invasion, proliferation, differentiation, and survival; reduces osteoclast bone resorption
11498	Dasatinib	10 mg	≥98%	A potent inhibitor of the non-receptor tyrosine kinases Abl and Src as well as other members of the Src family; inhibits Abl, Src, and Lck with IC50 values of 0.05, 0.5, and 0.4 nM, respectively; has potential therapeutic value in some forms of cancer and fibrotic disease
11498	Dasatinib	100 mg	≥98%	A potent inhibitor of the non-receptor tyrosine kinases Abl and Src as well as other members of the Src family; inhibits Abl, Src, and Lck with IC50 values of 0.05, 0.5, and 0.4 nM, respectively; has potential therapeutic value in some forms of cancer and fibrotic disease
11498	Dasatinib	250 mg	≥98%	A potent inhibitor of the non-receptor tyrosine kinases Abl and Src as well as other members of the Src family; inhibits Abl, Src, and Lck with IC50 values of 0.05, 0.5, and 0.4 nM, respectively; has potential therapeutic value in some forms of cancer and fibrotic disease
11498	Dasatinib	50 mg	≥98%	A potent inhibitor of the non-receptor tyrosine kinases Abl and Src as well as other members of the Src family; inhibits Abl, Src, and Lck with IC50 values of 0.05, 0.5, and 0.4 nM, respectively; has potential therapeutic value in some forms of cancer and fibrotic disease
11569	GSK1059615	10 mg	≥98%	A potent, reversible, ATP-competitive, thiazolidinedione inhibitor of PI3Kα (IC50 = 2 nM) and the common activating mutants of p100α (E542K, E545K, and H1047R) found in cancer; prevents proliferation in BT474 tumor xenografts and reduces MAPK signaling with twice daily dosing at 25 mg/kg
11569	GSK1059615	25 mg	≥98%	A potent, reversible, ATP-competitive, thiazolidinedione inhibitor of PI3Kα (IC50 = 2 nM) and the common activating mutants of p100α (E542K, E545K, and H1047R) found in cancer; prevents proliferation in BT474 tumor xenografts and reduces MAPK signaling with twice daily dosing at 25 mg/kg
11569	GSK1059615	5 mg	≥98%	A potent, reversible, ATP-competitive, thiazolidinedione inhibitor of PI3Kα (IC50 = 2 nM) and the common activating mutants of p100α (E542K, E545K, and H1047R) found in cancer; prevents proliferation in BT474 tumor xenografts and reduces MAPK signaling with twice daily dosing at 25 mg/kg
11569	GSK1059615	50 mg	≥98%	A potent, reversible, ATP-competitive, thiazolidinedione inhibitor of PI3Kα (IC50 = 2 nM) and the common activating mutants of p100α (E542K, E545K, and H1047R) found in cancer; prevents proliferation in BT474 tumor xenografts and reduces MAPK signaling with twice daily dosing at 25 mg/kg
11580	CI-1040	10 mg	≥98%	A potent inhibitor of MEK in (IC50 = 2.3 nM; Kd = 74 nM when activated with ATP) that suppresses phosphorylation of ERK in mouse colon 26 tumors (IC50 = 35 nM)
11580	CI-1040	25 mg	≥98%	A potent inhibitor of MEK in (IC50 = 2.3 nM; Kd = 74 nM when activated with ATP) that suppresses phosphorylation of ERK in mouse colon 26 tumors (IC50 = 35 nM)

11580	CI-1040	5 mg	≥98%	A potent inhibitor of MEK in (IC50 = 2.3 nM; Kd = 74 nM when activated with ATP) that suppresses phosphorylation of ERK in mouse colon 26 tumors (IC50 = 35 nM)
11580	CI-1040	50 mg	≥98%	A potent inhibitor of MEK in (IC50 = 2.3 nM; Kd = 74 nM when activated with ATP) that suppresses phosphorylation of ERK in mouse colon 26 tumors (IC50 = 35 nM)
11587	NVP-BKM120	1 mg	≥95%	An inhibitor of the class I PI3K isoforms p110α (IC50 = 52 nM) and p110β (IC50 = 166 nM); selective for these isoforms over the class III PI3K Vps34 (IC50 = 2,410 nM), mTOR (IC50 = 2,866 nM), PI4Kβ (IC50 = >25,000 nM), and a variety of kinases (IC50s = >10,000 nM); inhibits proliferation of human tumor and glioma cell lines, with p53 wild-type glioma cells more sensitive than p53 mutant/deleted glioma cells (IC50s = 1.28 and 2.08 µM, respectively); crosses the blood brain barrier; increases survival in a U87 glioma mouse xenograft intracranial tumor model when orally administered at 20 and 40 mg/kg once per week
11587	NVP-BKM120	10 mg	≥95%	An inhibitor of the class I PI3K isoforms p110α (IC50 = 52 nM) and p110β (IC50 = 166 nM); selective for these isoforms over the class III PI3K Vps34 (IC50 = 2,410 nM), mTOR (IC50 = 2,866 nM), PI4Kβ (IC50 = >25,000 nM), and a variety of kinases (IC50s = >10,000 nM); inhibits proliferation of human tumor and glioma cell lines, with p53 wild-type glioma cells more sensitive than p53 mutant/deleted glioma cells (IC50s = 1.28 and 2.08 µM, respectively); crosses the blood brain barrier; increases survival in a U87 glioma mouse xenograft intracranial tumor model when orally administered at 20 and 40 mg/kg once per week
11587	NVP-BKM120	5 mg	≥95%	An inhibitor of the class I PI3K isoforms p110α (IC50 = 52 nM) and p110β (IC50 = 166 nM); selective for these isoforms over the class III PI3K Vps34 (IC50 = 2,410 nM), mTOR (IC50 = 2,866 nM), PI4Kβ (IC50 = >25,000 nM), and a variety of kinases (IC50s = >10,000 nM); inhibits proliferation of human tumor and glioma cell lines, with p53 wild-type glioma cells more sensitive than p53 mutant/deleted glioma cells (IC50s = 1.28 and 2.08 µM, respectively); crosses the blood brain barrier; increases survival in a U87 glioma mouse xenograft intracranial tumor model when orally administered at 20 and 40 mg/kg once per week
11587	NVP-BKM120	50 mg	≥95%	An inhibitor of the class I PI3K isoforms p110α (IC50 = 52 nM) and p110β (IC50 = 166 nM); selective for these isoforms over the class III PI3K Vps34 (IC50 = 2,410 nM), mTOR (IC50 = 2,866 nM), PI4Kβ (IC50 = >25,000 nM), and a variety of kinases (IC50s = >10,000 nM); inhibits proliferation of human tumor and glioma cell lines, with p53 wild-type glioma cells more sensitive than p53 mutant/deleted glioma cells (IC50s = 1.28 and 2.08 µM, respectively); crosses the blood brain barrier; increases survival in a U87 glioma mouse xenograft intracranial tumor model when orally administered at 20 and 40 mg/kg once per week
11588	AZD 8330	1 mg	≥98%	A selective allosteric inhibitor of MEK1/2 (IC50 = 7 nM); orally bioavailable, inhibiting ERK phosphorylation in vivo and tumor growth in a Calu-6 nude rat xenograft model
11588	AZD 8330	10 mg	≥98%	A selective allosteric inhibitor of MEK1/2 (IC50 = 7 nM); orally bioavailable, inhibiting ERK phosphorylation in vivo and tumor growth in a Calu-6 nude rat xenograft model
11588	AZD 8330	5 mg	≥98%	A selective allosteric inhibitor of MEK1/2 (IC50 = 7 nM); orally bioavailable, inhibiting ERK phosphorylation in vivo and tumor growth in a Calu-6 nude rat xenograft model
11588	AZD 8330	50 mg	≥98%	A selective allosteric inhibitor of MEK1/2 (IC50 = 7 nM); orally bioavailable, inhibiting ERK phosphorylation in vivo and tumor growth in a Calu-6 nude rat xenograft model
11589	IC-87114	1 mg	≥98%	A cell-permeable selective inhibitor of the PI3K catalytic subunit p110δ (IC50 = 0.5 µM). It less effectively inhibits p110γ and p110β (IC50 = 29 and 75 µM, respectively) and has no significant effect on p110α and several other kinases
11589	IC-87114	10 mg	≥98%	A cell-permeable selective inhibitor of the PI3K catalytic subunit p110δ (IC50 = 0.5 µM). It less effectively inhibits p110γ and p110β (IC50 = 29 and 75 µM, respectively) and has no significant effect on p110α and several other kinases
11589	IC-87114	5 mg	≥98%	A cell-permeable selective inhibitor of the PI3K catalytic subunit p110δ (IC50 = 0.5 µM). It less effectively inhibits p110γ and p110β (IC50 = 29 and 75 µM, respectively) and has no significant effect on p110α and several other kinases
11589	IC-87114	50 mg	≥98%	A cell-permeable selective inhibitor of the PI3K catalytic subunit p110δ (IC50 = 0.5 µM). It less effectively inhibits p110γ and p110β (IC50 = 29 and 75 µM, respectively) and has no significant effect on p110α and several other kinases
11590	Temsirolimus	1 mg	≥98%	A dihydroxymethyl propionic acid ester of rapamycin with improved solubility that specifically inhibits mTOR signaling with a potency similar to that of rapamycin; demonstrates cytostatic activity in various mouse models of human tumors, including glioblastomas, prostate carcinoma, pancreatic, liver, breast cancers, and medulloblastoma

11590	Temsirolimus	10 mg	≥98%	A dihydroxymethyl propionic acid ester of rapamycin with improved solubility that specifically inhibits mTOR signaling with a potency similar to that of rapamycin; demonstrates cytostatic activity in various mouse models of human tumors, including glioblastomas, prostate carcinoma, pancreatic, liver, breast cancers, and medulloblastoma
11590	Temsirolimus	25 mg	≥98%	A dihydroxymethyl propionic acid ester of rapamycin with improved solubility that specifically inhibits mTOR signaling with a potency similar to that of rapamycin; demonstrates cytostatic activity in various mouse models of human tumors, including glioblastomas, prostate carcinoma, pancreatic, liver, breast cancers, and medulloblastoma
11590	Temsirolimus	5 mg	≥98%	A dihydroxymethyl propionic acid ester of rapamycin with improved solubility that specifically inhibits mTOR signaling with a potency similar to that of rapamycin; demonstrates cytostatic activity in various mouse models of human tumors, including glioblastomas, prostate carcinoma, pancreatic, liver, breast cancers, and medulloblastoma
11593	MK-2206 (hydrochlori	1 mg	≥98%	An orally active, allosteric Akt inhibitor (IC50s = 5, 12, and 65 nM for Akt1, 2, and 3, respectively); inhibits cell proliferation of human cancer cell lines synergistically in combination with other topoisomerase inhibitors, antimetabolites, antimicrotubule agents, DNA cross-linkers or growth factor inhibitors
11593	MK-2206 (hydrochlori	10 mg	≥98%	An orally active, allosteric Akt inhibitor (IC50s = 5, 12, and 65 nM for Akt1, 2, and 3, respectively); inhibits cell proliferation of human cancer cell lines synergistically in combination with other topoisomerase inhibitors, antimetabolites, antimicrotubule agents, DNA cross-linkers or growth factor inhibitors
11593	MK-2206 (hydrochlori	25 mg	≥98%	An orally active, allosteric Akt inhibitor (IC50s = 5, 12, and 65 nM for Akt1, 2, and 3, respectively); inhibits cell proliferation of human cancer cell lines synergistically in combination with other topoisomerase inhibitors, antimetabolites, antimicrotubule agents, DNA cross-linkers or growth factor inhibitors
11593	MK-2206 (hydrochlori	5 mg	≥98%	An orally active, allosteric Akt inhibitor (IC50s = 5, 12, and 65 nM for Akt1, 2, and 3, respectively); inhibits cell proliferation of human cancer cell lines synergistically in combination with other topoisomerase inhibitors, antimetabolites, antimicrotubule agents, DNA cross-linkers or growth factor inhibitors
11597	Everolimus	10 mg	≥95%	A hydroxyethyl ether rapamycin derivative that inhibits mTOR signaling through both mTORC1 and mTORC2 when added to cells at 20 nM; orally available with superior pharmacokinetics and pharmacodynamics over rapamycin
11597	Everolimus	25 mg	≥95%	A hydroxyethyl ether rapamycin derivative that inhibits mTOR signaling through both mTORC1 and mTORC2 when added to cells at 20 nM; orally available with superior pharmacokinetics and pharmacodynamics over rapamycin
11597	Everolimus	5 mg	≥95%	A hydroxyethyl ether rapamycin derivative that inhibits mTOR signaling through both mTORC1 and mTORC2 when added to cells at 20 nM; orally available with superior pharmacokinetics and pharmacodynamics over rapamycin
11598	Tofacitinib (citrate)	10 mg	≥98%	A JAX inhibitor (IC50s = 6.1, 12, and 8 nM for JAK1, JAK2, and JAK3, respectively); selective for JAK1-3 over ROCK2 and Lck (IC50s = 3,400 and 3,870 nM, respectively) as well as 28 additional kinases in enzyme assays (IC50s = >10,000 nM); inhibits IL-2-mediated phosphorylation of JAK3 and STAT5 (30 ng/ml); prevents rejection and prolongs survival in murine and cynomolgus monkey models of heterotopic heart and kidney transplantation
11598	Tofacitinib (citrate)	25 mg	≥98%	A JAX inhibitor (IC50s = 6.1, 12, and 8 nM for JAK1, JAK2, and JAK3, respectively); selective for JAK1-3 over ROCK2 and Lck (IC50s = 3,400 and 3,870 nM, respectively) as well as 28 additional kinases in enzyme assays (IC50s = >10,000 nM); inhibits IL-2-mediated phosphorylation of JAK3 and STAT5 (30 ng/ml); prevents rejection and prolongs survival in murine and cynomolgus monkey models of heterotopic heart and kidney transplantation
11598	Tofacitinib (citrate)	5 mg	≥98%	A JAX inhibitor (IC50s = 6.1, 12, and 8 nM for JAK1, JAK2, and JAK3, respectively); selective for JAK1-3 over ROCK2 and Lck (IC50s = 3,400 and 3,870 nM, respectively) as well as 28 additional kinases in enzyme assays (IC50s = >10,000 nM); inhibits IL-2-mediated phosphorylation of JAK3 and STAT5 (30 ng/ml); prevents rejection and prolongs survival in murine and cynomolgus monkey models of heterotopic heart and kidney transplantation
11598	Tofacitinib (citrate)	50 mg	≥98%	A JAX inhibitor (IC50s = 6.1, 12, and 8 nM for JAK1, JAK2, and JAK3, respectively); selective for JAK1-3 over ROCK2 and Lck (IC50s = 3,400 and 3,870 nM, respectively) as well as 28 additional kinases in enzyme assays (IC50s = >10,000 nM); inhibits IL-2-mediated phosphorylation of JAK3 and STAT5 (30 ng/ml); prevents rejection and prolongs survival in murine and cynomolgus monkey models of heterotopic heart and kidney transplantation

11599	AZD 6244	10 mg	≥95%	A potent, highly selective inhibitor of MEK1 and MEK2 (IC50 = 14-99 and 530 nM, respectively); weakly inhibits EGFR (IC50 = 7.0 μM) and has no effect on a large panel of other kinases; suppresses growth and induces apoptosis and differentiation within tumors
11599	AZD 6244	100 mg	≥95%	A potent, highly selective inhibitor of MEK1 and MEK2 (IC50 = 14-99 and 530 nM, respectively); weakly inhibits EGFR (IC50 = 7.0 μM) and has no effect on a large panel of other kinases; suppresses growth and induces apoptosis and differentiation within tumors
11599	AZD 6244	25 mg	≥95%	A potent, highly selective inhibitor of MEK1 and MEK2 (IC50 = 14-99 and 530 nM, respectively); weakly inhibits EGFR (IC50 = 7.0 μM) and has no effect on a large panel of other kinases; suppresses growth and induces apoptosis and differentiation within tumors
11599	AZD 6244	50 mg	≥95%	A potent, highly selective inhibitor of MEK1 and MEK2 (IC50 = 14-99 and 530 nM, respectively); weakly inhibits EGFR (IC50 = 7.0 μM) and has no effect on a large panel of other kinases; suppresses growth and induces apoptosis and differentiation within tumors
11600	GDC-0941	10 mg	≥98%	A potent pan inhibitor of class I catalytic subunits of PI3K, inhibiting p110α, β, δ, and γ with IC50 values of 3, 33, 3, and 75 nM, respectively; inhibits the growth of certain types of cancer cells, and blocks signaling through PI3K to Akt, both in cells and in vivo
11600	GDC-0941	100 mg	≥98%	A potent pan inhibitor of class I catalytic subunits of PI3K, inhibiting p110α, β, δ, and γ with IC50 values of 3, 33, 3, and 75 nM, respectively; inhibits the growth of certain types of cancer cells, and blocks signaling through PI3K to Akt, both in cells and in vivo
11600	GDC-0941	50 mg	≥98%	A potent pan inhibitor of class I catalytic subunits of PI3K, inhibiting p110α, β, δ, and γ with IC50 values of 3, 33, 3, and 75 nM, respectively; inhibits the growth of certain types of cancer cells, and blocks signaling through PI3K to Akt, both in cells and in vivo
11601	Enzastaurin	10 mg	≥98%	A potent inhibitor of PKCβ (IC50 = 6 nM), with modest selectivity over PKCα, γ, and ε (IC50 = 39, 83, and 110 nM, respectively); at 3 μM, also inhibits signaling through the Akt pathway; suppresses angiogenesis, induces apoptosis, and reduces proliferation of cultured tumor cells
11601	Enzastaurin	25 mg	≥98%	A potent inhibitor of PKCβ (IC50 = 6 nM), with modest selectivity over PKCα, γ, and ε (IC50 = 39, 83, and 110 nM, respectively); at 3 μM, also inhibits signaling through the Akt pathway; suppresses angiogenesis, induces apoptosis, and reduces proliferation of cultured tumor cells
11601	Enzastaurin	5 mg	≥98%	A potent inhibitor of PKCβ (IC50 = 6 nM), with modest selectivity over PKCα, γ, and ε (IC50 = 39, 83, and 110 nM, respectively); at 3 μM, also inhibits signaling through the Akt pathway; suppresses angiogenesis, induces apoptosis, and reduces proliferation of cultured tumor cells
11601	Enzastaurin	50 mg	≥98%	A potent inhibitor of PKCβ (IC50 = 6 nM), with modest selectivity over PKCα, γ, and ε (IC50 = 39, 83, and 110 nM, respectively); at 3 μM, also inhibits signaling through the Akt pathway; suppresses angiogenesis, induces apoptosis, and reduces proliferation of cultured tumor cells
11602	AZD 1152-HQPA	1 mg	≥98%	A highly selective inhibitor of Aurora kinase B (IC50 = 0.37 nM); inhibits the proliferation of hematopoietic malignant cells (IC50s = 3-40 nM) and tumor xenograft growth in vivo
11602	AZD 1152-HQPA	10 mg	≥98%	A highly selective inhibitor of Aurora kinase B (IC50 = 0.37 nM); inhibits the proliferation of hematopoietic malignant cells (IC50s = 3-40 nM) and tumor xenograft growth in vivo
11602	AZD 1152-HQPA	25 mg	≥98%	A highly selective inhibitor of Aurora kinase B (IC50 = 0.37 nM); inhibits the proliferation of hematopoietic malignant cells (IC50s = 3-40 nM) and tumor xenograft growth in vivo
11602	AZD 1152-HQPA	5 mg	≥98%	A highly selective inhibitor of Aurora kinase B (IC50 = 0.37 nM); inhibits the proliferation of hematopoietic malignant cells (IC50s = 3-40 nM) and tumor xenograft growth in vivo
11609	Ruxolitinib	1 mg	≥98%	A potent ATP mimetic that inhibits both JAK1 and JAK2 with IC50 values of 2.7 and 4.5 nM, respectively; blocks IL-6 signaling (IC50 = 281 nM) and proliferation of JAK2V617F+ Ba/F3 cells (IC50 = 127 nM); reduces splenomegaly, decreases circulating levels of IL-6 and TNF-α, eliminates neoplastic cells, and prolongs survival in a mouse model of JAK2V617F+ MPN
11609	Ruxolitinib	10 mg	≥98%	A potent ATP mimetic that inhibits both JAK1 and JAK2 with IC50 values of 2.7 and 4.5 nM, respectively; blocks IL-6 signaling (IC50 = 281 nM) and proliferation of JAK2V617F+ Ba/F3 cells (IC50 = 127 nM); reduces splenomegaly, decreases circulating levels of IL-6 and TNF-α, eliminates neoplastic cells, and prolongs survival in a mouse model of JAK2V617F+ MPN
11609	Ruxolitinib	25 mg	≥98%	A potent ATP mimetic that inhibits both JAK1 and JAK2 with IC50 values of 2.7 and 4.5 nM, respectively; blocks IL-6 signaling (IC50 = 281 nM) and proliferation of JAK2V617F+ Ba/F3 cells (IC50 = 127 nM); reduces splenomegaly, decreases circulating levels of IL-6 and TNF-α, eliminates neoplastic cells, and prolongs survival in a mouse model of JAK2V617F+ MPN
11609	Ruxolitinib	5 mg	≥98%	A potent ATP mimetic that inhibits both JAK1 and JAK2 with IC50 values of 2.7 and 4.5 nM, respectively; blocks IL-6 signaling (IC50 = 281 nM) and proliferation of JAK2V617F+ Ba/F3 cells (IC50 = 127 nM); reduces splenomegaly, decreases circulating levels of IL-6 and TNF-α, eliminates neoplastic cells, and prolongs survival in a mouse model of JAK2V617F+ MPN

11656	Cl-Necrostatin-1	1 mg	≥95%	A RIPK1 inhibitor; inhibits RIPK1 activity at 0.3, 3, and 30 µM; inhibits TNF-α-induced necroptosis in FADD-deficient Jurkat cells (EC50 = 180 nM); reduces infarct size when administered i.c.v. pre- and post-occlusion, or post-occlusion only, as 2 µl of a 4 mM solution in a mouse model of MCAO
11656	Cl-Necrostatin-1	10 mg	≥95%	A RIPK1 inhibitor; inhibits RIPK1 activity at 0.3, 3, and 30 µM; inhibits TNF-α-induced necroptosis in FADD-deficient Jurkat cells (EC50 = 180 nM); reduces infarct size when administered i.c.v. pre- and post-occlusion, or post-occlusion only, as 2 µl of a 4 mM solution in a mouse model of MCAO
11656	Cl-Necrostatin-1	5 mg	≥95%	A RIPK1 inhibitor; inhibits RIPK1 activity at 0.3, 3, and 30 µM; inhibits TNF-α-induced necroptosis in FADD-deficient Jurkat cells (EC50 = 180 nM); reduces infarct size when administered i.c.v. pre- and post-occlusion, or post-occlusion only, as 2 µl of a 4 mM solution in a mouse model of MCAO
11658	Necrostatin-1	10 mg	≥98%	An inhibitor of RIP1 kinase that prevents the death of TNF-α-treated FADD-deficient Jurkat cells with an EC50 value of 490 nM
11658	Necrostatin-1	100 mg	≥98%	An inhibitor of RIP1 kinase that prevents the death of TNF-α-treated FADD-deficient Jurkat cells with an EC50 value of 490 nM
11658	Necrostatin-1	5 mg	≥98%	An inhibitor of RIP1 kinase that prevents the death of TNF-α-treated FADD-deficient Jurkat cells with an EC50 value of 490 nM
11658	Necrostatin-1	50 mg	≥98%	An inhibitor of RIP1 kinase that prevents the death of TNF-α-treated FADD-deficient Jurkat cells with an EC50 value of 490 nM
11673	α-acetyl Boswellic Aci	1 mg	≥99%	A pentacyclic triterpene; inhibits LPS-induced TNF-α mRNA expression in monocytes as well as NF-κB activity in HEK293 cells at 10 µM; inhibits IKK-mediated phosphorylation of IκBα in monocytes
11673	α-acetyl Boswellic Aci	10 mg	≥99%	A pentacyclic triterpene; inhibits LPS-induced TNF-α mRNA expression in monocytes as well as NF-κB activity in HEK293 cells at 10 µM; inhibits IKK-mediated phosphorylation of IκBα in monocytes
11673	α-acetyl Boswellic Aci	5 mg	≥99%	A pentacyclic triterpene; inhibits LPS-induced TNF-α mRNA expression in monocytes as well as NF-κB activity in HEK293 cells at 10 µM; inhibits IKK-mediated phosphorylation of IκBα in monocytes
11691	K145 (hydrochloride)	1 mg	≥98%	A selective inhibitor of SPHK2 (Ki = 6.4 µM; IC50s = 4.3 and >10 µM for human recombinant SPHK2 and SPHK1, respectively); inhibits SPHK2 activity in U937 cells at 10 µM; inhibits tumor growth in a U937 mouse xenograft model at 15 mg/kg; improves glucose tolerance and regulates gluconeogenesis by stimulating insulin-dependent Akt/FoxO1 signaling in a mouse model of dexamethasone-induced insulin resistance at 30 mg/kg
11691	K145 (hydrochloride)	5 mg	≥98%	A selective inhibitor of SPHK2 (Ki = 6.4 µM; IC50s = 4.3 and >10 µM for human recombinant SPHK2 and SPHK1, respectively); inhibits SPHK2 activity in U937 cells at 10 µM; inhibits tumor growth in a U937 mouse xenograft model at 15 mg/kg; improves glucose tolerance and regulates gluconeogenesis by stimulating insulin-dependent Akt/FoxO1 signaling in a mouse model of dexamethasone-induced insulin resistance at 30 mg/kg
11691	K145 (hydrochloride)	500 µg	≥98%	A selective inhibitor of SPHK2 (Ki = 6.4 µM; IC50s = 4.3 and >10 µM for human recombinant SPHK2 and SPHK1, respectively); inhibits SPHK2 activity in U937 cells at 10 µM; inhibits tumor growth in a U937 mouse xenograft model at 15 mg/kg; improves glucose tolerance and regulates gluconeogenesis by stimulating insulin-dependent Akt/FoxO1 signaling in a mouse model of dexamethasone-induced insulin resistance at 30 mg/kg
11704	SL 0101-1	1 mg	≥98%	A kaempferol glycoside that selectively inhibits RSK2 with an IC50 value of 89 nM (Ki = 1 µM) without interfering with upstream activators of RSK, including ERK, MEK, EGFR, and PKC; inhibits the proliferation of MCF-7 breast cancer cells at 100 µM and attenuates angiotensin II-induced cell proliferation at 30 µM
11704	SL 0101-1	10 mg	≥98%	A kaempferol glycoside that selectively inhibits RSK2 with an IC50 value of 89 nM (Ki = 1 µM) without interfering with upstream activators of RSK, including ERK, MEK, EGFR, and PKC; inhibits the proliferation of MCF-7 breast cancer cells at 100 µM and attenuates angiotensin II-induced cell proliferation at 30 µM
11704	SL 0101-1	5 mg	≥98%	A kaempferol glycoside that selectively inhibits RSK2 with an IC50 value of 89 nM (Ki = 1 µM) without interfering with upstream activators of RSK, including ERK, MEK, EGFR, and PKC; inhibits the proliferation of MCF-7 breast cancer cells at 100 µM and attenuates angiotensin II-induced cell proliferation at 30 µM
11704	SL 0101-1	500 µg	≥98%	A kaempferol glycoside that selectively inhibits RSK2 with an IC50 value of 89 nM (Ki = 1 µM) without interfering with upstream activators of RSK, including ERK, MEK, EGFR, and PKC; inhibits the proliferation of MCF-7 breast cancer cells at 100 µM and attenuates angiotensin II-induced cell proliferation at 30 µM
11793	SB-505124	1 mg	≥98%	Inhibits ALK5- (IC50 = 47 nM), ALK4- (IC50 = 129 nM), and ALK7-dependent activation of downstream SMAD2 and SMAD3 and TGF-β–induced MAP kinase pathway components without altering ALK1-3 or ALK6-induced SMAD signaling

11793	SB-505124	10 mg	≥98%	Inhibits ALK5- (IC50 = 47 nM), ALK4- (IC50 = 129 nM), and ALK7-dependent activation of downstream SMAD2 and SMAD3 and TGF-β–induced MAP kinase pathway components without altering ALK1-3 or ALK6-induced SMAD signaling
11793	SB-505124	25 mg	≥98%	Inhibits ALK5- (IC50 = 47 nM), ALK4- (IC50 = 129 nM), and ALK7-dependent activation of downstream SMAD2 and SMAD3 and TGF-β–induced MAP kinase pathway components without altering ALK1-3 or ALK6-induced SMAD signaling
11793	SB-505124	5 mg	≥98%	Inhibits ALK5- (IC50 = 47 nM), ALK4- (IC50 = 129 nM), and ALK7-dependent activation of downstream SMAD2 and SMAD3 and TGF-β–induced MAP kinase pathway components without altering ALK1-3 or ALK6-induced SMAD signaling
11796	Wedelolactone	1 mg	≥98%	A natural coumestan that inhibits NF-κB signaling at the level of IKK action, resulting in suppression of NF-κB-mediated gene expression at concentrations of 1-100 µM; also inhibits hepatitis C virus NS5B polymerase in vitro (IC50 = 36 µM), STAT1 dephosphorylation (50 µM), and EZH2-EED interactions (Kd = 2.8 µM)
11796	Wedelolactone	5 mg	≥98%	A natural coumestan that inhibits NF-κB signaling at the level of IKK action, resulting in suppression of NF-κB-mediated gene expression at concentrations of 1-100 µM; also inhibits hepatitis C virus NS5B polymerase in vitro (IC50 = 36 µM), STAT1 dephosphorylation (50 µM), and EZH2-EED interactions (Kd = 2.8 µM)
11796	Wedelolactone	500 µg	≥98%	A natural coumestan that inhibits NF-κB signaling at the level of IKK action, resulting in suppression of NF-κB-mediated gene expression at concentrations of 1-100 µM; also inhibits hepatitis C virus NS5B polymerase in vitro (IC50 = 36 µM), STAT1 dephosphorylation (50 µM), and EZH2-EED interactions (Kd = 2.8 µM)
11801	ML-7 (hydrochloride)	1 mg	≥95%	Inhibits smooth MLCK (Ki = 0.3 µM) 10-fold more potently than its parent compound ML-9
11801	ML-7 (hydrochloride)	10 mg	≥95%	Inhibits smooth MLCK (Ki = 0.3 µM) 10-fold more potently than its parent compound ML-9
11801	ML-7 (hydrochloride)	5 mg	≥95%	Inhibits smooth MLCK (Ki = 0.3 µM) 10-fold more potently than its parent compound ML-9
11801	ML-7 (hydrochloride)	50 mg	≥95%	Inhibits smooth MLCK (Ki = 0.3 µM) 10-fold more potently than its parent compound ML-9
11802	LDN-193189	1 mg	≥95%	Inhibits BMP type 1 receptor-induced phosphorylation of SMAD1/5/8 (IC50 = 4.9 nM); shows specificity for ALK1, 2, 3, and 6 (IC50s = 0.8, 0.8, 5.3, and 16.7 nM, respectively) over ALK4 and 5 (IC50s = 101 and 350 nM, respectively)
11802	LDN-193189	10 mg	≥95%	Inhibits BMP type 1 receptor-induced phosphorylation of SMAD1/5/8 (IC50 = 4.9 nM); shows specificity for ALK1, 2, 3, and 6 (IC50s = 0.8, 0.8, 5.3, and 16.7 nM, respectively) over ALK4 and 5 (IC50s = 101 and 350 nM, respectively)
11802	LDN-193189	5 mg	≥95%	Inhibits BMP type 1 receptor-induced phosphorylation of SMAD1/5/8 (IC50 = 4.9 nM); shows specificity for ALK1, 2, 3, and 6 (IC50s = 0.8, 0.8, 5.3, and 16.7 nM, respectively) over ALK4 and 5 (IC50s = 101 and 350 nM, respectively)
11811	INK128	1 mg	≥98%	An inhibitor of TORC1/2, acting as a sub-nanomolar ATP-dependent inhibitor of mTOR kinase; interferes with the growth of cell lines which are resistant to rapamycin and pan-PI3K inhibitors; inhibits angiogenesis and tumor growth in several xenograft models; reduces invasion and metastasis
11811	INK128	10 mg	≥98%	An inhibitor of TORC1/2, acting as a sub-nanomolar ATP-dependent inhibitor of mTOR kinase; interferes with the growth of cell lines which are resistant to rapamycin and pan-PI3K inhibitors; inhibits angiogenesis and tumor growth in several xenograft models; reduces invasion and metastasis
11811	INK128	5 mg	≥98%	An inhibitor of TORC1/2, acting as a sub-nanomolar ATP-dependent inhibitor of mTOR kinase; interferes with the growth of cell lines which are resistant to rapamycin and pan-PI3K inhibitors; inhibits angiogenesis and tumor growth in several xenograft models; reduces invasion and metastasis
11811	INK128	50 mg	≥98%	An inhibitor of TORC1/2, acting as a sub-nanomolar ATP-dependent inhibitor of mTOR kinase; interferes with the growth of cell lines which are resistant to rapamycin and pan-PI3K inhibitors; inhibits angiogenesis and tumor growth in several xenograft models; reduces invasion and metastasis
11838	Embelin	10 mg	≥95%	A natural benzoquinone which directly binds and inhibits XIAP (IC50 = 4.1 µM); blocks growth while activating caspases and promoting apoptosis in cancer cells expressing high levels of XIAP; prevents NF-κB activation by inhibiting IKK; protects against XIAP- and caspase-dependent inflammation
11838	Embelin	100 mg	≥95%	A natural benzoquinone which directly binds and inhibits XIAP (IC50 = 4.1 µM); blocks growth while activating caspases and promoting apoptosis in cancer cells expressing high levels of XIAP; prevents NF-κB activation by inhibiting IKK; protects against XIAP- and caspase-dependent inflammation
11838	Embelin	50 mg	≥95%	A natural benzoquinone which directly binds and inhibits XIAP (IC50 = 4.1 µM); blocks growth while activating caspases and promoting apoptosis in cancer cells expressing high levels of XIAP; prevents NF-κB activation by inhibiting IKK; protects against XIAP- and caspase-dependent inflammation

11967	Dorsomorphin	10 mg	≥98%	A potent, reversible inhibitor of AMPK (Ki = 109 nM); dose-dependently inhibits the bone morphogenetic protein type 1 receptors ACTR-I (ALK2), BMPR-IA (ALK3), and BMPR-IB (ALK6); downregulates the Akt/mTOR pathway to induce autophagy in U251 human glioma cells
11967	Dorsomorphin	5 mg	≥98%	A potent, reversible inhibitor of AMPK (Ki = 109 nM); dose-dependently inhibits the bone morphogenetic protein type 1 receptors ACTR-I (ALK2), BMPR-IA (ALK3), and BMPR-IB (ALK6); downregulates the Akt/mTOR pathway to induce autophagy in U251 human glioma cells
11967	Dorsomorphin	50 mg	≥98%	A potent, reversible inhibitor of AMPK (Ki = 109 nM); dose-dependently inhibits the bone morphogenetic protein type 1 receptors ACTR-I (ALK2), BMPR-IA (ALK3), and BMPR-IB (ALK6); downregulates the Akt/mTOR pathway to induce autophagy in U251 human glioma cells
12006	Rottlerin	10 mg	≥90%	Inhibits PKCδ (IC50 = 3 μM), CAM kinase III, and a wide range of protein kinases, including PRAK and MAPKAP-K2 (IC50s = 1.9 and 5 μM, respectively); stimulates autophagy by targeting a signaling cascade upstream of mTORC1
12006	Rottlerin	50 mg	≥90%	Inhibits PKCδ (IC50 = 3 μM), CAM kinase III, and a wide range of protein kinases, including PRAK and MAPKAP-K2 (IC50s = 1.9 and 5 μM, respectively); stimulates autophagy by targeting a signaling cascade upstream of mTORC1
12030	Bosutinib	10 mg	≥98%	An inhibitor of c-Src and Abl kinases (IC50s = 1.2 and 1 nM, respectively); inhibits the kinases EPHB2, TrkA, TrkB, and TXK (IC50s = 8.5, 22, 27, and 40 nM, respectively) among others; inhibits Src-dependent cell proliferation (IC50 = 100 nM); reduces tumor growth in unstaged and staged Src-transformed fibroblast mouse xenograft models at 30 or 25 mg/kg, respectively, twice per day; induces complete tumor regression in a K562 mouse xenograft model at 100 mg/kg once per day for five days
12030	Bosutinib	100 mg	≥98%	An inhibitor of c-Src and Abl kinases (IC50s = 1.2 and 1 nM, respectively); inhibits the kinases EPHB2, TrkA, TrkB, and TXK (IC50s = 8.5, 22, 27, and 40 nM, respectively) among others; inhibits Src-dependent cell proliferation (IC50 = 100 nM); reduces tumor growth in unstaged and staged Src-transformed fibroblast mouse xenograft models at 30 or 25 mg/kg, respectively, twice per day; induces complete tumor regression in a K562 mouse xenograft model at 100 mg/kg once per day for five days
12030	Bosutinib	5 mg	≥98%	An inhibitor of c-Src and Abl kinases (IC50s = 1.2 and 1 nM, respectively); inhibits the kinases EPHB2, TrkA, TrkB, and TXK (IC50s = 8.5, 22, 27, and 40 nM, respectively) among others; inhibits Src-dependent cell proliferation (IC50 = 100 nM); reduces tumor growth in unstaged and staged Src-transformed fibroblast mouse xenograft models at 30 or 25 mg/kg, respectively, twice per day; induces complete tumor regression in a K562 mouse xenograft model at 100 mg/kg once per day for five days
12030	Bosutinib	50 mg	≥98%	An inhibitor of c-Src and Abl kinases (IC50s = 1.2 and 1 nM, respectively); inhibits the kinases EPHB2, TrkA, TrkB, and TXK (IC50s = 8.5, 22, 27, and 40 nM, respectively) among others; inhibits Src-dependent cell proliferation (IC50 = 100 nM); reduces tumor growth in unstaged and staged Src-transformed fibroblast mouse xenograft models at 30 or 25 mg/kg, respectively, twice per day; induces complete tumor regression in a K562 mouse xenograft model at 100 mg/kg once per day for five days
12076	Canertinib (hydrochlo	10 mg	≥98%	An irreversible quinazoline-based HER family tyrosine kinase inhibitor with IC50 values of 0.8, 19, and 7 nM for blocking in vitro activity of EGFR, HER2, and HER4, respectively; inhibits the proliferation of various tumor cells
12076	Canertinib (hydrochlo	25 mg	≥98%	An irreversible quinazoline-based HER family tyrosine kinase inhibitor with IC50 values of 0.8, 19, and 7 nM for blocking in vitro activity of EGFR, HER2, and HER4, respectively; inhibits the proliferation of various tumor cells
12076	Canertinib (hydrochlo	5 mg	≥98%	An irreversible quinazoline-based HER family tyrosine kinase inhibitor with IC50 values of 0.8, 19, and 7 nM for blocking in vitro activity of EGFR, HER2, and HER4, respectively; inhibits the proliferation of various tumor cells
12076	Canertinib (hydrochlo	50 mg	≥98%	An irreversible quinazoline-based HER family tyrosine kinase inhibitor with IC50 values of 0.8, 19, and 7 nM for blocking in vitro activity of EGFR, HER2, and HER4, respectively; inhibits the proliferation of various tumor cells
12087	(R)-Crizotinib	10 mg	≥98%	A potent, orally bioavailable, ATP-competitive small-molecule dual inhibitor of c-MET (IC50 = 8 nM) and ALK (IC50 = 20 nM) receptor tyrosine kinases; shows antitumor efficacy in multiple tumor models implanted in athymic mice that express activated c-MET or ALK fusion proteins (IC50s = 5-20 nM)
12087	(R)-Crizotinib	5 mg	≥98%	A potent, orally bioavailable, ATP-competitive small-molecule dual inhibitor of c-MET (IC50 = 8 nM) and ALK (IC50 = 20 nM) receptor tyrosine kinases; shows antitumor efficacy in multiple tumor models implanted in athymic mice that express activated c-MET or ALK fusion proteins (IC50s = 5-20 nM)
12087	(R)-Crizotinib	50 mg	≥98%	A potent, orally bioavailable, ATP-competitive small-molecule dual inhibitor of c-MET (IC50 = 8 nM) and ALK (IC50 = 20 nM) receptor tyrosine kinases; shows antitumor efficacy in multiple tumor models implanted in athymic mice that express activated c-MET or ALK fusion proteins (IC50s = 5-20 nM)

12094	Lestaurtinib	1 mg	≥98%	A staurosporine analog that potently inhibits JAK2 kinase (IC50 = 1 nM) and downstream targets STAT5 (IC50 = 10-30 nM) and STAT3 in a human erythroleukemic cell line expressing the JAK2V617F mutation; potently inhibits the epigenetic kinase PRK1 (PKN1) in vitro (IC50 = 8.6 nM)
12094	Lestaurtinib	10 mg	≥98%	A staurosporine analog that potently inhibits JAK2 kinase (IC50 = 1 nM) and downstream targets STAT5 (IC50 = 10-30 nM) and STAT3 in a human erythroleukemic cell line expressing the JAK2V617F mutation; potently inhibits the epigenetic kinase PRK1 (PKN1) in vitro (IC50 = 8.6 nM)
12094	Lestaurtinib	5 mg	≥98%	A staurosporine analog that potently inhibits JAK2 kinase (IC50 = 1 nM) and downstream targets STAT5 (IC50 = 10-30 nM) and STAT3 in a human erythroleukemic cell line expressing the JAK2V617F mutation; potently inhibits the epigenetic kinase PRK1 (PKN1) in vitro (IC50 = 8.6 nM)
12094	Lestaurtinib	500 µg	≥98%	A staurosporine analog that potently inhibits JAK2 kinase (IC50 = 1 nM) and downstream targets STAT5 (IC50 = 10-30 nM) and STAT3 in a human erythroleukemic cell line expressing the JAK2V617F mutation; potently inhibits the epigenetic kinase PRK1 (PKN1) in vitro (IC50 = 8.6 nM)
12096	Mubritinib	10 mg	≥98%	A selective inhibitor of the HER2, inhibiting HER2 phosphorylation with an IC50 value of 6 nM; without effect on EGFR, FGFR, PDGFR, Jak1, Src, and Blk (IC50 > 25 µM); inhibits the proliferation of breast, bladder, kidney, and prostate cancer cells in vitro and in vivo
12096	Mubritinib	100 mg	≥98%	A selective inhibitor of the HER2, inhibiting HER2 phosphorylation with an IC50 value of 6 nM; without effect on EGFR, FGFR, PDGFR, Jak1, Src, and Blk (IC50 > 25 µM); inhibits the proliferation of breast, bladder, kidney, and prostate cancer cells in vitro and in vivo
12096	Mubritinib	5 mg	≥98%	A selective inhibitor of the HER2, inhibiting HER2 phosphorylation with an IC50 value of 6 nM; without effect on EGFR, FGFR, PDGFR, Jak1, Src, and Blk (IC50 > 25 µM); inhibits the proliferation of breast, bladder, kidney, and prostate cancer cells in vitro and in vivo
12096	Mubritinib	50 mg	≥98%	A selective inhibitor of the HER2, inhibiting HER2 phosphorylation with an IC50 value of 6 nM; without effect on EGFR, FGFR, PDGFR, Jak1, Src, and Blk (IC50 > 25 µM); inhibits the proliferation of breast, bladder, kidney, and prostate cancer cells in vitro and in vivo
12097	Pazopanib	10 mg	≥98%	A multi-kinase inhibitor; inhibits VEGFR1, VEGFR2, and VEGFR3 (IC50s = 10, 30, and 47 nM, respectively); inhibits PDGFRα, PDGFRβ, and c-Kit (IC50s = 71, 84, and 74 nM, respectively) as well as additional receptor tyrosine kinases; inhibits VEGF-induced upregulation of ICAM-1 and VCAM-1 and inhibits adhesion of multiple myeloma cells to HUVECs and proliferation of multiple myeloma cells; reduces tumor growth, induces apoptosis, decreases angiogenesis, and increases survival in a multiple myeloma mouse xenograft model at 30 and 100 mg/kg
12097	Pazopanib	100 mg	≥98%	A multi-kinase inhibitor; inhibits VEGFR1, VEGFR2, and VEGFR3 (IC50s = 10, 30, and 47 nM, respectively); inhibits PDGFRα, PDGFRβ, and c-Kit (IC50s = 71, 84, and 74 nM, respectively) as well as additional receptor tyrosine kinases; inhibits VEGF-induced upregulation of ICAM-1 and VCAM-1 and inhibits adhesion of multiple myeloma cells to HUVECs and proliferation of multiple myeloma cells; reduces tumor growth, induces apoptosis, decreases angiogenesis, and increases survival in a multiple myeloma mouse xenograft model at 30 and 100 mg/kg
12097	Pazopanib	25 mg	≥98%	A multi-kinase inhibitor; inhibits VEGFR1, VEGFR2, and VEGFR3 (IC50s = 10, 30, and 47 nM, respectively); inhibits PDGFRα, PDGFRβ, and c-Kit (IC50s = 71, 84, and 74 nM, respectively) as well as additional receptor tyrosine kinases; inhibits VEGF-induced upregulation of ICAM-1 and VCAM-1 and inhibits adhesion of multiple myeloma cells to HUVECs and proliferation of multiple myeloma cells; reduces tumor growth, induces apoptosis, decreases angiogenesis, and increases survival in a multiple myeloma mouse xenograft model at 30 and 100 mg/kg
12097	Pazopanib	50 mg	≥98%	A multi-kinase inhibitor; inhibits VEGFR1, VEGFR2, and VEGFR3 (IC50s = 10, 30, and 47 nM, respectively); inhibits PDGFRα, PDGFRβ, and c-Kit (IC50s = 71, 84, and 74 nM, respectively) as well as additional receptor tyrosine kinases; inhibits VEGF-induced upregulation of ICAM-1 and VCAM-1 and inhibits adhesion of multiple myeloma cells to HUVECs and proliferation of multiple myeloma cells; reduces tumor growth, induces apoptosis, decreases angiogenesis, and increases survival in a multiple myeloma mouse xenograft model at 30 and 100 mg/kg
12098	Tandutinib	100 mg	≥95%	A potent antagonist of the type III receptor tyrosine kinases PDGFRβ, FLT3, and c-Kit (IC50 = 200, 220, and 170 nM, respectively); less potently inhibits CSF-1R (IC50 = 3.4 µM) and does not significantly inhibit other tyrosine or serine/threonine kinases
12098	Tandutinib	25 mg	≥95%	A potent antagonist of the type III receptor tyrosine kinases PDGFRβ, FLT3, and c-Kit (IC50 = 200, 220, and 170 nM, respectively); less potently inhibits CSF-1R (IC50 = 3.4 µM) and does not significantly inhibit other tyrosine or serine/threonine kinases
12098	Tandutinib	250 mg	≥95%	A potent antagonist of the type III receptor tyrosine kinases PDGFRβ, FLT3, and c-Kit (IC50 = 200, 220, and 170 nM, respectively); less potently inhibits CSF-1R (IC50 = 3.4 µM) and does not significantly inhibit other tyrosine or serine/threonine kinases
12098	Tandutinib	50 mg	≥95%	A potent antagonist of the type III receptor tyrosine kinases PDGFRβ, FLT3, and c-Kit (IC50 = 200, 220, and 170 nM, respectively); less potently inhibits CSF-1R (IC50 = 3.4 µM) and does not significantly inhibit other tyrosine or serine/threonine kinases
13031	SB-431542 (hydrate)	1 mg	≥98%	A potent and selective inhibitor of the TGF-β1 receptor ALK5 (IC50 = 94 nM), ALK4 (IC50 = 140 nM) and, less effectively, ALK7; suppresses renewal in embryonic and induced pluripotent stem cells and promotes their differentiation

13031	SB-431542 (hydrate)	10 mg	≥98%	A potent and selective inhibitor of the TGF-β1 receptor ALK5 (IC50 = 94 nM), ALK4 (IC50 = 140 nM) and, less effectively, ALK7; suppresses renewal in embryonic and induced pluripotent stem cells and promotes their differentiation
13031	SB-431542 (hydrate)	25 mg	≥98%	A potent and selective inhibitor of the TGF-β1 receptor ALK5 (IC50 = 94 nM), ALK4 (IC50 = 140 nM) and, less effectively, ALK7; suppresses renewal in embryonic and induced pluripotent stem cells and promotes their differentiation
13031	SB-431542 (hydrate)	5 mg	≥98%	A potent and selective inhibitor of the TGF-β1 receptor ALK5 (IC50 = 94 nM), ALK4 (IC50 = 140 nM) and, less effectively, ALK7; suppresses renewal in embryonic and induced pluripotent stem cells and promotes their differentiation
13032	PD 173074	10 mg	≥98%	A potent, selective inhibitor of FGFR tyrosine kinase activity, blocking autophosphorylation of FGFR1 (IC50 = 21.5 nM); impairs angiogenesis, as well as self-renewal of stem cells via ERK1/2 activation
13032	PD 173074	25 mg	≥98%	A potent, selective inhibitor of FGFR tyrosine kinase activity, blocking autophosphorylation of FGFR1 (IC50 = 21.5 nM); impairs angiogenesis, as well as self-renewal of stem cells via ERK1/2 activation
13032	PD 173074	5 mg	≥98%	A potent, selective inhibitor of FGFR tyrosine kinase activity, blocking autophosphorylation of FGFR1 (IC50 = 21.5 nM); impairs angiogenesis, as well as self-renewal of stem cells via ERK1/2 activation
13034	PD 0325901	1 mg	≥98%	A potent MEK inhibitor that suppresses phosphorylation of ERK in murine colon 26 tumors with an IC50 value of 0.33 nM; suppression of ERK activation with 1 µM PD 0325901 combined with 3 µM CHIR99021 (a glycogen synthase kinase-3 inhibitor) prevents cell differentiation and sustains self renewal of mouse embryonic stem cells for at least eight passages
13034	PD 0325901	10 mg	≥98%	A potent MEK inhibitor that suppresses phosphorylation of ERK in murine colon 26 tumors with an IC50 value of 0.33 nM; suppression of ERK activation with 1 µM PD 0325901 combined with 3 µM CHIR99021 (a glycogen synthase kinase-3 inhibitor) prevents cell differentiation and sustains self renewal of mouse embryonic stem cells for at least eight passages
13034	PD 0325901	25 mg	≥98%	A potent MEK inhibitor that suppresses phosphorylation of ERK in murine colon 26 tumors with an IC50 value of 0.33 nM; suppression of ERK activation with 1 µM PD 0325901 combined with 3 µM CHIR99021 (a glycogen synthase kinase-3 inhibitor) prevents cell differentiation and sustains self renewal of mouse embryonic stem cells for at least eight passages
13034	PD 0325901	5 mg	≥98%	A potent MEK inhibitor that suppresses phosphorylation of ERK in murine colon 26 tumors with an IC50 value of 0.33 nM; suppression of ERK activation with 1 µM PD 0325901 combined with 3 µM CHIR99021 (a glycogen synthase kinase-3 inhibitor) prevents cell differentiation and sustains self renewal of mouse embryonic stem cells for at least eight passages
13067	SB 203580	10 mg	≥98%	A specific, pyridinyl imidazole inhibitor of p38 MAPK that inhibits p38 MAPK activity (IC50 = 0.6 µM)
13067	SB 203580	100 mg	≥98%	A specific, pyridinyl imidazole inhibitor of p38 MAPK that inhibits p38 MAPK activity (IC50 = 0.6 µM)
13067	SB 203580	5 mg	≥98%	A specific, pyridinyl imidazole inhibitor of p38 MAPK that inhibits p38 MAPK activity (IC50 = 0.6 µM)
13067	SB 203580	50 mg	≥98%	A specific, pyridinyl imidazole inhibitor of p38 MAPK that inhibits p38 MAPK activity (IC50 = 0.6 µM)
13105	Masitinib	10 mg	≥98%	An inhibitor of c-Kit (IC50 = 200 nM); an inhibitor of PDGFRα, PDGFRβ, and Lyn B (IC50s = 540, 800, and 510 nM, respectively); inhibits stem cell factor-induced proliferation of Ba/F3 cells expressing wild-type KIT (IC50 = 150 nM), as well as those expressing the KIT mutants KITV559D and KITΔ27 (IC50s = 3 and 5 nM, respectively); an inhibitor of SARS-CoV-2 Mpro (Ki = 2.6 µM); inhibits replication of SARS-CoV-2 in infected A549 cells (EC50 = 3.2 µM); decreases lung and nose viral titers, as well as reduces lung inflammation and increases survival, in ACE2-humanized mice infected with SARS-CoV-2 at 25 mg/kg
13105	Masitinib	100 mg	≥98%	An inhibitor of c-Kit (IC50 = 200 nM); an inhibitor of PDGFRα, PDGFRβ, and Lyn B (IC50s = 540, 800, and 510 nM, respectively); inhibits stem cell factor-induced proliferation of Ba/F3 cells expressing wild-type KIT (IC50 = 150 nM), as well as those expressing the KIT mutants KITV559D and KITΔ27 (IC50s = 3 and 5 nM, respectively); an inhibitor of SARS-CoV-2 Mpro (Ki = 2.6 µM); inhibits replication of SARS-CoV-2 in infected A549 cells (EC50 = 3.2 µM); decreases lung and nose viral titers, as well as reduces lung inflammation and increases survival, in ACE2-humanized mice infected with SARS-CoV-2 at 25 mg/kg
13105	Masitinib	25 mg	≥98%	An inhibitor of c-Kit (IC50 = 200 nM); an inhibitor of PDGFRα, PDGFRβ, and Lyn B (IC50s = 540, 800, and 510 nM, respectively); inhibits stem cell factor-induced proliferation of Ba/F3 cells expressing wild-type KIT (IC50 = 150 nM), as well as those expressing the KIT mutants KITV559D and KITΔ27 (IC50s = 3 and 5 nM, respectively); an inhibitor of SARS-CoV-2 Mpro (Ki = 2.6 µM); inhibits replication of SARS-CoV-2 in infected A549 cells (EC50 = 3.2 µM); decreases lung and nose viral titers, as well as reduces lung inflammation and increases survival, in ACE2-humanized mice infected with SARS-CoV-2 at 25 mg/kg

13105	Masitinib	50 mg	≥98%	An inhibitor of c-Kit (IC50 = 200 nM); an inhibitor of PDGFRα, PDGFRβ, and Lyn B (IC50s = 540, 800, and 510 nM, respectively); inhibits stem cell factor-induced proliferation of Ba/F3 cells expressing wild-type KIT (IC50 = 150 nM), as well as those expressing the KIT mutants KITV559D and KITΔ27 (IC50s = 3 and 5 nM, respectively); an inhibitor of SARS-CoV-2 Mpro (Ki = 2.6 μM); inhibits replication of SARS-CoV-2 in infected A549 cells (EC50 = 3.2 μM); decreases lung and nose viral titers, as well as reduces lung inflammation and increases survival, in ACE2-humanized mice infected with SARS-CoV-2 at 25 mg/kg
13108	VX-702	10 mg	≥95%	A third generation inhibitor of p38 MAP kinases, binding to both p38α and p38β (Kd = 3.7 and 17 nM, respectively); inhibits IL-6, IL-1β, and TNF-α production in LPS-primed blood with IC50 values of 59, 122, and 99 ng/ml, respectively
13108	VX-702	25 mg	≥95%	A third generation inhibitor of p38 MAP kinases, binding to both p38α and p38β (Kd = 3.7 and 17 nM, respectively); inhibits IL-6, IL-1β, and TNF-α production in LPS-primed blood with IC50 values of 59, 122, and 99 ng/ml, respectively
13108	VX-702	5 mg	≥95%	A third generation inhibitor of p38 MAP kinases, binding to both p38α and p38β (Kd = 3.7 and 17 nM, respectively); inhibits IL-6, IL-1β, and TNF-α production in LPS-primed blood with IC50 values of 59, 122, and 99 ng/ml, respectively
13109	Emodin	100 mg	≥98%	A naturally-occurring anthraquinone with diverse effects, including the suppression of inflammation, dyslipidemia, and cancer; directly and selectively inhibits CK2 (IC50 = 0.89 μM) and the COP9 signalosome; acts as a phytoestrogen, blocking 17β-estradiol binding to ER with Ki values of 0.77 and 1.5 μM for ERα and ERβ, respectively
13109	Emodin	25 mg	≥98%	A naturally-occurring anthraquinone with diverse effects, including the suppression of inflammation, dyslipidemia, and cancer; directly and selectively inhibits CK2 (IC50 = 0.89 μM) and the COP9 signalosome; acts as a phytoestrogen, blocking 17β-estradiol binding to ER with Ki values of 0.77 and 1.5 μM for ERα and ERβ, respectively
13109	Emodin	50 mg	≥98%	A naturally-occurring anthraquinone with diverse effects, including the suppression of inflammation, dyslipidemia, and cancer; directly and selectively inhibits CK2 (IC50 = 0.89 μM) and the COP9 signalosome; acts as a phytoestrogen, blocking 17β-estradiol binding to ER with Ki values of 0.77 and 1.5 μM for ERα and ERβ, respectively
13111	AZD 4547	10 mg	≥98%	A selective inhibitor of the fibroblast growth factor receptor tyrosine kinase (IC50s = 0.2, 2.5, and 1.8 nM for FGFR1, 2, and 3, respectively); demonstrates antiproliferative activity in tumor cell lines expressing deregulated FGFRs (IC50s = 18-281 nM) and in an FGFR-driven human tumor xenograft model (12.5 mg/kg/day)
13111	AZD 4547	5 mg	≥98%	A selective inhibitor of the fibroblast growth factor receptor tyrosine kinase (IC50s = 0.2, 2.5, and 1.8 nM for FGFR1, 2, and 3, respectively); demonstrates antiproliferative activity in tumor cell lines expressing deregulated FGFRs (IC50s = 18-281 nM) and in an FGFR-driven human tumor xenograft model (12.5 mg/kg/day)
13111	AZD 4547	50 mg	≥98%	A selective inhibitor of the fibroblast growth factor receptor tyrosine kinase (IC50s = 0.2, 2.5, and 1.8 nM for FGFR1, 2, and 3, respectively); demonstrates antiproliferative activity in tumor cell lines expressing deregulated FGFRs (IC50s = 18-281 nM) and in an FGFR-driven human tumor xenograft model (12.5 mg/kg/day)
13122	CHIR99021	1 mg	≥95%	An aminopyrimidine derivative that inhibits GSK3α and GSK3β (IC50s = 10 and 6.7 nM, respectively); activates glycogen synthesis in CHO-IR cells (EC50 = 0.8 μM) and in isolated type 1 diabetic rat skeletal muscle; has been shown to promote self-renewal of embryonic stem cells
13122	CHIR99021	10 mg	≥95%	An aminopyrimidine derivative that inhibits GSK3α and GSK3β (IC50s = 10 and 6.7 nM, respectively); activates glycogen synthesis in CHO-IR cells (EC50 = 0.8 μM) and in isolated type 1 diabetic rat skeletal muscle; has been shown to promote self-renewal of embryonic stem cells
13122	CHIR99021	25 mg	≥95%	An aminopyrimidine derivative that inhibits GSK3α and GSK3β (IC50s = 10 and 6.7 nM, respectively); activates glycogen synthesis in CHO-IR cells (EC50 = 0.8 μM) and in isolated type 1 diabetic rat skeletal muscle; has been shown to promote self-renewal of embryonic stem cells
13122	CHIR99021	5 mg	≥95%	An aminopyrimidine derivative that inhibits GSK3α and GSK3β (IC50s = 10 and 6.7 nM, respectively); activates glycogen synthesis in CHO-IR cells (EC50 = 0.8 μM) and in isolated type 1 diabetic rat skeletal muscle; has been shown to promote self-renewal of embryonic stem cells
13123	BIO	1 mg	≥98%	A cell-permeable bis-indolo (indirubin) compound that acts as a highly potent, selective, reversible, and ATP-competitive inhibitor of GSK3α/β (IC50 = 5 nM); inhibition of GSK activates the Wnt-signaling pathway and sustains pluripotency in human and mouse ESCs; maintains self-renewal in human and mouse embryonic stem cells as well as induces the differentiation of neonatal cardiomyocytes
13123	BIO	10 mg	≥98%	A cell-permeable bis-indolo (indirubin) compound that acts as a highly potent, selective, reversible, and ATP-competitive inhibitor of GSK3α/β (IC50 = 5 nM); inhibition of GSK activates the Wnt-signaling pathway and sustains pluripotency in human and mouse ESCs; maintains self-renewal in human and mouse embryonic stem cells as well as induces the differentiation of neonatal cardiomyocytes

13123	BIO	25 mg	≥98%	A cell-permeable bis-indolo (indirubin) compound that acts as a highly potent, selective, reversible, and ATP-competitive inhibitor of GSK3α/β (IC50 = 5 nM); inhibition of GSK activates the Wnt-signaling pathway and sustains pluripotency in human and mouse ESCs; maintains self-renewal in human and mouse embryonic stem cells as well as induces the differentiation of neonatal cardiomyocytes
13123	BIO	5 mg	≥98%	A cell-permeable bis-indolo (indirubin) compound that acts as a highly potent, selective, reversible, and ATP-competitive inhibitor of GSK3α/β (IC50 = 5 nM); inhibition of GSK activates the Wnt-signaling pathway and sustains pluripotency in human and mouse ESCs; maintains self-renewal in human and mouse embryonic stem cells as well as induces the differentiation of neonatal cardiomyocytes
13139	Imatinib (mesylate)	100 mg	≥98%	An inhibitor of the receptor tyrosine kinases c-Abl, Bcr-Abl, PDGFR, and c-Kit; inhibits ligand-stimulated autophosphorylation of PDGFR and c-Kit (IC50s = ~0.3 and ~0.1 μM, respectively); inhibits the proliferation of Bcr-Abl-dependent R10(–) cells (IC50s = ~35-40 nM) and HMC-1 cells expressing constitutively active c-Kit in a concentration-dependent manner; prolongs survival in a mouse model of chronic myeloid leukemia at 100 mg/kg twice daily; inhibits replication of MERS-CoV and SARS-CoV in Vero E6 cells at 25 and 50 μM; reduces viral titers in IBV-infected Vero cells at 10 μM
13139	Imatinib (mesylate)	25 mg	≥98%	An inhibitor of the receptor tyrosine kinases c-Abl, Bcr-Abl, PDGFR, and c-Kit; inhibits ligand-stimulated autophosphorylation of PDGFR and c-Kit (IC50s = ~0.3 and ~0.1 μM, respectively); inhibits the proliferation of Bcr-Abl-dependent R10(–) cells (IC50s = ~35-40 nM) and HMC-1 cells expressing constitutively active c-Kit in a concentration-dependent manner; prolongs survival in a mouse model of chronic myeloid leukemia at 100 mg/kg twice daily; inhibits replication of MERS-CoV and SARS-CoV in Vero E6 cells at 25 and 50 μM; reduces viral titers in IBV-infected Vero cells at 10 μM
13139	Imatinib (mesylate)	50 mg	≥98%	An inhibitor of the receptor tyrosine kinases c-Abl, Bcr-Abl, PDGFR, and c-Kit; inhibits ligand-stimulated autophosphorylation of PDGFR and c-Kit (IC50s = ~0.3 and ~0.1 μM, respectively); inhibits the proliferation of Bcr-Abl-dependent R10(–) cells (IC50s = ~35-40 nM) and HMC-1 cells expressing constitutively active c-Kit in a concentration-dependent manner; prolongs survival in a mouse model of chronic myeloid leukemia at 100 mg/kg twice daily; inhibits replication of MERS-CoV and SARS-CoV in Vero E6 cells at 25 and 50 μM; reduces viral titers in IBV-infected Vero cells at 10 μM
13139	Imatinib (mesylate)	500 mg	≥98%	An inhibitor of the receptor tyrosine kinases c-Abl, Bcr-Abl, PDGFR, and c-Kit; inhibits ligand-stimulated autophosphorylation of PDGFR and c-Kit (IC50s = ~0.3 and ~0.1 μM, respectively); inhibits the proliferation of Bcr-Abl-dependent R10(–) cells (IC50s = ~35-40 nM) and HMC-1 cells expressing constitutively active c-Kit in a concentration-dependent manner; prolongs survival in a mouse model of chronic myeloid leukemia at 100 mg/kg twice daily; inhibits replication of MERS-CoV and SARS-CoV in Vero E6 cells at 25 and 50 μM; reduces viral titers in IBV-infected Vero cells at 10 μM
13159	Sunitinib (malate)	1 mg	≥98%	A multi-kinase inhibitor; inhibits FLK1 (Ki = 9 nM), PDGFRβ (Ki = 8 nM), and FLT3; at least 10-fold selective for FLK1 and PDGFRβ over a variety of tyrosine kinases in a panel, including EGFR, Cdk2, Met, IGFR-1, Abl, and Src; inhibits VEGF-dependent FLK1 and PDGF-dependent PDGFRβ phosphorylation (IC50s = 10 and 10 nM, respectively); inhibits phosphorylation of FLT3 and FLT3-ITD (IC50s = 250 and 50 nM, respectively); decreases VEGF- and FGF-induced proliferation of HUVECs; IC50s = 30 and 700 nM, respectively); reduces tumor growth in a variety of mouse xenograft models at 20-80 mg/kg per day
13159	Sunitinib (malate)	10 mg	≥98%	A multi-kinase inhibitor; inhibits FLK1 (Ki = 9 nM), PDGFRβ (Ki = 8 nM), and FLT3; at least 10-fold selective for FLK1 and PDGFRβ over a variety of tyrosine kinases in a panel, including EGFR, Cdk2, Met, IGFR-1, Abl, and Src; inhibits VEGF-dependent FLK1 and PDGF-dependent PDGFRβ phosphorylation (IC50s = 10 and 10 nM, respectively); inhibits phosphorylation of FLT3 and FLT3-ITD (IC50s = 250 and 50 nM, respectively); decreases VEGF- and FGF-induced proliferation of HUVECs; IC50s = 30 and 700 nM, respectively); reduces tumor growth in a variety of mouse xenograft models at 20-80 mg/kg per day
13159	Sunitinib (malate)	5 mg	≥98%	A multi-kinase inhibitor; inhibits FLK1 (Ki = 9 nM), PDGFRβ (Ki = 8 nM), and FLT3; at least 10-fold selective for FLK1 and PDGFRβ over a variety of tyrosine kinases in a panel, including EGFR, Cdk2, Met, IGFR-1, Abl, and Src; inhibits VEGF-dependent FLK1 and PDGF-dependent PDGFRβ phosphorylation (IC50s = 10 and 10 nM, respectively); inhibits phosphorylation of FLT3 and FLT3-ITD (IC50s = 250 and 50 nM, respectively); decreases VEGF- and FGF-induced proliferation of HUVECs; IC50s = 30 and 700 nM, respectively); reduces tumor growth in a variety of mouse xenograft models at 20-80 mg/kg per day

13159	Sunitinib (malate)	50 mg	≥98%	A multi-kinase inhibitor; inhibits FLK1 (Ki = 9 nM), PDGFRβ (Ki = 8 nM), and FLT3; at least 10-fold selective for FLK1 and PDGFRβ over a variety of tyrosine kinases in a panel, including EGFR, Cdk2, Met, IGFR-1, Abl, and Src; inhibits VEGF-dependent FLK1 and PDGF-dependent PDGFRβ phosphorylation (IC50s = 10 and 10 nM, respectively); inhibits phosphorylation of FLT3 and FLT3-ITD (IC50s = 250 and 50 nM, respectively); decreases VEGF- and FGF-induced proliferation of HUVECs; IC50s = 30 and 700 nM, respectively); reduces tumor growth in a variety of mouse xenograft models at 20-80 mg/kg per day
13166	Gefitinib	1 g	≥98%	An EGFR inhibitor (IC50s = 0.023-0.079 μM); inhibits colony formation of GEO colon, ZR-75-1 and MCF-10A breast, and OVCAR-3 ovarian cancer cell lines in soft agar assays (IC50s = 0.2-0.4 μM); induces apoptosis and inhibits EGFR autophosphorylation in the same cells from 0.1-1 μM; reduces tumor volume and increases survival in a GEO mouse xenograft model at 1.25, 2.5, and 5 mg/kg
13166	Gefitinib	250 mg	≥98%	An EGFR inhibitor (IC50s = 0.023-0.079 μM); inhibits colony formation of GEO colon, ZR-75-1 and MCF-10A breast, and OVCAR-3 ovarian cancer cell lines in soft agar assays (IC50s = 0.2-0.4 μM); induces apoptosis and inhibits EGFR autophosphorylation in the same cells from 0.1-1 μM; reduces tumor volume and increases survival in a GEO mouse xenograft model at 1.25, 2.5, and 5 mg/kg
13166	Gefitinib	5 g	≥98%	An EGFR inhibitor (IC50s = 0.023-0.079 μM); inhibits colony formation of GEO colon, ZR-75-1 and MCF-10A breast, and OVCAR-3 ovarian cancer cell lines in soft agar assays (IC50s = 0.2-0.4 μM); induces apoptosis and inhibits EGFR autophosphorylation in the same cells from 0.1-1 μM; reduces tumor volume and increases survival in a GEO mouse xenograft model at 1.25, 2.5, and 5 mg/kg
13166	Gefitinib	500 mg	≥98%	An EGFR inhibitor (IC50s = 0.023-0.079 μM); inhibits colony formation of GEO colon, ZR-75-1 and MCF-10A breast, and OVCAR-3 ovarian cancer cell lines in soft agar assays (IC50s = 0.2-0.4 μM); induces apoptosis and inhibits EGFR autophosphorylation in the same cells from 0.1-1 μM; reduces tumor volume and increases survival in a GEO mouse xenograft model at 1.25, 2.5, and 5 mg/kg
13182	SU 5402	1 mg	≥95%	An inhibitor of the tyrosine kinase domains of VEGFR2, FGFR1, and PDGFRβ (IC50s = 0.02, 0.03, and 0.51 μM, respectively)
13182	SU 5402	10 mg	≥95%	An inhibitor of the tyrosine kinase domains of VEGFR2, FGFR1, and PDGFRβ (IC50s = 0.02, 0.03, and 0.51 μM, respectively)
13182	SU 5402	25 mg	≥95%	An inhibitor of the tyrosine kinase domains of VEGFR2, FGFR1, and PDGFRβ (IC50s = 0.02, 0.03, and 0.51 μM, respectively)
13182	SU 5402	5 mg	≥95%	An inhibitor of the tyrosine kinase domains of VEGFR2, FGFR1, and PDGFRβ (IC50s = 0.02, 0.03, and 0.51 μM, respectively)
13198	PP2	1 mg	≥95%	A potent, reversible, ATP-competitive, and selective inhibitor of the Src family of protein tyrosine kinases: p56lck (IC50 = 4 nM), p59fynT (IC50 = 5 nM), Hck (IC50 = 5 nM)
13198	PP2	10 mg	≥95%	A potent, reversible, ATP-competitive, and selective inhibitor of the Src family of protein tyrosine kinases: p56lck (IC50 = 4 nM), p59fynT (IC50 = 5 nM), Hck (IC50 = 5 nM)
13198	PP2	25 mg	≥95%	A potent, reversible, ATP-competitive, and selective inhibitor of the Src family of protein tyrosine kinases: p56lck (IC50 = 4 nM), p59fynT (IC50 = 5 nM), Hck (IC50 = 5 nM)
13198	PP2	5 mg	≥95%	A potent, reversible, ATP-competitive, and selective inhibitor of the Src family of protein tyrosine kinases: p56lck (IC50 = 4 nM), p59fynT (IC50 = 5 nM), Hck (IC50 = 5 nM)
13242	3-Methyladenine	100 mg	≥95%	A specific inhibitor of PI3K activity and a widely used inhibitor of the autophagy; at 5 mM, inhibits protein degradation in rat hepatocytes by 65% and blocks class I, II, and III PI3Ks, including some downstream targets
13242	3-Methyladenine	25 mg	≥95%	A specific inhibitor of PI3K activity and a widely used inhibitor of the autophagy; at 5 mM, inhibits protein degradation in rat hepatocytes by 65% and blocks class I, II, and III PI3Ks, including some downstream targets
13242	3-Methyladenine	50 mg	≥95%	A specific inhibitor of PI3K activity and a widely used inhibitor of the autophagy; at 5 mM, inhibits protein degradation in rat hepatocytes by 65% and blocks class I, II, and III PI3Ks, including some downstream targets
13298	Bisindolylmaleimide I	10 mg	≥95%	A highly selective, cell-permeable, and reversible PKC inhibitor (Ki = 14 nM); competitive inhibitor for the ATP binding site of PKC; highly selective for PKCα, β1, β2, γ, δ, and ε isozymes; inhibits GSK3 in primary adipocyte lysates (IC50 = 360 nM) and in GSK3β immunoprecipitates derived from rat epididymal adipocytes (IC50 = 170 nM); competitively antagonizes the 5-HT3 receptor with a Ki value of 61 nM
13298	Bisindolylmaleimide I	25 mg	≥95%	A highly selective, cell-permeable, and reversible PKC inhibitor (Ki = 14 nM); competitive inhibitor for the ATP binding site of PKC; highly selective for PKCα, β1, β2, γ, δ, and ε isozymes; inhibits GSK3 in primary adipocyte lysates (IC50 = 360 nM) and in GSK3β immunoprecipitates derived from rat epididymal adipocytes (IC50 = 170 nM); competitively antagonizes the 5-HT3 receptor with a Ki value of 61 nM

13298	Bisindolylmaleimide I	5 mg	≥95%	A highly selective, cell-permeable, and reversible PKC inhibitor (Ki = 14 nM); competitive inhibitor for the ATP binding site of PKC; highly selective for PKCα, β1, β2, γ, δ, and ε isozymes; inhibits GSK3 in primary adipocyte lysates (IC50 = 360 nM) and in GSK3β immunoprecipitates derived from rat epididymal adipocytes (IC50 = 170 nM); competitively antagonizes the 5-HT3 receptor with a Ki value of 61 nM
13298	Bisindolylmaleimide I	50 mg	≥95%	A highly selective, cell-permeable, and reversible PKC inhibitor (Ki = 14 nM); competitive inhibitor for the ATP binding site of PKC; highly selective for PKCα, β1, β2, γ, δ, and ε isozymes; inhibits GSK3 in primary adipocyte lysates (IC50 = 360 nM) and in GSK3β immunoprecipitates derived from rat epididymal adipocytes (IC50 = 170 nM); competitively antagonizes the 5-HT3 receptor with a Ki value of 61 nM
13299	Bisindolylmaleimide IV	1 mg	≥98%	A cell permeable inhibitor of PKC with IC50 values reported to range from 0.10 to 0.55 µM; designed to be more discriminative than its parent compound, the non-selective PKC inhibitor, staurosporine (Catalog No. 81590); also inhibits protein kinase A with IC50 values ranging from 2 to 11.8 µM
13299	Bisindolylmaleimide IV	10 mg	≥98%	A cell permeable inhibitor of PKC with IC50 values reported to range from 0.10 to 0.55 µM; designed to be more discriminative than its parent compound, the non-selective PKC inhibitor, staurosporine (Catalog No. 81590); also inhibits protein kinase A with IC50 values ranging from 2 to 11.8 µM
13299	Bisindolylmaleimide IV	25 mg	≥98%	A cell permeable inhibitor of PKC with IC50 values reported to range from 0.10 to 0.55 µM; designed to be more discriminative than its parent compound, the non-selective PKC inhibitor, staurosporine (Catalog No. 81590); also inhibits protein kinase A with IC50 values ranging from 2 to 11.8 µM
13299	Bisindolylmaleimide IV	5 mg	≥98%	A cell permeable inhibitor of PKC with IC50 values reported to range from 0.10 to 0.55 µM; designed to be more discriminative than its parent compound, the non-selective PKC inhibitor, staurosporine (Catalog No. 81590); also inhibits protein kinase A with IC50 values ranging from 2 to 11.8 µM
13300	Bisindolylmaleimide V	1 mg	≥98%	A weak inhibitor of PKC demonstrating an IC50 value >100 µM; blocks the activation of mitogen-stimulated protein kinase p70s6k/p85s6k (S6K) in vivo with an IC50 value of 8 µM
13300	Bisindolylmaleimide V	10 mg	≥98%	A weak inhibitor of PKC demonstrating an IC50 value >100 µM; blocks the activation of mitogen-stimulated protein kinase p70s6k/p85s6k (S6K) in vivo with an IC50 value of 8 µM
13300	Bisindolylmaleimide V	25 mg	≥98%	A weak inhibitor of PKC demonstrating an IC50 value >100 µM; blocks the activation of mitogen-stimulated protein kinase p70s6k/p85s6k (S6K) in vivo with an IC50 value of 8 µM
13300	Bisindolylmaleimide V	5 mg	≥98%	A weak inhibitor of PKC demonstrating an IC50 value >100 µM; blocks the activation of mitogen-stimulated protein kinase p70s6k/p85s6k (S6K) in vivo with an IC50 value of 8 µM
13305	D 4476	1 mg	≥98%	A cell-permeant inhibitor of CK1 (IC50 = 200 nM from S. pombe, 300 nM for CK1δ); only weakly affects the activities of a panel of kinases tested
13305	D 4476	10 mg	≥98%	A cell-permeant inhibitor of CK1 (IC50 = 200 nM from S. pombe, 300 nM for CK1δ); only weakly affects the activities of a panel of kinases tested
13305	D 4476	5 mg	≥98%	A cell-permeant inhibitor of CK1 (IC50 = 200 nM from S. pombe, 300 nM for CK1δ); only weakly affects the activities of a panel of kinases tested
13305	D 4476	50 mg	≥98%	A cell-permeant inhibitor of CK1 (IC50 = 200 nM from S. pombe, 300 nM for CK1δ); only weakly affects the activities of a panel of kinases tested
13308	NU 7026	10 mg	≥95%	A cell-permeable, potent, specific, and ATP-competitive inhibitor of DNA-PK (IC50 = 230 nM); poorly inhibits PI3K (IC50 = 13 µM) and is inactive against ATM, ATR, and PARP-1
13308	NU 7026	25 mg	≥95%	A cell-permeable, potent, specific, and ATP-competitive inhibitor of DNA-PK (IC50 = 230 nM); poorly inhibits PI3K (IC50 = 13 µM) and is inactive against ATM, ATR, and PARP-1
13308	NU 7026	5 mg	≥95%	A cell-permeable, potent, specific, and ATP-competitive inhibitor of DNA-PK (IC50 = 230 nM); poorly inhibits PI3K (IC50 = 13 µM) and is inactive against ATM, ATR, and PARP-1
13308	NU 7026	50 mg	≥95%	A cell-permeable, potent, specific, and ATP-competitive inhibitor of DNA-PK (IC50 = 230 nM); poorly inhibits PI3K (IC50 = 13 µM) and is inactive against ATM, ATR, and PARP-1
13310	Gö 6976	1 mg	≥98%	A PKCα and PKCβ1 inhibitor with IC50 values of 2.3 and 6.2 nM, respectively; also inhibits the checkpoint kinases Chk1/2 and abrogates DNA damage-induced cell cycle arrest, leading to cytotoxicity in p53 mutant tumor cells
13310	Gö 6976	5 mg	≥98%	A PKCα and PKCβ1 inhibitor with IC50 values of 2.3 and 6.2 nM, respectively; also inhibits the checkpoint kinases Chk1/2 and abrogates DNA damage-induced cell cycle arrest, leading to cytotoxicity in p53 mutant tumor cells

13310	Gö 6976	500 µg	≥98%	A PKCα and PKCβ1 inhibitor with IC50 values of 2.3 and 6.2 nM, respectively; also inhibits the checkpoint kinases Chk1/2 and abrogates DNA damage-induced cell cycle arrest, leading to cytotoxicity in p53 mutant tumor cells
13311	Gö 6983	1 mg	≥98%	Inhibits several isoforms of protein kinase C (PKC; IC50 = 7, 7, 6, 10, 60, and 20,000 nM for PKCα, PKCβ, PKCγ, PKCδ, PKCζ, and PKCµ, respectively); provides cardioprotective effects in myocardial ischemia/reperfusion
13311	Gö 6983	10 mg	≥98%	Inhibits several isoforms of protein kinase C (PKC; IC50 = 7, 7, 6, 10, 60, and 20,000 nM for PKCα, PKCβ, PKCγ, PKCδ, PKCζ, and PKCµ, respectively); provides cardioprotective effects in myocardial ischemia/reperfusion
13311	Gö 6983	5 mg	≥98%	Inhibits several isoforms of protein kinase C (PKC; IC50 = 7, 7, 6, 10, 60, and 20,000 nM for PKCα, PKCβ, PKCγ, PKCδ, PKCζ, and PKCµ, respectively); provides cardioprotective effects in myocardial ischemia/reperfusion
13312	H-9 (hydrochloride)	10 mg	≥98%	A potent competitive inhibitor of PKC, PKG, and PKA with Ki values of 18, 0.87, and 1.9 µM, repectively
13312	H-9 (hydrochloride)	25 mg	≥98%	A potent competitive inhibitor of PKC, PKG, and PKA with Ki values of 18, 0.87, and 1.9 µM, repectively
13312	H-9 (hydrochloride)	5 mg	≥98%	A potent competitive inhibitor of PKC, PKG, and PKA with Ki values of 18, 0.87, and 1.9 µM, repectively
13312	H-9 (hydrochloride)	50 mg	≥98%	A potent competitive inhibitor of PKC, PKG, and PKA with Ki values of 18, 0.87, and 1.9 µM, repectively
13313	IKK-16 (hydrochloride	10 mg	≥98%	A potent inhibitor of IκB kinases (IKKs), displaying IC50 values of 200, 40, and 70 nM for IKKα, IKKβ, and IKK complex, respectively, in cell-free assays; effective in cells and in animals
13313	IKK-16 (hydrochloride	25 mg	≥98%	A potent inhibitor of IκB kinases (IKKs), displaying IC50 values of 200, 40, and 70 nM for IKKα, IKKβ, and IKK complex, respectively, in cell-free assays; effective in cells and in animals
13313	IKK-16 (hydrochloride	5 mg	≥98%	A potent inhibitor of IκB kinases (IKKs), displaying IC50 values of 200, 40, and 70 nM for IKKα, IKKβ, and IKK complex, respectively, in cell-free assays; effective in cells and in animals
13313	IKK-16 (hydrochloride	50 mg	≥98%	A potent inhibitor of IκB kinases (IKKs), displaying IC50 values of 200, 40, and 70 nM for IKKα, IKKβ, and IKK complex, respectively, in cell-free assays; effective in cells and in animals
13314	Indirubin-3'-monoxim	1 mg	≥98%	A potent inhibitor of GSK3β (IC50 = 22 nM), preventing tau phosphorylation both in vitro and in vivo
13314	Indirubin-3'-monoxim	10 mg	≥98%	A potent inhibitor of GSK3β (IC50 = 22 nM), preventing tau phosphorylation both in vitro and in vivo
13314	Indirubin-3'-monoxim	5 mg	≥98%	A potent inhibitor of GSK3β (IC50 = 22 nM), preventing tau phosphorylation both in vitro and in vivo
13314	Indirubin-3'-monoxim	50 mg	≥98%	A potent inhibitor of GSK3β (IC50 = 22 nM), preventing tau phosphorylation both in vitro and in vivo
13317	NU 6102	1 mg	≥95%	A potent inhibitor of Cdk1 and Cdk2 (Kis = 9 and 6 nM; IC50s = 9.5 and 5.4 nM, respectively); 20 µM delays cell entry into mitosis and prevents proper cytokinesis, rendering binucleated cells with an abnormal number of centrosomes
13317	NU 6102	5 mg	≥95%	A potent inhibitor of Cdk1 and Cdk2 (Kis = 9 and 6 nM; IC50s = 9.5 and 5.4 nM, respectively); 20 µM delays cell entry into mitosis and prevents proper cytokinesis, rendering binucleated cells with an abnormal number of centrosomes
13318	KN-62	1 mg	≥98%	A selective, cell permeable inhibitor of CaMKII (IC50 = 900 nM)
13318	KN-62	10 mg	≥98%	A selective, cell permeable inhibitor of CaMKII (IC50 = 900 nM)
13318	KN-62	25 mg	≥98%	A selective, cell permeable inhibitor of CaMKII (IC50 = 900 nM)
13318	KN-62	5 mg	≥98%	A selective, cell permeable inhibitor of CaMKII (IC50 = 900 nM)
13319	KN-93	1 mg	≥98%	A selective inhibitor of CaMKII, competitively blocking CaM binding to the kinase (Ki = 370 nM); inhibits histamine-induced aminopyrine uptake in parietal cells (IC50 = 300 nM)
13319	KN-93	10 mg	≥98%	A selective inhibitor of CaMKII, competitively blocking CaM binding to the kinase (Ki = 370 nM); inhibits histamine-induced aminopyrine uptake in parietal cells (IC50 = 300 nM)
13319	KN-93	5 mg	≥98%	A selective inhibitor of CaMKII, competitively blocking CaM binding to the kinase (Ki = 370 nM); inhibits histamine-induced aminopyrine uptake in parietal cells (IC50 = 300 nM)
13322	CGP 57380	1 mg	≥95%	A selective inhibitor of MNK1 in vitro (IC50 = 2.2 µM), with no inhibitory activity against p38, JNK1, ERK1/2, PKC, or Src-like kinases; blocks the phosphorylation of eIF4E in response to TNF-α, arsenite, anisomycin, PMA, or fetal calf serum in 293 cells (IC50 = 3 µM)
13322	CGP 57380	10 mg	≥95%	A selective inhibitor of MNK1 in vitro (IC50 = 2.2 µM), with no inhibitory activity against p38, JNK1, ERK1/2, PKC, or Src-like kinases; blocks the phosphorylation of eIF4E in response to TNF-α, arsenite, anisomycin, PMA, or fetal calf serum in 293 cells (IC50 = 3 µM)

13322	CGP 57380	25 mg	≥95%	A selective inhibitor of MNK1 in vitro (IC50 = 2.2 µM), with no inhibitory activity against p38, JNK1, ERK1/2, PKC, or Src-like kinases; blocks the phosphorylation of eIF4E in response to TNF-α, arsenite, anisomycin, PMA, or fetal calf serum in 293 cells (IC50 = 3 µM)
13322	CGP 57380	5 mg	≥95%	A selective inhibitor of MNK1 in vitro (IC50 = 2.2 µM), with no inhibitory activity against p38, JNK1, ERK1/2, PKC, or Src-like kinases; blocks the phosphorylation of eIF4E in response to TNF-α, arsenite, anisomycin, PMA, or fetal calf serum in 293 cells (IC50 = 3 µM)
13325	Iso-Olomoucine	10 mg	≥98%	An inactive stereoisomer (IC50 ≥ 1 mM) of the Cdk5 inhibitor olomoucine; may have utility as a control compound for determining Cdk5 specificity; rapidly inhibits dopamine transporter activity in rat dorsal striatal synaptosomes with an IC50 value of ~37 µM
13325	Iso-Olomoucine	25 mg	≥98%	An inactive stereoisomer (IC50 ≥ 1 mM) of the Cdk5 inhibitor olomoucine; may have utility as a control compound for determining Cdk5 specificity; rapidly inhibits dopamine transporter activity in rat dorsal striatal synaptosomes with an IC50 value of ~37 µM
13325	Iso-Olomoucine	5 mg	≥98%	An inactive stereoisomer (IC50 ≥ 1 mM) of the Cdk5 inhibitor olomoucine; may have utility as a control compound for determining Cdk5 specificity; rapidly inhibits dopamine transporter activity in rat dorsal striatal synaptosomes with an IC50 value of ~37 µM
13325	Iso-Olomoucine	50 mg	≥98%	An inactive stereoisomer (IC50 ≥ 1 mM) of the Cdk5 inhibitor olomoucine; may have utility as a control compound for determining Cdk5 specificity; rapidly inhibits dopamine transporter activity in rat dorsal striatal synaptosomes with an IC50 value of ~37 µM
13329	PD 158780	1 mg	≥98%	A reversible inhibitor of the auto and transphosphorylation kinase activity of the ErbB receptor tyrosine kinase superfamily: EGFR (IC50 = 8 µM), ErbB-2 (IC50 = 49 nM), ErbB3, and ErbB4 (IC50 = 52 nM); induces G1 cell cycle arrest in MCF10A breast cancer cells
13329	PD 158780	10 mg	≥98%	A reversible inhibitor of the auto and transphosphorylation kinase activity of the ErbB receptor tyrosine kinase superfamily: EGFR (IC50 = 8 µM), ErbB-2 (IC50 = 49 nM), ErbB3, and ErbB4 (IC50 = 52 nM); induces G1 cell cycle arrest in MCF10A breast cancer cells
13329	PD 158780	25 mg	≥98%	A reversible inhibitor of the auto and transphosphorylation kinase activity of the ErbB receptor tyrosine kinase superfamily: EGFR (IC50 = 8 µM), ErbB-2 (IC50 = 49 nM), ErbB3, and ErbB4 (IC50 = 52 nM); induces G1 cell cycle arrest in MCF10A breast cancer cells
13329	PD 158780	5 mg	≥98%	A reversible inhibitor of the auto and transphosphorylation kinase activity of the ErbB receptor tyrosine kinase superfamily: EGFR (IC50 = 8 µM), ErbB-2 (IC50 = 49 nM), ErbB3, and ErbB4 (IC50 = 52 nM); induces G1 cell cycle arrest in MCF10A breast cancer cells
13330	1-NM-PP1	1 mg	≥95%	A cell permeable inhibitor of kinases that have been mutated, by a single base substitution, to become 'analog sensitive' (as), as compared to the wild type kinase; inhibits v-Src-as1, with an I338G substitution, preferentially over v-Src (IC50 = 4.2 nM versus 28 µM, respectively); used to elucidate functions of several kinases in both mammalian and yeast systems
13330	1-NM-PP1	10 mg	≥95%	A cell permeable inhibitor of kinases that have been mutated, by a single base substitution, to become 'analog sensitive' (as), as compared to the wild type kinase; inhibits v-Src-as1, with an I338G substitution, preferentially over v-Src (IC50 = 4.2 nM versus 28 µM, respectively); used to elucidate functions of several kinases in both mammalian and yeast systems
13330	1-NM-PP1	25 mg	≥95%	A cell permeable inhibitor of kinases that have been mutated, by a single base substitution, to become 'analog sensitive' (as), as compared to the wild type kinase; inhibits v-Src-as1, with an I338G substitution, preferentially over v-Src (IC50 = 4.2 nM versus 28 µM, respectively); used to elucidate functions of several kinases in both mammalian and yeast systems
13330	1-NM-PP1	5 mg	≥95%	A cell permeable inhibitor of kinases that have been mutated, by a single base substitution, to become 'analog sensitive' (as), as compared to the wild type kinase; inhibits v-Src-as1, with an I338G substitution, preferentially over v-Src (IC50 = 4.2 nM versus 28 µM, respectively); used to elucidate functions of several kinases in both mammalian and yeast systems
13332	(S)-Glycyl-H-1152 (hyd	1 mg	≥98%	A selective and potent ROCK inhibitor (IC50 = 11.8 nM for ROCK2); poorly inhibits CaMKII, PKG, and Aurora A (IC50 = 2.57, 2.35, and 3.26 µM, respectively) as well as PKA or PKC (IC50 ≥10 µM for each)
13332	(S)-Glycyl-H-1152 (hyd	10 mg	≥98%	A selective and potent ROCK inhibitor (IC50 = 11.8 nM for ROCK2); poorly inhibits CaMKII, PKG, and Aurora A (IC50 = 2.57, 2.35, and 3.26 µM, respectively) as well as PKA or PKC (IC50 ≥10 µM for each)
13332	(S)-Glycyl-H-1152 (hyd	5 mg	≥98%	A selective and potent ROCK inhibitor (IC50 = 11.8 nM for ROCK2); poorly inhibits CaMKII, PKG, and Aurora A (IC50 = 2.57, 2.35, and 3.26 µM, respectively) as well as PKA or PKC (IC50 ≥10 µM for each)
13332	(S)-Glycyl-H-1152 (hyd	500 µg	≥98%	A selective and potent ROCK inhibitor (IC50 = 11.8 nM for ROCK2); poorly inhibits CaMKII, PKG, and Aurora A (IC50 = 2.57, 2.35, and 3.26 µM, respectively) as well as PKA or PKC (IC50 ≥10 µM for each)
13333	Bisindolylmaleimide V	1 mg	≥98%	A selective PKC inhibitor (IC50 = 158 nM for rat brain PKC) that acts at the ATP binding site of PKC; exhibits PKC isozyme specificity with preference for PKCα over PKCβI, PKCβII, PKCγ, or PKCε (IC50s = 53, 195, 163, 213, and 175 nM, respectively)

13333	Bisindolylmaleimide V	10 mg	≥98%	A selective PKC inhibitor (IC50 = 158 nM for rat brain PKC) that acts at the ATP binding site of PKC; exhibits PKC isozyme specificity with preference for PKCα over PKCβI, PKCβII, PKCγ, or PKCε (IC50s = 53, 195, 163, 213, and 175 nM, respectively)
13333	Bisindolylmaleimide V	5 mg	≥98%	A selective PKC inhibitor (IC50 = 158 nM for rat brain PKC) that acts at the ATP binding site of PKC; exhibits PKC isozyme specificity with preference for PKCα over PKCβI, PKCβII, PKCγ, or PKCε (IC50s = 53, 195, 163, 213, and 175 nM, respectively)
13334	Bisindolylmaleimide I	1 mg	≥98%	A potent, cell-permeable inhibitor of PKC isoforms (IC50 = 5, 24, 14, 27, and 24 nM for PKC-α, PKC-βI, PKC-βII, PKC-γ, and PKC-ε, respectively)
13334	Bisindolylmaleimide I	10 mg	≥98%	A potent, cell-permeable inhibitor of PKC isoforms (IC50 = 5, 24, 14, 27, and 24 nM for PKC-α, PKC-βI, PKC-βII, PKC-γ, and PKC-ε, respectively)
13334	Bisindolylmaleimide I	5 mg	≥98%	A potent, cell-permeable inhibitor of PKC isoforms (IC50 = 5, 24, 14, 27, and 24 nM for PKC-α, PKC-βI, PKC-βII, PKC-γ, and PKC-ε, respectively)
13335	SB 218078	1 mg	≥98%	An inhibitor of Chk1 that blocks phosphorylation of cdc25 with an IC50 value of 15 nM; releases G2 cell cycle arrest induced by γ-irradiation or topotecan
13337	ST638	1 mg	≥98%	A tyrosine kinase inhibitor (IC50 = 370 nM)
13337	ST638	10 mg	≥98%	A tyrosine kinase inhibitor (IC50 = 370 nM)
13337	ST638	25 mg	≥98%	A tyrosine kinase inhibitor (IC50 = 370 nM)
13337	ST638	5 mg	≥98%	A tyrosine kinase inhibitor (IC50 = 370 nM)
13338	SU6656	1 mg	≥95%	A selective inhibitor of Src kinases, including Src, Yes, Lyn, and Fyn (IC50 = 280, 20, 130, and 170 nM, respectively)
13338	SU6656	10 mg	≥95%	A selective inhibitor of Src kinases, including Src, Yes, Lyn, and Fyn (IC50 = 280, 20, 130, and 170 nM, respectively)
13338	SU6656	25 mg	≥95%	A selective inhibitor of Src kinases, including Src, Yes, Lyn, and Fyn (IC50 = 280, 20, 130, and 170 nM, respectively)
13338	SU6656	5 mg	≥95%	A selective inhibitor of Src kinases, including Src, Yes, Lyn, and Fyn (IC50 = 280, 20, 130, and 170 nM, respectively)
13341	LY364947	10 mg	≥98%	A selective inhibitor of TGF-β RI, with an IC50 value of 59 nM; poorly inhibits TGF-β RII (IC50 = 400 nM), p38 MAPK (IC50 = 740 nM), and MLK7 (IC50 = 1,400 nM); inhibits TGF-β-induced cell growth (IC50 = 89 nM) and Smad phosphorylation
13341	LY364947	25 mg	≥98%	A selective inhibitor of TGF-β RI, with an IC50 value of 59 nM; poorly inhibits TGF-β RII (IC50 = 400 nM), p38 MAPK (IC50 = 740 nM), and MLK7 (IC50 = 1,400 nM); inhibits TGF-β-induced cell growth (IC50 = 89 nM) and Smad phosphorylation
13341	LY364947	5 mg	≥98%	A selective inhibitor of TGF-β RI, with an IC50 value of 59 nM; poorly inhibits TGF-β RII (IC50 = 400 nM), p38 MAPK (IC50 = 740 nM), and MLK7 (IC50 = 1,400 nM); inhibits TGF-β-induced cell growth (IC50 = 89 nM) and Smad phosphorylation
13341	LY364947	50 mg	≥98%	A selective inhibitor of TGF-β RI, with an IC50 value of 59 nM; poorly inhibits TGF-β RII (IC50 = 400 nM), p38 MAPK (IC50 = 740 nM), and MLK7 (IC50 = 1,400 nM); inhibits TGF-β-induced cell growth (IC50 = 89 nM) and Smad phosphorylation
13342	SU 5416	10 mg	≥98%	A tyrosine kinase inhibitor best known as an inhibitor of VEGFR2 (FLK1/KDR) and a suppressor of tumor vascularization, preventing the growth of multiple tumor types
13342	SU 5416	100 mg	≥98%	A tyrosine kinase inhibitor best known as an inhibitor of VEGFR2 (FLK1/KDR) and a suppressor of tumor vascularization, preventing the growth of multiple tumor types
13342	SU 5416	25 mg	≥98%	A tyrosine kinase inhibitor best known as an inhibitor of VEGFR2 (FLK1/KDR) and a suppressor of tumor vascularization, preventing the growth of multiple tumor types
13342	SU 5416	50 mg	≥98%	A tyrosine kinase inhibitor best known as an inhibitor of VEGFR2 (FLK1/KDR) and a suppressor of tumor vascularization, preventing the growth of multiple tumor types
13344	SB 203580 (hydrochlo	10 mg	≥98%	A formulation with greater solubility in organic solvents than standard SB 203580
13344	SB 203580 (hydrochlo	25 mg	≥98%	A formulation with greater solubility in organic solvents than standard SB 203580
13344	SB 203580 (hydrochlo	5 mg	≥98%	A formulation with greater solubility in organic solvents than standard SB 203580
13344	SB 203580 (hydrochlo	50 mg	≥98%	A formulation with greater solubility in organic solvents than standard SB 203580
13346	Rapamycin	1 mg	≥95%	An allosteric inhibitor of mTORC1; inhibits growth of Rh1 and Rh30 rhabdomyosarcoma cells in serum-free medium, with 50% inhibition observed at 0.1 and 0.5 ng/ml, respectively, and increases apoptosis in these cells at 100 ng/ml; induces autophagy in a variety of cell types; inhibits IL-2-induced proliferation of IL-2-dependent T cells by 50% at <5 pM
13346	Rapamycin	10 mg	≥95%	An allosteric inhibitor of mTORC1; inhibits growth of Rh1 and Rh30 rhabdomyosarcoma cells in serum-free medium, with 50% inhibition observed at 0.1 and 0.5 ng/ml, respectively, and increases apoptosis in these cells at 100 ng/ml; induces autophagy in a variety of cell types; inhibits IL-2-induced proliferation of IL-2-dependent T cells by 50% at <5 pM

13346	Rapamycin	25 mg	≥95%	An allosteric inhibitor of mTORC1; inhibits growth of Rh1 and Rh30 rhabdomyosarcoma cells in serum-free medium, with 50% inhibition observed at 0.1 and 0.5 ng/ml, respectively, and increases apoptosis in these cells at 100 ng/ml; induces autophagy in a variety of cell types; inhibits IL-2-induced proliferation of IL-2-dependent T cells by 50% at <5 pM
13346	Rapamycin	5 mg	≥95%	An allosteric inhibitor of mTORC1; inhibits growth of Rh1 and Rh30 rhabdomyosarcoma cells in serum-free medium, with 50% inhibition observed at 0.1 and 0.5 ng/ml, respectively, and increases apoptosis in these cells at 100 ng/ml; induces autophagy in a variety of cell types; inhibits IL-2-induced proliferation of IL-2-dependent T cells by 50% at <5 pM
13371	CAY10621	1 mg	≥98%	A selective inhibitor of SPHK1
13371	CAY10621	10 mg	≥98%	A selective inhibitor of SPHK1
13371	CAY10621	25 mg	≥98%	A selective inhibitor of SPHK1
13371	CAY10621	5 mg	≥98%	A selective inhibitor of SPHK1
13514	K252c	1 mg	≥98%	A cell-permeable PKC inhibitor (IC50s = 2.45 and 25.7 µM for PKC and PKA, respectively); reduces focus formation in gangciclovir-sensitive and -resistant human cytomegalovirus (HCMV) strains with IC50s of 0.32 and 0.17 µM for HCMV A6245 and HCMV-6, respectively; inhibits the non-kinase enzymes β-lactamase, chymotrypsin, and malate dehydrogenase with IC50s of 8, 10, and 8 µM
13514	K252c	10 mg	≥98%	A cell-permeable PKC inhibitor (IC50s = 2.45 and 25.7 µM for PKC and PKA, respectively); reduces focus formation in gangciclovir-sensitive and -resistant human cytomegalovirus (HCMV) strains with IC50s of 0.32 and 0.17 µM for HCMV A6245 and HCMV-6, respectively; inhibits the non-kinase enzymes β-lactamase, chymotrypsin, and malate dehydrogenase with IC50s of 8, 10, and 8 µM
13514	K252c	5 mg	≥98%	A cell-permeable PKC inhibitor (IC50s = 2.45 and 25.7 µM for PKC and PKA, respectively); reduces focus formation in gangciclovir-sensitive and -resistant human cytomegalovirus (HCMV) strains with IC50s of 0.32 and 0.17 µM for HCMV A6245 and HCMV-6, respectively; inhibits the non-kinase enzymes β-lactamase, chymotrypsin, and malate dehydrogenase with IC50s of 8, 10, and 8 µM
13516	Arcyriaflavin A	1 mg	≥95%	A CDK4 and CaMKII inhibitor (IC50s = 140 and 25 nM, respectively); selective for CDK4 and CaMKII over PKA and PKC (IC50s = >2 and >100 µM, respectively); inhibits replication of HCMV in vitro (IC50 = 200 nM); inhibits proliferation of HCT116 and NCI H460 carcinoma cells in vitro (IC50s = 850 and 590 nM, respectively); inhibits proliferation and induces apoptosis of ECSCs
13516	Arcyriaflavin A	10 mg	≥95%	A CDK4 and CaMKII inhibitor (IC50s = 140 and 25 nM, respectively); selective for CDK4 and CaMKII over PKA and PKC (IC50s = >2 and >100 µM, respectively); inhibits replication of HCMV in vitro (IC50 = 200 nM); inhibits proliferation of HCT116 and NCI H460 carcinoma cells in vitro (IC50s = 850 and 590 nM, respectively); inhibits proliferation and induces apoptosis of ECSCs
13516	Arcyriaflavin A	5 mg	≥95%	A CDK4 and CaMKII inhibitor (IC50s = 140 and 25 nM, respectively); selective for CDK4 and CaMKII over PKA and PKC (IC50s = >2 and >100 µM, respectively); inhibits replication of HCMV in vitro (IC50 = 200 nM); inhibits proliferation of HCT116 and NCI H460 carcinoma cells in vitro (IC50s = 850 and 590 nM, respectively); inhibits proliferation and induces apoptosis of ECSCs
13576	YM-201636	1 mg	≥95%	A cell-permeable and selective inhibitor of PIKfyve (IC50 = 33 nM); reversibly impairs endosomal trafficking in NIH3T3 cells and blocks retroviral exit by budding from cells; inhibits basal and insulin-activated 2-deoxyglucose uptake (IC50 = 54 nM) in adipocytes
13576	YM-201636	10 mg	≥95%	A cell-permeable and selective inhibitor of PIKfyve (IC50 = 33 nM); reversibly impairs endosomal trafficking in NIH3T3 cells and blocks retroviral exit by budding from cells; inhibits basal and insulin-activated 2-deoxyglucose uptake (IC50 = 54 nM) in adipocytes
13576	YM-201636	5 mg	≥95%	A cell-permeable and selective inhibitor of PIKfyve (IC50 = 33 nM); reversibly impairs endosomal trafficking in NIH3T3 cells and blocks retroviral exit by budding from cells; inhibits basal and insulin-activated 2-deoxyglucose uptake (IC50 = 54 nM) in adipocytes
13578	VEGFR2 Kinase Inhibit	1 mg	≥95%	A potent, cell-permeable inhibitor of mouse VEGFR2 kinase (IC50 = 70 nM); has little or no effect against PDGFR, EGFR or IGF1R kinases (IC50 > 100 µM)
13578	VEGFR2 Kinase Inhibit	10 mg	≥95%	A potent, cell-permeable inhibitor of mouse VEGFR2 kinase (IC50 = 70 nM); has little or no effect against PDGFR, EGFR or IGF1R kinases (IC50 > 100 µM)
13578	VEGFR2 Kinase Inhibit	5 mg	≥95%	A potent, cell-permeable inhibitor of mouse VEGFR2 kinase (IC50 = 70 nM); has little or no effect against PDGFR, EGFR or IGF1R kinases (IC50 > 100 µM)
13578	VEGFR2 Kinase Inhibit	500 µg	≥95%	A potent, cell-permeable inhibitor of mouse VEGFR2 kinase (IC50 = 70 nM); has little or no effect against PDGFR, EGFR or IGF1R kinases (IC50 > 100 µM)

13597	Ku-0063794	10 mg	≥98%	A cell-permeable, selective dual inhibitor of mTORC1 and mTORC2 (IC50 = 10 nM); not affect the activity of 76 other protein kinases or seven lipid kinases, including PI3Ks; induces G1-cell cycle arrest and autophagy; inhibits tumor growth in a xenograft model of renal cell carcinoma
13597	Ku-0063794	100 mg	≥98%	A cell-permeable, selective dual inhibitor of mTORC1 and mTORC2 (IC50 = 10 nM); not affect the activity of 76 other protein kinases or seven lipid kinases, including PI3Ks; induces G1-cell cycle arrest and autophagy; inhibits tumor growth in a xenograft model of renal cell carcinoma
13597	Ku-0063794	5 mg	≥98%	A cell-permeable, selective dual inhibitor of mTORC1 and mTORC2 (IC50 = 10 nM); not affect the activity of 76 other protein kinases or seven lipid kinases, including PI3Ks; induces G1-cell cycle arrest and autophagy; inhibits tumor growth in a xenograft model of renal cell carcinoma
13597	Ku-0063794	50 mg	≥98%	A cell-permeable, selective dual inhibitor of mTORC1 and mTORC2 (IC50 = 10 nM); not affect the activity of 76 other protein kinases or seven lipid kinases, including PI3Ks; induces G1-cell cycle arrest and autophagy; inhibits tumor growth in a xenograft model of renal cell carcinoma
13600	MK-0457	100 mg	≥98%	A potent pan-Aurora kinase inhibitor that favors Aurora A (Ki = 0.6 nM) over Aurora B (Ki = 18 nM) or Aurora C (Ki = 4.6 nM); inhibits proliferation of clear cell renal carcinoma (IC50 = 2/M phase
13600	MK-0457	25 mg	≥98%	A potent pan-Aurora kinase inhibitor that favors Aurora A (Ki = 0.6 nM) over Aurora B (Ki = 18 nM) or Aurora C (Ki = 4.6 nM); inhibits proliferation of clear cell renal carcinoma (IC50 = 2/M phase
13600	MK-0457	250 mg	≥98%	A potent pan-Aurora kinase inhibitor that favors Aurora A (Ki = 0.6 nM) over Aurora B (Ki = 18 nM) or Aurora C (Ki = 4.6 nM); inhibits proliferation of clear cell renal carcinoma (IC50 = 2/M phase
13600	MK-0457	50 mg	≥98%	A potent pan-Aurora kinase inhibitor that favors Aurora A (Ki = 0.6 nM) over Aurora B (Ki = 18 nM) or Aurora C (Ki = 4.6 nM); inhibits proliferation of clear cell renal carcinoma (IC50 = 2/M phase
13601	ZM 447439	10 mg	≥98%	A selective inhibitor of Aurora B kinase (IC50 = 10 μM), less potently inhibiting Aurora C and A (IC50 = 250 and 1,000 nM, respectively); has been used to study the role of Aurora B in molecular events associated with mitosis and cytokinesis; selectively inhibits proliferating cells rather than non-dividing cells
13601	ZM 447439	5 mg	≥98%	A selective inhibitor of Aurora B kinase (IC50 = 10 μM), less potently inhibiting Aurora C and A (IC50 = 250 and 1,000 nM, respectively); has been used to study the role of Aurora B in molecular events associated with mitosis and cytokinesis; selectively inhibits proliferating cells rather than non-dividing cells
13601	ZM 447439	50 mg	≥98%	A selective inhibitor of Aurora B kinase (IC50 = 10 μM), less potently inhibiting Aurora C and A (IC50 = 250 and 1,000 nM, respectively); has been used to study the role of Aurora B in molecular events associated with mitosis and cytokinesis; selectively inhibits proliferating cells rather than non-dividing cells
13602	MLN8237	1 mg	≥98%	An Aurora A kinase inhibitor (IC50 = 1 nM); selective for Aurora A over Aurora B kinase (IC50 = 396.5 nM); induces cell cycle arrest at the G2/M phase and chromosomal misalignment in HCT116 cells at 50 nM; inhibits tumor growth in a Calu-6 NSCLC mouse xenograft model at 20 mg/kg
13602	MLN8237	10 mg	≥98%	An Aurora A kinase inhibitor (IC50 = 1 nM); selective for Aurora A over Aurora B kinase (IC50 = 396.5 nM); induces cell cycle arrest at the G2/M phase and chromosomal misalignment in HCT116 cells at 50 nM; inhibits tumor growth in a Calu-6 NSCLC mouse xenograft model at 20 mg/kg
13602	MLN8237	5 mg	≥98%	An Aurora A kinase inhibitor (IC50 = 1 nM); selective for Aurora A over Aurora B kinase (IC50 = 396.5 nM); induces cell cycle arrest at the G2/M phase and chromosomal misalignment in HCT116 cells at 50 nM; inhibits tumor growth in a Calu-6 NSCLC mouse xenograft model at 20 mg/kg
13604	WYE-354	10 mg	≥98%	A selective, potent, and cell-permeable inhibitor of mTOR (IC50 = 4.3 nM) which blocks signaling through both mTORC1 and mTORC2; induces G1 cell cycle arrest in both rapamycin-sensitive and rapamycin-resistant cancer cell lines and reduces tumor growth in nude mice with PTEN-null tumors
13604	WYE-354	25 mg	≥98%	A selective, potent, and cell-permeable inhibitor of mTOR (IC50 = 4.3 nM) which blocks signaling through both mTORC1 and mTORC2; induces G1 cell cycle arrest in both rapamycin-sensitive and rapamycin-resistant cancer cell lines and reduces tumor growth in nude mice with PTEN-null tumors
13604	WYE-354	5 mg	≥98%	A selective, potent, and cell-permeable inhibitor of mTOR (IC50 = 4.3 nM) which blocks signaling through both mTORC1 and mTORC2; induces G1 cell cycle arrest in both rapamycin-sensitive and rapamycin-resistant cancer cell lines and reduces tumor growth in nude mice with PTEN-null tumors
13604	WYE-354	50 mg	≥98%	A selective, potent, and cell-permeable inhibitor of mTOR (IC50 = 4.3 nM) which blocks signaling through both mTORC1 and mTORC2; induces G1 cell cycle arrest in both rapamycin-sensitive and rapamycin-resistant cancer cell lines and reduces tumor growth in nude mice with PTEN-null tumors

13614	GW 856553X	1 mg	≥98%	A dual p38α and p38β MAPK inhibitor (Kis = 0.0079 and 0.025 µM, respectively, in cell-free assays); selective for p38α and p38β MAPK over p38γ and p38δ MAPK at 10 µM; inhibits LPS-induced TNF-α production in isolated rat and human PBMCs (IC50s = 0.6 and 0.13 µM, respectively); decreases disease severity in a mouse model of collagen-induced arthritis at 0.8-20 mg/kg; improves survival, normalizes blood pressure, and reduces increases in plasma levels of HDL, LDL, and triglycerides in spontaneously hypertensive stroke-prone rats fed a high-salt high-fat diet
13614	GW 856553X	10 mg	≥98%	A dual p38α and p38β MAPK inhibitor (Kis = 0.0079 and 0.025 µM, respectively, in cell-free assays); selective for p38α and p38β MAPK over p38γ and p38δ MAPK at 10 µM; inhibits LPS-induced TNF-α production in isolated rat and human PBMCs (IC50s = 0.6 and 0.13 µM, respectively); decreases disease severity in a mouse model of collagen-induced arthritis at 0.8-20 mg/kg; improves survival, normalizes blood pressure, and reduces increases in plasma levels of HDL, LDL, and triglycerides in spontaneously hypertensive stroke-prone rats fed a high-salt high-fat diet
13614	GW 856553X	25 mg	≥98%	A dual p38α and p38β MAPK inhibitor (Kis = 0.0079 and 0.025 µM, respectively, in cell-free assays); selective for p38α and p38β MAPK over p38γ and p38δ MAPK at 10 µM; inhibits LPS-induced TNF-α production in isolated rat and human PBMCs (IC50s = 0.6 and 0.13 µM, respectively); decreases disease severity in a mouse model of collagen-induced arthritis at 0.8-20 mg/kg; improves survival, normalizes blood pressure, and reduces increases in plasma levels of HDL, LDL, and triglycerides in spontaneously hypertensive stroke-prone rats fed a high-salt high-fat diet
13614	GW 856553X	5 mg	≥98%	A dual p38α and p38β MAPK inhibitor (Kis = 0.0079 and 0.025 µM, respectively, in cell-free assays); selective for p38α and p38β MAPK over p38γ and p38δ MAPK at 10 µM; inhibits LPS-induced TNF-α production in isolated rat and human PBMCs (IC50s = 0.6 and 0.13 µM, respectively); decreases disease severity in a mouse model of collagen-induced arthritis at 0.8-20 mg/kg; improves survival, normalizes blood pressure, and reduces increases in plasma levels of HDL, LDL, and triglycerides in spontaneously hypertensive stroke-prone rats fed a high-salt high-fat diet
13622	AS-041164	10 mg	≥98%	A potent inhibitor of PI3K with selectivity for the class IB isoform PI3Kγ (IC50 = 70 nM), compared to PI3Kα (IC50 = 240 nM), PI3Kβ (IC50 = 1.45 µM), and PI3Kδ (IC50 =1.70 µM); shows little or no activity against 38 other common kinases
13622	AS-041164	25 mg	≥98%	A potent inhibitor of PI3K with selectivity for the class IB isoform PI3Kγ (IC50 = 70 nM), compared to PI3Kα (IC50 = 240 nM), PI3Kβ (IC50 = 1.45 µM), and PI3Kδ (IC50 =1.70 µM); shows little or no activity against 38 other common kinases
13622	AS-041164	5 mg	≥98%	A potent inhibitor of PI3K with selectivity for the class IB isoform PI3Kγ (IC50 = 70 nM), compared to PI3Kα (IC50 = 240 nM), PI3Kβ (IC50 = 1.45 µM), and PI3Kδ (IC50 =1.70 µM); shows little or no activity against 38 other common kinases
13622	AS-041164	50 mg	≥98%	A potent inhibitor of PI3K with selectivity for the class IB isoform PI3Kγ (IC50 = 70 nM), compared to PI3Kα (IC50 = 240 nM), PI3Kβ (IC50 = 1.45 µM), and PI3Kδ (IC50 =1.70 µM); shows little or no activity against 38 other common kinases
13641	NVP-AEW541 (hydroc	1 mg	≥98%	A selective IGF-1R kinase inhibitor (IC50 = 0.086 µM); prevents IGF-I-mediated survival and proliferation of MCF-7 cells (IC50 = 0.16 and 1.64 µM, respectively); dose-dependently inhibits tumor growth in a mouse NWT-21 fibrosarcoma tumor model
13641	NVP-AEW541 (hydroc	10 mg	≥98%	A selective IGF-1R kinase inhibitor (IC50 = 0.086 µM); prevents IGF-I-mediated survival and proliferation of MCF-7 cells (IC50 = 0.16 and 1.64 µM, respectively); dose-dependently inhibits tumor growth in a mouse NWT-21 fibrosarcoma tumor model
13641	NVP-AEW541 (hydroc	5 mg	≥98%	A selective IGF-1R kinase inhibitor (IC50 = 0.086 µM); prevents IGF-I-mediated survival and proliferation of MCF-7 cells (IC50 = 0.16 and 1.64 µM, respectively); dose-dependently inhibits tumor growth in a mouse NWT-21 fibrosarcoma tumor model
13641	NVP-AEW541 (hydroc	500 µg	≥98%	A selective IGF-1R kinase inhibitor (IC50 = 0.086 µM); prevents IGF-I-mediated survival and proliferation of MCF-7 cells (IC50 = 0.16 and 1.64 µM, respectively); dose-dependently inhibits tumor growth in a mouse NWT-21 fibrosarcoma tumor model
13643	PP242	1 mg	≥95%	An inhibitor of the active site of mTOR kinase in both mTORC1 and mTORC2 (IC50 = 8 nM); shown to cause the death of leukemia cells more potently than rapamycin and, in vivo, delays leukemia onset and augments the effects of tyrosine kinase inhibitors in suppressing leukemic expansion and extending survival
13643	PP242	10 mg	≥95%	An inhibitor of the active site of mTOR kinase in both mTORC1 and mTORC2 (IC50 = 8 nM); shown to cause the death of leukemia cells more potently than rapamycin and, in vivo, delays leukemia onset and augments the effects of tyrosine kinase inhibitors in suppressing leukemic expansion and extending survival
13643	PP242	25 mg	≥95%	An inhibitor of the active site of mTOR kinase in both mTORC1 and mTORC2 (IC50 = 8 nM); shown to cause the death of leukemia cells more potently than rapamycin and, in vivo, delays leukemia onset and augments the effects of tyrosine kinase inhibitors in suppressing leukemic expansion and extending survival

13643	PP242	5 mg	≥95%	An inhibitor of the active site of mTOR kinase in both mTORC1 and mTORC2 (IC50 = 8 nM); shown to cause the death of leukemia cells more potently than rapamycin and, in vivo, delays leukemia onset and augments the effects of tyrosine kinase inhibitors in suppressing leukemic expansion and extending survival
13645	PX 866	1 mg	≥95%	A ring-opened analog of wortmannin that potently and irreversible inhibits PI3K (IC50 = 0.1-88 nM); less potently blocks the activity of mTOR (IC50 = 3.1 µM); exhibits single agent in vivo anti-tumor activity and increases the anti-tumor effects of cisplatin and radiation treatment
13645	PX 866	10 mg	≥95%	A ring-opened analog of wortmannin that potently and irreversible inhibits PI3K (IC50 = 0.1-88 nM); less potently blocks the activity of mTOR (IC50 = 3.1 µM); exhibits single agent in vivo anti-tumor activity and increases the anti-tumor effects of cisplatin and radiation treatment
13645	PX 866	5 mg	≥95%	A ring-opened analog of wortmannin that potently and irreversible inhibits PI3K (IC50 = 0.1-88 nM); less potently blocks the activity of mTOR (IC50 = 3.1 µM); exhibits single agent in vivo anti-tumor activity and increases the anti-tumor effects of cisplatin and radiation treatment
13647	AZD 1152 (hydrochlor	1 mg	≥95%	An orally bioavailable prodrug of AZD 1152-HQPA, a selective inhibitor of Aurora kinase B (IC50 = 0.36 nM)
13647	AZD 1152 (hydrochlor	10 mg	≥95%	An orally bioavailable prodrug of AZD 1152-HQPA, a selective inhibitor of Aurora kinase B (IC50 = 0.36 nM)
13647	AZD 1152 (hydrochlor	25 mg	≥95%	An orally bioavailable prodrug of AZD 1152-HQPA, a selective inhibitor of Aurora kinase B (IC50 = 0.36 nM)
13647	AZD 1152 (hydrochlor	5 mg	≥95%	An orally bioavailable prodrug of AZD 1152-HQPA, a selective inhibitor of Aurora kinase B (IC50 = 0.36 nM)
13653	ABT-869	1 mg	≥98%	A dual VEGFR and PDGFR family kinase inhibitor (IC50s = 0.003, 0.004, 0.004, 0.19, 0.066, 0.003, and 0.014 µM for VEGFR1, VEGFR2, FLT3, VEGFR3, PDGFRβ, CSF-1R, and KIT, respectively); is selective for these kinases over RET, FGFR, Src, EGFR, and c-Met (IC50s = 1.9, >12.5, >50, >50, and >50 µM, respectively); inhibits Tie2 (IC50 = 0.17 µM); inhibits the proliferation of HT-29, MDA-MB-435, 9L, and MV4-11 cells (IC50s = 1.3, 2.4, 0.27, and 0.004 µM, respectively); induces apoptosis in MV4-11 cells (IC50 = 0.03 µM); inhibits VEGF-induced uterine edema in mice (ED50 = 0.5 mg/kg); improves survival in a MOLM-13 leukemia mouse xenograft model at 1, 3, and 10 mg/kg
13653	ABT-869	10 mg	≥98%	A dual VEGFR and PDGFR family kinase inhibitor (IC50s = 0.003, 0.004, 0.004, 0.19, 0.066, 0.003, and 0.014 µM for VEGFR1, VEGFR2, FLT3, VEGFR3, PDGFRβ, CSF-1R, and KIT, respectively); is selective for these kinases over RET, FGFR, Src, EGFR, and c-Met (IC50s = 1.9, >12.5, >50, >50, and >50 µM, respectively); inhibits Tie2 (IC50 = 0.17 µM); inhibits the proliferation of HT-29, MDA-MB-435, 9L, and MV4-11 cells (IC50s = 1.3, 2.4, 0.27, and 0.004 µM, respectively); induces apoptosis in MV4-11 cells (IC50 = 0.03 µM); inhibits VEGF-induced uterine edema in mice (ED50 = 0.5 mg/kg); improves survival in a MOLM-13 leukemia mouse xenograft model at 1, 3, and 10 mg/kg
13653	ABT-869	5 mg	≥98%	A dual VEGFR and PDGFR family kinase inhibitor (IC50s = 0.003, 0.004, 0.004, 0.19, 0.066, 0.003, and 0.014 µM for VEGFR1, VEGFR2, FLT3, VEGFR3, PDGFRβ, CSF-1R, and KIT, respectively); is selective for these kinases over RET, FGFR, Src, EGFR, and c-Met (IC50s = 1.9, >12.5, >50, >50, and >50 µM, respectively); inhibits Tie2 (IC50 = 0.17 µM); inhibits the proliferation of HT-29, MDA-MB-435, 9L, and MV4-11 cells (IC50s = 1.3, 2.4, 0.27, and 0.004 µM, respectively); induces apoptosis in MV4-11 cells (IC50 = 0.03 µM); inhibits VEGF-induced uterine edema in mice (ED50 = 0.5 mg/kg); improves survival in a MOLM-13 leukemia mouse xenograft model at 1, 3, and 10 mg/kg
13671	Wortmannin-Rapamy	1 mg	≥98%	Consists of analogs of 17-hydroxy wortmannin and rapamycin conjugated via a prodrug linker, which are released upon hydrolysis of the prodrug linker in vivo; inhibits the growth of tumors in mice better than rapamycin alone
13671	Wortmannin-Rapamy	5 mg	≥98%	Consists of analogs of 17-hydroxy wortmannin and rapamycin conjugated via a prodrug linker, which are released upon hydrolysis of the prodrug linker in vivo; inhibits the growth of tumors in mice better than rapamycin alone
13671	Wortmannin-Rapamy	500 µg	≥98%	Consists of analogs of 17-hydroxy wortmannin and rapamycin conjugated via a prodrug linker, which are released upon hydrolysis of the prodrug linker in vivo; inhibits the growth of tumors in mice better than rapamycin alone
13687	CAY10622	1 mg	≥98%	A potent inhibitor of ROCK1 and ROCK2 (IC50s = 6 and 4 nM, respectively)
13687	CAY10622	10 mg	≥98%	A potent inhibitor of ROCK1 and ROCK2 (IC50s = 6 and 4 nM, respectively)
13687	CAY10622	5 mg	≥98%	A potent inhibitor of ROCK1 and ROCK2 (IC50s = 6 and 4 nM, respectively)
13812	17β-hydroxy Wortma	1 mg	≥98%	An analog of wortmannin; irreversibly binds PI3K; inhibits recombinant PI3K and mTOR (IC50 = 2.7 and 193 nM, respectively) and prevents the growth of LNCap cells (IC50 = 1.46 µM)
13812	17β-hydroxy Wortma	10 mg	≥98%	An analog of wortmannin; irreversibly binds PI3K; inhibits recombinant PI3K and mTOR (IC50 = 2.7 and 193 nM, respectively) and prevents the growth of LNCap cells (IC50 = 1.46 µM)
13812	17β-hydroxy Wortma	5 mg	≥98%	An analog of wortmannin; irreversibly binds PI3K; inhibits recombinant PI3K and mTOR (IC50 = 2.7 and 193 nM, respectively) and prevents the growth of LNCap cells (IC50 = 1.46 µM)

13812	17β-hydroxy Wortma	500 µg	≥98%	An analog of wortmannin; irreversibly binds PI3K; inhibits recombinant PI3K and mTOR (IC50 = 2.7 and 193 nM, respectively) and prevents the growth of LNCap cells (IC50 = 1.46 µM)
13813	Axitinib	100 mg	≥98%	A VEGFR inhibitor (IC50s = 1.2, 0.25, and 0.29 nM for VEGFR1, -2, and -3, respectively); inhibits c-Kit and PDGFRβ (IC50s = 1.7 and 1.6 nM, respectively); inhibits VEGF-induced migration of and tube formation by HUVECs; reduces microvessel density, a marker of angiogenesis, and tumor growth in MV522 colon carcinoma, A375 melanoma, SN12C GFP renal carcinoma, and U87 glioma mouse xenograft models from 1-100 mg/kg
13813	Axitinib	50 mg	≥98%	A VEGFR inhibitor (IC50s = 1.2, 0.25, and 0.29 nM for VEGFR1, -2, and -3, respectively); inhibits c-Kit and PDGFRβ (IC50s = 1.7 and 1.6 nM, respectively); inhibits VEGF-induced migration of and tube formation by HUVECs; reduces microvessel density, a marker of angiogenesis, and tumor growth in MV522 colon carcinoma, A375 melanoma, SN12C GFP renal carcinoma, and U87 glioma mouse xenograft models from 1-100 mg/kg
13813	Axitinib	500 mg	≥98%	A VEGFR inhibitor (IC50s = 1.2, 0.25, and 0.29 nM for VEGFR1, -2, and -3, respectively); inhibits c-Kit and PDGFRβ (IC50s = 1.7 and 1.6 nM, respectively); inhibits VEGF-induced migration of and tube formation by HUVECs; reduces microvessel density, a marker of angiogenesis, and tumor growth in MV522 colon carcinoma, A375 melanoma, SN12C GFP renal carcinoma, and U87 glioma mouse xenograft models from 1-100 mg/kg
13838	CAY10626	1 mg	≥98%	A potent, dual PI3Kα/mTOR inhibitor (IC50s = 0.9 and 0.6 nM, respectively); inhibits MDA361 (breast) and PC3 (prostate) tumor cell growth (IC50s = in vivo
13838	CAY10626	10 mg	≥98%	A potent, dual PI3Kα/mTOR inhibitor (IC50s = 0.9 and 0.6 nM, respectively); inhibits MDA361 (breast) and PC3 (prostate) tumor cell growth (IC50s = in vivo
13838	CAY10626	25 mg	≥98%	A potent, dual PI3Kα/mTOR inhibitor (IC50s = 0.9 and 0.6 nM, respectively); inhibits MDA361 (breast) and PC3 (prostate) tumor cell growth (IC50s = in vivo
13838	CAY10626	5 mg	≥98%	A potent, dual PI3Kα/mTOR inhibitor (IC50s = 0.9 and 0.6 nM, respectively); inhibits MDA361 (breast) and PC3 (prostate) tumor cell growth (IC50s = in vivo
13858	NVP-231	1 mg	≥98%	A potent and reversible inhibitor of ceramide kinase (IC50 = 12 nM); selective for ceramide kinase over SPHK1, SPHK2, DAGKa, PI3Ka, PI4Kb, VPS34, GCS, SMS-1, and CERT (IC50s = >5 mM); inhibits C1P formation and cell death in COS-CerK cells; inhibits C1P formation and tube formation in murine dermal microvascular endothelial cells at 100 nM
13858	NVP-231	10 mg	≥98%	A potent and reversible inhibitor of ceramide kinase (IC50 = 12 nM); selective for ceramide kinase over SPHK1, SPHK2, DAGKa, PI3Ka, PI4Kb, VPS34, GCS, SMS-1, and CERT (IC50s = >5 mM); inhibits C1P formation and cell death in COS-CerK cells; inhibits C1P formation and tube formation in murine dermal microvascular endothelial cells at 100 nM
13858	NVP-231	25 mg	≥98%	A potent and reversible inhibitor of ceramide kinase (IC50 = 12 nM); selective for ceramide kinase over SPHK1, SPHK2, DAGKa, PI3Ka, PI4Kb, VPS34, GCS, SMS-1, and CERT (IC50s = >5 mM); inhibits C1P formation and cell death in COS-CerK cells; inhibits C1P formation and tube formation in murine dermal microvascular endothelial cells at 100 nM
13858	NVP-231	5 mg	≥98%	A potent and reversible inhibitor of ceramide kinase (IC50 = 12 nM); selective for ceramide kinase over SPHK1, SPHK2, DAGKa, PI3Ka, PI4Kb, VPS34, GCS, SMS-1, and CERT (IC50s = >5 mM); inhibits C1P formation and cell death in COS-CerK cells; inhibits C1P formation and tube formation in murine dermal microvascular endothelial cells at 100 nM
13864	KN-93 (hydrochloride	1 mg	≥98%	A selective inhibitor of CaMKII, competitively blocking CaM binding to the kinase (Ki = 370 nM); inhibits histamine-induced aminopyrine uptake in parietal cells (IC50 = 300 nM)
13864	KN-93 (hydrochloride	10 mg	≥98%	A selective inhibitor of CaMKII, competitively blocking CaM binding to the kinase (Ki = 370 nM); inhibits histamine-induced aminopyrine uptake in parietal cells (IC50 = 300 nM)
13864	KN-93 (hydrochloride	5 mg	≥98%	A selective inhibitor of CaMKII, competitively blocking CaM binding to the kinase (Ki = 370 nM); inhibits histamine-induced aminopyrine uptake in parietal cells (IC50 = 300 nM)
13873	SU 6668	1 mg	≥98%	An inhibitor of PDGFRβ, VEGFR2, and FGFR1 (IC50 = 0.06, 2.4, and 3.0 µM, respectively) but not EGFR (IC50 >100 µM); suppresses tumor growth, blocks angiogenesis in tumors, and induces apoptosis of tumor vasculature and regression of established tumors; also inhibits Aurora kinases B and C (IC50 = 35 and 210 nM, respectively) and may target other kinases

13873	SU 6668	10 mg	≥98%	An inhibitor of PDGFRβ, VEGFR2, and FGFR1 (IC50 = 0.06, 2.4, and 3.0 µM, respectively) but not EGFR (IC50 >100 µM); suppresses tumor growth, blocks angiogenesis in tumors, and induces apoptosis of tumor vasculature and regression of established tumors; also inhibits Aurora kinases B and C (IC50 = 35 and 210 nM, respectively) and may target other kinases
13873	SU 6668	5 mg	≥98%	An inhibitor of PDGFRβ, VEGFR2, and FGFR1 (IC50 = 0.06, 2.4, and 3.0 µM, respectively) but not EGFR (IC50 >100 µM); suppresses tumor growth, blocks angiogenesis in tumors, and induces apoptosis of tumor vasculature and regression of established tumors; also inhibits Aurora kinases B and C (IC50 = 35 and 210 nM, respectively) and may target other kinases
13964	LY333531 (hydrochlor	1 mg	≥98%	A PKCβ inhibitor (IC50s = 4.7 and 5.9 nM for PKCβ1 and PKCβ2, respectively); selective for PKCβ1 and PKCβ2 over PKCα, -γ, -δ, -ε, -ζ, and -η (IC50s = 360, 300, 250, >100,000, and 52 nM, respectively); inhibits GSK3β (IC50 = 39.4 nM); inhibits PMA-induced NET formation in primary human neutrophils at 1 µM; increases the mechanical nociceptive threshold in a rat model of STZ-induced diabetic hyperalgesia
13964	LY333531 (hydrochlor	5 mg	≥98%	A PKCβ inhibitor (IC50s = 4.7 and 5.9 nM for PKCβ1 and PKCβ2, respectively); selective for PKCβ1 and PKCβ2 over PKCα, -γ, -δ, -ε, -ζ, and -η (IC50s = 360, 300, 250, >100,000, and 52 nM, respectively); inhibits GSK3β (IC50 = 39.4 nM); inhibits PMA-induced NET formation in primary human neutrophils at 1 µM; increases the mechanical nociceptive threshold in a rat model of STZ-induced diabetic hyperalgesia
13975	AD57 (hydrochloride)	1 mg	≥98%	A polypharmacological cancer therapeutic; potently inhibits RET (IC50 = 2 nM) and reduces the activity of numerous other kinases by more than 80% when given at 1 µM in Drosophila; interferes with kinases downstream of RET, including Src, Raf, and S6K
13975	AD57 (hydrochloride)	10 mg	≥98%	A polypharmacological cancer therapeutic; potently inhibits RET (IC50 = 2 nM) and reduces the activity of numerous other kinases by more than 80% when given at 1 µM in Drosophila; interferes with kinases downstream of RET, including Src, Raf, and S6K
13975	AD57 (hydrochloride)	5 mg	≥98%	A polypharmacological cancer therapeutic; potently inhibits RET (IC50 = 2 nM) and reduces the activity of numerous other kinases by more than 80% when given at 1 µM in Drosophila; interferes with kinases downstream of RET, including Src, Raf, and S6K
14006	(R)-CR8	1 mg	≥98%	A second-generation analog of (R)-roscovitine that inhibits Cdk1, 2, 5, and 9 (IC50s = 0.09, 0.072-0.041, 0.11, and 0.18 µM, respectively) with improved potency over its parent compound; also inhibits CK1δ/ε (IC50 = 0.40 µM) and GSK-3α/β (IC50 = 12 µM)
14006	(R)-CR8	10 mg	≥98%	A second-generation analog of (R)-roscovitine that inhibits Cdk1, 2, 5, and 9 (IC50s = 0.09, 0.072-0.041, 0.11, and 0.18 µM, respectively) with improved potency over its parent compound; also inhibits CK1δ/ε (IC50 = 0.40 µM) and GSK-3α/β (IC50 = 12 µM)
14006	(R)-CR8	5 mg	≥98%	A second-generation analog of (R)-roscovitine that inhibits Cdk1, 2, 5, and 9 (IC50s = 0.09, 0.072-0.041, 0.11, and 0.18 µM, respectively) with improved potency over its parent compound; also inhibits CK1δ/ε (IC50 = 0.40 µM) and GSK-3α/β (IC50 = 12 µM)
14155	Indirubin	10 mg	≥98%	A natural product with anti-inflammatory, anti-tumor, and neuroprotective effects; inhibits GSK-3 (IC50 = 2.5 µM) and Cdk1 and 5 (IC50 = 10 µM for both isoforms)
14155	Indirubin	25 mg	≥98%	A natural product with anti-inflammatory, anti-tumor, and neuroprotective effects; inhibits GSK-3 (IC50 = 2.5 µM) and Cdk1 and 5 (IC50 = 10 µM for both isoforms)
14155	Indirubin	5 mg	≥98%	A natural product with anti-inflammatory, anti-tumor, and neuroprotective effects; inhibits GSK-3 (IC50 = 2.5 µM) and Cdk1 and 5 (IC50 = 10 µM for both isoforms)
14155	Indirubin	50 mg	≥98%	A natural product with anti-inflammatory, anti-tumor, and neuroprotective effects; inhibits GSK-3 (IC50 = 2.5 µM) and Cdk1 and 5 (IC50 = 10 µM for both isoforms)
14156	SD 169	10 mg	≥97%	A selective inhibitor of the MAP kinases p38α (IC50 = 3.2 nM) and p38β (IC50 = 122 nM); has no inhibitory effect against a panel of other kinases when tested in vitro at 50 µM; orally active, significantly reducing p38 MAP kinase expression in T cells of NOD mice when delivered in chow at 600 mg/kg
14156	SD 169	25 mg	≥97%	A selective inhibitor of the MAP kinases p38α (IC50 = 3.2 nM) and p38β (IC50 = 122 nM); has no inhibitory effect against a panel of other kinases when tested in vitro at 50 µM; orally active, significantly reducing p38 MAP kinase expression in T cells of NOD mice when delivered in chow at 600 mg/kg
14156	SD 169	5 mg	≥97%	A selective inhibitor of the MAP kinases p38α (IC50 = 3.2 nM) and p38β (IC50 = 122 nM); has no inhibitory effect against a panel of other kinases when tested in vitro at 50 µM; orally active, significantly reducing p38 MAP kinase expression in T cells of NOD mice when delivered in chow at 600 mg/kg

14181	Amlexanox	1 g	≥98%	An anti-inflammatory and anti-allergic compound which is useful in the amelioration of aphthous ulcers, commonly used as a 5% topical oral paste; associates with the calcium-binding proteins S100A12 and S100A13, inhibits the release of FGF1, and, at 1 mM, induces changes in the actin cytoskeleton
14181	Amlexanox	5 g	≥98%	An anti-inflammatory and anti-allergic compound which is useful in the amelioration of aphthous ulcers, commonly used as a 5% topical oral paste; associates with the calcium-binding proteins S100A12 and S100A13, inhibits the release of FGF1, and, at 1 mM, induces changes in the actin cytoskeleton
14181	Amlexanox	500 mg	≥98%	An anti-inflammatory and anti-allergic compound which is useful in the amelioration of aphthous ulcers, commonly used as a 5% topical oral paste; associates with the calcium-binding proteins S100A12 and S100A13, inhibits the release of FGF1, and, at 1 mM, induces changes in the actin cytoskeleton
14185	Torin 2	10 mg	≥98%	An potent, selective inhibitor of cellular mTOR activity (EC50 = 0.3 nM) with more than 800-fold selectivity for mTOR over PI3K (EC50 = 200 nM) and improved bioavailability compared to Torin 1
14185	Torin 2	25 mg	≥98%	An potent, selective inhibitor of cellular mTOR activity (EC50 = 0.3 nM) with more than 800-fold selectivity for mTOR over PI3K (EC50 = 200 nM) and improved bioavailability compared to Torin 1
14185	Torin 2	5 mg	≥98%	An potent, selective inhibitor of cellular mTOR activity (EC50 = 0.3 nM) with more than 800-fold selectivity for mTOR over PI3K (EC50 = 200 nM) and improved bioavailability compared to Torin 1
14187	S14161	1 mg	≥99%	A small molecule inhibitor of cyclins D1-D3 expression that inhibits PI3K activity and arrests cells at the G0/G1 phase in a dose-dependent manner (5-10 μM); induces apoptosis in myeloma and leukemia cell lines (IC50s = < 10 μM) and delays tumor growth in mouse models of leukemia
14187	S14161	5 mg	≥99%	A small molecule inhibitor of cyclins D1-D3 expression that inhibits PI3K activity and arrests cells at the G0/G1 phase in a dose-dependent manner (5-10 μM); induces apoptosis in myeloma and leukemia cell lines (IC50s = < 10 μM) and delays tumor growth in mouse models of leukemia
14198	10Z-Hymenialdisine	500 μg	≥97%	A natural alkaloid that blocks potently inhibits MEK-1 (IC50 = 9 nM); also inhibits numerous kinases in vitro, most notably GSK3β, CDK1/cyclin B, CDK5/p25, CK1, and CDK2/cyclin E (IC50s = 10, 22, 28, 35, and 40 nM, respectively), as well as, less potently, ERK1/2, several isoforms of PKC, and NF-κB
14244	PP1 (Src Inhibitor)	1 mg	≥98%	A potent, reversible, ATP-competitive, and selective inhibitor of the Src family of protein tyrosine kinases: p56lck (IC50 = 5 nM), p59fynT (IC50 = 6 nM), Hck (IC50 = 20 nM)
14244	PP1 (Src Inhibitor)	10 mg	≥98%	A potent, reversible, ATP-competitive, and selective inhibitor of the Src family of protein tyrosine kinases: p56lck (IC50 = 5 nM), p59fynT (IC50 = 6 nM), Hck (IC50 = 20 nM)
14244	PP1 (Src Inhibitor)	25 mg	≥98%	A potent, reversible, ATP-competitive, and selective inhibitor of the Src family of protein tyrosine kinases: p56lck (IC50 = 5 nM), p59fynT (IC50 = 6 nM), Hck (IC50 = 20 nM)
14244	PP1 (Src Inhibitor)	5 mg	≥98%	A potent, reversible, ATP-competitive, and selective inhibitor of the Src family of protein tyrosine kinases: p56lck (IC50 = 5 nM), p59fynT (IC50 = 6 nM), Hck (IC50 = 20 nM)
14245	Thiazovivin	1 mg	≥98%	A ROCK inhibitor (effectively inhibits activity at 2 μM) that improves survival and reprogramming efficiency of iPSCs > 200 fold when used in combination with SB 431542 and PD0325091
14245	Thiazovivin	10 mg	≥98%	A ROCK inhibitor (effectively inhibits activity at 2 μM) that improves survival and reprogramming efficiency of iPSCs > 200 fold when used in combination with SB 431542 and PD0325091
14245	Thiazovivin	25 mg	≥98%	A ROCK inhibitor (effectively inhibits activity at 2 μM) that improves survival and reprogramming efficiency of iPSCs > 200 fold when used in combination with SB 431542 and PD0325091
14245	Thiazovivin	5 mg	≥98%	A ROCK inhibitor (effectively inhibits activity at 2 μM) that improves survival and reprogramming efficiency of iPSCs > 200 fold when used in combination with SB 431542 and PD0325091
14273	MS-1020	1 mg	≥95%	A cell-permeable inhibitor of JAK3, strongly inhibiting constitutive autophosphorylation of JAK3 in L540 cells when used at 30-50 μM; without effect on other JAK isoforms and several other kinases, including Src, Lyn, Akt, EGFR, and ERK1/2

14303	3CAI	1 g	≥95%	An inhibitor of Akt1 and Akt2 with anticancer activity; inhibits Akt1 and Akt2 in a kinase assay, but has no effect on MEK1, JNK1, ERK1, or PBK at 1 μM; increases apoptosis in HCT116 and HT-29 colon cancer cells at 4 μM; inhibits growth of HCT116 cells in vitro; reduces tumor growth in an HCT116 mouse xenograft model at 30 mg/kg; decreases status epilepticus-induced vasogenic edema and reduces increases in eNOS levels in the piriform cortex in rats at 25 μM
14303	3CAI	250 mg	≥95%	An inhibitor of Akt1 and Akt2 with anticancer activity; inhibits Akt1 and Akt2 in a kinase assay, but has no effect on MEK1, JNK1, ERK1, or PBK at 1 μM; increases apoptosis in HCT116 and HT-29 colon cancer cells at 4 μM; inhibits growth of HCT116 cells in vitro; reduces tumor growth in an HCT116 mouse xenograft model at 30 mg/kg; decreases status epilepticus-induced vasogenic edema and reduces increases in eNOS levels in the piriform cortex in rats at 25 μM
14303	3CAI	500 mg	≥95%	An inhibitor of Akt1 and Akt2 with anticancer activity; inhibits Akt1 and Akt2 in a kinase assay, but has no effect on MEK1, JNK1, ERK1, or PBK at 1 μM; increases apoptosis in HCT116 and HT-29 colon cancer cells at 4 μM; inhibits growth of HCT116 cells in vitro; reduces tumor growth in an HCT116 mouse xenograft model at 30 mg/kg; decreases status epilepticus-induced vasogenic edema and reduces increases in eNOS levels in the piriform cortex in rats at 25 μM
14307	CZC-24832	10 mg	≥98%	A PI3Kγ inhibitor (IC50 = 0.025 μM in a binding assay); selective for PI3Kγ over PI3Kδ, PI3Kα, and PI3Kβ (IC50s = 7.9, >10, and 1.26 μM, respectively, in binding assays), as well as a panel of 154 lipid and protein kinases; inhibits C5a-induced phosphorylation of Akt in RAW 264.7 macrophages (IC50 = 1.2 μM); inhibits fMLP-induced migration of isolated human granulocytes (IC50 = 1 μM); decreases disease severity in a mouse model of collagen-induced arthritis at 3 and 10 mg/kg
14307	CZC-24832	25 mg	≥98%	A PI3Kγ inhibitor (IC50 = 0.025 μM in a binding assay); selective for PI3Kγ over PI3Kδ, PI3Kα, and PI3Kβ (IC50s = 7.9, >10, and 1.26 μM, respectively, in binding assays), as well as a panel of 154 lipid and protein kinases; inhibits C5a-induced phosphorylation of Akt in RAW 264.7 macrophages (IC50 = 1.2 μM); inhibits fMLP-induced migration of isolated human granulocytes (IC50 = 1 μM); decreases disease severity in a mouse model of collagen-induced arthritis at 3 and 10 mg/kg
14307	CZC-24832	5 mg	≥98%	A PI3Kγ inhibitor (IC50 = 0.025 μM in a binding assay); selective for PI3Kγ over PI3Kδ, PI3Kα, and PI3Kβ (IC50s = 7.9, >10, and 1.26 μM, respectively, in binding assays), as well as a panel of 154 lipid and protein kinases; inhibits C5a-induced phosphorylation of Akt in RAW 264.7 macrophages (IC50 = 1.2 μM); inhibits fMLP-induced migration of isolated human granulocytes (IC50 = 1 μM); decreases disease severity in a mouse model of collagen-induced arthritis at 3 and 10 mg/kg
14307	CZC-24832	50 mg	≥98%	A PI3Kγ inhibitor (IC50 = 0.025 μM in a binding assay); selective for PI3Kγ over PI3Kδ, PI3Kα, and PI3Kβ (IC50s = 7.9, >10, and 1.26 μM, respectively, in binding assays), as well as a panel of 154 lipid and protein kinases; inhibits C5a-induced phosphorylation of Akt in RAW 264.7 macrophages (IC50 = 1.2 μM); inhibits fMLP-induced migration of isolated human granulocytes (IC50 = 1 μM); decreases disease severity in a mouse model of collagen-induced arthritis at 3 and 10 mg/kg
14309	ANA-12	1 mg	≥98%	A TrkB receptor antagonist that prevents activation of the receptor by BDNF (IC50s = 45.6 nM and 41.1 μM for the high and low affinity sites of the receptor, respectively); demonstrates antianxiety and antidepressant properties in mouse models
14309	ANA-12	10 mg	≥98%	A TrkB receptor antagonist that prevents activation of the receptor by BDNF (IC50s = 45.6 nM and 41.1 μM for the high and low affinity sites of the receptor, respectively); demonstrates antianxiety and antidepressant properties in mouse models
14309	ANA-12	25 mg	≥98%	A TrkB receptor antagonist that prevents activation of the receptor by BDNF (IC50s = 45.6 nM and 41.1 μM for the high and low affinity sites of the receptor, respectively); demonstrates antianxiety and antidepressant properties in mouse models
14309	ANA-12	5 mg	≥98%	A TrkB receptor antagonist that prevents activation of the receptor by BDNF (IC50s = 45.6 nM and 41.1 μM for the high and low affinity sites of the receptor, respectively); demonstrates antianxiety and antidepressant properties in mouse models
14325	2-deoxy-D-Glucose	1 g	≥98%	A glucose antimetabolite and an inhibitor of glycolysis; inhibits hexokinase, as well as phosphoglucose isomerase; induces apoptosis in SK-BR-3 cells at 16 mM; inhibits the growth of 143B osteosarcoma cells cultured under hypoxic conditions at 2 mg/ml; reduces tumor growth in 143B osteosarcoma and MV522 non-small cell lung cancer mouse xenograft models when used alone or in combination with doxorubicin or paclitaxel at 500 mg/kg

14325	2-deoxy-D-Glucose	10 g	≥98%	A glucose antimetabolite and an inhibitor of glycolysis; inhibits hexokinase, as well as phosphoglucose isomerase; induces apoptosis in SK-BR-3 cells at 16 mM; inhibits the growth of 143B osteosarcoma cells cultured under hypoxic conditions at 2 mg/ml; reduces tumor growth in 143B osteosarcoma and MV522 non-small cell lung cancer mouse xenograft models when used alone or in combination with doxorubicin or paclitaxel at 500 mg/kg
14325	2-deoxy-D-Glucose	25 g	≥98%	A glucose antimetabolite and an inhibitor of glycolysis; inhibits hexokinase, as well as phosphoglucose isomerase; induces apoptosis in SK-BR-3 cells at 16 mM; inhibits the growth of 143B osteosarcoma cells cultured under hypoxic conditions at 2 mg/ml; reduces tumor growth in 143B osteosarcoma and MV522 non-small cell lung cancer mouse xenograft models when used alone or in combination with doxorubicin or paclitaxel at 500 mg/kg
14325	2-deoxy-D-Glucose	5 g	≥98%	A glucose antimetabolite and an inhibitor of glycolysis; inhibits hexokinase, as well as phosphoglucose isomerase; induces apoptosis in SK-BR-3 cells at 16 mM; inhibits the growth of 143B osteosarcoma cells cultured under hypoxic conditions at 2 mg/ml; reduces tumor growth in 143B osteosarcoma and MV522 non-small cell lung cancer mouse xenograft models when used alone or in combination with doxorubicin or paclitaxel at 500 mg/kg
14399	MK2 Inhibitor IV	10 mg	≥95%	A highly selective, non-ATP competitive inhibitor of p38/mitogen-activated protein kinase-activated protein kinase 2 (IC50 = 0.11 μM); inhibits TNF-α (IC50 = 4.4 μM) and IL-6 (IC50 = 5.2 μM) secretion from the human THP-1 acute monocytic leukemia cell line
14399	MK2 Inhibitor IV	25 mg	≥95%	A highly selective, non-ATP competitive inhibitor of p38/mitogen-activated protein kinase-activated protein kinase 2 (IC50 = 0.11 μM); inhibits TNF-α (IC50 = 4.4 μM) and IL-6 (IC50 = 5.2 μM) secretion from the human THP-1 acute monocytic leukemia cell line
14399	MK2 Inhibitor IV	5 mg	≥95%	A highly selective, non-ATP competitive inhibitor of p38/mitogen-activated protein kinase-activated protein kinase 2 (IC50 = 0.11 μM); inhibits TNF-α (IC50 = 4.4 μM) and IL-6 (IC50 = 5.2 μM) secretion from the human THP-1 acute monocytic leukemia cell line
14413	HA-1100 (hydrochlori	1 mg	≥98%	A cell-permeable inhibitor of ROCK (Ki = 150 nM); less effectively inhibits PKA (Ki = 2.2 μM)
14413	HA-1100 (hydrochlori	10 mg	≥98%	A cell-permeable inhibitor of ROCK (Ki = 150 nM); less effectively inhibits PKA (Ki = 2.2 μM)
14413	HA-1100 (hydrochlori	25 mg	≥98%	A cell-permeable inhibitor of ROCK (Ki = 150 nM); less effectively inhibits PKA (Ki = 2.2 μM)
14413	HA-1100 (hydrochlori	5 mg	≥98%	A cell-permeable inhibitor of ROCK (Ki = 150 nM); less effectively inhibits PKA (Ki = 2.2 μM)
14428	Alsterpaullone	1 mg	≥98%	An ATP-competitive, selective inhibitor of Cdk1/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p25 and GSK3α/β with IC50 values of 35, 15, 200, 40, and 4 nM, respectively.
14428	Alsterpaullone	5 mg	≥98%	An ATP-competitive, selective inhibitor of Cdk1/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p25 and GSK3α/β with IC50 values of 35, 15, 200, 40, and 4 nM, respectively.
14436	Borrelidin	1 mg	≥98%	A bacterial secondary metabolite which displays potent antiangiogenic activity, preventing tube formation in rat aorta explants (IC50 = 0.8 nM) and inducing apoptosis in endothelial cells; powerful inhibitor of both eukaryotic and bacterial threonyl tRNA synthetase; effective anti-malarial drug
14436	Borrelidin	500 μg	≥98%	A bacterial secondary metabolite which displays potent antiangiogenic activity, preventing tube formation in rat aorta explants (IC50 = 0.8 nM) and inducing apoptosis in endothelial cells; powerful inhibitor of both eukaryotic and bacterial threonyl tRNA synthetase; effective anti-malarial drug
14453	TBB	10 mg	≥98%	An inhibitor of CK2 (IC50 = 0.15 μM); inhibits PIM3 and DYRK2 (IC50s = 0.86 and 0.99 μM, respectively) and other protein kinases with IC50 values in the low micromolar range but displays less than 10% inhibition at 26 additional kinases up to 10 μM
14453	TBB	25 mg	≥98%	An inhibitor of CK2 (IC50 = 0.15 μM); inhibits PIM3 and DYRK2 (IC50s = 0.86 and 0.99 μM, respectively) and other protein kinases with IC50 values in the low micromolar range but displays less than 10% inhibition at 26 additional kinases up to 10 μM
14453	TBB	5 mg	≥98%	An inhibitor of CK2 (IC50 = 0.15 μM); inhibits PIM3 and DYRK2 (IC50s = 0.86 and 0.99 μM, respectively) and other protein kinases with IC50 values in the low micromolar range but displays less than 10% inhibition at 26 additional kinases up to 10 μM
14453	TBB	50 mg	≥98%	An inhibitor of CK2 (IC50 = 0.15 μM); inhibits PIM3 and DYRK2 (IC50s = 0.86 and 0.99 μM, respectively) and other protein kinases with IC50 values in the low micromolar range but displays less than 10% inhibition at 26 additional kinases up to 10 μM
14485	FAK Inhibitor 14	10 mg	≥95%	A direct inhibitor of FAK1 autophosphorylation, blocking phosphorylation of Y397 (IC50 = 1 μM); no known significant effect on the activity of a range of other kinases; promotes cell detachment and inhibits cell adhesion of cells in culture; blocks tumor growth in vivo

14485	FAK Inhibitor 14	100 mg	≥95%	A direct inhibitor of FAK1 autophosphorylation, blocking phosphorylation of Y397 (IC50 = 1 µM); no known significant effect on the activity of a range of other kinases; promotes cell detachment and inhibits cell adhesion of cells in culture; blocks tumor growth in vivo
14485	FAK Inhibitor 14	25 mg	≥95%	A direct inhibitor of FAK1 autophosphorylation, blocking phosphorylation of Y397 (IC50 = 1 µM); no known significant effect on the activity of a range of other kinases; promotes cell detachment and inhibits cell adhesion of cells in culture; blocks tumor growth in vivo
14485	FAK Inhibitor 14	50 mg	≥95%	A direct inhibitor of FAK1 autophosphorylation, blocking phosphorylation of Y397 (IC50 = 1 µM); no known significant effect on the activity of a range of other kinases; promotes cell detachment and inhibits cell adhesion of cells in culture; blocks tumor growth in vivo
14504	ACHP	1 mg	≥98%	An inhibitor of IKKβ and IKKα (IC50s = 8.5 and 250 nM, respectively); selective for IKKβ and IKKα over IKKγ, Syk, and MKK4 (IC50s = >20 µM for all); reduces the constitutive phosphorylation of IκBα and NF-κB p65 in U266 and NCU-MM-2 cells at 50 µM; prevents TNF-α-induced activation of NF-κB in U266 cells at 0.1 µM; inhibits the growth of U266, NCU-MM-2, ILKM2, and BJAB cells (IC50s = 18.3, 27.6, 34.6, and 17.6 µM, respectively); prevents TNF-α-induced HIV-1 replication in latently HIV-1-infected OM10.1 cells (EC50 = 0.56 µM); prevents PMA-and imiquimod-induced skin inflammation in mice at 5 mg/kg
14504	ACHP	5 mg	≥98%	An inhibitor of IKKβ and IKKα (IC50s = 8.5 and 250 nM, respectively); selective for IKKβ and IKKα over IKKγ, Syk, and MKK4 (IC50s = >20 µM for all); reduces the constitutive phosphorylation of IκBα and NF-κB p65 in U266 and NCU-MM-2 cells at 50 µM; prevents TNF-α-induced activation of NF-κB in U266 cells at 0.1 µM; inhibits the growth of U266, NCU-MM-2, ILKM2, and BJAB cells (IC50s = 18.3, 27.6, 34.6, and 17.6 µM, respectively); prevents TNF-α-induced HIV-1 replication in latently HIV-1-infected OM10.1 cells (EC50 = 0.56 µM); prevents PMA-and imiquimod-induced skin inflammation in mice at 5 mg/kg
14529	AG-1295	1 mg	≥98%	A quinoxaline-type tyrphostin that acts as a potent and selective inhibitor of PDGF receptor kinase in vitro and in Swiss 3T3 cells (IC50s range from 0.3-1 µM); inhibits PDGF-stimulated DNA synthesis (IC50 = 2.5 µM) without affecting activity of the EGF receptor
14529	AG-1295	10 mg	≥98%	A quinoxaline-type tyrphostin that acts as a potent and selective inhibitor of PDGF receptor kinase in vitro and in Swiss 3T3 cells (IC50s range from 0.3-1 µM); inhibits PDGF-stimulated DNA synthesis (IC50 = 2.5 µM) without affecting activity of the EGF receptor
14529	AG-1295	25 mg	≥98%	A quinoxaline-type tyrphostin that acts as a potent and selective inhibitor of PDGF receptor kinase in vitro and in Swiss 3T3 cells (IC50s range from 0.3-1 µM); inhibits PDGF-stimulated DNA synthesis (IC50 = 2.5 µM) without affecting activity of the EGF receptor
14529	AG-1295	5 mg	≥98%	A quinoxaline-type tyrphostin that acts as a potent and selective inhibitor of PDGF receptor kinase in vitro and in Swiss 3T3 cells (IC50s range from 0.3-1 µM); inhibits PDGF-stimulated DNA synthesis (IC50 = 2.5 µM) without affecting activity of the EGF receptor
14567	PF-05212384	1 mg	≥98%	A potent, dual PI3K/mTOR inhibitor (IC50 values are 0.4 and 5.4 nM for PI3Kα and PI3Kγ, respectively, and 1.6 nM for mTOR); active both in vitro and in vivo, inhibiting the growth of cancer cells in culture or in xenografts in mice when delivered intravenously
14567	PF-05212384	10 mg	≥98%	A potent, dual PI3K/mTOR inhibitor (IC50 values are 0.4 and 5.4 nM for PI3Kα and PI3Kγ, respectively, and 1.6 nM for mTOR); active both in vitro and in vivo, inhibiting the growth of cancer cells in culture or in xenografts in mice when delivered intravenously
14567	PF-05212384	5 mg	≥98%	A potent, dual PI3K/mTOR inhibitor (IC50 values are 0.4 and 5.4 nM for PI3Kα and PI3Kγ, respectively, and 1.6 nM for mTOR); active both in vitro and in vivo, inhibiting the growth of cancer cells in culture or in xenografts in mice when delivered intravenously
14579	Purvalanol A	10 mg	≥98%	A potent, cell-permeable, and selective inhibitor of CDKs (IC50s = 4, 70, 35, 850, and 75 nM for cdc2/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, Cdk4/cyclin D1 and Cdk5-p35, respectively); reversibly arrests synchronized cells in the G1 and G2 phase of the cell cycle, inhibiting both cell proliferation and cell death
14579	Purvalanol A	100 mg	≥98%	A potent, cell-permeable, and selective inhibitor of CDKs (IC50s = 4, 70, 35, 850, and 75 nM for cdc2/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, Cdk4/cyclin D1 and Cdk5-p35, respectively); reversibly arrests synchronized cells in the G1 and G2 phase of the cell cycle, inhibiting both cell proliferation and cell death
14579	Purvalanol A	5 mg	≥98%	A potent, cell-permeable, and selective inhibitor of CDKs (IC50s = 4, 70, 35, 850, and 75 nM for cdc2/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, Cdk4/cyclin D1 and Cdk5-p35, respectively); reversibly arrests synchronized cells in the G1 and G2 phase of the cell cycle, inhibiting both cell proliferation and cell death
14579	Purvalanol A	50 mg	≥98%	A potent, cell-permeable, and selective inhibitor of CDKs (IC50s = 4, 70, 35, 850, and 75 nM for cdc2/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, Cdk4/cyclin D1 and Cdk5-p35, respectively); reversibly arrests synchronized cells in the G1 and G2 phase of the cell cycle, inhibiting both cell proliferation and cell death

14588	PF-670462 (hydrochlo	10 mg	≥99%	A potent inhibitor of the CK1 isoforms CK1ε and CK1δ (IC50 = 7.7 and 14 nM, respectively); less effectively inhibits a wide variety of related or common kinases; disrupts circadian rhythms in cells and animals; blocks the locomotor response to amphetamines in mice
14588	PF-670462 (hydrochlo	50 mg	≥99%	A potent inhibitor of the CK1 isoforms CK1ε and CK1δ (IC50 = 7.7 and 14 nM, respectively); less effectively inhibits a wide variety of related or common kinases; disrupts circadian rhythms in cells and animals; blocks the locomotor response to amphetamines in mice
14592	Src Kinase Inhibitor I	1 mg	≥98%	A potent competitive inhibitor of both Src and Lck (IC50 = 44 and 88 nM, respectively), as well as Csk and Yes; also inhibits RIP-2
14592	Src Kinase Inhibitor I	10 mg	≥98%	A potent competitive inhibitor of both Src and Lck (IC50 = 44 and 88 nM, respectively), as well as Csk and Yes; also inhibits RIP-2
14592	Src Kinase Inhibitor I	5 mg	≥98%	A potent competitive inhibitor of both Src and Lck (IC50 = 44 and 88 nM, respectively), as well as Csk and Yes; also inhibits RIP-2
14592	Src Kinase Inhibitor I	50 mg	≥98%	A potent competitive inhibitor of both Src and Lck (IC50 = 44 and 88 nM, respectively), as well as Csk and Yes; also inhibits RIP-2
14603	GSK2578215A	10 mg	≥98%	A potent, selective inhibitor of LRRK2 (IC50 = 8.9 nM) that also inhibits the G2019S mutant of LRRK2 (IC50 = 10.1 nM)
14603	GSK2578215A	25 mg	≥98%	A potent, selective inhibitor of LRRK2 (IC50 = 8.9 nM) that also inhibits the G2019S mutant of LRRK2 (IC50 = 10.1 nM)
14603	GSK2578215A	5 mg	≥98%	A potent, selective inhibitor of LRRK2 (IC50 = 8.9 nM) that also inhibits the G2019S mutant of LRRK2 (IC50 = 10.1 nM)
14603	GSK2578215A	50 mg	≥98%	A potent, selective inhibitor of LRRK2 (IC50 = 8.9 nM) that also inhibits the G2019S mutant of LRRK2 (IC50 = 10.1 nM)
14617	DMXAA	1 mg	≥98%	A tumor vascular disrupting agent, inducing apoptosis in tumor vascular endothelium resulting in necrosis at the tumor core; potently activates the STING/TBK1/IRF3 signaling pathway in mouse leukocytes, inducing type-I-IFN production; inhibits VEGFR1 and VEGFR2 (IC50 = 119 and 11 µM, respectively)
14617	DMXAA	10 mg	≥98%	A tumor vascular disrupting agent, inducing apoptosis in tumor vascular endothelium resulting in necrosis at the tumor core; potently activates the STING/TBK1/IRF3 signaling pathway in mouse leukocytes, inducing type-I-IFN production; inhibits VEGFR1 and VEGFR2 (IC50 = 119 and 11 µM, respectively)
14617	DMXAA	25 mg	≥98%	A tumor vascular disrupting agent, inducing apoptosis in tumor vascular endothelium resulting in necrosis at the tumor core; potently activates the STING/TBK1/IRF3 signaling pathway in mouse leukocytes, inducing type-I-IFN production; inhibits VEGFR1 and VEGFR2 (IC50 = 119 and 11 µM, respectively)
14617	DMXAA	5 mg	≥98%	A tumor vascular disrupting agent, inducing apoptosis in tumor vascular endothelium resulting in necrosis at the tumor core; potently activates the STING/TBK1/IRF3 signaling pathway in mouse leukocytes, inducing type-I-IFN production; inhibits VEGFR1 and VEGFR2 (IC50 = 119 and 11 µM, respectively)
14662	Zaltoprofen	10 mg	≥98%	An NSAID that displays slight preferential inhibition for COX-2 (IC50s = 1.3 and 0.34 µM for COX-1 and COX-2, respectively); also inhibits bradykinin-induced nociceptive responses by blocking the activation of PKC
14662	Zaltoprofen	100 mg	≥98%	An NSAID that displays slight preferential inhibition for COX-2 (IC50s = 1.3 and 0.34 µM for COX-1 and COX-2, respectively); also inhibits bradykinin-induced nociceptive responses by blocking the activation of PKC
14662	Zaltoprofen	250 mg	≥98%	An NSAID that displays slight preferential inhibition for COX-2 (IC50s = 1.3 and 0.34 µM for COX-1 and COX-2, respectively); also inhibits bradykinin-induced nociceptive responses by blocking the activation of PKC
14662	Zaltoprofen	50 mg	≥98%	An NSAID that displays slight preferential inhibition for COX-2 (IC50s = 1.3 and 0.34 µM for COX-1 and COX-2, respectively); also inhibits bradykinin-induced nociceptive responses by blocking the activation of PKC
14666	BMS-536924	1 mg	≥98%	A dual inhibitor of IGF-1R kinase and IR (IC50s = 100 and 73 nM, respectively); blocks IFG-1R autophosphorylation and signaling through MEK1/2 and Akt, leading to G1 arrest and apoptosis in ML-1 cells; reverses EMT in MCF10A cells overexpressing constitutively activated IGF-1R
14666	BMS-536924	10 mg	≥98%	A dual inhibitor of IGF-1R kinase and IR (IC50s = 100 and 73 nM, respectively); blocks IFG-1R autophosphorylation and signaling through MEK1/2 and Akt, leading to G1 arrest and apoptosis in ML-1 cells; reverses EMT in MCF10A cells overexpressing constitutively activated IGF-1R
14666	BMS-536924	25 mg	≥98%	A dual inhibitor of IGF-1R kinase and IR (IC50s = 100 and 73 nM, respectively); blocks IFG-1R autophosphorylation and signaling through MEK1/2 and Akt, leading to G1 arrest and apoptosis in ML-1 cells; reverses EMT in MCF10A cells overexpressing constitutively activated IGF-1R
14666	BMS-536924	5 mg	≥98%	A dual inhibitor of IGF-1R kinase and IR (IC50s = 100 and 73 nM, respectively); blocks IFG-1R autophosphorylation and signaling through MEK1/2 and Akt, leading to G1 arrest and apoptosis in ML-1 cells; reverses EMT in MCF10A cells overexpressing constitutively activated IGF-1R
14696	TG101209	1 mg	≥98%	A potent inhibitor of the tyrosine kinases JAK2, FLT3, RET, and JAK3 (IC50 = 6, 25, 17, and 169 nM, respectively); induces cell cycle arrest and apoptosis in leukemic cell lines and CD45+ myeloma cells

14696	TG101209	10 mg	≥98%	A potent inhibitor of the tyrosine kinases JAK2, FLT3, RET, and JAK3 (IC50 = 6, 25, 17, and 169 nM, respectively); induces cell cycle arrest and apoptosis in leukemic cell lines and CD45+ myeloma cells
14696	TG101209	25 mg	≥98%	A potent inhibitor of the tyrosine kinases JAK2, FLT3, RET, and JAK3 (IC50 = 6, 25, 17, and 169 nM, respectively); induces cell cycle arrest and apoptosis in leukemic cell lines and CD45+ myeloma cells
14696	TG101209	5 mg	≥98%	A potent inhibitor of the tyrosine kinases JAK2, FLT3, RET, and JAK3 (IC50 = 6, 25, 17, and 169 nM, respectively); induces cell cycle arrest and apoptosis in leukemic cell lines and CD45+ myeloma cells
14703	PHA-665752	1 mg	≥98%	An active-site inhibitor of the catalytic activity of c-Met kinase (Ki = 4 nM; IC50 = 9 nM) that exhibits >50-fold selectivity for c-Met over a panel of tyrosine and serine-threonine kinases; inhibits c-Met phosphorylation, as well as cell proliferation and cell motility, of various tumor cells (IC50s = 18-50 nM)
14703	PHA-665752	10 mg	≥98%	An active-site inhibitor of the catalytic activity of c-Met kinase (Ki = 4 nM; IC50 = 9 nM) that exhibits >50-fold selectivity for c-Met over a panel of tyrosine and serine-threonine kinases; inhibits c-Met phosphorylation, as well as cell proliferation and cell motility, of various tumor cells (IC50s = 18-50 nM)
14703	PHA-665752	25 mg	≥98%	An active-site inhibitor of the catalytic activity of c-Met kinase (Ki = 4 nM; IC50 = 9 nM) that exhibits >50-fold selectivity for c-Met over a panel of tyrosine and serine-threonine kinases; inhibits c-Met phosphorylation, as well as cell proliferation and cell motility, of various tumor cells (IC50s = 18-50 nM)
14703	PHA-665752	5 mg	≥98%	An active-site inhibitor of the catalytic activity of c-Met kinase (Ki = 4 nM; IC50 = 9 nM) that exhibits >50-fold selectivity for c-Met over a panel of tyrosine and serine-threonine kinases; inhibits c-Met phosphorylation, as well as cell proliferation and cell motility, of various tumor cells (IC50s = 18-50 nM)
14704	GSK3β Inhibitor VIII	10 mg	≥98%	A selective, ATP-competitive inhibitor of the serine/threonine kinase, glycogen synthase kinase 3β (Ki = 38 nM; IC50 = 104 nM); demonstrates neuroprotective effects by inhibiting tau phosphorylation (IC50 = 2.7 μM) at a GSK3-specific site (Ser396) in cells stably expressing human four-repeat tau protein and also by protecting β-amyloid-exposed N2A neuroblastoma cells against cell death
14704	GSK3β Inhibitor VIII	5 mg	≥98%	A selective, ATP-competitive inhibitor of the serine/threonine kinase, glycogen synthase kinase 3β (Ki = 38 nM; IC50 = 104 nM); demonstrates neuroprotective effects by inhibiting tau phosphorylation (IC50 = 2.7 μM) at a GSK3-specific site (Ser396) in cells stably expressing human four-repeat tau protein and also by protecting β-amyloid-exposed N2A neuroblastoma cells against cell death
14704	GSK3β Inhibitor VIII	50 mg	≥98%	A selective, ATP-competitive inhibitor of the serine/threonine kinase, glycogen synthase kinase 3β (Ki = 38 nM; IC50 = 104 nM); demonstrates neuroprotective effects by inhibiting tau phosphorylation (IC50 = 2.7 μM) at a GSK3-specific site (Ser396) in cells stably expressing human four-repeat tau protein and also by protecting β-amyloid-exposed N2A neuroblastoma cells against cell death
14706	Vandetanib	10 mg	≥98%	A multi-kinase inhibitor that inhibits VEGFR2, VEGFR3, VEGFR1, EGFR, PDGFRβ, Tie-2, and FGFR1 (IC50s = 40, 110, 1,600, 500, 1,100, 2,500, and 3,600 nM, respectively, in cell-free assays); also binds to 142 additional kinases in a panel of 442 kinases (Kds = 4.6-7,900 nM); induces apoptosis and cell cycle arrest at the G0/G1 phase in GEO colon and OVCAR-3 ovarian cancer cells at 1 and 2.5 μM; inhibits proliferation of HAK1-B, KYN-2, and Huh7 hepatocarcinoma cells and HUVECs (IC50s = 10, 8.1, 9.4, and 7.1 μM, respectively); increases survival and decreases tumor angiogenesis and VEGFR2 levels in a D54MG glioblastoma mouse xenograft model at 200 mg/kg; reduces tumor growth in a variety of mouse xenograft models at 25-100 mg/kg per day
14706	Vandetanib	100 mg	≥98%	A multi-kinase inhibitor that inhibits VEGFR2, VEGFR3, VEGFR1, EGFR, PDGFRβ, Tie-2, and FGFR1 (IC50s = 40, 110, 1,600, 500, 1,100, 2,500, and 3,600 nM, respectively, in cell-free assays); also binds to 142 additional kinases in a panel of 442 kinases (Kds = 4.6-7,900 nM); induces apoptosis and cell cycle arrest at the G0/G1 phase in GEO colon and OVCAR-3 ovarian cancer cells at 1 and 2.5 μM; inhibits proliferation of HAK1-B, KYN-2, and Huh7 hepatocarcinoma cells and HUVECs (IC50s = 10, 8.1, 9.4, and 7.1 μM, respectively); increases survival and decreases tumor angiogenesis and VEGFR2 levels in a D54MG glioblastoma mouse xenograft model at 200 mg/kg; reduces tumor growth in a variety of mouse xenograft models at 25-100 mg/kg per day

14706	Vandetanib	25 mg	≥98%	A multi-kinase inhibitor that inhibits VEGFR2, VEGFR3, VEGFR1, EGFR, PDGFRβ, Tie-2, and FGFR1 (IC50s = 40, 110, 1,600, 500, 1,100, 2,500, and 3,600 nM, respectively, in cell-free assays); also binds to 142 additional kinases in a panel of 442 kinases (Kds = 4.6-7,900 nM); induces apoptosis and cell cycle arrest at the G0/G1 phase in GEO colon and OVCAR-3 ovarian cancer cells at 1 and 2.5 μM; inhibits proliferation of HAK1-B, KYN-2, and Huh7 hepatocarcinoma cells and HUVECs (IC50s = 10, 8.1, 9.4, and 7.1 μM, respectively); increases survival and decreases tumor angiogenesis and VEGFR2 levels in a D54MG glioblastoma mouse xenograft model at 200 mg/kg; reduces tumor growth in a variety of mouse xenograft models at 25-100 mg/kg per day
14706	Vandetanib	5 mg	≥98%	A multi-kinase inhibitor that inhibits VEGFR2, VEGFR3, VEGFR1, EGFR, PDGFRβ, Tie-2, and FGFR1 (IC50s = 40, 110, 1,600, 500, 1,100, 2,500, and 3,600 nM, respectively, in cell-free assays); also binds to 142 additional kinases in a panel of 442 kinases (Kds = 4.6-7,900 nM); induces apoptosis and cell cycle arrest at the G0/G1 phase in GEO colon and OVCAR-3 ovarian cancer cells at 1 and 2.5 μM; inhibits proliferation of HAK1-B, KYN-2, and Huh7 hepatocarcinoma cells and HUVECs (IC50s = 10, 8.1, 9.4, and 7.1 μM, respectively); increases survival and decreases tumor angiogenesis and VEGFR2 levels in a D54MG glioblastoma mouse xenograft model at 200 mg/kg; reduces tumor growth in a variety of mouse xenograft models at 25-100 mg/kg per day
14707	Dinaciclib	10 mg	≥98%	A pan-CDK inhibitor (IC50s = 3, 1, 1, and 4 nM for CDK1, CDK2, CDK5, and CDK9, respectively) that inhibits DNA synthesis in A2780 ovarian cancer cells (IC50 = 4 nM); 5 mg/kg prevents tumor growth by 50% in an A2780 ovarian carcinoma mouse xenograft model; active against a broad spectrum of human tumor cell lines in vitro (IC50s = 7-17 nM)
14707	Dinaciclib	25 mg	≥98%	A pan-CDK inhibitor (IC50s = 3, 1, 1, and 4 nM for CDK1, CDK2, CDK5, and CDK9, respectively) that inhibits DNA synthesis in A2780 ovarian cancer cells (IC50 = 4 nM); 5 mg/kg prevents tumor growth by 50% in an A2780 ovarian carcinoma mouse xenograft model; active against a broad spectrum of human tumor cell lines in vitro (IC50s = 7-17 nM)
14707	Dinaciclib	5 mg	≥98%	A pan-CDK inhibitor (IC50s = 3, 1, 1, and 4 nM for CDK1, CDK2, CDK5, and CDK9, respectively) that inhibits DNA synthesis in A2780 ovarian cancer cells (IC50 = 4 nM); 5 mg/kg prevents tumor growth by 50% in an A2780 ovarian carcinoma mouse xenograft model; active against a broad spectrum of human tumor cell lines in vitro (IC50s = 7-17 nM)
14708	BX-912	1 mg	≥98%	A potent, ATP-competitive inhibitor of PDK1 (IC50 = 26 nM)
14708	BX-912	10 mg	≥98%	A potent, ATP-competitive inhibitor of PDK1 (IC50 = 26 nM)
14708	BX-912	25 mg	≥98%	A potent, ATP-competitive inhibitor of PDK1 (IC50 = 26 nM)
14708	BX-912	5 mg	≥98%	A potent, ATP-competitive inhibitor of PDK1 (IC50 = 26 nM)
14751	Shikonin	10 mg	≥98%	A naturally occurring naphthoquinine; increases glucose uptake by adipocytes and inhibits PTEN activity; inhibits glycolysis in cancer cells by inhibiting tumor-specific pyruvate kinase M2; inhibits leukocyte migration, downregulates chemokine receptor expression, and inhibits HIV-1 replication; reduces joint swelling and cartilage destruction in a mouse model of collagen-induced arthritis
14751	Shikonin	100 mg	≥98%	A naturally occurring naphthoquinine; increases glucose uptake by adipocytes and inhibits PTEN activity; inhibits glycolysis in cancer cells by inhibiting tumor-specific pyruvate kinase M2; inhibits leukocyte migration, downregulates chemokine receptor expression, and inhibits HIV-1 replication; reduces joint swelling and cartilage destruction in a mouse model of collagen-induced arthritis
14751	Shikonin	5 mg	≥98%	A naturally occurring naphthoquinine; increases glucose uptake by adipocytes and inhibits PTEN activity; inhibits glycolysis in cancer cells by inhibiting tumor-specific pyruvate kinase M2; inhibits leukocyte migration, downregulates chemokine receptor expression, and inhibits HIV-1 replication; reduces joint swelling and cartilage destruction in a mouse model of collagen-induced arthritis
14751	Shikonin	50 mg	≥98%	A naturally occurring naphthoquinine; increases glucose uptake by adipocytes and inhibits PTEN activity; inhibits glycolysis in cancer cells by inhibiting tumor-specific pyruvate kinase M2; inhibits leukocyte migration, downregulates chemokine receptor expression, and inhibits HIV-1 replication; reduces joint swelling and cartilage destruction in a mouse model of collagen-induced arthritis
14759	IPA-3	10 mg	≥95%	A cell-permeable allosteric inhibitor of PAK1 that is non-competitive with respect to ATP binding (IC50 = 2.5 μM); binds covalently to the PAK1 regulatory domain (apparent Kd = 1.9 uM) and prevents binding to the upstream activator Cdc42
14759	IPA-3	25 mg	≥95%	A cell-permeable allosteric inhibitor of PAK1 that is non-competitive with respect to ATP binding (IC50 = 2.5 μM); binds covalently to the PAK1 regulatory domain (apparent Kd = 1.9 uM) and prevents binding to the upstream activator Cdc42
14759	IPA-3	5 mg	≥95%	A cell-permeable allosteric inhibitor of PAK1 that is non-competitive with respect to ATP binding (IC50 = 2.5 μM); binds covalently to the PAK1 regulatory domain (apparent Kd = 1.9 uM) and prevents binding to the upstream activator Cdc42

14759	IPA-3	50 mg	≥95%	A cell-permeable allosteric inhibitor of PAK1 that is non-competitive with respect to ATP binding (IC50 = 2.5 µM); binds covalently to the PAK1 regulatory domain (apparent Kd = 1.9 uM) and prevents binding to the upstream activator Cdc42
14794	ALK5 Inhibitor II	1 mg	≥98%	A selective inhibitor of the TGF-β type1 receptor ALK5 (IC50s = 4, 18, and 23 nM for ALK5 autophosphorylation, TGF-β cellular assay, and ALK5 binding in HepG2 cells, respectively); used to induce stem cell pluripotency by replacing the reprogramming transcription factor Sox2 via inhibition of the TGF-β signaling pathway and induction of Nanog transcription
14794	ALK5 Inhibitor II	10 mg	≥98%	A selective inhibitor of the TGF-β type1 receptor ALK5 (IC50s = 4, 18, and 23 nM for ALK5 autophosphorylation, TGF-β cellular assay, and ALK5 binding in HepG2 cells, respectively); used to induce stem cell pluripotency by replacing the reprogramming transcription factor Sox2 via inhibition of the TGF-β signaling pathway and induction of Nanog transcription
14794	ALK5 Inhibitor II	25 mg	≥98%	A selective inhibitor of the TGF-β type1 receptor ALK5 (IC50s = 4, 18, and 23 nM for ALK5 autophosphorylation, TGF-β cellular assay, and ALK5 binding in HepG2 cells, respectively); used to induce stem cell pluripotency by replacing the reprogramming transcription factor Sox2 via inhibition of the TGF-β signaling pathway and induction of Nanog transcription
14794	ALK5 Inhibitor II	5 mg	≥98%	A selective inhibitor of the TGF-β type1 receptor ALK5 (IC50s = 4, 18, and 23 nM for ALK5 autophosphorylation, TGF-β cellular assay, and ALK5 binding in HepG2 cells, respectively); used to induce stem cell pluripotency by replacing the reprogramming transcription factor Sox2 via inhibition of the TGF-β signaling pathway and induction of Nanog transcription
14796	SU 9516	1 mg	≥98%	A potent inhibitor of several CDKs with selectivity for Cdk2 (IC50s = 22, 40, and 200 nM for Cdk2/cyclin A, Cdk1/cyclin B, and Cdk4/cyclin D1); has anti-proliferative and pro-apoptotic activity in tumor cells
14796	SU 9516	10 mg	≥98%	A potent inhibitor of several CDKs with selectivity for Cdk2 (IC50s = 22, 40, and 200 nM for Cdk2/cyclin A, Cdk1/cyclin B, and Cdk4/cyclin D1); has anti-proliferative and pro-apoptotic activity in tumor cells
14796	SU 9516	25 mg	≥98%	A potent inhibitor of several CDKs with selectivity for Cdk2 (IC50s = 22, 40, and 200 nM for Cdk2/cyclin A, Cdk1/cyclin B, and Cdk4/cyclin D1); has anti-proliferative and pro-apoptotic activity in tumor cells
14796	SU 9516	5 mg	≥98%	A potent inhibitor of several CDKs with selectivity for Cdk2 (IC50s = 22, 40, and 200 nM for Cdk2/cyclin A, Cdk1/cyclin B, and Cdk4/cyclin D1); has anti-proliferative and pro-apoptotic activity in tumor cells
14826	W-7 (hydrochloride)	10 mg	≥98%	A cell-permeable antagonist of calmodulin (Ki = 11 µM); also associates, at lower affinities, with calcium-binding domains of other proteins, including troponin C and myosin light chain kinase (Ki = 70 and 300 µM, respectively)
14826	W-7 (hydrochloride)	100 mg	≥98%	A cell-permeable antagonist of calmodulin (Ki = 11 µM); also associates, at lower affinities, with calcium-binding domains of other proteins, including troponin C and myosin light chain kinase (Ki = 70 and 300 µM, respectively)
14826	W-7 (hydrochloride)	50 mg	≥98%	A cell-permeable antagonist of calmodulin (Ki = 11 µM); also associates, at lower affinities, with calcium-binding domains of other proteins, including troponin C and myosin light chain kinase (Ki = 70 and 300 µM, respectively)
14829	Syk Inhibitor	1 mg	≥95% (mixture	An oxindole compound that potently blocks Syk activity (IC50 = 14 nM) and inhibits FcεRI-mediated rat RBL-2H3 basophil cell degranulation (EC50 = 313 nM); 2 µM completely abolishes convulxin-induced platelet aggregation and shape change
14829	Syk Inhibitor	10 mg	≥95% (mixture	An oxindole compound that potently blocks Syk activity (IC50 = 14 nM) and inhibits FcεRI-mediated rat RBL-2H3 basophil cell degranulation (EC50 = 313 nM); 2 µM completely abolishes convulxin-induced platelet aggregation and shape change
14829	Syk Inhibitor	500 µg	≥95% (mixture	An oxindole compound that potently blocks Syk activity (IC50 = 14 nM) and inhibits FcεRI-mediated rat RBL-2H3 basophil cell degranulation (EC50 = 313 nM); 2 µM completely abolishes convulxin-induced platelet aggregation and shape change
14831	TBCA	1 mg	≥98%	A selective, cell-permeable inhibitor of CK2 (IC50 = 0.11 µM, Ki = 77 nM) that has minimal effect on a panel of 28 other kinases; induces cell death in Jurkat adult T cell leukemia cells (DC50 = 7.7 µM), driving caspase-dependent degradation of poly-ADP ribose polymerase while inhibiting CK2 activity
14831	TBCA	10 mg	≥98%	A selective, cell-permeable inhibitor of CK2 (IC50 = 0.11 µM, Ki = 77 nM) that has minimal effect on a panel of 28 other kinases; induces cell death in Jurkat adult T cell leukemia cells (DC50 = 7.7 µM), driving caspase-dependent degradation of poly-ADP ribose polymerase while inhibiting CK2 activity
14831	TBCA	25 mg	≥98%	A selective, cell-permeable inhibitor of CK2 (IC50 = 0.11 µM, Ki = 77 nM) that has minimal effect on a panel of 28 other kinases; induces cell death in Jurkat adult T cell leukemia cells (DC50 = 7.7 µM), driving caspase-dependent degradation of poly-ADP ribose polymerase while inhibiting CK2 activity

14831	TBCA	5 mg	≥98%	A selective, cell-permeable inhibitor of CK2 (IC50 = 0.11 µM, Ki = 77 nM) that has minimal effect on a panel of 28 other kinases; induces cell death in Jurkat adult T cell leukemia cells (DC50 = 7.7 µM), driving caspase-dependent degradation of poly-ADP ribose polymerase while inhibiting CK2 activity
14833	AG-1024	1 mg	≥98%	A selective inhibitor of IGF-1R that inhibits insulin-stimulated cellular proliferation and IGF-1R autophosphorylation with IC50 values of 0.4 and 7 µM, respectively; inhibits proliferation of human breast cancer MCF-7 cells (10 nM) and human prostate cancer DU145 cells (IC50 = 2.5 µM)
14833	AG-1024	10 mg	≥98%	A selective inhibitor of IGF-1R that inhibits insulin-stimulated cellular proliferation and IGF-1R autophosphorylation with IC50 values of 0.4 and 7 µM, respectively; inhibits proliferation of human breast cancer MCF-7 cells (10 nM) and human prostate cancer DU145 cells (IC50 = 2.5 µM)
14833	AG-1024	5 mg	≥98%	A selective inhibitor of IGF-1R that inhibits insulin-stimulated cellular proliferation and IGF-1R autophosphorylation with IC50 values of 0.4 and 7 µM, respectively; inhibits proliferation of human breast cancer MCF-7 cells (10 nM) and human prostate cancer DU145 cells (IC50 = 2.5 µM)
14847	HKI 357	1 mg	≥98%	An irreversible dual inhibitor of EGFR and HER2 (IC50s = 34 and 33 nM, respectively); inhibits proliferation of A431, SK-BR-3, and SW620 cancer cell lines (IC50s = 120, 2.5, and 511 nM, respectively); suppresses EGFR autophosphorylation and phosphorylation of the downstream effectors AKT and ERK in NCI-H1650 and NCI-H1650(G7) cells; inhibits tumor growth in BT474, A431, and SUM190 mouse xenograft models (10 mg/kg)
14847	HKI 357	10 mg	≥98%	An irreversible dual inhibitor of EGFR and HER2 (IC50s = 34 and 33 nM, respectively); inhibits proliferation of A431, SK-BR-3, and SW620 cancer cell lines (IC50s = 120, 2.5, and 511 nM, respectively); suppresses EGFR autophosphorylation and phosphorylation of the downstream effectors AKT and ERK in NCI-H1650 and NCI-H1650(G7) cells; inhibits tumor growth in BT474, A431, and SUM190 mouse xenograft models (10 mg/kg)
14847	HKI 357	5 mg	≥98%	An irreversible dual inhibitor of EGFR and HER2 (IC50s = 34 and 33 nM, respectively); inhibits proliferation of A431, SK-BR-3, and SW620 cancer cell lines (IC50s = 120, 2.5, and 511 nM, respectively); suppresses EGFR autophosphorylation and phosphorylation of the downstream effectors AKT and ERK in NCI-H1650 and NCI-H1650(G7) cells; inhibits tumor growth in BT474, A431, and SUM190 mouse xenograft models (10 mg/kg)
14861	SU11274	1 mg	≥95%	A potent, selective, ATP-competitive inhibitor of c-Met (IC50 = 20 nM); induces apoptosis and cell cycle arrest in transformed Ba/F3 cells and cancer cell lines
14861	SU11274	5 mg	≥95%	A potent, selective, ATP-competitive inhibitor of c-Met (IC50 = 20 nM); induces apoptosis and cell cycle arrest in transformed Ba/F3 cells and cancer cell lines
14861	SU11274	500 µg	≥95%	A potent, selective, ATP-competitive inhibitor of c-Met (IC50 = 20 nM); induces apoptosis and cell cycle arrest in transformed Ba/F3 cells and cancer cell lines
14862	PS-1145	1 mg	≥98%	A potent inhibitor of IKKβ (IC50 = 88-100 nM); used to elucidate roles for NF-κB both in cells and in vivo
14862	PS-1145	5 mg	≥98%	A potent inhibitor of IKKβ (IC50 = 88-100 nM); used to elucidate roles for NF-κB both in cells and in vivo
14862	PS-1145	500 µg	≥98%	A potent inhibitor of IKKβ (IC50 = 88-100 nM); used to elucidate roles for NF-κB both in cells and in vivo
14868	Vatalanib (hydrochlor	10 mg	≥98%	An antagonist of VEGFR1, VEGFR2, and VEGFR3 with IC50 values of 77, 37, and 190 nM, respectively; less potently inhibits PDGF and c-Kit (IC50 = 600 and 700 nM) and has no effect on additional kinases; completely blocks retinal neovascularization in oxygen-induced ischemic retinopathy in mice
14868	Vatalanib (hydrochlor	100 mg	≥98%	An antagonist of VEGFR1, VEGFR2, and VEGFR3 with IC50 values of 77, 37, and 190 nM, respectively; less potently inhibits PDGF and c-Kit (IC50 = 600 and 700 nM) and has no effect on additional kinases; completely blocks retinal neovascularization in oxygen-induced ischemic retinopathy in mice
14868	Vatalanib (hydrochlor	25 mg	≥98%	An antagonist of VEGFR1, VEGFR2, and VEGFR3 with IC50 values of 77, 37, and 190 nM, respectively; less potently inhibits PDGF and c-Kit (IC50 = 600 and 700 nM) and has no effect on additional kinases; completely blocks retinal neovascularization in oxygen-induced ischemic retinopathy in mice
14868	Vatalanib (hydrochlor	50 mg	≥98%	An antagonist of VEGFR1, VEGFR2, and VEGFR3 with IC50 values of 77, 37, and 190 nM, respectively; less potently inhibits PDGF and c-Kit (IC50 = 600 and 700 nM) and has no effect on additional kinases; completely blocks retinal neovascularization in oxygen-induced ischemic retinopathy in mice
14870	Akt Inhibitor VIII	1 mg	≥98%	A potent, allosteric inhibitor of Akt1 and Akt2 (IC50 = 58 and 210 nM, respectively) that less effectively blocks Akt3 activity (IC50 = 2.2 µM); cell permeable, blocking insulin regulation of FOXO1 activity at 1 µM in rat hepatoma cells
14870	Akt Inhibitor VIII	10 mg	≥98%	A potent, allosteric inhibitor of Akt1 and Akt2 (IC50 = 58 and 210 nM, respectively) that less effectively blocks Akt3 activity (IC50 = 2.2 µM); cell permeable, blocking insulin regulation of FOXO1 activity at 1 µM in rat hepatoma cells

14870	Akt Inhibitor VIII	5 mg	≥98%	A potent, allosteric inhibitor of Akt1 and Akt2 (IC50 = 58 and 210 nM, respectively) that less effectively blocks Akt3 activity (IC50 = 2.2 µM); cell permeable, blocking insulin regulation of FOXO1 activity at 1 µM in rat hepatoma cells
14870	Akt Inhibitor VIII	500 µg	≥98%	A potent, allosteric inhibitor of Akt1 and Akt2 (IC50 = 58 and 210 nM, respectively) that less effectively blocks Akt3 activity (IC50 = 2.2 µM); cell permeable, blocking insulin regulation of FOXO1 activity at 1 µM in rat hepatoma cells
14871	KRN 633	1 mg	≥95%	A selective inhibitor of VEGFR kinase activity (IC50s = 170, 160, and 125 nM for VEGFR1, 2, and 3, respectively); suppresses VEGF-dependent activation of MAPK and cell proliferation and demonstrates antitumor and antiangiogenic activity
14871	KRN 633	10 mg	≥95%	A selective inhibitor of VEGFR kinase activity (IC50s = 170, 160, and 125 nM for VEGFR1, 2, and 3, respectively); suppresses VEGF-dependent activation of MAPK and cell proliferation and demonstrates antitumor and antiangiogenic activity
14871	KRN 633	5 mg	≥95%	A selective inhibitor of VEGFR kinase activity (IC50s = 170, 160, and 125 nM for VEGFR1, 2, and 3, respectively); suppresses VEGF-dependent activation of MAPK and cell proliferation and demonstrates antitumor and antiangiogenic activity
14871	KRN 633	50 mg	≥95%	A selective inhibitor of VEGFR kinase activity (IC50s = 170, 160, and 125 nM for VEGFR1, 2, and 3, respectively); suppresses VEGF-dependent activation of MAPK and cell proliferation and demonstrates antitumor and antiangiogenic activity
14873	Debromohymenialdis	100 µg	≥95%	A marine sponge alkaloid that inhibits Chk1 and Chk2 (IC50 = 3 and 3.5 µM, respectively), blocking G2 arrest; also inhibits MEK-1 (IC50 = 881 nM), GSK3β (IC50 = 1.39 µM), Cdk5/p25 (IC50 = 9.12 µM), Brk (IC50 = 0.6 µM), and other kinases largely unrelated to DNA damage/repair and cell cycling
14879	PD 153035 (hydrochlo	10 mg	≥98%	A highly potent, reversible inhibitor of the EGFR (Ki = 5.2 pM; IC50 = 29 pM); rapidly suppresses autophosphorylation of EGFR in fibroblasts and human epidermoid carcinoma cells
14879	PD 153035 (hydrochlo	25 mg	≥98%	A highly potent, reversible inhibitor of the EGFR (Ki = 5.2 pM; IC50 = 29 pM); rapidly suppresses autophosphorylation of EGFR in fibroblasts and human epidermoid carcinoma cells
14879	PD 153035 (hydrochlo	5 mg	≥98%	A highly potent, reversible inhibitor of the EGFR (Ki = 5.2 pM; IC50 = 29 pM); rapidly suppresses autophosphorylation of EGFR in fibroblasts and human epidermoid carcinoma cells
14879	PD 153035 (hydrochlo	50 mg	≥98%	A highly potent, reversible inhibitor of the EGFR (Ki = 5.2 pM; IC50 = 29 pM); rapidly suppresses autophosphorylation of EGFR in fibroblasts and human epidermoid carcinoma cells
14881	NU 7441	1 mg	≥98%	A selective DNA-PK inhibitor (IC50 = 14 nM) that increases the cytotoxicity of ionizing radiation and etoposide in human colon cancer cell lines in vitro and potentiates the effects of etoposide in mice bearing human colon cancer xenograft tumors in vivo
14881	NU 7441	10 mg	≥98%	A selective DNA-PK inhibitor (IC50 = 14 nM) that increases the cytotoxicity of ionizing radiation and etoposide in human colon cancer cell lines in vitro and potentiates the effects of etoposide in mice bearing human colon cancer xenograft tumors in vivo
14881	NU 7441	25 mg	≥98%	A selective DNA-PK inhibitor (IC50 = 14 nM) that increases the cytotoxicity of ionizing radiation and etoposide in human colon cancer cell lines in vitro and potentiates the effects of etoposide in mice bearing human colon cancer xenograft tumors in vivo
14881	NU 7441	5 mg	≥98%	A selective DNA-PK inhibitor (IC50 = 14 nM) that increases the cytotoxicity of ionizing radiation and etoposide in human colon cancer cell lines in vitro and potentiates the effects of etoposide in mice bearing human colon cancer xenograft tumors in vivo
14883	GNF-5837	1 mg	≥95%	A potent, bioavailable pan-Trk inhibitor that blocks the proliferation of cells expressing TEL-TrkA, TEL-TrkB, and TEL-TrkC (IC50s = 7, 9, and 11 nM, respectively); inhibits the growth of Ba/F3 and RIE cells expressing both TrkA and NGF with IC50 values of 42 and 17 nM, respectively
14883	GNF-5837	10 mg	≥95%	A potent, bioavailable pan-Trk inhibitor that blocks the proliferation of cells expressing TEL-TrkA, TEL-TrkB, and TEL-TrkC (IC50s = 7, 9, and 11 nM, respectively); inhibits the growth of Ba/F3 and RIE cells expressing both TrkA and NGF with IC50 values of 42 and 17 nM, respectively
14883	GNF-5837	5 mg	≥95%	A potent, bioavailable pan-Trk inhibitor that blocks the proliferation of cells expressing TEL-TrkA, TEL-TrkB, and TEL-TrkC (IC50s = 7, 9, and 11 nM, respectively); inhibits the growth of Ba/F3 and RIE cells expressing both TrkA and NGF with IC50 values of 42 and 17 nM, respectively
14913	Arctigenin	10 mg	≥95%	An extract from A. lappa, a burdock plant traditionally used in Japanese Kampo medicine for its antioxidant, anti-inflammatory, antiproliferative, and antiviral activity
14913	Arctigenin	100 mg	≥95%	An extract from A. lappa, a burdock plant traditionally used in Japanese Kampo medicine for its antioxidant, anti-inflammatory, antiproliferative, and antiviral activity
14913	Arctigenin	25 mg	≥95%	An extract from A. lappa, a burdock plant traditionally used in Japanese Kampo medicine for its antioxidant, anti-inflammatory, antiproliferative, and antiviral activity

14913	Arctigenin	50 mg	≥95%	An extract from A. lappa, a burdock plant traditionally used in Japanese Kampo medicine for its antioxidant, anti-inflammatory, antiproliferative, and antiviral activity
14924	PF-573228	1 mg	≥95%	A selective FAK inhibitor (IC50s = 4 and 30-100 nM for a purified recombinant catalytic fragment of FAK and in cultured cells, respectively) that can inhibit chemotactic and haptotactic migration of cells as well as prevent focal adhesion turnover
14924	PF-573228	10 mg	≥95%	A selective FAK inhibitor (IC50s = 4 and 30-100 nM for a purified recombinant catalytic fragment of FAK and in cultured cells, respectively) that can inhibit chemotactic and haptotactic migration of cells as well as prevent focal adhesion turnover
14924	PF-573228	5 mg	≥95%	A selective FAK inhibitor (IC50s = 4 and 30-100 nM for a purified recombinant catalytic fragment of FAK and in cultured cells, respectively) that can inhibit chemotactic and haptotactic migration of cells as well as prevent focal adhesion turnover
14924	PF-573228	50 mg	≥95%	A selective FAK inhibitor (IC50s = 4 and 30-100 nM for a purified recombinant catalytic fragment of FAK and in cultured cells, respectively) that can inhibit chemotactic and haptotactic migration of cells as well as prevent focal adhesion turnover
14932	BX-795	10 mg	≥98%	A potent, ATP-competitive inhibitor of PDK1 in vitro (IC50 = 11 nM) and in cells (IC50 = 300 nM); also inhibits ERK8, MNK2, Aurora B, Aurora C, MARKs 1-4,TBK1, IKKε, and additional kinases at comparable concentrations
14932	BX-795	25 mg	≥98%	A potent, ATP-competitive inhibitor of PDK1 in vitro (IC50 = 11 nM) and in cells (IC50 = 300 nM); also inhibits ERK8, MNK2, Aurora B, Aurora C, MARKs 1-4,TBK1, IKKε, and additional kinases at comparable concentrations
14932	BX-795	5 mg	≥98%	A potent, ATP-competitive inhibitor of PDK1 in vitro (IC50 = 11 nM) and in cells (IC50 = 300 nM); also inhibits ERK8, MNK2, Aurora B, Aurora C, MARKs 1-4,TBK1, IKKε, and additional kinases at comparable concentrations
14932	BX-795	50 mg	≥98%	A potent, ATP-competitive inhibitor of PDK1 in vitro (IC50 = 11 nM) and in cells (IC50 = 300 nM); also inhibits ERK8, MNK2, Aurora B, Aurora C, MARKs 1-4,TBK1, IKKε, and additional kinases at comparable concentrations
14942	Resveratrol-3-O-Sulfa	1 mg	≥95%	An active metabolite of resveratrol; decreases the expression of IL-1α, IL-1β, and IL-6 by 61.2, 76.6, and 42.2%, respectively, in U-937 macrophages at 1 μM; decreases growth of Caco-2 cells at 10-100 μM and induces apoptosis at 25 and 50 μM; binds to mitoNEET (IC50 = 3.36 μM) in the TZD binding pocket
14942	Resveratrol-3-O-Sulfa	500 μg	≥95%	An active metabolite of resveratrol; decreases the expression of IL-1α, IL-1β, and IL-6 by 61.2, 76.6, and 42.2%, respectively, in U-937 macrophages at 1 μM; decreases growth of Caco-2 cells at 10-100 μM and induces apoptosis at 25 and 50 μM; binds to mitoNEET (IC50 = 3.36 μM) in the TZD binding pocket
14955	HA-100 (hydrochlorid	10 mg	≥95%	An inhibitor of PKA, PKC, and PKG (IC50s = 8, 12, and 4 μM, respectively); less effectively blocks the activity of MLCK (IC50 = 240 μM)
14955	HA-100 (hydrochlorid	25 mg	≥95%	An inhibitor of PKA, PKC, and PKG (IC50s = 8, 12, and 4 μM, respectively); less effectively blocks the activity of MLCK (IC50 = 240 μM)
14955	HA-100 (hydrochlorid	5 mg	≥95%	An inhibitor of PKA, PKC, and PKG (IC50s = 8, 12, and 4 μM, respectively); less effectively blocks the activity of MLCK (IC50 = 240 μM)
14955	HA-100 (hydrochlorid	50 mg	≥95%	An inhibitor of PKA, PKC, and PKG (IC50s = 8, 12, and 4 μM, respectively); less effectively blocks the activity of MLCK (IC50 = 240 μM)
14970	PD 334581	1 mg	≥98%	A MEK inhibitor (IC50 = 0.032 μM in C26 colon carcinoma cells)
14970	PD 334581	5 mg	≥98%	A MEK inhibitor (IC50 = 0.032 μM in C26 colon carcinoma cells)
14974	SNS-314 (mesylate)	1 mg	≥98%	A pan-Aurora kinase inhibitor (IC50s = 9, 31, and 3.4 nM for Aurora A, B, and C, respectively); inhibits TRKB, TRKA, FLT4, FMS, DDR2, AXL, and C-RAF (IC50s = 5-100 nM); inhibits Aurora B phosphorylation of histone H3 in HCT116 human colorectal carcinoma cells in vitro (EC50 = <16 nM) and in a mouse xenograft model at a dose of 50 mg/kg; inhibits tumor growth in A2780 ovarian, A375 melanoma, H1299 lung, MDA-MB-231 breast, and PC3 prostate cancer mouse xenograft models
14974	SNS-314 (mesylate)	10 mg	≥98%	A pan-Aurora kinase inhibitor (IC50s = 9, 31, and 3.4 nM for Aurora A, B, and C, respectively); inhibits TRKB, TRKA, FLT4, FMS, DDR2, AXL, and C-RAF (IC50s = 5-100 nM); inhibits Aurora B phosphorylation of histone H3 in HCT116 human colorectal carcinoma cells in vitro (EC50 = <16 nM) and in a mouse xenograft model at a dose of 50 mg/kg; inhibits tumor growth in A2780 ovarian, A375 melanoma, H1299 lung, MDA-MB-231 breast, and PC3 prostate cancer mouse xenograft models
14974	SNS-314 (mesylate)	5 mg	≥98%	A pan-Aurora kinase inhibitor (IC50s = 9, 31, and 3.4 nM for Aurora A, B, and C, respectively); inhibits TRKB, TRKA, FLT4, FMS, DDR2, AXL, and C-RAF (IC50s = 5-100 nM); inhibits Aurora B phosphorylation of histone H3 in HCT116 human colorectal carcinoma cells in vitro (EC50 = <16 nM) and in a mouse xenograft model at a dose of 50 mg/kg; inhibits tumor growth in A2780 ovarian, A375 melanoma, H1299 lung, MDA-MB-231 breast, and PC3 prostate cancer mouse xenograft models

14974	SNS-314 (mesylate)	50 mg	≥98%	A pan-Aurora kinase inhibitor (IC50s = 9, 31, and 3.4 nM for Aurora A, B, and C, respectively); inhibits TRKB, TRKA, FLT4, FMS, DDR2, AXL, and C-RAF (IC50s = 5-100 nM); inhibits Aurora B phosphorylation of histone H3 in HCT116 human colorectal carcinoma cells in vitro (EC50 = <16 nM) and in a mouse xenograft model at a dose of 50 mg/kg; inhibits tumor growth in A2780 ovarian, A375 melanoma, H1299 lung, MDA-MB-231 breast, and PC3 prostate cancer mouse xenograft models
14976	TAS 301	1 mg	≥98%	An inhibitor of Ca2+ mobilization, CaM kinase II activation (10 μM); inhibits PKC signaling, phosphorylation of focal adhesion kinase and paxillin (10 μM); inhibits VSMC migration and proliferation and arterial intimal thickening in vivo (3-100 mg/kg in rats)
14976	TAS 301	10 mg	≥98%	An inhibitor of Ca2+ mobilization, CaM kinase II activation (10 μM); inhibits PKC signaling, phosphorylation of focal adhesion kinase and paxillin (10 μM); inhibits VSMC migration and proliferation and arterial intimal thickening in vivo (3-100 mg/kg in rats)
14976	TAS 301	5 mg	≥98%	An inhibitor of Ca2+ mobilization, CaM kinase II activation (10 μM); inhibits PKC signaling, phosphorylation of focal adhesion kinase and paxillin (10 μM); inhibits VSMC migration and proliferation and arterial intimal thickening in vivo (3-100 mg/kg in rats)
14978	AS-1892802	1 mg	≥98%	A potent ROCK inhibitor (IC50s = 122, 52, and 57 nM for human ROCK1, ROCK2, and rat ROCK2, respectively); selective for ROCK1 and 2 over a panel of 167 kinases and a panel of 63 ion channels, receptors, and enzymes at a concentration of 10 μM; inhibits PKACα and PRKX (IC50s = 200 and 325 nM, respectively); reduces weight imbalance deficits (ED50 = 0.15 mg/kg) in rats in a monoiodoacetate-induced model of non-inflammatory arthritis; has analgesic-like effects in a rat model of streptozotocin-induced diabetic neuropathy; reduces cartilage damage and weight imbalance deficits in a rat model of osteoarthritis.
14978	AS-1892802	10 mg	≥98%	A potent ROCK inhibitor (IC50s = 122, 52, and 57 nM for human ROCK1, ROCK2, and rat ROCK2, respectively); selective for ROCK1 and 2 over a panel of 167 kinases and a panel of 63 ion channels, receptors, and enzymes at a concentration of 10 μM; inhibits PKACα and PRKX (IC50s = 200 and 325 nM, respectively); reduces weight imbalance deficits (ED50 = 0.15 mg/kg) in rats in a monoiodoacetate-induced model of non-inflammatory arthritis; has analgesic-like effects in a rat model of streptozotocin-induced diabetic neuropathy; reduces cartilage damage and weight imbalance deficits in a rat model of osteoarthritis.
14978	AS-1892802	25 mg	≥98%	A potent ROCK inhibitor (IC50s = 122, 52, and 57 nM for human ROCK1, ROCK2, and rat ROCK2, respectively); selective for ROCK1 and 2 over a panel of 167 kinases and a panel of 63 ion channels, receptors, and enzymes at a concentration of 10 μM; inhibits PKACα and PRKX (IC50s = 200 and 325 nM, respectively); reduces weight imbalance deficits (ED50 = 0.15 mg/kg) in rats in a monoiodoacetate-induced model of non-inflammatory arthritis; has analgesic-like effects in a rat model of streptozotocin-induced diabetic neuropathy; reduces cartilage damage and weight imbalance deficits in a rat model of osteoarthritis.
14978	AS-1892802	5 mg	≥98%	A potent ROCK inhibitor (IC50s = 122, 52, and 57 nM for human ROCK1, ROCK2, and rat ROCK2, respectively); selective for ROCK1 and 2 over a panel of 167 kinases and a panel of 63 ion channels, receptors, and enzymes at a concentration of 10 μM; inhibits PKACα and PRKX (IC50s = 200 and 325 nM, respectively); reduces weight imbalance deficits (ED50 = 0.15 mg/kg) in rats in a monoiodoacetate-induced model of non-inflammatory arthritis; has analgesic-like effects in a rat model of streptozotocin-induced diabetic neuropathy; reduces cartilage damage and weight imbalance deficits in a rat model of osteoarthritis.
15015	PF-03814735	1 mg	≥95%	A reversible inhibitor of both Aurora A and B kinases (IC50s = 0.8 and 5 nM, respectively); also inhibits FLT1, FAK, TrkA, Met, and FGFR1 (IC50s = 10, 22, 30, 100, and 100 nM, respectively)
15015	PF-03814735	10 mg	≥95%	A reversible inhibitor of both Aurora A and B kinases (IC50s = 0.8 and 5 nM, respectively); also inhibits FLT1, FAK, TrkA, Met, and FGFR1 (IC50s = 10, 22, 30, 100, and 100 nM, respectively)
15015	PF-03814735	5 mg	≥95%	A reversible inhibitor of both Aurora A and B kinases (IC50s = 0.8 and 5 nM, respectively); also inhibits FLT1, FAK, TrkA, Met, and FGFR1 (IC50s = 10, 22, 30, 100, and 100 nM, respectively)
15015	PF-03814735	50 mg	≥95%	A reversible inhibitor of both Aurora A and B kinases (IC50s = 0.8 and 5 nM, respectively); also inhibits FLT1, FAK, TrkA, Met, and FGFR1 (IC50s = 10, 22, 30, 100, and 100 nM, respectively)
15018	PF-04708671	10 mg	≥98%	A specific, cell-permeable inhibitor of S6K1 (IC50 = 160 nM); does not inhibit S6K2, MSK, or RSK, or many other unrelated kinases, under conditions in which it inhibits S6K1 activity
15018	PF-04708671	100 mg	≥98%	A specific, cell-permeable inhibitor of S6K1 (IC50 = 160 nM); does not inhibit S6K2, MSK, or RSK, or many other unrelated kinases, under conditions in which it inhibits S6K1 activity

15018	PF-04708671	25 mg	≥98%	A specific, cell-permeable inhibitor of S6K1 (IC50 = 160 nM); does not inhibit S6K2, MSK, or RSK, or many other unrelated kinases, under conditions in which it inhibits S6K1 activity
15018	PF-04708671	50 mg	≥98%	A specific, cell-permeable inhibitor of S6K1 (IC50 = 160 nM); does not inhibit S6K2, MSK, or RSK, or many other unrelated kinases, under conditions in which it inhibits S6K1 activity
15115	TPCA-1	1 mg	≥98%	A selective inhibitor of IKK2 (IC50s = 17.9 nM and 0.40 µM for IKK2 and IKK1, respectively); reduces the severity and onset of collagen-induced arthritis in mice and blocks cytokine release in an antigen-driven rat model of lung inflammation
15115	TPCA-1	10 mg	≥98%	A selective inhibitor of IKK2 (IC50s = 17.9 nM and 0.40 µM for IKK2 and IKK1, respectively); reduces the severity and onset of collagen-induced arthritis in mice and blocks cytokine release in an antigen-driven rat model of lung inflammation
15115	TPCA-1	5 mg	≥98%	A selective inhibitor of IKK2 (IC50s = 17.9 nM and 0.40 µM for IKK2 and IKK1, respectively); reduces the severity and onset of collagen-induced arthritis in mice and blocks cytokine release in an antigen-driven rat model of lung inflammation
15115	TPCA-1	500 µg	≥98%	A selective inhibitor of IKK2 (IC50s = 17.9 nM and 0.40 µM for IKK2 and IKK1, respectively); reduces the severity and onset of collagen-induced arthritis in mice and blocks cytokine release in an antigen-driven rat model of lung inflammation
15135	LCK Inhibitor	1 mg	≥95%	A pyrrolopyrimidine that selectively blocks the activity of two forms of the LCK kinase, LCK (64-509) and LCKCD with IC50 values of 50 = 4 and 25 mg/kg when administered either ip or orally)
15135	LCK Inhibitor	10 mg	≥95%	A pyrrolopyrimidine that selectively blocks the activity of two forms of the LCK kinase, LCK (64-509) and LCKCD with IC50 values of 50 = 4 and 25 mg/kg when administered either ip or orally)
15135	LCK Inhibitor	25 mg	≥95%	A pyrrolopyrimidine that selectively blocks the activity of two forms of the LCK kinase, LCK (64-509) and LCKCD with IC50 values of 50 = 4 and 25 mg/kg when administered either ip or orally)
15135	LCK Inhibitor	5 mg	≥95%	A pyrrolopyrimidine that selectively blocks the activity of two forms of the LCK kinase, LCK (64-509) and LCKCD with IC50 values of 50 = 4 and 25 mg/kg when administered either ip or orally)
15142	PLX4720	1 mg	≥95%	An orally-available, highly selective inhibitor of B-RafV600E (IC50 = 13 nM); less effective against wild type B-Raf (IC50 = 160 nM) as well as several other kinases; induces cell cycle arrest and apoptosis in cells and xenografts expressing the mutant of B-Raf
15142	PLX4720	10 mg	≥95%	An orally-available, highly selective inhibitor of B-RafV600E (IC50 = 13 nM); less effective against wild type B-Raf (IC50 = 160 nM) as well as several other kinases; induces cell cycle arrest and apoptosis in cells and xenografts expressing the mutant of B-Raf
15142	PLX4720	25 mg	≥95%	An orally-available, highly selective inhibitor of B-RafV600E (IC50 = 13 nM); less effective against wild type B-Raf (IC50 = 160 nM) as well as several other kinases; induces cell cycle arrest and apoptosis in cells and xenografts expressing the mutant of B-Raf
15142	PLX4720	5 mg	≥95%	An orally-available, highly selective inhibitor of B-RafV600E (IC50 = 13 nM); less effective against wild type B-Raf (IC50 = 160 nM) as well as several other kinases; induces cell cycle arrest and apoptosis in cells and xenografts expressing the mutant of B-Raf
15146	JAK Inhibitor I	1 mg	≥98%	A pyridine-containing tetracycle that interferes with JAK kinase activity interacting within the ATP-binding cleft (IC50s = 15, 1, and 5 nM for JAK1, 2, and 3, respectively); block IL-2 and IL-4-dependent proliferation of mouse T-cell lymphoma cells (IC50s = 50-100 nM)
15146	JAK Inhibitor I	10 mg	≥98%	A pyridine-containing tetracycle that interferes with JAK kinase activity interacting within the ATP-binding cleft (IC50s = 15, 1, and 5 nM for JAK1, 2, and 3, respectively); block IL-2 and IL-4-dependent proliferation of mouse T-cell lymphoma cells (IC50s = 50-100 nM)
15146	JAK Inhibitor I	5 mg	≥98%	A pyridine-containing tetracycle that interferes with JAK kinase activity interacting within the ATP-binding cleft (IC50s = 15, 1, and 5 nM for JAK1, 2, and 3, respectively); block IL-2 and IL-4-dependent proliferation of mouse T-cell lymphoma cells (IC50s = 50-100 nM)
15146	JAK Inhibitor I	500 µg	≥98%	A pyridine-containing tetracycle that interferes with JAK kinase activity interacting within the ATP-binding cleft (IC50s = 15, 1, and 5 nM for JAK1, 2, and 3, respectively); block IL-2 and IL-4-dependent proliferation of mouse T-cell lymphoma cells (IC50s = 50-100 nM)
15149	Ro 3306	1 mg	≥95%	A cell-permeable, reversible inhibitor of Cdk1, showing preference for Cdk1/cyclin B1 (Ki = 35 nM) over Cdk1/cyclin A (Ki = 110 nM); also inhibits Cdk2 (Ki = 340 nM), PKCδ (Ki = 318 nM), and SGK (Ki = 497 nM) but not Cdk4; reversibly arrests proliferating cells at the G2/M phase border, allowing cell synchronization
15149	Ro 3306	10 mg	≥95%	A cell-permeable, reversible inhibitor of Cdk1, showing preference for Cdk1/cyclin B1 (Ki = 35 nM) over Cdk1/cyclin A (Ki = 110 nM); also inhibits Cdk2 (Ki = 340 nM), PKCδ (Ki = 318 nM), and SGK (Ki = 497 nM) but not Cdk4; reversibly arrests proliferating cells at the G2/M phase border, allowing cell synchronization

15149	Ro 3306	5 mg	≥95%	A cell-permeable, reversible inhibitor of Cdk1, showing preference for Cdk1/cyclin B1 (Ki = 35 nM) over Cdk1/cyclin A (Ki = 110 nM); also inhibits Cdk2 (Ki = 340 nM), PKCδ (Ki = 318 nM), and SGK (Ki = 497 nM) but not Cdk4; reversibly arrests proliferating cells at the G2/M phase border, allowing cell synchronization
15149	Ro 3306	50 mg	≥95%	A cell-permeable, reversible inhibitor of Cdk1, showing preference for Cdk1/cyclin B1 (Ki = 35 nM) over Cdk1/cyclin A (Ki = 110 nM); also inhibits Cdk2 (Ki = 340 nM), PKCδ (Ki = 318 nM), and SGK (Ki = 497 nM) but not Cdk4; reversibly arrests proliferating cells at the G2/M phase border, allowing cell synchronization
15154	Cdk2 Inhibitor II	1 mg	≥95%	A 3-(benzylidne)indolin-2-one analog that selectively and potently inhibits Cdk2 (IC50 = 60 nM)
15154	Cdk2 Inhibitor II	5 mg	≥95%	A 3-(benzylidne)indolin-2-one analog that selectively and potently inhibits Cdk2 (IC50 = 60 nM)
15154	Cdk2 Inhibitor II	500 µg	≥95%	A 3-(benzylidne)indolin-2-one analog that selectively and potently inhibits Cdk2 (IC50 = 60 nM)
15206	MNS	10 mg	≥95%	Blocks and reverses platelet aggregation induced by such triggers as collagen, U-46619, and ADP (IC50 = 1.1, 2.1, and 4.1 µM, respectively); reduces tyrosine phosphorylation in stimulated platelets and inhibits recombinant human Syk and Src (IC50 = 2.8 and 27.3 µM, respectively) in vitro
15206	MNS	100 mg	≥95%	Blocks and reverses platelet aggregation induced by such triggers as collagen, U-46619, and ADP (IC50 = 1.1, 2.1, and 4.1 µM, respectively); reduces tyrosine phosphorylation in stimulated platelets and inhibits recombinant human Syk and Src (IC50 = 2.8 and 27.3 µM, respectively) in vitro
15206	MNS	50 mg	≥95%	Blocks and reverses platelet aggregation induced by such triggers as collagen, U-46619, and ADP (IC50 = 1.1, 2.1, and 4.1 µM, respectively); reduces tyrosine phosphorylation in stimulated platelets and inhibits recombinant human Syk and Src (IC50 = 2.8 and 27.3 µM, respectively) in vitro
15206	MNS	500 mg	≥95%	Blocks and reverses platelet aggregation induced by such triggers as collagen, U-46619, and ADP (IC50 = 1.1, 2.1, and 4.1 µM, respectively); reduces tyrosine phosphorylation in stimulated platelets and inhibits recombinant human Syk and Src (IC50 = 2.8 and 27.3 µM, respectively) in vitro
15220	Dovitinib	10 mg	≥98%	A multi-kinase inhibitor; inhibits FLT3, CSF1R, c-Kit, FGFR1, FGFR3, VEGFR1, -2, and -3, PDFGRα, and PDGFRβ (IC50s = 1, 36, 2, 8, 9, 10, 13, 8, 27, and 210 nM, respectively); inhibits proliferation of human multiple myeloma cell lines expressing mutant, but not wild-type, FGFR3 (IC50s = 90-550 and >2,500 nM, respectively); decreases FGF-induced ERK1/2 phosphorylation and induces apoptosis in patient-derived multiple myeloma cells at 500 nM; inhibits bFGF-induced angiogenesis in a Matrigel™ plug assay in mice at 3-300 mg/kg for 8 days; reduces tumor growth in KM12L4A, DU145, and MV4-11 mouse xenograft models (ED50s = 17, 23, and 3 mg/kg per day, respectively)
15220	Dovitinib	25 mg	≥98%	A multi-kinase inhibitor; inhibits FLT3, CSF1R, c-Kit, FGFR1, FGFR3, VEGFR1, -2, and -3, PDFGRα, and PDGFRβ (IC50s = 1, 36, 2, 8, 9, 10, 13, 8, 27, and 210 nM, respectively); inhibits proliferation of human multiple myeloma cell lines expressing mutant, but not wild-type, FGFR3 (IC50s = 90-550 and >2,500 nM, respectively); decreases FGF-induced ERK1/2 phosphorylation and induces apoptosis in patient-derived multiple myeloma cells at 500 nM; inhibits bFGF-induced angiogenesis in a Matrigel™ plug assay in mice at 3-300 mg/kg for 8 days; reduces tumor growth in KM12L4A, DU145, and MV4-11 mouse xenograft models (ED50s = 17, 23, and 3 mg/kg per day, respectively)
15220	Dovitinib	5 mg	≥98%	A multi-kinase inhibitor; inhibits FLT3, CSF1R, c-Kit, FGFR1, FGFR3, VEGFR1, -2, and -3, PDFGRα, and PDGFRβ (IC50s = 1, 36, 2, 8, 9, 10, 13, 8, 27, and 210 nM, respectively); inhibits proliferation of human multiple myeloma cell lines expressing mutant, but not wild-type, FGFR3 (IC50s = 90-550 and >2,500 nM, respectively); decreases FGF-induced ERK1/2 phosphorylation and induces apoptosis in patient-derived multiple myeloma cells at 500 nM; inhibits bFGF-induced angiogenesis in a Matrigel™ plug assay in mice at 3-300 mg/kg for 8 days; reduces tumor growth in KM12L4A, DU145, and MV4-11 mouse xenograft models (ED50s = 17, 23, and 3 mg/kg per day, respectively)
15220	Dovitinib	50 mg	≥98%	A multi-kinase inhibitor; inhibits FLT3, CSF1R, c-Kit, FGFR1, FGFR3, VEGFR1, -2, and -3, PDFGRα, and PDGFRβ (IC50s = 1, 36, 2, 8, 9, 10, 13, 8, 27, and 210 nM, respectively); inhibits proliferation of human multiple myeloma cell lines expressing mutant, but not wild-type, FGFR3 (IC50s = 90-550 and >2,500 nM, respectively); decreases FGF-induced ERK1/2 phosphorylation and induces apoptosis in patient-derived multiple myeloma cells at 500 nM; inhibits bFGF-induced angiogenesis in a Matrigel™ plug assay in mice at 3-300 mg/kg for 8 days; reduces tumor growth in KM12L4A, DU145, and MV4-11 mouse xenograft models (ED50s = 17, 23, and 3 mg/kg per day, respectively)
15250	AZD6482	1 mg	≥98%	A selective PI3K inhibitor that targets the β isoform more potently than PI3Kδ, PI3Kγ, or PI3Kα (IC50s = 0.69, 13.6, 47.8, and 136 nM, respectively); blocks Akt signaling and tumor growth in a large number of cancer cell lines and suppresses the growth of PTEN-deficient xenograft tumors in mice
15250	AZD6482	10 mg	≥98%	A selective PI3K inhibitor that targets the β isoform more potently than PI3Kδ, PI3Kγ, or PI3Kα (IC50s = 0.69, 13.6, 47.8, and 136 nM, respectively); blocks Akt signaling and tumor growth in a large number of cancer cell lines and suppresses the growth of PTEN-deficient xenograft tumors in mice
15250	AZD6482	25 mg	≥98%	A selective PI3K inhibitor that targets the β isoform more potently than PI3Kδ, PI3Kγ, or PI3Kα (IC50s = 0.69, 13.6, 47.8, and 136 nM, respectively); blocks Akt signaling and tumor growth in a large number of cancer cell lines and suppresses the growth of PTEN-deficient xenograft tumors in mice

15250	AZD6482	5 mg	≥98%	A selective PI3K inhibitor that targets the β isoform more potently than PI3Kδ, PI3Kγ, or PI3Kα (IC50s = 0.69, 13.6, 47.8, and 136 nM, respectively); blocks Akt signaling and tumor growth in a large number of cancer cell lines and suppresses the growth of PTEN-deficient xenograft tumors in mice
15255	R 1530	1 mg	≥98%	A multi-kinase inhibitor that targets over 20 kinases, including angiogenesis-related receptor tyrosine kinases (Kds = 61, 88, and 15 nM for FGFR1, PDGFRβ, and VEGFR2, respectively); also inhibits FLT1, KIT, PLK4, and RET with Kd values of 9, 26, 11, and 22 nM, respectively
15255	R 1530	10 mg	≥98%	A multi-kinase inhibitor that targets over 20 kinases, including angiogenesis-related receptor tyrosine kinases (Kds = 61, 88, and 15 nM for FGFR1, PDGFRβ, and VEGFR2, respectively); also inhibits FLT1, KIT, PLK4, and RET with Kd values of 9, 26, 11, and 22 nM, respectively
15255	R 1530	25 mg	≥98%	A multi-kinase inhibitor that targets over 20 kinases, including angiogenesis-related receptor tyrosine kinases (Kds = 61, 88, and 15 nM for FGFR1, PDGFRβ, and VEGFR2, respectively); also inhibits FLT1, KIT, PLK4, and RET with Kd values of 9, 26, 11, and 22 nM, respectively
15255	R 1530	5 mg	≥98%	A multi-kinase inhibitor that targets over 20 kinases, including angiogenesis-related receptor tyrosine kinases (Kds = 61, 88, and 15 nM for FGFR1, PDGFRβ, and VEGFR2, respectively); also inhibits FLT1, KIT, PLK4, and RET with Kd values of 9, 26, 11, and 22 nM, respectively
15262	GSK429286A	1 mg	≥98%	A cell-permeable inhibitor of ROCK (IC50 = 14 nM); reverses adrenalin-induced contraction of rat aortic rings (IC50 = 190 nM); produces a dose-dependent decrease in mean arterial pressure in spontaneously-hypertensive rats
15262	GSK429286A	10 mg	≥98%	A cell-permeable inhibitor of ROCK (IC50 = 14 nM); reverses adrenalin-induced contraction of rat aortic rings (IC50 = 190 nM); produces a dose-dependent decrease in mean arterial pressure in spontaneously-hypertensive rats
15262	GSK429286A	5 mg	≥98%	A cell-permeable inhibitor of ROCK (IC50 = 14 nM); reverses adrenalin-induced contraction of rat aortic rings (IC50 = 190 nM); produces a dose-dependent decrease in mean arterial pressure in spontaneously-hypertensive rats
15264	BI-D1870	1 mg	≥95%	A cell permeable, ATP-competitive inhibitor of the four vertebrate isoforms of RSK, RSK1-4 (IC50s = 31, 24, 18, and 15 nM, respectively); also significantly inhibits PLK1, Aurora B, MELK, and MST2 at 100 nM
15264	BI-D1870	10 mg	≥95%	A cell permeable, ATP-competitive inhibitor of the four vertebrate isoforms of RSK, RSK1-4 (IC50s = 31, 24, 18, and 15 nM, respectively); also significantly inhibits PLK1, Aurora B, MELK, and MST2 at 100 nM
15264	BI-D1870	5 mg	≥95%	A cell permeable, ATP-competitive inhibitor of the four vertebrate isoforms of RSK, RSK1-4 (IC50s = 31, 24, 18, and 15 nM, respectively); also significantly inhibits PLK1, Aurora B, MELK, and MST2 at 100 nM
15279	CAL-101	10 mg	≥98%	A cell permeable inhibitor of the PI3K catalytic subunit p110δ (IC50 = 2.5 nM) that demonstrates 40- to 300-fold selectivity against other PI3K class I enzymes (IC50s = 820, 565, and 89 nM for p110α, β, and γ, respectively); blocks constitutive PI3K signaling in malignant B-cell lines and primary patient tumor cells, resulting in decreased phosphorylation of Akt and other downstream effectors, an increase in poly(ADP-ribose) polymerase and apoptosis
15279	CAL-101	25 mg	≥98%	A cell permeable inhibitor of the PI3K catalytic subunit p110δ (IC50 = 2.5 nM) that demonstrates 40- to 300-fold selectivity against other PI3K class I enzymes (IC50s = 820, 565, and 89 nM for p110α, β, and γ, respectively); blocks constitutive PI3K signaling in malignant B-cell lines and primary patient tumor cells, resulting in decreased phosphorylation of Akt and other downstream effectors, an increase in poly(ADP-ribose) polymerase and apoptosis
15279	CAL-101	5 mg	≥98%	A cell permeable inhibitor of the PI3K catalytic subunit p110δ (IC50 = 2.5 nM) that demonstrates 40- to 300-fold selectivity against other PI3K class I enzymes (IC50s = 820, 565, and 89 nM for p110α, β, and γ, respectively); blocks constitutive PI3K signaling in malignant B-cell lines and primary patient tumor cells, resulting in decreased phosphorylation of Akt and other downstream effectors, an increase in poly(ADP-ribose) polymerase and apoptosis
15279	CAL-101	50 mg	≥98%	A cell permeable inhibitor of the PI3K catalytic subunit p110δ (IC50 = 2.5 nM) that demonstrates 40- to 300-fold selectivity against other PI3K class I enzymes (IC50s = 820, 565, and 89 nM for p110α, β, and γ, respectively); blocks constitutive PI3K signaling in malignant B-cell lines and primary patient tumor cells, resulting in decreased phosphorylation of Akt and other downstream effectors, an increase in poly(ADP-ribose) polymerase and apoptosis
15312	LY2157299	1 mg	≥98%	A small molecule inhibitor of the TGF-β receptor type 1 kinase (IC50 = 56 nM) that has been used to study the role of TGF-β signaling in triple negative breast cancer cells and hepatocellular carcinoma cells
15312	LY2157299	10 mg	≥98%	A small molecule inhibitor of the TGF-β receptor type 1 kinase (IC50 = 56 nM) that has been used to study the role of TGF-β signaling in triple negative breast cancer cells and hepatocellular carcinoma cells

15312	LY2157299	5 mg	≥98%	A small molecule inhibitor of the TGF-β receptor type 1 kinase (IC50 = 56 nM) that has been used to study the role of TGF-β signaling in triple negative breast cancer cells and hepatocellular carcinoma cells
15312	LY2157299	50 mg	≥98%	A small molecule inhibitor of the TGF-β receptor type 1 kinase (IC50 = 56 nM) that has been used to study the role of TGF-β signaling in triple negative breast cancer cells and hepatocellular carcinoma cells
15317	CID-2011756	10 mg	≥95%	An inhibitor of all three PKD isoforms (IC50s = 3.2, 0.6, and 0.7 µM for PKD1, PKD2, and PKD3, respectively); cell permeable, blocking the phosphorylation of PKD1 on Ser916 (an autocatalytic target) in LNCaP prostate cancer cells in response to phorbol esters (EC50 = 10 µM)
15317	CID-2011756	25 mg	≥95%	An inhibitor of all three PKD isoforms (IC50s = 3.2, 0.6, and 0.7 µM for PKD1, PKD2, and PKD3, respectively); cell permeable, blocking the phosphorylation of PKD1 on Ser916 (an autocatalytic target) in LNCaP prostate cancer cells in response to phorbol esters (EC50 = 10 µM)
15317	CID-2011756	5 mg	≥95%	An inhibitor of all three PKD isoforms (IC50s = 3.2, 0.6, and 0.7 µM for PKD1, PKD2, and PKD3, respectively); cell permeable, blocking the phosphorylation of PKD1 on Ser916 (an autocatalytic target) in LNCaP prostate cancer cells in response to phorbol esters (EC50 = 10 µM)
15320	LY2584702 (tosylate)	1 mg	≥98%	A p70S6K inhibitor (IC50 = 0.004 µM); selective for p70S6K over a panel of 83 kinases; inhibits the phosphorylation of S6 in HCT116 cells (IC50 = 0.1-0.24 µM); decreases triglyceride levels and apolipoprotein B secretion in TSC2 knockdown HepG2 cells; suppresses self-renewal of primary mouse bone marrow stromal cells at 2 µM; reduces tumor growth in an HCT116 colon cancer mouse xenograft model (ED50 = 2.3 mg/kg)
15320	LY2584702 (tosylate)	10 mg	≥98%	A p70S6K inhibitor (IC50 = 0.004 µM); selective for p70S6K over a panel of 83 kinases; inhibits the phosphorylation of S6 in HCT116 cells (IC50 = 0.1-0.24 µM); decreases triglyceride levels and apolipoprotein B secretion in TSC2 knockdown HepG2 cells; suppresses self-renewal of primary mouse bone marrow stromal cells at 2 µM; reduces tumor growth in an HCT116 colon cancer mouse xenograft model (ED50 = 2.3 mg/kg)
15320	LY2584702 (tosylate)	25 mg	≥98%	A p70S6K inhibitor (IC50 = 0.004 µM); selective for p70S6K over a panel of 83 kinases; inhibits the phosphorylation of S6 in HCT116 cells (IC50 = 0.1-0.24 µM); decreases triglyceride levels and apolipoprotein B secretion in TSC2 knockdown HepG2 cells; suppresses self-renewal of primary mouse bone marrow stromal cells at 2 µM; reduces tumor growth in an HCT116 colon cancer mouse xenograft model (ED50 = 2.3 mg/kg)
15320	LY2584702 (tosylate)	5 mg	≥98%	A p70S6K inhibitor (IC50 = 0.004 µM); selective for p70S6K over a panel of 83 kinases; inhibits the phosphorylation of S6 in HCT116 cells (IC50 = 0.1-0.24 µM); decreases triglyceride levels and apolipoprotein B secretion in TSC2 knockdown HepG2 cells; suppresses self-renewal of primary mouse bone marrow stromal cells at 2 µM; reduces tumor growth in an HCT116 colon cancer mouse xenograft model (ED50 = 2.3 mg/kg)
15323	PKR Inhibitor	1 mg	≥95%	Binds the ATP-binding site of PKR and blocks autophosphorylation (IC50 = 186-210 nM); protects neuroblastoma cells against cell damage triggered by ER stress; prevents phosphorylation of FADD, preventing apoptosis; reduces phosphorylation of PKR and eIF2α in the brain, enhancing long-term memory storage
15323	PKR Inhibitor	10 mg	≥95%	Binds the ATP-binding site of PKR and blocks autophosphorylation (IC50 = 186-210 nM); protects neuroblastoma cells against cell damage triggered by ER stress; prevents phosphorylation of FADD, preventing apoptosis; reduces phosphorylation of PKR and eIF2α in the brain, enhancing long-term memory storage
15323	PKR Inhibitor	25 mg	≥95%	Binds the ATP-binding site of PKR and blocks autophosphorylation (IC50 = 186-210 nM); protects neuroblastoma cells against cell damage triggered by ER stress; prevents phosphorylation of FADD, preventing apoptosis; reduces phosphorylation of PKR and eIF2α in the brain, enhancing long-term memory storage
15323	PKR Inhibitor	5 mg	≥95%	Binds the ATP-binding site of PKR and blocks autophosphorylation (IC50 = 186-210 nM); protects neuroblastoma cells against cell damage triggered by ER stress; prevents phosphorylation of FADD, preventing apoptosis; reduces phosphorylation of PKR and eIF2α in the brain, enhancing long-term memory storage
15325	STO-609 (acetate)	1 mg	≥98%	A CaMKK inhibitor (IC50s = 120 and 40 ng/ml for CaMKKα and CaMKKβ, respectively); selective for CaMKKs over CaMKI, CaMKII, CaMKIV, MLCK, PKC, PKA, and p42 MAPK (IC50s = ≥ 10,000 ng/ml for all); inhibits phosphorylation of CaMKI and AMPK in chicken sperm in the presence of extracellular calcium, as well as reduces chicken sperm motility; decreases Npy and Agrp expression and cumulative food intake in mice at 20 µM 0.5 µL/hour, i.c.v.; increases cortical, striatal, and total infarct volume in a mouse model of MCAO-induced focal transient cerebral ischemia at 3 µg/animal, i.c.v.

15325	STO-609 (acetate)	10 mg	≥98%	A CaMKK inhibitor (IC50s = 120 and 40 ng/ml for CaMKKα and CaMKKβ, respectively); selective for CaMKKs over CaMKI, CaMKII, CaMKIV, MLCK, PKC, PKA, and p42 MAPK (IC50s = ≥ 10,000 ng/ml for all); inhibits phosphorylation of CaMKI and AMPK in chicken sperm in the presence of extracellular calcium, as well as reduces chicken sperm motility; decreases Npy and Agrp expression and cumulative food intake in mice at 20 µM 0.5 µL/hour, i.c.v.; increases cortical, striatal, and total infarct volume in a mouse model of MCAO-induced focal transient cerebral ischemia at 3 µg/animal, i.c.v.
15325	STO-609 (acetate)	25 mg	≥98%	A CaMKK inhibitor (IC50s = 120 and 40 ng/ml for CaMKKα and CaMKKβ, respectively); selective for CaMKKs over CaMKI, CaMKII, CaMKIV, MLCK, PKC, PKA, and p42 MAPK (IC50s = ≥ 10,000 ng/ml for all); inhibits phosphorylation of CaMKI and AMPK in chicken sperm in the presence of extracellular calcium, as well as reduces chicken sperm motility; decreases Npy and Agrp expression and cumulative food intake in mice at 20 µM 0.5 µL/hour, i.c.v.; increases cortical, striatal, and total infarct volume in a mouse model of MCAO-induced focal transient cerebral ischemia at 3 µg/animal, i.c.v.
15325	STO-609 (acetate)	5 mg	≥98%	A CaMKK inhibitor (IC50s = 120 and 40 ng/ml for CaMKKα and CaMKKβ, respectively); selective for CaMKKs over CaMKI, CaMKII, CaMKIV, MLCK, PKC, PKA, and p42 MAPK (IC50s = ≥ 10,000 ng/ml for all); inhibits phosphorylation of CaMKI and AMPK in chicken sperm in the presence of extracellular calcium, as well as reduces chicken sperm motility; decreases Npy and Agrp expression and cumulative food intake in mice at 20 µM 0.5 µL/hour, i.c.v.; increases cortical, striatal, and total infarct volume in a mouse model of MCAO-induced focal transient cerebral ischemia at 3 µg/animal, i.c.v.
15336	AZ 628	1 mg	≥98%	A quinazilinone that inhibits several Raf kinases, including B-Raf, B-RafV600E, and c-Raf-1 (IC50s = 105, 34, and 29 nM in vitro); inhibits anchorage-dependent and -independent growth, induces cell cycle arrest, and causes apoptosis in colon and melanoma cell lines carrying B-RafV600E mutations
15336	AZ 628	10 mg	≥98%	A quinazilinone that inhibits several Raf kinases, including B-Raf, B-RafV600E, and c-Raf-1 (IC50s = 105, 34, and 29 nM in vitro); inhibits anchorage-dependent and -independent growth, induces cell cycle arrest, and causes apoptosis in colon and melanoma cell lines carrying B-RafV600E mutations
15336	AZ 628	25 mg	≥98%	A quinazilinone that inhibits several Raf kinases, including B-Raf, B-RafV600E, and c-Raf-1 (IC50s = 105, 34, and 29 nM in vitro); inhibits anchorage-dependent and -independent growth, induces cell cycle arrest, and causes apoptosis in colon and melanoma cell lines carrying B-RafV600E mutations
15336	AZ 628	5 mg	≥98%	A quinazilinone that inhibits several Raf kinases, including B-Raf, B-RafV600E, and c-Raf-1 (IC50s = 105, 34, and 29 nM in vitro); inhibits anchorage-dependent and -independent growth, induces cell cycle arrest, and causes apoptosis in colon and melanoma cell lines carrying B-RafV600E mutations
15337	CRT0066101 (hydroch	1 mg	≥95%	A pan inhibitor PKD (IC50s = 1, 2.5, and 2 nM for PKD1, PKD2, and PKD3, respectively); blocks cell proliferation, induces apoptosis, and reduces the viability of pancreatic cancer cells both in vitro and in vivo
15337	CRT0066101 (hydroch	10 mg	≥95%	A pan inhibitor PKD (IC50s = 1, 2.5, and 2 nM for PKD1, PKD2, and PKD3, respectively); blocks cell proliferation, induces apoptosis, and reduces the viability of pancreatic cancer cells both in vitro and in vivo
15337	CRT0066101 (hydroch	5 mg	≥95%	A pan inhibitor PKD (IC50s = 1, 2.5, and 2 nM for PKD1, PKD2, and PKD3, respectively); blocks cell proliferation, induces apoptosis, and reduces the viability of pancreatic cancer cells both in vitro and in vivo
15344	Ku-0060648	1 mg	≥98%	A dual inhibitor of DNA-PK and PI3K
15344	Ku-0060648	10 mg	≥98%	A dual inhibitor of DNA-PK and PI3K
15344	Ku-0060648	25 mg	≥98%	A dual inhibitor of DNA-PK and PI3K
15344	Ku-0060648	5 mg	≥98%	A dual inhibitor of DNA-PK and PI3K
15352	YZ9	10 mg	≥98%	A potent inhibitor of the glycolysis enzyme PFKFB3, with an IC50 value of 183 nM in vitro; avidly competes with F6P at PFKFB3 (Ki = 94 nM); cell permeable, inhibiting the growth of HeLa cells with a GI50 value of 2.7 µM
15352	YZ9	100 mg	≥98%	A potent inhibitor of the glycolysis enzyme PFKFB3, with an IC50 value of 183 nM in vitro; avidly competes with F6P at PFKFB3 (Ki = 94 nM); cell permeable, inhibiting the growth of HeLa cells with a GI50 value of 2.7 µM
15352	YZ9	5 mg	≥98%	A potent inhibitor of the glycolysis enzyme PFKFB3, with an IC50 value of 183 nM in vitro; avidly competes with F6P at PFKFB3 (Ki = 94 nM); cell permeable, inhibiting the growth of HeLa cells with a GI50 value of 2.7 µM

15352	YZ9	50 mg	≥98%	A potent inhibitor of the glycolysis enzyme PFKFB3, with an IC50 value of 183 nM in vitro; avidly competes with F6P at PFKFB3 (Ki = 94 nM); cell permeable, inhibiting the growth of HeLa cells with a GI50 value of 2.7 µM
15363	EGFR Inhibitor	1 mg	≥98%	A cell permeable, selective inhibitor of the EGFR kinase (IC50s = 21, 63, and 4 nM for EGFR and the L858R and L861Q EGFR mutants, respectively)
15363	EGFR Inhibitor	25 mg	≥98%	A cell permeable, selective inhibitor of the EGFR kinase (IC50s = 21, 63, and 4 nM for EGFR and the L858R and L861Q EGFR mutants, respectively)
15363	EGFR Inhibitor	5 mg	≥98%	A cell permeable, selective inhibitor of the EGFR kinase (IC50s = 21, 63, and 4 nM for EGFR and the L858R and L861Q EGFR mutants, respectively)
15371	Butein	1 mg	≥95%	A plant polyphenol that is classified as a chalcone; a potent antioxidant that affects the numerous pathways modulated by oxidant tone, including inflammation, cancer, and immune response
15371	Butein	10 mg	≥95%	A plant polyphenol that is classified as a chalcone; a potent antioxidant that affects the numerous pathways modulated by oxidant tone, including inflammation, cancer, and immune response
15371	Butein	5 mg	≥95%	A plant polyphenol that is classified as a chalcone; a potent antioxidant that affects the numerous pathways modulated by oxidant tone, including inflammation, cancer, and immune response
15383	Calphostin C	100 µg	≥95%	A specific PKC inhibitor (IC50 = 50 nM versus an IC50 > 50 µM for PKA) whose activation depends on exposure to light; also inhibits phospholipase D1 and D2 (IC50s = 100 nM); demonstrates antitumor activity
15383	Calphostin C	500 µg	≥95%	A specific PKC inhibitor (IC50 = 50 nM versus an IC50 > 50 µM for PKA) whose activation depends on exposure to light; also inhibits phospholipase D1 and D2 (IC50s = 100 nM); demonstrates antitumor activity
15399	Xanthohumol	1 mg	≥98%	A natural prenylated chalcone that induces protective detoxification enzymes, at least in part via the Nrf2 pathway; inhibits PDK1 (IC50 = 6.6 µM) but not PKC in an in vitro assay; also can have anti-inflammatory, antioxidant, anti-carcinogenic, and osteogenic effects
15399	Xanthohumol	10 mg	≥98%	A natural prenylated chalcone that induces protective detoxification enzymes, at least in part via the Nrf2 pathway; inhibits PDK1 (IC50 = 6.6 µM) but not PKC in an in vitro assay; also can have anti-inflammatory, antioxidant, anti-carcinogenic, and osteogenic effects
15399	Xanthohumol	25 mg	≥98%	A natural prenylated chalcone that induces protective detoxification enzymes, at least in part via the Nrf2 pathway; inhibits PDK1 (IC50 = 6.6 µM) but not PKC in an in vitro assay; also can have anti-inflammatory, antioxidant, anti-carcinogenic, and osteogenic effects
15399	Xanthohumol	5 mg	≥98%	A natural prenylated chalcone that induces protective detoxification enzymes, at least in part via the Nrf2 pathway; inhibits PDK1 (IC50 = 6.6 µM) but not PKC in an in vitro assay; also can have anti-inflammatory, antioxidant, anti-carcinogenic, and osteogenic effects
15406	AZD 5363	1 mg	≥98%	A pan-Akt inhibitor (Akt1, 2, and 3 IC50s = 3, 7, and 7 nM, respectively) that also inhibits P70S6K and PKA (IC50s = 6 and 7 nM, respectively) and shows >75% inhibition at 1 µM against ROCK2, MKK1, MSK1, MSK2, PKCγ, PKGα, PKGβ, PRKX, RSK2, and RSK3; inhibits the proliferation of various tumor cell lines both in vitro and in vivo, demonstrating the greatest sensitivity towards breast cancer derived-cells or those with PIK3CA and/or PTEN mutations
15406	AZD 5363	10 mg	≥98%	A pan-Akt inhibitor (Akt1, 2, and 3 IC50s = 3, 7, and 7 nM, respectively) that also inhibits P70S6K and PKA (IC50s = 6 and 7 nM, respectively) and shows >75% inhibition at 1 µM against ROCK2, MKK1, MSK1, MSK2, PKCγ, PKGα, PKGβ, PRKX, RSK2, and RSK3; inhibits the proliferation of various tumor cell lines both in vitro and in vivo, demonstrating the greatest sensitivity towards breast cancer derived-cells or those with PIK3CA and/or PTEN mutations
15406	AZD 5363	25 mg	≥98%	A pan-Akt inhibitor (Akt1, 2, and 3 IC50s = 3, 7, and 7 nM, respectively) that also inhibits P70S6K and PKA (IC50s = 6 and 7 nM, respectively) and shows >75% inhibition at 1 µM against ROCK2, MKK1, MSK1, MSK2, PKCγ, PKGα, PKGβ, PRKX, RSK2, and RSK3; inhibits the proliferation of various tumor cell lines both in vitro and in vivo, demonstrating the greatest sensitivity towards breast cancer derived-cells or those with PIK3CA and/or PTEN mutations
15406	AZD 5363	5 mg	≥98%	A pan-Akt inhibitor (Akt1, 2, and 3 IC50s = 3, 7, and 7 nM, respectively) that also inhibits P70S6K and PKA (IC50s = 6 and 7 nM, respectively) and shows >75% inhibition at 1 µM against ROCK2, MKK1, MSK1, MSK2, PKCγ, PKGα, PKGβ, PRKX, RSK2, and RSK3; inhibits the proliferation of various tumor cell lines both in vitro and in vivo, demonstrating the greatest sensitivity towards breast cancer derived-cells or those with PIK3CA and/or PTEN mutations
15409	LY2109761	1 mg	≥98%	A small molecule inhibitor of the TGF-β receptor type 1/type II kinases (IC50 = 69 nM); used to study the role of TGF-β signaling in tumor cell migration and metastasis; disrupts Smad-2 phosphorylation, an immediate downstream target of the kinase activity
15409	LY2109761	10 mg	≥98%	A small molecule inhibitor of the TGF-β receptor type 1/type II kinases (IC50 = 69 nM); used to study the role of TGF-β signaling in tumor cell migration and metastasis; disrupts Smad-2 phosphorylation, an immediate downstream target of the kinase activity

15409	LY2109761	5 mg	≥98%	A small molecule inhibitor of the TGF-β receptor type 1/type II kinases (IC50 = 69 nM); used to study the role of TGF-β signaling in tumor cell migration and metastasis; disrupts Smad-2 phosphorylation, an immediate downstream target of the kinase activity
15411	GW 2580	1 mg	≥98%	A selective inhibitor of cFMS kinase (IC50 = 0.03 μM) that prevents CSF-1-induced monocyte growth with an IC50 value of 0.14 μM; at 75-100 mg/kg, inhibits joint connective tissue and bone degradation in mouse models of arthritis
15411	GW 2580	10 mg	≥98%	A selective inhibitor of cFMS kinase (IC50 = 0.03 μM) that prevents CSF-1-induced monocyte growth with an IC50 value of 0.14 μM; at 75-100 mg/kg, inhibits joint connective tissue and bone degradation in mouse models of arthritis
15411	GW 2580	25 mg	≥98%	A selective inhibitor of cFMS kinase (IC50 = 0.03 μM) that prevents CSF-1-induced monocyte growth with an IC50 value of 0.14 μM; at 75-100 mg/kg, inhibits joint connective tissue and bone degradation in mouse models of arthritis
15411	GW 2580	5 mg	≥98%	A selective inhibitor of cFMS kinase (IC50 = 0.03 μM) that prevents CSF-1-induced monocyte growth with an IC50 value of 0.14 μM; at 75-100 mg/kg, inhibits joint connective tissue and bone degradation in mouse models of arthritis
15500	Cercosporamide	2.5 mg	≥95%	A natural antifungal phytotoxin that selectively and potently inhibits fungal Pkc1, which are central to cell wall integrity (IC50 = 25 nM for Candida Pkc1); potently inhibits MAPK-interacting kinases Mnk1 and Mnk2 (IC50 = 115 and 11 nM, respectively), reducing protein translation in cancer cells
15500	Cercosporamide	500 µg	≥95%	A natural antifungal phytotoxin that selectively and potently inhibits fungal Pkc1, which are central to cell wall integrity (IC50 = 25 nM for Candida Pkc1); potently inhibits MAPK-interacting kinases Mnk1 and Mnk2 (IC50 = 115 and 11 nM, respectively), reducing protein translation in cancer cells
15504	Herbimycin A	2.5 mg	≥99%	A benzoquinone ansamycin antibiotic that acts as a cell-permeable inhibitor of non-receptor tyrosine kinases and Hsp90; inhibits Bcr-Abl with an IC50 value of 5 μM, a concentration that also effectively blocks Src, Yes, Fps, Ros, and ErbB; binds Hsp90 and destabilizes client proteins, including Src, Bcr-Abl, and ErbB2
15504	Herbimycin A	500 µg	≥99%	A benzoquinone ansamycin antibiotic that acts as a cell-permeable inhibitor of non-receptor tyrosine kinases and Hsp90; inhibits Bcr-Abl with an IC50 value of 5 μM, a concentration that also effectively blocks Src, Yes, Fps, Ros, and ErbB; binds Hsp90 and destabilizes client proteins, including Src, Bcr-Abl, and ErbB2
15514	LY303511 (hydrochlor	1 mg	≥98%	An inhibitor of mTOR-dependent phosphorylation of S6K; reduces cell proliferation in human lung epithelial adenocarcinoma cells, blocking G2/M progression and inhibiting CK2 activity
15514	LY303511 (hydrochlor	5 mg	≥98%	An inhibitor of mTOR-dependent phosphorylation of S6K; reduces cell proliferation in human lung epithelial adenocarcinoma cells, blocking G2/M progression and inhibiting CK2 activity
15526	ALK5 Inhibitor II (hydr	1 mg	≥98%	A selective inhibitor of the TGF-β type 1 receptor ALK5 (IC50s = 4, 18, and 23 nM for ALK5 autophosphorylation, TGF-β cellular assay, and ALK5 binding in HepG2 cells, respectively); used to induce stem cell pluripotency by replacing the reprogramming transcription factor Sox2 via inhibition of the TGF-β signaling pathway and induction of Nanog transcription
15526	ALK5 Inhibitor II (hydr	10 mg	≥98%	A selective inhibitor of the TGF-β type 1 receptor ALK5 (IC50s = 4, 18, and 23 nM for ALK5 autophosphorylation, TGF-β cellular assay, and ALK5 binding in HepG2 cells, respectively); used to induce stem cell pluripotency by replacing the reprogramming transcription factor Sox2 via inhibition of the TGF-β signaling pathway and induction of Nanog transcription
15526	ALK5 Inhibitor II (hydr	25 mg	≥98%	A selective inhibitor of the TGF-β type 1 receptor ALK5 (IC50s = 4, 18, and 23 nM for ALK5 autophosphorylation, TGF-β cellular assay, and ALK5 binding in HepG2 cells, respectively); used to induce stem cell pluripotency by replacing the reprogramming transcription factor Sox2 via inhibition of the TGF-β signaling pathway and induction of Nanog transcription
15526	ALK5 Inhibitor II (hydr	5 mg	≥98%	A selective inhibitor of the TGF-β type 1 receptor ALK5 (IC50s = 4, 18, and 23 nM for ALK5 autophosphorylation, TGF-β cellular assay, and ALK5 binding in HepG2 cells, respectively); used to induce stem cell pluripotency by replacing the reprogramming transcription factor Sox2 via inhibition of the TGF-β signaling pathway and induction of Nanog transcription
15543	HNMPA	1 mg	≥95%	A cell imperbeable tyrosine kinase inhibitor that blocks receptor serine and tyrosine phosphorylation; inhibits the insulin-stimulated autophosphorylation of the 95-kDa β-subunit of the insulin receptor (IC50 = 200 μM in vitro)
15543	HNMPA	10 mg	≥95%	A cell imperbeable tyrosine kinase inhibitor that blocks receptor serine and tyrosine phosphorylation; inhibits the insulin-stimulated autophosphorylation of the 95-kDa β-subunit of the insulin receptor (IC50 = 200 μM in vitro)
15543	HNMPA	25 mg	≥95%	A cell imperbeable tyrosine kinase inhibitor that blocks receptor serine and tyrosine phosphorylation; inhibits the insulin-stimulated autophosphorylation of the 95-kDa β-subunit of the insulin receptor (IC50 = 200 μM in vitro)

15543	HNMPA	5 mg	≥95%	A cell imperbeable tyrosine kinase inhibitor that blocks receptor serine and tyrosine phosphorylation; inhibits the insulin-stimulated autophosphorylation of the 95-kDa β-subunit of the insulin receptor (IC50 = 200 µM in vitro)
15544	FR180204	1 mg	≥98%	A potent cell-permeable inhibitor of ERK1 and ERK2 (Ki = 310 and 140 nM, respectively); much less effective against p38α (IC50 = 10 µM) and does not inhibit a range of other serine/threonine or tyrosine kinases; blocks ERK-mediated signaling from TGF-β to AP-1 (IC50 = 3.1 µM)
15544	FR180204	10 mg	≥98%	A potent cell-permeable inhibitor of ERK1 and ERK2 (Ki = 310 and 140 nM, respectively); much less effective against p38α (IC50 = 10 µM) and does not inhibit a range of other serine/threonine or tyrosine kinases; blocks ERK-mediated signaling from TGF-β to AP-1 (IC50 = 3.1 µM)
15544	FR180204	25 mg	≥98%	A potent cell-permeable inhibitor of ERK1 and ERK2 (Ki = 310 and 140 nM, respectively); much less effective against p38α (IC50 = 10 µM) and does not inhibit a range of other serine/threonine or tyrosine kinases; blocks ERK-mediated signaling from TGF-β to AP-1 (IC50 = 3.1 µM)
15544	FR180204	5 mg	≥98%	A potent cell-permeable inhibitor of ERK1 and ERK2 (Ki = 310 and 140 nM, respectively); much less effective against p38α (IC50 = 10 µM) and does not inhibit a range of other serine/threonine or tyrosine kinases; blocks ERK-mediated signaling from TGF-β to AP-1 (IC50 = 3.1 µM)
15553	ON-01910 (sodium sa	1 mg	≥98%	A potent, non-ATP-competitive inhibitor of Plk1 (IC50 = 9 nM); induces apoptosis in a wide array of tumor cell lines (GI50 = 50-200 nM); active in vivo when administered intraperitoneally and synergizes with chemotherapeutic agents
15553	ON-01910 (sodium sa	10 mg	≥98%	A potent, non-ATP-competitive inhibitor of Plk1 (IC50 = 9 nM); induces apoptosis in a wide array of tumor cell lines (GI50 = 50-200 nM); active in vivo when administered intraperitoneally and synergizes with chemotherapeutic agents
15553	ON-01910 (sodium sa	25 mg	≥98%	A potent, non-ATP-competitive inhibitor of Plk1 (IC50 = 9 nM); induces apoptosis in a wide array of tumor cell lines (GI50 = 50-200 nM); active in vivo when administered intraperitoneally and synergizes with chemotherapeutic agents
15553	ON-01910 (sodium sa	5 mg	≥98%	A potent, non-ATP-competitive inhibitor of Plk1 (IC50 = 9 nM); induces apoptosis in a wide array of tumor cell lines (GI50 = 50-200 nM); active in vivo when administered intraperitoneally and synergizes with chemotherapeutic agents
15569	Akt Inhibitor IV	1 mg	≥95%	An inhibitor of Akt activation; inhibits Akt-mediated nuclear export of FOXO1a (IC50 = 625 nM) and reduces phosphorylation of Akt at Ser473 and Thr308 in a dose-dependent manner; inhibits replication of PIV5 in HeLa cells (IC50 = 520 nM); reduces the growth of cancer cells (IC50 = 0.3 µM for both Jurkat and HeLa cells) via a reduction in mitochondrial polarization and increased production of ROS
15569	Akt Inhibitor IV	10 mg	≥95%	An inhibitor of Akt activation; inhibits Akt-mediated nuclear export of FOXO1a (IC50 = 625 nM) and reduces phosphorylation of Akt at Ser473 and Thr308 in a dose-dependent manner; inhibits replication of PIV5 in HeLa cells (IC50 = 520 nM); reduces the growth of cancer cells (IC50 = 0.3 µM for both Jurkat and HeLa cells) via a reduction in mitochondrial polarization and increased production of ROS
15569	Akt Inhibitor IV	25 mg	≥95%	An inhibitor of Akt activation; inhibits Akt-mediated nuclear export of FOXO1a (IC50 = 625 nM) and reduces phosphorylation of Akt at Ser473 and Thr308 in a dose-dependent manner; inhibits replication of PIV5 in HeLa cells (IC50 = 520 nM); reduces the growth of cancer cells (IC50 = 0.3 µM for both Jurkat and HeLa cells) via a reduction in mitochondrial polarization and increased production of ROS
15569	Akt Inhibitor IV	5 mg	≥95%	An inhibitor of Akt activation; inhibits Akt-mediated nuclear export of FOXO1a (IC50 = 625 nM) and reduces phosphorylation of Akt at Ser473 and Thr308 in a dose-dependent manner; inhibits replication of PIV5 in HeLa cells (IC50 = 520 nM); reduces the growth of cancer cells (IC50 = 0.3 µM for both Jurkat and HeLa cells) via a reduction in mitochondrial polarization and increased production of ROS
15578	CHIR98014	1 mg	≥95%	A reversible, cell-permeable inhibitor of GSK3α and GSK3β (IC50 = 0.65 and 0.58 nM, respectively); stimulates glycogen synthase in cells (EC50 = 106 nM), potentiates insulin-dependent glucose transport in isolated muscle strips, and improves glucose disposal in diabetic animals
15578	CHIR98014	10 mg	≥95%	A reversible, cell-permeable inhibitor of GSK3α and GSK3β (IC50 = 0.65 and 0.58 nM, respectively); stimulates glycogen synthase in cells (EC50 = 106 nM), potentiates insulin-dependent glucose transport in isolated muscle strips, and improves glucose disposal in diabetic animals
15578	CHIR98014	25 mg	≥95%	A reversible, cell-permeable inhibitor of GSK3α and GSK3β (IC50 = 0.65 and 0.58 nM, respectively); stimulates glycogen synthase in cells (EC50 = 106 nM), potentiates insulin-dependent glucose transport in isolated muscle strips, and improves glucose disposal in diabetic animals
15578	CHIR98014	5 mg	≥95%	A reversible, cell-permeable inhibitor of GSK3α and GSK3β (IC50 = 0.65 and 0.58 nM, respectively); stimulates glycogen synthase in cells (EC50 = 106 nM), potentiates insulin-dependent glucose transport in isolated muscle strips, and improves glucose disposal in diabetic animals
15595	PP3	1 mg	≥98%	An inactive analog of the Src tyrosine kinase inhibitors PP1 and PP2
15595	PP3	10 mg	≥98%	An inactive analog of the Src tyrosine kinase inhibitors PP1 and PP2
15595	PP3	5 mg	≥98%	An inactive analog of the Src tyrosine kinase inhibitors PP1 and PP2
15598	SL 327	1 mg	≥95% (mixture	A selective inhibitor of MEK1 and MEK2 (IC50s = 0.18 and 0.22 µM), the kinases upstream of ERK1/2; rapidly passes the blood-brain barrier and has been used to dissect the effect of RAS/RAF/MEK/ERK signaling pathway inhibition on behavior

15598	SL 327	10 mg	≥95% (mixture	A selective inhibitor of MEK1 and MEK2 (IC50s = 0.18 and 0.22 μM), the kinases upstream of ERK1/2; rapidly passes the blood-brain barrier and has been used to dissect the effect of RAS/RAF/MEK/ERK signaling pathway inhibition on behavior
15598	SL 327	25 mg	≥95% (mixture	A selective inhibitor of MEK1 and MEK2 (IC50s = 0.18 and 0.22 μM), the kinases upstream of ERK1/2; rapidly passes the blood-brain barrier and has been used to dissect the effect of RAS/RAF/MEK/ERK signaling pathway inhibition on behavior
15598	SL 327	5 mg	≥95% (mixture	A selective inhibitor of MEK1 and MEK2 (IC50s = 0.18 and 0.22 μM), the kinases upstream of ERK1/2; rapidly passes the blood-brain barrier and has been used to dissect the effect of RAS/RAF/MEK/ERK signaling pathway inhibition on behavior
15624	JNK Inhibitor IX	10 mg	≥98%	A thienylnaphthamide compound that selectively targets the ATP binding site of JNK2 and JNK3 (pIC50s = 6.5 and 6.7, respectively)
15624	JNK Inhibitor IX	25 mg	≥98%	A thienylnaphthamide compound that selectively targets the ATP binding site of JNK2 and JNK3 (pIC50s = 6.5 and 6.7, respectively)
15624	JNK Inhibitor IX	5 mg	≥98%	A thienylnaphthamide compound that selectively targets the ATP binding site of JNK2 and JNK3 (pIC50s = 6.5 and 6.7, respectively)
15624	JNK Inhibitor IX	50 mg	≥98%	A thienylnaphthamide compound that selectively targets the ATP binding site of JNK2 and JNK3 (pIC50s = 6.5 and 6.7, respectively)
15627	Pelitinib	1 mg	≥98%	A cyanoquinoline that irreversibly inhibits the receptor tyrosine kinases EGFR (IC50 = 39 nM) and HER2 (IC50 = 1.2 μM); disrupts Akt and MAPK pathways, inducing apoptosis and suppressing the growth of tumor cell lines
15627	Pelitinib	10 mg	≥98%	A cyanoquinoline that irreversibly inhibits the receptor tyrosine kinases EGFR (IC50 = 39 nM) and HER2 (IC50 = 1.2 μM); disrupts Akt and MAPK pathways, inducing apoptosis and suppressing the growth of tumor cell lines
15627	Pelitinib	25 mg	≥98%	A cyanoquinoline that irreversibly inhibits the receptor tyrosine kinases EGFR (IC50 = 39 nM) and HER2 (IC50 = 1.2 μM); disrupts Akt and MAPK pathways, inducing apoptosis and suppressing the growth of tumor cell lines
15627	Pelitinib	5 mg	≥98%	A cyanoquinoline that irreversibly inhibits the receptor tyrosine kinases EGFR (IC50 = 39 nM) and HER2 (IC50 = 1.2 μM); disrupts Akt and MAPK pathways, inducing apoptosis and suppressing the growth of tumor cell lines
15781	ISCK03	1 mg	≥95%	A cell-permeable inhibitor of SCF-mediated c-kit activation, completely blocking phosphorylation of c-kit in human melanoma cells at a concentration between 1 and 5 μM; prevents SCF-mediated downstream phosphorylation of p44/p42 ERK
15781	ISCK03	10 mg	≥95%	A cell-permeable inhibitor of SCF-mediated c-kit activation, completely blocking phosphorylation of c-kit in human melanoma cells at a concentration between 1 and 5 μM; prevents SCF-mediated downstream phosphorylation of p44/p42 ERK
15781	ISCK03	25 mg	≥95%	A cell-permeable inhibitor of SCF-mediated c-kit activation, completely blocking phosphorylation of c-kit in human melanoma cells at a concentration between 1 and 5 μM; prevents SCF-mediated downstream phosphorylation of p44/p42 ERK
15781	ISCK03	5 mg	≥95%	A cell-permeable inhibitor of SCF-mediated c-kit activation, completely blocking phosphorylation of c-kit in human melanoma cells at a concentration between 1 and 5 μM; prevents SCF-mediated downstream phosphorylation of p44/p42 ERK
15867	Fialuridine	1 mg	≥98%	A nucleoside analog with antiviral activity, inhibiting thymidine kinases from herpes simplex virus types 1 and 2 with Ki values of 0.14 and 0.95 μM, while blocking green monkey Vero cell thymidine kinase less effectively (Ki = 53 μM)
15867	Fialuridine	10 mg	≥98%	A nucleoside analog with antiviral activity, inhibiting thymidine kinases from herpes simplex virus types 1 and 2 with Ki values of 0.14 and 0.95 μM, while blocking green monkey Vero cell thymidine kinase less effectively (Ki = 53 μM)
15867	Fialuridine	25 mg	≥98%	A nucleoside analog with antiviral activity, inhibiting thymidine kinases from herpes simplex virus types 1 and 2 with Ki values of 0.14 and 0.95 μM, while blocking green monkey Vero cell thymidine kinase less effectively (Ki = 53 μM)
15867	Fialuridine	5 mg	≥98%	A nucleoside analog with antiviral activity, inhibiting thymidine kinases from herpes simplex virus types 1 and 2 with Ki values of 0.14 and 0.95 μM, while blocking green monkey Vero cell thymidine kinase less effectively (Ki = 53 μM)
15924	CID755673	1 mg	≥98%	A selective small molecule inhibitor of PKD (IC50s = 182, 280, 227 nM for PKD1, 2, and 3, respectively); 25 μM has been shown to inhibit prostate cancer cell proliferation, cell migration, and invasion
15924	CID755673	10 mg	≥98%	A selective small molecule inhibitor of PKD (IC50s = 182, 280, 227 nM for PKD1, 2, and 3, respectively); 25 μM has been shown to inhibit prostate cancer cell proliferation, cell migration, and invasion
15924	CID755673	25 mg	≥98%	A selective small molecule inhibitor of PKD (IC50s = 182, 280, 227 nM for PKD1, 2, and 3, respectively); 25 μM has been shown to inhibit prostate cancer cell proliferation, cell migration, and invasion
15924	CID755673	5 mg	≥98%	A selective small molecule inhibitor of PKD (IC50s = 182, 280, 227 nM for PKD1, 2, and 3, respectively); 25 μM has been shown to inhibit prostate cancer cell proliferation, cell migration, and invasion

15943	MK2 Inhibitor III	1 mg	≥95%	A potent, cell-permeable inhibitor of MK2 (IC50 = 8.5 nM); less potently blocks MK3 and MK5 (IC50s = 210 and 81 nM, respectively) and is weak or inactive against several other kinases, including other p38 MAP kinase targets; prevents LPS-induced synthesis of TNF-α in human monocyte-like U937 cells (IC50 = 4.4 μM)
15943	MK2 Inhibitor III	5 mg	≥95%	A potent, cell-permeable inhibitor of MK2 (IC50 = 8.5 nM); less potently blocks MK3 and MK5 (IC50s = 210 and 81 nM, respectively) and is weak or inactive against several other kinases, including other p38 MAP kinase targets; prevents LPS-induced synthesis of TNF-α in human monocyte-like U937 cells (IC50 = 4.4 μM)
15943	MK2 Inhibitor III	500 μg	≥95%	A potent, cell-permeable inhibitor of MK2 (IC50 = 8.5 nM); less potently blocks MK3 and MK5 (IC50s = 210 and 81 nM, respectively) and is weak or inactive against several other kinases, including other p38 MAP kinase targets; prevents LPS-induced synthesis of TNF-α in human monocyte-like U937 cells (IC50 = 4.4 μM)
15944	ERK Inhibitor	1 mg	≥95%	A cell-permeable inhibitor that binds ERK2 near its docking domain (KD = 5 μM); blocks ERK-specific phosphorylation of Rsk-1 and TCF/Elk-1 but does not affect ERK1/2 phosphorylation by MEK1/2; completely prevents proliferation of several cancer cell lines
15944	ERK Inhibitor	5 mg	≥95%	A cell-permeable inhibitor that binds ERK2 near its docking domain (KD = 5 μM); blocks ERK-specific phosphorylation of Rsk-1 and TCF/Elk-1 but does not affect ERK1/2 phosphorylation by MEK1/2; completely prevents proliferation of several cancer cell lines
15944	ERK Inhibitor	500 μg	≥95%	A cell-permeable inhibitor that binds ERK2 near its docking domain (KD = 5 μM); blocks ERK-specific phosphorylation of Rsk-1 and TCF/Elk-1 but does not affect ERK1/2 phosphorylation by MEK1/2; completely prevents proliferation of several cancer cell lines
15946	JNK Inhibitor VIII	1 mg	≥98%	An aminopyridine compound that inhibits JNK1, JNK2, and JNK3 (Kis = 2, 4, and 52 nM, respectively); inhibits the phosphorylation of the JNK substrate c-Jun in HepG2 cells (EC50 = 920 nM)
15946	JNK Inhibitor VIII	10 mg	≥98%	An aminopyridine compound that inhibits JNK1, JNK2, and JNK3 (Kis = 2, 4, and 52 nM, respectively); inhibits the phosphorylation of the JNK substrate c-Jun in HepG2 cells (EC50 = 920 nM)
15946	JNK Inhibitor VIII	5 mg	≥98%	An aminopyridine compound that inhibits JNK1, JNK2, and JNK3 (Kis = 2, 4, and 52 nM, respectively); inhibits the phosphorylation of the JNK substrate c-Jun in HepG2 cells (EC50 = 920 nM)
15995	PKG Inhibitor	1 mg	≥95%	A specific cGMP-dependent PKG inhibitor (Ki = 86 μM); a nonphosphorylatable synthetic peptide analogous to a substrate corresponding to the serine-32 phosphorylation site in histone H2B
15995	PKG Inhibitor	10 mg	≥95%	A specific cGMP-dependent PKG inhibitor (Ki = 86 μM); a nonphosphorylatable synthetic peptide analogous to a substrate corresponding to the serine-32 phosphorylation site in histone H2B
15995	PKG Inhibitor	5 mg	≥95%	A specific cGMP-dependent PKG inhibitor (Ki = 86 μM); a nonphosphorylatable synthetic peptide analogous to a substrate corresponding to the serine-32 phosphorylation site in histone H2B
15996	PKA Inhibitor (5-24) (t	1 mg	≥95%	A synthetic peptide inhibitor of PKA (cAMP-dependent protein kinase) (Ki = 2.3 nM)
15996	PKA Inhibitor (5-24) (t	5 mg	≥95%	A synthetic peptide inhibitor of PKA (cAMP-dependent protein kinase) (Ki = 2.3 nM)
15996	PKA Inhibitor (5-24) (t	500 μg	≥95%	A synthetic peptide inhibitor of PKA (cAMP-dependent protein kinase) (Ki = 2.3 nM)
16109	TIC10	1 mg	≥98%	Induces the expression of TRAIL at 1-5 μM in a p53-independent manner; orally active, stable, and crosses the blood-brain barrier; suppresses the growth of orthotopic human glioblastoma multiforme tumors in mice
16109	TIC10	10 mg	≥98%	Induces the expression of TRAIL at 1-5 μM in a p53-independent manner; orally active, stable, and crosses the blood-brain barrier; suppresses the growth of orthotopic human glioblastoma multiforme tumors in mice
16109	TIC10	25 mg	≥98%	Induces the expression of TRAIL at 1-5 μM in a p53-independent manner; orally active, stable, and crosses the blood-brain barrier; suppresses the growth of orthotopic human glioblastoma multiforme tumors in mice
16109	TIC10	5 mg	≥98%	Induces the expression of TRAIL at 1-5 μM in a p53-independent manner; orally active, stable, and crosses the blood-brain barrier; suppresses the growth of orthotopic human glioblastoma multiforme tumors in mice
16168	MAZ51	1 mg	≥95%	A selective antagonist of the activation of VEGFR-3 by VEGF-C (IC50 = 1 μM); does not inhibit ligand-induced autophosphorylation of VEGFR-2, EGFR, IGF-1R, or PDGFRβ; reduces proliferation and induces apoptosis in a variety of cancer cells in vitro and suppresses tumor growth in vivo
16168	MAZ51	10 mg	≥95%	A selective antagonist of the activation of VEGFR-3 by VEGF-C (IC50 = 1 μM); does not inhibit ligand-induced autophosphorylation of VEGFR-2, EGFR, IGF-1R, or PDGFRβ; reduces proliferation and induces apoptosis in a variety of cancer cells in vitro and suppresses tumor growth in vivo

16168	MAZ51	25 mg	≥95%	A selective antagonist of the activation of VEGFR-3 by VEGF-C (IC50 = 1 μM); does not inhibit ligand-induced autophosphorylation of VEGFR-2, EGFR, IGF-1R, or PDGFRβ; reduces proliferation and induces apoptosis in a variety of cancer cells in vitro and suppresses tumor growth in vivo
16168	MAZ51	5 mg	≥95%	A selective antagonist of the activation of VEGFR-3 by VEGF-C (IC50 = 1 μM); does not inhibit ligand-induced autophosphorylation of VEGFR-2, EGFR, IGF-1R, or PDGFRβ; reduces proliferation and induces apoptosis in a variety of cancer cells in vitro and suppresses tumor growth in vivo
16177	NU 6027	1 mg	≥98%	An inhibitor of both CDK1 and CDK2 (IC50s =2.9 and 2.2 μM, respectively); inhibits cellular ataxia telangiectasia mutated and Rad3-related kinase activity (IC50 = 6.7 μM) and impairs G2/M arrest in various human cancer cells, potentiating the cytotoxic effects of DNA-damaging, anticancer agents such as cisplatin
16177	NU 6027	10 mg	≥98%	An inhibitor of both CDK1 and CDK2 (IC50s =2.9 and 2.2 μM, respectively); inhibits cellular ataxia telangiectasia mutated and Rad3-related kinase activity (IC50 = 6.7 μM) and impairs G2/M arrest in various human cancer cells, potentiating the cytotoxic effects of DNA-damaging, anticancer agents such as cisplatin
16177	NU 6027	5 mg	≥98%	An inhibitor of both CDK1 and CDK2 (IC50s =2.9 and 2.2 μM, respectively); inhibits cellular ataxia telangiectasia mutated and Rad3-related kinase activity (IC50 = 6.7 μM) and impairs G2/M arrest in various human cancer cells, potentiating the cytotoxic effects of DNA-damaging, anticancer agents such as cisplatin
16177	NU 6027	50 mg	≥98%	An inhibitor of both CDK1 and CDK2 (IC50s =2.9 and 2.2 μM, respectively); inhibits cellular ataxia telangiectasia mutated and Rad3-related kinase activity (IC50 = 6.7 μM) and impairs G2/M arrest in various human cancer cells, potentiating the cytotoxic effects of DNA-damaging, anticancer agents such as cisplatin
16178	WHI-P154	10 mg	≥98%	A quinazoline derivative that exhibits immunosuppressive effects by selectively inhibiting JAK3 (IC50 = 1.8 μM versus IC50s > 10 μM for JAK1 and JAK2); also inhibits EGFR (IC50 = 4 nM) and VEGFR as well as the non-receptor tyrosine kinases, Abl, Lck, and Src
16178	WHI-P154	25 mg	≥98%	A quinazoline derivative that exhibits immunosuppressive effects by selectively inhibiting JAK3 (IC50 = 1.8 μM versus IC50s > 10 μM for JAK1 and JAK2); also inhibits EGFR (IC50 = 4 nM) and VEGFR as well as the non-receptor tyrosine kinases, Abl, Lck, and Src
16178	WHI-P154	5 mg	≥98%	A quinazoline derivative that exhibits immunosuppressive effects by selectively inhibiting JAK3 (IC50 = 1.8 μM versus IC50s > 10 μM for JAK1 and JAK2); also inhibits EGFR (IC50 = 4 nM) and VEGFR as well as the non-receptor tyrosine kinases, Abl, Lck, and Src
16226	NQDI-1	1 mg	≥95%	A selective inhibitor of ASK1 (IC50 = 3 μM; Ki = 500 nM); promotes survival of induced pluripotent stem cell populations and protects neurons from reactive oxygen species-induced apoptosis in a model of ischemia
16226	NQDI-1	10 mg	≥95%	A selective inhibitor of ASK1 (IC50 = 3 μM; Ki = 500 nM); promotes survival of induced pluripotent stem cell populations and protects neurons from reactive oxygen species-induced apoptosis in a model of ischemia
16226	NQDI-1	25 mg	≥95%	A selective inhibitor of ASK1 (IC50 = 3 μM; Ki = 500 nM); promotes survival of induced pluripotent stem cell populations and protects neurons from reactive oxygen species-induced apoptosis in a model of ischemia
16226	NQDI-1	5 mg	≥95%	A selective inhibitor of ASK1 (IC50 = 3 μM; Ki = 500 nM); promotes survival of induced pluripotent stem cell populations and protects neurons from reactive oxygen species-induced apoptosis in a model of ischemia
16231	AT7519 (hydrochlorid	1 mg	≥98%	An ATP-competitive inhibitor of Cdk1, 2, 4, 5, 6, and 9 with IC50 values of 210, 47, 100, 13, 170, and 50s = 40-940 nM in vitro) and human tumor xenograft models, inhibiting cell cycle progression and inducing apoptosis
16231	AT7519 (hydrochlorid	10 mg	≥98%	An ATP-competitive inhibitor of Cdk1, 2, 4, 5, 6, and 9 with IC50 values of 210, 47, 100, 13, 170, and 50s = 40-940 nM in vitro) and human tumor xenograft models, inhibiting cell cycle progression and inducing apoptosis
16231	AT7519 (hydrochlorid	25 mg	≥98%	An ATP-competitive inhibitor of Cdk1, 2, 4, 5, 6, and 9 with IC50 values of 210, 47, 100, 13, 170, and 50s = 40-940 nM in vitro) and human tumor xenograft models, inhibiting cell cycle progression and inducing apoptosis
16231	AT7519 (hydrochlorid	5 mg	≥98%	An ATP-competitive inhibitor of Cdk1, 2, 4, 5, 6, and 9 with IC50 values of 210, 47, 100, 13, 170, and 50s = 40-940 nM in vitro) and human tumor xenograft models, inhibiting cell cycle progression and inducing apoptosis
16237	AZD 9291	1 mg	≥98%	An irreversible inhibitor of EGFR sensitizing and T790M resistance mutations (IC50s = 15-17 nM) while sparing the wild-type EGFR (IC50 = 480 nM); inhibits tumor growth in a xenograft mouse model at oral doses of 5-10 mg/kg
16237	AZD 9291	10 mg	≥98%	An irreversible inhibitor of EGFR sensitizing and T790M resistance mutations (IC50s = 15-17 nM) while sparing the wild-type EGFR (IC50 = 480 nM); inhibits tumor growth in a xenograft mouse model at oral doses of 5-10 mg/kg

16237	AZD 9291	5 mg	≥98%	An irreversible inhibitor of EGFR sensitizing and T790M resistance mutations (IC50s = 15-17 nM) while sparing the wild-type EGFR (IC50 = 480 nM); inhibits tumor growth in a xenograft mouse model at oral doses of 5-10 mg/kg
16237	AZD 9291	50 mg	≥98%	An irreversible inhibitor of EGFR sensitizing and T790M resistance mutations (IC50s = 15-17 nM) while sparing the wild-type EGFR (IC50 = 480 nM); inhibits tumor growth in a xenograft mouse model at oral doses of 5-10 mg/kg
16238	BIX02188	1 mg	≥95%	A potent inhibitor of MEK5 (IC50 = 4.3 nM) and moderate inhibitor of ERK5 and TGFβR1 (IC50s = 810 and 1800 nM, respectively)
16238	BIX02188	10 mg	≥95%	A potent inhibitor of MEK5 (IC50 = 4.3 nM) and moderate inhibitor of ERK5 and TGFβR1 (IC50s = 810 and 1800 nM, respectively)
16238	BIX02188	25 mg	≥95%	A potent inhibitor of MEK5 (IC50 = 4.3 nM) and moderate inhibitor of ERK5 and TGFβR1 (IC50s = 810 and 1800 nM, respectively)
16238	BIX02188	5 mg	≥95%	A potent inhibitor of MEK5 (IC50 = 4.3 nM) and moderate inhibitor of ERK5 and TGFβR1 (IC50s = 810 and 1800 nM, respectively)
16242	CGK733	10 mg	≥98%	An anticancer compound; originally identified as an ATM and ATR kinase inhibitor in a study that has since been retracted; inhibits irradiation-induced ATM kinase activation in HEK293 cells at 10 μM but does not inhibit irradiation-induced phosphorylation of ATM or Chk2 in H460 or UV radiation-induced Chk1 phosphorylation at the same concentration; inhibits ATM kinase activity in a D54 glioblastoma mouse xenograft model at 25 mg/kg; reduces tumor growth in a CNE-2 nasopharyngeal carcinoma mouse xenograft model
16242	CGK733	25 mg	≥98%	An anticancer compound; originally identified as an ATM and ATR kinase inhibitor in a study that has since been retracted; inhibits irradiation-induced ATM kinase activation in HEK293 cells at 10 μM but does not inhibit irradiation-induced phosphorylation of ATM or Chk2 in H460 or UV radiation-induced Chk1 phosphorylation at the same concentration; inhibits ATM kinase activity in a D54 glioblastoma mouse xenograft model at 25 mg/kg; reduces tumor growth in a CNE-2 nasopharyngeal carcinoma mouse xenograft model
16242	CGK733	5 mg	≥98%	An anticancer compound; originally identified as an ATM and ATR kinase inhibitor in a study that has since been retracted; inhibits irradiation-induced ATM kinase activation in HEK293 cells at 10 μM but does not inhibit irradiation-induced phosphorylation of ATM or Chk2 in H460 or UV radiation-induced Chk1 phosphorylation at the same concentration; inhibits ATM kinase activity in a D54 glioblastoma mouse xenograft model at 25 mg/kg; reduces tumor growth in a CNE-2 nasopharyngeal carcinoma mouse xenograft model
16242	CGK733	50 mg	≥98%	An anticancer compound; originally identified as an ATM and ATR kinase inhibitor in a study that has since been retracted; inhibits irradiation-induced ATM kinase activation in HEK293 cells at 10 μM but does not inhibit irradiation-induced phosphorylation of ATM or Chk2 in H460 or UV radiation-induced Chk1 phosphorylation at the same concentration; inhibits ATM kinase activity in a D54 glioblastoma mouse xenograft model at 25 mg/kg; reduces tumor growth in a CNE-2 nasopharyngeal carcinoma mouse xenograft model
16244	CO-1686	1 mg	≥98%	An irreversible inhibitor of mutant forms of EGFR including T790M (Ki = 21.5 nM) with minimal activity at the wild-type EGFR (Ki = 303.3 nM); inhibits the proliferation of NSCLC cells expressing mutant EGFR (GI50s = 7-32 nM) and demonstrates anti-tumor activity in NSCLC EGFR mutant xenograft and transgenic models
16244	CO-1686	10 mg	≥98%	An irreversible inhibitor of mutant forms of EGFR including T790M (Ki = 21.5 nM) with minimal activity at the wild-type EGFR (Ki = 303.3 nM); inhibits the proliferation of NSCLC cells expressing mutant EGFR (GI50s = 7-32 nM) and demonstrates anti-tumor activity in NSCLC EGFR mutant xenograft and transgenic models
16244	CO-1686	5 mg	≥98%	An irreversible inhibitor of mutant forms of EGFR including T790M (Ki = 21.5 nM) with minimal activity at the wild-type EGFR (Ki = 303.3 nM); inhibits the proliferation of NSCLC cells expressing mutant EGFR (GI50s = 7-32 nM) and demonstrates anti-tumor activity in NSCLC EGFR mutant xenograft and transgenic models
16245	CX-6258	1 mg	≥98%	A potent, reversible, orally bioavailable inhibitor of Pim-1, -2, and -3 (IC50s = 5, 25, and 16 nM, respectively); dose-dependently blocks the phosphorylation of the Pim targets Bad, 4E-BP1, and NKX3.1; acts synergistically with chemotherapeutic drugs
16245	CX-6258	10 mg	≥98%	A potent, reversible, orally bioavailable inhibitor of Pim-1, -2, and -3 (IC50s = 5, 25, and 16 nM, respectively); dose-dependently blocks the phosphorylation of the Pim targets Bad, 4E-BP1, and NKX3.1; acts synergistically with chemotherapeutic drugs
16245	CX-6258	25 mg	≥98%	A potent, reversible, orally bioavailable inhibitor of Pim-1, -2, and -3 (IC50s = 5, 25, and 16 nM, respectively); dose-dependently blocks the phosphorylation of the Pim targets Bad, 4E-BP1, and NKX3.1; acts synergistically with chemotherapeutic drugs
16245	CX-6258	5 mg	≥98%	A potent, reversible, orally bioavailable inhibitor of Pim-1, -2, and -3 (IC50s = 5, 25, and 16 nM, respectively); dose-dependently blocks the phosphorylation of the Pim targets Bad, 4E-BP1, and NKX3.1; acts synergistically with chemotherapeutic drugs
16246	CYT387	1 mg	≥98%	An ATP-competitive inhibitor of JAK1 and JAK2 (IC50s = 11 and 18 nM, respectively); causes growth suppression and apoptosis in JAK2-dependent hematopoietic cell lines; is efficacious in a mouse model of JAK2V617F-dependent myeloproliferative neoplasms

16246	CYT387	10 mg	≥98%	An ATP-competitive inhibitor of JAK1 and JAK2 (IC50s = 11 and 18 nM, respectively); causes growth suppression and apoptosis in JAK2-dependent hematopoietic cell lines; is efficacious in a mouse model of JAK2V617F-dependent myeloproliferative neoplasms
16246	CYT387	5 mg	≥98%	An ATP-competitive inhibitor of JAK1 and JAK2 (IC50s = 11 and 18 nM, respectively); causes growth suppression and apoptosis in JAK2-dependent hematopoietic cell lines; is efficacious in a mouse model of JAK2V617F-dependent myeloproliferative neoplasms
16246	CYT387	50 mg	≥98%	An ATP-competitive inhibitor of JAK1 and JAK2 (IC50s = 11 and 18 nM, respectively); causes growth suppression and apoptosis in JAK2-dependent hematopoietic cell lines; is efficacious in a mouse model of JAK2V617F-dependent myeloproliferative neoplasms
16249	Foretinib	1 mg	≥98%	A broad-spectrum TK inhibitor that targets members of the HGF and VEGF receptor TK families, as well as KIT, Flt-3, PDGFRβ, and Tie-2, at nanomolar concentrations;reduces tumor burden in an experimental model of lung metastasis
16249	Foretinib	10 mg	≥98%	A broad-spectrum TK inhibitor that targets members of the HGF and VEGF receptor TK families, as well as KIT, Flt-3, PDGFRβ, and Tie-2, at nanomolar concentrations;reduces tumor burden in an experimental model of lung metastasis
16249	Foretinib	25 mg	≥98%	A broad-spectrum TK inhibitor that targets members of the HGF and VEGF receptor TK families, as well as KIT, Flt-3, PDGFRβ, and Tie-2, at nanomolar concentrations;reduces tumor burden in an experimental model of lung metastasis
16249	Foretinib	5 mg	≥98%	A broad-spectrum TK inhibitor that targets members of the HGF and VEGF receptor TK families, as well as KIT, Flt-3, PDGFRβ, and Tie-2, at nanomolar concentrations;reduces tumor burden in an experimental model of lung metastasis
16251	GNE-0877	1 mg	≥98%	A selective, brain-penetrable LRRK2 inhibitor (Ki = 0.7 nM); inhibits LRRK2 Ser1292 autophosphorylation in BAC transgenic mice expressing human LRRK2 protein with the G2019S Parkinson's disease mutation (IC50 = 3 nM in vivo)
16251	GNE-0877	5 mg	≥98%	A selective, brain-penetrable LRRK2 inhibitor (Ki = 0.7 nM); inhibits LRRK2 Ser1292 autophosphorylation in BAC transgenic mice expressing human LRRK2 protein with the G2019S Parkinson's disease mutation (IC50 = 3 nM in vivo)
16251	GNE-0877	500 µg	≥98%	A selective, brain-penetrable LRRK2 inhibitor (Ki = 0.7 nM); inhibits LRRK2 Ser1292 autophosphorylation in BAC transgenic mice expressing human LRRK2 protein with the G2019S Parkinson's disease mutation (IC50 = 3 nM in vivo)
16252	GNE-7915	10 mg	≥98%	A selective, brain-penetrable LRRK2 inhibitor (Kis = 2 and 18.7 nM in biochemical and cell-based assays, respectively); inhibits LRRK2 Ser1292 autophosphorylation in BAC transgenic mice expressing human LRRK2 protein with the G2019S Parkinson's disease mutation (IC50 = 20 nM in vivo)
16252	GNE-7915	5 mg	≥98%	A selective, brain-penetrable LRRK2 inhibitor (Kis = 2 and 18.7 nM in biochemical and cell-based assays, respectively); inhibits LRRK2 Ser1292 autophosphorylation in BAC transgenic mice expressing human LRRK2 protein with the G2019S Parkinson's disease mutation (IC50 = 20 nM in vivo)
16252	GNE-7915	50 mg	≥98%	A selective, brain-penetrable LRRK2 inhibitor (Kis = 2 and 18.7 nM in biochemical and cell-based assays, respectively); inhibits LRRK2 Ser1292 autophosphorylation in BAC transgenic mice expressing human LRRK2 protein with the G2019S Parkinson's disease mutation (IC50 = 20 nM in vivo)
16253	GNF-2	1 mg	≥98%	An allosteric inhibitor of Bcr-Abl (IC50 = 267 nM); selective for Bcr-Abl over c-Abl and a panel of 63 additional kinases at 10 µM; inhibits proliferation of Ba/F3 cells (IC50 = 138 nM); reduces viral titers in IBV-infected Vero cells at 10 µM; inhibits LPS-induced production of NO and TNF-α in BV-2 microglia at 10 and 20 µM; reduces paw edema and increases the latency to paw withdrawal in a mouse model of inflammatory pain at 1 and 20 mg/kg; decreases mechanical and thermal hyperalgesia in a mouse model of STZ-induced diabetic neuropathy
16253	GNF-2	10 mg	≥98%	An allosteric inhibitor of Bcr-Abl (IC50 = 267 nM); selective for Bcr-Abl over c-Abl and a panel of 63 additional kinases at 10 µM; inhibits proliferation of Ba/F3 cells (IC50 = 138 nM); reduces viral titers in IBV-infected Vero cells at 10 µM; inhibits LPS-induced production of NO and TNF-α in BV-2 microglia at 10 and 20 µM; reduces paw edema and increases the latency to paw withdrawal in a mouse model of inflammatory pain at 1 and 20 mg/kg; decreases mechanical and thermal hyperalgesia in a mouse model of STZ-induced diabetic neuropathy
16253	GNF-2	5 mg	≥98%	An allosteric inhibitor of Bcr-Abl (IC50 = 267 nM); selective for Bcr-Abl over c-Abl and a panel of 63 additional kinases at 10 µM; inhibits proliferation of Ba/F3 cells (IC50 = 138 nM); reduces viral titers in IBV-infected Vero cells at 10 µM; inhibits LPS-induced production of NO and TNF-α in BV-2 microglia at 10 and 20 µM; reduces paw edema and increases the latency to paw withdrawal in a mouse model of inflammatory pain at 1 and 20 mg/kg; decreases mechanical and thermal hyperalgesia in a mouse model of STZ-induced diabetic neuropathy
16253	GNF-2	50 mg	≥98%	An allosteric inhibitor of Bcr-Abl (IC50 = 267 nM); selective for Bcr-Abl over c-Abl and a panel of 63 additional kinases at 10 µM; inhibits proliferation of Ba/F3 cells (IC50 = 138 nM); reduces viral titers in IBV-infected Vero cells at 10 µM; inhibits LPS-induced production of NO and TNF-α in BV-2 microglia at 10 and 20 µM; reduces paw edema and increases the latency to paw withdrawal in a mouse model of inflammatory pain at 1 and 20 mg/kg; decreases mechanical and thermal hyperalgesia in a mouse model of STZ-induced diabetic neuropathy

16254	GNF-5	10 mg	≥95%	An allosteric inhibitor of Bcr-Abl (IC50 = 0.121 μM); inhibits the Bcr-Abl mutants Bcr-AblG250E, Bcr-AblE255V, and Bcr-AblM351T (IC50s = 4.52, 0.38, and 0.93 μM, respectively); reduces viral titers in IBV-infected Vero cells at 10 μM; increases survival in a recalcitrant mutant Bcr-AblT315I mouse bone marrow transplantation model at 75 mg/kg
16254	GNF-5	25 mg	≥95%	An allosteric inhibitor of Bcr-Abl (IC50 = 0.121 μM); inhibits the Bcr-Abl mutants Bcr-AblG250E, Bcr-AblE255V, and Bcr-AblM351T (IC50s = 4.52, 0.38, and 0.93 μM, respectively); reduces viral titers in IBV-infected Vero cells at 10 μM; increases survival in a recalcitrant mutant Bcr-AblT315I mouse bone marrow transplantation model at 75 mg/kg
16254	GNF-5	5 mg	≥95%	An allosteric inhibitor of Bcr-Abl (IC50 = 0.121 μM); inhibits the Bcr-Abl mutants Bcr-AblG250E, Bcr-AblE255V, and Bcr-AblM351T (IC50s = 4.52, 0.38, and 0.93 μM, respectively); reduces viral titers in IBV-infected Vero cells at 10 μM; increases survival in a recalcitrant mutant Bcr-AblT315I mouse bone marrow transplantation model at 75 mg/kg
16254	GNF-5	50 mg	≥95%	An allosteric inhibitor of Bcr-Abl (IC50 = 0.121 μM); inhibits the Bcr-Abl mutants Bcr-AblG250E, Bcr-AblE255V, and Bcr-AblM351T (IC50s = 4.52, 0.38, and 0.93 μM, respectively); reduces viral titers in IBV-infected Vero cells at 10 μM; increases survival in a recalcitrant mutant Bcr-AblT315I mouse bone marrow transplantation model at 75 mg/kg
16255	GW 788388	1 mg	≥98%	A selective inhibitor of TGF-β type 1 receptor (TGFBR1 or ALK5; IC50 = 18 nM); inhibits the expression of collagen type I in cells (IC50 = 93 nM) and in mice when given orally at 10 mg/kg once a day; reduces typical features of fibrosis
16255	GW 788388	10 mg	≥98%	A selective inhibitor of TGF-β type 1 receptor (TGFBR1 or ALK5; IC50 = 18 nM); inhibits the expression of collagen type I in cells (IC50 = 93 nM) and in mice when given orally at 10 mg/kg once a day; reduces typical features of fibrosis
16255	GW 788388	25 mg	≥98%	A selective inhibitor of TGF-β type 1 receptor (TGFBR1 or ALK5; IC50 = 18 nM); inhibits the expression of collagen type I in cells (IC50 = 93 nM) and in mice when given orally at 10 mg/kg once a day; reduces typical features of fibrosis
16255	GW 788388	5 mg	≥98%	A selective inhibitor of TGF-β type 1 receptor (TGFBR1 or ALK5; IC50 = 18 nM); inhibits the expression of collagen type I in cells (IC50 = 93 nM) and in mice when given orally at 10 mg/kg once a day; reduces typical features of fibrosis
16273	PD 0332991 (hydroch	1 mg	≥95%	An orally active, selective inhibitor of Cdk4 (IC50 = 11 nM) and Cdk6 (IC50 = 16 nM) with antiproliferative activity against retinoblastoma-positive tumor cells, blocking retinoblastoma phosphorylation and inducing G1 arrest; used to demonstrate a role for insulin-activated cyclin D1-Cdk4 signaling in the control of glucose metabolism
16273	PD 0332991 (hydroch	10 mg	≥95%	An orally active, selective inhibitor of Cdk4 (IC50 = 11 nM) and Cdk6 (IC50 = 16 nM) with antiproliferative activity against retinoblastoma-positive tumor cells, blocking retinoblastoma phosphorylation and inducing G1 arrest; used to demonstrate a role for insulin-activated cyclin D1-Cdk4 signaling in the control of glucose metabolism
16273	PD 0332991 (hydroch	25 mg	≥95%	An orally active, selective inhibitor of Cdk4 (IC50 = 11 nM) and Cdk6 (IC50 = 16 nM) with antiproliferative activity against retinoblastoma-positive tumor cells, blocking retinoblastoma phosphorylation and inducing G1 arrest; used to demonstrate a role for insulin-activated cyclin D1-Cdk4 signaling in the control of glucose metabolism
16273	PD 0332991 (hydroch	5 mg	≥95%	An orally active, selective inhibitor of Cdk4 (IC50 = 11 nM) and Cdk6 (IC50 = 16 nM) with antiproliferative activity against retinoblastoma-positive tumor cells, blocking retinoblastoma phosphorylation and inducing G1 arrest; used to demonstrate a role for insulin-activated cyclin D1-Cdk4 signaling in the control of glucose metabolism
16274	Ibrutinib	1 mg	≥98%	An irreversible inhibitor of BTK (IC50 = 0.5 nM) that selectively blocks B cell activation, promoting apoptosis and preventing homing to the protective tumor microenvironment, at concentrations that do not affect T cell receptor signaling (1,000-fold more potent); studied clinically for the treatment of diseases associated with B cell antigen receptor signaling, including MCL, CLL, and non-Hodgkin
16274	Ibrutinib	10 mg	≥98%	An irreversible inhibitor of BTK (IC50 = 0.5 nM) that selectively blocks B cell activation, promoting apoptosis and preventing homing to the protective tumor microenvironment, at concentrations that do not affect T cell receptor signaling (1,000-fold more potent); studied clinically for the treatment of diseases associated with B cell antigen receptor signaling, including MCL, CLL, and non-Hodgkin
16274	Ibrutinib	5 mg	≥98%	An irreversible inhibitor of BTK (IC50 = 0.5 nM) that selectively blocks B cell activation, promoting apoptosis and preventing homing to the protective tumor microenvironment, at concentrations that do not affect T cell receptor signaling (1,000-fold more potent); studied clinically for the treatment of diseases associated with B cell antigen receptor signaling, including MCL, CLL, and non-Hodgkin

16274	Ibrutinib	50 mg	≥98%	An irreversible inhibitor of BTK (IC50 = 0.5 nM) that selectively blocks B cell activation, promoting apoptosis and preventing homing to the protective tumor microenvironment, at concentrations that do not affect T cell receptor signaling (1,000-fold more potent); studied clinically for the treatment of diseases associated with B cell antigen receptor signaling, including MCL, CLL, and non-Hodgkin
16278	RKI-1447	10 mg	≥98%	A ROCK1 and 2 inhibitor (IC50s = 14.5 and 6.2 nM, respectively) that functions by binding to the ATP binding site of the kinase; suppresses the activation of ROCK substrates MLC-2 and the MLC phosphatase PP1 regulatory subunit MYPT1 at 100 nM in cancer cells
16278	RKI-1447	5 mg	≥98%	A ROCK1 and 2 inhibitor (IC50s = 14.5 and 6.2 nM, respectively) that functions by binding to the ATP binding site of the kinase; suppresses the activation of ROCK substrates MLC-2 and the MLC phosphatase PP1 regulatory subunit MYPT1 at 100 nM in cancer cells
16278	RKI-1447	50 mg	≥98%	A ROCK1 and 2 inhibitor (IC50s = 14.5 and 6.2 nM, respectively) that functions by binding to the ATP binding site of the kinase; suppresses the activation of ROCK substrates MLC-2 and the MLC phosphatase PP1 regulatory subunit MYPT1 at 100 nM in cancer cells
16281	SB-525334	1 mg	≥98%	A potent inhibitor of the TGF-β receptor 1 (TGF-β R1, ALK5) kinase (IC50 = 14.36 nM); blocks TGF-β1-induced phosphorylation and nuclear translocation of SMAD2/3 as well as TGF-β1-directed gene expression; effective in vivo, preventing the development of fibrosis in animals
16281	SB-525334	10 mg	≥98%	A potent inhibitor of the TGF-β receptor 1 (TGF-β R1, ALK5) kinase (IC50 = 14.36 nM); blocks TGF-β1-induced phosphorylation and nuclear translocation of SMAD2/3 as well as TGF-β1-directed gene expression; effective in vivo, preventing the development of fibrosis in animals
16281	SB-525334	5 mg	≥98%	A potent inhibitor of the TGF-β receptor 1 (TGF-β R1, ALK5) kinase (IC50 = 14.36 nM); blocks TGF-β1-induced phosphorylation and nuclear translocation of SMAD2/3 as well as TGF-β1-directed gene expression; effective in vivo, preventing the development of fibrosis in animals
16281	SB-525334	50 mg	≥98%	A potent inhibitor of the TGF-β receptor 1 (TGF-β R1, ALK5) kinase (IC50 = 14.36 nM); blocks TGF-β1-induced phosphorylation and nuclear translocation of SMAD2/3 as well as TGF-β1-directed gene expression; effective in vivo, preventing the development of fibrosis in animals
16284	SRPIN340	1 mg	≥95%	An inhibitor of SRPK1 (Ki = 0.89 μM); suppresses the propagation of viruses in mammalian cells; modulates alternative splicing of VEGF, reducing neovascularization both in cells and in animals
16284	SRPIN340	10 mg	≥95%	An inhibitor of SRPK1 (Ki = 0.89 μM); suppresses the propagation of viruses in mammalian cells; modulates alternative splicing of VEGF, reducing neovascularization both in cells and in animals
16284	SRPIN340	25 mg	≥95%	An inhibitor of SRPK1 (Ki = 0.89 μM); suppresses the propagation of viruses in mammalian cells; modulates alternative splicing of VEGF, reducing neovascularization both in cells and in animals
16284	SRPIN340	5 mg	≥95%	An inhibitor of SRPK1 (Ki = 0.89 μM); suppresses the propagation of viruses in mammalian cells; modulates alternative splicing of VEGF, reducing neovascularization both in cells and in animals
16285	TAK-632	1 mg	≥98%	A selective slow off-rate inhibitor of Raf kinases (IC50s = 8.3, 2.4, and 1.4 nM for wild type B-Raf, mutant B-RafV600E, and c-Raf, respectively); shows significant antiproliferative activity against mutated BRAF or mutated NRAS cancer cell lines and xenograft models
16285	TAK-632	10 mg	≥98%	A selective slow off-rate inhibitor of Raf kinases (IC50s = 8.3, 2.4, and 1.4 nM for wild type B-Raf, mutant B-RafV600E, and c-Raf, respectively); shows significant antiproliferative activity against mutated BRAF or mutated NRAS cancer cell lines and xenograft models
16285	TAK-632	5 mg	≥98%	A selective slow off-rate inhibitor of Raf kinases (IC50s = 8.3, 2.4, and 1.4 nM for wild type B-Raf, mutant B-RafV600E, and c-Raf, respectively); shows significant antiproliferative activity against mutated BRAF or mutated NRAS cancer cell lines and xenograft models
16285	TAK-632	50 mg	≥98%	A selective slow off-rate inhibitor of Raf kinases (IC50s = 8.3, 2.4, and 1.4 nM for wild type B-Raf, mutant B-RafV600E, and c-Raf, respectively); shows significant antiproliferative activity against mutated BRAF or mutated NRAS cancer cell lines and xenograft models
16286	TCS PIM-1 1	10 mg	≥98%	An ATP-competitive Pim-1 kinase inhibitor (IC50 = 50 nM) that displays selectivity over the related kinases, Pim-2 and MEK1/2 (IC50s = >20 μM)
16286	TCS PIM-1 1	100 mg	≥98%	An ATP-competitive Pim-1 kinase inhibitor (IC50 = 50 nM) that displays selectivity over the related kinases, Pim-2 and MEK1/2 (IC50s = >20 μM)
16286	TCS PIM-1 1	5 mg	≥98%	An ATP-competitive Pim-1 kinase inhibitor (IC50 = 50 nM) that displays selectivity over the related kinases, Pim-2 and MEK1/2 (IC50s = >20 μM)
16286	TCS PIM-1 1	50 mg	≥98%	An ATP-competitive Pim-1 kinase inhibitor (IC50 = 50 nM) that displays selectivity over the related kinases, Pim-2 and MEK1/2 (IC50s = >20 μM)
16287	TDZD-8	10 mg	≥98%	A non-ATP competitive inhibitor of GSK3β (IC50 = 2 μM) that binds to the active site of GSK3β; used to study the role of GSK-3β during stem cell differentiation as well as in cell and animal models of Alzheimer's disease and other neurodegenerative disorders
16287	TDZD-8	25 mg	≥98%	A non-ATP competitive inhibitor of GSK3β (IC50 = 2 μM) that binds to the active site of GSK3β; used to study the role of GSK-3β during stem cell differentiation as well as in cell and animal models of Alzheimer's disease and other neurodegenerative disorders
16287	TDZD-8	5 mg	≥98%	A non-ATP competitive inhibitor of GSK3β (IC50 = 2 μM) that binds to the active site of GSK3β; used to study the role of GSK-3β during stem cell differentiation as well as in cell and animal models of Alzheimer's disease and other neurodegenerative disorders

16289	TG101348	1 mg	≥98%	A JAK2 inhibitor (IC50 = 3 nM for wild-type and JAK2V617F enzymes); is 35-, 334-, and 135-fold selective for JAK2 over JAK1, JAK3, and TYK2, respectively; selective for JAK2 over a panel of 34 kinases at 500 nM; inhibits FLT3 and RET (IC50s = 15 and 48 nM, respectively); reduces the proliferation of HEL cells as well as Ba/F3 murine cells expressing JAK2V617F (IC50s = 305 and 270 nM, respectively); inhibits the differentiation of hematopoietic stem cells and myeloid progenitor cells isolated from patients with polycythemia vera at 300 nM; improves survival and reduces spleen weight in a syngeneic mouse model of polycythemia vera induced by transplantation of Jak2V617F-expressing whole bone marrow at 60 and 120 mg/kg
16289	TG101348	10 mg	≥98%	A JAK2 inhibitor (IC50 = 3 nM for wild-type and JAK2V617F enzymes); is 35-, 334-, and 135-fold selective for JAK2 over JAK1, JAK3, and TYK2, respectively; selective for JAK2 over a panel of 34 kinases at 500 nM; inhibits FLT3 and RET (IC50s = 15 and 48 nM, respectively); reduces the proliferation of HEL cells as well as Ba/F3 murine cells expressing JAK2V617F (IC50s = 305 and 270 nM, respectively); inhibits the differentiation of hematopoietic stem cells and myeloid progenitor cells isolated from patients with polycythemia vera at 300 nM; improves survival and reduces spleen weight in a syngeneic mouse model of polycythemia vera induced by transplantation of Jak2V617F-expressing whole bone marrow at 60 and 120 mg/kg
16289	TG101348	25 mg	≥98%	A JAK2 inhibitor (IC50 = 3 nM for wild-type and JAK2V617F enzymes); is 35-, 334-, and 135-fold selective for JAK2 over JAK1, JAK3, and TYK2, respectively; selective for JAK2 over a panel of 34 kinases at 500 nM; inhibits FLT3 and RET (IC50s = 15 and 48 nM, respectively); reduces the proliferation of HEL cells as well as Ba/F3 murine cells expressing JAK2V617F (IC50s = 305 and 270 nM, respectively); inhibits the differentiation of hematopoietic stem cells and myeloid progenitor cells isolated from patients with polycythemia vera at 300 nM; improves survival and reduces spleen weight in a syngeneic mouse model of polycythemia vera induced by transplantation of Jak2V617F-expressing whole bone marrow at 60 and 120 mg/kg
16289	TG101348	5 mg	≥98%	A JAK2 inhibitor (IC50 = 3 nM for wild-type and JAK2V617F enzymes); is 35-, 334-, and 135-fold selective for JAK2 over JAK1, JAK3, and TYK2, respectively; selective for JAK2 over a panel of 34 kinases at 500 nM; inhibits FLT3 and RET (IC50s = 15 and 48 nM, respectively); reduces the proliferation of HEL cells as well as Ba/F3 murine cells expressing JAK2V617F (IC50s = 305 and 270 nM, respectively); inhibits the differentiation of hematopoietic stem cells and myeloid progenitor cells isolated from patients with polycythemia vera at 300 nM; improves survival and reduces spleen weight in a syngeneic mouse model of polycythemia vera induced by transplantation of Jak2V617F-expressing whole bone marrow at 60 and 120 mg/kg
16292	Trametinib	100 mg	≥95%	An inhibitor of MEK1 and -2; inhibits B-RAF- and C-RAF-induced phosphorylation of MEK1 (IC50s = 3.4 and 1.8 nM, respectively) and MEK2 (IC50s = 1.6 and 0.92 nM, respectively); inhibits the growth of two human colorectal cancer cell lines expressing mutant B-RAF (IC50s = 0.48 and 0.52 nM) and seven cell lines expressing mutant K-Ras (IC50s = 2.2-174 nM) but does not inhibit the growth of wild-type COLO 320DM cells expressing both B-RAF and K-Ras (IC50 = >10,000 nM); reduces tumor growth in HT-29 and COLO 205 mouse xenograft models at 0.3 and 1 mg/kg per day; decreases M. tuberculosis-induced increases in hind paw volume in a rat model of arthritis at 0.03 and 0.1 mg/kg per day
16292	Trametinib	25 mg	≥95%	An inhibitor of MEK1 and -2; inhibits B-RAF- and C-RAF-induced phosphorylation of MEK1 (IC50s = 3.4 and 1.8 nM, respectively) and MEK2 (IC50s = 1.6 and 0.92 nM, respectively); inhibits the growth of two human colorectal cancer cell lines expressing mutant B-RAF (IC50s = 0.48 and 0.52 nM) and seven cell lines expressing mutant K-Ras (IC50s = 2.2-174 nM) but does not inhibit the growth of wild-type COLO 320DM cells expressing both B-RAF and K-Ras (IC50 = >10,000 nM); reduces tumor growth in HT-29 and COLO 205 mouse xenograft models at 0.3 and 1 mg/kg per day; decreases M. tuberculosis-induced increases in hind paw volume in a rat model of arthritis at 0.03 and 0.1 mg/kg per day
16292	Trametinib	250 mg	≥95%	An inhibitor of MEK1 and -2; inhibits B-RAF- and C-RAF-induced phosphorylation of MEK1 (IC50s = 3.4 and 1.8 nM, respectively) and MEK2 (IC50s = 1.6 and 0.92 nM, respectively); inhibits the growth of two human colorectal cancer cell lines expressing mutant B-RAF (IC50s = 0.48 and 0.52 nM) and seven cell lines expressing mutant K-Ras (IC50s = 2.2-174 nM) but does not inhibit the growth of wild-type COLO 320DM cells expressing both B-RAF and K-Ras (IC50 = >10,000 nM); reduces tumor growth in HT-29 and COLO 205 mouse xenograft models at 0.3 and 1 mg/kg per day; decreases M. tuberculosis-induced increases in hind paw volume in a rat model of arthritis at 0.03 and 0.1 mg/kg per day

16292	Trametinib	50 mg	≥95%	An inhibitor of MEK1 and -2; inhibits B-RAF- and C-RAF-induced phosphorylation of MEK1 (IC50s = 3.4 and 1.8 nM, respectively) and MEK2 (IC50s = 1.6 and 0.92 nM, respectively); inhibits the growth of two human colorectal cancer cell lines expressing mutant B-RAF (IC50s = 0.48 and 0.52 nM) and seven cell lines expressing mutant K-Ras (IC50s = 2.2-174 nM) but does not inhibit the growth of wild-type COLO 320DM cells expressing both B-RAF and K-Ras (IC50 = >10,000 nM); reduces tumor growth in HT-29 and COLO 205 mouse xenograft models at 0.3 and 1 mg/kg per day; decreases M. tuberculosis-induced increases in hind paw volume in a rat model of arthritis at 0.03 and 0.1 mg/kg per day
16294	VS-5584	1 mg	≥98%	A purine analog that inhibits mTOR (IC50 = 37 nM) and PI3K (IC50s = 16, 68, 25, and 42 nM for the α, β, γ, and δ isoforms, respectively); demonstrates broad anti-proliferative sensitivity leading to tumor growth inhibition in human tumor models
16294	VS-5584	10 mg	≥98%	A purine analog that inhibits mTOR (IC50 = 37 nM) and PI3K (IC50s = 16, 68, 25, and 42 nM for the α, β, γ, and δ isoforms, respectively); demonstrates broad anti-proliferative sensitivity leading to tumor growth inhibition in human tumor models
16294	VS-5584	5 mg	≥98%	A purine analog that inhibits mTOR (IC50 = 37 nM) and PI3K (IC50s = 16, 68, 25, and 42 nM for the α, β, γ, and δ isoforms, respectively); demonstrates broad anti-proliferative sensitivity leading to tumor growth inhibition in human tumor models
16297	WZ4002	10 mg	≥98%	An irreversible EGFR tyrosine kinase inhibitor that blocks ATP-dependent autophosphorylation of EGFR carrying the T790M mutation as well as an L858R mutation (IC50 = 8 nM); effective in mouse models of lung cancer driven by EGFRT790M
16297	WZ4002	100 mg	≥98%	An irreversible EGFR tyrosine kinase inhibitor that blocks ATP-dependent autophosphorylation of EGFR carrying the T790M mutation as well as an L858R mutation (IC50 = 8 nM); effective in mouse models of lung cancer driven by EGFRT790M
16297	WZ4002	5 mg	≥98%	An irreversible EGFR tyrosine kinase inhibitor that blocks ATP-dependent autophosphorylation of EGFR carrying the T790M mutation as well as an L858R mutation (IC50 = 8 nM); effective in mouse models of lung cancer driven by EGFRT790M
16297	WZ4002	50 mg	≥98%	An irreversible EGFR tyrosine kinase inhibitor that blocks ATP-dependent autophosphorylation of EGFR carrying the T790M mutation as well as an L858R mutation (IC50 = 8 nM); effective in mouse models of lung cancer driven by EGFRT790M
16298	XL019	1 mg	≥90%	A potent, bioavailable JAK inhibitor with preference for JAK2 (IC50 = 2 nM) over JAK1 and JAK3 (IC50s = 130 and 250 nM, respectively); effective against JAK2V617F as well as JAK2 and inhibits phosphorylation of STAT5 in vivo
16298	XL019	10 mg	≥90%	A potent, bioavailable JAK inhibitor with preference for JAK2 (IC50 = 2 nM) over JAK1 and JAK3 (IC50s = 130 and 250 nM, respectively); effective against JAK2V617F as well as JAK2 and inhibits phosphorylation of STAT5 in vivo
16298	XL019	25 mg	≥90%	A potent, bioavailable JAK inhibitor with preference for JAK2 (IC50 = 2 nM) over JAK1 and JAK3 (IC50s = 130 and 250 nM, respectively); effective against JAK2V617F as well as JAK2 and inhibits phosphorylation of STAT5 in vivo
16298	XL019	5 mg	≥90%	A potent, bioavailable JAK inhibitor with preference for JAK2 (IC50 = 2 nM) over JAK1 and JAK3 (IC50s = 130 and 250 nM, respectively); effective against JAK2V617F as well as JAK2 and inhibits phosphorylation of STAT5 in vivo
16329	BIO-Acetoxime	1 mg	≥95%	A potent inhibitor of GSK3α/β (IC50 = 10 nM), with selectivity over Cdk5/p25, Cdk2/A, and Cdk1/B (IC50s = 2.4, 4.3, and 63 μM, respectively); suppresses the cytopathic effects of herpes viruses and reduces viral yields in human oral epithelial cells
16329	BIO-Acetoxime	10 mg	≥95%	A potent inhibitor of GSK3α/β (IC50 = 10 nM), with selectivity over Cdk5/p25, Cdk2/A, and Cdk1/B (IC50s = 2.4, 4.3, and 63 μM, respectively); suppresses the cytopathic effects of herpes viruses and reduces viral yields in human oral epithelial cells
16329	BIO-Acetoxime	5 mg	≥95%	A potent inhibitor of GSK3α/β (IC50 = 10 nM), with selectivity over Cdk5/p25, Cdk2/A, and Cdk1/B (IC50s = 2.4, 4.3, and 63 μM, respectively); suppresses the cytopathic effects of herpes viruses and reduces viral yields in human oral epithelial cells
16336	Ku-55933	1 mg	≥98%	A potent ATP-competitive inhibitor of ATM kinase (IC50 = 13 nM; Ki = 2.2 nM); sensitizes cells to both ionizing radiation and chemotherapeutic agents; induces senescent breast, lung, and colon carcinoma cells to undergo cell death; inhibits HIV-1 replication in C8166 human T-lymphocyte cells (IC50 = 2.4 μM)
16336	Ku-55933	10 mg	≥98%	A potent ATP-competitive inhibitor of ATM kinase (IC50 = 13 nM; Ki = 2.2 nM); sensitizes cells to both ionizing radiation and chemotherapeutic agents; induces senescent breast, lung, and colon carcinoma cells to undergo cell death; inhibits HIV-1 replication in C8166 human T-lymphocyte cells (IC50 = 2.4 μM)
16336	Ku-55933	5 mg	≥98%	A potent ATP-competitive inhibitor of ATM kinase (IC50 = 13 nM; Ki = 2.2 nM); sensitizes cells to both ionizing radiation and chemotherapeutic agents; induces senescent breast, lung, and colon carcinoma cells to undergo cell death; inhibits HIV-1 replication in C8166 human T-lymphocyte cells (IC50 = 2.4 μM)

16336	Ku-55933	50 mg	≥98%	A potent ATP-competitive inhibitor of ATM kinase (IC50 = 13 nM; Ki = 2.2 nM); sensitizes cells to both ionizing radiation and chemotherapeutic agents; induces senescent breast, lung, and colon carcinoma cells to undergo cell death; inhibits HIV-1 replication in C8166 human T-lymphocyte cells (IC50 = 2.4 μM)
16351	AAL-993	1 mg	≥95%	A potent inhibitor of VEGF receptors, inhibiting VEGFR1, 2, and 3 with IC50 values of 130, 23, and 18 nM, respectively; orally bioavailable in vivo, blocking VEGF-induced angiogenesis and preventing the growth of primary tumors and spontaneous peripheral metastases in mice
16351	AAL-993	5 mg	≥95%	A potent inhibitor of VEGF receptors, inhibiting VEGFR1, 2, and 3 with IC50 values of 130, 23, and 18 nM, respectively; orally bioavailable in vivo, blocking VEGF-induced angiogenesis and preventing the growth of primary tumors and spontaneous peripheral metastases in mice
16354	SU 1498	1 mg	≥98%	A selective inhibitor of VEGFR2 (aka FLK1; IC50 = 700 nM), having negligible activity at several other serine/threonine and tyrosine kinases; effectively blocks signaling through VEGFR2 both in vitro and in vivo
16354	SU 1498	5 mg	≥98%	A selective inhibitor of VEGFR2 (aka FLK1; IC50 = 700 nM), having negligible activity at several other serine/threonine and tyrosine kinases; effectively blocks signaling through VEGFR2 both in vitro and in vivo
16354	SU 1498	500 µg	≥98%	A selective inhibitor of VEGFR2 (aka FLK1; IC50 = 700 nM), having negligible activity at several other serine/threonine and tyrosine kinases; effectively blocks signaling through VEGFR2 both in vitro and in vivo
16401	UNC3230	1 mg	≥95%	A selective, small molecule inhibitor of PIP5K1C (IC50 = 41 nM, Kd = 51 nM); decreases PIP2 membrane levels in cultured DRG neurons by 45%, significantly reducing calcium signaling; displays antinociceptive effects in mouse models of chronic pain
16401	UNC3230	10 mg	≥95%	A selective, small molecule inhibitor of PIP5K1C (IC50 = 41 nM, Kd = 51 nM); decreases PIP2 membrane levels in cultured DRG neurons by 45%, significantly reducing calcium signaling; displays antinociceptive effects in mouse models of chronic pain
16401	UNC3230	5 mg	≥95%	A selective, small molecule inhibitor of PIP5K1C (IC50 = 41 nM, Kd = 51 nM); decreases PIP2 membrane levels in cultured DRG neurons by 45%, significantly reducing calcium signaling; displays antinociceptive effects in mouse models of chronic pain
16401	UNC3230	50 mg	≥95%	A selective, small molecule inhibitor of PIP5K1C (IC50 = 41 nM, Kd = 51 nM); decreases PIP2 membrane levels in cultured DRG neurons by 45%, significantly reducing calcium signaling; displays antinociceptive effects in mouse models of chronic pain
16423	SGI-1776	1 mg	≥98%	A potent inhibitor of all three human Pim kinases (IC50s = 7, 363, and 69 nM for Pim-1, Pim-2, and Pim-3, respectively); induces apoptosis in lymphocytes from patients with CML or ALL; enhances the activity of sunitinib against renal cell carcinoma and resensitizes chemoresistant cancer cells to taxanes
16423	SGI-1776	10 mg	≥98%	A potent inhibitor of all three human Pim kinases (IC50s = 7, 363, and 69 nM for Pim-1, Pim-2, and Pim-3, respectively); induces apoptosis in lymphocytes from patients with CML or ALL; enhances the activity of sunitinib against renal cell carcinoma and resensitizes chemoresistant cancer cells to taxanes
16423	SGI-1776	5 mg	≥98%	A potent inhibitor of all three human Pim kinases (IC50s = 7, 363, and 69 nM for Pim-1, Pim-2, and Pim-3, respectively); induces apoptosis in lymphocytes from patients with CML or ALL; enhances the activity of sunitinib against renal cell carcinoma and resensitizes chemoresistant cancer cells to taxanes
16423	SGI-1776	50 mg	≥98%	A potent inhibitor of all three human Pim kinases (IC50s = 7, 363, and 69 nM for Pim-1, Pim-2, and Pim-3, respectively); induces apoptosis in lymphocytes from patients with CML or ALL; enhances the activity of sunitinib against renal cell carcinoma and resensitizes chemoresistant cancer cells to taxanes
16426	CUDC-101	10 mg	≥98%	A multi-target inhibitor that potently blocks EGFR and HER2 (IC50s = 2.4 and 16.4 nM, respectively) and inhibits the activity of class I and class II HDACs at nanomolar concentrations (e.g., IC50s = 4.5, 12.6, 13.2, and 11.4 nM for HDAC1, 2, 4, and 5, respectively)
16426	CUDC-101	25 mg	≥98%	A multi-target inhibitor that potently blocks EGFR and HER2 (IC50s = 2.4 and 16.4 nM, respectively) and inhibits the activity of class I and class II HDACs at nanomolar concentrations (e.g., IC50s = 4.5, 12.6, 13.2, and 11.4 nM for HDAC1, 2, 4, and 5, respectively)
16426	CUDC-101	5 mg	≥98%	A multi-target inhibitor that potently blocks EGFR and HER2 (IC50s = 2.4 and 16.4 nM, respectively) and inhibits the activity of class I and class II HDACs at nanomolar concentrations (e.g., IC50s = 4.5, 12.6, 13.2, and 11.4 nM for HDAC1, 2, 4, and 5, respectively)
16426	CUDC-101	50 mg	≥98%	A multi-target inhibitor that potently blocks EGFR and HER2 (IC50s = 2.4 and 16.4 nM, respectively) and inhibits the activity of class I and class II HDACs at nanomolar concentrations (e.g., IC50s = 4.5, 12.6, 13.2, and 11.4 nM for HDAC1, 2, 4, and 5, respectively)
16487	Hemin chloride	1 g	≥96%	An oxidized form of heme that inhibits eIF2αK1, a repressor of eIF-2α; used experimentally to induce the expression of heme oxygenase-1 in cells and in animals

16487	Hemin chloride	10 g	≥96%	An oxidized form of heme that inhibits eIF2αK1, a repressor of eIF-2α; used experimentally to induce the expression of heme oxygenase-1 in cells and in animals
16487	Hemin chloride	25 g	≥96%	An oxidized form of heme that inhibits eIF2αK1, a repressor of eIF-2α; used experimentally to induce the expression of heme oxygenase-1 in cells and in animals
16487	Hemin chloride	5 g	≥96%	An oxidized form of heme that inhibits eIF2αK1, a repressor of eIF-2α; used experimentally to induce the expression of heme oxygenase-1 in cells and in animals
16499	A-443654	1 mg	≥98%	A pan Akt inhibitor (Ki = 160 pmol/L for all three isoforms) that interferes with mitotic progression and bipolar spindle formation; slows the progression of Akt-dependent tumors in vivo; concomitantly increases Akt Thr308 and Ser473 phosphorylation via a rapid feedback reaction
16499	A-443654	5 mg	≥98%	A pan Akt inhibitor (Ki = 160 pmol/L for all three isoforms) that interferes with mitotic progression and bipolar spindle formation; slows the progression of Akt-dependent tumors in vivo; concomitantly increases Akt Thr308 and Ser473 phosphorylation via a rapid feedback reaction
16499	A-443654	500 µg	≥98%	A pan Akt inhibitor (Ki = 160 pmol/L for all three isoforms) that interferes with mitotic progression and bipolar spindle formation; slows the progression of Akt-dependent tumors in vivo; concomitantly increases Akt Thr308 and Ser473 phosphorylation via a rapid feedback reaction
16548	D-Mannoheptulose	10 mg	≥98%	A heptose that inhibits glucokinases and hexokinases from diverse organisms through competition with D-glucose (Ki = 0.25 mM); blocks glucose oxidation and glucose-mediated insulin release from pancreatic islet cells
16548	D-Mannoheptulose	25 mg	≥98%	A heptose that inhibits glucokinases and hexokinases from diverse organisms through competition with D-glucose (Ki = 0.25 mM); blocks glucose oxidation and glucose-mediated insulin release from pancreatic islet cells
16548	D-Mannoheptulose	5 mg	≥98%	A heptose that inhibits glucokinases and hexokinases from diverse organisms through competition with D-glucose (Ki = 0.25 mM); blocks glucose oxidation and glucose-mediated insulin release from pancreatic islet cells
16548	D-Mannoheptulose	50 mg	≥98%	A heptose that inhibits glucokinases and hexokinases from diverse organisms through competition with D-glucose (Ki = 0.25 mM); blocks glucose oxidation and glucose-mediated insulin release from pancreatic islet cells
16553	CHIR124	1 mg	≥95%	A selective, cell-permeable, quinolone-based inhibitor of Chk1 (IC50 = 0.3 nM versus 0.7 µM for Chk1 and Chk2, respectively); inhibits p53-mutant solid tumor cell growth in synergy with topoisomerase I poisons or ionizing radiation, potentiating tumor apoptosis
16553	CHIR124	10 mg	≥95%	A selective, cell-permeable, quinolone-based inhibitor of Chk1 (IC50 = 0.3 nM versus 0.7 µM for Chk1 and Chk2, respectively); inhibits p53-mutant solid tumor cell growth in synergy with topoisomerase I poisons or ionizing radiation, potentiating tumor apoptosis
16553	CHIR124	25 mg	≥95%	A selective, cell-permeable, quinolone-based inhibitor of Chk1 (IC50 = 0.3 nM versus 0.7 µM for Chk1 and Chk2, respectively); inhibits p53-mutant solid tumor cell growth in synergy with topoisomerase I poisons or ionizing radiation, potentiating tumor apoptosis
16553	CHIR124	5 mg	≥95%	A selective, cell-permeable, quinolone-based inhibitor of Chk1 (IC50 = 0.3 nM versus 0.7 µM for Chk1 and Chk2, respectively); inhibits p53-mutant solid tumor cell growth in synergy with topoisomerase I poisons or ionizing radiation, potentiating tumor apoptosis
16613	UNC2025	10 mg	≥98%	A potent, orally bioavailable inhibitor of the tyrosine kinases Mer and Flt3 (IC50s = 0.74 and 0.80 nM, respectively); blocks colony formation of Mer- and Flt3-dependent tumor cell lines and inhibits Mer phosphorylation in bone marrow leukemia cells in vivo
16613	UNC2025	25 mg	≥98%	A potent, orally bioavailable inhibitor of the tyrosine kinases Mer and Flt3 (IC50s = 0.74 and 0.80 nM, respectively); blocks colony formation of Mer- and Flt3-dependent tumor cell lines and inhibits Mer phosphorylation in bone marrow leukemia cells in vivo
16613	UNC2025	5 mg	≥98%	A potent, orally bioavailable inhibitor of the tyrosine kinases Mer and Flt3 (IC50s = 0.74 and 0.80 nM, respectively); blocks colony formation of Mer- and Flt3-dependent tumor cell lines and inhibits Mer phosphorylation in bone marrow leukemia cells in vivo
16613	UNC2025	50 mg	≥98%	A potent, orally bioavailable inhibitor of the tyrosine kinases Mer and Flt3 (IC50s = 0.74 and 0.80 nM, respectively); blocks colony formation of Mer- and Flt3-dependent tumor cell lines and inhibits Mer phosphorylation in bone marrow leukemia cells in vivo
16619	SD 208	1 mg	≥98%	A potent inhibitor of TGF-βRI kinase (EC50 = 48 nM) that has minimal or no effect at a variety of other kinases; blocks both autocrine and paracrine TGF-β signaling in glioma cells; is orally bioavailable and prevents TGF-β-induced Smad phosphorylation in spleens and brains of mice
16619	SD 208	10 mg	≥98%	A potent inhibitor of TGF-βRI kinase (EC50 = 48 nM) that has minimal or no effect at a variety of other kinases; blocks both autocrine and paracrine TGF-β signaling in glioma cells; is orally bioavailable and prevents TGF-β-induced Smad phosphorylation in spleens and brains of mice
16619	SD 208	25 mg	≥98%	A potent inhibitor of TGF-βRI kinase (EC50 = 48 nM) that has minimal or no effect at a variety of other kinases; blocks both autocrine and paracrine TGF-β signaling in glioma cells; is orally bioavailable and prevents TGF-β-induced Smad phosphorylation in spleens and brains of mice

16619	SD 208	5 mg	≥98%	A potent inhibitor of TGF-βRI kinase (EC50 = 48 nM) that has minimal or no effect at a variety of other kinases; blocks both autocrine and paracrine TGF-β signaling in glioma cells; is orally bioavailable and prevents TGF-β-induced Smad phosphorylation in spleens and brains of mice
16643	SB-590885	1 mg	≥98%	A potent inhibitor of B-Raf (Kd = 0.3 nM) that less effectively inhibits c-Raf (Ki = 1.72 nM) and has little effect at 46 other kinases; blocks activation of ERK1/2 and anchorage-independent cell proliferation of melanoma cells with either wild type or V600E B-Raf at nanomolar concentrations
16643	SB-590885	10 mg	≥98%	A potent inhibitor of B-Raf (Kd = 0.3 nM) that less effectively inhibits c-Raf (Ki = 1.72 nM) and has little effect at 46 other kinases; blocks activation of ERK1/2 and anchorage-independent cell proliferation of melanoma cells with either wild type or V600E B-Raf at nanomolar concentrations
16643	SB-590885	25 mg	≥98%	A potent inhibitor of B-Raf (Kd = 0.3 nM) that less effectively inhibits c-Raf (Ki = 1.72 nM) and has little effect at 46 other kinases; blocks activation of ERK1/2 and anchorage-independent cell proliferation of melanoma cells with either wild type or V600E B-Raf at nanomolar concentrations
16643	SB-590885	5 mg	≥98%	A potent inhibitor of B-Raf (Kd = 0.3 nM) that less effectively inhibits c-Raf (Ki = 1.72 nM) and has little effect at 46 other kinases; blocks activation of ERK1/2 and anchorage-independent cell proliferation of melanoma cells with either wild type or V600E B-Raf at nanomolar concentrations
16667	BMS 345541 (hydroch	1 mg	≥98%	A selective, cell permeable inhibitor of the IκB kinases IKKα and IKKβ (IC50s = 4 and 0.3 μM); inhibits signaling through NF-κB both in cells and in vivo, showing excellent pharmacokinetics in mice
16667	BMS 345541 (hydroch	10 mg	≥98%	A selective, cell permeable inhibitor of the IκB kinases IKKα and IKKβ (IC50s = 4 and 0.3 μM); inhibits signaling through NF-κB both in cells and in vivo, showing excellent pharmacokinetics in mice
16667	BMS 345541 (hydroch	25 mg	≥98%	A selective, cell permeable inhibitor of the IκB kinases IKKα and IKKβ (IC50s = 4 and 0.3 μM); inhibits signaling through NF-κB both in cells and in vivo, showing excellent pharmacokinetics in mice
16667	BMS 345541 (hydroch	5 mg	≥98%	A selective, cell permeable inhibitor of the IκB kinases IKKα and IKKβ (IC50s = 4 and 0.3 μM); inhibits signaling through NF-κB both in cells and in vivo, showing excellent pharmacokinetics in mice
16676	AZD 1080	1 mg	≥95%	A potent, selective, brain permeable inhibitor of GSK3α and GSK3β (Kis = 6.9 and 31 nM, respectively); shows good bioavailability after oral administration in vivo, inhibiting hippocampal tau phosphorylation and reversing cognitive deficits induced by the NMDA receptor antagonist (+)-MK-801
16676	AZD 1080	10 mg	≥95%	A potent, selective, brain permeable inhibitor of GSK3α and GSK3β (Kis = 6.9 and 31 nM, respectively); shows good bioavailability after oral administration in vivo, inhibiting hippocampal tau phosphorylation and reversing cognitive deficits induced by the NMDA receptor antagonist (+)-MK-801
16676	AZD 1080	25 mg	≥95%	A potent, selective, brain permeable inhibitor of GSK3α and GSK3β (Kis = 6.9 and 31 nM, respectively); shows good bioavailability after oral administration in vivo, inhibiting hippocampal tau phosphorylation and reversing cognitive deficits induced by the NMDA receptor antagonist (+)-MK-801
16676	AZD 1080	5 mg	≥95%	A potent, selective, brain permeable inhibitor of GSK3α and GSK3β (Kis = 6.9 and 31 nM, respectively); shows good bioavailability after oral administration in vivo, inhibiting hippocampal tau phosphorylation and reversing cognitive deficits induced by the NMDA receptor antagonist (+)-MK-801
16678	K02288	1 mg	≥98%	An ALK1 and ALK2 inhibitor (IC50s = 1.8 and 1.1 nM, respectively) that can prevent BMP4-induced SMAD1/5/8 pathway activation in vitro (IC50 = 100 nM) without affecting TGF-β signaling; less selective for ALK3, 4, 5, and 6 subtypes and the type II BMP receptor ActRIIA (IC50s = 34.4, 302, 321, 6.4, and 220 nM, respectively)
16678	K02288	10 mg	≥98%	An ALK1 and ALK2 inhibitor (IC50s = 1.8 and 1.1 nM, respectively) that can prevent BMP4-induced SMAD1/5/8 pathway activation in vitro (IC50 = 100 nM) without affecting TGF-β signaling; less selective for ALK3, 4, 5, and 6 subtypes and the type II BMP receptor ActRIIA (IC50s = 34.4, 302, 321, 6.4, and 220 nM, respectively)
16678	K02288	5 mg	≥98%	An ALK1 and ALK2 inhibitor (IC50s = 1.8 and 1.1 nM, respectively) that can prevent BMP4-induced SMAD1/5/8 pathway activation in vitro (IC50 = 100 nM) without affecting TGF-β signaling; less selective for ALK3, 4, 5, and 6 subtypes and the type II BMP receptor ActRIIA (IC50s = 34.4, 302, 321, 6.4, and 220 nM, respectively)
16678	K02288	50 mg	≥98%	An ALK1 and ALK2 inhibitor (IC50s = 1.8 and 1.1 nM, respectively) that can prevent BMP4-induced SMAD1/5/8 pathway activation in vitro (IC50 = 100 nM) without affecting TGF-β signaling; less selective for ALK3, 4, 5, and 6 subtypes and the type II BMP receptor ActRIIA (IC50s = 34.4, 302, 321, 6.4, and 220 nM, respectively)

16679	DMH1	1 mg	≥98%	A potent inhibitor of the kinase activity of ALK2 (IC50 = 13-108 nM); disrupts dorsoventral development in zebrafish; affects stem cell development, increasing cardiomyocyte progenitors and promoting neurogenesis; inhibits the growth of lung cancer cells, reducing tumor growth in a xenograft model
16679	DMH1	10 mg	≥98%	A potent inhibitor of the kinase activity of ALK2 (IC50 = 13-108 nM); disrupts dorsoventral development in zebrafish; affects stem cell development, increasing cardiomyocyte progenitors and promoting neurogenesis; inhibits the growth of lung cancer cells, reducing tumor growth in a xenograft model
16679	DMH1	5 mg	≥98%	A potent inhibitor of the kinase activity of ALK2 (IC50 = 13-108 nM); disrupts dorsoventral development in zebrafish; affects stem cell development, increasing cardiomyocyte progenitors and promoting neurogenesis; inhibits the growth of lung cancer cells, reducing tumor growth in a xenograft model
16679	DMH1	50 mg	≥98%	A potent inhibitor of the kinase activity of ALK2 (IC50 = 13-108 nM); disrupts dorsoventral development in zebrafish; affects stem cell development, increasing cardiomyocyte progenitors and promoting neurogenesis; inhibits the growth of lung cancer cells, reducing tumor growth in a xenograft model
16705	LY2784544	1 mg	≥98%	A potent, ATP-competitive inhibitor of JAK2 that less effectively inhibits JAK3 (IC50s = 3 and 48 nM, respectively); inhibits JAK2 containing the V617F mutation (IC50 = 20 nM); reduces the growth of Ba/F3 pro-B-cells in SCID mice without affecting erythroid progenitors, reticulocytes, or platelets
16705	LY2784544	10 mg	≥98%	A potent, ATP-competitive inhibitor of JAK2 that less effectively inhibits JAK3 (IC50s = 3 and 48 nM, respectively); inhibits JAK2 containing the V617F mutation (IC50 = 20 nM); reduces the growth of Ba/F3 pro-B-cells in SCID mice without affecting erythroid progenitors, reticulocytes, or platelets
16705	LY2784544	25 mg	≥98%	A potent, ATP-competitive inhibitor of JAK2 that less effectively inhibits JAK3 (IC50s = 3 and 48 nM, respectively); inhibits JAK2 containing the V617F mutation (IC50 = 20 nM); reduces the growth of Ba/F3 pro-B-cells in SCID mice without affecting erythroid progenitors, reticulocytes, or platelets
16705	LY2784544	5 mg	≥98%	A potent, ATP-competitive inhibitor of JAK2 that less effectively inhibits JAK3 (IC50s = 3 and 48 nM, respectively); inhibits JAK2 containing the V617F mutation (IC50 = 20 nM); reduces the growth of Ba/F3 pro-B-cells in SCID mice without affecting erythroid progenitors, reticulocytes, or platelets
16707	Baricitinib	100 mg	≥95%	A JAK1 and JAK2 inhibitor (IC50s = 0.0059 and 0.0057 μM, respectively); selective for JAK1 and JAK2 over JAK3, TYK2, c-Met, and Chk2 (IC50s = >0.4, 0.053, >10, and >1 μM, respectively); inhibits IL-6-induced phosphorylation of STAT3 in isolated human PBMCs and rat whole blood (IC50s = 0.044 and 0.128 μM, respectively); reduces disease severity in a type II collagen-induced mouse model of arthritis at 3 and 10 mg/kg; decreases lung macrophage infiltration and disease severity in rhesus monkeys infected with SARS-CoV-2 at 4 mg/animal
16707	Baricitinib	25 mg	≥95%	A JAK1 and JAK2 inhibitor (IC50s = 0.0059 and 0.0057 μM, respectively); selective for JAK1 and JAK2 over JAK3, TYK2, c-Met, and Chk2 (IC50s = >0.4, 0.053, >10, and >1 μM, respectively); inhibits IL-6-induced phosphorylation of STAT3 in isolated human PBMCs and rat whole blood (IC50s = 0.044 and 0.128 μM, respectively); reduces disease severity in a type II collagen-induced mouse model of arthritis at 3 and 10 mg/kg; decreases lung macrophage infiltration and disease severity in rhesus monkeys infected with SARS-CoV-2 at 4 mg/animal
16707	Baricitinib	250 mg	≥95%	A JAK1 and JAK2 inhibitor (IC50s = 0.0059 and 0.0057 μM, respectively); selective for JAK1 and JAK2 over JAK3, TYK2, c-Met, and Chk2 (IC50s = >0.4, 0.053, >10, and >1 μM, respectively); inhibits IL-6-induced phosphorylation of STAT3 in isolated human PBMCs and rat whole blood (IC50s = 0.044 and 0.128 μM, respectively); reduces disease severity in a type II collagen-induced mouse model of arthritis at 3 and 10 mg/kg; decreases lung macrophage infiltration and disease severity in rhesus monkeys infected with SARS-CoV-2 at 4 mg/animal
16707	Baricitinib	50 mg	≥95%	A JAK1 and JAK2 inhibitor (IC50s = 0.0059 and 0.0057 μM, respectively); selective for JAK1 and JAK2 over JAK3, TYK2, c-Met, and Chk2 (IC50s = >0.4, 0.053, >10, and >1 μM, respectively); inhibits IL-6-induced phosphorylation of STAT3 in isolated human PBMCs and rat whole blood (IC50s = 0.044 and 0.128 μM, respectively); reduces disease severity in a type II collagen-induced mouse model of arthritis at 3 and 10 mg/kg; decreases lung macrophage infiltration and disease severity in rhesus monkeys infected with SARS-CoV-2 at 4 mg/animal
16708	SR 3677	1 mg	≥95%	A potent inhibitor of ROCK2 and ROCK1 in enzyme and cell-based assays (IC50s = 3 and 56 nM, respectively); efficacious at inhibiting myosin light chain phosphorylation and increasing aqueous humor outflow in porcine eyes in an ex vivo model of glaucoma treatment

16708	SR 3677	10 mg	≥95%	A potent inhibitor of ROCK2 and ROCK1 in enzyme and cell-based assays (IC50s = 3 and 56 nM, respectively); efficacious at inhibiting myosin light chain phosphorylation and increasing aqueous humor outflow in porcine eyes in an ex vivo model of glaucoma treatment
16708	SR 3677	25 mg	≥95%	A potent inhibitor of ROCK2 and ROCK1 in enzyme and cell-based assays (IC50s = 3 and 56 nM, respectively); efficacious at inhibiting myosin light chain phosphorylation and increasing aqueous humor outflow in porcine eyes in an ex vivo model of glaucoma treatment
16708	SR 3677	5 mg	≥95%	A potent inhibitor of ROCK2 and ROCK1 in enzyme and cell-based assays (IC50s = 3 and 56 nM, respectively); efficacious at inhibiting myosin light chain phosphorylation and increasing aqueous humor outflow in porcine eyes in an ex vivo model of glaucoma treatment
16709	Pacritinib	1 mg	≥98%	An inhibitor of both FLT3 and JAK2 (IC50s = 22 and 23 nM, respectively); blocks the activities of the FLT3 D835Y mutant, FLT3 with ITDs, and JAK2 with a V617F substitution (IC50s = 6, 20-180, and 220 nM, respectively); orally bioavailable, inhibiting tumor growth and metastasis in xenografts in mice
16709	Pacritinib	5 mg	≥98%	An inhibitor of both FLT3 and JAK2 (IC50s = 22 and 23 nM, respectively); blocks the activities of the FLT3 D835Y mutant, FLT3 with ITDs, and JAK2 with a V617F substitution (IC50s = 6, 20-180, and 220 nM, respectively); orally bioavailable, inhibiting tumor growth and metastasis in xenografts in mice
16709	Pacritinib	500 µg	≥98%	An inhibitor of both FLT3 and JAK2 (IC50s = 22 and 23 nM, respectively); blocks the activities of the FLT3 D835Y mutant, FLT3 with ITDs, and JAK2 with a V617F substitution (IC50s = 6, 20-180, and 220 nM, respectively); orally bioavailable, inhibiting tumor growth and metastasis in xenografts in mice
16714	NVP-BSK805 (hydroch	1 mg	≥98%	A potent inhibitor of JAK2 that also inhibits the JAK2V617F mutant enzyme (IC50s for both enzymes ~ 0.5 nM); orally bioavailable with a long half-life in vivo, suppressing leukemic cell spreading and splenomegaly in JAK2V617F cell-driven disease in mice
16714	NVP-BSK805 (hydroch	10 mg	≥98%	A potent inhibitor of JAK2 that also inhibits the JAK2V617F mutant enzyme (IC50s for both enzymes ~ 0.5 nM); orally bioavailable with a long half-life in vivo, suppressing leukemic cell spreading and splenomegaly in JAK2V617F cell-driven disease in mice
16714	NVP-BSK805 (hydroch	5 mg	≥98%	A potent inhibitor of JAK2 that also inhibits the JAK2V617F mutant enzyme (IC50s for both enzymes ~ 0.5 nM); orally bioavailable with a long half-life in vivo, suppressing leukemic cell spreading and splenomegaly in JAK2V617F cell-driven disease in mice
16718	CZC-8004	1 mg	≥98%	An aminopyrimidine that binds a range of tyrosine kinases, including ABL, BTK, FAK, FER, JAK1, SRC, SYK, TEC, TNK1, TYK2, and YES
16718	CZC-8004	10 mg	≥98%	An aminopyrimidine that binds a range of tyrosine kinases, including ABL, BTK, FAK, FER, JAK1, SRC, SYK, TEC, TNK1, TYK2, and YES
16718	CZC-8004	5 mg	≥98%	An aminopyrimidine that binds a range of tyrosine kinases, including ABL, BTK, FAK, FER, JAK1, SRC, SYK, TEC, TNK1, TYK2, and YES
16718	CZC-8004	500 µg	≥98%	An aminopyrimidine that binds a range of tyrosine kinases, including ABL, BTK, FAK, FER, JAK1, SRC, SYK, TEC, TNK1, TYK2, and YES
16726	Sotrastaurin	1 mg	≥98%	A PKC inhibitor that displays immunosuppressive activity, blocking T cell activation through the disruption of downstream NF-κB signaling; inhibits PKCα, βI, δ, ε, η, and θ with Ki values of 0.95, 0.64, 2.1, 3.2, 1.8, and 0.22 nM, respectively; also inhibits GSK3α and GSK3β (IC50s = 229 and 172 nM, respectively), which activates Wnt/β-catenin signaling and is important for adult stem cell maintenance
16726	Sotrastaurin	10 mg	≥98%	A PKC inhibitor that displays immunosuppressive activity, blocking T cell activation through the disruption of downstream NF-κB signaling; inhibits PKCα, βI, δ, ε, η, and θ with Ki values of 0.95, 0.64, 2.1, 3.2, 1.8, and 0.22 nM, respectively; also inhibits GSK3α and GSK3β (IC50s = 229 and 172 nM, respectively), which activates Wnt/β-catenin signaling and is important for adult stem cell maintenance
16726	Sotrastaurin	5 mg	≥98%	A PKC inhibitor that displays immunosuppressive activity, blocking T cell activation through the disruption of downstream NF-κB signaling; inhibits PKCα, βI, δ, ε, η, and θ with Ki values of 0.95, 0.64, 2.1, 3.2, 1.8, and 0.22 nM, respectively; also inhibits GSK3α and GSK3β (IC50s = 229 and 172 nM, respectively), which activates Wnt/β-catenin signaling and is important for adult stem cell maintenance
16727	Tideglusib	10 mg	≥98%	A thiadiazolidinone that prevents inflammation and neurodegeneration when injected into rat hippocampus concurrently with kainic acid; irreversibly inhibits GSK3β with an IC50 value of 5 nM when used with a one hour preincubation, increasing to 0.1-1 µM without preincubation
16727	Tideglusib	25 mg	≥98%	A thiadiazolidinone that prevents inflammation and neurodegeneration when injected into rat hippocampus concurrently with kainic acid; irreversibly inhibits GSK3β with an IC50 value of 5 nM when used with a one hour preincubation, increasing to 0.1-1 µM without preincubation
16727	Tideglusib	5 mg	≥98%	A thiadiazolidinone that prevents inflammation and neurodegeneration when injected into rat hippocampus concurrently with kainic acid; irreversibly inhibits GSK3β with an IC50 value of 5 nM when used with a one hour preincubation, increasing to 0.1-1 µM without preincubation
16727	Tideglusib	50 mg	≥98%	A thiadiazolidinone that prevents inflammation and neurodegeneration when injected into rat hippocampus concurrently with kainic acid; irreversibly inhibits GSK3β with an IC50 value of 5 nM when used with a one hour preincubation, increasing to 0.1-1 µM without preincubation

16728	AZD 2858	1 mg	≥98%	A GSK3β inhibitor (Ki = 4.9 nM) that crosses the blood brain barrier and inhibits tau phosphorylation (IC50 = 76 nM in vitro); stabilizes β-catenin and increases bone mass (via Wnt activation) in rats after a two-week treatment with a maximum effective oral dose of 20 mg/kg once daily
16728	AZD 2858	10 mg	≥98%	A GSK3β inhibitor (Ki = 4.9 nM) that crosses the blood brain barrier and inhibits tau phosphorylation (IC50 = 76 nM in vitro); stabilizes β-catenin and increases bone mass (via Wnt activation) in rats after a two-week treatment with a maximum effective oral dose of 20 mg/kg once daily
16728	AZD 2858	5 mg	≥98%	A GSK3β inhibitor (Ki = 4.9 nM) that crosses the blood brain barrier and inhibits tau phosphorylation (IC50 = 76 nM in vitro); stabilizes β-catenin and increases bone mass (via Wnt activation) in rats after a two-week treatment with a maximum effective oral dose of 20 mg/kg once daily
16729	ZM 39923 (hydrochlo	1 mg	≥98%	An inhibitor of JAK3 (IC50 = 79 nM); also inhibits the transglutaminases TGM2 and Factor XIIIa (IC50s= 10 and 25 nM, respectively) in the absence of dithiothreitol; breaks down in neutral buffer to form ZM 449829
16729	ZM 39923 (hydrochlo	10 mg	≥98%	An inhibitor of JAK3 (IC50 = 79 nM); also inhibits the transglutaminases TGM2 and Factor XIIIa (IC50s= 10 and 25 nM, respectively) in the absence of dithiothreitol; breaks down in neutral buffer to form ZM 449829
16729	ZM 39923 (hydrochlo	5 mg	≥98%	An inhibitor of JAK3 (IC50 = 79 nM); also inhibits the transglutaminases TGM2 and Factor XIIIa (IC50s= 10 and 25 nM, respectively) in the absence of dithiothreitol; breaks down in neutral buffer to form ZM 449829
16731	AZ 960	1 mg	≥98%	A potent JAK2 inhibitor (Ki = 0.45 nM in vitro) that decrease STAT3/5 phosphorylation and inhibits cell proliferation (GI50 = 33 nM) in a JAK2 V617F mutated cell line; induces apoptosis in human T cell lymophotropic virus type 1-infected (IC50 = ~1 µM), downregulating phosphorylated forms of JAK2 and Bcl-2 family proteins
16731	AZ 960	10 mg	≥98%	A potent JAK2 inhibitor (Ki = 0.45 nM in vitro) that decrease STAT3/5 phosphorylation and inhibits cell proliferation (GI50 = 33 nM) in a JAK2 V617F mutated cell line; induces apoptosis in human T cell lymophotropic virus type 1-infected (IC50 = ~1 µM), downregulating phosphorylated forms of JAK2 and Bcl-2 family proteins
16731	AZ 960	5 mg	≥98%	A potent JAK2 inhibitor (Ki = 0.45 nM in vitro) that decrease STAT3/5 phosphorylation and inhibits cell proliferation (GI50 = 33 nM) in a JAK2 V617F mutated cell line; induces apoptosis in human T cell lymophotropic virus type 1-infected (IC50 = ~1 µM), downregulating phosphorylated forms of JAK2 and Bcl-2 family proteins
16732	CEP-33779	1 mg	≥95%	A potent, orally available inhibitor of JAK2 (IC50 = 1.3 nM); reduces the production of inflammatory cytokines and blocks disease development in mouse models of lupus and arthritis; induces regression of established colorectal tumors in mice, reducing angiogenesis and proliferation of tumor cells
16732	CEP-33779	5 mg	≥95%	A potent, orally available inhibitor of JAK2 (IC50 = 1.3 nM); reduces the production of inflammatory cytokines and blocks disease development in mouse models of lupus and arthritis; induces regression of established colorectal tumors in mice, reducing angiogenesis and proliferation of tumor cells
16732	CEP-33779	500 µg	≥95%	A potent, orally available inhibitor of JAK2 (IC50 = 1.3 nM); reduces the production of inflammatory cytokines and blocks disease development in mouse models of lupus and arthritis; induces regression of established colorectal tumors in mice, reducing angiogenesis and proliferation of tumor cells
16733	1-Azakenpaullone	1 mg	≥98%	Inhibits GSK3β more potently (IC50 = 18 nM) than CDK1/cyclin B or CDK5/p25 (IC50s = 2.0 and 4.2 µM, respectively); stimulates the proliferation of human islets and drives the differentiation of mouse embryonic stem cells and Nematostella larvae
16733	1-Azakenpaullone	10 mg	≥98%	Inhibits GSK3β more potently (IC50 = 18 nM) than CDK1/cyclin B or CDK5/p25 (IC50s = 2.0 and 4.2 µM, respectively); stimulates the proliferation of human islets and drives the differentiation of mouse embryonic stem cells and Nematostella larvae
16733	1-Azakenpaullone	5 mg	≥98%	Inhibits GSK3β more potently (IC50 = 18 nM) than CDK1/cyclin B or CDK5/p25 (IC50s = 2.0 and 4.2 µM, respectively); stimulates the proliferation of human islets and drives the differentiation of mouse embryonic stem cells and Nematostella larvae
16772	R-59-022	1 mg	≥98%	An inhibitor of DGK (IC50 = 2.8 µM), increasing DAG-dependent PKC activity; blocks vascular contraction induced by U-46619 (Item No. 16450); induces apoptosis in glioblastoma cells without being toxic to non-cancerous cells; inhibits A. thaliana DGK2 (IC50 = 50 µM) and suppresses root growth but does not affect DGK7 at 50 µM
16772	R-59-022	10 mg	≥98%	An inhibitor of DGK (IC50 = 2.8 µM), increasing DAG-dependent PKC activity; blocks vascular contraction induced by U-46619 (Item No. 16450); induces apoptosis in glioblastoma cells without being toxic to non-cancerous cells; inhibits A. thaliana DGK2 (IC50 = 50 µM) and suppresses root growth but does not affect DGK7 at 50 µM

16772	R-59-022	5 mg	≥98%	An inhibitor of DGK (IC50 = 2.8 µM), increasing DAG-dependent PKC activity; blocks vascular contraction induced by U-46619 (Item No. 16450); induces apoptosis in glioblastoma cells without being toxic to non-cancerous cells; inhibits A. thaliana DGK2 (IC50 = 50 µM) and suppresses root growth but does not affect DGK7 at 50 µM
16772	R-59-022	50 mg	≥98%	An inhibitor of DGK (IC50 = 2.8 µM), increasing DAG-dependent PKC activity; blocks vascular contraction induced by U-46619 (Item No. 16450); induces apoptosis in glioblastoma cells without being toxic to non-cancerous cells; inhibits A. thaliana DGK2 (IC50 = 50 µM) and suppresses root growth but does not affect DGK7 at 50 µM
16779	CX-4945	1 mg	≥98%	A potent, orally bioavailable inhibitor of casein kinase 2 (CK2; Ki = 0.38 nM); inhibits proliferation in a panel of cancer cell lines that overexpress CK2 and prevents tumor growth of breast and pancreatic cancer cell xenografts in mice
16779	CX-4945	10 mg	≥98%	A potent, orally bioavailable inhibitor of casein kinase 2 (CK2; Ki = 0.38 nM); inhibits proliferation in a panel of cancer cell lines that overexpress CK2 and prevents tumor growth of breast and pancreatic cancer cell xenografts in mice
16779	CX-4945	5 mg	≥98%	A potent, orally bioavailable inhibitor of casein kinase 2 (CK2; Ki = 0.38 nM); inhibits proliferation in a panel of cancer cell lines that overexpress CK2 and prevents tumor growth of breast and pancreatic cancer cell xenografts in mice
16779	CX-4945	500 µg	≥98%	A potent, orally bioavailable inhibitor of casein kinase 2 (CK2; Ki = 0.38 nM); inhibits proliferation in a panel of cancer cell lines that overexpress CK2 and prevents tumor growth of breast and pancreatic cancer cell xenografts in mice
16800	IPI-145	1 mg	≥98%	A potent, selective, and orally bioavailable inhibitor of PI3Kγ and PI3Kδ (IC50s = 0.24 and 50 nM, respectively); has profound effects in collagen-induced and adjuvant-induced arthritis, ovalbumin-induced asthma, and systemic lupus erythematosus animal models
16800	IPI-145	10 mg	≥98%	A potent, selective, and orally bioavailable inhibitor of PI3Kγ and PI3Kδ (IC50s = 0.24 and 50 nM, respectively); has profound effects in collagen-induced and adjuvant-induced arthritis, ovalbumin-induced asthma, and systemic lupus erythematosus animal models
16800	IPI-145	5 mg	≥98%	A potent, selective, and orally bioavailable inhibitor of PI3Kγ and PI3Kδ (IC50s = 0.24 and 50 nM, respectively); has profound effects in collagen-induced and adjuvant-induced arthritis, ovalbumin-induced asthma, and systemic lupus erythematosus animal models
16800	IPI-145	500 µg	≥98%	A potent, selective, and orally bioavailable inhibitor of PI3Kγ and PI3Kδ (IC50s = 0.24 and 50 nM, respectively); has profound effects in collagen-induced and adjuvant-induced arthritis, ovalbumin-induced asthma, and systemic lupus erythematosus animal models
16848	AT7867	10 mg	≥98%	A potent and orally bioavailable inhibitor of Akt isoforms Akt1, 2, and 3 (IC50s = 32, 17, and 47 nM, respectively); inhibits growth and induces apoptosis in a variety of cancer cell lines in vitro and suppresses tumor growth of PTEN-deficient xenografts in mice
16848	AT7867	25 mg	≥98%	A potent and orally bioavailable inhibitor of Akt isoforms Akt1, 2, and 3 (IC50s = 32, 17, and 47 nM, respectively); inhibits growth and induces apoptosis in a variety of cancer cell lines in vitro and suppresses tumor growth of PTEN-deficient xenografts in mice
16848	AT7867	5 mg	≥98%	A potent and orally bioavailable inhibitor of Akt isoforms Akt1, 2, and 3 (IC50s = 32, 17, and 47 nM, respectively); inhibits growth and induces apoptosis in a variety of cancer cell lines in vitro and suppresses tumor growth of PTEN-deficient xenografts in mice
16873	OTSSP167 (hydrochlo	1 mg	≥95%	A potent inhibitor of MELK (IC50 = 0.41 nM); blocks the phosphorylation of MELK-specific substrates and reduces the ability of MCF-7 breast cancer cells to invade and form spheroids in Matrigel; suppresses the growth of xenograft tumors in mice
16873	OTSSP167 (hydrochlo	10 mg	≥95%	A potent inhibitor of MELK (IC50 = 0.41 nM); blocks the phosphorylation of MELK-specific substrates and reduces the ability of MCF-7 breast cancer cells to invade and form spheroids in Matrigel; suppresses the growth of xenograft tumors in mice
16873	OTSSP167 (hydrochlo	5 mg	≥95%	A potent inhibitor of MELK (IC50 = 0.41 nM); blocks the phosphorylation of MELK-specific substrates and reduces the ability of MCF-7 breast cancer cells to invade and form spheroids in Matrigel; suppresses the growth of xenograft tumors in mice
16891	GSK690693	1 mg	≥95%	An ATP-competitive, pan-Akt kinase inhibitor (IC50s = 2, 13, and 9 nM for Akt1, 2, and 3, respectively) that inhibits proliferation and induces apoptosis in various human tumor cells in vitro and in xenografts in immunocompromised mice
16891	GSK690693	10 mg	≥95%	An ATP-competitive, pan-Akt kinase inhibitor (IC50s = 2, 13, and 9 nM for Akt1, 2, and 3, respectively) that inhibits proliferation and induces apoptosis in various human tumor cells in vitro and in xenografts in immunocompromised mice
16891	GSK690693	25 mg	≥95%	An ATP-competitive, pan-Akt kinase inhibitor (IC50s = 2, 13, and 9 nM for Akt1, 2, and 3, respectively) that inhibits proliferation and induces apoptosis in various human tumor cells in vitro and in xenografts in immunocompromised mice
16891	GSK690693	5 mg	≥95%	An ATP-competitive, pan-Akt kinase inhibitor (IC50s = 2, 13, and 9 nM for Akt1, 2, and 3, respectively) that inhibits proliferation and induces apoptosis in various human tumor cells in vitro and in xenografts in immunocompromised mice
16898	JX-401	1 mg	≥95%	A potent, reversible inhibitor of the p38α isoform of MAP kinase (IC50 = 32 nM) that does not inhibit the p38γ isoform

16898	JX-401	10 mg	≥95%	A potent, reversible inhibitor of the p38α isoform of MAP kinase (IC50 = 32 nM) that does not inhibit the p38γ isoform
16898	JX-401	5 mg	≥95%	A potent, reversible inhibitor of the p38α isoform of MAP kinase (IC50 = 32 nM) that does not inhibit the p38γ isoform
16898	JX-401	50 mg	≥95%	A potent, reversible inhibitor of the p38α isoform of MAP kinase (IC50 = 32 nM) that does not inhibit the p38γ isoform
16915	GW 441756	1 mg	≥95%	A potent, selective inhibitor of TrkA (IC50 = 2 nM); used to clarify the role of TrkA in regulating cell function
16915	GW 441756	10 mg	≥95%	A potent, selective inhibitor of TrkA (IC50 = 2 nM); used to clarify the role of TrkA in regulating cell function
16915	GW 441756	5 mg	≥95%	A potent, selective inhibitor of TrkA (IC50 = 2 nM); used to clarify the role of TrkA in regulating cell function
16947	N-Desmethyl Imatinib	1 mg	≥95%	A major active metabolite of imatinib; formed through demethylation of imatinib by CYP3A4; has the same in vitro potency at Bcr-ABL kinase as imatinib (IC50 = 38 nM for both) but is only present in plasma at 10-15% of the levels of imatinib
16947	N-Desmethyl Imatinib	10 mg	≥95%	A major active metabolite of imatinib; formed through demethylation of imatinib by CYP3A4; has the same in vitro potency at Bcr-ABL kinase as imatinib (IC50 = 38 nM for both) but is only present in plasma at 10-15% of the levels of imatinib
16947	N-Desmethyl Imatinib	5 mg	≥95%	A major active metabolite of imatinib; formed through demethylation of imatinib by CYP3A4; has the same in vitro potency at Bcr-ABL kinase as imatinib (IC50 = 38 nM for both) but is only present in plasma at 10-15% of the levels of imatinib
16947	N-Desmethyl Imatinib	500 µg	≥95%	A major active metabolite of imatinib; formed through demethylation of imatinib by CYP3A4; has the same in vitro potency at Bcr-ABL kinase as imatinib (IC50 = 38 nM for both) but is only present in plasma at 10-15% of the levels of imatinib
16968	ZM 306416	1 mg	≥98%	Inhibits KDR and Flt VEGF receptors with IC50 values of 100 nM and 2 µM, respectively; also inhibits EGFR kinase (IC50 < 10 nM), reducing proliferation of EGFR-dependent cancer cells
16968	ZM 306416	10 mg	≥98%	Inhibits KDR and Flt VEGF receptors with IC50 values of 100 nM and 2 µM, respectively; also inhibits EGFR kinase (IC50 < 10 nM), reducing proliferation of EGFR-dependent cancer cells
16968	ZM 306416	5 mg	≥98%	Inhibits KDR and Flt VEGF receptors with IC50 values of 100 nM and 2 µM, respectively; also inhibits EGFR kinase (IC50 < 10 nM), reducing proliferation of EGFR-dependent cancer cells
16974	Skepinone-L	1 mg	≥98%	An ATP-competitive inhibitor of p38 MAPK isoform p38α (IC50s = 5 nM) and p38β (97% inhibition at 1 µM); has little effect on a range of other kinases, including p38γ and p38δ; blocks the phosphorylation of HSP27, a p38 MAPK substrate, in response to stimulation with anisomycin in HeLa cells (IC50 = 25 nM)
16974	Skepinone-L	10 mg	≥98%	An ATP-competitive inhibitor of p38 MAPK isoform p38α (IC50s = 5 nM) and p38β (97% inhibition at 1 µM); has little effect on a range of other kinases, including p38γ and p38δ; blocks the phosphorylation of HSP27, a p38 MAPK substrate, in response to stimulation with anisomycin in HeLa cells (IC50 = 25 nM)
16974	Skepinone-L	5 mg	≥98%	An ATP-competitive inhibitor of p38 MAPK isoform p38α (IC50s = 5 nM) and p38β (97% inhibition at 1 µM); has little effect on a range of other kinases, including p38γ and p38δ; blocks the phosphorylation of HSP27, a p38 MAPK substrate, in response to stimulation with anisomycin in HeLa cells (IC50 = 25 nM)
16974	Skepinone-L	500 µg	≥98%	An ATP-competitive inhibitor of p38 MAPK isoform p38α (IC50s = 5 nM) and p38β (97% inhibition at 1 µM); has little effect on a range of other kinases, including p38γ and p38δ; blocks the phosphorylation of HSP27, a p38 MAPK substrate, in response to stimulation with anisomycin in HeLa cells (IC50 = 25 nM)
16978	AZD 8055	1 mg	≥98%	A potent, selective ATP-competitive inhibitor of mTOR (IC50 = 0.8 nM); inhibits proliferation of A549 (IC50 = 53 nM) and H838 cells (IC50 = 20 nM) as well as several human tumor xenografts (>65% at 20 mg/kg)
16978	AZD 8055	10 mg	≥98%	A potent, selective ATP-competitive inhibitor of mTOR (IC50 = 0.8 nM); inhibits proliferation of A549 (IC50 = 53 nM) and H838 cells (IC50 = 20 nM) as well as several human tumor xenografts (>65% at 20 mg/kg)
16978	AZD 8055	5 mg	≥98%	A potent, selective ATP-competitive inhibitor of mTOR (IC50 = 0.8 nM); inhibits proliferation of A549 (IC50 = 53 nM) and H838 cells (IC50 = 20 nM) as well as several human tumor xenografts (>65% at 20 mg/kg)
16978	AZD 8055	50 mg	≥98%	A potent, selective ATP-competitive inhibitor of mTOR (IC50 = 0.8 nM); inhibits proliferation of A549 (IC50 = 53 nM) and H838 cells (IC50 = 20 nM) as well as several human tumor xenografts (>65% at 20 mg/kg)
16979	SAR405	1 mg	≥98%	A selective inhibitor of Vps34 (IC50 = 1.2 nM); alters vesicle trafficking and inhibits autophagy by blocking autophagosome formation; synergizes with everolimus in preventing the proliferation of renal tumor cell lines

16979	SAR405	5 mg	≥98%	A selective inhibitor of Vps34 (IC50 = 1.2 nM); alters vesicle trafficking and inhibits autophagy by blocking autophagosome formation; synergizes with everolimus in preventing the proliferation of renal tumor cell lines
16979	SAR405	500 µg	≥98%	A selective inhibitor of Vps34 (IC50 = 1.2 nM); alters vesicle trafficking and inhibits autophagy by blocking autophagosome formation; synergizes with everolimus in preventing the proliferation of renal tumor cell lines
16985	Rp-Cyclic AMPS (trieth	1 mg	≥98%	A non-hydrolyzable phosphorothioate analog of cAMP that competitively inhibits cAMP-dependent protein kinases (PKA) I and II (IC50s = 12.5 and 4.5 µM, respectively); broadly used in research involving cAMP-dependent signaling in vitro and in vivo
16985	Rp-Cyclic AMPS (trieth	5 mg	≥98%	A non-hydrolyzable phosphorothioate analog of cAMP that competitively inhibits cAMP-dependent protein kinases (PKA) I and II (IC50s = 12.5 and 4.5 µM, respectively); broadly used in research involving cAMP-dependent signaling in vitro and in vivo
16985	Rp-Cyclic AMPS (trieth	500 µg	≥98%	A non-hydrolyzable phosphorothioate analog of cAMP that competitively inhibits cAMP-dependent protein kinases (PKA) I and II (IC50s = 12.5 and 4.5 µM, respectively); broadly used in research involving cAMP-dependent signaling in vitro and in vivo
16986	BYL719	10 mg	≥98%	An inhibitor of PI3Kα (IC50s = 4.6, 4, and 4.8 nM for wild-type, E545K mutant, and H1047R mutant PI3K, respectively); selective for PI3Kα over PI3Kβ, PI3Kδ, PI3Kγ, and PI4Kβ (IC50s = 1,156, 290, 250, and 581 nM, respectively), as well as VPS34, mTOR, DNA-PK, and ATR (IC50s = >9,100 nM for all); reduces tumor volume in a PI3Kα-dependent Rat1-myr-p110α mouse xenograft model at 12.5, 25, and 50 mg/kg; also reduces tumor burden in THP-1 AML and MCF-7 breast cancer mouse xenograft models
16986	BYL719	25 mg	≥98%	An inhibitor of PI3Kα (IC50s = 4.6, 4, and 4.8 nM for wild-type, E545K mutant, and H1047R mutant PI3K, respectively); selective for PI3Kα over PI3Kβ, PI3Kδ, PI3Kγ, and PI4Kβ (IC50s = 1,156, 290, 250, and 581 nM, respectively), as well as VPS34, mTOR, DNA-PK, and ATR (IC50s = >9,100 nM for all); reduces tumor volume in a PI3Kα-dependent Rat1-myr-p110α mouse xenograft model at 12.5, 25, and 50 mg/kg; also reduces tumor burden in THP-1 AML and MCF-7 breast cancer mouse xenograft models
16986	BYL719	5 mg	≥98%	An inhibitor of PI3Kα (IC50s = 4.6, 4, and 4.8 nM for wild-type, E545K mutant, and H1047R mutant PI3K, respectively); selective for PI3Kα over PI3Kβ, PI3Kδ, PI3Kγ, and PI4Kβ (IC50s = 1,156, 290, 250, and 581 nM, respectively), as well as VPS34, mTOR, DNA-PK, and ATR (IC50s = >9,100 nM for all); reduces tumor volume in a PI3Kα-dependent Rat1-myr-p110α mouse xenograft model at 12.5, 25, and 50 mg/kg; also reduces tumor burden in THP-1 AML and MCF-7 breast cancer mouse xenograft models
16989	Dabrafenib	10 mg	≥98%	An ATP-competitive Raf kinase inhibitor (IC50s = 0.64, 0.68, and 5 nM for wild-type B-RAF kinase, mutant B-RAFV600E, and wild-type C-RAF kinase, respectively); also inhibits ALK5, LIMK1, SIK2, PDK2, NEK11, CK1, and BRK (IC50s = 11, 15, 27, 57, 20, 41, and 79 nM, respectively) in a panel of 270 kinases at 300 nM; inhibits the growth of 16 cancer cell lines expressing mutant B-RAFV600E (GI50s = 50s = 50s = V600E-expressing A375P melanoma cells; reduces tumor growth in an A375P mouse xenograft model at 3-100 mg/kg
16989	Dabrafenib	25 mg	≥98%	An ATP-competitive Raf kinase inhibitor (IC50s = 0.64, 0.68, and 5 nM for wild-type B-RAF kinase, mutant B-RAFV600E, and wild-type C-RAF kinase, respectively); also inhibits ALK5, LIMK1, SIK2, PDK2, NEK11, CK1, and BRK (IC50s = 11, 15, 27, 57, 20, 41, and 79 nM, respectively) in a panel of 270 kinases at 300 nM; inhibits the growth of 16 cancer cell lines expressing mutant B-RAFV600E (GI50s = 50s = 50s = V600E-expressing A375P melanoma cells; reduces tumor growth in an A375P mouse xenograft model at 3-100 mg/kg
16989	Dabrafenib	5 mg	≥98%	An ATP-competitive Raf kinase inhibitor (IC50s = 0.64, 0.68, and 5 nM for wild-type B-RAF kinase, mutant B-RAFV600E, and wild-type C-RAF kinase, respectively); also inhibits ALK5, LIMK1, SIK2, PDK2, NEK11, CK1, and BRK (IC50s = 11, 15, 27, 57, 20, 41, and 79 nM, respectively) in a panel of 270 kinases at 300 nM; inhibits the growth of 16 cancer cell lines expressing mutant B-RAFV600E (GI50s = 50s = 50s = V600E-expressing A375P melanoma cells; reduces tumor growth in an A375P mouse xenograft model at 3-100 mg/kg
16989	Dabrafenib	50 mg	≥98%	An ATP-competitive Raf kinase inhibitor (IC50s = 0.64, 0.68, and 5 nM for wild-type B-RAF kinase, mutant B-RAFV600E, and wild-type C-RAF kinase, respectively); also inhibits ALK5, LIMK1, SIK2, PDK2, NEK11, CK1, and BRK (IC50s = 11, 15, 27, 57, 20, 41, and 79 nM, respectively) in a panel of 270 kinases at 300 nM; inhibits the growth of 16 cancer cell lines expressing mutant B-RAFV600E (GI50s = 50s = 50s = V600E-expressing A375P melanoma cells; reduces tumor growth in an A375P mouse xenograft model at 3-100 mg/kg
16991	RAF265	1 mg	≥98%	A dual inhibitor of mutant B-RafV600E and VEGFR2 (EC50s = 0.14 and 0.19 µM, respectively, in cell-based assays) that also inhibits wild-type B-Raf, PDGFR, CSF1R, RET, c-KIT, SRC, and STE20 (IC50s = 20-100 nM)
16991	RAF265	10 mg	≥98%	A dual inhibitor of mutant B-RafV600E and VEGFR2 (EC50s = 0.14 and 0.19 µM, respectively, in cell-based assays) that also inhibits wild-type B-Raf, PDGFR, CSF1R, RET, c-KIT, SRC, and STE20 (IC50s = 20-100 nM)

16991	RAF265	5 mg	≥98%	A dual inhibitor of mutant B-RafV600E and VEGFR2 (EC50s = 0.14 and 0.19 µM, respectively, in cell-based assays) that also inhibits wild-type B-Raf, PDGFR, CSF1R, RET, c-KIT, SRC, and STE20 (IC50s = 20-100 nM)
16991	RAF265	50 mg	≥98%	A dual inhibitor of mutant B-RafV600E and VEGFR2 (EC50s = 0.14 and 0.19 µM, respectively, in cell-based assays) that also inhibits wild-type B-Raf, PDGFR, CSF1R, RET, c-KIT, SRC, and STE20 (IC50s = 20-100 nM)
16993	GDC 0879	1 mg	≥95%	An inhibitor of B-RafV600E (IC50 = 0.13 nM for human recombinant enzyme); selective for B-RafV600E over a panel of 140 kinases at 1 µM; inhibits phosphorylation of ERK in MALME-3M cells (IC50 = 63 nM) as well as phosphorylation of MEK1 in COLO 205 and A375 cells that express B-RafV600E (IC50s = 29 and 59 nM, respectively); inhibits tumor growth in an A375 mouse xenograft model from 15-200 mg/kg
16993	GDC 0879	10 mg	≥95%	An inhibitor of B-RafV600E (IC50 = 0.13 nM for human recombinant enzyme); selective for B-RafV600E over a panel of 140 kinases at 1 µM; inhibits phosphorylation of ERK in MALME-3M cells (IC50 = 63 nM) as well as phosphorylation of MEK1 in COLO 205 and A375 cells that express B-RafV600E (IC50s = 29 and 59 nM, respectively); inhibits tumor growth in an A375 mouse xenograft model from 15-200 mg/kg
16993	GDC 0879	25 mg	≥95%	An inhibitor of B-RafV600E (IC50 = 0.13 nM for human recombinant enzyme); selective for B-RafV600E over a panel of 140 kinases at 1 µM; inhibits phosphorylation of ERK in MALME-3M cells (IC50 = 63 nM) as well as phosphorylation of MEK1 in COLO 205 and A375 cells that express B-RafV600E (IC50s = 29 and 59 nM, respectively); inhibits tumor growth in an A375 mouse xenograft model from 15-200 mg/kg
16993	GDC 0879	5 mg	≥95%	An inhibitor of B-RafV600E (IC50 = 0.13 nM for human recombinant enzyme); selective for B-RafV600E over a panel of 140 kinases at 1 µM; inhibits phosphorylation of ERK in MALME-3M cells (IC50 = 63 nM) as well as phosphorylation of MEK1 in COLO 205 and A375 cells that express B-RafV600E (IC50s = 29 and 59 nM, respectively); inhibits tumor growth in an A375 mouse xenograft model from 15-200 mg/kg
16994	Encorafenib	1 mg	≥98%	A selective inhibitor of B-RafV600E mutant melanoma cell proliferation (EC50 = 4 nM) with little activity against wild-type B-Raf or a panel of 100 other kinases (IC50s = 900 nM); decreases phosphorylation of the B-Raf substrate MEK at oral doses of 6 mg/kg in human melanoma xenograft models
16994	Encorafenib	5 mg	≥98%	A selective inhibitor of B-RafV600E mutant melanoma cell proliferation (EC50 = 4 nM) with little activity against wild-type B-Raf or a panel of 100 other kinases (IC50s = 900 nM); decreases phosphorylation of the B-Raf substrate MEK at oral doses of 6 mg/kg in human melanoma xenograft models
16994	Encorafenib	500 µg	≥98%	A selective inhibitor of B-RafV600E mutant melanoma cell proliferation (EC50 = 4 nM) with little activity against wild-type B-Raf or a panel of 100 other kinases (IC50s = 900 nM); decreases phosphorylation of the B-Raf substrate MEK at oral doses of 6 mg/kg in human melanoma xenograft models
16996	Binimetinib	10 mg	≥98%	An orally bioavailable inhibitor of MEK1/2 (IC50 = 12 nM) that inhibits ERK phosphorylation in various cancer cell lines (IC50s≥ 5 nM); efficacious in several xenograft tumor models in mice, including those bearing K-Ras or B-RAF mutations, as well as in clinical studies using patients with N-Ras melanoma, non-small cell lung cancer, or biliary tract cancer
16996	Binimetinib	100 mg	≥98%	An orally bioavailable inhibitor of MEK1/2 (IC50 = 12 nM) that inhibits ERK phosphorylation in various cancer cell lines (IC50s≥ 5 nM); efficacious in several xenograft tumor models in mice, including those bearing K-Ras or B-RAF mutations, as well as in clinical studies using patients with N-Ras melanoma, non-small cell lung cancer, or biliary tract cancer
16996	Binimetinib	5 mg	≥98%	An orally bioavailable inhibitor of MEK1/2 (IC50 = 12 nM) that inhibits ERK phosphorylation in various cancer cell lines (IC50s≥ 5 nM); efficacious in several xenograft tumor models in mice, including those bearing K-Ras or B-RAF mutations, as well as in clinical studies using patients with N-Ras melanoma, non-small cell lung cancer, or biliary tract cancer
16996	Binimetinib	50 mg	≥98%	An orally bioavailable inhibitor of MEK1/2 (IC50 = 12 nM) that inhibits ERK phosphorylation in various cancer cell lines (IC50s≥ 5 nM); efficacious in several xenograft tumor models in mice, including those bearing K-Ras or B-RAF mutations, as well as in clinical studies using patients with N-Ras melanoma, non-small cell lung cancer, or biliary tract cancer
16997	Refametinib	1 mg	≥95%	An allosteric, selective inhibitor of MEK1 and MEK2 (IC50s = 19 and 47 nM, respectively); blocks phosphorylation of ERK1/2 across several human cancer cell lines differing in tissue origin and BRAF mutational status (EC50s = 2.5-16 nM); orally available and active in human tumor xenograft models
16997	Refametinib	10 mg	≥95%	An allosteric, selective inhibitor of MEK1 and MEK2 (IC50s = 19 and 47 nM, respectively); blocks phosphorylation of ERK1/2 across several human cancer cell lines differing in tissue origin and BRAF mutational status (EC50s = 2.5-16 nM); orally available and active in human tumor xenograft models

16997	Refametinib	5 mg	≥95%	An allosteric, selective inhibitor of MEK1 and MEK2 (IC50s = 19 and 47 nM, respectively); blocks phosphorylation of ERK1/2 across several human cancer cell lines differing in tissue origin and BRAF mutational status (EC50s = 2.5-16 nM); orally available and active in human tumor xenograft models
16997	Refametinib	50 mg	≥95%	An allosteric, selective inhibitor of MEK1 and MEK2 (IC50s = 19 and 47 nM, respectively); blocks phosphorylation of ERK1/2 across several human cancer cell lines differing in tissue origin and BRAF mutational status (EC50s = 2.5-16 nM); orally available and active in human tumor xenograft models
16998	TAK-733	1 mg	≥98%	A MEK1 inhibitor (IC50 = 3.2 nM); inhibits ERK phosphorylation in vitro (EC50 = 1.9 nM); inhibits proliferation of A375 and COLO 205 cells (EC50s = 3.1 and 2.1 nM, respectively) and 14 cutaneous melanoma cell lines (IC50s = V600E mutations
16998	TAK-733	10 mg	≥98%	A MEK1 inhibitor (IC50 = 3.2 nM); inhibits ERK phosphorylation in vitro (EC50 = 1.9 nM); inhibits proliferation of A375 and COLO 205 cells (EC50s = 3.1 and 2.1 nM, respectively) and 14 cutaneous melanoma cell lines (IC50s = V600E mutations
16998	TAK-733	5 mg	≥98%	A MEK1 inhibitor (IC50 = 3.2 nM); inhibits ERK phosphorylation in vitro (EC50 = 1.9 nM); inhibits proliferation of A375 and COLO 205 cells (EC50s = 3.1 and 2.1 nM, respectively) and 14 cutaneous melanoma cell lines (IC50s = V600E mutations
16998	TAK-733	500 µg	≥98%	A MEK1 inhibitor (IC50 = 3.2 nM); inhibits ERK phosphorylation in vitro (EC50 = 1.9 nM); inhibits proliferation of A375 and COLO 205 cells (EC50s = 3.1 and 2.1 nM, respectively) and 14 cutaneous melanoma cell lines (IC50s = V600E mutations
16999	BIX02189	10 mg	≥98%	A potent inhibitor of both MEK5 and ERK5 (IC50s = 1.5 and 59 nM, respectively); minimally inhibits a panel of related kinases, including MEK1/2 and ERK1/2; blocks sorbitol-induced phosphorylation of ERK5, without affecting phosphorylation of ERK1/2, in HeLa cells
16999	BIX02189	25 mg	≥98%	A potent inhibitor of both MEK5 and ERK5 (IC50s = 1.5 and 59 nM, respectively); minimally inhibits a panel of related kinases, including MEK1/2 and ERK1/2; blocks sorbitol-induced phosphorylation of ERK5, without affecting phosphorylation of ERK1/2, in HeLa cells
16999	BIX02189	5 mg	≥98%	A potent inhibitor of both MEK5 and ERK5 (IC50s = 1.5 and 59 nM, respectively); minimally inhibits a panel of related kinases, including MEK1/2 and ERK1/2; blocks sorbitol-induced phosphorylation of ERK5, without affecting phosphorylation of ERK1/2, in HeLa cells
17001	GSK650394	10 mg	≥98%	An SGK1 inhibitor (IC50s = 62 and 103 nM for SGK1 and SGK2, respectively) that demonstrates greater than 30-fold selectivity for SGK1 over Akt and other related kinases; inhibits the androgen-stimulated growth of human prostate carcinoma LNCaP cells (IC50 ~ 1 µM)
17001	GSK650394	25 mg	≥98%	An SGK1 inhibitor (IC50s = 62 and 103 nM for SGK1 and SGK2, respectively) that demonstrates greater than 30-fold selectivity for SGK1 over Akt and other related kinases; inhibits the androgen-stimulated growth of human prostate carcinoma LNCaP cells (IC50 ~ 1 µM)
17001	GSK650394	5 mg	≥98%	An SGK1 inhibitor (IC50s = 62 and 103 nM for SGK1 and SGK2, respectively) that demonstrates greater than 30-fold selectivity for SGK1 over Akt and other related kinases; inhibits the androgen-stimulated growth of human prostate carcinoma LNCaP cells (IC50 ~ 1 µM)
17001	GSK650394	50 mg	≥98%	An SGK1 inhibitor (IC50s = 62 and 103 nM for SGK1 and SGK2, respectively) that demonstrates greater than 30-fold selectivity for SGK1 over Akt and other related kinases; inhibits the androgen-stimulated growth of human prostate carcinoma LNCaP cells (IC50 ~ 1 µM)
17002	PIK-III	1 mg	≥98%	A selective inhibitor of Vps34 (PI3K type 3; IC50 = 18 nM); acutely inhibits autophagy and de novo lipidation of LC3, leading to stabilization of autophagy substrates
17002	PIK-III	10 mg	≥98%	A selective inhibitor of Vps34 (PI3K type 3; IC50 = 18 nM); acutely inhibits autophagy and de novo lipidation of LC3, leading to stabilization of autophagy substrates
17002	PIK-III	25 mg	≥98%	A selective inhibitor of Vps34 (PI3K type 3; IC50 = 18 nM); acutely inhibits autophagy and de novo lipidation of LC3, leading to stabilization of autophagy substrates
17002	PIK-III	5 mg	≥98%	A selective inhibitor of Vps34 (PI3K type 3; IC50 = 18 nM); acutely inhibits autophagy and de novo lipidation of LC3, leading to stabilization of autophagy substrates
17034	PF-543 (hydrochloride	1 mg	≥98%	A potent inhibitor of SPHK1 (IC50 = 2 nM); inhibits S1P binding to human recombinant SPHK1 (Ki = 3.6 nM); selective for SPHK1 over SPHK2 (IC50 = 356 nM) as well as a panel of protein and lipid kinases and S1P receptors at 10 µM; inhibits the formation of S1P in 1483 cells and human whole blood (EC50s = 8.4 and 26.7 nM, respectively); prevents sickling, hemolysis, and inflammation in a transgenic mouse model of sickle cell disease
17034	PF-543 (hydrochloride	10 mg	≥98%	A potent inhibitor of SPHK1 (IC50 = 2 nM); inhibits S1P binding to human recombinant SPHK1 (Ki = 3.6 nM); selective for SPHK1 over SPHK2 (IC50 = 356 nM) as well as a panel of protein and lipid kinases and S1P receptors at 10 µM; inhibits the formation of S1P in 1483 cells and human whole blood (EC50s = 8.4 and 26.7 nM, respectively); prevents sickling, hemolysis, and inflammation in a transgenic mouse model of sickle cell disease

17034	PF-543 (hydrochloride	25 mg	≥98%	A potent inhibitor of SPHK1 (IC50 = 2 nM); inhibits S1P binding to human recombinant SPHK1 (Ki = 3.6 nM); selective for SPHK1 over SPHK2 (IC50 = 356 nM) as well as a panel of protein and lipid kinases and S1P receptors at 10 µM; inhibits the formation of S1P in 1483 cells and human whole blood (EC50s = 8.4 and 26.7 nM, respectively); prevents sickling, hemolysis, and inflammation in a transgenic mouse model of sickle cell disease
17034	PF-543 (hydrochloride	5 mg	≥98%	A potent inhibitor of SPHK1 (IC50 = 2 nM); inhibits S1P binding to human recombinant SPHK1 (Ki = 3.6 nM); selective for SPHK1 over SPHK2 (IC50 = 356 nM) as well as a panel of protein and lipid kinases and S1P receptors at 10 µM; inhibits the formation of S1P in 1483 cells and human whole blood (EC50s = 8.4 and 26.7 nM, respectively); prevents sickling, hemolysis, and inflammation in a transgenic mouse model of sickle cell disease
17052	OTS964 (hydrochlorid	1 mg	≥98%	An inhibitor of TOPK (IC50 = 28 nM); specifically blocks cytokinesis, leading to apoptosis, in cancer cells in vitro and in mice
17052	OTS964 (hydrochlorid	5 mg	≥98%	An inhibitor of TOPK (IC50 = 28 nM); specifically blocks cytokinesis, leading to apoptosis, in cancer cells in vitro and in mice
17052	OTS964 (hydrochlorid	500 µg	≥98%	An inhibitor of TOPK (IC50 = 28 nM); specifically blocks cytokinesis, leading to apoptosis, in cancer cells in vitro and in mice
17053	OTS514	1 mg	≥95%	An inhibitor of TOPK (IC50 = 2.6 nM); selectively inhibits growth of patient-derived AML cells over normal CD34+ cells; inhibits growth of small cell lung, kidney, and ovarian cancer cell lines (IC50s = 0.4-42.6 nM); increases survival in a peritoneal mouse dissemination model of ovarian cancer at 25 and 50 mg/kg; dose-dependently inhibits tumor growth in an A549 mouse xenograft model at 1, 2.5, and 5 mg/kg
17053	OTS514	5 mg	≥95%	An inhibitor of TOPK (IC50 = 2.6 nM); selectively inhibits growth of patient-derived AML cells over normal CD34+ cells; inhibits growth of small cell lung, kidney, and ovarian cancer cell lines (IC50s = 0.4-42.6 nM); increases survival in a peritoneal mouse dissemination model of ovarian cancer at 25 and 50 mg/kg; dose-dependently inhibits tumor growth in an A549 mouse xenograft model at 1, 2.5, and 5 mg/kg
17053	OTS514	500 µg	≥95%	An inhibitor of TOPK (IC50 = 2.6 nM); selectively inhibits growth of patient-derived AML cells over normal CD34+ cells; inhibits growth of small cell lung, kidney, and ovarian cancer cell lines (IC50s = 0.4-42.6 nM); increases survival in a peritoneal mouse dissemination model of ovarian cancer at 25 and 50 mg/kg; dose-dependently inhibits tumor growth in an A549 mouse xenograft model at 1, 2.5, and 5 mg/kg
17054	CD532	10 mg	≥98%	An inhibitor of Aurora A kinase activity (IC50 = 48 nM) and the Aurora A-N-Myc protein-protein interaction; inhibits several CDKs, FGFRs, MEKs, and PDGFRs, as well as FLT3, KIT, and RET at 10 µM; induces degradation of N-Myc in SK-N-BE(2) neuroblastoma cells (EC50 = 223 nM); prevents S-phase entry in SK-N-BE(2) cells at 1 µM; reduces tumor growth and increases survival in a MYCN-amplified SMS-KCN neuroblastoma mouse xenograft model 25 mg/kg
17054	CD532	25 mg	≥98%	An inhibitor of Aurora A kinase activity (IC50 = 48 nM) and the Aurora A-N-Myc protein-protein interaction; inhibits several CDKs, FGFRs, MEKs, and PDGFRs, as well as FLT3, KIT, and RET at 10 µM; induces degradation of N-Myc in SK-N-BE(2) neuroblastoma cells (EC50 = 223 nM); prevents S-phase entry in SK-N-BE(2) cells at 1 µM; reduces tumor growth and increases survival in a MYCN-amplified SMS-KCN neuroblastoma mouse xenograft model 25 mg/kg
17054	CD532	5 mg	≥98%	An inhibitor of Aurora A kinase activity (IC50 = 48 nM) and the Aurora A-N-Myc protein-protein interaction; inhibits several CDKs, FGFRs, MEKs, and PDGFRs, as well as FLT3, KIT, and RET at 10 µM; induces degradation of N-Myc in SK-N-BE(2) neuroblastoma cells (EC50 = 223 nM); prevents S-phase entry in SK-N-BE(2) cells at 1 µM; reduces tumor growth and increases survival in a MYCN-amplified SMS-KCN neuroblastoma mouse xenograft model 25 mg/kg
17054	CD532	50 mg	≥98%	An inhibitor of Aurora A kinase activity (IC50 = 48 nM) and the Aurora A-N-Myc protein-protein interaction; inhibits several CDKs, FGFRs, MEKs, and PDGFRs, as well as FLT3, KIT, and RET at 10 µM; induces degradation of N-Myc in SK-N-BE(2) neuroblastoma cells (EC50 = 223 nM); prevents S-phase entry in SK-N-BE(2) cells at 1 µM; reduces tumor growth and increases survival in a MYCN-amplified SMS-KCN neuroblastoma mouse xenograft model 25 mg/kg
17055	KD 025	10 mg	≥98%	A ROCK2 inhibitor (IC50 = 0.105 µM); selective for ROCK2 over ROCK1 (IC50 = 24 µM); decreases the expression of CTGF and induces remodeling of the actin cytoskeleton in isolated human ileal fibrotic smooth muscle cells at 10 µM; inhibits heat-killed C. albicans- or S. epidermidis-induced production of IL-17 in isolated human PBMCs at 1.25-10 µM; reduces infarct volume in a mouse model of cerebral ischemia induced by transient MCAO at 100 and 200 mg/kg; decreases disease severity in a mouse model of sclerodermatous chronic GVHD at 150 mg/kg
17055	KD 025	100 mg	≥98%	A ROCK2 inhibitor (IC50 = 0.105 µM); selective for ROCK2 over ROCK1 (IC50 = 24 µM); decreases the expression of CTGF and induces remodeling of the actin cytoskeleton in isolated human ileal fibrotic smooth muscle cells at 10 µM; inhibits heat-killed C. albicans- or S. epidermidis-induced production of IL-17 in isolated human PBMCs at 1.25-10 µM; reduces infarct volume in a mouse model of cerebral ischemia induced by transient MCAO at 100 and 200 mg/kg; decreases disease severity in a mouse model of sclerodermatous chronic GVHD at 150 mg/kg

17055	KD 025	25 mg	≥98%	A ROCK2 inhibitor (IC50 = 0.105 µM); selective for ROCK2 over ROCK1 (IC50 = 24 µM); decreases the expression of CTGF and induces remodeling of the actin cytoskeleton in isolated human ileal fibrotic smooth muscle cells at 10 µM; inhibits heat-killed C. albicans- or S. epidermidis-induced production of IL-17 in isolated human PBMCs at 1.25-10 µM; reduces infarct volume in a mouse model of cerebral ischemia induced by transient MCAO at 100 and 200 mg/kg; decreases disease severity in a mouse model of sclerodermatous chronic GVHD at 150 mg/kg
17055	KD 025	50 mg	≥98%	A ROCK2 inhibitor (IC50 = 0.105 µM); selective for ROCK2 over ROCK1 (IC50 = 24 µM); decreases the expression of CTGF and induces remodeling of the actin cytoskeleton in isolated human ileal fibrotic smooth muscle cells at 10 µM; inhibits heat-killed C. albicans- or S. epidermidis-induced production of IL-17 in isolated human PBMCs at 1.25-10 µM; reduces infarct volume in a mouse model of cerebral ischemia induced by transient MCAO at 100 and 200 mg/kg; decreases disease severity in a mouse model of sclerodermatous chronic GVHD at 150 mg/kg
17120	CH5183284	1 mg	≥95%	A potent, selective inhibitor of the kinase activity of fibroblast growth factor receptors (FGFRs) 1, 2, and 3 (IC50s = 9.3, 7.6, and 22 nM, respectively); inhibits the growth of cancer cells expressing FGFR genetic alterations both in vitro and in xenograft mouse models
17120	CH5183284	10 mg	≥95%	A potent, selective inhibitor of the kinase activity of fibroblast growth factor receptors (FGFRs) 1, 2, and 3 (IC50s = 9.3, 7.6, and 22 nM, respectively); inhibits the growth of cancer cells expressing FGFR genetic alterations both in vitro and in xenograft mouse models
17120	CH5183284	25 mg	≥95%	A potent, selective inhibitor of the kinase activity of fibroblast growth factor receptors (FGFRs) 1, 2, and 3 (IC50s = 9.3, 7.6, and 22 nM, respectively); inhibits the growth of cancer cells expressing FGFR genetic alterations both in vitro and in xenograft mouse models
17120	CH5183284	5 mg	≥95%	A potent, selective inhibitor of the kinase activity of fibroblast growth factor receptors (FGFRs) 1, 2, and 3 (IC50s = 9.3, 7.6, and 22 nM, respectively); inhibits the growth of cancer cells expressing FGFR genetic alterations both in vitro and in xenograft mouse models
17135	Tivantinib	1 mg	≥98%	An inhibitor of c-Met (Ki = 0.355 µM); selective for c-Met over a panel of 229 additional kinases at 10 µM; inhibits tubulin polymerization in a cell-free assay; cytotoxic to c-Met-dependent and -independent cancer cell lines from 0.1-1 µM; reduces tumor growth in HT-29, MKN45, and MDA-MB-231 mouse xenograft models at 200 mg/kg
17135	Tivantinib	10 mg	≥98%	An inhibitor of c-Met (Ki = 0.355 µM); selective for c-Met over a panel of 229 additional kinases at 10 µM; inhibits tubulin polymerization in a cell-free assay; cytotoxic to c-Met-dependent and -independent cancer cell lines from 0.1-1 µM; reduces tumor growth in HT-29, MKN45, and MDA-MB-231 mouse xenograft models at 200 mg/kg
17135	Tivantinib	5 mg	≥98%	An inhibitor of c-Met (Ki = 0.355 µM); selective for c-Met over a panel of 229 additional kinases at 10 µM; inhibits tubulin polymerization in a cell-free assay; cytotoxic to c-Met-dependent and -independent cancer cell lines from 0.1-1 µM; reduces tumor growth in HT-29, MKN45, and MDA-MB-231 mouse xenograft models at 200 mg/kg
17142	Rp-8-CPT-Cyclic AMP	1 mg	≥98%	A lipophilic and non-hydrolyzable cAMP analog that acts as a site-selective inhibitor of PKA type I and II, with preference towards site A of type I and site B of type II
17142	Rp-8-CPT-Cyclic AMP	500 µg	≥98%	A lipophilic and non-hydrolyzable cAMP analog that acts as a site-selective inhibitor of PKA type I and II, with preference towards site A of type I and site B of type II
17224	BPIQ-I	1 mg	≥95%	A quinazoline that inhibits the tyrosine kinase activity of EGFR (IC50 = 0.025 nM); inhibits the growth of SKOV3 and MDA-468 tumor cell lines (EC50s = 6.5 and 30 µM, respectively)
17224	BPIQ-I	5 mg	≥95%	A quinazoline that inhibits the tyrosine kinase activity of EGFR (IC50 = 0.025 nM); inhibits the growth of SKOV3 and MDA-468 tumor cell lines (EC50s = 6.5 and 30 µM, respectively)
17224	BPIQ-I	500 µg	≥95%	A quinazoline that inhibits the tyrosine kinase activity of EGFR (IC50 = 0.025 nM); inhibits the growth of SKOV3 and MDA-468 tumor cell lines (EC50s = 6.5 and 30 µM, respectively)
17226	BPIQ-II (hydrochloride	1 mg	≥98%	A linear imidazoquinazoline that potently and selectively inhibits the tyrosine kinase activity of EGFR (IC50 = 8 pM)
17226	BPIQ-II (hydrochloride	5 mg	≥98%	A linear imidazoquinazoline that potently and selectively inhibits the tyrosine kinase activity of EGFR (IC50 = 8 pM)
17226	BPIQ-II (hydrochloride	500 µg	≥98%	A linear imidazoquinazoline that potently and selectively inhibits the tyrosine kinase activity of EGFR (IC50 = 8 pM)
17254	Compound 56	1 mg	≥95%	A highly potent inhibitor of the tyrosine kinase activity of EGFR (IC50 = 0.006 nM); inhibits EGFR activity in pancreatic cancer cell lines and induces the differentiation of rat mesenchymal stem cells
17254	Compound 56	500 µg	≥95%	A highly potent inhibitor of the tyrosine kinase activity of EGFR (IC50 = 0.006 nM); inhibits EGFR activity in pancreatic cancer cell lines and induces the differentiation of rat mesenchymal stem cells

17259	AG957	1 mg	≥98%	A tyrphostin that targets transforming Bcr-Abl fusion proteins (p185Bcr-Abl, p210Bcr-Abl, as well as normal c-Abl (IC50s = 4.3, 1, and 7.1 µM, respectively, for human proteins); also inhibits EGFR (IC50 = 0.25 µM)
17259	AG957	10 mg	≥98%	A tyrphostin that targets transforming Bcr-Abl fusion proteins (p185Bcr-Abl, p210Bcr-Abl, as well as normal c-Abl (IC50s = 4.3, 1, and 7.1 µM, respectively, for human proteins); also inhibits EGFR (IC50 = 0.25 µM)
17259	AG957	5 mg	≥98%	A tyrphostin that targets transforming Bcr-Abl fusion proteins (p185Bcr-Abl, p210Bcr-Abl, as well as normal c-Abl (IC50s = 4.3, 1, and 7.1 µM, respectively, for human proteins); also inhibits EGFR (IC50 = 0.25 µM)
17260	IC261	1 mg	≥95%	A reversible, ATP-competitive inhibitor of CK1δ and CK1ε (IC50 = ~1 µM for both), as well as CK1α (IC50 = 16 µM); at 1 µM, inhibits cytokinesis in primary mouse embryo fibroblasts; used to elucidate the role of CK1 in cells and in whole organisms
17260	IC261	10 mg	≥95%	A reversible, ATP-competitive inhibitor of CK1δ and CK1ε (IC50 = ~1 µM for both), as well as CK1α (IC50 = 16 µM); at 1 µM, inhibits cytokinesis in primary mouse embryo fibroblasts; used to elucidate the role of CK1 in cells and in whole organisms
17260	IC261	25 mg	≥95%	A reversible, ATP-competitive inhibitor of CK1δ and CK1ε (IC50 = ~1 µM for both), as well as CK1α (IC50 = 16 µM); at 1 µM, inhibits cytokinesis in primary mouse embryo fibroblasts; used to elucidate the role of CK1 in cells and in whole organisms
17260	IC261	5 mg	≥95%	A reversible, ATP-competitive inhibitor of CK1δ and CK1ε (IC50 = ~1 µM for both), as well as CK1α (IC50 = 16 µM); at 1 µM, inhibits cytokinesis in primary mouse embryo fibroblasts; used to elucidate the role of CK1 in cells and in whole organisms
17271	NU 6140	1 mg	≥98%	A Cdk2 inhibitor (IC50 = 0.41 µM) that demonstrates 10- to 36-fold selectivity against Cdk2-cyclin A compared to Cdk1-cyclin B, Cdk4-cyclin D, Cdk5-p25, or Cdk7-cyclin H; induces cell-cycle arrest at the G2-M phase
17271	NU 6140	10 mg	≥98%	A Cdk2 inhibitor (IC50 = 0.41 µM) that demonstrates 10- to 36-fold selectivity against Cdk2-cyclin A compared to Cdk1-cyclin B, Cdk4-cyclin D, Cdk5-p25, or Cdk7-cyclin H; induces cell-cycle arrest at the G2-M phase
17271	NU 6140	5 mg	≥98%	A Cdk2 inhibitor (IC50 = 0.41 µM) that demonstrates 10- to 36-fold selectivity against Cdk2-cyclin A compared to Cdk1-cyclin B, Cdk4-cyclin D, Cdk5-p25, or Cdk7-cyclin H; induces cell-cycle arrest at the G2-M phase
17271	NU 6140	500 µg	≥98%	A Cdk2 inhibitor (IC50 = 0.41 µM) that demonstrates 10- to 36-fold selectivity against Cdk2-cyclin A compared to Cdk1-cyclin B, Cdk4-cyclin D, Cdk5-p25, or Cdk7-cyclin H; induces cell-cycle arrest at the G2-M phase
17276	IKK2 Inhibitor VI	1 mg	≥95%	A potent, cell-permeable, reversible inhibitor of IKK2 (IC50 = 13 nM); used to evaluate the role of the canonical, IκB-dependent NF-κB signaling pathway in cellular responses
17276	IKK2 Inhibitor VI	5 mg	≥95%	A potent, cell-permeable, reversible inhibitor of IKK2 (IC50 = 13 nM); used to evaluate the role of the canonical, IκB-dependent NF-κB signaling pathway in cellular responses
17276	IKK2 Inhibitor VI	500 µg	≥95%	A potent, cell-permeable, reversible inhibitor of IKK2 (IC50 = 13 nM); used to evaluate the role of the canonical, IκB-dependent NF-κB signaling pathway in cellular responses
17290	IMD 0354	1 mg	≥98%	An IKKβ (IKK2) inhibitor that blocks NF-κB phosphorylation (IC50 = ~250 nM) and subsequent NF-κB p65 nuclear translocation; exhibits cardioprotective and anti-cancer properties
17290	IMD 0354	10 mg	≥98%	An IKKβ (IKK2) inhibitor that blocks NF-κB phosphorylation (IC50 = ~250 nM) and subsequent NF-κB p65 nuclear translocation; exhibits cardioprotective and anti-cancer properties
17290	IMD 0354	5 mg	≥98%	An IKKβ (IKK2) inhibitor that blocks NF-κB phosphorylation (IC50 = ~250 nM) and subsequent NF-κB p65 nuclear translocation; exhibits cardioprotective and anti-cancer properties
17290	IMD 0354	50 mg	≥98%	An IKKβ (IKK2) inhibitor that blocks NF-κB phosphorylation (IC50 = ~250 nM) and subsequent NF-κB p65 nuclear translocation; exhibits cardioprotective and anti-cancer properties
17309	NG 52	1 mg	≥98%	A tri-substituted purine that binds to the ATP-binding site of yeast cyclin-dependent kinases, inhibiting Cdc28p and Pho85p (IC50s = 7 and 2 µM, respectively); inhibits the growth of S. cerevisiae (GI50 = 30 µM)
17309	NG 52	10 mg	≥98%	A tri-substituted purine that binds to the ATP-binding site of yeast cyclin-dependent kinases, inhibiting Cdc28p and Pho85p (IC50s = 7 and 2 µM, respectively); inhibits the growth of S. cerevisiae (GI50 = 30 µM)
17309	NG 52	5 mg	≥98%	A tri-substituted purine that binds to the ATP-binding site of yeast cyclin-dependent kinases, inhibiting Cdc28p and Pho85p (IC50s = 7 and 2 µM, respectively); inhibits the growth of S. cerevisiae (GI50 = 30 µM)

17309	NG 52	500 µg	≥98%	A tri-substituted purine that binds to the ATP-binding site of yeast cyclin-dependent kinases, inhibiting Cdc28p and Pho85p (IC50s = 7 and 2 µM, respectively); inhibits the growth of S. cerevisiae (GI50 = 30 µM)
17325	MK2a Inhibitor	1 mg	≥98%	A substrate-selective p38α MAPK inhibitor; selectively inhibits p38α-dependent phosphorylation of MK2 over ATF2 (Kiapps = 330 and >20,000 nM, respectively, in cell-free assays); inhibits proliferation of U87, A172, and U251 glioblastoma cells (EC50s = 0.6-1 µM) via inhibition of tubulin polymerization and induction of apoptosis
17325	MK2a Inhibitor	10 mg	≥98%	A substrate-selective p38α MAPK inhibitor; selectively inhibits p38α-dependent phosphorylation of MK2 over ATF2 (Kiapps = 330 and >20,000 nM, respectively, in cell-free assays); inhibits proliferation of U87, A172, and U251 glioblastoma cells (EC50s = 0.6-1 µM) via inhibition of tubulin polymerization and induction of apoptosis
17325	MK2a Inhibitor	5 mg	≥98%	A substrate-selective p38α MAPK inhibitor; selectively inhibits p38α-dependent phosphorylation of MK2 over ATF2 (Kiapps = 330 and >20,000 nM, respectively, in cell-free assays); inhibits proliferation of U87, A172, and U251 glioblastoma cells (EC50s = 0.6-1 µM) via inhibition of tubulin polymerization and induction of apoptosis
17325	MK2a Inhibitor	50 mg	≥98%	A substrate-selective p38α MAPK inhibitor; selectively inhibits p38α-dependent phosphorylation of MK2 over ATF2 (Kiapps = 330 and >20,000 nM, respectively, in cell-free assays); inhibits proliferation of U87, A172, and U251 glioblastoma cells (EC50s = 0.6-1 µM) via inhibition of tubulin polymerization and induction of apoptosis
17329	Picropodophyllotoxin	1 mg	≥98%	A potent and selective inhibitor of IGF-1R (IC50 = 6 nM) causes cell cycle arrest and induces apoptosis in cancer cells both in vitro and in vivo
17329	Picropodophyllotoxin	10 mg	≥98%	A potent and selective inhibitor of IGF-1R (IC50 = 6 nM) causes cell cycle arrest and induces apoptosis in cancer cells both in vitro and in vivo
17329	Picropodophyllotoxin	25 mg	≥98%	A potent and selective inhibitor of IGF-1R (IC50 = 6 nM) causes cell cycle arrest and induces apoptosis in cancer cells both in vitro and in vivo
17329	Picropodophyllotoxin	5 mg	≥98%	A potent and selective inhibitor of IGF-1R (IC50 = 6 nM) causes cell cycle arrest and induces apoptosis in cancer cells both in vitro and in vivo
17371	Toyocamycin (hydrate	1 mg	≥98%	A natural adenosine analog that prevents IRE1α-induced mRNA cleavage (IC50 = 80 nM) and inhibits constitutive activation of XBP1 in multiple myeloma cell lines; used to study IRE1α action in the endoplasmic reticulum stress response
17371	Toyocamycin (hydrate	10 mg	≥98%	A natural adenosine analog that prevents IRE1α-induced mRNA cleavage (IC50 = 80 nM) and inhibits constitutive activation of XBP1 in multiple myeloma cell lines; used to study IRE1α action in the endoplasmic reticulum stress response
17371	Toyocamycin (hydrate	25 mg	≥98%	A natural adenosine analog that prevents IRE1α-induced mRNA cleavage (IC50 = 80 nM) and inhibits constitutive activation of XBP1 in multiple myeloma cell lines; used to study IRE1α action in the endoplasmic reticulum stress response
17371	Toyocamycin (hydrate	5 mg	≥98%	A natural adenosine analog that prevents IRE1α-induced mRNA cleavage (IC50 = 80 nM) and inhibits constitutive activation of XBP1 in multiple myeloma cell lines; used to study IRE1α action in the endoplasmic reticulum stress response
17372	GSK2656157	10 mg	≥98%	A selective inhibitor of PERK (IC50 = 0.9 nM); blocks both stress-induced PERK autophosphorylation and eIF2α substrate phosphorylation and decreases levels of ATF4 and CHOP in multiple cell lines
17372	GSK2656157	25 mg	≥98%	A selective inhibitor of PERK (IC50 = 0.9 nM); blocks both stress-induced PERK autophosphorylation and eIF2α substrate phosphorylation and decreases levels of ATF4 and CHOP in multiple cell lines
17372	GSK2656157	5 mg	≥98%	A selective inhibitor of PERK (IC50 = 0.9 nM); blocks both stress-induced PERK autophosphorylation and eIF2α substrate phosphorylation and decreases levels of ATF4 and CHOP in multiple cell lines
17372	GSK2656157	50 mg	≥98%	A selective inhibitor of PERK (IC50 = 0.9 nM); blocks both stress-induced PERK autophosphorylation and eIF2α substrate phosphorylation and decreases levels of ATF4 and CHOP in multiple cell lines
17376	GSK2606414	1 mg	≥98%	A selective PERK inhibitor (IC50 = 0.4 nM); inhibits PERK activation in cells and the growth of a human tumor xenograft in mice
17376	GSK2606414	10 mg	≥98%	A selective PERK inhibitor (IC50 = 0.4 nM); inhibits PERK activation in cells and the growth of a human tumor xenograft in mice
17376	GSK2606414	5 mg	≥98%	A selective PERK inhibitor (IC50 = 0.4 nM); inhibits PERK activation in cells and the growth of a human tumor xenograft in mice
17376	GSK2606414	50 mg	≥98%	A selective PERK inhibitor (IC50 = 0.4 nM); inhibits PERK activation in cells and the growth of a human tumor xenograft in mice
17377	GSK2126458	1 mg	≥98%	A potent inhibitor of PI3K isoforms (Kis = 19, 130, 24, and 60 pM for p110α, β, δ, and γ, respectively); also inhibits mTOR in both mTORC1 and mTORC2 (Kis = 180 and 300 nM, respectively); orally bioavailable, displays favorable pharmacokinetics, and shows efficacy in tumor growth models
17377	GSK2126458	10 mg	≥98%	A potent inhibitor of PI3K isoforms (Kis = 19, 130, 24, and 60 pM for p110α, β, δ, and γ, respectively); also inhibits mTOR in both mTORC1 and mTORC2 (Kis = 180 and 300 nM, respectively); orally bioavailable, displays favorable pharmacokinetics, and shows efficacy in tumor growth models

17377	GSK2126458	5 mg	≥98%	A potent inhibitor of PI3K isoforms (Kis = 19, 130, 24, and 60 pM for p110α, β, δ, and γ, respectively); also inhibits mTOR in both mTORC1 and mTORC2 (Kis = 180 and 300 nM, respectively); orally bioavailable, displays favorable pharmacokinetics, and shows efficacy in tumor growth models
17377	GSK2126458	50 mg	≥98%	A potent inhibitor of PI3K isoforms (Kis = 19, 130, 24, and 60 pM for p110α, β, δ, and γ, respectively); also inhibits mTOR in both mTORC1 and mTORC2 (Kis = 180 and 300 nM, respectively); orally bioavailable, displays favorable pharmacokinetics, and shows efficacy in tumor growth models
17378	AZD 2014	1 mg	≥98%	A potent, selective, ATP-competitive mTORC1/2 dual inhibitor (IC50 = 2.81 nM against the isolated recombinant enzyme); exhibits >1,000-fold selectivity against all PI3K isoforms; has broad antiproliferative effects across multiple cell lines, reduces tumor growth in in vivo models of ER+ breast cancer, and acts as a radiosensitizer
17378	AZD 2014	10 mg	≥98%	A potent, selective, ATP-competitive mTORC1/2 dual inhibitor (IC50 = 2.81 nM against the isolated recombinant enzyme); exhibits >1,000-fold selectivity against all PI3K isoforms; has broad antiproliferative effects across multiple cell lines, reduces tumor growth in in vivo models of ER+ breast cancer, and acts as a radiosensitizer
17378	AZD 2014	25 mg	≥98%	A potent, selective, ATP-competitive mTORC1/2 dual inhibitor (IC50 = 2.81 nM against the isolated recombinant enzyme); exhibits >1,000-fold selectivity against all PI3K isoforms; has broad antiproliferative effects across multiple cell lines, reduces tumor growth in in vivo models of ER+ breast cancer, and acts as a radiosensitizer
17378	AZD 2014	5 mg	≥98%	A potent, selective, ATP-competitive mTORC1/2 dual inhibitor (IC50 = 2.81 nM against the isolated recombinant enzyme); exhibits >1,000-fold selectivity against all PI3K isoforms; has broad antiproliferative effects across multiple cell lines, reduces tumor growth in in vivo models of ER+ breast cancer, and acts as a radiosensitizer
17379	OSI-027	1 mg	≥98%	An inhibitor of the catalytic site of mTOR, inhibiting both mTORC1 and mTORC2 (IC50s = 22 and 65 nM, respectively); prohibits proliferation, induces autophagy, and potentiates apoptosis in BCR-ABL transformed cells and other cancer cells at 10 µM; effective in vivo
17379	OSI-027	10 mg	≥98%	An inhibitor of the catalytic site of mTOR, inhibiting both mTORC1 and mTORC2 (IC50s = 22 and 65 nM, respectively); prohibits proliferation, induces autophagy, and potentiates apoptosis in BCR-ABL transformed cells and other cancer cells at 10 µM; effective in vivo
17379	OSI-027	5 mg	≥98%	An inhibitor of the catalytic site of mTOR, inhibiting both mTORC1 and mTORC2 (IC50s = 22 and 65 nM, respectively); prohibits proliferation, induces autophagy, and potentiates apoptosis in BCR-ABL transformed cells and other cancer cells at 10 µM; effective in vivo
17379	OSI-027	50 mg	≥98%	An inhibitor of the catalytic site of mTOR, inhibiting both mTORC1 and mTORC2 (IC50s = 22 and 65 nM, respectively); prohibits proliferation, induces autophagy, and potentiates apoptosis in BCR-ABL transformed cells and other cancer cells at 10 µM; effective in vivo
17380	GSK2636771	1 mg	≥98%	An orally bioavailable inhibitor of PI3K p110β that decreases cell viability and Akt phosphorylation in p100β-dependent PTEN-deficient PC-3 prostate and BT549 and HCC70 breast cancer cell lines
17380	GSK2636771	10 mg	≥98%	An orally bioavailable inhibitor of PI3K p110β that decreases cell viability and Akt phosphorylation in p100β-dependent PTEN-deficient PC-3 prostate and BT549 and HCC70 breast cancer cell lines
17380	GSK2636771	5 mg	≥98%	An orally bioavailable inhibitor of PI3K p110β that decreases cell viability and Akt phosphorylation in p100β-dependent PTEN-deficient PC-3 prostate and BT549 and HCC70 breast cancer cell lines
17380	GSK2636771	500 µg	≥98%	An orally bioavailable inhibitor of PI3K p110β that decreases cell viability and Akt phosphorylation in p100β-dependent PTEN-deficient PC-3 prostate and BT549 and HCC70 breast cancer cell lines
17381	ZSTK474	10 mg	≥98%	A selective inhibitor of class I PI3K isoforms (IC50s = 17, 53, and 6 nM for p110β, -γ, and -δ, respectively); orally bioavailable, showing strong antitumor activity against human cancer xenografts in mice
17381	ZSTK474	25 mg	≥98%	A selective inhibitor of class I PI3K isoforms (IC50s = 17, 53, and 6 nM for p110β, -γ, and -δ, respectively); orally bioavailable, showing strong antitumor activity against human cancer xenografts in mice
17381	ZSTK474	5 mg	≥98%	A selective inhibitor of class I PI3K isoforms (IC50s = 17, 53, and 6 nM for p110β, -γ, and -δ, respectively); orally bioavailable, showing strong antitumor activity against human cancer xenografts in mice
17381	ZSTK474	50 mg	≥98%	A selective inhibitor of class I PI3K isoforms (IC50s = 17, 53, and 6 nM for p110β, -γ, and -δ, respectively); orally bioavailable, showing strong antitumor activity against human cancer xenografts in mice
17382	A-66	1 mg	≥98%	A potent, selective inhibitor of the PI3K isoform p110α (IC50 = 32 nM in a cell-free assay); suppresses the growth of SK-OV-3 tumor xenografts and impairs all measures of in vivo insulin action in mice

17382	A-66	10 mg	≥98%	A potent, selective inhibitor of the PI3K isoform p110α (IC50 = 32 nM in a cell-free assay); suppresses the growth of SK-OV-3 tumor xenografts and impairs all measures of in vivo insulin action in mice
17382	A-66	25 mg	≥98%	A potent, selective inhibitor of the PI3K isoform p110α (IC50 = 32 nM in a cell-free assay); suppresses the growth of SK-OV-3 tumor xenografts and impairs all measures of in vivo insulin action in mice
17382	A-66	5 mg	≥98%	A potent, selective inhibitor of the PI3K isoform p110α (IC50 = 32 nM in a cell-free assay); suppresses the growth of SK-OV-3 tumor xenografts and impairs all measures of in vivo insulin action in mice
17383	AMG 319	1 mg	≥98%	A potent, selective inhibitor of PI3Kδ (IC50 = 18 nM); blocks anti-IgM/CD40L-induced proliferation (IC50 = 8.6 nM) and reduces Akt phosphorylation (IC50 = 1.5 nM) in B cells; reduces inflammation in two animal models
17383	AMG 319	10 mg	≥98%	A potent, selective inhibitor of PI3Kδ (IC50 = 18 nM); blocks anti-IgM/CD40L-induced proliferation (IC50 = 8.6 nM) and reduces Akt phosphorylation (IC50 = 1.5 nM) in B cells; reduces inflammation in two animal models
17383	AMG 319	25 mg	≥98%	A potent, selective inhibitor of PI3Kδ (IC50 = 18 nM); blocks anti-IgM/CD40L-induced proliferation (IC50 = 8.6 nM) and reduces Akt phosphorylation (IC50 = 1.5 nM) in B cells; reduces inflammation in two animal models
17383	AMG 319	5 mg	≥98%	A potent, selective inhibitor of PI3Kδ (IC50 = 18 nM); blocks anti-IgM/CD40L-induced proliferation (IC50 = 8.6 nM) and reduces Akt phosphorylation (IC50 = 1.5 nM) in B cells; reduces inflammation in two animal models
17384	AZD 8186	1 mg	≥98%	A selective PI3Kβ/δ inhibitor (IC50 = 3, 17, and 752 nM for PI3Kβ, δ, and α, respectively); shows no significant binding against a panel of 442 other kinases; inhibits growth of a range of cell lines, with preferential activity in cells with PTEN mutation or deficiency; orally bioavailable
17384	AZD 8186	10 mg	≥98%	A selective PI3Kβ/δ inhibitor (IC50 = 3, 17, and 752 nM for PI3Kβ, δ, and α, respectively); shows no significant binding against a panel of 442 other kinases; inhibits growth of a range of cell lines, with preferential activity in cells with PTEN mutation or deficiency; orally bioavailable
17384	AZD 8186	25 mg	≥98%	A selective PI3Kβ/δ inhibitor (IC50 = 3, 17, and 752 nM for PI3Kβ, δ, and α, respectively); shows no significant binding against a panel of 442 other kinases; inhibits growth of a range of cell lines, with preferential activity in cells with PTEN mutation or deficiency; orally bioavailable
17384	AZD 8186	5 mg	≥98%	A selective PI3Kβ/δ inhibitor (IC50 = 3, 17, and 752 nM for PI3Kβ, δ, and α, respectively); shows no significant binding against a panel of 442 other kinases; inhibits growth of a range of cell lines, with preferential activity in cells with PTEN mutation or deficiency; orally bioavailable
17385	BI-2536	1 mg	≥95%	A selective inhibitor of Plk1 (IC50 = 0.83 nM); induces mitotic arrest and apoptosis in diverse human cancer cell lines and drives regression of human tumor xenografts in nude mice; also an inhibitor of BRD4 (IC50 = 25 nM)
17385	BI-2536	10 mg	≥95%	A selective inhibitor of Plk1 (IC50 = 0.83 nM); induces mitotic arrest and apoptosis in diverse human cancer cell lines and drives regression of human tumor xenografts in nude mice; also an inhibitor of BRD4 (IC50 = 25 nM)
17385	BI-2536	5 mg	≥95%	A selective inhibitor of Plk1 (IC50 = 0.83 nM); induces mitotic arrest and apoptosis in diverse human cancer cell lines and drives regression of human tumor xenografts in nude mice; also an inhibitor of BRD4 (IC50 = 25 nM)
17385	BI-2536	50 mg	≥95%	A selective inhibitor of Plk1 (IC50 = 0.83 nM); induces mitotic arrest and apoptosis in diverse human cancer cell lines and drives regression of human tumor xenografts in nude mice; also an inhibitor of BRD4 (IC50 = 25 nM)
17387	GDC-0032	1 mg	≥98%	A potent inhibitor of PI3K isoforms α, δ, and γ (IC50s = 0.28, 0.12, and 0.97 nM, respectively) that is 31 times less potent at PI3Kβ; has increased potency in cancer cell lines harboring PIK3CA-activating alterations, and is effective in vivo
17387	GDC-0032	10 mg	≥98%	A potent inhibitor of PI3K isoforms α, δ, and γ (IC50s = 0.28, 0.12, and 0.97 nM, respectively) that is 31 times less potent at PI3Kβ; has increased potency in cancer cell lines harboring PIK3CA-activating alterations, and is effective in vivo
17387	GDC-0032	5 mg	≥98%	A potent inhibitor of PI3K isoforms α, δ, and γ (IC50s = 0.28, 0.12, and 0.97 nM, respectively) that is 31 times less potent at PI3Kβ; has increased potency in cancer cell lines harboring PIK3CA-activating alterations, and is effective in vivo
17388	GSK2269557	1 mg	≥98%	A selective PI3Kδ inhibitor (pKi = 9.9) that is active in a brown Norway rat acute ovalbumin-induced allergic asthma model of Th2-driven lung inflammation (ED50 = 67 μg/kg)
17388	GSK2269557	10 mg	≥98%	A selective PI3Kδ inhibitor (pKi = 9.9) that is active in a brown Norway rat acute ovalbumin-induced allergic asthma model of Th2-driven lung inflammation (ED50 = 67 μg/kg)
17388	GSK2269557	25 mg	≥98%	A selective PI3Kδ inhibitor (pKi = 9.9) that is active in a brown Norway rat acute ovalbumin-induced allergic asthma model of Th2-driven lung inflammation (ED50 = 67 μg/kg)

17388	GSK2269557	5 mg	≥98%	A selective PI3Kδ inhibitor (pKi = 9.9) that is active in a brown Norway rat acute ovalbumin-induced allergic asthma model of Th2-driven lung inflammation (ED50 = 67 µg/kg)
17391	SAR260301	1 mg	≥98%	A selective inhibitor of PI3Kβ (IC50 = 52 nM); demonstrates significant in vivo activity in a UACC-62 xenograft model in mice
17391	SAR260301	10 mg	≥98%	A selective inhibitor of PI3Kβ (IC50 = 52 nM); demonstrates significant in vivo activity in a UACC-62 xenograft model in mice
17391	SAR260301	25 mg	≥98%	A selective inhibitor of PI3Kβ (IC50 = 52 nM); demonstrates significant in vivo activity in a UACC-62 xenograft model in mice
17391	SAR260301	5 mg	≥98%	A selective inhibitor of PI3Kβ (IC50 = 52 nM); demonstrates significant in vivo activity in a UACC-62 xenograft model in mice
17392	Vps34-IN1	1 mg	≥98%	A potent and selective inhibitor of Vps34 (IC50 = 25 nM in vitro); dose-dependently inhibits generation of PtdIns-(3)-p, which is essential to the formation and trafficking of endsomes and autophagosomes, without affecting the ability of class I PI3K to regulate Akt; induces a rapid and pronounced loss of phosphorylation on serum- and glucocorticoid-regulated kinase 3
17392	Vps34-IN1	10 mg	≥98%	A potent and selective inhibitor of Vps34 (IC50 = 25 nM in vitro); dose-dependently inhibits generation of PtdIns-(3)-p, which is essential to the formation and trafficking of endsomes and autophagosomes, without affecting the ability of class I PI3K to regulate Akt; induces a rapid and pronounced loss of phosphorylation on serum- and glucocorticoid-regulated kinase 3
17392	Vps34-IN1	25 mg	≥98%	A potent and selective inhibitor of Vps34 (IC50 = 25 nM in vitro); dose-dependently inhibits generation of PtdIns-(3)-p, which is essential to the formation and trafficking of endsomes and autophagosomes, without affecting the ability of class I PI3K to regulate Akt; induces a rapid and pronounced loss of phosphorylation on serum- and glucocorticoid-regulated kinase 3
17392	Vps34-IN1	5 mg	≥98%	A potent and selective inhibitor of Vps34 (IC50 = 25 nM in vitro); dose-dependently inhibits generation of PtdIns-(3)-p, which is essential to the formation and trafficking of endsomes and autophagosomes, without affecting the ability of class I PI3K to regulate Akt; induces a rapid and pronounced loss of phosphorylation on serum- and glucocorticoid-regulated kinase 3
17410	SU 5614	1 mg	≥98%	A multi-kinase inhibitor; inhibits growth and induces apoptosis in Ba/F3 and AML cell lines expressing constitutively active FLT3 (IC50s = 150-650 nM) but not those expressing TEL-ABL, TEL-JAK2, or BCR-ABL (IC50s = >10 µM); inhibits C-KIT, VEGFR, and PDGFRβ in vitro (IC50s = 0.03, 0.46, and 0.36 µM, respectively)
17410	SU 5614	10 mg	≥98%	A multi-kinase inhibitor; inhibits growth and induces apoptosis in Ba/F3 and AML cell lines expressing constitutively active FLT3 (IC50s = 150-650 nM) but not those expressing TEL-ABL, TEL-JAK2, or BCR-ABL (IC50s = >10 µM); inhibits C-KIT, VEGFR, and PDGFRβ in vitro (IC50s = 0.03, 0.46, and 0.36 µM, respectively)
17410	SU 5614	25 mg	≥98%	A multi-kinase inhibitor; inhibits growth and induces apoptosis in Ba/F3 and AML cell lines expressing constitutively active FLT3 (IC50s = 150-650 nM) but not those expressing TEL-ABL, TEL-JAK2, or BCR-ABL (IC50s = >10 µM); inhibits C-KIT, VEGFR, and PDGFRβ in vitro (IC50s = 0.03, 0.46, and 0.36 µM, respectively)
17410	SU 5614	5 mg	≥98%	A multi-kinase inhibitor; inhibits growth and induces apoptosis in Ba/F3 and AML cell lines expressing constitutively active FLT3 (IC50s = 150-650 nM) but not those expressing TEL-ABL, TEL-JAK2, or BCR-ABL (IC50s = >10 µM); inhibits C-KIT, VEGFR, and PDGFRβ in vitro (IC50s = 0.03, 0.46, and 0.36 µM, respectively)
17459	(5Z)-7-Oxozeaenol	1 mg	≥99%	A natural resorcylic lactone derived from fungi that selectively inhibits purified TAK-1 (IC50 = 8.1 nM when co-expressed with the TAK-1-binding protein, TAB1); irreversibly blocks IL-1-induced activation of TAK-1, NF-κB, and JNK/p38 (IC50s = 65-83 nM) and sensitizes cells to TRAIL- and TNF-α-induced apoptosis in vitro
17459	(5Z)-7-Oxozeaenol	5 mg	≥99%	A natural resorcylic lactone derived from fungi that selectively inhibits purified TAK-1 (IC50 = 8.1 nM when co-expressed with the TAK-1-binding protein, TAB1); irreversibly blocks IL-1-induced activation of TAK-1, NF-κB, and JNK/p38 (IC50s = 65-83 nM) and sensitizes cells to TRAIL- and TNF-α-induced apoptosis in vitro
17476	PKCε Inhibitor Peptide	1 mg	≥95%	A synthetic peptide corresponding to an amino acid sequence found in the amino terminal C2 domain of most mammalian forms of PKŒ; selectively and reversibly inhibits the translocation of PKCε to intracellular membranes, blocking activation
17476	PKCε Inhibitor Peptide	10 mg	≥95%	A synthetic peptide corresponding to an amino acid sequence found in the amino terminal C2 domain of most mammalian forms of PKŒ; selectively and reversibly inhibits the translocation of PKCε to intracellular membranes, blocking activation
17476	PKCε Inhibitor Peptide	5 mg	≥95%	A synthetic peptide corresponding to an amino acid sequence found in the amino terminal C2 domain of most mammalian forms of PKŒ; selectively and reversibly inhibits the translocation of PKCε to intracellular membranes, blocking activation

17476	PKCε Inhibitor Peptide	500 µg	≥95%	A synthetic peptide corresponding to an amino acid sequence found in the amino terminal C2 domain of most mammalian forms of PKCŒ; selectively and reversibly inhibits the translocation of PKCε to intracellular membranes, blocking activation
17478	PKCα (C2-4) Inhibitor	1 mg	≥95%	A synthetic peptide that blocks PKC activity in HepG2 cells stimulated with calcium and diacylglycerol when applied at 10 µM
17478	PKCα (C2-4) Inhibitor	5 mg	≥95%	A synthetic peptide that blocks PKC activity in HepG2 cells stimulated with calcium and diacylglycerol when applied at 10 µM
17478	PKCα (C2-4) Inhibitor	500 µg	≥95%	A synthetic peptide that blocks PKC activity in HepG2 cells stimulated with calcium and diacylglycerol when applied at 10 µM
17482	PKCζ Pseudosubstrate	1 mg	≥95%	A synthetic peptide that that selectively, reversibly, and substrate-competitively inhibits PKCζ activity and, thus, is used to delineate the signaling functions of PKCζ
17482	PKCζ Pseudosubstrate	5 mg	≥95%	A synthetic peptide that that selectively, reversibly, and substrate-competitively inhibits PKCζ activity and, thus, is used to delineate the signaling functions of PKCζ
17482	PKCζ Pseudosubstrate	500 µg	≥95%	A synthetic peptide that that selectively, reversibly, and substrate-competitively inhibits PKCζ activity and, thus, is used to delineate the signaling functions of PKCζ
17483	PKCθ Pseudosubstrate	1 mg	≥95%	A synthetic peptide that corresponds to amino acid residues of the pseudosubstrate domain of PKCθ
17483	PKCθ Pseudosubstrate	500 µg	≥95%	A synthetic peptide that corresponds to amino acid residues of the pseudosubstrate domain of PKCθ
17486	PKA Inhibitor Fragmer	1 mg		A synthetic peptide inhibitor of PKA (Ki = 1.7 nM)
17486	PKA Inhibitor Fragmer	10 mg		A synthetic peptide inhibitor of PKA (Ki = 1.7 nM)
17486	PKA Inhibitor Fragmer	5 mg		A synthetic peptide inhibitor of PKA (Ki = 1.7 nM)
17486	PKA Inhibitor Fragmer	500 µg		A synthetic peptide inhibitor of PKA (Ki = 1.7 nM)
17502	Ku-60019	1 mg	≥98%	A potent, reversible inhibitor of ATM kinase (IC50 = 6.3 nM), blocking the phosphorylation of ATM substrate proteins; sensitizes glioma cells to radiation and inhibits migration and invasion of glioma cells in vitro; produces radiosensitization and increases survival in vivo when administered intra-tumorally
17502	Ku-60019	10 mg	≥98%	A potent, reversible inhibitor of ATM kinase (IC50 = 6.3 nM), blocking the phosphorylation of ATM substrate proteins; sensitizes glioma cells to radiation and inhibits migration and invasion of glioma cells in vitro; produces radiosensitization and increases survival in vivo when administered intra-tumorally
17502	Ku-60019	25 mg	≥98%	A potent, reversible inhibitor of ATM kinase (IC50 = 6.3 nM), blocking the phosphorylation of ATM substrate proteins; sensitizes glioma cells to radiation and inhibits migration and invasion of glioma cells in vitro; produces radiosensitization and increases survival in vivo when administered intra-tumorally
17502	Ku-60019	5 mg	≥98%	A potent, reversible inhibitor of ATM kinase (IC50 = 6.3 nM), blocking the phosphorylation of ATM substrate proteins; sensitizes glioma cells to radiation and inhibits migration and invasion of glioma cells in vitro; produces radiosensitization and increases survival in vivo when administered intra-tumorally
17505	BMS 754807	1 mg	≥98%	A reversible, orally bioavailable dual inhibitor of IGF-1R and InsR tyrosine kinases (IC50s = 1.8 and 1.7 nM, respectively); inhibits cell proliferation or induces apoptosis in a variety of cancer cells in vitro; inhibits the growth of tumor xenografts in mice
17505	BMS 754807	10 mg	≥98%	A reversible, orally bioavailable dual inhibitor of IGF-1R and InsR tyrosine kinases (IC50s = 1.8 and 1.7 nM, respectively); inhibits cell proliferation or induces apoptosis in a variety of cancer cells in vitro; inhibits the growth of tumor xenografts in mice
17505	BMS 754807	5 mg	≥98%	A reversible, orally bioavailable dual inhibitor of IGF-1R and InsR tyrosine kinases (IC50s = 1.8 and 1.7 nM, respectively); inhibits cell proliferation or induces apoptosis in a variety of cancer cells in vitro; inhibits the growth of tumor xenografts in mice
17511	Bisindolylmaleimide X	1 mg	≥98%	A cell-permeable, reversible, ATP-competitive PKC inhibitor (IC50 = 15 nM, rat brain PKC); inhibits PKCα, βI, βII, γ, and ε with IC50 values of 8, 8, 14, 13, and 39 nM, respectively; also inhibits Cdk2 (IC50 = 200 nM) and GSK3α/β; used to activate mesenchymal stem cells and target their delivery to sites of inflammation
17511	Bisindolylmaleimide X	5 mg	≥98%	A cell-permeable, reversible, ATP-competitive PKC inhibitor (IC50 = 15 nM, rat brain PKC); inhibits PKCα, βI, βII, γ, and ε with IC50 values of 8, 8, 14, 13, and 39 nM, respectively; also inhibits Cdk2 (IC50 = 200 nM) and GSK3α/β; used to activate mesenchymal stem cells and target their delivery to sites of inflammation
17540	IRAK-1/4 Inhibitor	1 mg	≥98%	A benzimidazole that selectively disrupts the activity of IRAK 1 and 4 (IC50 = 0.3 and 0.2 µM, respectively)
17540	IRAK-1/4 Inhibitor	10 mg	≥98%	A benzimidazole that selectively disrupts the activity of IRAK 1 and 4 (IC50 = 0.3 and 0.2 µM, respectively)

17540	IRAK-1/4 Inhibitor	25 mg	≥98%	A benzimidazole that selectively disrupts the activity of IRAK 1 and 4 (IC50 = 0.3 and 0.2 µM, respectively)
17540	IRAK-1/4 Inhibitor	5 mg	≥98%	A benzimidazole that selectively disrupts the activity of IRAK 1 and 4 (IC50 = 0.3 and 0.2 µM, respectively)
17541	Aurora Kinase Inhibito	1 mg	≥98%	A cell-permeable anilinoquinazoline that blocks the activity of Aurora A (IC50 = 0.39 µM); blocks MCF-7 cells proliferation with an IC50 value of 1.25 µM
17541	Aurora Kinase Inhibito	10 mg	≥98%	A cell-permeable anilinoquinazoline that blocks the activity of Aurora A (IC50 = 0.39 µM); blocks MCF-7 cells proliferation with an IC50 value of 1.25 µM
17541	Aurora Kinase Inhibito	5 mg	≥98%	A cell-permeable anilinoquinazoline that blocks the activity of Aurora A (IC50 = 0.39 µM); blocks MCF-7 cells proliferation with an IC50 value of 1.25 µM
17541	Aurora Kinase Inhibito	500 µg	≥98%	A cell-permeable anilinoquinazoline that blocks the activity of Aurora A (IC50 = 0.39 µM); blocks MCF-7 cells proliferation with an IC50 value of 1.25 µM
17542	JNK Inhibitor V	1 mg	≥98% (sum of	An ATP-competitive inhibitor of JNK1, JNK2, and JNK3 (IC50s = 150, 220, and 70 nM, respectively); effective in vivo in gerbils, mice, and rats via oral, intravenous, or intraperitoneal administration
17542	JNK Inhibitor V	10 mg	≥98% (sum of	An ATP-competitive inhibitor of JNK1, JNK2, and JNK3 (IC50s = 150, 220, and 70 nM, respectively); effective in vivo in gerbils, mice, and rats via oral, intravenous, or intraperitoneal administration
17542	JNK Inhibitor V	25 mg	≥98% (sum of	An ATP-competitive inhibitor of JNK1, JNK2, and JNK3 (IC50s = 150, 220, and 70 nM, respectively); effective in vivo in gerbils, mice, and rats via oral, intravenous, or intraperitoneal administration
17542	JNK Inhibitor V	5 mg	≥98% (sum of	An ATP-competitive inhibitor of JNK1, JNK2, and JNK3 (IC50s = 150, 220, and 70 nM, respectively); effective in vivo in gerbils, mice, and rats via oral, intravenous, or intraperitoneal administration
17543	GTP 14564	1 mg	≥98%	An inhibitor of class III receptor tyrosine kinases (IC50s = 0.3 µM for c-Fms, c-Kit, ITD-FLT3 and 1 µM for PDGFRβ); blocks the proliferation of leukemia cells stimulated with FLT3 ligand by preventing the activation of STAT5
17543	GTP 14564	5 mg	≥98%	An inhibitor of class III receptor tyrosine kinases (IC50s = 0.3 µM for c-Fms, c-Kit, ITD-FLT3 and 1 µM for PDGFRβ); blocks the proliferation of leukemia cells stimulated with FLT3 ligand by preventing the activation of STAT5
17543	GTP 14564	500 µg	≥98%	An inhibitor of class III receptor tyrosine kinases (IC50s = 0.3 µM for c-Fms, c-Kit, ITD-FLT3 and 1 µM for PDGFRβ); blocks the proliferation of leukemia cells stimulated with FLT3 ligand by preventing the activation of STAT5
17544	VEGFR2 Kinase Inhibit	1 mg	≥95%	A reversible, cell-permeable inhibitor of VEGFR2's kinase activity (IC50 = 70 nM); less potently inhibits PDGFRβ (IC50 = 920 nM); blocks the growth of human umbilical vein endothelial cells stimulated with either VEGF or PDGF (IC50s = 110 nM and 2 µM, respectively)
17544	VEGFR2 Kinase Inhibit	5 mg	≥95%	A reversible, cell-permeable inhibitor of VEGFR2's kinase activity (IC50 = 70 nM); less potently inhibits PDGFRβ (IC50 = 920 nM); blocks the growth of human umbilical vein endothelial cells stimulated with either VEGF or PDGF (IC50s = 110 nM and 2 µM, respectively)
17544	VEGFR2 Kinase Inhibit	500 µg	≥95%	A reversible, cell-permeable inhibitor of VEGFR2's kinase activity (IC50 = 70 nM); less potently inhibits PDGFRβ (IC50 = 920 nM); blocks the growth of human umbilical vein endothelial cells stimulated with either VEGF or PDGF (IC50s = 110 nM and 2 µM, respectively)
17551	DMPQ (hydrochloride	1 mg	≥98%	A potent inhibitor of human PDGFRβ (IC50 = 80 nM)
17551	DMPQ (hydrochloride	10 mg	≥98%	A potent inhibitor of human PDGFRβ (IC50 = 80 nM)
17551	DMPQ (hydrochloride	5 mg	≥98%	A potent inhibitor of human PDGFRβ (IC50 = 80 nM)
17552	Chk2 Inhibitor II	1 mg	≥98%	A selective, ATP-competitive inhibitor of the DNA damage control kinase, Chk2 (IC50 = 15 nM); prevents apoptosis in human T-cells exposed to ionizing radiation (EC50 = 3-7.6 µM)
17552	Chk2 Inhibitor II	10 mg	≥98%	A selective, ATP-competitive inhibitor of the DNA damage control kinase, Chk2 (IC50 = 15 nM); prevents apoptosis in human T-cells exposed to ionizing radiation (EC50 = 3-7.6 µM)
17552	Chk2 Inhibitor II	5 mg	≥98%	A selective, ATP-competitive inhibitor of the DNA damage control kinase, Chk2 (IC50 = 15 nM); prevents apoptosis in human T-cells exposed to ionizing radiation (EC50 = 3-7.6 µM)
17568	EGFR/ErbB2 Inhibitor	1 mg	≥95%	A cell-permeable inhibitor of EGFR and c-ErbB2 (IC50s = 20 and 79 nM, respectively); inhibits the proliferation of cancer cells overexpressing either c-ErbB2 or EGFR (IC50s = 2.3-2.5 µM)
17568	EGFR/ErbB2 Inhibitor	5 mg	≥95%	A cell-permeable inhibitor of EGFR and c-ErbB2 (IC50s = 20 and 79 nM, respectively); inhibits the proliferation of cancer cells overexpressing either c-ErbB2 or EGFR (IC50s = 2.3-2.5 µM)

17569	Adenosine Kinase Inh	1 mg	≥98%	A non-nucleoside pyridopyrimidine compound that selectively blocks the action of adenosine kinase in an adenosine-competitive manner (IC50 = 1.7 nM in cell-free assays); suppresses nociception in various rodent pain models
17569	Adenosine Kinase Inh	10 mg	≥98%	A non-nucleoside pyridopyrimidine compound that selectively blocks the action of adenosine kinase in an adenosine-competitive manner (IC50 = 1.7 nM in cell-free assays); suppresses nociception in various rodent pain models
17569	Adenosine Kinase Inh	5 mg	≥98%	A non-nucleoside pyridopyrimidine compound that selectively blocks the action of adenosine kinase in an adenosine-competitive manner (IC50 = 1.7 nM in cell-free assays); suppresses nociception in various rodent pain models
17587	VE-821	1 mg	≥98%	An ATP-competitive inhibitor of ATR (IC50 = 26 nM); augments DNA damage and cell death of cancer cells in response to radiation under normal and hypoxic conditions; sensitizes cancer cells to chemotherapy
17587	VE-821	10 mg	≥98%	An ATP-competitive inhibitor of ATR (IC50 = 26 nM); augments DNA damage and cell death of cancer cells in response to radiation under normal and hypoxic conditions; sensitizes cancer cells to chemotherapy
17587	VE-821	5 mg	≥98%	An ATP-competitive inhibitor of ATR (IC50 = 26 nM); augments DNA damage and cell death of cancer cells in response to radiation under normal and hypoxic conditions; sensitizes cancer cells to chemotherapy
17589	AZ 20	1 mg	≥98%	A potent, selective inhibitor of ATR (IC50 = 5 nM); inhibits the growth of LoVo colorectal adenocarcinoma cells in vitro and significantly reduces the growth of LoVo xenografts in mice
17589	AZ 20	10 mg	≥98%	A potent, selective inhibitor of ATR (IC50 = 5 nM); inhibits the growth of LoVo colorectal adenocarcinoma cells in vitro and significantly reduces the growth of LoVo xenografts in mice
17589	AZ 20	25 mg	≥98%	A potent, selective inhibitor of ATR (IC50 = 5 nM); inhibits the growth of LoVo colorectal adenocarcinoma cells in vitro and significantly reduces the growth of LoVo xenografts in mice
17589	AZ 20	5 mg	≥98%	A potent, selective inhibitor of ATR (IC50 = 5 nM); inhibits the growth of LoVo colorectal adenocarcinoma cells in vitro and significantly reduces the growth of LoVo xenografts in mice
17590	Autocamtide-2-relate	1 mg	≥95%	A selective CaMKII inhibitor (IC50 = 40 nM) that was designed based on the sequence around the autophosphorylation site (Thr286/Thr287) in the autoinhibitory domain of the protein kinase
17590	Autocamtide-2-relate	10 mg	≥95%	A selective CaMKII inhibitor (IC50 = 40 nM) that was designed based on the sequence around the autophosphorylation site (Thr286/Thr287) in the autoinhibitory domain of the protein kinase
17590	Autocamtide-2-relate	5 mg	≥95%	A selective CaMKII inhibitor (IC50 = 40 nM) that was designed based on the sequence around the autophosphorylation site (Thr286/Thr287) in the autoinhibitory domain of the protein kinase
17640	ML-347	1 mg	≥95%	Selectively inhibits ALK1 (IC50 = 46 nM) and ALK2 (IC50 = 32 nM) with >300-fold selectivity over ALK3, ALK6, and VEGF type 2 receptor; inhibits BMP4 signaling with an IC50 value of 152 nM in a functional assay
17640	ML-347	10 mg	≥95%	Selectively inhibits ALK1 (IC50 = 46 nM) and ALK2 (IC50 = 32 nM) with >300-fold selectivity over ALK3, ALK6, and VEGF type 2 receptor; inhibits BMP4 signaling with an IC50 value of 152 nM in a functional assay
17640	ML-347	5 mg	≥95%	Selectively inhibits ALK1 (IC50 = 46 nM) and ALK2 (IC50 = 32 nM) with >300-fold selectivity over ALK3, ALK6, and VEGF type 2 receptor; inhibits BMP4 signaling with an IC50 value of 152 nM in a functional assay
17640	ML-347	50 mg	≥95%	Selectively inhibits ALK1 (IC50 = 46 nM) and ALK2 (IC50 = 32 nM) with >300-fold selectivity over ALK3, ALK6, and VEGF type 2 receptor; inhibits BMP4 signaling with an IC50 value of 152 nM in a functional assay
17648	Cdk4 Inhibitor	1 mg	≥90%	A cell-permeable, asymmetrical indolocarbazole that exhibits antiproliferative activity by selectively blocking cyclin D1/Cdk4 (IC50 = 0.8 µM); inhibits HCT116 and NCI-H460 tumor cell growth (IC50s 1 cell cycle arrest
17648	Cdk4 Inhibitor	5 mg	≥90%	A cell-permeable, asymmetrical indolocarbazole that exhibits antiproliferative activity by selectively blocking cyclin D1/Cdk4 (IC50 = 0.8 µM); inhibits HCT116 and NCI-H460 tumor cell growth (IC50s 1 cell cycle arrest
17648	Cdk4 Inhibitor	500 µg	≥90%	A cell-permeable, asymmetrical indolocarbazole that exhibits antiproliferative activity by selectively blocking cyclin D1/Cdk4 (IC50 = 0.8 µM); inhibits HCT116 and NCI-H460 tumor cell growth (IC50s 1 cell cycle arrest
17649	PD 174265	1 mg	≥98%	A potent, cell-permeable inhibitor of the tyrosine kinase activity of the epidermal growth factor (EGF) receptor (IC50 = 0.45 nM); effective in cells, blocking tyrosine phosphorylation induced by either EGF or heregulin (IC50s = 39 and 220 nM, respectively)

17649	PD 174265	5 mg	≥98%	A potent, cell-permeable inhibitor of the tyrosine kinase activity of the epidermal growth factor (EGF) receptor (IC50 = 0.45 nM); effective in cells, blocking tyrosine phosphorylation induced by either EGF or heregulin (IC50s = 39 and 220 nM, respectively)
17649	PD 174265	500 µg	≥98%	A potent, cell-permeable inhibitor of the tyrosine kinase activity of the epidermal growth factor (EGF) receptor (IC50 = 0.45 nM); effective in cells, blocking tyrosine phosphorylation induced by either EGF or heregulin (IC50s = 39 and 220 nM, respectively)
17650	p38 MAPK Inhibitor	1 mg	≥98%	A potent inhibitor of p38 MAP kinase (IC50 = 35 nM)
17650	p38 MAPK Inhibitor	5 mg	≥98%	A potent inhibitor of p38 MAP kinase (IC50 = 35 nM)
17650	p38 MAPK Inhibitor	500 µg	≥98%	A potent inhibitor of p38 MAP kinase (IC50 = 35 nM)
17652	BIIB-057	1 mg	≥98%	A potent, selective, orally bioavailable inhibitor of Syk (IC50 = 1 nM); blocks B cell receptor-mediated cell signaling and activation in whole blood (IC50s = 0.27 and 0.28 µM, respectively); inhibits inflammation and tumor growth in animal models of rheumatoid arthritis and non-Hodgkin lymphoma, respectively
17652	BIIB-057	10 mg	≥98%	A potent, selective, orally bioavailable inhibitor of Syk (IC50 = 1 nM); blocks B cell receptor-mediated cell signaling and activation in whole blood (IC50s = 0.27 and 0.28 µM, respectively); inhibits inflammation and tumor growth in animal models of rheumatoid arthritis and non-Hodgkin lymphoma, respectively
17652	BIIB-057	5 mg	≥98%	A potent, selective, orally bioavailable inhibitor of Syk (IC50 = 1 nM); blocks B cell receptor-mediated cell signaling and activation in whole blood (IC50s = 0.27 and 0.28 µM, respectively); inhibits inflammation and tumor growth in animal models of rheumatoid arthritis and non-Hodgkin lymphoma, respectively
17652	BIIB-057	500 µg	≥98%	A potent, selective, orally bioavailable inhibitor of Syk (IC50 = 1 nM); blocks B cell receptor-mediated cell signaling and activation in whole blood (IC50s = 0.27 and 0.28 µM, respectively); inhibits inflammation and tumor growth in animal models of rheumatoid arthritis and non-Hodgkin lymphoma, respectively
17653	GS-9973	1 mg	≥95%	A potent Syk inhibitor (IC50 = 7.7 nM) that demonstrates 10-35-fold selectivity for Syk over a panel of 359 nonmutant kinases; used to reduce chronic lymphocytic leukemia cell survival and to disrupt chemokine signaling at nanomolar concentrations in conjunction with the PI3Kδ inhibitor CAL-101
17653	GS-9973	10 mg	≥95%	A potent Syk inhibitor (IC50 = 7.7 nM) that demonstrates 10-35-fold selectivity for Syk over a panel of 359 nonmutant kinases; used to reduce chronic lymphocytic leukemia cell survival and to disrupt chemokine signaling at nanomolar concentrations in conjunction with the PI3Kδ inhibitor CAL-101
17653	GS-9973	5 mg	≥95%	A potent Syk inhibitor (IC50 = 7.7 nM) that demonstrates 10-35-fold selectivity for Syk over a panel of 359 nonmutant kinases; used to reduce chronic lymphocytic leukemia cell survival and to disrupt chemokine signaling at nanomolar concentrations in conjunction with the PI3Kδ inhibitor CAL-101
17653	GS-9973	50 mg	≥95%	A potent Syk inhibitor (IC50 = 7.7 nM) that demonstrates 10-35-fold selectivity for Syk over a panel of 359 nonmutant kinases; used to reduce chronic lymphocytic leukemia cell survival and to disrupt chemokine signaling at nanomolar concentrations in conjunction with the PI3Kδ inhibitor CAL-101
17654	VEGFR Tyrosine Kinas	1 mg	≥98%	Inhibits the kinase activities of VEGFR2 (KDR), VEGFR1 (FLT1), and c-Kit (IC50s = 20, 180, and 240 nM, respectively); possesses antiangiogenic and antitumor properties
17654	VEGFR Tyrosine Kinas	5 mg	≥98%	Inhibits the kinase activities of VEGFR2 (KDR), VEGFR1 (FLT1), and c-Kit (IC50s = 20, 180, and 240 nM, respectively); possesses antiangiogenic and antitumor properties
17665	PF-431396	1 mg	≥98%	A dual inhibitor of FAK and PYK2 (IC50s = 2 and 11 nM, respectively) that increases bone formation, promoting osteoblast recruitment and activity in ovariectomized rats
17665	PF-431396	10 mg	≥98%	A dual inhibitor of FAK and PYK2 (IC50s = 2 and 11 nM, respectively) that increases bone formation, promoting osteoblast recruitment and activity in ovariectomized rats
17665	PF-431396	5 mg	≥98%	A dual inhibitor of FAK and PYK2 (IC50s = 2 and 11 nM, respectively) that increases bone formation, promoting osteoblast recruitment and activity in ovariectomized rats
17665	PF-431396	50 mg	≥98%	A dual inhibitor of FAK and PYK2 (IC50s = 2 and 11 nM, respectively) that increases bone formation, promoting osteoblast recruitment and activity in ovariectomized rats

17666	LEE011	1 mg	≥95%	A selective cyclin D1/CDK4 and cyclin D3/CDK6 inhibitor (nm IC50) that inhibits retinoblastoma protein phosphorylation, which prevents CDK-mediated G1-S phase transition, arresting the cell cycle in the G1 phase, suppressing DNA synthesis, and inhibiting cancer cell growth; reduces proliferation of several human neuroblastoma-derived cell lines (mean IC50 = 306 nM)
17666	LEE011	10 mg	≥95%	A selective cyclin D1/CDK4 and cyclin D3/CDK6 inhibitor (nm IC50) that inhibits retinoblastoma protein phosphorylation, which prevents CDK-mediated G1-S phase transition, arresting the cell cycle in the G1 phase, suppressing DNA synthesis, and inhibiting cancer cell growth; reduces proliferation of several human neuroblastoma-derived cell lines (mean IC50 = 306 nM)
17666	LEE011	5 mg	≥95%	A selective cyclin D1/CDK4 and cyclin D3/CDK6 inhibitor (nm IC50) that inhibits retinoblastoma protein phosphorylation, which prevents CDK-mediated G1-S phase transition, arresting the cell cycle in the G1 phase, suppressing DNA synthesis, and inhibiting cancer cell growth; reduces proliferation of several human neuroblastoma-derived cell lines (mean IC50 = 306 nM)
17666	LEE011	500 µg	≥95%	A selective cyclin D1/CDK4 and cyclin D3/CDK6 inhibitor (nm IC50) that inhibits retinoblastoma protein phosphorylation, which prevents CDK-mediated G1-S phase transition, arresting the cell cycle in the G1 phase, suppressing DNA synthesis, and inhibiting cancer cell growth; reduces proliferation of several human neuroblastoma-derived cell lines (mean IC50 = 306 nM)
17668	PND1186	10 mg	≥98%	A potent reversible FAK inhibitor (IC50 = 1.5 nM against the recombinant enzyme and 100 nM in breast carcinoma cells)
17668	PND1186	25 mg	≥98%	A potent reversible FAK inhibitor (IC50 = 1.5 nM against the recombinant enzyme and 100 nM in breast carcinoma cells)
17668	PND1186	5 mg	≥98%	A potent reversible FAK inhibitor (IC50 = 1.5 nM against the recombinant enzyme and 100 nM in breast carcinoma cells)
17668	PND1186	50 mg	≥98%	A potent reversible FAK inhibitor (IC50 = 1.5 nM against the recombinant enzyme and 100 nM in breast carcinoma cells)
17669	Filgotinib	10 mg	≥98%	A JAK1 inhibitor (IC50 = 10 nM); selective for JAK1 over JAK3 (IC50 = 810 nM) but also inhibits JAK2 and Tyk2 (IC50s = 28 and 116 nM, respectively), as well as Abl, FLT1, -3 and -4, FMS, Mer, and TBK1 activity by >35% in a panel of 177 tyrosine kinases at 1 µM; inhibits IL-6-induced phosphorylation of STAT1 in CD4+ T cells (IC50 = 629 nM in isolated human whole blood); reduces hind paw macrophage and T cell infiltration and bone erosion in a rat model of collagen-induced arthritis at 0.1-30 mg/kg per day for 15 days
17669	Filgotinib	25 mg	≥98%	A JAK1 inhibitor (IC50 = 10 nM); selective for JAK1 over JAK3 (IC50 = 810 nM) but also inhibits JAK2 and Tyk2 (IC50s = 28 and 116 nM, respectively), as well as Abl, FLT1, -3 and -4, FMS, Mer, and TBK1 activity by >35% in a panel of 177 tyrosine kinases at 1 µM; inhibits IL-6-induced phosphorylation of STAT1 in CD4+ T cells (IC50 = 629 nM in isolated human whole blood); reduces hind paw macrophage and T cell infiltration and bone erosion in a rat model of collagen-induced arthritis at 0.1-30 mg/kg per day for 15 days
17669	Filgotinib	5 mg	≥98%	A JAK1 inhibitor (IC50 = 10 nM); selective for JAK1 over JAK3 (IC50 = 810 nM) but also inhibits JAK2 and Tyk2 (IC50s = 28 and 116 nM, respectively), as well as Abl, FLT1, -3 and -4, FMS, Mer, and TBK1 activity by >35% in a panel of 177 tyrosine kinases at 1 µM; inhibits IL-6-induced phosphorylation of STAT1 in CD4+ T cells (IC50 = 629 nM in isolated human whole blood); reduces hind paw macrophage and T cell infiltration and bone erosion in a rat model of collagen-induced arthritis at 0.1-30 mg/kg per day for 15 days
17670	TAE684	1 mg	≥95%	A selective ALK inhibitor that blocks the proliferation of ALCL-derived and ALK-dependent cell lines (IC50s = 2-5 nM); suppresses tumor growth in in vivo models of ALK-positive ALCL and neuroblastoma; also inhibits the activity of the Parkinson's disease-linked LRRK2 (IC50s = 7.8 and 6.1 nM for wild-type and G2019S mutant LRRK2, respectively)
17670	TAE684	10 mg	≥95%	A selective ALK inhibitor that blocks the proliferation of ALCL-derived and ALK-dependent cell lines (IC50s = 2-5 nM); suppresses tumor growth in in vivo models of ALK-positive ALCL and neuroblastoma; also inhibits the activity of the Parkinson's disease-linked LRRK2 (IC50s = 7.8 and 6.1 nM for wild-type and G2019S mutant LRRK2, respectively)
17670	TAE684	5 mg	≥95%	A selective ALK inhibitor that blocks the proliferation of ALCL-derived and ALK-dependent cell lines (IC50s = 2-5 nM); suppresses tumor growth in in vivo models of ALK-positive ALCL and neuroblastoma; also inhibits the activity of the Parkinson's disease-linked LRRK2 (IC50s = 7.8 and 6.1 nM for wild-type and G2019S mutant LRRK2, respectively)
17670	TAE684	50 mg	≥95%	A selective ALK inhibitor that blocks the proliferation of ALCL-derived and ALK-dependent cell lines (IC50s = 2-5 nM); suppresses tumor growth in in vivo models of ALK-positive ALCL and neuroblastoma; also inhibits the activity of the Parkinson's disease-linked LRRK2 (IC50s = 7.8 and 6.1 nM for wild-type and G2019S mutant LRRK2, respectively)
17671	AMG 706	1 mg	≥98%	A multikinase inhibitor that predominantly targets receptor tyrosine kinases, including VEGFR1, VEGFR2, VEGFR3, c-Kit, PDGFR, and RET (IC50s = 2, 3, 6, 8, 84, and 59 nM, respectively); blocks VEGF-induced angiogenesis in the rat corneal model and induces regression of established A431 xenografts in mice

17671	AMG 706	10 mg	≥98%	A multikinase inhibitor that predominantly targets receptor tyrosine kinases, including VEGFR1, VEGFR2, VEGFR3, c-Kit, PDGFR, and RET (IC50s = 2, 3, 6, 8, 84, and 59 nM, respectively); blocks VEGF-induced angiogenesis in the rat corneal model and induces regression of established A431 xenografts in mice
17671	AMG 706	5 mg	≥98%	A multikinase inhibitor that predominantly targets receptor tyrosine kinases, including VEGFR1, VEGFR2, VEGFR3, c-Kit, PDGFR, and RET (IC50s = 2, 3, 6, 8, 84, and 59 nM, respectively); blocks VEGF-induced angiogenesis in the rat corneal model and induces regression of established A431 xenografts in mice
17671	AMG 706	50 mg	≥98%	A multikinase inhibitor that predominantly targets receptor tyrosine kinases, including VEGFR1, VEGFR2, VEGFR3, c-Kit, PDGFR, and RET (IC50s = 2, 3, 6, 8, 84, and 59 nM, respectively); blocks VEGF-induced angiogenesis in the rat corneal model and induces regression of established A431 xenografts in mice
17673	IM-12	1 mg	≥98%	A non-symmetrically substituted indolylmaleimide that increases β-catenin levels by inhibiting GSK3β (IC50 = 53 nM); reduces proliferation and increases differentiation of a ReNCell VM cell line derived from human ventral midbrain
17673	IM-12	10 mg	≥98%	A non-symmetrically substituted indolylmaleimide that increases β-catenin levels by inhibiting GSK3β (IC50 = 53 nM); reduces proliferation and increases differentiation of a ReNCell VM cell line derived from human ventral midbrain
17673	IM-12	25 mg	≥98%	A non-symmetrically substituted indolylmaleimide that increases β-catenin levels by inhibiting GSK3β (IC50 = 53 nM); reduces proliferation and increases differentiation of a ReNCell VM cell line derived from human ventral midbrain
17673	IM-12	5 mg	≥98%	A non-symmetrically substituted indolylmaleimide that increases β-catenin levels by inhibiting GSK3β (IC50 = 53 nM); reduces proliferation and increases differentiation of a ReNCell VM cell line derived from human ventral midbrain
17684	JAK2 Inhibitor V	1 mg	≥95%	A selective inhibitor of the autophosphorylation of wild type and V617F mutant forms of JAK2, displaying IC50 values between 10 and 30 μM; blocks the proliferation of erythroleukemia cells and human hematopoietic progenitor cells expressing JAK2-V617F
17684	JAK2 Inhibitor V	10 mg	≥95%	A selective inhibitor of the autophosphorylation of wild type and V617F mutant forms of JAK2, displaying IC50 values between 10 and 30 μM; blocks the proliferation of erythroleukemia cells and human hematopoietic progenitor cells expressing JAK2-V617F
17684	JAK2 Inhibitor V	25 mg	≥95%	A selective inhibitor of the autophosphorylation of wild type and V617F mutant forms of JAK2, displaying IC50 values between 10 and 30 μM; blocks the proliferation of erythroleukemia cells and human hematopoietic progenitor cells expressing JAK2-V617F
17684	JAK2 Inhibitor V	5 mg	≥95%	A selective inhibitor of the autophosphorylation of wild type and V617F mutant forms of JAK2, displaying IC50 values between 10 and 30 μM; blocks the proliferation of erythroleukemia cells and human hematopoietic progenitor cells expressing JAK2-V617F
17685	NVP-TAE226	1 mg	≥98%	A FAK inhibitor (IC50 = 5.5 nM) that also inhibits IGF-1R (IC50 = 0.16 μM); inhibits glioma and ovarian tumor growth in in vivo tumor models
17685	NVP-TAE226	10 mg	≥98%	A FAK inhibitor (IC50 = 5.5 nM) that also inhibits IGF-1R (IC50 = 0.16 μM); inhibits glioma and ovarian tumor growth in in vivo tumor models
17685	NVP-TAE226	25 mg	≥98%	A FAK inhibitor (IC50 = 5.5 nM) that also inhibits IGF-1R (IC50 = 0.16 μM); inhibits glioma and ovarian tumor growth in in vivo tumor models
17685	NVP-TAE226	5 mg	≥98%	A FAK inhibitor (IC50 = 5.5 nM) that also inhibits IGF-1R (IC50 = 0.16 μM); inhibits glioma and ovarian tumor growth in in vivo tumor models
17686	LH 846	1 mg	≥98%	A selective inhibitor of CK1δ (IC50 = 290 nM); inhibits CK1δ-dependent phosphorylation and degradation of PER1 protein and lengthens the circadian period in U2OS cells
17686	LH 846	10 mg	≥98%	A selective inhibitor of CK1δ (IC50 = 290 nM); inhibits CK1δ-dependent phosphorylation and degradation of PER1 protein and lengthens the circadian period in U2OS cells
17686	LH 846	25 mg	≥98%	A selective inhibitor of CK1δ (IC50 = 290 nM); inhibits CK1δ-dependent phosphorylation and degradation of PER1 protein and lengthens the circadian period in U2OS cells
17686	LH 846	5 mg	≥98%	A selective inhibitor of CK1δ (IC50 = 290 nM); inhibits CK1δ-dependent phosphorylation and degradation of PER1 protein and lengthens the circadian period in U2OS cells
17689	PFK15	10 mg	≥95%	A selective inhibitor of PFKFB3 (IC50 = 207 nM); rapidly induces apoptosis in transformed cells, suppresses glucose uptake and growth of Lewis lung carcinomas in syngeneic mice, and yields antitumor effects in human xenograft models of cancer in athymic mice
17689	PFK15	25 mg	≥95%	A selective inhibitor of PFKFB3 (IC50 = 207 nM); rapidly induces apoptosis in transformed cells, suppresses glucose uptake and growth of Lewis lung carcinomas in syngeneic mice, and yields antitumor effects in human xenograft models of cancer in athymic mice
17689	PFK15	5 mg	≥95%	A selective inhibitor of PFKFB3 (IC50 = 207 nM); rapidly induces apoptosis in transformed cells, suppresses glucose uptake and growth of Lewis lung carcinomas in syngeneic mice, and yields antitumor effects in human xenograft models of cancer in athymic mice

17689	PFK15	50 mg	≥95%	A selective inhibitor of PFKFB3 (IC50 = 207 nM); rapidly induces apoptosis in transformed cells, suppresses glucose uptake and growth of Lewis lung carcinomas in syngeneic mice, and yields antitumor effects in human xenograft models of cancer in athymic mice
17693	AZ191	1 mg	≥98%	A DYRK1B inhibitor (IC50 = 17 nM) that demonstrates 5-fold and 110-fold selectivity against the related family members DYRK1A and DYRK2, respectively; used as a probe to elucidate the mechanism of DYRK1B regulation of cell cycle progression
17693	AZ191	10 mg	≥98%	A DYRK1B inhibitor (IC50 = 17 nM) that demonstrates 5-fold and 110-fold selectivity against the related family members DYRK1A and DYRK2, respectively; used as a probe to elucidate the mechanism of DYRK1B regulation of cell cycle progression
17693	AZ191	25 mg	≥98%	A DYRK1B inhibitor (IC50 = 17 nM) that demonstrates 5-fold and 110-fold selectivity against the related family members DYRK1A and DYRK2, respectively; used as a probe to elucidate the mechanism of DYRK1B regulation of cell cycle progression
17693	AZ191	5 mg	≥98%	A DYRK1B inhibitor (IC50 = 17 nM) that demonstrates 5-fold and 110-fold selectivity against the related family members DYRK1A and DYRK2, respectively; used as a probe to elucidate the mechanism of DYRK1B regulation of cell cycle progression
17698	LDN-212854	1 mg	≥98%	A selective ALK2 inhibitor (IC50 = 1.3 nM) that less potently inhibits ALK1 and ALK3 (IC50 = 2.4 and 85.8 nM, respectively) and demonstrates over 1,500-fold selectivity against the closely related activin and TGF-β type I receptors (i.e., ALK4 and ALK5); inhibits BMP6-induced osteogenic differentiation with an IC50 value of 10 nM
17698	LDN-212854	10 mg	≥98%	A selective ALK2 inhibitor (IC50 = 1.3 nM) that less potently inhibits ALK1 and ALK3 (IC50 = 2.4 and 85.8 nM, respectively) and demonstrates over 1,500-fold selectivity against the closely related activin and TGF-β type I receptors (i.e., ALK4 and ALK5); inhibits BMP6-induced osteogenic differentiation with an IC50 value of 10 nM
17698	LDN-212854	25 mg	≥98%	A selective ALK2 inhibitor (IC50 = 1.3 nM) that less potently inhibits ALK1 and ALK3 (IC50 = 2.4 and 85.8 nM, respectively) and demonstrates over 1,500-fold selectivity against the closely related activin and TGF-β type I receptors (i.e., ALK4 and ALK5); inhibits BMP6-induced osteogenic differentiation with an IC50 value of 10 nM
17698	LDN-212854	5 mg	≥98%	A selective ALK2 inhibitor (IC50 = 1.3 nM) that less potently inhibits ALK1 and ALK3 (IC50 = 2.4 and 85.8 nM, respectively) and demonstrates over 1,500-fold selectivity against the closely related activin and TGF-β type I receptors (i.e., ALK4 and ALK5); inhibits BMP6-induced osteogenic differentiation with an IC50 value of 10 nM
17701	TAK-960	1 mg	≥95%	A selective inhibitor of Plks (IC50s = 0.8, 16.9, and 50.2 nM for Plk1, Plk2, and Plk3, respectively); inhibits the proliferation of various cancer cell lines and prevents tumor growth in several human cancer cell xenograft models
17701	TAK-960	10 mg	≥95%	A selective inhibitor of Plks (IC50s = 0.8, 16.9, and 50.2 nM for Plk1, Plk2, and Plk3, respectively); inhibits the proliferation of various cancer cell lines and prevents tumor growth in several human cancer cell xenograft models
17701	TAK-960	5 mg	≥95%	A selective inhibitor of Plks (IC50s = 0.8, 16.9, and 50.2 nM for Plk1, Plk2, and Plk3, respectively); inhibits the proliferation of various cancer cell lines and prevents tumor growth in several human cancer cell xenograft models
17701	TAK-960	50 mg	≥95%	A selective inhibitor of Plks (IC50s = 0.8, 16.9, and 50.2 nM for Plk1, Plk2, and Plk3, respectively); inhibits the proliferation of various cancer cell lines and prevents tumor growth in several human cancer cell xenograft models
17702	TTP 22	1 mg	≥95%	A selective CK2 inhibitor (IC50 = 100 nM)
17702	TTP 22	10 mg	≥95%	A selective CK2 inhibitor (IC50 = 100 nM)
17702	TTP 22	5 mg	≥95%	A selective CK2 inhibitor (IC50 = 100 nM)
17702	TTP 22	50 mg	≥95%	A selective CK2 inhibitor (IC50 = 100 nM)
17703	UNC2250	1 mg	≥98%	A selective inhibitor of Mer kinase activity, blocking the steady-state phosphorylation of endogenous Mer in 697 B-ALL cells with an IC50 value of 9.8 nM; inhibits Mer activity in cells and displays good pharmacokinetic properties in mice following intravenous or oral administration
17703	UNC2250	10 mg	≥98%	A selective inhibitor of Mer kinase activity, blocking the steady-state phosphorylation of endogenous Mer in 697 B-ALL cells with an IC50 value of 9.8 nM; inhibits Mer activity in cells and displays good pharmacokinetic properties in mice following intravenous or oral administration
17703	UNC2250	5 mg	≥98%	A selective inhibitor of Mer kinase activity, blocking the steady-state phosphorylation of endogenous Mer in 697 B-ALL cells with an IC50 value of 9.8 nM; inhibits Mer activity in cells and displays good pharmacokinetic properties in mice following intravenous or oral administration
17703	UNC2250	50 mg	≥98%	A selective inhibitor of Mer kinase activity, blocking the steady-state phosphorylation of endogenous Mer in 697 B-ALL cells with an IC50 value of 9.8 nM; inhibits Mer activity in cells and displays good pharmacokinetic properties in mice following intravenous or oral administration

17708	Linsitinib	1 mg	≥98%	A dual inhibitor of IGF-1R and InsR kinases (IC50s = 35 and 75 nM, respectively); inhibits proliferation of tumor cell lines in vitro and has antitumor efficacy in an IGF-1R-driven xenograft mouse model when administered orally
17708	Linsitinib	10 mg	≥98%	A dual inhibitor of IGF-1R and InsR kinases (IC50s = 35 and 75 nM, respectively); inhibits proliferation of tumor cell lines in vitro and has antitumor efficacy in an IGF-1R-driven xenograft mouse model when administered orally
17708	Linsitinib	5 mg	≥98%	A dual inhibitor of IGF-1R and InsR kinases (IC50s = 35 and 75 nM, respectively); inhibits proliferation of tumor cell lines in vitro and has antitumor efficacy in an IGF-1R-driven xenograft mouse model when administered orally
17714	Toceranib	1 mg	≥95%	A small molecule, multi-targeted receptor tyrosine kinase inhibitor; blocks the autophosphorylation of both wild type and mutant forms of Kit in response to stem cell factor, resulting in cell death; active in vivo and commonly used against solid tumors in dogs
17714	Toceranib	10 mg	≥95%	A small molecule, multi-targeted receptor tyrosine kinase inhibitor; blocks the autophosphorylation of both wild type and mutant forms of Kit in response to stem cell factor, resulting in cell death; active in vivo and commonly used against solid tumors in dogs
17714	Toceranib	5 mg	≥95%	A small molecule, multi-targeted receptor tyrosine kinase inhibitor; blocks the autophosphorylation of both wild type and mutant forms of Kit in response to stem cell factor, resulting in cell death; active in vivo and commonly used against solid tumors in dogs
17714	Toceranib	50 mg	≥95%	A small molecule, multi-targeted receptor tyrosine kinase inhibitor; blocks the autophosphorylation of both wild type and mutant forms of Kit in response to stem cell factor, resulting in cell death; active in vivo and commonly used against solid tumors in dogs
17737	Defactinib	1 mg	≥98%	A dose-dependent inhibitor of FAK, with maximal inhibition of FAK autophosphorylation in cells achieved at 10 µM; restores the chemosensitivity of taxane-resistant cells to paclitaxel; orally bioavailable, inhibiting FAK and augmenting paclitaxel action against ovarian cancer cell tumors in mice
17737	Defactinib	10 mg	≥98%	A dose-dependent inhibitor of FAK, with maximal inhibition of FAK autophosphorylation in cells achieved at 10 µM; restores the chemosensitivity of taxane-resistant cells to paclitaxel; orally bioavailable, inhibiting FAK and augmenting paclitaxel action against ovarian cancer cell tumors in mice
17737	Defactinib	25 mg	≥98%	A dose-dependent inhibitor of FAK, with maximal inhibition of FAK autophosphorylation in cells achieved at 10 µM; restores the chemosensitivity of taxane-resistant cells to paclitaxel; orally bioavailable, inhibiting FAK and augmenting paclitaxel action against ovarian cancer cell tumors in mice
17737	Defactinib	5 mg	≥98%	A dose-dependent inhibitor of FAK, with maximal inhibition of FAK autophosphorylation in cells achieved at 10 µM; restores the chemosensitivity of taxane-resistant cells to paclitaxel; orally bioavailable, inhibiting FAK and augmenting paclitaxel action against ovarian cancer cell tumors in mice
17740	LY2835219 (methanes	1 mg	≥95%	An orally-bioavailable dual inhibitor of CDK4 and CDK6 (IC50s = 2 and 10 nM, respectively); has antitumor action against xenografts when used alone or in combination with other chemotherapeutic compounds
17740	LY2835219 (methanes	10 mg	≥95%	An orally-bioavailable dual inhibitor of CDK4 and CDK6 (IC50s = 2 and 10 nM, respectively); has antitumor action against xenografts when used alone or in combination with other chemotherapeutic compounds
17740	LY2835219 (methanes	5 mg	≥95%	An orally-bioavailable dual inhibitor of CDK4 and CDK6 (IC50s = 2 and 10 nM, respectively); has antitumor action against xenografts when used alone or in combination with other chemotherapeutic compounds
17741	AZD 2932	1 mg	≥98%	A multi-kinase inhibitor (IC50s = 4, 8, 100, 9, and 7 nM for VEGFR2, PDGFRβ, CSF1R, c-KIT, and FLT3 receptor tyrosine kinases, respectively); inhibits Pdgfrα phosphorylation (IC50 = 2 nM) in lysates from C6 rat glial tumors; reduces tumor growth and inhibits Pdgfrβ and Vegfr2 phosphorylation in a 1:1 ratio in a C6 mouse xenograft model
17741	AZD 2932	10 mg	≥98%	A multi-kinase inhibitor (IC50s = 4, 8, 100, 9, and 7 nM for VEGFR2, PDGFRβ, CSF1R, c-KIT, and FLT3 receptor tyrosine kinases, respectively); inhibits Pdgfrα phosphorylation (IC50 = 2 nM) in lysates from C6 rat glial tumors; reduces tumor growth and inhibits Pdgfrβ and Vegfr2 phosphorylation in a 1:1 ratio in a C6 mouse xenograft model
17741	AZD 2932	25 mg	≥98%	A multi-kinase inhibitor (IC50s = 4, 8, 100, 9, and 7 nM for VEGFR2, PDGFRβ, CSF1R, c-KIT, and FLT3 receptor tyrosine kinases, respectively); inhibits Pdgfrα phosphorylation (IC50 = 2 nM) in lysates from C6 rat glial tumors; reduces tumor growth and inhibits Pdgfrβ and Vegfr2 phosphorylation in a 1:1 ratio in a C6 mouse xenograft model

17741	AZD 2932	5 mg	≥98%	A multi-kinase inhibitor (IC50s = 4, 8, 100, 9, and 7 nM for VEGFR2, PDGFRβ, CSF1R, c-KIT, and FLT3 receptor tyrosine kinases, respectively); inhibits Pdgfrα phosphorylation (IC50 = 2 nM) in lysates from C6 rat glial tumors; reduces tumor growth and inhibits Pdgfrβ and Vegfr2 phosphorylation in a 1:1 ratio in a C6 mouse xenograft model
17807	L-779,450	1 mg	≥98%	An ATP-competitive B-Raf inhibitor (IC50 = 10 nM; Kd = 2.4 nM) that inhibits cell proliferation both in B-Raf mutated and wild-type melanoma cell lines
17807	L-779,450	10 mg	≥98%	An ATP-competitive B-Raf inhibitor (IC50 = 10 nM; Kd = 2.4 nM) that inhibits cell proliferation both in B-Raf mutated and wild-type melanoma cell lines
17807	L-779,450	5 mg	≥98%	An ATP-competitive B-Raf inhibitor (IC50 = 10 nM; Kd = 2.4 nM) that inhibits cell proliferation both in B-Raf mutated and wild-type melanoma cell lines
17807	L-779,450	50 mg	≥98%	An ATP-competitive B-Raf inhibitor (IC50 = 10 nM; Kd = 2.4 nM) that inhibits cell proliferation both in B-Raf mutated and wild-type melanoma cell lines
17808	KP372-1	1 mg	≥95% (sum of	A specific Akt inhibitor that has been shown to inhibit proliferation and to induce apoptosis of thyroid cancer cells (IC50 = 30-60 nM in vitro); inhibits Akt, PDK1, and FLT3 in acute myelogenous leukemia cells, decreasing the colony-forming ability of these cells (IC50 <200 nM)
17808	KP372-1	10 mg	≥95% (sum of	A specific Akt inhibitor that has been shown to inhibit proliferation and to induce apoptosis of thyroid cancer cells (IC50 = 30-60 nM in vitro); inhibits Akt, PDK1, and FLT3 in acute myelogenous leukemia cells, decreasing the colony-forming ability of these cells (IC50 <200 nM)
17808	KP372-1	5 mg	≥95% (sum of	A specific Akt inhibitor that has been shown to inhibit proliferation and to induce apoptosis of thyroid cancer cells (IC50 = 30-60 nM in vitro); inhibits Akt, PDK1, and FLT3 in acute myelogenous leukemia cells, decreasing the colony-forming ability of these cells (IC50 <200 nM)
17809	Pim-1 Inhibitor 2	1 mg	≥98%	A potent Pim-1 inhibitor (Ki = 91 nM) that targets the ATP-binding kinase hinge region
17809	Pim-1 Inhibitor 2	10 mg	≥98%	A potent Pim-1 inhibitor (Ki = 91 nM) that targets the ATP-binding kinase hinge region
17809	Pim-1 Inhibitor 2	5 mg	≥98%	A potent Pim-1 inhibitor (Ki = 91 nM) that targets the ATP-binding kinase hinge region
17858	Tie2 Kinase Inhibitor	1 mg	≥95%	Reversibly and selectively blocks Tie2 kinase activity (IC50 = 250 nM); reduces angiogenesis in a Matrigel neovascularization assay and delays tumor growth in MOPC-315 plasmacytoma and SVR angiosarcoma xenograft models
17858	Tie2 Kinase Inhibitor	10 mg	≥95%	Reversibly and selectively blocks Tie2 kinase activity (IC50 = 250 nM); reduces angiogenesis in a Matrigel neovascularization assay and delays tumor growth in MOPC-315 plasmacytoma and SVR angiosarcoma xenograft models
17858	Tie2 Kinase Inhibitor	5 mg	≥95%	Reversibly and selectively blocks Tie2 kinase activity (IC50 = 250 nM); reduces angiogenesis in a Matrigel neovascularization assay and delays tumor growth in MOPC-315 plasmacytoma and SVR angiosarcoma xenograft models
17858	Tie2 Kinase Inhibitor	500 µg	≥95%	Reversibly and selectively blocks Tie2 kinase activity (IC50 = 250 nM); reduces angiogenesis in a Matrigel neovascularization assay and delays tumor growth in MOPC-315 plasmacytoma and SVR angiosarcoma xenograft models
17859	PF-477736	10 mg	≥98%	An ATP-competitive Chk1 inhibitor (Ki = 0.49 nM) that demonstrates 100-fold selectivity over Chk2; abrogates DNA damage-induced cell cycle arrest in tumor cell lines and xenografts, potentiating the antiproliferative effects of various chemotherapeutics
17859	PF-477736	25 mg	≥98%	An ATP-competitive Chk1 inhibitor (Ki = 0.49 nM) that demonstrates 100-fold selectivity over Chk2; abrogates DNA damage-induced cell cycle arrest in tumor cell lines and xenografts, potentiating the antiproliferative effects of various chemotherapeutics
17859	PF-477736	5 mg	≥98%	An ATP-competitive Chk1 inhibitor (Ki = 0.49 nM) that demonstrates 100-fold selectivity over Chk2; abrogates DNA damage-induced cell cycle arrest in tumor cell lines and xenografts, potentiating the antiproliferative effects of various chemotherapeutics
17859	PF-477736	50 mg	≥98%	An ATP-competitive Chk1 inhibitor (Ki = 0.49 nM) that demonstrates 100-fold selectivity over Chk2; abrogates DNA damage-induced cell cycle arrest in tumor cell lines and xenografts, potentiating the antiproliferative effects of various chemotherapeutics
17860	3MB-PP1	1 mg	≥98%	A bulky purine analog that acts as a selective, ATP-competitive, analog-sensitive Plk1 allele inhibitor; blocks mitotic progression in cells expressing analog-sensitive Plk1 alleles at 10 µM and selectively sensitizes Plk1 to small-molecule inhibitors
17860	3MB-PP1	10 mg	≥98%	A bulky purine analog that acts as a selective, ATP-competitive, analog-sensitive Plk1 allele inhibitor; blocks mitotic progression in cells expressing analog-sensitive Plk1 alleles at 10 µM and selectively sensitizes Plk1 to small-molecule inhibitors
17860	3MB-PP1	5 mg	≥98%	A bulky purine analog that acts as a selective, ATP-competitive, analog-sensitive Plk1 allele inhibitor; blocks mitotic progression in cells expressing analog-sensitive Plk1 alleles at 10 µM and selectively sensitizes Plk1 to small-molecule inhibitors

17904	SNS-032	1 mg	≥98%	A selective, ATP-competitive inhibitor of Cdk9, 2, and 7 with IC50 values of 4, 38, and 62 nM, respectively; blocks the cell cycle, inhibits transcription, and induces apoptosis in multiple myeloma RPMI-8226 cells with an IC90 value of 0.3 μM
17904	SNS-032	10 mg	≥98%	A selective, ATP-competitive inhibitor of Cdk9, 2, and 7 with IC50 values of 4, 38, and 62 nM, respectively; blocks the cell cycle, inhibits transcription, and induces apoptosis in multiple myeloma RPMI-8226 cells with an IC90 value of 0.3 μM
17904	SNS-032	5 mg	≥98%	A selective, ATP-competitive inhibitor of Cdk9, 2, and 7 with IC50 values of 4, 38, and 62 nM, respectively; blocks the cell cycle, inhibits transcription, and induces apoptosis in multiple myeloma RPMI-8226 cells with an IC90 value of 0.3 μM
17904	SNS-032	50 mg	≥98%	A selective, ATP-competitive inhibitor of Cdk9, 2, and 7 with IC50 values of 4, 38, and 62 nM, respectively; blocks the cell cycle, inhibits transcription, and induces apoptosis in multiple myeloma RPMI-8226 cells with an IC90 value of 0.3 μM
17905	R547	1 mg	≥98%	An inhibitor of the cyclin-dependent kinases Cdk1/cyclin B, Cdk2/cyclin E, and Cdk4/cyclin D1 (Kis = 1-3 nM); inhibits tumor cell proliferation (IC50s≤ 0.6 μM in vitro), inducing cell cycle arrest and apoptosis as well as reducing phosphorylation of the retinoblastoma protein
17905	R547	5 mg	≥98%	An inhibitor of the cyclin-dependent kinases Cdk1/cyclin B, Cdk2/cyclin E, and Cdk4/cyclin D1 (Kis = 1-3 nM); inhibits tumor cell proliferation (IC50s≤ 0.6 μM in vitro), inducing cell cycle arrest and apoptosis as well as reducing phosphorylation of the retinoblastoma protein
17922	3-(4-Pyridyl)indole	10 mg	≥98%	A ROCK1 inhibitor (IC50 = 25 μM) that promotes cell spreading, inhibits membrane blebbing, and induces dissolution of actin stress fibers in a wound healing assay; also inhibits ROCK2 and PRK2 with similar potency, while inhibiting MSK-1 and PKA with relatively weaker potency
17922	3-(4-Pyridyl)indole	25 mg	≥98%	A ROCK1 inhibitor (IC50 = 25 μM) that promotes cell spreading, inhibits membrane blebbing, and induces dissolution of actin stress fibers in a wound healing assay; also inhibits ROCK2 and PRK2 with similar potency, while inhibiting MSK-1 and PKA with relatively weaker potency
17922	3-(4-Pyridyl)indole	5 mg	≥98%	A ROCK1 inhibitor (IC50 = 25 μM) that promotes cell spreading, inhibits membrane blebbing, and induces dissolution of actin stress fibers in a wound healing assay; also inhibits ROCK2 and PRK2 with similar potency, while inhibiting MSK-1 and PKA with relatively weaker potency
17922	3-(4-Pyridyl)indole	50 mg	≥98%	A ROCK1 inhibitor (IC50 = 25 μM) that promotes cell spreading, inhibits membrane blebbing, and induces dissolution of actin stress fibers in a wound healing assay; also inhibits ROCK2 and PRK2 with similar potency, while inhibiting MSK-1 and PKA with relatively weaker potency
17931	PF-04217903	1 mg	≥98%	A c-Met inhibitor (Ki = 4.8 nM); >1,000-fold selective for c-Met over a panel of 150 kinases; inhibits the proliferation of and induces apoptosis in GTL-16 cells (IC50s = 12 and 31 nM, respectively); inhibits HGF-induced migration of H441 cells (IC50 = 11 nM); reduces tumor growth in a GTL-16 mouse xenograft model at 1-30 mg/kg
17931	PF-04217903	10 mg	≥98%	A c-Met inhibitor (Ki = 4.8 nM); >1,000-fold selective for c-Met over a panel of 150 kinases; inhibits the proliferation of and induces apoptosis in GTL-16 cells (IC50s = 12 and 31 nM, respectively); inhibits HGF-induced migration of H441 cells (IC50 = 11 nM); reduces tumor growth in a GTL-16 mouse xenograft model at 1-30 mg/kg
17931	PF-04217903	25 mg	≥98%	A c-Met inhibitor (Ki = 4.8 nM); >1,000-fold selective for c-Met over a panel of 150 kinases; inhibits the proliferation of and induces apoptosis in GTL-16 cells (IC50s = 12 and 31 nM, respectively); inhibits HGF-induced migration of H441 cells (IC50 = 11 nM); reduces tumor growth in a GTL-16 mouse xenograft model at 1-30 mg/kg
17931	PF-04217903	5 mg	≥98%	A c-Met inhibitor (Ki = 4.8 nM); >1,000-fold selective for c-Met over a panel of 150 kinases; inhibits the proliferation of and induces apoptosis in GTL-16 cells (IC50s = 12 and 31 nM, respectively); inhibits HGF-induced migration of H441 cells (IC50 = 11 nM); reduces tumor growth in a GTL-16 mouse xenograft model at 1-30 mg/kg
17974	Cdk4/6 Inhibitor IV	1 mg	≥98%	A cell-permeable triaminopyrimidine that selectively and reversibly blocks Cdk4/cyclin D1 and Cdk6/cyclin D1 activity (IC50s = 1.5 and 5.6 μM, respectively); induces cell cycle arrest in the G1 phase and apoptosis in asynchronous cell lines; suppresses tumor growth in mice bearing human HCT116 colon carcinoma xenografts
17974	Cdk4/6 Inhibitor IV	10 mg	≥98%	A cell-permeable triaminopyrimidine that selectively and reversibly blocks Cdk4/cyclin D1 and Cdk6/cyclin D1 activity (IC50s = 1.5 and 5.6 μM, respectively); induces cell cycle arrest in the G1 phase and apoptosis in asynchronous cell lines; suppresses tumor growth in mice bearing human HCT116 colon carcinoma xenografts
17974	Cdk4/6 Inhibitor IV	5 mg	≥98%	A cell-permeable triaminopyrimidine that selectively and reversibly blocks Cdk4/cyclin D1 and Cdk6/cyclin D1 activity (IC50s = 1.5 and 5.6 μM, respectively); induces cell cycle arrest in the G1 phase and apoptosis in asynchronous cell lines; suppresses tumor growth in mice bearing human HCT116 colon carcinoma xenografts
17985	6H05 (trifluoroacetate	1 mg	≥98%	An allosteric inhibitor of oncogenic K-Ras(G12C); disrupts both switch-I and switch-II, altering the native nucleotide preference to favor GDP over GTP, which impedes binding to Raf

17985	6H05 (trifluoroacetate	10 mg	≥98%	An allosteric inhibitor of oncogenic K-Ras(G12C); disrupts both switch-I and switch-II, altering the native nucleotide preference to favor GDP over GTP, which impedes binding to Raf
17985	6H05 (trifluoroacetate	25 mg	≥98%	An allosteric inhibitor of oncogenic K-Ras(G12C); disrupts both switch-I and switch-II, altering the native nucleotide preference to favor GDP over GTP, which impedes binding to Raf
17985	6H05 (trifluoroacetate	5 mg	≥98%	An allosteric inhibitor of oncogenic K-Ras(G12C); disrupts both switch-I and switch-II, altering the native nucleotide preference to favor GDP over GTP, which impedes binding to Raf
17986	Quizartinib	1 mg	≥98%	A selective FLT3 inhibitor (Kd = 1.6 nM) that inhibits the proliferation of MV4-11 cells both in vitro (IC50 = 0.56 nM) and in in vivo mouse models of FLT3-ITD acute myeloid leukemia
17986	Quizartinib	10 mg	≥98%	A selective FLT3 inhibitor (Kd = 1.6 nM) that inhibits the proliferation of MV4-11 cells both in vitro (IC50 = 0.56 nM) and in in vivo mouse models of FLT3-ITD acute myeloid leukemia
17986	Quizartinib	5 mg	≥98%	A selective FLT3 inhibitor (Kd = 1.6 nM) that inhibits the proliferation of MV4-11 cells both in vitro (IC50 = 0.56 nM) and in in vivo mouse models of FLT3-ITD acute myeloid leukemia
17986	Quizartinib	500 µg	≥98%	A selective FLT3 inhibitor (Kd = 1.6 nM) that inhibits the proliferation of MV4-11 cells both in vitro (IC50 = 0.56 nM) and in in vivo mouse models of FLT3-ITD acute myeloid leukemia
17988	Afuresertib (hydrochl	1 mg	≥98%	A pan-Akt inhibitor (IC50s = 0.08, 2, and 2.6 nM for Akt1, -2, and -3, respectively); selective for Akt over a panel of 13 kinases (IC50s = >100 nM) but does inhibit PKA, PKG1α, and PKG1β (IC50s = 1.3, 0.9, and 4 nM, respectively); inhibits tumor growth in an SKOV3 mouse xenograft model at 10, 30, and 100 mg/kg
17988	Afuresertib (hydrochl	10 mg	≥98%	A pan-Akt inhibitor (IC50s = 0.08, 2, and 2.6 nM for Akt1, -2, and -3, respectively); selective for Akt over a panel of 13 kinases (IC50s = >100 nM) but does inhibit PKA, PKG1α, and PKG1β (IC50s = 1.3, 0.9, and 4 nM, respectively); inhibits tumor growth in an SKOV3 mouse xenograft model at 10, 30, and 100 mg/kg
17988	Afuresertib (hydrochl	25 mg	≥98%	A pan-Akt inhibitor (IC50s = 0.08, 2, and 2.6 nM for Akt1, -2, and -3, respectively); selective for Akt over a panel of 13 kinases (IC50s = >100 nM) but does inhibit PKA, PKG1α, and PKG1β (IC50s = 1.3, 0.9, and 4 nM, respectively); inhibits tumor growth in an SKOV3 mouse xenograft model at 10, 30, and 100 mg/kg
17988	Afuresertib (hydrochl	5 mg	≥98%	A pan-Akt inhibitor (IC50s = 0.08, 2, and 2.6 nM for Akt1, -2, and -3, respectively); selective for Akt over a panel of 13 kinases (IC50s = >100 nM) but does inhibit PKA, PKG1α, and PKG1β (IC50s = 1.3, 0.9, and 4 nM, respectively); inhibits tumor growth in an SKOV3 mouse xenograft model at 10, 30, and 100 mg/kg
17989	AG-1557	10 mg	≥95%	An EGFR inhibitor (pIC50 = 8.194)
17989	AG-1557	25 mg	≥95%	An EGFR inhibitor (pIC50 = 8.194)
17989	AG-1557	5 mg	≥95%	An EGFR inhibitor (pIC50 = 8.194)
17989	AG-1557	50 mg	≥95%	An EGFR inhibitor (pIC50 = 8.194)
17993	AVL-292	1 mg	≥98%	A covalent BTK inhibitor (IC50 = 5.9 nM); selective for BTK over a panel of 61 kinases when used at 1 µM but does inhibit additional Tec family kinases BMX, Itk, Tec, and TXK (IC50s = 0.7, 36, 6.2, and 8.9 nM, respectively); inhibits naïve human B cell proliferation (EC50 = 3 nM); reduces joint damage, pannus formation, cartilage degradation, and bone erosion in a mouse model of rheumatoid arthritis induced by collagen at 3, 10, and 30 mg/kg
17993	AVL-292	10 mg	≥98%	A covalent BTK inhibitor (IC50 = 5.9 nM); selective for BTK over a panel of 61 kinases when used at 1 µM but does inhibit additional Tec family kinases BMX, Itk, Tec, and TXK (IC50s = 0.7, 36, 6.2, and 8.9 nM, respectively); inhibits naïve human B cell proliferation (EC50 = 3 nM); reduces joint damage, pannus formation, cartilage degradation, and bone erosion in a mouse model of rheumatoid arthritis induced by collagen at 3, 10, and 30 mg/kg
17993	AVL-292	5 mg	≥98%	A covalent BTK inhibitor (IC50 = 5.9 nM); selective for BTK over a panel of 61 kinases when used at 1 µM but does inhibit additional Tec family kinases BMX, Itk, Tec, and TXK (IC50s = 0.7, 36, 6.2, and 8.9 nM, respectively); inhibits naïve human B cell proliferation (EC50 = 3 nM); reduces joint damage, pannus formation, cartilage degradation, and bone erosion in a mouse model of rheumatoid arthritis induced by collagen at 3, 10, and 30 mg/kg

17993	AVL-292	50 mg	≥98%	A covalent BTK inhibitor (IC50 = 5.9 nM); selective for BTK over a panel of 61 kinases when used at 1 μM but does inhibit additional Tec family kinases BMX, Itk, Tec, and TXK (IC50s = 0.7, 36, 6.2, and 8.9 nM, respectively); inhibits naïve human B cell proliferation (EC50 = 3 nM); reduces joint damage, pannus formation, cartilage degradation, and bone erosion in a mouse model of rheumatioid arthritis induced by collagen at 3, 10, and 30 mg/kg
17994	AZ 5104	10 mg	≥95%	An active, demethylated metabolite of AZD 9291
17994	AZ 5104	25 mg	≥95%	An active, demethylated metabolite of AZD 9291
17994	AZ 5104	5 mg	≥95%	An active, demethylated metabolite of AZD 9291
17994	AZ 5104	50 mg	≥95%	An active, demethylated metabolite of AZD 9291
17996	BS-181 (hydrochloride	1 mg	≥98%	A selective Cdk7 inhibitor that blocks the activity of Cdk-activating kinase (IC50 = 21 nM); inhibits the growth of cancer cell lines in vitro and MCF-7 human xenografts in nude mice
17996	BS-181 (hydrochloride	10 mg	≥98%	A selective Cdk7 inhibitor that blocks the activity of Cdk-activating kinase (IC50 = 21 nM); inhibits the growth of cancer cell lines in vitro and MCF-7 human xenografts in nude mice
17996	BS-181 (hydrochloride	5 mg	≥98%	A selective Cdk7 inhibitor that blocks the activity of Cdk-activating kinase (IC50 = 21 nM); inhibits the growth of cancer cell lines in vitro and MCF-7 human xenografts in nude mice
17996	BS-181 (hydrochloride	50 mg	≥98%	A selective Cdk7 inhibitor that blocks the activity of Cdk-activating kinase (IC50 = 21 nM); inhibits the growth of cancer cell lines in vitro and MCF-7 human xenografts in nude mice
17998	CZC-54252	1 mg	≥98%	An LRRK2 inhibitor with IC50s = 1.28 and 1.85 nM for wild-type and G2019S mutant forms of LRRK2, respectively; protects against neuronal injury induced by LRRK2-G2019S mutant activity in primary human neurons (EC50 = 1 nM)
17998	CZC-54252	10 mg	≥98%	An LRRK2 inhibitor with IC50s = 1.28 and 1.85 nM for wild-type and G2019S mutant forms of LRRK2, respectively; protects against neuronal injury induced by LRRK2-G2019S mutant activity in primary human neurons (EC50 = 1 nM)
17998	CZC-54252	25 mg	≥98%	An LRRK2 inhibitor with IC50s = 1.28 and 1.85 nM for wild-type and G2019S mutant forms of LRRK2, respectively; protects against neuronal injury induced by LRRK2-G2019S mutant activity in primary human neurons (EC50 = 1 nM)
17998	CZC-54252	5 mg	≥98%	An LRRK2 inhibitor with IC50s = 1.28 and 1.85 nM for wild-type and G2019S mutant forms of LRRK2, respectively; protects against neuronal injury induced by LRRK2-G2019S mutant activity in primary human neurons (EC50 = 1 nM)
18002	kb NB 142-70	10 mg	≥98%	A selective PKD inhibitor (IC50s = 28.3, 58.7, and 53.2 nM for PKD1, 2, and 3, respectively); inhibits prostate cancer cell migration and invasion, as well as reduces wound healing in vitro.
18002	kb NB 142-70	25 mg	≥98%	A selective PKD inhibitor (IC50s = 28.3, 58.7, and 53.2 nM for PKD1, 2, and 3, respectively); inhibits prostate cancer cell migration and invasion, as well as reduces wound healing in vitro.
18002	kb NB 142-70	5 mg	≥98%	A selective PKD inhibitor (IC50s = 28.3, 58.7, and 53.2 nM for PKD1, 2, and 3, respectively); inhibits prostate cancer cell migration and invasion, as well as reduces wound healing in vitro.
18002	kb NB 142-70	50 mg	≥98%	A selective PKD inhibitor (IC50s = 28.3, 58.7, and 53.2 nM for PKD1, 2, and 3, respectively); inhibits prostate cancer cell migration and invasion, as well as reduces wound healing in vitro.
18004	Ki8751	10 mg	≥98%	A potent, orally available inhibitor of the kinase activity of VEGFR2 (IC50 = 0.9 nM); suppresses the growth of VEGF-stimulated HUVECs at nanomolar concentrations; shows significant anti-tumor activity against assorted human tumor xenografts in nude mice
18004	Ki8751	25 mg	≥98%	A potent, orally available inhibitor of the kinase activity of VEGFR2 (IC50 = 0.9 nM); suppresses the growth of VEGF-stimulated HUVECs at nanomolar concentrations; shows significant anti-tumor activity against assorted human tumor xenografts in nude mice
18004	Ki8751	5 mg	≥98%	A potent, orally available inhibitor of the kinase activity of VEGFR2 (IC50 = 0.9 nM); suppresses the growth of VEGF-stimulated HUVECs at nanomolar concentrations; shows significant anti-tumor activity against assorted human tumor xenografts in nude mice
18004	Ki8751	50 mg	≥98%	A potent, orally available inhibitor of the kinase activity of VEGFR2 (IC50 = 0.9 nM); suppresses the growth of VEGF-stimulated HUVECs at nanomolar concentrations; shows significant anti-tumor activity against assorted human tumor xenografts in nude mice
18006	LDN-214117	1 mg	≥98%	A selective ALK1 and ALK2 inhibitor (IC50s = 24 nM for each) with preference over ALK3 (IC50 = 1.17 μM) and other related activin and TGF-β type I receptors (IC50s = 3, 0.1, and 16 μM for ALK5, BMP6, and TGF-β, respectively)

18006	LDN-214117	10 mg	≥98%	A selective ALK1 and ALK2 inhibitor (IC50s = 24 nM for each) with preference over ALK3 (IC50 = 1.17 µM) and other related activin and TGF-β type I receptors (IC50s = 3, 0.1, and 16 µM for ALK5, BMP6, and TGF-β, respectively)
18006	LDN-214117	25 mg	≥98%	A selective ALK1 and ALK2 inhibitor (IC50s = 24 nM for each) with preference over ALK3 (IC50 = 1.17 µM) and other related activin and TGF-β type I receptors (IC50s = 3, 0.1, and 16 µM for ALK5, BMP6, and TGF-β, respectively)
18006	LDN-214117	5 mg	≥98%	A selective ALK1 and ALK2 inhibitor (IC50s = 24 nM for each) with preference over ALK3 (IC50 = 1.17 µM) and other related activin and TGF-β type I receptors (IC50s = 3, 0.1, and 16 µM for ALK5, BMP6, and TGF-β, respectively)
18011	XL147	10 mg	≥98%	A class I PI3K inhibitor (IC50s = 0.039, 0.036, 0.023, and 0.383 µM for p110α, -δ, -γ, and -β, respectively); selective for class I PI3Ks over Vps34, DNA-PK, and mTOR (IC50s = 6.974, 4.75, and >15 µM, respectively); inhibits proliferation of MCF-7 and PC3 cells (IC50s = 9.669 and 16.492 µM, respectively); reduces tumor growth in a BT474 breast cancer mouse xenograft model when administered alone or in combination with trastuzumab or lapatinib
18011	XL147	25 mg	≥98%	A class I PI3K inhibitor (IC50s = 0.039, 0.036, 0.023, and 0.383 µM for p110α, -δ, -γ, and -β, respectively); selective for class I PI3Ks over Vps34, DNA-PK, and mTOR (IC50s = 6.974, 4.75, and >15 µM, respectively); inhibits proliferation of MCF-7 and PC3 cells (IC50s = 9.669 and 16.492 µM, respectively); reduces tumor growth in a BT474 breast cancer mouse xenograft model when administered alone or in combination with trastuzumab or lapatinib
18011	XL147	5 mg	≥98%	A class I PI3K inhibitor (IC50s = 0.039, 0.036, 0.023, and 0.383 µM for p110α, -δ, -γ, and -β, respectively); selective for class I PI3Ks over Vps34, DNA-PK, and mTOR (IC50s = 6.974, 4.75, and >15 µM, respectively); inhibits proliferation of MCF-7 and PC3 cells (IC50s = 9.669 and 16.492 µM, respectively); reduces tumor growth in a BT474 breast cancer mouse xenograft model when administered alone or in combination with trastuzumab or lapatinib
18011	XL147	50 mg	≥98%	A class I PI3K inhibitor (IC50s = 0.039, 0.036, 0.023, and 0.383 µM for p110α, -δ, -γ, and -β, respectively); selective for class I PI3Ks over Vps34, DNA-PK, and mTOR (IC50s = 6.974, 4.75, and >15 µM, respectively); inhibits proliferation of MCF-7 and PC3 cells (IC50s = 9.669 and 16.492 µM, respectively); reduces tumor growth in a BT474 breast cancer mouse xenograft model when administered alone or in combination with trastuzumab or lapatinib
18012	PLX647	10 mg	≥95%	A dual inhibitor of FMS and KIT (IC50s = 28 and 16 nM, respectively); is selective for FMS and KIT but does inhibit FLT3 and KDR (IC50s = 91 and 130 nM, respectively) in a panel of 400 kinases at 1 µM; inhibits proliferation of Ba/F3 cells expressing constitutively active FMS or KIT (IC50s = 92 and 180 nM, respectively) as well as ligand-dependent growth of M-NFS-60 and M-07e cells (IC50s = 380 and 230 nM, respectively); reduces TNF-α and IL-6 release in a rat model of LPS-induced cytokine release at 40 mg/kg; reduces mast cell degranulation in a mouse model of PCA; inhibits bone destruction and delays disease progression in a mouse model of CIA; reverses bone osteolysis and allodynia in a syngeneic rat model of cancer-induced bone pain
18012	PLX647	25 mg	≥95%	A dual inhibitor of FMS and KIT (IC50s = 28 and 16 nM, respectively); is selective for FMS and KIT but does inhibit FLT3 and KDR (IC50s = 91 and 130 nM, respectively) in a panel of 400 kinases at 1 µM; inhibits proliferation of Ba/F3 cells expressing constitutively active FMS or KIT (IC50s = 92 and 180 nM, respectively) as well as ligand-dependent growth of M-NFS-60 and M-07e cells (IC50s = 380 and 230 nM, respectively); reduces TNF-α and IL-6 release in a rat model of LPS-induced cytokine release at 40 mg/kg; reduces mast cell degranulation in a mouse model of PCA; inhibits bone destruction and delays disease progression in a mouse model of CIA; reverses bone osteolysis and allodynia in a syngeneic rat model of cancer-induced bone pain
18012	PLX647	5 mg	≥95%	A dual inhibitor of FMS and KIT (IC50s = 28 and 16 nM, respectively); is selective for FMS and KIT but does inhibit FLT3 and KDR (IC50s = 91 and 130 nM, respectively) in a panel of 400 kinases at 1 µM; inhibits proliferation of Ba/F3 cells expressing constitutively active FMS or KIT (IC50s = 92 and 180 nM, respectively) as well as ligand-dependent growth of M-NFS-60 and M-07e cells (IC50s = 380 and 230 nM, respectively); reduces TNF-α and IL-6 release in a rat model of LPS-induced cytokine release at 40 mg/kg; reduces mast cell degranulation in a mouse model of PCA; inhibits bone destruction and delays disease progression in a mouse model of CIA; reverses bone osteolysis and allodynia in a syngeneic rat model of cancer-induced bone pain

18012	PLX647	50 mg	≥95%	A dual inhibitor of FMS and KIT (IC50s = 28 and 16 nM, respectively); is selective for FMS and KIT but does inhibit FLT3 and KDR (IC50s = 91 and 130 nM, respectively) in a panel of 400 kinases at 1 µM; inhibits proliferation of Ba/F3 cells expressing constitutively active FMS or KIT (IC50s = 92 and 180 nM, respectively) as well as ligand-dependent growth of M-NFS-60 and M-07e cells (IC50s = 380 and 230 nM, respectively); reduces TNF-α and IL-6 release in a rat model of LPS-induced cytokine release at 40 mg/kg; reduces mast cell degranulation in a mouse model of PCA; inhibits bone destruction and delays disease progression in a mouse model of CIA; reverses bone osteolysis and allodynia in a syngeneic rat model of cancer-induced bone pain
18075	VX-745	1 mg	≥98%	A p38α MAPK inhibitor (IC50 = 9 nM); selective for p38α over p38β MAPK (Ki = 220 nM) as well as ERK, JNK, and a panel of 50 kinases at 2 µM; inhibits LPS-induced production of IL-1β and TNF-α in isolated human PBMCs (IC50s = 45 and 51 nM, respectively); reduces disease severity in a type II collagen-induced mouse model of arthritis at 10 mg/kg
18075	VX-745	10 mg	≥98%	A p38α MAPK inhibitor (IC50 = 9 nM); selective for p38α over p38β MAPK (Ki = 220 nM) as well as ERK, JNK, and a panel of 50 kinases at 2 µM; inhibits LPS-induced production of IL-1β and TNF-α in isolated human PBMCs (IC50s = 45 and 51 nM, respectively); reduces disease severity in a type II collagen-induced mouse model of arthritis at 10 mg/kg
18075	VX-745	5 mg	≥98%	A p38α MAPK inhibitor (IC50 = 9 nM); selective for p38α over p38β MAPK (Ki = 220 nM) as well as ERK, JNK, and a panel of 50 kinases at 2 µM; inhibits LPS-induced production of IL-1β and TNF-α in isolated human PBMCs (IC50s = 45 and 51 nM, respectively); reduces disease severity in a type II collagen-induced mouse model of arthritis at 10 mg/kg
18075	VX-745	50 mg	≥98%	A p38α MAPK inhibitor (IC50 = 9 nM); selective for p38α over p38β MAPK (Ki = 220 nM) as well as ERK, JNK, and a panel of 50 kinases at 2 µM; inhibits LPS-induced production of IL-1β and TNF-α in isolated human PBMCs (IC50s = 45 and 51 nM, respectively); reduces disease severity in a type II collagen-induced mouse model of arthritis at 10 mg/kg
18080	PD 153035	1 mg	≥98%	A potent, selective, reversible inhibitor of epidermal growth factor receptor (EGFR) kinase (Ki = 5.2 pM; IC50 = 29 pM); rapidly suppresses autophosphorylation of EGFR in fibroblasts and human epidermoid carcinoma cells
18080	PD 153035	10 mg	≥98%	A potent, selective, reversible inhibitor of epidermal growth factor receptor (EGFR) kinase (Ki = 5.2 pM; IC50 = 29 pM); rapidly suppresses autophosphorylation of EGFR in fibroblasts and human epidermoid carcinoma cells
18080	PD 153035	25 mg	≥98%	A potent, selective, reversible inhibitor of epidermal growth factor receptor (EGFR) kinase (Ki = 5.2 pM; IC50 = 29 pM); rapidly suppresses autophosphorylation of EGFR in fibroblasts and human epidermoid carcinoma cells
18080	PD 153035	5 mg	≥98%	A potent, selective, reversible inhibitor of epidermal growth factor receptor (EGFR) kinase (Ki = 5.2 pM; IC50 = 29 pM); rapidly suppresses autophosphorylation of EGFR in fibroblasts and human epidermoid carcinoma cells
18092	DDR1-IN-1 (hydrate)	1 mg	≥95%	A selective DDR1 inhibitor (IC50 = 105 nM; EC50 = 87 nM; inhibits colorectal cancer cell lines when used in combination with the PI3K/mTOR inhibitor, GSK2126458
18092	DDR1-IN-1 (hydrate)	10 mg	≥95%	A selective DDR1 inhibitor (IC50 = 105 nM; EC50 = 87 nM; inhibits colorectal cancer cell lines when used in combination with the PI3K/mTOR inhibitor, GSK2126458
18092	DDR1-IN-1 (hydrate)	5 mg	≥95%	A selective DDR1 inhibitor (IC50 = 105 nM; EC50 = 87 nM; inhibits colorectal cancer cell lines when used in combination with the PI3K/mTOR inhibitor, GSK2126458
18093	SGX523	1 mg	≥98%	A potent, selective, ATP-competitive inhibitor that blocks the tyrosine kinase activity of c-Met with an IC50 value of 4 nM
18093	SGX523	10 mg	≥98%	A potent, selective, ATP-competitive inhibitor that blocks the tyrosine kinase activity of c-Met with an IC50 value of 4 nM
18093	SGX523	25 mg	≥98%	A potent, selective, ATP-competitive inhibitor that blocks the tyrosine kinase activity of c-Met with an IC50 value of 4 nM
18093	SGX523	5 mg	≥98%	A potent, selective, ATP-competitive inhibitor that blocks the tyrosine kinase activity of c-Met with an IC50 value of 4 nM
18094	LRRK2-IN-1	1 mg	≥95%	A potent, selective inhibitor of LRRK2 that inhibits both wild-type and G2019S mutant LRRK2 (IC50s = 13 and 6 nM, respectively); stimulates macroautophagy in H4 neuroglioma cells
18094	LRRK2-IN-1	10 mg	≥95%	A potent, selective inhibitor of LRRK2 that inhibits both wild-type and G2019S mutant LRRK2 (IC50s = 13 and 6 nM, respectively); stimulates macroautophagy in H4 neuroglioma cells
18094	LRRK2-IN-1	5 mg	≥95%	A potent, selective inhibitor of LRRK2 that inhibits both wild-type and G2019S mutant LRRK2 (IC50s = 13 and 6 nM, respectively); stimulates macroautophagy in H4 neuroglioma cells

18095	GSK2334470	10 mg	≥98%	A selective PDK1 inhibitor (IC50 = ~10 nM) that even at 100-fold higher concentrations does not affect the activity of 93 other protein kinases, including that of 13 closely related AGC kinase family members; suppresses T-loop phosphorylation and activation of SGK, S6K1, and RSK, as well as the activation of Akt
18095	GSK2334470	25 mg	≥98%	A selective PDK1 inhibitor (IC50 = ~10 nM) that even at 100-fold higher concentrations does not affect the activity of 93 other protein kinases, including that of 13 closely related AGC kinase family members; suppresses T-loop phosphorylation and activation of SGK, S6K1, and RSK, as well as the activation of Akt
18095	GSK2334470	5 mg	≥98%	A selective PDK1 inhibitor (IC50 = ~10 nM) that even at 100-fold higher concentrations does not affect the activity of 93 other protein kinases, including that of 13 closely related AGC kinase family members; suppresses T-loop phosphorylation and activation of SGK, S6K1, and RSK, as well as the activation of Akt
18095	GSK2334470	50 mg	≥98%	A selective PDK1 inhibitor (IC50 = ~10 nM) that even at 100-fold higher concentrations does not affect the activity of 93 other protein kinases, including that of 13 closely related AGC kinase family members; suppresses T-loop phosphorylation and activation of SGK, S6K1, and RSK, as well as the activation of Akt
18096	JNK Inhibitor XVI	1 mg	≥95%	A selective, irreversible JNK inhibitor (IC50s = 4.67, 18.7, and 0.98 nM for JNK1, 2, and 3, respectively); prevents phosphorylation of c-Jun in A375 and HeLa cells (EC50s = 338 and 486 nM, respectively)
18096	JNK Inhibitor XVI	10 mg	≥95%	A selective, irreversible JNK inhibitor (IC50s = 4.67, 18.7, and 0.98 nM for JNK1, 2, and 3, respectively); prevents phosphorylation of c-Jun in A375 and HeLa cells (EC50s = 338 and 486 nM, respectively)
18096	JNK Inhibitor XVI	25 mg	≥95%	A selective, irreversible JNK inhibitor (IC50s = 4.67, 18.7, and 0.98 nM for JNK1, 2, and 3, respectively); prevents phosphorylation of c-Jun in A375 and HeLa cells (EC50s = 338 and 486 nM, respectively)
18096	JNK Inhibitor XVI	5 mg	≥95%	A selective, irreversible JNK inhibitor (IC50s = 4.67, 18.7, and 0.98 nM for JNK1, 2, and 3, respectively); prevents phosphorylation of c-Jun in A375 and HeLa cells (EC50s = 338 and 486 nM, respectively)
18098	ML167	1 mg	≥98%	A selective, ATP-competitive inhibitor of Clk4 (IC50 = 136 nM)
18098	ML167	10 mg	≥98%	A selective, ATP-competitive inhibitor of Clk4 (IC50 = 136 nM)
18098	ML167	5 mg	≥98%	A selective, ATP-competitive inhibitor of Clk4 (IC50 = 136 nM)
18099	GSK461364	1 mg	≥95%	A potent, reversible, and selective inhibitor of Plk1 (Ki = 2.2 nM); dose-dependently halts cell cycling in diverse proliferating cancer cell lines and, at higher doses, triggers apoptosis; effective in vivo, inducing tumor growth inhibition or growth delay in xenograft models in mice
18099	GSK461364	10 mg	≥95%	A potent, reversible, and selective inhibitor of Plk1 (Ki = 2.2 nM); dose-dependently halts cell cycling in diverse proliferating cancer cell lines and, at higher doses, triggers apoptosis; effective in vivo, inducing tumor growth inhibition or growth delay in xenograft models in mice
18099	GSK461364	25 mg	≥95%	A potent, reversible, and selective inhibitor of Plk1 (Ki = 2.2 nM); dose-dependently halts cell cycling in diverse proliferating cancer cell lines and, at higher doses, triggers apoptosis; effective in vivo, inducing tumor growth inhibition or growth delay in xenograft models in mice
18099	GSK461364	5 mg	≥95%	A potent, reversible, and selective inhibitor of Plk1 (Ki = 2.2 nM); dose-dependently halts cell cycling in diverse proliferating cancer cell lines and, at higher doses, triggers apoptosis; effective in vivo, inducing tumor growth inhibition or growth delay in xenograft models in mice
18130	UCN-01	1 mg	≥95%	A synthetic derivative of staurosporine that inhibits a variety of kinases, including Akt, protein kinase C (IC50 = 30 nM), PDK1 (IC50 = 6 nM) and cyclin-dependent kinases (IC50s = 300-600 nM for Cdk1 and Cdk2); arrests tumor cells in the G1/S phase of the cell cycle and prevents nucleotide excision repair by inhibiting the G2 checkpoint kinase Chk1 (IC50 = 7 nM), leading to apoptosis
18131	SCH 900776	1 mg	≥95%	A functionally selective inhibitor of Chk1 (Kd = 2 nM; IC50 = 3 nM); interacts synergistically with DNA antimetabolite agents in vitro and in vivo to selectively induce double-strand DNA breaks and cell death in tumor cells
18131	SCH 900776	10 mg	≥95%	A functionally selective inhibitor of Chk1 (Kd = 2 nM; IC50 = 3 nM); interacts synergistically with DNA antimetabolite agents in vitro and in vivo to selectively induce double-strand DNA breaks and cell death in tumor cells
18131	SCH 900776	5 mg	≥95%	A functionally selective inhibitor of Chk1 (Kd = 2 nM; IC50 = 3 nM); interacts synergistically with DNA antimetabolite agents in vitro and in vivo to selectively induce double-strand DNA breaks and cell death in tumor cells
18131	SCH 900776	500 µg	≥95%	A functionally selective inhibitor of Chk1 (Kd = 2 nM; IC50 = 3 nM); interacts synergistically with DNA antimetabolite agents in vitro and in vivo to selectively induce double-strand DNA breaks and cell death in tumor cells

18168	A-419259 (hydrochlor	1 mg	≥95%	An inhibitor of Src family kinases, including Src, LCK, Lyn, and Hck (IC50s = 9, 50 = 3,000 nM) and PKC (IC50 = >33 µM); inhibits growth of Ph-+ K-562 and Meg-01 myeloid leukemia cells (IC50s = 0.1-0.3 and 0.1 µM, respectively), but not Ph- TF-1 and HEL cells; induces apoptosis in K-562 cells in a concentration-dependent manner; inhibits differentiation of murine embryonic stem cells while maintaining pluripotency at 300 nM; reduces the total number of AML cells, as well as AML stem cells, in the bone marrow and spleen of human patient-derived AML mouse xenograft models at 30 mg/kg twice daily
18168	A-419259 (hydrochlor	10 mg	≥95%	An inhibitor of Src family kinases, including Src, LCK, Lyn, and Hck (IC50s = 9, 50 = 3,000 nM) and PKC (IC50 = >33 µM); inhibits growth of Ph-+ K-562 and Meg-01 myeloid leukemia cells (IC50s = 0.1-0.3 and 0.1 µM, respectively), but not Ph- TF-1 and HEL cells; induces apoptosis in K-562 cells in a concentration-dependent manner; inhibits differentiation of murine embryonic stem cells while maintaining pluripotency at 300 nM; reduces the total number of AML cells, as well as AML stem cells, in the bone marrow and spleen of human patient-derived AML mouse xenograft models at 30 mg/kg twice daily
18168	A-419259 (hydrochlor	25 mg	≥95%	An inhibitor of Src family kinases, including Src, LCK, Lyn, and Hck (IC50s = 9, 50 = 3,000 nM) and PKC (IC50 = >33 µM); inhibits growth of Ph-+ K-562 and Meg-01 myeloid leukemia cells (IC50s = 0.1-0.3 and 0.1 µM, respectively), but not Ph- TF-1 and HEL cells; induces apoptosis in K-562 cells in a concentration-dependent manner; inhibits differentiation of murine embryonic stem cells while maintaining pluripotency at 300 nM; reduces the total number of AML cells, as well as AML stem cells, in the bone marrow and spleen of human patient-derived AML mouse xenograft models at 30 mg/kg twice daily
18168	A-419259 (hydrochlor	5 mg	≥95%	An inhibitor of Src family kinases, including Src, LCK, Lyn, and Hck (IC50s = 9, 50 = 3,000 nM) and PKC (IC50 = >33 µM); inhibits growth of Ph-+ K-562 and Meg-01 myeloid leukemia cells (IC50s = 0.1-0.3 and 0.1 µM, respectively), but not Ph- TF-1 and HEL cells; induces apoptosis in K-562 cells in a concentration-dependent manner; inhibits differentiation of murine embryonic stem cells while maintaining pluripotency at 300 nM; reduces the total number of AML cells, as well as AML stem cells, in the bone marrow and spleen of human patient-derived AML mouse xenograft models at 30 mg/kg twice daily
18193	BI-6727	1 mg	≥98%	A dihydropteridinone that inhibits Plk1, Plk2, and Plk3 (IC50s = 0.87, 5, and 56 nM, respectively), inducing mitotic arrest and apoptosis; inhibits proliferation of multiple cancer cell lines (EC50s = 11-37 nM) and prevents the growth of various human carcinoma xenografts in mice
18193	BI-6727	10 mg	≥98%	A dihydropteridinone that inhibits Plk1, Plk2, and Plk3 (IC50s = 0.87, 5, and 56 nM, respectively), inducing mitotic arrest and apoptosis; inhibits proliferation of multiple cancer cell lines (EC50s = 11-37 nM) and prevents the growth of various human carcinoma xenografts in mice
18193	BI-6727	25 mg	≥98%	A dihydropteridinone that inhibits Plk1, Plk2, and Plk3 (IC50s = 0.87, 5, and 56 nM, respectively), inducing mitotic arrest and apoptosis; inhibits proliferation of multiple cancer cell lines (EC50s = 11-37 nM) and prevents the growth of various human carcinoma xenografts in mice
18193	BI-6727	5 mg	≥98%	A dihydropteridinone that inhibits Plk1, Plk2, and Plk3 (IC50s = 0.87, 5, and 56 nM, respectively), inducing mitotic arrest and apoptosis; inhibits proliferation of multiple cancer cell lines (EC50s = 11-37 nM) and prevents the growth of various human carcinoma xenografts in mice
18194	CCT128930	1 mg	≥95%	An ATP-competitive inhibitor of Akt2 (IC50 = 6 nM); blocks the phosphorylation of Akt targets, inhibits proliferation of multiple tumor cell lines in vitro, and prevents the growth of human tumor xenografts in mice
18194	CCT128930	10 mg	≥95%	An ATP-competitive inhibitor of Akt2 (IC50 = 6 nM); blocks the phosphorylation of Akt targets, inhibits proliferation of multiple tumor cell lines in vitro, and prevents the growth of human tumor xenografts in mice
18194	CCT128930	5 mg	≥95%	An ATP-competitive inhibitor of Akt2 (IC50 = 6 nM); blocks the phosphorylation of Akt targets, inhibits proliferation of multiple tumor cell lines in vitro, and prevents the growth of human tumor xenografts in mice
18194	CCT128930	50 mg	≥95%	An ATP-competitive inhibitor of Akt2 (IC50 = 6 nM); blocks the phosphorylation of Akt targets, inhibits proliferation of multiple tumor cell lines in vitro, and prevents the growth of human tumor xenografts in mice
18202	Syk Inhibitor II	1 mg	≥98%	A cell-permeable, selective, and reversible inhibitor of Syk (IC50 = 41 nM); prevents FcεRI-mediated 5-HT release in RBL-2H3 cells in vitro (IC50 = 460 nM) and inhibits passive cutaneous anaphylaxis reactions in mice (ID50 = 13.2 mg/kg, s.c.)
18202	Syk Inhibitor II	5 mg	≥98%	A cell-permeable, selective, and reversible inhibitor of Syk (IC50 = 41 nM); prevents FcεRI-mediated 5-HT release in RBL-2H3 cells in vitro (IC50 = 460 nM) and inhibits passive cutaneous anaphylaxis reactions in mice (ID50 = 13.2 mg/kg, s.c.)
18202	Syk Inhibitor II	500 µg	≥98%	A cell-permeable, selective, and reversible inhibitor of Syk (IC50 = 41 nM); prevents FcεRI-mediated 5-HT release in RBL-2H3 cells in vitro (IC50 = 460 nM) and inhibits passive cutaneous anaphylaxis reactions in mice (ID50 = 13.2 mg/kg, s.c.)
18218	PHA-767491 (hydroch	10 mg	≥98%	An inhibitor of Cdc7 kinase (IC50 = 10 nM) as well as Cdk9, (IC50 = 34 nM); induces apoptotic cell death in multiple cancer cell types at 10 µM

18218	PHA-767491 (hydroch	25 mg	≥98%	An inhibitor of Cdc7 kinase (IC50 = 10 nM) as well as Cdk9, (IC50 = 34 nM); induces apoptotic cell death in multiple cancer cell types at 10 µM
18218	PHA-767491 (hydroch	5 mg	≥98%	An inhibitor of Cdc7 kinase (IC50 = 10 nM) as well as Cdk9, (IC50 = 34 nM); induces apoptotic cell death in multiple cancer cell types at 10 µM
18218	PHA-767491 (hydroch	50 mg	≥98%	An inhibitor of Cdc7 kinase (IC50 = 10 nM) as well as Cdk9, (IC50 = 34 nM); induces apoptotic cell death in multiple cancer cell types at 10 µM
18244	Genistein-d4	1 mg	≥99% deutera	An internal standard for the quantification of genistein by GC- or LC-MS
18244	Genistein-d4	5 mg	≥99% deutera	An internal standard for the quantification of genistein by GC- or LC-MS
18244	Genistein-d4	500 µg	≥99% deutera	An internal standard for the quantification of genistein by GC- or LC-MS
18257	Imatinib-d3	1 mg	≥99% deutera	An internal standard for the quantification of imatinib by GC- or LC-MS
18257	Imatinib-d3	500 µg	≥99% deutera	An internal standard for the quantification of imatinib by GC- or LC-MS
18271	Pexidartinib	10 mg	≥98%	A brain-penetrant inhibitor of CSF1R, as well as c-Kit and FLT3 (IC50s = 20, 10, and 160 nM in vitro, respectively); blocks macrophage recruitment in mammary tumor-bearing mice and blocks glioblastoma invasion in both cell culture and a mouse model of glioblastoma multiforme
18271	Pexidartinib	25 mg	≥98%	A brain-penetrant inhibitor of CSF1R, as well as c-Kit and FLT3 (IC50s = 20, 10, and 160 nM in vitro, respectively); blocks macrophage recruitment in mammary tumor-bearing mice and blocks glioblastoma invasion in both cell culture and a mouse model of glioblastoma multiforme
18271	Pexidartinib	5 mg	≥98%	A brain-penetrant inhibitor of CSF1R, as well as c-Kit and FLT3 (IC50s = 20, 10, and 160 nM in vitro, respectively); blocks macrophage recruitment in mammary tumor-bearing mice and blocks glioblastoma invasion in both cell culture and a mouse model of glioblastoma multiforme
18271	Pexidartinib	50 mg	≥98%	A brain-penetrant inhibitor of CSF1R, as well as c-Kit and FLT3 (IC50s = 20, 10, and 160 nM in vitro, respectively); blocks macrophage recruitment in mammary tumor-bearing mice and blocks glioblastoma invasion in both cell culture and a mouse model of glioblastoma multiforme
18298	Ulixertinib (hydrochlo	1 mg	≥98%	A reversible ERK1/2 inhibitor (IC50 50 value of 180 nM
18298	Ulixertinib (hydrochlo	10 mg	≥98%	A reversible ERK1/2 inhibitor (IC50 50 value of 180 nM
18298	Ulixertinib (hydrochlo	25 mg	≥98%	A reversible ERK1/2 inhibitor (IC50 50 value of 180 nM
18298	Ulixertinib (hydrochlo	5 mg	≥98%	A reversible ERK1/2 inhibitor (IC50 50 value of 180 nM
18301	BI-847325	1 mg	≥98%	A selective dual MEK/Aurora kinase inhibitor (IC50s = 3, 25, 15, 25, and 4 nM for X. laevis Aurora B, human Aurora A and Aurora C, and human MEK1 and MEK2, respectively); inhibits the growth and survival of both treatment-naïve and drug-resistant melanoma both in vitro and in vivo, decreasing the expression of MEK and Mcl-1 while increasing the expression of pro-apoptotic protein Bim
18301	BI-847325	5 mg	≥98%	A selective dual MEK/Aurora kinase inhibitor (IC50s = 3, 25, 15, 25, and 4 nM for X. laevis Aurora B, human Aurora A and Aurora C, and human MEK1 and MEK2, respectively); inhibits the growth and survival of both treatment-naïve and drug-resistant melanoma both in vitro and in vivo, decreasing the expression of MEK and Mcl-1 while increasing the expression of pro-apoptotic protein Bim
18303	GDC-0980	1 mg	≥98%	A potent inhibitor of class I PI3K isoforms (IC50 values of 5, 27, 7, and 14 nM for PI3Kα, β, δ, and γ, respectively) and mTOR (Ki = 17 nM); induces cell cycle arrest or apoptosis in a range of cancer cell lines; effective in vivo, suppressing the growth of a number of tumor xenografts in mice
18303	GDC-0980	10 mg	≥98%	A potent inhibitor of class I PI3K isoforms (IC50 values of 5, 27, 7, and 14 nM for PI3Kα, β, δ, and γ, respectively) and mTOR (Ki = 17 nM); induces cell cycle arrest or apoptosis in a range of cancer cell lines; effective in vivo, suppressing the growth of a number of tumor xenografts in mice
18303	GDC-0980	25 mg	≥98%	A potent inhibitor of class I PI3K isoforms (IC50 values of 5, 27, 7, and 14 nM for PI3Kα, β, δ, and γ, respectively) and mTOR (Ki = 17 nM); induces cell cycle arrest or apoptosis in a range of cancer cell lines; effective in vivo, suppressing the growth of a number of tumor xenografts in mice
18303	GDC-0980	5 mg	≥98%	A potent inhibitor of class I PI3K isoforms (IC50 values of 5, 27, 7, and 14 nM for PI3Kα, β, δ, and γ, respectively) and mTOR (Ki = 17 nM); induces cell cycle arrest or apoptosis in a range of cancer cell lines; effective in vivo, suppressing the growth of a number of tumor xenografts in mice
18315	MCB-613	1 mg	≥95%	A small molecule stimulator of SRC-1, SRC-2, and SRC-3 that selectively induces paraptosis in a variety of cancer cells in vitro and reduces tumor growth in a xenograft mouse model; can increase the interaction of SRCs with the coactivators CBP and CARM1 and can induce ER stress coupled to the generation of reactive oxygen species
18315	MCB-613	10 mg	≥95%	A small molecule stimulator of SRC-1, SRC-2, and SRC-3 that selectively induces paraptosis in a variety of cancer cells in vitro and reduces tumor growth in a xenograft mouse model; can increase the interaction of SRCs with the coactivators CBP and CARM1 and can induce ER stress coupled to the generation of reactive oxygen species
18315	MCB-613	25 mg	≥95%	A small molecule stimulator of SRC-1, SRC-2, and SRC-3 that selectively induces paraptosis in a variety of cancer cells in vitro and reduces tumor growth in a xenograft mouse model; can increase the interaction of SRCs with the coactivators CBP and CARM1 and can induce ER stress coupled to the generation of reactive oxygen species

18315	MCB-613	5 mg	≥95%	A small molecule stimulator of SRC-1, SRC-2, and SRC-3 that selectively induces paraptosis in a variety of cancer cells in vitro and reduces tumor growth in a xenograft mouse model; can increase the interaction of SRCs with the coactivators CBP and CARM1 and can induce ER stress coupled to the generation of reactive oxygen species
18371	PF-06463922	1 mg	≥98%	An ATP-competitive, selective inhibitor of ALK (Ki = i = 0.7 nM) with strong activity against all known ALK and ROS1 mutants identified in patients; orally available with efficient blood-brain barrier penetration
18371	PF-06463922	10 mg	≥98%	An ATP-competitive, selective inhibitor of ALK (Ki = i = 0.7 nM) with strong activity against all known ALK and ROS1 mutants identified in patients; orally available with efficient blood-brain barrier penetration
18371	PF-06463922	5 mg	≥98%	An ATP-competitive, selective inhibitor of ALK (Ki = i = 0.7 nM) with strong activity against all known ALK and ROS1 mutants identified in patients; orally available with efficient blood-brain barrier penetration
18372	WYE-125132	1 mg	≥98%	An ATP-competitive inhibitor of mTOR (IC50 = 0.19 nM) that inhibits signaling through both mTORC1 and mTORC2; effective in diverse cancer models, both in vitro and in vivo, blocking mTOR signaling and preventing growth in breast, lung, renal, and glioma cancer cells and tumor xenografts in mice
18372	WYE-125132	10 mg	≥98%	An ATP-competitive inhibitor of mTOR (IC50 = 0.19 nM) that inhibits signaling through both mTORC1 and mTORC2; effective in diverse cancer models, both in vitro and in vivo, blocking mTOR signaling and preventing growth in breast, lung, renal, and glioma cancer cells and tumor xenografts in mice
18372	WYE-125132	5 mg	≥98%	An ATP-competitive inhibitor of mTOR (IC50 = 0.19 nM) that inhibits signaling through both mTORC1 and mTORC2; effective in diverse cancer models, both in vitro and in vivo, blocking mTOR signaling and preventing growth in breast, lung, renal, and glioma cancer cells and tumor xenografts in mice
18372	WYE-125132	500 µg	≥98%	An ATP-competitive inhibitor of mTOR (IC50 = 0.19 nM) that inhibits signaling through both mTORC1 and mTORC2; effective in diverse cancer models, both in vitro and in vivo, blocking mTOR signaling and preventing growth in breast, lung, renal, and glioma cancer cells and tumor xenografts in mice
18381	Bikinin	10 mg	≥98%	An inhibitor of several ASK isoforms when given at a concentration of 10 µM, leaving residual kinase activity at less than 10% for ASKα, γ, ε, ζ, η, ι, and 20% for ASKθ, without inhibiting isoforms β and δ; activates signaling induced by brassinosteroids
18381	Bikinin	25 mg	≥98%	An inhibitor of several ASK isoforms when given at a concentration of 10 µM, leaving residual kinase activity at less than 10% for ASKα, γ, ε, ζ, η, ι, and 20% for ASKθ, without inhibiting isoforms β and δ; activates signaling induced by brassinosteroids
18381	Bikinin	5 mg	≥98%	An inhibitor of several ASK isoforms when given at a concentration of 10 µM, leaving residual kinase activity at less than 10% for ASKα, γ, ε, ζ, η, ι, and 20% for ASKθ, without inhibiting isoforms β and δ; activates signaling induced by brassinosteroids
18381	Bikinin	50 mg	≥98%	An inhibitor of several ASK isoforms when given at a concentration of 10 µM, leaving residual kinase activity at less than 10% for ASKα, γ, ε, ζ, η, ι, and 20% for ASKθ, without inhibiting isoforms β and δ; activates signaling induced by brassinosteroids
18387	Danusertib	1 mg	≥95%	A pan-Aurora kinase inhibitor (IC50s = 13, 79, and 61 nM for Aurora A, B, and C, respectively) that also targets Abl, Ret, Trka and FGFR1 (IC50s = 25, 31, 31, and 47 nM, respectively); exhibits anti-proliferative and pro-apoptotic activity against a panel of cancer cells in vitro and diverse xenografts in mice
18387	Danusertib	10 mg	≥95%	A pan-Aurora kinase inhibitor (IC50s = 13, 79, and 61 nM for Aurora A, B, and C, respectively) that also targets Abl, Ret, Trka and FGFR1 (IC50s = 25, 31, 31, and 47 nM, respectively); exhibits anti-proliferative and pro-apoptotic activity against a panel of cancer cells in vitro and diverse xenografts in mice
18387	Danusertib	5 mg	≥95%	A pan-Aurora kinase inhibitor (IC50s = 13, 79, and 61 nM for Aurora A, B, and C, respectively) that also targets Abl, Ret, Trka and FGFR1 (IC50s = 25, 31, 31, and 47 nM, respectively); exhibits anti-proliferative and pro-apoptotic activity against a panel of cancer cells in vitro and diverse xenografts in mice
18387	Danusertib	50 mg	≥95%	A pan-Aurora kinase inhibitor (IC50s = 13, 79, and 61 nM for Aurora A, B, and C, respectively) that also targets Abl, Ret, Trka and FGFR1 (IC50s = 25, 31, 31, and 47 nM, respectively); exhibits anti-proliferative and pro-apoptotic activity against a panel of cancer cells in vitro and diverse xenografts in mice

18388	PHA-793887	1 mg	≥95%	A CDK inhibitor (IC50s = 8, 8, 5, and 10 nM for Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p25, and Cdk7/cyclin H, respectively); selective for these CDKs over Cdk1/cyclin B, Cdk4/cyclin D1, Cdk9/cyclin T1, and GSK3β (IC50s = 60, 62, 138, and 79 nM, respectively), as well as a panel of 36 other kinases at 10 µM; inhibits the proliferation of A2780, HCT116, and BxPC-3 cells (IC50 = 0.088, 0.163, and 3.444 µM, respectively); inhibits reactivation of latent HIV-1 induced by prostratin, panobinostat, or JQ-1 in 24ST1NLESG cells (IC50s = 88, 163, and 3,444 nM, respectively); reduces tumor growth and increases survival in HL-60 and K562 leukemia mouse xenograft models at 20 mg/kg
18388	PHA-793887	10 mg	≥95%	A CDK inhibitor (IC50s = 8, 8, 5, and 10 nM for Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p25, and Cdk7/cyclin H, respectively); selective for these CDKs over Cdk1/cyclin B, Cdk4/cyclin D1, Cdk9/cyclin T1, and GSK3β (IC50s = 60, 62, 138, and 79 nM, respectively), as well as a panel of 36 other kinases at 10 µM; inhibits the proliferation of A2780, HCT116, and BxPC-3 cells (IC50 = 0.088, 0.163, and 3.444 µM, respectively); inhibits reactivation of latent HIV-1 induced by prostratin, panobinostat, or JQ-1 in 24ST1NLESG cells (IC50s = 88, 163, and 3,444 nM, respectively); reduces tumor growth and increases survival in HL-60 and K562 leukemia mouse xenograft models at 20 mg/kg
18388	PHA-793887	5 mg	≥95%	A CDK inhibitor (IC50s = 8, 8, 5, and 10 nM for Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p25, and Cdk7/cyclin H, respectively); selective for these CDKs over Cdk1/cyclin B, Cdk4/cyclin D1, Cdk9/cyclin T1, and GSK3β (IC50s = 60, 62, 138, and 79 nM, respectively), as well as a panel of 36 other kinases at 10 µM; inhibits the proliferation of A2780, HCT116, and BxPC-3 cells (IC50 = 0.088, 0.163, and 3.444 µM, respectively); inhibits reactivation of latent HIV-1 induced by prostratin, panobinostat, or JQ-1 in 24ST1NLESG cells (IC50s = 88, 163, and 3,444 nM, respectively); reduces tumor growth and increases survival in HL-60 and K562 leukemia mouse xenograft models at 20 mg/kg
18388	PHA-793887	50 mg	≥95%	A CDK inhibitor (IC50s = 8, 8, 5, and 10 nM for Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p25, and Cdk7/cyclin H, respectively); selective for these CDKs over Cdk1/cyclin B, Cdk4/cyclin D1, Cdk9/cyclin T1, and GSK3β (IC50s = 60, 62, 138, and 79 nM, respectively), as well as a panel of 36 other kinases at 10 µM; inhibits the proliferation of A2780, HCT116, and BxPC-3 cells (IC50 = 0.088, 0.163, and 3.444 µM, respectively); inhibits reactivation of latent HIV-1 induced by prostratin, panobinostat, or JQ-1 in 24ST1NLESG cells (IC50s = 88, 163, and 3,444 nM, respectively); reduces tumor growth and increases survival in HL-60 and K562 leukemia mouse xenograft models at 20 mg/kg
18390	NVP-ADW742	1 mg	≥98%	A selective IGF-1R inhibitor (IC50 = 0.17 µM); inhibits tumor proliferation both in vitro and in a mouse model of multiple myeloma
18390	NVP-ADW742	10 mg	≥98%	A selective IGF-1R inhibitor (IC50 = 0.17 µM); inhibits tumor proliferation both in vitro and in a mouse model of multiple myeloma
18390	NVP-ADW742	5 mg	≥98%	A selective IGF-1R inhibitor (IC50 = 0.17 µM); inhibits tumor proliferation both in vitro and in a mouse model of multiple myeloma
18390	NVP-ADW742	50 mg	≥98%	A selective IGF-1R inhibitor (IC50 = 0.17 µM); inhibits tumor proliferation both in vitro and in a mouse model of multiple myeloma
18396	A-77-01	1 mg	≥98%	A potent inhibitor of the TGF-β1 receptor ALK5 (IC550 = 25 nM), blocking SMAD2 phosphorylation and growth inhibitory effects of TGF-β; prevents EMT transition in NMuMG cells treated with TGF-β
18396	A-77-01	10 mg	≥98%	A potent inhibitor of the TGF-β1 receptor ALK5 (IC550 = 25 nM), blocking SMAD2 phosphorylation and growth inhibitory effects of TGF-β; prevents EMT transition in NMuMG cells treated with TGF-β
18396	A-77-01	25 mg	≥98%	A potent inhibitor of the TGF-β1 receptor ALK5 (IC550 = 25 nM), blocking SMAD2 phosphorylation and growth inhibitory effects of TGF-β; prevents EMT transition in NMuMG cells treated with TGF-β
18396	A-77-01	5 mg	≥98%	A potent inhibitor of the TGF-β1 receptor ALK5 (IC550 = 25 nM), blocking SMAD2 phosphorylation and growth inhibitory effects of TGF-β; prevents EMT transition in NMuMG cells treated with TGF-β
18404	Neratinib	10 mg	≥98%	A dual inhibitor of EGFR and HER2 (IC50s = 92 and 59 nM, respectively); selective for EGFR and HER2 over a panel of 12 kinases (IC50s = >5,000 nM) but does inhibit VEGFR2 and Src (IC50s = 800 and 1,400 nM, respectively); inhibits the proliferation of NCI H508 colorectal cancer cells expressing wild-type or mutant forms of HER2 (IC50s = 0.2-3 nM); reduces tumor growth in BT474 breast and SKOV3 ovarian cancer mouse xenograft models at 40 mg/kg
18404	Neratinib	25 mg	≥98%	A dual inhibitor of EGFR and HER2 (IC50s = 92 and 59 nM, respectively); selective for EGFR and HER2 over a panel of 12 kinases (IC50s = >5,000 nM) but does inhibit VEGFR2 and Src (IC50s = 800 and 1,400 nM, respectively); inhibits the proliferation of NCI H508 colorectal cancer cells expressing wild-type or mutant forms of HER2 (IC50s = 0.2-3 nM); reduces tumor growth in BT474 breast and SKOV3 ovarian cancer mouse xenograft models at 40 mg/kg

18404	Neratinib	5 mg	≥98%	A dual inhibitor of EGFR and HER2 (IC50s = 92 and 59 nM, respectively); selective for EGFR and HER2 over a panel of 12 kinases (IC50s = >5,000 nM) but does inhibit VEGFR2 and Src (IC50s = 800 and 1,400 nM, respectively); inhibits the proliferation of NCI H508 colorectal cancer cells expressing wild-type or mutant forms of HER2 (IC50s = 0.2-3 nM); reduces tumor growth in BT474 breast and SKOV3 ovarian cancer mouse xenograft models at 40 mg/kg
18405	BLU-9931	1 mg	≥98%	A selective inhibitor of FGFR4 (IC50s = 3, 591, 493, and 150 nM for FGFR4, 1, 2, and 3, respectively); inhibits proliferation of HCC cells (EC50s = 0.02-0.11 µM) and demonstrates antitumor activity in mice bearing HCC xenografts when administered orally at 100 mg/kg
18405	BLU-9931	10 mg	≥98%	A selective inhibitor of FGFR4 (IC50s = 3, 591, 493, and 150 nM for FGFR4, 1, 2, and 3, respectively); inhibits proliferation of HCC cells (EC50s = 0.02-0.11 µM) and demonstrates antitumor activity in mice bearing HCC xenografts when administered orally at 100 mg/kg
18405	BLU-9931	25 mg	≥98%	A selective inhibitor of FGFR4 (IC50s = 3, 591, 493, and 150 nM for FGFR4, 1, 2, and 3, respectively); inhibits proliferation of HCC cells (EC50s = 0.02-0.11 µM) and demonstrates antitumor activity in mice bearing HCC xenografts when administered orally at 100 mg/kg
18405	BLU-9931	5 mg	≥98%	A selective inhibitor of FGFR4 (IC50s = 3, 591, 493, and 150 nM for FGFR4, 1, 2, and 3, respectively); inhibits proliferation of HCC cells (EC50s = 0.02-0.11 µM) and demonstrates antitumor activity in mice bearing HCC xenografts when administered orally at 100 mg/kg
18406	CEP-28122	1 mg	≥98%	A potent inhibitor of ALK (IC50 = 1.9 nM) that induces concentration-dependent growth inhibition or cytotoxicity of ALK-positive cancer cells; inhibits ALK tyrosine phosphorylation in tumor xenografts in mice for more than 12 hours following single oral dosing at 30 mg/kg
18406	CEP-28122	10 mg	≥98%	A potent inhibitor of ALK (IC50 = 1.9 nM) that induces concentration-dependent growth inhibition or cytotoxicity of ALK-positive cancer cells; inhibits ALK tyrosine phosphorylation in tumor xenografts in mice for more than 12 hours following single oral dosing at 30 mg/kg
18406	CEP-28122	25 mg	≥98%	A potent inhibitor of ALK (IC50 = 1.9 nM) that induces concentration-dependent growth inhibition or cytotoxicity of ALK-positive cancer cells; inhibits ALK tyrosine phosphorylation in tumor xenografts in mice for more than 12 hours following single oral dosing at 30 mg/kg
18406	CEP-28122	5 mg	≥98%	A potent inhibitor of ALK (IC50 = 1.9 nM) that induces concentration-dependent growth inhibition or cytotoxicity of ALK-positive cancer cells; inhibits ALK tyrosine phosphorylation in tumor xenografts in mice for more than 12 hours following single oral dosing at 30 mg/kg
18412	GDC-0068	1 mg	≥98%	A selective, ATP-competitive, pan-Akt inhibitor that targets Akt1, 2, and 3 (IC50s = 5, 18, and 8 nM, respectivley); blocks Akt signaling both in cultured tumor cell lines and tumor xenograft models
18412	GDC-0068	10 mg	≥98%	A selective, ATP-competitive, pan-Akt inhibitor that targets Akt1, 2, and 3 (IC50s = 5, 18, and 8 nM, respectivley); blocks Akt signaling both in cultured tumor cell lines and tumor xenograft models
18412	GDC-0068	25 mg	≥98%	A selective, ATP-competitive, pan-Akt inhibitor that targets Akt1, 2, and 3 (IC50s = 5, 18, and 8 nM, respectivley); blocks Akt signaling both in cultured tumor cell lines and tumor xenograft models
18412	GDC-0068	5 mg	≥98%	A selective, ATP-competitive, pan-Akt inhibitor that targets Akt1, 2, and 3 (IC50s = 5, 18, and 8 nM, respectivley); blocks Akt signaling both in cultured tumor cell lines and tumor xenograft models
18414	CGI1746	1 mg	≥98%	A potent, selective inhibitor of BTK (IC50 = 1.9 nM); prevents BCR-mediated B lymphocyte proliferation; reduces cytokine levels within joints and ameliorates symptoms in a mouse model of autoantibody-induced arthritis
18414	CGI1746	10 mg	≥98%	A potent, selective inhibitor of BTK (IC50 = 1.9 nM); prevents BCR-mediated B lymphocyte proliferation; reduces cytokine levels within joints and ameliorates symptoms in a mouse model of autoantibody-induced arthritis
18414	CGI1746	25 mg	≥98%	A potent, selective inhibitor of BTK (IC50 = 1.9 nM); prevents BCR-mediated B lymphocyte proliferation; reduces cytokine levels within joints and ameliorates symptoms in a mouse model of autoantibody-induced arthritis
18414	CGI1746	5 mg	≥98%	A potent, selective inhibitor of BTK (IC50 = 1.9 nM); prevents BCR-mediated B lymphocyte proliferation; reduces cytokine levels within joints and ameliorates symptoms in a mouse model of autoantibody-induced arthritis
18416	AEE788	1 mg	≥98%	An inhibitor of EGFR and VEGFR tyrosine kinases (IC50s = 2, 6, 77, and 59 nM for EGFR, ErbB2, KDR, and FLT1, respectively); demonstrates antitumor activity and anti-angiogenic activity in numerous in vitro and in vivo models
18416	AEE788	10 mg	≥98%	An inhibitor of EGFR and VEGFR tyrosine kinases (IC50s = 2, 6, 77, and 59 nM for EGFR, ErbB2, KDR, and FLT1, respectively); demonstrates antitumor activity and anti-angiogenic activity in numerous in vitro and in vivo models
18416	AEE788	25 mg	≥98%	An inhibitor of EGFR and VEGFR tyrosine kinases (IC50s = 2, 6, 77, and 59 nM for EGFR, ErbB2, KDR, and FLT1, respectively); demonstrates antitumor activity and anti-angiogenic activity in numerous in vitro and in vivo models

18416	AEE788	5 mg	≥98%	An inhibitor of EGFR and VEGFR tyrosine kinases (IC50s = 2, 6, 77, and 59 nM for EGFR, ErbB2, KDR, and FLT1, respectively); demonstrates antitumor activity and anti-angiogenic activity in numerous in vitro and in vivo models
18423	Menaquinone 4	1 g	≥98%	A homolog of vitamin K2; formed primarily via conversion of vitamin K1 in vivo; halts the cell cycle at the G1 phase in HepG2, Hep3B, and Huh7 hepatocellular carcinoma cells in a concentration-dependent manner; inhibits IκB, IκBα phosphorylation, and the transcriptional activity of NF-κB
18423	Menaquinone 4	100 mg	≥98%	A homolog of vitamin K2; formed primarily via conversion of vitamin K1 in vivo; halts the cell cycle at the G1 phase in HepG2, Hep3B, and Huh7 hepatocellular carcinoma cells in a concentration-dependent manner; inhibits IκB, IκBα phosphorylation, and the transcriptional activity of NF-κB
18423	Menaquinone 4	250 mg	≥98%	A homolog of vitamin K2; formed primarily via conversion of vitamin K1 in vivo; halts the cell cycle at the G1 phase in HepG2, Hep3B, and Huh7 hepatocellular carcinoma cells in a concentration-dependent manner; inhibits IκB, IκBα phosphorylation, and the transcriptional activity of NF-κB
18423	Menaquinone 4	500 mg	≥98%	A homolog of vitamin K2; formed primarily via conversion of vitamin K1 in vivo; halts the cell cycle at the G1 phase in HepG2, Hep3B, and Huh7 hepatocellular carcinoma cells in a concentration-dependent manner; inhibits IκB, IκBα phosphorylation, and the transcriptional activity of NF-κB
18441	Rp-8-bromo-Cyclic GM	1 mg	≥99%	A cell-permeable cGMP analog that binds cGK without activating it, resulting in competitive inhibition; blocks the relaxation of rat tail arteries induced by the nitric oxide donor SIN-1
18441	Rp-8-bromo-Cyclic GM	5 mg	≥99%	A cell-permeable cGMP analog that binds cGK without activating it, resulting in competitive inhibition; blocks the relaxation of rat tail arteries induced by the nitric oxide donor SIN-1
18445	Rp-8-pCPT-Cyclic GMP	1 mg	≥99%	A stable, cell-permeable cGMP analog that competitively inhibits cGMP-dependent protein kinases (cGKs), including cGK Iα and cGK II (IC50s = 18.3 and 0.16 µM, respectively); blocks the relaxation of rat tail arteries induced by the nitric oxide donor SIN-1
18462	FLT3 Inhibitor	10 mg	≥98%	A cell-permeable, ATP-competitive inhibitor of FLT3 (IC50 = 27 nM) that blocks the proliferation of myelomonocytic leukemia MV4-11 cells (IC50 = 0.41 µM)
18462	FLT3 Inhibitor	25 mg	≥98%	A cell-permeable, ATP-competitive inhibitor of FLT3 (IC50 = 27 nM) that blocks the proliferation of myelomonocytic leukemia MV4-11 cells (IC50 = 0.41 µM)
18462	FLT3 Inhibitor	5 mg	≥98%	A cell-permeable, ATP-competitive inhibitor of FLT3 (IC50 = 27 nM) that blocks the proliferation of myelomonocytic leukemia MV4-11 cells (IC50 = 0.41 µM)
18462	FLT3 Inhibitor	50 mg	≥98%	A cell-permeable, ATP-competitive inhibitor of FLT3 (IC50 = 27 nM) that blocks the proliferation of myelomonocytic leukemia MV4-11 cells (IC50 = 0.41 µM)
18464	XL184	1 mg	≥98%	A VEGFR2 inhibitor (IC50 = 0.035 nM); selective for VEGFR2 over Ron, EGFR, IGF-1R, and EphA4/B4; inhibits c-Met, RET, c-Kit, Axl, FLT3, and Tie2 (IC50s = 1.3, 5.2, 4.6, 7, 11.3, and 14.3 nM, respectively); inhibits VEGF-induced tubule formation in HMVECs at 4.6 nM; reduces HGF-induced migration and invasion of B16/F10 cells at 123 nM; induces tumor regression in an MDA-MB-231 breast cancer mouse xenograft model at 60 mg/kg; does not increase the number of pulmonary tumor foci in an MDA-MB-231 mouse metastasis model; protects primary placental fibroblasts from Zika virus infection
18464	XL184	10 mg	≥98%	A VEGFR2 inhibitor (IC50 = 0.035 nM); selective for VEGFR2 over Ron, EGFR, IGF-1R, and EphA4/B4; inhibits c-Met, RET, c-Kit, Axl, FLT3, and Tie2 (IC50s = 1.3, 5.2, 4.6, 7, 11.3, and 14.3 nM, respectively); inhibits VEGF-induced tubule formation in HMVECs at 4.6 nM; reduces HGF-induced migration and invasion of B16/F10 cells at 123 nM; induces tumor regression in an MDA-MB-231 breast cancer mouse xenograft model at 60 mg/kg; does not increase the number of pulmonary tumor foci in an MDA-MB-231 mouse metastasis model; protects primary placental fibroblasts from Zika virus infection
18464	XL184	5 mg	≥98%	A VEGFR2 inhibitor (IC50 = 0.035 nM); selective for VEGFR2 over Ron, EGFR, IGF-1R, and EphA4/B4; inhibits c-Met, RET, c-Kit, Axl, FLT3, and Tie2 (IC50s = 1.3, 5.2, 4.6, 7, 11.3, and 14.3 nM, respectively); inhibits VEGF-induced tubule formation in HMVECs at 4.6 nM; reduces HGF-induced migration and invasion of B16/F10 cells at 123 nM; induces tumor regression in an MDA-MB-231 breast cancer mouse xenograft model at 60 mg/kg; does not increase the number of pulmonary tumor foci in an MDA-MB-231 mouse metastasis model; protects primary placental fibroblasts from Zika virus infection

18464	XL184	50 mg	≥98%	A VEGFR2 inhibitor (IC50 = 0.035 nM); selective for VEGFR2 over Ron, EGFR, IGF-1R, and EphA4/B4; inhibits c-Met, RET, c-Kit, Axl, FLT3, and Tie2 (IC50s = 1.3, 5.2, 4.6, 7, 11.3, and 14.3 nM, respectively); inhibits VEGF-induced tubule formation in HMVECs at 4.6 nM; reduces HGF-induced migration and invasion of B16/F10 cells at 123 nM; induces tumor regression in an MDA-MB-231 breast cancer mouse xenograft model at 60 mg/kg; does not increase the number of pulmonary tumor foci in an MDA-MB-231 mouse metastasis model; protects primary placental fibroblasts from Zika virus infection
18477	SBI-0206965	10 mg	≥98%	An inhibitor of ULK1 (IC50 = 108 nM) that is less effective against ULK2 (IC50 = 711 nM); suppresses autophagy induced by mTOR inhibition and blocks ULK1-dependent cell survival following nutrient deprivation
18477	SBI-0206965	100 mg	≥98%	An inhibitor of ULK1 (IC50 = 108 nM) that is less effective against ULK2 (IC50 = 711 nM); suppresses autophagy induced by mTOR inhibition and blocks ULK1-dependent cell survival following nutrient deprivation
18477	SBI-0206965	25 mg	≥98%	An inhibitor of ULK1 (IC50 = 108 nM) that is less effective against ULK2 (IC50 = 711 nM); suppresses autophagy induced by mTOR inhibition and blocks ULK1-dependent cell survival following nutrient deprivation
18477	SBI-0206965	5 mg	≥98%	An inhibitor of ULK1 (IC50 = 108 nM) that is less effective against ULK2 (IC50 = 711 nM); suppresses autophagy induced by mTOR inhibition and blocks ULK1-dependent cell survival following nutrient deprivation
18489	NVP-BHG712	1 mg	≥98%	A selective, orally bioavailable inhibitor of EphB4 kinase autophosphorylation (ED50 =25 nM); inhibits VEGF-directed vessel formation in an in vivo mouse model of angiogenesis
18489	NVP-BHG712	10 mg	≥98%	A selective, orally bioavailable inhibitor of EphB4 kinase autophosphorylation (ED50 =25 nM); inhibits VEGF-directed vessel formation in an in vivo mouse model of angiogenesis
18489	NVP-BHG712	25 mg	≥98%	A selective, orally bioavailable inhibitor of EphB4 kinase autophosphorylation (ED50 =25 nM); inhibits VEGF-directed vessel formation in an in vivo mouse model of angiogenesis
18489	NVP-BHG712	5 mg	≥98%	A selective, orally bioavailable inhibitor of EphB4 kinase autophosphorylation (ED50 =25 nM); inhibits VEGF-directed vessel formation in an in vivo mouse model of angiogenesis
18491	ASP3026	1 mg	≥98%	An ALK inhibitor (IC50s = 3.5, 10, and 5.4 nM for the wild-type, ALKF1174L, and ALKR1275Q enzymes, respectively); selective for ALK over a panel of 86 kinases at 1,000 nM but also inhibits ROS1 and TNK2 (IC50s = 8.9 and 5.8 nM, respectively); inhibits the proliferation of Ba/F3 cells expressing NPM-ALK or ELM4-ALK fusion proteins (IC50s = 84 and 56 nM, respectively), as well as several crizotinib-resistant Ba/F3 cells expressing NPM-ALK or ELM4-ALK mutants; induces tumor regression in an NCI H2228 NSCLC mouse xenograft model at 10 and 30 mg/kg
18491	ASP3026	10 mg	≥98%	An ALK inhibitor (IC50s = 3.5, 10, and 5.4 nM for the wild-type, ALKF1174L, and ALKR1275Q enzymes, respectively); selective for ALK over a panel of 86 kinases at 1,000 nM but also inhibits ROS1 and TNK2 (IC50s = 8.9 and 5.8 nM, respectively); inhibits the proliferation of Ba/F3 cells expressing NPM-ALK or ELM4-ALK fusion proteins (IC50s = 84 and 56 nM, respectively), as well as several crizotinib-resistant Ba/F3 cells expressing NPM-ALK or ELM4-ALK mutants; induces tumor regression in an NCI H2228 NSCLC mouse xenograft model at 10 and 30 mg/kg
18491	ASP3026	25 mg	≥98%	An ALK inhibitor (IC50s = 3.5, 10, and 5.4 nM for the wild-type, ALKF1174L, and ALKR1275Q enzymes, respectively); selective for ALK over a panel of 86 kinases at 1,000 nM but also inhibits ROS1 and TNK2 (IC50s = 8.9 and 5.8 nM, respectively); inhibits the proliferation of Ba/F3 cells expressing NPM-ALK or ELM4-ALK fusion proteins (IC50s = 84 and 56 nM, respectively), as well as several crizotinib-resistant Ba/F3 cells expressing NPM-ALK or ELM4-ALK mutants; induces tumor regression in an NCI H2228 NSCLC mouse xenograft model at 10 and 30 mg/kg
18491	ASP3026	5 mg	≥98%	An ALK inhibitor (IC50s = 3.5, 10, and 5.4 nM for the wild-type, ALKF1174L, and ALKR1275Q enzymes, respectively); selective for ALK over a panel of 86 kinases at 1,000 nM but also inhibits ROS1 and TNK2 (IC50s = 8.9 and 5.8 nM, respectively); inhibits the proliferation of Ba/F3 cells expressing NPM-ALK or ELM4-ALK fusion proteins (IC50s = 84 and 56 nM, respectively), as well as several crizotinib-resistant Ba/F3 cells expressing NPM-ALK or ELM4-ALK mutants; induces tumor regression in an NCI H2228 NSCLC mouse xenograft model at 10 and 30 mg/kg
18493	Tivozanib (hydrate)	1 mg	≥95%	An orally available, selective VEGFR inhibitor (IC50s = 0.21, 0.16, and 0.24 nM for VEGFR1, VEGFR2, and VEGFR3, respectively); also inhibits c-Kit and PDGFRβ (IC50s = 1.63 and 1.72 nM, respectively)
18493	Tivozanib (hydrate)	10 mg	≥95%	An orally available, selective VEGFR inhibitor (IC50s = 0.21, 0.16, and 0.24 nM for VEGFR1, VEGFR2, and VEGFR3, respectively); also inhibits c-Kit and PDGFRβ (IC50s = 1.63 and 1.72 nM, respectively)
18493	Tivozanib (hydrate)	5 mg	≥95%	An orally available, selective VEGFR inhibitor (IC50s = 0.21, 0.16, and 0.24 nM for VEGFR1, VEGFR2, and VEGFR3, respectively); also inhibits c-Kit and PDGFRβ (IC50s = 1.63 and 1.72 nM, respectively)

18494	JNJ-7706621	1 mg	≥98%	A dual inhibitor of Cdks and Aurora kinases; inhibits Cdk1/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, Cdk3/cyclin E, Cdk4/cyclin D1, Cdk6/cyclin D1, Aurora A, and Aurora B in vitro (IC50s = 9, 4, 3, 58, 253, 175, 11, and 15 nM, respectively); blocks the growth of cancer cells in vitro and in vivo
18494	JNJ-7706621	10 mg	≥98%	A dual inhibitor of Cdks and Aurora kinases; inhibits Cdk1/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, Cdk3/cyclin E, Cdk4/cyclin D1, Cdk6/cyclin D1, Aurora A, and Aurora B in vitro (IC50s = 9, 4, 3, 58, 253, 175, 11, and 15 nM, respectively); blocks the growth of cancer cells in vitro and in vivo
18494	JNJ-7706621	5 mg	≥98%	A dual inhibitor of Cdks and Aurora kinases; inhibits Cdk1/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, Cdk3/cyclin E, Cdk4/cyclin D1, Cdk6/cyclin D1, Aurora A, and Aurora B in vitro (IC50s = 9, 4, 3, 58, 253, 175, 11, and 15 nM, respectively); blocks the growth of cancer cells in vitro and in vivo
18498	Regorafenib	10 mg	≥98%	A multi-kinase inhibitor; inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ (IC50s = 1.5, 2.5, 4.2, 7, 13, and 22 nM, respectively); inhibits B-RAF, VEGFR3, FGFR, and Tie2 (IC50s = 28, 46, 202, and 311 nM, respectively); reduces tumor size in the MDA-MB-231 breast and 786-O renal cancer mouse xenograft models at 10 mg/kg; reduces tumor microvessel area and inhibits tumor growth in a panel of mouse xenograft models
18498	Regorafenib	25 mg	≥98%	A multi-kinase inhibitor; inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ (IC50s = 1.5, 2.5, 4.2, 7, 13, and 22 nM, respectively); inhibits B-RAF, VEGFR3, FGFR, and Tie2 (IC50s = 28, 46, 202, and 311 nM, respectively); reduces tumor size in the MDA-MB-231 breast and 786-O renal cancer mouse xenograft models at 10 mg/kg; reduces tumor microvessel area and inhibits tumor growth in a panel of mouse xenograft models
18498	Regorafenib	5 mg	≥98%	A multi-kinase inhibitor; inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ (IC50s = 1.5, 2.5, 4.2, 7, 13, and 22 nM, respectively); inhibits B-RAF, VEGFR3, FGFR, and Tie2 (IC50s = 28, 46, 202, and 311 nM, respectively); reduces tumor size in the MDA-MB-231 breast and 786-O renal cancer mouse xenograft models at 10 mg/kg; reduces tumor microvessel area and inhibits tumor growth in a panel of mouse xenograft models
18498	Regorafenib	50 mg	≥98%	A multi-kinase inhibitor; inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ (IC50s = 1.5, 2.5, 4.2, 7, 13, and 22 nM, respectively); inhibits B-RAF, VEGFR3, FGFR, and Tie2 (IC50s = 28, 46, 202, and 311 nM, respectively); reduces tumor size in the MDA-MB-231 breast and 786-O renal cancer mouse xenograft models at 10 mg/kg; reduces tumor microvessel area and inhibits tumor growth in a panel of mouse xenograft models
18499	PF-562271 (besylate)	1 mg	≥98%	An ATP-competitive, reversible inhibitor of FAK (IC50 = 1.5 nM) and PYK2 (IC50 = 14 nM); inhibits FAK phosphorylation (EC50 = 93 ng/ml) in glioblastoma-bearing mice and has been shown to regress tumors in multiple xenograft models
18499	PF-562271 (besylate)	10 mg	≥98%	An ATP-competitive, reversible inhibitor of FAK (IC50 = 1.5 nM) and PYK2 (IC50 = 14 nM); inhibits FAK phosphorylation (EC50 = 93 ng/ml) in glioblastoma-bearing mice and has been shown to regress tumors in multiple xenograft models
18499	PF-562271 (besylate)	5 mg	≥98%	An ATP-competitive, reversible inhibitor of FAK (IC50 = 1.5 nM) and PYK2 (IC50 = 14 nM); inhibits FAK phosphorylation (EC50 = 93 ng/ml) in glioblastoma-bearing mice and has been shown to regress tumors in multiple xenograft models
18499	PF-562271 (besylate)	50 mg	≥98%	An ATP-competitive, reversible inhibitor of FAK (IC50 = 1.5 nM) and PYK2 (IC50 = 14 nM); inhibits FAK phosphorylation (EC50 = 93 ng/ml) in glioblastoma-bearing mice and has been shown to regress tumors in multiple xenograft models
18501	R788 (sodium salt)	1 mg	≥95%	A prodrug of R406, an inhibitor of Syk (Ki = 30 nM); produces anti-inflammatory and immunomodulating effects by inhibiting Syk-mediated IgG Fcγ receptor signaling
18501	R788 (sodium salt)	10 mg	≥95%	A prodrug of R406, an inhibitor of Syk (Ki = 30 nM); produces anti-inflammatory and immunomodulating effects by inhibiting Syk-mediated IgG Fcγ receptor signaling
18501	R788 (sodium salt)	5 mg	≥95%	A prodrug of R406, an inhibitor of Syk (Ki = 30 nM); produces anti-inflammatory and immunomodulating effects by inhibiting Syk-mediated IgG Fcγ receptor signaling
18516	CH5424802	1 mg	≥95%	An orally available, selective inhibitor of ALK (IC50 = 1.9 nM) that also inhibits F1174L, R1275Q, and L1196M mutants of ALK (IC50s = 1.0, 3.5, and 1.6 nM, respectively); inhibits the growth of tumors in mouse xenograft models of nonsmall cell lung cancer and anaplastic large-cell lymphoma
18516	CH5424802	10 mg	≥95%	An orally available, selective inhibitor of ALK (IC50 = 1.9 nM) that also inhibits F1174L, R1275Q, and L1196M mutants of ALK (IC50s = 1.0, 3.5, and 1.6 nM, respectively); inhibits the growth of tumors in mouse xenograft models of nonsmall cell lung cancer and anaplastic large-cell lymphoma
18516	CH5424802	5 mg	≥95%	An orally available, selective inhibitor of ALK (IC50 = 1.9 nM) that also inhibits F1174L, R1275Q, and L1196M mutants of ALK (IC50s = 1.0, 3.5, and 1.6 nM, respectively); inhibits the growth of tumors in mouse xenograft models of nonsmall cell lung cancer and anaplastic large-cell lymphoma
18517	BMS-777607	1 mg	≥98%	An inhibitor of the Met kinase family (IC50s = 1.8, 3.9, 4.3, and 1.1 nM, respectively for Ron, Met, Tyro-3, and Axl); also inhibits Mer, FLT3, Aurora B, Lck, and VEGFR2 at higher concentrations (IC50s = 14, 16, 78, 120, and 180 nM, respectively); induces polyploidy with multiple sets of chromosomes, as well as suppresses metastasis in cancer cells

18517	BMS-777607	10 mg	≥98%	An inhibitor of the Met kinase family (IC50s = 1.8, 3.9, 4.3, and 1.1 nM, respectively for Ron, Met, Tyro-3, and Axl); also inhibits Mer, FLT3, Aurora B, Lck, and VEGFR2 at higher concentrations (IC50s = 14, 16, 78, 120, and 180 nM, respectively); induces polyploidy with multiple sets of chromosomes, as well as suppresses metastasis in cancer cells
18517	BMS-777607	5 mg	≥98%	An inhibitor of the Met kinase family (IC50s = 1.8, 3.9, 4.3, and 1.1 nM, respectively for Ron, Met, Tyro-3, and Axl); also inhibits Mer, FLT3, Aurora B, Lck, and VEGFR2 at higher concentrations (IC50s = 14, 16, 78, 120, and 180 nM, respectively); induces polyploidy with multiple sets of chromosomes, as well as suppresses metastasis in cancer cells
18517	BMS-777607	50 mg	≥98%	An inhibitor of the Met kinase family (IC50s = 1.8, 3.9, 4.3, and 1.1 nM, respectively for Ron, Met, Tyro-3, and Axl); also inhibits Mer, FLT3, Aurora B, Lck, and VEGFR2 at higher concentrations (IC50s = 14, 16, 78, 120, and 180 nM, respectively); induces polyploidy with multiple sets of chromosomes, as well as suppresses metastasis in cancer cells
18521	Y11	1 mg	≥95%	Inhibits FAK1 autophosphorylation by blocking phosphorylation of Y397; decreases cell viability of T47D breast cancer and C8161 melanoma cell lines at 100 µM
18521	Y11	10 mg	≥95%	Inhibits FAK1 autophosphorylation by blocking phosphorylation of Y397; decreases cell viability of T47D breast cancer and C8161 melanoma cell lines at 100 µM
18521	Y11	25 mg	≥95%	Inhibits FAK1 autophosphorylation by blocking phosphorylation of Y397; decreases cell viability of T47D breast cancer and C8161 melanoma cell lines at 100 µM
18521	Y11	5 mg	≥95%	Inhibits FAK1 autophosphorylation by blocking phosphorylation of Y397; decreases cell viability of T47D breast cancer and C8161 melanoma cell lines at 100 µM
18532	CRT5	1 mg	≥98%	A pyrazine benzamide that prevents activation of all three isoforms of PKD in endothelial cells treated with VEGF (IC50s = 1, 2, and 1.5 nM for PKD1, PKD2, and PKD3, respectively); decreases VEGF-induced endothelial migration, proliferation, and tubulogenesis
18532	CRT5	10 mg	≥98%	A pyrazine benzamide that prevents activation of all three isoforms of PKD in endothelial cells treated with VEGF (IC50s = 1, 2, and 1.5 nM for PKD1, PKD2, and PKD3, respectively); decreases VEGF-induced endothelial migration, proliferation, and tubulogenesis
18532	CRT5	25 mg	≥98%	A pyrazine benzamide that prevents activation of all three isoforms of PKD in endothelial cells treated with VEGF (IC50s = 1, 2, and 1.5 nM for PKD1, PKD2, and PKD3, respectively); decreases VEGF-induced endothelial migration, proliferation, and tubulogenesis
18532	CRT5	5 mg	≥98%	A pyrazine benzamide that prevents activation of all three isoforms of PKD in endothelial cells treated with VEGF (IC50s = 1, 2, and 1.5 nM for PKD1, PKD2, and PKD3, respectively); decreases VEGF-induced endothelial migration, proliferation, and tubulogenesis
18604	Akt Inhibitor XI	1 mg	≥95%	A cell-permeable, copper-containing 3-formylchromone derivative that inhibits Akt in an array of cancer cells (IC50s = 10-34 µM); also causes NF-κB inactivation in an orthotopic pancreatic tumor model using COLO 357 cells
18604	Akt Inhibitor XI	10 mg	≥95%	A cell-permeable, copper-containing 3-formylchromone derivative that inhibits Akt in an array of cancer cells (IC50s = 10-34 µM); also causes NF-κB inactivation in an orthotopic pancreatic tumor model using COLO 357 cells
18604	Akt Inhibitor XI	25 mg	≥95%	A cell-permeable, copper-containing 3-formylchromone derivative that inhibits Akt in an array of cancer cells (IC50s = 10-34 µM); also causes NF-κB inactivation in an orthotopic pancreatic tumor model using COLO 357 cells
18604	Akt Inhibitor XI	5 mg	≥95%	A cell-permeable, copper-containing 3-formylchromone derivative that inhibits Akt in an array of cancer cells (IC50s = 10-34 µM); also causes NF-κB inactivation in an orthotopic pancreatic tumor model using COLO 357 cells
18609	2-Aminopurine (hydrc	100 mg	≥98%	A fluorescent analog of guanosine and adenosine that is used as a site-specific probe of nucleic acid structure and dynamics, such as studies of base stacking interactions and DNA base flipping; ex/em = 320/381 nm, respectively, when adjusted to reduce interference with DNA base absorption as well as tryptophan fluorescence; inhibits PKR
18609	2-Aminopurine (hydrc	250 mg	≥98%	A fluorescent analog of guanosine and adenosine that is used as a site-specific probe of nucleic acid structure and dynamics, such as studies of base stacking interactions and DNA base flipping; ex/em = 320/381 nm, respectively, when adjusted to reduce interference with DNA base absorption as well as tryptophan fluorescence; inhibits PKR
18609	2-Aminopurine (hydrc	50 mg	≥98%	A fluorescent analog of guanosine and adenosine that is used as a site-specific probe of nucleic acid structure and dynamics, such as studies of base stacking interactions and DNA base flipping; ex/em = 320/381 nm, respectively, when adjusted to reduce interference with DNA base absorption as well as tryptophan fluorescence; inhibits PKR

18609	2-Aminopurine (hydrc	500 mg	≥98%	A fluorescent analog of guanosine and adenosine that is used as a site-specific probe of nucleic acid structure and dynamics, such as studies of base stacking interactions and DNA base flipping; ex/em = 320/381 nm, respectively, when adjusted to reduce interference with DNA base absorption as well as tryptophan fluorescence; inhibits PKR
18624	Safingol	1 mg	≥98%	A dual inhibitor of PKC and SPHK; inhibits PKC by binding at the regulatory phorbol-binding domain (IC50 = 24 μM); inhibits SPHK (Ki = ~5 μM); restores sensitivity to cisplatin in resistant AGScis5 cells and N87 gastric cancer cells from 0.2-6 μM
18624	Safingol	10 mg	≥98%	A dual inhibitor of PKC and SPHK; inhibits PKC by binding at the regulatory phorbol-binding domain (IC50 = 24 μM); inhibits SPHK (Ki = ~5 μM); restores sensitivity to cisplatin in resistant AGScis5 cells and N87 gastric cancer cells from 0.2-6 μM
18624	Safingol	25 mg	≥98%	A dual inhibitor of PKC and SPHK; inhibits PKC by binding at the regulatory phorbol-binding domain (IC50 = 24 μM); inhibits SPHK (Ki = ~5 μM); restores sensitivity to cisplatin in resistant AGScis5 cells and N87 gastric cancer cells from 0.2-6 μM
18624	Safingol	5 mg	≥98%	A dual inhibitor of PKC and SPHK; inhibits PKC by binding at the regulatory phorbol-binding domain (IC50 = 24 μM); inhibits SPHK (Ki = ~5 μM); restores sensitivity to cisplatin in resistant AGScis5 cells and N87 gastric cancer cells from 0.2-6 μM
18645	Quercetagetin	1 mg	≥98%	A flavonol that selectively inhibits Pim-1 (IC50 = 0.34 μM) compared to Pim-2, PKA, RSK2, and JNK (IC50s = 3.45, 21.2, 2.82, and 4.6 μM, respectively); inhibits Pim-1 activity in intact RWPE2 prostate cancer cells (ED50 = 5.5 μM) significantly inhibiting their growth
18645	Quercetagetin	5 mg	≥98%	A flavonol that selectively inhibits Pim-1 (IC50 = 0.34 μM) compared to Pim-2, PKA, RSK2, and JNK (IC50s = 3.45, 21.2, 2.82, and 4.6 μM, respectively); inhibits Pim-1 activity in intact RWPE2 prostate cancer cells (ED50 = 5.5 μM) significantly inhibiting their growth
18645	Quercetagetin	500 µg	≥98%	A flavonol that selectively inhibits Pim-1 (IC50 = 0.34 μM) compared to Pim-2, PKA, RSK2, and JNK (IC50s = 3.45, 21.2, 2.82, and 4.6 μM, respectively); inhibits Pim-1 activity in intact RWPE2 prostate cancer cells (ED50 = 5.5 μM) significantly inhibiting their growth
18715	A-674563	1 mg	≥95%	An orally available, reversible inhibitor of Akt (Ki = 11 nM for Akt1); also inhibits PKA and Cdk2 with IC50 values of 16 and 46 nM, respectively; reduces phosphorylation of Akt downstream targets in cells and slows proliferation of tumor cells both in vitro and in vivo
18715	A-674563	10 mg	≥95%	An orally available, reversible inhibitor of Akt (Ki = 11 nM for Akt1); also inhibits PKA and Cdk2 with IC50 values of 16 and 46 nM, respectively; reduces phosphorylation of Akt downstream targets in cells and slows proliferation of tumor cells both in vitro and in vivo
18715	A-674563	5 mg	≥95%	An orally available, reversible inhibitor of Akt (Ki = 11 nM for Akt1); also inhibits PKA and Cdk2 with IC50 values of 16 and 46 nM, respectively; reduces phosphorylation of Akt downstream targets in cells and slows proliferation of tumor cells both in vitro and in vivo
18715	A-674563	500 µg	≥95%	An orally available, reversible inhibitor of Akt (Ki = 11 nM for Akt1); also inhibits PKA and Cdk2 with IC50 values of 16 and 46 nM, respectively; reduces phosphorylation of Akt downstream targets in cells and slows proliferation of tumor cells both in vitro and in vivo
18718	RWJ 67657	1 mg	≥95%	An orally active, selective inhibitor of p38α and p38β (IC50s = 1 and 11 μM, respectively, in vitro); blocks the release of TNF-α and IL-1β from peripheral blood mononuclear cells stimulated with LPS (IC50s = 3 and 11 nM, respectively) and inhibits TNF-α production in LPS-treated mice and rats
18718	RWJ 67657	10 mg	≥95%	An orally active, selective inhibitor of p38α and p38β (IC50s = 1 and 11 μM, respectively, in vitro); blocks the release of TNF-α and IL-1β from peripheral blood mononuclear cells stimulated with LPS (IC50s = 3 and 11 nM, respectively) and inhibits TNF-α production in LPS-treated mice and rats
18718	RWJ 67657	5 mg	≥95%	An orally active, selective inhibitor of p38α and p38β (IC50s = 1 and 11 μM, respectively, in vitro); blocks the release of TNF-α and IL-1β from peripheral blood mononuclear cells stimulated with LPS (IC50s = 3 and 11 nM, respectively) and inhibits TNF-α production in LPS-treated mice and rats
18718	RWJ 67657	50 mg	≥95%	An orally active, selective inhibitor of p38α and p38β (IC50s = 1 and 11 μM, respectively, in vitro); blocks the release of TNF-α and IL-1β from peripheral blood mononuclear cells stimulated with LPS (IC50s = 3 and 11 nM, respectively) and inhibits TNF-α production in LPS-treated mice and rats
18722	Oclacitinib	1 mg	≥98%	A JAK family kinase inhibitor (IC50s = 10, 18, 99, and 84 nM for JAK1, JAK2, JAK3, and TYK2, respectively); selective for JAK kinases over a panel of 38 additional kinases at 1 μM; inhibits LPS-induced increases in IL-12 and TNF-α levels in murine BMDCs in a concentration-dependent manner; topical administration reduces scratching behavior and ear edema, as well as decreases levels of IL-1β, IL-4, and IL-6 in ear skin, in a mouse model of TDI-induced allergic dermatitis at 0.1, 0.25, and 0.5%

18722	Oclacitinib	10 mg	≥98%	A JAK family kinase inhibitor (IC50s = 10, 18, 99, and 84 nM for JAK1, JAK2, JAK3, and TYK2, respectively); selective for JAK kinases over a panel of 38 additional kinases at 1 μM; inhibits LPS-induced increases in IL-12 and TNF-α levels in murine BMDCs in a concentration-dependent manner; topical administration reduces scratching behavior and ear edema, as well as decreases levels of IL-1β, IL-4, and IL-6 in ear skin, in a mouse model of TDI-induced allergic dermatitis at 0.1, 0.25, and 0.5%
18722	Oclacitinib	5 mg	≥98%	A JAK family kinase inhibitor (IC50s = 10, 18, 99, and 84 nM for JAK1, JAK2, JAK3, and TYK2, respectively); selective for JAK kinases over a panel of 38 additional kinases at 1 μM; inhibits LPS-induced increases in IL-12 and TNF-α levels in murine BMDCs in a concentration-dependent manner; topical administration reduces scratching behavior and ear edema, as well as decreases levels of IL-1β, IL-4, and IL-6 in ear skin, in a mouse model of TDI-induced allergic dermatitis at 0.1, 0.25, and 0.5%
18722	Oclacitinib	50 mg	≥98%	A JAK family kinase inhibitor (IC50s = 10, 18, 99, and 84 nM for JAK1, JAK2, JAK3, and TYK2, respectively); selective for JAK kinases over a panel of 38 additional kinases at 1 μM; inhibits LPS-induced increases in IL-12 and TNF-α levels in murine BMDCs in a concentration-dependent manner; topical administration reduces scratching behavior and ear edema, as well as decreases levels of IL-1β, IL-4, and IL-6 in ear skin, in a mouse model of TDI-induced allergic dermatitis at 0.1, 0.25, and 0.5%
18740	Cdk1/5 Inhibitor	1 mg	≥95%	Inhibitor of Cdk1/cyclin B and Cdk/p25 (IC50s = 600 and 400 nM, respectively)
18740	Cdk1/5 Inhibitor	10 mg	≥95%	Inhibitor of Cdk1/cyclin B and Cdk/p25 (IC50s = 600 and 400 nM, respectively)
18740	Cdk1/5 Inhibitor	5 mg	≥95%	Inhibitor of Cdk1/cyclin B and Cdk/p25 (IC50s = 600 and 400 nM, respectively)
18749	SB 202474	1 mg	≥97%	A structural analog of SB 202190 and SB 203580 that is used as a negative control in studies of p38 inhibition
18761	CCT251545	1 mg	≥95%	An orally bioavailable inhibitor of Wnt signaling (IC50 = 5 nM); a potent and selective inhibitor of Cdk8 and Cdk19 that alters Wnt pathway-regulated gene expression
18761	CCT251545	10 mg	≥95%	An orally bioavailable inhibitor of Wnt signaling (IC50 = 5 nM); a potent and selective inhibitor of Cdk8 and Cdk19 that alters Wnt pathway-regulated gene expression
18761	CCT251545	5 mg	≥95%	An orally bioavailable inhibitor of Wnt signaling (IC50 = 5 nM); a potent and selective inhibitor of Cdk8 and Cdk19 that alters Wnt pathway-regulated gene expression
18774	LY2409881	1 mg	≥98%	A selective inhibitor of IKK2 (IC50 = 30 nM); suppresses constitutively activated NF-κB and induces apoptosis in lymphoma cells both in vitro and in preclinical mouse models of B and T cell lymphoma
18774	LY2409881	10 mg	≥98%	A selective inhibitor of IKK2 (IC50 = 30 nM); suppresses constitutively activated NF-κB and induces apoptosis in lymphoma cells both in vitro and in preclinical mouse models of B and T cell lymphoma
18774	LY2409881	25 mg	≥98%	A selective inhibitor of IKK2 (IC50 = 30 nM); suppresses constitutively activated NF-κB and induces apoptosis in lymphoma cells both in vitro and in preclinical mouse models of B and T cell lymphoma
18774	LY2409881	5 mg	≥98%	A selective inhibitor of IKK2 (IC50 = 30 nM); suppresses constitutively activated NF-κB and induces apoptosis in lymphoma cells both in vitro and in preclinical mouse models of B and T cell lymphoma
18775	ALK-IN-1	1 mg	≥98%	A potent inhibitor of ALK (IC50 = 0.07 nM) that is less effective at IGF-1R and InsR (IC50s = 3.2 and 100 nM, respectively); drives cell death in (ALK+) Karpas-299 lymphoma cells with an IC50 value of 41.5 nM, while killing (ALK-) U937 cells with an IC50 value of 1,718 nM
18775	ALK-IN-1	10 mg	≥98%	A potent inhibitor of ALK (IC50 = 0.07 nM) that is less effective at IGF-1R and InsR (IC50s = 3.2 and 100 nM, respectively); drives cell death in (ALK+) Karpas-299 lymphoma cells with an IC50 value of 41.5 nM, while killing (ALK-) U937 cells with an IC50 value of 1,718 nM
18775	ALK-IN-1	5 mg	≥98%	A potent inhibitor of ALK (IC50 = 0.07 nM) that is less effective at IGF-1R and InsR (IC50s = 3.2 and 100 nM, respectively); drives cell death in (ALK+) Karpas-299 lymphoma cells with an IC50 value of 41.5 nM, while killing (ALK-) U937 cells with an IC50 value of 1,718 nM
18775	ALK-IN-1	50 mg	≥98%	A potent inhibitor of ALK (IC50 = 0.07 nM) that is less effective at IGF-1R and InsR (IC50s = 3.2 and 100 nM, respectively); drives cell death in (ALK+) Karpas-299 lymphoma cells with an IC50 value of 41.5 nM, while killing (ALK-) U937 cells with an IC50 value of 1,718 nM
18776	CEP-32496	1 mg	≥95%	A potent inhibitor of B-RafV600E (Kd = 14 nM in an in vitro binding assay); blocks B-RafV600E–dependent phosphorylation of MEK in human melanoma A375 and colorectal cancer COLO 205 cells (IC50s = 78 and 60 nM, respectively); displays good oral bioavailability
18776	CEP-32496	10 mg	≥95%	A potent inhibitor of B-RafV600E (Kd = 14 nM in an in vitro binding assay); blocks B-RafV600E–dependent phosphorylation of MEK in human melanoma A375 and colorectal cancer COLO 205 cells (IC50s = 78 and 60 nM, respectively); displays good oral bioavailability

18776	CEP-32496	5 mg	≥95%	A potent inhibitor of B-RafV600E (Kd = 14 nM in an in vitro binding assay); blocks B-RafV600E–dependent phosphorylation of MEK in human melanoma A375 and colorectal cancer COLO 205 cells (IC50s = 78 and 60 nM, respectively); displays good oral bioavailability
18776	CEP-32496	500 µg	≥95%	A potent inhibitor of B-RafV600E (Kd = 14 nM in an in vitro binding assay); blocks B-RafV600E–dependent phosphorylation of MEK in human melanoma A375 and colorectal cancer COLO 205 cells (IC50s = 78 and 60 nM, respectively); displays good oral bioavailability
18777	Altiratinib	1 mg	≥98%	A multiple kinase inhibitor, blocking Met, Tie2, VEGF2, TrkA, TrkB, and TrkC with IC50 values of 2.7, 8.0, 9.2, 0.85, 4.6, and 0.83 nM, respectively; orally bioavailable and penetrates the blood brain barrier, suppressing the growth of subcutaneous and intracerebroventricular xenograft tumors in mice
18777	Altiratinib	10 mg	≥98%	A multiple kinase inhibitor, blocking Met, Tie2, VEGF2, TrkA, TrkB, and TrkC with IC50 values of 2.7, 8.0, 9.2, 0.85, 4.6, and 0.83 nM, respectively; orally bioavailable and penetrates the blood brain barrier, suppressing the growth of subcutaneous and intracerebroventricular xenograft tumors in mice
18777	Altiratinib	25 mg	≥98%	A multiple kinase inhibitor, blocking Met, Tie2, VEGF2, TrkA, TrkB, and TrkC with IC50 values of 2.7, 8.0, 9.2, 0.85, 4.6, and 0.83 nM, respectively; orally bioavailable and penetrates the blood brain barrier, suppressing the growth of subcutaneous and intracerebroventricular xenograft tumors in mice
18777	Altiratinib	5 mg	≥98%	A multiple kinase inhibitor, blocking Met, Tie2, VEGF2, TrkA, TrkB, and TrkC with IC50 values of 2.7, 8.0, 9.2, 0.85, 4.6, and 0.83 nM, respectively; orally bioavailable and penetrates the blood brain barrier, suppressing the growth of subcutaneous and intracerebroventricular xenograft tumors in mice
18805	Syk Inhibitor II (hydro	1 mg	≥98%	A cell-permeable, selective, and reversible inhibitor of Syk (IC50 = 41 nM); prevents FcεRI-mediated 5-HT release in RBL-2H3 cells in vitro (IC50 = 460 nM) and inhibits passive cutaneous anaphylaxis reactions in mice (ID50 = 13.2 mg/kg, s.c.)
18805	Syk Inhibitor II (hydro	5 mg	≥98%	A cell-permeable, selective, and reversible inhibitor of Syk (IC50 = 41 nM); prevents FcεRI-mediated 5-HT release in RBL-2H3 cells in vitro (IC50 = 460 nM) and inhibits passive cutaneous anaphylaxis reactions in mice (ID50 = 13.2 mg/kg, s.c.)
18805	Syk Inhibitor II (hydro	500 µg	≥98%	A cell-permeable, selective, and reversible inhibitor of Syk (IC50 = 41 nM); prevents FcεRI-mediated 5-HT release in RBL-2H3 cells in vitro (IC50 = 460 nM) and inhibits passive cutaneous anaphylaxis reactions in mice (ID50 = 13.2 mg/kg, s.c.)
18823	Rp-8-bromo-PET-Cycli	1 mg	≥99%	A cell permeable, competitive, and reversible inhibitor of cGKs that blocks activation of cGKI and cGKII by cGMP (Kis = 35 and 30 nM); less potently inhibits PKA (Ki = 11 µM) and cGMP-induced activation of cyclic nucleotide-gated channels (IC50 = 25 µM); resistant to hydrolysis by PDE11
18823	Rp-8-bromo-PET-Cycli	5 mg	≥99%	A cell permeable, competitive, and reversible inhibitor of cGKs that blocks activation of cGKI and cGKII by cGMP (Kis = 35 and 30 nM); less potently inhibits PKA (Ki = 11 µM) and cGMP-induced activation of cyclic nucleotide-gated channels (IC50 = 25 µM); resistant to hydrolysis by PDE11
18858	SP 600125, negative c	1 mg	≥97%	A methylated analog of SP 600125 that has much lower affinity for JNK isoforms (IC50s = 18 and 24 µM for JNK2 and JNK3, respectively)
18859	Cdk1/2 Inhibitor III	1 mg	≥95%	A cell-permeable inhibitor of Cdk1/cyclin B and Cdk2/cyclin A (IC50s = 0.6 and 0.5 nM, respectively); blocks the growth of several cancer cell lines (IC50 values range from 20 to 92 nM)
18859	Cdk1/2 Inhibitor III	10 mg	≥95%	A cell-permeable inhibitor of Cdk1/cyclin B and Cdk2/cyclin A (IC50s = 0.6 and 0.5 nM, respectively); blocks the growth of several cancer cell lines (IC50 values range from 20 to 92 nM)
18859	Cdk1/2 Inhibitor III	5 mg	≥95%	A cell-permeable inhibitor of Cdk1/cyclin B and Cdk2/cyclin A (IC50s = 0.6 and 0.5 nM, respectively); blocks the growth of several cancer cell lines (IC50 values range from 20 to 92 nM)
18867	CC-401	1 mg	≥98%	A potent, selective inhibitor of all three JNK isoforms (Ki values range from 25 to 50 nM); bioavailable when delivered by gavage, blocking JNK signaling and renal fibrosis in a rat obstructed kidney model; decreases hepatic necrosis and apoptosis after orthotopic liver transplantation in rats
18867	CC-401	10 mg	≥98%	A potent, selective inhibitor of all three JNK isoforms (Ki values range from 25 to 50 nM); bioavailable when delivered by gavage, blocking JNK signaling and renal fibrosis in a rat obstructed kidney model; decreases hepatic necrosis and apoptosis after orthotopic liver transplantation in rats
18867	CC-401	5 mg	≥98%	A potent, selective inhibitor of all three JNK isoforms (Ki values range from 25 to 50 nM); bioavailable when delivered by gavage, blocking JNK signaling and renal fibrosis in a rat obstructed kidney model; decreases hepatic necrosis and apoptosis after orthotopic liver transplantation in rats
18873	Crenolanib	1 mg	≥95%	An orally bioavailable, selective inhibitor of PDGFRα, PDGFRβ, and FLT3 (IC50s = 11, 3.2, and 4 nM, respectively); also inhibits mutant forms of these kinases, including the D842V-containing form of PDGFR and D835Y and internal tandem duplication mutations of FLT3, at nanomolar concentrations

18873	Crenolanib	10 mg	≥95%	An orally bioavailable, selective inhibitor of PDGFRα, PDGFRβ, and FLT3 (IC50s = 11, 3.2, and 4 nM, respectively); also inhibits mutant forms of these kinases, including the D842V-containing form of PDGFR and D835Y and internal tandem duplication mutations of FLT3, at nanomolar concentrations
18873	Crenolanib	5 mg	≥95%	An orally bioavailable, selective inhibitor of PDGFRα, PDGFRβ, and FLT3 (IC50s = 11, 3.2, and 4 nM, respectively); also inhibits mutant forms of these kinases, including the D842V-containing form of PDGFR and D835Y and internal tandem duplication mutations of FLT3, at nanomolar concentrations
18873	Crenolanib	50 mg	≥95%	An orally bioavailable, selective inhibitor of PDGFRα, PDGFRβ, and FLT3 (IC50s = 11, 3.2, and 4 nM, respectively); also inhibits mutant forms of these kinases, including the D842V-containing form of PDGFR and D835Y and internal tandem duplication mutations of FLT3, at nanomolar concentrations
18886	4,5,6,7-Tetrabromobe	25 mg	≥98%	A selective, ATP-competitive inhibitor of CK2 with Ki values ranging from 0.5-1 μM
18886	4,5,6,7-Tetrabromobe	250 mg	≥98%	A selective, ATP-competitive inhibitor of CK2 with Ki values ranging from 0.5-1 μM
18910	BAW 2881	1 mg	≥98%	A VEGFR inhibitor (IC50s = 0.82, 0.037, and 0.42 μM for hVEGFR1, 2, and 3, respectively); also inhibits Tie2 and RET with IC50 values of 0.65 and 0.41, respectively; reduces inflammation in a mouse model of psoriasis and in pig models of contact hypersensitivity and UV-B-induced erythema
18910	BAW 2881	10 mg	≥98%	A VEGFR inhibitor (IC50s = 0.82, 0.037, and 0.42 μM for hVEGFR1, 2, and 3, respectively); also inhibits Tie2 and RET with IC50 values of 0.65 and 0.41, respectively; reduces inflammation in a mouse model of psoriasis and in pig models of contact hypersensitivity and UV-B-induced erythema
18910	BAW 2881	25 mg	≥98%	A VEGFR inhibitor (IC50s = 0.82, 0.037, and 0.42 μM for hVEGFR1, 2, and 3, respectively); also inhibits Tie2 and RET with IC50 values of 0.65 and 0.41, respectively; reduces inflammation in a mouse model of psoriasis and in pig models of contact hypersensitivity and UV-B-induced erythema
18910	BAW 2881	5 mg	≥98%	A VEGFR inhibitor (IC50s = 0.82, 0.037, and 0.42 μM for hVEGFR1, 2, and 3, respectively); also inhibits Tie2 and RET with IC50 values of 0.65 and 0.41, respectively; reduces inflammation in a mouse model of psoriasis and in pig models of contact hypersensitivity and UV-B-induced erythema
19077	GSK3β Inhibitor II	10 mg	≥95%	A potent inhibitor of GSK3β (IC50 = 390 nM) that does not inhibit GSK-3α
19077	GSK3β Inhibitor II	5 mg	≥95%	A potent inhibitor of GSK3β (IC50 = 390 nM) that does not inhibit GSK-3α
19081	CL 387,785	1 mg	≥95%	A potent, irreversible inhibitor of EGFR kinase activity (IC50 = 370 pM); halts cell cycling in cells that overexpress EGFR or c-ErbB2 (IC50s = 31-125 nM); profoundly blocks the growth of EGFR-overexpressing tumors in nude mice when given orally at 80 mg/kg/day for 10 days
19081	CL 387,785	10 mg	≥95%	A potent, irreversible inhibitor of EGFR kinase activity (IC50 = 370 pM); halts cell cycling in cells that overexpress EGFR or c-ErbB2 (IC50s = 31-125 nM); profoundly blocks the growth of EGFR-overexpressing tumors in nude mice when given orally at 80 mg/kg/day for 10 days
19081	CL 387,785	5 mg	≥95%	A potent, irreversible inhibitor of EGFR kinase activity (IC50 = 370 pM); halts cell cycling in cells that overexpress EGFR or c-ErbB2 (IC50s = 31-125 nM); profoundly blocks the growth of EGFR-overexpressing tumors in nude mice when given orally at 80 mg/kg/day for 10 days
19089	LDN-192960 (hydroch	10 mg	≥98%	An inhibitor of haspin and DYRK2 (IC50s = 10 and 48 nM, respectively); selective for haspin and DYRK2 over TRKB, CLK1, DYRK1A, DYRK3, ROS, HIPK1, HIPK2, PIM-1, and PIM-2 kinases (IC50s = 720-91,000 nM)
19089	LDN-192960 (hydroch	25 mg	≥98%	An inhibitor of haspin and DYRK2 (IC50s = 10 and 48 nM, respectively); selective for haspin and DYRK2 over TRKB, CLK1, DYRK1A, DYRK3, ROS, HIPK1, HIPK2, PIM-1, and PIM-2 kinases (IC50s = 720-91,000 nM)
19089	LDN-192960 (hydroch	5 mg	≥98%	An inhibitor of haspin and DYRK2 (IC50s = 10 and 48 nM, respectively); selective for haspin and DYRK2 over TRKB, CLK1, DYRK1A, DYRK3, ROS, HIPK1, HIPK2, PIM-1, and PIM-2 kinases (IC50s = 720-91,000 nM)
19089	LDN-192960 (hydroch	50 mg	≥98%	An inhibitor of haspin and DYRK2 (IC50s = 10 and 48 nM, respectively); selective for haspin and DYRK2 over TRKB, CLK1, DYRK1A, DYRK3, ROS, HIPK1, HIPK2, PIM-1, and PIM-2 kinases (IC50s = 720-91,000 nM)
19091	HTH-01-015	1 mg	≥95%	A selective inhibitor of NUAK1 (IC50 = 100 nM); partially inhibits the phosphorylation of the NUAK1 substrate MYPT1 at Ser445; inhibits proliferation and migration of mouse embryonic fibroblasts and U2OS cells at 10 μM in cell-based assays
19091	HTH-01-015	10 mg	≥95%	A selective inhibitor of NUAK1 (IC50 = 100 nM); partially inhibits the phosphorylation of the NUAK1 substrate MYPT1 at Ser445; inhibits proliferation and migration of mouse embryonic fibroblasts and U2OS cells at 10 μM in cell-based assays
19091	HTH-01-015	5 mg	≥95%	A selective inhibitor of NUAK1 (IC50 = 100 nM); partially inhibits the phosphorylation of the NUAK1 substrate MYPT1 at Ser445; inhibits proliferation and migration of mouse embryonic fibroblasts and U2OS cells at 10 μM in cell-based assays
19115	Purvalanol B	1 mg	≥95%	A CDK inhibitor that most potently inhibits Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p35, and Cdc2/cyclin B (IC50s = 6, 9, 6, and 6 nM, respectively); inhibits the growth of parasites, including Plasmodium, at micromolar doses

19115	Purvalanol B	10 mg	≥95%	A CDK inhibitor that most potently inhibits Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p35, and Cdc2/cyclin B (IC50s = 6, 9, 6, and 6 nM, respectively); inhibits the growth of parasites, including Plasmodium, at micromolar doses
19115	Purvalanol B	25 mg	≥95%	A CDK inhibitor that most potently inhibits Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p35, and Cdc2/cyclin B (IC50s = 6, 9, 6, and 6 nM, respectively); inhibits the growth of parasites, including Plasmodium, at micromolar doses
19115	Purvalanol B	5 mg	≥95%	A CDK inhibitor that most potently inhibits Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p35, and Cdc2/cyclin B (IC50s = 6, 9, 6, and 6 nM, respectively); inhibits the growth of parasites, including Plasmodium, at micromolar doses
19129	TC-S 7001	1 mg	≥95%	A ROCK inhibitor (IC50s = 0.6 and 1.1 nM, respectively, for human ROCK1 and ROCK2); selective for ROCK over MLCK and ZIP-kinase (IC50s = 7,400 and 4,100 nM, respectively), as well as 110 kinases in a panel at 1-10 µM, but does inhibit TRK and FLT3 (IC50s = 252 and 303 nM, respectively); reduces ROCK2-induced MBS phosphorylation at 3 nM; inhibits phenylephrine-induced contraction of isolated rabbit saphenous artery (IC50 = 65 nM); decreases blood pressure in normotensive and hypertensive rats at 3 and 10 mg/kg; decreases right ventricular systolic pressure and total pulmonary resistance in a rat model of monocrotaline-induced pulmonary hypertension at 10 mg/kg per day
19129	TC-S 7001	5 mg	≥95%	A ROCK inhibitor (IC50s = 0.6 and 1.1 nM, respectively, for human ROCK1 and ROCK2); selective for ROCK over MLCK and ZIP-kinase (IC50s = 7,400 and 4,100 nM, respectively), as well as 110 kinases in a panel at 1-10 µM, but does inhibit TRK and FLT3 (IC50s = 252 and 303 nM, respectively); reduces ROCK2-induced MBS phosphorylation at 3 nM; inhibits phenylephrine-induced contraction of isolated rabbit saphenous artery (IC50 = 65 nM); decreases blood pressure in normotensive and hypertensive rats at 3 and 10 mg/kg; decreases right ventricular systolic pressure and total pulmonary resistance in a rat model of monocrotaline-induced pulmonary hypertension at 10 mg/kg per day
19129	TC-S 7001	500 µg	≥95%	A ROCK inhibitor (IC50s = 0.6 and 1.1 nM, respectively, for human ROCK1 and ROCK2); selective for ROCK over MLCK and ZIP-kinase (IC50s = 7,400 and 4,100 nM, respectively), as well as 110 kinases in a panel at 1-10 µM, but does inhibit TRK and FLT3 (IC50s = 252 and 303 nM, respectively); reduces ROCK2-induced MBS phosphorylation at 3 nM; inhibits phenylephrine-induced contraction of isolated rabbit saphenous artery (IC50 = 65 nM); decreases blood pressure in normotensive and hypertensive rats at 3 and 10 mg/kg; decreases right ventricular systolic pressure and total pulmonary resistance in a rat model of monocrotaline-induced pulmonary hypertension at 10 mg/kg per day
19142	SB 239063	1 mg	≥98%	A selective p38 MAP kinase inhibitor (IC50 = 44 nM for p38α) that has been shown to reduce inflammatory cytokine production and is neuroprotective following oral administration in vivo
19142	SB 239063	5 mg	≥98%	A selective p38 MAP kinase inhibitor (IC50 = 44 nM for p38α) that has been shown to reduce inflammatory cytokine production and is neuroprotective following oral administration in vivo
19142	SB 239063	500 µg	≥98%	A selective p38 MAP kinase inhibitor (IC50 = 44 nM for p38α) that has been shown to reduce inflammatory cytokine production and is neuroprotective following oral administration in vivo
19147	URMC-099	1 mg	≥95%	An orally bioavailable, brain-penetrant inhibitor of MLKs (IC50s = 19, 42, 14, and 150 nM for MLK1, MLK2, MLK3, and the related MLK family member DLK, respectively); also inhibits LRRK2 activity (IC50 = 11 nM); demonstrates anti-inflammatory and neuroprotective effects both in vitro and in vivo
19147	URMC-099	10 mg	≥95%	An orally bioavailable, brain-penetrant inhibitor of MLKs (IC50s = 19, 42, 14, and 150 nM for MLK1, MLK2, MLK3, and the related MLK family member DLK, respectively); also inhibits LRRK2 activity (IC50 = 11 nM); demonstrates anti-inflammatory and neuroprotective effects both in vitro and in vivo
19147	URMC-099	25 mg	≥95%	An orally bioavailable, brain-penetrant inhibitor of MLKs (IC50s = 19, 42, 14, and 150 nM for MLK1, MLK2, MLK3, and the related MLK family member DLK, respectively); also inhibits LRRK2 activity (IC50 = 11 nM); demonstrates anti-inflammatory and neuroprotective effects both in vitro and in vivo
19147	URMC-099	5 mg	≥95%	An orally bioavailable, brain-penetrant inhibitor of MLKs (IC50s = 19, 42, 14, and 150 nM for MLK1, MLK2, MLK3, and the related MLK family member DLK, respectively); also inhibits LRRK2 activity (IC50 = 11 nM); demonstrates anti-inflammatory and neuroprotective effects both in vitro and in vivo
19151	KIRA6	1 mg	≥98%	An ATP-competitive, allosteric inhibitor of IRE1α RNase kinase activity (IC50 = 0.6 µM); prevents IRE1α oligomerization and promotes cell survival under ER stress in rat models of retinal degeneration and diabetes
19151	KIRA6	10 mg	≥98%	An ATP-competitive, allosteric inhibitor of IRE1α RNase kinase activity (IC50 = 0.6 µM); prevents IRE1α oligomerization and promotes cell survival under ER stress in rat models of retinal degeneration and diabetes

19151	KIRA6	5 mg	≥98%	An ATP-competitive, allosteric inhibitor of IRE1α RNase kinase activity (IC50 = 0.6 µM); prevents IRE1α oligomerization and promotes cell survival under ER stress in rat models of retinal degeneration and diabetes
19152	MKC-3946	1 mg	≥98%	An inhibitor of IRE1α; inhibits ER stress induced XBP1 splicing and reduces expression of the XBP1 target genes SEC61A1, p58IPK, and ERdj4 in RPMI 8226 cells; cytotoxic to multiple myeloma cell lines but has no effect on normal mononuclear cells; reduces tumor growth and XBP1 splicing in an RPMI 8226 mouse xenograft model (100 mg/kg)
19152	MKC-3946	10 mg	≥98%	An inhibitor of IRE1α; inhibits ER stress induced XBP1 splicing and reduces expression of the XBP1 target genes SEC61A1, p58IPK, and ERdj4 in RPMI 8226 cells; cytotoxic to multiple myeloma cell lines but has no effect on normal mononuclear cells; reduces tumor growth and XBP1 splicing in an RPMI 8226 mouse xenograft model (100 mg/kg)
19152	MKC-3946	25 mg	≥98%	An inhibitor of IRE1α; inhibits ER stress induced XBP1 splicing and reduces expression of the XBP1 target genes SEC61A1, p58IPK, and ERdj4 in RPMI 8226 cells; cytotoxic to multiple myeloma cell lines but has no effect on normal mononuclear cells; reduces tumor growth and XBP1 splicing in an RPMI 8226 mouse xenograft model (100 mg/kg)
19152	MKC-3946	5 mg	≥98%	An inhibitor of IRE1α; inhibits ER stress induced XBP1 splicing and reduces expression of the XBP1 target genes SEC61A1, p58IPK, and ERdj4 in RPMI 8226 cells; cytotoxic to multiple myeloma cell lines but has no effect on normal mononuclear cells; reduces tumor growth and XBP1 splicing in an RPMI 8226 mouse xenograft model (100 mg/kg)
19156	HS-173	1 mg	≥98%	A PI3Kα inhibitor (IC50 = 0.8 nM) that demonstrates antiproliferative activity in T47D, SK-BR-3, and MCF-7 cells with IC50 values of 0.6, 1.5, and 7.8 µM, respectively; induces apoptosis and blocks angiogenesis both in vitro and in vivo
19156	HS-173	10 mg	≥98%	A PI3Kα inhibitor (IC50 = 0.8 nM) that demonstrates antiproliferative activity in T47D, SK-BR-3, and MCF-7 cells with IC50 values of 0.6, 1.5, and 7.8 µM, respectively; induces apoptosis and blocks angiogenesis both in vitro and in vivo
19156	HS-173	25 mg	≥98%	A PI3Kα inhibitor (IC50 = 0.8 nM) that demonstrates antiproliferative activity in T47D, SK-BR-3, and MCF-7 cells with IC50 values of 0.6, 1.5, and 7.8 µM, respectively; induces apoptosis and blocks angiogenesis both in vitro and in vivo
19156	HS-173	5 mg	≥98%	A PI3Kα inhibitor (IC50 = 0.8 nM) that demonstrates antiproliferative activity in T47D, SK-BR-3, and MCF-7 cells with IC50 values of 0.6, 1.5, and 7.8 µM, respectively; induces apoptosis and blocks angiogenesis both in vitro and in vivo
19157	BGJ398	1 mg	≥98%	A pan FGFR inhibitor (IC50s = 0.9, 1.4, and 1 nM for FGFR1, FGFR2, and FGFR3, respectively); suppresses proliferation of cancer cells with wild-type FGFR3 overexpression and in an RT112 bladder cancer xenograft mouse model overexpressing wild-type FGFR3
19157	BGJ398	10 mg	≥98%	A pan FGFR inhibitor (IC50s = 0.9, 1.4, and 1 nM for FGFR1, FGFR2, and FGFR3, respectively); suppresses proliferation of cancer cells with wild-type FGFR3 overexpression and in an RT112 bladder cancer xenograft mouse model overexpressing wild-type FGFR3
19157	BGJ398	25 mg	≥98%	A pan FGFR inhibitor (IC50s = 0.9, 1.4, and 1 nM for FGFR1, FGFR2, and FGFR3, respectively); suppresses proliferation of cancer cells with wild-type FGFR3 overexpression and in an RT112 bladder cancer xenograft mouse model overexpressing wild-type FGFR3
19157	BGJ398	5 mg	≥98%	A pan FGFR inhibitor (IC50s = 0.9, 1.4, and 1 nM for FGFR1, FGFR2, and FGFR3, respectively); suppresses proliferation of cancer cells with wild-type FGFR3 overexpression and in an RT112 bladder cancer xenograft mouse model overexpressing wild-type FGFR3
19159	LL-Z 1640-4	1 mg	≥99%	A resorcylic acid lactone with antiviral and antiprotozoan activity; used as negative control for MAP3K inhibitor (5Z)-7-oxo zeaenol (Item No. 17459)
19159	LL-Z 1640-4	5 mg	≥99%	A resorcylic acid lactone with antiviral and antiprotozoan activity; used as negative control for MAP3K inhibitor (5Z)-7-oxo zeaenol (Item No. 17459)
19164	TX1-85-1	1 mg	≥98%	An inhibitor of ErbB3 (IC50 = 23 nM); binds to ErbB2, Lyn, and several other Src family kinases at 2 µM; inhibits phosphorylation of Akt and ERK1/2 in ErbB3-dependent HCC2935 and OVCAR-8 cells at 5 and 2 µM, respectively; does not inhibit proliferation of ErbB3-dependent PC9 GR4, HCC827 GR8, or OVCAR-8 cells (EC50s = ≥10 µM)
19164	TX1-85-1	10 mg	≥98%	An inhibitor of ErbB3 (IC50 = 23 nM); binds to ErbB2, Lyn, and several other Src family kinases at 2 µM; inhibits phosphorylation of Akt and ERK1/2 in ErbB3-dependent HCC2935 and OVCAR-8 cells at 5 and 2 µM, respectively; does not inhibit proliferation of ErbB3-dependent PC9 GR4, HCC827 GR8, or OVCAR-8 cells (EC50s = ≥10 µM)
19164	TX1-85-1	5 mg	≥98%	An inhibitor of ErbB3 (IC50 = 23 nM); binds to ErbB2, Lyn, and several other Src family kinases at 2 µM; inhibits phosphorylation of Akt and ERK1/2 in ErbB3-dependent HCC2935 and OVCAR-8 cells at 5 and 2 µM, respectively; does not inhibit proliferation of ErbB3-dependent PC9 GR4, HCC827 GR8, or OVCAR-8 cells (EC50s = ≥10 µM)

19165	BMX-IN-1	1 mg	≥95%	An irreversible inhibitor of BMX (IC50 = 8 nM) and BTK (IC50 = 10.4 nM); inhibits the proliferation of Tel-BMX-transformed Ba/F3 prostate cancer cells (GI50 = 25 nM), as well as RV-1, DU-145, PC-3, and VCAP prostate cancer cell lines (GI50s = 2.54, 4.38, 5.37, and 2.46 µM, respectively)
19165	BMX-IN-1	5 mg	≥95%	An irreversible inhibitor of BMX (IC50 = 8 nM) and BTK (IC50 = 10.4 nM); inhibits the proliferation of Tel-BMX-transformed Ba/F3 prostate cancer cells (GI50 = 25 nM), as well as RV-1, DU-145, PC-3, and VCAP prostate cancer cell lines (GI50s = 2.54, 4.38, 5.37, and 2.46 µM, respectively)
19165	BMX-IN-1	500 µg	≥95%	An irreversible inhibitor of BMX (IC50 = 8 nM) and BTK (IC50 = 10.4 nM); inhibits the proliferation of Tel-BMX-transformed Ba/F3 prostate cancer cells (GI50 = 25 nM), as well as RV-1, DU-145, PC-3, and VCAP prostate cancer cell lines (GI50s = 2.54, 4.38, 5.37, and 2.46 µM, respectively)
19166	SCH 772984	1 mg	≥95%	A potent, selective inhibitor of ERK1 and ERK2 (IC50s = 4 and 1 nM, respectively); has nanomolar cytotoxicity in tumor cells with mutations in BRAF, NRAS, or KRAS; effective in vivo, inducing regression of xenograft tumors in mice
19166	SCH 772984	10 mg	≥95%	A potent, selective inhibitor of ERK1 and ERK2 (IC50s = 4 and 1 nM, respectively); has nanomolar cytotoxicity in tumor cells with mutations in BRAF, NRAS, or KRAS; effective in vivo, inducing regression of xenograft tumors in mice
19166	SCH 772984	5 mg	≥95%	A potent, selective inhibitor of ERK1 and ERK2 (IC50s = 4 and 1 nM, respectively); has nanomolar cytotoxicity in tumor cells with mutations in BRAF, NRAS, or KRAS; effective in vivo, inducing regression of xenograft tumors in mice
19167	MK-5108	1 mg	≥95%	A potent inhibitor of Aurora A (IC50 = 0.064 nM) that less potently inhibits Aurora B and Aurora C (IC50s =14 and 12 nM, respectively); blocks cell cycle progression and induces apoptosis in a diverse range of human tumor types; effective in vivo
19167	MK-5108	10 mg	≥95%	A potent inhibitor of Aurora A (IC50 = 0.064 nM) that less potently inhibits Aurora B and Aurora C (IC50s =14 and 12 nM, respectively); blocks cell cycle progression and induces apoptosis in a diverse range of human tumor types; effective in vivo
19167	MK-5108	5 mg	≥95%	A potent inhibitor of Aurora A (IC50 = 0.064 nM) that less potently inhibits Aurora B and Aurora C (IC50s =14 and 12 nM, respectively); blocks cell cycle progression and induces apoptosis in a diverse range of human tumor types; effective in vivo
19168	BMS-265246	1 mg	≥95%	A cell-permeable inhibitor of Cdk1/cyclin B and Cdk2/cyclin E (IC50s = 6 and 9 nM, respectively); blocks the cycling of HCT116 cells (EC50 = 0.29-0.49 µM)
19168	BMS-265246	5 mg	≥95%	A cell-permeable inhibitor of Cdk1/cyclin B and Cdk2/cyclin E (IC50s = 6 and 9 nM, respectively); blocks the cycling of HCT116 cells (EC50 = 0.29-0.49 µM)
19169	Bafetinib	1 mg	≥95%	A Bcr-Abl kinase inhibitor (IC50 = 5.8 nM) that is 25- to 55-fold more potent than imatinib in vitro and ≥10-fold more potent in vivo; inhibits 12 out of the 13 most frequent imatinib-resistant Bcr-Abl point mutations, but not the T315I mutation; also targets the Src family kinase Lyn (IC50 = 19 nM)
19169	Bafetinib	10 mg	≥95%	A Bcr-Abl kinase inhibitor (IC50 = 5.8 nM) that is 25- to 55-fold more potent than imatinib in vitro and ≥10-fold more potent in vivo; inhibits 12 out of the 13 most frequent imatinib-resistant Bcr-Abl point mutations, but not the T315I mutation; also targets the Src family kinase Lyn (IC50 = 19 nM)
19169	Bafetinib	5 mg	≥95%	A Bcr-Abl kinase inhibitor (IC50 = 5.8 nM) that is 25- to 55-fold more potent than imatinib in vitro and ≥10-fold more potent in vivo; inhibits 12 out of the 13 most frequent imatinib-resistant Bcr-Abl point mutations, but not the T315I mutation; also targets the Src family kinase Lyn (IC50 = 19 nM)
19170	CP 673,451	1 mg	≥98%	A selective inhibitor of PDGFRβ and PDGFRα kinases (IC50s = 1 and 10 nM, respectively); antiangiogenic and antitumor activity in several in vivo tumor models
19170	CP 673,451	10 mg	≥98%	A selective inhibitor of PDGFRβ and PDGFRα kinases (IC50s = 1 and 10 nM, respectively); antiangiogenic and antitumor activity in several in vivo tumor models
19170	CP 673,451	5 mg	≥98%	A selective inhibitor of PDGFRβ and PDGFRα kinases (IC50s = 1 and 10 nM, respectively); antiangiogenic and antitumor activity in several in vivo tumor models
19171	PF-4800567	1 mg	≥98%	A selective inhibitor of casein kinase 1ε (CK1ε; IC50 = 32 nM) with greater than 20-fold selectivity over CK1δ; blocks CK1ε-mediated PER3 nuclear localization and PER2 degradation, both of which are proteins important for maintaining circadian rhythms in cells
19171	PF-4800567	10 mg	≥98%	A selective inhibitor of casein kinase 1ε (CK1ε; IC50 = 32 nM) with greater than 20-fold selectivity over CK1δ; blocks CK1ε-mediated PER3 nuclear localization and PER2 degradation, both of which are proteins important for maintaining circadian rhythms in cells
19171	PF-4800567	25 mg	≥98%	A selective inhibitor of casein kinase 1ε (CK1ε; IC50 = 32 nM) with greater than 20-fold selectivity over CK1δ; blocks CK1ε-mediated PER3 nuclear localization and PER2 degradation, both of which are proteins important for maintaining circadian rhythms in cells

19171	PF-4800567	5 mg	≥98%	A selective inhibitor of casein kinase 1ε (CK1ε; IC50 = 32 nM) with greater than 20-fold selectivity over CK1δ; blocks CK1ε-mediated PER3 nuclear localization and PER2 degradation, both of which are proteins important for maintaining circadian rhythms in cells
19172	CP 724,714	1 mg	≥95%	A selective inhibitor of HER2/ErbB2 (IC50 = 10 nM); inhibits the proliferation of ErbB2-amplified cells, including BT474 and SK-BR-3 (IC50s = 0.25 and 0.95 μM, respectively) and demonstrates antitumor activity in various human tumor xenograft models
19172	CP 724,714	10 mg	≥95%	A selective inhibitor of HER2/ErbB2 (IC50 = 10 nM); inhibits the proliferation of ErbB2-amplified cells, including BT474 and SK-BR-3 (IC50s = 0.25 and 0.95 μM, respectively) and demonstrates antitumor activity in various human tumor xenograft models
19172	CP 724,714	25 mg	≥95%	A selective inhibitor of HER2/ErbB2 (IC50 = 10 nM); inhibits the proliferation of ErbB2-amplified cells, including BT474 and SK-BR-3 (IC50s = 0.25 and 0.95 μM, respectively) and demonstrates antitumor activity in various human tumor xenograft models
19172	CP 724,714	5 mg	≥95%	A selective inhibitor of HER2/ErbB2 (IC50 = 10 nM); inhibits the proliferation of ErbB2-amplified cells, including BT474 and SK-BR-3 (IC50s = 0.25 and 0.95 μM, respectively) and demonstrates antitumor activity in various human tumor xenograft models
19173	XMD8-92	1 mg	≥98%	A selective ERK5 inhibitor (Kd = 80 nM); less potently inhibits DCAMKL2, TNK1, and Plk4 (Kds = 190, 890, and 600 nM, respectively); blocks ERK5 autophosphorylation, ERK5-mediated phosphorylation of PML, and PML-dependent activation of p21; inhibits bFGF-induced angiogenesis in a Matrigel™ plug assay in mice; reduces tumor growth in a HeLa mouse xenograft model at 50 mg/kg twice per day; binds BRD4 (Kd = 170 nM for BRD4 bromodomain 1)
19173	XMD8-92	10 mg	≥98%	A selective ERK5 inhibitor (Kd = 80 nM); less potently inhibits DCAMKL2, TNK1, and Plk4 (Kds = 190, 890, and 600 nM, respectively); blocks ERK5 autophosphorylation, ERK5-mediated phosphorylation of PML, and PML-dependent activation of p21; inhibits bFGF-induced angiogenesis in a Matrigel™ plug assay in mice; reduces tumor growth in a HeLa mouse xenograft model at 50 mg/kg twice per day; binds BRD4 (Kd = 170 nM for BRD4 bromodomain 1)
19173	XMD8-92	25 mg	≥98%	A selective ERK5 inhibitor (Kd = 80 nM); less potently inhibits DCAMKL2, TNK1, and Plk4 (Kds = 190, 890, and 600 nM, respectively); blocks ERK5 autophosphorylation, ERK5-mediated phosphorylation of PML, and PML-dependent activation of p21; inhibits bFGF-induced angiogenesis in a Matrigel™ plug assay in mice; reduces tumor growth in a HeLa mouse xenograft model at 50 mg/kg twice per day; binds BRD4 (Kd = 170 nM for BRD4 bromodomain 1)
19173	XMD8-92	5 mg	≥98%	A selective ERK5 inhibitor (Kd = 80 nM); less potently inhibits DCAMKL2, TNK1, and Plk4 (Kds = 190, 890, and 600 nM, respectively); blocks ERK5 autophosphorylation, ERK5-mediated phosphorylation of PML, and PML-dependent activation of p21; inhibits bFGF-induced angiogenesis in a Matrigel™ plug assay in mice; reduces tumor growth in a HeLa mouse xenograft model at 50 mg/kg twice per day; binds BRD4 (Kd = 170 nM for BRD4 bromodomain 1)
19174	GNE-3511	1 mg	≥98%	A selective and highly potent inhibitor of DLK; also inhibits phosphorylated JNK (IC50 = 30 nM); selective over other MAP kinases, JNKs, and MLKs; protects primary neurons in an in vitro axon degeneration assay (IC50 = 107 nM); decreases p-c-Jun expression in a mouse MPTP model of Parkinson's disease
19174	GNE-3511	10 mg	≥98%	A selective and highly potent inhibitor of DLK; also inhibits phosphorylated JNK (IC50 = 30 nM); selective over other MAP kinases, JNKs, and MLKs; protects primary neurons in an in vitro axon degeneration assay (IC50 = 107 nM); decreases p-c-Jun expression in a mouse MPTP model of Parkinson's disease
19174	GNE-3511	25 mg	≥98%	A selective and highly potent inhibitor of DLK; also inhibits phosphorylated JNK (IC50 = 30 nM); selective over other MAP kinases, JNKs, and MLKs; protects primary neurons in an in vitro axon degeneration assay (IC50 = 107 nM); decreases p-c-Jun expression in a mouse MPTP model of Parkinson's disease
19174	GNE-3511	5 mg	≥98%	A selective and highly potent inhibitor of DLK; also inhibits phosphorylated JNK (IC50 = 30 nM); selective over other MAP kinases, JNKs, and MLKs; protects primary neurons in an in vitro axon degeneration assay (IC50 = 107 nM); decreases p-c-Jun expression in a mouse MPTP model of Parkinson's disease
19175	Mps1-IN-1	1 mg	≥98%	A selective inhibitor of Mps1 kinase (IC50 = 367 nM); disrupts the recruitment of Mad2 to kinetochores and increases the frequency of multipolar mitosis in U2OS cells
19175	Mps1-IN-1	10 mg	≥98%	A selective inhibitor of Mps1 kinase (IC50 = 367 nM); disrupts the recruitment of Mad2 to kinetochores and increases the frequency of multipolar mitosis in U2OS cells

19175	Mps1-IN-1	5 mg	≥98%	A selective inhibitor of Mps1 kinase (IC50 = 367 nM); disrupts the recruitment of Mad2 to kinetochores and increases the frequency of multipolar mitosis in U2OS cells
19175	Mps1-IN-1	500 µg	≥98%	A selective inhibitor of Mps1 kinase (IC50 = 367 nM); disrupts the recruitment of Mad2 to kinetochores and increases the frequency of multipolar mitosis in U2OS cells
19176	AMG 900	1 mg	≥98%	A selective Aurora kinase inhibitor (IC50s = 5, 4, and 1 nM for Aurora A, B, and C, respectively); inhibits the proliferation of 26 different tumor cell lines in vitro and is broadly active in multiple xenograft models
19176	AMG 900	10 mg	≥98%	A selective Aurora kinase inhibitor (IC50s = 5, 4, and 1 nM for Aurora A, B, and C, respectively); inhibits the proliferation of 26 different tumor cell lines in vitro and is broadly active in multiple xenograft models
19176	AMG 900	25 mg	≥98%	A selective Aurora kinase inhibitor (IC50s = 5, 4, and 1 nM for Aurora A, B, and C, respectively); inhibits the proliferation of 26 different tumor cell lines in vitro and is broadly active in multiple xenograft models
19176	AMG 900	5 mg	≥98%	A selective Aurora kinase inhibitor (IC50s = 5, 4, and 1 nM for Aurora A, B, and C, respectively); inhibits the proliferation of 26 different tumor cell lines in vitro and is broadly active in multiple xenograft models
19177	WZ4003	1 mg	≥98%	A selective inhibitor of NUAK1 and NUAK2 (IC50s = 20 and 100 nM, respectively); inhibits the phosphorylation of the NUAK1 substrate MYPT1 at Ser445; inhibits proliferation and migration of mouse embryonic fibroblasts and U2OS cells at 10 µM in cell-based assays
19177	WZ4003	10 mg	≥98%	A selective inhibitor of NUAK1 and NUAK2 (IC50s = 20 and 100 nM, respectively); inhibits the phosphorylation of the NUAK1 substrate MYPT1 at Ser445; inhibits proliferation and migration of mouse embryonic fibroblasts and U2OS cells at 10 µM in cell-based assays
19177	WZ4003	25 mg	≥98%	A selective inhibitor of NUAK1 and NUAK2 (IC50s = 20 and 100 nM, respectively); inhibits the phosphorylation of the NUAK1 substrate MYPT1 at Ser445; inhibits proliferation and migration of mouse embryonic fibroblasts and U2OS cells at 10 µM in cell-based assays
19177	WZ4003	5 mg	≥98%	A selective inhibitor of NUAK1 and NUAK2 (IC50s = 20 and 100 nM, respectively); inhibits the phosphorylation of the NUAK1 substrate MYPT1 at Ser445; inhibits proliferation and migration of mouse embryonic fibroblasts and U2OS cells at 10 µM in cell-based assays
19178	CCT241533 (hydrochl	1 mg	≥98%	A selective Chk2 inhibitor (IC50 = 3 nM); potentiates the cytotoxicity of the PARP inhibitors, rucaparib and olaparib
19178	CCT241533 (hydrochl	10 mg	≥98%	A selective Chk2 inhibitor (IC50 = 3 nM); potentiates the cytotoxicity of the PARP inhibitors, rucaparib and olaparib
19178	CCT241533 (hydrochl	5 mg	≥98%	A selective Chk2 inhibitor (IC50 = 3 nM); potentiates the cytotoxicity of the PARP inhibitors, rucaparib and olaparib
19178	CCT241533 (hydrochl	500 µg	≥98%	A selective Chk2 inhibitor (IC50 = 3 nM); potentiates the cytotoxicity of the PARP inhibitors, rucaparib and olaparib
19179	HG-9-91-01	1 mg	≥95%	An inhibitor of SIKs (IC50s = 0.92, 6.6, and 9.6 nM for SIK1, SIK2, and SIK3, respectively); increases LPS-stimulated IL-10 production and suppresses pro-inflammatory cytokine secretion in bone marrow-derived
19179	HG-9-91-01	10 mg	≥95%	An inhibitor of SIKs (IC50s = 0.92, 6.6, and 9.6 nM for SIK1, SIK2, and SIK3, respectively); increases LPS-stimulated IL-10 production and suppresses pro-inflammatory cytokine secretion in bone marrow-derived
19179	HG-9-91-01	5 mg	≥95%	An inhibitor of SIKs (IC50s = 0.92, 6.6, and 9.6 nM for SIK1, SIK2, and SIK3, respectively); increases LPS-stimulated IL-10 production and suppresses pro-inflammatory cytokine secretion in bone marrow-derived
19179	HG-9-91-01	500 µg	≥95%	An inhibitor of SIKs (IC50s = 0.92, 6.6, and 9.6 nM for SIK1, SIK2, and SIK3, respectively); increases LPS-stimulated IL-10 production and suppresses pro-inflammatory cytokine secretion in bone marrow-derived
19180	GSK269962	1 mg	≥95%	A selective ROCK inhibitor (IC50s = 1.6 and 6 nM for ROCK1 and ROCK2, respectively); blocks the generation of inflammatory cytokines in LPS-stimulated monocytes and induces vasorelaxation in preconstricted rat aorta (IC50 = 35 nM)
19180	GSK269962	10 mg	≥95%	A selective ROCK inhibitor (IC50s = 1.6 and 6 nM for ROCK1 and ROCK2, respectively); blocks the generation of inflammatory cytokines in LPS-stimulated monocytes and induces vasorelaxation in preconstricted rat aorta (IC50 = 35 nM)
19180	GSK269962	25 mg	≥95%	A selective ROCK inhibitor (IC50s = 1.6 and 6 nM for ROCK1 and ROCK2, respectively); blocks the generation of inflammatory cytokines in LPS-stimulated monocytes and induces vasorelaxation in preconstricted rat aorta (IC50 = 35 nM)
19180	GSK269962	5 mg	≥95%	A selective ROCK inhibitor (IC50s = 1.6 and 6 nM for ROCK1 and ROCK2, respectively); blocks the generation of inflammatory cytokines in LPS-stimulated monocytes and induces vasorelaxation in preconstricted rat aorta (IC50 = 35 nM)
19181	MLCK Inhibitor Peptid	1 mg	≥95%	A selective, cell-permeable inhibitor of MLCK (IC50 = 50 nM)
19181	MLCK Inhibitor Peptid	10 mg	≥95%	A selective, cell-permeable inhibitor of MLCK (IC50 = 50 nM)
19181	MLCK Inhibitor Peptid	5 mg	≥95%	A selective, cell-permeable inhibitor of MLCK (IC50 = 50 nM)

19181	MLCK Inhibitor Peptid	500 µg	≥95%	A selective, cell-permeable inhibitor of MLCK (IC50 = 50 nM)
19182	VER-246608	1 mg	≥98%	A pan-PDHK inhibitor (IC50s = 35, 84, 40, and 91 nM for PDHK1, -2, -3, and -4, respectively); selective for PDHKs over Hsp90 (IC50 = >100 µM), as well as a panel of 97 kinases at 10 µM; decreases L-lactate production in PC3 cells cultured in D-glucose- and L-glutamine-depleted media at 10 and 20 µM; reduces the growth of, and induces cell cycle arrest at the G1 phase in, serum-starved PC3 cells at 20 µM
19182	VER-246608	10 mg	≥98%	A pan-PDHK inhibitor (IC50s = 35, 84, 40, and 91 nM for PDHK1, -2, -3, and -4, respectively); selective for PDHKs over Hsp90 (IC50 = >100 µM), as well as a panel of 97 kinases at 10 µM; decreases L-lactate production in PC3 cells cultured in D-glucose- and L-glutamine-depleted media at 10 and 20 µM; reduces the growth of, and induces cell cycle arrest at the G1 phase in, serum-starved PC3 cells at 20 µM
19182	VER-246608	25 mg	≥98%	A pan-PDHK inhibitor (IC50s = 35, 84, 40, and 91 nM for PDHK1, -2, -3, and -4, respectively); selective for PDHKs over Hsp90 (IC50 = >100 µM), as well as a panel of 97 kinases at 10 µM; decreases L-lactate production in PC3 cells cultured in D-glucose- and L-glutamine-depleted media at 10 and 20 µM; reduces the growth of, and induces cell cycle arrest at the G1 phase in, serum-starved PC3 cells at 20 µM
19182	VER-246608	5 mg	≥98%	A pan-PDHK inhibitor (IC50s = 35, 84, 40, and 91 nM for PDHK1, -2, -3, and -4, respectively); selective for PDHKs over Hsp90 (IC50 = >100 µM), as well as a panel of 97 kinases at 10 µM; decreases L-lactate production in PC3 cells cultured in D-glucose- and L-glutamine-depleted media at 10 and 20 µM; reduces the growth of, and induces cell cycle arrest at the G1 phase in, serum-starved PC3 cells at 20 µM
19183	BIX 02565	1 mg	≥98%	A potent RSK2 inhibitor (IC50 = 1.1 nM) that also demonstrates off-target binding at multiple adrenergic receptor subtypes that are important for vascular tone and cardiac function (IC50s = 0.052-1.820 µM for adrenergic α1A, α1B, α1D, α2A, β2, and imidazoline I2 receptors); also inhibits LRRK2 and PRKD1 (IC50s = 16 and 35 nM, respectively)
19183	BIX 02565	5 mg	≥98%	A potent RSK2 inhibitor (IC50 = 1.1 nM) that also demonstrates off-target binding at multiple adrenergic receptor subtypes that are important for vascular tone and cardiac function (IC50s = 0.052-1.820 µM for adrenergic α1A, α1B, α1D, α2A, β2, and imidazoline I2 receptors); also inhibits LRRK2 and PRKD1 (IC50s = 16 and 35 nM, respectively)
19183	BIX 02565	500 µg	≥98%	A potent RSK2 inhibitor (IC50 = 1.1 nM) that also demonstrates off-target binding at multiple adrenergic receptor subtypes that are important for vascular tone and cardiac function (IC50s = 0.052-1.820 µM for adrenergic α1A, α1B, α1D, α2A, β2, and imidazoline I2 receptors); also inhibits LRRK2 and PRKD1 (IC50s = 16 and 35 nM, respectively)
19184	BI-605906	1 mg	≥98%	An IKKβ inhibitor (IC50 = 380 nM); selective for IKKβ over insulin-like growth factor 1 (IGF1; IC50 = 7.6 µM) and over 100 kinases in a panel up to 10 µM; partially inhibits IL-1-stimulated activation of IKKε/TBK1 in vitro; inhibits TNF-α-dependent IkB degradation and expression of the proinflammatory cytokines IL-6, IL-1β, and CXCL1/2 without affecting lipogenic gene expression or glucose production in murine primary hepatocytes
19184	BI-605906	10 mg	≥98%	An IKKβ inhibitor (IC50 = 380 nM); selective for IKKβ over insulin-like growth factor 1 (IGF1; IC50 = 7.6 µM) and over 100 kinases in a panel up to 10 µM; partially inhibits IL-1-stimulated activation of IKKε/TBK1 in vitro; inhibits TNF-α-dependent IkB degradation and expression of the proinflammatory cytokines IL-6, IL-1β, and CXCL1/2 without affecting lipogenic gene expression or glucose production in murine primary hepatocytes
19184	BI-605906	5 mg	≥98%	An IKKβ inhibitor (IC50 = 380 nM); selective for IKKβ over insulin-like growth factor 1 (IGF1; IC50 = 7.6 µM) and over 100 kinases in a panel up to 10 µM; partially inhibits IL-1-stimulated activation of IKKε/TBK1 in vitro; inhibits TNF-α-dependent IkB degradation and expression of the proinflammatory cytokines IL-6, IL-1β, and CXCL1/2 without affecting lipogenic gene expression or glucose production in murine primary hepatocytes
19186	PF-3758309	10 mg	≥98%	An ATP-competitive inhibitor of PAK4, preventing the phosphorylation of the PAK4 substrate GEF-H1 (IC50 = 1.3 nM) and blocking anchorage-independent growth of a panel of tumor cell lines (IC50 = 4.7 nM); blocks the growth of multiple human tumor xenografts
19186	PF-3758309	25 mg	≥98%	An ATP-competitive inhibitor of PAK4, preventing the phosphorylation of the PAK4 substrate GEF-H1 (IC50 = 1.3 nM) and blocking anchorage-independent growth of a panel of tumor cell lines (IC50 = 4.7 nM); blocks the growth of multiple human tumor xenografts
19186	PF-3758309	5 mg	≥98%	An ATP-competitive inhibitor of PAK4, preventing the phosphorylation of the PAK4 substrate GEF-H1 (IC50 = 1.3 nM) and blocking anchorage-independent growth of a panel of tumor cell lines (IC50 = 4.7 nM); blocks the growth of multiple human tumor xenografts
19231	EW-7197	1 mg	≥98%	A potent inhibitor of ALK5 (IC50 = 12.9 nM); also inhibits ALK2 and ALK4 at nanomolar concentrations; used to block TGF-β signaling and EMT in animal models of cancer and fibrosis

19231	EW-7197	10 mg	≥98%	A potent inhibitor of ALK5 (IC50 = 12.9 nM); also inhibits ALK2 and ALK4 at nanomolar concentrations; used to block TGF-β signaling and EMT in animal models of cancer and fibrosis
19231	EW-7197	5 mg	≥98%	A potent inhibitor of ALK5 (IC50 = 12.9 nM); also inhibits ALK2 and ALK4 at nanomolar concentrations; used to block TGF-β signaling and EMT in animal models of cancer and fibrosis
19241	GDC-0326	1 mg	≥98%	A selective inhibitor of PI3Kα (Ki = 0.2 nM); is 133-, 20-, and 51-fold selective for PI3Kα over PI3Kβ, PI3Kδ, and PI3Kγ, respectively; inhibits proliferation of MCF7-neo/HER2 and PC3 cells (EC50s = 0.1 and 2.2 μM, respectively); induces tumor regression in a KPL-4 mouse xenograft model at 6.25 mg/kg; reduces tumor growth, tumor vasculature, and the number of liver and lymph node metastases in the RIP1-Tag2 transgenic mouse model of pancreatic neuroendocrine tumors
19241	GDC-0326	10 mg	≥98%	A selective inhibitor of PI3Kα (Ki = 0.2 nM); is 133-, 20-, and 51-fold selective for PI3Kα over PI3Kβ, PI3Kδ, and PI3Kγ, respectively; inhibits proliferation of MCF7-neo/HER2 and PC3 cells (EC50s = 0.1 and 2.2 μM, respectively); induces tumor regression in a KPL-4 mouse xenograft model at 6.25 mg/kg; reduces tumor growth, tumor vasculature, and the number of liver and lymph node metastases in the RIP1-Tag2 transgenic mouse model of pancreatic neuroendocrine tumors
19241	GDC-0326	25 mg	≥98%	A selective inhibitor of PI3Kα (Ki = 0.2 nM); is 133-, 20-, and 51-fold selective for PI3Kα over PI3Kβ, PI3Kδ, and PI3Kγ, respectively; inhibits proliferation of MCF7-neo/HER2 and PC3 cells (EC50s = 0.1 and 2.2 μM, respectively); induces tumor regression in a KPL-4 mouse xenograft model at 6.25 mg/kg; reduces tumor growth, tumor vasculature, and the number of liver and lymph node metastases in the RIP1-Tag2 transgenic mouse model of pancreatic neuroendocrine tumors
19241	GDC-0326	5 mg	≥98%	A selective inhibitor of PI3Kα (Ki = 0.2 nM); is 133-, 20-, and 51-fold selective for PI3Kα over PI3Kβ, PI3Kδ, and PI3Kγ, respectively; inhibits proliferation of MCF7-neo/HER2 and PC3 cells (EC50s = 0.1 and 2.2 μM, respectively); induces tumor regression in a KPL-4 mouse xenograft model at 6.25 mg/kg; reduces tumor growth, tumor vasculature, and the number of liver and lymph node metastases in the RIP1-Tag2 transgenic mouse model of pancreatic neuroendocrine tumors
19280	Nilotinib-d6	1 mg	≥99% deutera	An internal standard for the quantification of nilotinib by GC- or LC-MS
19282	AZD 7545	1 mg	≥98%	An inhibitor of PDKs, resulting in an increase in PDH activity (EC50 = 5.2 nM for PDK2); less potently inhibits PDK1 and PDK3 (IC50s = 87 and 600 nM, respectively)
19282	AZD 7545	10 mg	≥98%	An inhibitor of PDKs, resulting in an increase in PDH activity (EC50 = 5.2 nM for PDK2); less potently inhibits PDK1 and PDK3 (IC50s = 87 and 600 nM, respectively)
19282	AZD 7545	25 mg	≥98%	An inhibitor of PDKs, resulting in an increase in PDH activity (EC50 = 5.2 nM for PDK2); less potently inhibits PDK1 and PDK3 (IC50s = 87 and 600 nM, respectively)
19282	AZD 7545	5 mg	≥98%	An inhibitor of PDKs, resulting in an increase in PDH activity (EC50 = 5.2 nM for PDK2); less potently inhibits PDK1 and PDK3 (IC50s = 87 and 600 nM, respectively)
19305	MLi-2	1 mg	≥98%	An LRRK2 inhibitor (IC50 = 0.76 nM); >100-fold selective for LRRK2 over a panel of 308 protein kinases, as well as a panel of receptors and ion channels, at 10 μM; increases GCase activity in dopaminergic neurons differentiated from induced pluripotent stem cells generated from skin fibroblasts isolated from patients with Parkinson's disease expressing LRRK2 mutations at 600 nM; inhibits cortical LRRK2 phosphorylation in the MitoPark mouse model of Parkinson's disease at 30 mg/kg
19305	MLi-2	10 mg	≥98%	An LRRK2 inhibitor (IC50 = 0.76 nM); >100-fold selective for LRRK2 over a panel of 308 protein kinases, as well as a panel of receptors and ion channels, at 10 μM; increases GCase activity in dopaminergic neurons differentiated from induced pluripotent stem cells generated from skin fibroblasts isolated from patients with Parkinson's disease expressing LRRK2 mutations at 600 nM; inhibits cortical LRRK2 phosphorylation in the MitoPark mouse model of Parkinson's disease at 30 mg/kg
19305	MLi-2	5 mg	≥98%	An LRRK2 inhibitor (IC50 = 0.76 nM); >100-fold selective for LRRK2 over a panel of 308 protein kinases, as well as a panel of receptors and ion channels, at 10 μM; increases GCase activity in dopaminergic neurons differentiated from induced pluripotent stem cells generated from skin fibroblasts isolated from patients with Parkinson's disease expressing LRRK2 mutations at 600 nM; inhibits cortical LRRK2 phosphorylation in the MitoPark mouse model of Parkinson's disease at 30 mg/kg
19308	PF-4989216	1 mg	≥98%	An orally bioavailable broad-spectrum PI3K inhibitor (IC50s = 2, 142, 65, 1, and 110 nM for p110α, p110β, p110γ, p110δ, and VPS34, respectively)
19308	PF-4989216	10 mg	≥98%	An orally bioavailable broad-spectrum PI3K inhibitor (IC50s = 2, 142, 65, 1, and 110 nM for p110α, p110β, p110γ, p110δ, and VPS34, respectively)

19308	PF-4989216	25 mg	≥98%	An orally bioavailable broad-spectrum PI3K inhibitor (IC50s = 2, 142, 65, 1, and 110 nM for p110α, p110β, p110γ, p110δ, and VPS34, respectively)
19308	PF-4989216	5 mg	≥98%	An orally bioavailable broad-spectrum PI3K inhibitor (IC50s = 2, 142, 65, 1, and 110 nM for p110α, p110β, p110γ, p110δ, and VPS34, respectively)
19309	AZD 3264	1 mg	≥98%	A novel inhibitor of IKK2
19309	AZD 3264	10 mg	≥98%	A novel inhibitor of IKK2
19309	AZD 3264	25 mg	≥98%	A novel inhibitor of IKK2
19309	AZD 3264	5 mg	≥98%	A novel inhibitor of IKK2
19374	Ceritinib	1 mg	≥98%	An ALK inhibitor (IC50 = 0.2 nM); selective for ALK over IGF-1R, InsR, STK22D, and FLT3 (IC50s = 8, 7, 23, and 60 nM, respectively) as well as a panel of 25 additional kinases (IC50s = >0.26 μM for all); inhibits the proliferation of Ba/F3 cells expressing the fusion protein NPM-ALK or ELM4-ALK (IC50s = 0.02 and 0.021 μM, respectively), as well as several crizotinib-resistant NPM-ALK and ELM4-ALK mutants; reduces tumor growth in an H2228 NSCLC rat xenograft model at 10 mg/kg per day and induces tumor regression at 25 mg/kg per day; induces tumor regression in a Karpas299 lymphoma rat xenograft model at 25 and 50 mg/kg per day
19374	Ceritinib	10 mg	≥98%	An ALK inhibitor (IC50 = 0.2 nM); selective for ALK over IGF-1R, InsR, STK22D, and FLT3 (IC50s = 8, 7, 23, and 60 nM, respectively) as well as a panel of 25 additional kinases (IC50s = >0.26 μM for all); inhibits the proliferation of Ba/F3 cells expressing the fusion protein NPM-ALK or ELM4-ALK (IC50s = 0.02 and 0.021 μM, respectively), as well as several crizotinib-resistant NPM-ALK and ELM4-ALK mutants; reduces tumor growth in an H2228 NSCLC rat xenograft model at 10 mg/kg per day and induces tumor regression at 25 mg/kg per day; induces tumor regression in a Karpas299 lymphoma rat xenograft model at 25 and 50 mg/kg per day
19374	Ceritinib	25 mg	≥98%	An ALK inhibitor (IC50 = 0.2 nM); selective for ALK over IGF-1R, InsR, STK22D, and FLT3 (IC50s = 8, 7, 23, and 60 nM, respectively) as well as a panel of 25 additional kinases (IC50s = >0.26 μM for all); inhibits the proliferation of Ba/F3 cells expressing the fusion protein NPM-ALK or ELM4-ALK (IC50s = 0.02 and 0.021 μM, respectively), as well as several crizotinib-resistant NPM-ALK and ELM4-ALK mutants; reduces tumor growth in an H2228 NSCLC rat xenograft model at 10 mg/kg per day and induces tumor regression at 25 mg/kg per day; induces tumor regression in a Karpas299 lymphoma rat xenograft model at 25 and 50 mg/kg per day
19374	Ceritinib	5 mg	≥98%	An ALK inhibitor (IC50 = 0.2 nM); selective for ALK over IGF-1R, InsR, STK22D, and FLT3 (IC50s = 8, 7, 23, and 60 nM, respectively) as well as a panel of 25 additional kinases (IC50s = >0.26 μM for all); inhibits the proliferation of Ba/F3 cells expressing the fusion protein NPM-ALK or ELM4-ALK (IC50s = 0.02 and 0.021 μM, respectively), as well as several crizotinib-resistant NPM-ALK and ELM4-ALK mutants; reduces tumor growth in an H2228 NSCLC rat xenograft model at 10 mg/kg per day and induces tumor regression at 25 mg/kg per day; induces tumor regression in a Karpas299 lymphoma rat xenograft model at 25 and 50 mg/kg per day
19375	Lenvatinib	1 mg	≥98%	An inhibitor of VEGFR2 and VEGFR3 (IC50s = 4 and 5.2 nM, respectively); also inhibits VEGFR1, FGFR1, PDGFRα , PDGFRβ and Kit (IC50s = 22, 46, 51, 39, and 100 nM, respectively); reduces tumor growth in an H146 small cell lung cancer mouse xenograft model at 30 mg/kg, twice per day, and induces tumor regression at 100 mg/kg, twice per day
19375	Lenvatinib	10 mg	≥98%	An inhibitor of VEGFR2 and VEGFR3 (IC50s = 4 and 5.2 nM, respectively); also inhibits VEGFR1, FGFR1, PDGFRα , PDGFRβ and Kit (IC50s = 22, 46, 51, 39, and 100 nM, respectively); reduces tumor growth in an H146 small cell lung cancer mouse xenograft model at 30 mg/kg, twice per day, and induces tumor regression at 100 mg/kg, twice per day
19375	Lenvatinib	25 mg	≥98%	An inhibitor of VEGFR2 and VEGFR3 (IC50s = 4 and 5.2 nM, respectively); also inhibits VEGFR1, FGFR1, PDGFRα , PDGFRβ and Kit (IC50s = 22, 46, 51, 39, and 100 nM, respectively); reduces tumor growth in an H146 small cell lung cancer mouse xenograft model at 30 mg/kg, twice per day, and induces tumor regression at 100 mg/kg, twice per day
19375	Lenvatinib	5 mg	≥98%	An inhibitor of VEGFR2 and VEGFR3 (IC50s = 4 and 5.2 nM, respectively); also inhibits VEGFR1, FGFR1, PDGFRα , PDGFRβ and Kit (IC50s = 22, 46, 51, 39, and 100 nM, respectively); reduces tumor growth in an H146 small cell lung cancer mouse xenograft model at 30 mg/kg, twice per day, and induces tumor regression at 100 mg/kg, twice per day
19396	LDN-193189 (hydroch	1 mg	≥98%	Inhibits BMP type I receptor-induced phosphorylation of SMAD1/5/8 (IC50 = 4.9 nM); shows specificity for ALK1, 2, 3, and 6 (IC50s = 0.8, 0.8, 5.3, and 16.7 nM, respectively) over ALK4 and 5 (IC50s = 101 and 350 nM, respectively)
19396	LDN-193189 (hydroch	10 mg	≥98%	Inhibits BMP type I receptor-induced phosphorylation of SMAD1/5/8 (IC50 = 4.9 nM); shows specificity for ALK1, 2, 3, and 6 (IC50s = 0.8, 0.8, 5.3, and 16.7 nM, respectively) over ALK4 and 5 (IC50s = 101 and 350 nM, respectively)

19396	LDN-193189 (hydroch	25 mg	≥98%	Inhibits BMP type I receptor-induced phosphorylation of SMAD1/5/8 (IC50 = 4.9 nM); shows specificity for ALK1, 2, 3, and 6 (IC50s = 0.8, 0.8, 5.3, and 16.7 nM, respectively) over ALK4 and 5 (IC50s = 101 and 350 nM, respectively)
19396	LDN-193189 (hydroch	5 mg	≥98%	Inhibits BMP type I receptor-induced phosphorylation of SMAD1/5/8 (IC50 = 4.9 nM); shows specificity for ALK1, 2, 3, and 6 (IC50s = 0.8, 0.8, 5.3, and 16.7 nM, respectively) over ALK4 and 5 (IC50s = 101 and 350 nM, respectively)
19401	Mps1-IN-2	1 mg	≥98%	An inhibitor of Mps1 (IC50 = 145 nM); 1,000-fold selective for Mps1 over a panel of 352 kinases at 10 mM, but does inhibit Plk1 (Kd = 61 nM)
19401	Mps1-IN-2	10 mg	≥98%	An inhibitor of Mps1 (IC50 = 145 nM); 1,000-fold selective for Mps1 over a panel of 352 kinases at 10 mM, but does inhibit Plk1 (Kd = 61 nM)
19401	Mps1-IN-2	25 mg	≥98%	An inhibitor of Mps1 (IC50 = 145 nM); 1,000-fold selective for Mps1 over a panel of 352 kinases at 10 mM, but does inhibit Plk1 (Kd = 61 nM)
19401	Mps1-IN-2	5 mg	≥98%	An inhibitor of Mps1 (IC50 = 145 nM); 1,000-fold selective for Mps1 over a panel of 352 kinases at 10 mM, but does inhibit Plk1 (Kd = 61 nM)
19420	CC-115	1 mg	≥95%	A dual inhibitor of mTOR and DNA-PK (IC50s = 0.021 and 0.013 μM, respectively); selective for mTOR and DNA-PK over PI3Kα, ATM, and ATR (IC50s = 0.85, >30, and >30 μM, respectively); inhibits growth in a panel of 123 cancer cell lines, including breast, head and neck, and lung cancer cells (GI50s = 0.015-1.77 μM); inhibits NHEJ in CAL-51, MDA-MB-231, PC3, and HCT116 cells (IC50s = 3.15, 2.16, 2.72, and 6.35 μM, respectively); reduces tumor growth in a PC3 prostate cancer mouse xenograft model at 0.25, 0.5, and 1 mg/kg twice per day
19420	CC-115	10 mg	≥95%	A dual inhibitor of mTOR and DNA-PK (IC50s = 0.021 and 0.013 μM, respectively); selective for mTOR and DNA-PK over PI3Kα, ATM, and ATR (IC50s = 0.85, >30, and >30 μM, respectively); inhibits growth in a panel of 123 cancer cell lines, including breast, head and neck, and lung cancer cells (GI50s = 0.015-1.77 μM); inhibits NHEJ in CAL-51, MDA-MB-231, PC3, and HCT116 cells (IC50s = 3.15, 2.16, 2.72, and 6.35 μM, respectively); reduces tumor growth in a PC3 prostate cancer mouse xenograft model at 0.25, 0.5, and 1 mg/kg twice per day
19420	CC-115	25 mg	≥95%	A dual inhibitor of mTOR and DNA-PK (IC50s = 0.021 and 0.013 μM, respectively); selective for mTOR and DNA-PK over PI3Kα, ATM, and ATR (IC50s = 0.85, >30, and >30 μM, respectively); inhibits growth in a panel of 123 cancer cell lines, including breast, head and neck, and lung cancer cells (GI50s = 0.015-1.77 μM); inhibits NHEJ in CAL-51, MDA-MB-231, PC3, and HCT116 cells (IC50s = 3.15, 2.16, 2.72, and 6.35 μM, respectively); reduces tumor growth in a PC3 prostate cancer mouse xenograft model at 0.25, 0.5, and 1 mg/kg twice per day
19420	CC-115	5 mg	≥95%	A dual inhibitor of mTOR and DNA-PK (IC50s = 0.021 and 0.013 μM, respectively); selective for mTOR and DNA-PK over PI3Kα, ATM, and ATR (IC50s = 0.85, >30, and >30 μM, respectively); inhibits growth in a panel of 123 cancer cell lines, including breast, head and neck, and lung cancer cells (GI50s = 0.015-1.77 μM); inhibits NHEJ in CAL-51, MDA-MB-231, PC3, and HCT116 cells (IC50s = 3.15, 2.16, 2.72, and 6.35 μM, respectively); reduces tumor growth in a PC3 prostate cancer mouse xenograft model at 0.25, 0.5, and 1 mg/kg twice per day
19421	BMS-3	1 mg	≥95%	A potent inhibitor of activated LIMK1 and LIMK2 (IC50s = 5 and 6 nM, respectively)
19421	BMS-3	10 mg	≥95%	A potent inhibitor of activated LIMK1 and LIMK2 (IC50s = 5 and 6 nM, respectively)
19421	BMS-3	25 mg	≥95%	A potent inhibitor of activated LIMK1 and LIMK2 (IC50s = 5 and 6 nM, respectively)
19421	BMS-3	5 mg	≥95%	A potent inhibitor of activated LIMK1 and LIMK2 (IC50s = 5 and 6 nM, respectively)
19440	Cochlioquinone A	2.5 mg	≥99%	An inhibitor of DGK (Ki = 3.1 μM) and DGAT (IC50 = 5.6 μM); reduces the concentration of phosphatidic acid in T cell lymphoma (IC50 = 3 μM); binds to human CCR5 chemokine receptors with an IC50 value of 11 μM
19440	Cochlioquinone A	500 µg	≥99%	An inhibitor of DGK (Ki = 3.1 μM) and DGAT (IC50 = 5.6 μM); reduces the concentration of phosphatidic acid in T cell lymphoma (IC50 = 3 μM); binds to human CCR5 chemokine receptors with an IC50 value of 11 μM
19447	Narasin (sodium salt)	25 mg	≥95%	An ionophore antibiotic used in veterinary practice as a coccidiostat for gastrointestinal parasites; inhibits NF-κB signaling via inhibition of IκBα phosphorylation (IC50 = 3.2 μM) and stimulates TRAIL-mediated apoptosis in glioma cells via ER stress
19447	Narasin (sodium salt)	5 mg	≥95%	An ionophore antibiotic used in veterinary practice as a coccidiostat for gastrointestinal parasites; inhibits NF-κB signaling via inhibition of IκBα phosphorylation (IC50 = 3.2 μM) and stimulates TRAIL-mediated apoptosis in glioma cells via ER stress
19475	YLF-466D	1 mg	≥98%	An AMPK activator at a concentration of 150 μM in platelets; inhibits thrombin-, ADP-, and collagen-induced platelet aggregation (IC50s = 84, 55, and 87 μM, respectively); inhibits whole blood aggregation; improves glucose tolerance in mouse models of diabetes
19475	YLF-466D	10 mg	≥98%	An AMPK activator at a concentration of 150 μM in platelets; inhibits thrombin-, ADP-, and collagen-induced platelet aggregation (IC50s = 84, 55, and 87 μM, respectively); inhibits whole blood aggregation; improves glucose tolerance in mouse models of diabetes
19475	YLF-466D	5 mg	≥98%	An AMPK activator at a concentration of 150 μM in platelets; inhibits thrombin-, ADP-, and collagen-induced platelet aggregation (IC50s = 84, 55, and 87 μM, respectively); inhibits whole blood aggregation; improves glucose tolerance in mouse models of diabetes

19476	Entrectinib	1 mg	≥98%	An inhibitor of TrkA (IC50 = 1.7 nM), TrkB (IC50 = 0.1 nM), and TrkC (IC50 = 0.1 nM), as well as ROS1 (IC50 = 0.2 nM) and ALK (IC50 = 1.6 nM); blocks proliferation of ALK-dependent cell lines, including those with L1196M or C1156Y resistance mutations; induces tumor regression in mice bearing various Trk, ROS1, or ALK-driven xenografts
19476	Entrectinib	10 mg	≥98%	An inhibitor of TrkA (IC50 = 1.7 nM), TrkB (IC50 = 0.1 nM), and TrkC (IC50 = 0.1 nM), as well as ROS1 (IC50 = 0.2 nM) and ALK (IC50 = 1.6 nM); blocks proliferation of ALK-dependent cell lines, including those with L1196M or C1156Y resistance mutations; induces tumor regression in mice bearing various Trk, ROS1, or ALK-driven xenografts
19476	Entrectinib	5 mg	≥98%	An inhibitor of TrkA (IC50 = 1.7 nM), TrkB (IC50 = 0.1 nM), and TrkC (IC50 = 0.1 nM), as well as ROS1 (IC50 = 0.2 nM) and ALK (IC50 = 1.6 nM); blocks proliferation of ALK-dependent cell lines, including those with L1196M or C1156Y resistance mutations; induces tumor regression in mice bearing various Trk, ROS1, or ALK-driven xenografts
19477	AST-487	1 mg	≥98%	An inhibitor of RET (IC50 = 0.88 μM), FLT3 (Ki = 0.12 μM), KDR, c-Abl, and c-Kit; demonstrates antiproliferative activity in various cancer cells, including those with RET or FLT3 mutations
19477	AST-487	10 mg	≥98%	An inhibitor of RET (IC50 = 0.88 μM), FLT3 (Ki = 0.12 μM), KDR, c-Abl, and c-Kit; demonstrates antiproliferative activity in various cancer cells, including those with RET or FLT3 mutations
19477	AST-487	25 mg	≥98%	An inhibitor of RET (IC50 = 0.88 μM), FLT3 (Ki = 0.12 μM), KDR, c-Abl, and c-Kit; demonstrates antiproliferative activity in various cancer cells, including those with RET or FLT3 mutations
19477	AST-487	5 mg	≥98%	An inhibitor of RET (IC50 = 0.88 μM), FLT3 (Ki = 0.12 μM), KDR, c-Abl, and c-Kit; demonstrates antiproliferative activity in various cancer cells, including those with RET or FLT3 mutations
19479	GDC-0623	1 mg	≥98%	A potent, ATP-uncompetitive inhibitor of MEK1 (Ki = 0.13 nM in the presence of ATP); inhibits the proliferation of A375 BRAF(V600E) and HCT116 KRAS(G13D)-mutant cancer cell lines (EC50 = 7 and 42 nM, respectively); upregulates pro-apoptotic BIM
19479	GDC-0623	10 mg	≥98%	A potent, ATP-uncompetitive inhibitor of MEK1 (Ki = 0.13 nM in the presence of ATP); inhibits the proliferation of A375 BRAF(V600E) and HCT116 KRAS(G13D)-mutant cancer cell lines (EC50 = 7 and 42 nM, respectively); upregulates pro-apoptotic BIM
19479	GDC-0623	25 mg	≥98%	A potent, ATP-uncompetitive inhibitor of MEK1 (Ki = 0.13 nM in the presence of ATP); inhibits the proliferation of A375 BRAF(V600E) and HCT116 KRAS(G13D)-mutant cancer cell lines (EC50 = 7 and 42 nM, respectively); upregulates pro-apoptotic BIM
19479	GDC-0623	5 mg	≥98%	A potent, ATP-uncompetitive inhibitor of MEK1 (Ki = 0.13 nM in the presence of ATP); inhibits the proliferation of A375 BRAF(V600E) and HCT116 KRAS(G13D)-mutant cancer cell lines (EC50 = 7 and 42 nM, respectively); upregulates pro-apoptotic BIM
19481	HM61713	1 mg	≥98%	An inhibitor of mutant EGFR (IC50 = 0.01 μM for EGFRT790M/L858R); selective for EGFRT790M/L858R over PI3Kα (IC50 = >10 μM); cytotoxic to A549, H1975, H460, and MCF-7 cells (IC50s = 4.29, 0.52, 5.29, and 26.9 μM, respectively); reduces tumor growth in an ETS1-overexpressing doxorubicin-resistant K562 leukemia mouse xenograft model at 30 mg/kg in combination with doxorubicin
19481	HM61713	10 mg	≥98%	An inhibitor of mutant EGFR (IC50 = 0.01 μM for EGFRT790M/L858R); selective for EGFRT790M/L858R over PI3Kα (IC50 = >10 μM); cytotoxic to A549, H1975, H460, and MCF-7 cells (IC50s = 4.29, 0.52, 5.29, and 26.9 μM, respectively); reduces tumor growth in an ETS1-overexpressing doxorubicin-resistant K562 leukemia mouse xenograft model at 30 mg/kg in combination with doxorubicin
19481	HM61713	25 mg	≥98%	An inhibitor of mutant EGFR (IC50 = 0.01 μM for EGFRT790M/L858R); selective for EGFRT790M/L858R over PI3Kα (IC50 = >10 μM); cytotoxic to A549, H1975, H460, and MCF-7 cells (IC50s = 4.29, 0.52, 5.29, and 26.9 μM, respectively); reduces tumor growth in an ETS1-overexpressing doxorubicin-resistant K562 leukemia mouse xenograft model at 30 mg/kg in combination with doxorubicin
19481	HM61713	5 mg	≥98%	An inhibitor of mutant EGFR (IC50 = 0.01 μM for EGFRT790M/L858R); selective for EGFRT790M/L858R over PI3Kα (IC50 = >10 μM); cytotoxic to A549, H1975, H460, and MCF-7 cells (IC50s = 4.29, 0.52, 5.29, and 26.9 μM, respectively); reduces tumor growth in an ETS1-overexpressing doxorubicin-resistant K562 leukemia mouse xenograft model at 30 mg/kg in combination with doxorubicin
19488	RO4987655	1 mg	≥98%	A MEK inhibitor (IC50 = 5 nM); selective for MEK over 400 kinases at 10 μM; inhibits proliferation of COLO 205, HT-29, QG56, MIA PaCa-2, and C32 cells (IC50s = 0.86, 1.7, 9.5, 3.3, and 8.4 nM, respectively); reduces tumor growth in a variety of mouse xenograft models; inhibits the phosphorylation of ERK in tumor tissue in an HT-29 mouse xenograft model at 6.25 mg/kg per day; acts synergistically with everolimus to reduce tumor volume in an HCT116 mouse xenograft model

19488	RO4987655	10 mg	≥98%	A MEK inhibitor (IC50 = 5 nM); selective for MEK over 400 kinases at 10 μM; inhibits proliferation of COLO 205, HT-29, QG56, MIA PaCa-2, and C32 cells (IC50s = 0.86, 1.7, 9.5, 3.3, and 8.4 nM, respectively); reduces tumor growth in a variety of mouse xenograft models; inhibits the phosphorylation of ERK in tumor tissue in an HT-29 mouse xenograft model at 6.25 mg/kg per day; acts synergistically with everolimus to reduce tumor volume in an HCT116 mouse xenograft model
19488	RO4987655	25 mg	≥98%	A MEK inhibitor (IC50 = 5 nM); selective for MEK over 400 kinases at 10 μM; inhibits proliferation of COLO 205, HT-29, QG56, MIA PaCa-2, and C32 cells (IC50s = 0.86, 1.7, 9.5, 3.3, and 8.4 nM, respectively); reduces tumor growth in a variety of mouse xenograft models; inhibits the phosphorylation of ERK in tumor tissue in an HT-29 mouse xenograft model at 6.25 mg/kg per day; acts synergistically with everolimus to reduce tumor volume in an HCT116 mouse xenograft model
19488	RO4987655	5 mg	≥98%	A MEK inhibitor (IC50 = 5 nM); selective for MEK over 400 kinases at 10 μM; inhibits proliferation of COLO 205, HT-29, QG56, MIA PaCa-2, and C32 cells (IC50s = 0.86, 1.7, 9.5, 3.3, and 8.4 nM, respectively); reduces tumor growth in a variety of mouse xenograft models; inhibits the phosphorylation of ERK in tumor tissue in an HT-29 mouse xenograft model at 6.25 mg/kg per day; acts synergistically with everolimus to reduce tumor volume in an HCT116 mouse xenograft model
19513	VX-509	1 mg	≥98%	A selective JAK3 inhibitor (Ki = 2.5 nM; IC50 = 50-170 nM); reduces proinflammatory responses in a rat collagen-induced arthritis model and a mouse model of oxazolone-induced delayed-type hypersensitivity
19513	VX-509	10 mg	≥98%	A selective JAK3 inhibitor (Ki = 2.5 nM; IC50 = 50-170 nM); reduces proinflammatory responses in a rat collagen-induced arthritis model and a mouse model of oxazolone-induced delayed-type hypersensitivity
19513	VX-509	25 mg	≥98%	A selective JAK3 inhibitor (Ki = 2.5 nM; IC50 = 50-170 nM); reduces proinflammatory responses in a rat collagen-induced arthritis model and a mouse model of oxazolone-induced delayed-type hypersensitivity
19513	VX-509	5 mg	≥98%	A selective JAK3 inhibitor (Ki = 2.5 nM; IC50 = 50-170 nM); reduces proinflammatory responses in a rat collagen-induced arthritis model and a mouse model of oxazolone-induced delayed-type hypersensitivity
19514	INK1117	1 mg	≥98%	An inhibitor of PI3Kα that is selective for p110α in vitro (IC50 = 15 nM for p110α vs. >1 μM for other isoforms, as well as for mTOR) and in cells when used at 1 μM
19514	INK1117	10 mg	≥98%	An inhibitor of PI3Kα that is selective for p110α in vitro (IC50 = 15 nM for p110α vs. >1 μM for other isoforms, as well as for mTOR) and in cells when used at 1 μM
19514	INK1117	25 mg	≥98%	An inhibitor of PI3Kα that is selective for p110α in vitro (IC50 = 15 nM for p110α vs. >1 μM for other isoforms, as well as for mTOR) and in cells when used at 1 μM
19514	INK1117	5 mg	≥98%	An inhibitor of PI3Kα that is selective for p110α in vitro (IC50 = 15 nM for p110α vs. >1 μM for other isoforms, as well as for mTOR) and in cells when used at 1 μM
19535	Tie2 Inhibitor 7	1 mg	≥95%	Blocks Tie2 kinase activity (Ki = 1.3 μM), inhibiting angiopoietin 1-induced Tie2 autophosphorylation and downstream signaling (IC50 = 0.3 μM); prevents endothelial cell tube formation and aberrant vessel growth in a rat model of Matrigel-induced choroidal neovascularization
19535	Tie2 Inhibitor 7	5 mg	≥95%	Blocks Tie2 kinase activity (Ki = 1.3 μM), inhibiting angiopoietin 1-induced Tie2 autophosphorylation and downstream signaling (IC50 = 0.3 μM); prevents endothelial cell tube formation and aberrant vessel growth in a rat model of Matrigel-induced choroidal neovascularization
19535	Tie2 Inhibitor 7	500 µg	≥95%	Blocks Tie2 kinase activity (Ki = 1.3 μM), inhibiting angiopoietin 1-induced Tie2 autophosphorylation and downstream signaling (IC50 = 0.3 μM); prevents endothelial cell tube formation and aberrant vessel growth in a rat model of Matrigel-induced choroidal neovascularization
19555	SU 16f	1 mg	≥98%	A potent inhibitor of PDGFRβ (IC50 = 10 nM); inhibits VEGFR2 (IC50 = 140 nM); selectively inhibits PDGF- over VEFG-, FGF-, and EGF-induced cell proliferation (IC50s = 0.11, 10, 10, and 21.9 μM, respectively); accelerates downregulation of fibroblast genes and increases the yield of beating clusters in HFFs treated with 15 compounds to induce a cardiac myocyte-like phenotype
19555	SU 16f	10 mg	≥98%	A potent inhibitor of PDGFRβ (IC50 = 10 nM); inhibits VEGFR2 (IC50 = 140 nM); selectively inhibits PDGF- over VEFG-, FGF-, and EGF-induced cell proliferation (IC50s = 0.11, 10, 10, and 21.9 μM, respectively); accelerates downregulation of fibroblast genes and increases the yield of beating clusters in HFFs treated with 15 compounds to induce a cardiac myocyte-like phenotype
19555	SU 16f	5 mg	≥98%	A potent inhibitor of PDGFRβ (IC50 = 10 nM); inhibits VEGFR2 (IC50 = 140 nM); selectively inhibits PDGF- over VEFG-, FGF-, and EGF-induced cell proliferation (IC50s = 0.11, 10, 10, and 21.9 μM, respectively); accelerates downregulation of fibroblast genes and increases the yield of beating clusters in HFFs treated with 15 compounds to induce a cardiac myocyte-like phenotype

19563	Cobimetinib	1 mg	≥98%	A selective, orally available inhibitor of MEK1 (IC50 = 4.2 nM); induces differentiation and apoptosis in cancer cells lines
19563	Cobimetinib	10 mg	≥98%	A selective, orally available inhibitor of MEK1 (IC50 = 4.2 nM); induces differentiation and apoptosis in cancer cells lines
19563	Cobimetinib	25 mg	≥98%	A selective, orally available inhibitor of MEK1 (IC50 = 4.2 nM); induces differentiation and apoptosis in cancer cells lines
19563	Cobimetinib	5 mg	≥98%	A selective, orally available inhibitor of MEK1 (IC50 = 4.2 nM); induces differentiation and apoptosis in cancer cells lines
19573	MeBIO	1 mg	≥95%	A control analog of the GSK3α/β inhibitor, BIO; displays minimal activity against Cdk1/Cyclin B, GSK3α/β, and Cdk5/p25 (IC50s = 92.0, 44-100, and >100 μM, respectively); AhR agonist (EC50s = 20 and 93 nM for yeast and a hepatoma cell line, respectively)
19573	MeBIO	10 mg	≥95%	A control analog of the GSK3α/β inhibitor, BIO; displays minimal activity against Cdk1/Cyclin B, GSK3α/β, and Cdk5/p25 (IC50s = 92.0, 44-100, and >100 μM, respectively); AhR agonist (EC50s = 20 and 93 nM for yeast and a hepatoma cell line, respectively)
19573	MeBIO	5 mg	≥95%	A control analog of the GSK3α/β inhibitor, BIO; displays minimal activity against Cdk1/Cyclin B, GSK3α/β, and Cdk5/p25 (IC50s = 92.0, 44-100, and >100 μM, respectively); AhR agonist (EC50s = 20 and 93 nM for yeast and a hepatoma cell line, respectively)
19578	Vinpocetine	100 mg	≥98%	An inhibitor of PDE1 that has diverse cerebral and neurological effects in vivo; also directly inhibits IKKβ (IC50 = 17 μM in a cell-free system) and blocks TNF-α- and LPS-mediated activation of NF-κB in cells and in vivo
19578	Vinpocetine	25 mg	≥98%	An inhibitor of PDE1 that has diverse cerebral and neurological effects in vivo; also directly inhibits IKKβ (IC50 = 17 μM in a cell-free system) and blocks TNF-α- and LPS-mediated activation of NF-κB in cells and in vivo
19578	Vinpocetine	250 mg	≥98%	An inhibitor of PDE1 that has diverse cerebral and neurological effects in vivo; also directly inhibits IKKβ (IC50 = 17 μM in a cell-free system) and blocks TNF-α- and LPS-mediated activation of NF-κB in cells and in vivo
19578	Vinpocetine	50 mg	≥98%	An inhibitor of PDE1 that has diverse cerebral and neurological effects in vivo; also directly inhibits IKKβ (IC50 = 17 μM in a cell-free system) and blocks TNF-α- and LPS-mediated activation of NF-κB in cells and in vivo
19607	Viridiol	1 mg	≥95%	A fungal steroid that demonstrates phytotoxic activity and is reported to inhibit PI3K
19607	Viridiol	250 μg	≥95%	A fungal steroid that demonstrates phytotoxic activity and is reported to inhibit PI3K
19619	7BIO	10 mg	≥99%	A caspase-independent (nonapoptotic) cell death inducer; inhibits FLT3 (IC50 = 0.34 μM) and DYRK1A and DYRK2 (IC50s = 1.9 and 1.3 μM, respectively); also inhibits Aurora B and C kinases (IC50s = 4.6 and 0.7 μM, respectively)
19619	7BIO	50 mg	≥99%	A caspase-independent (nonapoptotic) cell death inducer; inhibits FLT3 (IC50 = 0.34 μM) and DYRK1A and DYRK2 (IC50s = 1.9 and 1.3 μM, respectively); also inhibits Aurora B and C kinases (IC50s = 4.6 and 0.7 μM, respectively)
19626	BLZ-945	1 mg	≥98%	A selective CSF1R inhibitor (IC50 = 1 nM) that inhibits CSF1-dependent proliferation (EC50 = 67 nM in bone marrow-derived macrophages); blocks tumor progression and significantly improves survival in glioma-bearing mice as well as in mouse models of breast and cervical cancer
19626	BLZ-945	10 mg	≥98%	A selective CSF1R inhibitor (IC50 = 1 nM) that inhibits CSF1-dependent proliferation (EC50 = 67 nM in bone marrow-derived macrophages); blocks tumor progression and significantly improves survival in glioma-bearing mice as well as in mouse models of breast and cervical cancer
19626	BLZ-945	5 mg	≥98%	A selective CSF1R inhibitor (IC50 = 1 nM) that inhibits CSF1-dependent proliferation (EC50 = 67 nM in bone marrow-derived macrophages); blocks tumor progression and significantly improves survival in glioma-bearing mice as well as in mouse models of breast and cervical cancer
19626	BLZ-945	50 mg	≥98%	A selective CSF1R inhibitor (IC50 = 1 nM) that inhibits CSF1-dependent proliferation (EC50 = 67 nM in bone marrow-derived macrophages); blocks tumor progression and significantly improves survival in glioma-bearing mice as well as in mouse models of breast and cervical cancer
19627	NPS 1034	1 mg	≥95%	A dual inhibitor of the receptor tyrosine kinase activities of MET (IC50 = 48 nM) and AXL (IC50 = 10.3 nM)
19627	NPS 1034	10 mg	≥95%	A dual inhibitor of the receptor tyrosine kinase activities of MET (IC50 = 48 nM) and AXL (IC50 = 10.3 nM)
19627	NPS 1034	25 mg	≥95%	A dual inhibitor of the receptor tyrosine kinase activities of MET (IC50 = 48 nM) and AXL (IC50 = 10.3 nM)
19627	NPS 1034	5 mg	≥95%	A dual inhibitor of the receptor tyrosine kinase activities of MET (IC50 = 48 nM) and AXL (IC50 = 10.3 nM)
19675	MLN2480	1 mg	≥98%	An orally bioavailable pan-Raf kinase inhibitor that inhibits MAP kinase pathway signaling in BRAF-mutant melanoma models
19675	MLN2480	10 mg	≥98%	An orally bioavailable pan-Raf kinase inhibitor that inhibits MAP kinase pathway signaling in BRAF-mutant melanoma models
19675	MLN2480	25 mg	≥98%	An orally bioavailable pan-Raf kinase inhibitor that inhibits MAP kinase pathway signaling in BRAF-mutant melanoma models
19675	MLN2480	5 mg	≥98%	An orally bioavailable pan-Raf kinase inhibitor that inhibits MAP kinase pathway signaling in BRAF-mutant melanoma models
19696	(S)-p38 MAPK Inhibito	1 mg	≥98%	A methylsulfanylimidazole that inhibits p38 MAP kinase (IC50 = 0.90 μM in vitro); potently blocks the release of TNF-α and IL-1β from human peripheral blood mononuclear cells (IC50s = 0.37 and 0.044 μM, respectively)

19696	(S)-p38 MAPK Inhibito	10 mg	≥98%	A methylsulfanylimidazole that inhibits p38 MAP kinase (IC50 = 0.90 µM in vitro); potently blocks the release of TNF-α and IL-1β from human peripheral blood mononuclear cells (IC50s = 0.37 and 0.044 µM, respectively)
19696	(S)-p38 MAPK Inhibito	5 mg	≥98%	A methylsulfanylimidazole that inhibits p38 MAP kinase (IC50 = 0.90 µM in vitro); potently blocks the release of TNF-α and IL-1β from human peripheral blood mononuclear cells (IC50s = 0.37 and 0.044 µM, respectively)
19696	(S)-p38 MAPK Inhibito	500 µg	≥98%	A methylsulfanylimidazole that inhibits p38 MAP kinase (IC50 = 0.90 µM in vitro); potently blocks the release of TNF-α and IL-1β from human peripheral blood mononuclear cells (IC50s = 0.37 and 0.044 µM, respectively)
19710	Tpl2 Kinase Inhibitor	1 mg	≥95%	A Tpl2 inhibitor (IC50 = 0.05 µM); selective for Tpl2 over MEK, p38 MAPK, Src, MK2, and PKC (IC50s = >40, 180, >400, 110, and >400 µM, respectively); inhibits LPS-induced TNF-α production in isolated human monocytes and whole blood (IC50s = 0.7 and 8.5 µM, respectively); enhances differentiation induced by calcitriol in HL-60 and U937 cells at 5 µM; inhibits the proliferation of KG-1a leukemia cells at 5 µM
19710	Tpl2 Kinase Inhibitor	10 mg	≥95%	A Tpl2 inhibitor (IC50 = 0.05 µM); selective for Tpl2 over MEK, p38 MAPK, Src, MK2, and PKC (IC50s = >40, 180, >400, 110, and >400 µM, respectively); inhibits LPS-induced TNF-α production in isolated human monocytes and whole blood (IC50s = 0.7 and 8.5 µM, respectively); enhances differentiation induced by calcitriol in HL-60 and U937 cells at 5 µM; inhibits the proliferation of KG-1a leukemia cells at 5 µM
19710	Tpl2 Kinase Inhibitor	25 mg	≥95%	A Tpl2 inhibitor (IC50 = 0.05 µM); selective for Tpl2 over MEK, p38 MAPK, Src, MK2, and PKC (IC50s = >40, 180, >400, 110, and >400 µM, respectively); inhibits LPS-induced TNF-α production in isolated human monocytes and whole blood (IC50s = 0.7 and 8.5 µM, respectively); enhances differentiation induced by calcitriol in HL-60 and U937 cells at 5 µM; inhibits the proliferation of KG-1a leukemia cells at 5 µM
19710	Tpl2 Kinase Inhibitor	5 mg	≥95%	A Tpl2 inhibitor (IC50 = 0.05 µM); selective for Tpl2 over MEK, p38 MAPK, Src, MK2, and PKC (IC50s = >40, 180, >400, 110, and >400 µM, respectively); inhibits LPS-induced TNF-α production in isolated human monocytes and whole blood (IC50s = 0.7 and 8.5 µM, respectively); enhances differentiation induced by calcitriol in HL-60 and U937 cells at 5 µM; inhibits the proliferation of KG-1a leukemia cells at 5 µM
19719	EAI045	1 mg	≥98%	A potent inhibitor of mutant EGFRs (IC50s = 0.076, 0.049, 0.002, and 1.6 µM for recombinant EGFRL858R, EGFRT790M, EGFRL858R/T790M, and wild-type EGFR, respectively); inhibits phosphorylation of EGFR in a concentration-dependent manner in H1975 cells; reduces proliferation of Ba/F3 cells expressing EGFRL858R/T790M and EGFRL858R/T790M/I941R from 0.01-10 µM; induces tumor regression and reduces EGFR signaling in mice bearing EGFRL858R/T790M, EGFRExon19del/T790M, and EGFRL858R/T790M/C797S tumors at 60 mg/kg/day with cetuximab
19719	EAI045	10 mg	≥98%	A potent inhibitor of mutant EGFRs (IC50s = 0.076, 0.049, 0.002, and 1.6 µM for recombinant EGFRL858R, EGFRT790M, EGFRL858R/T790M, and wild-type EGFR, respectively); inhibits phosphorylation of EGFR in a concentration-dependent manner in H1975 cells; reduces proliferation of Ba/F3 cells expressing EGFRL858R/T790M and EGFRL858R/T790M/I941R from 0.01-10 µM; induces tumor regression and reduces EGFR signaling in mice bearing EGFRL858R/T790M, EGFRExon19del/T790M, and EGFRL858R/T790M/C797S tumors at 60 mg/kg/day with cetuximab
19719	EAI045	25 mg	≥98%	A potent inhibitor of mutant EGFRs (IC50s = 0.076, 0.049, 0.002, and 1.6 µM for recombinant EGFRL858R, EGFRT790M, EGFRL858R/T790M, and wild-type EGFR, respectively); inhibits phosphorylation of EGFR in a concentration-dependent manner in H1975 cells; reduces proliferation of Ba/F3 cells expressing EGFRL858R/T790M and EGFRL858R/T790M/I941R from 0.01-10 µM; induces tumor regression and reduces EGFR signaling in mice bearing EGFRL858R/T790M, EGFRExon19del/T790M, and EGFRL858R/T790M/C797S tumors at 60 mg/kg/day with cetuximab
19719	EAI045	5 mg	≥98%	A potent inhibitor of mutant EGFRs (IC50s = 0.076, 0.049, 0.002, and 1.6 µM for recombinant EGFRL858R, EGFRT790M, EGFRL858R/T790M, and wild-type EGFR, respectively); inhibits phosphorylation of EGFR in a concentration-dependent manner in H1975 cells; reduces proliferation of Ba/F3 cells expressing EGFRL858R/T790M and EGFRL858R/T790M/I941R from 0.01-10 µM; induces tumor regression and reduces EGFR signaling in mice bearing EGFRL858R/T790M, EGFRExon19del/T790M, and EGFRL858R/T790M/C797S tumors at 60 mg/kg/day with cetuximab
19739	GSK583	10 mg	≥98%	A selective inhibitor of RIP2 kinase (IC50 = 5 nM), a central component of the innate immune system
19739	GSK583	100 mg	≥98%	A selective inhibitor of RIP2 kinase (IC50 = 5 nM), a central component of the innate immune system
19739	GSK583	25 mg	≥98%	A selective inhibitor of RIP2 kinase (IC50 = 5 nM), a central component of the innate immune system
19739	GSK583	50 mg	≥98%	A selective inhibitor of RIP2 kinase (IC50 = 5 nM), a central component of the innate immune system
19755	Petunidin (chloride)	1 mg	≥98%	An O-methylated anthocyanidin that imparts blue-red pigments to flowers, fruits, and red wine; suppresses the activity of focal adhesion kinase and the proliferation of HCT116 colon cancer cells
19755	Petunidin (chloride)	10 mg	≥98%	An O-methylated anthocyanidin that imparts blue-red pigments to flowers, fruits, and red wine; suppresses the activity of focal adhesion kinase and the proliferation of HCT116 colon cancer cells

19755	Petunidin (chloride)	25 mg	≥98%	An O-methylated anthocyanidin that imparts blue-red pigments to flowers, fruits, and red wine; suppresses the activity of focal adhesion kinase and the proliferation of HCT116 colon cancer cells
19755	Petunidin (chloride)	5 mg	≥98%	An O-methylated anthocyanidin that imparts blue-red pigments to flowers, fruits, and red wine; suppresses the activity of focal adhesion kinase and the proliferation of HCT116 colon cancer cells
19778	AP26113	1 mg	≥98%	An orally bioavailable inhibitor of ALK (IC50 < 100 nM in Ba/F3 cells); a pan-ALK inhibitor that also inhibits several ALK mutants that confer resistance to other ALK inhibitors
19778	AP26113	10 mg	≥98%	An orally bioavailable inhibitor of ALK (IC50 < 100 nM in Ba/F3 cells); a pan-ALK inhibitor that also inhibits several ALK mutants that confer resistance to other ALK inhibitors
19778	AP26113	25 mg	≥98%	An orally bioavailable inhibitor of ALK (IC50 < 100 nM in Ba/F3 cells); a pan-ALK inhibitor that also inhibits several ALK mutants that confer resistance to other ALK inhibitors
19778	AP26113	5 mg	≥98%	An orally bioavailable inhibitor of ALK (IC50 < 100 nM in Ba/F3 cells); a pan-ALK inhibitor that also inhibits several ALK mutants that confer resistance to other ALK inhibitors
19809	ETP-46464	1 mg	≥98%	An ATR inhibitor (IC50 = 25 nM) that also inhibits mTOR and DNA-PK (IC50s = 0.6 and 36 nM, respectively); generates replicative stress, leading to chromosomal breakage in the presence of conditions that stall replication forks
19809	ETP-46464	10 mg	≥98%	An ATR inhibitor (IC50 = 25 nM) that also inhibits mTOR and DNA-PK (IC50s = 0.6 and 36 nM, respectively); generates replicative stress, leading to chromosomal breakage in the presence of conditions that stall replication forks
19809	ETP-46464	5 mg	≥98%	An ATR inhibitor (IC50 = 25 nM) that also inhibits mTOR and DNA-PK (IC50s = 0.6 and 36 nM, respectively); generates replicative stress, leading to chromosomal breakage in the presence of conditions that stall replication forks
19811	NSC 109555	1 mg	≥98%	An inhibitor of Chk2 (IC50 = 200 nM in a cell-free kinase assay); selective for Chk2 over Chk1 and 16 kinases in a panel but does inhibit Brk, c-Met, IGFR, and LCK (IC50s = 210, 6,000, 7,400, and 7,100 nM, respectively); inhibits Chk2 autophosphorylation and phosphorylation of the Chk2 substrate histone H1 in vitro (IC50 = 240 nM); inhibits the growth of, and induces autophagy in, L1210 leukemia cells in vitro; potentiates gemcitabine-induced cytotoxicity in MIA PaCa-2, CFPAC-1, PANC-1, and BxPC-3 pancreatic cancer cells, as well as reduces gemcitabine-induced increases in Chk2 phosphorylation and enhances gemcitabine-induced production of ROS in MIA PaCa-2 cells at 1,250 nM
19811	NSC 109555	10 mg	≥98%	An inhibitor of Chk2 (IC50 = 200 nM in a cell-free kinase assay); selective for Chk2 over Chk1 and 16 kinases in a panel but does inhibit Brk, c-Met, IGFR, and LCK (IC50s = 210, 6,000, 7,400, and 7,100 nM, respectively); inhibits Chk2 autophosphorylation and phosphorylation of the Chk2 substrate histone H1 in vitro (IC50 = 240 nM); inhibits the growth of, and induces autophagy in, L1210 leukemia cells in vitro; potentiates gemcitabine-induced cytotoxicity in MIA PaCa-2, CFPAC-1, PANC-1, and BxPC-3 pancreatic cancer cells, as well as reduces gemcitabine-induced increases in Chk2 phosphorylation and enhances gemcitabine-induced production of ROS in MIA PaCa-2 cells at 1,250 nM
19811	NSC 109555	5 mg	≥98%	An inhibitor of Chk2 (IC50 = 200 nM in a cell-free kinase assay); selective for Chk2 over Chk1 and 16 kinases in a panel but does inhibit Brk, c-Met, IGFR, and LCK (IC50s = 210, 6,000, 7,400, and 7,100 nM, respectively); inhibits Chk2 autophosphorylation and phosphorylation of the Chk2 substrate histone H1 in vitro (IC50 = 240 nM); inhibits the growth of, and induces autophagy in, L1210 leukemia cells in vitro; potentiates gemcitabine-induced cytotoxicity in MIA PaCa-2, CFPAC-1, PANC-1, and BxPC-3 pancreatic cancer cells, as well as reduces gemcitabine-induced increases in Chk2 phosphorylation and enhances gemcitabine-induced production of ROS in MIA PaCa-2 cells at 1,250 nM
19811	NSC 109555	50 mg	≥98%	An inhibitor of Chk2 (IC50 = 200 nM in a cell-free kinase assay); selective for Chk2 over Chk1 and 16 kinases in a panel but does inhibit Brk, c-Met, IGFR, and LCK (IC50s = 210, 6,000, 7,400, and 7,100 nM, respectively); inhibits Chk2 autophosphorylation and phosphorylation of the Chk2 substrate histone H1 in vitro (IC50 = 240 nM); inhibits the growth of, and induces autophagy in, L1210 leukemia cells in vitro; potentiates gemcitabine-induced cytotoxicity in MIA PaCa-2, CFPAC-1, PANC-1, and BxPC-3 pancreatic cancer cells, as well as reduces gemcitabine-induced increases in Chk2 phosphorylation and enhances gemcitabine-induced production of ROS in MIA PaCa-2 cells at 1,250 nM
19815	HI TOPK 032	1 mg	≥95%	An inhibitor of TOPK (IC50 = ~2 µM), Chk1 (IC50 = 9.6 µM), and MEK1 (40% inhibition at 5 µM); decreases the growth of colon cancer and glioma initiating cells in vitro and suppresses tumor growth in vivo
19815	HI TOPK 032	10 mg	≥95%	An inhibitor of TOPK (IC50 = ~2 µM), Chk1 (IC50 = 9.6 µM), and MEK1 (40% inhibition at 5 µM); decreases the growth of colon cancer and glioma initiating cells in vitro and suppresses tumor growth in vivo

19815	HI TOPK 032	5 mg	≥95%	An inhibitor of TOPK (IC50 = ~2 μM), Chk1 (IC50 = 9.6 μM), and MEK1 (40% inhibition at 5 μM); decreases the growth of colon cancer and glioma initiating cells in vitro and suppresses tumor growth in vivo
19837	FIIN-2	1 mg	≥98%	An irreversible FGFR inhibitor (IC50s = 3.09, 4.3, 27, and 45.3 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively); inhibits cell proliferation of transformed Ba/F3 cell lines and demonstrates antiproliferative activity in cells dependent upon the gatekeeper mutants of FGFR1 or FGFR2
19837	FIIN-2	10 mg	≥98%	An irreversible FGFR inhibitor (IC50s = 3.09, 4.3, 27, and 45.3 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively); inhibits cell proliferation of transformed Ba/F3 cell lines and demonstrates antiproliferative activity in cells dependent upon the gatekeeper mutants of FGFR1 or FGFR2
19837	FIIN-2	25 mg	≥98%	An irreversible FGFR inhibitor (IC50s = 3.09, 4.3, 27, and 45.3 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively); inhibits cell proliferation of transformed Ba/F3 cell lines and demonstrates antiproliferative activity in cells dependent upon the gatekeeper mutants of FGFR1 or FGFR2
19837	FIIN-2	5 mg	≥98%	An irreversible FGFR inhibitor (IC50s = 3.09, 4.3, 27, and 45.3 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively); inhibits cell proliferation of transformed Ba/F3 cell lines and demonstrates antiproliferative activity in cells dependent upon the gatekeeper mutants of FGFR1 or FGFR2
19899	Acalabrutinib	1 mg	≥95%	An irreversible BTK inhibitor; dose-dependently inhibits B cell receptor signaling in primary CLL cells
19899	Acalabrutinib	10 mg	≥95%	An irreversible BTK inhibitor; dose-dependently inhibits B cell receptor signaling in primary CLL cells
19899	Acalabrutinib	25 mg	≥95%	An irreversible BTK inhibitor; dose-dependently inhibits B cell receptor signaling in primary CLL cells
19899	Acalabrutinib	5 mg	≥95%	An irreversible BTK inhibitor; dose-dependently inhibits B cell receptor signaling in primary CLL cells
19902	ON-123300	1 mg	≥98%	A multi-kinase inhibitor; inhibits ARK5, Cdk4, and Cdk6 (IC50s = 3.87, 9.82, and 4.95 nM, respectively); inhibits FYN, PDGFRβ, Abl, and PI3Kδ (IC50s = 11.09, 26, 53.32, and 144 nM, respectively) among others; inhibits proliferation in a panel of 38 cancer cell lines (GI50s = 0.05-5 μM); also inhibits proliferation of U87 glioma cells (IC50 = 3.4 μM); reduces tumor growth in an MDA-MB-231 mouse xenograft model at 50 mg/kg every other day
19902	ON-123300	10 mg	≥98%	A multi-kinase inhibitor; inhibits ARK5, Cdk4, and Cdk6 (IC50s = 3.87, 9.82, and 4.95 nM, respectively); inhibits FYN, PDGFRβ, Abl, and PI3Kδ (IC50s = 11.09, 26, 53.32, and 144 nM, respectively) among others; inhibits proliferation in a panel of 38 cancer cell lines (GI50s = 0.05-5 μM); also inhibits proliferation of U87 glioma cells (IC50 = 3.4 μM); reduces tumor growth in an MDA-MB-231 mouse xenograft model at 50 mg/kg every other day
19902	ON-123300	25 mg	≥98%	A multi-kinase inhibitor; inhibits ARK5, Cdk4, and Cdk6 (IC50s = 3.87, 9.82, and 4.95 nM, respectively); inhibits FYN, PDGFRβ, Abl, and PI3Kδ (IC50s = 11.09, 26, 53.32, and 144 nM, respectively) among others; inhibits proliferation in a panel of 38 cancer cell lines (GI50s = 0.05-5 μM); also inhibits proliferation of U87 glioma cells (IC50 = 3.4 μM); reduces tumor growth in an MDA-MB-231 mouse xenograft model at 50 mg/kg every other day
19902	ON-123300	5 mg	≥98%	A multi-kinase inhibitor; inhibits ARK5, Cdk4, and Cdk6 (IC50s = 3.87, 9.82, and 4.95 nM, respectively); inhibits FYN, PDGFRβ, Abl, and PI3Kδ (IC50s = 11.09, 26, 53.32, and 144 nM, respectively) among others; inhibits proliferation in a panel of 38 cancer cell lines (GI50s = 0.05-5 μM); also inhibits proliferation of U87 glioma cells (IC50 = 3.4 μM); reduces tumor growth in an MDA-MB-231 mouse xenograft model at 50 mg/kg every other day
19904	Uprosertib	1 mg	≥98%	A selective, orally bioavailable inhibitor of Akt (IC50s = 180, 328, and 38 nM for Akt1, Akt2, and Akt3, respectively); preferentially inhibits the proliferation of human cancer cells lines with Akt pathway activation via PI3K/PTEN mutation or loss
19904	Uprosertib	10 mg	≥98%	A selective, orally bioavailable inhibitor of Akt (IC50s = 180, 328, and 38 nM for Akt1, Akt2, and Akt3, respectively); preferentially inhibits the proliferation of human cancer cells lines with Akt pathway activation via PI3K/PTEN mutation or loss
19904	Uprosertib	25 mg	≥98%	A selective, orally bioavailable inhibitor of Akt (IC50s = 180, 328, and 38 nM for Akt1, Akt2, and Akt3, respectively); preferentially inhibits the proliferation of human cancer cells lines with Akt pathway activation via PI3K/PTEN mutation or loss
19904	Uprosertib	5 mg	≥98%	A selective, orally bioavailable inhibitor of Akt (IC50s = 180, 328, and 38 nM for Akt1, Akt2, and Akt3, respectively); preferentially inhibits the proliferation of human cancer cells lines with Akt pathway activation via PI3K/PTEN mutation or loss
19905	MRT68921	1 mg	≥98%	An inhibitor of ULK1 and ULK2 (IC50s = 2.9 and 1.1 nM, respectively); blocks autophagy in cells
19905	MRT68921	10 mg	≥98%	An inhibitor of ULK1 and ULK2 (IC50s = 2.9 and 1.1 nM, respectively); blocks autophagy in cells
19905	MRT68921	25 mg	≥98%	An inhibitor of ULK1 and ULK2 (IC50s = 2.9 and 1.1 nM, respectively); blocks autophagy in cells
19905	MRT68921	5 mg	≥98%	An inhibitor of ULK1 and ULK2 (IC50s = 2.9 and 1.1 nM, respectively); blocks autophagy in cells
19913	LJH685	1 mg	≥98%	An inhibitor of RSKs (IC50s = 6, 5, and 4 nM for RSK1, 2, and 3, respectively in vitro); blocks RSK activity in cells
19913	LJH685	10 mg	≥98%	An inhibitor of RSKs (IC50s = 6, 5, and 4 nM for RSK1, 2, and 3, respectively in vitro); blocks RSK activity in cells
19913	LJH685	25 mg	≥98%	An inhibitor of RSKs (IC50s = 6, 5, and 4 nM for RSK1, 2, and 3, respectively in vitro); blocks RSK activity in cells
19913	LJH685	5 mg	≥98%	An inhibitor of RSKs (IC50s = 6, 5, and 4 nM for RSK1, 2, and 3, respectively in vitro); blocks RSK activity in cells

19916	MRT67307 (hydrochlo	1 mg	≥95%	A kinase inhibitor that inhibits TBK1, MARK1-4, IKKε, and NUAK1 (IC50 values are 19, 27-52, 160, and 230 nM, respectively), SIKs (IC50s = 250, 67, and 430 nM for SIK1, SIK2, and SIK3, respectively) and ULK1 and ULK2 (IC50s = 45 and 38 nM, respectively)
19916	MRT67307 (hydrochlo	10 mg	≥95%	A kinase inhibitor that inhibits TBK1, MARK1-4, IKKε, and NUAK1 (IC50 values are 19, 27-52, 160, and 230 nM, respectively), SIKs (IC50s = 250, 67, and 430 nM for SIK1, SIK2, and SIK3, respectively) and ULK1 and ULK2 (IC50s = 45 and 38 nM, respectively)
19916	MRT67307 (hydrochlo	25 mg	≥95%	A kinase inhibitor that inhibits TBK1, MARK1-4, IKKε, and NUAK1 (IC50 values are 19, 27-52, 160, and 230 nM, respectively), SIKs (IC50s = 250, 67, and 430 nM for SIK1, SIK2, and SIK3, respectively) and ULK1 and ULK2 (IC50s = 45 and 38 nM, respectively)
19916	MRT67307 (hydrochlo	5 mg	≥95%	A kinase inhibitor that inhibits TBK1, MARK1-4, IKKε, and NUAK1 (IC50 values are 19, 27-52, 160, and 230 nM, respectively), SIKs (IC50s = 250, 67, and 430 nM for SIK1, SIK2, and SIK3, respectively) and ULK1 and ULK2 (IC50s = 45 and 38 nM, respectively)
19917	CC-223	1 mg	≥98%	A potent, selective inhibitor of mTOR (IC50 = 16 nM); inhibits growth and induces apoptosis in hematologic and solid tumor cell lines in vitro; inhibits multiple solid tumor xenografts in vivo
19917	CC-223	10 mg	≥98%	A potent, selective inhibitor of mTOR (IC50 = 16 nM); inhibits growth and induces apoptosis in hematologic and solid tumor cell lines in vitro; inhibits multiple solid tumor xenografts in vivo
19917	CC-223	25 mg	≥98%	A potent, selective inhibitor of mTOR (IC50 = 16 nM); inhibits growth and induces apoptosis in hematologic and solid tumor cell lines in vitro; inhibits multiple solid tumor xenografts in vivo
19917	CC-223	5 mg	≥98%	A potent, selective inhibitor of mTOR (IC50 = 16 nM); inhibits growth and induces apoptosis in hematologic and solid tumor cell lines in vitro; inhibits multiple solid tumor xenografts in vivo
19918	GNF-7	1 mg	≥98%	A multi-kinase inhibitor (IC50s = 25, 8, 61, 122, 136, and 133 nM for ACK1, GCK, Bcr-AblT315I, Bcr-AblE255V, Bcr-AblG250E, and c-Abl, respectively); inhibits the growth of Ba/F3 cells transformed with wild-type Bcr-Abl, Bcr-AblT315I, Bcr-AblE255V, and Bcr-AblG250E (IC50s = 50s = 1 and 5 nM, respectively); reduces tumor growth in a Bcr-AblT315I Ba/F3 mouse xenograft model at 10 and 20 mg/kg; reduces tumor volume in an OCI-AML3 mouse xenograft model at 8 mg/kg
19918	GNF-7	10 mg	≥98%	A multi-kinase inhibitor (IC50s = 25, 8, 61, 122, 136, and 133 nM for ACK1, GCK, Bcr-AblT315I, Bcr-AblE255V, Bcr-AblG250E, and c-Abl, respectively); inhibits the growth of Ba/F3 cells transformed with wild-type Bcr-Abl, Bcr-AblT315I, Bcr-AblE255V, and Bcr-AblG250E (IC50s = 50s = 1 and 5 nM, respectively); reduces tumor growth in a Bcr-AblT315I Ba/F3 mouse xenograft model at 10 and 20 mg/kg; reduces tumor volume in an OCI-AML3 mouse xenograft model at 8 mg/kg
19918	GNF-7	25 mg	≥98%	A multi-kinase inhibitor (IC50s = 25, 8, 61, 122, 136, and 133 nM for ACK1, GCK, Bcr-AblT315I, Bcr-AblE255V, Bcr-AblG250E, and c-Abl, respectively); inhibits the growth of Ba/F3 cells transformed with wild-type Bcr-Abl, Bcr-AblT315I, Bcr-AblE255V, and Bcr-AblG250E (IC50s = 50s = 1 and 5 nM, respectively); reduces tumor growth in a Bcr-AblT315I Ba/F3 mouse xenograft model at 10 and 20 mg/kg; reduces tumor volume in an OCI-AML3 mouse xenograft model at 8 mg/kg
19918	GNF-7	5 mg	≥98%	A multi-kinase inhibitor (IC50s = 25, 8, 61, 122, 136, and 133 nM for ACK1, GCK, Bcr-AblT315I, Bcr-AblE255V, Bcr-AblG250E, and c-Abl, respectively); inhibits the growth of Ba/F3 cells transformed with wild-type Bcr-Abl, Bcr-AblT315I, Bcr-AblE255V, and Bcr-AblG250E (IC50s = 50s = 1 and 5 nM, respectively); reduces tumor growth in a Bcr-AblT315I Ba/F3 mouse xenograft model at 10 and 20 mg/kg; reduces tumor volume in an OCI-AML3 mouse xenograft model at 8 mg/kg
19923	Radotinib	1 mg	≥98%	A selective second generation Bcr-Abl tyrosine kinase inhibitor (IC50 = 30.6 nM); targets PDGFRα and β (IC50s = 75.5 and 130 nM, respectively); reduces viability and promotes differentiation in human acute myeloid leukemia cells
19923	Radotinib	10 mg	≥98%	A selective second generation Bcr-Abl tyrosine kinase inhibitor (IC50 = 30.6 nM); targets PDGFRα and β (IC50s = 75.5 and 130 nM, respectively); reduces viability and promotes differentiation in human acute myeloid leukemia cells
19923	Radotinib	25 mg	≥98%	A selective second generation Bcr-Abl tyrosine kinase inhibitor (IC50 = 30.6 nM); targets PDGFRα and β (IC50s = 75.5 and 130 nM, respectively); reduces viability and promotes differentiation in human acute myeloid leukemia cells
19923	Radotinib	5 mg	≥98%	A selective second generation Bcr-Abl tyrosine kinase inhibitor (IC50 = 30.6 nM); targets PDGFRα and β (IC50s = 75.5 and 130 nM, respectively); reduces viability and promotes differentiation in human acute myeloid leukemia cells
19924	LJI308	1 mg	≥98%	A selective and potent inhibitor of RSKs (IC50 = 4-13 nM for RSK isoforms 1-3); reduces phosphorylation of YB1 in MDA-MB-231 cells bearing activating mutations in the MAPK signaling pathway (EC50 = 0.21 μM); reduces H358 growth in soft agar and colony forming assays.

19924	LJI308	10 mg	≥98%	A selective and potent inhibitor of RSKs (IC50 = 4-13 nM for RSK isoforms 1-3); reduces phosphorylation of YB1 in MDA-MB-231 cells bearing activating mutations in the MAPK signaling pathway (EC50 = 0.21 μM); reduces H358 growth in soft agar and colony forming assays.
19924	LJI308	25 mg	≥98%	A selective and potent inhibitor of RSKs (IC50 = 4-13 nM for RSK isoforms 1-3); reduces phosphorylation of YB1 in MDA-MB-231 cells bearing activating mutations in the MAPK signaling pathway (EC50 = 0.21 μM); reduces H358 growth in soft agar and colony forming assays.
19924	LJI308	5 mg	≥98%	A selective and potent inhibitor of RSKs (IC50 = 4-13 nM for RSK isoforms 1-3); reduces phosphorylation of YB1 in MDA-MB-231 cells bearing activating mutations in the MAPK signaling pathway (EC50 = 0.21 μM); reduces H358 growth in soft agar and colony forming assays.
19931	AZD 3759	1 mg	≥98%	A brain penetrant inhibitor of EGFR (IC50s = 0.3, 0.2, and 0.2 nM for wild-type, L858R-mutant, and exon 19 deletion-containing EGFRs, respectively); selective for EGFR over 115 other kinases, exhibiting 50s = 7.7 and 7.0 nM, respectively) but has no effect on H838 cells that express wild-type EGFR (GI50 = 21,556 nM); inhibits tumor growth by 78% and induces tumor regression at doses of 7.5 and 15 mg/kg, p.o., respectively in a PC-9 mouse model of NSCLC brain metastasis
19931	AZD 3759	10 mg	≥98%	A brain penetrant inhibitor of EGFR (IC50s = 0.3, 0.2, and 0.2 nM for wild-type, L858R-mutant, and exon 19 deletion-containing EGFRs, respectively); selective for EGFR over 115 other kinases, exhibiting 50s = 7.7 and 7.0 nM, respectively) but has no effect on H838 cells that express wild-type EGFR (GI50 = 21,556 nM); inhibits tumor growth by 78% and induces tumor regression at doses of 7.5 and 15 mg/kg, p.o., respectively in a PC-9 mouse model of NSCLC brain metastasis
19931	AZD 3759	25 mg	≥98%	A brain penetrant inhibitor of EGFR (IC50s = 0.3, 0.2, and 0.2 nM for wild-type, L858R-mutant, and exon 19 deletion-containing EGFRs, respectively); selective for EGFR over 115 other kinases, exhibiting 50s = 7.7 and 7.0 nM, respectively) but has no effect on H838 cells that express wild-type EGFR (GI50 = 21,556 nM); inhibits tumor growth by 78% and induces tumor regression at doses of 7.5 and 15 mg/kg, p.o., respectively in a PC-9 mouse model of NSCLC brain metastasis
19931	AZD 3759	5 mg	≥98%	A brain penetrant inhibitor of EGFR (IC50s = 0.3, 0.2, and 0.2 nM for wild-type, L858R-mutant, and exon 19 deletion-containing EGFRs, respectively); selective for EGFR over 115 other kinases, exhibiting 50s = 7.7 and 7.0 nM, respectively) but has no effect on H838 cells that express wild-type EGFR (GI50 = 21,556 nM); inhibits tumor growth by 78% and induces tumor regression at doses of 7.5 and 15 mg/kg, p.o., respectively in a PC-9 mouse model of NSCLC brain metastasis
19932	TCS ERK 11e	1 mg	≥98%	A selective inhibitor of ERK2 (Ki 50 = 48 nM)
19932	TCS ERK 11e	10 mg	≥98%	A selective inhibitor of ERK2 (Ki 50 = 48 nM)
19932	TCS ERK 11e	25 mg	≥98%	A selective inhibitor of ERK2 (Ki 50 = 48 nM)
19932	TCS ERK 11e	5 mg	≥98%	A selective inhibitor of ERK2 (Ki 50 = 48 nM)
19955	CAY10717	1 mg	≥95%	A multi-targeted kinase inhibitor; exhibits greater than 40% inhibition of 34 of 104 kinases in an enzymatic assay at a concentration of 100 nM; has activity at multiple oncogenic kinases (IC50 values less than 50 nM); highly cytotoxic against a cancer cell panel that includes chemotherapy-sensitive and -resistant cell lines (EC50s = 0.4-158 nM); inhibits the growth of HUVECs (EC50 = 34 nM)
19955	CAY10717	10 mg	≥95%	A multi-targeted kinase inhibitor; exhibits greater than 40% inhibition of 34 of 104 kinases in an enzymatic assay at a concentration of 100 nM; has activity at multiple oncogenic kinases (IC50 values less than 50 nM); highly cytotoxic against a cancer cell panel that includes chemotherapy-sensitive and -resistant cell lines (EC50s = 0.4-158 nM); inhibits the growth of HUVECs (EC50 = 34 nM)
19955	CAY10717	25 mg	≥95%	A multi-targeted kinase inhibitor; exhibits greater than 40% inhibition of 34 of 104 kinases in an enzymatic assay at a concentration of 100 nM; has activity at multiple oncogenic kinases (IC50 values less than 50 nM); highly cytotoxic against a cancer cell panel that includes chemotherapy-sensitive and -resistant cell lines (EC50s = 0.4-158 nM); inhibits the growth of HUVECs (EC50 = 34 nM)
19955	CAY10717	5 mg	≥95%	A multi-targeted kinase inhibitor; exhibits greater than 40% inhibition of 34 of 104 kinases in an enzymatic assay at a concentration of 100 nM; has activity at multiple oncogenic kinases (IC50 values less than 50 nM); highly cytotoxic against a cancer cell panel that includes chemotherapy-sensitive and -resistant cell lines (EC50s = 0.4-158 nM); inhibits the growth of HUVECs (EC50 = 34 nM)
19959	eCF506	1 mg	≥98%	An inhibitor of Src kinases (IC50s = 50 = 479 nM), as well as KIT, mTOR, PDGFRα, and RET (IC50s = >100 μM for all); completely inhibits Src and FAK phosphorylation at 100 nM; inhibits proliferation of MCF-7 cells (EC50 = 9 nM); reduces levels of activated Src kinase in tumor tissue in an HCT116 mouse xenograft model at 50 mg/kg per day

19959	eCF506	10 mg	≥98%	An inhibitor of Src kinases (IC50s = 50 = 479 nM), as well as KIT, mTOR, PDGFRα, and RET (IC50s = >100 μM for all); completely inhibits Src and FAK phosphorylation at 100 nM; inhibits proliferation of MCF-7 cells (EC50 = 9 nM); reduces levels of activated Src kinase in tumor tissue in an HCT116 mouse xenograft model at 50 mg/kg per day
19959	eCF506	25 mg	≥98%	An inhibitor of Src kinases (IC50s = 50 = 479 nM), as well as KIT, mTOR, PDGFRα, and RET (IC50s = >100 μM for all); completely inhibits Src and FAK phosphorylation at 100 nM; inhibits proliferation of MCF-7 cells (EC50 = 9 nM); reduces levels of activated Src kinase in tumor tissue in an HCT116 mouse xenograft model at 50 mg/kg per day
19959	eCF506	5 mg	≥98%	An inhibitor of Src kinases (IC50s = 50 = 479 nM), as well as KIT, mTOR, PDGFRα, and RET (IC50s = >100 μM for all); completely inhibits Src and FAK phosphorylation at 100 nM; inhibits proliferation of MCF-7 cells (EC50 = 9 nM); reduces levels of activated Src kinase in tumor tissue in an HCT116 mouse xenograft model at 50 mg/kg per day
19964	NVS-PAK1-1	10 mg	≥98%	An allosteric inhibitor of PAK1 (Kd = 7 nM); has an IC50 value of 5.2 nM in a PAK1 dephosphorylation assay; selective for PAK1 over PAK2 (Kd = 400 nM) and over a panel of 442 kinases; inhibits phosphorylation of MEK Ser289 at 6-20 μM but does not inhibit proliferation of Su86.86 cells at concentrations lower than 2 μM
19964	NVS-PAK1-1	25 mg	≥98%	An allosteric inhibitor of PAK1 (Kd = 7 nM); has an IC50 value of 5.2 nM in a PAK1 dephosphorylation assay; selective for PAK1 over PAK2 (Kd = 400 nM) and over a panel of 442 kinases; inhibits phosphorylation of MEK Ser289 at 6-20 μM but does not inhibit proliferation of Su86.86 cells at concentrations lower than 2 μM
19964	NVS-PAK1-1	5 mg	≥98%	An allosteric inhibitor of PAK1 (Kd = 7 nM); has an IC50 value of 5.2 nM in a PAK1 dephosphorylation assay; selective for PAK1 over PAK2 (Kd = 400 nM) and over a panel of 442 kinases; inhibits phosphorylation of MEK Ser289 at 6-20 μM but does not inhibit proliferation of Su86.86 cells at concentrations lower than 2 μM
19965	NVS-PAK1-C	1 mg	≥98%	A negative control for NVS-PAK1-1
19965	NVS-PAK1-C	5 mg	≥98%	A negative control for NVS-PAK1-1
19991	AZ 3146	10 mg	≥98%	A selective Mps1 inhibitor (IC50 = 35 nM); inhibits the recruitment of Mad1, Mad2, and CENP-E to kinetochores
19991	AZ 3146	25 mg	≥98%	A selective Mps1 inhibitor (IC50 = 35 nM); inhibits the recruitment of Mad1, Mad2, and CENP-E to kinetochores
19991	AZ 3146	5 mg	≥98%	A selective Mps1 inhibitor (IC50 = 35 nM); inhibits the recruitment of Mad1, Mad2, and CENP-E to kinetochores
19991	AZ 3146	50 mg	≥98%	A selective Mps1 inhibitor (IC50 = 35 nM); inhibits the recruitment of Mad1, Mad2, and CENP-E to kinetochores
20049	HG-10-102-01	1 mg	≥98%	An inhibitor of LRRK2 (IC50 = 20.3 nM); also inhibits G2019S, A2016T, and [G2019S+A2016T] mutants of LRRK2 (IC50s = 3.2, 153, and 95.9 nM, respectively); brain penetrant and inhibits Ser910 and Ser935 phosphorylation of both wild-type and G2019S mutant LRRK2
20049	HG-10-102-01	10 mg	≥98%	An inhibitor of LRRK2 (IC50 = 20.3 nM); also inhibits G2019S, A2016T, and [G2019S+A2016T] mutants of LRRK2 (IC50s = 3.2, 153, and 95.9 nM, respectively); brain penetrant and inhibits Ser910 and Ser935 phosphorylation of both wild-type and G2019S mutant LRRK2
20049	HG-10-102-01	25 mg	≥98%	An inhibitor of LRRK2 (IC50 = 20.3 nM); also inhibits G2019S, A2016T, and [G2019S+A2016T] mutants of LRRK2 (IC50s = 3.2, 153, and 95.9 nM, respectively); brain penetrant and inhibits Ser910 and Ser935 phosphorylation of both wild-type and G2019S mutant LRRK2
20049	HG-10-102-01	5 mg	≥98%	An inhibitor of LRRK2 (IC50 = 20.3 nM); also inhibits G2019S, A2016T, and [G2019S+A2016T] mutants of LRRK2 (IC50s = 3.2, 153, and 95.9 nM, respectively); brain penetrant and inhibits Ser910 and Ser935 phosphorylation of both wild-type and G2019S mutant LRRK2
20056	INCB 28060	10 mg	≥98%	An inhibitor of HGFR potently blocking in vitro kinase activity (IC50 = 0.13 nM) as well as constitutive or HGF-stimulated activity in cells (IC50 values range from 0.3 to 1.1 nM); orally bioavailable, inhibiting the growth of HGFR-dependent tumors in mice
20056	INCB 28060	5 mg	≥98%	An inhibitor of HGFR potently blocking in vitro kinase activity (IC50 = 0.13 nM) as well as constitutive or HGF-stimulated activity in cells (IC50 values range from 0.3 to 1.1 nM); orally bioavailable, inhibiting the growth of HGFR-dependent tumors in mice
20056	INCB 28060	50 mg	≥98%	An inhibitor of HGFR potently blocking in vitro kinase activity (IC50 = 0.13 nM) as well as constitutive or HGF-stimulated activity in cells (IC50 values range from 0.3 to 1.1 nM); orally bioavailable, inhibiting the growth of HGFR-dependent tumors in mice
20076	Cerdulatinib	10 mg	≥98%	A dual inhibitor of Syk and JAK (IC50s = 32, 12, 6, 8, and 0.5 nM for Syk, JAK1, JAK2, JAK3, and TYK2, respectively); exhibits nanomolar inhibition of other kinases; inhibits JAK1/3-mediated STAT phosphorylation with IC50 values ranging from 0.16 to 1 μM; antitumor activity with IC50 values ranging from 0.05 to 2.1 μM against DLBCL tumor cell lines

20076	Cerdulatinib	25 mg	≥98%	A dual inhibitor of Syk and JAK (IC50s = 32, 12, 6, 8, and 0.5 nM for Syk, JAK1, JAK2, JAK3, and TYK2, respectively); exhibits nanomolar inhibition of other kinases; inhibits JAK1/3-mediated STAT phosphorylation with IC50 values ranging from 0.16 to 1 μM; antitumor activity with IC50 values ranging from 0.05 to 2.1 μM against DLBCL tumor cell lines
20076	Cerdulatinib	5 mg	≥98%	A dual inhibitor of Syk and JAK (IC50s = 32, 12, 6, 8, and 0.5 nM for Syk, JAK1, JAK2, JAK3, and TYK2, respectively); exhibits nanomolar inhibition of other kinases; inhibits JAK1/3-mediated STAT phosphorylation with IC50 values ranging from 0.16 to 1 μM; antitumor activity with IC50 values ranging from 0.05 to 2.1 μM against DLBCL tumor cell lines
20076	Cerdulatinib	50 mg	≥98%	A dual inhibitor of Syk and JAK (IC50s = 32, 12, 6, 8, and 0.5 nM for Syk, JAK1, JAK2, JAK3, and TYK2, respectively); exhibits nanomolar inhibition of other kinases; inhibits JAK1/3-mediated STAT phosphorylation with IC50 values ranging from 0.16 to 1 μM; antitumor activity with IC50 values ranging from 0.05 to 2.1 μM against DLBCL tumor cell lines
20097	MGCD-265	1 mg	≥98%	A c-Met and VEGFR2 inhibitor (IC50s = 0.029 and 0.01 μM, respectively); selective for c-Met and VEGFR2 over Chk1, EGFR, GSK3β, IGF-1R, IKKβ, JAK2, and JNK1 at 0.1 μM; inhibits VEGFR1, VEGFR3, Ron, Tie2, FLT3, c-Kit, Abl, and TrkA by 80-100% at 0.1 μM; binds to Smo in HEK293T cell membranes expressing the human receptor (Ki = 0.0417 μM for the wild-type receptor); inhibits Gli1-mediated transcription in a reporter assay in gefitinib-resistant HCC827 cells; inhibits HGF-induced migration of A549 cells and VEGF-induced proliferation of HUVECs (IC50s = 2 and 0.025 μM, respectively); reduces tumor growth in several mouse xenograft models, including prostate, colorectal, and gastric cancer models at 20 mg/kg
20097	MGCD-265	10 mg	≥98%	A c-Met and VEGFR2 inhibitor (IC50s = 0.029 and 0.01 μM, respectively); selective for c-Met and VEGFR2 over Chk1, EGFR, GSK3β, IGF-1R, IKKβ, JAK2, and JNK1 at 0.1 μM; inhibits VEGFR1, VEGFR3, Ron, Tie2, FLT3, c-Kit, Abl, and TrkA by 80-100% at 0.1 μM; binds to Smo in HEK293T cell membranes expressing the human receptor (Ki = 0.0417 μM for the wild-type receptor); inhibits Gli1-mediated transcription in a reporter assay in gefitinib-resistant HCC827 cells; inhibits HGF-induced migration of A549 cells and VEGF-induced proliferation of HUVECs (IC50s = 2 and 0.025 μM, respectively); reduces tumor growth in several mouse xenograft models, including prostate, colorectal, and gastric cancer models at 20 mg/kg
20097	MGCD-265	5 mg	≥98%	A c-Met and VEGFR2 inhibitor (IC50s = 0.029 and 0.01 μM, respectively); selective for c-Met and VEGFR2 over Chk1, EGFR, GSK3β, IGF-1R, IKKβ, JAK2, and JNK1 at 0.1 μM; inhibits VEGFR1, VEGFR3, Ron, Tie2, FLT3, c-Kit, Abl, and TrkA by 80-100% at 0.1 μM; binds to Smo in HEK293T cell membranes expressing the human receptor (Ki = 0.0417 μM for the wild-type receptor); inhibits Gli1-mediated transcription in a reporter assay in gefitinib-resistant HCC827 cells; inhibits HGF-induced migration of A549 cells and VEGF-induced proliferation of HUVECs (IC50s = 2 and 0.025 μM, respectively); reduces tumor growth in several mouse xenograft models, including prostate, colorectal, and gastric cancer models at 20 mg/kg
20097	MGCD-265	50 mg	≥98%	A c-Met and VEGFR2 inhibitor (IC50s = 0.029 and 0.01 μM, respectively); selective for c-Met and VEGFR2 over Chk1, EGFR, GSK3β, IGF-1R, IKKβ, JAK2, and JNK1 at 0.1 μM; inhibits VEGFR1, VEGFR3, Ron, Tie2, FLT3, c-Kit, Abl, and TrkA by 80-100% at 0.1 μM; binds to Smo in HEK293T cell membranes expressing the human receptor (Ki = 0.0417 μM for the wild-type receptor); inhibits Gli1-mediated transcription in a reporter assay in gefitinib-resistant HCC827 cells; inhibits HGF-induced migration of A549 cells and VEGF-induced proliferation of HUVECs (IC50s = 2 and 0.025 μM, respectively); reduces tumor growth in several mouse xenograft models, including prostate, colorectal, and gastric cancer models at 20 mg/kg
20111	SGI-7079	1 mg	≥98%	An Axl kinase inhibitor; inhibits proliferation of inflammatory breast cancer cells (IC50s = 0.43 and 0.15 μM for SUM149 and KPL-4 cells, respectively); synergistically increases the potency of erlotinib on EGFR inhibition; dose-dependently inhibits tumor growth in a mouse xenograft model of non-small cell lung cancer
20111	SGI-7079	10 mg	≥98%	An Axl kinase inhibitor; inhibits proliferation of inflammatory breast cancer cells (IC50s = 0.43 and 0.15 μM for SUM149 and KPL-4 cells, respectively); synergistically increases the potency of erlotinib on EGFR inhibition; dose-dependently inhibits tumor growth in a mouse xenograft model of non-small cell lung cancer
20111	SGI-7079	25 mg	≥98%	An Axl kinase inhibitor; inhibits proliferation of inflammatory breast cancer cells (IC50s = 0.43 and 0.15 μM for SUM149 and KPL-4 cells, respectively); synergistically increases the potency of erlotinib on EGFR inhibition; dose-dependently inhibits tumor growth in a mouse xenograft model of non-small cell lung cancer
20111	SGI-7079	5 mg	≥98%	An Axl kinase inhibitor; inhibits proliferation of inflammatory breast cancer cells (IC50s = 0.43 and 0.15 μM for SUM149 and KPL-4 cells, respectively); synergistically increases the potency of erlotinib on EGFR inhibition; dose-dependently inhibits tumor growth in a mouse xenograft model of non-small cell lung cancer

20116	ML-281	1 mg	≥98%	An inhibitor of STK33 (IC50 = 14 nM); has 700- and 550-fold selectivity for STK33 over PKA and Aurora B kinase, respectively; selective over 81 other kinases in a panel at a concentration of 1 μM; inhibits FLT3 and VEGFR2/KDR by greater than 25% at a concentration of 1 μM; does not decrease viability of KRAS-dependent or KRAS-independent cell lines
20116	ML-281	10 mg	≥98%	An inhibitor of STK33 (IC50 = 14 nM); has 700- and 550-fold selectivity for STK33 over PKA and Aurora B kinase, respectively; selective over 81 other kinases in a panel at a concentration of 1 μM; inhibits FLT3 and VEGFR2/KDR by greater than 25% at a concentration of 1 μM; does not decrease viability of KRAS-dependent or KRAS-independent cell lines
20116	ML-281	25 mg	≥98%	An inhibitor of STK33 (IC50 = 14 nM); has 700- and 550-fold selectivity for STK33 over PKA and Aurora B kinase, respectively; selective over 81 other kinases in a panel at a concentration of 1 μM; inhibits FLT3 and VEGFR2/KDR by greater than 25% at a concentration of 1 μM; does not decrease viability of KRAS-dependent or KRAS-independent cell lines
20116	ML-281	5 mg	≥98%	An inhibitor of STK33 (IC50 = 14 nM); has 700- and 550-fold selectivity for STK33 over PKA and Aurora B kinase, respectively; selective over 81 other kinases in a panel at a concentration of 1 μM; inhibits FLT3 and VEGFR2/KDR by greater than 25% at a concentration of 1 μM; does not decrease viability of KRAS-dependent or KRAS-independent cell lines
20212	NPC-15437 (hydrochl	1 mg	≥95%	A selective PKC inhibitor (IC50 = 19 μM); inhibits phorbol ester- (Ki = 5 μM) and phosphatidylserine-induced (Ki = 12 μM) PKC activity but does not affect the activity of cAMP-dependent or Ca2+/calmodulin-dependent protein kinases
20212	NPC-15437 (hydrochl	5 mg	≥95%	A selective PKC inhibitor (IC50 = 19 μM); inhibits phorbol ester- (Ki = 5 μM) and phosphatidylserine-induced (Ki = 12 μM) PKC activity but does not affect the activity of cAMP-dependent or Ca2+/calmodulin-dependent protein kinases
20212	NPC-15437 (hydrochl	500 μg	≥95%	A selective PKC inhibitor (IC50 = 19 μM); inhibits phorbol ester- (Ki = 5 μM) and phosphatidylserine-induced (Ki = 12 μM) PKC activity but does not affect the activity of cAMP-dependent or Ca2+/calmodulin-dependent protein kinases
20213	SU 4312	1 mg	≥98%	A selective inhibitor of VEGFR2 and PDGFR tyrosine kinases (IC50s = 0.8 and 19.4 μM, respectively); inhibits VEGF-dependent angiogenesis in a zebrafish assay (IC50 = 1.8 μM) without affecting normal cells; neuroprotective
20213	SU 4312	10 mg	≥98%	A selective inhibitor of VEGFR2 and PDGFR tyrosine kinases (IC50s = 0.8 and 19.4 μM, respectively); inhibits VEGF-dependent angiogenesis in a zebrafish assay (IC50 = 1.8 μM) without affecting normal cells; neuroprotective
20213	SU 4312	25 mg	≥98%	A selective inhibitor of VEGFR2 and PDGFR tyrosine kinases (IC50s = 0.8 and 19.4 μM, respectively); inhibits VEGF-dependent angiogenesis in a zebrafish assay (IC50 = 1.8 μM) without affecting normal cells; neuroprotective
20213	SU 4312	5 mg	≥98%	A selective inhibitor of VEGFR2 and PDGFR tyrosine kinases (IC50s = 0.8 and 19.4 μM, respectively); inhibits VEGF-dependent angiogenesis in a zebrafish assay (IC50 = 1.8 μM) without affecting normal cells; neuroprotective
20214	BRD7389	1 mg	≥95%	An inhibitor of RSKs (IC50s = 1.5, 2.4, and 1.2 μM for RSK1, RSK2, and RSK3, respectively); causes mouse αTC1 pancreatic α cells to adopt several morphological and gene expression features of β cells, including increased insulin expression
20214	BRD7389	10 mg	≥95%	An inhibitor of RSKs (IC50s = 1.5, 2.4, and 1.2 μM for RSK1, RSK2, and RSK3, respectively); causes mouse αTC1 pancreatic α cells to adopt several morphological and gene expression features of β cells, including increased insulin expression
20214	BRD7389	5 mg	≥95%	An inhibitor of RSKs (IC50s = 1.5, 2.4, and 1.2 μM for RSK1, RSK2, and RSK3, respectively); causes mouse αTC1 pancreatic α cells to adopt several morphological and gene expression features of β cells, including increased insulin expression
20215	SR 3576	1 mg	≥98%	A JNK3 inhibitor (IC50 = 7 nM); selective for JNK3 over JNK1 and p38 MAP kinase (IC50s = 0.17 and >20 μM, respectively); inhibits c-Jun phosphorylation in INS-1 cells (IC50 = 1.3 μM)
20215	SR 3576	5 mg	≥98%	A JNK3 inhibitor (IC50 = 7 nM); selective for JNK3 over JNK1 and p38 MAP kinase (IC50s = 0.17 and >20 μM, respectively); inhibits c-Jun phosphorylation in INS-1 cells (IC50 = 1.3 μM)
20221	UCN-02	1 mg	≥95%	A PKC inhibitor (IC50 = 62 nM) that is cytotoxic to the growth of HeLa S3 cells
20221	UCN-02	5 mg	≥95%	A PKC inhibitor (IC50 = 62 nM) that is cytotoxic to the growth of HeLa S3 cells
20235	AZD 1208	1 mg	≥98%	A potent, selective, and orally available inhibitor of Pim kinase (IC50s = 0.4, 5.0, and 1.9 nM for Pim-1, Pim-2, and Pim-3, respectively); causes cell cycle arrest and apoptosis in MOLM-16 cells and inhibits the growth of MOLM-16 xenograft tumors in mice
20235	AZD 1208	10 mg	≥98%	A potent, selective, and orally available inhibitor of Pim kinase (IC50s = 0.4, 5.0, and 1.9 nM for Pim-1, Pim-2, and Pim-3, respectively); causes cell cycle arrest and apoptosis in MOLM-16 cells and inhibits the growth of MOLM-16 xenograft tumors in mice

20235	AZD 1208	25 mg	≥98%	A potent, selective, and orally available inhibitor of Pim kinase (IC50s = 0.4, 5.0, and 1.9 nM for Pim-1, Pim-2, and Pim-3, respectively); causes cell cycle arrest and apoptosis in MOLM-16 cells and inhibits the growth of MOLM-16 xenograft tumors in mice
20235	AZD 1208	5 mg	≥98%	A potent, selective, and orally available inhibitor of Pim kinase (IC50s = 0.4, 5.0, and 1.9 nM for Pim-1, Pim-2, and Pim-3, respectively); causes cell cycle arrest and apoptosis in MOLM-16 cells and inhibits the growth of MOLM-16 xenograft tumors in mice
20237	XL388	10 mg	≥98%	An orally bioavailable and ATP-competitive inhibitor of mTOR (IC50 = 9.9 nM); selective for mTOR over a panel of more than 140 kinases, including various PI3Ks (IC50s = >3,000 nM); inhibits mTORC1 and mTORC2 in vitro (IC50s = 8 and 166 nM, respectively); induces cytotoxicity in MG-63, U2OS, and Saos-2 osteosarcoma and 786-0 kidney cancer cells and increases apoptosis in 786-0 and MG-63 cells; induces cell cycle arrest at the G1 phase and increases autophagy in MG-63 cells; reduces tumor growth in an MCF-7 breast cancer mouse xenograft model at 50 and 100 mg/kg; inhibits phosphorylation of mTORC1 and mTORC2 substrates p70S6K, S6, 4E-BP1, and Akt in MCF-7 and PC-3 xenograft tumors at 100 mg/kg; reduces tumor growth in U2OS and 786-0 mouse xenograft models at 20 mg/kg
20237	XL388	25 mg	≥98%	An orally bioavailable and ATP-competitive inhibitor of mTOR (IC50 = 9.9 nM); selective for mTOR over a panel of more than 140 kinases, including various PI3Ks (IC50s = >3,000 nM); inhibits mTORC1 and mTORC2 in vitro (IC50s = 8 and 166 nM, respectively); induces cytotoxicity in MG-63, U2OS, and Saos-2 osteosarcoma and 786-0 kidney cancer cells and increases apoptosis in 786-0 and MG-63 cells; induces cell cycle arrest at the G1 phase and increases autophagy in MG-63 cells; reduces tumor growth in an MCF-7 breast cancer mouse xenograft model at 50 and 100 mg/kg; inhibits phosphorylation of mTORC1 and mTORC2 substrates p70S6K, S6, 4E-BP1, and Akt in MCF-7 and PC-3 xenograft tumors at 100 mg/kg; reduces tumor growth in U2OS and 786-0 mouse xenograft models at 20 mg/kg
20237	XL388	5 mg	≥98%	An orally bioavailable and ATP-competitive inhibitor of mTOR (IC50 = 9.9 nM); selective for mTOR over a panel of more than 140 kinases, including various PI3Ks (IC50s = >3,000 nM); inhibits mTORC1 and mTORC2 in vitro (IC50s = 8 and 166 nM, respectively); induces cytotoxicity in MG-63, U2OS, and Saos-2 osteosarcoma and 786-0 kidney cancer cells and increases apoptosis in 786-0 and MG-63 cells; induces cell cycle arrest at the G1 phase and increases autophagy in MG-63 cells; reduces tumor growth in an MCF-7 breast cancer mouse xenograft model at 50 and 100 mg/kg; inhibits phosphorylation of mTORC1 and mTORC2 substrates p70S6K, S6, 4E-BP1, and Akt in MCF-7 and PC-3 xenograft tumors at 100 mg/kg; reduces tumor growth in U2OS and 786-0 mouse xenograft models at 20 mg/kg
20237	XL388	50 mg	≥98%	An orally bioavailable and ATP-competitive inhibitor of mTOR (IC50 = 9.9 nM); selective for mTOR over a panel of more than 140 kinases, including various PI3Ks (IC50s = >3,000 nM); inhibits mTORC1 and mTORC2 in vitro (IC50s = 8 and 166 nM, respectively); induces cytotoxicity in MG-63, U2OS, and Saos-2 osteosarcoma and 786-0 kidney cancer cells and increases apoptosis in 786-0 and MG-63 cells; induces cell cycle arrest at the G1 phase and increases autophagy in MG-63 cells; reduces tumor growth in an MCF-7 breast cancer mouse xenograft model at 50 and 100 mg/kg; inhibits phosphorylation of mTORC1 and mTORC2 substrates p70S6K, S6, 4E-BP1, and Akt in MCF-7 and PC-3 xenograft tumors at 100 mg/kg; reduces tumor growth in U2OS and 786-0 mouse xenograft models at 20 mg/kg
20244	PH-797804	1 mg	≥98%	A selective p38α MAPK inhibitor (IC50 = 26 nM in a cell-free assay); demonstrates anti-inflammatory activity in chronic disease models
20244	PH-797804	10 mg	≥98%	A selective p38α MAPK inhibitor (IC50 = 26 nM in a cell-free assay); demonstrates anti-inflammatory activity in chronic disease models
20244	PH-797804	25 mg	≥98%	A selective p38α MAPK inhibitor (IC50 = 26 nM in a cell-free assay); demonstrates anti-inflammatory activity in chronic disease models
20244	PH-797804	5 mg	≥98%	A selective p38α MAPK inhibitor (IC50 = 26 nM in a cell-free assay); demonstrates anti-inflammatory activity in chronic disease models
20308	GSK481	1 mg	≥98%	A selective inhibitor of RIP1 that blocks autophosphorylation of Ser166 on wild-type human RIP1 with an IC50 value of 2.8 nM; inhibits RIP1 from human and cynomolgus monkey but is at least 100-fold less potent against non-primate RIP1
20308	GSK481	10 mg	≥98%	A selective inhibitor of RIP1 that blocks autophosphorylation of Ser166 on wild-type human RIP1 with an IC50 value of 2.8 nM; inhibits RIP1 from human and cynomolgus monkey but is at least 100-fold less potent against non-primate RIP1
20308	GSK481	25 mg	≥98%	A selective inhibitor of RIP1 that blocks autophosphorylation of Ser166 on wild-type human RIP1 with an IC50 value of 2.8 nM; inhibits RIP1 from human and cynomolgus monkey but is at least 100-fold less potent against non-primate RIP1
20308	GSK481	5 mg	≥98%	A selective inhibitor of RIP1 that blocks autophosphorylation of Ser166 on wild-type human RIP1 with an IC50 value of 2.8 nM; inhibits RIP1 from human and cynomolgus monkey but is at least 100-fold less potent against non-primate RIP1
20351	LY2603618	1 mg	≥98%	A Chk1 inhibitor (IC50 = 7 nM) that prevents the repair of DNA caused by DNA-damaging agents; used in xenograft tumor models to potentiate the antitumor efficacy of various chemotherapeutic agents

20351	LY2603618	10 mg	≥98%	A Chk1 inhibitor (IC50 = 7 nM) that prevents the repair of DNA caused by DNA-damaging agents; used in xenograft tumor models to potentiate the antitumor efficacy of various chemotherapeutic agents
20351	LY2603618	25 mg	≥98%	A Chk1 inhibitor (IC50 = 7 nM) that prevents the repair of DNA caused by DNA-damaging agents; used in xenograft tumor models to potentiate the antitumor efficacy of various chemotherapeutic agents
20351	LY2603618	5 mg	≥98%	A Chk1 inhibitor (IC50 = 7 nM) that prevents the repair of DNA caused by DNA-damaging agents; used in xenograft tumor models to potentiate the antitumor efficacy of various chemotherapeutic agents
20354	Copanlisib	1 mg	≥98%	An inhibitor of class I PI3K isoforms (IC50s = 0.5, 3.7, 6.4, and 0.7 nM for α, β, γ, and δ, respectively); inhibits PI3K signaling and induces tumor regression via apoptosis in xenograft tumors in mice
20354	Copanlisib	10 mg	≥98%	An inhibitor of class I PI3K isoforms (IC50s = 0.5, 3.7, 6.4, and 0.7 nM for α, β, γ, and δ, respectively); inhibits PI3K signaling and induces tumor regression via apoptosis in xenograft tumors in mice
20354	Copanlisib	5 mg	≥98%	An inhibitor of class I PI3K isoforms (IC50s = 0.5, 3.7, 6.4, and 0.7 nM for α, β, γ, and δ, respectively); inhibits PI3K signaling and induces tumor regression via apoptosis in xenograft tumors in mice
20384	RPI-1	1 mg	≥98%	An ATP-dependent Ret kinase inhibitor that prevents metastasis both in vitro and in vivo
20384	RPI-1	10 mg	≥98%	An ATP-dependent Ret kinase inhibitor that prevents metastasis both in vitro and in vivo
20384	RPI-1	25 mg	≥98%	An ATP-dependent Ret kinase inhibitor that prevents metastasis both in vitro and in vivo
20384	RPI-1	5 mg	≥98%	An ATP-dependent Ret kinase inhibitor that prevents metastasis both in vitro and in vivo
20453	LDN-211904	1 mg	≥95%	An inhibitor of EphB3 (IC50 = 79 nM), an RTK subtype expressed during embryonic development and following central nervous system damage and some cancer cell growth
20453	LDN-211904	5 mg	≥95%	An inhibitor of EphB3 (IC50 = 79 nM), an RTK subtype expressed during embryonic development and following central nervous system damage and some cancer cell growth
20456	OXA-01	1 mg	≥98%	A dual inhibitor of mTORC1 and mTORC2 (IC50s = 11 and 29 nM, respectively); reduces VEGF production in tumors in association with decreased vessel sprouting
20456	OXA-01	10 mg	≥98%	A dual inhibitor of mTORC1 and mTORC2 (IC50s = 11 and 29 nM, respectively); reduces VEGF production in tumors in association with decreased vessel sprouting
20456	OXA-01	25 mg	≥98%	A dual inhibitor of mTORC1 and mTORC2 (IC50s = 11 and 29 nM, respectively); reduces VEGF production in tumors in association with decreased vessel sprouting
20456	OXA-01	5 mg	≥98%	A dual inhibitor of mTORC1 and mTORC2 (IC50s = 11 and 29 nM, respectively); reduces VEGF production in tumors in association with decreased vessel sprouting
20536	RN-486	1 mg	≥98%	A selective BTK inhibitor (Kds = 0.31 nM; IC50 = 4 nM); produces anti-inflammatory and bone-protective effects in mouse collagen-induced arthritis and rat adjuvant-induced arthritis models
20536	RN-486	10 mg	≥98%	A selective BTK inhibitor (Kds = 0.31 nM; IC50 = 4 nM); produces anti-inflammatory and bone-protective effects in mouse collagen-induced arthritis and rat adjuvant-induced arthritis models
20536	RN-486	5 mg	≥98%	A selective BTK inhibitor (Kds = 0.31 nM; IC50 = 4 nM); produces anti-inflammatory and bone-protective effects in mouse collagen-induced arthritis and rat adjuvant-induced arthritis models
20573	CP21R7	1 mg	≥98%	A potent and selective inhibitor of GSK3β; used as an activator of stem cells prior to the induction of differentiation of stem cells to endothelial and smooth muscle cells
20573	CP21R7	10 mg	≥98%	A potent and selective inhibitor of GSK3β; used as an activator of stem cells prior to the induction of differentiation of stem cells to endothelial and smooth muscle cells
20573	CP21R7	25 mg	≥98%	A potent and selective inhibitor of GSK3β; used as an activator of stem cells prior to the induction of differentiation of stem cells to endothelial and smooth muscle cells
20573	CP21R7	5 mg	≥98%	A potent and selective inhibitor of GSK3β; used as an activator of stem cells prior to the induction of differentiation of stem cells to endothelial and smooth muscle cells

20707	DSP-4	1 mg	≥95%	A noradrenergic neurotoxin; inhibits the uptake of norepinephrine in rat cortical homogenates; reduces dopamine-β-hydroxylase activity in rat brain and selectively depletes norepinephrine in rat cortex and locus coeruleus over the ventral forebrain, hypothalamus, and periphery; impairs tactile learning in the novel object recognition task in rats at 50 mg/kg; decreases exploration in a novel open area and neophilia in a complex exploration test in rats
20707	DSP-4	10 mg	≥95%	A noradrenergic neurotoxin; inhibits the uptake of norepinephrine in rat cortical homogenates; reduces dopamine-β-hydroxylase activity in rat brain and selectively depletes norepinephrine in rat cortex and locus coeruleus over the ventral forebrain, hypothalamus, and periphery; impairs tactile learning in the novel object recognition task in rats at 50 mg/kg; decreases exploration in a novel open area and neophilia in a complex exploration test in rats
20707	DSP-4	5 mg	≥95%	A noradrenergic neurotoxin; inhibits the uptake of norepinephrine in rat cortical homogenates; reduces dopamine-β-hydroxylase activity in rat brain and selectively depletes norepinephrine in rat cortex and locus coeruleus over the ventral forebrain, hypothalamus, and periphery; impairs tactile learning in the novel object recognition task in rats at 50 mg/kg; decreases exploration in a novel open area and neophilia in a complex exploration test in rats
20709	FIIN-3	1 mg	≥98%	An inhibitor of FGFRs (IC50s = 13, 21, 31, and 35 nM for recombinant FGFR1-4, respectively); selective for FGFRs over a panel of 456 kinases (1 μM); inhibits EGFR (IC50 =204 nM); inhibits growth of Ba/F3 cells dependent on the kinase activity of wild-type FGFR1-4 as well as gatekeeper mutant FGFR2 and FGFR3 (EC50s = TEL/V564M-dependent Ba/F3 cells; inhibits growth in a panel of cancer cell lines (EC50s = 1.4-499 nM)
20709	FIIN-3	10 mg	≥98%	An inhibitor of FGFRs (IC50s = 13, 21, 31, and 35 nM for recombinant FGFR1-4, respectively); selective for FGFRs over a panel of 456 kinases (1 μM); inhibits EGFR (IC50 =204 nM); inhibits growth of Ba/F3 cells dependent on the kinase activity of wild-type FGFR1-4 as well as gatekeeper mutant FGFR2 and FGFR3 (EC50s = TEL/V564M-dependent Ba/F3 cells; inhibits growth in a panel of cancer cell lines (EC50s = 1.4-499 nM)
20709	FIIN-3	25 mg	≥98%	An inhibitor of FGFRs (IC50s = 13, 21, 31, and 35 nM for recombinant FGFR1-4, respectively); selective for FGFRs over a panel of 456 kinases (1 μM); inhibits EGFR (IC50 =204 nM); inhibits growth of Ba/F3 cells dependent on the kinase activity of wild-type FGFR1-4 as well as gatekeeper mutant FGFR2 and FGFR3 (EC50s = TEL/V564M-dependent Ba/F3 cells; inhibits growth in a panel of cancer cell lines (EC50s = 1.4-499 nM)
20709	FIIN-3	5 mg	≥98%	An inhibitor of FGFRs (IC50s = 13, 21, 31, and 35 nM for recombinant FGFR1-4, respectively); selective for FGFRs over a panel of 456 kinases (1 μM); inhibits EGFR (IC50 =204 nM); inhibits growth of Ba/F3 cells dependent on the kinase activity of wild-type FGFR1-4 as well as gatekeeper mutant FGFR2 and FGFR3 (EC50s = TEL/V564M-dependent Ba/F3 cells; inhibits growth in a panel of cancer cell lines (EC50s = 1.4-499 nM)
20710	PLX7904	1 mg	≥98%	A RAF inhibitor (IC50s = 2.4, 140, and 91 nM for mutant B-RAFV600E, wild-type B-RAF, and C-RAF, respectively); inhibits phosphorylation of ERK in A375 and COLO 829 cells (IC50s = 16 and 18 nM, respectively); does not induce paradoxical pERK activation and proliferation of cancer cell lines (EC50s = >200 μM); inhibits tumor growth in a mouse COLO 205 colon cancer xenograft model
20710	PLX7904	10 mg	≥98%	A RAF inhibitor (IC50s = 2.4, 140, and 91 nM for mutant B-RAFV600E, wild-type B-RAF, and C-RAF, respectively); inhibits phosphorylation of ERK in A375 and COLO 829 cells (IC50s = 16 and 18 nM, respectively); does not induce paradoxical pERK activation and proliferation of cancer cell lines (EC50s = >200 μM); inhibits tumor growth in a mouse COLO 205 colon cancer xenograft model
20710	PLX7904	25 mg	≥98%	A RAF inhibitor (IC50s = 2.4, 140, and 91 nM for mutant B-RAFV600E, wild-type B-RAF, and C-RAF, respectively); inhibits phosphorylation of ERK in A375 and COLO 829 cells (IC50s = 16 and 18 nM, respectively); does not induce paradoxical pERK activation and proliferation of cancer cell lines (EC50s = >200 μM); inhibits tumor growth in a mouse COLO 205 colon cancer xenograft model
20710	PLX7904	5 mg	≥98%	A RAF inhibitor (IC50s = 2.4, 140, and 91 nM for mutant B-RAFV600E, wild-type B-RAF, and C-RAF, respectively); inhibits phosphorylation of ERK in A375 and COLO 829 cells (IC50s = 16 and 18 nM, respectively); does not induce paradoxical pERK activation and proliferation of cancer cell lines (EC50s = >200 μM); inhibits tumor growth in a mouse COLO 205 colon cancer xenograft model
20711	FRAX1036	1 mg	≥98%	A selective PAK1 inhibitor that induces apoptosis in breast cancer cells and has been used to inhibit oncogenic KRAS signaling in non-small cell lung cancer cells
20711	FRAX1036	10 mg	≥98%	A selective PAK1 inhibitor that induces apoptosis in breast cancer cells and has been used to inhibit oncogenic KRAS signaling in non-small cell lung cancer cells
20711	FRAX1036	25 mg	≥98%	A selective PAK1 inhibitor that induces apoptosis in breast cancer cells and has been used to inhibit oncogenic KRAS signaling in non-small cell lung cancer cells

20711	FRAX1036	5 mg	≥98%	A selective PAK1 inhibitor that induces apoptosis in breast cancer cells and has been used to inhibit oncogenic KRAS signaling in non-small cell lung cancer cells
20764	Dicoumarol	1 g	≥98%	A competitive NQO1 inhibitor; inhibits recombinant hNQO1 (IC50s =2.6 and 404 nM in the absence and presence of 2 µM BSA, respectively); has antiproliferative activity against MIA PaCa-2 pancreas and HCT116 colon carcinoma cell lines (IC50s = 52 and 19 µM, respectively); inhibits SAPK activity in HEK293 cells (IC50 = 19-33 µM); inhibits TNF-α and LPS-induced NF-κB activation; has antiproliferative activity against FL5.12 lymphocytic and MCF-7 breast carcinoma cells (100 µM)
20764	Dicoumarol	10 g	≥98%	A competitive NQO1 inhibitor; inhibits recombinant hNQO1 (IC50s =2.6 and 404 nM in the absence and presence of 2 µM BSA, respectively); has antiproliferative activity against MIA PaCa-2 pancreas and HCT116 colon carcinoma cell lines (IC50s = 52 and 19 µM, respectively); inhibits SAPK activity in HEK293 cells (IC50 = 19-33 µM); inhibits TNF-α and LPS-induced NF-κB activation; has antiproliferative activity against FL5.12 lymphocytic and MCF-7 breast carcinoma cells (100 µM)
20764	Dicoumarol	5 g	≥98%	A competitive NQO1 inhibitor; inhibits recombinant hNQO1 (IC50s =2.6 and 404 nM in the absence and presence of 2 µM BSA, respectively); has antiproliferative activity against MIA PaCa-2 pancreas and HCT116 colon carcinoma cell lines (IC50s = 52 and 19 µM, respectively); inhibits SAPK activity in HEK293 cells (IC50 = 19-33 µM); inhibits TNF-α and LPS-induced NF-κB activation; has antiproliferative activity against FL5.12 lymphocytic and MCF-7 breast carcinoma cells (100 µM)
20826	Daphnetin	10 mg	≥90%	A coumarin derivative with diverse biological activities; inhibits EGFR, PKA, and PKC in vitro (IC50s = 7.67, 9.33, and 25.01 µM, respectively); inhibits cell proliferation (IC50 = 73 µM) in MCF-7 breast carcinoma cells; decreases the generation of ROS and production of MDA and increases SOD activity and the GSH:GSSG ratio in RAW 264.7 cells; prevents t-BHP-induced cytotoxicity and ROS overproduction in wild-type, but not Nrf2-/-, RAW 264.7 cells and increases the expression of proteins downstream of Nrf2
20826	Daphnetin	100 mg	≥90%	A coumarin derivative with diverse biological activities; inhibits EGFR, PKA, and PKC in vitro (IC50s = 7.67, 9.33, and 25.01 µM, respectively); inhibits cell proliferation (IC50 = 73 µM) in MCF-7 breast carcinoma cells; decreases the generation of ROS and production of MDA and increases SOD activity and the GSH:GSSG ratio in RAW 264.7 cells; prevents t-BHP-induced cytotoxicity and ROS overproduction in wild-type, but not Nrf2-/-, RAW 264.7 cells and increases the expression of proteins downstream of Nrf2
20826	Daphnetin	25 mg	≥90%	A coumarin derivative with diverse biological activities; inhibits EGFR, PKA, and PKC in vitro (IC50s = 7.67, 9.33, and 25.01 µM, respectively); inhibits cell proliferation (IC50 = 73 µM) in MCF-7 breast carcinoma cells; decreases the generation of ROS and production of MDA and increases SOD activity and the GSH:GSSG ratio in RAW 264.7 cells; prevents t-BHP-induced cytotoxicity and ROS overproduction in wild-type, but not Nrf2-/-, RAW 264.7 cells and increases the expression of proteins downstream of Nrf2
20826	Daphnetin	50 mg	≥90%	A coumarin derivative with diverse biological activities; inhibits EGFR, PKA, and PKC in vitro (IC50s = 7.67, 9.33, and 25.01 µM, respectively); inhibits cell proliferation (IC50 = 73 µM) in MCF-7 breast carcinoma cells; decreases the generation of ROS and production of MDA and increases SOD activity and the GSH:GSSG ratio in RAW 264.7 cells; prevents t-BHP-induced cytotoxicity and ROS overproduction in wild-type, but not Nrf2-/-, RAW 264.7 cells and increases the expression of proteins downstream of Nrf2
20840	TX-1918	1 mg	≥98%	A selective eEF-2K inhibitor (IC50 = 440 nM); disrupts the proliferation of HepG2 and HCT116 tumor cells (EC50s = 2.07 and 230 µM, respectively) with low mitochondrial toxicity
20840	TX-1918	10 mg	≥98%	A selective eEF-2K inhibitor (IC50 = 440 nM); disrupts the proliferation of HepG2 and HCT116 tumor cells (EC50s = 2.07 and 230 µM, respectively) with low mitochondrial toxicity
20840	TX-1918	5 mg	≥98%	A selective eEF-2K inhibitor (IC50 = 440 nM); disrupts the proliferation of HepG2 and HCT116 tumor cells (EC50s = 2.07 and 230 µM, respectively) with low mitochondrial toxicity
20843	LY2874455	1 mg	≥98%	A pan-FGFR inhibitor (IC50s = 2.8, 2.6, 6.4, 6, and 7 nM for FGFR1, FGFR2, FGFR3, FGFR4, and VEGFR2, respectively); inhibits proliferation of KMS-11, OPM-2, SNU-16, and KATO-III cancer cells in vitro and in tumor xenografts in mice
20843	LY2874455	10 mg	≥98%	A pan-FGFR inhibitor (IC50s = 2.8, 2.6, 6.4, 6, and 7 nM for FGFR1, FGFR2, FGFR3, FGFR4, and VEGFR2, respectively); inhibits proliferation of KMS-11, OPM-2, SNU-16, and KATO-III cancer cells in vitro and in tumor xenografts in mice
20843	LY2874455	25 mg	≥98%	A pan-FGFR inhibitor (IC50s = 2.8, 2.6, 6.4, 6, and 7 nM for FGFR1, FGFR2, FGFR3, FGFR4, and VEGFR2, respectively); inhibits proliferation of KMS-11, OPM-2, SNU-16, and KATO-III cancer cells in vitro and in tumor xenografts in mice

20843	LY2874455	5 mg	≥98%	A pan-FGFR inhibitor (IC50s = 2.8, 2.6, 6.4, 6, and 7 nM for FGFR1, FGFR2, FGFR3, FGFR4, and VEGFR2, respectively); inhibits proliferation of KMS-11, OPM-2, SNU-16, and KATO-III cancer cells in vitro and in tumor xenografts in mice
20924	(±)-Necrostatin-2	1 mg	≥98%	A RIPK1 inhibitor; 6 mg/kg/day prevents TNF-induced mortality in a murine model of SIRS; decreases irradiation-induced LDH release and cell death in murine embryonic Cyt c-/- cells; 1.6 mg/kg/day prevents angiotensin II-induced elastin degradation and aortic inflammation in a murine AAA model
20924	(±)-Necrostatin-2	10 mg	≥98%	A RIPK1 inhibitor; 6 mg/kg/day prevents TNF-induced mortality in a murine model of SIRS; decreases irradiation-induced LDH release and cell death in murine embryonic Cyt c-/- cells; 1.6 mg/kg/day prevents angiotensin II-induced elastin degradation and aortic inflammation in a murine AAA model
20924	(±)-Necrostatin-2	5 mg	≥98%	A RIPK1 inhibitor; 6 mg/kg/day prevents TNF-induced mortality in a murine model of SIRS; decreases irradiation-induced LDH release and cell death in murine embryonic Cyt c-/- cells; 1.6 mg/kg/day prevents angiotensin II-induced elastin degradation and aortic inflammation in a murine AAA model
20971	Pamapimod	1 mg	≥98%	A potent, selective inhibitor of p38α MAPK (IC50 = 14 nM); blocks inflammatory signaling in cells, whole blood, and synovial explants; orally bioavailable, abrogating inflammation, bone, and pain in animal models
20971	Pamapimod	5 mg	≥98%	A potent, selective inhibitor of p38α MAPK (IC50 = 14 nM); blocks inflammatory signaling in cells, whole blood, and synovial explants; orally bioavailable, abrogating inflammation, bone, and pain in animal models
20971	Pamapimod	500 µg	≥98%	A potent, selective inhibitor of p38α MAPK (IC50 = 14 nM); blocks inflammatory signaling in cells, whole blood, and synovial explants; orally bioavailable, abrogating inflammation, bone, and pain in animal models
20972	Selonsertib	1 mg	≥95%	An ASK1 inhibitor (IC50 = 5.01 nM); decreases apoptosis and stellate cell activation in an in vitro 3D-human liver microtissue model of palmitic acid-induced NASH at 1 µM; sensitizes KB-C2 ABCB1-expressing epidermoid carcinoma cells to doxorubicin and paclitaxel; reduces hepatic necrosis and increases in serum TNF-α, IL-6, and CCL2 in a mouse model of LPS/D-galactosamine-induced acute liver failure at 15, 30, or 60 mg/kg
20972	Selonsertib	10 mg	≥95%	An ASK1 inhibitor (IC50 = 5.01 nM); decreases apoptosis and stellate cell activation in an in vitro 3D-human liver microtissue model of palmitic acid-induced NASH at 1 µM; sensitizes KB-C2 ABCB1-expressing epidermoid carcinoma cells to doxorubicin and paclitaxel; reduces hepatic necrosis and increases in serum TNF-α, IL-6, and CCL2 in a mouse model of LPS/D-galactosamine-induced acute liver failure at 15, 30, or 60 mg/kg
20972	Selonsertib	5 mg	≥95%	An ASK1 inhibitor (IC50 = 5.01 nM); decreases apoptosis and stellate cell activation in an in vitro 3D-human liver microtissue model of palmitic acid-induced NASH at 1 µM; sensitizes KB-C2 ABCB1-expressing epidermoid carcinoma cells to doxorubicin and paclitaxel; reduces hepatic necrosis and increases in serum TNF-α, IL-6, and CCL2 in a mouse model of LPS/D-galactosamine-induced acute liver failure at 15, 30, or 60 mg/kg
20972	Selonsertib	500 µg	≥95%	An ASK1 inhibitor (IC50 = 5.01 nM); decreases apoptosis and stellate cell activation in an in vitro 3D-human liver microtissue model of palmitic acid-induced NASH at 1 µM; sensitizes KB-C2 ABCB1-expressing epidermoid carcinoma cells to doxorubicin and paclitaxel; reduces hepatic necrosis and increases in serum TNF-α, IL-6, and CCL2 in a mouse model of LPS/D-galactosamine-induced acute liver failure at 15, 30, or 60 mg/kg
20979	PQ401	1 mg	≥98%	An inhibitor of IGF-1R; inhibits autophosphorylation of the recombinant IGF-1R kinase domain (IC50 = 50 = 12 µM); reduces cell viability of U87MG glioma cells (IC50 = 5 µM) and induces apoptosis and inhibits cell migration in a concentration-dependent manner; inhibits IGF-1-stimulated proliferation of MCF-7 cells in vitro (IC50 = 6 µM) and reduces tumor growth in an MCNeuA model of murine breast cancer at 50 and 100 mg/kg; has antimalarial activity against P. falciparum strain 3D7 (EC50 = 53 nM)
20979	PQ401	10 mg	≥98%	An inhibitor of IGF-1R; inhibits autophosphorylation of the recombinant IGF-1R kinase domain (IC50 = 50 = 12 µM); reduces cell viability of U87MG glioma cells (IC50 = 5 µM) and induces apoptosis and inhibits cell migration in a concentration-dependent manner; inhibits IGF-1-stimulated proliferation of MCF-7 cells in vitro (IC50 = 6 µM) and reduces tumor growth in an MCNeuA model of murine breast cancer at 50 and 100 mg/kg; has antimalarial activity against P. falciparum strain 3D7 (EC50 = 53 nM)
20979	PQ401	5 mg	≥98%	An inhibitor of IGF-1R; inhibits autophosphorylation of the recombinant IGF-1R kinase domain (IC50 = 50 = 12 µM); reduces cell viability of U87MG glioma cells (IC50 = 5 µM) and induces apoptosis and inhibits cell migration in a concentration-dependent manner; inhibits IGF-1-stimulated proliferation of MCF-7 cells in vitro (IC50 = 6 µM) and reduces tumor growth in an MCNeuA model of murine breast cancer at 50 and 100 mg/kg; has antimalarial activity against P. falciparum strain 3D7 (EC50 = 53 nM)

20979	PQ401	50 mg	≥98%	An inhibitor of IGF-1R; inhibits autophosphorylation of the recombinant IGF-1R kinase domain (IC50 = 50 = 12 µM); reduces cell viability of U87MG glioma cells (IC50 = 5 µM) and induces apoptosis and inhibits cell migration in a concentration-dependent manner; inhibits IGF-1-stimulated proliferation of MCF-7 cells in vitro (IC50 = 6 µM) and reduces tumor growth in an MCNeuA model of murine breast cancer at 50 and 100 mg/kg; has antimalarial activity against P. falciparum strain 3D7 (EC50 = 53 nM)
21029	SD-1029	1 mg	≥80% (mixture	A JAK2 inhibitor; inhibits autophosphorylation of recombinant JAK2 at 30 and 100 µM; decreases levels of phosphorylated JAK2, but not JAK1 or Src, in MDA-MB-468 and OVCAR8TR cells at 10 µM; decreases levels of phosphorylated STAT3 in MDA-MB-468, MDA-BM-435, OVCAR8TR, and SKOV3TR cells and inhibits IL-6-induced nuclear translocation of STAT3 in BHK-21 and U2OS cells at 10 µM; decreases the viability of and increases levels of cleaved caspase-3 in SNU-387, SNU-398, HepG2, and Huh7 hepatocellular carcinoma cells at 10 µM; inhibits hepatitis A virus replication in GL37 cells at 100 and 1,000 nM
21029	SD-1029	5 mg	≥80% (mixture	A JAK2 inhibitor; inhibits autophosphorylation of recombinant JAK2 at 30 and 100 µM; decreases levels of phosphorylated JAK2, but not JAK1 or Src, in MDA-MB-468 and OVCAR8TR cells at 10 µM; decreases levels of phosphorylated STAT3 in MDA-MB-468, MDA-BM-435, OVCAR8TR, and SKOV3TR cells and inhibits IL-6-induced nuclear translocation of STAT3 in BHK-21 and U2OS cells at 10 µM; decreases the viability of and increases levels of cleaved caspase-3 in SNU-387, SNU-398, HepG2, and Huh7 hepatocellular carcinoma cells at 10 µM; inhibits hepatitis A virus replication in GL37 cells at 100 and 1,000 nM
21035	AZD 6738	1 mg	≥98%	A selective ATR inhibitor (IC50 = 1 nM); inhibits the proliferation of various solid and hematological cell lines either as monotherapy or when used in combination with DNA damaging chemotherapy agents or ionizing radiation
21035	AZD 6738	10 mg	≥98%	A selective ATR inhibitor (IC50 = 1 nM); inhibits the proliferation of various solid and hematological cell lines either as monotherapy or when used in combination with DNA damaging chemotherapy agents or ionizing radiation
21035	AZD 6738	25 mg	≥98%	A selective ATR inhibitor (IC50 = 1 nM); inhibits the proliferation of various solid and hematological cell lines either as monotherapy or when used in combination with DNA damaging chemotherapy agents or ionizing radiation
21035	AZD 6738	5 mg	≥98%	A selective ATR inhibitor (IC50 = 1 nM); inhibits the proliferation of various solid and hematological cell lines either as monotherapy or when used in combination with DNA damaging chemotherapy agents or ionizing radiation
21044	CVT-313	1 mg	≥98%	A selective, competitive inhibitor of Cdk2 (IC50 = 0.5 µM in vitro); induces cell cycle arrest at the G1/S boundary
21044	CVT-313	10 mg	≥98%	A selective, competitive inhibitor of Cdk2 (IC50 = 0.5 µM in vitro); induces cell cycle arrest at the G1/S boundary
21044	CVT-313	5 mg	≥98%	A selective, competitive inhibitor of Cdk2 (IC50 = 0.5 µM in vitro); induces cell cycle arrest at the G1/S boundary
21059	PD 168393	1 mg	≥95%	A cell-permeable, irreversible inhibitor of EGFR kinase activity (IC50 = 0.70 nM); used in cells and in vivo to irreversibly inhibit EGFR signaling
21059	PD 168393	10 mg	≥95%	A cell-permeable, irreversible inhibitor of EGFR kinase activity (IC50 = 0.70 nM); used in cells and in vivo to irreversibly inhibit EGFR signaling
21059	PD 168393	25 mg	≥95%	A cell-permeable, irreversible inhibitor of EGFR kinase activity (IC50 = 0.70 nM); used in cells and in vivo to irreversibly inhibit EGFR signaling
21059	PD 168393	5 mg	≥95%	A cell-permeable, irreversible inhibitor of EGFR kinase activity (IC50 = 0.70 nM); used in cells and in vivo to irreversibly inhibit EGFR signaling
21072	BMS-5	1 mg	≥98%	A potent inhibitor of LIMK1 and LIMK2 (IC50s = 7 and 8 nM, respectively)
21072	BMS-5	10 mg	≥98%	A potent inhibitor of LIMK1 and LIMK2 (IC50s = 7 and 8 nM, respectively)
21072	BMS-5	5 mg	≥98%	A potent inhibitor of LIMK1 and LIMK2 (IC50s = 7 and 8 nM, respectively)
21073	Bohemine	1 mg	≥98%	A Cdk inhibitor (IC50s = 4.6, 8.3, and 2.7 µM for Cdk2/cyclin E, Cdk2/cyclin A, Cdk9/cyclin T1, respectively); suppresses tumor cell growth, inducing G1 and G2 phase cell cycle arrest
21073	Bohemine	5 mg	≥98%	A Cdk inhibitor (IC50s = 4.6, 8.3, and 2.7 µM for Cdk2/cyclin E, Cdk2/cyclin A, Cdk9/cyclin T1, respectively); suppresses tumor cell growth, inducing G1 and G2 phase cell cycle arrest
21088	BMS-911543	1 mg	≥98%	A potent and selective inhibitor of JAK2 (IC50s = 1, 356, 73, and 66 nM for JAK2, JAK1, JAK3, and TYK2, respectively); exhibits antiproliferative activity in cell lines engineered to express the JAK2V617F activating mutation (IC50s = 60-70 nM)
21088	BMS-911543	10 mg	≥98%	A potent and selective inhibitor of JAK2 (IC50s = 1, 356, 73, and 66 nM for JAK2, JAK1, JAK3, and TYK2, respectively); exhibits antiproliferative activity in cell lines engineered to express the JAK2V617F activating mutation (IC50s = 60-70 nM)
21088	BMS-911543	25 mg	≥98%	A potent and selective inhibitor of JAK2 (IC50s = 1, 356, 73, and 66 nM for JAK2, JAK1, JAK3, and TYK2, respectively); exhibits antiproliferative activity in cell lines engineered to express the JAK2V617F activating mutation (IC50s = 60-70 nM)

21088	BMS-911543	5 mg	≥98%	A potent and selective inhibitor of JAK2 (IC50s = 1, 356, 73, and 66 nM for JAK2, JAK1, JAK3, and TYK2, respectively); exhibits antiproliferative activity in cell lines engineered to express the JAK2V617F activating mutation (IC50s = 60-70 nM)
21089	CGP 77675 (hydrate)	1 mg	≥98%	An inhibitor of Src family kinases that blocks the phosphorylation of peptide substrates and autophosphorylation of purified c-Src (IC50s = 5-20 and 40 nM, respectively); also inhibits Lck and c-Yes with low nanomolar IC50 values
21089	CGP 77675 (hydrate)	10 mg	≥98%	An inhibitor of Src family kinases that blocks the phosphorylation of peptide substrates and autophosphorylation of purified c-Src (IC50s = 5-20 and 40 nM, respectively); also inhibits Lck and c-Yes with low nanomolar IC50 values
21089	CGP 77675 (hydrate)	25 mg	≥98%	An inhibitor of Src family kinases that blocks the phosphorylation of peptide substrates and autophosphorylation of purified c-Src (IC50s = 5-20 and 40 nM, respectively); also inhibits Lck and c-Yes with low nanomolar IC50 values
21089	CGP 77675 (hydrate)	5 mg	≥98%	An inhibitor of Src family kinases that blocks the phosphorylation of peptide substrates and autophosphorylation of purified c-Src (IC50s = 5-20 and 40 nM, respectively); also inhibits Lck and c-Yes with low nanomolar IC50 values
21107	GDC-0994	1 mg	≥98%	A potent and selective ERK1/2 inhibitor (IC50s = 6.1 and 4.1 nM, respectively); cell-permeable and orally bioavailable
21107	GDC-0994	10 mg	≥98%	A potent and selective ERK1/2 inhibitor (IC50s = 6.1 and 4.1 nM, respectively); cell-permeable and orally bioavailable
21107	GDC-0994	5 mg	≥98%	A potent and selective ERK1/2 inhibitor (IC50s = 6.1 and 4.1 nM, respectively); cell-permeable and orally bioavailable
21107	GDC-0994	500 µg	≥98%	A potent and selective ERK1/2 inhibitor (IC50s = 6.1 and 4.1 nM, respectively); cell-permeable and orally bioavailable
21118	eCF309	1 mg	≥98%	A selective inhibitor of mTOR (IC50 = 15 nM in vitro and in cells)
21118	eCF309	500 µg	≥98%	A selective inhibitor of mTOR (IC50 = 15 nM in vitro and in cells)
21136	TAS 120	1 mg	≥98%	An orally bioavailable inhibitor of FGFRs that irreversibly inhibits all four FGFR subtypes at nanomolar concentrations; blocks the proliferation of human cancer cell lines with FGFR gene abnormalities
21136	TAS 120	10 mg	≥98%	An orally bioavailable inhibitor of FGFRs that irreversibly inhibits all four FGFR subtypes at nanomolar concentrations; blocks the proliferation of human cancer cell lines with FGFR gene abnormalities
21136	TAS 120	5 mg	≥98%	An orally bioavailable inhibitor of FGFRs that irreversibly inhibits all four FGFR subtypes at nanomolar concentrations; blocks the proliferation of human cancer cell lines with FGFR gene abnormalities
21136	TAS 120	500 µg	≥98%	An orally bioavailable inhibitor of FGFRs that irreversibly inhibits all four FGFR subtypes at nanomolar concentrations; blocks the proliferation of human cancer cell lines with FGFR gene abnormalities
21180	Bisindolylmaleimide I	1 mg	≥98%	A highly selective, cell-permeable, and reversible PKC inhibitor (Ki = 14 nM); competitive inhibitor for the ATP binding site of PKC; highly selective for PKCα, β1, β2, γ, δ, and ε isozymes; inhibits GSK3 in primary adipocyte lysates (IC50 = 360 nM) and in GSK3β immunoprecipitates derived from rat epididymal adipocytes (IC50 = 170 nM); competitively antagonizes the 5-HT3 receptor with a Ki value of 61 nM
21180	Bisindolylmaleimide I	5 mg	≥98%	A highly selective, cell-permeable, and reversible PKC inhibitor (Ki = 14 nM); competitive inhibitor for the ATP binding site of PKC; highly selective for PKCα, β1, β2, γ, δ, and ε isozymes; inhibits GSK3 in primary adipocyte lysates (IC50 = 360 nM) and in GSK3β immunoprecipitates derived from rat epididymal adipocytes (IC50 = 170 nM); competitively antagonizes the 5-HT3 receptor with a Ki value of 61 nM
21180	Bisindolylmaleimide I	500 µg	≥98%	A highly selective, cell-permeable, and reversible PKC inhibitor (Ki = 14 nM); competitive inhibitor for the ATP binding site of PKC; highly selective for PKCα, β1, β2, γ, δ, and ε isozymes; inhibits GSK3 in primary adipocyte lysates (IC50 = 360 nM) and in GSK3β immunoprecipitates derived from rat epididymal adipocytes (IC50 = 170 nM); competitively antagonizes the 5-HT3 receptor with a Ki value of 61 nM
21182	DMAT	1 mg	≥98%	A cell-permeable inhibitor of CK2 (IC50 = 0.13 µM); also inhibits Pim-1, Pim-3, HIPK2, and HIPK3 (IC50s = 0.15, 0.097, 0.37, and 0.59 µM, respectively); blocks cell growth and induces cell death in cancer cells, both in culture and in mouse xenografts
21182	DMAT	10 mg	≥98%	A cell-permeable inhibitor of CK2 (IC50 = 0.13 µM); also inhibits Pim-1, Pim-3, HIPK2, and HIPK3 (IC50s = 0.15, 0.097, 0.37, and 0.59 µM, respectively); blocks cell growth and induces cell death in cancer cells, both in culture and in mouse xenografts
21182	DMAT	25 mg	≥98%	A cell-permeable inhibitor of CK2 (IC50 = 0.13 µM); also inhibits Pim-1, Pim-3, HIPK2, and HIPK3 (IC50s = 0.15, 0.097, 0.37, and 0.59 µM, respectively); blocks cell growth and induces cell death in cancer cells, both in culture and in mouse xenografts
21182	DMAT	5 mg	≥98%	A cell-permeable inhibitor of CK2 (IC50 = 0.13 µM); also inhibits Pim-1, Pim-3, HIPK2, and HIPK3 (IC50s = 0.15, 0.097, 0.37, and 0.59 µM, respectively); blocks cell growth and induces cell death in cancer cells, both in culture and in mouse xenografts

21183	BI-78D3	1 mg	≥98%	An inhibitor of JNK (IC50 = 280 nM); competitive for JNK1 binding with pepJIP1 (IC50 = 500 nM); selective for JNK over p38α, mTOR, and PI3Kα; inhibits c-Jun phosphorylation induced by TNF-α (EC50 = 12.4 µM); restores insulin sensitivity in a mouse model of type 2 diabetes when administered at 25 mg/kg 30 minutes prior to insulin; reduces human prostate strip contractions induced by phenylephrine or norepinephrine when applied at 30 µM and reduces phosphorylation of c-Jun, a JNK substrate
21183	BI-78D3	10 mg	≥98%	An inhibitor of JNK (IC50 = 280 nM); competitive for JNK1 binding with pepJIP1 (IC50 = 500 nM); selective for JNK over p38α, mTOR, and PI3Kα; inhibits c-Jun phosphorylation induced by TNF-α (EC50 = 12.4 µM); restores insulin sensitivity in a mouse model of type 2 diabetes when administered at 25 mg/kg 30 minutes prior to insulin; reduces human prostate strip contractions induced by phenylephrine or norepinephrine when applied at 30 µM and reduces phosphorylation of c-Jun, a JNK substrate
21183	BI-78D3	25 mg	≥98%	An inhibitor of JNK (IC50 = 280 nM); competitive for JNK1 binding with pepJIP1 (IC50 = 500 nM); selective for JNK over p38α, mTOR, and PI3Kα; inhibits c-Jun phosphorylation induced by TNF-α (EC50 = 12.4 µM); restores insulin sensitivity in a mouse model of type 2 diabetes when administered at 25 mg/kg 30 minutes prior to insulin; reduces human prostate strip contractions induced by phenylephrine or norepinephrine when applied at 30 µM and reduces phosphorylation of c-Jun, a JNK substrate
21183	BI-78D3	5 mg	≥98%	An inhibitor of JNK (IC50 = 280 nM); competitive for JNK1 binding with pepJIP1 (IC50 = 500 nM); selective for JNK over p38α, mTOR, and PI3Kα; inhibits c-Jun phosphorylation induced by TNF-α (EC50 = 12.4 µM); restores insulin sensitivity in a mouse model of type 2 diabetes when administered at 25 mg/kg 30 minutes prior to insulin; reduces human prostate strip contractions induced by phenylephrine or norepinephrine when applied at 30 µM and reduces phosphorylation of c-Jun, a JNK substrate
21184	Chk2 Inhibitor	1 mg	≥95%	A Chk2 inhibitor (IC50 = 13.5 nM); selective for Chk2 over Chk1 (IC50 = 220.4 nM); inhibits Chk2 autophosphorylation at Ser516 in non-cancerous 184B5 cells that contain wild-type p53 and in MDA-MB-231 cells that contain mutated p53 at 0.1-30 µM; enhances survival of 184B5, but not MDA-MB-231, cells following ionizing radiation; inhibits PMA-induced production of IL-2 in Jurkat cells and LPS-induced TNF-α production in THP-1 cells (IC50s = 3.5 and 8.2 µM, respectively); inhibits the growth of CEM leukemia T cells (GI50 = 1.73 µM)
21184	Chk2 Inhibitor	500 µg	≥95%	A Chk2 inhibitor (IC50 = 13.5 nM); selective for Chk2 over Chk1 (IC50 = 220.4 nM); inhibits Chk2 autophosphorylation at Ser516 in non-cancerous 184B5 cells that contain wild-type p53 and in MDA-MB-231 cells that contain mutated p53 at 0.1-30 µM; enhances survival of 184B5, but not MDA-MB-231, cells following ionizing radiation; inhibits PMA-induced production of IL-2 in Jurkat cells and LPS-induced TNF-α production in THP-1 cells (IC50s = 3.5 and 8.2 µM, respectively); inhibits the growth of CEM leukemia T cells (GI50 = 1.73 µM)
21185	NVP-BEZ235 (hydroch	10 mg	≥98%	A potent dual inhibitor of PI3K and mTOR that is well tolerated, displays disease stasis when administered orally, and enhances the efficacy of other anticancer agents when used in in vivo combination studies; inhibits PI3K isoforms and mutants with low nanomolar IC50 values; directly blocks cell growth and indirectly inhibits angiogenesis
21185	NVP-BEZ235 (hydroch	100 mg	≥98%	A potent dual inhibitor of PI3K and mTOR that is well tolerated, displays disease stasis when administered orally, and enhances the efficacy of other anticancer agents when used in in vivo combination studies; inhibits PI3K isoforms and mutants with low nanomolar IC50 values; directly blocks cell growth and indirectly inhibits angiogenesis
21185	NVP-BEZ235 (hydroch	25 mg	≥98%	A potent dual inhibitor of PI3K and mTOR that is well tolerated, displays disease stasis when administered orally, and enhances the efficacy of other anticancer agents when used in in vivo combination studies; inhibits PI3K isoforms and mutants with low nanomolar IC50 values; directly blocks cell growth and indirectly inhibits angiogenesis
21185	NVP-BEZ235 (hydroch	50 mg	≥98%	A potent dual inhibitor of PI3K and mTOR that is well tolerated, displays disease stasis when administered orally, and enhances the efficacy of other anticancer agents when used in in vivo combination studies; inhibits PI3K isoforms and mutants with low nanomolar IC50 values; directly blocks cell growth and indirectly inhibits angiogenesis
21187	PI-103 (hydrochloride	1 mg	≥98%	A potent, cell-permeable, ATP-competitive inhibitor of PI3K family members (IC50 = 2, 8, 20, 26, 48, 83, 88, and 150 nM for DNA-PK, p110α, mTORC1, PI3-KC2β, p110δ, mTORC2, p110β, and p110γ, respectively)
21187	PI-103 (hydrochloride	10 mg	≥98%	A potent, cell-permeable, ATP-competitive inhibitor of PI3K family members (IC50 = 2, 8, 20, 26, 48, 83, 88, and 150 nM for DNA-PK, p110α, mTORC1, PI3-KC2β, p110δ, mTORC2, p110β, and p110γ, respectively)
21187	PI-103 (hydrochloride	5 mg	≥98%	A potent, cell-permeable, ATP-competitive inhibitor of PI3K family members (IC50 = 2, 8, 20, 26, 48, 83, 88, and 150 nM for DNA-PK, p110α, mTORC1, PI3-KC2β, p110δ, mTORC2, p110β, and p110γ, respectively)

21187	PI-103 (hydrochloride	50 mg	≥98%	A potent, cell-permeable, ATP-competitive inhibitor of PI3K family members (IC50 = 2, 8, 20, 26, 48, 83, 88, and 150 nM for DNA-PK, p110α, mTORC1, PI3-KC2β, p110δ, mTORC2, p110β, and p110γ, respectively)
21189	TNP	1 mg	≥98%	An IP6K (IC50 = 0.55 μM; Ki = 0.24 μM) and IP3K (IC50 = 10.2 μM; Ki = 4.3 μM) inhibitor; reduces IP7 and IP8 levels; inhibits insulin release in MIN6 cells; increases intracellular calcium levels in a concentration-dependent manner (5-20 μM) in HL-60 cells; increases intracellular calcium and induces degranulation of mast cells
21189	TNP	10 mg	≥98%	An IP6K (IC50 = 0.55 μM; Ki = 0.24 μM) and IP3K (IC50 = 10.2 μM; Ki = 4.3 μM) inhibitor; reduces IP7 and IP8 levels; inhibits insulin release in MIN6 cells; increases intracellular calcium levels in a concentration-dependent manner (5-20 μM) in HL-60 cells; increases intracellular calcium and induces degranulation of mast cells
21189	TNP	5 mg	≥98%	An IP6K (IC50 = 0.55 μM; Ki = 0.24 μM) and IP3K (IC50 = 10.2 μM; Ki = 4.3 μM) inhibitor; reduces IP7 and IP8 levels; inhibits insulin release in MIN6 cells; increases intracellular calcium levels in a concentration-dependent manner (5-20 μM) in HL-60 cells; increases intracellular calcium and induces degranulation of mast cells
21189	TNP	50 mg	≥98%	An IP6K (IC50 = 0.55 μM; Ki = 0.24 μM) and IP3K (IC50 = 10.2 μM; Ki = 4.3 μM) inhibitor; reduces IP7 and IP8 levels; inhibits insulin release in MIN6 cells; increases intracellular calcium levels in a concentration-dependent manner (5-20 μM) in HL-60 cells; increases intracellular calcium and induces degranulation of mast cells
21190	GSK3 Inhibitor XIII	1 mg	≥98%	An inhibitor of GSK3 (34% inhibition when used at a concentration of 2.5 μM); inhibits androgen receptor transactivation and translocation to the nucleus in PCa prostate cancer cells; increases nuclear export of the androgen receptor in PC3 prostate cancer cells; dose-dependently potentiates peak current densities
21190	GSK3 Inhibitor XIII	5 mg	≥98%	An inhibitor of GSK3 (34% inhibition when used at a concentration of 2.5 μM); inhibits androgen receptor transactivation and translocation to the nucleus in PCa prostate cancer cells; increases nuclear export of the androgen receptor in PC3 prostate cancer cells; dose-dependently potentiates peak current densities
21190	GSK3 Inhibitor XIII	500 µg	≥98%	An inhibitor of GSK3 (34% inhibition when used at a concentration of 2.5 μM); inhibits androgen receptor transactivation and translocation to the nucleus in PCa prostate cancer cells; increases nuclear export of the androgen receptor in PC3 prostate cancer cells; dose-dependently potentiates peak current densities
21192	Necrostatin-1 Inactive	1 mg	≥98%	A demethylated variant of necrostatin-1 that inhibits IDO; ~ 100-fold less effective than Nec-1 in inhibiting RIP1 kinase in vitro and 10-fold less potent than Nec-1 in a mouse necroptosis assay; inhibits TNF-induced systemic inflammatory response syndrome in vivo
21192	Necrostatin-1 Inactive	10 mg	≥98%	A demethylated variant of necrostatin-1 that inhibits IDO; ~ 100-fold less effective than Nec-1 in inhibiting RIP1 kinase in vitro and 10-fold less potent than Nec-1 in a mouse necroptosis assay; inhibits TNF-induced systemic inflammatory response syndrome in vivo
21192	Necrostatin-1 Inactive	5 mg	≥98%	A demethylated variant of necrostatin-1 that inhibits IDO; ~ 100-fold less effective than Nec-1 in inhibiting RIP1 kinase in vitro and 10-fold less potent than Nec-1 in a mouse necroptosis assay; inhibits TNF-induced systemic inflammatory response syndrome in vivo
21192	Necrostatin-1 Inactive	50 mg	≥98%	A demethylated variant of necrostatin-1 that inhibits IDO; ~ 100-fold less effective than Nec-1 in inhibiting RIP1 kinase in vitro and 10-fold less potent than Nec-1 in a mouse necroptosis assay; inhibits TNF-induced systemic inflammatory response syndrome in vivo
21193	FLT3 Inhibitor III	1 mg	≥98%	A potent, highly selective inhibitor of FLT3 (IC50 = 50 nM); used to study signaling through FLT3 and FLT3-ITD in cells
21193	FLT3 Inhibitor III	5 mg	≥98%	A potent, highly selective inhibitor of FLT3 (IC50 = 50 nM); used to study signaling through FLT3 and FLT3-ITD in cells
21195	CDK/CRK Inhibitor	1 mg	≥98%	A CDK/CRK-specific kinase inhibitor (IC50s = 9-839 nM, in vitro); selective, exhibiting less than 20% inhibition of 60 non-CDK/CRK kinases, at a concentration of 1 μM; induces cell cycle arrest in the G1 phase, endoreduplication, and apoptosis in HCT116 cells; exhibits broad anti-tumor activity with an average GI50 value of 50 = 40 nM)
21195	CDK/CRK Inhibitor	5 mg	≥98%	A CDK/CRK-specific kinase inhibitor (IC50s = 9-839 nM, in vitro); selective, exhibiting less than 20% inhibition of 60 non-CDK/CRK kinases, at a concentration of 1 μM; induces cell cycle arrest in the G1 phase, endoreduplication, and apoptosis in HCT116 cells; exhibits broad anti-tumor activity with an average GI50 value of 50 = 40 nM)
21196	PP121	10 mg	≥98%	A potent dual inhibitor of tyrosine and phosphoinositide kinases (IC50s = 2-60 nM for p110α, mTOR, Src, Abl, and VEGFR); demonstrates >90% inhibition of tyrosine kinases and 50 = 50 nM) in vitro; blocks VEGF-driven HUVEC tube formation (IC50 = 0.31 nM); inhibits MEKK2/MAP3K2 (IC50 = 31 nM)

21196	PP121	25 mg	≥98%	A potent dual inhibitor of tyrosine and phosphoinositide kinases (IC50s = 2-60 nM for p110α, mTOR, Src, Abl, and VEGFR); demonstrates >90% inhibition of tyrosine kinases and 50 = 50 nM) in vitro; blocks VEGF-driven HUVEC tube formation (IC50 = 0.31 nM); inhibits MEKK2/MAP3K2 (IC50 = 31 nM)
21196	PP121	5 mg	≥98%	A potent dual inhibitor of tyrosine and phosphoinositide kinases (IC50s = 2-60 nM for p110α, mTOR, Src, Abl, and VEGFR); demonstrates >90% inhibition of tyrosine kinases and 50 = 50 nM) in vitro; blocks VEGF-driven HUVEC tube formation (IC50 = 0.31 nM); inhibits MEKK2/MAP3K2 (IC50 = 31 nM)
21196	PP121	50 mg	≥98%	A potent dual inhibitor of tyrosine and phosphoinositide kinases (IC50s = 2-60 nM for p110α, mTOR, Src, Abl, and VEGFR); demonstrates >90% inhibition of tyrosine kinases and 50 = 50 nM) in vitro; blocks VEGF-driven HUVEC tube formation (IC50 = 0.31 nM); inhibits MEKK2/MAP3K2 (IC50 = 31 nM)
21197	PI3-Kinase α Inhibitor	1 mg	≥98%	An inhibitor of PI3K p110α (IC50 = 2 nM in an enzyme assay); selective for p110α over p110β, p110γ, and PI3K C2β (IC50s = 16, 660, and 220 nM, respectively); inhibits mTOR (IC50 = 49 nM); inhibits proliferation in A375 melanoma cells (IC50 = 0.58 μM)
21197	PI3-Kinase α Inhibitor	10 mg	≥98%	An inhibitor of PI3K p110α (IC50 = 2 nM in an enzyme assay); selective for p110α over p110β, p110γ, and PI3K C2β (IC50s = 16, 660, and 220 nM, respectively); inhibits mTOR (IC50 = 49 nM); inhibits proliferation in A375 melanoma cells (IC50 = 0.58 μM)
21197	PI3-Kinase α Inhibitor	5 mg	≥98%	An inhibitor of PI3K p110α (IC50 = 2 nM in an enzyme assay); selective for p110α over p110β, p110γ, and PI3K C2β (IC50s = 16, 660, and 220 nM, respectively); inhibits mTOR (IC50 = 49 nM); inhibits proliferation in A375 melanoma cells (IC50 = 0.58 μM)
21198	GSK3β Inhibitor XVIII	1 mg	≥98%	An inhibitor of GSK3β (IC50 = 64 nM); induces expression of a luciferase reporter in HEK293 cells expressing wild-type Wnt (EC50 = ~1.25 μM) but not in cells expressing a β-catenin/TCF binding site-mutant Wnt; induces proliferation of R7T1 β-cells (EC50 = 1,143 nM) and rat primary β-cells
21198	GSK3β Inhibitor XVIII	10 mg	≥98%	An inhibitor of GSK3β (IC50 = 64 nM); induces expression of a luciferase reporter in HEK293 cells expressing wild-type Wnt (EC50 = ~1.25 μM) but not in cells expressing a β-catenin/TCF binding site-mutant Wnt; induces proliferation of R7T1 β-cells (EC50 = 1,143 nM) and rat primary β-cells
21198	GSK3β Inhibitor XVIII	25 mg	≥98%	An inhibitor of GSK3β (IC50 = 64 nM); induces expression of a luciferase reporter in HEK293 cells expressing wild-type Wnt (EC50 = ~1.25 μM) but not in cells expressing a β-catenin/TCF binding site-mutant Wnt; induces proliferation of R7T1 β-cells (EC50 = 1,143 nM) and rat primary β-cells
21198	GSK3β Inhibitor XVIII	5 mg	≥98%	An inhibitor of GSK3β (IC50 = 64 nM); induces expression of a luciferase reporter in HEK293 cells expressing wild-type Wnt (EC50 = ~1.25 μM) but not in cells expressing a β-catenin/TCF binding site-mutant Wnt; induces proliferation of R7T1 β-cells (EC50 = 1,143 nM) and rat primary β-cells
21199	WYE-23	1 mg	≥98%	An inhibitor of mTOR (IC50 = 0.45 nM); selective for mTOR over PI3Kα (IC50 = 661 nM); inhibits cell growth in LNCaP cells (IC50 = 42 nM)
21199	WYE-23	10 mg	≥98%	An inhibitor of mTOR (IC50 = 0.45 nM); selective for mTOR over PI3Kα (IC50 = 661 nM); inhibits cell growth in LNCaP cells (IC50 = 42 nM)
21199	WYE-23	5 mg	≥98%	An inhibitor of mTOR (IC50 = 0.45 nM); selective for mTOR over PI3Kα (IC50 = 661 nM); inhibits cell growth in LNCaP cells (IC50 = 42 nM)
21199	WYE-23	500 µg	≥98%	An inhibitor of mTOR (IC50 = 0.45 nM); selective for mTOR over PI3Kα (IC50 = 661 nM); inhibits cell growth in LNCaP cells (IC50 = 42 nM)
21200	WYE-28	1 mg	≥98%	An inhibitor of mTOR (IC50 = 0.08 nM); selective for mTOR over PI3Kα (IC50 = 6 nM); inhibits cell growth in LNCaP cells (IC50 = <1 nM)
21200	WYE-28	10 mg	≥98%	An inhibitor of mTOR (IC50 = 0.08 nM); selective for mTOR over PI3Kα (IC50 = 6 nM); inhibits cell growth in LNCaP cells (IC50 = <1 nM)
21200	WYE-28	5 mg	≥98%	An inhibitor of mTOR (IC50 = 0.08 nM); selective for mTOR over PI3Kα (IC50 = 6 nM); inhibits cell growth in LNCaP cells (IC50 = <1 nM)
21200	WYE-28	500 µg	≥98%	An inhibitor of mTOR (IC50 = 0.08 nM); selective for mTOR over PI3Kα (IC50 = 6 nM); inhibits cell growth in LNCaP cells (IC50 = <1 nM)
21201	SB 202190 (hydrochlo	1 mg	≥98%	A potent, selective, and cell-permeable inhibitor of p38 MAP kinases; inhibits p38α (SAPK2A, MAPK14) and p38β (SAPK2B, MAPK11) with IC50 values of 50 and 100 nM, respectively; has negligible effects on a range of other kinases when used at a concentration of 10 μM; including other MAP kinases such as ERK and JNK
21201	SB 202190 (hydrochlo	10 mg	≥98%	A potent, selective, and cell-permeable inhibitor of p38 MAP kinases; inhibits p38α (SAPK2A, MAPK14) and p38β (SAPK2B, MAPK11) with IC50 values of 50 and 100 nM, respectively; has negligible effects on a range of other kinases when used at a concentration of 10 μM; including other MAP kinases such as ERK and JNK
21201	SB 202190 (hydrochlo	25 mg	≥98%	A potent, selective, and cell-permeable inhibitor of p38 MAP kinases; inhibits p38α (SAPK2A, MAPK14) and p38β (SAPK2B, MAPK11) with IC50 values of 50 and 100 nM, respectively; has negligible effects on a range of other kinases when used at a concentration of 10 μM; including other MAP kinases such as ERK and JNK
21201	SB 202190 (hydrochlo	5 mg	≥98%	A potent, selective, and cell-permeable inhibitor of p38 MAP kinases; inhibits p38α (SAPK2A, MAPK14) and p38β (SAPK2B, MAPK11) with IC50 values of 50 and 100 nM, respectively; has negligible effects on a range of other kinases when used at a concentration of 10 μM; including other MAP kinases such as ERK and JNK

21202	PKI-179 (hydrochlorid	1 mg	≥98%	A dual PI3K and mTOR inhibitor; inhibits PI3K (IC50s = 8, 24, 17, and 74 nM for isoforms α, β, δ, and γ, respectively); inhibits PI3Kα mutants, E545K and H1047R (IC50s = 14 and 11 nM, respectively); inhibits mTOR (IC50 = 0.42 nM); antiproliferative against MDA-361 (breast) and PC3MM2 (prostate) cell lines (IC50s = 22 and 29 nM, respectively); inhibits tumor growth in MDA-361 mouse xenografts (50 mg/kg)
21202	PKI-179 (hydrochlorid	10 mg	≥98%	A dual PI3K and mTOR inhibitor; inhibits PI3K (IC50s = 8, 24, 17, and 74 nM for isoforms α, β, δ, and γ, respectively); inhibits PI3Kα mutants, E545K and H1047R (IC50s = 14 and 11 nM, respectively); inhibits mTOR (IC50 = 0.42 nM); antiproliferative against MDA-361 (breast) and PC3MM2 (prostate) cell lines (IC50s = 22 and 29 nM, respectively); inhibits tumor growth in MDA-361 mouse xenografts (50 mg/kg)
21202	PKI-179 (hydrochlorid	5 mg	≥98%	A dual PI3K and mTOR inhibitor; inhibits PI3K (IC50s = 8, 24, 17, and 74 nM for isoforms α, β, δ, and γ, respectively); inhibits PI3Kα mutants, E545K and H1047R (IC50s = 14 and 11 nM, respectively); inhibits mTOR (IC50 = 0.42 nM); antiproliferative against MDA-361 (breast) and PC3MM2 (prostate) cell lines (IC50s = 22 and 29 nM, respectively); inhibits tumor growth in MDA-361 mouse xenografts (50 mg/kg)
21203	PX-13-17OH	1 mg	≥98%	A PI3K inhibitor; inhibits PI3Kα, PI3Kβ, PI3Kɣ, and PI3Kδ (IC50s = 6.4, 13, 8, and 11 nM, respectively) over mTOR (IC50 = 2.9 μM); 420-fold selective for PI3K in a panel of 20 lipid and protein kinases; inhibits phosphorylation of Akt and S6K in PTEN-negative U87MG cells at 0.03-1 μg/ml; inhibits tumor growth in a U87MG mouse xenograft model at 2.5-10 mg/kg
21203	PX-13-17OH	10 mg	≥98%	A PI3K inhibitor; inhibits PI3Kα, PI3Kβ, PI3Kɣ, and PI3Kδ (IC50s = 6.4, 13, 8, and 11 nM, respectively) over mTOR (IC50 = 2.9 μM); 420-fold selective for PI3K in a panel of 20 lipid and protein kinases; inhibits phosphorylation of Akt and S6K in PTEN-negative U87MG cells at 0.03-1 μg/ml; inhibits tumor growth in a U87MG mouse xenograft model at 2.5-10 mg/kg
21203	PX-13-17OH	5 mg	≥98%	A PI3K inhibitor; inhibits PI3Kα, PI3Kβ, PI3Kɣ, and PI3Kδ (IC50s = 6.4, 13, 8, and 11 nM, respectively) over mTOR (IC50 = 2.9 μM); 420-fold selective for PI3K in a panel of 20 lipid and protein kinases; inhibits phosphorylation of Akt and S6K in PTEN-negative U87MG cells at 0.03-1 μg/ml; inhibits tumor growth in a U87MG mouse xenograft model at 2.5-10 mg/kg
21204	PX-866-17OH	1 mg	≥98%	An active metabolite of PX-866; inhibits PI3Kα, PI3Kβ, PI3Kɣ, and PI3Kδ (IC50s = 14, 57, 131, and 148 nM, respectively)
21204	PX-866-17OH	10 mg	≥98%	An active metabolite of PX-866; inhibits PI3Kα, PI3Kβ, PI3Kɣ, and PI3Kδ (IC50s = 14, 57, 131, and 148 nM, respectively)
21204	PX-866-17OH	5 mg	≥98%	An active metabolite of PX-866; inhibits PI3Kα, PI3Kβ, PI3Kɣ, and PI3Kδ (IC50s = 14, 57, 131, and 148 nM, respectively)
21205	CYC-116	1 mg	≥98%	A potent Aurora kinase inhibitor (Kis = 8.0 and 9.2 nM for Aurora A and B kinases, respectively); selective over against a panel of CDKs and other kinases, with the exception of Flt-3 (Ki = 44 nM); exhibits broad-spectrum antiproliferative activity against a panel of human cancer cell lines (mean IC50 = 0.54 μM); orally bioavailable
21205	CYC-116	10 mg	≥98%	A potent Aurora kinase inhibitor (Kis = 8.0 and 9.2 nM for Aurora A and B kinases, respectively); selective over against a panel of CDKs and other kinases, with the exception of Flt-3 (Ki = 44 nM); exhibits broad-spectrum antiproliferative activity against a panel of human cancer cell lines (mean IC50 = 0.54 μM); orally bioavailable
21205	CYC-116	25 mg	≥98%	A potent Aurora kinase inhibitor (Kis = 8.0 and 9.2 nM for Aurora A and B kinases, respectively); selective over against a panel of CDKs and other kinases, with the exception of Flt-3 (Ki = 44 nM); exhibits broad-spectrum antiproliferative activity against a panel of human cancer cell lines (mean IC50 = 0.54 μM); orally bioavailable
21205	CYC-116	5 mg	≥98%	A potent Aurora kinase inhibitor (Kis = 8.0 and 9.2 nM for Aurora A and B kinases, respectively); selective over against a panel of CDKs and other kinases, with the exception of Flt-3 (Ki = 44 nM); exhibits broad-spectrum antiproliferative activity against a panel of human cancer cell lines (mean IC50 = 0.54 μM); orally bioavailable
21207	Dorsomorphin (hydro	1 mg	≥98%	A potent, reversible inhibitor of AMPK (Ki = 109 nM); dose-dependently inhibits the bone morphogenetic protein type 1 receptors ACTR-I (ALK2), BMPR-IA (ALK3), and BMPR-IB (ALK6); downregulates the Akt/mTOR pathway to induce autophagy in U251 human glioma cells
21207	Dorsomorphin (hydro	10 mg	≥98%	A potent, reversible inhibitor of AMPK (Ki = 109 nM); dose-dependently inhibits the bone morphogenetic protein type 1 receptors ACTR-I (ALK2), BMPR-IA (ALK3), and BMPR-IB (ALK6); downregulates the Akt/mTOR pathway to induce autophagy in U251 human glioma cells
21207	Dorsomorphin (hydro	25 mg	≥98%	A potent, reversible inhibitor of AMPK (Ki = 109 nM); dose-dependently inhibits the bone morphogenetic protein type 1 receptors ACTR-I (ALK2), BMPR-IA (ALK3), and BMPR-IB (ALK6); downregulates the Akt/mTOR pathway to induce autophagy in U251 human glioma cells
21207	Dorsomorphin (hydro	5 mg	≥98%	A potent, reversible inhibitor of AMPK (Ki = 109 nM); dose-dependently inhibits the bone morphogenetic protein type 1 receptors ACTR-I (ALK2), BMPR-IA (ALK3), and BMPR-IB (ALK6); downregulates the Akt/mTOR pathway to induce autophagy in U251 human glioma cells

21209	LX7101 (hydrochlorid	1 mg	≥98%	A potent inhibitor of LIMK1, LIMK2, ROCK1, and ROCK2 kinases (IC50s = 32, 4.3, 69, and 32 nM, respectively); selective, showing no cross reactivity in a panel of binding assays including 78 receptors, at a concentration of 10 µM; topical administration (3 µl of 1 mg/ml solution) to the eye reduces intraocular pressure in a dexamethasone-induced mouse model of glaucoma
21209	LX7101 (hydrochlorid	10 mg	≥98%	A potent inhibitor of LIMK1, LIMK2, ROCK1, and ROCK2 kinases (IC50s = 32, 4.3, 69, and 32 nM, respectively); selective, showing no cross reactivity in a panel of binding assays including 78 receptors, at a concentration of 10 µM; topical administration (3 µl of 1 mg/ml solution) to the eye reduces intraocular pressure in a dexamethasone-induced mouse model of glaucoma
21209	LX7101 (hydrochlorid	5 mg	≥98%	A potent inhibitor of LIMK1, LIMK2, ROCK1, and ROCK2 kinases (IC50s = 32, 4.3, 69, and 32 nM, respectively); selective, showing no cross reactivity in a panel of binding assays including 78 receptors, at a concentration of 10 µM; topical administration (3 µl of 1 mg/ml solution) to the eye reduces intraocular pressure in a dexamethasone-induced mouse model of glaucoma
21221	R-59-949	1 mg	≥98%	A DGK-α inhibitor (IC50 = 300 nM in isolated platelet plasma membranes); increases diacylglycerol-dependent PKC activity, serotonin secretion, and aggregation of thrombin-stimulated platelets; inhibits PDGF-induced DGK-α activity in intact VSMCs; inhibits high K+- and glucose-induced insulin secretion in MIN6 pancreatic β-cells in a dose-dependent manner; prevents retinal neovascularization in a mouse model of oxygen-induced retinopathy
21221	R-59-949	10 mg	≥98%	A DGK-α inhibitor (IC50 = 300 nM in isolated platelet plasma membranes); increases diacylglycerol-dependent PKC activity, serotonin secretion, and aggregation of thrombin-stimulated platelets; inhibits PDGF-induced DGK-α activity in intact VSMCs; inhibits high K+- and glucose-induced insulin secretion in MIN6 pancreatic β-cells in a dose-dependent manner; prevents retinal neovascularization in a mouse model of oxygen-induced retinopathy
21221	R-59-949	25 mg	≥98%	A DGK-α inhibitor (IC50 = 300 nM in isolated platelet plasma membranes); increases diacylglycerol-dependent PKC activity, serotonin secretion, and aggregation of thrombin-stimulated platelets; inhibits PDGF-induced DGK-α activity in intact VSMCs; inhibits high K+- and glucose-induced insulin secretion in MIN6 pancreatic β-cells in a dose-dependent manner; prevents retinal neovascularization in a mouse model of oxygen-induced retinopathy
21221	R-59-949	5 mg	≥98%	A DGK-α inhibitor (IC50 = 300 nM in isolated platelet plasma membranes); increases diacylglycerol-dependent PKC activity, serotonin secretion, and aggregation of thrombin-stimulated platelets; inhibits PDGF-induced DGK-α activity in intact VSMCs; inhibits high K+- and glucose-induced insulin secretion in MIN6 pancreatic β-cells in a dose-dependent manner; prevents retinal neovascularization in a mouse model of oxygen-induced retinopathy
21226	Adenosine 5'-phospho	1 mg	≥95%	An inhibitor of ATP sulfurylase (Ki = 18, 2500, and 1500 nM in humans, S. cerevisiae, P. chrysogenum, respectively) and APS kinase (Ki = 47.5 µM); prevents sulfation
21226	Adenosine 5'-phospho	10 mg	≥95%	An inhibitor of ATP sulfurylase (Ki = 18, 2500, and 1500 nM in humans, S. cerevisiae, P. chrysogenum, respectively) and APS kinase (Ki = 47.5 µM); prevents sulfation
21226	Adenosine 5'-phospho	25 mg	≥95%	An inhibitor of ATP sulfurylase (Ki = 18, 2500, and 1500 nM in humans, S. cerevisiae, P. chrysogenum, respectively) and APS kinase (Ki = 47.5 µM); prevents sulfation
21226	Adenosine 5'-phospho	5 mg	≥95%	An inhibitor of ATP sulfurylase (Ki = 18, 2500, and 1500 nM in humans, S. cerevisiae, P. chrysogenum, respectively) and APS kinase (Ki = 47.5 µM); prevents sulfation
21229	p38 MAPK Inhibitor V	1 mg	≥98%	An inhibitor of p38α (IC50 = 39 nM) and p38β MAP kinases with 82 and 93% inhibition, respectively, in a kinase assay (1 µM); selective for p38α and 38β, lacking activity at p38γ, p38δ, ERK1/2, and JNK1 at 1 µM; inhibits IL-1β, TNF-α, IL-6, IL-8, and IL-10, but not IFN-γ release from human peripheral blood mononuclear cells (IC50s = 30, 5, 17, 4, 10, and >1,000 nM, respectively); decreases ear swelling in mouse models of allergic and chronic irritative contact dermatitis (0.5 mg/ear, topical)
21229	p38 MAPK Inhibitor V	10 mg	≥98%	An inhibitor of p38α (IC50 = 39 nM) and p38β MAP kinases with 82 and 93% inhibition, respectively, in a kinase assay (1 µM); selective for p38α and 38β, lacking activity at p38γ, p38δ, ERK1/2, and JNK1 at 1 µM; inhibits IL-1β, TNF-α, IL-6, IL-8, and IL-10, but not IFN-γ release from human peripheral blood mononuclear cells (IC50s = 30, 5, 17, 4, 10, and >1,000 nM, respectively); decreases ear swelling in mouse models of allergic and chronic irritative contact dermatitis (0.5 mg/ear, topical)

21229	p38 MAPK Inhibitor V	5 mg	≥98%	An inhibitor of p38α (IC50 = 39 nM) and p38β MAP kinases with 82 and 93% inhibition, respectively, in a kinase assay (1 μM); selective for p38α and 38β, lacking activity at p38γ, p38δ, ERK1/2, and JNK1 at 1 μM; inhibits IL-1β, TNF-α, IL-6, IL-8, and IL-10, but not IFN-γ release from human peripheral blood mononuclear cells (IC50s = 30, 5, 17, 4, 10, and >1,000 nM, respectively); decreases ear swelling in mouse models of allergic and chronic irritative contact dermatitis (0.5 mg/ear, topical)
21241	SBE 13 (hydrochloride	10 mg	≥98%	A potent inhibitor of Plk1(IC50 = 0.2 nM) that targets the inactive conformation of the enzyme; exhibits no activity against aurora A kinase and less effectively inhibites Plk2 (IC50 > 66 μM) and Plk3 (IC50 = 875 nM); induces cell cycle arrest, reduces cell proliferation, and induces apoptosis
21241	SBE 13 (hydrochloride	25 mg	≥98%	A potent inhibitor of Plk1(IC50 = 0.2 nM) that targets the inactive conformation of the enzyme; exhibits no activity against aurora A kinase and less effectively inhibites Plk2 (IC50 > 66 μM) and Plk3 (IC50 = 875 nM); induces cell cycle arrest, reduces cell proliferation, and induces apoptosis
21241	SBE 13 (hydrochloride	5 mg	≥98%	A potent inhibitor of Plk1(IC50 = 0.2 nM) that targets the inactive conformation of the enzyme; exhibits no activity against aurora A kinase and less effectively inhibites Plk2 (IC50 > 66 μM) and Plk3 (IC50 = 875 nM); induces cell cycle arrest, reduces cell proliferation, and induces apoptosis
21241	SBE 13 (hydrochloride	50 mg	≥98%	A potent inhibitor of Plk1(IC50 = 0.2 nM) that targets the inactive conformation of the enzyme; exhibits no activity against aurora A kinase and less effectively inhibites Plk2 (IC50 > 66 μM) and Plk3 (IC50 = 875 nM); induces cell cycle arrest, reduces cell proliferation, and induces apoptosis
21266	MK-1775	10 mg	≥98%	An inhibitor of the checkpoint kinase Wee1 (IC50 = 5.2 nM) that prevents phosphorylation of Cdc2 at tryosine15, which abrogates the G2 DNA damage checkpoint; induces apoptosis in combination with several DNA damaging agents selectively in p53-deficient tumor cell lines
21266	MK-1775	25 mg	≥98%	An inhibitor of the checkpoint kinase Wee1 (IC50 = 5.2 nM) that prevents phosphorylation of Cdc2 at tryosine15, which abrogates the G2 DNA damage checkpoint; induces apoptosis in combination with several DNA damaging agents selectively in p53-deficient tumor cell lines
21266	MK-1775	5 mg	≥98%	An inhibitor of the checkpoint kinase Wee1 (IC50 = 5.2 nM) that prevents phosphorylation of Cdc2 at tryosine15, which abrogates the G2 DNA damage checkpoint; induces apoptosis in combination with several DNA damaging agents selectively in p53-deficient tumor cell lines
21266	MK-1775	50 mg	≥98%	An inhibitor of the checkpoint kinase Wee1 (IC50 = 5.2 nM) that prevents phosphorylation of Cdc2 at tryosine15, which abrogates the G2 DNA damage checkpoint; induces apoptosis in combination with several DNA damaging agents selectively in p53-deficient tumor cell lines
21268	Apatinib	10 mg	≥98%	A selective VEGFR2 inhibitor (IC50 = 1 nM); inhibits the proliferation of HUVECs stimulated by FBS and prevents the growth of several established human tumor xenograft models
21268	Apatinib	25 mg	≥98%	A selective VEGFR2 inhibitor (IC50 = 1 nM); inhibits the proliferation of HUVECs stimulated by FBS and prevents the growth of several established human tumor xenograft models
21268	Apatinib	5 mg	≥98%	A selective VEGFR2 inhibitor (IC50 = 1 nM); inhibits the proliferation of HUVECs stimulated by FBS and prevents the growth of several established human tumor xenograft models
21268	Apatinib	50 mg	≥98%	A selective VEGFR2 inhibitor (IC50 = 1 nM); inhibits the proliferation of HUVECs stimulated by FBS and prevents the growth of several established human tumor xenograft models
21278	CEP-37440	1 mg	≥98%	A dual inhibitor of FAK1 (IC50s = 2.0 and 80 nM for in vitro enzyme and cellular inhibition, respectively) and ALK (IC50s = 3.1 and 22 nM for in vitro enzyme and cellular inhibition, respectively); blocks the proliferation of breast cancer cell lines in vitro or in vivo
21278	CEP-37440	10 mg	≥98%	A dual inhibitor of FAK1 (IC50s = 2.0 and 80 nM for in vitro enzyme and cellular inhibition, respectively) and ALK (IC50s = 3.1 and 22 nM for in vitro enzyme and cellular inhibition, respectively); blocks the proliferation of breast cancer cell lines in vitro or in vivo
21278	CEP-37440	25 mg	≥98%	A dual inhibitor of FAK1 (IC50s = 2.0 and 80 nM for in vitro enzyme and cellular inhibition, respectively) and ALK (IC50s = 3.1 and 22 nM for in vitro enzyme and cellular inhibition, respectively); blocks the proliferation of breast cancer cell lines in vitro or in vivo
21278	CEP-37440	5 mg	≥98%	A dual inhibitor of FAK1 (IC50s = 2.0 and 80 nM for in vitro enzyme and cellular inhibition, respectively) and ALK (IC50s = 3.1 and 22 nM for in vitro enzyme and cellular inhibition, respectively); blocks the proliferation of breast cancer cell lines in vitro or in vivo
21283	PIK-293	1 mg	≥98%	A selective inhibitor of the PI3K catalytic subunit p110δ (IC50s = 0.24 μM)
21283	PIK-293	10 mg	≥98%	A selective inhibitor of the PI3K catalytic subunit p110δ (IC50s = 0.24 μM)
21283	PIK-293	25 mg	≥98%	A selective inhibitor of the PI3K catalytic subunit p110δ (IC50s = 0.24 μM)
21283	PIK-293	5 mg	≥98%	A selective inhibitor of the PI3K catalytic subunit p110δ (IC50s = 0.24 μM)
21333	AMG 337	1 mg	≥98%	A selective inhibitor of c-Met kinase activity (IC50 = 1 nM) and adaptor protein Gab-1 phosphorylation, which subsequently blocks downstream PI3K and MAPK pathways; inhibits cell proliferation in various c-Met-dependent tumor models

21333	AMG 337	10 mg	≥98%	A selective inhibitor of c-Met kinase activity (IC50 = 1 nM) and adaptor protein Gab-1 phosphorylation, which subsequently blocks downstream PI3K and MAPK pathways; inhibits cell proliferation in various c-Met-dependent tumor models
21333	AMG 337	25 mg	≥98%	A selective inhibitor of c-Met kinase activity (IC50 = 1 nM) and adaptor protein Gab-1 phosphorylation, which subsequently blocks downstream PI3K and MAPK pathways; inhibits cell proliferation in various c-Met-dependent tumor models
21333	AMG 337	5 mg	≥98%	A selective inhibitor of c-Met kinase activity (IC50 = 1 nM) and adaptor protein Gab-1 phosphorylation, which subsequently blocks downstream PI3K and MAPK pathways; inhibits cell proliferation in various c-Met-dependent tumor models
21341	Ensartinib	1 mg	≥98%	A potent and selective inhibitor of ALK (IC50 50 = 15 nM); reduces H3122 xenograft growth
21341	Ensartinib	10 mg	≥98%	A potent and selective inhibitor of ALK (IC50 50 = 15 nM); reduces H3122 xenograft growth
21341	Ensartinib	25 mg	≥98%	A potent and selective inhibitor of ALK (IC50 50 = 15 nM); reduces H3122 xenograft growth
21341	Ensartinib	5 mg	≥98%	A potent and selective inhibitor of ALK (IC50 50 = 15 nM); reduces H3122 xenograft growth
21342	FGFR4-IN-1	1 mg	≥98%	An inhibitor of FGFR4 (IC50 = 1.3 nM); selective for FGFR4 over FGFR1 and a panel of 36 kinases (IC50s = >10 μM for all); inhibits proliferation of Hep3B and Huh7 hepatic cancer cells with IC50 values of 1.1 and 2.5 nM, respectively; reduces tumor growth by 62.7 and 70.8% in a Huh7 mouse xenograft model at 30 and 100 mg/kg per day, respectively
21342	FGFR4-IN-1	10 mg	≥98%	An inhibitor of FGFR4 (IC50 = 1.3 nM); selective for FGFR4 over FGFR1 and a panel of 36 kinases (IC50s = >10 μM for all); inhibits proliferation of Hep3B and Huh7 hepatic cancer cells with IC50 values of 1.1 and 2.5 nM, respectively; reduces tumor growth by 62.7 and 70.8% in a Huh7 mouse xenograft model at 30 and 100 mg/kg per day, respectively
21342	FGFR4-IN-1	25 mg	≥98%	An inhibitor of FGFR4 (IC50 = 1.3 nM); selective for FGFR4 over FGFR1 and a panel of 36 kinases (IC50s = >10 μM for all); inhibits proliferation of Hep3B and Huh7 hepatic cancer cells with IC50 values of 1.1 and 2.5 nM, respectively; reduces tumor growth by 62.7 and 70.8% in a Huh7 mouse xenograft model at 30 and 100 mg/kg per day, respectively
21342	FGFR4-IN-1	5 mg	≥98%	An inhibitor of FGFR4 (IC50 = 1.3 nM); selective for FGFR4 over FGFR1 and a panel of 36 kinases (IC50s = >10 μM for all); inhibits proliferation of Hep3B and Huh7 hepatic cancer cells with IC50 values of 1.1 and 2.5 nM, respectively; reduces tumor growth by 62.7 and 70.8% in a Huh7 mouse xenograft model at 30 and 100 mg/kg per day, respectively
21346	GDC-0853	1 mg	≥98%	A BTK inhibitor (Kis = 0.91, 1.6, 1.3, 12.6, and 3.4 nM for wild-type BTK, BTKC481S, BTKC481R, BTKT474I, and BTKT474M, respectively); selective for BTK over a panel of 287 additional kinases at 1 μM; inhibits anti-IgM antibody-induced BTK phosphorylation in B cells (IC50 = 3.1 nM), as well as anti-IgM- or CD40L-induced proliferation of B cells (IC50s = 1.2 and 1.4 nM, respectively); reduces ankle thickness and cartilage damage in a rat model of collagen-induced arthritis
21346	GDC-0853	10 mg	≥98%	A BTK inhibitor (Kis = 0.91, 1.6, 1.3, 12.6, and 3.4 nM for wild-type BTK, BTKC481S, BTKC481R, BTKT474I, and BTKT474M, respectively); selective for BTK over a panel of 287 additional kinases at 1 μM; inhibits anti-IgM antibody-induced BTK phosphorylation in B cells (IC50 = 3.1 nM), as well as anti-IgM- or CD40L-induced proliferation of B cells (IC50s = 1.2 and 1.4 nM, respectively); reduces ankle thickness and cartilage damage in a rat model of collagen-induced arthritis
21346	GDC-0853	25 mg	≥98%	A BTK inhibitor (Kis = 0.91, 1.6, 1.3, 12.6, and 3.4 nM for wild-type BTK, BTKC481S, BTKC481R, BTKT474I, and BTKT474M, respectively); selective for BTK over a panel of 287 additional kinases at 1 μM; inhibits anti-IgM antibody-induced BTK phosphorylation in B cells (IC50 = 3.1 nM), as well as anti-IgM- or CD40L-induced proliferation of B cells (IC50s = 1.2 and 1.4 nM, respectively); reduces ankle thickness and cartilage damage in a rat model of collagen-induced arthritis
21346	GDC-0853	5 mg	≥98%	A BTK inhibitor (Kis = 0.91, 1.6, 1.3, 12.6, and 3.4 nM for wild-type BTK, BTKC481S, BTKC481R, BTKT474I, and BTKT474M, respectively); selective for BTK over a panel of 287 additional kinases at 1 μM; inhibits anti-IgM antibody-induced BTK phosphorylation in B cells (IC50 = 3.1 nM), as well as anti-IgM- or CD40L-induced proliferation of B cells (IC50s = 1.2 and 1.4 nM, respectively); reduces ankle thickness and cartilage damage in a rat model of collagen-induced arthritis
21347	ZM 323881 (hydrochl	1 mg	≥98%	A potent and selective VEGFR2 inhibitor; selective for VEGFR2 over VEGFR1, PDGFRβ, FGFR1, EGFR, and ErbB2 at concentrations greater than 50 μM; inhibits VEGF-A-stimulated cell proliferation of HUVECs (IC50 = 8 nM)
21347	ZM 323881 (hydrochl	10 mg	≥98%	A potent and selective VEGFR2 inhibitor; selective for VEGFR2 over VEGFR1, PDGFRβ, FGFR1, EGFR, and ErbB2 at concentrations greater than 50 μM; inhibits VEGF-A-stimulated cell proliferation of HUVECs (IC50 = 8 nM)

21347	ZM 323881 (hydrochl	25 mg	≥98%	A potent and selective VEGFR2 inhibitor; selective for VEGFR2 over VEGFR1, PDGFRβ, FGFR1, EGFR, and ErbB2 at concentrations greater than 50 µM; inhibits VEGF-A-stimulated cell proliferation of HUVECs (IC50 = 8 nM)
21347	ZM 323881 (hydrochl	5 mg	≥98%	A potent and selective VEGFR2 inhibitor; selective for VEGFR2 over VEGFR1, PDGFRβ, FGFR1, EGFR, and ErbB2 at concentrations greater than 50 µM; inhibits VEGF-A-stimulated cell proliferation of HUVECs (IC50 = 8 nM)
21386	BFH772	1 mg	≥95%	An inhibitor of VEGFR2 (IC50 = 0.0027 µM for the human receptor); selective for human VEGFR2 over mouse VEGFR2 and human VEGFR1 and VEGFR3 (IC50s = 1.5, 1.7, and 1.1 µM, respectively), as well as 40-fold selective over B-RAF, RET, and Tie2; inhibits VEGF-induced proliferation of HUVECs (IC50 = <0.01 nM); inhibits VEGF-induced increases in tissue weight and Tie2 levels in an angiogenesis chamber implant model in mice at 1 and 3 mg/kg per day; inhibits primary tumor and metastasis growth in a B16 melanoma mouse model at 3 mg/kg per day
21386	BFH772	10 mg	≥95%	An inhibitor of VEGFR2 (IC50 = 0.0027 µM for the human receptor); selective for human VEGFR2 over mouse VEGFR2 and human VEGFR1 and VEGFR3 (IC50s = 1.5, 1.7, and 1.1 µM, respectively), as well as 40-fold selective over B-RAF, RET, and Tie2; inhibits VEGF-induced proliferation of HUVECs (IC50 = <0.01 nM); inhibits VEGF-induced increases in tissue weight and Tie2 levels in an angiogenesis chamber implant model in mice at 1 and 3 mg/kg per day; inhibits primary tumor and metastasis growth in a B16 melanoma mouse model at 3 mg/kg per day
21386	BFH772	25 mg	≥95%	An inhibitor of VEGFR2 (IC50 = 0.0027 µM for the human receptor); selective for human VEGFR2 over mouse VEGFR2 and human VEGFR1 and VEGFR3 (IC50s = 1.5, 1.7, and 1.1 µM, respectively), as well as 40-fold selective over B-RAF, RET, and Tie2; inhibits VEGF-induced proliferation of HUVECs (IC50 = <0.01 nM); inhibits VEGF-induced increases in tissue weight and Tie2 levels in an angiogenesis chamber implant model in mice at 1 and 3 mg/kg per day; inhibits primary tumor and metastasis growth in a B16 melanoma mouse model at 3 mg/kg per day
21386	BFH772	5 mg	≥95%	An inhibitor of VEGFR2 (IC50 = 0.0027 µM for the human receptor); selective for human VEGFR2 over mouse VEGFR2 and human VEGFR1 and VEGFR3 (IC50s = 1.5, 1.7, and 1.1 µM, respectively), as well as 40-fold selective over B-RAF, RET, and Tie2; inhibits VEGF-induced proliferation of HUVECs (IC50 = <0.01 nM); inhibits VEGF-induced increases in tissue weight and Tie2 levels in an angiogenesis chamber implant model in mice at 1 and 3 mg/kg per day; inhibits primary tumor and metastasis growth in a B16 melanoma mouse model at 3 mg/kg per day
21387	Avitinib	1 mg	≥98%	A selective inhibitor of mutant EGFR that exhibits a 298-fold increase in potency compared with wild-type EGFR; oral administration at 500 mg/kg regresses tumors with EGFR-active and T790M mutations in a xenograft model
21387	Avitinib	10 mg	≥98%	A selective inhibitor of mutant EGFR that exhibits a 298-fold increase in potency compared with wild-type EGFR; oral administration at 500 mg/kg regresses tumors with EGFR-active and T790M mutations in a xenograft model
21387	Avitinib	25 mg	≥98%	A selective inhibitor of mutant EGFR that exhibits a 298-fold increase in potency compared with wild-type EGFR; oral administration at 500 mg/kg regresses tumors with EGFR-active and T790M mutations in a xenograft model
21387	Avitinib	5 mg	≥98%	A selective inhibitor of mutant EGFR that exhibits a 298-fold increase in potency compared with wild-type EGFR; oral administration at 500 mg/kg regresses tumors with EGFR-active and T790M mutations in a xenograft model
21388	ARQ-092	1 mg	≥98%	A selective, allosteric, orally bioavailable, pan-Akt inhibitor (IC50s = 5.0, 4.5, and 16 nM for Akt1, Akt2, and Akt3, respectively)
21388	ARQ-092	10 mg	≥98%	A selective, allosteric, orally bioavailable, pan-Akt inhibitor (IC50s = 5.0, 4.5, and 16 nM for Akt1, Akt2, and Akt3, respectively)
21388	ARQ-092	25 mg	≥98%	A selective, allosteric, orally bioavailable, pan-Akt inhibitor (IC50s = 5.0, 4.5, and 16 nM for Akt1, Akt2, and Akt3, respectively)
21388	ARQ-092	5 mg	≥98%	A selective, allosteric, orally bioavailable, pan-Akt inhibitor (IC50s = 5.0, 4.5, and 16 nM for Akt1, Akt2, and Akt3, respectively)
21415	NU 2058	10 mg	≥98%	An inhibitor of Cdk1 and Cdk2 (IC50s = 7.0 and 17 µM, respectively)
21415	NU 2058	100 mg	≥98%	An inhibitor of Cdk1 and Cdk2 (IC50s = 7.0 and 17 µM, respectively)
21415	NU 2058	5 mg	≥98%	An inhibitor of Cdk1 and Cdk2 (IC50s = 7.0 and 17 µM, respectively)
21415	NU 2058	50 mg	≥98%	An inhibitor of Cdk1 and Cdk2 (IC50s = 7.0 and 17 µM, respectively)
21424	Aminopurvalanol A	1 mg	≥98%	A selective CDK inhibitor; inhibits Cdk1/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, and Cdk5/p35 (IC50s = 33, 33, 28, and 20 nM, respectively); 90-fold selective for CDKs over ERK1, ERK2, PKC-δ, PKA, CK1, and insulin receptor tyrosine kinase; over 3,000-fold selective over a range of other kinases; antiproliferative (GI50s = 30-1,000 nM); inhibits mitotic division; preferentially arrests cells in G2/M phase
21424	Aminopurvalanol A	5 mg	≥98%	A selective CDK inhibitor; inhibits Cdk1/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, and Cdk5/p35 (IC50s = 33, 33, 28, and 20 nM, respectively); 90-fold selective for CDKs over ERK1, ERK2, PKC-δ, PKA, CK1, and insulin receptor tyrosine kinase; over 3,000-fold selective over a range of other kinases; antiproliferative (GI50s = 30-1,000 nM); inhibits mitotic division; preferentially arrests cells in G2/M phase

21429	KX2-391	10 mg	≥98%	A Src kinase inhibitor (IC50 = ~20 nM); selective for Src over PDGFR, EGFR, JAK1, JAK2, Lck, and ZAP-70; induces cell cycle arrest at the G2/M phase and apoptosis in ERα-positive breast cancer cells; inhibits the growth of Huh7, PLC/PRF/5, Hep3B, and HepG2 cells (GI50s = 9, 13, 26, and 60 nM, respectively); decreases spleen weight and the number of splenic leukemia cells in a mouse model of FLT3-ITD-F691L AML
21429	KX2-391	100 mg	≥98%	A Src kinase inhibitor (IC50 = ~20 nM); selective for Src over PDGFR, EGFR, JAK1, JAK2, Lck, and ZAP-70; induces cell cycle arrest at the G2/M phase and apoptosis in ERα-positive breast cancer cells; inhibits the growth of Huh7, PLC/PRF/5, Hep3B, and HepG2 cells (GI50s = 9, 13, 26, and 60 nM, respectively); decreases spleen weight and the number of splenic leukemia cells in a mouse model of FLT3-ITD-F691L AML
21429	KX2-391	5 mg	≥98%	A Src kinase inhibitor (IC50 = ~20 nM); selective for Src over PDGFR, EGFR, JAK1, JAK2, Lck, and ZAP-70; induces cell cycle arrest at the G2/M phase and apoptosis in ERα-positive breast cancer cells; inhibits the growth of Huh7, PLC/PRF/5, Hep3B, and HepG2 cells (GI50s = 9, 13, 26, and 60 nM, respectively); decreases spleen weight and the number of splenic leukemia cells in a mouse model of FLT3-ITD-F691L AML
21429	KX2-391	50 mg	≥98%	A Src kinase inhibitor (IC50 = ~20 nM); selective for Src over PDGFR, EGFR, JAK1, JAK2, Lck, and ZAP-70; induces cell cycle arrest at the G2/M phase and apoptosis in ERα-positive breast cancer cells; inhibits the growth of Huh7, PLC/PRF/5, Hep3B, and HepG2 cells (GI50s = 9, 13, 26, and 60 nM, respectively); decreases spleen weight and the number of splenic leukemia cells in a mouse model of FLT3-ITD-F691L AML
21434	H-7 (hydrochloride)	10 mg	≥98%	A non-selective protein kinase inhibitor (IC50s = 20, 36, 7, and 420 µM for PKC, A, G, and M, respectively); has been widely used to characterize the functional roles of PKC in a multitude of cellular processes
21434	H-7 (hydrochloride)	25 mg	≥98%	A non-selective protein kinase inhibitor (IC50s = 20, 36, 7, and 420 µM for PKC, A, G, and M, respectively); has been widely used to characterize the functional roles of PKC in a multitude of cellular processes
21434	H-7 (hydrochloride)	5 mg	≥98%	A non-selective protein kinase inhibitor (IC50s = 20, 36, 7, and 420 µM for PKC, A, G, and M, respectively); has been widely used to characterize the functional roles of PKC in a multitude of cellular processes
21434	H-7 (hydrochloride)	50 mg	≥98%	A non-selective protein kinase inhibitor (IC50s = 20, 36, 7, and 420 µM for PKC, A, G, and M, respectively); has been widely used to characterize the functional roles of PKC in a multitude of cellular processes
21435	PD 089828	1 mg	≥98%	An inhibitor of EGFR, PDGFβ, FGF, and c-Src (IC50s = 0.15, 1.76, 5.47, and 0.18 µM, respectively); inhibits MAPK (IC50 = 7.1 µM); selective over insulin receptor tyrosine kinase, PKC, and CDK4 (IC50s = >50 µM); decreases PDGF-BB-, EGF-, and bFGF-induced phosphorylation of PDGFR, EGFR, and FGFR1 in vitro; decreases serum-stimulated growth (IC50 = 1.8 µM after 8 days) and migration (IC50 = 4.5 µM) of rat aortic smooth muscle cells
21435	PD 089828	5 mg	≥98%	An inhibitor of EGFR, PDGFβ, FGF, and c-Src (IC50s = 0.15, 1.76, 5.47, and 0.18 µM, respectively); inhibits MAPK (IC50 = 7.1 µM); selective over insulin receptor tyrosine kinase, PKC, and CDK4 (IC50s = >50 µM); decreases PDGF-BB-, EGF-, and bFGF-induced phosphorylation of PDGFR, EGFR, and FGFR1 in vitro; decreases serum-stimulated growth (IC50 = 1.8 µM after 8 days) and migration (IC50 = 4.5 µM) of rat aortic smooth muscle cells
21444	Manzamine A	1 mg	≥98%	A β-carboline alkaloid with diverse activities; inhibits GSK3β and CDK5 (IC50s = 10.2 and 1.5 µM, respectively); inhibits the growth of L5178y mouse lymphoma cells (ED50 = 1.8 µg/mL); inhibits the growth of B. subtilis and S. aureus; reduces RT activity in supernatant from human PBMCs infected with HIV-1 (EC50 = 4.2 µM); reduces the amount of P. berghei in infected mice by over 90% relative to the control at 100 µmol/kg, i.p.; inhibits the growth of S. littoralis larva by 80% when added to the diet at 132 ppm
21444	Manzamine A	500 µg	≥98%	A β-carboline alkaloid with diverse activities; inhibits GSK3β and CDK5 (IC50s = 10.2 and 1.5 µM, respectively); inhibits the growth of L5178y mouse lymphoma cells (ED50 = 1.8 µg/mL); inhibits the growth of B. subtilis and S. aureus; reduces RT activity in supernatant from human PBMCs infected with HIV-1 (EC50 = 4.2 µM); reduces the amount of P. berghei in infected mice by over 90% relative to the control at 100 µmol/kg, i.p.; inhibits the growth of S. littoralis larva by 80% when added to the diet at 132 ppm
21461	Amuvatinib	1 mg	≥98%	A multi-targeted RTK inhibitor that inhibits c-Kit, PDGFRα, and c-Met (IC50s = 10, 40, and 81 nM, respectively); sensitizes cancer cells to radiation and chemotherapeutic compounds, in part by inhibiting homologous recombination
21461	Amuvatinib	10 mg	≥98%	A multi-targeted RTK inhibitor that inhibits c-Kit, PDGFRα, and c-Met (IC50s = 10, 40, and 81 nM, respectively); sensitizes cancer cells to radiation and chemotherapeutic compounds, in part by inhibiting homologous recombination
21461	Amuvatinib	25 mg	≥98%	A multi-targeted RTK inhibitor that inhibits c-Kit, PDGFRα, and c-Met (IC50s = 10, 40, and 81 nM, respectively); sensitizes cancer cells to radiation and chemotherapeutic compounds, in part by inhibiting homologous recombination

21461	Amuvatinib	5 mg	≥98%	A multi-targeted RTK inhibitor that inhibits c-Kit, PDGFRα, and c-Met (IC50s = 10, 40, and 81 nM, respectively); sensitizes cancer cells to radiation and chemotherapeutic compounds, in part by inhibiting homologous recombination
21465	Rebastinib	1 mg	≥98%	An orally bioavailable tyrosine kinase inhibitor that inhibits Abl1 (IC50 = 0.8 nM), Abl1T315I (IC50 = 4 nM), and Abl1H396P; also inhibits the Src family kinases Src, Lyn, Fgr, and Hck and the tyrosine kinases KDR, FLT3, and Tie2 at nanomolar concentrations
21465	Rebastinib	10 mg	≥98%	An orally bioavailable tyrosine kinase inhibitor that inhibits Abl1 (IC50 = 0.8 nM), Abl1T315I (IC50 = 4 nM), and Abl1H396P; also inhibits the Src family kinases Src, Lyn, Fgr, and Hck and the tyrosine kinases KDR, FLT3, and Tie2 at nanomolar concentrations
21465	Rebastinib	25 mg	≥98%	An orally bioavailable tyrosine kinase inhibitor that inhibits Abl1 (IC50 = 0.8 nM), Abl1T315I (IC50 = 4 nM), and Abl1H396P; also inhibits the Src family kinases Src, Lyn, Fgr, and Hck and the tyrosine kinases KDR, FLT3, and Tie2 at nanomolar concentrations
21465	Rebastinib	5 mg	≥98%	An orally bioavailable tyrosine kinase inhibitor that inhibits Abl1 (IC50 = 0.8 nM), Abl1T315I (IC50 = 4 nM), and Abl1H396P; also inhibits the Src family kinases Src, Lyn, Fgr, and Hck and the tyrosine kinases KDR, FLT3, and Tie2 at nanomolar concentrations
21469	G-5555	1 mg	≥98%	A PAK1 inhibitor (Ki =3.7 nM); selective for PAK1 over the majority of targets in a panel of 235 kinases but does inhibit PAK2, PAK3, KHS1, LCK, MST3, MST4, SIK2, and YSK1 by greater than 70% (IC50s = 9-52 nM); inhibits phosphorylation of MEK (IC50 = 69 nM in EBC1 cells); reduces phosphorylation of MEK in tumors from an H292 NSCLC mouse xenograft model (10, 20, and 30 mg/kg); inhibits hERG channels by less than 50% at a concentration of 10 µM
21469	G-5555	10 mg	≥98%	A PAK1 inhibitor (Ki =3.7 nM); selective for PAK1 over the majority of targets in a panel of 235 kinases but does inhibit PAK2, PAK3, KHS1, LCK, MST3, MST4, SIK2, and YSK1 by greater than 70% (IC50s = 9-52 nM); inhibits phosphorylation of MEK (IC50 = 69 nM in EBC1 cells); reduces phosphorylation of MEK in tumors from an H292 NSCLC mouse xenograft model (10, 20, and 30 mg/kg); inhibits hERG channels by less than 50% at a concentration of 10 µM
21469	G-5555	5 mg	≥98%	A PAK1 inhibitor (Ki =3.7 nM); selective for PAK1 over the majority of targets in a panel of 235 kinases but does inhibit PAK2, PAK3, KHS1, LCK, MST3, MST4, SIK2, and YSK1 by greater than 70% (IC50s = 9-52 nM); inhibits phosphorylation of MEK (IC50 = 69 nM in EBC1 cells); reduces phosphorylation of MEK in tumors from an H292 NSCLC mouse xenograft model (10, 20, and 30 mg/kg); inhibits hERG channels by less than 50% at a concentration of 10 µM
21469	G-5555	500 µg	≥98%	A PAK1 inhibitor (Ki =3.7 nM); selective for PAK1 over the majority of targets in a panel of 235 kinases but does inhibit PAK2, PAK3, KHS1, LCK, MST3, MST4, SIK2, and YSK1 by greater than 70% (IC50s = 9-52 nM); inhibits phosphorylation of MEK (IC50 = 69 nM in EBC1 cells); reduces phosphorylation of MEK in tumors from an H292 NSCLC mouse xenograft model (10, 20, and 30 mg/kg); inhibits hERG channels by less than 50% at a concentration of 10 µM
21472	KN-93 (phosphate)	1 mg	≥98%	A CaMKII inhibitor (Ki = 370 nM) that inhibits the α- and β-subunits of CaMKII
21472	KN-93 (phosphate)	10 mg	≥98%	A CaMKII inhibitor (Ki = 370 nM) that inhibits the α- and β-subunits of CaMKII
21472	KN-93 (phosphate)	25 mg	≥98%	A CaMKII inhibitor (Ki = 370 nM) that inhibits the α- and β-subunits of CaMKII
21472	KN-93 (phosphate)	5 mg	≥98%	A CaMKII inhibitor (Ki = 370 nM) that inhibits the α- and β-subunits of CaMKII
21474	PHA-848125	1 mg	≥98%	An ATP-competitive inhibitor of Cdks that most potently inhibits Cdk2/cyclin A (IC50 = 45 nM); more than 3-fold less potent at Cdks 1, 3, 4, 5, and 7
21474	PHA-848125	10 mg	≥98%	An ATP-competitive inhibitor of Cdks that most potently inhibits Cdk2/cyclin A (IC50 = 45 nM); more than 3-fold less potent at Cdks 1, 3, 4, 5, and 7
21474	PHA-848125	5 mg	≥98%	An ATP-competitive inhibitor of Cdks that most potently inhibits Cdk2/cyclin A (IC50 = 45 nM); more than 3-fold less potent at Cdks 1, 3, 4, 5, and 7
21475	CNX-774	1 mg	≥98%	A potent, selective, and irreversible BTK inhibitor
21475	CNX-774	10 mg	≥98%	A potent, selective, and irreversible BTK inhibitor
21475	CNX-774	25 mg	≥98%	A potent, selective, and irreversible BTK inhibitor
21475	CNX-774	5 mg	≥98%	A potent, selective, and irreversible BTK inhibitor
21482	Bentamapimod	1 mg	≥98%	A selective, orally bioavailable inhibitor of JNK1, JNK2, and JNK3 (IC50s = 80, 90, and 230 nM, respectively); induces regression of endometriotic lesions without suppressing estrogen action in animal models of endometriosis
21482	Bentamapimod	10 mg	≥98%	A selective, orally bioavailable inhibitor of JNK1, JNK2, and JNK3 (IC50s = 80, 90, and 230 nM, respectively); induces regression of endometriotic lesions without suppressing estrogen action in animal models of endometriosis
21482	Bentamapimod	25 mg	≥98%	A selective, orally bioavailable inhibitor of JNK1, JNK2, and JNK3 (IC50s = 80, 90, and 230 nM, respectively); induces regression of endometriotic lesions without suppressing estrogen action in animal models of endometriosis

21482	Bentamapimod	5 mg	≥98%	A selective, orally bioavailable inhibitor of JNK1, JNK2, and JNK3 (IC50s = 80, 90, and 230 nM, respectively); induces regression of endometriotic lesions without suppressing estrogen action in animal models of endometriosis
21490	LY2606368	1 mg	≥98%	A Chk1 inhibitor (Ki = 0.9 nM); IC50 values of 2/M checkpoint in HeLa cells; induces apoptosis in gastric cancer cell lines
21490	LY2606368	10 mg	≥98%	A Chk1 inhibitor (Ki = 0.9 nM); IC50 values of 2/M checkpoint in HeLa cells; induces apoptosis in gastric cancer cell lines
21490	LY2606368	25 mg	≥98%	A Chk1 inhibitor (Ki = 0.9 nM); IC50 values of 2/M checkpoint in HeLa cells; induces apoptosis in gastric cancer cell lines
21490	LY2606368	5 mg	≥98%	A Chk1 inhibitor (Ki = 0.9 nM); IC50 values of 2/M checkpoint in HeLa cells; induces apoptosis in gastric cancer cell lines
21503	Gilteritinib	1 mg	≥98%	A FLT3 inhibitor (IC50 = 5 nM for the wild-type enzyme); inhibits various FLT3 mutants (IC50s = 1.4-12.2 nM); also inhibits Axl and c-Kit (IC50s = 41 and 102 nM, respectively); decreases the viability of blast cells isolated from patients with relapsed AML in a concentration-dependent manner
21503	Gilteritinib	10 mg	≥98%	A FLT3 inhibitor (IC50 = 5 nM for the wild-type enzyme); inhibits various FLT3 mutants (IC50s = 1.4-12.2 nM); also inhibits Axl and c-Kit (IC50s = 41 and 102 nM, respectively); decreases the viability of blast cells isolated from patients with relapsed AML in a concentration-dependent manner
21503	Gilteritinib	25 mg	≥98%	A FLT3 inhibitor (IC50 = 5 nM for the wild-type enzyme); inhibits various FLT3 mutants (IC50s = 1.4-12.2 nM); also inhibits Axl and c-Kit (IC50s = 41 and 102 nM, respectively); decreases the viability of blast cells isolated from patients with relapsed AML in a concentration-dependent manner
21503	Gilteritinib	5 mg	≥98%	A FLT3 inhibitor (IC50 = 5 nM for the wild-type enzyme); inhibits various FLT3 mutants (IC50s = 1.4-12.2 nM); also inhibits Axl and c-Kit (IC50s = 41 and 102 nM, respectively); decreases the viability of blast cells isolated from patients with relapsed AML in a concentration-dependent manner
21504	LY3009120	10 mg	≥98%	An inhibitor of A-Raf, B-Raf, and c-Raf (IC50s = 44, 31-47, and 42 nM, respectively, in whole cell lysates); inhibits B-Raf mutants V600E and V600E+G468A (IC50s = 5.8 and 17 nM, respectively, in biochemical assays); induces Raf dimerization and inhibits kinase activity of induced dimers
21504	LY3009120	25 mg	≥98%	An inhibitor of A-Raf, B-Raf, and c-Raf (IC50s = 44, 31-47, and 42 nM, respectively, in whole cell lysates); inhibits B-Raf mutants V600E and V600E+G468A (IC50s = 5.8 and 17 nM, respectively, in biochemical assays); induces Raf dimerization and inhibits kinase activity of induced dimers
21504	LY3009120	5 mg	≥98%	An inhibitor of A-Raf, B-Raf, and c-Raf (IC50s = 44, 31-47, and 42 nM, respectively, in whole cell lysates); inhibits B-Raf mutants V600E and V600E+G468A (IC50s = 5.8 and 17 nM, respectively, in biochemical assays); induces Raf dimerization and inhibits kinase activity of induced dimers
21504	LY3009120	50 mg	≥98%	An inhibitor of A-Raf, B-Raf, and c-Raf (IC50s = 44, 31-47, and 42 nM, respectively, in whole cell lysates); inhibits B-Raf mutants V600E and V600E+G468A (IC50s = 5.8 and 17 nM, respectively, in biochemical assays); induces Raf dimerization and inhibits kinase activity of induced dimers
21506	XL228	10 mg	≥98%	A tyrosine kinase inhibitor; inhibits IGF-1R and FGFR2 (IC50s = 1.6 and 50s = 5, 3.1, 2, and 6.1 nM, respectively); inhibits proliferation of CML and ALL cell lines (IC50s = <100 nM)
21506	XL228	25 mg	≥98%	A tyrosine kinase inhibitor; inhibits IGF-1R and FGFR2 (IC50s = 1.6 and 50s = 5, 3.1, 2, and 6.1 nM, respectively); inhibits proliferation of CML and ALL cell lines (IC50s = <100 nM)
21506	XL228	5 mg	≥98%	A tyrosine kinase inhibitor; inhibits IGF-1R and FGFR2 (IC50s = 1.6 and 50s = 5, 3.1, 2, and 6.1 nM, respectively); inhibits proliferation of CML and ALL cell lines (IC50s = <100 nM)
21506	XL228	50 mg	≥98%	A tyrosine kinase inhibitor; inhibits IGF-1R and FGFR2 (IC50s = 1.6 and 50s = 5, 3.1, 2, and 6.1 nM, respectively); inhibits proliferation of CML and ALL cell lines (IC50s = <100 nM)
21508	GZD-824	1 mg	≥98%	Inhibitor of a broad spectrum of Bcr/Abl tyrosine kinase mutants (IC50s = 0.34 and 0.68 nM for wild-type Bcr/Abl and Bcr/AblT315I, respectively); suppresses proliferation of Bcr/Abl-positive K562 and Ku812 CML cells (IC50s = 0.2 and 0.13 nM, respectively) and induces tumor regression in mouse xenograft tumor models driven by either wild-type or mutant Bcr/Abl
21508	GZD-824	10 mg	≥98%	Inhibitor of a broad spectrum of Bcr/Abl tyrosine kinase mutants (IC50s = 0.34 and 0.68 nM for wild-type Bcr/Abl and Bcr/AblT315I, respectively); suppresses proliferation of Bcr/Abl-positive K562 and Ku812 CML cells (IC50s = 0.2 and 0.13 nM, respectively) and induces tumor regression in mouse xenograft tumor models driven by either wild-type or mutant Bcr/Abl
21508	GZD-824	25 mg	≥98%	Inhibitor of a broad spectrum of Bcr/Abl tyrosine kinase mutants (IC50s = 0.34 and 0.68 nM for wild-type Bcr/Abl and Bcr/AblT315I, respectively); suppresses proliferation of Bcr/Abl-positive K562 and Ku812 CML cells (IC50s = 0.2 and 0.13 nM, respectively) and induces tumor regression in mouse xenograft tumor models driven by either wild-type or mutant Bcr/Abl
21508	GZD-824	5 mg	≥98%	Inhibitor of a broad spectrum of Bcr/Abl tyrosine kinase mutants (IC50s = 0.34 and 0.68 nM for wild-type Bcr/Abl and Bcr/AblT315I, respectively); suppresses proliferation of Bcr/Abl-positive K562 and Ku812 CML cells (IC50s = 0.2 and 0.13 nM, respectively) and induces tumor regression in mouse xenograft tumor models driven by either wild-type or mutant Bcr/Abl

21518	RSM-932A	1 mg	≥95%	A selective inhibitor of CHOKα (IC50s = 1 and >50 μM for CHOKα and β, respectively); induces apoptosis via CHOP signaling and ER stress in MDA-MB-231, MCF-7, SW620, and H460 cancer cells; inhibits the growth of HT-29 colon cancer cells in vitro (IC50 = 1.15 μM) and in vivo in a mouse xenograft model (ED50 = 7.5 mg/kg)
21518	RSM-932A	10 mg	≥95%	A selective inhibitor of CHOKα (IC50s = 1 and >50 μM for CHOKα and β, respectively); induces apoptosis via CHOP signaling and ER stress in MDA-MB-231, MCF-7, SW620, and H460 cancer cells; inhibits the growth of HT-29 colon cancer cells in vitro (IC50 = 1.15 μM) and in vivo in a mouse xenograft model (ED50 = 7.5 mg/kg)
21518	RSM-932A	5 mg	≥95%	A selective inhibitor of CHOKα (IC50s = 1 and >50 μM for CHOKα and β, respectively); induces apoptosis via CHOP signaling and ER stress in MDA-MB-231, MCF-7, SW620, and H460 cancer cells; inhibits the growth of HT-29 colon cancer cells in vitro (IC50 = 1.15 μM) and in vivo in a mouse xenograft model (ED50 = 7.5 mg/kg)
21523	R428	1 mg	≥98%	An inhibitor of Axl kinase (EC50 = 14 nM); orally bioavailable, blocks angiogenesis in corneal micropocket and tumor models, and reduces metastatic burden while extending survival in mouse models of breast cancer metastasis
21523	R428	10 mg	≥98%	An inhibitor of Axl kinase (EC50 = 14 nM); orally bioavailable, blocks angiogenesis in corneal micropocket and tumor models, and reduces metastatic burden while extending survival in mouse models of breast cancer metastasis
21523	R428	25 mg	≥98%	An inhibitor of Axl kinase (EC50 = 14 nM); orally bioavailable, blocks angiogenesis in corneal micropocket and tumor models, and reduces metastatic burden while extending survival in mouse models of breast cancer metastasis
21560	LY2835219	1 mg	≥98%	An orally bioavailable dual inhibitor of Cdk4 and Cdk6 (IC50s = 2 and 10 nM, respectively); has antitumor action against xenografts when used alone or in combination with other chemotherapeutic compounds
21560	LY2835219	10 mg	≥98%	An orally bioavailable dual inhibitor of Cdk4 and Cdk6 (IC50s = 2 and 10 nM, respectively); has antitumor action against xenografts when used alone or in combination with other chemotherapeutic compounds
21560	LY2835219	25 mg	≥98%	An orally bioavailable dual inhibitor of Cdk4 and Cdk6 (IC50s = 2 and 10 nM, respectively); has antitumor action against xenografts when used alone or in combination with other chemotherapeutic compounds
21560	LY2835219	5 mg	≥98%	An orally bioavailable dual inhibitor of Cdk4 and Cdk6 (IC50s = 2 and 10 nM, respectively); has antitumor action against xenografts when used alone or in combination with other chemotherapeutic compounds
21561	SKLB610	1 mg	≥98%	An inhibitor of VEGFR2; inhibits VEGFR2 activity by 97% but also inhibits FGFR2 and PDGFRβ activity by 65 and 55%, respectively, at 10 μM; selective for VEGFR2, FGFR2, and PDGFRβ over PI3K, EGFR, Aurora A, Cdk2/cyclin E, and Cdk6/cyclin D3 at 10 μM; inhibits VEGF- and bFGF-induced proliferation of HUVECs (IC50s = 2.2 and 4.7 μM, respectively); inhibits HUVEC capillary tube formation and migration at 2.5 and 10 μM, respectively; inhibits proliferation of a variety of cancer cells, including A549, HCT116, MDA-MB-231, Raji and DU145 cells (IC50s = 5.7, 5.3, 25.6, 6.4, and 6.3 μM, respectively); reduces tumor growth in A549 and HCT116 mouse xenograft models at 50 mg/kg per day
21561	SKLB610	10 mg	≥98%	An inhibitor of VEGFR2; inhibits VEGFR2 activity by 97% but also inhibits FGFR2 and PDGFRβ activity by 65 and 55%, respectively, at 10 μM; selective for VEGFR2, FGFR2, and PDGFRβ over PI3K, EGFR, Aurora A, Cdk2/cyclin E, and Cdk6/cyclin D3 at 10 μM; inhibits VEGF- and bFGF-induced proliferation of HUVECs (IC50s = 2.2 and 4.7 μM, respectively); inhibits HUVEC capillary tube formation and migration at 2.5 and 10 μM, respectively; inhibits proliferation of a variety of cancer cells, including A549, HCT116, MDA-MB-231, Raji and DU145 cells (IC50s = 5.7, 5.3, 25.6, 6.4, and 6.3 μM, respectively); reduces tumor growth in A549 and HCT116 mouse xenograft models at 50 mg/kg per day
21561	SKLB610	25 mg	≥98%	An inhibitor of VEGFR2; inhibits VEGFR2 activity by 97% but also inhibits FGFR2 and PDGFRβ activity by 65 and 55%, respectively, at 10 μM; selective for VEGFR2, FGFR2, and PDGFRβ over PI3K, EGFR, Aurora A, Cdk2/cyclin E, and Cdk6/cyclin D3 at 10 μM; inhibits VEGF- and bFGF-induced proliferation of HUVECs (IC50s = 2.2 and 4.7 μM, respectively); inhibits HUVEC capillary tube formation and migration at 2.5 and 10 μM, respectively; inhibits proliferation of a variety of cancer cells, including A549, HCT116, MDA-MB-231, Raji and DU145 cells (IC50s = 5.7, 5.3, 25.6, 6.4, and 6.3 μM, respectively); reduces tumor growth in A549 and HCT116 mouse xenograft models at 50 mg/kg per day
21561	SKLB610	5 mg	≥98%	An inhibitor of VEGFR2; inhibits VEGFR2 activity by 97% but also inhibits FGFR2 and PDGFRβ activity by 65 and 55%, respectively, at 10 μM; selective for VEGFR2, FGFR2, and PDGFRβ over PI3K, EGFR, Aurora A, Cdk2/cyclin E, and Cdk6/cyclin D3 at 10 μM; inhibits VEGF- and bFGF-induced proliferation of HUVECs (IC50s = 2.2 and 4.7 μM, respectively); inhibits HUVEC capillary tube formation and migration at 2.5 and 10 μM, respectively; inhibits proliferation of a variety of cancer cells, including A549, HCT116, MDA-MB-231, Raji and DU145 cells (IC50s = 5.7, 5.3, 25.6, 6.4, and 6.3 μM, respectively); reduces tumor growth in A549 and HCT116 mouse xenograft models at 50 mg/kg per day

21562	kb-NB77-78	1 mg	≥98%	An inactive analog of the PKD inhibitor CID755673; does not bind PKD1 in a fluorescence polarization assay and has no effect on PKD1 phosphorylation in LNCaP cancer cells
21562	kb-NB77-78	10 mg	≥98%	An inactive analog of the PKD inhibitor CID755673; does not bind PKD1 in a fluorescence polarization assay and has no effect on PKD1 phosphorylation in LNCaP cancer cells
21562	kb-NB77-78	25 mg	≥98%	An inactive analog of the PKD inhibitor CID755673; does not bind PKD1 in a fluorescence polarization assay and has no effect on PKD1 phosphorylation in LNCaP cancer cells
21562	kb-NB77-78	5 mg	≥98%	An inactive analog of the PKD inhibitor CID755673; does not bind PKD1 in a fluorescence polarization assay and has no effect on PKD1 phosphorylation in LNCaP cancer cells
21567	Afatinib (maleate)	1 g	≥95%	An inhibitor of EGFR and ErbB2 (IC50s = 0.5 and 14 nM, respectively); increases the cytotoxicity of adriamycin in a concentration-dependent manner in multidrug-resistant A549T lung cancer cells overexpressing P-glycoprotein; reduces tumor growth in ErbB2-amplified NCI-N87 and NUGC4 gastric cancer mouse xenograft models at 20 mg/kg
21567	Afatinib (maleate)	250 mg	≥95%	An inhibitor of EGFR and ErbB2 (IC50s = 0.5 and 14 nM, respectively); increases the cytotoxicity of adriamycin in a concentration-dependent manner in multidrug-resistant A549T lung cancer cells overexpressing P-glycoprotein; reduces tumor growth in ErbB2-amplified NCI-N87 and NUGC4 gastric cancer mouse xenograft models at 20 mg/kg
21567	Afatinib (maleate)	5 g	≥95%	An inhibitor of EGFR and ErbB2 (IC50s = 0.5 and 14 nM, respectively); increases the cytotoxicity of adriamycin in a concentration-dependent manner in multidrug-resistant A549T lung cancer cells overexpressing P-glycoprotein; reduces tumor growth in ErbB2-amplified NCI-N87 and NUGC4 gastric cancer mouse xenograft models at 20 mg/kg
21567	Afatinib (maleate)	500 mg	≥95%	An inhibitor of EGFR and ErbB2 (IC50s = 0.5 and 14 nM, respectively); increases the cytotoxicity of adriamycin in a concentration-dependent manner in multidrug-resistant A549T lung cancer cells overexpressing P-glycoprotein; reduces tumor growth in ErbB2-amplified NCI-N87 and NUGC4 gastric cancer mouse xenograft models at 20 mg/kg
21582	SPHINX31	1 mg	≥98%	A potent inhibitor of SRPK1 (IC50 = 5.9 nM); inhibits phosphorylation of SRSF1, an SRPK1 substrate, in PC3 cells (EC50 = 360 nM); increases expression of the anti-angiogenic VEGF-A165b splice variant in RPE cells; inhibits blood vessel growth and macrophage infiltration in the eyes of a mouse model of choroidal neovascularization (2 µg per eye)
21582	SPHINX31	10 mg	≥98%	A potent inhibitor of SRPK1 (IC50 = 5.9 nM); inhibits phosphorylation of SRSF1, an SRPK1 substrate, in PC3 cells (EC50 = 360 nM); increases expression of the anti-angiogenic VEGF-A165b splice variant in RPE cells; inhibits blood vessel growth and macrophage infiltration in the eyes of a mouse model of choroidal neovascularization (2 µg per eye)
21582	SPHINX31	25 mg	≥98%	A potent inhibitor of SRPK1 (IC50 = 5.9 nM); inhibits phosphorylation of SRSF1, an SRPK1 substrate, in PC3 cells (EC50 = 360 nM); increases expression of the anti-angiogenic VEGF-A165b splice variant in RPE cells; inhibits blood vessel growth and macrophage infiltration in the eyes of a mouse model of choroidal neovascularization (2 µg per eye)
21582	SPHINX31	5 mg	≥98%	A potent inhibitor of SRPK1 (IC50 = 5.9 nM); inhibits phosphorylation of SRSF1, an SRPK1 substrate, in PC3 cells (EC50 = 360 nM); increases expression of the anti-angiogenic VEGF-A165b splice variant in RPE cells; inhibits blood vessel growth and macrophage infiltration in the eyes of a mouse model of choroidal neovascularization (2 µg per eye)
21584	Rp-8-bromo-Cyclic AM	1 mg	≥98%	A membrane-permeable antagonist of cAMP-dependent PKAs; resistant to hydrolysis by cyclic nucleotide PDEs
21584	Rp-8-bromo-Cyclic AM	5 mg	≥98%	A membrane-permeable antagonist of cAMP-dependent PKAs; resistant to hydrolysis by cyclic nucleotide PDEs
21584	Rp-8-bromo-Cyclic AM	500 µg	≥98%	A membrane-permeable antagonist of cAMP-dependent PKAs; resistant to hydrolysis by cyclic nucleotide PDEs
21597	AT-13148	1 mg	≥98%	An orally bioavailable and ATP-competitive multi-AGC kinase inhibitor; inhibits Akt1, 2, and 3 (IC50s = 38, 402, and 50 nM, respectively); inhibits p70S6K, PKA, and ROCK1 and ROCK2 (IC50s = 3-8 nM); antiproliferative against cancer cell lines with genetic mutations in PI3K-Akt-mTOR or RAS-RAF pathways (GI50s = 1.54-3.77 µM); inhibits growth of MES-SA uterine sarcoma and BT474 breast cancer xenografts in mice (50 mg/kg, p.o.); inhibits ROCK-dependent phosphorylation of MLC2 over a 24-hour period in 4599 mouse melanoma cells (EC50 = 0.1 µM); reduces motility of 4699 melanoma cells in murine xenograft model

21597	AT-13148	10 mg	≥98%	An orally bioavailable and ATP-competitive multi-AGC kinase inhibitor; inhibits Akt1, 2, and 3 (IC50s = 38, 402, and 50 nM, respectively); inhibits p70S6K, PKA, and ROCK1 and ROCK2 (IC50s = 3-8 nM); antiproliferative against cancer cell lines with genetic mutations in PI3K-Akt-mTOR or RAS-RAF pathways (GI50s = 1.54-3.77 μM); inhibits growth of MES-SA uterine sarcoma and BT474 breast cancer xenografts in mice (50 mg/kg, p.o.); inhibits ROCK-dependent phosphorylation of MLC2 over a 24-hour period in 4599 mouse melanoma cells (EC50 = 0.1 μM); reduces motility of 4699 melanoma cells in murine xenograft model
21597	AT-13148	25 mg	≥98%	An orally bioavailable and ATP-competitive multi-AGC kinase inhibitor; inhibits Akt1, 2, and 3 (IC50s = 38, 402, and 50 nM, respectively); inhibits p70S6K, PKA, and ROCK1 and ROCK2 (IC50s = 3-8 nM); antiproliferative against cancer cell lines with genetic mutations in PI3K-Akt-mTOR or RAS-RAF pathways (GI50s = 1.54-3.77 μM); inhibits growth of MES-SA uterine sarcoma and BT474 breast cancer xenografts in mice (50 mg/kg, p.o.); inhibits ROCK-dependent phosphorylation of MLC2 over a 24-hour period in 4599 mouse melanoma cells (EC50 = 0.1 μM); reduces motility of 4699 melanoma cells in murine xenograft model
21597	AT-13148	5 mg	≥98%	An orally bioavailable and ATP-competitive multi-AGC kinase inhibitor; inhibits Akt1, 2, and 3 (IC50s = 38, 402, and 50 nM, respectively); inhibits p70S6K, PKA, and ROCK1 and ROCK2 (IC50s = 3-8 nM); antiproliferative against cancer cell lines with genetic mutations in PI3K-Akt-mTOR or RAS-RAF pathways (GI50s = 1.54-3.77 μM); inhibits growth of MES-SA uterine sarcoma and BT474 breast cancer xenografts in mice (50 mg/kg, p.o.); inhibits ROCK-dependent phosphorylation of MLC2 over a 24-hour period in 4599 mouse melanoma cells (EC50 = 0.1 μM); reduces motility of 4699 melanoma cells in murine xenograft model
21598	AZD 5438	10 mg	≥98%	A potent inhibitor of Cdk1, Cdk2, and Cdk9 (IC50s = 16, 6, and 20 nM, respectively); inhibits kinase activity of Cdk5/p25 and GSK3β; induces cell cycle arrest by inhibiting phosphorylation of CDK-dependent substrates; has in vivo antiproliferative activity against a range of tumor cell lines (IC50s ranging from 200-1,700 nM); in vivo oral administration inhibits growth of human tumor xenografts and inhibits cell cycle proteins
21598	AZD 5438	25 mg	≥98%	A potent inhibitor of Cdk1, Cdk2, and Cdk9 (IC50s = 16, 6, and 20 nM, respectively); inhibits kinase activity of Cdk5/p25 and GSK3β; induces cell cycle arrest by inhibiting phosphorylation of CDK-dependent substrates; has in vivo antiproliferative activity against a range of tumor cell lines (IC50s ranging from 200-1,700 nM); in vivo oral administration inhibits growth of human tumor xenografts and inhibits cell cycle proteins
21598	AZD 5438	5 mg	≥98%	A potent inhibitor of Cdk1, Cdk2, and Cdk9 (IC50s = 16, 6, and 20 nM, respectively); inhibits kinase activity of Cdk5/p25 and GSK3β; induces cell cycle arrest by inhibiting phosphorylation of CDK-dependent substrates; has in vivo antiproliferative activity against a range of tumor cell lines (IC50s ranging from 200-1,700 nM); in vivo oral administration inhibits growth of human tumor xenografts and inhibits cell cycle proteins
21598	AZD 5438	50 mg	≥98%	A potent inhibitor of Cdk1, Cdk2, and Cdk9 (IC50s = 16, 6, and 20 nM, respectively); inhibits kinase activity of Cdk5/p25 and GSK3β; induces cell cycle arrest by inhibiting phosphorylation of CDK-dependent substrates; has in vivo antiproliferative activity against a range of tumor cell lines (IC50s ranging from 200-1,700 nM); in vivo oral administration inhibits growth of human tumor xenografts and inhibits cell cycle proteins
21600	Aurora A Inhibitor I	1 mg	≥98%	A potent and selective inhibitor of Aurora A kinase (IC50s = 3.4 and 3,400 nM for Aurora A and Aurora B, respectively); prevents centrosome separation and reduces phosphorylated Aurora A, but not phosphorylated histone H3, levels at the centrosomes; reduces the proliferation of HCT116 and HT-29 colorectal carcinoma cells in vitro (IC50s = 0.19 and 2.9 μM, respectively)
21600	Aurora A Inhibitor I	10 mg	≥98%	A potent and selective inhibitor of Aurora A kinase (IC50s = 3.4 and 3,400 nM for Aurora A and Aurora B, respectively); prevents centrosome separation and reduces phosphorylated Aurora A, but not phosphorylated histone H3, levels at the centrosomes; reduces the proliferation of HCT116 and HT-29 colorectal carcinoma cells in vitro (IC50s = 0.19 and 2.9 μM, respectively)
21600	Aurora A Inhibitor I	25 mg	≥98%	A potent and selective inhibitor of Aurora A kinase (IC50s = 3.4 and 3,400 nM for Aurora A and Aurora B, respectively); prevents centrosome separation and reduces phosphorylated Aurora A, but not phosphorylated histone H3, levels at the centrosomes; reduces the proliferation of HCT116 and HT-29 colorectal carcinoma cells in vitro (IC50s = 0.19 and 2.9 μM, respectively)
21600	Aurora A Inhibitor I	5 mg	≥98%	A potent and selective inhibitor of Aurora A kinase (IC50s = 3.4 and 3,400 nM for Aurora A and Aurora B, respectively); prevents centrosome separation and reduces phosphorylated Aurora A, but not phosphorylated histone H3, levels at the centrosomes; reduces the proliferation of HCT116 and HT-29 colorectal carcinoma cells in vitro (IC50s = 0.19 and 2.9 μM, respectively)
21638	SF2523	1 mg	≥98%	A dual inhibitor of PI3K and BRD4 (IC50s = 16, and 241 and 1,550 nM for PI3K, and BRD4 bromodomains 1 and 2, respectively); reduces MYCN gene expression and decreases MYCN and cyclin D1 protein levels; inhibits phosphorylation of Akt in SKNBE2 cells; reduces tumor volume and protein levels of MYCN and cyclin D1 in a MYCN-amplified SKNBE2 neuroblastoma xenograft model in mice; reduces tumor growth and the number of colonic lymph node metastases in the murine orthotopic pancreatic Panc02 carcinoma model

21638	SF2523	10 mg	≥98%	A dual inhibitor of PI3K and BRD4 (IC50s = 16, and 241 and 1,550 nM for PI3K, and BRD4 bromodomains 1 and 2, respectively); reduces MYCN gene expression and decreases MYCN and cyclin D1 protein levels; inhibits phosphorylation of Akt in SKNBE2 cells; reduces tumor volume and protein levels of MYCN and cyclin D1 in a MYCN-amplified SKNBE2 neuroblastoma xenograft model in mice; reduces tumor growth and the number of colonic lymph node metastases in the murine orthotopic pancreatic Panc02 carcinoma model
21638	SF2523	5 mg	≥98%	A dual inhibitor of PI3K and BRD4 (IC50s = 16, and 241 and 1,550 nM for PI3K, and BRD4 bromodomains 1 and 2, respectively); reduces MYCN gene expression and decreases MYCN and cyclin D1 protein levels; inhibits phosphorylation of Akt in SKNBE2 cells; reduces tumor volume and protein levels of MYCN and cyclin D1 in a MYCN-amplified SKNBE2 neuroblastoma xenograft model in mice; reduces tumor growth and the number of colonic lymph node metastases in the murine orthotopic pancreatic Panc02 carcinoma model
21638	SF2523	500 µg	≥98%	A dual inhibitor of PI3K and BRD4 (IC50s = 16, and 241 and 1,550 nM for PI3K, and BRD4 bromodomains 1 and 2, respectively); reduces MYCN gene expression and decreases MYCN and cyclin D1 protein levels; inhibits phosphorylation of Akt in SKNBE2 cells; reduces tumor volume and protein levels of MYCN and cyclin D1 in a MYCN-amplified SKNBE2 neuroblastoma xenograft model in mice; reduces tumor growth and the number of colonic lymph node metastases in the murine orthotopic pancreatic Panc02 carcinoma model
21660	BAY 12-17389	1 mg	≥95%	An orally bioavailable inhibitor of Mps1 (TTK; IC50 = 0.27 nM); inactivates the spindle assembly checkpoint, accelerates mitosis, and causes chromosomal misalignment and missegregation
21660	BAY 12-17389	10 mg	≥95%	An orally bioavailable inhibitor of Mps1 (TTK; IC50 = 0.27 nM); inactivates the spindle assembly checkpoint, accelerates mitosis, and causes chromosomal misalignment and missegregation
21660	BAY 12-17389	25 mg	≥95%	An orally bioavailable inhibitor of Mps1 (TTK; IC50 = 0.27 nM); inactivates the spindle assembly checkpoint, accelerates mitosis, and causes chromosomal misalignment and missegregation
21660	BAY 12-17389	5 mg	≥95%	An orally bioavailable inhibitor of Mps1 (TTK; IC50 = 0.27 nM); inactivates the spindle assembly checkpoint, accelerates mitosis, and causes chromosomal misalignment and missegregation
21669	Ro 3280	1 mg	≥98%	A selective Plk1 inhibitor (IC50s = 3 and 6 nM in an enzymatic assay and H82 lung cancer cells, respectively); over 500-fold selective over a panel of 318 kinases; inhibits tumor growth in a mouse xenograft model; increases autophagy and mTOR phosphorylation in NB4 cells; induces apoptosis in cancer cell lines
21669	Ro 3280	10 mg	≥98%	A selective Plk1 inhibitor (IC50s = 3 and 6 nM in an enzymatic assay and H82 lung cancer cells, respectively); over 500-fold selective over a panel of 318 kinases; inhibits tumor growth in a mouse xenograft model; increases autophagy and mTOR phosphorylation in NB4 cells; induces apoptosis in cancer cell lines
21669	Ro 3280	25 mg	≥98%	A selective Plk1 inhibitor (IC50s = 3 and 6 nM in an enzymatic assay and H82 lung cancer cells, respectively); over 500-fold selective over a panel of 318 kinases; inhibits tumor growth in a mouse xenograft model; increases autophagy and mTOR phosphorylation in NB4 cells; induces apoptosis in cancer cell lines
21669	Ro 3280	5 mg	≥98%	A selective Plk1 inhibitor (IC50s = 3 and 6 nM in an enzymatic assay and H82 lung cancer cells, respectively); over 500-fold selective over a panel of 318 kinases; inhibits tumor growth in a mouse xenograft model; increases autophagy and mTOR phosphorylation in NB4 cells; induces apoptosis in cancer cell lines
21711	N6-Benzyladenine	100 g	≥98%	A synthetic cytokinin; stimulates plant growth and development; inhibits plant respiratory kinase; increases post-harvest life of green vegetables; increases lipid and DHA production in Aurantiochytrium; induces differentiation of myeloid leukemia cells into granulocytes
21711	N6-Benzyladenine	25 g	≥98%	A synthetic cytokinin; stimulates plant growth and development; inhibits plant respiratory kinase; increases post-harvest life of green vegetables; increases lipid and DHA production in Aurantiochytrium; induces differentiation of myeloid leukemia cells into granulocytes
21711	N6-Benzyladenine	250 g	≥98%	A synthetic cytokinin; stimulates plant growth and development; inhibits plant respiratory kinase; increases post-harvest life of green vegetables; increases lipid and DHA production in Aurantiochytrium; induces differentiation of myeloid leukemia cells into granulocytes
21711	N6-Benzyladenine	50 g	≥98%	A synthetic cytokinin; stimulates plant growth and development; inhibits plant respiratory kinase; increases post-harvest life of green vegetables; increases lipid and DHA production in Aurantiochytrium; induces differentiation of myeloid leukemia cells into granulocytes
21715	Fascaplysin (chloride)	1 mg	≥95%	A selective Cdk4/ cyclin D1 inhibitor (IC50 = 0.35 µM) with antiproliferative activity
21715	Fascaplysin (chloride)	5 mg	≥95%	A selective Cdk4/ cyclin D1 inhibitor (IC50 = 0.35 µM) with antiproliferative activity

21717	SAR407899	1 mg	≥98%	An ATP-competitive inhibitor of ROCK1 and ROCK2 (IC50s = 102 and 276 nM, respectively at a concentration of 40 µM ATP); selective for ROCK over 79 other kinases at IC50 values up to 10 µM but had IC50 values ranging from 1 to 10 µM for RSK, PKB, PKCδ, and MSK-1; selective for ROCK over 115 receptor and enzyme targets at IC50 values up to 10 µM, but it does inhibit the serotonin transporter and µ-opioid receptors with IC50s values of 1.1 and 8.9 µM, respectively; inhibits ROCK-mediated phosphorylation of MYPT, thrombin-induced stress fiber formation, PDGF-induced proliferation, and MCP-1-stimulated chemotaxis; relaxes precontracted isolated arteries from various species (IC50s = 122-280 nM) and precontracted corpora cavernosa in both healthy and diabetic animals (IC50s = 0.05-0.42 µM); inhibits ET-1-induced constriction of rat and human arteries (Emaxs = 24-83% of control)
21717	SAR407899	10 mg	≥98%	An ATP-competitive inhibitor of ROCK1 and ROCK2 (IC50s = 102 and 276 nM, respectively at a concentration of 40 µM ATP); selective for ROCK over 79 other kinases at IC50 values up to 10 µM but had IC50 values ranging from 1 to 10 µM for RSK, PKB, PKCδ, and MSK-1; selective for ROCK over 115 receptor and enzyme targets at IC50 values up to 10 µM, but it does inhibit the serotonin transporter and µ-opioid receptors with IC50s values of 1.1 and 8.9 µM, respectively; inhibits ROCK-mediated phosphorylation of MYPT, thrombin-induced stress fiber formation, PDGF-induced proliferation, and MCP-1-stimulated chemotaxis; relaxes precontracted isolated arteries from various species (IC50s = 122-280 nM) and precontracted corpora cavernosa in both healthy and diabetic animals (IC50s = 0.05-0.42 µM); inhibits ET-1-induced constriction of rat and human arteries (Emaxs = 24-83% of control)
21717	SAR407899	25 mg	≥98%	An ATP-competitive inhibitor of ROCK1 and ROCK2 (IC50s = 102 and 276 nM, respectively at a concentration of 40 µM ATP); selective for ROCK over 79 other kinases at IC50 values up to 10 µM but had IC50 values ranging from 1 to 10 µM for RSK, PKB, PKCδ, and MSK-1; selective for ROCK over 115 receptor and enzyme targets at IC50 values up to 10 µM, but it does inhibit the serotonin transporter and µ-opioid receptors with IC50s values of 1.1 and 8.9 µM, respectively; inhibits ROCK-mediated phosphorylation of MYPT, thrombin-induced stress fiber formation, PDGF-induced proliferation, and MCP-1-stimulated chemotaxis; relaxes precontracted isolated arteries from various species (IC50s = 122-280 nM) and precontracted corpora cavernosa in both healthy and diabetic animals (IC50s = 0.05-0.42 µM); inhibits ET-1-induced constriction of rat and human arteries (Emaxs = 24-83% of control)
21717	SAR407899	5 mg	≥98%	An ATP-competitive inhibitor of ROCK1 and ROCK2 (IC50s = 102 and 276 nM, respectively at a concentration of 40 µM ATP); selective for ROCK over 79 other kinases at IC50 values up to 10 µM but had IC50 values ranging from 1 to 10 µM for RSK, PKB, PKCδ, and MSK-1; selective for ROCK over 115 receptor and enzyme targets at IC50 values up to 10 µM, but it does inhibit the serotonin transporter and µ-opioid receptors with IC50s values of 1.1 and 8.9 µM, respectively; inhibits ROCK-mediated phosphorylation of MYPT, thrombin-induced stress fiber formation, PDGF-induced proliferation, and MCP-1-stimulated chemotaxis; relaxes precontracted isolated arteries from various species (IC50s = 122-280 nM) and precontracted corpora cavernosa in both healthy and diabetic animals (IC50s = 0.05-0.42 µM); inhibits ET-1-induced constriction of rat and human arteries (Emaxs = 24-83% of control)
21751	βARK1 Inhibitor	1 mg	≥95% (mixture	An inhibitor of GRK2/βARK1 (IC50 = 126 µM); selective for GRK2/βARK1 over PKA at concentrations up to 1 mM; decreases systolic blood pressure in ob/ob and nicotinamide plus streptozotocin-induced mouse models of type 2 diabetes at 200 µg/kg; improves clonidine-induced relaxation of precontracted isolated aortic rings and improves glucose tolerance in the ob/ob mouse model; inhibits serotonin- or neurotensin-induced DIR in the rat ventral tegmental area in vitro
21751	βARK1 Inhibitor	10 mg	≥95% (mixture	An inhibitor of GRK2/βARK1 (IC50 = 126 µM); selective for GRK2/βARK1 over PKA at concentrations up to 1 mM; decreases systolic blood pressure in ob/ob and nicotinamide plus streptozotocin-induced mouse models of type 2 diabetes at 200 µg/kg; improves clonidine-induced relaxation of precontracted isolated aortic rings and improves glucose tolerance in the ob/ob mouse model; inhibits serotonin- or neurotensin-induced DIR in the rat ventral tegmental area in vitro
21751	βARK1 Inhibitor	25 mg	≥95% (mixture	An inhibitor of GRK2/βARK1 (IC50 = 126 µM); selective for GRK2/βARK1 over PKA at concentrations up to 1 mM; decreases systolic blood pressure in ob/ob and nicotinamide plus streptozotocin-induced mouse models of type 2 diabetes at 200 µg/kg; improves clonidine-induced relaxation of precontracted isolated aortic rings and improves glucose tolerance in the ob/ob mouse model; inhibits serotonin- or neurotensin-induced DIR in the rat ventral tegmental area in vitro

21751	βARK1 Inhibitor	5 mg	≥95% (mixture	An inhibitor of GRK2/βARK1 (IC50 = 126 µM); selective for GRK2/βARK1 over PKA at concentrations up to 1 mM; decreases systolic blood pressure in ob/ob and nicotinamide plus streptozotocin-induced mouse models of type 2 diabetes at 200 µg/kg; improves clonidine-induced relaxation of precontracted isolated aortic rings and improves glucose tolerance in the ob/ob mouse model; inhibits serotonin- or neurotensin-induced DIR in the rat ventral tegmental area in vitro
21757	GSK2292767	1 mg	≥98%	A potent and selective inhibitor of PI3Kδ (Ki = 79 pM); has >1,000-fold selectivity for PI3Kδ over isoforms PI3Kα, PI3Kβ, and PI3Kγ (Kis = 501, 630, and 501 nM, respectively); >100-fold selective for PI3Kδ over a panel of 250 kinases; inhibits IFNγ and IL-2 production (IC50s = 1.9 and 3.16 nM, respectively) in a human lung parenchyma assay; protects against eosinophil recruitment (ED50 = 35 µg/kg) in the brown Norway rat acute ovalbumin model of Th2-driven lung inflammation
21757	GSK2292767	10 mg	≥98%	A potent and selective inhibitor of PI3Kδ (Ki = 79 pM); has >1,000-fold selectivity for PI3Kδ over isoforms PI3Kα, PI3Kβ, and PI3Kγ (Kis = 501, 630, and 501 nM, respectively); >100-fold selective for PI3Kδ over a panel of 250 kinases; inhibits IFNγ and IL-2 production (IC50s = 1.9 and 3.16 nM, respectively) in a human lung parenchyma assay; protects against eosinophil recruitment (ED50 = 35 µg/kg) in the brown Norway rat acute ovalbumin model of Th2-driven lung inflammation
21757	GSK2292767	25 mg	≥98%	A potent and selective inhibitor of PI3Kδ (Ki = 79 pM); has >1,000-fold selectivity for PI3Kδ over isoforms PI3Kα, PI3Kβ, and PI3Kγ (Kis = 501, 630, and 501 nM, respectively); >100-fold selective for PI3Kδ over a panel of 250 kinases; inhibits IFNγ and IL-2 production (IC50s = 1.9 and 3.16 nM, respectively) in a human lung parenchyma assay; protects against eosinophil recruitment (ED50 = 35 µg/kg) in the brown Norway rat acute ovalbumin model of Th2-driven lung inflammation
21757	GSK2292767	5 mg	≥98%	A potent and selective inhibitor of PI3Kδ (Ki = 79 pM); has >1,000-fold selectivity for PI3Kδ over isoforms PI3Kα, PI3Kβ, and PI3Kγ (Kis = 501, 630, and 501 nM, respectively); >100-fold selective for PI3Kδ over a panel of 250 kinases; inhibits IFNγ and IL-2 production (IC50s = 1.9 and 3.16 nM, respectively) in a human lung parenchyma assay; protects against eosinophil recruitment (ED50 = 35 µg/kg) in the brown Norway rat acute ovalbumin model of Th2-driven lung inflammation
21765	Butyrolactone I	1 mg	≥95%	A Cdk1 inhibitor (IC50 = 20 µg/ml in PC-14 cells); induces dose-dependent G2/M arrest, inhibits DNA synthesis, and decreases Cdk1 protein expression in vitro; has antitumor effects in non-small lung, small cell lung, and prostate cancer cell lines (average IC50 = 50 µg/ml); inhibits in vitro Cdk1 phosphorylation of tau; inhibits in vivo phosphorylation of transcription factor E2F-1; increases biogenesis of the secondary metabolite lovastatin and conidiation in A. terreus
21765	Butyrolactone I	5 mg	≥95%	A Cdk1 inhibitor (IC50 = 20 µg/ml in PC-14 cells); induces dose-dependent G2/M arrest, inhibits DNA synthesis, and decreases Cdk1 protein expression in vitro; has antitumor effects in non-small lung, small cell lung, and prostate cancer cell lines (average IC50 = 50 µg/ml); inhibits in vitro Cdk1 phosphorylation of tau; inhibits in vivo phosphorylation of transcription factor E2F-1; increases biogenesis of the secondary metabolite lovastatin and conidiation in A. terreus
21769	Compound 401	1 mg	≥98%	A dual inhibitor of mTOR and DNA-PK (IC50s = 0.28 and 5.3 µM, respectively); selective for DNA-PK and mTOR over PI3K, ATM, and ATR (IC50s = >100 µM for all); inhibits phosphorylation of the mTOR targets S6K1 and Akt in Rat-1 fibroblasts and in M059J glioma cells that lack DNA-PK at 10 µM; inhibits proliferation of TSC1-/- MEFs (IC50 = 2 µM) but not TSC1+/+ MEFs; induces apoptosis in TSC1-/- MEFs
21769	Compound 401	10 mg	≥98%	A dual inhibitor of mTOR and DNA-PK (IC50s = 0.28 and 5.3 µM, respectively); selective for DNA-PK and mTOR over PI3K, ATM, and ATR (IC50s = >100 µM for all); inhibits phosphorylation of the mTOR targets S6K1 and Akt in Rat-1 fibroblasts and in M059J glioma cells that lack DNA-PK at 10 µM; inhibits proliferation of TSC1-/- MEFs (IC50 = 2 µM) but not TSC1+/+ MEFs; induces apoptosis in TSC1-/- MEFs
21769	Compound 401	25 mg	≥98%	A dual inhibitor of mTOR and DNA-PK (IC50s = 0.28 and 5.3 µM, respectively); selective for DNA-PK and mTOR over PI3K, ATM, and ATR (IC50s = >100 µM for all); inhibits phosphorylation of the mTOR targets S6K1 and Akt in Rat-1 fibroblasts and in M059J glioma cells that lack DNA-PK at 10 µM; inhibits proliferation of TSC1-/- MEFs (IC50 = 2 µM) but not TSC1+/+ MEFs; induces apoptosis in TSC1-/- MEFs
21769	Compound 401	5 mg	≥98%	A dual inhibitor of mTOR and DNA-PK (IC50s = 0.28 and 5.3 µM, respectively); selective for DNA-PK and mTOR over PI3K, ATM, and ATR (IC50s = >100 µM for all); inhibits phosphorylation of the mTOR targets S6K1 and Akt in Rat-1 fibroblasts and in M059J glioma cells that lack DNA-PK at 10 µM; inhibits proliferation of TSC1-/- MEFs (IC50 = 2 µM) but not TSC1+/+ MEFs; induces apoptosis in TSC1-/- MEFs
21772	INH6	1 mg	≥98%	A Hec1/Nek2 inhibitor; inhibits proliferation in human breast, cervical, and leukemia cell lines with IC50 values of 1.7 and 2.1, 2.4, and 2.5 µM, respectively, for MDA-MB-231 and MDA-MB-468, HeLa, and K562 cells; co-precipitates with cellular Hec1; reduces Nek2 protein levels (at 6.25 µM); disrupts spindle formation; induces apoptosis

21772	INH6	10 mg	≥98%	A Hec1/Nek2 inhibitor; inhibits proliferation in human breast, cervical, and leukemia cell lines with IC50 values of 1.7 and 2.1, 2.4, and 2.5 µM, respectively, for MDA-MB-231 and MDA-MB-468, HeLa, and K562 cells; co-precipitates with cellular Hec1; reduces Nek2 protein levels (at 6.25 µM); disrupts spindle formation; induces apoptosis
21772	INH6	25 mg	≥98%	A Hec1/Nek2 inhibitor; inhibits proliferation in human breast, cervical, and leukemia cell lines with IC50 values of 1.7 and 2.1, 2.4, and 2.5 µM, respectively, for MDA-MB-231 and MDA-MB-468, HeLa, and K562 cells; co-precipitates with cellular Hec1; reduces Nek2 protein levels (at 6.25 µM); disrupts spindle formation; induces apoptosis
21772	INH6	5 mg	≥98%	A Hec1/Nek2 inhibitor; inhibits proliferation in human breast, cervical, and leukemia cell lines with IC50 values of 1.7 and 2.1, 2.4, and 2.5 µM, respectively, for MDA-MB-231 and MDA-MB-468, HeLa, and K562 cells; co-precipitates with cellular Hec1; reduces Nek2 protein levels (at 6.25 µM); disrupts spindle formation; induces apoptosis
21773	CP 547,632	1 mg	≥98%	A potent inhibitor of VEGFR2 and bFGF (IC50s = 11 and 9 nM, respectively); selective over EGFR, PDGRβ, and related tyrosine kinases; inhibits VEGFR2 autophosphorylation induced by VEGF in vitro (IC50 = 6 nM) and in a xenograft mouse model (EC50 = 590 nM); decreases angiogenesis induced by VEGF or bFGF; suppresses tumor growth in athymic mice
21773	CP 547,632	5 mg	≥98%	A potent inhibitor of VEGFR2 and bFGF (IC50s = 11 and 9 nM, respectively); selective over EGFR, PDGRβ, and related tyrosine kinases; inhibits VEGFR2 autophosphorylation induced by VEGF in vitro (IC50 = 6 nM) and in a xenograft mouse model (EC50 = 590 nM); decreases angiogenesis induced by VEGF or bFGF; suppresses tumor growth in athymic mice
21773	CP 547,632	500 µg	≥98%	A potent inhibitor of VEGFR2 and bFGF (IC50s = 11 and 9 nM, respectively); selective over EGFR, PDGRβ, and related tyrosine kinases; inhibits VEGFR2 autophosphorylation induced by VEGF in vitro (IC50 = 6 nM) and in a xenograft mouse model (EC50 = 590 nM); decreases angiogenesis induced by VEGF or bFGF; suppresses tumor growth in athymic mice
21776	AGL 2263	1 mg	≥98%	An inhibitor of IGF-1R (IC50 = 0.43 µM); inhibits IR, PKB, and Src in a cell-free assay (IC50s = 0.4, 55, and 2.2 µM, respectively); inhibits IGF-1R autophosphorylation and phosphorylation of the downstream elements, IRS-1, PKB, and ERK2 in an ATP-independent manner; inhibits colony formation of PC3, LNCaP, MCF-7, and MDA-MB-468 cancer cells (IC50s = 4.3, 9, 17, and 6 µM, respectively)
21776	AGL 2263	10 mg	≥98%	An inhibitor of IGF-1R (IC50 = 0.43 µM); inhibits IR, PKB, and Src in a cell-free assay (IC50s = 0.4, 55, and 2.2 µM, respectively); inhibits IGF-1R autophosphorylation and phosphorylation of the downstream elements, IRS-1, PKB, and ERK2 in an ATP-independent manner; inhibits colony formation of PC3, LNCaP, MCF-7, and MDA-MB-468 cancer cells (IC50s = 4.3, 9, 17, and 6 µM, respectively)
21776	AGL 2263	5 mg	≥98%	An inhibitor of IGF-1R (IC50 = 0.43 µM); inhibits IR, PKB, and Src in a cell-free assay (IC50s = 0.4, 55, and 2.2 µM, respectively); inhibits IGF-1R autophosphorylation and phosphorylation of the downstream elements, IRS-1, PKB, and ERK2 in an ATP-independent manner; inhibits colony formation of PC3, LNCaP, MCF-7, and MDA-MB-468 cancer cells (IC50s = 4.3, 9, 17, and 6 µM, respectively)
21808	GNE-495	1 mg	≥95%	An orally bioavailable, potent, and selective MAP4K4 inhibitor (IC50 = 3.7 nM); showed positive effects on pathological angiogenesis
21808	GNE-495	10 mg	≥95%	An orally bioavailable, potent, and selective MAP4K4 inhibitor (IC50 = 3.7 nM); showed positive effects on pathological angiogenesis
21808	GNE-495	25 mg	≥95%	An orally bioavailable, potent, and selective MAP4K4 inhibitor (IC50 = 3.7 nM); showed positive effects on pathological angiogenesis
21808	GNE-495	5 mg	≥95%	An orally bioavailable, potent, and selective MAP4K4 inhibitor (IC50 = 3.7 nM); showed positive effects on pathological angiogenesis
21811	PI-828	1 mg	≥98%	A potent inhibitor of PI3K (IC50s = 9.8, 183, 227, and 1,967 nM for p110β, p110α, p110δ, and p110γ, respectively); has been immobilized on solid surface; interacts with non-PI3K cellular proteins such as mTOR, ALDH1, BRD4, CKIIα, and GSK-3β.
21811	PI-828	10 mg	≥98%	A potent inhibitor of PI3K (IC50s = 9.8, 183, 227, and 1,967 nM for p110β, p110α, p110δ, and p110γ, respectively); has been immobilized on solid surface; interacts with non-PI3K cellular proteins such as mTOR, ALDH1, BRD4, CKIIα, and GSK-3β.
21811	PI-828	5 mg	≥98%	A potent inhibitor of PI3K (IC50s = 9.8, 183, 227, and 1,967 nM for p110β, p110α, p110δ, and p110γ, respectively); has been immobilized on solid surface; interacts with non-PI3K cellular proteins such as mTOR, ALDH1, BRD4, CKIIα, and GSK-3β.
21813	JNJ-42756493	1 mg	≥98%	A pan-FGFR inhibitor (IC50s = 1.2, 2.5, 3, and 5.7 nM for FGFR1, -2, -3, and -4, respectively); selective for FGFRs over VEGFR2 (IC50 = 36.8 nM); inhibits the proliferation of Ba/F3 cells expressing FGFR1, 3, or 4 (IC50s = 22.1, 13.2, and 25 nM, respectively); reduces tumor growth in a SNU-16 gastric cancer mouse xenograft model at 10 and 30 mg/kg
21813	JNJ-42756493	10 mg	≥98%	A pan-FGFR inhibitor (IC50s = 1.2, 2.5, 3, and 5.7 nM for FGFR1, -2, -3, and -4, respectively); selective for FGFRs over VEGFR2 (IC50 = 36.8 nM); inhibits the proliferation of Ba/F3 cells expressing FGFR1, 3, or 4 (IC50s = 22.1, 13.2, and 25 nM, respectively); reduces tumor growth in a SNU-16 gastric cancer mouse xenograft model at 10 and 30 mg/kg

21813	JNJ-42756493	25 mg	≥98%	A pan-FGFR inhibitor (IC50s = 1.2, 2.5, 3, and 5.7 nM for FGFR1, -2, -3, and -4, respectively); selective for FGFRs over VEGFR2 (IC50 = 36.8 nM); inhibits the proliferation of Ba/F3 cells expressing FGFR1, 3, or 4 (IC50s = 22.1, 13.2, and 25 nM, respectively); reduces tumor growth in a SNU-16 gastric cancer mouse xenograft model at 10 and 30 mg/kg
21813	JNJ-42756493	5 mg	≥98%	A pan-FGFR inhibitor (IC50s = 1.2, 2.5, 3, and 5.7 nM for FGFR1, -2, -3, and -4, respectively); selective for FGFRs over VEGFR2 (IC50 = 36.8 nM); inhibits the proliferation of Ba/F3 cells expressing FGFR1, 3, or 4 (IC50s = 22.1, 13.2, and 25 nM, respectively); reduces tumor growth in a SNU-16 gastric cancer mouse xenograft model at 10 and 30 mg/kg
21851	Aurora Kinase Inhibito	1 mg	≥98%	A potent inhibitor of Aurora A kinase (IC50 = 42 nM); selective for Aurora A over BMX, BTK, IGF-1R, c-Src, TRKB, SYK, and EGFR (IC50s = 386, 3,550, 591, 1,980, 2,510, 887, and >10,000 nM, respectively)
21851	Aurora Kinase Inhibito	5 mg	≥98%	A potent inhibitor of Aurora A kinase (IC50 = 42 nM); selective for Aurora A over BMX, BTK, IGF-1R, c-Src, TRKB, SYK, and EGFR (IC50s = 386, 3,550, 591, 1,980, 2,510, 887, and >10,000 nM, respectively)
21851	Aurora Kinase Inhibito	500 µg	≥98%	A potent inhibitor of Aurora A kinase (IC50 = 42 nM); selective for Aurora A over BMX, BTK, IGF-1R, c-Src, TRKB, SYK, and EGFR (IC50s = 386, 3,550, 591, 1,980, 2,510, 887, and >10,000 nM, respectively)
21873	Aloisine RP106	1 mg	≥98%	An inhibitor of Cdk1, Cdk5, and GSK3 (IC50s = 0.70, 1.5, and 0.92 µM, respectively); a derivative of the aloisines A and B
21873	Aloisine RP106	10 mg	≥98%	An inhibitor of Cdk1, Cdk5, and GSK3 (IC50s = 0.70, 1.5, and 0.92 µM, respectively); a derivative of the aloisines A and B
21873	Aloisine RP106	25 mg	≥98%	An inhibitor of Cdk1, Cdk5, and GSK3 (IC50s = 0.70, 1.5, and 0.92 µM, respectively); a derivative of the aloisines A and B
21873	Aloisine RP106	5 mg	≥98%	An inhibitor of Cdk1, Cdk5, and GSK3 (IC50s = 0.70, 1.5, and 0.92 µM, respectively); a derivative of the aloisines A and B
21891	Taurocholic Acid-d4 (s	1 mg	≥99% deutera	An internal standard for the quantification of taurocholic acid by GC- or LC-MS
21891	Taurocholic Acid-d4 (s	5 mg	≥99% deutera	An internal standard for the quantification of taurocholic acid by GC- or LC-MS
21891	Taurocholic Acid-d4 (s	500 µg	≥99% deutera	An internal standard for the quantification of taurocholic acid by GC- or LC-MS
21896	PKI-166	1 mg	≥98%	An inhibitor of EGFR (IC50 = 0.0007 µM for the intracellular kinase domain); selective for the EGFR intracellular kinase domain over the serine/threonine kinases PKC-α and Cdc2/cyclin B (IC50s = >100 and 78 µM, respectively), as well as FLK, c-Met, and Tek (IC50 = >1 µM for all), but does inhibit c-Src, c-Abl, VEGFR2/KDR, FLT1, and c-Kit (IC50s = 0.103, 0.028, 0.327, 0.962, and 2.21 µM, respectively); enhances the cytotoxicity of gemcitabine in L3.6pl cells; reduces tumor growth and metastasis and increases survival in an L3.6pl mouse xenograft model at 100 mg/kg per day with additive effects when administered in combination with gemcitabine; reduces tumor growth and inhibits angiogenesis in an SN12-PM6 human renal cell carcinoma mouse orthotopic model
21896	PKI-166	10 mg	≥98%	An inhibitor of EGFR (IC50 = 0.0007 µM for the intracellular kinase domain); selective for the EGFR intracellular kinase domain over the serine/threonine kinases PKC-α and Cdc2/cyclin B (IC50s = >100 and 78 µM, respectively), as well as FLK, c-Met, and Tek (IC50 = >1 µM for all), but does inhibit c-Src, c-Abl, VEGFR2/KDR, FLT1, and c-Kit (IC50s = 0.103, 0.028, 0.327, 0.962, and 2.21 µM, respectively); enhances the cytotoxicity of gemcitabine in L3.6pl cells; reduces tumor growth and metastasis and increases survival in an L3.6pl mouse xenograft model at 100 mg/kg per day with additive effects when administered in combination with gemcitabine; reduces tumor growth and inhibits angiogenesis in an SN12-PM6 human renal cell carcinoma mouse orthotopic model
21896	PKI-166	25 mg	≥98%	An inhibitor of EGFR (IC50 = 0.0007 µM for the intracellular kinase domain); selective for the EGFR intracellular kinase domain over the serine/threonine kinases PKC-α and Cdc2/cyclin B (IC50s = >100 and 78 µM, respectively), as well as FLK, c-Met, and Tek (IC50 = >1 µM for all), but does inhibit c-Src, c-Abl, VEGFR2/KDR, FLT1, and c-Kit (IC50s = 0.103, 0.028, 0.327, 0.962, and 2.21 µM, respectively); enhances the cytotoxicity of gemcitabine in L3.6pl cells; reduces tumor growth and metastasis and increases survival in an L3.6pl mouse xenograft model at 100 mg/kg per day with additive effects when administered in combination with gemcitabine; reduces tumor growth and inhibits angiogenesis in an SN12-PM6 human renal cell carcinoma mouse orthotopic model
21896	PKI-166	5 mg	≥98%	An inhibitor of EGFR (IC50 = 0.0007 µM for the intracellular kinase domain); selective for the EGFR intracellular kinase domain over the serine/threonine kinases PKC-α and Cdc2/cyclin B (IC50s = >100 and 78 µM, respectively), as well as FLK, c-Met, and Tek (IC50 = >1 µM for all), but does inhibit c-Src, c-Abl, VEGFR2/KDR, FLT1, and c-Kit (IC50s = 0.103, 0.028, 0.327, 0.962, and 2.21 µM, respectively); enhances the cytotoxicity of gemcitabine in L3.6pl cells; reduces tumor growth and metastasis and increases survival in an L3.6pl mouse xenograft model at 100 mg/kg per day with additive effects when administered in combination with gemcitabine; reduces tumor growth and inhibits angiogenesis in an SN12-PM6 human renal cell carcinoma mouse orthotopic model

21903	MP-A08	1 mg	≥98%	An inhibitor of SPHK1 and SPHK2 (Kis = 27 and 6.9 µM, respectively); selective for SPHK1/2 over a panel of 140 human protein kinases at concentrations up to 25 µM; reduces generation of cellular S1P without inducing SPHK1 degradation in Jurkat cells; induces a 3.7-, 3.5-, and 5.8-fold increase in C-18 ceramide, C-20 ceramide, and C20:1-ceramide levels, respectively; reduces proliferation of a variety of human cancer cell lines (EC50s = 8-44.9 µM); reduces tumor vasculature and volume as well as S1P protein levels in A549 human lung adenocarcinoma xenografts in mice
21903	MP-A08	10 mg	≥98%	An inhibitor of SPHK1 and SPHK2 (Kis = 27 and 6.9 µM, respectively); selective for SPHK1/2 over a panel of 140 human protein kinases at concentrations up to 25 µM; reduces generation of cellular S1P without inducing SPHK1 degradation in Jurkat cells; induces a 3.7-, 3.5-, and 5.8-fold increase in C-18 ceramide, C-20 ceramide, and C20:1-ceramide levels, respectively; reduces proliferation of a variety of human cancer cell lines (EC50s = 8-44.9 µM); reduces tumor vasculature and volume as well as S1P protein levels in A549 human lung adenocarcinoma xenografts in mice
21903	MP-A08	25 mg	≥98%	An inhibitor of SPHK1 and SPHK2 (Kis = 27 and 6.9 µM, respectively); selective for SPHK1/2 over a panel of 140 human protein kinases at concentrations up to 25 µM; reduces generation of cellular S1P without inducing SPHK1 degradation in Jurkat cells; induces a 3.7-, 3.5-, and 5.8-fold increase in C-18 ceramide, C-20 ceramide, and C20:1-ceramide levels, respectively; reduces proliferation of a variety of human cancer cell lines (EC50s = 8-44.9 µM); reduces tumor vasculature and volume as well as S1P protein levels in A549 human lung adenocarcinoma xenografts in mice
21903	MP-A08	5 mg	≥98%	An inhibitor of SPHK1 and SPHK2 (Kis = 27 and 6.9 µM, respectively); selective for SPHK1/2 over a panel of 140 human protein kinases at concentrations up to 25 µM; reduces generation of cellular S1P without inducing SPHK1 degradation in Jurkat cells; induces a 3.7-, 3.5-, and 5.8-fold increase in C-18 ceramide, C-20 ceramide, and C20:1-ceramide levels, respectively; reduces proliferation of a variety of human cancer cell lines (EC50s = 8-44.9 µM); reduces tumor vasculature and volume as well as S1P protein levels in A549 human lung adenocarcinoma xenografts in mice
21957	eFT508	1 mg	≥98%	A potent inhibitor of MNK1 and MNK2 (IC50s = 50 = <50 nM); has a half-life of 5.3 hours in rats
21957	eFT508	10 mg	≥98%	A potent inhibitor of MNK1 and MNK2 (IC50s = 50 = <50 nM); has a half-life of 5.3 hours in rats
21957	eFT508	25 mg	≥98%	A potent inhibitor of MNK1 and MNK2 (IC50s = 50 = <50 nM); has a half-life of 5.3 hours in rats
21957	eFT508	5 mg	≥98%	A potent inhibitor of MNK1 and MNK2 (IC50s = 50 = <50 nM); has a half-life of 5.3 hours in rats
21981	YMU1	10 mg	≥98%	A thymidylate kinase inhibitor (IC50 = 610 nM); selective for thymidylate kinase over thymidine kinase 1; reduces dTTP levels by 30-40% in p58-/- HCT116 cells; sensitizes a variety of cancer cell lines to doxorubicin; reduces tumor growth in a p53-/- HCT116 mouse xenograft model at 5 mg/kg three times per week for four weeks
21981	YMU1	5 mg	≥98%	A thymidylate kinase inhibitor (IC50 = 610 nM); selective for thymidylate kinase over thymidine kinase 1; reduces dTTP levels by 30-40% in p58-/- HCT116 cells; sensitizes a variety of cancer cell lines to doxorubicin; reduces tumor growth in a p53-/- HCT116 mouse xenograft model at 5 mg/kg three times per week for four weeks
21995	Ansatrienin A	1 mg	≥98%	An ansamycin antibiotic and antifungal; inhibits bone resorption (IC50 = 64 nM); inhibits pp60c-srcM kinase (IC50 = 100 nM); inhibits TNF-α-induced expression of ICAM-1 (IC50 = 570 nM); potentiates chemotherapeutic action; oxidized form of ansatrienin B
21995	Ansatrienin A	5 mg	≥98%	An ansamycin antibiotic and antifungal; inhibits bone resorption (IC50 = 64 nM); inhibits pp60c-srcM kinase (IC50 = 100 nM); inhibits TNF-α-induced expression of ICAM-1 (IC50 = 570 nM); potentiates chemotherapeutic action; oxidized form of ansatrienin B
21996	Ansatrienin B	1 mg	≥95%	An ansamycin antibiotic and antifungal; inhibits bone resorption (IC50 = 21 nM) and pp60c-src kinase (IC50 = 50 nM); inhibits L-leucine incorporation during protein synthesis (IC50 = 58 nM); inhibits TNF-α-induced ICAM1 expression (IC50 = 300 nM); potentiates the action of chemotherapeutics; hydroquinone of ansatrienin A
21996	Ansatrienin B	5 mg	≥95%	An ansamycin antibiotic and antifungal; inhibits bone resorption (IC50 = 21 nM) and pp60c-src kinase (IC50 = 50 nM); inhibits L-leucine incorporation during protein synthesis (IC50 = 58 nM); inhibits TNF-α-induced ICAM1 expression (IC50 = 300 nM); potentiates the action of chemotherapeutics; hydroquinone of ansatrienin A

22081	API-1	1 mg	≥98%	An Akt inhibitor that reduces the level of phosphorylated Akt (IC50 = ~0.8 µM); binds Akt and blocks its translocation to the cell membrane; reduces cell proliferation in cancer cell lines, induces apoptosis, and, at a dose of 10 mg/kg/day, decreases tumor growth in a mouse xenograft model; inhibits cell growth (IC50s = 2-5 µM) and induces apoptosis in NSCLC and HNSCC cell lines; increases cleavage of caspases 8, 9, and 3; reduces c-FLIP levels through ubiquitin/proteasome-mediated degradation; synergistically induces apoptosis in combination with TRAIL/APO-2L
22081	API-1	10 mg	≥98%	An Akt inhibitor that reduces the level of phosphorylated Akt (IC50 = ~0.8 µM); binds Akt and blocks its translocation to the cell membrane; reduces cell proliferation in cancer cell lines, induces apoptosis, and, at a dose of 10 mg/kg/day, decreases tumor growth in a mouse xenograft model; inhibits cell growth (IC50s = 2-5 µM) and induces apoptosis in NSCLC and HNSCC cell lines; increases cleavage of caspases 8, 9, and 3; reduces c-FLIP levels through ubiquitin/proteasome-mediated degradation; synergistically induces apoptosis in combination with TRAIL/APO-2L
22081	API-1	5 mg	≥98%	An Akt inhibitor that reduces the level of phosphorylated Akt (IC50 = ~0.8 µM); binds Akt and blocks its translocation to the cell membrane; reduces cell proliferation in cancer cell lines, induces apoptosis, and, at a dose of 10 mg/kg/day, decreases tumor growth in a mouse xenograft model; inhibits cell growth (IC50s = 2-5 µM) and induces apoptosis in NSCLC and HNSCC cell lines; increases cleavage of caspases 8, 9, and 3; reduces c-FLIP levels through ubiquitin/proteasome-mediated degradation; synergistically induces apoptosis in combination with TRAIL/APO-2L
22083	XMU-MP-1	1 mg	≥98%	An inhibitor of MST1 and MST2 (IC50s = 71.1 and 38.1 nM, respectively); is selective for MST1 and 2 over a panel of 468 kinases at a concentration of 1 µM; inhibits phosphorylation of MOB1, LATS1 and 2, and YAP in HepG2 cells as well as MST1 and 2 autophosphorylation in RAW 264.7, U2OS, SW480, RPE1, SNU423, and HepG2 cells in a concentration-dependent manner; prevents cell death induced by overexpression of MST2; enhances liver regeneration in mice post partial hepatectomy and reduces liver fibrosis in a mouse model of chronic liver injury when administered at a dose of 1 mg/kg
22083	XMU-MP-1	10 mg	≥98%	An inhibitor of MST1 and MST2 (IC50s = 71.1 and 38.1 nM, respectively); is selective for MST1 and 2 over a panel of 468 kinases at a concentration of 1 µM; inhibits phosphorylation of MOB1, LATS1 and 2, and YAP in HepG2 cells as well as MST1 and 2 autophosphorylation in RAW 264.7, U2OS, SW480, RPE1, SNU423, and HepG2 cells in a concentration-dependent manner; prevents cell death induced by overexpression of MST2; enhances liver regeneration in mice post partial hepatectomy and reduces liver fibrosis in a mouse model of chronic liver injury when administered at a dose of 1 mg/kg
22083	XMU-MP-1	25 mg	≥98%	An inhibitor of MST1 and MST2 (IC50s = 71.1 and 38.1 nM, respectively); is selective for MST1 and 2 over a panel of 468 kinases at a concentration of 1 µM; inhibits phosphorylation of MOB1, LATS1 and 2, and YAP in HepG2 cells as well as MST1 and 2 autophosphorylation in RAW 264.7, U2OS, SW480, RPE1, SNU423, and HepG2 cells in a concentration-dependent manner; prevents cell death induced by overexpression of MST2; enhances liver regeneration in mice post partial hepatectomy and reduces liver fibrosis in a mouse model of chronic liver injury when administered at a dose of 1 mg/kg
22083	XMU-MP-1	5 mg	≥98%	An inhibitor of MST1 and MST2 (IC50s = 71.1 and 38.1 nM, respectively); is selective for MST1 and 2 over a panel of 468 kinases at a concentration of 1 µM; inhibits phosphorylation of MOB1, LATS1 and 2, and YAP in HepG2 cells as well as MST1 and 2 autophosphorylation in RAW 264.7, U2OS, SW480, RPE1, SNU423, and HepG2 cells in a concentration-dependent manner; prevents cell death induced by overexpression of MST2; enhances liver regeneration in mice post partial hepatectomy and reduces liver fibrosis in a mouse model of chronic liver injury when administered at a dose of 1 mg/kg
22093	Rapamycin-d3	1 mg	≥98% deutera	An internal standard for the quantification of rapamycin by GC- or LC-MS
22093	Rapamycin-d3	500 µg	≥98% deutera	An internal standard for the quantification of rapamycin by GC- or LC-MS
22101	Erlotinib-d6 (hydrochl	1 mg	≥99% deutera	An internal standard for the quantification of erlotinib by GC- or LC-MS
22106	Apigenin-d5	1 mg	≥99% deutera	An internal standard for the quantification of apigenin by GC- or LC-MS
22106	Apigenin-d5	500 µg	≥99% deutera	An internal standard for the quantification of apigenin by GC- or LC-MS
22128	SSR 128129E	1 mg	≥98%	An FGFR inhibitor (IC50 = 1.9 nM); reduces FGF2-induced endothelial cell proliferation and migration (IC50s = 31 and 15.2 nM, respectively); reduces proliferation of cells expressing FGFR1-4 at 100 nM; reduces disease severity and enhances physical performance in a mouse model of arthritis at 30 mg/kg per day; reduces tumor growth and metastasis in a Panc02 mouse orthotopic tumor model; reduces atherosclerotic lesion size in the aortic sinus of apoE-/- mice at 50 mg/kg per day; reduces intimal hyperplasia following jugular vein-to-artery bypass grafting surgery in rats

22128	SSR 128129E	10 mg	≥98%	An FGFR inhibitor (IC50 = 1.9 nM); reduces FGF2-induced endothelial cell proliferation and migration (IC50s = 31 and 15.2 nM, respectively); reduces proliferation of cells expressing FGFR1-4 at 100 nM; reduces disease severity and enhances physical performance in a mouse model of arthritis at 30 mg/kg per day; reduces tumor growth and metastasis in a Panc02 mouse orthotopic tumor model; reduces atherosclerotic lesion size in the aortic sinus of apoE-/- mice at 50 mg/kg per day; reduces intimal hyperplasia following jugular vein-to-artery bypass grafting surgery in rats
22128	SSR 128129E	25 mg	≥98%	An FGFR inhibitor (IC50 = 1.9 nM); reduces FGF2-induced endothelial cell proliferation and migration (IC50s = 31 and 15.2 nM, respectively); reduces proliferation of cells expressing FGFR1-4 at 100 nM; reduces disease severity and enhances physical performance in a mouse model of arthritis at 30 mg/kg per day; reduces tumor growth and metastasis in a Panc02 mouse orthotopic tumor model; reduces atherosclerotic lesion size in the aortic sinus of apoE-/- mice at 50 mg/kg per day; reduces intimal hyperplasia following jugular vein-to-artery bypass grafting surgery in rats
22128	SSR 128129E	5 mg	≥98%	An FGFR inhibitor (IC50 = 1.9 nM); reduces FGF2-induced endothelial cell proliferation and migration (IC50s = 31 and 15.2 nM, respectively); reduces proliferation of cells expressing FGFR1-4 at 100 nM; reduces disease severity and enhances physical performance in a mouse model of arthritis at 30 mg/kg per day; reduces tumor growth and metastasis in a Panc02 mouse orthotopic tumor model; reduces atherosclerotic lesion size in the aortic sinus of apoE-/- mice at 50 mg/kg per day; reduces intimal hyperplasia following jugular vein-to-artery bypass grafting surgery in rats
22136	MPI-0479605	1 mg	≥98%	A potent inhibitor of MPS1 (IC50 = 1.8 nM); selective for MPS1 over a panel of 79 kinases at a concentration of 500 nM; induces time-dependent degradation of cyclin B and securin and decreases phosphorylation of BUBR1 resulting in failed cytokinesis in HeLa cells arrested by nocodazole; causes misalignment of chromosomes at the anaphase plate and aneuploidy in A549 cells and slows cell cycle progression of HCT116 and COLO 205 cells irrespective of p53 activity; reduces tumor volume in an HCT116 mouse colon cancer xenograft model in a dose-dependent manner
22136	MPI-0479605	10 mg	≥98%	A potent inhibitor of MPS1 (IC50 = 1.8 nM); selective for MPS1 over a panel of 79 kinases at a concentration of 500 nM; induces time-dependent degradation of cyclin B and securin and decreases phosphorylation of BUBR1 resulting in failed cytokinesis in HeLa cells arrested by nocodazole; causes misalignment of chromosomes at the anaphase plate and aneuploidy in A549 cells and slows cell cycle progression of HCT116 and COLO 205 cells irrespective of p53 activity; reduces tumor volume in an HCT116 mouse colon cancer xenograft model in a dose-dependent manner
22136	MPI-0479605	25 mg	≥98%	A potent inhibitor of MPS1 (IC50 = 1.8 nM); selective for MPS1 over a panel of 79 kinases at a concentration of 500 nM; induces time-dependent degradation of cyclin B and securin and decreases phosphorylation of BUBR1 resulting in failed cytokinesis in HeLa cells arrested by nocodazole; causes misalignment of chromosomes at the anaphase plate and aneuploidy in A549 cells and slows cell cycle progression of HCT116 and COLO 205 cells irrespective of p53 activity; reduces tumor volume in an HCT116 mouse colon cancer xenograft model in a dose-dependent manner
22136	MPI-0479605	5 mg	≥98%	A potent inhibitor of MPS1 (IC50 = 1.8 nM); selective for MPS1 over a panel of 79 kinases at a concentration of 500 nM; induces time-dependent degradation of cyclin B and securin and decreases phosphorylation of BUBR1 resulting in failed cytokinesis in HeLa cells arrested by nocodazole; causes misalignment of chromosomes at the anaphase plate and aneuploidy in A549 cells and slows cell cycle progression of HCT116 and COLO 205 cells irrespective of p53 activity; reduces tumor volume in an HCT116 mouse colon cancer xenograft model in a dose-dependent manner
22139	G-749	1 mg	≥98%	An FLT3 kinase inhibitor (IC50s = 2.1-38.1 nM for wild-type and constitutively active mutant FLT3s); inhibits growth of human leukemia cell lines that express FLT3-ITD mutant kinase (IC50s = 3.5 and 7.5 nM for MV4-11 and Molm-14 cells, respectively); reduces tumor growth and increases survival in a dose-dependent manner in MV4-11 and Molm-14 murine leukemia xenograft models; reduces growth of bone marrow blasts derived from acute myeloid leukemia patients
22139	G-749	10 mg	≥98%	An FLT3 kinase inhibitor (IC50s = 2.1-38.1 nM for wild-type and constitutively active mutant FLT3s); inhibits growth of human leukemia cell lines that express FLT3-ITD mutant kinase (IC50s = 3.5 and 7.5 nM for MV4-11 and Molm-14 cells, respectively); reduces tumor growth and increases survival in a dose-dependent manner in MV4-11 and Molm-14 murine leukemia xenograft models; reduces growth of bone marrow blasts derived from acute myeloid leukemia patients
22139	G-749	25 mg	≥98%	An FLT3 kinase inhibitor (IC50s = 2.1-38.1 nM for wild-type and constitutively active mutant FLT3s); inhibits growth of human leukemia cell lines that express FLT3-ITD mutant kinase (IC50s = 3.5 and 7.5 nM for MV4-11 and Molm-14 cells, respectively); reduces tumor growth and increases survival in a dose-dependent manner in MV4-11 and Molm-14 murine leukemia xenograft models; reduces growth of bone marrow blasts derived from acute myeloid leukemia patients

22139	G-749	5 mg	≥98%	An FLT3 kinase inhibitor (IC50s = 2.1-38.1 nM for wild-type and constitutively active mutant FLT3s); inhibits growth of human leukemia cell lines that express FLT3-ITD mutant kinase (IC50s = 3.5 and 7.5 nM for MV4-11 and Molm-14 cells, respectively); reduces tumor growth and increases survival in a dose-dependent manner in MV4-11 and Molm-14 murine leukemia xenograft models; reduces growth of bone marrow blasts derived from acute myeloid leukemia patients
22140	T5601640	1 mg	≥98%	An inhibitor of LIMK2; reduces p-cofilin in Nf1-/- MEFs (IC50 = 30 μM); decreases actin stress fiber formation, inhibits cell migration, and inhibits colony formation when used at a concentration of 50 μM; inhibits proliferation of ST88-14, U87, and PANC-1 cells (IC50s = 18.3, 7.4, and 35.2 μM, respectively); decreases p-cofilin levels by 20, 24, and 46% in ST88-14, U87, and PANC-1 cells, respectively; decreases tumor volume in a PANC-1 nude mouse xenograft model when used at a dose of 60 mg/kg
22140	T5601640	10 mg	≥98%	An inhibitor of LIMK2; reduces p-cofilin in Nf1-/- MEFs (IC50 = 30 μM); decreases actin stress fiber formation, inhibits cell migration, and inhibits colony formation when used at a concentration of 50 μM; inhibits proliferation of ST88-14, U87, and PANC-1 cells (IC50s = 18.3, 7.4, and 35.2 μM, respectively); decreases p-cofilin levels by 20, 24, and 46% in ST88-14, U87, and PANC-1 cells, respectively; decreases tumor volume in a PANC-1 nude mouse xenograft model when used at a dose of 60 mg/kg
22140	T5601640	25 mg	≥98%	An inhibitor of LIMK2; reduces p-cofilin in Nf1-/- MEFs (IC50 = 30 μM); decreases actin stress fiber formation, inhibits cell migration, and inhibits colony formation when used at a concentration of 50 μM; inhibits proliferation of ST88-14, U87, and PANC-1 cells (IC50s = 18.3, 7.4, and 35.2 μM, respectively); decreases p-cofilin levels by 20, 24, and 46% in ST88-14, U87, and PANC-1 cells, respectively; decreases tumor volume in a PANC-1 nude mouse xenograft model when used at a dose of 60 mg/kg
22140	T5601640	5 mg	≥98%	An inhibitor of LIMK2; reduces p-cofilin in Nf1-/- MEFs (IC50 = 30 μM); decreases actin stress fiber formation, inhibits cell migration, and inhibits colony formation when used at a concentration of 50 μM; inhibits proliferation of ST88-14, U87, and PANC-1 cells (IC50s = 18.3, 7.4, and 35.2 μM, respectively); decreases p-cofilin levels by 20, 24, and 46% in ST88-14, U87, and PANC-1 cells, respectively; decreases tumor volume in a PANC-1 nude mouse xenograft model when used at a dose of 60 mg/kg
22142	NVP-BGT226	1 mg	≥98%	A dual PI3K and mTOR inhibitor (EC50s = 4, 63, and 38 nM for PI3Kα, β, and γ isoforms, respectively, in a filter binding assay); binds to class I and class III PI3Ks (EC50s = 55.8 and 7.03 nM, for HsPI3Kβ and HsVps34, respectively); decreases protein levels of phosphorylated mTOR and Akt; inhibits the growth of squamous cell carcinoma cell lines, HONE-1, and a variant of HONE-1 resistant to cisplatin (IC50s = 7.4-27.8, 22.6, and 30.1 nM, respectively); inhibits tumor growth in a FaDu mouse xenograft model at doses of 2.5 and 5 mg/kg daily for three weeks
22142	NVP-BGT226	10 mg	≥98%	A dual PI3K and mTOR inhibitor (EC50s = 4, 63, and 38 nM for PI3Kα, β, and γ isoforms, respectively, in a filter binding assay); binds to class I and class III PI3Ks (EC50s = 55.8 and 7.03 nM, for HsPI3Kβ and HsVps34, respectively); decreases protein levels of phosphorylated mTOR and Akt; inhibits the growth of squamous cell carcinoma cell lines, HONE-1, and a variant of HONE-1 resistant to cisplatin (IC50s = 7.4-27.8, 22.6, and 30.1 nM, respectively); inhibits tumor growth in a FaDu mouse xenograft model at doses of 2.5 and 5 mg/kg daily for three weeks
22142	NVP-BGT226	25 mg	≥98%	A dual PI3K and mTOR inhibitor (EC50s = 4, 63, and 38 nM for PI3Kα, β, and γ isoforms, respectively, in a filter binding assay); binds to class I and class III PI3Ks (EC50s = 55.8 and 7.03 nM, for HsPI3Kβ and HsVps34, respectively); decreases protein levels of phosphorylated mTOR and Akt; inhibits the growth of squamous cell carcinoma cell lines, HONE-1, and a variant of HONE-1 resistant to cisplatin (IC50s = 7.4-27.8, 22.6, and 30.1 nM, respectively); inhibits tumor growth in a FaDu mouse xenograft model at doses of 2.5 and 5 mg/kg daily for three weeks
22142	NVP-BGT226	5 mg	≥98%	A dual PI3K and mTOR inhibitor (EC50s = 4, 63, and 38 nM for PI3Kα, β, and γ isoforms, respectively, in a filter binding assay); binds to class I and class III PI3Ks (EC50s = 55.8 and 7.03 nM, for HsPI3Kβ and HsVps34, respectively); decreases protein levels of phosphorylated mTOR and Akt; inhibits the growth of squamous cell carcinoma cell lines, HONE-1, and a variant of HONE-1 resistant to cisplatin (IC50s = 7.4-27.8, 22.6, and 30.1 nM, respectively); inhibits tumor growth in a FaDu mouse xenograft model at doses of 2.5 and 5 mg/kg daily for three weeks
22143	Golvatinib	1 mg	≥98%	A dual inhibitor of c-Met and VEGFR2; inhibits autophosphorylation of c-Met and phosphorylation of VEGFR2 (IC50s = 14 and 16 nM, respectively); inhibits proliferation in a variety of cancer cell lines; inhibits proliferation of HUVECs stimulated with HGF and VEGF but not bFGF (IC50s = 17, 84, and >1,000 nM); reduces tumor volume dose-dependently in nude mouse xenograft models using MKN45, Hs746T, SNU-5, or EBC-1 cells; increases survival of nude mice implanted with MKN45 cancer cells

22143	Golvatinib	10 mg	≥98%	A dual inhibitor of c-Met and VEGFR2; inhibits autophosphorylation of c-Met and phosphorylation of VEGFR2 (IC50s = 14 and 16 nM, respectively); inhibits proliferation in a variety of cancer cell lines; inhibits proliferation of HUVECs stimulated with HGF and VEGF but not bFGF (IC50s = 17, 84, and >1,000 nM); reduces tumor volume dose-dependently in nude mouse xenograft models using MKN45, Hs746T, SNU-5, or EBC-1 cells; increases survival of nude mice implanted with MKN45 cancer cells
22143	Golvatinib	25 mg	≥98%	A dual inhibitor of c-Met and VEGFR2; inhibits autophosphorylation of c-Met and phosphorylation of VEGFR2 (IC50s = 14 and 16 nM, respectively); inhibits proliferation in a variety of cancer cell lines; inhibits proliferation of HUVECs stimulated with HGF and VEGF but not bFGF (IC50s = 17, 84, and >1,000 nM); reduces tumor volume dose-dependently in nude mouse xenograft models using MKN45, Hs746T, SNU-5, or EBC-1 cells; increases survival of nude mice implanted with MKN45 cancer cells
22143	Golvatinib	5 mg	≥98%	A dual inhibitor of c-Met and VEGFR2; inhibits autophosphorylation of c-Met and phosphorylation of VEGFR2 (IC50s = 14 and 16 nM, respectively); inhibits proliferation in a variety of cancer cell lines; inhibits proliferation of HUVECs stimulated with HGF and VEGF but not bFGF (IC50s = 17, 84, and >1,000 nM); reduces tumor volume dose-dependently in nude mouse xenograft models using MKN45, Hs746T, SNU-5, or EBC-1 cells; increases survival of nude mice implanted with MKN45 cancer cells
22175	Cercosporin	1 mg	≥95%	A cytotoxic phytotoxin; produces ROS in plant hosts; has light-activated cytotoxic effects (CC50s = 241, 282, and 174 nM in HeLa, A432, and MCF-7 cells, respectively); a selective inhibitor of PKC (IC50 = 600-1,300 nM) with no activity on PKA or PPK
22175	Cercosporin	5 mg	≥95%	A cytotoxic phytotoxin; produces ROS in plant hosts; has light-activated cytotoxic effects (CC50s = 241, 282, and 174 nM in HeLa, A432, and MCF-7 cells, respectively); a selective inhibitor of PKC (IC50 = 600-1,300 nM) with no activity on PKA or PPK
22197	CTX-0294885	1 mg	≥98%	A broad spectrum kinase inhibitor used in proteomics; inhibits FAK, Flt3, JAK2, JAK3, Src, Aurora kinase A, and VEGF receptor 3 (IC50s = 4, 1, 3, 28, 2, 18, and 3 nM, respectively); binds to kinases from every major group and captures all members of the AKT family of proteins; captured 235 kinases from MDA-MB-231 breast cancer cells using large-scale kinome profiling
22197	CTX-0294885	10 mg	≥98%	A broad spectrum kinase inhibitor used in proteomics; inhibits FAK, Flt3, JAK2, JAK3, Src, Aurora kinase A, and VEGF receptor 3 (IC50s = 4, 1, 3, 28, 2, 18, and 3 nM, respectively); binds to kinases from every major group and captures all members of the AKT family of proteins; captured 235 kinases from MDA-MB-231 breast cancer cells using large-scale kinome profiling
22197	CTX-0294885	25 mg	≥98%	A broad spectrum kinase inhibitor used in proteomics; inhibits FAK, Flt3, JAK2, JAK3, Src, Aurora kinase A, and VEGF receptor 3 (IC50s = 4, 1, 3, 28, 2, 18, and 3 nM, respectively); binds to kinases from every major group and captures all members of the AKT family of proteins; captured 235 kinases from MDA-MB-231 breast cancer cells using large-scale kinome profiling
22197	CTX-0294885	5 mg	≥98%	A broad spectrum kinase inhibitor used in proteomics; inhibits FAK, Flt3, JAK2, JAK3, Src, Aurora kinase A, and VEGF receptor 3 (IC50s = 4, 1, 3, 28, 2, 18, and 3 nM, respectively); binds to kinases from every major group and captures all members of the AKT family of proteins; captured 235 kinases from MDA-MB-231 breast cancer cells using large-scale kinome profiling
22198	KX1-004	1 mg	≥98%	An inhibitor of Src-PTK; protects against a permanent threshold shift and outer hair cell loss in chinchillas following noise exposure when used at 30, 50, or 100 µM, applied to the round window membrane; effective against chronic noise exposure in chinchillas when administered at 50 mg/kg, s.c.
22198	KX1-004	10 mg	≥98%	An inhibitor of Src-PTK; protects against a permanent threshold shift and outer hair cell loss in chinchillas following noise exposure when used at 30, 50, or 100 µM, applied to the round window membrane; effective against chronic noise exposure in chinchillas when administered at 50 mg/kg, s.c.
22198	KX1-004	25 mg	≥98%	An inhibitor of Src-PTK; protects against a permanent threshold shift and outer hair cell loss in chinchillas following noise exposure when used at 30, 50, or 100 µM, applied to the round window membrane; effective against chronic noise exposure in chinchillas when administered at 50 mg/kg, s.c.
22198	KX1-004	5 mg	≥98%	An inhibitor of Src-PTK; protects against a permanent threshold shift and outer hair cell loss in chinchillas following noise exposure when used at 30, 50, or 100 µM, applied to the round window membrane; effective against chronic noise exposure in chinchillas when administered at 50 mg/kg, s.c.
22205	FRAX597	1 mg	≥98%	A PAK inhibitor selective for group I PAKs (IC50s = 7.7, 12.8, and 19.3 nM for PAK 1, 2, and 3, respectively) over group II PAKs (IC50 > 10 µM for PAK4 and 50 = 70 nM); reduces proliferation and survival of transformed Schwann cells, ovarian, and pancreatic cells; works synergistically with gemcitabine in pancreatic cancer models in vitro and in vivo

22205	FRAX597	10 mg	≥98%	A PAK inhibitor selective for group I PAKs (IC50s = 7.7, 12.8, and 19.3 nM for PAK 1, 2, and 3, respectively) over group II PAKs (IC50 > 10 µM for PAK4 and 50 = 70 nM); reduces proliferation and survival of transformed Schwann cells, ovarian, and pancreatic cells; works synergistically with gemcitabine in pancreatic cancer models in vitro and in vivo
22205	FRAX597	25 mg	≥98%	A PAK inhibitor selective for group I PAKs (IC50s = 7.7, 12.8, and 19.3 nM for PAK 1, 2, and 3, respectively) over group II PAKs (IC50 > 10 µM for PAK4 and 50 = 70 nM); reduces proliferation and survival of transformed Schwann cells, ovarian, and pancreatic cells; works synergistically with gemcitabine in pancreatic cancer models in vitro and in vivo
22205	FRAX597	5 mg	≥98%	A PAK inhibitor selective for group I PAKs (IC50s = 7.7, 12.8, and 19.3 nM for PAK 1, 2, and 3, respectively) over group II PAKs (IC50 > 10 µM for PAK4 and 50 = 70 nM); reduces proliferation and survival of transformed Schwann cells, ovarian, and pancreatic cells; works synergistically with gemcitabine in pancreatic cancer models in vitro and in vivo
22207	KW 2449	10 mg	≥98%	A multi-kinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase (IC50s = 6.6, 14, 4, and 48 nM, respectively); has growth inhibitory activity against leukemia cells expressing FLT3 with activating mutations (GI50s = 11-46 nM); suppresses phosphorylation of FLT3 and STAT5 in MOLM-13 cells in a dose-dependent manner in vitro; inhibits colony formation of human primary AML cells with wild-type or activated mutant FLT3; induces MOLM-13 xenograft regression in a dose-dependent manner in vivo
22207	KW 2449	25 mg	≥98%	A multi-kinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase (IC50s = 6.6, 14, 4, and 48 nM, respectively); has growth inhibitory activity against leukemia cells expressing FLT3 with activating mutations (GI50s = 11-46 nM); suppresses phosphorylation of FLT3 and STAT5 in MOLM-13 cells in a dose-dependent manner in vitro; inhibits colony formation of human primary AML cells with wild-type or activated mutant FLT3; induces MOLM-13 xenograft regression in a dose-dependent manner in vivo
22207	KW 2449	5 mg	≥98%	A multi-kinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase (IC50s = 6.6, 14, 4, and 48 nM, respectively); has growth inhibitory activity against leukemia cells expressing FLT3 with activating mutations (GI50s = 11-46 nM); suppresses phosphorylation of FLT3 and STAT5 in MOLM-13 cells in a dose-dependent manner in vitro; inhibits colony formation of human primary AML cells with wild-type or activated mutant FLT3; induces MOLM-13 xenograft regression in a dose-dependent manner in vivo
22207	KW 2449	50 mg	≥98%	A multi-kinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase (IC50s = 6.6, 14, 4, and 48 nM, respectively); has growth inhibitory activity against leukemia cells expressing FLT3 with activating mutations (GI50s = 11-46 nM); suppresses phosphorylation of FLT3 and STAT5 in MOLM-13 cells in a dose-dependent manner in vitro; inhibits colony formation of human primary AML cells with wild-type or activated mutant FLT3; induces MOLM-13 xenograft regression in a dose-dependent manner in vivo
22211	LY2090314	1 mg	≥98%	A potent and selective inhibitor of GSK3 (IC50s = 1.5 and 0.9 for human recombinant GSK3α and GSK2β, respectively); has >10-fold selectivity for GSK3 against a panel of 40 kinases at a concentration of 20 µM; induces time-dependent stabilization of β-catenin total protein and activates Wnt signaling in vitro; has potent antiproliferative activity in BRAF wild-type/NRAS mutant and BRAF mutant melanoma cell lines (IC50s = 6.0-11.8 nM) but has limited to no activity in non-melanoma cell lines (IC50s = 430 to >20,000 nM); knockdown of β-catenin in A375 and M14 melanoma cells induces LY2090314 resistance in vitro; reduces tumor volume in a murine A375 xenograft model as a single agent and synergizes with decabarzine for a greater antitumor effect
22211	LY2090314	10 mg	≥98%	A potent and selective inhibitor of GSK3 (IC50s = 1.5 and 0.9 for human recombinant GSK3α and GSK2β, respectively); has >10-fold selectivity for GSK3 against a panel of 40 kinases at a concentration of 20 µM; induces time-dependent stabilization of β-catenin total protein and activates Wnt signaling in vitro; has potent antiproliferative activity in BRAF wild-type/NRAS mutant and BRAF mutant melanoma cell lines (IC50s = 6.0-11.8 nM) but has limited to no activity in non-melanoma cell lines (IC50s = 430 to >20,000 nM); knockdown of β-catenin in A375 and M14 melanoma cells induces LY2090314 resistance in vitro; reduces tumor volume in a murine A375 xenograft model as a single agent and synergizes with decabarzine for a greater antitumor effect
22211	LY2090314	25 mg	≥98%	A potent and selective inhibitor of GSK3 (IC50s = 1.5 and 0.9 for human recombinant GSK3α and GSK2β, respectively); has >10-fold selectivity for GSK3 against a panel of 40 kinases at a concentration of 20 µM; induces time-dependent stabilization of β-catenin total protein and activates Wnt signaling in vitro; has potent antiproliferative activity in BRAF wild-type/NRAS mutant and BRAF mutant melanoma cell lines (IC50s = 6.0-11.8 nM) but has limited to no activity in non-melanoma cell lines (IC50s = 430 to >20,000 nM); knockdown of β-catenin in A375 and M14 melanoma cells induces LY2090314 resistance in vitro; reduces tumor volume in a murine A375 xenograft model as a single agent and synergizes with decabarzine for a greater antitumor effect

22211	LY2090314	5 mg	≥98%	A potent and selective inhibitor of GSK3 (IC50s = 1.5 and 0.9 for human recombinant GSK3α and GSK2β, respectively); has >10-fold selectivity for GSK3 against a panel of 40 kinases at a concentration of 20 μM; induces time-dependent stabilization of β-catenin total protein and activates Wnt signaling in vitro; has potent antiproliferative activity in BRAF wild-type/NRAS mutant and BRAF mutant melanoma cell lines (IC50s = 6.0-11.8 nM) but has limited to no activity in non-melanoma cell lines (IC50s = 430 to >20,000 nM); knockdown of β-catenin in A375 and M14 melanoma cells induces LY2090314 resistance in vitro; reduces tumor volume in a murine A375 xenograft model as a single agent and synergizes with decabarzine for a greater antitumor effect
22219	p38 MAPK Inhibitor IV	10 mg	≥98%	An ATP-competitive inhibitor of p38 MAPKs; inhibits p38α, p38β, p38 , and p38δ MAPKs (IC50s = 0.13, 0.55, 5.47, and 8.63 μM, respectively); inhibits LPS-induced TNF-α and IL-1β cytokine production in human peripheral blood mononuclear cells(IC50s = 22 and 44 nM, respectively)
22219	p38 MAPK Inhibitor IV	25 mg	≥98%	An ATP-competitive inhibitor of p38 MAPKs; inhibits p38α, p38β, p38 , and p38δ MAPKs (IC50s = 0.13, 0.55, 5.47, and 8.63 μM, respectively); inhibits LPS-induced TNF-α and IL-1β cytokine production in human peripheral blood mononuclear cells(IC50s = 22 and 44 nM, respectively)
22219	p38 MAPK Inhibitor IV	5 mg	≥98%	An ATP-competitive inhibitor of p38 MAPKs; inhibits p38α, p38β, p38 , and p38δ MAPKs (IC50s = 0.13, 0.55, 5.47, and 8.63 μM, respectively); inhibits LPS-induced TNF-α and IL-1β cytokine production in human peripheral blood mononuclear cells(IC50s = 22 and 44 nM, respectively)
22257	DB07268	1 mg	≥98%	A potent inhibitor of JNK1 (IC50 = 9 nM); binds to the ATP site of JNK1; selective for JNK1 over P38, ERK2, AKT1, CHK1, and PAK4 among others
22257	DB07268	10 mg	≥98%	A potent inhibitor of JNK1 (IC50 = 9 nM); binds to the ATP site of JNK1; selective for JNK1 over P38, ERK2, AKT1, CHK1, and PAK4 among others
22257	DB07268	25 mg	≥98%	A potent inhibitor of JNK1 (IC50 = 9 nM); binds to the ATP site of JNK1; selective for JNK1 over P38, ERK2, AKT1, CHK1, and PAK4 among others
22257	DB07268	5 mg	≥98%	A potent inhibitor of JNK1 (IC50 = 9 nM); binds to the ATP site of JNK1; selective for JNK1 over P38, ERK2, AKT1, CHK1, and PAK4 among others
22258	Ki20227	1 mg	≥98%	A c-Fms kinase inhibitor (IC50 = 2 nM); inhibits CSF1-dependent c-Fms phosphorylation in a dose-dependent manner in RAW264.7 cells; reduces CSF1-dependent growth of M-NFS-60 cells (IC50 = 14 nM); suppresses development of TRAP-positive osteoclast-like cells from murine bone marrow (IC50 = 40 nM); decreases the number and area of osteolytic lesions on femurs and tibiae in a murine A375 subcutaneous xenograft model; reduces TNF-α infiltration and osteolytic bone destruction in a CIA mouse model
22258	Ki20227	10 mg	≥98%	A c-Fms kinase inhibitor (IC50 = 2 nM); inhibits CSF1-dependent c-Fms phosphorylation in a dose-dependent manner in RAW264.7 cells; reduces CSF1-dependent growth of M-NFS-60 cells (IC50 = 14 nM); suppresses development of TRAP-positive osteoclast-like cells from murine bone marrow (IC50 = 40 nM); decreases the number and area of osteolytic lesions on femurs and tibiae in a murine A375 subcutaneous xenograft model; reduces TNF-α infiltration and osteolytic bone destruction in a CIA mouse model
22258	Ki20227	25 mg	≥98%	A c-Fms kinase inhibitor (IC50 = 2 nM); inhibits CSF1-dependent c-Fms phosphorylation in a dose-dependent manner in RAW264.7 cells; reduces CSF1-dependent growth of M-NFS-60 cells (IC50 = 14 nM); suppresses development of TRAP-positive osteoclast-like cells from murine bone marrow (IC50 = 40 nM); decreases the number and area of osteolytic lesions on femurs and tibiae in a murine A375 subcutaneous xenograft model; reduces TNF-α infiltration and osteolytic bone destruction in a CIA mouse model
22258	Ki20227	5 mg	≥98%	A c-Fms kinase inhibitor (IC50 = 2 nM); inhibits CSF1-dependent c-Fms phosphorylation in a dose-dependent manner in RAW264.7 cells; reduces CSF1-dependent growth of M-NFS-60 cells (IC50 = 14 nM); suppresses development of TRAP-positive osteoclast-like cells from murine bone marrow (IC50 = 40 nM); decreases the number and area of osteolytic lesions on femurs and tibiae in a murine A375 subcutaneous xenograft model; reduces TNF-α infiltration and osteolytic bone destruction in a CIA mouse model
22292	N-desethyl Sunitinib	1 mg	≥95%	An active metabolite of sunitinib; formed when sunitinib undergoes N-de-ethylation by CYP3A4; is pharmacologically active having similar inhibitory activity to sunitinib
22292	N-desethyl Sunitinib	10 mg	≥95%	An active metabolite of sunitinib; formed when sunitinib undergoes N-de-ethylation by CYP3A4; is pharmacologically active having similar inhibitory activity to sunitinib
22292	N-desethyl Sunitinib	5 mg	≥95%	An active metabolite of sunitinib; formed when sunitinib undergoes N-de-ethylation by CYP3A4; is pharmacologically active having similar inhibitory activity to sunitinib
22292	N-desethyl Sunitinib	500 µg	≥95%	An active metabolite of sunitinib; formed when sunitinib undergoes N-de-ethylation by CYP3A4; is pharmacologically active having similar inhibitory activity to sunitinib

22356	Sphingosine (d16:1)	1 mg	≥95%	An atypical sphingolipid; inhibits PKC in a mixed micelle activity assay; reduces PMA-induced superoxide production in isolated human neutrophils and reduces the growth of CHO cells (IC50s = 1 and 3.2 μM, respectively); plasma levels of sphingolipids containing sphingosine (d16:1) are associated with dietary intake of saturated fatty acids and protein in ethnic Chinese individuals; plasma levels of sphingolipids containing sphingosine (d16:1) are decreased in patients with type 2 diabetes
22356	Sphingosine (d16:1)	10 mg	≥95%	An atypical sphingolipid; inhibits PKC in a mixed micelle activity assay; reduces PMA-induced superoxide production in isolated human neutrophils and reduces the growth of CHO cells (IC50s = 1 and 3.2 μM, respectively); plasma levels of sphingolipids containing sphingosine (d16:1) are associated with dietary intake of saturated fatty acids and protein in ethnic Chinese individuals; plasma levels of sphingolipids containing sphingosine (d16:1) are decreased in patients with type 2 diabetes
22356	Sphingosine (d16:1)	25 mg	≥95%	An atypical sphingolipid; inhibits PKC in a mixed micelle activity assay; reduces PMA-induced superoxide production in isolated human neutrophils and reduces the growth of CHO cells (IC50s = 1 and 3.2 μM, respectively); plasma levels of sphingolipids containing sphingosine (d16:1) are associated with dietary intake of saturated fatty acids and protein in ethnic Chinese individuals; plasma levels of sphingolipids containing sphingosine (d16:1) are decreased in patients with type 2 diabetes
22356	Sphingosine (d16:1)	5 mg	≥95%	An atypical sphingolipid; inhibits PKC in a mixed micelle activity assay; reduces PMA-induced superoxide production in isolated human neutrophils and reduces the growth of CHO cells (IC50s = 1 and 3.2 μM, respectively); plasma levels of sphingolipids containing sphingosine (d16:1) are associated with dietary intake of saturated fatty acids and protein in ethnic Chinese individuals; plasma levels of sphingolipids containing sphingosine (d16:1) are decreased in patients with type 2 diabetes
22364	Gefitinib-d6	1 mg	≥99% deutera	An internal standard for the quantification of gefitinib by GC- or LC-MS
22364	Gefitinib-d6	500 µg	≥99% deutera	An internal standard for the quantification of gefitinib by GC- or LC-MS
22365	O-Desmethyl Gefitinib	1 mg	≥95%	A major active metabolite of gefitinib in human plasma; inhibits EGFR in subcellular assays similarly to gefitinib (IC50s = 36 and 22 nM, respectively); less active than gefitinib in whole cell assays (IC50s = 760 and 49 nM, respectively); does not reduce tumor growth as well as gefitinib in a LoVo tumor mouse xenograft model
22365	O-Desmethyl Gefitinib	5 mg	≥95%	A major active metabolite of gefitinib in human plasma; inhibits EGFR in subcellular assays similarly to gefitinib (IC50s = 36 and 22 nM, respectively); less active than gefitinib in whole cell assays (IC50s = 760 and 49 nM, respectively); does not reduce tumor growth as well as gefitinib in a LoVo tumor mouse xenograft model
22365	O-Desmethyl Gefitinib	500 µg	≥95%	A major active metabolite of gefitinib in human plasma; inhibits EGFR in subcellular assays similarly to gefitinib (IC50s = 36 and 22 nM, respectively); less active than gefitinib in whole cell assays (IC50s = 760 and 49 nM, respectively); does not reduce tumor growth as well as gefitinib in a LoVo tumor mouse xenograft model
22368	Dasatinib-d8	1 mg	≥99% deutera	An internal standard for the quantification of GC- or LC-MS
22368	Dasatinib-d8	500 µg	≥99% deutera	An internal standard for the quantification of GC- or LC-MS
22387	Syringin	10 mg	≥98%	A modulator of acetylcholine release; dose-dependently (50, 75, and 100 µg/kg, i.v.) decreases plasma glucose levels and increases insulin-like immunoreactivity and C-peptide in rats; increases β-endorphin; increases autophagy through AMPKα activation preventing cardiac hypertrophy progression
22387	Syringin	25 mg	≥98%	A modulator of acetylcholine release; dose-dependently (50, 75, and 100 µg/kg, i.v.) decreases plasma glucose levels and increases insulin-like immunoreactivity and C-peptide in rats; increases β-endorphin; increases autophagy through AMPKα activation preventing cardiac hypertrophy progression
22387	Syringin	5 mg	≥98%	A modulator of acetylcholine release; dose-dependently (50, 75, and 100 µg/kg, i.v.) decreases plasma glucose levels and increases insulin-like immunoreactivity and C-peptide in rats; increases β-endorphin; increases autophagy through AMPKα activation preventing cardiac hypertrophy progression
22387	Syringin	50 mg	≥98%	A modulator of acetylcholine release; dose-dependently (50, 75, and 100 µg/kg, i.v.) decreases plasma glucose levels and increases insulin-like immunoreactivity and C-peptide in rats; increases β-endorphin; increases autophagy through AMPKα activation preventing cardiac hypertrophy progression

22409	Nazartinib	1 mg	≥98%	An inhibitor of mutant EGFRs; selective for EGFR mutant cell lines, including H3255 and HCC827 lung adenocarcinoma cells (IC50s = 6.11 and 1.52 nM, respectively) and resistant H1975 NSCLC cells (IC50 = 4.18 nM), over cells expressing wild-type EGFR (IC50 = 160.6 nM for HaCaT keratinocytes); decreases phosphorylation of EGFR in H3255, HCC827, and H1975 cells (EC50s = 5, 1, and 3 nM) and inhibits cell proliferation of H3255, HCC827, and H1975 cells (EC50s = 9, 11, and 25 nM) but does not affect cell proliferation in cell lines containing wild-type EGFR; reduces tumor growth in an HCC827 lung adenocarcinoma mouse xenograft model at doses ranging from 3 to 100 mg/kg per day
22409	Nazartinib	10 mg	≥98%	An inhibitor of mutant EGFRs; selective for EGFR mutant cell lines, including H3255 and HCC827 lung adenocarcinoma cells (IC50s = 6.11 and 1.52 nM, respectively) and resistant H1975 NSCLC cells (IC50 = 4.18 nM), over cells expressing wild-type EGFR (IC50 = 160.6 nM for HaCaT keratinocytes); decreases phosphorylation of EGFR in H3255, HCC827, and H1975 cells (EC50s = 5, 1, and 3 nM) and inhibits cell proliferation of H3255, HCC827, and H1975 cells (EC50s = 9, 11, and 25 nM) but does not affect cell proliferation in cell lines containing wild-type EGFR; reduces tumor growth in an HCC827 lung adenocarcinoma mouse xenograft model at doses ranging from 3 to 100 mg/kg per day
22409	Nazartinib	25 mg	≥98%	An inhibitor of mutant EGFRs; selective for EGFR mutant cell lines, including H3255 and HCC827 lung adenocarcinoma cells (IC50s = 6.11 and 1.52 nM, respectively) and resistant H1975 NSCLC cells (IC50 = 4.18 nM), over cells expressing wild-type EGFR (IC50 = 160.6 nM for HaCaT keratinocytes); decreases phosphorylation of EGFR in H3255, HCC827, and H1975 cells (EC50s = 5, 1, and 3 nM) and inhibits cell proliferation of H3255, HCC827, and H1975 cells (EC50s = 9, 11, and 25 nM) but does not affect cell proliferation in cell lines containing wild-type EGFR; reduces tumor growth in an HCC827 lung adenocarcinoma mouse xenograft model at doses ranging from 3 to 100 mg/kg per day
22409	Nazartinib	5 mg	≥98%	An inhibitor of mutant EGFRs; selective for EGFR mutant cell lines, including H3255 and HCC827 lung adenocarcinoma cells (IC50s = 6.11 and 1.52 nM, respectively) and resistant H1975 NSCLC cells (IC50 = 4.18 nM), over cells expressing wild-type EGFR (IC50 = 160.6 nM for HaCaT keratinocytes); decreases phosphorylation of EGFR in H3255, HCC827, and H1975 cells (EC50s = 5, 1, and 3 nM) and inhibits cell proliferation of H3255, HCC827, and H1975 cells (EC50s = 9, 11, and 25 nM) but does not affect cell proliferation in cell lines containing wild-type EGFR; reduces tumor growth in an HCC827 lung adenocarcinoma mouse xenograft model at doses ranging from 3 to 100 mg/kg per day
22437	Poziotinib	1 mg	≥95%	An inhibitor of EGFRs (IC50s = 3.2, 5.3, 23.5, 4.2, and 2.2 nM for wild-type EGFR, HER2, HER4, EGFRT790M, and EGFRL858R/T790M, respectively); has greater than 100- to 1,000-fold selectivity for EGFR kinases in vitro over 30 other kinases; inhibits growth of wild-type and mutant EGFR kinase-dependent lung, breast, and gastric cancer cell lines (GI50s = 0.6-5.7 nM); inhibits EGFR phosphorylation and induces apoptosis in vitro; reduces tumor size in an HCC827 non-small cell lung cancer mouse xenograft model
22437	Poziotinib	10 mg	≥95%	An inhibitor of EGFRs (IC50s = 3.2, 5.3, 23.5, 4.2, and 2.2 nM for wild-type EGFR, HER2, HER4, EGFRT790M, and EGFRL858R/T790M, respectively); has greater than 100- to 1,000-fold selectivity for EGFR kinases in vitro over 30 other kinases; inhibits growth of wild-type and mutant EGFR kinase-dependent lung, breast, and gastric cancer cell lines (GI50s = 0.6-5.7 nM); inhibits EGFR phosphorylation and induces apoptosis in vitro; reduces tumor size in an HCC827 non-small cell lung cancer mouse xenograft model
22437	Poziotinib	25 mg	≥95%	An inhibitor of EGFRs (IC50s = 3.2, 5.3, 23.5, 4.2, and 2.2 nM for wild-type EGFR, HER2, HER4, EGFRT790M, and EGFRL858R/T790M, respectively); has greater than 100- to 1,000-fold selectivity for EGFR kinases in vitro over 30 other kinases; inhibits growth of wild-type and mutant EGFR kinase-dependent lung, breast, and gastric cancer cell lines (GI50s = 0.6-5.7 nM); inhibits EGFR phosphorylation and induces apoptosis in vitro; reduces tumor size in an HCC827 non-small cell lung cancer mouse xenograft model
22437	Poziotinib	5 mg	≥95%	An inhibitor of EGFRs (IC50s = 3.2, 5.3, 23.5, 4.2, and 2.2 nM for wild-type EGFR, HER2, HER4, EGFRT790M, and EGFRL858R/T790M, respectively); has greater than 100- to 1,000-fold selectivity for EGFR kinases in vitro over 30 other kinases; inhibits growth of wild-type and mutant EGFR kinase-dependent lung, breast, and gastric cancer cell lines (GI50s = 0.6-5.7 nM); inhibits EGFR phosphorylation and induces apoptosis in vitro; reduces tumor size in an HCC827 non-small cell lung cancer mouse xenograft model
22438	BLU-554	1 mg	≥95%	A potent inhibitor of recombinant FGFR4 (IC50 50 < 10 nM), a marker of FGFR4 inhibition, in MDA-MB453 cells
22438	BLU-554	10 mg	≥95%	A potent inhibitor of recombinant FGFR4 (IC50 50 < 10 nM), a marker of FGFR4 inhibition, in MDA-MB453 cells
22438	BLU-554	25 mg	≥95%	A potent inhibitor of recombinant FGFR4 (IC50 50 < 10 nM), a marker of FGFR4 inhibition, in MDA-MB453 cells
22438	BLU-554	5 mg	≥95%	A potent inhibitor of recombinant FGFR4 (IC50 50 < 10 nM), a marker of FGFR4 inhibition, in MDA-MB453 cells

22464	PD 166866	1 mg	≥98%	A potent inhibitor of FGFR1 (IC50 = 52.4 nM; Ki = 45.2 nM); selective for FGFR1 over PDGFR, EGFR, C-SRC, MEK, PKC, insulin receptor tyrosine kinase, and CDK4 (IC50s = >50 μM); inhibits FGFR1 autophosphorylation in NIH3T3 and L6 cells (IC50s = 10.8 and 3.1 nM, respectively); inhibits phosphorylation of MAPK (IC50 = 4.3 and 7.9 nM for the 44- and 42-kDa MAPK isoforms, respectively); reduces FGF- but not EGF- or PDGF-stimulated growth of L6 cells and inhibits microvessel outgrowth from human placental arteries in vitro; inhibits growth of NSCLC cell lines a dose-dependent manner; reduces migration of VL-8 cells at a concentration of 10 μM
22464	PD 166866	10 mg	≥98%	A potent inhibitor of FGFR1 (IC50 = 52.4 nM; Ki = 45.2 nM); selective for FGFR1 over PDGFR, EGFR, C-SRC, MEK, PKC, insulin receptor tyrosine kinase, and CDK4 (IC50s = >50 μM); inhibits FGFR1 autophosphorylation in NIH3T3 and L6 cells (IC50s = 10.8 and 3.1 nM, respectively); inhibits phosphorylation of MAPK (IC50 = 4.3 and 7.9 nM for the 44- and 42-kDa MAPK isoforms, respectively); reduces FGF- but not EGF- or PDGF-stimulated growth of L6 cells and inhibits microvessel outgrowth from human placental arteries in vitro; inhibits growth of NSCLC cell lines a dose-dependent manner; reduces migration of VL-8 cells at a concentration of 10 μM
22464	PD 166866	25 mg	≥98%	A potent inhibitor of FGFR1 (IC50 = 52.4 nM; Ki = 45.2 nM); selective for FGFR1 over PDGFR, EGFR, C-SRC, MEK, PKC, insulin receptor tyrosine kinase, and CDK4 (IC50s = >50 μM); inhibits FGFR1 autophosphorylation in NIH3T3 and L6 cells (IC50s = 10.8 and 3.1 nM, respectively); inhibits phosphorylation of MAPK (IC50 = 4.3 and 7.9 nM for the 44- and 42-kDa MAPK isoforms, respectively); reduces FGF- but not EGF- or PDGF-stimulated growth of L6 cells and inhibits microvessel outgrowth from human placental arteries in vitro; inhibits growth of NSCLC cell lines a dose-dependent manner; reduces migration of VL-8 cells at a concentration of 10 μM
22464	PD 166866	5 mg	≥98%	A potent inhibitor of FGFR1 (IC50 = 52.4 nM; Ki = 45.2 nM); selective for FGFR1 over PDGFR, EGFR, C-SRC, MEK, PKC, insulin receptor tyrosine kinase, and CDK4 (IC50s = >50 μM); inhibits FGFR1 autophosphorylation in NIH3T3 and L6 cells (IC50s = 10.8 and 3.1 nM, respectively); inhibits phosphorylation of MAPK (IC50 = 4.3 and 7.9 nM for the 44- and 42-kDa MAPK isoforms, respectively); reduces FGF- but not EGF- or PDGF-stimulated growth of L6 cells and inhibits microvessel outgrowth from human placental arteries in vitro; inhibits growth of NSCLC cell lines a dose-dependent manner; reduces migration of VL-8 cells at a concentration of 10 μM
22466	CC-930	1 mg	≥98%	A potent JNK inhibitor (IC50s = 61, 7, and 6 nM for JNK1, JNK2, and JNK3, respectively); selective for MAP kinases; selective for JNKs over other MAPK family proteins (IC50s = 3,400 and 480 nM for p38α and ERK1, respectively); inhibits JNK in a cell lysate assay (IC50 = 200 nM); blocks phosphorylation of c-Jun in LPS-stimulated human PBMCs; inhibits TNF-α production induced by LPS when administered to rats at doses of 10 and 30 mg/kg; reduces lung fibrosis in a mouse pulmonary fibrosis model
22466	CC-930	10 mg	≥98%	A potent JNK inhibitor (IC50s = 61, 7, and 6 nM for JNK1, JNK2, and JNK3, respectively); selective for MAP kinases; selective for JNKs over other MAPK family proteins (IC50s = 3,400 and 480 nM for p38α and ERK1, respectively); inhibits JNK in a cell lysate assay (IC50 = 200 nM); blocks phosphorylation of c-Jun in LPS-stimulated human PBMCs; inhibits TNF-α production induced by LPS when administered to rats at doses of 10 and 30 mg/kg; reduces lung fibrosis in a mouse pulmonary fibrosis model
22466	CC-930	25 mg	≥98%	A potent JNK inhibitor (IC50s = 61, 7, and 6 nM for JNK1, JNK2, and JNK3, respectively); selective for MAP kinases; selective for JNKs over other MAPK family proteins (IC50s = 3,400 and 480 nM for p38α and ERK1, respectively); inhibits JNK in a cell lysate assay (IC50 = 200 nM); blocks phosphorylation of c-Jun in LPS-stimulated human PBMCs; inhibits TNF-α production induced by LPS when administered to rats at doses of 10 and 30 mg/kg; reduces lung fibrosis in a mouse pulmonary fibrosis model
22466	CC-930	5 mg	≥98%	A potent JNK inhibitor (IC50s = 61, 7, and 6 nM for JNK1, JNK2, and JNK3, respectively); selective for MAP kinases; selective for JNKs over other MAPK family proteins (IC50s = 3,400 and 480 nM for p38α and ERK1, respectively); inhibits JNK in a cell lysate assay (IC50 = 200 nM); blocks phosphorylation of c-Jun in LPS-stimulated human PBMCs; inhibits TNF-α production induced by LPS when administered to rats at doses of 10 and 30 mg/kg; reduces lung fibrosis in a mouse pulmonary fibrosis model
22474	AZD 3147	1 mg	≥98%	A dual mTORC1/mTORC2 inhibitor (IC50s = 40.7 and 5.75 nM, respectively, in MDA-MB-468 cells); selective for mTOR over PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ (IC50s = 1.51, 912, 5,495, 9,333, and 6,310 nM, respectively, in enzyme assays)
22474	AZD 3147	10 mg	≥98%	A dual mTORC1/mTORC2 inhibitor (IC50s = 40.7 and 5.75 nM, respectively, in MDA-MB-468 cells); selective for mTOR over PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ (IC50s = 1.51, 912, 5,495, 9,333, and 6,310 nM, respectively, in enzyme assays)
22474	AZD 3147	5 mg	≥98%	A dual mTORC1/mTORC2 inhibitor (IC50s = 40.7 and 5.75 nM, respectively, in MDA-MB-468 cells); selective for mTOR over PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ (IC50s = 1.51, 912, 5,495, 9,333, and 6,310 nM, respectively, in enzyme assays)

22474	AZD 3147	500 µg	≥98%	A dual mTORC1/mTORC2 inhibitor (IC50s = 40.7 and 5.75 nM, respectively, in MDA-MB-468 cells); selective for mTOR over PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ (IC50s = 1.51, 912, 5,495, 9,333, and 6,310 nM, respectively, in enzyme assays)
22476	PRT060318	10 mg	≥98%	A potent and selective Syk inhibitor (IC50 = 4 nM); inhibits 92% of Syk activity, while other kinases retain >70% activity, at a concentration of 50 nM in a panel of 270 kinases; inhibits convulxin-induced aggregation of human platelet-rich plasma (IC50 = 2.5 µM); prevents thrombosis in a transgenic mouse model of heparin-induced thrombocytopenia; induces CLL B cell apoptosis and inhibits the secretion of chemokines CCL3, CCL4, and CXCL13; inhibits CLL B cell chemotaxis and pseudoemperipolesis
22476	PRT060318	25 mg	≥98%	A potent and selective Syk inhibitor (IC50 = 4 nM); inhibits 92% of Syk activity, while other kinases retain >70% activity, at a concentration of 50 nM in a panel of 270 kinases; inhibits convulxin-induced aggregation of human platelet-rich plasma (IC50 = 2.5 µM); prevents thrombosis in a transgenic mouse model of heparin-induced thrombocytopenia; induces CLL B cell apoptosis and inhibits the secretion of chemokines CCL3, CCL4, and CXCL13; inhibits CLL B cell chemotaxis and pseudoemperipolesis
22476	PRT060318	5 mg	≥98%	A potent and selective Syk inhibitor (IC50 = 4 nM); inhibits 92% of Syk activity, while other kinases retain >70% activity, at a concentration of 50 nM in a panel of 270 kinases; inhibits convulxin-induced aggregation of human platelet-rich plasma (IC50 = 2.5 µM); prevents thrombosis in a transgenic mouse model of heparin-induced thrombocytopenia; induces CLL B cell apoptosis and inhibits the secretion of chemokines CCL3, CCL4, and CXCL13; inhibits CLL B cell chemotaxis and pseudoemperipolesis
22552	Afatinib-d6	1 mg	≥99% deutera	An internal standard for the quantification of afatinib by GC- or LC-MS
22552	Afatinib-d6	500 µg	≥99% deutera	An internal standard for the quantification of afatinib by GC- or LC-MS
22559	Everolimus-d4	1 mg	≥99% deutera	An internal standard for the quantificaiton of everolimus by GC- or LC-MS
22559	Everolimus-d4	500 µg	≥99% deutera	An internal standard for the quantificaiton of everolimus by GC- or LC-MS
22561	Ibrutinib-d5	1 mg	≥99% deutera	An internal standard for the quantification of ibrutinib by GC- or LC-MS
22561	Ibrutinib-d5	5 mg	≥99% deutera	An internal standard for the quantification of ibrutinib by GC- or LC-MS
22561	Ibrutinib-d5	500 µg	≥99% deutera	An internal standard for the quantification of ibrutinib by GC- or LC-MS
22614	Sunitinib-d10	5 mg	≥99% deutera	An internal standard for the quantification of sunitinib by GC- or LC-MS
22698	PF-6274484	1 mg	≥98%	An EGFR inhibitor (IC50s = 0.18 and 0.14 nM for wild-type EGFR and inhibitor-resistant EGFRL858R/T790M, respectively); inhibits the autophosphorylation of wild-type EGFR in A549 cells and EGFRL858R/T790M in H1975 cells (IC50s = 5.8 and 6.6 nM, respectively)
22698	PF-6274484	10 mg	≥98%	An EGFR inhibitor (IC50s = 0.18 and 0.14 nM for wild-type EGFR and inhibitor-resistant EGFRL858R/T790M, respectively); inhibits the autophosphorylation of wild-type EGFR in A549 cells and EGFRL858R/T790M in H1975 cells (IC50s = 5.8 and 6.6 nM, respectively)
22698	PF-6274484	5 mg	≥98%	An EGFR inhibitor (IC50s = 0.18 and 0.14 nM for wild-type EGFR and inhibitor-resistant EGFRL858R/T790M, respectively); inhibits the autophosphorylation of wild-type EGFR in A549 cells and EGFRL858R/T790M in H1975 cells (IC50s = 5.8 and 6.6 nM, respectively)
22706	Palomid 529	10 mg	≥98%	An inhibitor of mTORC1 and mTORC2 formation; inhibits VEGF-driven and bFGF-driven endothelial cell proliferation (IC50s = 20 and 30 nM, respectively); reduces VEGF-A-driven phosphorylation of AktS473, an mTORC2 substrate; inhibits retinal neovascularization in mice with oxygen-induced retinopathy, Ad-VEGF-A-driven angiogenesis, and phosphorylation of AktS473 in vivo; has anticancer effects in glioma cancer cells and xenografts via AktS473 signaling downtstream of mTORC
22706	Palomid 529	25 mg	≥98%	An inhibitor of mTORC1 and mTORC2 formation; inhibits VEGF-driven and bFGF-driven endothelial cell proliferation (IC50s = 20 and 30 nM, respectively); reduces VEGF-A-driven phosphorylation of AktS473, an mTORC2 substrate; inhibits retinal neovascularization in mice with oxygen-induced retinopathy, Ad-VEGF-A-driven angiogenesis, and phosphorylation of AktS473 in vivo; has anticancer effects in glioma cancer cells and xenografts via AktS473 signaling downtstream of mTORC
22706	Palomid 529	5 mg	≥98%	An inhibitor of mTORC1 and mTORC2 formation; inhibits VEGF-driven and bFGF-driven endothelial cell proliferation (IC50s = 20 and 30 nM, respectively); reduces VEGF-A-driven phosphorylation of AktS473, an mTORC2 substrate; inhibits retinal neovascularization in mice with oxygen-induced retinopathy, Ad-VEGF-A-driven angiogenesis, and phosphorylation of AktS473 in vivo; has anticancer effects in glioma cancer cells and xenografts via AktS473 signaling downtstream of mTORC

22706	Palomid 529	50 mg	≥98%	An inhibitor of mTORC1 and mTORC2 formation; inhibits VEGF-driven and bFGF-driven endothelial cell proliferation (IC50s = 20 and 30 nM, respectively); reduces VEGF-A-driven phosphorylation of AktS473, an mTORC2 substrate; inhibits retinal neovascularization in mice with oxygen-induced retinopathy, Ad-VEGF-A-driven angiogenesis, and phosphorylation of AktS473 in vivo; has anticancer effects in glioma cancer cells and xenografts via AktS473 signaling downtstream of mTORC
22758	Epiblastin A	1 mg	≥98%	An inhibitor of CK1α, CK1δ, and CK1ε (IC50s = 8.9, 0.5, and 4.7 µM, respectively); reduces immunoprecipitation of CK1α, CK1δ, and CK1ε from HCT116 cell lysates in a concentration-dependent manner; induces reprogramming of mEpiSCs into ESCs
22758	Epiblastin A	5 mg	≥98%	An inhibitor of CK1α, CK1δ, and CK1ε (IC50s = 8.9, 0.5, and 4.7 µM, respectively); reduces immunoprecipitation of CK1α, CK1δ, and CK1ε from HCT116 cell lysates in a concentration-dependent manner; induces reprogramming of mEpiSCs into ESCs
22888	3-Methylcrotonyl Glyc	10 mg	≥98%	A metabolite; found in urine of patients with 3-methycrotonyl glycinuria; inhibits CO2 production and mitochondrial complex II-III and creatine kinase activity in rat cerebral cortex preparations in a concentration-dependent manner; inhibits the Na+/K+-ATPase in purified synaptic membranes from rat cerebrum
22888	3-Methylcrotonyl Glyc	100 mg	≥98%	A metabolite; found in urine of patients with 3-methycrotonyl glycinuria; inhibits CO2 production and mitochondrial complex II-III and creatine kinase activity in rat cerebral cortex preparations in a concentration-dependent manner; inhibits the Na+/K+-ATPase in purified synaptic membranes from rat cerebrum
22888	3-Methylcrotonyl Glyc	250 mg	≥98%	A metabolite; found in urine of patients with 3-methycrotonyl glycinuria; inhibits CO2 production and mitochondrial complex II-III and creatine kinase activity in rat cerebral cortex preparations in a concentration-dependent manner; inhibits the Na+/K+-ATPase in purified synaptic membranes from rat cerebrum
22888	3-Methylcrotonyl Glyc	50 mg	≥98%	A metabolite; found in urine of patients with 3-methycrotonyl glycinuria; inhibits CO2 production and mitochondrial complex II-III and creatine kinase activity in rat cerebral cortex preparations in a concentration-dependent manner; inhibits the Na+/K+-ATPase in purified synaptic membranes from rat cerebrum
22892	BMS 582949	1 mg	≥98%	A p38α MAP kinase inhibitor (IC50 = 13 nM); inhibits TNF-α production in PBMCs (IC50 = 50 nM); reduces LPS-induced TNF-α production up to 89% in mice at 5 mg/kg; reduces paw swelling in a rat adjuvant arthritis model when administered once per day (1, 10, or 100 mg/kg) or twice per day (1 or 5 mg/kg)
22892	BMS 582949	25 mg	≥98%	A p38α MAP kinase inhibitor (IC50 = 13 nM); inhibits TNF-α production in PBMCs (IC50 = 50 nM); reduces LPS-induced TNF-α production up to 89% in mice at 5 mg/kg; reduces paw swelling in a rat adjuvant arthritis model when administered once per day (1, 10, or 100 mg/kg) or twice per day (1 or 5 mg/kg)
22892	BMS 582949	5 mg	≥98%	A p38α MAP kinase inhibitor (IC50 = 13 nM); inhibits TNF-α production in PBMCs (IC50 = 50 nM); reduces LPS-induced TNF-α production up to 89% in mice at 5 mg/kg; reduces paw swelling in a rat adjuvant arthritis model when administered once per day (1, 10, or 100 mg/kg) or twice per day (1 or 5 mg/kg)
22905	JH-II-127	1 mg	≥98%	An inhibitor of wild-type and mutant forms of LRRK2; inhibits WT LRRK2, LRRK2G2019S, and LRRK2A2016T (IC50s = 6.6, 2.2, and 47.7 nM, respectively) but not LRRK2 containing both mutations (IC50 = 3,080 nM); inhibits phosphorylation of Ser910 and Ser935 of WT LRRK2 and LRRK2G2019S in vitro; inhibits Ser935 phosphorylation in vivo in mouse brain, spleen, and kidney at 30 mg/kg
22905	JH-II-127	10 mg	≥98%	An inhibitor of wild-type and mutant forms of LRRK2; inhibits WT LRRK2, LRRK2G2019S, and LRRK2A2016T (IC50s = 6.6, 2.2, and 47.7 nM, respectively) but not LRRK2 containing both mutations (IC50 = 3,080 nM); inhibits phosphorylation of Ser910 and Ser935 of WT LRRK2 and LRRK2G2019S in vitro; inhibits Ser935 phosphorylation in vivo in mouse brain, spleen, and kidney at 30 mg/kg
22905	JH-II-127	25 mg	≥98%	An inhibitor of wild-type and mutant forms of LRRK2; inhibits WT LRRK2, LRRK2G2019S, and LRRK2A2016T (IC50s = 6.6, 2.2, and 47.7 nM, respectively) but not LRRK2 containing both mutations (IC50 = 3,080 nM); inhibits phosphorylation of Ser910 and Ser935 of WT LRRK2 and LRRK2G2019S in vitro; inhibits Ser935 phosphorylation in vivo in mouse brain, spleen, and kidney at 30 mg/kg
22905	JH-II-127	5 mg	≥98%	An inhibitor of wild-type and mutant forms of LRRK2; inhibits WT LRRK2, LRRK2G2019S, and LRRK2A2016T (IC50s = 6.6, 2.2, and 47.7 nM, respectively) but not LRRK2 containing both mutations (IC50 = 3,080 nM); inhibits phosphorylation of Ser910 and Ser935 of WT LRRK2 and LRRK2G2019S in vitro; inhibits Ser935 phosphorylation in vivo in mouse brain, spleen, and kidney at 30 mg/kg

22913	APY-29	10 mg	≥98%	A modulator of IRE1α function; binds to the ATP-binding site on IRE1α, where it inhibits autophosphorylation (IC50 = 280 nM) and enhances its RNase function (EC50 = 460 nM); restores the ability of dephosphoylated IRE1α to cleave XBP1 mRNA in a dose-dependent manner; enhances IRE1α oligomerization in a crosslinking assay
22913	APY-29	25 mg	≥98%	A modulator of IRE1α function; binds to the ATP-binding site on IRE1α, where it inhibits autophosphorylation (IC50 = 280 nM) and enhances its RNase function (EC50 = 460 nM); restores the ability of dephosphoylated IRE1α to cleave XBP1 mRNA in a dose-dependent manner; enhances IRE1α oligomerization in a crosslinking assay
22913	APY-29	5 mg	≥98%	A modulator of IRE1α function; binds to the ATP-binding site on IRE1α, where it inhibits autophosphorylation (IC50 = 280 nM) and enhances its RNase function (EC50 = 460 nM); restores the ability of dephosphoylated IRE1α to cleave XBP1 mRNA in a dose-dependent manner; enhances IRE1α oligomerization in a crosslinking assay
22913	APY-29	50 mg	≥98%	A modulator of IRE1α function; binds to the ATP-binding site on IRE1α, where it inhibits autophosphorylation (IC50 = 280 nM) and enhances its RNase function (EC50 = 460 nM); restores the ability of dephosphoylated IRE1α to cleave XBP1 mRNA in a dose-dependent manner; enhances IRE1α oligomerization in a crosslinking assay
22929	R112	1 mg	≥98%	A Syk inhibitor (IC50 = 226 nM in cultured human mast cells); acts in an ATP-competitive and reversible manner (Ki = 96 nM); inhibits anti-IgE cross-linking-induced mast cell and basophil degranulation (EC50 = 353 and 280 nM, respectively); inhibits allergen-induced inhibits basophil degranulation (EC50 = 490 nM)
22929	R112	10 mg	≥98%	A Syk inhibitor (IC50 = 226 nM in cultured human mast cells); acts in an ATP-competitive and reversible manner (Ki = 96 nM); inhibits anti-IgE cross-linking-induced mast cell and basophil degranulation (EC50 = 353 and 280 nM, respectively); inhibits allergen-induced inhibits basophil degranulation (EC50 = 490 nM)
22929	R112	25 mg	≥98%	A Syk inhibitor (IC50 = 226 nM in cultured human mast cells); acts in an ATP-competitive and reversible manner (Ki = 96 nM); inhibits anti-IgE cross-linking-induced mast cell and basophil degranulation (EC50 = 353 and 280 nM, respectively); inhibits allergen-induced inhibits basophil degranulation (EC50 = 490 nM)
22929	R112	5 mg	≥98%	A Syk inhibitor (IC50 = 226 nM in cultured human mast cells); acts in an ATP-competitive and reversible manner (Ki = 96 nM); inhibits anti-IgE cross-linking-induced mast cell and basophil degranulation (EC50 = 353 and 280 nM, respectively); inhibits allergen-induced inhibits basophil degranulation (EC50 = 490 nM)
22931	CZC-25146	1 mg	≥98%	A potent LRRK2 inhibitor (IC50 = 4.76 nM for the human recombinant kinase); inhibits LRRK2G2019S (IC50 = 6.87 nM); reduces LRRK2G2019S-induced cell injury in rat primary cortical neurons
22931	CZC-25146	10 mg	≥98%	A potent LRRK2 inhibitor (IC50 = 4.76 nM for the human recombinant kinase); inhibits LRRK2G2019S (IC50 = 6.87 nM); reduces LRRK2G2019S-induced cell injury in rat primary cortical neurons
22931	CZC-25146	25 mg	≥98%	A potent LRRK2 inhibitor (IC50 = 4.76 nM for the human recombinant kinase); inhibits LRRK2G2019S (IC50 = 6.87 nM); reduces LRRK2G2019S-induced cell injury in rat primary cortical neurons
22931	CZC-25146	5 mg	≥98%	A potent LRRK2 inhibitor (IC50 = 4.76 nM for the human recombinant kinase); inhibits LRRK2G2019S (IC50 = 6.87 nM); reduces LRRK2G2019S-induced cell injury in rat primary cortical neurons
22933	RKI-1313	1 mg	≥98%	An inhibitor of ROCK1 and 2 (IC50s = 34 and 8 μM, respectively); has been used as a negative control for the ROCK inhibitor RKI-1447
22933	RKI-1313	10 mg	≥98%	An inhibitor of ROCK1 and 2 (IC50s = 34 and 8 μM, respectively); has been used as a negative control for the ROCK inhibitor RKI-1447
22933	RKI-1313	5 mg	≥98%	An inhibitor of ROCK1 and 2 (IC50s = 34 and 8 μM, respectively); has been used as a negative control for the ROCK inhibitor RKI-1447
22953	GSK1070916	1 mg	≥98%	A potent inhibitor of Aurora B and C (Kis = 0.38 and 1.5 nM, respectively); >250-fold selective for Aurora B and C over Aurora A; inhibits proliferation of A549 lung cancer cells in vitro (EC50 = 7 nM); inhibits proliferation in a panel of 100 tumor cell lines (EC50s = <10 nM); inhibits histone H3 phosphorylation in a COLO 205 mouse xenograft model and induces tumor regression in an HL-60 mouse xenograft model; reduces tumor growth in 10 mouse xenograft models
22953	GSK1070916	10 mg	≥98%	A potent inhibitor of Aurora B and C (Kis = 0.38 and 1.5 nM, respectively); >250-fold selective for Aurora B and C over Aurora A; inhibits proliferation of A549 lung cancer cells in vitro (EC50 = 7 nM); inhibits proliferation in a panel of 100 tumor cell lines (EC50s = <10 nM); inhibits histone H3 phosphorylation in a COLO 205 mouse xenograft model and induces tumor regression in an HL-60 mouse xenograft model; reduces tumor growth in 10 mouse xenograft models

22953	GSK1070916	25 mg	≥98%	A potent inhibitor of Aurora B and C (Kis = 0.38 and 1.5 nM, respectively); >250-fold selective for Aurora B and C over Aurora A; inhibits proliferation of A549 lung cancer cells in vitro (EC50 = 7 nM); inhibits proliferation in a panel of 100 tumor cell lines (EC50s = <10 nM); inhibits histone H3 phosphorylation in a COLO 205 mouse xenograft model and induces tumor regression in an HL-60 mouse xenograft model; reduces tumor growth in 10 mouse xenograft models
22953	GSK1070916	5 mg	≥98%	A potent inhibitor of Aurora B and C (Kis = 0.38 and 1.5 nM, respectively); >250-fold selective for Aurora B and C over Aurora A; inhibits proliferation of A549 lung cancer cells in vitro (EC50 = 7 nM); inhibits proliferation in a panel of 100 tumor cell lines (EC50s = <10 nM); inhibits histone H3 phosphorylation in a COLO 205 mouse xenograft model and induces tumor regression in an HL-60 mouse xenograft model; reduces tumor growth in 10 mouse xenograft models
22954	Peficitinib	1 mg	≥98%	A JAK inhibitor (IC50s = 3.9, 5, and 0.71 nM for JAK1-3, respectively); 14-fold selective for JAK1 and JAK3 over JAK2 in erythropoietin-induced leukemia cell proliferation assays; inhibits IL-2-induced proliferation of rat splenocytes (IC50 = 10 nM) and phosphorylation of STAT5 in rat and human whole blood (IC50s = 124 and 127 nM, respectively); reduces paw swelling (ED50 = 5.6 mg/kg) and bone destruction in a rat model of adjuvant-induced arthritis at 30 mg/kg
22954	Peficitinib	10 mg	≥98%	A JAK inhibitor (IC50s = 3.9, 5, and 0.71 nM for JAK1-3, respectively); 14-fold selective for JAK1 and JAK3 over JAK2 in erythropoietin-induced leukemia cell proliferation assays; inhibits IL-2-induced proliferation of rat splenocytes (IC50 = 10 nM) and phosphorylation of STAT5 in rat and human whole blood (IC50s = 124 and 127 nM, respectively); reduces paw swelling (ED50 = 5.6 mg/kg) and bone destruction in a rat model of adjuvant-induced arthritis at 30 mg/kg
22954	Peficitinib	5 mg	≥98%	A JAK inhibitor (IC50s = 3.9, 5, and 0.71 nM for JAK1-3, respectively); 14-fold selective for JAK1 and JAK3 over JAK2 in erythropoietin-induced leukemia cell proliferation assays; inhibits IL-2-induced proliferation of rat splenocytes (IC50 = 10 nM) and phosphorylation of STAT5 in rat and human whole blood (IC50s = 124 and 127 nM, respectively); reduces paw swelling (ED50 = 5.6 mg/kg) and bone destruction in a rat model of adjuvant-induced arthritis at 30 mg/kg
22955	GSK2256098	1 mg	≥98%	A FAK inhibitor; selective for FAK over 261 kinases; inhibits FAK autophosphorylation at Y397 in OVCAR8 ovarian, U87MG glioblastoma, and A549 lung cancer cell lines (IC50s = 15, 8.5, and 12 nM, respectively); induces apoptosis, decreases viability (IC50 = 25 μM), and inhibits colony formation in L3.6P1 cells; leads to lower tumor weight and fewer metastases in an orthotopic mouse model of uterine cancer at 75 mg/kg per day
22955	GSK2256098	10 mg	≥98%	A FAK inhibitor; selective for FAK over 261 kinases; inhibits FAK autophosphorylation at Y397 in OVCAR8 ovarian, U87MG glioblastoma, and A549 lung cancer cell lines (IC50s = 15, 8.5, and 12 nM, respectively); induces apoptosis, decreases viability (IC50 = 25 μM), and inhibits colony formation in L3.6P1 cells; leads to lower tumor weight and fewer metastases in an orthotopic mouse model of uterine cancer at 75 mg/kg per day
22955	GSK2256098	25 mg	≥98%	A FAK inhibitor; selective for FAK over 261 kinases; inhibits FAK autophosphorylation at Y397 in OVCAR8 ovarian, U87MG glioblastoma, and A549 lung cancer cell lines (IC50s = 15, 8.5, and 12 nM, respectively); induces apoptosis, decreases viability (IC50 = 25 μM), and inhibits colony formation in L3.6P1 cells; leads to lower tumor weight and fewer metastases in an orthotopic mouse model of uterine cancer at 75 mg/kg per day
22955	GSK2256098	5 mg	≥98%	A FAK inhibitor; selective for FAK over 261 kinases; inhibits FAK autophosphorylation at Y397 in OVCAR8 ovarian, U87MG glioblastoma, and A549 lung cancer cell lines (IC50s = 15, 8.5, and 12 nM, respectively); induces apoptosis, decreases viability (IC50 = 25 μM), and inhibits colony formation in L3.6P1 cells; leads to lower tumor weight and fewer metastases in an orthotopic mouse model of uterine cancer at 75 mg/kg per day
22956	ENMD-2076	1 mg	≥98%	A multi-kinase inhibitor; inhibits FLT3, RET, and Aurora A kinase (IC50s = 1.86, 10.4, and 14 nM, respectively); inhibits additional kinases involved in angiogenesis (IC50s = 50s = via oral gavage); decreases tumor vascular permeability and perfusion and inhibits tumor growth in human TNBC and colorectal cancer mouse xenograft models of (100 mg/kg via oral gavage)
22956	ENMD-2076	10 mg	≥98%	A multi-kinase inhibitor; inhibits FLT3, RET, and Aurora A kinase (IC50s = 1.86, 10.4, and 14 nM, respectively); inhibits additional kinases involved in angiogenesis (IC50s = 50s = via oral gavage); decreases tumor vascular permeability and perfusion and inhibits tumor growth in human TNBC and colorectal cancer mouse xenograft models of (100 mg/kg via oral gavage)
22956	ENMD-2076	5 mg	≥98%	A multi-kinase inhibitor; inhibits FLT3, RET, and Aurora A kinase (IC50s = 1.86, 10.4, and 14 nM, respectively); inhibits additional kinases involved in angiogenesis (IC50s = 50s = via oral gavage); decreases tumor vascular permeability and perfusion and inhibits tumor growth in human TNBC and colorectal cancer mouse xenograft models of (100 mg/kg via oral gavage)

22966	UNC569	1 mg	≥98%	A TAM family kinase inhibitor (IC50s = 2.9, 37, and 48 nM for Mer, Axl, and Tyro3, respectively); antiproliferative against ALL cells (IC50s = 0.5 and 1.2 µM for 697 and Jurkat cell lines, respectively); inhibits Mer phosphorylation (IC50s = 141 and 193 nM in 697 and Jurkat cell lines, respectively); decreases tumor burden by 47.8% relative to controls in human MYC transgenic zebrafish (4 µM); delays leukemia onset, reduces CNS infiltration, and prolongs survival of mice implanted with patient-derived Mer-expressing ALL primary cells (10 mg/kg)
22966	UNC569	10 mg	≥98%	A TAM family kinase inhibitor (IC50s = 2.9, 37, and 48 nM for Mer, Axl, and Tyro3, respectively); antiproliferative against ALL cells (IC50s = 0.5 and 1.2 µM for 697 and Jurkat cell lines, respectively); inhibits Mer phosphorylation (IC50s = 141 and 193 nM in 697 and Jurkat cell lines, respectively); decreases tumor burden by 47.8% relative to controls in human MYC transgenic zebrafish (4 µM); delays leukemia onset, reduces CNS infiltration, and prolongs survival of mice implanted with patient-derived Mer-expressing ALL primary cells (10 mg/kg)
22966	UNC569	25 mg	≥98%	A TAM family kinase inhibitor (IC50s = 2.9, 37, and 48 nM for Mer, Axl, and Tyro3, respectively); antiproliferative against ALL cells (IC50s = 0.5 and 1.2 µM for 697 and Jurkat cell lines, respectively); inhibits Mer phosphorylation (IC50s = 141 and 193 nM in 697 and Jurkat cell lines, respectively); decreases tumor burden by 47.8% relative to controls in human MYC transgenic zebrafish (4 µM); delays leukemia onset, reduces CNS infiltration, and prolongs survival of mice implanted with patient-derived Mer-expressing ALL primary cells (10 mg/kg)
22966	UNC569	5 mg	≥98%	A TAM family kinase inhibitor (IC50s = 2.9, 37, and 48 nM for Mer, Axl, and Tyro3, respectively); antiproliferative against ALL cells (IC50s = 0.5 and 1.2 µM for 697 and Jurkat cell lines, respectively); inhibits Mer phosphorylation (IC50s = 141 and 193 nM in 697 and Jurkat cell lines, respectively); decreases tumor burden by 47.8% relative to controls in human MYC transgenic zebrafish (4 µM); delays leukemia onset, reduces CNS infiltration, and prolongs survival of mice implanted with patient-derived Mer-expressing ALL primary cells (10 mg/kg)
22984	HG-14-10-04	1 mg	≥98%	An ALK inhibitor
22984	HG-14-10-04	10 mg	≥98%	An ALK inhibitor
22984	HG-14-10-04	25 mg	≥98%	An ALK inhibitor
22984	HG-14-10-04	5 mg	≥98%	An ALK inhibitor
22985	BLU-285	1 mg	≥98%	A dual inhibitor of KIT and PDGFRα mutant kinases (IC50s = 0.27 and 0.24 nM for KITD816V and PDGFRαD842V, respectively); >150-fold selective for KITD816V and PDGFRαD842V over a kinase panel at a concentration of 3 µM; has activity against a panel of KIT and PDGFRα loop mutants identified in patients with GISTs (IC50s = D814Y mastocytoma allograft mouse model and a GIST patient-derived mouse xenograft model in a dose-dependent manner when administered at doses ranging from 0.3-30 mg/kg
22985	BLU-285	10 mg	≥98%	A dual inhibitor of KIT and PDGFRα mutant kinases (IC50s = 0.27 and 0.24 nM for KITD816V and PDGFRαD842V, respectively); >150-fold selective for KITD816V and PDGFRαD842V over a kinase panel at a concentration of 3 µM; has activity against a panel of KIT and PDGFRα loop mutants identified in patients with GISTs (IC50s = D814Y mastocytoma allograft mouse model and a GIST patient-derived mouse xenograft model in a dose-dependent manner when administered at doses ranging from 0.3-30 mg/kg
22985	BLU-285	25 mg	≥98%	A dual inhibitor of KIT and PDGFRα mutant kinases (IC50s = 0.27 and 0.24 nM for KITD816V and PDGFRαD842V, respectively); >150-fold selective for KITD816V and PDGFRαD842V over a kinase panel at a concentration of 3 µM; has activity against a panel of KIT and PDGFRα loop mutants identified in patients with GISTs (IC50s = D814Y mastocytoma allograft mouse model and a GIST patient-derived mouse xenograft model in a dose-dependent manner when administered at doses ranging from 0.3-30 mg/kg
22985	BLU-285	5 mg	≥98%	A dual inhibitor of KIT and PDGFRα mutant kinases (IC50s = 0.27 and 0.24 nM for KITD816V and PDGFRαD842V, respectively); >150-fold selective for KITD816V and PDGFRαD842V over a kinase panel at a concentration of 3 µM; has activity against a panel of KIT and PDGFRα loop mutants identified in patients with GISTs (IC50s = D814Y mastocytoma allograft mouse model and a GIST patient-derived mouse xenograft model in a dose-dependent manner when administered at doses ranging from 0.3-30 mg/kg
22987	PFK158	10 mg	≥95%	A PFKFB3 inhibitor (IC50 = 137 nM for human recombinant PFKFB3); inhibits PFKFB3 and glycolysis in Jurkat cells (IC50s = 1.6 and 0.847 µM, respectively); inhibits the growth of leukemia cells in vitro (IC50 = 0.33 µM for Jurkat cells); reduces tumor volume in CT-26 murine colon carcinoma syngeneic model and a BxPC-3 pancreatic cancer mouse xenograft model; enhances activity of the anti-CTLA-4 antibody in the B16/F10 mouse model of melanoma

22987	PFK158	25 mg	≥95%	A PFKFB3 inhibitor (IC50 = 137 nM for human recombinant PFKFB3); inhibits PFKFB3 and glycolysis in Jurkat cells (IC50s = 1.6 and 0.847 µM, respectively); inhibits the growth of leukemia cells in vitro (IC50 = 0.33 µM for Jurkat cells); reduces tumor volume in CT-26 murine colon carcinoma syngeneic model and a BxPC-3 pancreatic cancer mouse xenograft model; enhances activity of the anti-CTLA-4 antibody in the B16/F10 mouse model of melanoma
22987	PFK158	5 mg	≥95%	A PFKFB3 inhibitor (IC50 = 137 nM for human recombinant PFKFB3); inhibits PFKFB3 and glycolysis in Jurkat cells (IC50s = 1.6 and 0.847 µM, respectively); inhibits the growth of leukemia cells in vitro (IC50 = 0.33 µM for Jurkat cells); reduces tumor volume in CT-26 murine colon carcinoma syngeneic model and a BxPC-3 pancreatic cancer mouse xenograft model; enhances activity of the anti-CTLA-4 antibody in the B16/F10 mouse model of melanoma
23023	WEHI-345	1 mg	≥98%	An inhibitor of RIPK2 (IC50 = 130 nM in a kinase assay using human recombinant RIPK2); selective for RIPK2 over RIPK1, 4, and 5 (Kds = 46, >10,000, >10,000, and >10,000 nM, respectively) and a panel of 95 kinases at a concentration of 1 µM; reduces levels of RIPK2 phosphorylation at Ser176 in MDP-stimulated BMDMs; decreases MDP-induced transcription of TNF and IL-6 in BMDMs and reduces mRNA levels of the NF-κB target genes TNF, IL-8, IL-1β, and A20 in MDP-stimulated THP-1 cells in a concentration-dependent manner; reduces plasma levels of TNF and delays disease onset in a mouse model of EAE when administered at doses ranging from 3-10 mg/kg
23023	WEHI-345	10 mg	≥98%	An inhibitor of RIPK2 (IC50 = 130 nM in a kinase assay using human recombinant RIPK2); selective for RIPK2 over RIPK1, 4, and 5 (Kds = 46, >10,000, >10,000, and >10,000 nM, respectively) and a panel of 95 kinases at a concentration of 1 µM; reduces levels of RIPK2 phosphorylation at Ser176 in MDP-stimulated BMDMs; decreases MDP-induced transcription of TNF and IL-6 in BMDMs and reduces mRNA levels of the NF-κB target genes TNF, IL-8, IL-1β, and A20 in MDP-stimulated THP-1 cells in a concentration-dependent manner; reduces plasma levels of TNF and delays disease onset in a mouse model of EAE when administered at doses ranging from 3-10 mg/kg
23023	WEHI-345	25 mg	≥98%	An inhibitor of RIPK2 (IC50 = 130 nM in a kinase assay using human recombinant RIPK2); selective for RIPK2 over RIPK1, 4, and 5 (Kds = 46, >10,000, >10,000, and >10,000 nM, respectively) and a panel of 95 kinases at a concentration of 1 µM; reduces levels of RIPK2 phosphorylation at Ser176 in MDP-stimulated BMDMs; decreases MDP-induced transcription of TNF and IL-6 in BMDMs and reduces mRNA levels of the NF-κB target genes TNF, IL-8, IL-1β, and A20 in MDP-stimulated THP-1 cells in a concentration-dependent manner; reduces plasma levels of TNF and delays disease onset in a mouse model of EAE when administered at doses ranging from 3-10 mg/kg
23023	WEHI-345	5 mg	≥98%	An inhibitor of RIPK2 (IC50 = 130 nM in a kinase assay using human recombinant RIPK2); selective for RIPK2 over RIPK1, 4, and 5 (Kds = 46, >10,000, >10,000, and >10,000 nM, respectively) and a panel of 95 kinases at a concentration of 1 µM; reduces levels of RIPK2 phosphorylation at Ser176 in MDP-stimulated BMDMs; decreases MDP-induced transcription of TNF and IL-6 in BMDMs and reduces mRNA levels of the NF-κB target genes TNF, IL-8, IL-1β, and A20 in MDP-stimulated THP-1 cells in a concentration-dependent manner; reduces plasma levels of TNF and delays disease onset in a mouse model of EAE when administered at doses ranging from 3-10 mg/kg
23029	FGF401	1 mg	≥95%	An FGFR4 inhibitor (IC50 = 1.9 nM); inhibits proliferation of Huh7 cells (IC50 = 12 nM) induces bile acid synthesis in dogs, increasing plasma and fecal levels of bile acids at 45 mg/kg per day for four weeks; decreases serum cholesterol at 5-45 mg/kg per day
23029	FGF401	10 mg	≥95%	An FGFR4 inhibitor (IC50 = 1.9 nM); inhibits proliferation of Huh7 cells (IC50 = 12 nM) induces bile acid synthesis in dogs, increasing plasma and fecal levels of bile acids at 45 mg/kg per day for four weeks; decreases serum cholesterol at 5-45 mg/kg per day
23029	FGF401	25 mg	≥95%	An FGFR4 inhibitor (IC50 = 1.9 nM); inhibits proliferation of Huh7 cells (IC50 = 12 nM) induces bile acid synthesis in dogs, increasing plasma and fecal levels of bile acids at 45 mg/kg per day for four weeks; decreases serum cholesterol at 5-45 mg/kg per day
23029	FGF401	5 mg	≥95%	An FGFR4 inhibitor (IC50 = 1.9 nM); inhibits proliferation of Huh7 cells (IC50 = 12 nM) induces bile acid synthesis in dogs, increasing plasma and fecal levels of bile acids at 45 mg/kg per day for four weeks; decreases serum cholesterol at 5-45 mg/kg per day
23204	FM-381	1 mg	≥98%	A potent JAK3 inhibitor (IC50 = 127 pM); 400-, 2,700-, and 3,600-fold selective for JAK3 over JAK1, JAK2, and TYK3 and only inhibits 11 kinases in a panel of 410 kinases at 500 nM; blocks JAK3-dependent STAT5 phosphorylation but not JAK3-independent STAT3 signaling in IL-2- and IL-6-stimulated T cells, respectively, at 1 µM
23204	FM-381	10 mg	≥98%	A potent JAK3 inhibitor (IC50 = 127 pM); 400-, 2,700-, and 3,600-fold selective for JAK3 over JAK1, JAK2, and TYK3 and only inhibits 11 kinases in a panel of 410 kinases at 500 nM; blocks JAK3-dependent STAT5 phosphorylation but not JAK3-independent STAT3 signaling in IL-2- and IL-6-stimulated T cells, respectively, at 1 µM

23204	FM-381	25 mg	≥98%	A potent JAK3 inhibitor (IC50 = 127 pM); 400-, 2,700-, and 3,600-fold selective for JAK3 over JAK1, JAK2, and TYK3 and only inhibits 11 kinases in a panel of 410 kinases at 500 nM; blocks JAK3-dependent STAT5 phosphorylation but not JAK3-independent STAT3 signaling in IL-2- and IL-6-stimulated T cells, respectively, at 1 μM
23204	FM-381	5 mg	≥98%	A potent JAK3 inhibitor (IC50 = 127 pM); 400-, 2,700-, and 3,600-fold selective for JAK3 over JAK1, JAK2, and TYK3 and only inhibits 11 kinases in a panel of 410 kinases at 500 nM; blocks JAK3-dependent STAT5 phosphorylation but not JAK3-independent STAT3 signaling in IL-2- and IL-6-stimulated T cells, respectively, at 1 μM
23205	Sappanone A	1 mg	≥98%	A homoisoflavonoid with diverse biological activities; inhibits FGFR1, KDR, c-Met, and c-Kit kinase activity (10 μM); inhibits viral NA (IC50s = 0.7, 1.1, and 1 μM for H1N1, H3N2, and H9N2 influenza viral NAs, respectively); has antibacterial and antifungal activities; reduces NO, IL-6, and PGE2 production in RAW264.7 cells; attenuates airway inflammation and mucus hypersecretion in a mouse model of ovalbumin-induced asthma
23205	Sappanone A	10 mg	≥98%	A homoisoflavonoid with diverse biological activities; inhibits FGFR1, KDR, c-Met, and c-Kit kinase activity (10 μM); inhibits viral NA (IC50s = 0.7, 1.1, and 1 μM for H1N1, H3N2, and H9N2 influenza viral NAs, respectively); has antibacterial and antifungal activities; reduces NO, IL-6, and PGE2 production in RAW264.7 cells; attenuates airway inflammation and mucus hypersecretion in a mouse model of ovalbumin-induced asthma
23205	Sappanone A	25 mg	≥98%	A homoisoflavonoid with diverse biological activities; inhibits FGFR1, KDR, c-Met, and c-Kit kinase activity (10 μM); inhibits viral NA (IC50s = 0.7, 1.1, and 1 μM for H1N1, H3N2, and H9N2 influenza viral NAs, respectively); has antibacterial and antifungal activities; reduces NO, IL-6, and PGE2 production in RAW264.7 cells; attenuates airway inflammation and mucus hypersecretion in a mouse model of ovalbumin-induced asthma
23205	Sappanone A	5 mg	≥98%	A homoisoflavonoid with diverse biological activities; inhibits FGFR1, KDR, c-Met, and c-Kit kinase activity (10 μM); inhibits viral NA (IC50s = 0.7, 1.1, and 1 μM for H1N1, H3N2, and H9N2 influenza viral NAs, respectively); has antibacterial and antifungal activities; reduces NO, IL-6, and PGE2 production in RAW264.7 cells; attenuates airway inflammation and mucus hypersecretion in a mouse model of ovalbumin-induced asthma
23215	Ruxolitinib (phosphat	1 mg	≥98%	A potent ATP mimetic that inhibits JAK1 and JAK2 with IC50 values of 2.7 and 4.5 nM, respectively; less selective for JAK3 (IC50 = 322 nM); blocks IL-6 signaling (IC50 = 281 nM) and proliferation of JAK2V617F+ Ba/F3 cells (IC50 = 127 nM); reduces splenomegaly, decreases circulating levels of IL-6 and TNF-α, eliminates neoplastic cells, and prolongs survival in a mouse model of JAK2V617F+ MPN
23215	Ruxolitinib (phosphat	10 mg	≥98%	A potent ATP mimetic that inhibits JAK1 and JAK2 with IC50 values of 2.7 and 4.5 nM, respectively; less selective for JAK3 (IC50 = 322 nM); blocks IL-6 signaling (IC50 = 281 nM) and proliferation of JAK2V617F+ Ba/F3 cells (IC50 = 127 nM); reduces splenomegaly, decreases circulating levels of IL-6 and TNF-α, eliminates neoplastic cells, and prolongs survival in a mouse model of JAK2V617F+ MPN
23215	Ruxolitinib (phosphat	25 mg	≥98%	A potent ATP mimetic that inhibits JAK1 and JAK2 with IC50 values of 2.7 and 4.5 nM, respectively; less selective for JAK3 (IC50 = 322 nM); blocks IL-6 signaling (IC50 = 281 nM) and proliferation of JAK2V617F+ Ba/F3 cells (IC50 = 127 nM); reduces splenomegaly, decreases circulating levels of IL-6 and TNF-α, eliminates neoplastic cells, and prolongs survival in a mouse model of JAK2V617F+ MPN
23215	Ruxolitinib (phosphat	5 mg	≥98%	A potent ATP mimetic that inhibits JAK1 and JAK2 with IC50 values of 2.7 and 4.5 nM, respectively; less selective for JAK3 (IC50 = 322 nM); blocks IL-6 signaling (IC50 = 281 nM) and proliferation of JAK2V617F+ Ba/F3 cells (IC50 = 127 nM); reduces splenomegaly, decreases circulating levels of IL-6 and TNF-α, eliminates neoplastic cells, and prolongs survival in a mouse model of JAK2V617F+ MPN
23245	HNMPA-(AM)3	1 mg	≥95%	A cell-permeable prodrug form of HNMPA; inhibits IRTK autophosphorylation in CHO cells expressing the human receptor in a concentration- and time-dependent manner; inhibits 2-deoxyglucose uptake but does not affect insulin-stimulated thymidine uptake in CHO cells (≤100 μM)
23245	HNMPA-(AM)3	10 mg	≥95%	A cell-permeable prodrug form of HNMPA; inhibits IRTK autophosphorylation in CHO cells expressing the human receptor in a concentration- and time-dependent manner; inhibits 2-deoxyglucose uptake but does not affect insulin-stimulated thymidine uptake in CHO cells (≤100 μM)
23245	HNMPA-(AM)3	5 mg	≥95%	A cell-permeable prodrug form of HNMPA; inhibits IRTK autophosphorylation in CHO cells expressing the human receptor in a concentration- and time-dependent manner; inhibits 2-deoxyglucose uptake but does not affect insulin-stimulated thymidine uptake in CHO cells (≤100 μM)
23247	AG-555	10 mg	≥95%	A tyrphostin EGFR inhibitor (IC50 = 0.7 μM); selectively inhibits EFGR over ErbB2 (IC50 = 35 μM); inhibits EGF-dependent growth of HER 14 cells (IC50 = 2.5 μM) as well as the growth of psoriatic keratinocytes isolated from patients with psoriasis from 1-50 μM; inhibits Mo-MuLV reverse transcriptase activity (IC50 = 10.8 μM) without affecting Mo-MuLV-infected NIH3T3 cell growth (IC50 = 210 μM)
23247	AG-555	25 mg	≥95%	A tyrphostin EGFR inhibitor (IC50 = 0.7 μM); selectively inhibits EFGR over ErbB2 (IC50 = 35 μM); inhibits EGF-dependent growth of HER 14 cells (IC50 = 2.5 μM) as well as the growth of psoriatic keratinocytes isolated from patients with psoriasis from 1-50 μM; inhibits Mo-MuLV reverse transcriptase activity (IC50 = 10.8 μM) without affecting Mo-MuLV-infected NIH3T3 cell growth (IC50 = 210 μM)

23247	AG-555	5 mg	≥95%	A tyrphostin EGFR inhibitor (IC50 = 0.7 µM); selectively inhibits EFGR over ErbB2 (IC50 = 35 µM); inhibits EGF-dependent growth of HER 14 cells (IC50 = 2.5 µM) as well as the growth of psoriatic keratinocytes isolated from patients with psoriasis from 1-50 µM; inhibits Mo-MuLV reverse transcriptase activity (IC50 = 10.8 µM) without affecting Mo-MuLV-infected NIH3T3 cell growth (IC50 = 210 µM)
23247	AG-555	50 mg	≥95%	A tyrphostin EGFR inhibitor (IC50 = 0.7 µM); selectively inhibits EFGR over ErbB2 (IC50 = 35 µM); inhibits EGF-dependent growth of HER 14 cells (IC50 = 2.5 µM) as well as the growth of psoriatic keratinocytes isolated from patients with psoriasis from 1-50 µM; inhibits Mo-MuLV reverse transcriptase activity (IC50 = 10.8 µM) without affecting Mo-MuLV-infected NIH3T3 cell growth (IC50 = 210 µM)
23259	LY2228820 (mesylate)	1 mg	≥98%	A potent inhibitor of p38α MAP kinase (IC50 = 7 nM for human recombinant p38α); inhibits LPS-induced TNF-α production in murine peritoneal macrophages and reduces phosphorylation of MK2 in RAW 264.7 cells (IC50s = 5.2 and 34.3 nM, respectively); inhibits TNF-α production in LPS-treated mice and reduces paw swelling and cartilage destruction in a rat model of chronic inflammation (TMED50s = <1, 1.5, and 1.5 mg/kg, respectively)
23259	LY2228820 (mesylate)	10 mg	≥98%	A potent inhibitor of p38α MAP kinase (IC50 = 7 nM for human recombinant p38α); inhibits LPS-induced TNF-α production in murine peritoneal macrophages and reduces phosphorylation of MK2 in RAW 264.7 cells (IC50s = 5.2 and 34.3 nM, respectively); inhibits TNF-α production in LPS-treated mice and reduces paw swelling and cartilage destruction in a rat model of chronic inflammation (TMED50s = <1, 1.5, and 1.5 mg/kg, respectively)
23259	LY2228820 (mesylate)	25 mg	≥98%	A potent inhibitor of p38α MAP kinase (IC50 = 7 nM for human recombinant p38α); inhibits LPS-induced TNF-α production in murine peritoneal macrophages and reduces phosphorylation of MK2 in RAW 264.7 cells (IC50s = 5.2 and 34.3 nM, respectively); inhibits TNF-α production in LPS-treated mice and reduces paw swelling and cartilage destruction in a rat model of chronic inflammation (TMED50s = <1, 1.5, and 1.5 mg/kg, respectively)
23259	LY2228820 (mesylate)	5 mg	≥98%	A potent inhibitor of p38α MAP kinase (IC50 = 7 nM for human recombinant p38α); inhibits LPS-induced TNF-α production in murine peritoneal macrophages and reduces phosphorylation of MK2 in RAW 264.7 cells (IC50s = 5.2 and 34.3 nM, respectively); inhibits TNF-α production in LPS-treated mice and reduces paw swelling and cartilage destruction in a rat model of chronic inflammation (TMED50s = <1, 1.5, and 1.5 mg/kg, respectively)
23288	SLC5111312 (hydroch	1 mg	≥98%	A dual SPHK1 and SPHK2 inhibitor (Kis = 0.73 and 0.9 µM, respectively, using human recombinant kinases); selective for Sphk2 over Sphk1 in mice (Kis = 1 and 20 µM, respectively); not selective in rat (Kis = 1.1 and 0.8 µM for Sphk2 and Sphk1, respectively); decreases S1P in vitro at concentrations of 0.1 and 0.3 µM; decreases S1P in Sphk1-/- knockout mice and in rat at a dose of 10 mg/kg
23288	SLC5111312 (hydroch	5 mg	≥98%	A dual SPHK1 and SPHK2 inhibitor (Kis = 0.73 and 0.9 µM, respectively, using human recombinant kinases); selective for Sphk2 over Sphk1 in mice (Kis = 1 and 20 µM, respectively); not selective in rat (Kis = 1.1 and 0.8 µM for Sphk2 and Sphk1, respectively); decreases S1P in vitro at concentrations of 0.1 and 0.3 µM; decreases S1P in Sphk1-/- knockout mice and in rat at a dose of 10 mg/kg
23288	SLC5111312 (hydroch	500 µg	≥98%	A dual SPHK1 and SPHK2 inhibitor (Kis = 0.73 and 0.9 µM, respectively, using human recombinant kinases); selective for Sphk2 over Sphk1 in mice (Kis = 1 and 20 µM, respectively); not selective in rat (Kis = 1.1 and 0.8 µM for Sphk2 and Sphk1, respectively); decreases S1P in vitro at concentrations of 0.1 and 0.3 µM; decreases S1P in Sphk1-/- knockout mice and in rat at a dose of 10 mg/kg
23289	SLM6031434	1 mg	≥98%	A selective inhibitor of SPHK2 (Kis = 0.4 and> 20 µM for mouse recombinant SPHK2 and SPHK1, respectively); decreases S1P and increases sphingosine levels in U937 monocytic leukemia cells in a concentration-dependent manner; reduces blood levels of S1P in SPHK1-/- but not SPHK2-/- mice; increases blood levels of S1P in wild-type mice and rats
23289	SLM6031434	10 mg	≥98%	A selective inhibitor of SPHK2 (Kis = 0.4 and> 20 µM for mouse recombinant SPHK2 and SPHK1, respectively); decreases S1P and increases sphingosine levels in U937 monocytic leukemia cells in a concentration-dependent manner; reduces blood levels of S1P in SPHK1-/- but not SPHK2-/- mice; increases blood levels of S1P in wild-type mice and rats
23289	SLM6031434	25 mg	≥98%	A selective inhibitor of SPHK2 (Kis = 0.4 and> 20 µM for mouse recombinant SPHK2 and SPHK1, respectively); decreases S1P and increases sphingosine levels in U937 monocytic leukemia cells in a concentration-dependent manner; reduces blood levels of S1P in SPHK1-/- but not SPHK2-/- mice; increases blood levels of S1P in wild-type mice and rats
23289	SLM6031434	5 mg	≥98%	A selective inhibitor of SPHK2 (Kis = 0.4 and> 20 µM for mouse recombinant SPHK2 and SPHK1, respectively); decreases S1P and increases sphingosine levels in U937 monocytic leukemia cells in a concentration-dependent manner; reduces blood levels of S1P in SPHK1-/- but not SPHK2-/- mice; increases blood levels of S1P in wild-type mice and rats

23300	GSK872	1 mg	≥98%	A selective inhibitor of RIPK3; >1,000-fold selectivity over 300 kinases in a fluorescence polarization assay at a concentration of 1 µM; inhibits TNF- and virus-induced necrosis in 3T3-SA fibroblasts; inhibits necrosis induced by TLR3
23300	GSK872	10 mg	≥98%	A selective inhibitor of RIPK3; >1,000-fold selectivity over 300 kinases in a fluorescence polarization assay at a concentration of 1 µM; inhibits TNF- and virus-induced necrosis in 3T3-SA fibroblasts; inhibits necrosis induced by TLR3
23300	GSK872	5 mg	≥98%	A selective inhibitor of RIPK3; >1,000-fold selectivity over 300 kinases in a fluorescence polarization assay at a concentration of 1 µM; inhibits TNF- and virus-induced necrosis in 3T3-SA fibroblasts; inhibits necrosis induced by TLR3
23346	7-oxo Staurosporine	1 mg	≥98%	An antibiotic; inhibits PKC, PKA, phosphorylase kinase, EGFR, and c-Src in vitro (IC50s = 9, 26, 5, 200, and 800 nM, respectively); induces cell cycle arrest in the G2/M phase in human leukemia K562 cells (MED = 30 ng/ml); is cytotoxic to doxorubicin-resistant and -susceptible P388 mouse leukemia cells (IC50s = 27 and 45 nM, respectively); inhibits growth of the mycelial, but not yeast form of C. albicans, C. krusei, C. tropicalis, and C. lusitaniae (MICs = 3.1-25 µg/ml)
23346	7-oxo Staurosporine	5 mg	≥98%	An antibiotic; inhibits PKC, PKA, phosphorylase kinase, EGFR, and c-Src in vitro (IC50s = 9, 26, 5, 200, and 800 nM, respectively); induces cell cycle arrest in the G2/M phase in human leukemia K562 cells (MED = 30 ng/ml); is cytotoxic to doxorubicin-resistant and -susceptible P388 mouse leukemia cells (IC50s = 27 and 45 nM, respectively); inhibits growth of the mycelial, but not yeast form of C. albicans, C. krusei, C. tropicalis, and C. lusitaniae (MICs = 3.1-25 µg/ml)
23353	XMD16-5	1 mg	≥98%	A TNK2 inhibitor (IC50 = 0.38 µM); decreases viability of Ba/F3 cells expressing the oncogenic TNK2 D163E and R806Q mutant proteins (IC50s = 16 and 77 nM, respectively)
23353	XMD16-5	10 mg	≥98%	A TNK2 inhibitor (IC50 = 0.38 µM); decreases viability of Ba/F3 cells expressing the oncogenic TNK2 D163E and R806Q mutant proteins (IC50s = 16 and 77 nM, respectively)
23353	XMD16-5	25 mg	≥98%	A TNK2 inhibitor (IC50 = 0.38 µM); decreases viability of Ba/F3 cells expressing the oncogenic TNK2 D163E and R806Q mutant proteins (IC50s = 16 and 77 nM, respectively)
23353	XMD16-5	5 mg	≥98%	A TNK2 inhibitor (IC50 = 0.38 µM); decreases viability of Ba/F3 cells expressing the oncogenic TNK2 D163E and R806Q mutant proteins (IC50s = 16 and 77 nM, respectively)
23354	XMD8-87	1 mg	≥98%	A TNK2 inhibitor (IC50 = 1.9 µM in HEK293T cells expressing human TNK2); selective for TNK2 over a panel of ~100 kinases with >90, and 50s = 0.1-77 nM) with no effect on cell expressing wild-type TNK2 (IC50 = >1 µM)
23354	XMD8-87	10 mg	≥98%	A TNK2 inhibitor (IC50 = 1.9 µM in HEK293T cells expressing human TNK2); selective for TNK2 over a panel of ~100 kinases with >90, and 50s = 0.1-77 nM) with no effect on cell expressing wild-type TNK2 (IC50 = >1 µM)
23367	Binucleine 2	1 mg	≥98%	An inhibitor of Drosophila Aurora B kinase (Ki = 0.36 µM); specific for Drosophila B kinase, with minimal inhibition of human or X. laevis Aurora B kinases at concentrations up to 100 µM; induces mitotic and cytokinesis defects in Drosophila Kc167 cells; prevents Drosophila S2 cells from assembling a contractile ring during cell division when used at a concentration of 40 µM
23367	Binucleine 2	10 mg	≥98%	An inhibitor of Drosophila Aurora B kinase (Ki = 0.36 µM); specific for Drosophila B kinase, with minimal inhibition of human or X. laevis Aurora B kinases at concentrations up to 100 µM; induces mitotic and cytokinesis defects in Drosophila Kc167 cells; prevents Drosophila S2 cells from assembling a contractile ring during cell division when used at a concentration of 40 µM
23367	Binucleine 2	5 mg	≥98%	An inhibitor of Drosophila Aurora B kinase (Ki = 0.36 µM); specific for Drosophila B kinase, with minimal inhibition of human or X. laevis Aurora B kinases at concentrations up to 100 µM; induces mitotic and cytokinesis defects in Drosophila Kc167 cells; prevents Drosophila S2 cells from assembling a contractile ring during cell division when used at a concentration of 40 µM
23381	5-(Hydroxymethyl)-2'-	10 mg	≥98%	A nucleoside analog; inhibits the replication of murine S180 lung carcinoma cells and Ehrlich ascites mammary carcinoma cells (ED50s = 8.5 and 4 µM, respectively) and multiple human leukemia cell lines (IC50s = 1.7-5.8 µM); acts synergistically with 5-FU against HT-29, HCT116, PANC-1, and EKVX cancer cells; inhibits HSV-1 pyrimidine 2'-deoxyribonucleoside kinase (Ki = 3.5 µM) and reduces HSV-1 viral titer to 0.05% of the control at a concentration of 200 µM; a DNA adduct formed in response to oxidative stress
23381	5-(Hydroxymethyl)-2'-	100 mg	≥98%	A nucleoside analog; inhibits the replication of murine S180 lung carcinoma cells and Ehrlich ascites mammary carcinoma cells (ED50s = 8.5 and 4 µM, respectively) and multiple human leukemia cell lines (IC50s = 1.7-5.8 µM); acts synergistically with 5-FU against HT-29, HCT116, PANC-1, and EKVX cancer cells; inhibits HSV-1 pyrimidine 2'-deoxyribonucleoside kinase (Ki = 3.5 µM) and reduces HSV-1 viral titer to 0.05% of the control at a concentration of 200 µM; a DNA adduct formed in response to oxidative stress

23381	5-(Hydroxymethyl)-2'-	25 mg	≥98%	A nucleoside analog; inhibits the replication of murine S180 lung carcinoma cells and Ehrlich ascites mammary carcinoma cells (ED50s = 8.5 and 4 μM, respectively) and multiple human leukemia cell lines (IC50s = 1.7-5.8 μM); acts synergistically with 5-FU against HT-29, HCT116, PANC-1, and EKVX cancer cells; inhibits HSV-1 pyrimidine 2'-deoxyribonucleoside kinase (Ki = 3.5 μM) and reduces HSV-1 viral titer to 0.05% of the control at a concentration of 200 μM; a DNA adduct formed in response to oxidative stress
23381	5-(Hydroxymethyl)-2'-	50 mg	≥98%	A nucleoside analog; inhibits the replication of murine S180 lung carcinoma cells and Ehrlich ascites mammary carcinoma cells (ED50s = 8.5 and 4 μM, respectively) and multiple human leukemia cell lines (IC50s = 1.7-5.8 μM); acts synergistically with 5-FU against HT-29, HCT116, PANC-1, and EKVX cancer cells; inhibits HSV-1 pyrimidine 2'-deoxyribonucleoside kinase (Ki = 3.5 μM) and reduces HSV-1 viral titer to 0.05% of the control at a concentration of 200 μM; a DNA adduct formed in response to oxidative stress
23382	N6-Methyladenosine	10 mg	≥95%	An activator of glycogen phosphorylase b (Ka = 22 μM); a non-competitive inhibitor of rat adenylate kinase II; has been used for immunoprecipitation of N6-methyladenosine
23382	N6-Methyladenosine	25 mg	≥95%	An activator of glycogen phosphorylase b (Ka = 22 μM); a non-competitive inhibitor of rat adenylate kinase II; has been used for immunoprecipitation of N6-methyladenosine
23382	N6-Methyladenosine	5 mg	≥95%	An activator of glycogen phosphorylase b (Ka = 22 μM); a non-competitive inhibitor of rat adenylate kinase II; has been used for immunoprecipitation of N6-methyladenosine
23394	Desmethyl Erlotinib	1 mg	≥98%	A metabolite of erlotinib
23394	Desmethyl Erlotinib	10 mg	≥98%	A metabolite of erlotinib
23394	Desmethyl Erlotinib	5 mg	≥98%	A metabolite of erlotinib
23397	TPX-0005	1 mg	≥98%	A multi-kinase inhibitor; inhibits TrkA, TrkB, and TrkC (IC50s = 0.83, 0.05, and 0.1 nM, respectively) as well as ROS1 (IC50 = 0.07 nM); inhibits a variety of other kinases, including ALK, JAK2, LYN, Src, and FAK (IC50s = 1.04, 1.04, 1.66, 5.3, and 6.96 nM, respectively); inhibits proliferation of PC-9, H1975, 11-18, HCC4006, and HCC827 cells (IC50s = 100, 100, 150, 148, and 430 nM, respectively) with additive or synergistic effects when used in combination with certain compounds, including osimertinib; reduces tumor growth in PC-9 and H1975 mouse xenograft models; potentiates the effect of osimertinib on tumor growth in vivo
23397	TPX-0005	10 mg	≥98%	A multi-kinase inhibitor; inhibits TrkA, TrkB, and TrkC (IC50s = 0.83, 0.05, and 0.1 nM, respectively) as well as ROS1 (IC50 = 0.07 nM); inhibits a variety of other kinases, including ALK, JAK2, LYN, Src, and FAK (IC50s = 1.04, 1.04, 1.66, 5.3, and 6.96 nM, respectively); inhibits proliferation of PC-9, H1975, 11-18, HCC4006, and HCC827 cells (IC50s = 100, 100, 150, 148, and 430 nM, respectively) with additive or synergistic effects when used in combination with certain compounds, including osimertinib; reduces tumor growth in PC-9 and H1975 mouse xenograft models; potentiates the effect of osimertinib on tumor growth in vivo
23397	TPX-0005	25 mg	≥98%	A multi-kinase inhibitor; inhibits TrkA, TrkB, and TrkC (IC50s = 0.83, 0.05, and 0.1 nM, respectively) as well as ROS1 (IC50 = 0.07 nM); inhibits a variety of other kinases, including ALK, JAK2, LYN, Src, and FAK (IC50s = 1.04, 1.04, 1.66, 5.3, and 6.96 nM, respectively); inhibits proliferation of PC-9, H1975, 11-18, HCC4006, and HCC827 cells (IC50s = 100, 100, 150, 148, and 430 nM, respectively) with additive or synergistic effects when used in combination with certain compounds, including osimertinib; reduces tumor growth in PC-9 and H1975 mouse xenograft models; potentiates the effect of osimertinib on tumor growth in vivo
23397	TPX-0005	5 mg	≥98%	A multi-kinase inhibitor; inhibits TrkA, TrkB, and TrkC (IC50s = 0.83, 0.05, and 0.1 nM, respectively) as well as ROS1 (IC50 = 0.07 nM); inhibits a variety of other kinases, including ALK, JAK2, LYN, Src, and FAK (IC50s = 1.04, 1.04, 1.66, 5.3, and 6.96 nM, respectively); inhibits proliferation of PC-9, H1975, 11-18, HCC4006, and HCC827 cells (IC50s = 100, 100, 150, 148, and 430 nM, respectively) with additive or synergistic effects when used in combination with certain compounds, including osimertinib; reduces tumor growth in PC-9 and H1975 mouse xenograft models; potentiates the effect of osimertinib on tumor growth in vivo
23398	LDC-4297	1 mg	≥98%	A CDK7 inhibitor (IC50 = 50s = >10, >10, and 1.71 μM); inhibits CDK2 and CDK1 (IC50s = 6.4 and 53.7 nM, respectively); induces apoptosis in A549, HeLa, and HCT116 cancer cells from 10-100 nM; inhibits HCMV replication in human fibroblasts (EC50 = 24.5 nM); reduces replication of various viruses (EC50s = 0.02-1.13 μM)
23398	LDC-4297	10 mg	≥98%	A CDK7 inhibitor (IC50 = 50s = >10, >10, and 1.71 μM); inhibits CDK2 and CDK1 (IC50s = 6.4 and 53.7 nM, respectively); induces apoptosis in A549, HeLa, and HCT116 cancer cells from 10-100 nM; inhibits HCMV replication in human fibroblasts (EC50 = 24.5 nM); reduces replication of various viruses (EC50s = 0.02-1.13 μM)

23398	LDC-4297	25 mg	≥98%	A CDK7 inhibitor (IC50 = 50s = >10, >10, and 1.71 μM); inhibits CDK2 and CDK1 (IC50s = 6.4 and 53.7 nM, respectively); induces apoptosis in A549, HeLa, and HCT116 cancer cells from 10-100 nM; inhibits HCMV replication in human fibroblasts (EC50 = 24.5 nM); reduces replication of various viruses (EC50s = 0.02-1.13 μM)
23398	LDC-4297	5 mg	≥98%	A CDK7 inhibitor (IC50 = 50s = >10, >10, and 1.71 μM); inhibits CDK2 and CDK1 (IC50s = 6.4 and 53.7 nM, respectively); induces apoptosis in A549, HeLa, and HCT116 cancer cells from 10-100 nM; inhibits HCMV replication in human fibroblasts (EC50 = 24.5 nM); reduces replication of various viruses (EC50s = 0.02-1.13 μM)
23427	PIK-294	1 mg	≥98%	A potent inhibitor of the PI3K catalytic subunit p110δ (IC50s = 10,000, 490, 10, and 160 nM, for p110 subunit isoforms α, β, δ, and γ, respectively); selective for PI3K p110 subunit isoforms over DNA-PK, mTOR, and eight tyrosine kinases; inhibits chemokinetic and chemotactic migration of neutrophils induced by CXCL8
23427	PIK-294	10 mg	≥98%	A potent inhibitor of the PI3K catalytic subunit p110δ (IC50s = 10,000, 490, 10, and 160 nM, for p110 subunit isoforms α, β, δ, and γ, respectively); selective for PI3K p110 subunit isoforms over DNA-PK, mTOR, and eight tyrosine kinases; inhibits chemokinetic and chemotactic migration of neutrophils induced by CXCL8
23427	PIK-294	25 mg	≥98%	A potent inhibitor of the PI3K catalytic subunit p110δ (IC50s = 10,000, 490, 10, and 160 nM, for p110 subunit isoforms α, β, δ, and γ, respectively); selective for PI3K p110 subunit isoforms over DNA-PK, mTOR, and eight tyrosine kinases; inhibits chemokinetic and chemotactic migration of neutrophils induced by CXCL8
23427	PIK-294	5 mg	≥98%	A potent inhibitor of the PI3K catalytic subunit p110δ (IC50s = 10,000, 490, 10, and 160 nM, for p110 subunit isoforms α, β, δ, and γ, respectively); selective for PI3K p110 subunit isoforms over DNA-PK, mTOR, and eight tyrosine kinases; inhibits chemokinetic and chemotactic migration of neutrophils induced by CXCL8
23428	CID797718	1 mg	≥98%	A PKD1 inhibitor (IC50 = 7 μM); also inhibits CAK and PLK1 but has no activity at AKT (IC50s = 8.4, 21.9, and >50 μM, respectively); inhibits PKD1 activity in LNCaP cells (IC50 = 0.21 μM); a byproduct in the synthesis of CID755673
23428	CID797718	10 mg	≥98%	A PKD1 inhibitor (IC50 = 7 μM); also inhibits CAK and PLK1 but has no activity at AKT (IC50s = 8.4, 21.9, and >50 μM, respectively); inhibits PKD1 activity in LNCaP cells (IC50 = 0.21 μM); a byproduct in the synthesis of CID755673
23428	CID797718	25 mg	≥98%	A PKD1 inhibitor (IC50 = 7 μM); also inhibits CAK and PLK1 but has no activity at AKT (IC50s = 8.4, 21.9, and >50 μM, respectively); inhibits PKD1 activity in LNCaP cells (IC50 = 0.21 μM); a byproduct in the synthesis of CID755673
23428	CID797718	5 mg	≥98%	A PKD1 inhibitor (IC50 = 7 μM); also inhibits CAK and PLK1 but has no activity at AKT (IC50s = 8.4, 21.9, and >50 μM, respectively); inhibits PKD1 activity in LNCaP cells (IC50 = 0.21 μM); a byproduct in the synthesis of CID755673
23434	B-RAF IN 1	1 mg	≥98%	An inhibitor of B-RAF and C-RAF (IC50s = 24 and 25 nM, respectively); selective over 13 other kinases at concentrations greater than 2 μM; inhibits p38α and CAMKII (IC50s = 216 and 822 nM, respectively); inhibits proliferation WM 266-4 and HT29 cells (IC50s = 920 and 780 nM, respectively)
23434	B-RAF IN 1	10 mg	≥98%	An inhibitor of B-RAF and C-RAF (IC50s = 24 and 25 nM, respectively); selective over 13 other kinases at concentrations greater than 2 μM; inhibits p38α and CAMKII (IC50s = 216 and 822 nM, respectively); inhibits proliferation WM 266-4 and HT29 cells (IC50s = 920 and 780 nM, respectively)
23434	B-RAF IN 1	25 mg	≥98%	An inhibitor of B-RAF and C-RAF (IC50s = 24 and 25 nM, respectively); selective over 13 other kinases at concentrations greater than 2 μM; inhibits p38α and CAMKII (IC50s = 216 and 822 nM, respectively); inhibits proliferation WM 266-4 and HT29 cells (IC50s = 920 and 780 nM, respectively)
23434	B-RAF IN 1	5 mg	≥98%	An inhibitor of B-RAF and C-RAF (IC50s = 24 and 25 nM, respectively); selective over 13 other kinases at concentrations greater than 2 μM; inhibits p38α and CAMKII (IC50s = 216 and 822 nM, respectively); inhibits proliferation WM 266-4 and HT29 cells (IC50s = 920 and 780 nM, respectively)
23439	Solcitinib	1 mg	≥98%	A JAK1 inhibitor (IC50 = 9.8 nM); >10-fold selective for JAK1 over JAK2, JAK3, and TYK2
23439	Solcitinib	10 mg	≥98%	A JAK1 inhibitor (IC50 = 9.8 nM); >10-fold selective for JAK1 over JAK2, JAK3, and TYK2
23439	Solcitinib	25 mg	≥98%	A JAK1 inhibitor (IC50 = 9.8 nM); >10-fold selective for JAK1 over JAK2, JAK3, and TYK2
23439	Solcitinib	5 mg	≥98%	A JAK1 inhibitor (IC50 = 9.8 nM); >10-fold selective for JAK1 over JAK2, JAK3, and TYK2
23440	WZ3146	1 mg	≥98%	An inhibitor of mutant EGFRs (IC50s = 2-2,740 nM); selective for EGFR mutants including EGFRL858R and EGFRDel E746_A750 (IC50s = 2 nM for both) over wild-type EGFR (IC50 = 750 nM); inhibits ERBB2Ins G776V,C and wild-type ERBB2 (IC50s = 10 and 24 nM, respectively, in Ba/F3 cells) but not the ERBB2 gatekeeper mutant; decreases phosphorylation of EGFR, AKT, and ERK1/2 in H1975 NSCLC cells at 10-1,000 nM; inhibits proliferation of PC-9 and PC-9 GR cells (EC50s = 15 and 3 nM, respectively)

23440	WZ3146	10 mg	≥98%	An inhibitor of mutant EGFRs (IC50s = 2-2,740 nM); selective for EGFR mutants including EGFRL858R and EGFRDel E746_A750 (IC50s = 2 nM for both) over wild-type EGFR (IC50 = 750 nM); inhibits ERBB2Ins G776V,C and wild-type ERBB2 (IC50s = 10 and 24 nM, respectively, in Ba/F3 cells) but not the ERBB2 gatekeeper mutant; decreases phosphorylation of EGFR, AKT, and ERK1/2 in H1975 NSCLC cells at 10-1,000 nM; inhibits proliferation of PC-9 and PC-9 GR cells (EC50s = 15 and 3 nM, respectively)
23440	WZ3146	5 mg	≥98%	An inhibitor of mutant EGFRs (IC50s = 2-2,740 nM); selective for EGFR mutants including EGFRL858R and EGFRDel E746_A750 (IC50s = 2 nM for both) over wild-type EGFR (IC50 = 750 nM); inhibits ERBB2Ins G776V,C and wild-type ERBB2 (IC50s = 10 and 24 nM, respectively, in Ba/F3 cells) but not the ERBB2 gatekeeper mutant; decreases phosphorylation of EGFR, AKT, and ERK1/2 in H1975 NSCLC cells at 10-1,000 nM; inhibits proliferation of PC-9 and PC-9 GR cells (EC50s = 15 and 3 nM, respectively)
23440	WZ3146	50 mg	≥98%	An inhibitor of mutant EGFRs (IC50s = 2-2,740 nM); selective for EGFR mutants including EGFRL858R and EGFRDel E746_A750 (IC50s = 2 nM for both) over wild-type EGFR (IC50 = 750 nM); inhibits ERBB2Ins G776V,C and wild-type ERBB2 (IC50s = 10 and 24 nM, respectively, in Ba/F3 cells) but not the ERBB2 gatekeeper mutant; decreases phosphorylation of EGFR, AKT, and ERK1/2 in H1975 NSCLC cells at 10-1,000 nM; inhibits proliferation of PC-9 and PC-9 GR cells (EC50s = 15 and 3 nM, respectively)
23441	Bimiralisib	1 mg	≥98%	A pan inhibitor of PI3Ks and an inhibitor of mTOR (IC50s = 33, 661, 708, 451, and 89 nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ, and mTOR, respectively); selective for these kinases over a panel of cell surface and nuclear receptors, membrane channels, transporters, kinases, proteases, and phosphodiesterases at a concentration of 10 µM; has anticancer activity (average GI50 = 0.7 µM across the NCI 60 human cancer cell line panel); reduces tumor growth in a dose-dependent manner in a PC3 prostate cancer mouse xenograft model
23441	Bimiralisib	10 mg	≥98%	A pan inhibitor of PI3Ks and an inhibitor of mTOR (IC50s = 33, 661, 708, 451, and 89 nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ, and mTOR, respectively); selective for these kinases over a panel of cell surface and nuclear receptors, membrane channels, transporters, kinases, proteases, and phosphodiesterases at a concentration of 10 µM; has anticancer activity (average GI50 = 0.7 µM across the NCI 60 human cancer cell line panel); reduces tumor growth in a dose-dependent manner in a PC3 prostate cancer mouse xenograft model
23441	Bimiralisib	25 mg	≥98%	A pan inhibitor of PI3Ks and an inhibitor of mTOR (IC50s = 33, 661, 708, 451, and 89 nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ, and mTOR, respectively); selective for these kinases over a panel of cell surface and nuclear receptors, membrane channels, transporters, kinases, proteases, and phosphodiesterases at a concentration of 10 µM; has anticancer activity (average GI50 = 0.7 µM across the NCI 60 human cancer cell line panel); reduces tumor growth in a dose-dependent manner in a PC3 prostate cancer mouse xenograft model
23441	Bimiralisib	5 mg	≥98%	A pan inhibitor of PI3Ks and an inhibitor of mTOR (IC50s = 33, 661, 708, 451, and 89 nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ, and mTOR, respectively); selective for these kinases over a panel of cell surface and nuclear receptors, membrane channels, transporters, kinases, proteases, and phosphodiesterases at a concentration of 10 µM; has anticancer activity (average GI50 = 0.7 µM across the NCI 60 human cancer cell line panel); reduces tumor growth in a dose-dependent manner in a PC3 prostate cancer mouse xenograft model
23446	GNE-9605	1 mg	≥98%	A potent LRRK2 inhibitor (IC50 = 18.7 nM); selective for LRRK2 over 178 kinases, inhibiting only TAK1-TAB1 >50% at a concentration of 0.1 µM; inhibits LRRK2 Ser1292 autophosphorylation in BAC transgenic mice expressing human LRRK2 protein with the G2019S mutation
23446	GNE-9605	10 mg	≥98%	A potent LRRK2 inhibitor (IC50 = 18.7 nM); selective for LRRK2 over 178 kinases, inhibiting only TAK1-TAB1 >50% at a concentration of 0.1 µM; inhibits LRRK2 Ser1292 autophosphorylation in BAC transgenic mice expressing human LRRK2 protein with the G2019S mutation
23446	GNE-9605	25 mg	≥98%	A potent LRRK2 inhibitor (IC50 = 18.7 nM); selective for LRRK2 over 178 kinases, inhibiting only TAK1-TAB1 >50% at a concentration of 0.1 µM; inhibits LRRK2 Ser1292 autophosphorylation in BAC transgenic mice expressing human LRRK2 protein with the G2019S mutation
23446	GNE-9605	5 mg	≥98%	A potent LRRK2 inhibitor (IC50 = 18.7 nM); selective for LRRK2 over 178 kinases, inhibiting only TAK1-TAB1 >50% at a concentration of 0.1 µM; inhibits LRRK2 Ser1292 autophosphorylation in BAC transgenic mice expressing human LRRK2 protein with the G2019S mutation
23452	WHI-P180	1 mg	≥98%	A multi-kinase inhibitor (IC50s = 4.5 and 66 nM for human recombinant RET and KDR, respectively); inhibits EGFR (IC50 = 4 µM); binds to TTBK1 (Kds = 0.46 and 0.24 µM for phosphorylated and non-phosphorylated TTBK1, respectively); inhibits JAK3-driven graft versus host disease responses in mice receiving allogenic bone marrow and splenocyte grafts; inhibits IgE-induced vascular hyperpermeability in a mouse model of passive anaphylaxis

23452	WHI-P180	5 mg	≥98%	A multi-kinase inhibitor (IC50s = 4.5 and 66 nM for human recombinant RET and KDR, respectively); inhibits EGFR (IC50 = 4 µM); binds to TTBK1 (Kds = 0.46 and 0.24 µM for phosphorylated and non-phosphorylated TTBK1, respectively); inhibits JAK3-driven graft versus host disease responses in mice receiving allogenic bone marrow and splenocyte grafts; inhibits IgE-induced vascular hyperpermeability in a mouse model of passive anaphylaxis
23452	WHI-P180	500 µg	≥98%	A multi-kinase inhibitor (IC50s = 4.5 and 66 nM for human recombinant RET and KDR, respectively); inhibits EGFR (IC50 = 4 µM); binds to TTBK1 (Kds = 0.46 and 0.24 µM for phosphorylated and non-phosphorylated TTBK1, respectively); inhibits JAK3-driven graft versus host disease responses in mice receiving allogenic bone marrow and splenocyte grafts; inhibits IgE-induced vascular hyperpermeability in a mouse model of passive anaphylaxis
23453	WHI-P258	1 mg	≥98%	A negative control for JAK3 inhibition; molecular modeling estimated a Ki value of 72 µM; inactive at JAK3 (IC50 = >300 µM)
23453	WHI-P258	5 mg	≥98%	A negative control for JAK3 inhibition; molecular modeling estimated a Ki value of 72 µM; inactive at JAK3 (IC50 = >300 µM)
23453	WHI-P258	500 µg	≥98%	A negative control for JAK3 inhibition; molecular modeling estimated a Ki value of 72 µM; inactive at JAK3 (IC50 = >300 µM)
23458	NVP-ACC789	1 mg	≥98%	An inhibitor of VEGFRs (IC50s = 0.38, 0.02, 0.18, and 0.23 µM for human VEGFR1, 2, 3, and mouse Vegfr2, respectively); selective for VEGFRs over FGFRs and PDGFRα (IC50s = >10 µM), but has activity at PDGFRβ (IC50 = 1.4 µM) in an enzyme assay; inhibits VEGF-induced VEGFR2 autophosphorylation (IC50 = 11.5 nM in CHO cells transfected with the human receptor); blocks bFGF- and VEGF-induced angiogenesis (ED50s = 9 and 26 mg/kg, respectively) in a mouse model of growth factor-induced angiogenesis
23458	NVP-ACC789	10 mg	≥98%	An inhibitor of VEGFRs (IC50s = 0.38, 0.02, 0.18, and 0.23 µM for human VEGFR1, 2, 3, and mouse Vegfr2, respectively); selective for VEGFRs over FGFRs and PDGFRα (IC50s = >10 µM), but has activity at PDGFRβ (IC50 = 1.4 µM) in an enzyme assay; inhibits VEGF-induced VEGFR2 autophosphorylation (IC50 = 11.5 nM in CHO cells transfected with the human receptor); blocks bFGF- and VEGF-induced angiogenesis (ED50s = 9 and 26 mg/kg, respectively) in a mouse model of growth factor-induced angiogenesis
23458	NVP-ACC789	5 mg	≥98%	An inhibitor of VEGFRs (IC50s = 0.38, 0.02, 0.18, and 0.23 µM for human VEGFR1, 2, 3, and mouse Vegfr2, respectively); selective for VEGFRs over FGFRs and PDGFRα (IC50s = >10 µM), but has activity at PDGFRβ (IC50 = 1.4 µM) in an enzyme assay; inhibits VEGF-induced VEGFR2 autophosphorylation (IC50 = 11.5 nM in CHO cells transfected with the human receptor); blocks bFGF- and VEGF-induced angiogenesis (ED50s = 9 and 26 mg/kg, respectively) in a mouse model of growth factor-induced angiogenesis
23498	Naquotinib	1 mg	≥98%	An irreversible inhibitor of mutant EGFRs; inhibits cell proliferation of Ba/F3 cells expressing various EGFR mutations (IC50s= 9-11 nM); selective for mutant EGFRs over wild-type EGFR (IC50 = 830 nM); reduces phosphorylated levels of EGFR, AKT, and ERK and decreases cell viability in NSCLC cells and cells carrying an exon 20 insertion mutation; reduces tumor growth in PC-9/NaqRc2 mouse xenograft model at 50 mg/kg per day
23498	Naquotinib	10 mg	≥98%	An irreversible inhibitor of mutant EGFRs; inhibits cell proliferation of Ba/F3 cells expressing various EGFR mutations (IC50s= 9-11 nM); selective for mutant EGFRs over wild-type EGFR (IC50 = 830 nM); reduces phosphorylated levels of EGFR, AKT, and ERK and decreases cell viability in NSCLC cells and cells carrying an exon 20 insertion mutation; reduces tumor growth in PC-9/NaqRc2 mouse xenograft model at 50 mg/kg per day
23498	Naquotinib	5 mg	≥98%	An irreversible inhibitor of mutant EGFRs; inhibits cell proliferation of Ba/F3 cells expressing various EGFR mutations (IC50s= 9-11 nM); selective for mutant EGFRs over wild-type EGFR (IC50 = 830 nM); reduces phosphorylated levels of EGFR, AKT, and ERK and decreases cell viability in NSCLC cells and cells carrying an exon 20 insertion mutation; reduces tumor growth in PC-9/NaqRc2 mouse xenograft model at 50 mg/kg per day
23690	Brivanib	1 mg	≥95%	An ATP-competitive inhibitor of human VEGFR1 and 2 and FGFR1 (IC50s = 380, 25, and 148 nM, respectively, for the human recombinant proteins); selective for VEGFR1 and 2 and FGFR1 over PDGFRβ, EGFR, LCK, PKCα, and JAK3 (IC50s = >1,900 nM; inhibits recombinant mouse Flk1 (IC50 = 89 nM); inhibits VEGF- and FGF-stimulated proliferation of HUVECs in vitro (IC50s = 40 and 276 nM, respectively); inhibits tumor growth by 85% and 97% when administered at 60 and 90 mg/kg p.o., respectively, for 10 days in an H3396 breast cancer mouse xenograft model; inhibits bile duct ligation-induced liver fibrosis in mice (25 mg/kg per day for 7 days, p.o.) and increases expression of PDGFβ, PDGFRβ, TGF-β1, TGF-β R2, FGF2, FGFR2, and VEGFR2 mRNAs

23690	Brivanib	10 mg	≥95%	An ATP-competitive inhibitor of human VEGFR1 and 2 and FGFR1 (IC50s = 380, 25, and 148 nM, respectively, for the human recombinant proteins); selective for VEGFR1 and 2 and FGFR1 over PDGFRβ, EGFR, LCK, PKCα, and JAK3 (IC50s = >1,900 nM; inhibits recombinant mouse Flk1 (IC50 = 89 nM); inhibits VEGF- and FGF-stimulated proliferation of HUVECs in vitro (IC50s = 40 and 276 nM, respectively); inhibits tumor growth by 85% and 97% when administered at 60 and 90 mg/kg p.o., respectively, for 10 days in an H3396 breast cancer mouse xenograft model; inhibits bile duct ligation-induced liver fibrosis in mice (25 mg/kg per day for 7 days, p.o.) and increases expression of PDGFβ, PDGFRβ, TGF-β1, TGF-β R2, FGF2, FGFR2, and VEGFR2 mRNAs
23690	Brivanib	25 mg	≥95%	An ATP-competitive inhibitor of human VEGFR1 and 2 and FGFR1 (IC50s = 380, 25, and 148 nM, respectively, for the human recombinant proteins); selective for VEGFR1 and 2 and FGFR1 over PDGFRβ, EGFR, LCK, PKCα, and JAK3 (IC50s = >1,900 nM; inhibits recombinant mouse Flk1 (IC50 = 89 nM); inhibits VEGF- and FGF-stimulated proliferation of HUVECs in vitro (IC50s = 40 and 276 nM, respectively); inhibits tumor growth by 85% and 97% when administered at 60 and 90 mg/kg p.o., respectively, for 10 days in an H3396 breast cancer mouse xenograft model; inhibits bile duct ligation-induced liver fibrosis in mice (25 mg/kg per day for 7 days, p.o.) and increases expression of PDGFβ, PDGFRβ, TGF-β1, TGF-β R2, FGF2, FGFR2, and VEGFR2 mRNAs
23690	Brivanib	5 mg	≥95%	An ATP-competitive inhibitor of human VEGFR1 and 2 and FGFR1 (IC50s = 380, 25, and 148 nM, respectively, for the human recombinant proteins); selective for VEGFR1 and 2 and FGFR1 over PDGFRβ, EGFR, LCK, PKCα, and JAK3 (IC50s = >1,900 nM; inhibits recombinant mouse Flk1 (IC50 = 89 nM); inhibits VEGF- and FGF-stimulated proliferation of HUVECs in vitro (IC50s = 40 and 276 nM, respectively); inhibits tumor growth by 85% and 97% when administered at 60 and 90 mg/kg p.o., respectively, for 10 days in an H3396 breast cancer mouse xenograft model; inhibits bile duct ligation-induced liver fibrosis in mice (25 mg/kg per day for 7 days, p.o.) and increases expression of PDGFβ, PDGFRβ, TGF-β1, TGF-β R2, FGF2, FGFR2, and VEGFR2 mRNAs
23772	TAK-901	1 mg	≥98%	A non-selective Aurora kinase inhibitor (IC50s = 3.1, 10, and 4.2 nM for Aurora A, B, and C, respectively); inhibits JAK3, c-Src, CLK2, FGR, YES1, LRRK2, FLT3, Fyn, Abl, and FGFR2 (IC50s = 1.2-6.4 nM); decreases histone H3 phosphorylation in human prostate PC3 cancer cells (EC50 = 0.16 μM) and inhibits c-Src, FAK, FGFR2, FLT3, Abl, and Axl autophosphorylation in a panel of cancer cell lines (EC50s = 0.19-3.7 μM); inhibits the growth of cancer cell lines (EC50s = 0.043-1.5 μM); inhibits histone H3 phosphorylation and reduces tumor growth in an A2780 ovarian cancer nude rat xenograft model (40 mg/kg per day, i.v.)
23772	TAK-901	10 mg	≥98%	A non-selective Aurora kinase inhibitor (IC50s = 3.1, 10, and 4.2 nM for Aurora A, B, and C, respectively); inhibits JAK3, c-Src, CLK2, FGR, YES1, LRRK2, FLT3, Fyn, Abl, and FGFR2 (IC50s = 1.2-6.4 nM); decreases histone H3 phosphorylation in human prostate PC3 cancer cells (EC50 = 0.16 μM) and inhibits c-Src, FAK, FGFR2, FLT3, Abl, and Axl autophosphorylation in a panel of cancer cell lines (EC50s = 0.19-3.7 μM); inhibits the growth of cancer cell lines (EC50s = 0.043-1.5 μM); inhibits histone H3 phosphorylation and reduces tumor growth in an A2780 ovarian cancer nude rat xenograft model (40 mg/kg per day, i.v.)
23772	TAK-901	25 mg	≥98%	A non-selective Aurora kinase inhibitor (IC50s = 3.1, 10, and 4.2 nM for Aurora A, B, and C, respectively); inhibits JAK3, c-Src, CLK2, FGR, YES1, LRRK2, FLT3, Fyn, Abl, and FGFR2 (IC50s = 1.2-6.4 nM); decreases histone H3 phosphorylation in human prostate PC3 cancer cells (EC50 = 0.16 μM) and inhibits c-Src, FAK, FGFR2, FLT3, Abl, and Axl autophosphorylation in a panel of cancer cell lines (EC50s = 0.19-3.7 μM); inhibits the growth of cancer cell lines (EC50s = 0.043-1.5 μM); inhibits histone H3 phosphorylation and reduces tumor growth in an A2780 ovarian cancer nude rat xenograft model (40 mg/kg per day, i.v.)
23772	TAK-901	5 mg	≥98%	A non-selective Aurora kinase inhibitor (IC50s = 3.1, 10, and 4.2 nM for Aurora A, B, and C, respectively); inhibits JAK3, c-Src, CLK2, FGR, YES1, LRRK2, FLT3, Fyn, Abl, and FGFR2 (IC50s = 1.2-6.4 nM); decreases histone H3 phosphorylation in human prostate PC3 cancer cells (EC50 = 0.16 μM) and inhibits c-Src, FAK, FGFR2, FLT3, Abl, and Axl autophosphorylation in a panel of cancer cell lines (EC50s = 0.19-3.7 μM); inhibits the growth of cancer cell lines (EC50s = 0.043-1.5 μM); inhibits histone H3 phosphorylation and reduces tumor growth in an A2780 ovarian cancer nude rat xenograft model (40 mg/kg per day, i.v.)
23820	RAF709	1 mg	≥98%	A potent inhibitor of B-RAF and C-RAF (IC50s = 0.4 and 0.5 nM, respectively); selective for RAF kinases exhibiting >99% inhibition of only B-RAF, B-RAFV600E, and C-RAF in a panel of 456 kinases; DDR1, DDR2, FRK, and PDGFRβ are also inhibited by >80% at a concentration of 1 μM; inhibits phosphorylation of MEK and ERK (EC50s = 0.02 and 0.1 μM, respectively) with minimal paradoxical activation, stabilizes BRAF-CRAF dimers (EC50 = 0.8 μM), and reduces proliferation of Calu-6 RAS mutant cells (EC50 = 0.95 μM); reduces ERK phosphorylation and decreases tumor volume without affecting total body weight in a Calu-6 mouse NSCLC xenograft model when administered at doses ranging from 10-200 mg/kg

23820	RAF709	10 mg	≥98%	A potent inhibitor of B-RAF and C-RAF (IC50s = 0.4 and 0.5 nM, respectively); selective for RAF kinases exhibiting >99% inhibition of only B-RAF, B-RAFV600E, and C-RAF in a panel of 456 kinases; DDR1, DDR2, FRK, and PDGFRβ are also inhibited by >80% at a concentration of 1 μM; inhibits phosphorylation of MEK and ERK (EC50s = 0.02 and 0.1 μM, respectively) with minimal paradoxical activation, stabilizes BRAF-CRAF dimers (EC50 = 0.8 μM), and reduces proliferation of Calu-6 RAS mutant cells (EC50 = 0.95 μM); reduces ERK phosphorylation and decreases tumor volume without affecting total body weight in a Calu-6 mouse NSCLC xenograft model when administered at doses ranging from 10-200 mg/kg
23820	RAF709	5 mg	≥98%	A potent inhibitor of B-RAF and C-RAF (IC50s = 0.4 and 0.5 nM, respectively); selective for RAF kinases exhibiting >99% inhibition of only B-RAF, B-RAFV600E, and C-RAF in a panel of 456 kinases; DDR1, DDR2, FRK, and PDGFRβ are also inhibited by >80% at a concentration of 1 μM; inhibits phosphorylation of MEK and ERK (EC50s = 0.02 and 0.1 μM, respectively) with minimal paradoxical activation, stabilizes BRAF-CRAF dimers (EC50 = 0.8 μM), and reduces proliferation of Calu-6 RAS mutant cells (EC50 = 0.95 μM); reduces ERK phosphorylation and decreases tumor volume without affecting total body weight in a Calu-6 mouse NSCLC xenograft model when administered at doses ranging from 10-200 mg/kg
23895	INDY	1 mg	≥98%	A DYRK1A inhibitor (Ki = 180 nM; IC50 = 240 nM); selective for DYRK1A over MAOA and B (100 μM); inhibits DYRK1A phosphorylation of tau in COS-7 cells expressing EGFP-DYRK1A and EGFP-tau in a concentration-dependent manner; induces proliferation of human and rat β-cells and increases insulin secretion by human islets in vitro; reverses developmental deformities induced by DYRK1A overexpression in X. laevis embryos
23895	INDY	10 mg	≥98%	A DYRK1A inhibitor (Ki = 180 nM; IC50 = 240 nM); selective for DYRK1A over MAOA and B (100 μM); inhibits DYRK1A phosphorylation of tau in COS-7 cells expressing EGFP-DYRK1A and EGFP-tau in a concentration-dependent manner; induces proliferation of human and rat β-cells and increases insulin secretion by human islets in vitro; reverses developmental deformities induced by DYRK1A overexpression in X. laevis embryos
23895	INDY	25 mg	≥98%	A DYRK1A inhibitor (Ki = 180 nM; IC50 = 240 nM); selective for DYRK1A over MAOA and B (100 μM); inhibits DYRK1A phosphorylation of tau in COS-7 cells expressing EGFP-DYRK1A and EGFP-tau in a concentration-dependent manner; induces proliferation of human and rat β-cells and increases insulin secretion by human islets in vitro; reverses developmental deformities induced by DYRK1A overexpression in X. laevis embryos
23895	INDY	5 mg	≥98%	A DYRK1A inhibitor (Ki = 180 nM; IC50 = 240 nM); selective for DYRK1A over MAOA and B (100 μM); inhibits DYRK1A phosphorylation of tau in COS-7 cells expressing EGFP-DYRK1A and EGFP-tau in a concentration-dependent manner; induces proliferation of human and rat β-cells and increases insulin secretion by human islets in vitro; reverses developmental deformities induced by DYRK1A overexpression in X. laevis embryos
23928	TMB 8 (hydrochloride	10 mg	≥98%	A non-competitive antagonist of nAChRs (IC50s = 390 and 350 nM, respectively, for human muscle-type and and α3β4 subunit-containing ganglionic nAChRs); an inhibitor of intracellular calcium availability in smooth and skeletal muscle; blocks the contractile response in isolated rabbit aortic strip when used at a concentration of 50 μM; inhibits calcium influx and efflux in isolated guinea pig ileum when used at a concentration of 65 μM; used in the study of intracellular calcium dynamics; dose-dependently inhibits PKC activity
23928	TMB 8 (hydrochloride	5 mg	≥98%	A non-competitive antagonist of nAChRs (IC50s = 390 and 350 nM, respectively, for human muscle-type and and α3β4 subunit-containing ganglionic nAChRs); an inhibitor of intracellular calcium availability in smooth and skeletal muscle; blocks the contractile response in isolated rabbit aortic strip when used at a concentration of 50 μM; inhibits calcium influx and efflux in isolated guinea pig ileum when used at a concentration of 65 μM; used in the study of intracellular calcium dynamics; dose-dependently inhibits PKC activity
23940	GSK3β Inhibitor XI	1 mg	≥98%	A potent inhibitor of GSK3β (Ki = 25 nM); inhibits GSK3β in HEK293 cells (EC50 = 32 nM)
23966	PD 198306	1 mg	≥98%	An orally bioavailable and potent inhibitor of MEK1/2 inhibitor (IC50 = 8 nM); selective for MEK1/2 over ERK, c-Src, PI3Kγ, and cyclin-dependent kinases (IC50s = >1 μM); reduces ERK1/2 phosphorylation and inhibits growth of HL-60 cells in vitro; reduces ERK1/2 phosphorylation and MMP-1 expression in a dose-dependent manner in a rabbit model of osteoarthritis when administered at doses ranging from 10-30 mg/kg; reduces ERK1/2 activity in the lumbar spinal cord and blocks static allodynia in rat models of streptozotocin- and chronic constriction injury-induced neuropathic pain
23966	PD 198306	10 mg	≥98%	An orally bioavailable and potent inhibitor of MEK1/2 inhibitor (IC50 = 8 nM); selective for MEK1/2 over ERK, c-Src, PI3Kγ, and cyclin-dependent kinases (IC50s = >1 μM); reduces ERK1/2 phosphorylation and inhibits growth of HL-60 cells in vitro; reduces ERK1/2 phosphorylation and MMP-1 expression in a dose-dependent manner in a rabbit model of osteoarthritis when administered at doses ranging from 10-30 mg/kg; reduces ERK1/2 activity in the lumbar spinal cord and blocks static allodynia in rat models of streptozotocin- and chronic constriction injury-induced neuropathic pain

23966	PD 198306	5 mg	≥98%	An orally bioavailable and potent inhibitor of MEK1/2 inhibitor (IC50 = 8 nM); selective for MEK1/2 over ERK, c-Src, PI3Kγ, and cyclin-dependent kinases (IC50s = >1 μM); reduces ERK1/2 phosphorylation and inhibits growth of HL-60 cells in vitro; reduces ERK1/2 phosphorylation and MMP-1 expression in a dose-dependent manner in a rabbit model of osteoarthritis when administered at doses ranging from 10-30 mg/kg; reduces ERK1/2 activity in the lumbar spinal cord and blocks static allodynia in rat models of streptozotocin- and chronic constriction injury-induced neuropathic pain
24023	GSK3179106	1 mg	≥98%	An inhibitor of RET kinase (IC50 = 0.4 nM); selective for RET kinase over VEGFR2/KDR (IC50 = 109 nM); reduces the number of abdominal contractions induced by colorectal distension in acetic acid-sensitized rats when administered at 10 mg/kg twice per day
24023	GSK3179106	10 mg	≥98%	An inhibitor of RET kinase (IC50 = 0.4 nM); selective for RET kinase over VEGFR2/KDR (IC50 = 109 nM); reduces the number of abdominal contractions induced by colorectal distension in acetic acid-sensitized rats when administered at 10 mg/kg twice per day
24023	GSK3179106	25 mg	≥98%	An inhibitor of RET kinase (IC50 = 0.4 nM); selective for RET kinase over VEGFR2/KDR (IC50 = 109 nM); reduces the number of abdominal contractions induced by colorectal distension in acetic acid-sensitized rats when administered at 10 mg/kg twice per day
24023	GSK3179106	5 mg	≥98%	An inhibitor of RET kinase (IC50 = 0.4 nM); selective for RET kinase over VEGFR2/KDR (IC50 = 109 nM); reduces the number of abdominal contractions induced by colorectal distension in acetic acid-sensitized rats when administered at 10 mg/kg twice per day
24058	GDC-0349	1 mg	≥98%	A potent inhibitor of mTOR (Ki = 3.8 nM); selective for mTOR over a panel of 266 kinases at a concentration of 1 μM; inhibits proliferation of PC3 prostate cancer cells in vitro (EC50 = 270 nM) and induces caspase-dependent apoptosis in HNSCC cells; oral administration inhibits tumor growth in MCF7-neo/Her-2 breast and PC3 prostate cancer mouse xenograft models in a dose-dependent manner (10-80 mg/kg)
24058	GDC-0349	10 mg	≥98%	A potent inhibitor of mTOR (Ki = 3.8 nM); selective for mTOR over a panel of 266 kinases at a concentration of 1 μM; inhibits proliferation of PC3 prostate cancer cells in vitro (EC50 = 270 nM) and induces caspase-dependent apoptosis in HNSCC cells; oral administration inhibits tumor growth in MCF7-neo/Her-2 breast and PC3 prostate cancer mouse xenograft models in a dose-dependent manner (10-80 mg/kg)
24058	GDC-0349	5 mg	≥98%	A potent inhibitor of mTOR (Ki = 3.8 nM); selective for mTOR over a panel of 266 kinases at a concentration of 1 μM; inhibits proliferation of PC3 prostate cancer cells in vitro (EC50 = 270 nM) and induces caspase-dependent apoptosis in HNSCC cells; oral administration inhibits tumor growth in MCF7-neo/Her-2 breast and PC3 prostate cancer mouse xenograft models in a dose-dependent manner (10-80 mg/kg)
24058	GDC-0349	500 µg	≥98%	A potent inhibitor of mTOR (Ki = 3.8 nM); selective for mTOR over a panel of 266 kinases at a concentration of 1 μM; inhibits proliferation of PC3 prostate cancer cells in vitro (EC50 = 270 nM) and induces caspase-dependent apoptosis in HNSCC cells; oral administration inhibits tumor growth in MCF7-neo/Her-2 breast and PC3 prostate cancer mouse xenograft models in a dose-dependent manner (10-80 mg/kg)
24161	Takinib	1 mg	≥98%	A TAK1 inhibitor (IC50 = 9.5 nM); selective for TAK1 over IRAK1, IRAK4, GCK, Clk2, and MINK1 (IC50s = 390, 120, 430, 430, and 1,900 nM, respectively); increases caspase-3/-7 activity and inhibits proliferation of TNF-α-stimulated, but not unstimulated, MDA-MB-231 cells; reduces phosphorylation of IKK, p38 MAPK, MAPK8, MAPK9, and c-Jun in TNF-α-stimulated MDA-MB-231 cells; inhibits IL-6 secretion in TNF-α-stimulated rheumatoid arthritis fibroblast-like synoviocytes; reduces inflammation and cartilage damage in knee joints in a mouse model of collagen type II-induced arthritis at 50 mg/kg per day
24161	Takinib	10 mg	≥98%	A TAK1 inhibitor (IC50 = 9.5 nM); selective for TAK1 over IRAK1, IRAK4, GCK, Clk2, and MINK1 (IC50s = 390, 120, 430, 430, and 1,900 nM, respectively); increases caspase-3/-7 activity and inhibits proliferation of TNF-α-stimulated, but not unstimulated, MDA-MB-231 cells; reduces phosphorylation of IKK, p38 MAPK, MAPK8, MAPK9, and c-Jun in TNF-α-stimulated MDA-MB-231 cells; inhibits IL-6 secretion in TNF-α-stimulated rheumatoid arthritis fibroblast-like synoviocytes; reduces inflammation and cartilage damage in knee joints in a mouse model of collagen type II-induced arthritis at 50 mg/kg per day
24161	Takinib	25 mg	≥98%	A TAK1 inhibitor (IC50 = 9.5 nM); selective for TAK1 over IRAK1, IRAK4, GCK, Clk2, and MINK1 (IC50s = 390, 120, 430, 430, and 1,900 nM, respectively); increases caspase-3/-7 activity and inhibits proliferation of TNF-α-stimulated, but not unstimulated, MDA-MB-231 cells; reduces phosphorylation of IKK, p38 MAPK, MAPK8, MAPK9, and c-Jun in TNF-α-stimulated MDA-MB-231 cells; inhibits IL-6 secretion in TNF-α-stimulated rheumatoid arthritis fibroblast-like synoviocytes; reduces inflammation and cartilage damage in knee joints in a mouse model of collagen type II-induced arthritis at 50 mg/kg per day

24161	Takinib	5 mg	≥98%	A TAK1 inhibitor (IC50 = 9.5 nM); selective for TAK1 over IRAK1, IRAK4, GCK, Clk2, and MINK1 (IC50s = 390, 120, 430, 430, and 1,900 nM, respectively); increases caspase-3/-7 activity and inhibits proliferation of TNF-α-stimulated, but not unstimulated, MDA-MB-231 cells; reduces phosphorylation of IKK, p38 MAPK, MAPK8, MAPK9, and c-Jun in TNF-α-stimulated MDA-MB-231 cells; inhibits IL-6 secretion in TNF-α-stimulated rheumatoid arthritis fibroblast-like synoviocytes; reduces inflammation and cartilage damage in knee joints in a mouse model of collagen type II-induced arthritis at 50 mg/kg per day
24188	PHT-427	10 mg	≥98%	An inhibitor of Akt and PDPK1 (Ki = 2.7 and 5.2 μM, respectively); binds to the pleckstrin homology binding domain; inhibits PDPK1 and Akt autophosphorylation in BxPC-3 prostate cancer cells (10 μM); reduces tumor growth in BxPC-3, Panc-1, MiaPaCa-2, PC3, SK-OV-3, A549, and MCF-7 xenograft mouse models (125-250 mg/kg); enhances the antitumor effect of paclitaxel in an MCF-7 breast cancer xenograft mouse model
24188	PHT-427	25 mg	≥98%	An inhibitor of Akt and PDPK1 (Ki = 2.7 and 5.2 μM, respectively); binds to the pleckstrin homology binding domain; inhibits PDPK1 and Akt autophosphorylation in BxPC-3 prostate cancer cells (10 μM); reduces tumor growth in BxPC-3, Panc-1, MiaPaCa-2, PC3, SK-OV-3, A549, and MCF-7 xenograft mouse models (125-250 mg/kg); enhances the antitumor effect of paclitaxel in an MCF-7 breast cancer xenograft mouse model
24188	PHT-427	5 mg	≥98%	An inhibitor of Akt and PDPK1 (Ki = 2.7 and 5.2 μM, respectively); binds to the pleckstrin homology binding domain; inhibits PDPK1 and Akt autophosphorylation in BxPC-3 prostate cancer cells (10 μM); reduces tumor growth in BxPC-3, Panc-1, MiaPaCa-2, PC3, SK-OV-3, A549, and MCF-7 xenograft mouse models (125-250 mg/kg); enhances the antitumor effect of paclitaxel in an MCF-7 breast cancer xenograft mouse model
24188	PHT-427	50 mg	≥98%	An inhibitor of Akt and PDPK1 (Ki = 2.7 and 5.2 μM, respectively); binds to the pleckstrin homology binding domain; inhibits PDPK1 and Akt autophosphorylation in BxPC-3 prostate cancer cells (10 μM); reduces tumor growth in BxPC-3, Panc-1, MiaPaCa-2, PC3, SK-OV-3, A549, and MCF-7 xenograft mouse models (125-250 mg/kg); enhances the antitumor effect of paclitaxel in an MCF-7 breast cancer xenograft mouse model
24195	NVP-BAG956	1 mg	≥98%	A dual PDK1 and class I PI3K inhibitor (IC50s = 245, 56, 446, 35, and 117 nM for PDK1, p110α, p110β, p110δ, and p110γ, respectively); inhibits phosphorylation of T308-PKB (IC50 = 45 nM) in and proliferation of U87MG cells (EC50 = 143 nM); induces cell cycle arrest at the G1 phase in MOLM-14 cells and reduces colony formation by patient-derived AML cells; reduces tumor burden in mice injected with 32D.p210-luc+cells when administered in combination with everolimus
24195	NVP-BAG956	10 mg	≥98%	A dual PDK1 and class I PI3K inhibitor (IC50s = 245, 56, 446, 35, and 117 nM for PDK1, p110α, p110β, p110δ, and p110γ, respectively); inhibits phosphorylation of T308-PKB (IC50 = 45 nM) in and proliferation of U87MG cells (EC50 = 143 nM); induces cell cycle arrest at the G1 phase in MOLM-14 cells and reduces colony formation by patient-derived AML cells; reduces tumor burden in mice injected with 32D.p210-luc+cells when administered in combination with everolimus
24195	NVP-BAG956	5 mg	≥98%	A dual PDK1 and class I PI3K inhibitor (IC50s = 245, 56, 446, 35, and 117 nM for PDK1, p110α, p110β, p110δ, and p110γ, respectively); inhibits phosphorylation of T308-PKB (IC50 = 45 nM) in and proliferation of U87MG cells (EC50 = 143 nM); induces cell cycle arrest at the G1 phase in MOLM-14 cells and reduces colony formation by patient-derived AML cells; reduces tumor burden in mice injected with 32D.p210-luc+cells when administered in combination with everolimus
24196	AZD 8931	1 mg	≥98%	A reversible inhibitor of ErbB1/EGFR, ErbB2/HER2, and ErbB3/HER3 (IC50s = 4, 3, and 4 nM, respectively, for autophosphorylation); suppresses cell growth and induces apoptosis in SUM149 and FC-IBC-02 human breast cancer cell lines at 0.01, 0.1, and 1 μM; inhibits tumor growth in BT474c, Calu-3, LoVo, FaDu, and PC-9 mouse xenograft models from 6.25-50 mg/kg; inhibits inflammatory breast cancer tumor growth in a mouse xenograft model when administered in combination with paclitaxel at 25 mg/kg per day
24196	AZD 8931	10 mg	≥98%	A reversible inhibitor of ErbB1/EGFR, ErbB2/HER2, and ErbB3/HER3 (IC50s = 4, 3, and 4 nM, respectively, for autophosphorylation); suppresses cell growth and induces apoptosis in SUM149 and FC-IBC-02 human breast cancer cell lines at 0.01, 0.1, and 1 μM; inhibits tumor growth in BT474c, Calu-3, LoVo, FaDu, and PC-9 mouse xenograft models from 6.25-50 mg/kg; inhibits inflammatory breast cancer tumor growth in a mouse xenograft model when administered in combination with paclitaxel at 25 mg/kg per day
24196	AZD 8931	25 mg	≥98%	A reversible inhibitor of ErbB1/EGFR, ErbB2/HER2, and ErbB3/HER3 (IC50s = 4, 3, and 4 nM, respectively, for autophosphorylation); suppresses cell growth and induces apoptosis in SUM149 and FC-IBC-02 human breast cancer cell lines at 0.01, 0.1, and 1 μM; inhibits tumor growth in BT474c, Calu-3, LoVo, FaDu, and PC-9 mouse xenograft models from 6.25-50 mg/kg; inhibits inflammatory breast cancer tumor growth in a mouse xenograft model when administered in combination with paclitaxel at 25 mg/kg per day

24196	AZD 8931	5 mg	≥98%	A reversible inhibitor of ErbB1/EGFR, ErbB2/HER2, and ErbB3/HER3 (IC50s = 4, 3, and 4 nM, respectively, for autophosphorylation); suppresses cell growth and induces apoptosis in SUM149 and FC-IBC-02 human breast cancer cell lines at 0.01, 0.1, and 1 μM; inhibits tumor growth in BT474c, Calu-3, LoVo, FaDu, and PC-9 mouse xenograft models from 6.25-50 mg/kg; inhibits inflammatory breast cancer tumor growth in a mouse xenograft model when administered in combination with paclitaxel at 25 mg/kg per day
24197	AMG 208	1 mg	≥98%	A potent c-Met inhibitor (IC50 = 5.2 nM for wild-type c-Met); inhibits VEGFR2 (IC50 = 112 nM)
24197	AMG 208	10 mg	≥98%	A potent c-Met inhibitor (IC50 = 5.2 nM for wild-type c-Met); inhibits VEGFR2 (IC50 = 112 nM)
24197	AMG 208	25 mg	≥98%	A potent c-Met inhibitor (IC50 = 5.2 nM for wild-type c-Met); inhibits VEGFR2 (IC50 = 112 nM)
24197	AMG 208	5 mg	≥98%	A potent c-Met inhibitor (IC50 = 5.2 nM for wild-type c-Met); inhibits VEGFR2 (IC50 = 112 nM)
24199	Hesperadin	1 mg	≥98%	A multi-kinase inhibitor; inhibits human Aurora kinase B (IC50 = 250 nM) and the T. brucei homolog Aurora kinase-1 (IC50 = 40 nM); inhibits AMPK, LCK, MKK1, MAPKAP-K1, CHK1, and PHK in a panel of 25 kinases at 1 μM; inhibits MEKK2 in ATPase and transphosphorylation assays (IC50s = 60 and 34 nM, respectively); induces polyploidy and defects in cytokinesis and spindle assembly as well as inhibits proliferation of HeLa cells and overrides paclitaxel- and monastrol-induced mitotic arrest from 50-100 nM; induces toxicity in HepG2 cells (TC50 = 50 = 0.22-2.21 μM); inhibits the growth of T. brucei, L. major promastigotes and amasigotes, and P. falciparum (EC50s = 0.01-2.37 μM)
24199	Hesperadin	10 mg	≥98%	A multi-kinase inhibitor; inhibits human Aurora kinase B (IC50 = 250 nM) and the T. brucei homolog Aurora kinase-1 (IC50 = 40 nM); inhibits AMPK, LCK, MKK1, MAPKAP-K1, CHK1, and PHK in a panel of 25 kinases at 1 μM; inhibits MEKK2 in ATPase and transphosphorylation assays (IC50s = 60 and 34 nM, respectively); induces polyploidy and defects in cytokinesis and spindle assembly as well as inhibits proliferation of HeLa cells and overrides paclitaxel- and monastrol-induced mitotic arrest from 50-100 nM; induces toxicity in HepG2 cells (TC50 = 50 = 0.22-2.21 μM); inhibits the growth of T. brucei, L. major promastigotes and amasigotes, and P. falciparum (EC50s = 0.01-2.37 μM)
24199	Hesperadin	25 mg	≥98%	A multi-kinase inhibitor; inhibits human Aurora kinase B (IC50 = 250 nM) and the T. brucei homolog Aurora kinase-1 (IC50 = 40 nM); inhibits AMPK, LCK, MKK1, MAPKAP-K1, CHK1, and PHK in a panel of 25 kinases at 1 μM; inhibits MEKK2 in ATPase and transphosphorylation assays (IC50s = 60 and 34 nM, respectively); induces polyploidy and defects in cytokinesis and spindle assembly as well as inhibits proliferation of HeLa cells and overrides paclitaxel- and monastrol-induced mitotic arrest from 50-100 nM; induces toxicity in HepG2 cells (TC50 = 50 = 0.22-2.21 μM); inhibits the growth of T. brucei, L. major promastigotes and amasigotes, and P. falciparum (EC50s = 0.01-2.37 μM)
24199	Hesperadin	5 mg	≥98%	A multi-kinase inhibitor; inhibits human Aurora kinase B (IC50 = 250 nM) and the T. brucei homolog Aurora kinase-1 (IC50 = 40 nM); inhibits AMPK, LCK, MKK1, MAPKAP-K1, CHK1, and PHK in a panel of 25 kinases at 1 μM; inhibits MEKK2 in ATPase and transphosphorylation assays (IC50s = 60 and 34 nM, respectively); induces polyploidy and defects in cytokinesis and spindle assembly as well as inhibits proliferation of HeLa cells and overrides paclitaxel- and monastrol-induced mitotic arrest from 50-100 nM; induces toxicity in HepG2 cells (TC50 = 50 = 0.22-2.21 μM); inhibits the growth of T. brucei, L. major promastigotes and amasigotes, and P. falciparum (EC50s = 0.01-2.37 μM)
24207	Unguinol	1 mg	≥95%	A depsidone; an inhibitor of PPDK (IC50 = 42.3 μM); inhibits the growth of C4, but not C3 plants; inhibits the growth of the bacteria S. aureus and V. harveyi (GI50s = 8.7 and 69.5 μM, respectively); inhibits the growth of H460, MCF-7, and SF-268 cancer cells (GI50s = 28.2, 50.8, and 44.3 μM, respectively)
24207	Unguinol	5 mg	≥95%	A depsidone; an inhibitor of PPDK (IC50 = 42.3 μM); inhibits the growth of C4, but not C3 plants; inhibits the growth of the bacteria S. aureus and V. harveyi (GI50s = 8.7 and 69.5 μM, respectively); inhibits the growth of H460, MCF-7, and SF-268 cancer cells (GI50s = 28.2, 50.8, and 44.3 μM, respectively)
24273	BI-882370	1 mg	≥95%	A RAF inhibitor (IC50s = 0.8, 0.8, and 0.6 nM for B-RAFV600E, wild-type B-RAF, and C-RAF in the DFG-out inactive conformation, respectively); selective for RAF over a panel of kinases, including LCK, KIT, Src, LYNA, LYNB, and PDGFR (IC50s = 49, 415, 485, 750, 715, and 1,220 nM, respectively); inhibits proliferation of human B-RAF-mutant melanoma cells at 1-10 nM; reduces tumor growth in multiple B-RAF-mutant melanoma and colorectal carcinoma mouse xenograft models at 25 mg/kg twice per day
24273	BI-882370	10 mg	≥95%	A RAF inhibitor (IC50s = 0.8, 0.8, and 0.6 nM for B-RAFV600E, wild-type B-RAF, and C-RAF in the DFG-out inactive conformation, respectively); selective for RAF over a panel of kinases, including LCK, KIT, Src, LYNA, LYNB, and PDGFR (IC50s = 49, 415, 485, 750, 715, and 1,220 nM, respectively); inhibits proliferation of human B-RAF-mutant melanoma cells at 1-10 nM; reduces tumor growth in multiple B-RAF-mutant melanoma and colorectal carcinoma mouse xenograft models at 25 mg/kg twice per day

24273	BI-882370	25 mg	≥95%	A RAF inhibitor (IC50s = 0.8, 0.8, and 0.6 nM for B-RAFV600E, wild-type B-RAF, and C-RAF in the DFG-out inactive conformation, respectively); selective for RAF over a panel of kinases, including LCK, KIT, Src, LYNA, LYNB, and PDGFR (IC50s = 49, 415, 485, 750, 715, and 1,220 nM, respectively); inhibits proliferation of human B-RAF-mutant melanoma cells at 1-10 nM; reduces tumor growth in multiple B-RAF-mutant melanoma and colorectal carcinoma mouse xenograft models at 25 mg/kg twice per day
24273	BI-882370	5 mg	≥95%	A RAF inhibitor (IC50s = 0.8, 0.8, and 0.6 nM for B-RAFV600E, wild-type B-RAF, and C-RAF in the DFG-out inactive conformation, respectively); selective for RAF over a panel of kinases, including LCK, KIT, Src, LYNA, LYNB, and PDGFR (IC50s = 49, 415, 485, 750, 715, and 1,220 nM, respectively); inhibits proliferation of human B-RAF-mutant melanoma cells at 1-10 nM; reduces tumor growth in multiple B-RAF-mutant melanoma and colorectal carcinoma mouse xenograft models at 25 mg/kg twice per day
24304	DNA-PK Inhibitor IV	10 mg	≥98%	An inhibitor of DNA-PK (IC50 = 400 nM); also inhibits p110β, p110δ, and p110γ (IC50s = 2.8, 5.1, and 37 nM, respectively); enhances radiation-induced cytotoxicity of HCT116 cells (100 µM)
24304	DNA-PK Inhibitor IV	25 mg	≥98%	An inhibitor of DNA-PK (IC50 = 400 nM); also inhibits p110β, p110δ, and p110γ (IC50s = 2.8, 5.1, and 37 nM, respectively); enhances radiation-induced cytotoxicity of HCT116 cells (100 µM)
24304	DNA-PK Inhibitor IV	50 mg	≥98%	An inhibitor of DNA-PK (IC50 = 400 nM); also inhibits p110β, p110δ, and p110γ (IC50s = 2.8, 5.1, and 37 nM, respectively); enhances radiation-induced cytotoxicity of HCT116 cells (100 µM)
24318	Calmodulin-Depender	500 µg	≥95%	A CaMKII inhibitor (IC50 = 52 nM); inhibits CaMKII-dependent phosphodiesterase activity (IC50 = 1.1 nM)
24372	L-erythro Sphingosine	1 mg	≥98%	A bioactive sphingolipid; synthetic stereoisomer of sphingosine; inhibits PKC in vitro (IC50 = 3.3 mol%); inhibits PMA-induced superoxide generation in neutrophils and reduces growth of CHO cells (IC50s = 1.3 and 2 µM, respectively); inhibits dephosphorylation of pRB (EC50 = 5 µM) and growth of MOLT-4 cells (IC50 = 3.7 µM)
24372	L-erythro Sphingosine	500 µg	≥98%	A bioactive sphingolipid; synthetic stereoisomer of sphingosine; inhibits PKC in vitro (IC50 = 3.3 mol%); inhibits PMA-induced superoxide generation in neutrophils and reduces growth of CHO cells (IC50s = 1.3 and 2 µM, respectively); inhibits dephosphorylation of pRB (EC50 = 5 µM) and growth of MOLT-4 cells (IC50 = 3.7 µM)
24373	Sphingosine (d14:1)	1 mg	≥98%	A bioactive sphingolipid; has been found in B. mori, P. clarkii, and A. aurita extracts; increases the germination rate of N. rileyi (EC50 = 0.0102 ng/ml); inhibits PKC in vitro (IC50 = 7.3 mol %); inhibits PMA-induced superoxide generation in neutrophils and reduces growth of CHO cells (IC50s = 19 and 8 µM, respectively)
24373	Sphingosine (d14:1)	10 mg	≥98%	A bioactive sphingolipid; has been found in B. mori, P. clarkii, and A. aurita extracts; increases the germination rate of N. rileyi (EC50 = 0.0102 ng/ml); inhibits PKC in vitro (IC50 = 7.3 mol %); inhibits PMA-induced superoxide generation in neutrophils and reduces growth of CHO cells (IC50s = 19 and 8 µM, respectively)
24373	Sphingosine (d14:1)	25 mg	≥98%	A bioactive sphingolipid; has been found in B. mori, P. clarkii, and A. aurita extracts; increases the germination rate of N. rileyi (EC50 = 0.0102 ng/ml); inhibits PKC in vitro (IC50 = 7.3 mol %); inhibits PMA-induced superoxide generation in neutrophils and reduces growth of CHO cells (IC50s = 19 and 8 µM, respectively)
24373	Sphingosine (d14:1)	5 mg	≥98%	A bioactive sphingolipid; has been found in B. mori, P. clarkii, and A. aurita extracts; increases the germination rate of N. rileyi (EC50 = 0.0102 ng/ml); inhibits PKC in vitro (IC50 = 7.3 mol %); inhibits PMA-induced superoxide generation in neutrophils and reduces growth of CHO cells (IC50s = 19 and 8 µM, respectively)
24667	TA-01	1 mg	≥98%	An inducer of cardiomyocyte differentiation; increases expression of the cardiomyocyte marker NKX2-5 by 2.2-fold and decreases expression of mesoderm markers and the pre-cardiac marker Isl-1 in HES-3 NKX2-5eGFP/w cells at <5 µM; inhibits CK1ε and CK1Δ and reduces expression of Wnt/β-catenin signaling pathway members
24667	TA-01	10 mg	≥98%	An inducer of cardiomyocyte differentiation; increases expression of the cardiomyocyte marker NKX2-5 by 2.2-fold and decreases expression of mesoderm markers and the pre-cardiac marker Isl-1 in HES-3 NKX2-5eGFP/w cells at <5 µM; inhibits CK1ε and CK1Δ and reduces expression of Wnt/β-catenin signaling pathway members
24667	TA-01	25 mg	≥98%	An inducer of cardiomyocyte differentiation; increases expression of the cardiomyocyte marker NKX2-5 by 2.2-fold and decreases expression of mesoderm markers and the pre-cardiac marker Isl-1 in HES-3 NKX2-5eGFP/w cells at <5 µM; inhibits CK1ε and CK1Δ and reduces expression of Wnt/β-catenin signaling pathway members

24667	TA-01	5 mg	≥98%	An inducer of cardiomyocyte differentiation; increases expression of the cardiomyocyte marker NKX2-5 by 2.2-fold and decreases expression of mesoderm markers and the pre-cardiac marker Isl-1 in HES-3 NKX2-5eGFP/w cells at <5 µM; inhibits CK1ε and CK1Δ and reduces expression of Wnt/β-catenin signaling pathway members
24668	TA-02	10 mg	≥98%	An inducer of cardiomyocyte differentiation; increases expression of the cardiomyocyte marker NKX2-5 by >2-fold and decreases expression of mesoderm markers and the pre-cardiac marker Isl-1 in HES-3 NKX2-5eGFP/w cells at 5 µM; inhibits CK1ε and CK1D and reduces expression of Wnt/β-catenin signaling pathway members
24668	TA-02	25 mg	≥98%	An inducer of cardiomyocyte differentiation; increases expression of the cardiomyocyte marker NKX2-5 by >2-fold and decreases expression of mesoderm markers and the pre-cardiac marker Isl-1 in HES-3 NKX2-5eGFP/w cells at 5 µM; inhibits CK1ε and CK1D and reduces expression of Wnt/β-catenin signaling pathway members
24668	TA-02	5 mg	≥98%	An inducer of cardiomyocyte differentiation; increases expression of the cardiomyocyte marker NKX2-5 by >2-fold and decreases expression of mesoderm markers and the pre-cardiac marker Isl-1 in HES-3 NKX2-5eGFP/w cells at 5 µM; inhibits CK1ε and CK1D and reduces expression of Wnt/β-catenin signaling pathway members
24681	PD 161570	1 mg	≥98%	An inhibitor of FGFR1 (IC50 = 40 nM); selective for FGFR1 over PDGFβ and EGFR (IC50s = 262 and 3,700 nM, respectively); inhibits constitutive phosphorylation of FGFR1 in Sf9 insect cells overexpressing human FGFR1 and in A121 ovarian carcinoma cells; inhibits growth of A121 cells in a time-dependent manner
24681	PD 161570	10 mg	≥98%	An inhibitor of FGFR1 (IC50 = 40 nM); selective for FGFR1 over PDGFβ and EGFR (IC50s = 262 and 3,700 nM, respectively); inhibits constitutive phosphorylation of FGFR1 in Sf9 insect cells overexpressing human FGFR1 and in A121 ovarian carcinoma cells; inhibits growth of A121 cells in a time-dependent manner
24681	PD 161570	5 mg	≥98%	An inhibitor of FGFR1 (IC50 = 40 nM); selective for FGFR1 over PDGFβ and EGFR (IC50s = 262 and 3,700 nM, respectively); inhibits constitutive phosphorylation of FGFR1 in Sf9 insect cells overexpressing human FGFR1 and in A121 ovarian carcinoma cells; inhibits growth of A121 cells in a time-dependent manner
24682	FRAX486	1 mg	≥98%	A group I PAK inhibitor (IC50s = 8.25, 39.5, and 55.3 nM for PAK1, PAK2, and PAK3, respectively); selective for group I PAKs over PAK4 (IC50 = 779 nM); reverses decreases in the mean density of apical dendritic spines in the temporal cortex in the Fmr1-/- mouse model of fragile X syndrome at 20 mg/kg; completely abolishes audiogenic seizures, hyperactivity, and stereotypical movements in Fmr1-/- mice at 30 mg/kg; events adolescent cortical dendritic spine loss and rescues prepulse inhibition deficits in a Disc1 knockdown mouse model of schizophrenia
24682	FRAX486	10 mg	≥98%	A group I PAK inhibitor (IC50s = 8.25, 39.5, and 55.3 nM for PAK1, PAK2, and PAK3, respectively); selective for group I PAKs over PAK4 (IC50 = 779 nM); reverses decreases in the mean density of apical dendritic spines in the temporal cortex in the Fmr1-/- mouse model of fragile X syndrome at 20 mg/kg; completely abolishes audiogenic seizures, hyperactivity, and stereotypical movements in Fmr1-/- mice at 30 mg/kg; events adolescent cortical dendritic spine loss and rescues prepulse inhibition deficits in a Disc1 knockdown mouse model of schizophrenia
24682	FRAX486	25 mg	≥98%	A group I PAK inhibitor (IC50s = 8.25, 39.5, and 55.3 nM for PAK1, PAK2, and PAK3, respectively); selective for group I PAKs over PAK4 (IC50 = 779 nM); reverses decreases in the mean density of apical dendritic spines in the temporal cortex in the Fmr1-/- mouse model of fragile X syndrome at 20 mg/kg; completely abolishes audiogenic seizures, hyperactivity, and stereotypical movements in Fmr1-/- mice at 30 mg/kg; events adolescent cortical dendritic spine loss and rescues prepulse inhibition deficits in a Disc1 knockdown mouse model of schizophrenia
24682	FRAX486	5 mg	≥98%	A group I PAK inhibitor (IC50s = 8.25, 39.5, and 55.3 nM for PAK1, PAK2, and PAK3, respectively); selective for group I PAKs over PAK4 (IC50 = 779 nM); reverses decreases in the mean density of apical dendritic spines in the temporal cortex in the Fmr1-/- mouse model of fragile X syndrome at 20 mg/kg; completely abolishes audiogenic seizures, hyperactivity, and stereotypical movements in Fmr1-/- mice at 30 mg/kg; events adolescent cortical dendritic spine loss and rescues prepulse inhibition deficits in a Disc1 knockdown mouse model of schizophrenia
24684	Centrinone	1 mg	≥95%	A Plk4 inhibitor (Ki = 0.16 nM); >1,100- and >2,800-fold selective for Plk4 over Aurora A and Aurora B kinases, respectively, and a panel of 442 kinases at 100 nM; depletes centrosomes and induces apoptosis in HeLa cells at 125 nM
24684	Centrinone	10 mg	≥95%	A Plk4 inhibitor (Ki = 0.16 nM); >1,100- and >2,800-fold selective for Plk4 over Aurora A and Aurora B kinases, respectively, and a panel of 442 kinases at 100 nM; depletes centrosomes and induces apoptosis in HeLa cells at 125 nM
24684	Centrinone	25 mg	≥95%	A Plk4 inhibitor (Ki = 0.16 nM); >1,100- and >2,800-fold selective for Plk4 over Aurora A and Aurora B kinases, respectively, and a panel of 442 kinases at 100 nM; depletes centrosomes and induces apoptosis in HeLa cells at 125 nM

24684	Centrinone	5 mg	≥95%	A Plk4 inhibitor (Ki = 0.16 nM); >1,100- and >2,800-fold selective for Plk4 over Aurora A and Aurora B kinases, respectively, and a panel of 442 kinases at 100 nM; depletes centrosomes and induces apoptosis in HeLa cells at 125 nM
24880	SKI 178	10 mg	≥98%	A non-selective inhibitor of SPHK1 and SPHK2; inhibits SPHK1 by 59.6% when used at a concentration of 10.7 µM; cytotoxic to a variety of cancer cell lines including PANC-1, A549, U251, and MCF-7 cells (IC50s = 0.1, 0.3, 0.5, and 1.3 µM, respectively); reduces the number of white blood cells to a normal range and increases survival in an MLL-AF9 AML mouse xenograft model; destabilizes and inhibits microtubule polymerization in an SPHK-independent manner
24880	SKI 178	5 mg	≥98%	A non-selective inhibitor of SPHK1 and SPHK2; inhibits SPHK1 by 59.6% when used at a concentration of 10.7 µM; cytotoxic to a variety of cancer cell lines including PANC-1, A549, U251, and MCF-7 cells (IC50s = 0.1, 0.3, 0.5, and 1.3 µM, respectively); reduces the number of white blood cells to a normal range and increases survival in an MLL-AF9 AML mouse xenograft model; destabilizes and inhibits microtubule polymerization in an SPHK-independent manner
24904	GSK1838705A	10 mg	≥95%	An IGF-1R and IR inhibitor (IC50s = 2 and 1.6 nM, respectively); selective for IGF-1R and IR over a panel of 47 kinases (IC50s = >1,600 nM); inhibits ALK (IC50 = 0.5 nM); inhibits ligand-induced phosphorylation of IGF-1R and IR as well as phosphorylation of Akt, IRS-1, and ERK in MCF-7 breast carcinoma cells; inhibits the growth of a panel of cancer cell lines (EC50s = 24-8,378 nM); completely inhibits IGF-1-induced phosphorylation of IGF-IR, Akt, and IRS-1 as well as reduces tumor growth in the COLO 205 and NIH-3T2/LISN mouse xenograft models at ≥1 and ≥10 mg/kg, respectively; induces tumor cell apoptosis and reduces tumor growth in U87MG glioma and PC3R prostate cancer mouse xenograft models
24904	GSK1838705A	25 mg	≥95%	An IGF-1R and IR inhibitor (IC50s = 2 and 1.6 nM, respectively); selective for IGF-1R and IR over a panel of 47 kinases (IC50s = >1,600 nM); inhibits ALK (IC50 = 0.5 nM); inhibits ligand-induced phosphorylation of IGF-1R and IR as well as phosphorylation of Akt, IRS-1, and ERK in MCF-7 breast carcinoma cells; inhibits the growth of a panel of cancer cell lines (EC50s = 24-8,378 nM); completely inhibits IGF-1-induced phosphorylation of IGF-IR, Akt, and IRS-1 as well as reduces tumor growth in the COLO 205 and NIH-3T2/LISN mouse xenograft models at ≥1 and ≥10 mg/kg, respectively; induces tumor cell apoptosis and reduces tumor growth in U87MG glioma and PC3R prostate cancer mouse xenograft models
24904	GSK1838705A	5 mg	≥95%	An IGF-1R and IR inhibitor (IC50s = 2 and 1.6 nM, respectively); selective for IGF-1R and IR over a panel of 47 kinases (IC50s = >1,600 nM); inhibits ALK (IC50 = 0.5 nM); inhibits ligand-induced phosphorylation of IGF-1R and IR as well as phosphorylation of Akt, IRS-1, and ERK in MCF-7 breast carcinoma cells; inhibits the growth of a panel of cancer cell lines (EC50s = 24-8,378 nM); completely inhibits IGF-1-induced phosphorylation of IGF-IR, Akt, and IRS-1 as well as reduces tumor growth in the COLO 205 and NIH-3T2/LISN mouse xenograft models at ≥1 and ≥10 mg/kg, respectively; induces tumor cell apoptosis and reduces tumor growth in U87MG glioma and PC3R prostate cancer mouse xenograft models
24904	GSK1838705A	50 mg	≥95%	An IGF-1R and IR inhibitor (IC50s = 2 and 1.6 nM, respectively); selective for IGF-1R and IR over a panel of 47 kinases (IC50s = >1,600 nM); inhibits ALK (IC50 = 0.5 nM); inhibits ligand-induced phosphorylation of IGF-1R and IR as well as phosphorylation of Akt, IRS-1, and ERK in MCF-7 breast carcinoma cells; inhibits the growth of a panel of cancer cell lines (EC50s = 24-8,378 nM); completely inhibits IGF-1-induced phosphorylation of IGF-IR, Akt, and IRS-1 as well as reduces tumor growth in the COLO 205 and NIH-3T2/LISN mouse xenograft models at ≥1 and ≥10 mg/kg, respectively; induces tumor cell apoptosis and reduces tumor growth in U87MG glioma and PC3R prostate cancer mouse xenograft models
24906	XL413 (hydrochloride)	10 mg	≥98%	A potent inhibitor of Cdc7 (IC50 = 3.4 nM); >60, >10, and >300-fold selective for Cdc7 over CK2, PIM1, and a panel of over 100 protein kinases, respectively; inhibits the growth of MDA-MB-231T and COLO 205 cells (IC50s = 118 and 140 nM, respectively); inhibits Cdc7-specific phosphorylation of MCM2 and induces cell cycle accumulation in the S and G2 phases in MDA-MB-231T and COLO 205 cells; inhibits MCM2 phosphorylation (ED50 = <3 mg/kg) and reduces tumor growth in a COLO 205 mouse xenograft model at 10, 30, and 100 mg/kg
24906	XL413 (hydrochloride)	25 mg	≥98%	A potent inhibitor of Cdc7 (IC50 = 3.4 nM); >60, >10, and >300-fold selective for Cdc7 over CK2, PIM1, and a panel of over 100 protein kinases, respectively; inhibits the growth of MDA-MB-231T and COLO 205 cells (IC50s = 118 and 140 nM, respectively); inhibits Cdc7-specific phosphorylation of MCM2 and induces cell cycle accumulation in the S and G2 phases in MDA-MB-231T and COLO 205 cells; inhibits MCM2 phosphorylation (ED50 = <3 mg/kg) and reduces tumor growth in a COLO 205 mouse xenograft model at 10, 30, and 100 mg/kg
24906	XL413 (hydrochloride)	5 mg	≥98%	A potent inhibitor of Cdc7 (IC50 = 3.4 nM); >60, >10, and >300-fold selective for Cdc7 over CK2, PIM1, and a panel of over 100 protein kinases, respectively; inhibits the growth of MDA-MB-231T and COLO 205 cells (IC50s = 118 and 140 nM, respectively); inhibits Cdc7-specific phosphorylation of MCM2 and induces cell cycle accumulation in the S and G2 phases in MDA-MB-231T and COLO 205 cells; inhibits MCM2 phosphorylation (ED50 = <3 mg/kg) and reduces tumor growth in a COLO 205 mouse xenograft model at 10, 30, and 100 mg/kg

24906	XL413 (hydrochloride)	50 mg	≥98%	A potent inhibitor of Cdc7 (IC50 = 3.4 nM); >60, >10, and >300-fold selective for Cdc7 over CK2, PIM1, and a panel of over 100 protein kinases, respectively; inhibits the growth of MDA-MB-231T and COLO 205 cells (IC50s = 118 and 140 nM, respectively); inhibits Cdc7-specific phosphorylation of MCM2 and induces cell cycle accumulation in the S and G2 phases in MDA-MB-231T and COLO 205 cells; inhibits MCM2 phosphorylation (ED50 = <3 mg/kg) and reduces tumor growth in a COLO 205 mouse xenograft model at 10, 30, and 100 mg/kg
24965	Verbascoside	1 mg	≥98%	A natural phenylpropanoid glucoside; inhibits PKC (IC50 = 25 µM); inhibits the growth of Gram-positive and Gram-negative bacteria, including S. aureus and E. coli (MICs = 16 and 32 µg/ml, respectively); dose-dependently reduces extracellular hydrogen peroxide and increases cell viability of PC12 cells at 0.1-10 µg/ml following MPP+ administration to induce apoptosis and oxidative stress; dose-dependently inhibits the growth of MGC803 adenocarcinoma cells at 10-20 µM; reduces colon damage and the expression of TNF-α, IL-1β, and iNOS in a rat model of DNBS-induced colitis at 0.2-2 mg/kg
24965	Verbascoside	10 mg	≥98%	A natural phenylpropanoid glucoside; inhibits PKC (IC50 = 25 µM); inhibits the growth of Gram-positive and Gram-negative bacteria, including S. aureus and E. coli (MICs = 16 and 32 µg/ml, respectively); dose-dependently reduces extracellular hydrogen peroxide and increases cell viability of PC12 cells at 0.1-10 µg/ml following MPP+ administration to induce apoptosis and oxidative stress; dose-dependently inhibits the growth of MGC803 adenocarcinoma cells at 10-20 µM; reduces colon damage and the expression of TNF-α, IL-1β, and iNOS in a rat model of DNBS-induced colitis at 0.2-2 mg/kg
24965	Verbascoside	25 mg	≥98%	A natural phenylpropanoid glucoside; inhibits PKC (IC50 = 25 µM); inhibits the growth of Gram-positive and Gram-negative bacteria, including S. aureus and E. coli (MICs = 16 and 32 µg/ml, respectively); dose-dependently reduces extracellular hydrogen peroxide and increases cell viability of PC12 cells at 0.1-10 µg/ml following MPP+ administration to induce apoptosis and oxidative stress; dose-dependently inhibits the growth of MGC803 adenocarcinoma cells at 10-20 µM; reduces colon damage and the expression of TNF-α, IL-1β, and iNOS in a rat model of DNBS-induced colitis at 0.2-2 mg/kg
24965	Verbascoside	5 mg	≥98%	A natural phenylpropanoid glucoside; inhibits PKC (IC50 = 25 µM); inhibits the growth of Gram-positive and Gram-negative bacteria, including S. aureus and E. coli (MICs = 16 and 32 µg/ml, respectively); dose-dependently reduces extracellular hydrogen peroxide and increases cell viability of PC12 cells at 0.1-10 µg/ml following MPP+ administration to induce apoptosis and oxidative stress; dose-dependently inhibits the growth of MGC803 adenocarcinoma cells at 10-20 µM; reduces colon damage and the expression of TNF-α, IL-1β, and iNOS in a rat model of DNBS-induced colitis at 0.2-2 mg/kg
24968	Schizandrin B	1 mg	≥98%	A dibenzocyclooctadiene with diverse biological activities; completely inhibits anti-CD3- and anti-CD28-induced release of IL-2, IL-3, IL-4, IL-6, and IFN-γ in T cells at 50 µM; reduces cell survival and UV-induced phosphorylation of p53 and Chk1 from 1-30 µM; reduces ATR kinase activity (IC50 = 7.25 µM); inhibits doxorubicin-induced lipid peroxidation, formation of DNA strand breaks, and NADPH oxidase-dependent oxygen production in mouse heart from 25-100 mg/kg; reduces the expression of p53, 3-nitrotyrosine, phosphorylated p38 MAPK and MAPKAPK-2, and MMP-2 and MMP-9; reduces tert-butylhydroperoxide-induced mortality and malondialdehyde formation and increases GSH levels and GSH-Px activity in mouse brain.
24968	Schizandrin B	10 mg	≥98%	A dibenzocyclooctadiene with diverse biological activities; completely inhibits anti-CD3- and anti-CD28-induced release of IL-2, IL-3, IL-4, IL-6, and IFN-γ in T cells at 50 µM; reduces cell survival and UV-induced phosphorylation of p53 and Chk1 from 1-30 µM; reduces ATR kinase activity (IC50 = 7.25 µM); inhibits doxorubicin-induced lipid peroxidation, formation of DNA strand breaks, and NADPH oxidase-dependent oxygen production in mouse heart from 25-100 mg/kg; reduces the expression of p53, 3-nitrotyrosine, phosphorylated p38 MAPK and MAPKAPK-2, and MMP-2 and MMP-9; reduces tert-butylhydroperoxide-induced mortality and malondialdehyde formation and increases GSH levels and GSH-Px activity in mouse brain.
24968	Schizandrin B	25 mg	≥98%	A dibenzocyclooctadiene with diverse biological activities; completely inhibits anti-CD3- and anti-CD28-induced release of IL-2, IL-3, IL-4, IL-6, and IFN-γ in T cells at 50 µM; reduces cell survival and UV-induced phosphorylation of p53 and Chk1 from 1-30 µM; reduces ATR kinase activity (IC50 = 7.25 µM); inhibits doxorubicin-induced lipid peroxidation, formation of DNA strand breaks, and NADPH oxidase-dependent oxygen production in mouse heart from 25-100 mg/kg; reduces the expression of p53, 3-nitrotyrosine, phosphorylated p38 MAPK and MAPKAPK-2, and MMP-2 and MMP-9; reduces tert-butylhydroperoxide-induced mortality and malondialdehyde formation and increases GSH levels and GSH-Px activity in mouse brain.

24968	Schizandrin B	5 mg	≥98%	A dibenzocyclooctadiene with diverse biological activities; completely inhibits anti-CD3- and anti-CD28-induced release of IL-2, IL-3, IL-4, IL-6, and IFN-γ in T cells at 50 µM; reduces cell survival and UV-induced phosphorylation of p53 and Chk1 from 1-30 µM; reduces ATR kinase activity (IC50 = 7.25 µM); inhibits doxorubicin-induced lipid peroxidation, formation of DNA strand breaks, and NADPH oxidase-dependent oxygen production in mouse heart from 25-100 mg/kg; reduces the expression of p53, 3-nitrotyrosine, phosphorylated p38 MAPK and MAPKAPK-2, and MMP-2 and MMP-9; reduces tert-butylhydroperoxide-induced mortality and malondialdehyde formation and increases GSH levels and GSH-Px activity in mouse brain.
25046	Tofacitinib-d3 (citrate	1 mg	≥99% deutera	An internal standard for the quantification of tofacitinib by GC- or LC-MS
25058	Alkannin	1 mg	≥98%	A naphthoquinone with diverse biological activities; enantiomer of shikonin; selectively inhibits tumor-specific PKM2 (IC50 = 0.3 µM) over PKM1 and PKL; inhibits proliferation of HCT116 and SW480 colorectal cancer cells (IC50s = 2.38 and 4.53 µM, respectively); halts the cell cycle at the G1 phase and induces apoptosis in HCT116 cells at 3 µM; increases levels of Hsp70 in untreated and UVB-irradiated HaCaT cells as well as inhibits UVB-induced DNA fragmentation and caspase-3 activity in HaCaT cells at 1 µM; active against methicillin-sensitive and -resistant S. aureus (MICs = 6.25 µg/ml) as well as vancomycin-sensitive and -resistant E. faecalis (MICs = 50 and 25 µg/ml, respectively); scavenges DPPH radicals in a cell-free assay (EC50 = 22 ppm)
25058	Alkannin	10 mg	≥98%	A naphthoquinone with diverse biological activities; enantiomer of shikonin; selectively inhibits tumor-specific PKM2 (IC50 = 0.3 µM) over PKM1 and PKL; inhibits proliferation of HCT116 and SW480 colorectal cancer cells (IC50s = 2.38 and 4.53 µM, respectively); halts the cell cycle at the G1 phase and induces apoptosis in HCT116 cells at 3 µM; increases levels of Hsp70 in untreated and UVB-irradiated HaCaT cells as well as inhibits UVB-induced DNA fragmentation and caspase-3 activity in HaCaT cells at 1 µM; active against methicillin-sensitive and -resistant S. aureus (MICs = 6.25 µg/ml) as well as vancomycin-sensitive and -resistant E. faecalis (MICs = 50 and 25 µg/ml, respectively); scavenges DPPH radicals in a cell-free assay (EC50 = 22 ppm)
25058	Alkannin	25 mg	≥98%	A naphthoquinone with diverse biological activities; enantiomer of shikonin; selectively inhibits tumor-specific PKM2 (IC50 = 0.3 µM) over PKM1 and PKL; inhibits proliferation of HCT116 and SW480 colorectal cancer cells (IC50s = 2.38 and 4.53 µM, respectively); halts the cell cycle at the G1 phase and induces apoptosis in HCT116 cells at 3 µM; increases levels of Hsp70 in untreated and UVB-irradiated HaCaT cells as well as inhibits UVB-induced DNA fragmentation and caspase-3 activity in HaCaT cells at 1 µM; active against methicillin-sensitive and -resistant S. aureus (MICs = 6.25 µg/ml) as well as vancomycin-sensitive and -resistant E. faecalis (MICs = 50 and 25 µg/ml, respectively); scavenges DPPH radicals in a cell-free assay (EC50 = 22 ppm)
25058	Alkannin	5 mg	≥98%	A naphthoquinone with diverse biological activities; enantiomer of shikonin; selectively inhibits tumor-specific PKM2 (IC50 = 0.3 µM) over PKM1 and PKL; inhibits proliferation of HCT116 and SW480 colorectal cancer cells (IC50s = 2.38 and 4.53 µM, respectively); halts the cell cycle at the G1 phase and induces apoptosis in HCT116 cells at 3 µM; increases levels of Hsp70 in untreated and UVB-irradiated HaCaT cells as well as inhibits UVB-induced DNA fragmentation and caspase-3 activity in HaCaT cells at 1 µM; active against methicillin-sensitive and -resistant S. aureus (MICs = 6.25 µg/ml) as well as vancomycin-sensitive and -resistant E. faecalis (MICs = 50 and 25 µg/ml, respectively); scavenges DPPH radicals in a cell-free assay (EC50 = 22 ppm)
25233	Ningetinib	1 mg	≥98%	A multi-kinase inhibitor; inhibits c-Met, VEGFR2/KDR, and Axl (IC50s = 19, 37, and 11 nM, respectively); inhibits tumor growth in MKN45, Caki-1, NCI-H441, Huh-7, U87MG, and MDA-MB-231 mouse xenograft models by 53-97% at 20 mg/kg
25233	Ningetinib	10 mg	≥98%	A multi-kinase inhibitor; inhibits c-Met, VEGFR2/KDR, and Axl (IC50s = 19, 37, and 11 nM, respectively); inhibits tumor growth in MKN45, Caki-1, NCI-H441, Huh-7, U87MG, and MDA-MB-231 mouse xenograft models by 53-97% at 20 mg/kg
25233	Ningetinib	25 mg	≥98%	A multi-kinase inhibitor; inhibits c-Met, VEGFR2/KDR, and Axl (IC50s = 19, 37, and 11 nM, respectively); inhibits tumor growth in MKN45, Caki-1, NCI-H441, Huh-7, U87MG, and MDA-MB-231 mouse xenograft models by 53-97% at 20 mg/kg
25233	Ningetinib	5 mg	≥98%	A multi-kinase inhibitor; inhibits c-Met, VEGFR2/KDR, and Axl (IC50s = 19, 37, and 11 nM, respectively); inhibits tumor growth in MKN45, Caki-1, NCI-H441, Huh-7, U87MG, and MDA-MB-231 mouse xenograft models by 53-97% at 20 mg/kg

25275	ALW-II-41-27	1 mg	≥95%	A multi-kinase inhibitor; inhibits EphB2, EphA3, Kit, FMS, VEGFR2/KDR, FLT1, FGR, Src, Lyn, BMX, and Bcr-Abl in tyrosine kinase-transformed Ba/F3 cells (EC50s = 50s = 51 and 14 nM, respectively); inhibits wild-type and mutant RET kinases (IC50s = 24.7, 94.2, and 15.8 nM for wild-type, RETV804L, and RETV804M, respectively); reduces growth of NCI-H2286 and HCC-366 cancer cells (GI50s = 0.51 and 0.65 µM, respectively) and RAT1 cells transformed by RETC634R or RETM918T (IC50s = 44 and 56 nM, respectively); inhibits tumor growth in vivo in a mouse PDX model of EphA2-overexpressing TNBC
25275	ALW-II-41-27	10 mg	≥95%	A multi-kinase inhibitor; inhibits EphB2, EphA3, Kit, FMS, VEGFR2/KDR, FLT1, FGR, Src, Lyn, BMX, and Bcr-Abl in tyrosine kinase-transformed Ba/F3 cells (EC50s = 50s = 51 and 14 nM, respectively); inhibits wild-type and mutant RET kinases (IC50s = 24.7, 94.2, and 15.8 nM for wild-type, RETV804L, and RETV804M, respectively); reduces growth of NCI-H2286 and HCC-366 cancer cells (GI50s = 0.51 and 0.65 µM, respectively) and RAT1 cells transformed by RETC634R or RETM918T (IC50s = 44 and 56 nM, respectively); inhibits tumor growth in vivo in a mouse PDX model of EphA2-overexpressing TNBC
25275	ALW-II-41-27	5 mg	≥95%	A multi-kinase inhibitor; inhibits EphB2, EphA3, Kit, FMS, VEGFR2/KDR, FLT1, FGR, Src, Lyn, BMX, and Bcr-Abl in tyrosine kinase-transformed Ba/F3 cells (EC50s = 50s = 51 and 14 nM, respectively); inhibits wild-type and mutant RET kinases (IC50s = 24.7, 94.2, and 15.8 nM for wild-type, RETV804L, and RETV804M, respectively); reduces growth of NCI-H2286 and HCC-366 cancer cells (GI50s = 0.51 and 0.65 µM, respectively) and RAT1 cells transformed by RETC634R or RETM918T (IC50s = 44 and 56 nM, respectively); inhibits tumor growth in vivo in a mouse PDX model of EphA2-overexpressing TNBC
25276	LY3200882	1 mg	≥95%	An inhibitor of TGF-βRI; inhibits TGF-β-induced SMAD phosphorylation in vitro and in vivo; exhibits antitumor activity in the 4T1-LP triple negative breast cancer orthotopic tumor model
25276	LY3200882	10 mg	≥95%	An inhibitor of TGF-βRI; inhibits TGF-β-induced SMAD phosphorylation in vitro and in vivo; exhibits antitumor activity in the 4T1-LP triple negative breast cancer orthotopic tumor model
25276	LY3200882	25 mg	≥95%	An inhibitor of TGF-βRI; inhibits TGF-β-induced SMAD phosphorylation in vitro and in vivo; exhibits antitumor activity in the 4T1-LP triple negative breast cancer orthotopic tumor model
25276	LY3200882	5 mg	≥95%	An inhibitor of TGF-βRI; inhibits TGF-β-induced SMAD phosphorylation in vitro and in vivo; exhibits antitumor activity in the 4T1-LP triple negative breast cancer orthotopic tumor model
25312	BIBF 1120-13C-d3	1 mg	≥99% deutera	An internal standard for the quantification of BIBF 1120 by GC- or LC-MS
25312	BIBF 1120-13C-d3	500 µg	≥99% deutera	An internal standard for the quantification of BIBF 1120 by GC- or LC-MS
25339	AMG 47a	10 mg	≥98%	A multi-kinase inhibitor; inhibits Lck, VEGFR2/KDR, p38α, and JAK3 (IC50s = 0.2, 1, 3, and 72 nM, respectively); selective for these kinases over a panel of additional kinases including SYK, JNK1, and PKAβ (IC50s = 292 to >25,000 nM) but does inhibit Src (IC50 = 2 nM); inhibits T cell proliferation in vitro in a mixed lymphocyte reaction assay (IC50 = 30 nM); decreases production of IL-2 induced by an anti-CD3 antibody in mice at 10, 30, and 100 mg/kg; decreases levels of mutant oncogene KRASG12V in HeLa cells in a reporter assay at 1 µM
25339	AMG 47a	25 mg	≥98%	A multi-kinase inhibitor; inhibits Lck, VEGFR2/KDR, p38α, and JAK3 (IC50s = 0.2, 1, 3, and 72 nM, respectively); selective for these kinases over a panel of additional kinases including SYK, JNK1, and PKAβ (IC50s = 292 to >25,000 nM) but does inhibit Src (IC50 = 2 nM); inhibits T cell proliferation in vitro in a mixed lymphocyte reaction assay (IC50 = 30 nM); decreases production of IL-2 induced by an anti-CD3 antibody in mice at 10, 30, and 100 mg/kg; decreases levels of mutant oncogene KRASG12V in HeLa cells in a reporter assay at 1 µM
25339	AMG 47a	5 mg	≥98%	A multi-kinase inhibitor; inhibits Lck, VEGFR2/KDR, p38α, and JAK3 (IC50s = 0.2, 1, 3, and 72 nM, respectively); selective for these kinases over a panel of additional kinases including SYK, JNK1, and PKAβ (IC50s = 292 to >25,000 nM) but does inhibit Src (IC50 = 2 nM); inhibits T cell proliferation in vitro in a mixed lymphocyte reaction assay (IC50 = 30 nM); decreases production of IL-2 induced by an anti-CD3 antibody in mice at 10, 30, and 100 mg/kg; decreases levels of mutant oncogene KRASG12V in HeLa cells in a reporter assay at 1 µM
25339	AMG 47a	50 mg	≥98%	A multi-kinase inhibitor; inhibits Lck, VEGFR2/KDR, p38α, and JAK3 (IC50s = 0.2, 1, 3, and 72 nM, respectively); selective for these kinases over a panel of additional kinases including SYK, JNK1, and PKAβ (IC50s = 292 to >25,000 nM) but does inhibit Src (IC50 = 2 nM); inhibits T cell proliferation in vitro in a mixed lymphocyte reaction assay (IC50 = 30 nM); decreases production of IL-2 induced by an anti-CD3 antibody in mice at 10, 30, and 100 mg/kg; decreases levels of mutant oncogene KRASG12V in HeLa cells in a reporter assay at 1 µM

25402	Micheliolide	1 mg	≥98%	A sesquiterpene lactone with diverse biological activities; an irreversible activator of PKM2 (EC50 = 6 nM); decreases viability of HL-60 cells at 5-20 μM; reduces M. tuberculosis-induced secretion of IL-1β and TNF-α, expression of COX-2, and production of NO in RAW 264.7 cells; decreases the severity of CIA in a mouse model of rheumatoid arthritis at 30 mg/kg
25402	Micheliolide	10 mg	≥98%	A sesquiterpene lactone with diverse biological activities; an irreversible activator of PKM2 (EC50 = 6 nM); decreases viability of HL-60 cells at 5-20 μM; reduces M. tuberculosis-induced secretion of IL-1β and TNF-α, expression of COX-2, and production of NO in RAW 264.7 cells; decreases the severity of CIA in a mouse model of rheumatoid arthritis at 30 mg/kg
25402	Micheliolide	25 mg	≥98%	A sesquiterpene lactone with diverse biological activities; an irreversible activator of PKM2 (EC50 = 6 nM); decreases viability of HL-60 cells at 5-20 μM; reduces M. tuberculosis-induced secretion of IL-1β and TNF-α, expression of COX-2, and production of NO in RAW 264.7 cells; decreases the severity of CIA in a mouse model of rheumatoid arthritis at 30 mg/kg
25402	Micheliolide	5 mg	≥98%	A sesquiterpene lactone with diverse biological activities; an irreversible activator of PKM2 (EC50 = 6 nM); decreases viability of HL-60 cells at 5-20 μM; reduces M. tuberculosis-induced secretion of IL-1β and TNF-α, expression of COX-2, and production of NO in RAW 264.7 cells; decreases the severity of CIA in a mouse model of rheumatoid arthritis at 30 mg/kg
25417	CP 466,722	1 mg	≥98%	An ATM kinase inhibitor; inhibits ionizing radiation-induced ATM autophosphorylation and phosphorylation of ATM targets in HeLa cells at 10 μM; selective for ATM over PI3K and PIKK in HFF(hTERT) and A-T(hTERT) fibroblasts, respectively; decreases cell survival in response to ionizing radiation in HeLa cells; cytotoxic to MCF-7 and SKBr-3 breast cancer cells (IC50s = 16.92 and 12.78 μM, respectively)
25417	CP 466,722	10 mg	≥98%	An ATM kinase inhibitor; inhibits ionizing radiation-induced ATM autophosphorylation and phosphorylation of ATM targets in HeLa cells at 10 μM; selective for ATM over PI3K and PIKK in HFF(hTERT) and A-T(hTERT) fibroblasts, respectively; decreases cell survival in response to ionizing radiation in HeLa cells; cytotoxic to MCF-7 and SKBr-3 breast cancer cells (IC50s = 16.92 and 12.78 μM, respectively)
25417	CP 466,722	25 mg	≥98%	An ATM kinase inhibitor; inhibits ionizing radiation-induced ATM autophosphorylation and phosphorylation of ATM targets in HeLa cells at 10 μM; selective for ATM over PI3K and PIKK in HFF(hTERT) and A-T(hTERT) fibroblasts, respectively; decreases cell survival in response to ionizing radiation in HeLa cells; cytotoxic to MCF-7 and SKBr-3 breast cancer cells (IC50s = 16.92 and 12.78 μM, respectively)
25417	CP 466,722	5 mg	≥98%	An ATM kinase inhibitor; inhibits ionizing radiation-induced ATM autophosphorylation and phosphorylation of ATM targets in HeLa cells at 10 μM; selective for ATM over PI3K and PIKK in HFF(hTERT) and A-T(hTERT) fibroblasts, respectively; decreases cell survival in response to ionizing radiation in HeLa cells; cytotoxic to MCF-7 and SKBr-3 breast cancer cells (IC50s = 16.92 and 12.78 μM, respectively)
25421	PD 0332991-d8	1 mg	≥99% deutera	An internal standard for the quantification of PD 0332991 by GC- or LC-MS
25421	PD 0332991-d8	500 μg	≥99% deutera	An internal standard for the quantification of PD 0332991 by GC- or LC-MS
25446	Pazopanib-d6	1 mg	≥99% deutera	An internal standard for the quantification of pazopanib by GC- or LC-MS
25446	Pazopanib-d6	500 μg	≥99% deutera	An internal standard for the quantification of pazopanib by GC- or LC-MS
25448	XMD17-109	1 mg	≥98%	A selective ERK5 inhibitor (IC50 = 0.162 μM in an enzyme assay); selective for ERK5 over a panel of more than 200 kinases at 10 μM; inhibits ERK5 phosphorylation (IC50 = 0.09 μM in HeLa cells); decreases AP-1 transcriptional activity (EC50 = 4.2 μM); inhibits human recombinant LRRK2[G2019S] (IC50 = 0.339 μM in an enzyme assay)
25448	XMD17-109	10 mg	≥98%	A selective ERK5 inhibitor (IC50 = 0.162 μM in an enzyme assay); selective for ERK5 over a panel of more than 200 kinases at 10 μM; inhibits ERK5 phosphorylation (IC50 = 0.09 μM in HeLa cells); decreases AP-1 transcriptional activity (EC50 = 4.2 μM); inhibits human recombinant LRRK2[G2019S] (IC50 = 0.339 μM in an enzyme assay)
25448	XMD17-109	25 mg	≥98%	A selective ERK5 inhibitor (IC50 = 0.162 μM in an enzyme assay); selective for ERK5 over a panel of more than 200 kinases at 10 μM; inhibits ERK5 phosphorylation (IC50 = 0.09 μM in HeLa cells); decreases AP-1 transcriptional activity (EC50 = 4.2 μM); inhibits human recombinant LRRK2[G2019S] (IC50 = 0.339 μM in an enzyme assay)
25448	XMD17-109	5 mg	≥98%	A selective ERK5 inhibitor (IC50 = 0.162 μM in an enzyme assay); selective for ERK5 over a panel of more than 200 kinases at 10 μM; inhibits ERK5 phosphorylation (IC50 = 0.09 μM in HeLa cells); decreases AP-1 transcriptional activity (EC50 = 4.2 μM); inhibits human recombinant LRRK2[G2019S] (IC50 = 0.339 μM in an enzyme assay)
25459	Lapatinib-d4 (tosylate	1 mg	≥99% deutera	An internal standard for the quantification of lapatinib by GC- or LC-MS
25459	Lapatinib-d4 (tosylate	500 μg	≥99% deutera	An internal standard for the quantification of lapatinib by GC- or LC-MS
25460	Bosutinib-d8	1 mg	≥99% deutera	An internal standard for the quantification of bosutinib by GC- or LC-MS

25460	Bosutinib-d8	500 µg	≥99% deutera	An internal standard for the quantification of bosutinib by GC- or LC-MS
25486	Regorafenib-13C-d3	1 mg	≥99% deutera	An internal standard for the quantification of regorafenib by GC- or LC-MS
25486	Regorafenib-13C-d3	500 µg	≥99% deutera	An internal standard for the quantification of regorafenib by GC- or LC-MS
25536	CCT241161	1 mg	≥98%	A multi-kinase inhibitor; inhibits B-RAF, B-RAFV600E, C-RAF, Src, and LCK (IC50s = 252, 15, 6, 15, and 3 nM, respectively); only inhibits RAFs, Src, LCK, and MAPKs in a panel of 63 kinases at 1 µM; inhibits MEK and ERK signaling in B-RAF mutant WM266.4 cells; inhibits growth of B-RAF mutant melanoma cells; induces tumor regression in a B-RAF mutant A375 mouse xenograft model at 20 mg/kg per day; inhibits ERK and Src signaling and induces tumor regression in B-RAF inhibitor-resistant PDX mouse models
25536	CCT241161	10 mg	≥98%	A multi-kinase inhibitor; inhibits B-RAF, B-RAFV600E, C-RAF, Src, and LCK (IC50s = 252, 15, 6, 15, and 3 nM, respectively); only inhibits RAFs, Src, LCK, and MAPKs in a panel of 63 kinases at 1 µM; inhibits MEK and ERK signaling in B-RAF mutant WM266.4 cells; inhibits growth of B-RAF mutant melanoma cells; induces tumor regression in a B-RAF mutant A375 mouse xenograft model at 20 mg/kg per day; inhibits ERK and Src signaling and induces tumor regression in B-RAF inhibitor-resistant PDX mouse models
25536	CCT241161	5 mg	≥98%	A multi-kinase inhibitor; inhibits B-RAF, B-RAFV600E, C-RAF, Src, and LCK (IC50s = 252, 15, 6, 15, and 3 nM, respectively); only inhibits RAFs, Src, LCK, and MAPKs in a panel of 63 kinases at 1 µM; inhibits MEK and ERK signaling in B-RAF mutant WM266.4 cells; inhibits growth of B-RAF mutant melanoma cells; induces tumor regression in a B-RAF mutant A375 mouse xenograft model at 20 mg/kg per day; inhibits ERK and Src signaling and induces tumor regression in B-RAF inhibitor-resistant PDX mouse models
25536	CCT241161	500 µg	≥98%	A multi-kinase inhibitor; inhibits B-RAF, B-RAFV600E, C-RAF, Src, and LCK (IC50s = 252, 15, 6, 15, and 3 nM, respectively); only inhibits RAFs, Src, LCK, and MAPKs in a panel of 63 kinases at 1 µM; inhibits MEK and ERK signaling in B-RAF mutant WM266.4 cells; inhibits growth of B-RAF mutant melanoma cells; induces tumor regression in a B-RAF mutant A375 mouse xenograft model at 20 mg/kg per day; inhibits ERK and Src signaling and induces tumor regression in B-RAF inhibitor-resistant PDX mouse models
25537	CCT196969	1 mg	≥95%	A multi-kinase inhibitor; inhibits B-RAF, B-RAFV600E, C-RAF, Src, and LCK (IC50s = 100, 40, 12, 26, and 14 nM, respectively); only inhibits RAFs, Src, LCK, and MAPKs in a panel of 63 kinases at 1 µM; inhibits MEK and ERK signaling in B-RAF mutant WM266.4 cells; inhibits growth of B-RAF mutant melanoma cells; induces tumor regression in a B-RAF mutant A375 mouse xenograft model at 20 mg/kg per day; inhibits ERK and Src signaling and induces tumor regression in B-RAF inhibitor-resistant PDX mouse models
25537	CCT196969	10 mg	≥95%	A multi-kinase inhibitor; inhibits B-RAF, B-RAFV600E, C-RAF, Src, and LCK (IC50s = 100, 40, 12, 26, and 14 nM, respectively); only inhibits RAFs, Src, LCK, and MAPKs in a panel of 63 kinases at 1 µM; inhibits MEK and ERK signaling in B-RAF mutant WM266.4 cells; inhibits growth of B-RAF mutant melanoma cells; induces tumor regression in a B-RAF mutant A375 mouse xenograft model at 20 mg/kg per day; inhibits ERK and Src signaling and induces tumor regression in B-RAF inhibitor-resistant PDX mouse models
25537	CCT196969	25 mg	≥95%	A multi-kinase inhibitor; inhibits B-RAF, B-RAFV600E, C-RAF, Src, and LCK (IC50s = 100, 40, 12, 26, and 14 nM, respectively); only inhibits RAFs, Src, LCK, and MAPKs in a panel of 63 kinases at 1 µM; inhibits MEK and ERK signaling in B-RAF mutant WM266.4 cells; inhibits growth of B-RAF mutant melanoma cells; induces tumor regression in a B-RAF mutant A375 mouse xenograft model at 20 mg/kg per day; inhibits ERK and Src signaling and induces tumor regression in B-RAF inhibitor-resistant PDX mouse models
25537	CCT196969	5 mg	≥95%	A multi-kinase inhibitor; inhibits B-RAF, B-RAFV600E, C-RAF, Src, and LCK (IC50s = 100, 40, 12, 26, and 14 nM, respectively); only inhibits RAFs, Src, LCK, and MAPKs in a panel of 63 kinases at 1 µM; inhibits MEK and ERK signaling in B-RAF mutant WM266.4 cells; inhibits growth of B-RAF mutant melanoma cells; induces tumor regression in a B-RAF mutant A375 mouse xenograft model at 20 mg/kg per day; inhibits ERK and Src signaling and induces tumor regression in B-RAF inhibitor-resistant PDX mouse models
25554	Mps1/TTK Inhibitor	1 mg	≥98%	An inhibitor of Mps1/TTK (IC50 = 5.8 nM); inhibits Mps1 phosphorylation of KNL1 and increases the rate of mitosis at 100 nM; increases the number of missegregated chromosomes at 50 and 100 nM; inhibits colony formation of DLD1, HCT116, and U2OS cells (IC50s = 24.6, 20.1, and 20.6 nM, respectively)
25554	Mps1/TTK Inhibitor	10 mg	≥98%	An inhibitor of Mps1/TTK (IC50 = 5.8 nM); inhibits Mps1 phosphorylation of KNL1 and increases the rate of mitosis at 100 nM; increases the number of missegregated chromosomes at 50 and 100 nM; inhibits colony formation of DLD1, HCT116, and U2OS cells (IC50s = 24.6, 20.1, and 20.6 nM, respectively)

25554	Mps1/TTK Inhibitor	25 mg	≥98%	An inhibitor of Mps1/TTK (IC50 = 5.8 nM); inhibits Mps1 phosphorylation of KNL1 and increases the rate of mitosis at 100 nM; increases the number of missegregated chromosomes at 50 and 100 nM; inhibits colony formation of DLD1, HCT116, and U2OS cells (IC50s = 24.6, 20.1, and 20.6 nM, respectively)
25554	Mps1/TTK Inhibitor	5 mg	≥98%	An inhibitor of Mps1/TTK (IC50 = 5.8 nM); inhibits Mps1 phosphorylation of KNL1 and increases the rate of mitosis at 100 nM; increases the number of missegregated chromosomes at 50 and 100 nM; inhibits colony formation of DLD1, HCT116, and U2OS cells (IC50s = 24.6, 20.1, and 20.6 nM, respectively)
25556	PKC-9	1 mg	≥95%	A PCKζ inhibitor; 8,000-, 20,671-, 711-, 918-, 1,895-, 12,424-, 10-, and 1,218-fold selective for PKCζ over PKCα, PKCβII, PKCγ, PKCδ, PKCε, PKCη, PKCι, and PKCθ, respectively; inhibits 27 additional kinases in a panel of 37 kinases at 10 µM
25556	PKC-9	10 mg	≥95%	A PCKζ inhibitor; 8,000-, 20,671-, 711-, 918-, 1,895-, 12,424-, 10-, and 1,218-fold selective for PKCζ over PKCα, PKCβII, PKCγ, PKCδ, PKCε, PKCη, PKCι, and PKCθ, respectively; inhibits 27 additional kinases in a panel of 37 kinases at 10 µM
25556	PKC-9	5 mg	≥95%	A PCKζ inhibitor; 8,000-, 20,671-, 711-, 918-, 1,895-, 12,424-, 10-, and 1,218-fold selective for PKCζ over PKCα, PKCβII, PKCγ, PKCδ, PKCε, PKCη, PKCι, and PKCθ, respectively; inhibits 27 additional kinases in a panel of 37 kinases at 10 µM
25605	A-419259	1 mg	≥98%	An inhibitor of Src family kinases, including Src, LCK, Lyn, and Hck (IC50s = 9, 50 = 3,000 nM) and PKC (IC50 = >33 µM); inhibits growth of Ph+ K-562 and Meg-01 myeloid leukemia cells (IC50s = 0.1-0.3 and 0.1 µM, respectively), but not Ph- TF-1 and HEL cells; induces apoptosis in K-562 cells in a concentration-dependent manner; inhibits differentiation of murine embryonic stem cells while maintaining pluripotency at 300 nM; reduces the total number of AML cells, as well as AML stem cells, in the bone marrow and spleen of human patient-derived AML mouse xenograft models at 30 mg/kg twice daily
25605	A-419259	10 mg	≥98%	An inhibitor of Src family kinases, including Src, LCK, Lyn, and Hck (IC50s = 9, 50 = 3,000 nM) and PKC (IC50 = >33 µM); inhibits growth of Ph+ K-562 and Meg-01 myeloid leukemia cells (IC50s = 0.1-0.3 and 0.1 µM, respectively), but not Ph- TF-1 and HEL cells; induces apoptosis in K-562 cells in a concentration-dependent manner; inhibits differentiation of murine embryonic stem cells while maintaining pluripotency at 300 nM; reduces the total number of AML cells, as well as AML stem cells, in the bone marrow and spleen of human patient-derived AML mouse xenograft models at 30 mg/kg twice daily
25605	A-419259	5 mg	≥98%	An inhibitor of Src family kinases, including Src, LCK, Lyn, and Hck (IC50s = 9, 50 = 3,000 nM) and PKC (IC50 = >33 µM); inhibits growth of Ph+ K-562 and Meg-01 myeloid leukemia cells (IC50s = 0.1-0.3 and 0.1 µM, respectively), but not Ph- TF-1 and HEL cells; induces apoptosis in K-562 cells in a concentration-dependent manner; inhibits differentiation of murine embryonic stem cells while maintaining pluripotency at 300 nM; reduces the total number of AML cells, as well as AML stem cells, in the bone marrow and spleen of human patient-derived AML mouse xenograft models at 30 mg/kg twice daily
25606	RK-20448	1 mg	≥98%	A multi-kinase inhibitor; inhibits Lck, Src, KDR/VEGF2R, and Tie-2 (IC50s = 0.24, 1.19, 10.74, and 5.85 µM, respectively) in an ATP-competitive manner; also inhibits BLK, Csk, Fyn, and Lyn (IC50s = 0.37, 4.27, 2.03, and 0.43 µM, respectively); the cis isomer of A-419259
25606	RK-20448	10 mg	≥98%	A multi-kinase inhibitor; inhibits Lck, Src, KDR/VEGF2R, and Tie-2 (IC50s = 0.24, 1.19, 10.74, and 5.85 µM, respectively) in an ATP-competitive manner; also inhibits BLK, Csk, Fyn, and Lyn (IC50s = 0.37, 4.27, 2.03, and 0.43 µM, respectively); the cis isomer of A-419259
25606	RK-20448	5 mg	≥98%	A multi-kinase inhibitor; inhibits Lck, Src, KDR/VEGF2R, and Tie-2 (IC50s = 0.24, 1.19, 10.74, and 5.85 µM, respectively) in an ATP-competitive manner; also inhibits BLK, Csk, Fyn, and Lyn (IC50s = 0.37, 4.27, 2.03, and 0.43 µM, respectively); the cis isomer of A-419259
25606	RK-20448	500 µg	≥98%	A multi-kinase inhibitor; inhibits Lck, Src, KDR/VEGF2R, and Tie-2 (IC50s = 0.24, 1.19, 10.74, and 5.85 µM, respectively) in an ATP-competitive manner; also inhibits BLK, Csk, Fyn, and Lyn (IC50s = 0.37, 4.27, 2.03, and 0.43 µM, respectively); the cis isomer of A-419259
25632	Compound 43 TAO Ki	1 mg	≥98%	An inhibitor of TAOKs (IC50s = 11 and 15 nM for TAOK1 and TAOK2, respectively); selective for TAOK1 and TAOK2 over 62 kinases in a panel, but does inhibit TAOK3 by 87% and seven additional kinases by 21-52%; inhibits proliferation of SK-BR-3, BT-549, and MCF-7 cells by 94, 82, and 46%, respectively, at a concentration of 10 µM; reduces tau phosphorylation in kinase assays at 5-60 µM and in HEK293 cells at 5, 10, and 30 µM; reduces tau phosphorylation in cortical neurons in a transgenic mouse model of tauopathy and in induced pluripotent stem cell-derived neurons from patients with frontotemporal lobar degeneration

25632	Compound 43 TAO Ki	10 mg	≥98%	An inhibitor of TAOKs (IC50s = 11 and 15 nM for TAOK1 and TAOK2, respectively); selective for TAOK1 and TAOK2 over 62 kinases in a panel, but does inhibit TAOK3 by 87% and seven additional kinases by 21-52%; inhibits proliferation of SK-BR-3, BT-549, and MCF-7 cells by 94, 82, and 46%, respectively, at a concentration of 10 µM; reduces tau phosphorylation in kinase assays at 5-60 µM and in HEK293 cells at 5, 10, and 30 µM; reduces tau phosphorylation in cortical neurons in a transgenic mouse model of tauopathy and in induced pluripotent stem cell-derived neurons from patients with frontotemporal lobar degeneration
25632	Compound 43 TAO Ki	5 mg	≥98%	An inhibitor of TAOKs (IC50s = 11 and 15 nM for TAOK1 and TAOK2, respectively); selective for TAOK1 and TAOK2 over 62 kinases in a panel, but does inhibit TAOK3 by 87% and seven additional kinases by 21-52%; inhibits proliferation of SK-BR-3, BT-549, and MCF-7 cells by 94, 82, and 46%, respectively, at a concentration of 10 µM; reduces tau phosphorylation in kinase assays at 5-60 µM and in HEK293 cells at 5, 10, and 30 µM; reduces tau phosphorylation in cortical neurons in a transgenic mouse model of tauopathy and in induced pluripotent stem cell-derived neurons from patients with frontotemporal lobar degeneration
25647	Tilfrinib	1 mg	≥98%	An inhibitor of BRK/PTK6 (IC50 = 3.15 nM); selective for BRK/PTK6 over HER2 (IC50 = 1,300 nM); inhibits the growth of MCF-7, HS-578/T, and BT-549 breast cancer cells in vitro (GI50s = 0.99, 1.02, and 1.58 µM, respectively)
25647	Tilfrinib	10 mg	≥98%	An inhibitor of BRK/PTK6 (IC50 = 3.15 nM); selective for BRK/PTK6 over HER2 (IC50 = 1,300 nM); inhibits the growth of MCF-7, HS-578/T, and BT-549 breast cancer cells in vitro (GI50s = 0.99, 1.02, and 1.58 µM, respectively)
25647	Tilfrinib	25 mg	≥98%	An inhibitor of BRK/PTK6 (IC50 = 3.15 nM); selective for BRK/PTK6 over HER2 (IC50 = 1,300 nM); inhibits the growth of MCF-7, HS-578/T, and BT-549 breast cancer cells in vitro (GI50s = 0.99, 1.02, and 1.58 µM, respectively)
25647	Tilfrinib	5 mg	≥98%	An inhibitor of BRK/PTK6 (IC50 = 3.15 nM); selective for BRK/PTK6 over HER2 (IC50 = 1,300 nM); inhibits the growth of MCF-7, HS-578/T, and BT-549 breast cancer cells in vitro (GI50s = 0.99, 1.02, and 1.58 µM, respectively)
25648	AZD 0156	10 mg	≥95%	An inhibitor of ATM kinase (IC50s = 0.04 and 0.57 nM in enzyme and cell-based assays, respectively); selective for ATM over other PIKK family kinases including DNA-PK, mTOR, PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ (IC50s = 0.14, 0.20, 0.32, 1.8, 1.1, and 0.27 µM, respectively, in enzyme assays); enhances the antitumor activity of irinotecan in an SW620 colon cancer mouse xenograft model at 20 mg/kg and olaparib in an HBCx-10 breast cancer PDX mouse model at 5 mg/kg, leading to tumor regression in both models
25648	AZD 0156	25 mg	≥95%	An inhibitor of ATM kinase (IC50s = 0.04 and 0.57 nM in enzyme and cell-based assays, respectively); selective for ATM over other PIKK family kinases including DNA-PK, mTOR, PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ (IC50s = 0.14, 0.20, 0.32, 1.8, 1.1, and 0.27 µM, respectively, in enzyme assays); enhances the antitumor activity of irinotecan in an SW620 colon cancer mouse xenograft model at 20 mg/kg and olaparib in an HBCx-10 breast cancer PDX mouse model at 5 mg/kg, leading to tumor regression in both models
25648	AZD 0156	5 mg	≥95%	An inhibitor of ATM kinase (IC50s = 0.04 and 0.57 nM in enzyme and cell-based assays, respectively); selective for ATM over other PIKK family kinases including DNA-PK, mTOR, PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ (IC50s = 0.14, 0.20, 0.32, 1.8, 1.1, and 0.27 µM, respectively, in enzyme assays); enhances the antitumor activity of irinotecan in an SW620 colon cancer mouse xenograft model at 20 mg/kg and olaparib in an HBCx-10 breast cancer PDX mouse model at 5 mg/kg, leading to tumor regression in both models
25648	AZD 0156	50 mg	≥95%	An inhibitor of ATM kinase (IC50s = 0.04 and 0.57 nM in enzyme and cell-based assays, respectively); selective for ATM over other PIKK family kinases including DNA-PK, mTOR, PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ (IC50s = 0.14, 0.20, 0.32, 1.8, 1.1, and 0.27 µM, respectively, in enzyme assays); enhances the antitumor activity of irinotecan in an SW620 colon cancer mouse xenograft model at 20 mg/kg and olaparib in an HBCx-10 breast cancer PDX mouse model at 5 mg/kg, leading to tumor regression in both models
25651	CUDC-907	10 mg	≥98%	A dual inhibitor of HDACs and PI3Ks; inhibits HDAC activity in HeLa nuclear extracts (IC50 = 50s = 50s = 2/M phase and apoptosis and decreases cellular migration and invasion in FTC-133, THJ-29T, XTC-1, and 8505C thyroid cancer cell lines; reduces tumor growth, the number of liver metastases, and HDAC2 expression in tumor tissue in the FTC-133 mouse xenograft model
25651	CUDC-907	25 mg	≥98%	A dual inhibitor of HDACs and PI3Ks; inhibits HDAC activity in HeLa nuclear extracts (IC50 = 50s = 50s = 2/M phase and apoptosis and decreases cellular migration and invasion in FTC-133, THJ-29T, XTC-1, and 8505C thyroid cancer cell lines; reduces tumor growth, the number of liver metastases, and HDAC2 expression in tumor tissue in the FTC-133 mouse xenograft model
25651	CUDC-907	5 mg	≥98%	A dual inhibitor of HDACs and PI3Ks; inhibits HDAC activity in HeLa nuclear extracts (IC50 = 50s = 50s = 2/M phase and apoptosis and decreases cellular migration and invasion in FTC-133, THJ-29T, XTC-1, and 8505C thyroid cancer cell lines; reduces tumor growth, the number of liver metastases, and HDAC2 expression in tumor tissue in the FTC-133 mouse xenograft model

25651	CUDC-907	50 mg	≥98%	A dual inhibitor of HDACs and PI3Ks; inhibits HDAC activity in HeLa nuclear extracts (IC50 = 50s = 50s = 2/M phase and apoptosis and decreases cellular migration and invasion in FTC-133, THJ-29T, XTC-1, and 8505C thyroid cancer cell lines; reduces tumor growth, the number of liver metastases, and HDAC2 expression in tumor tissue in the FTC-133 mouse xenograft model
25652	SGK1 Inhibitor	1 mg	≥95%	An inhibitor of SGK1 and SGK2 (IC50s = 4.8 and 2.8 nM, respectively); selective for SGK1 and SGK2 over SGK3 in the presence of a high concentration of ATP (IC50s = 0.442, 0.924, and 23.3 μM, respectively); only inhibits AMPK by more than 50% in a panel of 60 additional kinases at 1 μM; prevents phosphorylation of GSK3β in U2OS cells (IC50 = 1.4 μM); decreases cell viability in BYL719-insensitive HCC1954 cells when used in combination with BYL719; reduces tumor growth in an HCC1954 mouse xenograft model when administered at 50 mg/kg in combination with BYL719
25652	SGK1 Inhibitor	10 mg	≥95%	An inhibitor of SGK1 and SGK2 (IC50s = 4.8 and 2.8 nM, respectively); selective for SGK1 and SGK2 over SGK3 in the presence of a high concentration of ATP (IC50s = 0.442, 0.924, and 23.3 μM, respectively); only inhibits AMPK by more than 50% in a panel of 60 additional kinases at 1 μM; prevents phosphorylation of GSK3β in U2OS cells (IC50 = 1.4 μM); decreases cell viability in BYL719-insensitive HCC1954 cells when used in combination with BYL719; reduces tumor growth in an HCC1954 mouse xenograft model when administered at 50 mg/kg in combination with BYL719
25652	SGK1 Inhibitor	25 mg	≥95%	An inhibitor of SGK1 and SGK2 (IC50s = 4.8 and 2.8 nM, respectively); selective for SGK1 and SGK2 over SGK3 in the presence of a high concentration of ATP (IC50s = 0.442, 0.924, and 23.3 μM, respectively); only inhibits AMPK by more than 50% in a panel of 60 additional kinases at 1 μM; prevents phosphorylation of GSK3β in U2OS cells (IC50 = 1.4 μM); decreases cell viability in BYL719-insensitive HCC1954 cells when used in combination with BYL719; reduces tumor growth in an HCC1954 mouse xenograft model when administered at 50 mg/kg in combination with BYL719
25652	SGK1 Inhibitor	5 mg	≥95%	An inhibitor of SGK1 and SGK2 (IC50s = 4.8 and 2.8 nM, respectively); selective for SGK1 and SGK2 over SGK3 in the presence of a high concentration of ATP (IC50s = 0.442, 0.924, and 23.3 μM, respectively); only inhibits AMPK by more than 50% in a panel of 60 additional kinases at 1 μM; prevents phosphorylation of GSK3β in U2OS cells (IC50 = 1.4 μM); decreases cell viability in BYL719-insensitive HCC1954 cells when used in combination with BYL719; reduces tumor growth in an HCC1954 mouse xenograft model when administered at 50 mg/kg in combination with BYL719
25665	Oridonin	10 mg	≥98%	A diterpenoid with anti-inflammatory and anticancer properties; an inhibitor of AKT1 and AKT2 (IC50s = 8.4 and 8.9 μM, respectively); inhibits proliferation of KYSE70, KYSE410, and KYSE450 esophageal cancer cells, halts the cell cycle at the G2/M phase, and induces apoptosis at 20 μM; decreases the protein levels of phosphorylated AKT and reduces AKT activity; reduces tumor growth in patient-derived mouse tumor models at 40 and 160 mg/kg; an inhibitor of NLRP3 inflammasome assembly and activation; inhibits inflammation in wild-type, but not Nlrp3-/-, mice in a model of high-fat diet-induced type 2 diabetes at 3 mg/kg
25665	Oridonin	100 mg	≥98%	A diterpenoid with anti-inflammatory and anticancer properties; an inhibitor of AKT1 and AKT2 (IC50s = 8.4 and 8.9 μM, respectively); inhibits proliferation of KYSE70, KYSE410, and KYSE450 esophageal cancer cells, halts the cell cycle at the G2/M phase, and induces apoptosis at 20 μM; decreases the protein levels of phosphorylated AKT and reduces AKT activity; reduces tumor growth in patient-derived mouse tumor models at 40 and 160 mg/kg; an inhibitor of NLRP3 inflammasome assembly and activation; inhibits inflammation in wild-type, but not Nlrp3-/-, mice in a model of high-fat diet-induced type 2 diabetes at 3 mg/kg
25665	Oridonin	5 mg	≥98%	A diterpenoid with anti-inflammatory and anticancer properties; an inhibitor of AKT1 and AKT2 (IC50s = 8.4 and 8.9 μM, respectively); inhibits proliferation of KYSE70, KYSE410, and KYSE450 esophageal cancer cells, halts the cell cycle at the G2/M phase, and induces apoptosis at 20 μM; decreases the protein levels of phosphorylated AKT and reduces AKT activity; reduces tumor growth in patient-derived mouse tumor models at 40 and 160 mg/kg; an inhibitor of NLRP3 inflammasome assembly and activation; inhibits inflammation in wild-type, but not Nlrp3-/-, mice in a model of high-fat diet-induced type 2 diabetes at 3 mg/kg
25665	Oridonin	50 mg	≥98%	A diterpenoid with anti-inflammatory and anticancer properties; an inhibitor of AKT1 and AKT2 (IC50s = 8.4 and 8.9 μM, respectively); inhibits proliferation of KYSE70, KYSE410, and KYSE450 esophageal cancer cells, halts the cell cycle at the G2/M phase, and induces apoptosis at 20 μM; decreases the protein levels of phosphorylated AKT and reduces AKT activity; reduces tumor growth in patient-derived mouse tumor models at 40 and 160 mg/kg; an inhibitor of NLRP3 inflammasome assembly and activation; inhibits inflammation in wild-type, but not Nlrp3-/-, mice in a model of high-fat diet-induced type 2 diabetes at 3 mg/kg

25666	CCT244747	1 mg	≥98%	A potent Chk1 inhibitor (IC50 = 8 nM); selective for Chk1 over FLT3, Chk2, and CDK1 (IC50s = 600, >10,000, and >10,000 nM, respectively) as well as a panel of 121 additional kinases at 10 μM; reverses cell cycle arrest at the G2/M phase induced by etoposide and SN-38 in HT-29 cells and gemcitabine in SW620 cells; potentiates the genotoxicity of SN-38, gemcitabine, and etoposide in HT-29, SW620, MiaPaCa-2, and Calu-6 cells; in combination with irinotecan or gemcitabine, increases the delay of tumor growth in SW620 and Calu-6 mouse xenograft models, respectively, at 75 mg/kg
25666	CCT244747	10 mg	≥98%	A potent Chk1 inhibitor (IC50 = 8 nM); selective for Chk1 over FLT3, Chk2, and CDK1 (IC50s = 600, >10,000, and >10,000 nM, respectively) as well as a panel of 121 additional kinases at 10 μM; reverses cell cycle arrest at the G2/M phase induced by etoposide and SN-38 in HT-29 cells and gemcitabine in SW620 cells; potentiates the genotoxicity of SN-38, gemcitabine, and etoposide in HT-29, SW620, MiaPaCa-2, and Calu-6 cells; in combination with irinotecan or gemcitabine, increases the delay of tumor growth in SW620 and Calu-6 mouse xenograft models, respectively, at 75 mg/kg
25666	CCT244747	5 mg	≥98%	A potent Chk1 inhibitor (IC50 = 8 nM); selective for Chk1 over FLT3, Chk2, and CDK1 (IC50s = 600, >10,000, and >10,000 nM, respectively) as well as a panel of 121 additional kinases at 10 μM; reverses cell cycle arrest at the G2/M phase induced by etoposide and SN-38 in HT-29 cells and gemcitabine in SW620 cells; potentiates the genotoxicity of SN-38, gemcitabine, and etoposide in HT-29, SW620, MiaPaCa-2, and Calu-6 cells; in combination with irinotecan or gemcitabine, increases the delay of tumor growth in SW620 and Calu-6 mouse xenograft models, respectively, at 75 mg/kg
25749	CEP-40783	1 mg	≥98%	A multi-kinase inhibitor; inhibits Axl and c-MET (IC50s = 7 and 12 nM, respectively); inhibits Axl in 293GT cells expressing Axl and c-MET in NCI H1299 NSCLC cells (IC50s = 0.26 and 6 nM, respectively); inhibits TYRO3 and MER (IC50s = 3.5 and 1.89 nM, respectively); induces complete regression of tumors in an Axl/NIH3T3 mouse xenograft model at 0.3 mg/kg; induces tumor stasis and regression in an EBC-1 NSCLC mouse xenograft model at 3 and 10 mg/kg, respectively; reduces tumor growth in an MC38 mouse syngeneic model concomitantly with innate and adaptive immune cell activation
25749	CEP-40783	10 mg	≥98%	A multi-kinase inhibitor; inhibits Axl and c-MET (IC50s = 7 and 12 nM, respectively); inhibits Axl in 293GT cells expressing Axl and c-MET in NCI H1299 NSCLC cells (IC50s = 0.26 and 6 nM, respectively); inhibits TYRO3 and MER (IC50s = 3.5 and 1.89 nM, respectively); induces complete regression of tumors in an Axl/NIH3T3 mouse xenograft model at 0.3 mg/kg; induces tumor stasis and regression in an EBC-1 NSCLC mouse xenograft model at 3 and 10 mg/kg, respectively; reduces tumor growth in an MC38 mouse syngeneic model concomitantly with innate and adaptive immune cell activation
25749	CEP-40783	25 mg	≥98%	A multi-kinase inhibitor; inhibits Axl and c-MET (IC50s = 7 and 12 nM, respectively); inhibits Axl in 293GT cells expressing Axl and c-MET in NCI H1299 NSCLC cells (IC50s = 0.26 and 6 nM, respectively); inhibits TYRO3 and MER (IC50s = 3.5 and 1.89 nM, respectively); induces complete regression of tumors in an Axl/NIH3T3 mouse xenograft model at 0.3 mg/kg; induces tumor stasis and regression in an EBC-1 NSCLC mouse xenograft model at 3 and 10 mg/kg, respectively; reduces tumor growth in an MC38 mouse syngeneic model concomitantly with innate and adaptive immune cell activation
25749	CEP-40783	5 mg	≥98%	A multi-kinase inhibitor; inhibits Axl and c-MET (IC50s = 7 and 12 nM, respectively); inhibits Axl in 293GT cells expressing Axl and c-MET in NCI H1299 NSCLC cells (IC50s = 0.26 and 6 nM, respectively); inhibits TYRO3 and MER (IC50s = 3.5 and 1.89 nM, respectively); induces complete regression of tumors in an Axl/NIH3T3 mouse xenograft model at 0.3 mg/kg; induces tumor stasis and regression in an EBC-1 NSCLC mouse xenograft model at 3 and 10 mg/kg, respectively; reduces tumor growth in an MC38 mouse syngeneic model concomitantly with innate and adaptive immune cell activation
25832	Acumapimod	1 mg	≥98%	An inhibitor of p38α MAPK (IC50 = 50 = 0.3 mg/kg)
25832	Acumapimod	10 mg	≥98%	An inhibitor of p38α MAPK (IC50 = 50 = 0.3 mg/kg)
25832	Acumapimod	25 mg	≥98%	An inhibitor of p38α MAPK (IC50 = 50 = 0.3 mg/kg)
25832	Acumapimod	5 mg	≥98%	An inhibitor of p38α MAPK (IC50 = 50 = 0.3 mg/kg)
25861	4-(Dimethylamino)-1-	10 mg	≥95%	A pyridinium salt with anticholinesterase and antiproliferative activities; inhibits cholinesterase activity in rat brain homogenates (Kd = 33 μM); inhibits and yeast ChoK (IC50 = 17 μM); has antiproliferative activity against HT-29 colon cancer cells (IC50 = 2 μM)
25861	4-(Dimethylamino)-1-	100 mg	≥95%	A pyridinium salt with anticholinesterase and antiproliferative activities; inhibits cholinesterase activity in rat brain homogenates (Kd = 33 μM); inhibits and yeast ChoK (IC50 = 17 μM); has antiproliferative activity against HT-29 colon cancer cells (IC50 = 2 μM)

25861	4-(Dimethylamino)-1-	250 mg	≥95%	A pyridinium salt with anticholinesterase and antiproliferative activities; inhibits cholinesterase activity in rat brain homogenates (Kd = 33 µM); inhibits and yeast ChoK (IC50 = 17 µM); has antiproliferative activity against HT-29 colon cancer cells (IC50 = 2 µM)
25861	4-(Dimethylamino)-1-	50 mg	≥95%	A pyridinium salt with anticholinesterase and antiproliferative activities; inhibits cholinesterase activity in rat brain homogenates (Kd = 33 µM); inhibits and yeast ChoK (IC50 = 17 µM); has antiproliferative activity against HT-29 colon cancer cells (IC50 = 2 µM)
25978	LY2801653	1 mg	≥98%	A MET kinase inhibitor (Ki = 2 nM); inhibits MST1R, Axl, MNK1/2, FLT3, DDR1, and DDR2 (IC50s = 11, 2, 7, 7, 0.1, and 7 nM, respectively); inhibits HGF-induced MET autophosphorylation in H460 and S114 cells (IC50s = 35.2 and 59.2 nM, respectively) and inhibits growth of Ba/F3 cells transfected with MET-activating mutations (IC50s = 12-248 nM); completely blocks cell scattering induced by HGF in DU145 cells at 0.01-10 µM; reduces tumor growth in MET autocrine (U-87MG) and MET over-expression (H441) mouse xenograft models at 4 and 12 mg/kg
25978	LY2801653	10 mg	≥98%	A MET kinase inhibitor (Ki = 2 nM); inhibits MST1R, Axl, MNK1/2, FLT3, DDR1, and DDR2 (IC50s = 11, 2, 7, 7, 0.1, and 7 nM, respectively); inhibits HGF-induced MET autophosphorylation in H460 and S114 cells (IC50s = 35.2 and 59.2 nM, respectively) and inhibits growth of Ba/F3 cells transfected with MET-activating mutations (IC50s = 12-248 nM); completely blocks cell scattering induced by HGF in DU145 cells at 0.01-10 µM; reduces tumor growth in MET autocrine (U-87MG) and MET over-expression (H441) mouse xenograft models at 4 and 12 mg/kg
25978	LY2801653	5 mg	≥98%	A MET kinase inhibitor (Ki = 2 nM); inhibits MST1R, Axl, MNK1/2, FLT3, DDR1, and DDR2 (IC50s = 11, 2, 7, 7, 0.1, and 7 nM, respectively); inhibits HGF-induced MET autophosphorylation in H460 and S114 cells (IC50s = 35.2 and 59.2 nM, respectively) and inhibits growth of Ba/F3 cells transfected with MET-activating mutations (IC50s = 12-248 nM); completely blocks cell scattering induced by HGF in DU145 cells at 0.01-10 µM; reduces tumor growth in MET autocrine (U-87MG) and MET over-expression (H441) mouse xenograft models at 4 and 12 mg/kg
25978	LY2801653	50 mg	≥98%	A MET kinase inhibitor (Ki = 2 nM); inhibits MST1R, Axl, MNK1/2, FLT3, DDR1, and DDR2 (IC50s = 11, 2, 7, 7, 0.1, and 7 nM, respectively); inhibits HGF-induced MET autophosphorylation in H460 and S114 cells (IC50s = 35.2 and 59.2 nM, respectively) and inhibits growth of Ba/F3 cells transfected with MET-activating mutations (IC50s = 12-248 nM); completely blocks cell scattering induced by HGF in DU145 cells at 0.01-10 µM; reduces tumor growth in MET autocrine (U-87MG) and MET over-expression (H441) mouse xenograft models at 4 and 12 mg/kg
25983	Acalisib	1 mg	≥98%	An inhibitor of p110δ (IC50 = 12.7 nM); selective for p110δ over the class I PI3Ks subunits p110α, p110β, p110γ, the class II PI3K CIIβ, and the class III PI3K hVPS34 (IC50s = 5.4, 3.3, 1.4, 10, and 12.6 µM, respectively), as well as PIP5Kα, PIP5Kβ, DNA-PK, and mTOR (IC50s = >10 µM); reduces lamellipodia spreading and induces lamellipodia retraction in rat osteoclasts at 1 µM; reduces proliferation of multiple myeloma tumor cells alone and in combination with melphalan in vitro and reduces tumor growth when administered in combination with melphalan in an LAGk-2 mouse xenograft model
25983	Acalisib	10 mg	≥98%	An inhibitor of p110δ (IC50 = 12.7 nM); selective for p110δ over the class I PI3Ks subunits p110α, p110β, p110γ, the class II PI3K CIIβ, and the class III PI3K hVPS34 (IC50s = 5.4, 3.3, 1.4, 10, and 12.6 µM, respectively), as well as PIP5Kα, PIP5Kβ, DNA-PK, and mTOR (IC50s = >10 µM); reduces lamellipodia spreading and induces lamellipodia retraction in rat osteoclasts at 1 µM; reduces proliferation of multiple myeloma tumor cells alone and in combination with melphalan in vitro and reduces tumor growth when administered in combination with melphalan in an LAGk-2 mouse xenograft model
25983	Acalisib	25 mg	≥98%	An inhibitor of p110δ (IC50 = 12.7 nM); selective for p110δ over the class I PI3Ks subunits p110α, p110β, p110γ, the class II PI3K CIIβ, and the class III PI3K hVPS34 (IC50s = 5.4, 3.3, 1.4, 10, and 12.6 µM, respectively), as well as PIP5Kα, PIP5Kβ, DNA-PK, and mTOR (IC50s = >10 µM); reduces lamellipodia spreading and induces lamellipodia retraction in rat osteoclasts at 1 µM; reduces proliferation of multiple myeloma tumor cells alone and in combination with melphalan in vitro and reduces tumor growth when administered in combination with melphalan in an LAGk-2 mouse xenograft model
25983	Acalisib	5 mg	≥98%	An inhibitor of p110δ (IC50 = 12.7 nM); selective for p110δ over the class I PI3Ks subunits p110α, p110β, p110γ, the class II PI3K CIIβ, and the class III PI3K hVPS34 (IC50s = 5.4, 3.3, 1.4, 10, and 12.6 µM, respectively), as well as PIP5Kα, PIP5Kβ, DNA-PK, and mTOR (IC50s = >10 µM); reduces lamellipodia spreading and induces lamellipodia retraction in rat osteoclasts at 1 µM; reduces proliferation of multiple myeloma tumor cells alone and in combination with melphalan in vitro and reduces tumor growth when administered in combination with melphalan in an LAGk-2 mouse xenograft model
25988	LY3177833	10 mg	≥98%	An inhibitor of Cdc7 kinase (IC50 = 3.3 nM); inhibits phosphorylation of MCM2-S53 in H1299 cells (IC50 = 0.29 µM); LY3177833 reduces tumor growth in an SW620 mouse xenograft model at 10, 20, and 30 mg/kg twice per day

25988	LY3177833	25 mg	≥98%	An inhibitor of Cdc7 kinase (IC50 = 3.3 nM); inhibits phosphorylation of MCM2-S53 in H1299 cells (IC50 = 0.29 µM); LY3177833 reduces tumor growth in an SW620 mouse xenograft model at 10, 20, and 30 mg/kg twice per day
25988	LY3177833	5 mg	≥98%	An inhibitor of Cdc7 kinase (IC50 = 3.3 nM); inhibits phosphorylation of MCM2-S53 in H1299 cells (IC50 = 0.29 µM); LY3177833 reduces tumor growth in an SW620 mouse xenograft model at 10, 20, and 30 mg/kg twice per day
25988	LY3177833	50 mg	≥98%	An inhibitor of Cdc7 kinase (IC50 = 3.3 nM); inhibits phosphorylation of MCM2-S53 in H1299 cells (IC50 = 0.29 µM); LY3177833 reduces tumor growth in an SW620 mouse xenograft model at 10, 20, and 30 mg/kg twice per day
25989	PD 407824	1 mg	≥98%	An inhibitor of Chk1 and WEE1 (IC50s = 47 and 97 nM, respectively); selective for Chk1 and WEE1 over PKC (IC50 = 3.4 µM) and Cdk4 (IC50 = 3.75 µM); selective for Chk1 and WEE1 over c-Src and the PDGF and FGF receptors (IC50s = >50 µM for all), and other Cdks (IC50s = >50 µM); sensitizes SK-OV-3 and OVCAR-3 ovarian cancer cells, as well as cisplatin-resistant A2780cis cells, to cisplatin at 0.5 µM; induces myoblast differentiation into mature osteoblasts and hESC differentiation into cells with mesoderm or cytotrophoblast stem cell lineages when used in combination with BMP4
25989	PD 407824	10 mg	≥98%	An inhibitor of Chk1 and WEE1 (IC50s = 47 and 97 nM, respectively); selective for Chk1 and WEE1 over PKC (IC50 = 3.4 µM) and Cdk4 (IC50 = 3.75 µM); selective for Chk1 and WEE1 over c-Src and the PDGF and FGF receptors (IC50s = >50 µM for all), and other Cdks (IC50s = >50 µM); sensitizes SK-OV-3 and OVCAR-3 ovarian cancer cells, as well as cisplatin-resistant A2780cis cells, to cisplatin at 0.5 µM; induces myoblast differentiation into mature osteoblasts and hESC differentiation into cells with mesoderm or cytotrophoblast stem cell lineages when used in combination with BMP4
25989	PD 407824	5 mg	≥98%	An inhibitor of Chk1 and WEE1 (IC50s = 47 and 97 nM, respectively); selective for Chk1 and WEE1 over PKC (IC50 = 3.4 µM) and Cdk4 (IC50 = 3.75 µM); selective for Chk1 and WEE1 over c-Src and the PDGF and FGF receptors (IC50s = >50 µM for all), and other Cdks (IC50s = >50 µM); sensitizes SK-OV-3 and OVCAR-3 ovarian cancer cells, as well as cisplatin-resistant A2780cis cells, to cisplatin at 0.5 µM; induces myoblast differentiation into mature osteoblasts and hESC differentiation into cells with mesoderm or cytotrophoblast stem cell lineages when used in combination with BMP4
26024	Flavopiridol	100 mg	≥95%	An inhibitor of cyclin-dependent kinases (Cdks; IC50s = ~100, ~100, ~100, and 300 nM for Cdk1, Cdk2, Cdk4, and Cdk7, respectively); inhibits TEFb (Ki = 3 nM); inhibits transcription of a CMV promoter in HeLa nuclear extract (IC50 = 34 nM), Tat-stimulated transcription of an HIV-1 promotor (IC50 = 7 nM), and HIV-1 replication in HEK293T cells (IC50 = <10 nM); induces apoptosis and cyclin D1 depletion and delays tumor growth in an HN-12 head and neck carcinoma mouse xenograft model at 5 mg/kg; suppresses synovial hyperplasia and joint destruction in a mouse model of collagen-induced arthritis
26024	Flavopiridol	25 mg	≥95%	An inhibitor of cyclin-dependent kinases (Cdks; IC50s = ~100, ~100, ~100, and 300 nM for Cdk1, Cdk2, Cdk4, and Cdk7, respectively); inhibits TEFb (Ki = 3 nM); inhibits transcription of a CMV promoter in HeLa nuclear extract (IC50 = 34 nM), Tat-stimulated transcription of an HIV-1 promotor (IC50 = 7 nM), and HIV-1 replication in HEK293T cells (IC50 = <10 nM); induces apoptosis and cyclin D1 depletion and delays tumor growth in an HN-12 head and neck carcinoma mouse xenograft model at 5 mg/kg; suppresses synovial hyperplasia and joint destruction in a mouse model of collagen-induced arthritis
26024	Flavopiridol	5 mg	≥95%	An inhibitor of cyclin-dependent kinases (Cdks; IC50s = ~100, ~100, ~100, and 300 nM for Cdk1, Cdk2, Cdk4, and Cdk7, respectively); inhibits TEFb (Ki = 3 nM); inhibits transcription of a CMV promoter in HeLa nuclear extract (IC50 = 34 nM), Tat-stimulated transcription of an HIV-1 promotor (IC50 = 7 nM), and HIV-1 replication in HEK293T cells (IC50 = <10 nM); induces apoptosis and cyclin D1 depletion and delays tumor growth in an HN-12 head and neck carcinoma mouse xenograft model at 5 mg/kg; suppresses synovial hyperplasia and joint destruction in a mouse model of collagen-induced arthritis
26024	Flavopiridol	50 mg	≥95%	An inhibitor of cyclin-dependent kinases (Cdks; IC50s = ~100, ~100, ~100, and 300 nM for Cdk1, Cdk2, Cdk4, and Cdk7, respectively); inhibits TEFb (Ki = 3 nM); inhibits transcription of a CMV promoter in HeLa nuclear extract (IC50 = 34 nM), Tat-stimulated transcription of an HIV-1 promotor (IC50 = 7 nM), and HIV-1 replication in HEK293T cells (IC50 = <10 nM); induces apoptosis and cyclin D1 depletion and delays tumor growth in an HN-12 head and neck carcinoma mouse xenograft model at 5 mg/kg; suppresses synovial hyperplasia and joint destruction in a mouse model of collagen-induced arthritis

26035	NIH 12848	1 mg	≥95%	An inhibitor of PI5P4K (IC50 = ~1 μM); selective for PI5P4Kγ over PI5P4Kα and PI5P4Kβ (IC50s = >100 μM); inhibits translocation of the Na+/K+-ATPase to the plasma membrane in mpkCCD cells; an inhibitor of USP1/UAF complex deubiquitinase activity (IC50 = 7.9 μM); increases accumulation of monoubiquitinated PCNA in H1299 NSCLC cells at 20 μM
26035	NIH 12848	10 mg	≥95%	An inhibitor of PI5P4K (IC50 = ~1 μM); selective for PI5P4Kγ over PI5P4Kα and PI5P4Kβ (IC50s = >100 μM); inhibits translocation of the Na+/K+-ATPase to the plasma membrane in mpkCCD cells; an inhibitor of USP1/UAF complex deubiquitinase activity (IC50 = 7.9 μM); increases accumulation of monoubiquitinated PCNA in H1299 NSCLC cells at 20 μM
26035	NIH 12848	25 mg	≥95%	An inhibitor of PI5P4K (IC50 = ~1 μM); selective for PI5P4Kγ over PI5P4Kα and PI5P4Kβ (IC50s = >100 μM); inhibits translocation of the Na+/K+-ATPase to the plasma membrane in mpkCCD cells; an inhibitor of USP1/UAF complex deubiquitinase activity (IC50 = 7.9 μM); increases accumulation of monoubiquitinated PCNA in H1299 NSCLC cells at 20 μM
26035	NIH 12848	5 mg	≥95%	An inhibitor of PI5P4K (IC50 = ~1 μM); selective for PI5P4Kγ over PI5P4Kα and PI5P4Kβ (IC50s = >100 μM); inhibits translocation of the Na+/K+-ATPase to the plasma membrane in mpkCCD cells; an inhibitor of USP1/UAF complex deubiquitinase activity (IC50 = 7.9 μM); increases accumulation of monoubiquitinated PCNA in H1299 NSCLC cells at 20 μM
26072	H3B-6527	1 mg	≥98%	An FGFR4 inhibitor (IC50 = 50s = 320, 1,290, and 1,060 nM, respectively), as well as TAOK2, JNK2, and CSF1R (IC50s = 690, >10,000, and >10,000 nM, respectively); decreases cell growth (GI50 = 25 nM) and increases caspase-3/7 activity in Hep3B HCC cells; selectively inhibits cell growth in HCC cell lines that express high levels of FGF19; reduces tumor growth in a Hep3B HCC mouse xenograft model at 100 and 300 mg/kg
26072	H3B-6527	10 mg	≥98%	An FGFR4 inhibitor (IC50 = 50s = 320, 1,290, and 1,060 nM, respectively), as well as TAOK2, JNK2, and CSF1R (IC50s = 690, >10,000, and >10,000 nM, respectively); decreases cell growth (GI50 = 25 nM) and increases caspase-3/7 activity in Hep3B HCC cells; selectively inhibits cell growth in HCC cell lines that express high levels of FGF19; reduces tumor growth in a Hep3B HCC mouse xenograft model at 100 and 300 mg/kg
26072	H3B-6527	25 mg	≥98%	An FGFR4 inhibitor (IC50 = 50s = 320, 1,290, and 1,060 nM, respectively), as well as TAOK2, JNK2, and CSF1R (IC50s = 690, >10,000, and >10,000 nM, respectively); decreases cell growth (GI50 = 25 nM) and increases caspase-3/7 activity in Hep3B HCC cells; selectively inhibits cell growth in HCC cell lines that express high levels of FGF19; reduces tumor growth in a Hep3B HCC mouse xenograft model at 100 and 300 mg/kg
26072	H3B-6527	5 mg	≥98%	An FGFR4 inhibitor (IC50 = 50s = 320, 1,290, and 1,060 nM, respectively), as well as TAOK2, JNK2, and CSF1R (IC50s = 690, >10,000, and >10,000 nM, respectively); decreases cell growth (GI50 = 25 nM) and increases caspase-3/7 activity in Hep3B HCC cells; selectively inhibits cell growth in HCC cell lines that express high levels of FGF19; reduces tumor growth in a Hep3B HCC mouse xenograft model at 100 and 300 mg/kg
26081	Brivanib Alaninate	10 mg	≥98%	A prodrug form of brivanib; reduces hepatic angiogenesis and VEGF, TGF-β1, CD31, and phosphorylated VEGFR2 and FGFR levels in a bile duct-ligated rat model of cirrhosis at 3 mg/kg per day; reduces tumor growth in an L2987 non-small cell lung cancer mouse xenograft model, exhibiting 97% tumor growth inhibition at 107 mg/kg
26081	Brivanib Alaninate	25 mg	≥98%	A prodrug form of brivanib; reduces hepatic angiogenesis and VEGF, TGF-β1, CD31, and phosphorylated VEGFR2 and FGFR levels in a bile duct-ligated rat model of cirrhosis at 3 mg/kg per day; reduces tumor growth in an L2987 non-small cell lung cancer mouse xenograft model, exhibiting 97% tumor growth inhibition at 107 mg/kg
26081	Brivanib Alaninate	5 mg	≥98%	A prodrug form of brivanib; reduces hepatic angiogenesis and VEGF, TGF-β1, CD31, and phosphorylated VEGFR2 and FGFR levels in a bile duct-ligated rat model of cirrhosis at 3 mg/kg per day; reduces tumor growth in an L2987 non-small cell lung cancer mouse xenograft model, exhibiting 97% tumor growth inhibition at 107 mg/kg
26081	Brivanib Alaninate	50 mg	≥98%	A prodrug form of brivanib; reduces hepatic angiogenesis and VEGF, TGF-β1, CD31, and phosphorylated VEGFR2 and FGFR levels in a bile duct-ligated rat model of cirrhosis at 3 mg/kg per day; reduces tumor growth in an L2987 non-small cell lung cancer mouse xenograft model, exhibiting 97% tumor growth inhibition at 107 mg/kg
26125	PF-06700841 (tosylate	1 mg	≥98%	An inhibitor of JAK1 and TYK2 (IC50s = 17 and 23 nM, respectively); selective for JAK1 and TYK2 over JAK2 and JAK3 (IC50s = 77 and 6,494 nM, respectively); selectively inhibits IFN-α/STAT3 signaling over erythropoietin/STAT5 signaling in human whole blood (IC50s = 30 and 577 nM, respectively); reduces increases in hind paw volume in a rat model of adjuvant-induced arthritis in a dose-dependent manner
26125	PF-06700841 (tosylate	10 mg	≥98%	An inhibitor of JAK1 and TYK2 (IC50s = 17 and 23 nM, respectively); selective for JAK1 and TYK2 over JAK2 and JAK3 (IC50s = 77 and 6,494 nM, respectively); selectively inhibits IFN-α/STAT3 signaling over erythropoietin/STAT5 signaling in human whole blood (IC50s = 30 and 577 nM, respectively); reduces increases in hind paw volume in a rat model of adjuvant-induced arthritis in a dose-dependent manner

26125	PF-06700841 (tosylate	25 mg	≥98%	An inhibitor of JAK1 and TYK2 (IC50s = 17 and 23 nM, respectively); selective for JAK1 and TYK2 over JAK2 and JAK3 (IC50s = 77 and 6,494 nM, respectively); selectively inhibits IFN-α/STAT3 signaling over erythropoietin/STAT5 signaling in human whole blood (IC50s = 30 and 577 nM, respectively); reduces increases in hind paw volume in a rat model of adjuvant-induced arthritis in a dose-dependent manner
26125	PF-06700841 (tosylate	5 mg	≥98%	An inhibitor of JAK1 and TYK2 (IC50s = 17 and 23 nM, respectively); selective for JAK1 and TYK2 over JAK2 and JAK3 (IC50s = 77 and 6,494 nM, respectively); selectively inhibits IFN-α/STAT3 signaling over erythropoietin/STAT5 signaling in human whole blood (IC50s = 30 and 577 nM, respectively); reduces increases in hind paw volume in a rat model of adjuvant-induced arthritis in a dose-dependent manner
26126	Asciminib	1 mg	≥95%	An allosteric inhibitor of Abl1 (IC50 = 0.45 nM); selective for Abl1 over a panel of more than 60 additional kinases (IC50s = >10 μM), as well as ion channels, nuclear receptors, GPCRs, and transporters; inhibits the proliferation of Luc-Ba/F3 cells transformed with wild-type Bcr-Abl1 or the drug-resistant mutant Bcr-Abl1T315I (GI50s = 1 and 25 nM, respectively), as well as other drug-resistant mutants; reduces tumor growth in a KCL-22 CML mouse xenograft model at 3 mg/kg twice per day and induces tumor regression at ≥7.5 mg/kg twice per day
26126	Asciminib	10 mg	≥95%	An allosteric inhibitor of Abl1 (IC50 = 0.45 nM); selective for Abl1 over a panel of more than 60 additional kinases (IC50s = >10 μM), as well as ion channels, nuclear receptors, GPCRs, and transporters; inhibits the proliferation of Luc-Ba/F3 cells transformed with wild-type Bcr-Abl1 or the drug-resistant mutant Bcr-Abl1T315I (GI50s = 1 and 25 nM, respectively), as well as other drug-resistant mutants; reduces tumor growth in a KCL-22 CML mouse xenograft model at 3 mg/kg twice per day and induces tumor regression at ≥7.5 mg/kg twice per day
26126	Asciminib	5 mg	≥95%	An allosteric inhibitor of Abl1 (IC50 = 0.45 nM); selective for Abl1 over a panel of more than 60 additional kinases (IC50s = >10 μM), as well as ion channels, nuclear receptors, GPCRs, and transporters; inhibits the proliferation of Luc-Ba/F3 cells transformed with wild-type Bcr-Abl1 or the drug-resistant mutant Bcr-Abl1T315I (GI50s = 1 and 25 nM, respectively), as well as other drug-resistant mutants; reduces tumor growth in a KCL-22 CML mouse xenograft model at 3 mg/kg twice per day and induces tumor regression at ≥7.5 mg/kg twice per day
26170	TAK-715	10 mg	≥95%	An inhibitor of p38α MAPK (IC50 = 7.1 nM); selective for p38α over p38β (IC50 = 200 nM), as well as over p38γ/δ, JNK, ERK1, IKKβ, MEKK1, and TAK1 (IC50 = >10 μM for all) but also inhibits CK1δ and CK1ε; inhibits LPS-induced TNF-α release from THP-1 cells (IC50 = 48 nM); LPS-induced TNF-α production by 87.6% in mice at 10 mg/kg; reduces adjuvant-induced paw swelling in a rat model of rheumatoid arthritis at 30 mg/kg; inhibits Wnt3a-induced phosphorylation of hDvl2 in a p38α-independent manner
26170	TAK-715	25 mg	≥95%	An inhibitor of p38α MAPK (IC50 = 7.1 nM); selective for p38α over p38β (IC50 = 200 nM), as well as over p38γ/δ, JNK, ERK1, IKKβ, MEKK1, and TAK1 (IC50 = >10 μM for all) but also inhibits CK1δ and CK1ε; inhibits LPS-induced TNF-α release from THP-1 cells (IC50 = 48 nM); LPS-induced TNF-α production by 87.6% in mice at 10 mg/kg; reduces adjuvant-induced paw swelling in a rat model of rheumatoid arthritis at 30 mg/kg; inhibits Wnt3a-induced phosphorylation of hDvl2 in a p38α-independent manner
26170	TAK-715	5 mg	≥95%	An inhibitor of p38α MAPK (IC50 = 7.1 nM); selective for p38α over p38β (IC50 = 200 nM), as well as over p38γ/δ, JNK, ERK1, IKKβ, MEKK1, and TAK1 (IC50 = >10 μM for all) but also inhibits CK1δ and CK1ε; inhibits LPS-induced TNF-α release from THP-1 cells (IC50 = 48 nM); LPS-induced TNF-α production by 87.6% in mice at 10 mg/kg; reduces adjuvant-induced paw swelling in a rat model of rheumatoid arthritis at 30 mg/kg; inhibits Wnt3a-induced phosphorylation of hDvl2 in a p38α-independent manner
26170	TAK-715	50 mg	≥95%	An inhibitor of p38α MAPK (IC50 = 7.1 nM); selective for p38α over p38β (IC50 = 200 nM), as well as over p38γ/δ, JNK, ERK1, IKKβ, MEKK1, and TAK1 (IC50 = >10 μM for all) but also inhibits CK1δ and CK1ε; inhibits LPS-induced TNF-α release from THP-1 cells (IC50 = 48 nM); LPS-induced TNF-α production by 87.6% in mice at 10 mg/kg; reduces adjuvant-induced paw swelling in a rat model of rheumatoid arthritis at 30 mg/kg; inhibits Wnt3a-induced phosphorylation of hDvl2 in a p38α-independent manner
26172	AZD 3463	1 mg	≥98%	An ALK and IGF-1R inhibitor; inhibits ALK (IC50 = 15 nM); inhibits the proliferation of neuroblastoma cells with WT ALK (IC50s = 2.8-21.3 μM) or ALK containing activating mutations (IC50s = 1.7 and 16.49 μM for ALKF1174L and ALKD1091N, respectively); reduces tumor growth in neuroblastoma mouse xenograft models expressing WT ALK or the ALKF1174L mutation at 15 mg/kg per day for 21 days
26172	AZD 3463	10 mg	≥98%	An ALK and IGF-1R inhibitor; inhibits ALK (IC50 = 15 nM); inhibits the proliferation of neuroblastoma cells with WT ALK (IC50s = 2.8-21.3 μM) or ALK containing activating mutations (IC50s = 1.7 and 16.49 μM for ALKF1174L and ALKD1091N, respectively); reduces tumor growth in neuroblastoma mouse xenograft models expressing WT ALK or the ALKF1174L mutation at 15 mg/kg per day for 21 days
26172	AZD 3463	25 mg	≥98%	An ALK and IGF-1R inhibitor; inhibits ALK (IC50 = 15 nM); inhibits the proliferation of neuroblastoma cells with WT ALK (IC50s = 2.8-21.3 μM) or ALK containing activating mutations (IC50s = 1.7 and 16.49 μM for ALKF1174L and ALKD1091N, respectively); reduces tumor growth in neuroblastoma mouse xenograft models expressing WT ALK or the ALKF1174L mutation at 15 mg/kg per day for 21 days

26172	AZD 3463	5 mg	≥98%	An ALK and IGF-1R inhibitor; inhibits ALK (IC50 = 15 nM); inhibits the proliferation of neuroblastoma cells with WT ALK (IC50s = 2.8-21.3 μM) or ALK containing activating mutations (IC50s = 1.7 and 16.49 μM for ALKF1174L and ALKD1091N, respectively); reduces tumor growth in neuroblastoma mouse xenograft models expressing WT ALK or the ALKF1174L mutation at 15 mg/kg per day for 21 days
26174	c-Kit-IN-1	1 mg	≥98%	A dual inhibitor of c-Kit and c-MET (IC50s = 50s = 50 = <0.2 μM)
26174	c-Kit-IN-1	10 mg	≥98%	A dual inhibitor of c-Kit and c-MET (IC50s = 50s = 50 = <0.2 μM)
26174	c-Kit-IN-1	25 mg	≥98%	A dual inhibitor of c-Kit and c-MET (IC50s = 50s = 50 = <0.2 μM)
26174	c-Kit-IN-1	5 mg	≥98%	A dual inhibitor of c-Kit and c-MET (IC50s = 50s = 50 = <0.2 μM)
26180	BMS 794833	1 mg	≥98%	An inhibitor of c-Met and VEGFR2 (IC50s = 1.7 and 15 nM, respectively); inhibits proliferation of GTL-16 gastric carcinoma cells (IC50 = 39 nM); induces tumor stasis in GTL-16 and U87 mouse xenograft models at 25 mg/kg
26180	BMS 794833	10 mg	≥98%	An inhibitor of c-Met and VEGFR2 (IC50s = 1.7 and 15 nM, respectively); inhibits proliferation of GTL-16 gastric carcinoma cells (IC50 = 39 nM); induces tumor stasis in GTL-16 and U87 mouse xenograft models at 25 mg/kg
26180	BMS 794833	25 mg	≥98%	An inhibitor of c-Met and VEGFR2 (IC50s = 1.7 and 15 nM, respectively); inhibits proliferation of GTL-16 gastric carcinoma cells (IC50 = 39 nM); induces tumor stasis in GTL-16 and U87 mouse xenograft models at 25 mg/kg
26180	BMS 794833	5 mg	≥98%	An inhibitor of c-Met and VEGFR2 (IC50s = 1.7 and 15 nM, respectively); inhibits proliferation of GTL-16 gastric carcinoma cells (IC50 = 39 nM); induces tumor stasis in GTL-16 and U87 mouse xenograft models at 25 mg/kg
26182	GSK180736A	10 mg	≥98%	A ROCK1 and GRK2 inhibitor (IC50s = 14 and 0.77 μM, respectively); selective for GRK2 over GRK1, GRK5, and PKA (IC50 = >100 μM for all); selective for ROCK1 over RSK1 and p20S6K (IC50s = 3,100 and 2,850 nM, respectively); increases maximum contractility in isolated mouse cardiomyocytes at 1 μM
26182	GSK180736A	25 mg	≥98%	A ROCK1 and GRK2 inhibitor (IC50s = 14 and 0.77 μM, respectively); selective for GRK2 over GRK1, GRK5, and PKA (IC50 = >100 μM for all); selective for ROCK1 over RSK1 and p20S6K (IC50s = 3,100 and 2,850 nM, respectively); increases maximum contractility in isolated mouse cardiomyocytes at 1 μM
26182	GSK180736A	5 mg	≥98%	A ROCK1 and GRK2 inhibitor (IC50s = 14 and 0.77 μM, respectively); selective for GRK2 over GRK1, GRK5, and PKA (IC50 = >100 μM for all); selective for ROCK1 over RSK1 and p20S6K (IC50s = 3,100 and 2,850 nM, respectively); increases maximum contractility in isolated mouse cardiomyocytes at 1 μM
26182	GSK180736A	50 mg	≥98%	A ROCK1 and GRK2 inhibitor (IC50s = 14 and 0.77 μM, respectively); selective for GRK2 over GRK1, GRK5, and PKA (IC50 = >100 μM for all); selective for ROCK1 over RSK1 and p20S6K (IC50s = 3,100 and 2,850 nM, respectively); increases maximum contractility in isolated mouse cardiomyocytes at 1 μM
26184	CC-671	1 mg	≥95%	A dual inhibitor of Mps1/TTK and Clk2 (IC50s = 5 and 3 nM, respectively); selective for Mps1/TTK and Clk2 over a panel of 255 kinases at 3 μM; inhibit DYRK3, DYRK1A, PHKG, DYRK1B, and Clk1 (IC50s = 99, 104, 136, 157, and 300 nM, respectively); selectively inhibits the growth of Cal-51 TNBC cell over BT-474 luminal breast cancer cells (IC50s = 60 and 6,970 nM, respectively); reduces tumor volume in a Cal-51 mouse xenograft model at 20 mg/kg
26184	CC-671	10 mg	≥95%	A dual inhibitor of Mps1/TTK and Clk2 (IC50s = 5 and 3 nM, respectively); selective for Mps1/TTK and Clk2 over a panel of 255 kinases at 3 μM; inhibit DYRK3, DYRK1A, PHKG, DYRK1B, and Clk1 (IC50s = 99, 104, 136, 157, and 300 nM, respectively); selectively inhibits the growth of Cal-51 TNBC cell over BT-474 luminal breast cancer cells (IC50s = 60 and 6,970 nM, respectively); reduces tumor volume in a Cal-51 mouse xenograft model at 20 mg/kg
26184	CC-671	5 mg	≥95%	A dual inhibitor of Mps1/TTK and Clk2 (IC50s = 5 and 3 nM, respectively); selective for Mps1/TTK and Clk2 over a panel of 255 kinases at 3 μM; inhibit DYRK3, DYRK1A, PHKG, DYRK1B, and Clk1 (IC50s = 99, 104, 136, 157, and 300 nM, respectively); selectively inhibits the growth of Cal-51 TNBC cell over BT-474 luminal breast cancer cells (IC50s = 60 and 6,970 nM, respectively); reduces tumor volume in a Cal-51 mouse xenograft model at 20 mg/kg
26185	CCT241736	10 mg	≥90%	A dual inhibitor of Aurora kinase (Kds = 7.5 and 48 nM for Aurora A and B, respectively) and FLT3 (Kds = 6.2, 38, and 14 nM for wild-type, FLT3ITD, and FLT3D835Y, respectively); inhibits the activity of 22 additional kinases by >90% in a panel of 386 nonmutant kinases at 1 μM; inhibits cell growth of SW620, HCT116, MOLM-13, and MV4-11 cancer cells (GI50s = 1, 0.3, 0.1, and 0.3 μM, respectively); oral administration reduces tumor growth by 58% in an MV4-11 mouse xenograft model at 50 mg/kg

26185	CCT241736	25 mg	≥90%	A dual inhibitor of Aurora kinase (Kds = 7.5 and 48 nM for Aurora A and B, respectively) and FLT3 (Kds = 6.2, 38, and 14 nM for wild-type, FLT3ITD, and FLT3D835Y, respectively); inhibits the activity of 22 additional kinases by >90% in a panel of 386 nonmutant kinases at 1 μM; inhibits cell growth of SW620, HCT116, MOLM-13, and MV4-11 cancer cells (GI50s = 1, 0.3, 0.1, and 0.3 μM, respectively); oral administration reduces tumor growth by 58% in an MV4-11 mouse xenograft model at 50 mg/kg
26185	CCT241736	5 mg	≥90%	A dual inhibitor of Aurora kinase (Kds = 7.5 and 48 nM for Aurora A and B, respectively) and FLT3 (Kds = 6.2, 38, and 14 nM for wild-type, FLT3ITD, and FLT3D835Y, respectively); inhibits the activity of 22 additional kinases by >90% in a panel of 386 nonmutant kinases at 1 μM; inhibits cell growth of SW620, HCT116, MOLM-13, and MV4-11 cancer cells (GI50s = 1, 0.3, 0.1, and 0.3 μM, respectively); oral administration reduces tumor growth by 58% in an MV4-11 mouse xenograft model at 50 mg/kg
26185	CCT241736	50 mg	≥90%	A dual inhibitor of Aurora kinase (Kds = 7.5 and 48 nM for Aurora A and B, respectively) and FLT3 (Kds = 6.2, 38, and 14 nM for wild-type, FLT3ITD, and FLT3D835Y, respectively); inhibits the activity of 22 additional kinases by >90% in a panel of 386 nonmutant kinases at 1 μM; inhibits cell growth of SW620, HCT116, MOLM-13, and MV4-11 cancer cells (GI50s = 1, 0.3, 0.1, and 0.3 μM, respectively); oral administration reduces tumor growth by 58% in an MV4-11 mouse xenograft model at 50 mg/kg
26187	Pexmetinib	1 mg	≥98%	A dual inhibitor of Tie2 and p38 MAPK (IC50s = 1, 26, and 35 nM for Tie2, p38α, and p38β, respectively); inhibits Abl, ARG, FGFR, FLT1, FLT4, Fyn, HCK, LYN, and MINK (IC50s = 4, 10, 28, 47, 42, 41, 26, 25, and 26 nM, respectively); reduces proliferation of KG-1 and KT-1 leukemic cells in vitro
26187	Pexmetinib	10 mg	≥98%	A dual inhibitor of Tie2 and p38 MAPK (IC50s = 1, 26, and 35 nM for Tie2, p38α, and p38β, respectively); inhibits Abl, ARG, FGFR, FLT1, FLT4, Fyn, HCK, LYN, and MINK (IC50s = 4, 10, 28, 47, 42, 41, 26, 25, and 26 nM, respectively); reduces proliferation of KG-1 and KT-1 leukemic cells in vitro
26187	Pexmetinib	5 mg	≥98%	A dual inhibitor of Tie2 and p38 MAPK (IC50s = 1, 26, and 35 nM for Tie2, p38α, and p38β, respectively); inhibits Abl, ARG, FGFR, FLT1, FLT4, Fyn, HCK, LYN, and MINK (IC50s = 4, 10, 28, 47, 42, 41, 26, 25, and 26 nM, respectively); reduces proliferation of KG-1 and KT-1 leukemic cells in vitro
26188	UM-164	1 mg	≥98%	An inhibitor of Src and p38 MAPK kinases (Kds = 2.7, 2.2, and 5.5 nM for c-Src, p38α, and p38β, respectively); also inhibits Fyn, Yes, Lyn, Abl, Arg, Ack, Csk, EphB2, EphB4, and Zak at 500 nM; inhibits cell growth in a panel of TNBC cell lines (IC50s = 6.1-260 nM) and in a patient-derived TNBC cell line (IC50 = 320 nM); induces cell cycle arrest at the G1/S phase MDA-MB-231 and SUM149 cells at 1 μM; inhibits cell motility and invasion in MDA-MB-231 and SUM149 cells at ≥ 50 nM; reduces tumor growth in SUM149 and MDA-MB-231 mouse xenograft models at ≥10 mg/kg
26188	UM-164	10 mg	≥98%	An inhibitor of Src and p38 MAPK kinases (Kds = 2.7, 2.2, and 5.5 nM for c-Src, p38α, and p38β, respectively); also inhibits Fyn, Yes, Lyn, Abl, Arg, Ack, Csk, EphB2, EphB4, and Zak at 500 nM; inhibits cell growth in a panel of TNBC cell lines (IC50s = 6.1-260 nM) and in a patient-derived TNBC cell line (IC50 = 320 nM); induces cell cycle arrest at the G1/S phase MDA-MB-231 and SUM149 cells at 1 μM; inhibits cell motility and invasion in MDA-MB-231 and SUM149 cells at ≥ 50 nM; reduces tumor growth in SUM149 and MDA-MB-231 mouse xenograft models at ≥10 mg/kg
26188	UM-164	25 mg	≥98%	An inhibitor of Src and p38 MAPK kinases (Kds = 2.7, 2.2, and 5.5 nM for c-Src, p38α, and p38β, respectively); also inhibits Fyn, Yes, Lyn, Abl, Arg, Ack, Csk, EphB2, EphB4, and Zak at 500 nM; inhibits cell growth in a panel of TNBC cell lines (IC50s = 6.1-260 nM) and in a patient-derived TNBC cell line (IC50 = 320 nM); induces cell cycle arrest at the G1/S phase MDA-MB-231 and SUM149 cells at 1 μM; inhibits cell motility and invasion in MDA-MB-231 and SUM149 cells at ≥ 50 nM; reduces tumor growth in SUM149 and MDA-MB-231 mouse xenograft models at ≥10 mg/kg
26188	UM-164	5 mg	≥98%	An inhibitor of Src and p38 MAPK kinases (Kds = 2.7, 2.2, and 5.5 nM for c-Src, p38α, and p38β, respectively); also inhibits Fyn, Yes, Lyn, Abl, Arg, Ack, Csk, EphB2, EphB4, and Zak at 500 nM; inhibits cell growth in a panel of TNBC cell lines (IC50s = 6.1-260 nM) and in a patient-derived TNBC cell line (IC50 = 320 nM); induces cell cycle arrest at the G1/S phase MDA-MB-231 and SUM149 cells at 1 μM; inhibits cell motility and invasion in MDA-MB-231 and SUM149 cells at ≥ 50 nM; reduces tumor growth in SUM149 and MDA-MB-231 mouse xenograft models at ≥10 mg/kg
26190	MK-8745	10 mg	≥98%	An Aurora A kinase inhibitor (IC50 = 0.6 nM); selective for Aurora A over Aurora B kinase (IC50 = 280 nM); induces cell cycle arrest at the G2/M phase in non-Hodgkin lymphoma cells at 1 μM; induces apoptosis and polyploidy in p53-positive and -negative HCT116 colon cancer cells, respectively, at 5 μM; induces apoptosis in sarcoma, melanoma, and pancreatic cancer cell lines in a p53-dependent manner at 5 μM
26190	MK-8745	25 mg	≥98%	An Aurora A kinase inhibitor (IC50 = 0.6 nM); selective for Aurora A over Aurora B kinase (IC50 = 280 nM); induces cell cycle arrest at the G2/M phase in non-Hodgkin lymphoma cells at 1 μM; induces apoptosis and polyploidy in p53-positive and -negative HCT116 colon cancer cells, respectively, at 5 μM; induces apoptosis in sarcoma, melanoma, and pancreatic cancer cell lines in a p53-dependent manner at 5 μM
26190	MK-8745	5 mg	≥98%	An Aurora A kinase inhibitor (IC50 = 0.6 nM); selective for Aurora A over Aurora B kinase (IC50 = 280 nM); induces cell cycle arrest at the G2/M phase in non-Hodgkin lymphoma cells at 1 μM; induces apoptosis and polyploidy in p53-positive and -negative HCT116 colon cancer cells, respectively, at 5 μM; induces apoptosis in sarcoma, melanoma, and pancreatic cancer cell lines in a p53-dependent manner at 5 μM

26190	MK-8745	50 mg	≥98%	An Aurora A kinase inhibitor (IC50 = 0.6 nM); selective for Aurora A over Aurora B kinase (IC50 = 280 nM); induces cell cycle arrest at the G2/M phase in non-Hodgkin lymphoma cells at 1 μM; induces apoptosis and polyploidy in p53-positive and -negative HCT116 colon cancer cells, respectively, at 5 μM; induces apoptosis in sarcoma, melanoma, and pancreatic cancer cell lines in a p53-dependent manner at 5 μM
26203	Telatinib	10 mg	≥98%	A multi-kinase inhibitor; inhibits VEGFR2, VEGFR3, PDGFRα, and c-Kit (IC50s = 6, 4, 15, and 1 nM, respectively); binds to the transmembrane region of the ABCG2 efflux transporter and enhances intracellular accumulation of [3H]-mitoxantrone in ABCG2-overexpressing cells; decreases tumor growth rate and size in an H460/MX20 mouse xenograft model at 15 mg/kg
26203	Telatinib	25 mg	≥98%	A multi-kinase inhibitor; inhibits VEGFR2, VEGFR3, PDGFRα, and c-Kit (IC50s = 6, 4, 15, and 1 nM, respectively); binds to the transmembrane region of the ABCG2 efflux transporter and enhances intracellular accumulation of [3H]-mitoxantrone in ABCG2-overexpressing cells; decreases tumor growth rate and size in an H460/MX20 mouse xenograft model at 15 mg/kg
26203	Telatinib	5 mg	≥98%	A multi-kinase inhibitor; inhibits VEGFR2, VEGFR3, PDGFRα, and c-Kit (IC50s = 6, 4, 15, and 1 nM, respectively); binds to the transmembrane region of the ABCG2 efflux transporter and enhances intracellular accumulation of [3H]-mitoxantrone in ABCG2-overexpressing cells; decreases tumor growth rate and size in an H460/MX20 mouse xenograft model at 15 mg/kg
26203	Telatinib	50 mg	≥98%	A multi-kinase inhibitor; inhibits VEGFR2, VEGFR3, PDGFRα, and c-Kit (IC50s = 6, 4, 15, and 1 nM, respectively); binds to the transmembrane region of the ABCG2 efflux transporter and enhances intracellular accumulation of [3H]-mitoxantrone in ABCG2-overexpressing cells; decreases tumor growth rate and size in an H460/MX20 mouse xenograft model at 15 mg/kg
26210	HMN-214	1 mg	≥98%	A prodrug form of the PLK inhibitor HMN-176; decreases MDR1 expression in AB-A.1 cells and in tumors isolated from mice bearing multidrug resistant KB-A.1. xenografts; reduces tumor volume in PC3, WiDr, and A549 mouse xenograft models at 20 mg/kg per day; does not induce nerve toxicity in rabbit sciatic nerves in vivo at 30 mg/kg per day
26210	HMN-214	10 mg	≥98%	A prodrug form of the PLK inhibitor HMN-176; decreases MDR1 expression in AB-A.1 cells and in tumors isolated from mice bearing multidrug resistant KB-A.1. xenografts; reduces tumor volume in PC3, WiDr, and A549 mouse xenograft models at 20 mg/kg per day; does not induce nerve toxicity in rabbit sciatic nerves in vivo at 30 mg/kg per day
26210	HMN-214	25 mg	≥98%	A prodrug form of the PLK inhibitor HMN-176; decreases MDR1 expression in AB-A.1 cells and in tumors isolated from mice bearing multidrug resistant KB-A.1. xenografts; reduces tumor volume in PC3, WiDr, and A549 mouse xenograft models at 20 mg/kg per day; does not induce nerve toxicity in rabbit sciatic nerves in vivo at 30 mg/kg per day
26210	HMN-214	5 mg	≥98%	A prodrug form of the PLK inhibitor HMN-176; decreases MDR1 expression in AB-A.1 cells and in tumors isolated from mice bearing multidrug resistant KB-A.1. xenografts; reduces tumor volume in PC3, WiDr, and A549 mouse xenograft models at 20 mg/kg per day; does not induce nerve toxicity in rabbit sciatic nerves in vivo at 30 mg/kg per day
26380	AZ 32	1 mg	≥98%	An ATM kinase inhibitor (IC50 = 50s = 4.6 and >4.6 μM, respectively); enhances radiation-induced cytotoxicity in a panel of five human glioma cells expressing wild-type or mutant p53; increases survival in a U87-281G glioma orthotopic mouse xenograft model, as well as a NCI H2228 NSCLC mouse xenograft model of metastatic brain tumors, at 200 and 50 mg/kg, respectively, in combination with ionizing radiation
26380	AZ 32	10 mg	≥98%	An ATM kinase inhibitor (IC50 = 50s = 4.6 and >4.6 μM, respectively); enhances radiation-induced cytotoxicity in a panel of five human glioma cells expressing wild-type or mutant p53; increases survival in a U87-281G glioma orthotopic mouse xenograft model, as well as a NCI H2228 NSCLC mouse xenograft model of metastatic brain tumors, at 200 and 50 mg/kg, respectively, in combination with ionizing radiation
26380	AZ 32	25 mg	≥98%	An ATM kinase inhibitor (IC50 = 50s = 4.6 and >4.6 μM, respectively); enhances radiation-induced cytotoxicity in a panel of five human glioma cells expressing wild-type or mutant p53; increases survival in a U87-281G glioma orthotopic mouse xenograft model, as well as a NCI H2228 NSCLC mouse xenograft model of metastatic brain tumors, at 200 and 50 mg/kg, respectively, in combination with ionizing radiation
26380	AZ 32	5 mg	≥98%	An ATM kinase inhibitor (IC50 = 50s = 4.6 and >4.6 μM, respectively); enhances radiation-induced cytotoxicity in a panel of five human glioma cells expressing wild-type or mutant p53; increases survival in a U87-281G glioma orthotopic mouse xenograft model, as well as a NCI H2228 NSCLC mouse xenograft model of metastatic brain tumors, at 200 and 50 mg/kg, respectively, in combination with ionizing radiation
26383	Hispidulin	1 mg	≥95%	A flavonoid with diverse biological activities; inhibits PAF-, arachidonic acid-, and ADP-induced platelet aggregation (IC50s = 20, 4, and 13 μM, respectively); inhibits RANKL-induced osteoclastic differentiation of RAW 264.7 cells and BMMs; inhibits LPS-induced bone resorption in mice at 25 μg/kg; inhibits tumor growth in a Caki-2 mouse xenograft model; reduces sevoflurane-induced cognitive deficits in aged rats at 40 mg/kg; decreases infarct size and brain edema in a rat model of focal cerebral ischemia and reperfusion injury

26383	Hispidulin	10 mg	≥95%	A flavonoid with diverse biological activities; inhibits PAF-, arachidonic acid-, and ADP-induced platelet aggregation (IC50s = 20, 4, and 13 μM, respectively); inhibits RANKL-induced osteoclastic differentiation of RAW 264.7 cells and BMMs; inhibits LPS-induced bone resorption in mice at 25 μg/kg; inhibits tumor growth in a Caki-2 mouse xenograft model; reduces sevoflurane-induced cognitive deficits in aged rats at 40 mg/kg; decreases infarct size and brain edema in a rat model of focal cerebral ischemia and reperfusion injury
26383	Hispidulin	25 mg	≥95%	A flavonoid with diverse biological activities; inhibits PAF-, arachidonic acid-, and ADP-induced platelet aggregation (IC50s = 20, 4, and 13 μM, respectively); inhibits RANKL-induced osteoclastic differentiation of RAW 264.7 cells and BMMs; inhibits LPS-induced bone resorption in mice at 25 μg/kg; inhibits tumor growth in a Caki-2 mouse xenograft model; reduces sevoflurane-induced cognitive deficits in aged rats at 40 mg/kg; decreases infarct size and brain edema in a rat model of focal cerebral ischemia and reperfusion injury
26383	Hispidulin	5 mg	≥95%	A flavonoid with diverse biological activities; inhibits PAF-, arachidonic acid-, and ADP-induced platelet aggregation (IC50s = 20, 4, and 13 μM, respectively); inhibits RANKL-induced osteoclastic differentiation of RAW 264.7 cells and BMMs; inhibits LPS-induced bone resorption in mice at 25 μg/kg; inhibits tumor growth in a Caki-2 mouse xenograft model; reduces sevoflurane-induced cognitive deficits in aged rats at 40 mg/kg; decreases infarct size and brain edema in a rat model of focal cerebral ischemia and reperfusion injury
26386	THZ531	1 mg	≥95%	An inhibitor of Cdk12 and Cdk13 (IC50s = 158 and 69 nM for Cdk12/cyclin K and Cdk13/cyclin K, respectively); selective for Cdk12/cyclin K and Cdk13/cyclin K over Cdk9/cyclin T1 and Cdk7/cyclin H/MAT1 (IC50s = 10.5 and 8.5 μM, respectively); inhibits proliferation of Jurkat cells (IC50 = 50 nM); induces apoptosis in Jurkat cells in a concentration-dependent manner; reduces expression of genes associated with the DNA damage response, including BRCA1, FANCF, and ERCC4, in Jurkat cells at 50 nM
26386	THZ531	10 mg	≥95%	An inhibitor of Cdk12 and Cdk13 (IC50s = 158 and 69 nM for Cdk12/cyclin K and Cdk13/cyclin K, respectively); selective for Cdk12/cyclin K and Cdk13/cyclin K over Cdk9/cyclin T1 and Cdk7/cyclin H/MAT1 (IC50s = 10.5 and 8.5 μM, respectively); inhibits proliferation of Jurkat cells (IC50 = 50 nM); induces apoptosis in Jurkat cells in a concentration-dependent manner; reduces expression of genes associated with the DNA damage response, including BRCA1, FANCF, and ERCC4, in Jurkat cells at 50 nM
26386	THZ531	25 mg	≥95%	An inhibitor of Cdk12 and Cdk13 (IC50s = 158 and 69 nM for Cdk12/cyclin K and Cdk13/cyclin K, respectively); selective for Cdk12/cyclin K and Cdk13/cyclin K over Cdk9/cyclin T1 and Cdk7/cyclin H/MAT1 (IC50s = 10.5 and 8.5 μM, respectively); inhibits proliferation of Jurkat cells (IC50 = 50 nM); induces apoptosis in Jurkat cells in a concentration-dependent manner; reduces expression of genes associated with the DNA damage response, including BRCA1, FANCF, and ERCC4, in Jurkat cells at 50 nM
26386	THZ531	5 mg	≥95%	An inhibitor of Cdk12 and Cdk13 (IC50s = 158 and 69 nM for Cdk12/cyclin K and Cdk13/cyclin K, respectively); selective for Cdk12/cyclin K and Cdk13/cyclin K over Cdk9/cyclin T1 and Cdk7/cyclin H/MAT1 (IC50s = 10.5 and 8.5 μM, respectively); inhibits proliferation of Jurkat cells (IC50 = 50 nM); induces apoptosis in Jurkat cells in a concentration-dependent manner; reduces expression of genes associated with the DNA damage response, including BRCA1, FANCF, and ERCC4, in Jurkat cells at 50 nM
26410	CH5132799	10 mg	≥95%	An inhibitor of class I PI3K isoforms (IC50s = 14, 120, 500, and 36 nM for PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ, respectively); selective for these PI3K isoforms over PI3KC2α, PI3KC2β, Vps34, and mTOR (IC50s = 5,300, >10,000, >10,000, and 1,600 nM, respectively), as well as 26 additional protein kinases (IC50s = >10,000 nM); inhibits proliferation of HCT116, KPL-4, T47D, and SKOV3 cells containing the PI3KαH1047R activating mutation (IC50s = 200, 32, 56, and 120 nM, respectively); reduces tumor growth in a PC3 mouse xenograft model at 25 mg/kg per day
26410	CH5132799	25 mg	≥95%	An inhibitor of class I PI3K isoforms (IC50s = 14, 120, 500, and 36 nM for PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ, respectively); selective for these PI3K isoforms over PI3KC2α, PI3KC2β, Vps34, and mTOR (IC50s = 5,300, >10,000, >10,000, and 1,600 nM, respectively), as well as 26 additional protein kinases (IC50s = >10,000 nM); inhibits proliferation of HCT116, KPL-4, T47D, and SKOV3 cells containing the PI3KαH1047R activating mutation (IC50s = 200, 32, 56, and 120 nM, respectively); reduces tumor growth in a PC3 mouse xenograft model at 25 mg/kg per day
26410	CH5132799	5 mg	≥95%	An inhibitor of class I PI3K isoforms (IC50s = 14, 120, 500, and 36 nM for PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ, respectively); selective for these PI3K isoforms over PI3KC2α, PI3KC2β, Vps34, and mTOR (IC50s = 5,300, >10,000, >10,000, and 1,600 nM, respectively), as well as 26 additional protein kinases (IC50s = >10,000 nM); inhibits proliferation of HCT116, KPL-4, T47D, and SKOV3 cells containing the PI3KαH1047R activating mutation (IC50s = 200, 32, 56, and 120 nM, respectively); reduces tumor growth in a PC3 mouse xenograft model at 25 mg/kg per day

26410	CH5132799	50 mg	≥95%	An inhibitor of class I PI3K isoforms (IC50s = 14, 120, 500, and 36 nM for PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ, respectively); selective for these PI3K isoforms over PI3KC2α, PI3KC2β, Vps34, and mTOR (IC50s = 5,300, >10,000, >10,000, and 1,600 nM, respectively), as well as 26 additional protein kinases (IC50s = >10,000 nM); inhibits proliferation of HCT116, KPL-4, T47D, and SKOV3 cells containing the PI3KαH1047R activating mutation (IC50s = 200, 32, 56, and 120 nM, respectively); reduces tumor growth in a PC3 mouse xenograft model at 25 mg/kg per day
26416	IPI-549	1 mg	≥98%	An inhibitor of PI3Kγ (IC50s = 16, 3,200, 3,500, and >8,400 nM for PI3Kγ, PI3Kα, PI3Kβ, and PI3Kδ, respectively); selective for PI3Kγ over a panel of 468 mutant and nonmutant protein and lipid kinases and a panel of G protein-coupled receptors, ion channels, and transporters at 10 µM; inhibits migration of BMDMs (IC50 = 85 nM); sensitizes doxorubicin-resistant SW620/Ad300 cells to P-gp substrates, such as paclitaxel (IC50s = 710 and 6.7 nM for paclitaxel alone and in combination with IPI-549, respectively); enhances the tumor growth reduction of paclitaxel in an SW620/Ad300 mouse xenograft model at 3 mg/kg in combination with paclitaxel
26416	IPI-549	10 mg	≥98%	An inhibitor of PI3Kγ (IC50s = 16, 3,200, 3,500, and >8,400 nM for PI3Kγ, PI3Kα, PI3Kβ, and PI3Kδ, respectively); selective for PI3Kγ over a panel of 468 mutant and nonmutant protein and lipid kinases and a panel of G protein-coupled receptors, ion channels, and transporters at 10 µM; inhibits migration of BMDMs (IC50 = 85 nM); sensitizes doxorubicin-resistant SW620/Ad300 cells to P-gp substrates, such as paclitaxel (IC50s = 710 and 6.7 nM for paclitaxel alone and in combination with IPI-549, respectively); enhances the tumor growth reduction of paclitaxel in an SW620/Ad300 mouse xenograft model at 3 mg/kg in combination with paclitaxel
26416	IPI-549	25 mg	≥98%	An inhibitor of PI3Kγ (IC50s = 16, 3,200, 3,500, and >8,400 nM for PI3Kγ, PI3Kα, PI3Kβ, and PI3Kδ, respectively); selective for PI3Kγ over a panel of 468 mutant and nonmutant protein and lipid kinases and a panel of G protein-coupled receptors, ion channels, and transporters at 10 µM; inhibits migration of BMDMs (IC50 = 85 nM); sensitizes doxorubicin-resistant SW620/Ad300 cells to P-gp substrates, such as paclitaxel (IC50s = 710 and 6.7 nM for paclitaxel alone and in combination with IPI-549, respectively); enhances the tumor growth reduction of paclitaxel in an SW620/Ad300 mouse xenograft model at 3 mg/kg in combination with paclitaxel
26416	IPI-549	5 mg	≥98%	An inhibitor of PI3Kγ (IC50s = 16, 3,200, 3,500, and >8,400 nM for PI3Kγ, PI3Kα, PI3Kβ, and PI3Kδ, respectively); selective for PI3Kγ over a panel of 468 mutant and nonmutant protein and lipid kinases and a panel of G protein-coupled receptors, ion channels, and transporters at 10 µM; inhibits migration of BMDMs (IC50 = 85 nM); sensitizes doxorubicin-resistant SW620/Ad300 cells to P-gp substrates, such as paclitaxel (IC50s = 710 and 6.7 nM for paclitaxel alone and in combination with IPI-549, respectively); enhances the tumor growth reduction of paclitaxel in an SW620/Ad300 mouse xenograft model at 3 mg/kg in combination with paclitaxel
26536	BAY-1895344 (hydroc	1 mg	≥98%	An ATR inhibitor; inhibits proliferation in a panel of human tumor cell lines (mean IC50 = 78 nM); halts tumor growth in ovarian and colorectal mouse xenograft models and induces complete tumor remission in mantle cell lymphoma mouse xenograft models; exhibits synergistic anti-tumor activity with radium-223 in a mouse xenograft model of castration-resistant prostate cancer bone metastases
26536	BAY-1895344 (hydroc	10 mg	≥98%	An ATR inhibitor; inhibits proliferation in a panel of human tumor cell lines (mean IC50 = 78 nM); halts tumor growth in ovarian and colorectal mouse xenograft models and induces complete tumor remission in mantle cell lymphoma mouse xenograft models; exhibits synergistic anti-tumor activity with radium-223 in a mouse xenograft model of castration-resistant prostate cancer bone metastases
26536	BAY-1895344 (hydroc	25 mg	≥98%	An ATR inhibitor; inhibits proliferation in a panel of human tumor cell lines (mean IC50 = 78 nM); halts tumor growth in ovarian and colorectal mouse xenograft models and induces complete tumor remission in mantle cell lymphoma mouse xenograft models; exhibits synergistic anti-tumor activity with radium-223 in a mouse xenograft model of castration-resistant prostate cancer bone metastases
26536	BAY-1895344 (hydroc	5 mg	≥98%	An ATR inhibitor; inhibits proliferation in a panel of human tumor cell lines (mean IC50 = 78 nM); halts tumor growth in ovarian and colorectal mouse xenograft models and induces complete tumor remission in mantle cell lymphoma mouse xenograft models; exhibits synergistic anti-tumor activity with radium-223 in a mouse xenograft model of castration-resistant prostate cancer bone metastases
26676	Axitinib-13C-d3	1 mg	≥99% deutera	An internal standard for the quantification of axitinib by GC- or LC-MS
26676	Axitinib-13C-d3	500 µg	≥99% deutera	An internal standard for the quantification of axitinib by GC- or LC-MS
26762	(R)-Crizotinib-d5	1 mg	≥99% deutera	An internal standard for the quantification of (R)-crizotinib by GC- or LC-MS
26762	(R)-Crizotinib-d5	500 µg	≥99% deutera	An internal standard for the quantification of (R)-crizotinib by GC- or LC-MS

26792	B-RAF Inhibitor 1 (hyd	1 mg	≥98%	An inhibitor of Raf kinases (Kis = 0.3, 1, and 1 nM for C-RAF, B-RAF, and B-RAFV600E, respectively); selective for B-RAFV600E kinase domain over Lck, Tie2, KDR, and p38α (IC50s = 83, 120, 1,000, and >1,600 nM, respectively); inhibits phosphorylation of ERK in A375 melanoma cells (IC50 = 1.8 nM); reduces tumor growth in an A375 SQ2 mouse xenograft model (ED50 = 1.3 mg/kg per day) and induces 85% tumor regression at 5 mg/kg per day for 14 days; increases tumor growth in a MIA PaCa-2 mouse xenograft model at 5 and 10 mg/kg per day
26792	B-RAF Inhibitor 1 (hyd	10 mg	≥98%	An inhibitor of Raf kinases (Kis = 0.3, 1, and 1 nM for C-RAF, B-RAF, and B-RAFV600E, respectively); selective for B-RAFV600E kinase domain over Lck, Tie2, KDR, and p38α (IC50s = 83, 120, 1,000, and >1,600 nM, respectively); inhibits phosphorylation of ERK in A375 melanoma cells (IC50 = 1.8 nM); reduces tumor growth in an A375 SQ2 mouse xenograft model (ED50 = 1.3 mg/kg per day) and induces 85% tumor regression at 5 mg/kg per day for 14 days; increases tumor growth in a MIA PaCa-2 mouse xenograft model at 5 and 10 mg/kg per day
26792	B-RAF Inhibitor 1 (hyd	25 mg	≥98%	An inhibitor of Raf kinases (Kis = 0.3, 1, and 1 nM for C-RAF, B-RAF, and B-RAFV600E, respectively); selective for B-RAFV600E kinase domain over Lck, Tie2, KDR, and p38α (IC50s = 83, 120, 1,000, and >1,600 nM, respectively); inhibits phosphorylation of ERK in A375 melanoma cells (IC50 = 1.8 nM); reduces tumor growth in an A375 SQ2 mouse xenograft model (ED50 = 1.3 mg/kg per day) and induces 85% tumor regression at 5 mg/kg per day for 14 days; increases tumor growth in a MIA PaCa-2 mouse xenograft model at 5 and 10 mg/kg per day
26792	B-RAF Inhibitor 1 (hyd	5 mg	≥98%	An inhibitor of Raf kinases (Kis = 0.3, 1, and 1 nM for C-RAF, B-RAF, and B-RAFV600E, respectively); selective for B-RAFV600E kinase domain over Lck, Tie2, KDR, and p38α (IC50s = 83, 120, 1,000, and >1,600 nM, respectively); inhibits phosphorylation of ERK in A375 melanoma cells (IC50 = 1.8 nM); reduces tumor growth in an A375 SQ2 mouse xenograft model (ED50 = 1.3 mg/kg per day) and induces 85% tumor regression at 5 mg/kg per day for 14 days; increases tumor growth in a MIA PaCa-2 mouse xenograft model at 5 and 10 mg/kg per day
26804	PD 166285	1 mg	≥98%	A tyrosine kinase inhibitor; inhibits Src, FGFR1, EGFR, and PDGFRβ (IC50s = 8.4, 39.3, 87.5, and 98.3 nM, respectively), as well as WEE1 (IC50 = 24 nM); inhibits PDGF- or EGF-induced receptor autophosphorylation in VSMCs and A431 cells, respectively, and bFGF-induced tyrosine phosphorylation in Sf9 cells (IC50s = 6.5, 1,600, and 97.3 nM, respectively); inhibits chemotaxis and growth of, as well as adhesion to vitronectin by, VSMCs (IC50s = 80-120 nM); inhibits radiation-induced cell cycle arrest at the G2/M phase and enhances radiation-induced cell death in HT-29 cells; inhibits angiogenesis and induces tumor regression in a 16c murine mammary carcinoma model when administered in combination with PDT at 1, 5, and 10 mg/kg
26804	PD 166285	10 mg	≥98%	A tyrosine kinase inhibitor; inhibits Src, FGFR1, EGFR, and PDGFRβ (IC50s = 8.4, 39.3, 87.5, and 98.3 nM, respectively), as well as WEE1 (IC50 = 24 nM); inhibits PDGF- or EGF-induced receptor autophosphorylation in VSMCs and A431 cells, respectively, and bFGF-induced tyrosine phosphorylation in Sf9 cells (IC50s = 6.5, 1,600, and 97.3 nM, respectively); inhibits chemotaxis and growth of, as well as adhesion to vitronectin by, VSMCs (IC50s = 80-120 nM); inhibits radiation-induced cell cycle arrest at the G2/M phase and enhances radiation-induced cell death in HT-29 cells; inhibits angiogenesis and induces tumor regression in a 16c murine mammary carcinoma model when administered in combination with PDT at 1, 5, and 10 mg/kg
26804	PD 166285	25 mg	≥98%	A tyrosine kinase inhibitor; inhibits Src, FGFR1, EGFR, and PDGFRβ (IC50s = 8.4, 39.3, 87.5, and 98.3 nM, respectively), as well as WEE1 (IC50 = 24 nM); inhibits PDGF- or EGF-induced receptor autophosphorylation in VSMCs and A431 cells, respectively, and bFGF-induced tyrosine phosphorylation in Sf9 cells (IC50s = 6.5, 1,600, and 97.3 nM, respectively); inhibits chemotaxis and growth of, as well as adhesion to vitronectin by, VSMCs (IC50s = 80-120 nM); inhibits radiation-induced cell cycle arrest at the G2/M phase and enhances radiation-induced cell death in HT-29 cells; inhibits angiogenesis and induces tumor regression in a 16c murine mammary carcinoma model when administered in combination with PDT at 1, 5, and 10 mg/kg
26804	PD 166285	5 mg	≥98%	A tyrosine kinase inhibitor; inhibits Src, FGFR1, EGFR, and PDGFRβ (IC50s = 8.4, 39.3, 87.5, and 98.3 nM, respectively), as well as WEE1 (IC50 = 24 nM); inhibits PDGF- or EGF-induced receptor autophosphorylation in VSMCs and A431 cells, respectively, and bFGF-induced tyrosine phosphorylation in Sf9 cells (IC50s = 6.5, 1,600, and 97.3 nM, respectively); inhibits chemotaxis and growth of, as well as adhesion to vitronectin by, VSMCs (IC50s = 80-120 nM); inhibits radiation-induced cell cycle arrest at the G2/M phase and enhances radiation-induced cell death in HT-29 cells; inhibits angiogenesis and induces tumor regression in a 16c murine mammary carcinoma model when administered in combination with PDT at 1, 5, and 10 mg/kg

26808	CMPD101	1 mg	≥98%	A GRK2 and GRK3 inhibitor (IC50s = 18 and 5.4 nM, respectively); selective for GRK2 and GRK3 over GRK1, GRK5, GRK6, and GRK7 (IC50s = 3,100, 2,300, >30,000, and 25,000 nM, respectively), as well as ROCK2 and PKCα (IC50s = 1,400 and 8,100 nM, respectively); induces cAMP accumulation in HEK293 cells expressing human β2-adrenergic receptors (EC50 = 10 μM); inhibits electrical field stimulation-, norepinephrine-, phenylephrine-, endothelin-1-, and U-46619-induced contractions in isolated human prostate strips at 50 μM
26808	CMPD101	10 mg	≥98%	A GRK2 and GRK3 inhibitor (IC50s = 18 and 5.4 nM, respectively); selective for GRK2 and GRK3 over GRK1, GRK5, GRK6, and GRK7 (IC50s = 3,100, 2,300, >30,000, and 25,000 nM, respectively), as well as ROCK2 and PKCα (IC50s = 1,400 and 8,100 nM, respectively); induces cAMP accumulation in HEK293 cells expressing human β2-adrenergic receptors (EC50 = 10 μM); inhibits electrical field stimulation-, norepinephrine-, phenylephrine-, endothelin-1-, and U-46619-induced contractions in isolated human prostate strips at 50 μM
26808	CMPD101	25 mg	≥98%	A GRK2 and GRK3 inhibitor (IC50s = 18 and 5.4 nM, respectively); selective for GRK2 and GRK3 over GRK1, GRK5, GRK6, and GRK7 (IC50s = 3,100, 2,300, >30,000, and 25,000 nM, respectively), as well as ROCK2 and PKCα (IC50s = 1,400 and 8,100 nM, respectively); induces cAMP accumulation in HEK293 cells expressing human β2-adrenergic receptors (EC50 = 10 μM); inhibits electrical field stimulation-, norepinephrine-, phenylephrine-, endothelin-1-, and U-46619-induced contractions in isolated human prostate strips at 50 μM
26808	CMPD101	5 mg	≥98%	A GRK2 and GRK3 inhibitor (IC50s = 18 and 5.4 nM, respectively); selective for GRK2 and GRK3 over GRK1, GRK5, GRK6, and GRK7 (IC50s = 3,100, 2,300, >30,000, and 25,000 nM, respectively), as well as ROCK2 and PKCα (IC50s = 1,400 and 8,100 nM, respectively); induces cAMP accumulation in HEK293 cells expressing human β2-adrenergic receptors (EC50 = 10 μM); inhibits electrical field stimulation-, norepinephrine-, phenylephrine-, endothelin-1-, and U-46619-induced contractions in isolated human prostate strips at 50 μM
26817	SB-1317	10 mg	≥98%	A multi-kinase inhibitor; inhibits various CDKs (IC50s = 3-9 nM), as well as JAK family kinases (IC50s = 14-59 nM), wild-type and mutant FLT3s (IC50s = 19-27 nM), and Src family kinases (IC50s = 11-15 nM); inhibits proliferation in a panel of 12 liquid and six solid tumor cell lines (mean IC50 = 0.19 μM); induces cell cycle arrest at the G1 phase and apoptosis in MV4-11 AML cells; reduces tumor volume and increases survival in an MV4-11 mouse xenograft model at 10, 20, and 40 mg/kg
26817	SB-1317	25 mg	≥98%	A multi-kinase inhibitor; inhibits various CDKs (IC50s = 3-9 nM), as well as JAK family kinases (IC50s = 14-59 nM), wild-type and mutant FLT3s (IC50s = 19-27 nM), and Src family kinases (IC50s = 11-15 nM); inhibits proliferation in a panel of 12 liquid and six solid tumor cell lines (mean IC50 = 0.19 μM); induces cell cycle arrest at the G1 phase and apoptosis in MV4-11 AML cells; reduces tumor volume and increases survival in an MV4-11 mouse xenograft model at 10, 20, and 40 mg/kg
26817	SB-1317	5 mg	≥98%	A multi-kinase inhibitor; inhibits various CDKs (IC50s = 3-9 nM), as well as JAK family kinases (IC50s = 14-59 nM), wild-type and mutant FLT3s (IC50s = 19-27 nM), and Src family kinases (IC50s = 11-15 nM); inhibits proliferation in a panel of 12 liquid and six solid tumor cell lines (mean IC50 = 0.19 μM); induces cell cycle arrest at the G1 phase and apoptosis in MV4-11 AML cells; reduces tumor volume and increases survival in an MV4-11 mouse xenograft model at 10, 20, and 40 mg/kg
26817	SB-1317	50 mg	≥98%	A multi-kinase inhibitor; inhibits various CDKs (IC50s = 3-9 nM), as well as JAK family kinases (IC50s = 14-59 nM), wild-type and mutant FLT3s (IC50s = 19-27 nM), and Src family kinases (IC50s = 11-15 nM); inhibits proliferation in a panel of 12 liquid and six solid tumor cell lines (mean IC50 = 0.19 μM); induces cell cycle arrest at the G1 phase and apoptosis in MV4-11 AML cells; reduces tumor volume and increases survival in an MV4-11 mouse xenograft model at 10, 20, and 40 mg/kg
26911	Altenusin	1 mg	≥98%	A polyphenol fungal metabolite originally isolated from Alternaria that has diverse biological activities; an inhibitor of Src (IC50 = 20 nM); inhibits fibrillization of recombinant tau fragments in vitro; inhibits phosphorylation of tau in SH-SY5Y cells expressing human P301L mutant tau at 10 μM; an FXR agonist (EC50 = 3.2 μM); reduces blood glucose, serum insulin, and serum cholesterol levels, as well as hepatic lipogenic gene expression and steatosis, in a high fat diet-induced mouse model of obesity at 30 mg/kg; has antioxidant and antifungal properties
26911	Altenusin	5 mg	≥98%	A polyphenol fungal metabolite originally isolated from Alternaria that has diverse biological activities; an inhibitor of Src (IC50 = 20 nM); inhibits fibrillization of recombinant tau fragments in vitro; inhibits phosphorylation of tau in SH-SY5Y cells expressing human P301L mutant tau at 10 μM; an FXR agonist (EC50 = 3.2 μM); reduces blood glucose, serum insulin, and serum cholesterol levels, as well as hepatic lipogenic gene expression and steatosis, in a high fat diet-induced mouse model of obesity at 30 mg/kg; has antioxidant and antifungal properties

26911	Altenusin	500 µg	≥98%	A polyphenol fungal metabolite originally isolated from Alternaria that has diverse biological activities; an inhibitor of Src (IC50 = 20 nM); inhibits fibrillization of recombinant tau fragments in vitro; inhibits phosphorylation of tau in SH-SY5Y cells expressing human P301L mutant tau at 10 µM; an FXR agonist (EC50 = 3.2 µM); reduces blood glucose, serum insulin, and serum cholesterol levels, as well as hepatic lipogenic gene expression and steatosis, in a high fat diet-induced mouse model of obesity at 30 mg/kg; has antioxidant and antifungal properties
26955	Roridin E	1 mg	≥95%	A macrocyclic trichothecene mycotoxin that has been found in M. verrucaria; inhibits FGFR3, IGF-1R, PDGFRβ, and TrkB (IC50s = 0.4, 0.4, 1.4, and 1 µM, respectively); induces cytotoxicity in multiple breast cancer cell lines (IC50s = 0.02-0.05 nM); inhibits proliferation in a panel of additional cancer cell lines (IC50s = 50s = 1.74-7.68 nM); inhibits the growth of P. falciparum (EC50 = 0.15 ng/ml); induces phytotoxicity in duckweed and kudzu; toxic to mice (LD50 = 10 mg/kg, i.p.); also produced by the plant B. coridifiola, which is associated with livestock poisoning in South America
26955	Roridin E	500 µg	≥95%	A macrocyclic trichothecene mycotoxin that has been found in M. verrucaria; inhibits FGFR3, IGF-1R, PDGFRβ, and TrkB (IC50s = 0.4, 0.4, 1.4, and 1 µM, respectively); induces cytotoxicity in multiple breast cancer cell lines (IC50s = 0.02-0.05 nM); inhibits proliferation in a panel of additional cancer cell lines (IC50s = 50s = 1.74-7.68 nM); inhibits the growth of P. falciparum (EC50 = 0.15 ng/ml); induces phytotoxicity in duckweed and kudzu; toxic to mice (LD50 = 10 mg/kg, i.p.); also produced by the plant B. coridifiola, which is associated with livestock poisoning in South America
27048	SR 3029	10 mg	≥98%	An inhibitor of CK1δ and CK1ε (IC50s = 44 and 260 nM, respectively); selective for CK1δ and CK1ε over 438 kinases in a panel but also inhibits MYLK4, FLT3, Cdk4/cyclin D1, and MARK2 by >90% at 10 µM; inhibits Cdk4/cyclin D1, Cdk4/cyclin D3, Cdk6/cyclin D1, Cdk6/cyclin D3, and FLT3 (IC50s = 576, 368, 428, 427, and 3,000 nM, respectively); inhibits proliferation of A375 human melanoma cells in vitro (EC50 = 86 nM); reduces tumor growth and increases lifespan in MDA-MB-231 and MDA-MB-468 mouse xenograft models at 20 mg/kg per day; reduces the expression of the Wnt/β-catenin target CCND1 and decreases protein levels of nuclear β-catenin and cyclin D1 in mouse tumor tissue
27048	SR 3029	25 mg	≥98%	An inhibitor of CK1δ and CK1ε (IC50s = 44 and 260 nM, respectively); selective for CK1δ and CK1ε over 438 kinases in a panel but also inhibits MYLK4, FLT3, Cdk4/cyclin D1, and MARK2 by >90% at 10 µM; inhibits Cdk4/cyclin D1, Cdk4/cyclin D3, Cdk6/cyclin D1, Cdk6/cyclin D3, and FLT3 (IC50s = 576, 368, 428, 427, and 3,000 nM, respectively); inhibits proliferation of A375 human melanoma cells in vitro (EC50 = 86 nM); reduces tumor growth and increases lifespan in MDA-MB-231 and MDA-MB-468 mouse xenograft models at 20 mg/kg per day; reduces the expression of the Wnt/β-catenin target CCND1 and decreases protein levels of nuclear β-catenin and cyclin D1 in mouse tumor tissue
27048	SR 3029	5 mg	≥98%	An inhibitor of CK1δ and CK1ε (IC50s = 44 and 260 nM, respectively); selective for CK1δ and CK1ε over 438 kinases in a panel but also inhibits MYLK4, FLT3, Cdk4/cyclin D1, and MARK2 by >90% at 10 µM; inhibits Cdk4/cyclin D1, Cdk4/cyclin D3, Cdk6/cyclin D1, Cdk6/cyclin D3, and FLT3 (IC50s = 576, 368, 428, 427, and 3,000 nM, respectively); inhibits proliferation of A375 human melanoma cells in vitro (EC50 = 86 nM); reduces tumor growth and increases lifespan in MDA-MB-231 and MDA-MB-468 mouse xenograft models at 20 mg/kg per day; reduces the expression of the Wnt/β-catenin target CCND1 and decreases protein levels of nuclear β-catenin and cyclin D1 in mouse tumor tissue
27049	XL647	1 mg	≥98%	A multi-kinase inhibitor (IC50s = 0.3, 16, 1.5, 8.7, and 1.4 nM for EGFR, ErbB2, KDR, FLT4, and EphB4, respectively); selective for these kinases over a panel of 10 tyrosine kinases and 55 serine/threonine kinases at 10 µM; inhibits growth of A431 cells expressing wild-type EGFR and H1975 NSCLC cells expressing both EGFRL858R and EGFRT790M (IC50s = 13 and 920 nM, respectively); inhibits tumor growth and EGFR phosphorylation in an H1975 mouse xenograft model at 10, 30, and 100 mg/kg
27049	XL647	10 mg	≥98%	A multi-kinase inhibitor (IC50s = 0.3, 16, 1.5, 8.7, and 1.4 nM for EGFR, ErbB2, KDR, FLT4, and EphB4, respectively); selective for these kinases over a panel of 10 tyrosine kinases and 55 serine/threonine kinases at 10 µM; inhibits growth of A431 cells expressing wild-type EGFR and H1975 NSCLC cells expressing both EGFRL858R and EGFRT790M (IC50s = 13 and 920 nM, respectively); inhibits tumor growth and EGFR phosphorylation in an H1975 mouse xenograft model at 10, 30, and 100 mg/kg
27049	XL647	5 mg	≥98%	A multi-kinase inhibitor (IC50s = 0.3, 16, 1.5, 8.7, and 1.4 nM for EGFR, ErbB2, KDR, FLT4, and EphB4, respectively); selective for these kinases over a panel of 10 tyrosine kinases and 55 serine/threonine kinases at 10 µM; inhibits growth of A431 cells expressing wild-type EGFR and H1975 NSCLC cells expressing both EGFRL858R and EGFRT790M (IC50s = 13 and 920 nM, respectively); inhibits tumor growth and EGFR phosphorylation in an H1975 mouse xenograft model at 10, 30, and 100 mg/kg
27056	LOXO-101	1 mg	≥98%	A pan-Trk inhibitor (IC50s = 2-20 nM for TrkA, TrkB, and TrkC); selective for TrkA, -B, and -C over a panel of 226 kinases at 1 µM; inhibits the growth of CUTO-3.29, KM12, and MO-91 patient-derived cancer cell lines (IC50s = <100, <10, and <10 nM, respectively); reduces tumor growth in a KM12 mouse xenograft model at 60 and 200 mg/kg

27056	LOXO-101	10 mg	≥98%	A pan-Trk inhibitor (IC50s = 2-20 nM for TrkA, TrkB, and TrkC); selective for TrkA, -B, and -C over a panel of 226 kinases at 1 µM; inhibits the growth of CUTO-3.29, KM12, and MO-91 patient-derived cancer cell lines (IC50s = <100, <10, and <10 nM, respectively); reduces tumor growth in a KM12 mouse xenograft model at 60 and 200 mg/kg
27056	LOXO-101	25 mg	≥98%	A pan-Trk inhibitor (IC50s = 2-20 nM for TrkA, TrkB, and TrkC); selective for TrkA, -B, and -C over a panel of 226 kinases at 1 µM; inhibits the growth of CUTO-3.29, KM12, and MO-91 patient-derived cancer cell lines (IC50s = <100, <10, and <10 nM, respectively); reduces tumor growth in a KM12 mouse xenograft model at 60 and 200 mg/kg
27056	LOXO-101	5 mg	≥98%	A pan-Trk inhibitor (IC50s = 2-20 nM for TrkA, TrkB, and TrkC); selective for TrkA, -B, and -C over a panel of 226 kinases at 1 µM; inhibits the growth of CUTO-3.29, KM12, and MO-91 patient-derived cancer cell lines (IC50s = <100, <10, and <10 nM, respectively); reduces tumor growth in a KM12 mouse xenograft model at 60 and 200 mg/kg
27062	LOXO-195	1 mg	≥98%	An inhibitor of TrkA and TrkC (IC50s = 0.6 and G595R, TrkAG667C, TrkCG623R, and TrkCG696A (IC50s = 2, 9.8, 2.3, and 50 = 1.9 nM); selectively inhibits proliferation of Trk fusion-positive K12, CUTO-3, and MO-91 cell lines (IC50s = ≤5 nM) over Trk fusion-negative cell lines; reduces tumor growth in TrkA-dependent KM12, as well as NIH 3T3 ΔTrkA, ΔTrkA + TrkAG595R, and ΔTrkA + TrkAG667C mouse xenograft models at ≥30 mg/kg
27062	LOXO-195	10 mg	≥98%	An inhibitor of TrkA and TrkC (IC50s = 0.6 and G595R, TrkAG667C, TrkCG623R, and TrkCG696A (IC50s = 2, 9.8, 2.3, and 50 = 1.9 nM); selectively inhibits proliferation of Trk fusion-positive K12, CUTO-3, and MO-91 cell lines (IC50s = ≤5 nM) over Trk fusion-negative cell lines; reduces tumor growth in TrkA-dependent KM12, as well as NIH 3T3 ΔTrkA, ΔTrkA + TrkAG595R, and ΔTrkA + TrkAG667C mouse xenograft models at ≥30 mg/kg
27062	LOXO-195	5 mg	≥98%	An inhibitor of TrkA and TrkC (IC50s = 0.6 and G595R, TrkAG667C, TrkCG623R, and TrkCG696A (IC50s = 2, 9.8, 2.3, and 50 = 1.9 nM); selectively inhibits proliferation of Trk fusion-positive K12, CUTO-3, and MO-91 cell lines (IC50s = ≤5 nM) over Trk fusion-negative cell lines; reduces tumor growth in TrkA-dependent KM12, as well as NIH 3T3 ΔTrkA, ΔTrkA + TrkAG595R, and ΔTrkA + TrkAG667C mouse xenograft models at ≥30 mg/kg
27176	BIBF 1202	1 mg	≥95%	An active metabolite of BIBF 1120; inhibits VEGFR2 (IC50 = 62 nM)
27176	BIBF 1202	10 mg	≥95%	An active metabolite of BIBF 1120; inhibits VEGFR2 (IC50 = 62 nM)
27176	BIBF 1202	5 mg	≥95%	An active metabolite of BIBF 1120; inhibits VEGFR2 (IC50 = 62 nM)
27310	SU 5205	100 mg	≥98%	An inhibitor of VEGFR2/FLK1 (IC50 = 9.6 µM); inhibits HUVEC mitogenesis induced by VEGF or acidic FGF (IC50s = 0.9 and 0.6 µM, respectively)
27310	SU 5205	250 mg	≥98%	An inhibitor of VEGFR2/FLK1 (IC50 = 9.6 µM); inhibits HUVEC mitogenesis induced by VEGF or acidic FGF (IC50s = 0.9 and 0.6 µM, respectively)
27310	SU 5205	50 mg	≥98%	An inhibitor of VEGFR2/FLK1 (IC50 = 9.6 µM); inhibits HUVEC mitogenesis induced by VEGF or acidic FGF (IC50s = 0.9 and 0.6 µM, respectively)
27311	Lavendustin B	10 mg	≥95%	An inhibitor of Glut1 (Ki = 15 µM); an inhibitor of the interaction between HIV-1 integrase and LEDGF/p75 (IC50 = 94.07 µM); a weak inhibitor of tyrosine kinases (IC50 = 0.49 µg/ml); and has been used as a negative control for lavendustin A
27311	Lavendustin B	25 mg	≥95%	An inhibitor of Glut1 (Ki = 15 µM); an inhibitor of the interaction between HIV-1 integrase and LEDGF/p75 (IC50 = 94.07 µM); a weak inhibitor of tyrosine kinases (IC50 = 0.49 µg/ml); and has been used as a negative control for lavendustin A
27311	Lavendustin B	5 mg	≥95%	An inhibitor of Glut1 (Ki = 15 µM); an inhibitor of the interaction between HIV-1 integrase and LEDGF/p75 (IC50 = 94.07 µM); a weak inhibitor of tyrosine kinases (IC50 = 0.49 µg/ml); and has been used as a negative control for lavendustin A
27311	Lavendustin B	50 mg	≥95%	An inhibitor of Glut1 (Ki = 15 µM); an inhibitor of the interaction between HIV-1 integrase and LEDGF/p75 (IC50 = 94.07 µM); a weak inhibitor of tyrosine kinases (IC50 = 0.49 µg/ml); and has been used as a negative control for lavendustin A
27320	Autophinib	1 mg	≥98%	An ATP-competitive inhibitor of VPS34 (IC50 = 19 nM); inhibits autophagy induced by rapamycin or amino acid starvation (IC50s = 40 and 90 nM, respectively) in MCF-7 cells; induces apoptosis in amino acid-starved MCF-7 cells (EC50 = 234 nM)
27320	Autophinib	10 mg	≥98%	An ATP-competitive inhibitor of VPS34 (IC50 = 19 nM); inhibits autophagy induced by rapamycin or amino acid starvation (IC50s = 40 and 90 nM, respectively) in MCF-7 cells; induces apoptosis in amino acid-starved MCF-7 cells (EC50 = 234 nM)
27320	Autophinib	25 mg	≥98%	An ATP-competitive inhibitor of VPS34 (IC50 = 19 nM); inhibits autophagy induced by rapamycin or amino acid starvation (IC50s = 40 and 90 nM, respectively) in MCF-7 cells; induces apoptosis in amino acid-starved MCF-7 cells (EC50 = 234 nM)
27320	Autophinib	5 mg	≥98%	An ATP-competitive inhibitor of VPS34 (IC50 = 19 nM); inhibits autophagy induced by rapamycin or amino acid starvation (IC50s = 40 and 90 nM, respectively) in MCF-7 cells; induces apoptosis in amino acid-starved MCF-7 cells (EC50 = 234 nM)
27338	Sitravatinib	10 mg	≥98%	A multi-kinase inhibitor; inhibits 35 kinases (IC50s = 0.5-4,098 nM) in a panel of 55 RTKs; reduces proliferation in various cancer cells (IC50s = 340.1-1,830 nM) and decreases phosphorylation of IGF1-R, PDGFRβ, and Akt at 62.5-4,000 nM; decreases tumor growth in LPS141 and MPNST mouse xenograft models at 15 mg/kg per day

27338	Sitravatinib	25 mg	≥98%	A multi-kinase inhibitor; inhibits 35 kinases (IC50s = 0.5-4,098 nM) in a panel of 55 RTKs; reduces proliferation in various cancer cells (IC50s = 340.1-1,830 nM) and decreases phosphorylation of IGF1-R, PDGFRβ, and Akt at 62.5-4,000 nM; decreases tumor growth in LPS141 and MPNST mouse xenograft models at 15 mg/kg per day
27338	Sitravatinib	5 mg	≥98%	A multi-kinase inhibitor; inhibits 35 kinases (IC50s = 0.5-4,098 nM) in a panel of 55 RTKs; reduces proliferation in various cancer cells (IC50s = 340.1-1,830 nM) and decreases phosphorylation of IGF1-R, PDGFRβ, and Akt at 62.5-4,000 nM; decreases tumor growth in LPS141 and MPNST mouse xenograft models at 15 mg/kg per day
27338	Sitravatinib	50 mg	≥98%	A multi-kinase inhibitor; inhibits 35 kinases (IC50s = 0.5-4,098 nM) in a panel of 55 RTKs; reduces proliferation in various cancer cells (IC50s = 340.1-1,830 nM) and decreases phosphorylation of IGF1-R, PDGFRβ, and Akt at 62.5-4,000 nM; decreases tumor growth in LPS141 and MPNST mouse xenograft models at 15 mg/kg per day
27340	MLN8054	1 mg	≥98%	An inhibitor of Aurora A kinase (IC50 = 4 nM); selective for Aurora A over Aurora B, PKC, CaMKII, Cdk2E, CK2, LCK, PKA, Chk1, Chk2, Cdk1, and Plk1 (IC50s = 0.172-100 μM); induces cell cycle arrest at the G2/M phase and the formation of abnormal mitotic spindles in HCT116 colorectal and PC3 prostate cancer cells; inhibits the growth of various cancer cells (IC50s = 0.11-1.43 μM); reduces tumor volume in HCT116 and PC3 mouse xenograft models at 30 mg/kg
27340	MLN8054	10 mg	≥98%	An inhibitor of Aurora A kinase (IC50 = 4 nM); selective for Aurora A over Aurora B, PKC, CaMKII, Cdk2E, CK2, LCK, PKA, Chk1, Chk2, Cdk1, and Plk1 (IC50s = 0.172-100 μM); induces cell cycle arrest at the G2/M phase and the formation of abnormal mitotic spindles in HCT116 colorectal and PC3 prostate cancer cells; inhibits the growth of various cancer cells (IC50s = 0.11-1.43 μM); reduces tumor volume in HCT116 and PC3 mouse xenograft models at 30 mg/kg
27340	MLN8054	25 mg	≥98%	An inhibitor of Aurora A kinase (IC50 = 4 nM); selective for Aurora A over Aurora B, PKC, CaMKII, Cdk2E, CK2, LCK, PKA, Chk1, Chk2, Cdk1, and Plk1 (IC50s = 0.172-100 μM); induces cell cycle arrest at the G2/M phase and the formation of abnormal mitotic spindles in HCT116 colorectal and PC3 prostate cancer cells; inhibits the growth of various cancer cells (IC50s = 0.11-1.43 μM); reduces tumor volume in HCT116 and PC3 mouse xenograft models at 30 mg/kg
27340	MLN8054	5 mg	≥98%	An inhibitor of Aurora A kinase (IC50 = 4 nM); selective for Aurora A over Aurora B, PKC, CaMKII, Cdk2E, CK2, LCK, PKA, Chk1, Chk2, Cdk1, and Plk1 (IC50s = 0.172-100 μM); induces cell cycle arrest at the G2/M phase and the formation of abnormal mitotic spindles in HCT116 colorectal and PC3 prostate cancer cells; inhibits the growth of various cancer cells (IC50s = 0.11-1.43 μM); reduces tumor volume in HCT116 and PC3 mouse xenograft models at 30 mg/kg
27370	STK16-IN-1	10 mg	≥98%	An inhibitor of STK16 (IC50 = 295 nM); selective for STK16 over mTOR, PI3Kδ, and PI3Kγ (IC50s = 5,560, 856, and 867 nM, respectively, in an enzyme assay) and over 440 additional kinases in a KinomeScan profiling assay; decreases the growth of MCF-7 cells (GI50 = ~10 μM); potentiates the antiproliferative effects of colchicine, paclitaxel, doxorubicin, and cisplatin in MCF-7 cells at 2.5-5 μM
27370	STK16-IN-1	25 mg	≥98%	An inhibitor of STK16 (IC50 = 295 nM); selective for STK16 over mTOR, PI3Kδ, and PI3Kγ (IC50s = 5,560, 856, and 867 nM, respectively, in an enzyme assay) and over 440 additional kinases in a KinomeScan profiling assay; decreases the growth of MCF-7 cells (GI50 = ~10 μM); potentiates the antiproliferative effects of colchicine, paclitaxel, doxorubicin, and cisplatin in MCF-7 cells at 2.5-5 μM
27370	STK16-IN-1	5 mg	≥98%	An inhibitor of STK16 (IC50 = 295 nM); selective for STK16 over mTOR, PI3Kδ, and PI3Kγ (IC50s = 5,560, 856, and 867 nM, respectively, in an enzyme assay) and over 440 additional kinases in a KinomeScan profiling assay; decreases the growth of MCF-7 cells (GI50 = ~10 μM); potentiates the antiproliferative effects of colchicine, paclitaxel, doxorubicin, and cisplatin in MCF-7 cells at 2.5-5 μM
27370	STK16-IN-1	50 mg	≥98%	An inhibitor of STK16 (IC50 = 295 nM); selective for STK16 over mTOR, PI3Kδ, and PI3Kγ (IC50s = 5,560, 856, and 867 nM, respectively, in an enzyme assay) and over 440 additional kinases in a KinomeScan profiling assay; decreases the growth of MCF-7 cells (GI50 = ~10 μM); potentiates the antiproliferative effects of colchicine, paclitaxel, doxorubicin, and cisplatin in MCF-7 cells at 2.5-5 μM
27482	BQR-695	1 mg	≥98%	An antimalarial compound; inhibits recombinant P. vivax and human PI4K (IC50s = 3.5 and 90 nM, respectively); induces schizont-stage arrest and death of P. falciparum (IC50 = ~70 nM)
27482	BQR-695	10 mg	≥98%	An antimalarial compound; inhibits recombinant P. vivax and human PI4K (IC50s = 3.5 and 90 nM, respectively); induces schizont-stage arrest and death of P. falciparum (IC50 = ~70 nM)
27482	BQR-695	5 mg	≥98%	An antimalarial compound; inhibits recombinant P. vivax and human PI4K (IC50s = 3.5 and 90 nM, respectively); induces schizont-stage arrest and death of P. falciparum (IC50 = ~70 nM)

27579	NG 25 (hydrochloride	1 mg	≥98%	An inhibitor of MAP4K2 and TAK1 (IC50s = 21.7 and 149 nM, respectively); also inhibits the Src family kinases Src and LYN (IC50s = 113 and 12.9 nM, respectively) and Abl family kinases (IC50s = 75.2 nM), as well as CSK, FER, and p38α (IC50s = 56.4, 82.3, and 102 nM, respectively); prevents TNF-α-induced IKKα/β phosphorylation and IκB-α degradation in L929 cells at 100 nM; inhibits secretion of IFN-α and IFN-β induced by CpG type B and CL097, respectively, in Gen2.2 cells; decreases cell viability of HCT116KRASWT, and to a greater degree of HCT116KRASG13D, colorectal cancer cells; reduces tumor growth and increases the number of TUNEL-positive tumor cells in a CT26KRASG12D mouse orthotopic model of colorectal cancer
27579	NG 25 (hydrochloride	10 mg	≥98%	An inhibitor of MAP4K2 and TAK1 (IC50s = 21.7 and 149 nM, respectively); also inhibits the Src family kinases Src and LYN (IC50s = 113 and 12.9 nM, respectively) and Abl family kinases (IC50s = 75.2 nM), as well as CSK, FER, and p38α (IC50s = 56.4, 82.3, and 102 nM, respectively); prevents TNF-α-induced IKKα/β phosphorylation and IκB-α degradation in L929 cells at 100 nM; inhibits secretion of IFN-α and IFN-β induced by CpG type B and CL097, respectively, in Gen2.2 cells; decreases cell viability of HCT116KRASWT, and to a greater degree of HCT116KRASG13D, colorectal cancer cells; reduces tumor growth and increases the number of TUNEL-positive tumor cells in a CT26KRASG12D mouse orthotopic model of colorectal cancer
27579	NG 25 (hydrochloride	5 mg	≥98%	An inhibitor of MAP4K2 and TAK1 (IC50s = 21.7 and 149 nM, respectively); also inhibits the Src family kinases Src and LYN (IC50s = 113 and 12.9 nM, respectively) and Abl family kinases (IC50s = 75.2 nM), as well as CSK, FER, and p38α (IC50s = 56.4, 82.3, and 102 nM, respectively); prevents TNF-α-induced IKKα/β phosphorylation and IκB-α degradation in L929 cells at 100 nM; inhibits secretion of IFN-α and IFN-β induced by CpG type B and CL097, respectively, in Gen2.2 cells; decreases cell viability of HCT116KRASWT, and to a greater degree of HCT116KRASG13D, colorectal cancer cells; reduces tumor growth and increases the number of TUNEL-positive tumor cells in a CT26KRASG12D mouse orthotopic model of colorectal cancer
27597	Itacitinib	1 mg	≥95%	A JAK1 inhibitor; >20- and >200-fold selective for JAK1 over JAK2 and JAK3, respectively
27597	Itacitinib	10 mg	≥95%	A JAK1 inhibitor; >20- and >200-fold selective for JAK1 over JAK2 and JAK3, respectively
27597	Itacitinib	25 mg	≥95%	A JAK1 inhibitor; >20- and >200-fold selective for JAK1 over JAK2 and JAK3, respectively
27597	Itacitinib	5 mg	≥95%	A JAK1 inhibitor; >20- and >200-fold selective for JAK1 over JAK2 and JAK3, respectively
27598	CA-4948	1 mg	≥98%	An orally bioavailable inhibitor IRAK-4; has antitumor activity in ABC-type diffuse large B cell lymphoma PDX mouse models
27598	CA-4948	10 mg	≥98%	An orally bioavailable inhibitor IRAK-4; has antitumor activity in ABC-type diffuse large B cell lymphoma PDX mouse models
27598	CA-4948	25 mg	≥98%	An orally bioavailable inhibitor IRAK-4; has antitumor activity in ABC-type diffuse large B cell lymphoma PDX mouse models
27598	CA-4948	5 mg	≥98%	An orally bioavailable inhibitor IRAK-4; has antitumor activity in ABC-type diffuse large B cell lymphoma PDX mouse models
27605	Streptochlorin	1 mg	≥98%	A bacterial metabolite with diverse biological activities; inhibits TNF-α-induced NF-κB transcriptional activity and decreases proliferation of HUVECs at 5-20 μM; decreases viability of, as well as induces apoptosis and increases the production of ROS in Hep3B cells at 12 μg/ml; does not induce cytotoxicity in RBL-2H3 mast cells at concentrations up to 100 μM; prevents degranulation in antigen-stimulated mast cells, and inhibits Syk, LYN, and Fyn kinases, and reduces DNP-HSA-induced TNF-α and IL-4 secretion in RBL-2H3 mast cells; decreases swelling and reduces scratching behavior in a mouse model of DNFB-induced allergic dermatitis
27605	Streptochlorin	5 mg	≥98%	A bacterial metabolite with diverse biological activities; inhibits TNF-α-induced NF-κB transcriptional activity and decreases proliferation of HUVECs at 5-20 μM; decreases viability of, as well as induces apoptosis and increases the production of ROS in Hep3B cells at 12 μg/ml; does not induce cytotoxicity in RBL-2H3 mast cells at concentrations up to 100 μM; prevents degranulation in antigen-stimulated mast cells, and inhibits Syk, LYN, and Fyn kinases, and reduces DNP-HSA-induced TNF-α and IL-4 secretion in RBL-2H3 mast cells; decreases swelling and reduces scratching behavior in a mouse model of DNFB-induced allergic dermatitis
27636	Derazantinib	1 mg	≥95%	A multi-kinase inhibitor; a pan inhibitor of FGFR (IC50s = 4.5, 1.8, 4.5, and 34 nM for FGFR1, -2, -3, and -4, respectively); inhibits 18 tyrosine kinases and the calcium/calmodulin-dependent protein kinase QIK in a panel of 297 kinases (IC50s = 3-31 and 9.7 nM, respectively); decreases phosphorylation of FGFR in COS-1 cells expressing FGFR1, -2, -3, or -4 (IC50s = 10 μM, respectively) and inhibits the growth of 15 cancer cell lines with mutant, amplified, or translocated FGFR (GI50s = 0.1-1.7 μM); reduces tumor growth and decreases tumor protein levels of phosphorylated FGFR, FRS2, and ERK in a SNU-16 mouse xenograft model at 50 and 75 mg/kg

27636	Derazantinib	10 mg	≥95%	A multi-kinase inhibitor; a pan inhibitor of FGFR (IC50s = 4.5, 1.8, 4.5, and 34 nM for FGFR1, -2, -3, and -4, respectively); inhibits 18 tyrosine kinases and the calcium/calmodulin-dependent protein kinase QIK in a panel of 297 kinases (IC50s = 3-31 and 9.7 nM, respectively); decreases phosphorylation of FGFR in COS-1 cells expressing FGFR1, -2, -3, or -4 (IC50s = 10 μM, respectively) and inhibits the growth of 15 cancer cell lines with mutant, amplified, or translocated FGFR (GI50s = 0.1-1.7 μM); reduces tumor growth and decreases tumor protein levels of phosphorylated FGFR, FRS2, and ERK in a SNU-16 mouse xenograft model at 50 and 75 mg/kg
27636	Derazantinib	25 mg	≥95%	A multi-kinase inhibitor; a pan inhibitor of FGFR (IC50s = 4.5, 1.8, 4.5, and 34 nM for FGFR1, -2, -3, and -4, respectively); inhibits 18 tyrosine kinases and the calcium/calmodulin-dependent protein kinase QIK in a panel of 297 kinases (IC50s = 3-31 and 9.7 nM, respectively); decreases phosphorylation of FGFR in COS-1 cells expressing FGFR1, -2, -3, or -4 (IC50s = 10 μM, respectively) and inhibits the growth of 15 cancer cell lines with mutant, amplified, or translocated FGFR (GI50s = 0.1-1.7 μM); reduces tumor growth and decreases tumor protein levels of phosphorylated FGFR, FRS2, and ERK in a SNU-16 mouse xenograft model at 50 and 75 mg/kg
27636	Derazantinib	5 mg	≥95%	A multi-kinase inhibitor; a pan inhibitor of FGFR (IC50s = 4.5, 1.8, 4.5, and 34 nM for FGFR1, -2, -3, and -4, respectively); inhibits 18 tyrosine kinases and the calcium/calmodulin-dependent protein kinase QIK in a panel of 297 kinases (IC50s = 3-31 and 9.7 nM, respectively); decreases phosphorylation of FGFR in COS-1 cells expressing FGFR1, -2, -3, or -4 (IC50s = 10 μM, respectively) and inhibits the growth of 15 cancer cell lines with mutant, amplified, or translocated FGFR (GI50s = 0.1-1.7 μM); reduces tumor growth and decreases tumor protein levels of phosphorylated FGFR, FRS2, and ERK in a SNU-16 mouse xenograft model at 50 and 75 mg/kg
27650	JNJ-38877605	10 mg	≥98%	An ATP-competitive inhibitor of Met kinase (IC50 = 4 nM); at least 600-fold selective for Met in a panel of ~250 tyrosine and serine-threonine kinases; inhibits the growth of cancer cell lines with MET gene amplification (IC50s = 11-50 nM) but has no effect on the growth of control cells with normal MET gene copy number or no MET expression; sensitizes tumors to radiotherapy in U251 glioma and MDA-MB-231 breast cancer mouse xenograft models and increases apoptosis in irradiated tumors in the MDA-MB-231 mouse xenograft model at 50 mg/kgp; reduces tumor size by 6-fold and the number of blood vessels in tumors by 80% in an RU-P melanoma mouse xenograft model at 20 mg/kg
27650	JNJ-38877605	100 mg	≥98%	An ATP-competitive inhibitor of Met kinase (IC50 = 4 nM); at least 600-fold selective for Met in a panel of ~250 tyrosine and serine-threonine kinases; inhibits the growth of cancer cell lines with MET gene amplification (IC50s = 11-50 nM) but has no effect on the growth of control cells with normal MET gene copy number or no MET expression; sensitizes tumors to radiotherapy in U251 glioma and MDA-MB-231 breast cancer mouse xenograft models and increases apoptosis in irradiated tumors in the MDA-MB-231 mouse xenograft model at 50 mg/kgp; reduces tumor size by 6-fold and the number of blood vessels in tumors by 80% in an RU-P melanoma mouse xenograft model at 20 mg/kg
27650	JNJ-38877605	5 mg	≥98%	An ATP-competitive inhibitor of Met kinase (IC50 = 4 nM); at least 600-fold selective for Met in a panel of ~250 tyrosine and serine-threonine kinases; inhibits the growth of cancer cell lines with MET gene amplification (IC50s = 11-50 nM) but has no effect on the growth of control cells with normal MET gene copy number or no MET expression; sensitizes tumors to radiotherapy in U251 glioma and MDA-MB-231 breast cancer mouse xenograft models and increases apoptosis in irradiated tumors in the MDA-MB-231 mouse xenograft model at 50 mg/kgp; reduces tumor size by 6-fold and the number of blood vessels in tumors by 80% in an RU-P melanoma mouse xenograft model at 20 mg/kg
27650	JNJ-38877605	50 mg	≥98%	An ATP-competitive inhibitor of Met kinase (IC50 = 4 nM); at least 600-fold selective for Met in a panel of ~250 tyrosine and serine-threonine kinases; inhibits the growth of cancer cell lines with MET gene amplification (IC50s = 11-50 nM) but has no effect on the growth of control cells with normal MET gene copy number or no MET expression; sensitizes tumors to radiotherapy in U251 glioma and MDA-MB-231 breast cancer mouse xenograft models and increases apoptosis in irradiated tumors in the MDA-MB-231 mouse xenograft model at 50 mg/kgp; reduces tumor size by 6-fold and the number of blood vessels in tumors by 80% in an RU-P melanoma mouse xenograft model at 20 mg/kg
27651	Varlitinib	1 mg	≥98%	An inhibitor of EGFR and HER2 (IC50s = 7 and 2 nM, respectively); inhibits cell proliferation (IC50s = <20 μM) and induces apoptosis in MDA-MB-453 and MDA-MB-468 TNBC cells; inhibits phosphorylation of EGFR and ERK and reduces tumor weight in an MDA-MB-468 mouse xenograft model at 100 mg/kg
27651	Varlitinib	10 mg	≥98%	An inhibitor of EGFR and HER2 (IC50s = 7 and 2 nM, respectively); inhibits cell proliferation (IC50s = <20 μM) and induces apoptosis in MDA-MB-453 and MDA-MB-468 TNBC cells; inhibits phosphorylation of EGFR and ERK and reduces tumor weight in an MDA-MB-468 mouse xenograft model at 100 mg/kg

27651	Varlitinib	25 mg	≥98%	An inhibitor of EGFR and HER2 (IC50s = 7 and 2 nM, respectively); inhibits cell proliferation (IC50s = <20 μM) and induces apoptosis in MDA-MB-453 and MDA-MB-468 TNBC cells; inhibits phosphorylation of EGFR and ERK and reduces tumor weight in an MDA-MB-468 mouse xenograft model at 100 mg/kg
27651	Varlitinib	5 mg	≥98%	An inhibitor of EGFR and HER2 (IC50s = 7 and 2 nM, respectively); inhibits cell proliferation (IC50s = <20 μM) and induces apoptosis in MDA-MB-453 and MDA-MB-468 TNBC cells; inhibits phosphorylation of EGFR and ERK and reduces tumor weight in an MDA-MB-468 mouse xenograft model at 100 mg/kg
27652	TMCB	10 mg	≥98%	A dual inhibitor of CK2 and ERK8 (IC50 = 0.5 μM for both); binds to Pim-1, HIPK2, and DYRK1A (Kis = 8.65, 15.25, and 11.9 μM, respectively) and inhibits greater than 50% of the activity of five kinases, including CK2, ERK8, and DYRK2, in a panel of 78 kinases at 10 μM; induces apoptosis in Jurkat cells at 10-50 μM
27652	TMCB	5 mg	≥98%	A dual inhibitor of CK2 and ERK8 (IC50 = 0.5 μM for both); binds to Pim-1, HIPK2, and DYRK1A (Kis = 8.65, 15.25, and 11.9 μM, respectively) and inhibits greater than 50% of the activity of five kinases, including CK2, ERK8, and DYRK2, in a panel of 78 kinases at 10 μM; induces apoptosis in Jurkat cells at 10-50 μM
27653	DMH4	1 mg	≥98%	A VEGFR2 inhibitor (IC50 = 0.16 μM in a cell-free assay); selectively inhibits VEGFR2 over ALK2, ALK5, and AMPK (IC50s = 3.5, >30, and 8 μM, respectively, in a cell-free assay); inhibits growth of H460 and A549 cancer cells (GI50s = 13.3 and 2.8 μM, respectively) and reduces VEGF-induced tubule formation in HUVECs (IC50 = 1 μM)
27653	DMH4	10 mg	≥98%	A VEGFR2 inhibitor (IC50 = 0.16 μM in a cell-free assay); selectively inhibits VEGFR2 over ALK2, ALK5, and AMPK (IC50s = 3.5, >30, and 8 μM, respectively, in a cell-free assay); inhibits growth of H460 and A549 cancer cells (GI50s = 13.3 and 2.8 μM, respectively) and reduces VEGF-induced tubule formation in HUVECs (IC50 = 1 μM)
27653	DMH4	25 mg	≥98%	A VEGFR2 inhibitor (IC50 = 0.16 μM in a cell-free assay); selectively inhibits VEGFR2 over ALK2, ALK5, and AMPK (IC50s = 3.5, >30, and 8 μM, respectively, in a cell-free assay); inhibits growth of H460 and A549 cancer cells (GI50s = 13.3 and 2.8 μM, respectively) and reduces VEGF-induced tubule formation in HUVECs (IC50 = 1 μM)
27653	DMH4	5 mg	≥98%	A VEGFR2 inhibitor (IC50 = 0.16 μM in a cell-free assay); selectively inhibits VEGFR2 over ALK2, ALK5, and AMPK (IC50s = 3.5, >30, and 8 μM, respectively, in a cell-free assay); inhibits growth of H460 and A549 cancer cells (GI50s = 13.3 and 2.8 μM, respectively) and reduces VEGF-induced tubule formation in HUVECs (IC50 = 1 μM)
27655	Anlotinib (hydrochlori	1 mg	≥95%	An orally bioavailable tyrosine kinase inhibitor that inhibits human VEGFR1, VEGFR2, VEGFR3, PDGFRβ, and c-Kit (IC50s = 26.9, 0.2, 0.7, 115, and 14.8 nM, respectively); selective for these kinases over c-Met, c-Src, HER2, and EGFR (IC50s = >2,000 nM); inhibits FGFR1 (IC50 = 11.7 nM); inhibits the growth of SW620 and HT-29 colorectal, 786-O and Caki-1 renal, A549 and NCI-H526 lung, MDA-MB-231 breast, HMC-1 leukemia, A375 melanoma, and U-87MG glioblastoma cancer cells (IC50s = 3-12.5 μM); inhibits VEGF-induced migration (IC50 = 0.1 nM) and FBS-induced tube formation in HUVECs; inhibits VEGF-induced angiogenesis in a CAM assay at 1.5 nmol; decreases tumor volume by 83% and tumor angiogenesis by 91.2% in a SW620 xenograft mouse model at 3 mg/kg per day
27655	Anlotinib (hydrochlori	10 mg	≥95%	An orally bioavailable tyrosine kinase inhibitor that inhibits human VEGFR1, VEGFR2, VEGFR3, PDGFRβ, and c-Kit (IC50s = 26.9, 0.2, 0.7, 115, and 14.8 nM, respectively); selective for these kinases over c-Met, c-Src, HER2, and EGFR (IC50s = >2,000 nM); inhibits FGFR1 (IC50 = 11.7 nM); inhibits the growth of SW620 and HT-29 colorectal, 786-O and Caki-1 renal, A549 and NCI-H526 lung, MDA-MB-231 breast, HMC-1 leukemia, A375 melanoma, and U-87MG glioblastoma cancer cells (IC50s = 3-12.5 μM); inhibits VEGF-induced migration (IC50 = 0.1 nM) and FBS-induced tube formation in HUVECs; inhibits VEGF-induced angiogenesis in a CAM assay at 1.5 nmol; decreases tumor volume by 83% and tumor angiogenesis by 91.2% in a SW620 xenograft mouse model at 3 mg/kg per day
27655	Anlotinib (hydrochlori	25 mg	≥95%	An orally bioavailable tyrosine kinase inhibitor that inhibits human VEGFR1, VEGFR2, VEGFR3, PDGFRβ, and c-Kit (IC50s = 26.9, 0.2, 0.7, 115, and 14.8 nM, respectively); selective for these kinases over c-Met, c-Src, HER2, and EGFR (IC50s = >2,000 nM); inhibits FGFR1 (IC50 = 11.7 nM); inhibits the growth of SW620 and HT-29 colorectal, 786-O and Caki-1 renal, A549 and NCI-H526 lung, MDA-MB-231 breast, HMC-1 leukemia, A375 melanoma, and U-87MG glioblastoma cancer cells (IC50s = 3-12.5 μM); inhibits VEGF-induced migration (IC50 = 0.1 nM) and FBS-induced tube formation in HUVECs; inhibits VEGF-induced angiogenesis in a CAM assay at 1.5 nmol; decreases tumor volume by 83% and tumor angiogenesis by 91.2% in a SW620 xenograft mouse model at 3 mg/kg per day

27655	Anlotinib (hydrochlori	5 mg	≥95%	An orally bioavailable tyrosine kinase inhibitor that inhibits human VEGFR1, VEGFR2, VEGFR3, PDGFRβ, and c-Kit (IC50s = 26.9, 0.2, 0.7, 115, and 14.8 nM, respectively); selective for these kinases over c-Met, c-Src, HER2, and EGFR (IC50s = >2,000 nM); inhibits FGFR1 (IC50 = 11.7 nM); inhibits the growth of SW620 and HT-29 colorectal, 786-O and Caki-1 renal, A549 and NCI-H526 lung, MDA-MB-231 breast, HMC-1 leukemia, A375 melanoma, and U-87MG glioblastoma cancer cells (IC50s = 3-12.5 μM); inhibits VEGF-induced migration (IC50 = 0.1 nM) and FBS-induced tube formation in HUVECs; inhibits VEGF-induced angiogenesis in a CAM assay at 1.5 nmol; decreases tumor volume by 83% and tumor angiogenesis by 91.2% in a SW620 xenograft mouse model at 3 mg/kg per day
27656	Ginkgoneolic Acid	10 mg	≥95%	An anacardic acid with diverse biological activities; inhibits GPDH (IC50 = 3 μg/ml); inhibits PI3Kδ (IC50 = 2.49 μM) and IgE-mediated RBL-2H3 mast cell degranulation in vitro (IC50 = 2.4 μM); reduces S. mutans biofilm formation (MBIC50 = 4 μg/ml); molluscicidal against O. hupensis at 2 mg/L
27656	Ginkgoneolic Acid	100 mg	≥95%	An anacardic acid with diverse biological activities; inhibits GPDH (IC50 = 3 μg/ml); inhibits PI3Kδ (IC50 = 2.49 μM) and IgE-mediated RBL-2H3 mast cell degranulation in vitro (IC50 = 2.4 μM); reduces S. mutans biofilm formation (MBIC50 = 4 μg/ml); molluscicidal against O. hupensis at 2 mg/L
27656	Ginkgoneolic Acid	25 mg	≥95%	An anacardic acid with diverse biological activities; inhibits GPDH (IC50 = 3 μg/ml); inhibits PI3Kδ (IC50 = 2.49 μM) and IgE-mediated RBL-2H3 mast cell degranulation in vitro (IC50 = 2.4 μM); reduces S. mutans biofilm formation (MBIC50 = 4 μg/ml); molluscicidal against O. hupensis at 2 mg/L
27656	Ginkgoneolic Acid	50 mg	≥95%	An anacardic acid with diverse biological activities; inhibits GPDH (IC50 = 3 μg/ml); inhibits PI3Kδ (IC50 = 2.49 μM) and IgE-mediated RBL-2H3 mast cell degranulation in vitro (IC50 = 2.4 μM); reduces S. mutans biofilm formation (MBIC50 = 4 μg/ml); molluscicidal against O. hupensis at 2 mg/L
27664	PKI-402	1 mg	≥98%	A dual inhibitor of PI3K and mTOR (IC50s = 1.4, 9.2, and 1.7 nM for PI3Kα, PI3Kγ, and mTOR, respectively); reduces proliferation of MDA-MB-361 and PC3 cancer cells (IC50s = 8 and 21 nM, respectively); inhibits phosphorylation of Akt in MDA-MB-361 cells (IC50 = 5 nM); reduces intratumor phosphorylation of Akt and tumor growth in an MDA-MB-361 mouse xenograft model at 25, 50, and 100 mg/kg; inhibits tumor growth in U87MG glioma and A549 lung cancer mouse xenograft models
27664	PKI-402	10 mg	≥98%	A dual inhibitor of PI3K and mTOR (IC50s = 1.4, 9.2, and 1.7 nM for PI3Kα, PI3Kγ, and mTOR, respectively); reduces proliferation of MDA-MB-361 and PC3 cancer cells (IC50s = 8 and 21 nM, respectively); inhibits phosphorylation of Akt in MDA-MB-361 cells (IC50 = 5 nM); reduces intratumor phosphorylation of Akt and tumor growth in an MDA-MB-361 mouse xenograft model at 25, 50, and 100 mg/kg; inhibits tumor growth in U87MG glioma and A549 lung cancer mouse xenograft models
27664	PKI-402	25 mg	≥98%	A dual inhibitor of PI3K and mTOR (IC50s = 1.4, 9.2, and 1.7 nM for PI3Kα, PI3Kγ, and mTOR, respectively); reduces proliferation of MDA-MB-361 and PC3 cancer cells (IC50s = 8 and 21 nM, respectively); inhibits phosphorylation of Akt in MDA-MB-361 cells (IC50 = 5 nM); reduces intratumor phosphorylation of Akt and tumor growth in an MDA-MB-361 mouse xenograft model at 25, 50, and 100 mg/kg; inhibits tumor growth in U87MG glioma and A549 lung cancer mouse xenograft models
27664	PKI-402	5 mg	≥98%	A dual inhibitor of PI3K and mTOR (IC50s = 1.4, 9.2, and 1.7 nM for PI3Kα, PI3Kγ, and mTOR, respectively); reduces proliferation of MDA-MB-361 and PC3 cancer cells (IC50s = 8 and 21 nM, respectively); inhibits phosphorylation of Akt in MDA-MB-361 cells (IC50 = 5 nM); reduces intratumor phosphorylation of Akt and tumor growth in an MDA-MB-361 mouse xenograft model at 25, 50, and 100 mg/kg; inhibits tumor growth in U87MG glioma and A549 lung cancer mouse xenograft models
27668	CZ415	1 mg	≥98%	An mTOR inhibitor (Kd = 6.3 nM); 1,000-fold selective for mTOR over a panel of 285 kinases; inhibits phosphorylation of S6RP and Akt in HEK293T cells (IC50s = 14.5 and 14.8 nM, respectively); inhibits IFN-γ secretion in IL-2, anti-CD3, and anti-CD28 antibody-stimulated human whole blood (IC50 = 226 nM); reduces fore paw joint erythema and swelling in a mouse model of collagen-induced arthritis at 10 mg/kg; inhibits intratumor mTOR activity and reduces tumor growth in an OCC-1 oral cavity carcinoma mouse xenograft model at 20 mg/kg
27668	CZ415	10 mg	≥98%	An mTOR inhibitor (Kd = 6.3 nM); 1,000-fold selective for mTOR over a panel of 285 kinases; inhibits phosphorylation of S6RP and Akt in HEK293T cells (IC50s = 14.5 and 14.8 nM, respectively); inhibits IFN-γ secretion in IL-2, anti-CD3, and anti-CD28 antibody-stimulated human whole blood (IC50 = 226 nM); reduces fore paw joint erythema and swelling in a mouse model of collagen-induced arthritis at 10 mg/kg; inhibits intratumor mTOR activity and reduces tumor growth in an OCC-1 oral cavity carcinoma mouse xenograft model at 20 mg/kg
27668	CZ415	25 mg	≥98%	An mTOR inhibitor (Kd = 6.3 nM); 1,000-fold selective for mTOR over a panel of 285 kinases; inhibits phosphorylation of S6RP and Akt in HEK293T cells (IC50s = 14.5 and 14.8 nM, respectively); inhibits IFN-γ secretion in IL-2, anti-CD3, and anti-CD28 antibody-stimulated human whole blood (IC50 = 226 nM); reduces fore paw joint erythema and swelling in a mouse model of collagen-induced arthritis at 10 mg/kg; inhibits intratumor mTOR activity and reduces tumor growth in an OCC-1 oral cavity carcinoma mouse xenograft model at 20 mg/kg

27668	CZ415	5 mg	≥98%	An mTOR inhibitor (Kd = 6.3 nM); 1,000-fold selective for mTOR over a panel of 285 kinases; inhibits phosphorylation of S6RP and Akt in HEK293T cells (IC50s = 14.5 and 14.8 nM, respectively); inhibits IFN-γ secretion in IL-2, anti-CD3, and anti-CD28 antibody-stimulated human whole blood (IC50 = 226 nM); reduces fore paw joint erythema and swelling in a mouse model of collagen-induced arthritis at 10 mg/kg; inhibits intratumor mTOR activity and reduces tumor growth in an OCC-1 oral cavity carcinoma mouse xenograft model at 20 mg/kg
27671	GNE-317	10 mg	≥98%	A dual PI3Kα and mTOR inhibitor (apparent Kis = 2 and 9 nM, respectively); inhibits proliferation of PC3 and A172 cells (EC50s = 132 and 240 nM, respectively); reduces tumor growth in a U87MG/M glioblastoma mouse xenograft model at 10-40 mg/kg
27671	GNE-317	25 mg	≥98%	A dual PI3Kα and mTOR inhibitor (apparent Kis = 2 and 9 nM, respectively); inhibits proliferation of PC3 and A172 cells (EC50s = 132 and 240 nM, respectively); reduces tumor growth in a U87MG/M glioblastoma mouse xenograft model at 10-40 mg/kg
27671	GNE-317	5 mg	≥98%	A dual PI3Kα and mTOR inhibitor (apparent Kis = 2 and 9 nM, respectively); inhibits proliferation of PC3 and A172 cells (EC50s = 132 and 240 nM, respectively); reduces tumor growth in a U87MG/M glioblastoma mouse xenograft model at 10-40 mg/kg
27671	GNE-317	50 mg	≥98%	A dual PI3Kα and mTOR inhibitor (apparent Kis = 2 and 9 nM, respectively); inhibits proliferation of PC3 and A172 cells (EC50s = 132 and 240 nM, respectively); reduces tumor growth in a U87MG/M glioblastoma mouse xenograft model at 10-40 mg/kg
27799	LX2343	1 mg	≥98%	An inhibitor of BACE1 and PI3K (IC50s = 11.43 and 15.99 µM, respectively); inhibits STZ-induced accumulation of Aβ40 and Aβ42 in both HEK293-APPSW and CHO-APP cells in a concentration-dependent manner; inhibits STZ-induced increases in JNK and APPThr668 phosphorylation as well as sAPPβ protein levels; reduces levels of Aβ40 and Aβ42, as well as thioflavine S staining, in cortex and hippocampus in the APP/PS1 transgenic mouse model of Alzheimer's disease at 10 mg/kg/day; reduces cortical levels of p62 protein and PI3K, Akt, and mTOR phosphorylation; decreases path length and escape latency time in the Morris water maze in APP/PS1 mice at 10 mg/kg/day
27799	LX2343	10 mg	≥98%	An inhibitor of BACE1 and PI3K (IC50s = 11.43 and 15.99 µM, respectively); inhibits STZ-induced accumulation of Aβ40 and Aβ42 in both HEK293-APPSW and CHO-APP cells in a concentration-dependent manner; inhibits STZ-induced increases in JNK and APPThr668 phosphorylation as well as sAPPβ protein levels; reduces levels of Aβ40 and Aβ42, as well as thioflavine S staining, in cortex and hippocampus in the APP/PS1 transgenic mouse model of Alzheimer's disease at 10 mg/kg/day; reduces cortical levels of p62 protein and PI3K, Akt, and mTOR phosphorylation; decreases path length and escape latency time in the Morris water maze in APP/PS1 mice at 10 mg/kg/day
27799	LX2343	5 mg	≥98%	An inhibitor of BACE1 and PI3K (IC50s = 11.43 and 15.99 µM, respectively); inhibits STZ-induced accumulation of Aβ40 and Aβ42 in both HEK293-APPSW and CHO-APP cells in a concentration-dependent manner; inhibits STZ-induced increases in JNK and APPThr668 phosphorylation as well as sAPPβ protein levels; reduces levels of Aβ40 and Aβ42, as well as thioflavine S staining, in cortex and hippocampus in the APP/PS1 transgenic mouse model of Alzheimer's disease at 10 mg/kg/day; reduces cortical levels of p62 protein and PI3K, Akt, and mTOR phosphorylation; decreases path length and escape latency time in the Morris water maze in APP/PS1 mice at 10 mg/kg/day
27830	Sorafenib N-oxide	1 mg	≥98%	An active metabolite of sorafenib; inhibits FLT3-ITD (Kd = 70 nM); inhibits proliferation of MV4-11 AML cells expressing FLT3-ITD (IC50 = 25.8 nM); selective for AML cell lines containing FLT3-ITD over lines containing wild-type FLT3 (IC50s = 3.9-13.3 µM); a linear-mixed inhibitor of CYP3A4 (Ki = 15 µM)
27830	Sorafenib N-oxide	5 mg	≥98%	An active metabolite of sorafenib; inhibits FLT3-ITD (Kd = 70 nM); inhibits proliferation of MV4-11 AML cells expressing FLT3-ITD (IC50 = 25.8 nM); selective for AML cell lines containing FLT3-ITD over lines containing wild-type FLT3 (IC50s = 3.9-13.3 µM); a linear-mixed inhibitor of CYP3A4 (Ki = 15 µM)
27845	Dasatinib N-oxide	1 mg	≥95%	A major metabolite of dasatinib; a potential impurity in commercial preparations of dasatinib
27845	Dasatinib N-oxide	10 mg	≥95%	A major metabolite of dasatinib; a potential impurity in commercial preparations of dasatinib
27845	Dasatinib N-oxide	5 mg	≥95%	A major metabolite of dasatinib; a potential impurity in commercial preparations of dasatinib
27906	SEL120-34A	1 mg	≥98%	A dual inhibitor of Cdk8 and Cdk19 (IC50s = 4.4 and 10.4 nM, respectively); selective for Cdk8 and Cdk19 over a panel of CDK/cyclin complexes at 1 µM; inhibits IFN-γ-induced phosphorylation of STAT1 in HCT116 colon cancer cells at 0.1-5 µM; inhibits proliferation of MOLM-16, MV4-11, and KG-1 cells (GI50s = <1 µM); reduces tumor growth in a KG-1 mouse xenograft model at 60 mg/kg
27906	SEL120-34A	10 mg	≥98%	A dual inhibitor of Cdk8 and Cdk19 (IC50s = 4.4 and 10.4 nM, respectively); selective for Cdk8 and Cdk19 over a panel of CDK/cyclin complexes at 1 µM; inhibits IFN-γ-induced phosphorylation of STAT1 in HCT116 colon cancer cells at 0.1-5 µM; inhibits proliferation of MOLM-16, MV4-11, and KG-1 cells (GI50s = <1 µM); reduces tumor growth in a KG-1 mouse xenograft model at 60 mg/kg

27906	SEL120-34A	5 mg	≥98%	A dual inhibitor of Cdk8 and Cdk19 (IC50s = 4.4 and 10.4 nM, respectively); selective for Cdk8 and Cdk19 over a panel of CDK/cyclin complexes at 1 μM; inhibits IFN-γ-induced phosphorylation of STAT1 in HCT116 colon cancer cells at 0.1-5 μM; inhibits proliferation of MOLM-16, MV4-11, and KG-1 cells (GI50s = <1 μM); reduces tumor growth in a KG-1 mouse xenograft model at 60 mg/kg
27906	SEL120-34A	500 μg	≥98%	A dual inhibitor of Cdk8 and Cdk19 (IC50s = 4.4 and 10.4 nM, respectively); selective for Cdk8 and Cdk19 over a panel of CDK/cyclin complexes at 1 μM; inhibits IFN-γ-induced phosphorylation of STAT1 in HCT116 colon cancer cells at 0.1-5 μM; inhibits proliferation of MOLM-16, MV4-11, and KG-1 cells (GI50s = <1 μM); reduces tumor growth in a KG-1 mouse xenograft model at 60 mg/kg
27913	Hypothemycin	1 mg	≥98%	A resorcylic acid lactone polyketide with diverse biological activities; active against the fungi P. litchii, completely inhibiting spore germination when used at a concentration of 0.78 μg/ml; inhibits MEK (IC50 = 15 nM) and other protein kinases containing a conserved cysteine residue in the ATP-binding domain, including ERK, PDGFR, VEGF, PKD1, and MAPKAP5/MK5; inhibits TAK1 (IC50 = 33 nM); inhibits proliferation of A549, MV-4-11, and EOL1 cells (IC50s = 6, 0.006, and 0.0004 μM, respectively); reduces tumor growth in Ma44 and HCT116 mouse xenograft models at 25 mg/kg per day
27923	MRX-2843	1 mg	≥95%	A Mer and FLT3 inhibitor (IC50s = 1.3 and 1 nM, respectively); inhibits Axl and Tyro3 (IC50s = 15 and 17 nM, respectively); inhibits Mer phosphorylation in MOLM-14 and MV4-11 AML cells from 10-300 nM; reduces clonal expansion of Kasumi-1 AML cells (IC50 = 143.5 nM); increases survival in a NOMO-1 and MOLM-14 AML mouse xenograft models at 65 and 50 mg/kg, respectively
27923	MRX-2843	10 mg	≥95%	A Mer and FLT3 inhibitor (IC50s = 1.3 and 1 nM, respectively); inhibits Axl and Tyro3 (IC50s = 15 and 17 nM, respectively); inhibits Mer phosphorylation in MOLM-14 and MV4-11 AML cells from 10-300 nM; reduces clonal expansion of Kasumi-1 AML cells (IC50 = 143.5 nM); increases survival in a NOMO-1 and MOLM-14 AML mouse xenograft models at 65 and 50 mg/kg, respectively
27923	MRX-2843	5 mg	≥95%	A Mer and FLT3 inhibitor (IC50s = 1.3 and 1 nM, respectively); inhibits Axl and Tyro3 (IC50s = 15 and 17 nM, respectively); inhibits Mer phosphorylation in MOLM-14 and MV4-11 AML cells from 10-300 nM; reduces clonal expansion of Kasumi-1 AML cells (IC50 = 143.5 nM); increases survival in a NOMO-1 and MOLM-14 AML mouse xenograft models at 65 and 50 mg/kg, respectively
27936	LY3214996	1 mg	≥98%	An ERK1/2 inhibitor (IC50 = 5 nM for both); inhibits cell proliferation of tumor cells in vitro, including those expressing B-RAF, N-Ras, or K-Ras mutations in vitro; inhibits tumor growth in B-RAF or N-Ras mutant melanoma, B-RAF or K-Ras mutant colorectal, lung, and pancreatic cancer mouse xenograft models, as well as PDX mouse models
27936	LY3214996	10 mg	≥98%	An ERK1/2 inhibitor (IC50 = 5 nM for both); inhibits cell proliferation of tumor cells in vitro, including those expressing B-RAF, N-Ras, or K-Ras mutations in vitro; inhibits tumor growth in B-RAF or N-Ras mutant melanoma, B-RAF or K-Ras mutant colorectal, lung, and pancreatic cancer mouse xenograft models, as well as PDX mouse models
27936	LY3214996	25 mg	≥98%	An ERK1/2 inhibitor (IC50 = 5 nM for both); inhibits cell proliferation of tumor cells in vitro, including those expressing B-RAF, N-Ras, or K-Ras mutations in vitro; inhibits tumor growth in B-RAF or N-Ras mutant melanoma, B-RAF or K-Ras mutant colorectal, lung, and pancreatic cancer mouse xenograft models, as well as PDX mouse models
27936	LY3214996	5 mg	≥98%	An ERK1/2 inhibitor (IC50 = 5 nM for both); inhibits cell proliferation of tumor cells in vitro, including those expressing B-RAF, N-Ras, or K-Ras mutations in vitro; inhibits tumor growth in B-RAF or N-Ras mutant melanoma, B-RAF or K-Ras mutant colorectal, lung, and pancreatic cancer mouse xenograft models, as well as PDX mouse models
27953	Demethoxyviridiol	1 mg	≥95%	A mycotoxin; induces lethality in day-old cockerels (LD50 = 4.2 mg/kg); a PI3K inhibitor
27953	Demethoxyviridiol	5 mg	≥95%	A mycotoxin; induces lethality in day-old cockerels (LD50 = 4.2 mg/kg); a PI3K inhibitor
27977	GNE-477	10 mg	≥98%	A dual PI3K (IC50 = 4 nM for PI3Kα) and mTOR inhibitor (apparent Ki = 21 nM); inhibits proliferation of MCF-7.1 cells (EC50 = 143 nM); reduces tumor growth in a PC3-NCI tumor xenograft model at 1-20 mg/kg per day
27977	GNE-477	25 mg	≥98%	A dual PI3K (IC50 = 4 nM for PI3Kα) and mTOR inhibitor (apparent Ki = 21 nM); inhibits proliferation of MCF-7.1 cells (EC50 = 143 nM); reduces tumor growth in a PC3-NCI tumor xenograft model at 1-20 mg/kg per day
27977	GNE-477	5 mg	≥98%	A dual PI3K (IC50 = 4 nM for PI3Kα) and mTOR inhibitor (apparent Ki = 21 nM); inhibits proliferation of MCF-7.1 cells (EC50 = 143 nM); reduces tumor growth in a PC3-NCI tumor xenograft model at 1-20 mg/kg per day
27977	GNE-477	50 mg	≥98%	A dual PI3K (IC50 = 4 nM for PI3Kα) and mTOR inhibitor (apparent Ki = 21 nM); inhibits proliferation of MCF-7.1 cells (EC50 = 143 nM); reduces tumor growth in a PC3-NCI tumor xenograft model at 1-20 mg/kg per day

28078	Leniolisib	1 mg	≥98% (mixture	An inhibitor of PI3Kδ (IC50 = 0.011 µM); selective for PI3Kδ over PI3Kα, PI3Kβ, and PI3Kγ (IC50s = 0.244, 0.424, and 2.23 µM, respectively); inhibits phosphorylation of Akt in Rat-1 fibroblasts expressing P13K p110δ (IC50 = 0.056 µM); inhibits the MLR in isolated human PBMCs and isolated mouse splenocytes (IC50s = 0.079 and 0.033 µM, respectively); reduces the production of rat anti-rat collagen antibodies, as well as reduces paw swelling and joint erosion in a rat model of collagen-induced arthritis at 3 and 10 mg/kg
28078	Leniolisib	10 mg	≥98% (mixture	An inhibitor of PI3Kδ (IC50 = 0.011 µM); selective for PI3Kδ over PI3Kα, PI3Kβ, and PI3Kγ (IC50s = 0.244, 0.424, and 2.23 µM, respectively); inhibits phosphorylation of Akt in Rat-1 fibroblasts expressing P13K p110δ (IC50 = 0.056 µM); inhibits the MLR in isolated human PBMCs and isolated mouse splenocytes (IC50s = 0.079 and 0.033 µM, respectively); reduces the production of rat anti-rat collagen antibodies, as well as reduces paw swelling and joint erosion in a rat model of collagen-induced arthritis at 3 and 10 mg/kg
28078	Leniolisib	25 mg	≥98% (mixture	An inhibitor of PI3Kδ (IC50 = 0.011 µM); selective for PI3Kδ over PI3Kα, PI3Kβ, and PI3Kγ (IC50s = 0.244, 0.424, and 2.23 µM, respectively); inhibits phosphorylation of Akt in Rat-1 fibroblasts expressing P13K p110δ (IC50 = 0.056 µM); inhibits the MLR in isolated human PBMCs and isolated mouse splenocytes (IC50s = 0.079 and 0.033 µM, respectively); reduces the production of rat anti-rat collagen antibodies, as well as reduces paw swelling and joint erosion in a rat model of collagen-induced arthritis at 3 and 10 mg/kg
28078	Leniolisib	5 mg	≥98% (mixture	An inhibitor of PI3Kδ (IC50 = 0.011 µM); selective for PI3Kδ over PI3Kα, PI3Kβ, and PI3Kγ (IC50s = 0.244, 0.424, and 2.23 µM, respectively); inhibits phosphorylation of Akt in Rat-1 fibroblasts expressing P13K p110δ (IC50 = 0.056 µM); inhibits the MLR in isolated human PBMCs and isolated mouse splenocytes (IC50s = 0.079 and 0.033 µM, respectively); reduces the production of rat anti-rat collagen antibodies, as well as reduces paw swelling and joint erosion in a rat model of collagen-induced arthritis at 3 and 10 mg/kg
28136	Methylisothiazolinone	1 mL	≥98%	A biocide used for controlling microbial growth in industrial and household products; often used in a mixture with MCI; active against Gram-positive and Gram-negative bacteria, fungi, and yeast with MIC values of 0.0045, 0.0015, >0.01, and 0.0065% (w/w) for S. aureus, P. aeruginosa, A. niger, and C. albicans, respectively; MIC values are 7 to 200-fold lower when used in combination with MCI; decreases neurite outgrowth when used at concentrations of 0.1-3 µM; inhibits Src family kinases; can elicit contact sensitization
28136	Methylisothiazolinone	10 mL	≥98%	A biocide used for controlling microbial growth in industrial and household products; often used in a mixture with MCI; active against Gram-positive and Gram-negative bacteria, fungi, and yeast with MIC values of 0.0045, 0.0015, >0.01, and 0.0065% (w/w) for S. aureus, P. aeruginosa, A. niger, and C. albicans, respectively; MIC values are 7 to 200-fold lower when used in combination with MCI; decreases neurite outgrowth when used at concentrations of 0.1-3 µM; inhibits Src family kinases; can elicit contact sensitization
28136	Methylisothiazolinone	25 mL	≥98%	A biocide used for controlling microbial growth in industrial and household products; often used in a mixture with MCI; active against Gram-positive and Gram-negative bacteria, fungi, and yeast with MIC values of 0.0045, 0.0015, >0.01, and 0.0065% (w/w) for S. aureus, P. aeruginosa, A. niger, and C. albicans, respectively; MIC values are 7 to 200-fold lower when used in combination with MCI; decreases neurite outgrowth when used at concentrations of 0.1-3 µM; inhibits Src family kinases; can elicit contact sensitization
28136	Methylisothiazolinone	5 mL	≥98%	A biocide used for controlling microbial growth in industrial and household products; often used in a mixture with MCI; active against Gram-positive and Gram-negative bacteria, fungi, and yeast with MIC values of 0.0045, 0.0015, >0.01, and 0.0065% (w/w) for S. aureus, P. aeruginosa, A. niger, and C. albicans, respectively; MIC values are 7 to 200-fold lower when used in combination with MCI; decreases neurite outgrowth when used at concentrations of 0.1-3 µM; inhibits Src family kinases; can elicit contact sensitization
28231	LXH254	1 mg	≥98%	A pan-RAF inhibitor; selectively inhibits B-RAF and C-RAF over a panel of 456 human kinases; inhibits MAPK signaling in tumor cells expressing mutant B-RAFV600; induces tumor regression in various mouse xenograft models
28231	LXH254	10 mg	≥98%	A pan-RAF inhibitor; selectively inhibits B-RAF and C-RAF over a panel of 456 human kinases; inhibits MAPK signaling in tumor cells expressing mutant B-RAFV600; induces tumor regression in various mouse xenograft models
28231	LXH254	25 mg	≥98%	A pan-RAF inhibitor; selectively inhibits B-RAF and C-RAF over a panel of 456 human kinases; inhibits MAPK signaling in tumor cells expressing mutant B-RAFV600; induces tumor regression in various mouse xenograft models
28231	LXH254	5 mg	≥98%	A pan-RAF inhibitor; selectively inhibits B-RAF and C-RAF over a panel of 456 human kinases; inhibits MAPK signaling in tumor cells expressing mutant B-RAFV600; induces tumor regression in various mouse xenograft models
28268	CKI-7 (hydrochloride)	1 mg	≥98%	A CK1 inhibitor (Ki = 8.5 µM); elective for CK1 over CK2, PKC, CaMKII, and cyclic AMP-dependent protein kinase (IC50s = 90, >1,000, 195, and 550 µM, respectively); inhibits phosphorylation of a peptide substrate by Leishmania CK1.2 at 10 µM

28268	CKI-7 (hydrochloride)	10 mg	≥98%	A CK1 inhibitor (Ki = 8.5 µM); elective for CK1 over CK2, PKC, CaMKII, and cyclic AMP-dependent protein kinase (IC50s = 90, >1,000, 195, and 550 µM, respectively); inhibits phosphorylation of a peptide substrate by Leishmania CK1.2 at 10 µM
28268	CKI-7 (hydrochloride)	25 mg	≥98%	A CK1 inhibitor (Ki = 8.5 µM); elective for CK1 over CK2, PKC, CaMKII, and cyclic AMP-dependent protein kinase (IC50s = 90, >1,000, 195, and 550 µM, respectively); inhibits phosphorylation of a peptide substrate by Leishmania CK1.2 at 10 µM
28268	CKI-7 (hydrochloride)	5 mg	≥98%	A CK1 inhibitor (Ki = 8.5 µM); elective for CK1 over CK2, PKC, CaMKII, and cyclic AMP-dependent protein kinase (IC50s = 90, >1,000, 195, and 550 µM, respectively); inhibits phosphorylation of a peptide substrate by Leishmania CK1.2 at 10 µM
28279	A-484954	1 mg	≥98%	An eEF-2K inhibitor; reduces eEF-2K autophosphorylation in various cancer cells at 75 µM
28279	A-484954	10 mg	≥98%	An eEF-2K inhibitor; reduces eEF-2K autophosphorylation in various cancer cells at 75 µM
28279	A-484954	25 mg	≥98%	An eEF-2K inhibitor; reduces eEF-2K autophosphorylation in various cancer cells at 75 µM
28279	A-484954	5 mg	≥98%	An eEF-2K inhibitor; reduces eEF-2K autophosphorylation in various cancer cells at 75 µM
28381	PHA-680632	10 mg	≥98%	An inhibitor of Aurora A, B, and C kinases (IC50s = 27, 135, and 120 nM, respectively); has >15-fold selectivity for Aurora A kinase in a panel of 31 kinases; inhibits phosphorylation of serine 10 on histone H3 in U2OS cells (IC50 = 0.39 µM); inhibits proliferation of U2OS, HeLa, A549, HCT116, U937, and HL-60 cancer cell lines (IC50s = 1.6, 0.4, 0.6, 0.1, 0.1, and 0.1 µM, respectively); reduces the size of established tumors in transgenic v-Ha-ras mice and in an HL-60 human leukemia xenograft mouse model when administered at a dose of 45 mg/kg
28381	PHA-680632	25 mg	≥98%	An inhibitor of Aurora A, B, and C kinases (IC50s = 27, 135, and 120 nM, respectively); has >15-fold selectivity for Aurora A kinase in a panel of 31 kinases; inhibits phosphorylation of serine 10 on histone H3 in U2OS cells (IC50 = 0.39 µM); inhibits proliferation of U2OS, HeLa, A549, HCT116, U937, and HL-60 cancer cell lines (IC50s = 1.6, 0.4, 0.6, 0.1, 0.1, and 0.1 µM, respectively); reduces the size of established tumors in transgenic v-Ha-ras mice and in an HL-60 human leukemia xenograft mouse model when administered at a dose of 45 mg/kg
28381	PHA-680632	5 mg	≥98%	An inhibitor of Aurora A, B, and C kinases (IC50s = 27, 135, and 120 nM, respectively); has >15-fold selectivity for Aurora A kinase in a panel of 31 kinases; inhibits phosphorylation of serine 10 on histone H3 in U2OS cells (IC50 = 0.39 µM); inhibits proliferation of U2OS, HeLa, A549, HCT116, U937, and HL-60 cancer cell lines (IC50s = 1.6, 0.4, 0.6, 0.1, 0.1, and 0.1 µM, respectively); reduces the size of established tumors in transgenic v-Ha-ras mice and in an HL-60 human leukemia xenograft mouse model when administered at a dose of 45 mg/kg
28381	PHA-680632	50 mg	≥98%	An inhibitor of Aurora A, B, and C kinases (IC50s = 27, 135, and 120 nM, respectively); has >15-fold selectivity for Aurora A kinase in a panel of 31 kinases; inhibits phosphorylation of serine 10 on histone H3 in U2OS cells (IC50 = 0.39 µM); inhibits proliferation of U2OS, HeLa, A549, HCT116, U937, and HL-60 cancer cell lines (IC50s = 1.6, 0.4, 0.6, 0.1, 0.1, and 0.1 µM, respectively); reduces the size of established tumors in transgenic v-Ha-ras mice and in an HL-60 human leukemia xenograft mouse model when administered at a dose of 45 mg/kg
28385	SAR131675	1 mg	≥98%	An ATP-competitive inhibitor of VEGFR3 (IC50 = 23 nM); selective for VEGFR3 over VEGFR2 and VEGFR1 (IC50s = 230 and >3,000 nM, respectively); inhibits survival of human lymphatic cells cultured with the VEGFR3 ligands VEGF-C and VEGF-D over the non-specific ligand VEGF-A in vitro (IC50s = 14, 17, and 664 nM, respectively); decreases VEGF-C and VEGF-A-induced migration of HMVECs at 100 and 300 nM; reduces tumor size, decreases the number of pancreatic angiogenic islets, and increases survival in the RIP1-Tag2 transgenic mouse model of pancreatic neuroendocrine tumors at 100 mg/kg; decreases tumor size, levels of VEGFR3 in mammary tumor lysates, number of tumor-associated macrophages in mammary tumors, and the number of lung metastases in a 4T1 mouse allograft model at 100 mg/kg
28385	SAR131675	10 mg	≥98%	An ATP-competitive inhibitor of VEGFR3 (IC50 = 23 nM); selective for VEGFR3 over VEGFR2 and VEGFR1 (IC50s = 230 and >3,000 nM, respectively); inhibits survival of human lymphatic cells cultured with the VEGFR3 ligands VEGF-C and VEGF-D over the non-specific ligand VEGF-A in vitro (IC50s = 14, 17, and 664 nM, respectively); decreases VEGF-C and VEGF-A-induced migration of HMVECs at 100 and 300 nM; reduces tumor size, decreases the number of pancreatic angiogenic islets, and increases survival in the RIP1-Tag2 transgenic mouse model of pancreatic neuroendocrine tumors at 100 mg/kg; decreases tumor size, levels of VEGFR3 in mammary tumor lysates, number of tumor-associated macrophages in mammary tumors, and the number of lung metastases in a 4T1 mouse allograft model at 100 mg/kg

28385	SAR131675	25 mg	≥98%	An ATP-competitive inhibitor of VEGFR3 (IC50 = 23 nM); selective for VEGFR3 over VEGFR2 and VEGFR1 (IC50s = 230 and >3,000 nM, respectively); inhibits survival of human lymphatic cells cultured with the VEGFR3 ligands VEGF-C and VEGF-D over the non-specific ligand VEGF-A in vitro (IC50s = 14, 17, and 664 nM, respectively); decreases VEGF-C and VEGF-A-induced migration of HMVECs at 100 and 300 nM; reduces tumor size, decreases the number of pancreatic angiogenic islets, and increases survival in the RIP1-Tag2 transgenic mouse model of pancreatic neuroendocrine tumors at 100 mg/kg; decreases tumor size, levels of VEGFR3 in mammary tumor lysates, number of tumor-associated macrophages in mammary tumors, and the number of lung metastases in a 4T1 mouse allograft model at 100 mg/kg
28385	SAR131675	5 mg	≥98%	An ATP-competitive inhibitor of VEGFR3 (IC50 = 23 nM); selective for VEGFR3 over VEGFR2 and VEGFR1 (IC50s = 230 and >3,000 nM, respectively); inhibits survival of human lymphatic cells cultured with the VEGFR3 ligands VEGF-C and VEGF-D over the non-specific ligand VEGF-A in vitro (IC50s = 14, 17, and 664 nM, respectively); decreases VEGF-C and VEGF-A-induced migration of HMVECs at 100 and 300 nM; reduces tumor size, decreases the number of pancreatic angiogenic islets, and increases survival in the RIP1-Tag2 transgenic mouse model of pancreatic neuroendocrine tumors at 100 mg/kg; decreases tumor size, levels of VEGFR3 in mammary tumor lysates, number of tumor-associated macrophages in mammary tumors, and the number of lung metastases in a 4T1 mouse allograft model at 100 mg/kg
28458	Belizatinib	1 mg	≥98%	An inhibitor of ALK and tropomyosin-related kinases A/B/C (IC50s = 0.7 and <3 nM, respectively)
28458	Belizatinib	10 mg	≥98%	An inhibitor of ALK and tropomyosin-related kinases A/B/C (IC50s = 0.7 and <3 nM, respectively)
28458	Belizatinib	25 mg	≥98%	An inhibitor of ALK and tropomyosin-related kinases A/B/C (IC50s = 0.7 and <3 nM, respectively)
28458	Belizatinib	5 mg	≥98%	An inhibitor of ALK and tropomyosin-related kinases A/B/C (IC50s = 0.7 and <3 nM, respectively)
28459	Senexin B	1 mg	≥98%	An inhibitor of Cdk8 and Cdk19; inhibits Cdk8 (IC50s = 24-50 nM, depending on assay); selectively inhibits Cdk19 and Cdk8 by 98.6 and 97.8%, respectively, in a panel of >450 kinases at 2 µM but does inhibit MAP4K2 and YSK4 by 69 and 59%, respectively; inhibits cell growth in MCF-7, BT474, and T47D-ER/Luc breast cancer cells in estrogen-containing media at 1.25-5 µM; reduces tumor growth in an MCF-7 mouse xenograft model at 100 mg/kg twice per day; inhibits RANKL-induced differentiation of murine BMDMs into osteoclasts at 1 and 1.5 µM; increases the bone volume fraction and bone mineral density in injured tibiae in a rat model of cancellous bone injury and regeneration when administered locally at 1 µg
28459	Senexin B	10 mg	≥98%	An inhibitor of Cdk8 and Cdk19; inhibits Cdk8 (IC50s = 24-50 nM, depending on assay); selectively inhibits Cdk19 and Cdk8 by 98.6 and 97.8%, respectively, in a panel of >450 kinases at 2 µM but does inhibit MAP4K2 and YSK4 by 69 and 59%, respectively; inhibits cell growth in MCF-7, BT474, and T47D-ER/Luc breast cancer cells in estrogen-containing media at 1.25-5 µM; reduces tumor growth in an MCF-7 mouse xenograft model at 100 mg/kg twice per day; inhibits RANKL-induced differentiation of murine BMDMs into osteoclasts at 1 and 1.5 µM; increases the bone volume fraction and bone mineral density in injured tibiae in a rat model of cancellous bone injury and regeneration when administered locally at 1 µg
28459	Senexin B	25 mg	≥98%	An inhibitor of Cdk8 and Cdk19; inhibits Cdk8 (IC50s = 24-50 nM, depending on assay); selectively inhibits Cdk19 and Cdk8 by 98.6 and 97.8%, respectively, in a panel of >450 kinases at 2 µM but does inhibit MAP4K2 and YSK4 by 69 and 59%, respectively; inhibits cell growth in MCF-7, BT474, and T47D-ER/Luc breast cancer cells in estrogen-containing media at 1.25-5 µM; reduces tumor growth in an MCF-7 mouse xenograft model at 100 mg/kg twice per day; inhibits RANKL-induced differentiation of murine BMDMs into osteoclasts at 1 and 1.5 µM; increases the bone volume fraction and bone mineral density in injured tibiae in a rat model of cancellous bone injury and regeneration when administered locally at 1 µg
28459	Senexin B	5 mg	≥98%	An inhibitor of Cdk8 and Cdk19; inhibits Cdk8 (IC50s = 24-50 nM, depending on assay); selectively inhibits Cdk19 and Cdk8 by 98.6 and 97.8%, respectively, in a panel of >450 kinases at 2 µM but does inhibit MAP4K2 and YSK4 by 69 and 59%, respectively; inhibits cell growth in MCF-7, BT474, and T47D-ER/Luc breast cancer cells in estrogen-containing media at 1.25-5 µM; reduces tumor growth in an MCF-7 mouse xenograft model at 100 mg/kg twice per day; inhibits RANKL-induced differentiation of murine BMDMs into osteoclasts at 1 and 1.5 µM; increases the bone volume fraction and bone mineral density in injured tibiae in a rat model of cancellous bone injury and regeneration when administered locally at 1 µg

28463	CRT0066854	1 mg	≥98%	A PKCι and PKCζ inhibitor (IC50s = 132 and 639 nM, respectively); an inhibitor of ROCK2 (IC50 = 620 nM); is selective for PKCι, PKCζ, and ROCK2 over typical PKCs and 98 other kinases in a panel at 1 μM; decreases viability of A549 lung carcinoma cells (IC50 = 3.47 μM); decreases colony formation in HeLa cells by 65% at 1 μM; impairs lumen formation in MDCK cells in a Matrigel™ assay and migration of NRK-49F cells in a wound assay
28463	CRT0066854	10 mg	≥98%	A PKCι and PKCζ inhibitor (IC50s = 132 and 639 nM, respectively); an inhibitor of ROCK2 (IC50 = 620 nM); is selective for PKCι, PKCζ, and ROCK2 over typical PKCs and 98 other kinases in a panel at 1 μM; decreases viability of A549 lung carcinoma cells (IC50 = 3.47 μM); decreases colony formation in HeLa cells by 65% at 1 μM; impairs lumen formation in MDCK cells in a Matrigel™ assay and migration of NRK-49F cells in a wound assay
28463	CRT0066854	5 mg	≥98%	A PKCι and PKCζ inhibitor (IC50s = 132 and 639 nM, respectively); an inhibitor of ROCK2 (IC50 = 620 nM); is selective for PKCι, PKCζ, and ROCK2 over typical PKCs and 98 other kinases in a panel at 1 μM; decreases viability of A549 lung carcinoma cells (IC50 = 3.47 μM); decreases colony formation in HeLa cells by 65% at 1 μM; impairs lumen formation in MDCK cells in a Matrigel™ assay and migration of NRK-49F cells in a wound assay
28469	K252d	1 mg	≥70%	An indolocarbazole alkaloid found in Nocardiopsis; a PKC inhibitor; inhibits PKC isolated from rat brain (IC50 = 350 nM); inhibits calcium- and calmodulin-dependent phosphodiesterase isolated from bovine heart (IC50 = 46.2 μM)
28512	ASK1 Inhibitor 10	1 mg	≥98%	An orally bioavailable inhibitor of ASK1 (IC50 = 14 nM); selective for ASK1 over ASK2 (IC50 = 510 nM) as well as MEKK1, TAK-1, IKKβ, ERK1, JNK1, p38α, GSK3β, PKCθ, and B-RAF (IC50s = >10,000 nM for all); inhibits streptozotocin-induced increases in JNK and p38 phosphorylation in INS-1 pancreatic β cells in a concentration-dependent manner
28512	ASK1 Inhibitor 10	10 mg	≥98%	An orally bioavailable inhibitor of ASK1 (IC50 = 14 nM); selective for ASK1 over ASK2 (IC50 = 510 nM) as well as MEKK1, TAK-1, IKKβ, ERK1, JNK1, p38α, GSK3β, PKCθ, and B-RAF (IC50s = >10,000 nM for all); inhibits streptozotocin-induced increases in JNK and p38 phosphorylation in INS-1 pancreatic β cells in a concentration-dependent manner
28512	ASK1 Inhibitor 10	25 mg	≥98%	An orally bioavailable inhibitor of ASK1 (IC50 = 14 nM); selective for ASK1 over ASK2 (IC50 = 510 nM) as well as MEKK1, TAK-1, IKKβ, ERK1, JNK1, p38α, GSK3β, PKCθ, and B-RAF (IC50s = >10,000 nM for all); inhibits streptozotocin-induced increases in JNK and p38 phosphorylation in INS-1 pancreatic β cells in a concentration-dependent manner
28512	ASK1 Inhibitor 10	5 mg	≥98%	An orally bioavailable inhibitor of ASK1 (IC50 = 14 nM); selective for ASK1 over ASK2 (IC50 = 510 nM) as well as MEKK1, TAK-1, IKKβ, ERK1, JNK1, p38α, GSK3β, PKCθ, and B-RAF (IC50s = >10,000 nM for all); inhibits streptozotocin-induced increases in JNK and p38 phosphorylation in INS-1 pancreatic β cells in a concentration-dependent manner
28563	PQR530	1 mg	≥98%	A dual inhibitor of PI3Kα and mTOR (IC50s = 11.1 and 7.4 nM, respectively); inhibits phosphorylation of Akt and ribosomal S6 kinase in A2058 melanoma cells (IC50s = 62.2 and 61.1 nM, respectively); inhibits cell growth in a panel of 66 cancer cell lines (mean GI50 = 0.43 μM); reduces tumor growth in an OVCAR-3 mouse xenograft model at 25 mg/kg; decreases the number of seizures per week in a Tsc1GFAP conditional knockout mouse model of epilepsy
28563	PQR530	10 mg	≥98%	A dual inhibitor of PI3Kα and mTOR (IC50s = 11.1 and 7.4 nM, respectively); inhibits phosphorylation of Akt and ribosomal S6 kinase in A2058 melanoma cells (IC50s = 62.2 and 61.1 nM, respectively); inhibits cell growth in a panel of 66 cancer cell lines (mean GI50 = 0.43 μM); reduces tumor growth in an OVCAR-3 mouse xenograft model at 25 mg/kg; decreases the number of seizures per week in a Tsc1GFAP conditional knockout mouse model of epilepsy
28563	PQR530	25 mg	≥98%	A dual inhibitor of PI3Kα and mTOR (IC50s = 11.1 and 7.4 nM, respectively); inhibits phosphorylation of Akt and ribosomal S6 kinase in A2058 melanoma cells (IC50s = 62.2 and 61.1 nM, respectively); inhibits cell growth in a panel of 66 cancer cell lines (mean GI50 = 0.43 μM); reduces tumor growth in an OVCAR-3 mouse xenograft model at 25 mg/kg; decreases the number of seizures per week in a Tsc1GFAP conditional knockout mouse model of epilepsy
28563	PQR530	5 mg	≥98%	A dual inhibitor of PI3Kα and mTOR (IC50s = 11.1 and 7.4 nM, respectively); inhibits phosphorylation of Akt and ribosomal S6 kinase in A2058 melanoma cells (IC50s = 62.2 and 61.1 nM, respectively); inhibits cell growth in a panel of 66 cancer cell lines (mean GI50 = 0.43 μM); reduces tumor growth in an OVCAR-3 mouse xenograft model at 25 mg/kg; decreases the number of seizures per week in a Tsc1GFAP conditional knockout mouse model of epilepsy

28598	AZD 7648	1 mg	≥98%	An inhibitor of DNA-PK (IC50 = 0.63 nM in an enzyme assay); selective for DNA-PK over TTK (IC50 = 5.012 µM), as well as JAK1, JAK2, JAK3, Aurora A, and Aurora B (IC50s = >10 µM for all); reduces tumor growth in a FaDu ATM KO pharynx cancer mouse xenograft model at 37.5 or 75 mg/kg twice per day and induces tumor regression at these doses when administered in combination with the PARP inhibitor olaparib
28598	AZD 7648	10 mg	≥98%	An inhibitor of DNA-PK (IC50 = 0.63 nM in an enzyme assay); selective for DNA-PK over TTK (IC50 = 5.012 µM), as well as JAK1, JAK2, JAK3, Aurora A, and Aurora B (IC50s = >10 µM for all); reduces tumor growth in a FaDu ATM KO pharynx cancer mouse xenograft model at 37.5 or 75 mg/kg twice per day and induces tumor regression at these doses when administered in combination with the PARP inhibitor olaparib
28598	AZD 7648	25 mg	≥98%	An inhibitor of DNA-PK (IC50 = 0.63 nM in an enzyme assay); selective for DNA-PK over TTK (IC50 = 5.012 µM), as well as JAK1, JAK2, JAK3, Aurora A, and Aurora B (IC50s = >10 µM for all); reduces tumor growth in a FaDu ATM KO pharynx cancer mouse xenograft model at 37.5 or 75 mg/kg twice per day and induces tumor regression at these doses when administered in combination with the PARP inhibitor olaparib
28598	AZD 7648	5 mg	≥98%	An inhibitor of DNA-PK (IC50 = 0.63 nM in an enzyme assay); selective for DNA-PK over TTK (IC50 = 5.012 µM), as well as JAK1, JAK2, JAK3, Aurora A, and Aurora B (IC50s = >10 µM for all); reduces tumor growth in a FaDu ATM KO pharynx cancer mouse xenograft model at 37.5 or 75 mg/kg twice per day and induces tumor regression at these doses when administered in combination with the PARP inhibitor olaparib
28615	Lenvatinib-d4	1 mg	≥99% deutera	An internal standard for the quantification of lenvatinib by GC- or LC-MS
28706	Dovitinib-d8	1 mg	≥99% deutera	An internal standard for the quantification of dovitinib by GC- or LC-MS
28710	Vandetanib-d6	1 mg	≥99% deutera	An internal standard for the quantification of vandetanib by GC- or LC-MS
28710	Vandetanib-d6	5 mg	≥99% deutera	An internal standard for the quantification of vandetanib by GC- or LC-MS
28710	Vandetanib-d6	500 µg	≥99% deutera	An internal standard for the quantification of vandetanib by GC- or LC-MS
28757	TP-0903	1 mg	≥98%	An inhibitor of Axl (IC50 = 27 nM); exhibits greater than 50% inhibition of 11 kinases, including MER, TYRO3, JAK2, ALK, and Abl1, in a panel of 75 kinases at 200 nM, with IC50 values of 3 and 12.4 nM for Aurora A and B, respectively; decreases the phosphorylation of Akt and Axl in GAS6-stimulated, serum-starved PSN-1 pancreatic cancer cells (EC50s = 305 and 222 nM, respectively); decreases cell viability (IC50 = 6 nM) and induces cell cycle arrest at the G2/M phase in PSN-1 cells at 30 nM; reduces the viability of CRC cell lines (IC50s = 4.5-123 nM); exhibits 69 and 44% tumor growth inhibition in an HCT116 mouse xenograft model and a K-Ras-mutant CRC PDX mouse model, respectively, at 40 mg/kg
28757	TP-0903	10 mg	≥98%	An inhibitor of Axl (IC50 = 27 nM); exhibits greater than 50% inhibition of 11 kinases, including MER, TYRO3, JAK2, ALK, and Abl1, in a panel of 75 kinases at 200 nM, with IC50 values of 3 and 12.4 nM for Aurora A and B, respectively; decreases the phosphorylation of Akt and Axl in GAS6-stimulated, serum-starved PSN-1 pancreatic cancer cells (EC50s = 305 and 222 nM, respectively); decreases cell viability (IC50 = 6 nM) and induces cell cycle arrest at the G2/M phase in PSN-1 cells at 30 nM; reduces the viability of CRC cell lines (IC50s = 4.5-123 nM); exhibits 69 and 44% tumor growth inhibition in an HCT116 mouse xenograft model and a K-Ras-mutant CRC PDX mouse model, respectively, at 40 mg/kg
28757	TP-0903	25 mg	≥98%	An inhibitor of Axl (IC50 = 27 nM); exhibits greater than 50% inhibition of 11 kinases, including MER, TYRO3, JAK2, ALK, and Abl1, in a panel of 75 kinases at 200 nM, with IC50 values of 3 and 12.4 nM for Aurora A and B, respectively; decreases the phosphorylation of Akt and Axl in GAS6-stimulated, serum-starved PSN-1 pancreatic cancer cells (EC50s = 305 and 222 nM, respectively); decreases cell viability (IC50 = 6 nM) and induces cell cycle arrest at the G2/M phase in PSN-1 cells at 30 nM; reduces the viability of CRC cell lines (IC50s = 4.5-123 nM); exhibits 69 and 44% tumor growth inhibition in an HCT116 mouse xenograft model and a K-Ras-mutant CRC PDX mouse model, respectively, at 40 mg/kg
28757	TP-0903	5 mg	≥98%	An inhibitor of Axl (IC50 = 27 nM); exhibits greater than 50% inhibition of 11 kinases, including MER, TYRO3, JAK2, ALK, and Abl1, in a panel of 75 kinases at 200 nM, with IC50 values of 3 and 12.4 nM for Aurora A and B, respectively; decreases the phosphorylation of Akt and Axl in GAS6-stimulated, serum-starved PSN-1 pancreatic cancer cells (EC50s = 305 and 222 nM, respectively); decreases cell viability (IC50 = 6 nM) and induces cell cycle arrest at the G2/M phase in PSN-1 cells at 30 nM; reduces the viability of CRC cell lines (IC50s = 4.5-123 nM); exhibits 69 and 44% tumor growth inhibition in an HCT116 mouse xenograft model and a K-Ras-mutant CRC PDX mouse model, respectively, at 40 mg/kg
28759	GW843682X	1 mg	≥98%	A reversible, cell-permeable PLK inhibitor; selectively inhibits Plk1 and Plk3 (IC50s = 2.2 and 9.1 nM, respectively) over more than 30 other kinases in a cell-free assay; inhibits Plk1 activity in vitro in HeLa cells using a chimeric Plk1 reporter assay (IC50 = 0.14 µM); inhibits growth in nine cancer cell lines in a panel (IC50s = 0.11-0.7 µM) but not of PC3 human prostate cancer cells (IC50 = 6.82 µM) or non-cancerous human diploid fibroblasts (HDFs; IC50 = 6.14 µM); inhibits growth of MES-SA human uterine sarcoma cells, as well as of the drug-resistant, P-glycoprotein-expressing MES-SA/Dx5 subline (IC50s = 0.21 and 0.21 µM, respectively); inhibits the growth of patient-derived leukemia cells (IC50s = 2/M cell cycle arrest and apoptosis of H460 human lung and PALL-2 and MOLM13 human leukemia cancer cells in a concentration-dependent manner

28759	GW843682X	10 mg	≥98%	A reversible, cell-permeable PLK inhibitor; selectively inhibits Plk1 and Plk3 (IC50s = 2.2 and 9.1 nM, respectively) over more than 30 other kinases in a cell-free assay; inhibits Plk1 activity in vitro in HeLa cells using a chimeric Plk1 reporter assay (IC50 = 0.14 µM); inhibits growth in nine cancer cell lines in a panel (IC50s = 0.11-0.7 µM) but not of PC3 human prostate cancer cells (IC50 = 6.82 µM) or non-cancerous human diploid fibroblasts (HDFs; IC50 = 6.14 µM); inhibits growth of MES-SA human uterine sarcoma cells, as well as of the drug-resistant, P-glycoprotein-expressing MES-SA/Dx5 subline (IC50s = 0.21 and 0.21 µM, respectively); inhibits the growth of patient-derived leukemia cells (IC50s = 2/M cell cycle arrest and apoptosis of H460 human lung and PALL-2 and MOLM13 human leukemia cancer cells in a concentration-dependent manner
28759	GW843682X	5 mg	≥98%	A reversible, cell-permeable PLK inhibitor; selectively inhibits Plk1 and Plk3 (IC50s = 2.2 and 9.1 nM, respectively) over more than 30 other kinases in a cell-free assay; inhibits Plk1 activity in vitro in HeLa cells using a chimeric Plk1 reporter assay (IC50 = 0.14 µM); inhibits growth in nine cancer cell lines in a panel (IC50s = 0.11-0.7 µM) but not of PC3 human prostate cancer cells (IC50 = 6.82 µM) or non-cancerous human diploid fibroblasts (HDFs; IC50 = 6.14 µM); inhibits growth of MES-SA human uterine sarcoma cells, as well as of the drug-resistant, P-glycoprotein-expressing MES-SA/Dx5 subline (IC50s = 0.21 and 0.21 µM, respectively); inhibits the growth of patient-derived leukemia cells (IC50s = 2/M cell cycle arrest and apoptosis of H460 human lung and PALL-2 and MOLM13 human leukemia cancer cells in a concentration-dependent manner
28762	NMS-1286937	1 mg	≥98%	An inhibitor of Plk1 (IC50 = 2 nM); selective for Plk1 over Plk2 and Plk3 (IC50s = >10,000 nM for both); inhibits proliferation of A2780 cells (IC50 = 42 nM); halts the cell cycle at the G2/M phase in A2780 cells at 20-200 nmol/L and induces apoptosis; reduces tumor growth in an HCT116 mouse xenograft model at 60 mg/kg once per day; induces tumor regression in an HT-29 mouse xenograft model at 45 mg/kg in combination with CPT11
28762	NMS-1286937	10 mg	≥98%	An inhibitor of Plk1 (IC50 = 2 nM); selective for Plk1 over Plk2 and Plk3 (IC50s = >10,000 nM for both); inhibits proliferation of A2780 cells (IC50 = 42 nM); halts the cell cycle at the G2/M phase in A2780 cells at 20-200 nmol/L and induces apoptosis; reduces tumor growth in an HCT116 mouse xenograft model at 60 mg/kg once per day; induces tumor regression in an HT-29 mouse xenograft model at 45 mg/kg in combination with CPT11
28762	NMS-1286937	25 mg	≥98%	An inhibitor of Plk1 (IC50 = 2 nM); selective for Plk1 over Plk2 and Plk3 (IC50s = >10,000 nM for both); inhibits proliferation of A2780 cells (IC50 = 42 nM); halts the cell cycle at the G2/M phase in A2780 cells at 20-200 nmol/L and induces apoptosis; reduces tumor growth in an HCT116 mouse xenograft model at 60 mg/kg once per day; induces tumor regression in an HT-29 mouse xenograft model at 45 mg/kg in combination with CPT11
28762	NMS-1286937	5 mg	≥98%	An inhibitor of Plk1 (IC50 = 2 nM); selective for Plk1 over Plk2 and Plk3 (IC50s = >10,000 nM for both); inhibits proliferation of A2780 cells (IC50 = 42 nM); halts the cell cycle at the G2/M phase in A2780 cells at 20-200 nmol/L and induces apoptosis; reduces tumor growth in an HCT116 mouse xenograft model at 60 mg/kg once per day; induces tumor regression in an HT-29 mouse xenograft model at 45 mg/kg in combination with CPT11
28768	Ceritinib-d7	1 mg	≥99% deutera	An internal standard for the quantification of ceritinib by GC- or LC-MS
28775	CCT245737	10 mg	≥98%	A potent Chk1 inhibitor (IC50 = 1.3 nM); selective for Chk1 over Chk2 (IC50 = 2,440 nM); inhibits etoposide-induced G2 checkpoint arrest in HT-29 colon cancer cells (IC50 = 30 nM); inhibits gemcitabine-induced Chk1 autophosphorylation in an SW620 colon cancer mouse xenograft model at 300 mg/kg; reduces tumor volume when administered alone or in combination with gemcitabine in an HT-29 mouse xenograft model; reduces inguinal, brachial/axillary, and mesenteric lymph node weights in the Eµ-Myc driven transgenic mouse transplant model of lymph gland-infiltrating B cell lymphoma at 150 mg/kg
28775	CCT245737	5 mg	≥98%	A potent Chk1 inhibitor (IC50 = 1.3 nM); selective for Chk1 over Chk2 (IC50 = 2,440 nM); inhibits etoposide-induced G2 checkpoint arrest in HT-29 colon cancer cells (IC50 = 30 nM); inhibits gemcitabine-induced Chk1 autophosphorylation in an SW620 colon cancer mouse xenograft model at 300 mg/kg; reduces tumor volume when administered alone or in combination with gemcitabine in an HT-29 mouse xenograft model; reduces inguinal, brachial/axillary, and mesenteric lymph node weights in the Eµ-Myc driven transgenic mouse transplant model of lymph gland-infiltrating B cell lymphoma at 150 mg/kg
28797	Dabrafenib-d9	1 mg	≥99% deutera	An internal standard for the quantification of dabrafenib by GC- or LC-MS
28808	Oclacitinib-13C-d3	1 mg	≥99% deutera	An internal standard for the quantification of oclacitinib by GC- or LC-MS
28808	Oclacitinib-13C-d3	500 µg	≥99% deutera	An internal standard for the quantification of oclacitinib by GC- or LC-MS
28831	JNK Inhibitor VII	1 mg	≥98%	A non-selective JNK inhibitor (IC50s = 1.54, 1.99, and 0.75 nM for JNK1, -2, and -3, respectively); inhibits phosphorylation of c-Jun in HeLa and A375 cells (EC50s = 130 and 244 nM, respectively)
28831	JNK Inhibitor VII	10 mg	≥98%	A non-selective JNK inhibitor (IC50s = 1.54, 1.99, and 0.75 nM for JNK1, -2, and -3, respectively); inhibits phosphorylation of c-Jun in HeLa and A375 cells (EC50s = 130 and 244 nM, respectively)

28831	JNK Inhibitor VII	25 mg	≥98%	A non-selective JNK inhibitor (IC50s = 1.54, 1.99, and 0.75 nM for JNK1, -2, and -3, respectively); inhibits phosphorylation of c-Jun in HeLa and A375 cells (EC50s = 130 and 244 nM, respectively)
28831	JNK Inhibitor VII	5 mg	≥98%	A non-selective JNK inhibitor (IC50s = 1.54, 1.99, and 0.75 nM for JNK1, -2, and -3, respectively); inhibits phosphorylation of c-Jun in HeLa and A375 cells (EC50s = 130 and 244 nM, respectively)
28850	AMG-Tie2-1	1 mg	≥98%	An inhibitor of Tie2 and VEGFR2 (IC50s = 1 and 3 nM, respectively, in a HTRF assay); inhibits angiopoietin 1-induced Tie2 autophosphorylation in EA.hy926 human endothelial cells (IC50 = 10 nM).
28850	AMG-Tie2-1	10 mg	≥98%	An inhibitor of Tie2 and VEGFR2 (IC50s = 1 and 3 nM, respectively, in a HTRF assay); inhibits angiopoietin 1-induced Tie2 autophosphorylation in EA.hy926 human endothelial cells (IC50 = 10 nM).
28850	AMG-Tie2-1	25 mg	≥98%	An inhibitor of Tie2 and VEGFR2 (IC50s = 1 and 3 nM, respectively, in a HTRF assay); inhibits angiopoietin 1-induced Tie2 autophosphorylation in EA.hy926 human endothelial cells (IC50 = 10 nM).
28850	AMG-Tie2-1	5 mg	≥98%	An inhibitor of Tie2 and VEGFR2 (IC50s = 1 and 3 nM, respectively, in a HTRF assay); inhibits angiopoietin 1-induced Tie2 autophosphorylation in EA.hy926 human endothelial cells (IC50 = 10 nM).
28875	Filgotinib-d4	1 mg	≥99% deutera	An internal standard for the quantification of filgotinib by GC- or LC-MS
28875	Filgotinib-d4	5 mg	≥99% deutera	An internal standard for the quantification of filgotinib by GC- or LC-MS
28905	Ponatinib-d8	1 mg	≥99% deutera	An internal standard for the quantification of ponatinib by GC- or LC-MS
28913	BAY-1125976	1 mg	≥98%	An allosteric inhibitor of Akt1 and -2 (IC50s = 5.2 and 18 nM, respectively, in a time-resolved FRET assay); selective for Akt1 and -2 over Akt3 (IC50 = 427 nM in the same assay) but does inhibit the activity of FLT1, -3, -4, and Mer by >50% in a panel of 227 kinases at 1 µM; inhibits the proliferation of 23 cancer cell lines (IC50s = 0.02-10 µM) and reduces tumor growth in KPL-4, MCF-7, and PDX mouse xenograft models at 50 mg/kg per day
28913	BAY-1125976	10 mg	≥98%	An allosteric inhibitor of Akt1 and -2 (IC50s = 5.2 and 18 nM, respectively, in a time-resolved FRET assay); selective for Akt1 and -2 over Akt3 (IC50 = 427 nM in the same assay) but does inhibit the activity of FLT1, -3, -4, and Mer by >50% in a panel of 227 kinases at 1 µM; inhibits the proliferation of 23 cancer cell lines (IC50s = 0.02-10 µM) and reduces tumor growth in KPL-4, MCF-7, and PDX mouse xenograft models at 50 mg/kg per day
28913	BAY-1125976	25 mg	≥98%	An allosteric inhibitor of Akt1 and -2 (IC50s = 5.2 and 18 nM, respectively, in a time-resolved FRET assay); selective for Akt1 and -2 over Akt3 (IC50 = 427 nM in the same assay) but does inhibit the activity of FLT1, -3, -4, and Mer by >50% in a panel of 227 kinases at 1 µM; inhibits the proliferation of 23 cancer cell lines (IC50s = 0.02-10 µM) and reduces tumor growth in KPL-4, MCF-7, and PDX mouse xenograft models at 50 mg/kg per day
28913	BAY-1125976	5 mg	≥98%	An allosteric inhibitor of Akt1 and -2 (IC50s = 5.2 and 18 nM, respectively, in a time-resolved FRET assay); selective for Akt1 and -2 over Akt3 (IC50 = 427 nM in the same assay) but does inhibit the activity of FLT1, -3, -4, and Mer by >50% in a panel of 227 kinases at 1 µM; inhibits the proliferation of 23 cancer cell lines (IC50s = 0.02-10 µM) and reduces tumor growth in KPL-4, MCF-7, and PDX mouse xenograft models at 50 mg/kg per day
28924	Zanubrutinib	1 mg	≥98%	A potent and covalent BTK inhibitor (IC50 = 0.3 nM); selective for BTK over a panel of 304 kinases at 1 µM; inhibits EGFR, Tec, Blk, BMX, HER4, and TXK (IC50s = 0.62-33 nM); inhibits phosphorylation of BTK at Y233 (IC50 = 1.8 nM) in Ramos cells; reduces viability of REC-1 cells (IC50 = 0.36 nM); reduces tumor volume in an OCI-LY10 DLBCL mouse xenograft model at 2.5 and 7.5 mg/kg
28924	Zanubrutinib	10 mg	≥98%	A potent and covalent BTK inhibitor (IC50 = 0.3 nM); selective for BTK over a panel of 304 kinases at 1 µM; inhibits EGFR, Tec, Blk, BMX, HER4, and TXK (IC50s = 0.62-33 nM); inhibits phosphorylation of BTK at Y233 (IC50 = 1.8 nM) in Ramos cells; reduces viability of REC-1 cells (IC50 = 0.36 nM); reduces tumor volume in an OCI-LY10 DLBCL mouse xenograft model at 2.5 and 7.5 mg/kg
28924	Zanubrutinib	25 mg	≥98%	A potent and covalent BTK inhibitor (IC50 = 0.3 nM); selective for BTK over a panel of 304 kinases at 1 µM; inhibits EGFR, Tec, Blk, BMX, HER4, and TXK (IC50s = 0.62-33 nM); inhibits phosphorylation of BTK at Y233 (IC50 = 1.8 nM) in Ramos cells; reduces viability of REC-1 cells (IC50 = 0.36 nM); reduces tumor volume in an OCI-LY10 DLBCL mouse xenograft model at 2.5 and 7.5 mg/kg
28924	Zanubrutinib	5 mg	≥98%	A potent and covalent BTK inhibitor (IC50 = 0.3 nM); selective for BTK over a panel of 304 kinases at 1 µM; inhibits EGFR, Tec, Blk, BMX, HER4, and TXK (IC50s = 0.62-33 nM); inhibits phosphorylation of BTK at Y233 (IC50 = 1.8 nM) in Ramos cells; reduces viability of REC-1 cells (IC50 = 0.36 nM); reduces tumor volume in an OCI-LY10 DLBCL mouse xenograft model at 2.5 and 7.5 mg/kg

28927	PLX5622	1 mg	≥98%	A brain-penetrant CSF1R inhibitor (IC50 = 0.016 μM); selective for CSF1R over FLT3, Kit, Aurora C, and VEGFR2 (IC50s = 0.39, 0.86, 1, and 1.1 μM, respectively); greater than 100-fold selective for CSF1R over a panel of 230 kinases; reduces the number of Iba-1+ cells in the spinal cord dorsal horn in a mouse model of neuropathic pain induced by partial ligation of the sciatic nerve at 65 mg/kg; decreases macrophage levels of TNF-α and IL-1β and infiltration in the sciatic nerve and alleviates mechanical and cold allodynia in the same model; decreases the number of hippocampal microglia by 90%, as well as reduces the number and volume of retrosplenial and somatosensory cortical Aβ plaques in the 5XFAD mouse model of Alzheimer's disease at 1,200 ppm
28927	PLX5622	10 mg	≥98%	A brain-penetrant CSF1R inhibitor (IC50 = 0.016 μM); selective for CSF1R over FLT3, Kit, Aurora C, and VEGFR2 (IC50s = 0.39, 0.86, 1, and 1.1 μM, respectively); greater than 100-fold selective for CSF1R over a panel of 230 kinases; reduces the number of Iba-1+ cells in the spinal cord dorsal horn in a mouse model of neuropathic pain induced by partial ligation of the sciatic nerve at 65 mg/kg; decreases macrophage levels of TNF-α and IL-1β and infiltration in the sciatic nerve and alleviates mechanical and cold allodynia in the same model; decreases the number of hippocampal microglia by 90%, as well as reduces the number and volume of retrosplenial and somatosensory cortical Aβ plaques in the 5XFAD mouse model of Alzheimer's disease at 1,200 ppm
28927	PLX5622	25 mg	≥98%	A brain-penetrant CSF1R inhibitor (IC50 = 0.016 μM); selective for CSF1R over FLT3, Kit, Aurora C, and VEGFR2 (IC50s = 0.39, 0.86, 1, and 1.1 μM, respectively); greater than 100-fold selective for CSF1R over a panel of 230 kinases; reduces the number of Iba-1+ cells in the spinal cord dorsal horn in a mouse model of neuropathic pain induced by partial ligation of the sciatic nerve at 65 mg/kg; decreases macrophage levels of TNF-α and IL-1β and infiltration in the sciatic nerve and alleviates mechanical and cold allodynia in the same model; decreases the number of hippocampal microglia by 90%, as well as reduces the number and volume of retrosplenial and somatosensory cortical Aβ plaques in the 5XFAD mouse model of Alzheimer's disease at 1,200 ppm
28927	PLX5622	5 mg	≥98%	A brain-penetrant CSF1R inhibitor (IC50 = 0.016 μM); selective for CSF1R over FLT3, Kit, Aurora C, and VEGFR2 (IC50s = 0.39, 0.86, 1, and 1.1 μM, respectively); greater than 100-fold selective for CSF1R over a panel of 230 kinases; reduces the number of Iba-1+ cells in the spinal cord dorsal horn in a mouse model of neuropathic pain induced by partial ligation of the sciatic nerve at 65 mg/kg; decreases macrophage levels of TNF-α and IL-1β and infiltration in the sciatic nerve and alleviates mechanical and cold allodynia in the same model; decreases the number of hippocampal microglia by 90%, as well as reduces the number and volume of retrosplenial and somatosensory cortical Aβ plaques in the 5XFAD mouse model of Alzheimer's disease at 1,200 ppm
28952	Glumetinib	1 mg	≥98%	A potent c-Met inhibitor (IC50 = 0.42 nM); >2,400-fold selective for c-Met over a panel of 312 kinases; inhibits c-Met phosphorylation in and proliferation of MET-overexpressing EBC-1 lung and MKN45 gastric cancer cells from 0.001-1 μM; inhibits HGF-induced NCI H441 cell motility and invasion at 10 nM; reduces tumor volume in MKN45, SNU-5, and EBC-1 mouse xenograft models from 2.5-10 mg/kg; reduces tumor growth in MET amplification-containing NSCLC and HCC PDX mouse models
28952	Glumetinib	10 mg	≥98%	A potent c-Met inhibitor (IC50 = 0.42 nM); >2,400-fold selective for c-Met over a panel of 312 kinases; inhibits c-Met phosphorylation in and proliferation of MET-overexpressing EBC-1 lung and MKN45 gastric cancer cells from 0.001-1 μM; inhibits HGF-induced NCI H441 cell motility and invasion at 10 nM; reduces tumor volume in MKN45, SNU-5, and EBC-1 mouse xenograft models from 2.5-10 mg/kg; reduces tumor growth in MET amplification-containing NSCLC and HCC PDX mouse models
28952	Glumetinib	25 mg	≥98%	A potent c-Met inhibitor (IC50 = 0.42 nM); >2,400-fold selective for c-Met over a panel of 312 kinases; inhibits c-Met phosphorylation in and proliferation of MET-overexpressing EBC-1 lung and MKN45 gastric cancer cells from 0.001-1 μM; inhibits HGF-induced NCI H441 cell motility and invasion at 10 nM; reduces tumor volume in MKN45, SNU-5, and EBC-1 mouse xenograft models from 2.5-10 mg/kg; reduces tumor growth in MET amplification-containing NSCLC and HCC PDX mouse models
28952	Glumetinib	5 mg	≥98%	A potent c-Met inhibitor (IC50 = 0.42 nM); >2,400-fold selective for c-Met over a panel of 312 kinases; inhibits c-Met phosphorylation in and proliferation of MET-overexpressing EBC-1 lung and MKN45 gastric cancer cells from 0.001-1 μM; inhibits HGF-induced NCI H441 cell motility and invasion at 10 nM; reduces tumor volume in MKN45, SNU-5, and EBC-1 mouse xenograft models from 2.5-10 mg/kg; reduces tumor growth in MET amplification-containing NSCLC and HCC PDX mouse models
29012	UNC2881	10 mg	≥98%	An inhibitor of Mer kinase (IC50 = 4.3 nM); selective for Mer over Axl and TYRO3 (IC50s = 360 and 250 nM, respectively); inhibits phosphorylation of Mer in 697 B-ALL cells (IC50 = 21.9 nM); inhibits platelet aggregation and ATP release induced by type I equine fibrillar collagen in isolated human platelet-rich plasma at 3 μM

29012	UNC2881	25 mg	≥98%	An inhibitor of Mer kinase (IC50 = 4.3 nM); selective for Mer over Axl and TYRO3 (IC50s = 360 and 250 nM, respectively); inhibits phosphorylation of Mer in 697 B-ALL cells (IC50 = 21.9 nM); inhibits platelet aggregation and ATP release induced by type I equine fibrillar collagen in isolated human platelet-rich plasma at 3 µM
29012	UNC2881	5 mg	≥98%	An inhibitor of Mer kinase (IC50 = 4.3 nM); selective for Mer over Axl and TYRO3 (IC50s = 360 and 250 nM, respectively); inhibits phosphorylation of Mer in 697 B-ALL cells (IC50 = 21.9 nM); inhibits platelet aggregation and ATP release induced by type I equine fibrillar collagen in isolated human platelet-rich plasma at 3 µM
29012	UNC2881	50 mg	≥98%	An inhibitor of Mer kinase (IC50 = 4.3 nM); selective for Mer over Axl and TYRO3 (IC50s = 360 and 250 nM, respectively); inhibits phosphorylation of Mer in 697 B-ALL cells (IC50 = 21.9 nM); inhibits platelet aggregation and ATP release induced by type I equine fibrillar collagen in isolated human platelet-rich plasma at 3 µM
29019	KDU691	1 mg	≥98%	An antimalarial compound; inhibits the activity of recombinant P. vivax PI4K (IC50 = 1.5 nM); selective for P. vivax PI4K over recombinant human PI4KβIII and PI3Kα, -β, -ɣ, and -δ (IC50s = 7.9, 8.8, 2.4, 8, and 3.4 µM, respectively), as well as VPS34 (IC50 = >9.7 µM) and 36 additional kinases in a panel of lipid and protein kinases (IC50s = >10 µM); active against P. falciparum and P. yoelii schizonts (IC50s = 0.06 and 0.04 µM, respectively), as well as P. cynomolgi schizonts and hypnozoites (IC50s = 0.11 and 0.2 µM, respectively); completely prevents, but does not eradicate established, P. cynomolgi infection in rhesus monkeys at 20 mg/kg
29019	KDU691	10 mg	≥98%	An antimalarial compound; inhibits the activity of recombinant P. vivax PI4K (IC50 = 1.5 nM); selective for P. vivax PI4K over recombinant human PI4KβIII and PI3Kα, -β, -ɣ, and -δ (IC50s = 7.9, 8.8, 2.4, 8, and 3.4 µM, respectively), as well as VPS34 (IC50 = >9.7 µM) and 36 additional kinases in a panel of lipid and protein kinases (IC50s = >10 µM); active against P. falciparum and P. yoelii schizonts (IC50s = 0.06 and 0.04 µM, respectively), as well as P. cynomolgi schizonts and hypnozoites (IC50s = 0.11 and 0.2 µM, respectively); completely prevents, but does not eradicate established, P. cynomolgi infection in rhesus monkeys at 20 mg/kg
29019	KDU691	25 mg	≥98%	An antimalarial compound; inhibits the activity of recombinant P. vivax PI4K (IC50 = 1.5 nM); selective for P. vivax PI4K over recombinant human PI4KβIII and PI3Kα, -β, -ɣ, and -δ (IC50s = 7.9, 8.8, 2.4, 8, and 3.4 µM, respectively), as well as VPS34 (IC50 = >9.7 µM) and 36 additional kinases in a panel of lipid and protein kinases (IC50s = >10 µM); active against P. falciparum and P. yoelii schizonts (IC50s = 0.06 and 0.04 µM, respectively), as well as P. cynomolgi schizonts and hypnozoites (IC50s = 0.11 and 0.2 µM, respectively); completely prevents, but does not eradicate established, P. cynomolgi infection in rhesus monkeys at 20 mg/kg
29019	KDU691	5 mg	≥98%	An antimalarial compound; inhibits the activity of recombinant P. vivax PI4K (IC50 = 1.5 nM); selective for P. vivax PI4K over recombinant human PI4KβIII and PI3Kα, -β, -ɣ, and -δ (IC50s = 7.9, 8.8, 2.4, 8, and 3.4 µM, respectively), as well as VPS34 (IC50 = >9.7 µM) and 36 additional kinases in a panel of lipid and protein kinases (IC50s = >10 µM); active against P. falciparum and P. yoelii schizonts (IC50s = 0.06 and 0.04 µM, respectively), as well as P. cynomolgi schizonts and hypnozoites (IC50s = 0.11 and 0.2 µM, respectively); completely prevents, but does not eradicate established, P. cynomolgi infection in rhesus monkeys at 20 mg/kg
29029	Evobrutinib	1 mg	≥98%	A BTK inhibitor (IC50 = 8.9 nM); selective for BTK over a panel of 233 kinases at 1 µM; inhibits BTK in PBMCs (IC50 = 61 nM); inhibits B cell activation and proliferation in vitro (IC50s = 18.4 and 10.9 nM, respectively); inhibits mast cell degranulation in a mouse model of passive cutaneous anaphylaxis at 3.95, 19.8, and 39.5 mg/kg; reduces cartilage destruction in a rat model of collagen-induced arthritis at 1 and 3 mg/kg; decreases proteinuria, interstitial inflammation, and the number of glomerular lesions and preserves kidney function in a mouse model of SLE
29029	Evobrutinib	10 mg	≥98%	A BTK inhibitor (IC50 = 8.9 nM); selective for BTK over a panel of 233 kinases at 1 µM; inhibits BTK in PBMCs (IC50 = 61 nM); inhibits B cell activation and proliferation in vitro (IC50s = 18.4 and 10.9 nM, respectively); inhibits mast cell degranulation in a mouse model of passive cutaneous anaphylaxis at 3.95, 19.8, and 39.5 mg/kg; reduces cartilage destruction in a rat model of collagen-induced arthritis at 1 and 3 mg/kg; decreases proteinuria, interstitial inflammation, and the number of glomerular lesions and preserves kidney function in a mouse model of SLE
29029	Evobrutinib	25 mg	≥98%	A BTK inhibitor (IC50 = 8.9 nM); selective for BTK over a panel of 233 kinases at 1 µM; inhibits BTK in PBMCs (IC50 = 61 nM); inhibits B cell activation and proliferation in vitro (IC50s = 18.4 and 10.9 nM, respectively); inhibits mast cell degranulation in a mouse model of passive cutaneous anaphylaxis at 3.95, 19.8, and 39.5 mg/kg; reduces cartilage destruction in a rat model of collagen-induced arthritis at 1 and 3 mg/kg; decreases proteinuria, interstitial inflammation, and the number of glomerular lesions and preserves kidney function in a mouse model of SLE

29029	Evobrutinib	5 mg	≥98%	A BTK inhibitor (IC50 = 8.9 nM); selective for BTK over a panel of 233 kinases at 1 µM; inhibits BTK in PBMCs (IC50 = 61 nM); inhibits B cell activation and proliferation in vitro (IC50s = 18.4 and 10.9 nM, respectively); inhibits mast cell degranulation in a mouse model of passive cutaneous anaphylaxis at 3.95, 19.8, and 39.5 mg/kg; reduces cartilage destruction in a rat model of collagen-induced arthritis at 1 and 3 mg/kg; decreases proteinuria, interstitial inflammation, and the number of glomerular lesions and preserves kidney function in a mouse model of SLE
29036	PCI-29732	1 mg	≥98%	A multi-kinase inhibitor; inhibits BTK, LCK, and LYN (Kis = 8.2, 4.6, and 2.5 nM, respectively), as well as the activity of three receptor tyrosine kinases and seven non-receptor tyrosine kinases by greater than 90% in a panel of over 100 kinases at 10 µM; inhibits calcium flux in Ramos B cells and phosphorylation of PLCγ1 (IC50s = 0.53 and 0.33 µM, respectively); cytotoxic to S1-MI-80, H460/MX20, and KBv200 cancer cells overexpressing the ATP-binding cassette transporter (IC50s = 7.8, 6.3, and 6.02 µM, respectively); in combination with topotecan, reduces tumor growth in an H460/MX20 mouse xenograft model at 20 mg/kg
29036	PCI-29732	10 mg	≥98%	A multi-kinase inhibitor; inhibits BTK, LCK, and LYN (Kis = 8.2, 4.6, and 2.5 nM, respectively), as well as the activity of three receptor tyrosine kinases and seven non-receptor tyrosine kinases by greater than 90% in a panel of over 100 kinases at 10 µM; inhibits calcium flux in Ramos B cells and phosphorylation of PLCγ1 (IC50s = 0.53 and 0.33 µM, respectively); cytotoxic to S1-MI-80, H460/MX20, and KBv200 cancer cells overexpressing the ATP-binding cassette transporter (IC50s = 7.8, 6.3, and 6.02 µM, respectively); in combination with topotecan, reduces tumor growth in an H460/MX20 mouse xenograft model at 20 mg/kg
29036	PCI-29732	25 mg	≥98%	A multi-kinase inhibitor; inhibits BTK, LCK, and LYN (Kis = 8.2, 4.6, and 2.5 nM, respectively), as well as the activity of three receptor tyrosine kinases and seven non-receptor tyrosine kinases by greater than 90% in a panel of over 100 kinases at 10 µM; inhibits calcium flux in Ramos B cells and phosphorylation of PLCγ1 (IC50s = 0.53 and 0.33 µM, respectively); cytotoxic to S1-MI-80, H460/MX20, and KBv200 cancer cells overexpressing the ATP-binding cassette transporter (IC50s = 7.8, 6.3, and 6.02 µM, respectively); in combination with topotecan, reduces tumor growth in an H460/MX20 mouse xenograft model at 20 mg/kg
29036	PCI-29732	5 mg	≥98%	A multi-kinase inhibitor; inhibits BTK, LCK, and LYN (Kis = 8.2, 4.6, and 2.5 nM, respectively), as well as the activity of three receptor tyrosine kinases and seven non-receptor tyrosine kinases by greater than 90% in a panel of over 100 kinases at 10 µM; inhibits calcium flux in Ramos B cells and phosphorylation of PLCγ1 (IC50s = 0.53 and 0.33 µM, respectively); cytotoxic to S1-MI-80, H460/MX20, and KBv200 cancer cells overexpressing the ATP-binding cassette transporter (IC50s = 7.8, 6.3, and 6.02 µM, respectively); in combination with topotecan, reduces tumor growth in an H460/MX20 mouse xenograft model at 20 mg/kg
29039	AV-412	10 mg	≥98%	A dual inhibitor of EGFR and HER2 (IC50s = 1.4, 0.51, 0.79, 2.3, and 19 nM for the EGFR, EGFRL858R, EGFRT790M, EGFRL858R,T790M, and HER2 recombinant intracellular kinase domains, respectively); selective for EGFR and HER2 over IRK, MEK1, PKA, and PKC (IC50s = >10 µM) but also inhibits Abl, FLT1, and Src (IC50s = 41, 920, and 2,000 nM, respectively); induces ubiquitination and degradation of HER2 in SK-BR-3 cells at 10 and 30 µM; decreases levels of HER2 and ERα and increases levels of Hsp70 in MCF-7 cells at 10 µM; inhibits EGF-stimulated growth of A431 cells (IC50 = 0.1 µM); reduces tumor growth in an A431 mouse xenograft model at 10 and 30 mg/kg and in a BT-474 mouse xenograft model at 30 mg/kg
29039	AV-412	25 mg	≥98%	A dual inhibitor of EGFR and HER2 (IC50s = 1.4, 0.51, 0.79, 2.3, and 19 nM for the EGFR, EGFRL858R, EGFRT790M, EGFRL858R,T790M, and HER2 recombinant intracellular kinase domains, respectively); selective for EGFR and HER2 over IRK, MEK1, PKA, and PKC (IC50s = >10 µM) but also inhibits Abl, FLT1, and Src (IC50s = 41, 920, and 2,000 nM, respectively); induces ubiquitination and degradation of HER2 in SK-BR-3 cells at 10 and 30 µM; decreases levels of HER2 and ERα and increases levels of Hsp70 in MCF-7 cells at 10 µM; inhibits EGF-stimulated growth of A431 cells (IC50 = 0.1 µM); reduces tumor growth in an A431 mouse xenograft model at 10 and 30 mg/kg and in a BT-474 mouse xenograft model at 30 mg/kg
29039	AV-412	5 mg	≥98%	A dual inhibitor of EGFR and HER2 (IC50s = 1.4, 0.51, 0.79, 2.3, and 19 nM for the EGFR, EGFRL858R, EGFRT790M, EGFRL858R,T790M, and HER2 recombinant intracellular kinase domains, respectively); selective for EGFR and HER2 over IRK, MEK1, PKA, and PKC (IC50s = >10 µM) but also inhibits Abl, FLT1, and Src (IC50s = 41, 920, and 2,000 nM, respectively); induces ubiquitination and degradation of HER2 in SK-BR-3 cells at 10 and 30 µM; decreases levels of HER2 and ERα and increases levels of Hsp70 in MCF-7 cells at 10 µM; inhibits EGF-stimulated growth of A431 cells (IC50 = 0.1 µM); reduces tumor growth in an A431 mouse xenograft model at 10 and 30 mg/kg and in a BT-474 mouse xenograft model at 30 mg/kg

29039	AV-412	50 mg	≥98%	A dual inhibitor of EGFR and HER2 (IC50s = 1.4, 0.51, 0.79, 2.3, and 19 nM for the EGFR, EGFRL858R, EGFRT790M, EGFRL858R,T790M, and HER2 recombinant intracellular kinase domains, respectively); selective for EGFR and HER2 over IRK, MEK1, PKA, and PKC (IC50s = >10 μM) but also inhibits Abl, FLT1, and Src (IC50s = 41, 920, and 2,000 nM, respectively); induces ubiquitination and degradation of HER2 in SK-BR-3 cells at 10 and 30 μM; decreases levels of HER2 and ERα and increases levels of Hsp70 in MCF-7 cells at 10 μM; inhibits EGF-stimulated growth of A431 cells (IC50 = 0.1 μM); reduces tumor growth in an A431 mouse xenograft model at 10 and 30 mg/kg and in a BT-474 mouse xenograft model at 30 mg/kg
29053	CCT129202	1 mg	≥98%	An Aurora kinase inhibitor; inhibits Aurora A and B by 82 and 60%, respectively, at 1 μM in cell free assays; selective for Aurora A and B over a panel of 13 kinases at 1 μM; inhibits growth of various cancer cell lines (GI50s = 0.08-1.2 μM); induces DNA accumulation and cell cycle arrest at the G2/M phase, as well as apoptosis in HCT116 cells; increases the accumulation of doxorubicin and rhodamine 123 in MDR KBv200 and MCF-7/adr cells and increases the susceptibility of MDR KBv200, MCF-7/adr, S1-M1-80, and HL60/adr cells to cisplatin and doxorubicin; reduces tumor growth in an HCT116 mouse xenograft model at 100 mg/kg; potentiates the antitumor effects of vincristine in a KBv200 mouse xenograft model
29053	CCT129202	10 mg	≥98%	An Aurora kinase inhibitor; inhibits Aurora A and B by 82 and 60%, respectively, at 1 μM in cell free assays; selective for Aurora A and B over a panel of 13 kinases at 1 μM; inhibits growth of various cancer cell lines (GI50s = 0.08-1.2 μM); induces DNA accumulation and cell cycle arrest at the G2/M phase, as well as apoptosis in HCT116 cells; increases the accumulation of doxorubicin and rhodamine 123 in MDR KBv200 and MCF-7/adr cells and increases the susceptibility of MDR KBv200, MCF-7/adr, S1-M1-80, and HL60/adr cells to cisplatin and doxorubicin; reduces tumor growth in an HCT116 mouse xenograft model at 100 mg/kg; potentiates the antitumor effects of vincristine in a KBv200 mouse xenograft model
29053	CCT129202	5 mg	≥98%	An Aurora kinase inhibitor; inhibits Aurora A and B by 82 and 60%, respectively, at 1 μM in cell free assays; selective for Aurora A and B over a panel of 13 kinases at 1 μM; inhibits growth of various cancer cell lines (GI50s = 0.08-1.2 μM); induces DNA accumulation and cell cycle arrest at the G2/M phase, as well as apoptosis in HCT116 cells; increases the accumulation of doxorubicin and rhodamine 123 in MDR KBv200 and MCF-7/adr cells and increases the susceptibility of MDR KBv200, MCF-7/adr, S1-M1-80, and HL60/adr cells to cisplatin and doxorubicin; reduces tumor growth in an HCT116 mouse xenograft model at 100 mg/kg; potentiates the antitumor effects of vincristine in a KBv200 mouse xenograft model
29085	Voruciclib	1 mg	≥98%	A pan-CDK inhibitor (Kis = 0.626-9.1 nM); selective for CDKs over MAK and ICK (Kis = 259 and 481 nM, respectively), in a panel of 48 kinases; decreases Mcl-1 levels and increased cleaved PARP levels in six DLBCL cell lines at 0.5-5 μM; reduces tumor growth by 56.3% in a Ri-1 mouse xenograft model at 200 mg/kg
29085	Voruciclib	10 mg	≥98%	A pan-CDK inhibitor (Kis = 0.626-9.1 nM); selective for CDKs over MAK and ICK (Kis = 259 and 481 nM, respectively), in a panel of 48 kinases; decreases Mcl-1 levels and increased cleaved PARP levels in six DLBCL cell lines at 0.5-5 μM; reduces tumor growth by 56.3% in a Ri-1 mouse xenograft model at 200 mg/kg
29085	Voruciclib	5 mg	≥98%	A pan-CDK inhibitor (Kis = 0.626-9.1 nM); selective for CDKs over MAK and ICK (Kis = 259 and 481 nM, respectively), in a panel of 48 kinases; decreases Mcl-1 levels and increased cleaved PARP levels in six DLBCL cell lines at 0.5-5 μM; reduces tumor growth by 56.3% in a Ri-1 mouse xenograft model at 200 mg/kg
29144	Trametinib-13C-d3	1 mg	≥99% deutera	An internal standard for the quantification of trametinib by GC- or LC-MS
29155	GSK1904529A	1 mg	≥95%	A dual InsR and IGF-1R kinase inhibitor (IC50s = 25 and 27 nM, respectively, in a cell-free assay); selectively inhibits InsR and IGF-1R kinases over a panel of 45 serine/threonine and tyrosine kinases (IC50s = >1 μM for all); decreases proliferation of 13 cancer cell lines including multiple myeloma, sarcoma, colon, and breast cancer cells (IC50s = 35-189 nM) in a panel of 35 cell lines; reduces tumor growth in NIH3T3-LISN, COLO 205, HT-29, and BxPC3 mouse xenograft models at 30 mg/kg for 21 days
29155	GSK1904529A	10 mg	≥95%	A dual InsR and IGF-1R kinase inhibitor (IC50s = 25 and 27 nM, respectively, in a cell-free assay); selectively inhibits InsR and IGF-1R kinases over a panel of 45 serine/threonine and tyrosine kinases (IC50s = >1 μM for all); decreases proliferation of 13 cancer cell lines including multiple myeloma, sarcoma, colon, and breast cancer cells (IC50s = 35-189 nM) in a panel of 35 cell lines; reduces tumor growth in NIH3T3-LISN, COLO 205, HT-29, and BxPC3 mouse xenograft models at 30 mg/kg for 21 days
29155	GSK1904529A	25 mg	≥95%	A dual InsR and IGF-1R kinase inhibitor (IC50s = 25 and 27 nM, respectively, in a cell-free assay); selectively inhibits InsR and IGF-1R kinases over a panel of 45 serine/threonine and tyrosine kinases (IC50s = >1 μM for all); decreases proliferation of 13 cancer cell lines including multiple myeloma, sarcoma, colon, and breast cancer cells (IC50s = 35-189 nM) in a panel of 35 cell lines; reduces tumor growth in NIH3T3-LISN, COLO 205, HT-29, and BxPC3 mouse xenograft models at 30 mg/kg for 21 days

29155	GSK1904529A	5 mg	≥95%	A dual InsR and IGF-1R kinase inhibitor (IC50s = 25 and 27 nM, respectively, in a cell-free assay); selectively inhibits InsR and IGF-1R kinases over a panel of 45 serine/threonine and tyrosine kinases (IC50s = >1 μM for all); decreases proliferation of 13 cancer cell lines including multiple myeloma, sarcoma, colon, and breast cancer cells (IC50s = 35-189 nM) in a panel of 35 cell lines; reduces tumor growth in NIH3T3-LISN, COLO 205, HT-29, and BxPC3 mouse xenograft models at 30 mg/kg for 21 days
29157	TAK-285	1 mg	≥95%	A dual inhibitor of EGFR and HER2 (IC50s = 23 and 17 nM, respectively); selective for EGFR and HER2 over a panel of 36 kinases (IC50s = 250->10,000 nM); inhibits proliferation of BT474 cells (GI50 = 17 nM); induces tumor regression in a 4-1st gastric adenocarcinoma rat xenograft model at 25 and 50 mg/kg
29157	TAK-285	10 mg	≥95%	A dual inhibitor of EGFR and HER2 (IC50s = 23 and 17 nM, respectively); selective for EGFR and HER2 over a panel of 36 kinases (IC50s = 250->10,000 nM); inhibits proliferation of BT474 cells (GI50 = 17 nM); induces tumor regression in a 4-1st gastric adenocarcinoma rat xenograft model at 25 and 50 mg/kg
29157	TAK-285	25 mg	≥95%	A dual inhibitor of EGFR and HER2 (IC50s = 23 and 17 nM, respectively); selective for EGFR and HER2 over a panel of 36 kinases (IC50s = 250->10,000 nM); inhibits proliferation of BT474 cells (GI50 = 17 nM); induces tumor regression in a 4-1st gastric adenocarcinoma rat xenograft model at 25 and 50 mg/kg
29157	TAK-285	5 mg	≥95%	A dual inhibitor of EGFR and HER2 (IC50s = 23 and 17 nM, respectively); selective for EGFR and HER2 over a panel of 36 kinases (IC50s = 250->10,000 nM); inhibits proliferation of BT474 cells (GI50 = 17 nM); induces tumor regression in a 4-1st gastric adenocarcinoma rat xenograft model at 25 and 50 mg/kg
29166	AZD 8835	1 mg	≥98%	An inhibitor of PI3Kα and PI3Kδ (IC50s = 6.2 and 5.7 nM, respectively); selective for PI3Kα and PI3Kδ over PI3Kβ and PI3Kγ (IC50s = 431 and 90 nM, respectively); inhibits Akt phosphorylation in PIK3CA constitutively active mutant BT474 cells and Jeko-1 B cells that express endogenous PI3Kδ (IC50s = 57 and 49 nM, respectively); reduces tumor growth and Akt phosphorylation in an SKOV3 mouse xenograft model at 25 mg/kg; increases the activity of CD8+ effector T cells and reduces tumor growth in a C26 mouse syngeneic tumor model
29166	AZD 8835	10 mg	≥98%	An inhibitor of PI3Kα and PI3Kδ (IC50s = 6.2 and 5.7 nM, respectively); selective for PI3Kα and PI3Kδ over PI3Kβ and PI3Kγ (IC50s = 431 and 90 nM, respectively); inhibits Akt phosphorylation in PIK3CA constitutively active mutant BT474 cells and Jeko-1 B cells that express endogenous PI3Kδ (IC50s = 57 and 49 nM, respectively); reduces tumor growth and Akt phosphorylation in an SKOV3 mouse xenograft model at 25 mg/kg; increases the activity of CD8+ effector T cells and reduces tumor growth in a C26 mouse syngeneic tumor model
29166	AZD 8835	25 mg	≥98%	An inhibitor of PI3Kα and PI3Kδ (IC50s = 6.2 and 5.7 nM, respectively); selective for PI3Kα and PI3Kδ over PI3Kβ and PI3Kγ (IC50s = 431 and 90 nM, respectively); inhibits Akt phosphorylation in PIK3CA constitutively active mutant BT474 cells and Jeko-1 B cells that express endogenous PI3Kδ (IC50s = 57 and 49 nM, respectively); reduces tumor growth and Akt phosphorylation in an SKOV3 mouse xenograft model at 25 mg/kg; increases the activity of CD8+ effector T cells and reduces tumor growth in a C26 mouse syngeneic tumor model
29166	AZD 8835	5 mg	≥98%	An inhibitor of PI3Kα and PI3Kδ (IC50s = 6.2 and 5.7 nM, respectively); selective for PI3Kα and PI3Kδ over PI3Kβ and PI3Kγ (IC50s = 431 and 90 nM, respectively); inhibits Akt phosphorylation in PIK3CA constitutively active mutant BT474 cells and Jeko-1 B cells that express endogenous PI3Kδ (IC50s = 57 and 49 nM, respectively); reduces tumor growth and Akt phosphorylation in an SKOV3 mouse xenograft model at 25 mg/kg; increases the activity of CD8+ effector T cells and reduces tumor growth in a C26 mouse syngeneic tumor model
29196	DAPH	1 mg	≥98%	A phthalimide with diverse biological activities; an EGFR inhibitor that selectively inhibits the EGFR intracellular kinase domain over v-Abl, c-Src, PKCα, PKCβ1, PKCβ2, and PKCγ (IC50s = 0.3, >50, 16, 6, 30, 4.8, and 30 μM, respectively) and a panel of 11 other kinases; inhibits EGFR autophosphorylation in A431 human epidermoid carcinoma cell membrane preparations and intact cells (IC50s = 1 and 50 = 0.58 μM)
29196	DAPH	10 mg	≥98%	A phthalimide with diverse biological activities; an EGFR inhibitor that selectively inhibits the EGFR intracellular kinase domain over v-Abl, c-Src, PKCα, PKCβ1, PKCβ2, and PKCγ (IC50s = 0.3, >50, 16, 6, 30, 4.8, and 30 μM, respectively) and a panel of 11 other kinases; inhibits EGFR autophosphorylation in A431 human epidermoid carcinoma cell membrane preparations and intact cells (IC50s = 1 and 50 = 0.58 μM)
29196	DAPH	25 mg	≥98%	A phthalimide with diverse biological activities; an EGFR inhibitor that selectively inhibits the EGFR intracellular kinase domain over v-Abl, c-Src, PKCα, PKCβ1, PKCβ2, and PKCγ (IC50s = 0.3, >50, 16, 6, 30, 4.8, and 30 μM, respectively) and a panel of 11 other kinases; inhibits EGFR autophosphorylation in A431 human epidermoid carcinoma cell membrane preparations and intact cells (IC50s = 1 and 50 = 0.58 μM)

29196	DAPH	5 mg	≥98%	A phthalimide with diverse biological activities; an EGFR inhibitor that selectively inhibits the EGFR intracellular kinase domain over v-Abl, c-Src, PKCα, PKCβ1, PKCβ2, and PKCγ (IC50s = 0.3, >50, 16, 6, 30, 4.8, and 30 μM, respectively) and a panel of 11 other kinases; inhibits EGFR autophosphorylation in A431 human epidermoid carcinoma cell membrane preparations and intact cells (IC50s = 1 and 50 = 0.58 μM)
29197	Ro 5126766	1 mg	≥98%	A dual inhibitor of MEK1 (IC50 = 160 nM) and Raf kinases (IC50s = 56, 19, and 8.2 nM for C-RAF, B-RAF, and B-RAFV600E, respectively); selective for these kinases over a panel of 254 additional kinases at 10 μM; decreases MEK and ERK phosphorylation in a panel of seven cancer cell lines expressing mutant K-RasG13D, K-RasQ61K, K-RasG12D, H-RasG12D, or B-RAFV600E at 1 μM; inhibits proliferation of SK-MEL-28, SK-MEL-2, MIA PaCa-2, SW480, and HCT116 cancer cells (IC50s = 28-227 nM) but not A549, HCT15, or PC3 cancer cells (IC50s = >1,000 nM for all); reduces tumor growth in an HCT116 mouse xenograft model at 25 mg/kg four times per day
29197	Ro 5126766	5 mg	≥98%	A dual inhibitor of MEK1 (IC50 = 160 nM) and Raf kinases (IC50s = 56, 19, and 8.2 nM for C-RAF, B-RAF, and B-RAFV600E, respectively); selective for these kinases over a panel of 254 additional kinases at 10 μM; decreases MEK and ERK phosphorylation in a panel of seven cancer cell lines expressing mutant K-RasG13D, K-RasQ61K, K-RasG12D, H-RasG12D, or B-RAFV600E at 1 μM; inhibits proliferation of SK-MEL-28, SK-MEL-2, MIA PaCa-2, SW480, and HCT116 cancer cells (IC50s = 28-227 nM) but not A549, HCT15, or PC3 cancer cells (IC50s = >1,000 nM for all); reduces tumor growth in an HCT116 mouse xenograft model at 25 mg/kg four times per day
29200	SNS-062 analog	1 mg	≥98%	A BTK inhibitor (IC50 = <100 nM)
29200	SNS-062 analog	10 mg	≥98%	A BTK inhibitor (IC50 = <100 nM)
29200	SNS-062 analog	25 mg	≥98%	A BTK inhibitor (IC50 = <100 nM)
29200	SNS-062 analog	5 mg	≥98%	A BTK inhibitor (IC50 = <100 nM)
29213	KO947	1 mg	≥98%	An ERK inhibitor (IC50 = 50-fold selective for ERK over a panel of 450 kinases; reduces RSK phosphorylation in A375 cancer cells containing constitutively active B-RAFV600E (IC50 = 50 = 50-250 nM for all)
29213	KO947	10 mg	≥98%	An ERK inhibitor (IC50 = 50-fold selective for ERK over a panel of 450 kinases; reduces RSK phosphorylation in A375 cancer cells containing constitutively active B-RAFV600E (IC50 = 50 = 50-250 nM for all)
29213	KO947	25 mg	≥98%	An ERK inhibitor (IC50 = 50-fold selective for ERK over a panel of 450 kinases; reduces RSK phosphorylation in A375 cancer cells containing constitutively active B-RAFV600E (IC50 = 50 = 50-250 nM for all)
29213	KO947	5 mg	≥98%	An ERK inhibitor (IC50 = 50-fold selective for ERK over a panel of 450 kinases; reduces RSK phosphorylation in A375 cancer cells containing constitutively active B-RAFV600E (IC50 = 50 = 50-250 nM for all)
29214	WAY-600	1 mg	≥98%	An mTOR inhibitor (IC50 = 0.009 μM); selectively inhibits mTOR over PI3Kα and PI3Kɣ (IC50s = 1.96 and 8.45 μM, respectively) and 24 additional lipid and protein kinases in a panel (IC50s = >50 μM for all); decreases phosphorylation of Akt and S6K1 in a cell-free assay at 0.2, 1, and 5 μM; decreases proliferation of nine cancer cell lines, including breast, prostate, glioma, kidney, and colorectal cancer cells (IC50s = 0.6-2.5 μM); reduces tumor growth in a HepG2 mouse xenograft model at 10 mg/kg for 14 days
29214	WAY-600	10 mg	≥98%	An mTOR inhibitor (IC50 = 0.009 μM); selectively inhibits mTOR over PI3Kα and PI3Kɣ (IC50s = 1.96 and 8.45 μM, respectively) and 24 additional lipid and protein kinases in a panel (IC50s = >50 μM for all); decreases phosphorylation of Akt and S6K1 in a cell-free assay at 0.2, 1, and 5 μM; decreases proliferation of nine cancer cell lines, including breast, prostate, glioma, kidney, and colorectal cancer cells (IC50s = 0.6-2.5 μM); reduces tumor growth in a HepG2 mouse xenograft model at 10 mg/kg for 14 days
29214	WAY-600	5 mg	≥98%	An mTOR inhibitor (IC50 = 0.009 μM); selectively inhibits mTOR over PI3Kα and PI3Kɣ (IC50s = 1.96 and 8.45 μM, respectively) and 24 additional lipid and protein kinases in a panel (IC50s = >50 μM for all); decreases phosphorylation of Akt and S6K1 in a cell-free assay at 0.2, 1, and 5 μM; decreases proliferation of nine cancer cell lines, including breast, prostate, glioma, kidney, and colorectal cancer cells (IC50s = 0.6-2.5 μM); reduces tumor growth in a HepG2 mouse xenograft model at 10 mg/kg for 14 days
29220	PF-6260933	10 mg	≥98%	A MAP4K4 inhibitor (IC50 = 3.7 nM); selective for MAP4K4 over a panel of 41 kinases at 1 μM but also inhibits TNIK and MINK1 (IC50s = 15 and 8 nM, respectively); inhibits the replication of CMV strains AD169 and Merlin(R1111) strains in HFF cells (EC50s = 9.6 and 13.3 μM, respectively); inhibits collagen- or thrombin-induced aggregation of isolated human platelets by 70.9 and 61.2%, respectively, at 20 μM; decreases plaque formation in ApoE-/- mice fed a Western diet in a model of atherosclerosis at 10 mg/kg; decreases LPS-induced increases in TNF-α levels in wild-type mice and fasting blood glucose levels in ob/ob mice at 15 mg/kg

29220	PF-6260933	100 mg	≥98%	A MAP4K4 inhibitor (IC50 = 3.7 nM); selective for MAP4K4 over a panel of 41 kinases at 1 μM but also inhibits TNIK and MINK1 (IC50s = 15 and 8 nM, respectively); inhibits the replication of CMV strains AD169 and Merlin(R1111) strains in HFF cells (EC50s = 9.6 and 13.3 μM, respectively); inhibits collagen- or thrombin-induced aggregation of isolated human platelets by 70.9 and 61.2%, respectively, at 20 μM; decreases plaque formation in ApoE-/- mice fed a Western diet in a model of atherosclerosis at 10 mg/kg; decreases LPS-induced increases in TNF-α levels in wild-type mice and fasting blood glucose levels in ob/ob mice at 15 mg/kg
29220	PF-6260933	50 mg	≥98%	A MAP4K4 inhibitor (IC50 = 3.7 nM); selective for MAP4K4 over a panel of 41 kinases at 1 μM but also inhibits TNIK and MINK1 (IC50s = 15 and 8 nM, respectively); inhibits the replication of CMV strains AD169 and Merlin(R1111) strains in HFF cells (EC50s = 9.6 and 13.3 μM, respectively); inhibits collagen- or thrombin-induced aggregation of isolated human platelets by 70.9 and 61.2%, respectively, at 20 μM; decreases plaque formation in ApoE-/- mice fed a Western diet in a model of atherosclerosis at 10 mg/kg; decreases LPS-induced increases in TNF-α levels in wild-type mice and fasting blood glucose levels in ob/ob mice at 15 mg/kg
29224	GNE-493	1 mg	≥98%	A dual inhibitor of PI3K and mTOR (IC50s = 3.4, 12, 16, and 16 nM for PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ, respectively); inhibits proliferation of PC3 and MCF-7.1 cells (IC50s = 330 and 180 nM, respectively); reduces tumor volume in PC3 and MCF-7.1 mouse xenograft models at 10 mg/kg per day
29224	GNE-493	10 mg	≥98%	A dual inhibitor of PI3K and mTOR (IC50s = 3.4, 12, 16, and 16 nM for PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ, respectively); inhibits proliferation of PC3 and MCF-7.1 cells (IC50s = 330 and 180 nM, respectively); reduces tumor volume in PC3 and MCF-7.1 mouse xenograft models at 10 mg/kg per day
29224	GNE-493	25 mg	≥98%	A dual inhibitor of PI3K and mTOR (IC50s = 3.4, 12, 16, and 16 nM for PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ, respectively); inhibits proliferation of PC3 and MCF-7.1 cells (IC50s = 330 and 180 nM, respectively); reduces tumor volume in PC3 and MCF-7.1 mouse xenograft models at 10 mg/kg per day
29224	GNE-493	5 mg	≥98%	A dual inhibitor of PI3K and mTOR (IC50s = 3.4, 12, 16, and 16 nM for PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ, respectively); inhibits proliferation of PC3 and MCF-7.1 cells (IC50s = 330 and 180 nM, respectively); reduces tumor volume in PC3 and MCF-7.1 mouse xenograft models at 10 mg/kg per day
29225	Leucettine L41	1 mg	≥98%	An inhibitor of DYRK1A, DYRK2, CLK1, and CLK3 (IC50s = 0.04, 0.035, 0.015, and 4.5 μM, respectively); an inhibitor of GSK3α/β and Pim1 (IC50s = 0.41and 4.1 μM, respectively); inhibits TNF-α-induced SRp75 and SRp55 phosphorylation in human microvascular endothelial cells at 0.1-10 μM; modulates alternative pre-RNA splicing of a synthetic CLK1 minigene; prevents amyloid-β 25-35-induced lipid peroxidation and ROS accumulation in the hippocampus in a mouse model of Alzheimer's disease-like toxicity; prevents amyloid-β 25-35-induced memory deficits in the same model at 0.4, 1.2, and 4 μg
29225	Leucettine L41	10 mg	≥98%	An inhibitor of DYRK1A, DYRK2, CLK1, and CLK3 (IC50s = 0.04, 0.035, 0.015, and 4.5 μM, respectively); an inhibitor of GSK3α/β and Pim1 (IC50s = 0.41and 4.1 μM, respectively); inhibits TNF-α-induced SRp75 and SRp55 phosphorylation in human microvascular endothelial cells at 0.1-10 μM; modulates alternative pre-RNA splicing of a synthetic CLK1 minigene; prevents amyloid-β 25-35-induced lipid peroxidation and ROS accumulation in the hippocampus in a mouse model of Alzheimer's disease-like toxicity; prevents amyloid-β 25-35-induced memory deficits in the same model at 0.4, 1.2, and 4 μg
29225	Leucettine L41	5 mg	≥98%	An inhibitor of DYRK1A, DYRK2, CLK1, and CLK3 (IC50s = 0.04, 0.035, 0.015, and 4.5 μM, respectively); an inhibitor of GSK3α/β and Pim1 (IC50s = 0.41and 4.1 μM, respectively); inhibits TNF-α-induced SRp75 and SRp55 phosphorylation in human microvascular endothelial cells at 0.1-10 μM; modulates alternative pre-RNA splicing of a synthetic CLK1 minigene; prevents amyloid-β 25-35-induced lipid peroxidation and ROS accumulation in the hippocampus in a mouse model of Alzheimer's disease-like toxicity; prevents amyloid-β 25-35-induced memory deficits in the same model at 0.4, 1.2, and 4 μg
29226	NSC 781406	1 mg	≥98%	A dual inhibitor of PI3K and mTOR (IC50s = 2.0, 9.4, 2.7, 14, and 5.4 nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ, and mTOR, respectively); inhibits cell growth in the NCI-60 panel of cancer cell lines (mean GI50 = 65 nM); reduces tumor volume in a BEL-7404 hepatic cancer mouse xenograft model at 30 mg/kg
29226	NSC 781406	10 mg	≥98%	A dual inhibitor of PI3K and mTOR (IC50s = 2.0, 9.4, 2.7, 14, and 5.4 nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ, and mTOR, respectively); inhibits cell growth in the NCI-60 panel of cancer cell lines (mean GI50 = 65 nM); reduces tumor volume in a BEL-7404 hepatic cancer mouse xenograft model at 30 mg/kg
29226	NSC 781406	5 mg	≥98%	A dual inhibitor of PI3K and mTOR (IC50s = 2.0, 9.4, 2.7, 14, and 5.4 nM for PI3Kα, PI3Kβ, PI3Kγ, PI3Kδ, and mTOR, respectively); inhibits cell growth in the NCI-60 panel of cancer cell lines (mean GI50 = 65 nM); reduces tumor volume in a BEL-7404 hepatic cancer mouse xenograft model at 30 mg/kg

29230	GSK2982772	1 mg	≥98%	A RIPK1 inhibitor (IC50s = 16 and 2,500 nM for the human and mouse enzymes, respectively); >10,000-fold selective for RIPK1 over a panel of 339 kinases at 10 μM; inhibits necrotic cell death induced by a combination of TNF-α and the caspase inhibitor QVD-OPh in U937 human monocytic and L929 murine fibrosarcoma cells (IC50s = 6.3 and 1,300 nM, respectively); decreases IL-1β and IL-6 levels in intestinal mucosa tissue isolated from patients with ulcerative colitis at 3-300 nM; increases survival in a mouse model of TNF-α-induced lethal shock at 3, 10, and 50 mg/kg
29230	GSK2982772	10 mg	≥98%	A RIPK1 inhibitor (IC50s = 16 and 2,500 nM for the human and mouse enzymes, respectively); >10,000-fold selective for RIPK1 over a panel of 339 kinases at 10 μM; inhibits necrotic cell death induced by a combination of TNF-α and the caspase inhibitor QVD-OPh in U937 human monocytic and L929 murine fibrosarcoma cells (IC50s = 6.3 and 1,300 nM, respectively); decreases IL-1β and IL-6 levels in intestinal mucosa tissue isolated from patients with ulcerative colitis at 3-300 nM; increases survival in a mouse model of TNF-α-induced lethal shock at 3, 10, and 50 mg/kg
29230	GSK2982772	5 mg	≥98%	A RIPK1 inhibitor (IC50s = 16 and 2,500 nM for the human and mouse enzymes, respectively); >10,000-fold selective for RIPK1 over a panel of 339 kinases at 10 μM; inhibits necrotic cell death induced by a combination of TNF-α and the caspase inhibitor QVD-OPh in U937 human monocytic and L929 murine fibrosarcoma cells (IC50s = 6.3 and 1,300 nM, respectively); decreases IL-1β and IL-6 levels in intestinal mucosa tissue isolated from patients with ulcerative colitis at 3-300 nM; increases survival in a mouse model of TNF-α-induced lethal shock at 3, 10, and 50 mg/kg
29238	BX-517	10 mg	≥98%	An inhibitor of PDK1 (IC50 = 6 nM); inhibits PDK1-induced Akt2 activation in a cell-free assay (IC50 = 20 nM)
29238	BX-517	25 mg	≥98%	An inhibitor of PDK1 (IC50 = 6 nM); inhibits PDK1-induced Akt2 activation in a cell-free assay (IC50 = 20 nM)
29238	BX-517	5 mg	≥98%	An inhibitor of PDK1 (IC50 = 6 nM); inhibits PDK1-induced Akt2 activation in a cell-free assay (IC50 = 20 nM)
29238	BX-517	50 mg	≥98%	An inhibitor of PDK1 (IC50 = 6 nM); inhibits PDK1-induced Akt2 activation in a cell-free assay (IC50 = 20 nM)
29245	AMG 925	1 mg	≥95%	A dual inhibitor of FLT3 and Cdk4 (IC50s = 1 and 3 nM, respectively); selective for FLT3 and Cdk4 over Cdk1 (IC50 = 2.22 μM); also binds to FLT3ITD, FLT3D835Y, FLT3D835H, FLT3K663Q, and FLT3N841I (Kds = 1-4 nM); inhibits proliferation of MOLM-13, COLO 205, and U937 cancer cells (IC50s = 19, 55, and 52 nM, respectively); reduces intratumor levels of pSTAT5 and pRb and inhibits tumor growth in a MOLM-13 AML mouse xenograft model
29245	AMG 925	10 mg	≥95%	A dual inhibitor of FLT3 and Cdk4 (IC50s = 1 and 3 nM, respectively); selective for FLT3 and Cdk4 over Cdk1 (IC50 = 2.22 μM); also binds to FLT3ITD, FLT3D835Y, FLT3D835H, FLT3K663Q, and FLT3N841I (Kds = 1-4 nM); inhibits proliferation of MOLM-13, COLO 205, and U937 cancer cells (IC50s = 19, 55, and 52 nM, respectively); reduces intratumor levels of pSTAT5 and pRb and inhibits tumor growth in a MOLM-13 AML mouse xenograft model
29245	AMG 925	25 mg	≥95%	A dual inhibitor of FLT3 and Cdk4 (IC50s = 1 and 3 nM, respectively); selective for FLT3 and Cdk4 over Cdk1 (IC50 = 2.22 μM); also binds to FLT3ITD, FLT3D835Y, FLT3D835H, FLT3K663Q, and FLT3N841I (Kds = 1-4 nM); inhibits proliferation of MOLM-13, COLO 205, and U937 cancer cells (IC50s = 19, 55, and 52 nM, respectively); reduces intratumor levels of pSTAT5 and pRb and inhibits tumor growth in a MOLM-13 AML mouse xenograft model
29245	AMG 925	5 mg	≥95%	A dual inhibitor of FLT3 and Cdk4 (IC50s = 1 and 3 nM, respectively); selective for FLT3 and Cdk4 over Cdk1 (IC50 = 2.22 μM); also binds to FLT3ITD, FLT3D835Y, FLT3D835H, FLT3K663Q, and FLT3N841I (Kds = 1-4 nM); inhibits proliferation of MOLM-13, COLO 205, and U937 cancer cells (IC50s = 19, 55, and 52 nM, respectively); reduces intratumor levels of pSTAT5 and pRb and inhibits tumor growth in a MOLM-13 AML mouse xenograft model
29248	SAR20347	1 mg	≥98%	A JAK family kinase inhibitor (IC50s = 0.6, 23, 26, and 41 nM, for TYK2 and JAK1-3, respectively, in cell-free assays); inhibits IL-12-induced TYK2-dependent phosphorylation of STAT4 in NK-92 cells (IC50 = 126 nM) and IL-6-induced JAK1-dependent phosphorylated STAT3 signaling in TF-1 cells (IC50 = 345 nM); inhibits IL-12-induced INF-γ production and reporter gene activity in PBMCs at 5 μM; inhibits the production of serum IFN-γ in mice at 60 mg/kg; reduces keratinocyte activation and skin levels of IL-12, IL-23, IL-6, IL-22 and IFN-γ in a mouse model of imiquimod-induced psoriasis
29248	SAR20347	10 mg	≥98%	A JAK family kinase inhibitor (IC50s = 0.6, 23, 26, and 41 nM, for TYK2 and JAK1-3, respectively, in cell-free assays); inhibits IL-12-induced TYK2-dependent phosphorylation of STAT4 in NK-92 cells (IC50 = 126 nM) and IL-6-induced JAK1-dependent phosphorylated STAT3 signaling in TF-1 cells (IC50 = 345 nM); inhibits IL-12-induced INF-γ production and reporter gene activity in PBMCs at 5 μM; inhibits the production of serum IFN-γ in mice at 60 mg/kg; reduces keratinocyte activation and skin levels of IL-12, IL-23, IL-6, IL-22 and IFN-γ in a mouse model of imiquimod-induced psoriasis

29248	SAR20347	25 mg	≥98%	A JAK family kinase inhibitor (IC50s = 0.6, 23, 26, and 41 nM, for TYK2 and JAK1-3, respectively, in cell-free assays); inhibits IL-12-induced TYK2-dependent phosphorylation of STAT4 in NK-92 cells (IC50 = 126 nM) and IL-6-induced JAK1-dependent phosphorylated STAT3 signaling in TF-1 cells (IC50 = 345 nM); inhibits IL-12-induced INF-γ production and reporter gene activity in PBMCs at 5 μM; inhibits the production of serum IFN-γ in mice at 60 mg/kg; reduces keratinocyte activation and skin levels of IL-12, IL-23, IL-6, IL-22 and IFN-γ in a mouse model of imiquimod-induced psoriasis
29248	SAR20347	5 mg	≥98%	A JAK family kinase inhibitor (IC50s = 0.6, 23, 26, and 41 nM, for TYK2 and JAK1-3, respectively, in cell-free assays); inhibits IL-12-induced TYK2-dependent phosphorylation of STAT4 in NK-92 cells (IC50 = 126 nM) and IL-6-induced JAK1-dependent phosphorylated STAT3 signaling in TF-1 cells (IC50 = 345 nM); inhibits IL-12-induced INF-γ production and reporter gene activity in PBMCs at 5 μM; inhibits the production of serum IFN-γ in mice at 60 mg/kg; reduces keratinocyte activation and skin levels of IL-12, IL-23, IL-6, IL-22 and IFN-γ in a mouse model of imiquimod-induced psoriasis
29379	OSI-930	10 mg	≥98%	A dual inhibitor of Kit (IC50s = 80 and 629 nM for the actived and non-activated kinase, respectively, in cell-free assays) and the kinase insert domain receptor (KDR; IC50 = 9 nM); selective for these kinases over a panel of 13 additional kinases (IC50s = 1.3->10 μM) but also inhibits FLT1, CSF1R, C-RAF, and LCK (IC50s = 8, 15, 41, and 22 nM, respectively); inhibits Kit autophosphorylation in NCI-H526 and HMC-1 cells expressing wild-type Kit and Kit containing the constitutively active KitV560G mutation, respectively, and stem cell factor-induced Kit autophosphorylation in NCI-H526 cells expressing wild-type Kit (IC50s = 58.1 and 78.9 nM, respectively); inhibits VEGF-induced autophosphorylation of VEGFR2 in HUVECs (IC50 = 64.4 nM); decreases endothelial sprout formation by >50% in isolated rat aortic rings at 100 nM; reduces tumor growth in a variety of mouse xenograft models at 200 mg/kg per day
29379	OSI-930	25 mg	≥98%	A dual inhibitor of Kit (IC50s = 80 and 629 nM for the actived and non-activated kinase, respectively, in cell-free assays) and the kinase insert domain receptor (KDR; IC50 = 9 nM); selective for these kinases over a panel of 13 additional kinases (IC50s = 1.3->10 μM) but also inhibits FLT1, CSF1R, C-RAF, and LCK (IC50s = 8, 15, 41, and 22 nM, respectively); inhibits Kit autophosphorylation in NCI-H526 and HMC-1 cells expressing wild-type Kit and Kit containing the constitutively active KitV560G mutation, respectively, and stem cell factor-induced Kit autophosphorylation in NCI-H526 cells expressing wild-type Kit (IC50s = 58.1 and 78.9 nM, respectively); inhibits VEGF-induced autophosphorylation of VEGFR2 in HUVECs (IC50 = 64.4 nM); decreases endothelial sprout formation by >50% in isolated rat aortic rings at 100 nM; reduces tumor growth in a variety of mouse xenograft models at 200 mg/kg per day
29379	OSI-930	5 mg	≥98%	A dual inhibitor of Kit (IC50s = 80 and 629 nM for the actived and non-activated kinase, respectively, in cell-free assays) and the kinase insert domain receptor (KDR; IC50 = 9 nM); selective for these kinases over a panel of 13 additional kinases (IC50s = 1.3->10 μM) but also inhibits FLT1, CSF1R, C-RAF, and LCK (IC50s = 8, 15, 41, and 22 nM, respectively); inhibits Kit autophosphorylation in NCI-H526 and HMC-1 cells expressing wild-type Kit and Kit containing the constitutively active KitV560G mutation, respectively, and stem cell factor-induced Kit autophosphorylation in NCI-H526 cells expressing wild-type Kit (IC50s = 58.1 and 78.9 nM, respectively); inhibits VEGF-induced autophosphorylation of VEGFR2 in HUVECs (IC50 = 64.4 nM); decreases endothelial sprout formation by >50% in isolated rat aortic rings at 100 nM; reduces tumor growth in a variety of mouse xenograft models at 200 mg/kg per day
29379	OSI-930	50 mg	≥98%	A dual inhibitor of Kit (IC50s = 80 and 629 nM for the actived and non-activated kinase, respectively, in cell-free assays) and the kinase insert domain receptor (KDR; IC50 = 9 nM); selective for these kinases over a panel of 13 additional kinases (IC50s = 1.3->10 μM) but also inhibits FLT1, CSF1R, C-RAF, and LCK (IC50s = 8, 15, 41, and 22 nM, respectively); inhibits Kit autophosphorylation in NCI-H526 and HMC-1 cells expressing wild-type Kit and Kit containing the constitutively active KitV560G mutation, respectively, and stem cell factor-induced Kit autophosphorylation in NCI-H526 cells expressing wild-type Kit (IC50s = 58.1 and 78.9 nM, respectively); inhibits VEGF-induced autophosphorylation of VEGFR2 in HUVECs (IC50 = 64.4 nM); decreases endothelial sprout formation by >50% in isolated rat aortic rings at 100 nM; reduces tumor growth in a variety of mouse xenograft models at 200 mg/kg per day
29419	LDC000067	10 mg	≥98%	A Cdk9 inhibitor (IC50 = 44 nM); selective for Cdk9 over Cdk1, -2, -4, -6, and -7 (IC50s = 5.5, 2.44, 9.24, >10, and >10 μM, respectively) and a panel of 28 additional kinases at 10 μM; inhibits P-TEFb-dependent transcription in vitro and de novo RNA synthesis in A549 cells at 10 μM; induces apoptosis in A549 and MCF-7 cancer cells; prevents IL-1β-induced production of MMP-3, MMP-9, MMP-13, IL-6, IL-8, and TNF-α and NF-κB activation in SW 1353 chondrocytes; delays cartilage degeneration in a mouse model of ACLT at 7.5 mg/kg; prevents bone resorption in mouse models of ACLT- or LPS-induced osteoarthritis

29419	LDC000067	25 mg	≥98%	A Cdk9 inhibitor (IC50 = 44 nM); selective for Cdk9 over Cdk1, -2, -4, -6, and -7 (IC50s = 5.5, 2.44, 9.24, >10, and >10 μM, respectively) and a panel of 28 additional kinases at 10 μM; inhibits P-TEFb-dependent transcription in vitro and de novo RNA synthesis in A549 cells at 10 μM; induces apoptosis in A549 and MCF-7 cancer cells; prevents IL-1β-induced production of MMP-3, MMP-9, MMP-13, IL-6, IL-8, and TNF-α and NF-κB activation in SW 1353 chondrocytes; delays cartilage degeneration in a mouse model of ACLT at 7.5 mg/kg; prevents bone resorption in mouse models of ACLT- or LPS-induced osteoarthritis
29419	LDC000067	5 mg	≥98%	A Cdk9 inhibitor (IC50 = 44 nM); selective for Cdk9 over Cdk1, -2, -4, -6, and -7 (IC50s = 5.5, 2.44, 9.24, >10, and >10 μM, respectively) and a panel of 28 additional kinases at 10 μM; inhibits P-TEFb-dependent transcription in vitro and de novo RNA synthesis in A549 cells at 10 μM; induces apoptosis in A549 and MCF-7 cancer cells; prevents IL-1β-induced production of MMP-3, MMP-9, MMP-13, IL-6, IL-8, and TNF-α and NF-κB activation in SW 1353 chondrocytes; delays cartilage degeneration in a mouse model of ACLT at 7.5 mg/kg; prevents bone resorption in mouse models of ACLT- or LPS-induced osteoarthritis
29425	Fruquintinib	10 mg	≥98%	A VEGFR inhibitor (IC50s = 33, 35, and 0.5 nM for VEGFR1, -2, and -3, respectively); inhibits RET, FGFR1, and c-Kit (IC50s = 128, 181, and 458 nM, respectively) in a panel of 253 kinases; inhibits VEGF-A- induced proliferation of HUVECs and VEGF-C-induced proliferation of HLECs (IC50s = 1.7 and 4.2 nM, respectively); decreases tube formation by HUVECs by 74 and 94% at 30 and 300 nM, respectively; reduces tumor growth in BGC-823, HT-29, Caki-1, and NCI H460 mouse xenograft models at 0.5-20 mg/kg per day for 21 days
29425	Fruquintinib	100 mg	≥98%	A VEGFR inhibitor (IC50s = 33, 35, and 0.5 nM for VEGFR1, -2, and -3, respectively); inhibits RET, FGFR1, and c-Kit (IC50s = 128, 181, and 458 nM, respectively) in a panel of 253 kinases; inhibits VEGF-A- induced proliferation of HUVECs and VEGF-C-induced proliferation of HLECs (IC50s = 1.7 and 4.2 nM, respectively); decreases tube formation by HUVECs by 74 and 94% at 30 and 300 nM, respectively; reduces tumor growth in BGC-823, HT-29, Caki-1, and NCI H460 mouse xenograft models at 0.5-20 mg/kg per day for 21 days
29425	Fruquintinib	250 mg	≥98%	A VEGFR inhibitor (IC50s = 33, 35, and 0.5 nM for VEGFR1, -2, and -3, respectively); inhibits RET, FGFR1, and c-Kit (IC50s = 128, 181, and 458 nM, respectively) in a panel of 253 kinases; inhibits VEGF-A- induced proliferation of HUVECs and VEGF-C-induced proliferation of HLECs (IC50s = 1.7 and 4.2 nM, respectively); decreases tube formation by HUVECs by 74 and 94% at 30 and 300 nM, respectively; reduces tumor growth in BGC-823, HT-29, Caki-1, and NCI H460 mouse xenograft models at 0.5-20 mg/kg per day for 21 days
29425	Fruquintinib	50 mg	≥98%	A VEGFR inhibitor (IC50s = 33, 35, and 0.5 nM for VEGFR1, -2, and -3, respectively); inhibits RET, FGFR1, and c-Kit (IC50s = 128, 181, and 458 nM, respectively) in a panel of 253 kinases; inhibits VEGF-A- induced proliferation of HUVECs and VEGF-C-induced proliferation of HLECs (IC50s = 1.7 and 4.2 nM, respectively); decreases tube formation by HUVECs by 74 and 94% at 30 and 300 nM, respectively; reduces tumor growth in BGC-823, HT-29, Caki-1, and NCI H460 mouse xenograft models at 0.5-20 mg/kg per day for 21 days
29456	SMI-16a	10 mg	≥98%	A Pim-1 kinase inhibitor (IC50 = 63 nM); selective for Pim-1 over a panel of 60 kinases; inhibits phosphorylation of the Pim-1 target protein Bad in DU145-Pim cells and inhibits the growth of PC3, DU145, LNCaP, K562, and MV4-11 cancer cells at 5 μM
29456	SMI-16a	25 mg	≥98%	A Pim-1 kinase inhibitor (IC50 = 63 nM); selective for Pim-1 over a panel of 60 kinases; inhibits phosphorylation of the Pim-1 target protein Bad in DU145-Pim cells and inhibits the growth of PC3, DU145, LNCaP, K562, and MV4-11 cancer cells at 5 μM
29456	SMI-16a	5 mg	≥98%	A Pim-1 kinase inhibitor (IC50 = 63 nM); selective for Pim-1 over a panel of 60 kinases; inhibits phosphorylation of the Pim-1 target protein Bad in DU145-Pim cells and inhibits the growth of PC3, DU145, LNCaP, K562, and MV4-11 cancer cells at 5 μM
29458	GNE-2861	5 mg	≥98%	A group 2 PAK inhibitor (IC50s = 7.5, 126, and 36 nM for PAK4, -5, and -6, respectively); selective for group 2 PAKs over group 1 PAKs (IC50s = 5.42, 0.97, and >10 μM for PAK1, -2, and -3, respectively), as well as JAK3, KHS1, MAP4K4, and MINK1 at 1 μM; inhibits cell migration and reduces cell viability of MDA-MB-436 and MCF-10A PIK3CA cells from 0.1-50 μM; sensitizes drug-resistant MCF-7/LCC2 breast cancer cells to tamoxifen
29459	LDC-1267	1 mg	≥98%	A TAM family kinase inhibitor (IC50s = 5, 8, and 29 nM for Mer, Tyro3, and Axl, respectively); selective for TAM family kinases over a panel of 456 kinases at 1 μM, but does inhibit Met, Aurora B, LCK, and Src (IC50s = 35, 36, 51, and 338 nM, respectively); inhibits GAS6-induced suppression of proliferation and IFN-γ production in NKG2D-activated NK cells; adoptive transfer of treated NK cells decreases tumor growth but not metastasis in a B16/F10 murine melanoma model; reduces the number of metastases in B16/F10 murine melanoma and 4T1 murine mammary carcinoma models in an NK cell-dependent manner at 20 mg/kg, i.p.

29459	LDC-1267	10 mg	≥98%	A TAM family kinase inhibitor (IC50s = 5, 8, and 29 nM for Mer, Tyro3, and Axl, respectively); selective for TAM family kinases over a panel of 456 kinases at 1 µM, but does inhibit Met, Aurora B, LCK, and Src (IC50s = 35, 36, 51, and 338 nM, respectively); inhibits GAS6-induced suppression of proliferation and IFN-γ production in NKG2D-activated NK cells; adoptive transfer of treated NK cells decreases tumor growth but not metastasis in a B16/F10 murine melanoma model; reduces the number of metastases in B16/F10 murine melanoma and 4T1 murine mammary carcinoma models in an NK cell-dependent manner at 20 mg/kg, i.p.
29459	LDC-1267	25 mg	≥98%	A TAM family kinase inhibitor (IC50s = 5, 8, and 29 nM for Mer, Tyro3, and Axl, respectively); selective for TAM family kinases over a panel of 456 kinases at 1 µM, but does inhibit Met, Aurora B, LCK, and Src (IC50s = 35, 36, 51, and 338 nM, respectively); inhibits GAS6-induced suppression of proliferation and IFN-γ production in NKG2D-activated NK cells; adoptive transfer of treated NK cells decreases tumor growth but not metastasis in a B16/F10 murine melanoma model; reduces the number of metastases in B16/F10 murine melanoma and 4T1 murine mammary carcinoma models in an NK cell-dependent manner at 20 mg/kg, i.p.
29459	LDC-1267	5 mg	≥98%	A TAM family kinase inhibitor (IC50s = 5, 8, and 29 nM for Mer, Tyro3, and Axl, respectively); selective for TAM family kinases over a panel of 456 kinases at 1 µM, but does inhibit Met, Aurora B, LCK, and Src (IC50s = 35, 36, 51, and 338 nM, respectively); inhibits GAS6-induced suppression of proliferation and IFN-γ production in NKG2D-activated NK cells; adoptive transfer of treated NK cells decreases tumor growth but not metastasis in a B16/F10 murine melanoma model; reduces the number of metastases in B16/F10 murine melanoma and 4T1 murine mammary carcinoma models in an NK cell-dependent manner at 20 mg/kg, i.p.
29484	SCIO 469	1 mg	≥98%	A p38 MAPK inhibitor (IC50 = 9 nM for p38α); 10-fold selective for p38α over p38β MAPK and 2,000-fold selective over a panel of 20 additional kinases; inhibits secretion of IL-6 from multiple myeloma patient-derived BMSCs in a concentration-dependent manner; increases PS-341-induced growth inhibition, DNA fragmentation, and caspase-8 and PARP cleavage in MM.1S cells at 100 and 200 nM; reduces microvessel density and tumor load and increases survival in a 5T33MM murine myeloma model at 150 and 450 mg/kg
29484	SCIO 469	10 mg	≥98%	A p38 MAPK inhibitor (IC50 = 9 nM for p38α); 10-fold selective for p38α over p38β MAPK and 2,000-fold selective over a panel of 20 additional kinases; inhibits secretion of IL-6 from multiple myeloma patient-derived BMSCs in a concentration-dependent manner; increases PS-341-induced growth inhibition, DNA fragmentation, and caspase-8 and PARP cleavage in MM.1S cells at 100 and 200 nM; reduces microvessel density and tumor load and increases survival in a 5T33MM murine myeloma model at 150 and 450 mg/kg
29484	SCIO 469	5 mg	≥98%	A p38 MAPK inhibitor (IC50 = 9 nM for p38α); 10-fold selective for p38α over p38β MAPK and 2,000-fold selective over a panel of 20 additional kinases; inhibits secretion of IL-6 from multiple myeloma patient-derived BMSCs in a concentration-dependent manner; increases PS-341-induced growth inhibition, DNA fragmentation, and caspase-8 and PARP cleavage in MM.1S cells at 100 and 200 nM; reduces microvessel density and tumor load and increases survival in a 5T33MM murine myeloma model at 150 and 450 mg/kg
29487	AIM 100	10 mg	≥98%	An ACK1/TNK2 inhibitor (IC50 = 21.58 nM); selective for ACK1/TNK2 over Abl1, BTK, LCK, and LYN (IC50s = 705.9, 871.7, 432.3, and 346.7 nM, respectively), as well as a panel of 25 additional kinases; inhibits EGF-induced increases in ATM protein levels, ACK1/TNK2 and androgen receptor phosphorylation, and pTyr267-androgen receptor binding to the ATM enhancer in LAPC4 cells at 1 µM; inhibits the growth of LNCaP and LAPC4 cells in a concentration-dependent manner and induces cell cycle arrest at the G0/G1 phase at 3 µM; enhances radiation-induced tumor growth reduction in an LNCaP-caAck CRPC mouse xenograft model at 4 mg/kg
29487	AIM 100	25 mg	≥98%	An ACK1/TNK2 inhibitor (IC50 = 21.58 nM); selective for ACK1/TNK2 over Abl1, BTK, LCK, and LYN (IC50s = 705.9, 871.7, 432.3, and 346.7 nM, respectively), as well as a panel of 25 additional kinases; inhibits EGF-induced increases in ATM protein levels, ACK1/TNK2 and androgen receptor phosphorylation, and pTyr267-androgen receptor binding to the ATM enhancer in LAPC4 cells at 1 µM; inhibits the growth of LNCaP and LAPC4 cells in a concentration-dependent manner and induces cell cycle arrest at the G0/G1 phase at 3 µM; enhances radiation-induced tumor growth reduction in an LNCaP-caAck CRPC mouse xenograft model at 4 mg/kg
29487	AIM 100	5 mg	≥98%	An ACK1/TNK2 inhibitor (IC50 = 21.58 nM); selective for ACK1/TNK2 over Abl1, BTK, LCK, and LYN (IC50s = 705.9, 871.7, 432.3, and 346.7 nM, respectively), as well as a panel of 25 additional kinases; inhibits EGF-induced increases in ATM protein levels, ACK1/TNK2 and androgen receptor phosphorylation, and pTyr267-androgen receptor binding to the ATM enhancer in LAPC4 cells at 1 µM; inhibits the growth of LNCaP and LAPC4 cells in a concentration-dependent manner and induces cell cycle arrest at the G0/G1 phase at 3 µM; enhances radiation-induced tumor growth reduction in an LNCaP-caAck CRPC mouse xenograft model at 4 mg/kg

29487	AIM 100	50 mg	≥98%	An ACK1/TNK2 inhibitor (IC50 = 21.58 nM); selective for ACK1/TNK2 over Abl1, BTK, LCK, and LYN (IC50s = 705.9, 871.7, 432.3, and 346.7 nM, respectively), as well as a panel of 25 additional kinases; inhibits EGF-induced increases in ATM protein levels, ACK1/TNK2 and androgen receptor phosphorylation, and pTyr267-androgen receptor binding to the ATM enhancer in LAPC4 cells at 1 µM; inhibits the growth of LNCaP and LAPC4 cells in a concentration-dependent manner and induces cell cycle arrest at the G0/G1 phase at 3 µM; enhances radiation-induced tumor growth reduction in an LNCaP-caAck CRPC mouse xenograft model at 4 mg/kg
29498	AC-710	1 mg	≥98%	A PDGFR family kinase inhibitor (IC50s = 7.7, 10.5, 2, and 1.2 nM for PDGFRβ, CSF1R, FLT3, and c-Kit, respectively); >30-fold selective for PDGFR family kinases over a panel of 386 kinases, as well as over a panel of 5 CYP enzymes (IC50s = >40 µM); inhibits CSF1R-dependent M-NFS-60 murine leukemia cell proliferation and reduces tumor volume in an FLT3 mutant MV4-11 leukemia mouse xenograft model at 30 mg/kg
29498	AC-710	10 mg	≥98%	A PDGFR family kinase inhibitor (IC50s = 7.7, 10.5, 2, and 1.2 nM for PDGFRβ, CSF1R, FLT3, and c-Kit, respectively); >30-fold selective for PDGFR family kinases over a panel of 386 kinases, as well as over a panel of 5 CYP enzymes (IC50s = >40 µM); inhibits CSF1R-dependent M-NFS-60 murine leukemia cell proliferation and reduces tumor volume in an FLT3 mutant MV4-11 leukemia mouse xenograft model at 30 mg/kg
29498	AC-710	25 mg	≥98%	A PDGFR family kinase inhibitor (IC50s = 7.7, 10.5, 2, and 1.2 nM for PDGFRβ, CSF1R, FLT3, and c-Kit, respectively); >30-fold selective for PDGFR family kinases over a panel of 386 kinases, as well as over a panel of 5 CYP enzymes (IC50s = >40 µM); inhibits CSF1R-dependent M-NFS-60 murine leukemia cell proliferation and reduces tumor volume in an FLT3 mutant MV4-11 leukemia mouse xenograft model at 30 mg/kg
29498	AC-710	5 mg	≥98%	A PDGFR family kinase inhibitor (IC50s = 7.7, 10.5, 2, and 1.2 nM for PDGFRβ, CSF1R, FLT3, and c-Kit, respectively); >30-fold selective for PDGFR family kinases over a panel of 386 kinases, as well as over a panel of 5 CYP enzymes (IC50s = >40 µM); inhibits CSF1R-dependent M-NFS-60 murine leukemia cell proliferation and reduces tumor volume in an FLT3 mutant MV4-11 leukemia mouse xenograft model at 30 mg/kg
29499	RGB-286638	100 mg	≥98%	A multi-kinase inhibitor; inhibits a variety of kinases, including CDK2-7 and CDK9, FMS, JAK2, c-Src, GSK3β, TAK1, JNK1A1, JNK1A2, AMPK, and MEK1 (IC50s = 1-55 nM); inhibits proliferation of multiple myeloma cancer cell lines endogenously expressing mutant and wild-type p53 (EC50s = 20-70 nM), as well as patient-derived multiple myeloma cells at 50 and 100 nM; induces G1/S and G2/M cell cycle arrest and apoptosis of MM.1S human multiple myeloma cells at 50 nM; decreases tumor growth in an MM.1S mouse xenograft model at 30 and 40 mg/kg per day for 14 days
29499	RGB-286638	250 mg	≥98%	A multi-kinase inhibitor; inhibits a variety of kinases, including CDK2-7 and CDK9, FMS, JAK2, c-Src, GSK3β, TAK1, JNK1A1, JNK1A2, AMPK, and MEK1 (IC50s = 1-55 nM); inhibits proliferation of multiple myeloma cancer cell lines endogenously expressing mutant and wild-type p53 (EC50s = 20-70 nM), as well as patient-derived multiple myeloma cells at 50 and 100 nM; induces G1/S and G2/M cell cycle arrest and apoptosis of MM.1S human multiple myeloma cells at 50 nM; decreases tumor growth in an MM.1S mouse xenograft model at 30 and 40 mg/kg per day for 14 days
29499	RGB-286638	500 mg	≥98%	A multi-kinase inhibitor; inhibits a variety of kinases, including CDK2-7 and CDK9, FMS, JAK2, c-Src, GSK3β, TAK1, JNK1A1, JNK1A2, AMPK, and MEK1 (IC50s = 1-55 nM); inhibits proliferation of multiple myeloma cancer cell lines endogenously expressing mutant and wild-type p53 (EC50s = 20-70 nM), as well as patient-derived multiple myeloma cells at 50 and 100 nM; induces G1/S and G2/M cell cycle arrest and apoptosis of MM.1S human multiple myeloma cells at 50 nM; decreases tumor growth in an MM.1S mouse xenograft model at 30 and 40 mg/kg per day for 14 days
29505	AS-2444697 (hydroch	1 mg	≥95%	An IRAK4 inhibitor (IC50 = 21 nM); greater than 30-fold selective for IRAK4 over a panel of 146 kinases, but is less than 10-fold selective over PDGFRα, PDGFRβ, TrkA, TrkC, CLK1, Itk, and FLT3; inhibits IL-1β-induced IL-6 production and LPS-induced TNF-α production in cellular assays (IC50s = 250 and 47 nM, respectively); efficacious in rat models of adjuvant- and collagen-induced arthritis (ED50s = 2.7 and 1.6 mg/kg, respectively); reduces urinary protein excretion, the development of interstitial fibrosis and glomerulosclerosis, and renal mRNA expression of genes encoding IL-1β, IL-6, TNF-α, and CCL2 in the 5/6 nephrectomized rat model of chronic kidney disease from 0.3-3 mg/kg
29505	AS-2444697 (hydroch	10 mg	≥95%	An IRAK4 inhibitor (IC50 = 21 nM); greater than 30-fold selective for IRAK4 over a panel of 146 kinases, but is less than 10-fold selective over PDGFRα, PDGFRβ, TrkA, TrkC, CLK1, Itk, and FLT3; inhibits IL-1β-induced IL-6 production and LPS-induced TNF-α production in cellular assays (IC50s = 250 and 47 nM, respectively); efficacious in rat models of adjuvant- and collagen-induced arthritis (ED50s = 2.7 and 1.6 mg/kg, respectively); reduces urinary protein excretion, the development of interstitial fibrosis and glomerulosclerosis, and renal mRNA expression of genes encoding IL-1β, IL-6, TNF-α, and CCL2 in the 5/6 nephrectomized rat model of chronic kidney disease from 0.3-3 mg/kg

29505	AS-2444697 (hydroch	5 mg	≥95%	An IRAK4 inhibitor (IC50 = 21 nM); greater than 30-fold selective for IRAK4 over a panel of 146 kinases, but is less than 10-fold selective over PDGFRα, PDGFRβ, TrkA, TrkC, CLK1, Itk, and FLT3; inhibits IL-1β-induced IL-6 production and LPS-induced TNF-α production in cellular assays (IC50s = 250 and 47 nM, respectively); efficacious in rat models of adjuvant- and collagen-induced arthritis (ED50s = 2.7 and 1.6 mg/kg, respectively); reduces urinary protein excretion, the development of interstitial fibrosis and glomerulosclerosis, and renal mRNA expression of genes encoding IL-1β, IL-6, TNF-α, and CCL2 in the 5/6 nephrectomized rat model of chronic kidney disease from 0.3-3 mg/kg
29552	KY 05009	1 mg	≥98%	A TNIK inhibitor (Ki = 100 nM); inhibits TGF-β1-induced Wnt, NF-κB, ERK, and JNK signaling and prevents TGF-β1-induced EMT in A549 lung cancer cells at 10 μM; inhibits TNF-β1-induced A549 cell migration; induces apoptosis in RPMI-8226 multiple myeloma cells
29552	KY 05009	10 mg	≥98%	A TNIK inhibitor (Ki = 100 nM); inhibits TGF-β1-induced Wnt, NF-κB, ERK, and JNK signaling and prevents TGF-β1-induced EMT in A549 lung cancer cells at 10 μM; inhibits TNF-β1-induced A549 cell migration; induces apoptosis in RPMI-8226 multiple myeloma cells
29552	KY 05009	25 mg	≥98%	A TNIK inhibitor (Ki = 100 nM); inhibits TGF-β1-induced Wnt, NF-κB, ERK, and JNK signaling and prevents TGF-β1-induced EMT in A549 lung cancer cells at 10 μM; inhibits TNF-β1-induced A549 cell migration; induces apoptosis in RPMI-8226 multiple myeloma cells
29552	KY 05009	5 mg	≥98%	A TNIK inhibitor (Ki = 100 nM); inhibits TGF-β1-induced Wnt, NF-κB, ERK, and JNK signaling and prevents TGF-β1-induced EMT in A549 lung cancer cells at 10 μM; inhibits TNF-β1-induced A549 cell migration; induces apoptosis in RPMI-8226 multiple myeloma cells
29571	TP-3654	10 mg	≥98%	A Pim kinase inhibitor (Kis = 5, 239, and 42 nM for Pim-1, Pim-2, and Pim-3, respectively); inhibits 19 additional kinases, including PI3Kα, PI3Kγ, and PI3Kδ, with IC50 values 50 = 67 nM), as well as in UM-UC-3 cells; reduces tumor growth in UM-UC-3 bladder carcinoma and PC3 prostate adenocarcinoma mouse xenograft models at 200 mg/kg
29571	TP-3654	25 mg	≥98%	A Pim kinase inhibitor (Kis = 5, 239, and 42 nM for Pim-1, Pim-2, and Pim-3, respectively); inhibits 19 additional kinases, including PI3Kα, PI3Kγ, and PI3Kδ, with IC50 values 50 = 67 nM), as well as in UM-UC-3 cells; reduces tumor growth in UM-UC-3 bladder carcinoma and PC3 prostate adenocarcinoma mouse xenograft models at 200 mg/kg
29571	TP-3654	5 mg	≥98%	A Pim kinase inhibitor (Kis = 5, 239, and 42 nM for Pim-1, Pim-2, and Pim-3, respectively); inhibits 19 additional kinases, including PI3Kα, PI3Kγ, and PI3Kδ, with IC50 values 50 = 67 nM), as well as in UM-UC-3 cells; reduces tumor growth in UM-UC-3 bladder carcinoma and PC3 prostate adenocarcinoma mouse xenograft models at 200 mg/kg
29630	BIBX1382	1 mg	≥98%	An EGFR inhibitor (IC50 = 3 nM); selective for EGFR over HER2 (IC50 = 3,400 nM), as well as IGF-1R, β-InsRK, c-Met, c-Src, and VEGFR2 (IC50s = >10 μM); inhibits proliferation and colony formation in A549 cancer cells expressing mutant K-Ras, as well as FaDu cancer cells expressing wild-type K-Ras at 5 μM; enhances radiation-induced cytotoxicity in K-Ras-expressing A549 and MDA-MB-231 cancer cells, but not FaDu, HTB-35, or HH4dd cancer cells that express wild-type K-Ras; reduces tumor growth in A431 and FaDu mouse xenograft models at 70 and 60 mg/kg per day, respectively
29630	BIBX1382	10 mg	≥98%	An EGFR inhibitor (IC50 = 3 nM); selective for EGFR over HER2 (IC50 = 3,400 nM), as well as IGF-1R, β-InsRK, c-Met, c-Src, and VEGFR2 (IC50s = >10 μM); inhibits proliferation and colony formation in A549 cancer cells expressing mutant K-Ras, as well as FaDu cancer cells expressing wild-type K-Ras at 5 μM; enhances radiation-induced cytotoxicity in K-Ras-expressing A549 and MDA-MB-231 cancer cells, but not FaDu, HTB-35, or HH4dd cancer cells that express wild-type K-Ras; reduces tumor growth in A431 and FaDu mouse xenograft models at 70 and 60 mg/kg per day, respectively
29630	BIBX1382	25 mg	≥98%	An EGFR inhibitor (IC50 = 3 nM); selective for EGFR over HER2 (IC50 = 3,400 nM), as well as IGF-1R, β-InsRK, c-Met, c-Src, and VEGFR2 (IC50s = >10 μM); inhibits proliferation and colony formation in A549 cancer cells expressing mutant K-Ras, as well as FaDu cancer cells expressing wild-type K-Ras at 5 μM; enhances radiation-induced cytotoxicity in K-Ras-expressing A549 and MDA-MB-231 cancer cells, but not FaDu, HTB-35, or HH4dd cancer cells that express wild-type K-Ras; reduces tumor growth in A431 and FaDu mouse xenograft models at 70 and 60 mg/kg per day, respectively
29630	BIBX1382	5 mg	≥98%	An EGFR inhibitor (IC50 = 3 nM); selective for EGFR over HER2 (IC50 = 3,400 nM), as well as IGF-1R, β-InsRK, c-Met, c-Src, and VEGFR2 (IC50s = >10 μM); inhibits proliferation and colony formation in A549 cancer cells expressing mutant K-Ras, as well as FaDu cancer cells expressing wild-type K-Ras at 5 μM; enhances radiation-induced cytotoxicity in K-Ras-expressing A549 and MDA-MB-231 cancer cells, but not FaDu, HTB-35, or HH4dd cancer cells that express wild-type K-Ras; reduces tumor growth in A431 and FaDu mouse xenograft models at 70 and 60 mg/kg per day, respectively

29631	CGP 60474	1 mg	≥98%	A CDK inhibitor (IC50s = 0.017, 0.08, and 0.05 µM for Cdk1/cyclin B, Cdk2/cyclin A, and Cdk2/cyclin E, respectively); selective for these CDKs over Cdk4/cyclin D1 (IC50 = 0.7 µM) and a variety of other kinases but does inhibit PKCα and v-Abl (IC50s = 0.25 and 0.4 µM, respectively); inhibits proliferation of colon, breast, lung, prostate, and ovarian cancer cells (IC50s = 25-84, 21-280, 40 and 68, 17 and 20, and 18-38 nM, respectively); inhibits poly(I:C)-induced NF-κB nuclear translocation in J774.1 cells at 8 and 32 nM; reduces plasma IL-6 levels and increases survival in a mouse model of LPS-induced endotoxemia at 10 mg/kg
29631	CGP 60474	10 mg	≥98%	A CDK inhibitor (IC50s = 0.017, 0.08, and 0.05 µM for Cdk1/cyclin B, Cdk2/cyclin A, and Cdk2/cyclin E, respectively); selective for these CDKs over Cdk4/cyclin D1 (IC50 = 0.7 µM) and a variety of other kinases but does inhibit PKCα and v-Abl (IC50s = 0.25 and 0.4 µM, respectively); inhibits proliferation of colon, breast, lung, prostate, and ovarian cancer cells (IC50s = 25-84, 21-280, 40 and 68, 17 and 20, and 18-38 nM, respectively); inhibits poly(I:C)-induced NF-κB nuclear translocation in J774.1 cells at 8 and 32 nM; reduces plasma IL-6 levels and increases survival in a mouse model of LPS-induced endotoxemia at 10 mg/kg
29631	CGP 60474	5 mg	≥98%	A CDK inhibitor (IC50s = 0.017, 0.08, and 0.05 µM for Cdk1/cyclin B, Cdk2/cyclin A, and Cdk2/cyclin E, respectively); selective for these CDKs over Cdk4/cyclin D1 (IC50 = 0.7 µM) and a variety of other kinases but does inhibit PKCα and v-Abl (IC50s = 0.25 and 0.4 µM, respectively); inhibits proliferation of colon, breast, lung, prostate, and ovarian cancer cells (IC50s = 25-84, 21-280, 40 and 68, 17 and 20, and 18-38 nM, respectively); inhibits poly(I:C)-induced NF-κB nuclear translocation in J774.1 cells at 8 and 32 nM; reduces plasma IL-6 levels and increases survival in a mouse model of LPS-induced endotoxemia at 10 mg/kg
29633	Pericosine A	1 mg	≥70%	A fungal metabolite with anticancer activity; inhibits the growth of a variety of cancer cells, including breast, colon, lung, ovary, stomach, and prostate cell lines (GI50s = 0.05-24.55 µM); increases survival in a P388 mouse xenograft model at 25 mg/kg; inhibits EGFR by 40 to 70% at 100 µg/ml; reacts with organosulfur compounds in skunk spray to form odorless thioether products
29643	Benserazide-d3 (hydr	2.5 mg	≥99% deutera	An internal standard for the quantification of benserazide by GC- or LC-MS
29657	AC480	1 mg	≥98%	A dual inhibitor of EGFR and HER2 (IC50s = 22 and 32 nM, respectively); selective for EGFR and HER2 over HER4 (IC50 = 190 nM) and a panel of 21 additional kinases (IC50s = >2,500 nM for all); inhibits proliferation in a panel of EGFR and/or HER2 signaling-dependent cancer cells (IC50s = 0.24-0.94 µM); reduces tumor growth in a Sal2 murine salivary gland tumor model, as well as GEO colon and KPL4 breast cancer mouse xenograft models in a dose-dependent manner; reduces tumor cell motility, intravasation, and EGF-induced invasion in an MTLn3E metastatic mammary adenocarcinoma mouse xenograft model at 100 mg/kg
29657	AC480	10 mg	≥98%	A dual inhibitor of EGFR and HER2 (IC50s = 22 and 32 nM, respectively); selective for EGFR and HER2 over HER4 (IC50 = 190 nM) and a panel of 21 additional kinases (IC50s = >2,500 nM for all); inhibits proliferation in a panel of EGFR and/or HER2 signaling-dependent cancer cells (IC50s = 0.24-0.94 µM); reduces tumor growth in a Sal2 murine salivary gland tumor model, as well as GEO colon and KPL4 breast cancer mouse xenograft models in a dose-dependent manner; reduces tumor cell motility, intravasation, and EGF-induced invasion in an MTLn3E metastatic mammary adenocarcinoma mouse xenograft model at 100 mg/kg
29657	AC480	25 mg	≥98%	A dual inhibitor of EGFR and HER2 (IC50s = 22 and 32 nM, respectively); selective for EGFR and HER2 over HER4 (IC50 = 190 nM) and a panel of 21 additional kinases (IC50s = >2,500 nM for all); inhibits proliferation in a panel of EGFR and/or HER2 signaling-dependent cancer cells (IC50s = 0.24-0.94 µM); reduces tumor growth in a Sal2 murine salivary gland tumor model, as well as GEO colon and KPL4 breast cancer mouse xenograft models in a dose-dependent manner; reduces tumor cell motility, intravasation, and EGF-induced invasion in an MTLn3E metastatic mammary adenocarcinoma mouse xenograft model at 100 mg/kg
29657	AC480	5 mg	≥98%	A dual inhibitor of EGFR and HER2 (IC50s = 22 and 32 nM, respectively); selective for EGFR and HER2 over HER4 (IC50 = 190 nM) and a panel of 21 additional kinases (IC50s = >2,500 nM for all); inhibits proliferation in a panel of EGFR and/or HER2 signaling-dependent cancer cells (IC50s = 0.24-0.94 µM); reduces tumor growth in a Sal2 murine salivary gland tumor model, as well as GEO colon and KPL4 breast cancer mouse xenograft models in a dose-dependent manner; reduces tumor cell motility, intravasation, and EGF-induced invasion in an MTLn3E metastatic mammary adenocarcinoma mouse xenograft model at 100 mg/kg
29662	XMD8-85	10 mg	≥98%	An ERK5 inhibitor (IC50 = 87 nM in an enzyme assay); selective for ERK5 over TNK2 (IC50 = 959 nM), but does inhibit LRRK2G2019S (IC50 = 26 nM); inhibits EGF-induced ERK5 autophosphorylation in HeLa cells (EC50 = 0.19 µM)
29662	XMD8-85	25 mg	≥98%	An ERK5 inhibitor (IC50 = 87 nM in an enzyme assay); selective for ERK5 over TNK2 (IC50 = 959 nM), but does inhibit LRRK2G2019S (IC50 = 26 nM); inhibits EGF-induced ERK5 autophosphorylation in HeLa cells (EC50 = 0.19 µM)

29662	XMD8-85	5 mg	≥98%	An ERK5 inhibitor (IC50 = 87 nM in an enzyme assay); selective for ERK5 over TNK2 (IC50 = 959 nM), but does inhibit LRRK2G2019S (IC50 = 26 nM); inhibits EGF-induced ERK5 autophosphorylation in HeLa cells (EC50 = 0.19 µM)
29662	XMD8-85	50 mg	≥98%	An ERK5 inhibitor (IC50 = 87 nM in an enzyme assay); selective for ERK5 over TNK2 (IC50 = 959 nM), but does inhibit LRRK2G2019S (IC50 = 26 nM); inhibits EGF-induced ERK5 autophosphorylation in HeLa cells (EC50 = 0.19 µM)
29666	AG-528	10 mg	≥98%	A tyrphostin that inhibits EGFR and HER2 (IC50s = 12 and 4.9 µM, respectively, for inhibition of autophosphorylation); inhibits PanK3 (IC50 = 3 µM); inhibits EGF-dependent proliferation of HER14 cells (IC50 = 25 µM)
29666	AG-528	100 mg	≥98%	A tyrphostin that inhibits EGFR and HER2 (IC50s = 12 and 4.9 µM, respectively, for inhibition of autophosphorylation); inhibits PanK3 (IC50 = 3 µM); inhibits EGF-dependent proliferation of HER14 cells (IC50 = 25 µM)
29666	AG-528	250 mg	≥98%	A tyrphostin that inhibits EGFR and HER2 (IC50s = 12 and 4.9 µM, respectively, for inhibition of autophosphorylation); inhibits PanK3 (IC50 = 3 µM); inhibits EGF-dependent proliferation of HER14 cells (IC50 = 25 µM)
29666	AG-528	50 mg	≥98%	A tyrphostin that inhibits EGFR and HER2 (IC50s = 12 and 4.9 µM, respectively, for inhibition of autophosphorylation); inhibits PanK3 (IC50 = 3 µM); inhibits EGF-dependent proliferation of HER14 cells (IC50 = 25 µM)
29669	MSC2530818	1 mg	≥98%	A Cdk8 inhibitor (IC50 = 2.6 nM); selective for Cdk8 over a panel of 264 kinases at 1 µM but does inhibit GSK3α (IC50 = 691 nM); inhibits STAT1 phosphorylation in SW620 colorectal cancer cells (IC50 = 8 nM); inhibits Wnt-dependent transcription in LS 174T, COLO 205, and PA-1 cancer cells (IC50s = 32, 9, and 52 nM, respectively, in luciferase reporter assays); reduces tumor growth in a SW620 mouse xenograft model at 50 and 100 mg/kg
29669	MSC2530818	10 mg	≥98%	A Cdk8 inhibitor (IC50 = 2.6 nM); selective for Cdk8 over a panel of 264 kinases at 1 µM but does inhibit GSK3α (IC50 = 691 nM); inhibits STAT1 phosphorylation in SW620 colorectal cancer cells (IC50 = 8 nM); inhibits Wnt-dependent transcription in LS 174T, COLO 205, and PA-1 cancer cells (IC50s = 32, 9, and 52 nM, respectively, in luciferase reporter assays); reduces tumor growth in a SW620 mouse xenograft model at 50 and 100 mg/kg
29669	MSC2530818	25 mg	≥98%	A Cdk8 inhibitor (IC50 = 2.6 nM); selective for Cdk8 over a panel of 264 kinases at 1 µM but does inhibit GSK3α (IC50 = 691 nM); inhibits STAT1 phosphorylation in SW620 colorectal cancer cells (IC50 = 8 nM); inhibits Wnt-dependent transcription in LS 174T, COLO 205, and PA-1 cancer cells (IC50s = 32, 9, and 52 nM, respectively, in luciferase reporter assays); reduces tumor growth in a SW620 mouse xenograft model at 50 and 100 mg/kg
29669	MSC2530818	5 mg	≥98%	A Cdk8 inhibitor (IC50 = 2.6 nM); selective for Cdk8 over a panel of 264 kinases at 1 µM but does inhibit GSK3α (IC50 = 691 nM); inhibits STAT1 phosphorylation in SW620 colorectal cancer cells (IC50 = 8 nM); inhibits Wnt-dependent transcription in LS 174T, COLO 205, and PA-1 cancer cells (IC50s = 32, 9, and 52 nM, respectively, in luciferase reporter assays); reduces tumor growth in a SW620 mouse xenograft model at 50 and 100 mg/kg
29670	Lazertinib	10 mg	≥98%	An irreversible inhibitor of mutant EGFRs (IC50s = 1.7, 2, and 3.3 nM for EGFRL858R/T790M, EGFRDel19/T790M, and EGFRDel19, respectively); selective for mutant EGFRs over wild-type EGFR, HER2, and HER4 (IC50s = 76, 364, and 1,017 nM, respectively); reduces viability of Ba/F3 cells expressing mutant EGFRs (IC50s = 3.3-5.7 nM); reduces tumor volume in an EGFRT790M mutant H1975 NSCLC mouse xenograft model at 1, 3, and 10 mg/kg
29670	Lazertinib	25 mg	≥98%	An irreversible inhibitor of mutant EGFRs (IC50s = 1.7, 2, and 3.3 nM for EGFRL858R/T790M, EGFRDel19/T790M, and EGFRDel19, respectively); selective for mutant EGFRs over wild-type EGFR, HER2, and HER4 (IC50s = 76, 364, and 1,017 nM, respectively); reduces viability of Ba/F3 cells expressing mutant EGFRs (IC50s = 3.3-5.7 nM); reduces tumor volume in an EGFRT790M mutant H1975 NSCLC mouse xenograft model at 1, 3, and 10 mg/kg
29670	Lazertinib	5 mg	≥98%	An irreversible inhibitor of mutant EGFRs (IC50s = 1.7, 2, and 3.3 nM for EGFRL858R/T790M, EGFRDel19/T790M, and EGFRDel19, respectively); selective for mutant EGFRs over wild-type EGFR, HER2, and HER4 (IC50s = 76, 364, and 1,017 nM, respectively); reduces viability of Ba/F3 cells expressing mutant EGFRs (IC50s = 3.3-5.7 nM); reduces tumor volume in an EGFRT790M mutant H1975 NSCLC mouse xenograft model at 1, 3, and 10 mg/kg

29670	Lazertinib	50 mg	≥98%	An irreversible inhibitor of mutant EGFRs (IC50s = 1.7, 2, and 3.3 nM for EGFRL858R/T790M, EGFRDel19/T790M, and EGFRDel19, respectively); selective for mutant EGFRs over wild-type EGFR, HER2, and HER4 (IC50s = 76, 364, and 1,017 nM, respectively); reduces viability of Ba/F3 cells expressing mutant EGFRs (IC50s = 3.3-5.7 nM); reduces tumor volume in an EGFRT790M mutant H1975 NSCLC mouse xenograft model at 1, 3, and 10 mg/kg
29676	WNK-IN-11	10 mg	≥98%	An allosteric WNK1 inhibitor (IC50 = 4 nM); 57- and 1000-fold selective for WNK1 over WNK2 and WNK4, respectively, as well as a panel of 400 kinases at 10 µM; inhibits WNK1-mediated phosphorylation of OSR1 in HEK293 cells (EC50 = 0.352 µM)
29676	WNK-IN-11	25 mg	≥98%	An allosteric WNK1 inhibitor (IC50 = 4 nM); 57- and 1000-fold selective for WNK1 over WNK2 and WNK4, respectively, as well as a panel of 400 kinases at 10 µM; inhibits WNK1-mediated phosphorylation of OSR1 in HEK293 cells (EC50 = 0.352 µM)
29676	WNK-IN-11	5 mg	≥98%	An allosteric WNK1 inhibitor (IC50 = 4 nM); 57- and 1000-fold selective for WNK1 over WNK2 and WNK4, respectively, as well as a panel of 400 kinases at 10 µM; inhibits WNK1-mediated phosphorylation of OSR1 in HEK293 cells (EC50 = 0.352 µM)
29676	WNK-IN-11	50 mg	≥98%	An allosteric WNK1 inhibitor (IC50 = 4 nM); 57- and 1000-fold selective for WNK1 over WNK2 and WNK4, respectively, as well as a panel of 400 kinases at 10 µM; inhibits WNK1-mediated phosphorylation of OSR1 in HEK293 cells (EC50 = 0.352 µM)
29689	Purpurogallin	1 g	≥95%	A phenol; active against a range of bacteria (MICs = 11-110 µg/ml) and P. falciparum strain FCB1 clone NC-1 (IC50 = 55 µM); scavenges DPPH radicals in a cell-free assay and reduces hydrogen peroxide and radiation-induced production of ROS in HaCaT keratinocytes at 2, 5, and 10 µM; inhibits the activity of EGFR, GST, prolyl endopeptidase, and glyoxalase I (IC50s = 27.5, 8, 16, and 50 µM, respectively), as well as COMT (Ki = 0.074 µM), in cell-free assays
29689	Purpurogallin	100 mg	≥95%	A phenol; active against a range of bacteria (MICs = 11-110 µg/ml) and P. falciparum strain FCB1 clone NC-1 (IC50 = 55 µM); scavenges DPPH radicals in a cell-free assay and reduces hydrogen peroxide and radiation-induced production of ROS in HaCaT keratinocytes at 2, 5, and 10 µM; inhibits the activity of EGFR, GST, prolyl endopeptidase, and glyoxalase I (IC50s = 27.5, 8, 16, and 50 µM, respectively), as well as COMT (Ki = 0.074 µM), in cell-free assays
29689	Purpurogallin	50 mg	≥95%	A phenol; active against a range of bacteria (MICs = 11-110 µg/ml) and P. falciparum strain FCB1 clone NC-1 (IC50 = 55 µM); scavenges DPPH radicals in a cell-free assay and reduces hydrogen peroxide and radiation-induced production of ROS in HaCaT keratinocytes at 2, 5, and 10 µM; inhibits the activity of EGFR, GST, prolyl endopeptidase, and glyoxalase I (IC50s = 27.5, 8, 16, and 50 µM, respectively), as well as COMT (Ki = 0.074 µM), in cell-free assays
29689	Purpurogallin	500 mg	≥95%	A phenol; active against a range of bacteria (MICs = 11-110 µg/ml) and P. falciparum strain FCB1 clone NC-1 (IC50 = 55 µM); scavenges DPPH radicals in a cell-free assay and reduces hydrogen peroxide and radiation-induced production of ROS in HaCaT keratinocytes at 2, 5, and 10 µM; inhibits the activity of EGFR, GST, prolyl endopeptidase, and glyoxalase I (IC50s = 27.5, 8, 16, and 50 µM, respectively), as well as COMT (Ki = 0.074 µM), in cell-free assays
29706	Upadacitinib	1 mg	≥98%	A JAK1 inhibitor (IC50 = 47 nM); selective for JAK1 over JAK3 and Tyk2 (IC50s = 2,304 and 4,690 nM, respectively), as well as a panel of 83 additional kinases at 1 µM, but does inhibit JAK2, ROCK1, and ROCK2 (IC50s = 120, 920 and 430 nM, respectively); decreases cytokine-induced STAT phosphorylation in a variety of human cells (IC50s = 1.6-649 nM); reduces M. tuberculosis-induced paw swelling and bone erosion in a rat model of arthritis at 1, 3, and 10 mg/kg twice per day for 17 days
29706	Upadacitinib	10 mg	≥98%	A JAK1 inhibitor (IC50 = 47 nM); selective for JAK1 over JAK3 and Tyk2 (IC50s = 2,304 and 4,690 nM, respectively), as well as a panel of 83 additional kinases at 1 µM, but does inhibit JAK2, ROCK1, and ROCK2 (IC50s = 120, 920 and 430 nM, respectively); decreases cytokine-induced STAT phosphorylation in a variety of human cells (IC50s = 1.6-649 nM); reduces M. tuberculosis-induced paw swelling and bone erosion in a rat model of arthritis at 1, 3, and 10 mg/kg twice per day for 17 days
29706	Upadacitinib	25 mg	≥98%	A JAK1 inhibitor (IC50 = 47 nM); selective for JAK1 over JAK3 and Tyk2 (IC50s = 2,304 and 4,690 nM, respectively), as well as a panel of 83 additional kinases at 1 µM, but does inhibit JAK2, ROCK1, and ROCK2 (IC50s = 120, 920 and 430 nM, respectively); decreases cytokine-induced STAT phosphorylation in a variety of human cells (IC50s = 1.6-649 nM); reduces M. tuberculosis-induced paw swelling and bone erosion in a rat model of arthritis at 1, 3, and 10 mg/kg twice per day for 17 days

29706	Upadacitinib	5 mg	≥98%	A JAK1 inhibitor (IC50 = 47 nM); selective for JAK1 over JAK3 and Tyk2 (IC50s = 2,304 and 4,690 nM, respectively), as well as a panel of 83 additional kinases at 1 µM, but does inhibit JAK2, ROCK1, and ROCK2 (IC50s = 120, 920 and 430 nM, respectively); decreases cytokine-induced STAT phosphorylation in a variety of human cells (IC50s = 1.6-649 nM); reduces M. tuberculosis-induced paw swelling and bone erosion in a rat model of arthritis at 1, 3, and 10 mg/kg twice per day for 17 days
29708	AST-1306 (tosylate)	1 mg	≥98%	An irreversible EGFR, HER2, and HER4 inhibitor (IC50s = 0.5, 3, and 0.8 nM, respectively); selective for EGFR, HER2, and HER4 over a panel of 23 additional kinases (IC50s = >10 µM); inhibits EGFRT790M/L858R (IC50 = 12 nM in a cell-free assay); decreases EGFR, ERK1/2, and Akt phosphorylation in Calu-3, A549, and SKOV3 cancer cells from 0.001-1 µM; inhibits proliferation of various cancer cells (IC50s = 0.23-16 µM); reduces tumor growth in Calu-3, A549, SKOV3, and HO8910 mouse xenograft models at 25, 50, and 100 mg/kg per day
29708	AST-1306 (tosylate)	10 mg	≥98%	An irreversible EGFR, HER2, and HER4 inhibitor (IC50s = 0.5, 3, and 0.8 nM, respectively); selective for EGFR, HER2, and HER4 over a panel of 23 additional kinases (IC50s = >10 µM); inhibits EGFRT790M/L858R (IC50 = 12 nM in a cell-free assay); decreases EGFR, ERK1/2, and Akt phosphorylation in Calu-3, A549, and SKOV3 cancer cells from 0.001-1 µM; inhibits proliferation of various cancer cells (IC50s = 0.23-16 µM); reduces tumor growth in Calu-3, A549, SKOV3, and HO8910 mouse xenograft models at 25, 50, and 100 mg/kg per day
29708	AST-1306 (tosylate)	25 mg	≥98%	An irreversible EGFR, HER2, and HER4 inhibitor (IC50s = 0.5, 3, and 0.8 nM, respectively); selective for EGFR, HER2, and HER4 over a panel of 23 additional kinases (IC50s = >10 µM); inhibits EGFRT790M/L858R (IC50 = 12 nM in a cell-free assay); decreases EGFR, ERK1/2, and Akt phosphorylation in Calu-3, A549, and SKOV3 cancer cells from 0.001-1 µM; inhibits proliferation of various cancer cells (IC50s = 0.23-16 µM); reduces tumor growth in Calu-3, A549, SKOV3, and HO8910 mouse xenograft models at 25, 50, and 100 mg/kg per day
29708	AST-1306 (tosylate)	5 mg	≥98%	An irreversible EGFR, HER2, and HER4 inhibitor (IC50s = 0.5, 3, and 0.8 nM, respectively); selective for EGFR, HER2, and HER4 over a panel of 23 additional kinases (IC50s = >10 µM); inhibits EGFRT790M/L858R (IC50 = 12 nM in a cell-free assay); decreases EGFR, ERK1/2, and Akt phosphorylation in Calu-3, A549, and SKOV3 cancer cells from 0.001-1 µM; inhibits proliferation of various cancer cells (IC50s = 0.23-16 µM); reduces tumor growth in Calu-3, A549, SKOV3, and HO8910 mouse xenograft models at 25, 50, and 100 mg/kg per day
29718	PIM447 (hydrochlorid	1 mg	≥98%	A pan-Pim kinase inhibitor (Kis = 6, 18, and 9 pM for Pim-1, Pim-2, and Pim-3, respectively); selective for Pim kinases over a panel of 383 non-mutant kinases at 1 µM; inhibits cell growth in a panel of 26 AML cell lines (GI50s = 0.01-8.66 µM); reduces tumor growth and phosphorylation of the Pim kinase target pS6RP in a KG-1 AML mouse xenograft model at 30 and 100 mg/kg; reduces the tumor burden and prevents tumor-associated bone loss in a mouse model of bone marrow-disseminated human multiple myeloma
29718	PIM447 (hydrochlorid	5 mg	≥98%	A pan-Pim kinase inhibitor (Kis = 6, 18, and 9 pM for Pim-1, Pim-2, and Pim-3, respectively); selective for Pim kinases over a panel of 383 non-mutant kinases at 1 µM; inhibits cell growth in a panel of 26 AML cell lines (GI50s = 0.01-8.66 µM); reduces tumor growth and phosphorylation of the Pim kinase target pS6RP in a KG-1 AML mouse xenograft model at 30 and 100 mg/kg; reduces the tumor burden and prevents tumor-associated bone loss in a mouse model of bone marrow-disseminated human multiple myeloma
29719	PD 082106	1 mg	≥95%	An inhibitor of FLT3 kinase (IC50 = 0.015 µM); selective for FLT3 over Met, Ron, EGFR, and the insulin receptor (IC50s = >10 µM for all) but does inhibit DRAK2 (IC50 = 0.62 µM), as well as VEGFR2 and Aurora A (IC50s = 1.53 and 1.27 µM, respectively); inhibits proliferation of A549, SNU-638, HT-1080, HL-60, and MCF-7 cancer cells (IC50s = 13, 2.1, 3.4, 89, and 9 µM, respectively); inhibits proliferation of (IC50 = 5.1 µM), and induces apoptosis in, RK3E-ras cells and reduces tumor growth in RK3E-ras flank and oral tumor models; active against the parasite T. gondii (ID50 = 0.52 µM) with a TD50 value of 61 µM
29719	PD 082106	10 mg	≥95%	An inhibitor of FLT3 kinase (IC50 = 0.015 µM); selective for FLT3 over Met, Ron, EGFR, and the insulin receptor (IC50s = >10 µM for all) but does inhibit DRAK2 (IC50 = 0.62 µM), as well as VEGFR2 and Aurora A (IC50s = 1.53 and 1.27 µM, respectively); inhibits proliferation of A549, SNU-638, HT-1080, HL-60, and MCF-7 cancer cells (IC50s = 13, 2.1, 3.4, 89, and 9 µM, respectively); inhibits proliferation of (IC50 = 5.1 µM), and induces apoptosis in, RK3E-ras cells and reduces tumor growth in RK3E-ras flank and oral tumor models; active against the parasite T. gondii (ID50 = 0.52 µM) with a TD50 value of 61 µM
29719	PD 082106	5 mg	≥95%	An inhibitor of FLT3 kinase (IC50 = 0.015 µM); selective for FLT3 over Met, Ron, EGFR, and the insulin receptor (IC50s = >10 µM for all) but does inhibit DRAK2 (IC50 = 0.62 µM), as well as VEGFR2 and Aurora A (IC50s = 1.53 and 1.27 µM, respectively); inhibits proliferation of A549, SNU-638, HT-1080, HL-60, and MCF-7 cancer cells (IC50s = 13, 2.1, 3.4, 89, and 9 µM, respectively); inhibits proliferation of (IC50 = 5.1 µM), and induces apoptosis in, RK3E-ras cells and reduces tumor growth in RK3E-ras flank and oral tumor models; active against the parasite T. gondii (ID50 = 0.52 µM) with a TD50 value of 61 µM

29783	A-1070722	1 mg	≥98%	A GSK3β inhibitor (IC50 = <100 nM)
29783	A-1070722	10 mg	≥98%	A GSK3β inhibitor (IC50 = <100 nM)
29783	A-1070722	25 mg	≥98%	A GSK3β inhibitor (IC50 = <100 nM)
29783	A-1070722	5 mg	≥98%	A GSK3β inhibitor (IC50 = <100 nM)
29805	BPR1J-097	10 mg	≥95%	An FLT3 inhibitor (IC50 = 11 nM); selective for FLT3 over FLT1, KDR, Aurora A, and Aurora B kinases (IC50s = 211, 129, 340, and 876 nM, respectively); inhibits FLT3 activity and phosphorylation of STAT5 in MV4-11 AML cells containing the FLT3 activating mutant FLT3-ITD (IC50s = 10 and 1 nM, respectively); inhibits the growth of FLT3-dependent MOLM-13 and MV4-11 AML cells (GI50s = 21 and 46 nM, respectively); inhibits tumor growth in a MOLM-13 mouse xenograft model at 25 mg/kg
29805	BPR1J-097	100 mg	≥95%	An FLT3 inhibitor (IC50 = 11 nM); selective for FLT3 over FLT1, KDR, Aurora A, and Aurora B kinases (IC50s = 211, 129, 340, and 876 nM, respectively); inhibits FLT3 activity and phosphorylation of STAT5 in MV4-11 AML cells containing the FLT3 activating mutant FLT3-ITD (IC50s = 10 and 1 nM, respectively); inhibits the growth of FLT3-dependent MOLM-13 and MV4-11 AML cells (GI50s = 21 and 46 nM, respectively); inhibits tumor growth in a MOLM-13 mouse xenograft model at 25 mg/kg
29805	BPR1J-097	50 mg	≥95%	An FLT3 inhibitor (IC50 = 11 nM); selective for FLT3 over FLT1, KDR, Aurora A, and Aurora B kinases (IC50s = 211, 129, 340, and 876 nM, respectively); inhibits FLT3 activity and phosphorylation of STAT5 in MV4-11 AML cells containing the FLT3 activating mutant FLT3-ITD (IC50s = 10 and 1 nM, respectively); inhibits the growth of FLT3-dependent MOLM-13 and MV4-11 AML cells (GI50s = 21 and 46 nM, respectively); inhibits tumor growth in a MOLM-13 mouse xenograft model at 25 mg/kg
29814	CAY10746	1 mg	≥95%	A ROCK1 and ROCK2 inhibitor (IC50s = 14 and 3 nM, respectively); selective for ROCK1 and ROCK2 over PKA (IC50 = >10,000 nM) and over 387 recombinant human protein kinases in a panel of 394 kinases (IC50s = >10,000 nM for all) but does inhibit LIMK2, Aurora A, Aurora B, PKG1α, and PKG1β (IC50s = 46, 1,072, 1,239, 517, and 660 nM, respectively); inhibits phosphorylation of MYPT1 in SH-SY5Y cells at 0.1-10 µM; inhibits HUVEC migration at 1 µM; protects isolated mouse retinal neurons from apoptosis and oxidative stress induced by high glucose in an in vitro model of diabetic retinopathy; promotes high glucose-induced vessel regression in mouse retinal explants
29814	CAY10746	5 mg	≥95%	A ROCK1 and ROCK2 inhibitor (IC50s = 14 and 3 nM, respectively); selective for ROCK1 and ROCK2 over PKA (IC50 = >10,000 nM) and over 387 recombinant human protein kinases in a panel of 394 kinases (IC50s = >10,000 nM for all) but does inhibit LIMK2, Aurora A, Aurora B, PKG1α, and PKG1β (IC50s = 46, 1,072, 1,239, 517, and 660 nM, respectively); inhibits phosphorylation of MYPT1 in SH-SY5Y cells at 0.1-10 µM; inhibits HUVEC migration at 1 µM; protects isolated mouse retinal neurons from apoptosis and oxidative stress induced by high glucose in an in vitro model of diabetic retinopathy; promotes high glucose-induced vessel regression in mouse retinal explants
29814	CAY10746	500 µg	≥95%	A ROCK1 and ROCK2 inhibitor (IC50s = 14 and 3 nM, respectively); selective for ROCK1 and ROCK2 over PKA (IC50 = >10,000 nM) and over 387 recombinant human protein kinases in a panel of 394 kinases (IC50s = >10,000 nM for all) but does inhibit LIMK2, Aurora A, Aurora B, PKG1α, and PKG1β (IC50s = 46, 1,072, 1,239, 517, and 660 nM, respectively); inhibits phosphorylation of MYPT1 in SH-SY5Y cells at 0.1-10 µM; inhibits HUVEC migration at 1 µM; protects isolated mouse retinal neurons from apoptosis and oxidative stress induced by high glucose in an in vitro model of diabetic retinopathy; promotes high glucose-induced vessel regression in mouse retinal explants
29827	AZD 0364	1 mg	≥98%	An inhibitor of ERK2 (IC50 = 50s = 30, 400, 300, and 300 nM, respectively); reduces tumor growth and induces regression in a Calu-6 mouse xenograft model at 15 and 50 mg/kg per day, respectively
29827	AZD 0364	10 mg	≥98%	An inhibitor of ERK2 (IC50 = 50s = 30, 400, 300, and 300 nM, respectively); reduces tumor growth and induces regression in a Calu-6 mouse xenograft model at 15 and 50 mg/kg per day, respectively
29827	AZD 0364	5 mg	≥98%	An inhibitor of ERK2 (IC50 = 50s = 30, 400, 300, and 300 nM, respectively); reduces tumor growth and induces regression in a Calu-6 mouse xenograft model at 15 and 50 mg/kg per day, respectively
29832	Lenvatinib (mesylate)	1 g	≥98%	An inhibitor of VEGFR2 and VEGFR3 (IC50s = 4 and 5.2 nM, respectively); also inhibits VEGFR1, FGFR1, PDGFRα, PDGFRβ and KIT (IC50s = 22, 46, 51, 39, and 100 nM, respectively); reduces tumor growth in an H146 small cell lung cancer mouse xenograft model at 30 mg/kg, twice per day, and induces tumor regression at 100 mg/kg, twice per day
29832	Lenvatinib (mesylate)	5 g	≥98%	An inhibitor of VEGFR2 and VEGFR3 (IC50s = 4 and 5.2 nM, respectively); also inhibits VEGFR1, FGFR1, PDGFRα, PDGFRβ and KIT (IC50s = 22, 46, 51, 39, and 100 nM, respectively); reduces tumor growth in an H146 small cell lung cancer mouse xenograft model at 30 mg/kg, twice per day, and induces tumor regression at 100 mg/kg, twice per day

29832	Lenvatinib (mesylate)	500 mg	≥98%	An inhibitor of VEGFR2 and VEGFR3 (IC50s = 4 and 5.2 nM, respectively); also inhibits VEGFR1, FGFR1, PDGFRα, PDGFRβ and KIT (IC50s = 22, 46, 51, 39, and 100 nM, respectively); reduces tumor growth in an H146 small cell lung cancer mouse xenograft model at 30 mg/kg, twice per day, and induces tumor regression at 100 mg/kg, twice per day
29840	(5E)-7-Oxozeaenol	1 mg	≥95%	A resoryclic acid lactone; inhibits TAK-1 (IC50 = 1.3 µM); inhibits proliferation of MCF-7, H460, SF-268, HT-29, and MDA-MB-435 human cancer cells (IC50s = 4.9, 1.2, 5.6, 4.4, and 5.5 µM, respectively)
29840	(5E)-7-Oxozeaenol	5 mg	≥95%	A resoryclic acid lactone; inhibits TAK-1 (IC50 = 1.3 µM); inhibits proliferation of MCF-7, H460, SF-268, HT-29, and MDA-MB-435 human cancer cells (IC50s = 4.9, 1.2, 5.6, 4.4, and 5.5 µM, respectively)
29977	WYE-687	1 mg	≥98%	An mTOR inhibitor (IC50 = 0.007 µM); selective for mTOR over PI3Kα and PI3Kγ (IC50s = 0.81 and 3.11 µM, respectively), as well as a panel of 24 additional kinases (IC50s = >50 µM for all); decreases phosphorylation of the mTORC1 and mTORC2 substrates Akt and S6K1, respectively, in a cell-free assay at 0.2, 1, and 5 µM; decreases proliferation of nine cancer cell lines (IC50s = 0.18-1.25 µM); inhibits survival of HL-60 and U937 leukemia cells; reduces tumor growth in a U937 mouse xenograft model at 5 and 25 mg/kg
29977	WYE-687	10 mg	≥98%	An mTOR inhibitor (IC50 = 0.007 µM); selective for mTOR over PI3Kα and PI3Kγ (IC50s = 0.81 and 3.11 µM, respectively), as well as a panel of 24 additional kinases (IC50s = >50 µM for all); decreases phosphorylation of the mTORC1 and mTORC2 substrates Akt and S6K1, respectively, in a cell-free assay at 0.2, 1, and 5 µM; decreases proliferation of nine cancer cell lines (IC50s = 0.18-1.25 µM); inhibits survival of HL-60 and U937 leukemia cells; reduces tumor growth in a U937 mouse xenograft model at 5 and 25 mg/kg
29977	WYE-687	25 mg	≥98%	An mTOR inhibitor (IC50 = 0.007 µM); selective for mTOR over PI3Kα and PI3Kγ (IC50s = 0.81 and 3.11 µM, respectively), as well as a panel of 24 additional kinases (IC50s = >50 µM for all); decreases phosphorylation of the mTORC1 and mTORC2 substrates Akt and S6K1, respectively, in a cell-free assay at 0.2, 1, and 5 µM; decreases proliferation of nine cancer cell lines (IC50s = 0.18-1.25 µM); inhibits survival of HL-60 and U937 leukemia cells; reduces tumor growth in a U937 mouse xenograft model at 5 and 25 mg/kg
29977	WYE-687	5 mg	≥98%	An mTOR inhibitor (IC50 = 0.007 µM); selective for mTOR over PI3Kα and PI3Kγ (IC50s = 0.81 and 3.11 µM, respectively), as well as a panel of 24 additional kinases (IC50s = >50 µM for all); decreases phosphorylation of the mTORC1 and mTORC2 substrates Akt and S6K1, respectively, in a cell-free assay at 0.2, 1, and 5 µM; decreases proliferation of nine cancer cell lines (IC50s = 0.18-1.25 µM); inhibits survival of HL-60 and U937 leukemia cells; reduces tumor growth in a U937 mouse xenograft model at 5 and 25 mg/kg
29985	(S)-CR8	1 mg	≥98%	An inhibitor of cyclin-dependent kinases (IC50s = 0.15, 0.08, 0.06, 0.12, and 0.11 µM for Cdk1/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p25, and Cdk9/cyclin T, respectively); inhibits CK1δ/ε and DYRK1A (IC50s = 0.61 and 0.9 µM, respectively); reduces cell viability in human neuroblastoma cell lines, including SH-SY5Y, SK-N-AS, SK-N-BE, and IMR32 cells (IC50s = 0.43, 1.46, 0.13, and 0.14 µM, respectively)
29985	(S)-CR8	10 mg	≥98%	An inhibitor of cyclin-dependent kinases (IC50s = 0.15, 0.08, 0.06, 0.12, and 0.11 µM for Cdk1/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p25, and Cdk9/cyclin T, respectively); inhibits CK1δ/ε and DYRK1A (IC50s = 0.61 and 0.9 µM, respectively); reduces cell viability in human neuroblastoma cell lines, including SH-SY5Y, SK-N-AS, SK-N-BE, and IMR32 cells (IC50s = 0.43, 1.46, 0.13, and 0.14 µM, respectively)
29985	(S)-CR8	25 mg	≥98%	An inhibitor of cyclin-dependent kinases (IC50s = 0.15, 0.08, 0.06, 0.12, and 0.11 µM for Cdk1/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p25, and Cdk9/cyclin T, respectively); inhibits CK1δ/ε and DYRK1A (IC50s = 0.61 and 0.9 µM, respectively); reduces cell viability in human neuroblastoma cell lines, including SH-SY5Y, SK-N-AS, SK-N-BE, and IMR32 cells (IC50s = 0.43, 1.46, 0.13, and 0.14 µM, respectively)
29985	(S)-CR8	5 mg	≥98%	An inhibitor of cyclin-dependent kinases (IC50s = 0.15, 0.08, 0.06, 0.12, and 0.11 µM for Cdk1/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p25, and Cdk9/cyclin T, respectively); inhibits CK1δ/ε and DYRK1A (IC50s = 0.61 and 0.9 µM, respectively); reduces cell viability in human neuroblastoma cell lines, including SH-SY5Y, SK-N-AS, SK-N-BE, and IMR32 cells (IC50s = 0.43, 1.46, 0.13, and 0.14 µM, respectively)
29987	1,2,3,4-Tetrahydrosta	1 mg	≥95%	A mutant EGFR inhibitor (IC50 = 74 nM for EGFRT790M); selective for EGFRT790M over wild-type EGFR (IC50 = 390 nM); binds to JAK3
30058	CAY10749	1 mg	≥98%	A dual inhibitor of PARP and PI3K (IC50s = 6.03, 3.63, 5.62, and 7.41 nM for PARP1, PARP2, PI3Kα, and PI3Kδ, respectively); selective for these enzymes over PI3Kβ and PI3Kγ (IC50s = 288.4 and 831.76 nM, respectively) and a panel of 374 additional kinases at 1 µM; induces dsDNA break formation in a neutral comet assay and apoptosis in MDA-MB-468 breast cancer cells at 1 µM; inhibits proliferation of eight cancer cell lines (IC50s = 398.11-2,818.38 nM); reduces tumor growth by 73.4% in an MDA-MB-468 mouse xenograft model at 50 mg/kg twice per day

30058	CAY10749	10 mg	≥98%	A dual inhibitor of PARP and PI3K (IC50s = 6.03, 3.63, 5.62, and 7.41 nM for PARP1, PARP2, PI3Kα, and PI3Kδ, respectively); selective for these enzymes over PI3Kβ and PI3Kγ (IC50s = 288.4 and 831.76 nM, respectively) and a panel of 374 additional kinases at 1 µM; induces dsDNA break formation in a neutral comet assay and apoptosis in MDA-MB-468 breast cancer cells at 1 µM; inhibits proliferation of eight cancer cell lines (IC50s = 398.11-2,818.38 nM); reduces tumor growth by 73.4% in an MDA-MB-468 mouse xenograft model at 50 mg/kg twice per day
30058	CAY10749	5 mg	≥98%	A dual inhibitor of PARP and PI3K (IC50s = 6.03, 3.63, 5.62, and 7.41 nM for PARP1, PARP2, PI3Kα, and PI3Kδ, respectively); selective for these enzymes over PI3Kβ and PI3Kγ (IC50s = 288.4 and 831.76 nM, respectively) and a panel of 374 additional kinases at 1 µM; induces dsDNA break formation in a neutral comet assay and apoptosis in MDA-MB-468 breast cancer cells at 1 µM; inhibits proliferation of eight cancer cell lines (IC50s = 398.11-2,818.38 nM); reduces tumor growth by 73.4% in an MDA-MB-468 mouse xenograft model at 50 mg/kg twice per day
30062	WZ8040	10 mg	≥98%	An inhibitor of mutant EGFR (IC50s = 2-306 in Ba/F3 cells); selective for EGFR mutants, including the EGFRDel E746_A750 and EGFRL858R mutations conferring gefitinib sensitivity and the EGFRDel E746_A750/T790M mutation conferring gefitinib resistance (IC50s = 2, 6, and 6 nM in Ba/F3 cells), over wild-type EGFR (IC50 = 1,820 nM in HN11 cells); inhibits ERBB2Ins G776V,C and wild-type ERBB2 (IC50s = 20 and 32 nM, respectively, in Ba/F3 cells); inhibits proliferation of PC-9 cells harboring the EGFRDel E746_A750 mutation and gefitinib-resistant PC-9 GR cells harboring the EGFRT790M resistant allele (EC50s = 6 and 8 nM, respectively)
30062	WZ8040	25 mg	≥98%	An inhibitor of mutant EGFR (IC50s = 2-306 in Ba/F3 cells); selective for EGFR mutants, including the EGFRDel E746_A750 and EGFRL858R mutations conferring gefitinib sensitivity and the EGFRDel E746_A750/T790M mutation conferring gefitinib resistance (IC50s = 2, 6, and 6 nM in Ba/F3 cells), over wild-type EGFR (IC50 = 1,820 nM in HN11 cells); inhibits ERBB2Ins G776V,C and wild-type ERBB2 (IC50s = 20 and 32 nM, respectively, in Ba/F3 cells); inhibits proliferation of PC-9 cells harboring the EGFRDel E746_A750 mutation and gefitinib-resistant PC-9 GR cells harboring the EGFRT790M resistant allele (EC50s = 6 and 8 nM, respectively)
30062	WZ8040	5 mg	≥98%	An inhibitor of mutant EGFR (IC50s = 2-306 in Ba/F3 cells); selective for EGFR mutants, including the EGFRDel E746_A750 and EGFRL858R mutations conferring gefitinib sensitivity and the EGFRDel E746_A750/T790M mutation conferring gefitinib resistance (IC50s = 2, 6, and 6 nM in Ba/F3 cells), over wild-type EGFR (IC50 = 1,820 nM in HN11 cells); inhibits ERBB2Ins G776V,C and wild-type ERBB2 (IC50s = 20 and 32 nM, respectively, in Ba/F3 cells); inhibits proliferation of PC-9 cells harboring the EGFRDel E746_A750 mutation and gefitinib-resistant PC-9 GR cells harboring the EGFRT790M resistant allele (EC50s = 6 and 8 nM, respectively)
30062	WZ8040	50 mg	≥98%	An inhibitor of mutant EGFR (IC50s = 2-306 in Ba/F3 cells); selective for EGFR mutants, including the EGFRDel E746_A750 and EGFRL858R mutations conferring gefitinib sensitivity and the EGFRDel E746_A750/T790M mutation conferring gefitinib resistance (IC50s = 2, 6, and 6 nM in Ba/F3 cells), over wild-type EGFR (IC50 = 1,820 nM in HN11 cells); inhibits ERBB2Ins G776V,C and wild-type ERBB2 (IC50s = 20 and 32 nM, respectively, in Ba/F3 cells); inhibits proliferation of PC-9 cells harboring the EGFRDel E746_A750 mutation and gefitinib-resistant PC-9 GR cells harboring the EGFRT790M resistant allele (EC50s = 6 and 8 nM, respectively)
30063	TCS 21311	1 mg	≥95%	A JAK3 inhibitor (IC50 = 8 nM); selective for JAK3 over JAK1, JAK2, and TYK2 (IC50s = 1,017, 2,550, and 8,055 nM, respectively) but does inhibit GSK-3β, PKCα, and PKCθ (IC50s = 13, 68, and 3 nM, respectively); inhibits cytokine-induced STAT5 phosphorylation in CTLL and M-07 cells (IC50s = 1,294 and 525 nM, respectively) and TCR/CD28-mediated T cell activation in Jurkat cells (IC50 = 689 nM); increases proliferation of mouse embryonic NPCs and human iPSC-derived NPCs in the absence of BMP7 at 0.3 µM
30063	TCS 21311	10 mg	≥95%	A JAK3 inhibitor (IC50 = 8 nM); selective for JAK3 over JAK1, JAK2, and TYK2 (IC50s = 1,017, 2,550, and 8,055 nM, respectively) but does inhibit GSK-3β, PKCα, and PKCθ (IC50s = 13, 68, and 3 nM, respectively); inhibits cytokine-induced STAT5 phosphorylation in CTLL and M-07 cells (IC50s = 1,294 and 525 nM, respectively) and TCR/CD28-mediated T cell activation in Jurkat cells (IC50 = 689 nM); increases proliferation of mouse embryonic NPCs and human iPSC-derived NPCs in the absence of BMP7 at 0.3 µM
30063	TCS 21311	25 mg	≥95%	A JAK3 inhibitor (IC50 = 8 nM); selective for JAK3 over JAK1, JAK2, and TYK2 (IC50s = 1,017, 2,550, and 8,055 nM, respectively) but does inhibit GSK-3β, PKCα, and PKCθ (IC50s = 13, 68, and 3 nM, respectively); inhibits cytokine-induced STAT5 phosphorylation in CTLL and M-07 cells (IC50s = 1,294 and 525 nM, respectively) and TCR/CD28-mediated T cell activation in Jurkat cells (IC50 = 689 nM); increases proliferation of mouse embryonic NPCs and human iPSC-derived NPCs in the absence of BMP7 at 0.3 µM

30063	TCS 21311	5 mg	≥95%	A JAK3 inhibitor (IC50 = 8 nM); selective for JAK3 over JAK1, JAK2, and TYK2 (IC50s = 1,017, 2,550, and 8,055 nM, respectively) but does inhibit GSK-3β, PKCα, and PKCθ (IC50s = 13, 68, and 3 nM, respectively); inhibits cytokine-induced STAT5 phosphorylation in CTLL and M-07 cells (IC50s = 1,294 and 525 nM, respectively) and TCR/CD28-mediated T cell activation in Jurkat cells (IC50 = 689 nM); increases proliferation of mouse embryonic NPCs and human iPSC-derived NPCs in the absence of BMP7 at 0.3 µM
30069	ACTB-1003	1 mg	≥98%	A multi-kinase inhibitor (IC50s = 6, 2, 4, 5, and 32 nM for FGFR1, VEGFR2, Tie-2, RSK, and p70S6K, respectively); inhibits growth of OPM2 human multiple myeloma and murine Ba/F3-TEL-FGFR1 leukemia cells in vitro; inhibits tumor angiogenesis in an H460 mouse xenograft model; reduces tumor growth in an HCT116 mouse xenograft model when administered in combination with 5-FU or paclitaxel
30069	ACTB-1003	10 mg	≥98%	A multi-kinase inhibitor (IC50s = 6, 2, 4, 5, and 32 nM for FGFR1, VEGFR2, Tie-2, RSK, and p70S6K, respectively); inhibits growth of OPM2 human multiple myeloma and murine Ba/F3-TEL-FGFR1 leukemia cells in vitro; inhibits tumor angiogenesis in an H460 mouse xenograft model; reduces tumor growth in an HCT116 mouse xenograft model when administered in combination with 5-FU or paclitaxel
30069	ACTB-1003	5 mg	≥98%	A multi-kinase inhibitor (IC50s = 6, 2, 4, 5, and 32 nM for FGFR1, VEGFR2, Tie-2, RSK, and p70S6K, respectively); inhibits growth of OPM2 human multiple myeloma and murine Ba/F3-TEL-FGFR1 leukemia cells in vitro; inhibits tumor angiogenesis in an H460 mouse xenograft model; reduces tumor growth in an HCT116 mouse xenograft model when administered in combination with 5-FU or paclitaxel
30070	FLT3-IN-2	1 mg	≥98%	An inhibitor of FLT3, c-Kit, and c-FMS (IC50s = <1 µM for all)
30070	FLT3-IN-2	10 mg	≥98%	An inhibitor of FLT3, c-Kit, and c-FMS (IC50s = <1 µM for all)
30070	FLT3-IN-2	25 mg	≥98%	An inhibitor of FLT3, c-Kit, and c-FMS (IC50s = <1 µM for all)
30070	FLT3-IN-2	5 mg	≥98%	An inhibitor of FLT3, c-Kit, and c-FMS (IC50s = <1 µM for all)
30093	Icotinib	1 mg	≥98%	An EGFR inhibitor (IC50 = 2 nM); selective for EGFR over Abl, Abl2, and c-Src tyrosine kinases at 1,000 nM; inhibits EGFR-mediated tyrosine phosphorylation in A431 cells (IC50 = 45 nM); inhibits the growth of PC-9 and HCC827 NSCLC cells (IC50s = 50 = 8,800 nM), which do not; inhibits migration of HCC827 cells at 100 nM and increases apoptosis by 43.7% at 10 nM; reduces tumor growth in a variety of mouse xenograft models at 50-120 mg/kg per day
30093	Icotinib	10 mg	≥98%	An EGFR inhibitor (IC50 = 2 nM); selective for EGFR over Abl, Abl2, and c-Src tyrosine kinases at 1,000 nM; inhibits EGFR-mediated tyrosine phosphorylation in A431 cells (IC50 = 45 nM); inhibits the growth of PC-9 and HCC827 NSCLC cells (IC50s = 50 = 8,800 nM), which do not; inhibits migration of HCC827 cells at 100 nM and increases apoptosis by 43.7% at 10 nM; reduces tumor growth in a variety of mouse xenograft models at 50-120 mg/kg per day
30093	Icotinib	25 mg	≥98%	An EGFR inhibitor (IC50 = 2 nM); selective for EGFR over Abl, Abl2, and c-Src tyrosine kinases at 1,000 nM; inhibits EGFR-mediated tyrosine phosphorylation in A431 cells (IC50 = 45 nM); inhibits the growth of PC-9 and HCC827 NSCLC cells (IC50s = 50 = 8,800 nM), which do not; inhibits migration of HCC827 cells at 100 nM and increases apoptosis by 43.7% at 10 nM; reduces tumor growth in a variety of mouse xenograft models at 50-120 mg/kg per day
30093	Icotinib	5 mg	≥98%	An EGFR inhibitor (IC50 = 2 nM); selective for EGFR over Abl, Abl2, and c-Src tyrosine kinases at 1,000 nM; inhibits EGFR-mediated tyrosine phosphorylation in A431 cells (IC50 = 45 nM); inhibits the growth of PC-9 and HCC827 NSCLC cells (IC50s = 50 = 8,800 nM), which do not; inhibits migration of HCC827 cells at 100 nM and increases apoptosis by 43.7% at 10 nM; reduces tumor growth in a variety of mouse xenograft models at 50-120 mg/kg per day
30195	TG100713	1 mg	≥98%	An inhibitor of PI3K; (IC50s = 50, 24, 165, and 215 nM for PI3Kγ, PI3Kδ, PI3Kα, and PI3Kβ, respectively); inhibits proliferation of HUVECs at 10 µM; inhibits reactivation of latent HIV-1 induced by panobinostat in 24ST1NLESG cells
30195	TG100713	10 mg	≥98%	An inhibitor of PI3K; (IC50s = 50, 24, 165, and 215 nM for PI3Kγ, PI3Kδ, PI3Kα, and PI3Kβ, respectively); inhibits proliferation of HUVECs at 10 µM; inhibits reactivation of latent HIV-1 induced by panobinostat in 24ST1NLESG cells
30195	TG100713	25 mg	≥98%	An inhibitor of PI3K; (IC50s = 50, 24, 165, and 215 nM for PI3Kγ, PI3Kδ, PI3Kα, and PI3Kβ, respectively); inhibits proliferation of HUVECs at 10 µM; inhibits reactivation of latent HIV-1 induced by panobinostat in 24ST1NLESG cells
30195	TG100713	5 mg	≥98%	An inhibitor of PI3K; (IC50s = 50, 24, 165, and 215 nM for PI3Kγ, PI3Kδ, PI3Kα, and PI3Kβ, respectively); inhibits proliferation of HUVECs at 10 µM; inhibits reactivation of latent HIV-1 induced by panobinostat in 24ST1NLESG cells

30264	CNX-1351	1 mg	≥98%	A PI3Kα inhibitor (IC50 = 6.8 nM); selective for PI3Kα over PI3Kβ, -γ, and -δ (IC50s = 166, 240.3, and 3,020 nM, respectively), as well as PI3KC2A, PI3KC, PI4Kα, PI4Kβ, SPHK1, and SPHK2 (IC50s = >1 µM for all); inhibits phosphorylation of Akt in SKOV3 cells at 500 nM; inhibits the growth of SKOV3 and MCF-7 cancer cells (GI50s = 77.6 and 54.7 nM, respectively); inhibits Akt phosphorylation in mouse spleen at 100 mg/kg
30264	CNX-1351	10 mg	≥98%	A PI3Kα inhibitor (IC50 = 6.8 nM); selective for PI3Kα over PI3Kβ, -γ, and -δ (IC50s = 166, 240.3, and 3,020 nM, respectively), as well as PI3KC2A, PI3KC, PI4Kα, PI4Kβ, SPHK1, and SPHK2 (IC50s = >1 µM for all); inhibits phosphorylation of Akt in SKOV3 cells at 500 nM; inhibits the growth of SKOV3 and MCF-7 cancer cells (GI50s = 77.6 and 54.7 nM, respectively); inhibits Akt phosphorylation in mouse spleen at 100 mg/kg
30264	CNX-1351	25 mg	≥98%	A PI3Kα inhibitor (IC50 = 6.8 nM); selective for PI3Kα over PI3Kβ, -γ, and -δ (IC50s = 166, 240.3, and 3,020 nM, respectively), as well as PI3KC2A, PI3KC, PI4Kα, PI4Kβ, SPHK1, and SPHK2 (IC50s = >1 µM for all); inhibits phosphorylation of Akt in SKOV3 cells at 500 nM; inhibits the growth of SKOV3 and MCF-7 cancer cells (GI50s = 77.6 and 54.7 nM, respectively); inhibits Akt phosphorylation in mouse spleen at 100 mg/kg
30264	CNX-1351	5 mg	≥98%	A PI3Kα inhibitor (IC50 = 6.8 nM); selective for PI3Kα over PI3Kβ, -γ, and -δ (IC50s = 166, 240.3, and 3,020 nM, respectively), as well as PI3KC2A, PI3KC, PI4Kα, PI4Kβ, SPHK1, and SPHK2 (IC50s = >1 µM for all); inhibits phosphorylation of Akt in SKOV3 cells at 500 nM; inhibits the growth of SKOV3 and MCF-7 cancer cells (GI50s = 77.6 and 54.7 nM, respectively); inhibits Akt phosphorylation in mouse spleen at 100 mg/kg
30265	PD 318088	1 mg	≥98%	An allosteric inhibitor of MEK1; analog of the MEK inhibitor PD 184352; binds to MEK1 concurrently with Mg-ATP and stabilizes an inactive conformation of MEK1, as well as prevents formation of tetramers and higher-order oligomers
30265	PD 318088	10 mg	≥98%	An allosteric inhibitor of MEK1; analog of the MEK inhibitor PD 184352; binds to MEK1 concurrently with Mg-ATP and stabilizes an inactive conformation of MEK1, as well as prevents formation of tetramers and higher-order oligomers
30265	PD 318088	25 mg	≥98%	An allosteric inhibitor of MEK1; analog of the MEK inhibitor PD 184352; binds to MEK1 concurrently with Mg-ATP and stabilizes an inactive conformation of MEK1, as well as prevents formation of tetramers and higher-order oligomers
30265	PD 318088	5 mg	≥98%	An allosteric inhibitor of MEK1; analog of the MEK inhibitor PD 184352; binds to MEK1 concurrently with Mg-ATP and stabilizes an inactive conformation of MEK1, as well as prevents formation of tetramers and higher-order oligomers
30323	Voxtalisib	10 mg	≥98%	A dual inhibitor of PI3K and mTORC (IC50s = 9, 110, 43, 9, 160, and 910 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, mTORC1, and mTORC2, respectively); is selective for these kinases over VPS34 (IC50 = 9,100 nM) and a panel of 130 additional protein kinases at 1.5 µM but does inhibit DNAPK (IC50 = 150 nM); decreases EGF-induced PIP3 production in PC3 prostate cancer cells (IC50 = 290 nM); reduces Akt and S6RP phosphorylation in the same model (IC50s = 250 and 120 nM, respectively); inhibits proliferation and colony formation of PC3 cells (IC50s = 1,800 and 270 nM, respectively); reduces tumor growth and increases survival in a GBM-39 mouse xenograft model at 30 mg/kg twice per day either alone or in combination with temozolomide
30323	Voxtalisib	25 mg	≥98%	A dual inhibitor of PI3K and mTORC (IC50s = 9, 110, 43, 9, 160, and 910 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, mTORC1, and mTORC2, respectively); is selective for these kinases over VPS34 (IC50 = 9,100 nM) and a panel of 130 additional protein kinases at 1.5 µM but does inhibit DNAPK (IC50 = 150 nM); decreases EGF-induced PIP3 production in PC3 prostate cancer cells (IC50 = 290 nM); reduces Akt and S6RP phosphorylation in the same model (IC50s = 250 and 120 nM, respectively); inhibits proliferation and colony formation of PC3 cells (IC50s = 1,800 and 270 nM, respectively); reduces tumor growth and increases survival in a GBM-39 mouse xenograft model at 30 mg/kg twice per day either alone or in combination with temozolomide
30323	Voxtalisib	5 mg	≥98%	A dual inhibitor of PI3K and mTORC (IC50s = 9, 110, 43, 9, 160, and 910 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, mTORC1, and mTORC2, respectively); is selective for these kinases over VPS34 (IC50 = 9,100 nM) and a panel of 130 additional protein kinases at 1.5 µM but does inhibit DNAPK (IC50 = 150 nM); decreases EGF-induced PIP3 production in PC3 prostate cancer cells (IC50 = 290 nM); reduces Akt and S6RP phosphorylation in the same model (IC50s = 250 and 120 nM, respectively); inhibits proliferation and colony formation of PC3 cells (IC50s = 1,800 and 270 nM, respectively); reduces tumor growth and increases survival in a GBM-39 mouse xenograft model at 30 mg/kg twice per day either alone or in combination with temozolomide

30323	Voxtalisib	50 mg	≥98%	A dual inhibitor of PI3K and mTORC (IC50s = 9, 110, 43, 9, 160, and 910 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ, mTORC1, and mTORC2, respectively); is selective for these kinases over VPS34 (IC50 = 9,100 nM) and a panel of 130 additional protein kinases at 1.5 µM but does inhibit DNAPK (IC50 = 150 nM); decreases EGF-induced PIP3 production in PC3 prostate cancer cells (IC50 = 290 nM); reduces Akt and S6RP phosphorylation in the same model (IC50s = 250 and 120 nM, respectively); inhibits proliferation and colony formation of PC3 cells (IC50s = 1,800 and 270 nM, respectively); reduces tumor growth and increases survival in a GBM-39 mouse xenograft model at 30 mg/kg twice per day either alone or in combination with temozolomide
30324	VS-5584 analog	1 mg	≥98%	A dual inhibitor of PI3Kα and mTOR (IC50s = 17 and 150 nM, respectively); a desmethyl analog of VS-5584
30324	VS-5584 analog	10 mg	≥98%	A dual inhibitor of PI3Kα and mTOR (IC50s = 17 and 150 nM, respectively); a desmethyl analog of VS-5584
30324	VS-5584 analog	25 mg	≥98%	A dual inhibitor of PI3Kα and mTOR (IC50s = 17 and 150 nM, respectively); a desmethyl analog of VS-5584
30324	VS-5584 analog	5 mg	≥98%	A dual inhibitor of PI3Kα and mTOR (IC50s = 17 and 150 nM, respectively); a desmethyl analog of VS-5584
30382	CAY10756	1 mg	≥98%	An inhibitor of ASK1 (IC50 = 21 nM); inhibits autophosphorylation of ASK1 in HEK293T cells (IC50 = 138 M)
30382	CAY10756	5 mg	≥98%	An inhibitor of ASK1 (IC50 = 21 nM); inhibits autophosphorylation of ASK1 in HEK293T cells (IC50 = 138 M)
30382	CAY10756	500 µg	≥98%	An inhibitor of ASK1 (IC50 = 21 nM); inhibits autophosphorylation of ASK1 in HEK293T cells (IC50 = 138 M)
30434	SLM6031434 (hydroch	10 mg	≥98%	An SPHK2 inhibitor (Ki = 0.4 µM for the recombinant mouse enzyme); selective for SPHK2 over SPHK1 (Kis = >20 µM); decreases S1P and increases sphingosine levels in U937 monocytic leukemia cells in a concentration-dependent manner; reduces blood S1P levels in Sphk1-/-, but not Sphk2-/-, mice at 5 mg/kg; increases blood S1P levels in wild-type mice and rats
30434	SLM6031434 (hydroch	25 mg	≥98%	An SPHK2 inhibitor (Ki = 0.4 µM for the recombinant mouse enzyme); selective for SPHK2 over SPHK1 (Kis = >20 µM); decreases S1P and increases sphingosine levels in U937 monocytic leukemia cells in a concentration-dependent manner; reduces blood S1P levels in Sphk1-/-, but not Sphk2-/-, mice at 5 mg/kg; increases blood S1P levels in wild-type mice and rats
30434	SLM6031434 (hydroch	5 mg	≥98%	An SPHK2 inhibitor (Ki = 0.4 µM for the recombinant mouse enzyme); selective for SPHK2 over SPHK1 (Kis = >20 µM); decreases S1P and increases sphingosine levels in U937 monocytic leukemia cells in a concentration-dependent manner; reduces blood S1P levels in Sphk1-/-, but not Sphk2-/-, mice at 5 mg/kg; increases blood S1P levels in wild-type mice and rats
30434	SLM6031434 (hydroch	50 mg	≥98%	An SPHK2 inhibitor (Ki = 0.4 µM for the recombinant mouse enzyme); selective for SPHK2 over SPHK1 (Kis = >20 µM); decreases S1P and increases sphingosine levels in U937 monocytic leukemia cells in a concentration-dependent manner; reduces blood S1P levels in Sphk1-/-, but not Sphk2-/-, mice at 5 mg/kg; increases blood S1P levels in wild-type mice and rats
30436	Halicin	10 mg	≥98%	A JNK1 inhibitor (IC50 = 0.7 µM) with antidiabetic and antibiotic activity; selective for JNK1 over p38α, Furin, and lethal factor (IC50s = >100, >100, and >50 µM, respectively), as well as Akt at 100 µM; inhibits TNF-α-induced phosphorylation of c-Jun in a cell-based assay (EC50 = 6.23 µM); reduces blood glucose levels and restores insulin sensitivity in insulin insensitive mice at 25 mg/kg; active against carbapenem-resistant Enterobacteriaceae (MICs = 1-10 µg/ml), as well as multidrug-resistant A. baumannii and P. aeruginosa (MICs = 1-10 and 1-100 µg/ml, respectively); reduces the number of wound tissue CFUs in a mouse model of A. baumannii wound infection; reduces fecal bacterial load in a mouse model of C. difficile infection at 15 mg/kg
30436	Halicin	25 mg	≥98%	A JNK1 inhibitor (IC50 = 0.7 µM) with antidiabetic and antibiotic activity; selective for JNK1 over p38α, Furin, and lethal factor (IC50s = >100, >100, and >50 µM, respectively), as well as Akt at 100 µM; inhibits TNF-α-induced phosphorylation of c-Jun in a cell-based assay (EC50 = 6.23 µM); reduces blood glucose levels and restores insulin sensitivity in insulin insensitive mice at 25 mg/kg; active against carbapenem-resistant Enterobacteriaceae (MICs = 1-10 µg/ml), as well as multidrug-resistant A. baumannii and P. aeruginosa (MICs = 1-10 and 1-100 µg/ml, respectively); reduces the number of wound tissue CFUs in a mouse model of A. baumannii wound infection; reduces fecal bacterial load in a mouse model of C. difficile infection at 15 mg/kg
30436	Halicin	5 mg	≥98%	A JNK1 inhibitor (IC50 = 0.7 µM) with antidiabetic and antibiotic activity; selective for JNK1 over p38α, Furin, and lethal factor (IC50s = >100, >100, and >50 µM, respectively), as well as Akt at 100 µM; inhibits TNF-α-induced phosphorylation of c-Jun in a cell-based assay (EC50 = 6.23 µM); reduces blood glucose levels and restores insulin sensitivity in insulin insensitive mice at 25 mg/kg; active against carbapenem-resistant Enterobacteriaceae (MICs = 1-10 µg/ml), as well as multidrug-resistant A. baumannii and P. aeruginosa (MICs = 1-10 and 1-100 µg/ml, respectively); reduces the number of wound tissue CFUs in a mouse model of A. baumannii wound infection; reduces fecal bacterial load in a mouse model of C. difficile infection at 15 mg/kg

30436	Halicin	50 mg	≥98%	A JNK1 inhibitor (IC50 = 0.7 μM) with antidiabetic and antibiotic activity; selective for JNK1 over p38α, Furin, and lethal factor (IC50s = >100, >100, and >50 μM, respectively), as well as Akt at 100 μM; inhibits TNF-α-induced phosphorylation of c-Jun in a cell-based assay (EC50 = 6.23 μM); reduces blood glucose levels and restores insulin sensitivity in insulin insensitive mice at 25 mg/kg; active against carbapenem-resistant Enterobacteriaceae (MICs = 1-10 μg/ml), as well as multidrug-resistant A. baumannii and P. aeruginosa (MICs = 1-10 and 1-100 μg/ml, respectively); reduces the number of wound tissue CFUs in a mouse model of A. baumannii wound infection; reduces fecal bacterial load in a mouse model of C. difficile infection at 15 mg/kg
30602	ADTL-EI1712	1 mg	≥98%	A dual ERK1 and ERK5 inhibitor (IC50s = 40.43 and 64.5 nM, respectively); reduces ERK1 and ERK5 activity by 93.5% and 89.4%, respectively, but also inhibits ERK2 activity by 92.7%, in a panel of 100 kinases at 1 μM; inhibits proliferation of HL-60 and MKN74 cancer cells (IC50s = 1.26 and 2.55 μM, respectively); reduces tumor growth and intratumor phosphorylation of ERK1/2 and ERK5 in an MKN74 mouse xenograft model at 50 mg/kg per day
30602	ADTL-EI1712	10 mg	≥98%	A dual ERK1 and ERK5 inhibitor (IC50s = 40.43 and 64.5 nM, respectively); reduces ERK1 and ERK5 activity by 93.5% and 89.4%, respectively, but also inhibits ERK2 activity by 92.7%, in a panel of 100 kinases at 1 μM; inhibits proliferation of HL-60 and MKN74 cancer cells (IC50s = 1.26 and 2.55 μM, respectively); reduces tumor growth and intratumor phosphorylation of ERK1/2 and ERK5 in an MKN74 mouse xenograft model at 50 mg/kg per day
30602	ADTL-EI1712	25 mg	≥98%	A dual ERK1 and ERK5 inhibitor (IC50s = 40.43 and 64.5 nM, respectively); reduces ERK1 and ERK5 activity by 93.5% and 89.4%, respectively, but also inhibits ERK2 activity by 92.7%, in a panel of 100 kinases at 1 μM; inhibits proliferation of HL-60 and MKN74 cancer cells (IC50s = 1.26 and 2.55 μM, respectively); reduces tumor growth and intratumor phosphorylation of ERK1/2 and ERK5 in an MKN74 mouse xenograft model at 50 mg/kg per day
30602	ADTL-EI1712	5 mg	≥98%	A dual ERK1 and ERK5 inhibitor (IC50s = 40.43 and 64.5 nM, respectively); reduces ERK1 and ERK5 activity by 93.5% and 89.4%, respectively, but also inhibits ERK2 activity by 92.7%, in a panel of 100 kinases at 1 μM; inhibits proliferation of HL-60 and MKN74 cancer cells (IC50s = 1.26 and 2.55 μM, respectively); reduces tumor growth and intratumor phosphorylation of ERK1/2 and ERK5 in an MKN74 mouse xenograft model at 50 mg/kg per day
30610	CNX-2006	1 mg	≥98%	An irreversible inhibitor of mutant EGFRs; inhibits EGFR phosphorylation in PC-9 and HCC827 cells (IC50s = 55-104 nM), which express the EGFRDel E746_A750 mutation, and NCI H1975 and PC-9/GR4 cells (IC50s = 46 and 61 nM, respectively), which express the EGFRL858R/T790M and EGFRDel E746_A750/T790M mutations, respectively; >10-fold selective for cells expressing these mutants over A549 cells expressing wild-type EGFR; inhibits growth in a panel of NSCLC cells expressing wild-type or mutant EGFRs (GI50s = 0.34-8 and 0.003-3.6 μM, respectively); reduces tumor growth in an NCI H1975 mouse xenograft model at 25 and 50 mg/kg
30610	CNX-2006	10 mg	≥98%	An irreversible inhibitor of mutant EGFRs; inhibits EGFR phosphorylation in PC-9 and HCC827 cells (IC50s = 55-104 nM), which express the EGFRDel E746_A750 mutation, and NCI H1975 and PC-9/GR4 cells (IC50s = 46 and 61 nM, respectively), which express the EGFRL858R/T790M and EGFRDel E746_A750/T790M mutations, respectively; >10-fold selective for cells expressing these mutants over A549 cells expressing wild-type EGFR; inhibits growth in a panel of NSCLC cells expressing wild-type or mutant EGFRs (GI50s = 0.34-8 and 0.003-3.6 μM, respectively); reduces tumor growth in an NCI H1975 mouse xenograft model at 25 and 50 mg/kg
30610	CNX-2006	25 mg	≥98%	An irreversible inhibitor of mutant EGFRs; inhibits EGFR phosphorylation in PC-9 and HCC827 cells (IC50s = 55-104 nM), which express the EGFRDel E746_A750 mutation, and NCI H1975 and PC-9/GR4 cells (IC50s = 46 and 61 nM, respectively), which express the EGFRL858R/T790M and EGFRDel E746_A750/T790M mutations, respectively; >10-fold selective for cells expressing these mutants over A549 cells expressing wild-type EGFR; inhibits growth in a panel of NSCLC cells expressing wild-type or mutant EGFRs (GI50s = 0.34-8 and 0.003-3.6 μM, respectively); reduces tumor growth in an NCI H1975 mouse xenograft model at 25 and 50 mg/kg
30610	CNX-2006	5 mg	≥98%	An irreversible inhibitor of mutant EGFRs; inhibits EGFR phosphorylation in PC-9 and HCC827 cells (IC50s = 55-104 nM), which express the EGFRDel E746_A750 mutation, and NCI H1975 and PC-9/GR4 cells (IC50s = 46 and 61 nM, respectively), which express the EGFRL858R/T790M and EGFRDel E746_A750/T790M mutations, respectively; >10-fold selective for cells expressing these mutants over A549 cells expressing wild-type EGFR; inhibits growth in a panel of NSCLC cells expressing wild-type or mutant EGFRs (GI50s = 0.34-8 and 0.003-3.6 μM, respectively); reduces tumor growth in an NCI H1975 mouse xenograft model at 25 and 50 mg/kg

30618	PD 173955	1 mg	≥98%	A tyrosine kinase inhibitor; inhibits c-Src, Yes, and LCK (IC50s = 25, 22, and 5 nM, respectively), as well as Bcr-Abl and c-Kit (IC50s = 1-2 and 25 nM, respectively), and is selective for these kinases over InsR, α-FGFR, bFGFR, PDGFR, and PKC; induces cell cycle arrest at the G2/M phase in DU145 prostate, SKOV3 ovarian, HT-29 colon, A549 lung, and A431 skin cancer cell at 5,000 nM; inhibits proliferation of MDA-MB-468 and MCF-7 breast cancer cells (IC50s = 500 and 1,000 nM, respectively), as well as patient-derived peripheral blood CML progenitor cells (IC50= ~7.5 nM)
30618	PD 173955	10 mg	≥98%	A tyrosine kinase inhibitor; inhibits c-Src, Yes, and LCK (IC50s = 25, 22, and 5 nM, respectively), as well as Bcr-Abl and c-Kit (IC50s = 1-2 and 25 nM, respectively), and is selective for these kinases over InsR, α-FGFR, bFGFR, PDGFR, and PKC; induces cell cycle arrest at the G2/M phase in DU145 prostate, SKOV3 ovarian, HT-29 colon, A549 lung, and A431 skin cancer cell at 5,000 nM; inhibits proliferation of MDA-MB-468 and MCF-7 breast cancer cells (IC50s = 500 and 1,000 nM, respectively), as well as patient-derived peripheral blood CML progenitor cells (IC50= ~7.5 nM)
30618	PD 173955	25 mg	≥98%	A tyrosine kinase inhibitor; inhibits c-Src, Yes, and LCK (IC50s = 25, 22, and 5 nM, respectively), as well as Bcr-Abl and c-Kit (IC50s = 1-2 and 25 nM, respectively), and is selective for these kinases over InsR, α-FGFR, bFGFR, PDGFR, and PKC; induces cell cycle arrest at the G2/M phase in DU145 prostate, SKOV3 ovarian, HT-29 colon, A549 lung, and A431 skin cancer cell at 5,000 nM; inhibits proliferation of MDA-MB-468 and MCF-7 breast cancer cells (IC50s = 500 and 1,000 nM, respectively), as well as patient-derived peripheral blood CML progenitor cells (IC50= ~7.5 nM)
30618	PD 173955	5 mg	≥98%	A tyrosine kinase inhibitor; inhibits c-Src, Yes, and LCK (IC50s = 25, 22, and 5 nM, respectively), as well as Bcr-Abl and c-Kit (IC50s = 1-2 and 25 nM, respectively), and is selective for these kinases over InsR, α-FGFR, bFGFR, PDGFR, and PKC; induces cell cycle arrest at the G2/M phase in DU145 prostate, SKOV3 ovarian, HT-29 colon, A549 lung, and A431 skin cancer cell at 5,000 nM; inhibits proliferation of MDA-MB-468 and MCF-7 breast cancer cells (IC50s = 500 and 1,000 nM, respectively), as well as patient-derived peripheral blood CML progenitor cells (IC50= ~7.5 nM)
30619	PD 180970	1 mg	≥98%	A Bcr-Abl inhibitor; inhibits wild-type and mutant forms of Bcr-Abl, as well as the p210 isoform (IC50s = 5-48 nM); selective for Bcr-Abl over bFGFR and PDGFR (IC50s = 934 and 1,430 nM, respectively) but also inhibits Src, LCK, KIT, and EGFR (IC50s = 0.8, 1 phase and apoptosis in K562 cells at 50 nM; inhibits constitutive STAT3 DNA-binding activity in and proliferation of MDA-MB-468 breast cancer cells; inhibits proliferation of imatinib-resistant mutant p210 Bcr-AblY253F Ba/F3 cells
30619	PD 180970	10 mg	≥98%	A Bcr-Abl inhibitor; inhibits wild-type and mutant forms of Bcr-Abl, as well as the p210 isoform (IC50s = 5-48 nM); selective for Bcr-Abl over bFGFR and PDGFR (IC50s = 934 and 1,430 nM, respectively) but also inhibits Src, LCK, KIT, and EGFR (IC50s = 0.8, 1 phase and apoptosis in K562 cells at 50 nM; inhibits constitutive STAT3 DNA-binding activity in and proliferation of MDA-MB-468 breast cancer cells; inhibits proliferation of imatinib-resistant mutant p210 Bcr-AblY253F Ba/F3 cells
30619	PD 180970	5 mg	≥98%	A Bcr-Abl inhibitor; inhibits wild-type and mutant forms of Bcr-Abl, as well as the p210 isoform (IC50s = 5-48 nM); selective for Bcr-Abl over bFGFR and PDGFR (IC50s = 934 and 1,430 nM, respectively) but also inhibits Src, LCK, KIT, and EGFR (IC50s = 0.8, 1 phase and apoptosis in K562 cells at 50 nM; inhibits constitutive STAT3 DNA-binding activity in and proliferation of MDA-MB-468 breast cancer cells; inhibits proliferation of imatinib-resistant mutant p210 Bcr-AblY253F Ba/F3 cells
30686	SD-06	10 mg	≥98%	An inhibitor of p38α MAPK (IC50 = 0.016 µM); selective for p38α over p38β, p38γ, and p38δ MAPKs (IC50s = 0.677, >100, and >100 µM, respectively), as well as a panel of 54 additional kinases (IC50s = >3 µM for all); inhibits LPS-induced TNF-α, IL-6, and IL-1β release from primary human monocytes (IC50s = 79.4, 106.9, and 105.9 nM, respectively); decreases IL-1β-induced production of PGE2 in patient-derived RASFs (IC50 = 96.2 nM); reduces carrageenan-induced paw swelling and hyperalgesia in rats at 30 mg/kg; reduces the incidence of arthritis in a mouse model of collagen-induced arthritis; protects against joint and bone destruction in a rat model of streptococcal cell wall-induced arthritis
30686	SD-06	25 mg	≥98%	An inhibitor of p38α MAPK (IC50 = 0.016 µM); selective for p38α over p38β, p38γ, and p38δ MAPKs (IC50s = 0.677, >100, and >100 µM, respectively), as well as a panel of 54 additional kinases (IC50s = >3 µM for all); inhibits LPS-induced TNF-α, IL-6, and IL-1β release from primary human monocytes (IC50s = 79.4, 106.9, and 105.9 nM, respectively); decreases IL-1β-induced production of PGE2 in patient-derived RASFs (IC50 = 96.2 nM); reduces carrageenan-induced paw swelling and hyperalgesia in rats at 30 mg/kg; reduces the incidence of arthritis in a mouse model of collagen-induced arthritis; protects against joint and bone destruction in a rat model of streptococcal cell wall-induced arthritis
30686	SD-06	5 mg	≥98%	An inhibitor of p38α MAPK (IC50 = 0.016 µM); selective for p38α over p38β, p38γ, and p38δ MAPKs (IC50s = 0.677, >100, and >100 µM, respectively), as well as a panel of 54 additional kinases (IC50s = >3 µM for all); inhibits LPS-induced TNF-α, IL-6, and IL-1β release from primary human monocytes (IC50s = 79.4, 106.9, and 105.9 nM, respectively); decreases IL-1β-induced production of PGE2 in patient-derived RASFs (IC50 = 96.2 nM); reduces carrageenan-induced paw swelling and hyperalgesia in rats at 30 mg/kg; reduces the incidence of arthritis in a mouse model of collagen-induced arthritis; protects against joint and bone destruction in a rat model of streptococcal cell wall-induced arthritis

30686	SD-06	50 mg	≥98%	An inhibitor of p38α MAPK (IC50 = 0.016 µM); selective for p38α over p38β, p38γ, and p38δ MAPKs (IC50s = 0.677, >100, and >100 µM, respectively), as well as a panel of 54 additional kinases (IC50s = >3 µM for all); inhibits LPS-induced TNF-α, IL-6, and IL-1β release from primary human monocytes (IC50s = 79.4, 106.9, and 105.9 nM, respectively); decreases IL-1β-induced production of PGE2 in patient-derived RASFs (IC50 = 96.2 nM); reduces carrageenan-induced paw swelling and hyperalgesia in rats at 30 mg/kg; reduces the incidence of arthritis in a mouse model of collagen-induced arthritis; protects against joint and bone destruction in a rat model of streptococcal cell wall-induced arthritis
30767	Radotinib-d6	1 mg	≥99% deutera	An internal standard for the quantification of radotinib by GC- or LC-MS
30788	ZINC00881524	10 mg	≥98%	A ROCK inhibitor; decreases levels of ROCK1 in T47D and CAMA-1 breast cancer cells; decreases proliferation of T47D and CAMA-1 cells when used in combination with CNN1 knockdown
30788	ZINC00881524	100 mg	≥98%	A ROCK inhibitor; decreases levels of ROCK1 in T47D and CAMA-1 breast cancer cells; decreases proliferation of T47D and CAMA-1 cells when used in combination with CNN1 knockdown
30788	ZINC00881524	5 mg	≥98%	A ROCK inhibitor; decreases levels of ROCK1 in T47D and CAMA-1 breast cancer cells; decreases proliferation of T47D and CAMA-1 cells when used in combination with CNN1 knockdown
30788	ZINC00881524	50 mg	≥98%	A ROCK inhibitor; decreases levels of ROCK1 in T47D and CAMA-1 breast cancer cells; decreases proliferation of T47D and CAMA-1 cells when used in combination with CNN1 knockdown
30927	BMS 986142	1 mg	≥98%	A BTK inhibitor (IC50 = 0.5 nM); greater than 20-fold selective for BTK over a panel of 384 kinases; inhibits BCR stimulation-induced calcium flux in Ramos B cells (IC50 = 9 nM), as well as BCR stimulation-induced proliferation of, and CD86 surface expression in, peripheral B cells (IC50s = 3 and 4 nM, respectively); inhibits by Fcγ receptor stimulation-induced TNF-α production in human PBMCs (IC50 = 3 nM); reduces the percentage of mice with severe proteinuria and increases survival in an NZB/W lupus-prone mouse model at 30 mg/kg per day; reduces hind paw tibiotarsal joint bone resrption and inflammation in a CAIA mouse model at 5 and 20 mg/kg
30927	BMS 986142	5 mg	≥98%	A BTK inhibitor (IC50 = 0.5 nM); greater than 20-fold selective for BTK over a panel of 384 kinases; inhibits BCR stimulation-induced calcium flux in Ramos B cells (IC50 = 9 nM), as well as BCR stimulation-induced proliferation of, and CD86 surface expression in, peripheral B cells (IC50s = 3 and 4 nM, respectively); inhibits by Fcγ receptor stimulation-induced TNF-α production in human PBMCs (IC50 = 3 nM); reduces the percentage of mice with severe proteinuria and increases survival in an NZB/W lupus-prone mouse model at 30 mg/kg per day; reduces hind paw tibiotarsal joint bone resrption and inflammation in a CAIA mouse model at 5 and 20 mg/kg
30927	BMS 986142	500 µg	≥98%	A BTK inhibitor (IC50 = 0.5 nM); greater than 20-fold selective for BTK over a panel of 384 kinases; inhibits BCR stimulation-induced calcium flux in Ramos B cells (IC50 = 9 nM), as well as BCR stimulation-induced proliferation of, and CD86 surface expression in, peripheral B cells (IC50s = 3 and 4 nM, respectively); inhibits by Fcγ receptor stimulation-induced TNF-α production in human PBMCs (IC50 = 3 nM); reduces the percentage of mice with severe proteinuria and increases survival in an NZB/W lupus-prone mouse model at 30 mg/kg per day; reduces hind paw tibiotarsal joint bone resrption and inflammation in a CAIA mouse model at 5 and 20 mg/kg
30975	SB-772077B (hydroch	1 mg	≥98%	A ROCK inhibitor (IC50s = 5.6 and 6 nM for ROCK1 and ROCK2, respectively); selective for ROCK1 and ROCK2 over Akt1, Akt2, and Akt3 (IC50s = 324, 1,950, and 1,290 nM, respectively), as well as Cdk2, GSK3α, IKKβ, JNK3, and Plk (IC50s = ≥7,000 nM for all), but also inhibits RSK1 and MSK1 (IC50s = 35 and 14 nM, respectively); inhibits LPS-induced TNF-α and IL-6 production in THP-1 cells; induces relaxation of pre-contracted isolated rat aortic rings (IC50 = 39 nM); reduces blood pressure in spontaneously hypertensive rats in a dose-dependent manner and in DOCA-salt hypertensive rats at 1 mg/kg; reduces pulmonary and systemic arterial pressure and increases cardiac output in normotensive rats and rats with monocrotaline-induced pulmonary hypertension at 30, 100, and 300 µg/kg, i.v.
30975	SB-772077B (hydroch	5 mg	≥98%	A ROCK inhibitor (IC50s = 5.6 and 6 nM for ROCK1 and ROCK2, respectively); selective for ROCK1 and ROCK2 over Akt1, Akt2, and Akt3 (IC50s = 324, 1,950, and 1,290 nM, respectively), as well as Cdk2, GSK3α, IKKβ, JNK3, and Plk (IC50s = ≥7,000 nM for all), but also inhibits RSK1 and MSK1 (IC50s = 35 and 14 nM, respectively); inhibits LPS-induced TNF-α and IL-6 production in THP-1 cells; induces relaxation of pre-contracted isolated rat aortic rings (IC50 = 39 nM); reduces blood pressure in spontaneously hypertensive rats in a dose-dependent manner and in DOCA-salt hypertensive rats at 1 mg/kg; reduces pulmonary and systemic arterial pressure and increases cardiac output in normotensive rats and rats with monocrotaline-induced pulmonary hypertension at 30, 100, and 300 µg/kg, i.v.

30976	AS-2863619	1 mg	≥98%	A dual inhibitor of Cdk8 and Cdk19 (IC50s = 0.6 and 4.3 nM, respectively); induces Foxp3 expression in isolated mouse naïve T cells at 1 µM alone or synergistically with TGF-β; decreases ear edema and induces production of Foxp3+ Tregs in mice at 30 mg/kg; reduces disease severity in a mouse model of EAE
30976	AS-2863619	5 mg	≥98%	A dual inhibitor of Cdk8 and Cdk19 (IC50s = 0.6 and 4.3 nM, respectively); induces Foxp3 expression in isolated mouse naïve T cells at 1 µM alone or synergistically with TGF-β; decreases ear edema and induces production of Foxp3+ Tregs in mice at 30 mg/kg; reduces disease severity in a mouse model of EAE
30976	AS-2863619	500 µg	≥98%	A dual inhibitor of Cdk8 and Cdk19 (IC50s = 0.6 and 4.3 nM, respectively); induces Foxp3 expression in isolated mouse naïve T cells at 1 µM alone or synergistically with TGF-β; decreases ear edema and induces production of Foxp3+ Tregs in mice at 30 mg/kg; reduces disease severity in a mouse model of EAE
31002	Pantothenate Kinase I	1 mg	≥95%	A reversible inhibitor of pantothenate kinase (PanK; IC50s = 70, 92, and 25 nM for PanK1β, PanK2, and PanK3, respectively); inhibits CoA biosynthesis in C3A cells (IC50 = 0.9 µM); sensitizes cells to ferroptosis inducers
31002	Pantothenate Kinase I	10 mg	≥95%	A reversible inhibitor of pantothenate kinase (PanK; IC50s = 70, 92, and 25 nM for PanK1β, PanK2, and PanK3, respectively); inhibits CoA biosynthesis in C3A cells (IC50 = 0.9 µM); sensitizes cells to ferroptosis inducers
31002	Pantothenate Kinase I	25 mg	≥95%	A reversible inhibitor of pantothenate kinase (PanK; IC50s = 70, 92, and 25 nM for PanK1β, PanK2, and PanK3, respectively); inhibits CoA biosynthesis in C3A cells (IC50 = 0.9 µM); sensitizes cells to ferroptosis inducers
31002	Pantothenate Kinase I	5 mg	≥95%	A reversible inhibitor of pantothenate kinase (PanK; IC50s = 70, 92, and 25 nM for PanK1β, PanK2, and PanK3, respectively); inhibits CoA biosynthesis in C3A cells (IC50 = 0.9 µM); sensitizes cells to ferroptosis inducers
31033	HS-1371	10 mg	≥98%	A RIPK3 inhibitor (IC50 = 20.8 nM); inhibits basal RIPK3 autophosphorylation and TNF-α- or TRAIL-induced necroptosis in HT-29 cells at 5 µM; inhibits TNF-α Smac mimetic- and Z-VAD-induced necroptosis in HeLa and NCI-H2009 cancer cells ectopically expressing RIPK3
31033	HS-1371	100 mg	≥98%	A RIPK3 inhibitor (IC50 = 20.8 nM); inhibits basal RIPK3 autophosphorylation and TNF-α- or TRAIL-induced necroptosis in HT-29 cells at 5 µM; inhibits TNF-α Smac mimetic- and Z-VAD-induced necroptosis in HeLa and NCI-H2009 cancer cells ectopically expressing RIPK3
31033	HS-1371	5 mg	≥98%	A RIPK3 inhibitor (IC50 = 20.8 nM); inhibits basal RIPK3 autophosphorylation and TNF-α- or TRAIL-induced necroptosis in HT-29 cells at 5 µM; inhibits TNF-α Smac mimetic- and Z-VAD-induced necroptosis in HeLa and NCI-H2009 cancer cells ectopically expressing RIPK3
31033	HS-1371	50 mg	≥98%	A RIPK3 inhibitor (IC50 = 20.8 nM); inhibits basal RIPK3 autophosphorylation and TNF-α- or TRAIL-induced necroptosis in HT-29 cells at 5 µM; inhibits TNF-α Smac mimetic- and Z-VAD-induced necroptosis in HeLa and NCI-H2009 cancer cells ectopically expressing RIPK3
31054	THZ1-R	1 mg	≥98%	A non-cysteine reactive derivative of THZ1; inhibits Cdk7 (IC50s = 142-241 nM) less potently than THZ1; lacks antiproliferative activity against T-ALL cell lines
31055	THZ2	10 mg	≥98%	A Cdk7 inhibitor (IC50 = 13.9 nM); selective for Cdk7 over Cdk1, -2, -5, -8, and -9 (IC50s = 96.9, 222, 134, 6,830, and 194 nM, respectively); reduces proliferation of BT-549, HCC70, and MDA-MB-468 TNBC cells; reduces tumor volume in an MDA-MB-231 mouse xenograft model at 10 mg/kg; reduces tumor weight and volume, as well as the number of lung metastases, in an SJSA-1 osteosarcoma orthotopic mouse xenograft model
31055	THZ2	100 mg	≥98%	A Cdk7 inhibitor (IC50 = 13.9 nM); selective for Cdk7 over Cdk1, -2, -5, -8, and -9 (IC50s = 96.9, 222, 134, 6,830, and 194 nM, respectively); reduces proliferation of BT-549, HCC70, and MDA-MB-468 TNBC cells; reduces tumor volume in an MDA-MB-231 mouse xenograft model at 10 mg/kg; reduces tumor weight and volume, as well as the number of lung metastases, in an SJSA-1 osteosarcoma orthotopic mouse xenograft model
31055	THZ2	25 mg	≥98%	A Cdk7 inhibitor (IC50 = 13.9 nM); selective for Cdk7 over Cdk1, -2, -5, -8, and -9 (IC50s = 96.9, 222, 134, 6,830, and 194 nM, respectively); reduces proliferation of BT-549, HCC70, and MDA-MB-468 TNBC cells; reduces tumor volume in an MDA-MB-231 mouse xenograft model at 10 mg/kg; reduces tumor weight and volume, as well as the number of lung metastases, in an SJSA-1 osteosarcoma orthotopic mouse xenograft model
31055	THZ2	50 mg	≥98%	A Cdk7 inhibitor (IC50 = 13.9 nM); selective for Cdk7 over Cdk1, -2, -5, -8, and -9 (IC50s = 96.9, 222, 134, 6,830, and 194 nM, respectively); reduces proliferation of BT-549, HCC70, and MDA-MB-468 TNBC cells; reduces tumor volume in an MDA-MB-231 mouse xenograft model at 10 mg/kg; reduces tumor weight and volume, as well as the number of lung metastases, in an SJSA-1 osteosarcoma orthotopic mouse xenograft model

31082	BIBF 1120 (esylate)	1 g	≥98%	A VEGFR, FGFR, and PDGFR inhibitor (IC50s = 13-34, 37-610, 59, and 65 nM for VEGFR1-3, FGFR1-4, PDGFRα, and PDGFRβ, respectively); selective for VEGFR, FGFR, and PDGFR over a panel of 33 kinases but does inhibit FLT3, LCK, LYN, and Src (IC50s = 16-156 nM); inhibits growth factor-dependent proliferation of HUVECs, HSMECs, HUASMCs, and BRPs (EC50s = 7-290 nM); reduces tumor microvessel density and the number of PDGFRβ-expressing perivascular cells in a FaDu head and neck small cell carcinoma mouse xenograft model at 100 mg/kg; inhibits tumor growth in a Caki-1 renal cancer mouse xenograft model
31082	BIBF 1120 (esylate)	100 mg	≥98%	A VEGFR, FGFR, and PDGFR inhibitor (IC50s = 13-34, 37-610, 59, and 65 nM for VEGFR1-3, FGFR1-4, PDGFRα, and PDGFRβ, respectively); selective for VEGFR, FGFR, and PDGFR over a panel of 33 kinases but does inhibit FLT3, LCK, LYN, and Src (IC50s = 16-156 nM); inhibits growth factor-dependent proliferation of HUVECs, HSMECs, HUASMCs, and BRPs (EC50s = 7-290 nM); reduces tumor microvessel density and the number of PDGFRβ-expressing perivascular cells in a FaDu head and neck small cell carcinoma mouse xenograft model at 100 mg/kg; inhibits tumor growth in a Caki-1 renal cancer mouse xenograft model
31082	BIBF 1120 (esylate)	50 mg	≥98%	A VEGFR, FGFR, and PDGFR inhibitor (IC50s = 13-34, 37-610, 59, and 65 nM for VEGFR1-3, FGFR1-4, PDGFRα, and PDGFRβ, respectively); selective for VEGFR, FGFR, and PDGFR over a panel of 33 kinases but does inhibit FLT3, LCK, LYN, and Src (IC50s = 16-156 nM); inhibits growth factor-dependent proliferation of HUVECs, HSMECs, HUASMCs, and BRPs (EC50s = 7-290 nM); reduces tumor microvessel density and the number of PDGFRβ-expressing perivascular cells in a FaDu head and neck small cell carcinoma mouse xenograft model at 100 mg/kg; inhibits tumor growth in a Caki-1 renal cancer mouse xenograft model
31082	BIBF 1120 (esylate)	500 mg	≥98%	A VEGFR, FGFR, and PDGFR inhibitor (IC50s = 13-34, 37-610, 59, and 65 nM for VEGFR1-3, FGFR1-4, PDGFRα, and PDGFRβ, respectively); selective for VEGFR, FGFR, and PDGFR over a panel of 33 kinases but does inhibit FLT3, LCK, LYN, and Src (IC50s = 16-156 nM); inhibits growth factor-dependent proliferation of HUVECs, HSMECs, HUASMCs, and BRPs (EC50s = 7-290 nM); reduces tumor microvessel density and the number of PDGFRβ-expressing perivascular cells in a FaDu head and neck small cell carcinoma mouse xenograft model at 100 mg/kg; inhibits tumor growth in a Caki-1 renal cancer mouse xenograft model
31115	MLN0905	1 mg	≥98%	A Plk1 inhibitor (IC50 = 2 nM); inhibits 95% of Plk1 activity but also inhibits the activity of 10 additional kinases by greater than or equal to 90% in a panel of 359 kinases at 1 μM; reduces H3S10Ph in HT-29 colorectal cancer cells (EC30 = 9 nM); inhibits proliferation in a panel of six human lymphoma cell lines (IC50 = 3.2-24 nM)
31115	MLN0905	10 mg	≥98%	A Plk1 inhibitor (IC50 = 2 nM); inhibits 95% of Plk1 activity but also inhibits the activity of 10 additional kinases by greater than or equal to 90% in a panel of 359 kinases at 1 μM; reduces H3S10Ph in HT-29 colorectal cancer cells (EC30 = 9 nM); inhibits proliferation in a panel of six human lymphoma cell lines (IC50 = 3.2-24 nM)
31115	MLN0905	5 mg	≥98%	A Plk1 inhibitor (IC50 = 2 nM); inhibits 95% of Plk1 activity but also inhibits the activity of 10 additional kinases by greater than or equal to 90% in a panel of 359 kinases at 1 μM; reduces H3S10Ph in HT-29 colorectal cancer cells (EC30 = 9 nM); inhibits proliferation in a panel of six human lymphoma cell lines (IC50 = 3.2-24 nM)
31117	EMD 638683	1 mg	≥98%	An inhibitor of SGK1; inhibits SGK1 by 85% at 1 μM; >27-fold selective for SGK1 over a panel of 11 kinases, but does inhibit SGK2, SGK3, PRK2, and MSK1 by >50% at 1 μM; inhibits phosphorylation of the SGK1 target NDRG1 in HeLa cells (IC50 = 3.35 μM); increases radiation-induced apoptosis of Caco-2 colon carcinoma cells at 50 μM; dietary administration reduces the number of tumors in a mouse model of chemical carcinogenesis; prevents fructose and saline consumption-induced increases in systolic blood pressure in mice; decreases body weight, fasting blood glucose and HbA1c levels, and food intake in db/db diabetic mice; reduces angiotensin II-induced collagen deposition and cardiac fibrosis in mice
31117	EMD 638683	10 mg	≥98%	An inhibitor of SGK1; inhibits SGK1 by 85% at 1 μM; >27-fold selective for SGK1 over a panel of 11 kinases, but does inhibit SGK2, SGK3, PRK2, and MSK1 by >50% at 1 μM; inhibits phosphorylation of the SGK1 target NDRG1 in HeLa cells (IC50 = 3.35 μM); increases radiation-induced apoptosis of Caco-2 colon carcinoma cells at 50 μM; dietary administration reduces the number of tumors in a mouse model of chemical carcinogenesis; prevents fructose and saline consumption-induced increases in systolic blood pressure in mice; decreases body weight, fasting blood glucose and HbA1c levels, and food intake in db/db diabetic mice; reduces angiotensin II-induced collagen deposition and cardiac fibrosis in mice

31117	EMD 638683	25 mg	≥98%	An inhibitor of SGK1; inhibits SGK1 by 85% at 1 µM; >27-fold selective for SGK1 over a panel of 11 kinases, but does inhibit SGK2, SGK3, PRK2, and MSK1 by >50% at 1 µM; inhibits phosphorylation of the SGK1 target NDRG1 in HeLa cells (IC50 = 3.35 µM); increases radiation-induced apoptosis of Caco-2 colon carcinoma cells at 50 µM; dietary administration reduces the number of tumors in a mouse model of chemical carcinogenesis; prevents fructose and saline consumption-induced increases in systolic blood pressure in mice; decreases body weight, fasting blood glucose and HbA1c levels, and food intake in db/db diabetic mice; reduces angiotensin II-induced collagen deposition and cardiac fibrosis in mice
31117	EMD 638683	5 mg	≥98%	An inhibitor of SGK1; inhibits SGK1 by 85% at 1 µM; >27-fold selective for SGK1 over a panel of 11 kinases, but does inhibit SGK2, SGK3, PRK2, and MSK1 by >50% at 1 µM; inhibits phosphorylation of the SGK1 target NDRG1 in HeLa cells (IC50 = 3.35 µM); increases radiation-induced apoptosis of Caco-2 colon carcinoma cells at 50 µM; dietary administration reduces the number of tumors in a mouse model of chemical carcinogenesis; prevents fructose and saline consumption-induced increases in systolic blood pressure in mice; decreases body weight, fasting blood glucose and HbA1c levels, and food intake in db/db diabetic mice; reduces angiotensin II-induced collagen deposition and cardiac fibrosis in mice
31120	CCG-215022	1 mg	≥98%	A GRK inhibitor (IC50s = 3.9, 0.15, and 0.38 µM for GRK1, GRK2, and GRK5, respectively); selective for GRKs over PKA (IC50 = 120 µM); increases contractility in isoproterenol-stimulated isolated mouse cardiomyocytes at 500 nM; prevents the desensitization of histamine H1 receptor- and purinergic P2Y2 receptor-driven phospholipase C signaling in human ULTR myometrial cells and isolated rat MSMCs, respectively (IC50s = 3.09 and 2.95 µM, respectively)
31120	CCG-215022	10 mg	≥98%	A GRK inhibitor (IC50s = 3.9, 0.15, and 0.38 µM for GRK1, GRK2, and GRK5, respectively); selective for GRKs over PKA (IC50 = 120 µM); increases contractility in isoproterenol-stimulated isolated mouse cardiomyocytes at 500 nM; prevents the desensitization of histamine H1 receptor- and purinergic P2Y2 receptor-driven phospholipase C signaling in human ULTR myometrial cells and isolated rat MSMCs, respectively (IC50s = 3.09 and 2.95 µM, respectively)
31120	CCG-215022	25 mg	≥98%	A GRK inhibitor (IC50s = 3.9, 0.15, and 0.38 µM for GRK1, GRK2, and GRK5, respectively); selective for GRKs over PKA (IC50 = 120 µM); increases contractility in isoproterenol-stimulated isolated mouse cardiomyocytes at 500 nM; prevents the desensitization of histamine H1 receptor- and purinergic P2Y2 receptor-driven phospholipase C signaling in human ULTR myometrial cells and isolated rat MSMCs, respectively (IC50s = 3.09 and 2.95 µM, respectively)
31120	CCG-215022	5 mg	≥98%	A GRK inhibitor (IC50s = 3.9, 0.15, and 0.38 µM for GRK1, GRK2, and GRK5, respectively); selective for GRKs over PKA (IC50 = 120 µM); increases contractility in isoproterenol-stimulated isolated mouse cardiomyocytes at 500 nM; prevents the desensitization of histamine H1 receptor- and purinergic P2Y2 receptor-driven phospholipase C signaling in human ULTR myometrial cells and isolated rat MSMCs, respectively (IC50s = 3.09 and 2.95 µM, respectively)
31229	BX-320	1 mg	≥95%	An inhibitor of PDK1 (IC50 = 30 nM); selective for PDK1 over a panel of 10 additional kinases (IC50s = >820 nM for all); inhibits Akt and p70S6K1 phosphorylation in PC3 cells (IC50s = 1-3 µM); induces apoptosis in, and inhibits the growth of, MDA-MB-468 breast cancer cells (IC50s = 0.5 and 0.6 µM, respectively), as well as inhibits cell growth in a panel of cancer cells (IC50s = 0.12-1.2 µM); inhibits the growth of lung tumors in a LOX melanoma mouse model of blood-borne metastasis at 200 mg/kg
31229	BX-320	5 mg	≥95%	An inhibitor of PDK1 (IC50 = 30 nM); selective for PDK1 over a panel of 10 additional kinases (IC50s = >820 nM for all); inhibits Akt and p70S6K1 phosphorylation in PC3 cells (IC50s = 1-3 µM); induces apoptosis in, and inhibits the growth of, MDA-MB-468 breast cancer cells (IC50s = 0.5 and 0.6 µM, respectively), as well as inhibits cell growth in a panel of cancer cells (IC50s = 0.12-1.2 µM); inhibits the growth of lung tumors in a LOX melanoma mouse model of blood-borne metastasis at 200 mg/kg
31229	BX-320	500 µg	≥95%	An inhibitor of PDK1 (IC50 = 30 nM); selective for PDK1 over a panel of 10 additional kinases (IC50s = >820 nM for all); inhibits Akt and p70S6K1 phosphorylation in PC3 cells (IC50s = 1-3 µM); induces apoptosis in, and inhibits the growth of, MDA-MB-468 breast cancer cells (IC50s = 0.5 and 0.6 µM, respectively), as well as inhibits cell growth in a panel of cancer cells (IC50s = 0.12-1.2 µM); inhibits the growth of lung tumors in a LOX melanoma mouse model of blood-borne metastasis at 200 mg/kg
31358	STO-609	1 mg	≥95% (mixture	A CaMKK inhibitor (IC50s = 120 and 40 ng/ml for CaMKKα and CaMKKβ, respectively); selective for CaMKKs over CaMKI, CaMKII, CaMKIV, MLCK, PKC, PKA, and p42 MAPK (IC50s = ≥ 10,000 ng/ml for all); inhibits phosphorylation of CaMKI and AMPK in chicken sperm in the presence of extracellular calcium, as well as reduces chicken sperm motility; decreases Npy and Agrp expression and cumulative food intake in mice at 20 µM 0.5 µL/hour, i.c.v.; increases cortical, striatal, and total infarct volume in a mouse model of MCAO-induced focal transient cerebral ischemia at 3 µg/animal, i.c.v.

31358	STO-609	10 mg	≥95% (mixture	A CaMKK inhibitor (IC50s = 120 and 40 ng/ml for CaMKKα and CaMKKβ, respectively); selective for CaMKKs over CaMKI, CaMKII, CaMKIV, MLCK, PKC, PKA, and p42 MAPK (IC50s = ≥ 10,000 ng/ml for all); inhibits phosphorylation of CaMKI and AMPK in chicken sperm in the presence of extracellular calcium, as well as reduces chicken sperm motility; decreases Npy and Agrp expression and cumulative food intake in mice at 20 μM 0.5 μL/hour, i.c.v.; increases cortical, striatal, and total infarct volume in a mouse model of MCAO-induced focal transient cerebral ischemia at 3 μg/animal, i.c.v.
31358	STO-609	25 mg	≥95% (mixture	A CaMKK inhibitor (IC50s = 120 and 40 ng/ml for CaMKKα and CaMKKβ, respectively); selective for CaMKKs over CaMKI, CaMKII, CaMKIV, MLCK, PKC, PKA, and p42 MAPK (IC50s = ≥ 10,000 ng/ml for all); inhibits phosphorylation of CaMKI and AMPK in chicken sperm in the presence of extracellular calcium, as well as reduces chicken sperm motility; decreases Npy and Agrp expression and cumulative food intake in mice at 20 μM 0.5 μL/hour, i.c.v.; increases cortical, striatal, and total infarct volume in a mouse model of MCAO-induced focal transient cerebral ischemia at 3 μg/animal, i.c.v.
31358	STO-609	5 mg	≥95% (mixture	A CaMKK inhibitor (IC50s = 120 and 40 ng/ml for CaMKKα and CaMKKβ, respectively); selective for CaMKKs over CaMKI, CaMKII, CaMKIV, MLCK, PKC, PKA, and p42 MAPK (IC50s = ≥ 10,000 ng/ml for all); inhibits phosphorylation of CaMKI and AMPK in chicken sperm in the presence of extracellular calcium, as well as reduces chicken sperm motility; decreases Npy and Agrp expression and cumulative food intake in mice at 20 μM 0.5 μL/hour, i.c.v.; increases cortical, striatal, and total infarct volume in a mouse model of MCAO-induced focal transient cerebral ischemia at 3 μg/animal, i.c.v.
31411	Tucatinib	10 mg	≥98%	An inhibitor of HER2 (IC50 = 14 nM); inhibits the phosphorylation of HER2 in BT474 breast carcinoma cells (IC50 = 21 nM); inhibits phosphorylation of AKT and induces apoptosis in BT474 cells; inhibits tumor growth in NCI N87 gastric carcinoma and SKOV3 ovarian adenocarcinoma mouse xenograft models from 25-100 mg/kg; reduces intratumor phosphorylation of AKT and ERK and inhibits tumor growth in a BT474 mouse xenograft model
31411	Tucatinib	25 mg	≥98%	An inhibitor of HER2 (IC50 = 14 nM); inhibits the phosphorylation of HER2 in BT474 breast carcinoma cells (IC50 = 21 nM); inhibits phosphorylation of AKT and induces apoptosis in BT474 cells; inhibits tumor growth in NCI N87 gastric carcinoma and SKOV3 ovarian adenocarcinoma mouse xenograft models from 25-100 mg/kg; reduces intratumor phosphorylation of AKT and ERK and inhibits tumor growth in a BT474 mouse xenograft model
31411	Tucatinib	5 mg	≥98%	An inhibitor of HER2 (IC50 = 14 nM); inhibits the phosphorylation of HER2 in BT474 breast carcinoma cells (IC50 = 21 nM); inhibits phosphorylation of AKT and induces apoptosis in BT474 cells; inhibits tumor growth in NCI N87 gastric carcinoma and SKOV3 ovarian adenocarcinoma mouse xenograft models from 25-100 mg/kg; reduces intratumor phosphorylation of AKT and ERK and inhibits tumor growth in a BT474 mouse xenograft model
31411	Tucatinib	50 mg	≥98%	An inhibitor of HER2 (IC50 = 14 nM); inhibits the phosphorylation of HER2 in BT474 breast carcinoma cells (IC50 = 21 nM); inhibits phosphorylation of AKT and induces apoptosis in BT474 cells; inhibits tumor growth in NCI N87 gastric carcinoma and SKOV3 ovarian adenocarcinoma mouse xenograft models from 25-100 mg/kg; reduces intratumor phosphorylation of AKT and ERK and inhibits tumor growth in a BT474 mouse xenograft model
31451	ODM-203	10 mg	≥98%	A dual inhibitor of VEGFR and FGFR (IC50s = 5-26 and 6-35 nM for VEGFR1-3 and FGFR1-4, respectively); selective for VEGFR1-3 and FGFR1-4 over a panel of 308 kinases at 1 μM; inhibits PDGFRα, PDGFRβ, and DDR1 (IC50s = 35, 169, and 6 nM, respectively), as well as MAP4K4, MINK1, RET, SIK2, YES1, and Tie2 (IC50s = 49, 41, 8, 23, 152, and 174 nM, respectively; inhibits FGFR-dependent proliferation in H1581 lung, SNU-16 stomach, and RT4 bladder cancer cells (IC50s = 104, 132, and 192 nM, respectively) and VEGF-induced tube formation by HUVECs (IC50 = 33 nM); decreases tumor volume in a RT4 mouse xenograft model at 20 and 40 mg/kg; reduces tumor growth and intratumor phosphorylation of FGFR in a SNU-16 mouse xenograft model at 30 mg/kg
31451	ODM-203	25 mg	≥98%	A dual inhibitor of VEGFR and FGFR (IC50s = 5-26 and 6-35 nM for VEGFR1-3 and FGFR1-4, respectively); selective for VEGFR1-3 and FGFR1-4 over a panel of 308 kinases at 1 μM; inhibits PDGFRα, PDGFRβ, and DDR1 (IC50s = 35, 169, and 6 nM, respectively), as well as MAP4K4, MINK1, RET, SIK2, YES1, and Tie2 (IC50s = 49, 41, 8, 23, 152, and 174 nM, respectively; inhibits FGFR-dependent proliferation in H1581 lung, SNU-16 stomach, and RT4 bladder cancer cells (IC50s = 104, 132, and 192 nM, respectively) and VEGF-induced tube formation by HUVECs (IC50 = 33 nM); decreases tumor volume in a RT4 mouse xenograft model at 20 and 40 mg/kg; reduces tumor growth and intratumor phosphorylation of FGFR in a SNU-16 mouse xenograft model at 30 mg/kg

31451	ODM-203	5 mg	≥98%	A dual inhibitor of VEGFR and FGFR (IC50s = 5-26 and 6-35 nM for VEGFR1-3 and FGFR1-4, respectively); selective for VEGFR1-3 and FGFR1-4 over a panel of 308 kinases at 1 μM; inhibits PDGFRα, PDGFRβ, and DDR1 (IC50s = 35, 169, and 6 nM, respectively), as well as MAP4K4, MINK1, RET, SIK2, YES1, and Tie2 (IC50s = 49, 41, 8, 23, 152, and 174 nM, respectively; inhibits FGFR-dependent proliferation in H1581 lung, SNU-16 stomach, and RT4 bladder cancer cells (IC50s = 104, 132, and 192 nM, respectively) and VEGF-induced tube formation by HUVECs (IC50 = 33 nM); decreases tumor volume in a RT4 mouse xenograft model at 20 and 40 mg/kg; reduces tumor growth and intratumor phosphorylation of FGFR in a SNU-16 mouse xenograft model at 30 mg/kg
31451	ODM-203	50 mg	≥98%	A dual inhibitor of VEGFR and FGFR (IC50s = 5-26 and 6-35 nM for VEGFR1-3 and FGFR1-4, respectively); selective for VEGFR1-3 and FGFR1-4 over a panel of 308 kinases at 1 μM; inhibits PDGFRα, PDGFRβ, and DDR1 (IC50s = 35, 169, and 6 nM, respectively), as well as MAP4K4, MINK1, RET, SIK2, YES1, and Tie2 (IC50s = 49, 41, 8, 23, 152, and 174 nM, respectively; inhibits FGFR-dependent proliferation in H1581 lung, SNU-16 stomach, and RT4 bladder cancer cells (IC50s = 104, 132, and 192 nM, respectively) and VEGF-induced tube formation by HUVECs (IC50 = 33 nM); decreases tumor volume in a RT4 mouse xenograft model at 20 and 40 mg/kg; reduces tumor growth and intratumor phosphorylation of FGFR in a SNU-16 mouse xenograft model at 30 mg/kg
31455	LXS-196	1 mg	≥95%	A PKC inhibitor (IC50s = 1.9 and 0.4 nM for PKCα and PKCθ, respectively); selective for PKCα and PKCθ over GSK3β (IC50 = 3,100 nM); inhibits proliferation of TMD8 B cell lymphoma and 92.1 uveal melanoma cells (IC50s = 900 and 184 nM, respectively) but not SK-MEL-28 skin melanoma cells (IC50 = >10,000 nM)
31455	LXS-196	10 mg	≥95%	A PKC inhibitor (IC50s = 1.9 and 0.4 nM for PKCα and PKCθ, respectively); selective for PKCα and PKCθ over GSK3β (IC50 = 3,100 nM); inhibits proliferation of TMD8 B cell lymphoma and 92.1 uveal melanoma cells (IC50s = 900 and 184 nM, respectively) but not SK-MEL-28 skin melanoma cells (IC50 = >10,000 nM)
31455	LXS-196	25 mg	≥95%	A PKC inhibitor (IC50s = 1.9 and 0.4 nM for PKCα and PKCθ, respectively); selective for PKCα and PKCθ over GSK3β (IC50 = 3,100 nM); inhibits proliferation of TMD8 B cell lymphoma and 92.1 uveal melanoma cells (IC50s = 900 and 184 nM, respectively) but not SK-MEL-28 skin melanoma cells (IC50 = >10,000 nM)
31455	LXS-196	5 mg	≥95%	A PKC inhibitor (IC50s = 1.9 and 0.4 nM for PKCα and PKCθ, respectively); selective for PKCα and PKCθ over GSK3β (IC50 = 3,100 nM); inhibits proliferation of TMD8 B cell lymphoma and 92.1 uveal melanoma cells (IC50s = 900 and 184 nM, respectively) but not SK-MEL-28 skin melanoma cells (IC50 = >10,000 nM)
31457	ARN3236	1 mg	≥98%	An inhibitor of SIK2 (IC50 = 50s = 21.63 and 6.63 nM, respectively); inhibits TNF-α secretion in RAW 264.7 cells (IC50 = ~2.5 μM) and reduces phosphorylation of CRTC3 and HDAC4 in macrophages at 3 μM; inhibits growth of 10 ovarian cancer cell lines (IC50s = 0.8-2.6 μM) and increases sensitivity of eight of them to paclitaxel; halts the cell cycle at the G2/M phase and induces apoptosis and tetraploidy in SKOV3 cells at 1 μM; has an additive effect on reducing tumor growth when used in combination with paclitaxel in an ovarian cancer mouse xenograft model at 60 mg/kg per day
31457	ARN3236	10 mg	≥98%	An inhibitor of SIK2 (IC50 = 50s = 21.63 and 6.63 nM, respectively); inhibits TNF-α secretion in RAW 264.7 cells (IC50 = ~2.5 μM) and reduces phosphorylation of CRTC3 and HDAC4 in macrophages at 3 μM; inhibits growth of 10 ovarian cancer cell lines (IC50s = 0.8-2.6 μM) and increases sensitivity of eight of them to paclitaxel; halts the cell cycle at the G2/M phase and induces apoptosis and tetraploidy in SKOV3 cells at 1 μM; has an additive effect on reducing tumor growth when used in combination with paclitaxel in an ovarian cancer mouse xenograft model at 60 mg/kg per day
31457	ARN3236	25 mg	≥98%	An inhibitor of SIK2 (IC50 = 50s = 21.63 and 6.63 nM, respectively); inhibits TNF-α secretion in RAW 264.7 cells (IC50 = ~2.5 μM) and reduces phosphorylation of CRTC3 and HDAC4 in macrophages at 3 μM; inhibits growth of 10 ovarian cancer cell lines (IC50s = 0.8-2.6 μM) and increases sensitivity of eight of them to paclitaxel; halts the cell cycle at the G2/M phase and induces apoptosis and tetraploidy in SKOV3 cells at 1 μM; has an additive effect on reducing tumor growth when used in combination with paclitaxel in an ovarian cancer mouse xenograft model at 60 mg/kg per day

31457	ARN3236	5 mg	≥98%	An inhibitor of SIK2 (IC50 = 50s = 21.63 and 6.63 nM, respectively); inhibits TNF-α secretion in RAW 264.7 cells (IC50 = ~2.5 μM) and reduces phosphorylation of CRTC3 and HDAC4 in macrophages at 3 μM; inhibits growth of 10 ovarian cancer cell lines (IC50s = 0.8-2.6 μM) and increases sensitivity of eight of them to paclitaxel; halts the cell cycle at the G2/M phase and induces apoptosis and tetraploidy in SKOV3 cells at 1 μM; has an additive effect on reducing tumor growth when used in combination with paclitaxel in an ovarian cancer mouse xenograft model at 60 mg/kg per day
31458	GSK2983559	1 mg	≥98%	A RIPK2 inhibitor; inhibits RIPK2 by 65% in a kinase assay at 10 μM; inhibits VEGFR3 by greater than 90%, as well as 14 additional kinases by 60-89% in a panel of 344 kinases at 10 μM; reduces colonic damage in a mouse model of TNBS-induced colitis at 7.5 and 145 mg/kg twice per day; a prodrug
31458	GSK2983559	10 mg	≥98%	A RIPK2 inhibitor; inhibits RIPK2 by 65% in a kinase assay at 10 μM; inhibits VEGFR3 by greater than 90%, as well as 14 additional kinases by 60-89% in a panel of 344 kinases at 10 μM; reduces colonic damage in a mouse model of TNBS-induced colitis at 7.5 and 145 mg/kg twice per day; a prodrug
31458	GSK2983559	25 mg	≥98%	A RIPK2 inhibitor; inhibits RIPK2 by 65% in a kinase assay at 10 μM; inhibits VEGFR3 by greater than 90%, as well as 14 additional kinases by 60-89% in a panel of 344 kinases at 10 μM; reduces colonic damage in a mouse model of TNBS-induced colitis at 7.5 and 145 mg/kg twice per day; a prodrug
31458	GSK2983559	5 mg	≥98%	A RIPK2 inhibitor; inhibits RIPK2 by 65% in a kinase assay at 10 μM; inhibits VEGFR3 by greater than 90%, as well as 14 additional kinases by 60-89% in a panel of 344 kinases at 10 μM; reduces colonic damage in a mouse model of TNBS-induced colitis at 7.5 and 145 mg/kg twice per day; a prodrug
31460	Belvarafenib	1 mg	≥98%	An inhibitor of B-RAF and C-RAF (IC50s = 41, 7, and 2 nM for wild-type B-RAF, B-RAFV600E, and wild-type C-RAF, respectively); cytotoxic to B-RAFV600E-expressing A375 and SK-MEL-28 melanoma cells (IC50s = 57 and 69 nM, respectively), as well as COLO 205 and HCT116 colon and B-CPAP and CAL-62 thyroid cancer cells (IC50s = 116, 65, 43, and 479 nM, respectively); reduces tumor growth in A375, SK-MEL-28, SK-MEL-2, and SK-MEL-30 mouse xenograft models
31460	Belvarafenib	10 mg	≥98%	An inhibitor of B-RAF and C-RAF (IC50s = 41, 7, and 2 nM for wild-type B-RAF, B-RAFV600E, and wild-type C-RAF, respectively); cytotoxic to B-RAFV600E-expressing A375 and SK-MEL-28 melanoma cells (IC50s = 57 and 69 nM, respectively), as well as COLO 205 and HCT116 colon and B-CPAP and CAL-62 thyroid cancer cells (IC50s = 116, 65, 43, and 479 nM, respectively); reduces tumor growth in A375, SK-MEL-28, SK-MEL-2, and SK-MEL-30 mouse xenograft models
31460	Belvarafenib	25 mg	≥98%	An inhibitor of B-RAF and C-RAF (IC50s = 41, 7, and 2 nM for wild-type B-RAF, B-RAFV600E, and wild-type C-RAF, respectively); cytotoxic to B-RAFV600E-expressing A375 and SK-MEL-28 melanoma cells (IC50s = 57 and 69 nM, respectively), as well as COLO 205 and HCT116 colon and B-CPAP and CAL-62 thyroid cancer cells (IC50s = 116, 65, 43, and 479 nM, respectively); reduces tumor growth in A375, SK-MEL-28, SK-MEL-2, and SK-MEL-30 mouse xenograft models
31460	Belvarafenib	5 mg	≥98%	An inhibitor of B-RAF and C-RAF (IC50s = 41, 7, and 2 nM for wild-type B-RAF, B-RAFV600E, and wild-type C-RAF, respectively); cytotoxic to B-RAFV600E-expressing A375 and SK-MEL-28 melanoma cells (IC50s = 57 and 69 nM, respectively), as well as COLO 205 and HCT116 colon and B-CPAP and CAL-62 thyroid cancer cells (IC50s = 116, 65, 43, and 479 nM, respectively); reduces tumor growth in A375, SK-MEL-28, SK-MEL-2, and SK-MEL-30 mouse xenograft models
31462	NCL-00017509	1 mg	≥98%	A Nek2 inhibitor (IC50 = 56 nM)
31473	Alflutinib (mesylate)	10 mg	≥98%	An inhibitor of mutant EGFRs; selective for EGFRL858R, EGFRG719X, EGFRL858R, EGFRL861A, and EGFRT790M mutant EGFRs over wild-type EGFR; reduces tumor growth in an EGFRL858R and EGFRT790M-expressing LU1868 NSCLC PDX mouse model at 10 and 30 mg/kg
31473	Alflutinib (mesylate)	25 mg	≥98%	An inhibitor of mutant EGFRs; selective for EGFRL858R, EGFRG719X, EGFRL858R, EGFRL861A, and EGFRT790M mutant EGFRs over wild-type EGFR; reduces tumor growth in an EGFRL858R and EGFRT790M-expressing LU1868 NSCLC PDX mouse model at 10 and 30 mg/kg
31473	Alflutinib (mesylate)	5 mg	≥98%	An inhibitor of mutant EGFRs; selective for EGFRL858R, EGFRG719X, EGFRL858R, EGFRL861A, and EGFRT790M mutant EGFRs over wild-type EGFR; reduces tumor growth in an EGFRL858R and EGFRT790M-expressing LU1868 NSCLC PDX mouse model at 10 and 30 mg/kg
31473	Alflutinib (mesylate)	50 mg	≥98%	An inhibitor of mutant EGFRs; selective for EGFRL858R, EGFRG719X, EGFRL858R, EGFRL861A, and EGFRT790M mutant EGFRs over wild-type EGFR; reduces tumor growth in an EGFRL858R and EGFRT790M-expressing LU1868 NSCLC PDX mouse model at 10 and 30 mg/kg

31478	R1487 (hydrochloride	1 mg	≥98%	An inhibitor of p38α MAPK (IC50 = 10 nM); selective for p38α over p38β MAPK (Kds = 0.2 and 29 nM, respectively), as well as a panel of 306 additional kinases at 10 µM, but does inhibit 11 kinases by >85% at 10 µM; inhibits LPS-induced IL-1β production in isolated human whole blood (IC50 = 170 nM); inhibits LPS-induced production of TNF-α and IL-6 in rats (ED50s = 0.8 and 0.4 mg/kg); reduces yeast-induced hyperalgesia in rats (ED50 = 5.5 mg/kg)
31478	R1487 (hydrochloride	10 mg	≥98%	An inhibitor of p38α MAPK (IC50 = 10 nM); selective for p38α over p38β MAPK (Kds = 0.2 and 29 nM, respectively), as well as a panel of 306 additional kinases at 10 µM, but does inhibit 11 kinases by >85% at 10 µM; inhibits LPS-induced IL-1β production in isolated human whole blood (IC50 = 170 nM); inhibits LPS-induced production of TNF-α and IL-6 in rats (ED50s = 0.8 and 0.4 mg/kg); reduces yeast-induced hyperalgesia in rats (ED50 = 5.5 mg/kg)
31478	R1487 (hydrochloride	25 mg	≥98%	An inhibitor of p38α MAPK (IC50 = 10 nM); selective for p38α over p38β MAPK (Kds = 0.2 and 29 nM, respectively), as well as a panel of 306 additional kinases at 10 µM, but does inhibit 11 kinases by >85% at 10 µM; inhibits LPS-induced IL-1β production in isolated human whole blood (IC50 = 170 nM); inhibits LPS-induced production of TNF-α and IL-6 in rats (ED50s = 0.8 and 0.4 mg/kg); reduces yeast-induced hyperalgesia in rats (ED50 = 5.5 mg/kg)
31478	R1487 (hydrochloride	5 mg	≥98%	An inhibitor of p38α MAPK (IC50 = 10 nM); selective for p38α over p38β MAPK (Kds = 0.2 and 29 nM, respectively), as well as a panel of 306 additional kinases at 10 µM, but does inhibit 11 kinases by >85% at 10 µM; inhibits LPS-induced IL-1β production in isolated human whole blood (IC50 = 170 nM); inhibits LPS-induced production of TNF-α and IL-6 in rats (ED50s = 0.8 and 0.4 mg/kg); reduces yeast-induced hyperalgesia in rats (ED50 = 5.5 mg/kg)
31514	SU 14813	100 mg	≥95%	A dual VEGFR and PDGFR family kinase inhibitor (IC50s = 0.002, 0.05, 0.004, and 0.015 µM for VEGFR1, VEGFR2, PDGFRβ, and KIT, respectively); selective for these kinases over FGFR1, EGFR, Src, and c-Met (IC50s = 3.5, >20, 2.5, and 9 µM, respectively); inhibits VEGFR2, PDGFRβ, KIT, and FLT3-ITD phosphorylation in vitro (IC50s = 0.04, 0.02, 0.006, and 0.05 µM, respectively); inhibits PDGF-dependent proliferation of NIH3T3 cells overexpressing PDGFRβ, as well as OC1-AML5 cells expressing wild-type FLT3 and MV4-11 cells carrying the activating FLT3-ITD mutation; inhibits VEGF-induced survival of HUVECs (IC50 = 6.8 nM); reduces tumor growth in human acute myeloid leukemia, renal, and colon cancer, as well as rat glioma, mouse xenograft models when used at doses ranging from 10-80 mg/kg twice per day
31514	SU 14813	25 mg	≥95%	A dual VEGFR and PDGFR family kinase inhibitor (IC50s = 0.002, 0.05, 0.004, and 0.015 µM for VEGFR1, VEGFR2, PDGFRβ, and KIT, respectively); selective for these kinases over FGFR1, EGFR, Src, and c-Met (IC50s = 3.5, >20, 2.5, and 9 µM, respectively); inhibits VEGFR2, PDGFRβ, KIT, and FLT3-ITD phosphorylation in vitro (IC50s = 0.04, 0.02, 0.006, and 0.05 µM, respectively); inhibits PDGF-dependent proliferation of NIH3T3 cells overexpressing PDGFRβ, as well as OC1-AML5 cells expressing wild-type FLT3 and MV4-11 cells carrying the activating FLT3-ITD mutation; inhibits VEGF-induced survival of HUVECs (IC50 = 6.8 nM); reduces tumor growth in human acute myeloid leukemia, renal, and colon cancer, as well as rat glioma, mouse xenograft models when used at doses ranging from 10-80 mg/kg twice per day
31514	SU 14813	5 mg	≥95%	A dual VEGFR and PDGFR family kinase inhibitor (IC50s = 0.002, 0.05, 0.004, and 0.015 µM for VEGFR1, VEGFR2, PDGFRβ, and KIT, respectively); selective for these kinases over FGFR1, EGFR, Src, and c-Met (IC50s = 3.5, >20, 2.5, and 9 µM, respectively); inhibits VEGFR2, PDGFRβ, KIT, and FLT3-ITD phosphorylation in vitro (IC50s = 0.04, 0.02, 0.006, and 0.05 µM, respectively); inhibits PDGF-dependent proliferation of NIH3T3 cells overexpressing PDGFRβ, as well as OC1-AML5 cells expressing wild-type FLT3 and MV4-11 cells carrying the activating FLT3-ITD mutation; inhibits VEGF-induced survival of HUVECs (IC50 = 6.8 nM); reduces tumor growth in human acute myeloid leukemia, renal, and colon cancer, as well as rat glioma, mouse xenograft models when used at doses ranging from 10-80 mg/kg twice per day
31514	SU 14813	50 mg	≥95%	A dual VEGFR and PDGFR family kinase inhibitor (IC50s = 0.002, 0.05, 0.004, and 0.015 µM for VEGFR1, VEGFR2, PDGFRβ, and KIT, respectively); selective for these kinases over FGFR1, EGFR, Src, and c-Met (IC50s = 3.5, >20, 2.5, and 9 µM, respectively); inhibits VEGFR2, PDGFRβ, KIT, and FLT3-ITD phosphorylation in vitro (IC50s = 0.04, 0.02, 0.006, and 0.05 µM, respectively); inhibits PDGF-dependent proliferation of NIH3T3 cells overexpressing PDGFRβ, as well as OC1-AML5 cells expressing wild-type FLT3 and MV4-11 cells carrying the activating FLT3-ITD mutation; inhibits VEGF-induced survival of HUVECs (IC50 = 6.8 nM); reduces tumor growth in human acute myeloid leukemia, renal, and colon cancer, as well as rat glioma, mouse xenograft models when used at doses ranging from 10-80 mg/kg twice per day
31515	Dioctanoyl Glycol	10 mg	≥98%	A DGK inhibitor (Ki = 58 µM); reduces basal and thrombin-stimulated phosphatidic acid levels in washed isolated human platelets at 30, 100, and 500 µM; dietary administration inhibits the growth of S. litura and H. armigera second instar larvae (EC50s = 1.98 and 2.08 mg/ml, respectively) and induces mortality when applied as a spray (LC50s = 6.1 and 6.5 mg/ml, respectively)

31515	Dioctanoyl Glycol	25 mg	≥98%	A DGK inhibitor (Ki = 58 µM); reduces basal and thrombin-stimulated phosphatidic acid levels in washed isolated human platelets at 30, 100, and 500 µM; dietary administration inhibits the growth of S. litura and H. armigera second instar larvae (EC50s = 1.98 and 2.08 mg/ml, respectively) and induces mortality when applied as a spray (LC50s = 6.1 and 6.5 mg/ml, respectively)
31515	Dioctanoyl Glycol	5 mg	≥98%	A DGK inhibitor (Ki = 58 µM); reduces basal and thrombin-stimulated phosphatidic acid levels in washed isolated human platelets at 30, 100, and 500 µM; dietary administration inhibits the growth of S. litura and H. armigera second instar larvae (EC50s = 1.98 and 2.08 mg/ml, respectively) and induces mortality when applied as a spray (LC50s = 6.1 and 6.5 mg/ml, respectively)
31515	Dioctanoyl Glycol	50 mg	≥98%	A DGK inhibitor (Ki = 58 µM); reduces basal and thrombin-stimulated phosphatidic acid levels in washed isolated human platelets at 30, 100, and 500 µM; dietary administration inhibits the growth of S. litura and H. armigera second instar larvae (EC50s = 1.98 and 2.08 mg/ml, respectively) and induces mortality when applied as a spray (LC50s = 6.1 and 6.5 mg/ml, respectively)
31613	NMS-P715	1 mg	≥95%	An Mps1/TTK inhibitor (IC50 = 0.182 µM); selective for Mps1/TTK over a panel of 59 additional kinases (IC50s = >5 µM for all); accelerates mitosis, reducing the length of mitosis by approximately 3-fold, in U2OS cells; induces aneuploidy and apoptosis in A2780 ovarian cancer cells at 1 µM, as well as inhibits proliferation in a panel of 127 cancer cell lines (IC50s = 0.192-10 µM); reduces tumor growth in an A2780 mouse xenograft model at 90 mg/kg per day
31613	NMS-P715	10 mg	≥95%	An Mps1/TTK inhibitor (IC50 = 0.182 µM); selective for Mps1/TTK over a panel of 59 additional kinases (IC50s = >5 µM for all); accelerates mitosis, reducing the length of mitosis by approximately 3-fold, in U2OS cells; induces aneuploidy and apoptosis in A2780 ovarian cancer cells at 1 µM, as well as inhibits proliferation in a panel of 127 cancer cell lines (IC50s = 0.192-10 µM); reduces tumor growth in an A2780 mouse xenograft model at 90 mg/kg per day
31613	NMS-P715	25 mg	≥95%	An Mps1/TTK inhibitor (IC50 = 0.182 µM); selective for Mps1/TTK over a panel of 59 additional kinases (IC50s = >5 µM for all); accelerates mitosis, reducing the length of mitosis by approximately 3-fold, in U2OS cells; induces aneuploidy and apoptosis in A2780 ovarian cancer cells at 1 µM, as well as inhibits proliferation in a panel of 127 cancer cell lines (IC50s = 0.192-10 µM); reduces tumor growth in an A2780 mouse xenograft model at 90 mg/kg per day
31613	NMS-P715	5 mg	≥95%	An Mps1/TTK inhibitor (IC50 = 0.182 µM); selective for Mps1/TTK over a panel of 59 additional kinases (IC50s = >5 µM for all); accelerates mitosis, reducing the length of mitosis by approximately 3-fold, in U2OS cells; induces aneuploidy and apoptosis in A2780 ovarian cancer cells at 1 µM, as well as inhibits proliferation in a panel of 127 cancer cell lines (IC50s = 0.192-10 µM); reduces tumor growth in an A2780 mouse xenograft model at 90 mg/kg per day
31619	BIIB068	1 mg	≥98%	A BTK inhibitor (IC50 = <10 nM)
31619	BIIB068	10 mg	≥98%	A BTK inhibitor (IC50 = <10 nM)
31619	BIIB068	5 mg	≥98%	A BTK inhibitor (IC50 = <10 nM)
31631	9-Methoxyellipticine	1 mg	≥95%	An alkaloid with anticancer activity; intercalates into DNA; an inhibitor of wild-type c-Kit and c-KitD816V (IC50s = 0.8 and 0.6 µM, respectively); inhibits proliferation of Ba/F3 cells in the presence of SCF and Ba/F3 cells expressing c-KitD816V (IC50s = 0.5 and 0.3 µM, respectively); increases survival in rodent tumor models
31631	9-Methoxyellipticine	5 mg	≥95%	An alkaloid with anticancer activity; intercalates into DNA; an inhibitor of wild-type c-Kit and c-KitD816V (IC50s = 0.8 and 0.6 µM, respectively); inhibits proliferation of Ba/F3 cells in the presence of SCF and Ba/F3 cells expressing c-KitD816V (IC50s = 0.5 and 0.3 µM, respectively); increases survival in rodent tumor models
31754	Alofanib	100 mg	≥98%	An allosteric inhibitor of FGFR2; inhibits FGF2-induced phosphorylation of FRS2α in KATO III cells (IC50 = 10 nM); inhibits the growth of SKOV3 and Hs 578T cells (GI50s = 370 and 210 nM, respectively); inhibits bFGF-induced HUVEC proliferation (IC50 = 11 nM); inhibits SVEC4-10 cell tube formation at 50 nM; decreases the number of tumor microvessels by 50% in a SKOV3 ovarian serous carcinoma mouse model; reduces tumor growth in mouse xenograft models at 30 mg/kg per day
31754	Alofanib	25 mg	≥98%	An allosteric inhibitor of FGFR2; inhibits FGF2-induced phosphorylation of FRS2α in KATO III cells (IC50 = 10 nM); inhibits the growth of SKOV3 and Hs 578T cells (GI50s = 370 and 210 nM, respectively); inhibits bFGF-induced HUVEC proliferation (IC50 = 11 nM); inhibits SVEC4-10 cell tube formation at 50 nM; decreases the number of tumor microvessels by 50% in a SKOV3 ovarian serous carcinoma mouse model; reduces tumor growth in mouse xenograft models at 30 mg/kg per day

31754	Alofanib	5 mg	≥98%	An allosteric inhibitor of FGFR2; inhibits FGF2-induced phosphorylation of FRS2α in KATO III cells (IC50 = 10 nM); inhibits the growth of SKOV3 and Hs 578T cells (GI50s = 370 and 210 nM, respectively); inhibits bFGF-induced HUVEC proliferation (IC50 = 11 nM); inhibits SVEC4-10 cell tube formation at 50 nM; decreases the number of tumor microvessels by 50% in a SKOV3 ovarian serous carcinoma mouse model; reduces tumor growth in mouse xenograft models at 30 mg/kg per day
31754	Alofanib	50 mg	≥98%	An allosteric inhibitor of FGFR2; inhibits FGF2-induced phosphorylation of FRS2α in KATO III cells (IC50 = 10 nM); inhibits the growth of SKOV3 and Hs 578T cells (GI50s = 370 and 210 nM, respectively); inhibits bFGF-induced HUVEC proliferation (IC50 = 11 nM); inhibits SVEC4-10 cell tube formation at 50 nM; decreases the number of tumor microvessels by 50% in a SKOV3 ovarian serous carcinoma mouse model; reduces tumor growth in mouse xenograft models at 30 mg/kg per day
31761	PKCε Inhibitor Scramb	1 mg	≥95%	A negative control for PKCε inhibitor peptide; a scrambled peptide with identical amino acid composition to PKCε inhibitor peptide; intended for use as a negative control for PKCε inhibitor peptide activity
32518	Lanraplenib	1 mg	≥98%	A Syk inhibitor (IC50 = 6.2 nM); selective for Syk over a panel of 395 kinases but does inhibit JAK2 (IC50 = 120 nM); reduces anti-IgM- and anti-CD40-induced proliferation of isolated human B cells (EC50 = 108 nM); inhibits immune complex-induced production of TNF-α, IL-1β, and IL-6 in human macrophages (EC50s = 180, 90, and 700 nM, respectively); reduces proteinuria and increases survival in the NZBWF1 mouse model of SLE
32518	Lanraplenib	10 mg	≥98%	A Syk inhibitor (IC50 = 6.2 nM); selective for Syk over a panel of 395 kinases but does inhibit JAK2 (IC50 = 120 nM); reduces anti-IgM- and anti-CD40-induced proliferation of isolated human B cells (EC50 = 108 nM); inhibits immune complex-induced production of TNF-α, IL-1β, and IL-6 in human macrophages (EC50s = 180, 90, and 700 nM, respectively); reduces proteinuria and increases survival in the NZBWF1 mouse model of SLE
32518	Lanraplenib	5 mg	≥98%	A Syk inhibitor (IC50 = 6.2 nM); selective for Syk over a panel of 395 kinases but does inhibit JAK2 (IC50 = 120 nM); reduces anti-IgM- and anti-CD40-induced proliferation of isolated human B cells (EC50 = 108 nM); inhibits immune complex-induced production of TNF-α, IL-1β, and IL-6 in human macrophages (EC50s = 180, 90, and 700 nM, respectively); reduces proteinuria and increases survival in the NZBWF1 mouse model of SLE
32519	Simurosertib	1 mg	≥98%	An inhibitor of Cdc7 kinase (IC50 = 0.26 nM); selective for Cdc7 over Cdk2 and ROCK1 (IC50s = 6,300 and 430 nM, respectively); inhibits phosphorylation of MCM2 in HeLa cells (IC50 = 17 nM); reduces proliferation of COLO 205 cells (EC50 = 81 nM); inhibits the growth of a wide variety of cancer cells (GI50s = 30.2->10,000 nM); reduces intratumor levels of phosphorylated MCM2 in COLO 205 and SW948 mouse xenograft models at 80 mg/kg and reduces tumor growth in the same models when administered at doses of 40 or 60 mg/kg twice per day
32519	Simurosertib	10 mg	≥98%	An inhibitor of Cdc7 kinase (IC50 = 0.26 nM); selective for Cdc7 over Cdk2 and ROCK1 (IC50s = 6,300 and 430 nM, respectively); inhibits phosphorylation of MCM2 in HeLa cells (IC50 = 17 nM); reduces proliferation of COLO 205 cells (EC50 = 81 nM); inhibits the growth of a wide variety of cancer cells (GI50s = 30.2->10,000 nM); reduces intratumor levels of phosphorylated MCM2 in COLO 205 and SW948 mouse xenograft models at 80 mg/kg and reduces tumor growth in the same models when administered at doses of 40 or 60 mg/kg twice per day
32519	Simurosertib	5 mg	≥98%	An inhibitor of Cdc7 kinase (IC50 = 0.26 nM); selective for Cdc7 over Cdk2 and ROCK1 (IC50s = 6,300 and 430 nM, respectively); inhibits phosphorylation of MCM2 in HeLa cells (IC50 = 17 nM); reduces proliferation of COLO 205 cells (EC50 = 81 nM); inhibits the growth of a wide variety of cancer cells (GI50s = 30.2->10,000 nM); reduces intratumor levels of phosphorylated MCM2 in COLO 205 and SW948 mouse xenograft models at 80 mg/kg and reduces tumor growth in the same models when administered at doses of 40 or 60 mg/kg twice per day
32818	ONO-4059 (hydrochlo	10 mg	≥98%	A BTK inhibitor (IC50 = 2.2 nM); selective for BTK over LCK, LYN, and Fyn at 1 μM; inhibits B cell proliferation and activation in vitro and reduces tumor growth in a TMD8 mouse xenograft model
32818	ONO-4059 (hydrochlo	25 mg	≥98%	A BTK inhibitor (IC50 = 2.2 nM); selective for BTK over LCK, LYN, and Fyn at 1 μM; inhibits B cell proliferation and activation in vitro and reduces tumor growth in a TMD8 mouse xenograft model
32818	ONO-4059 (hydrochlo	5 mg	≥98%	A BTK inhibitor (IC50 = 2.2 nM); selective for BTK over LCK, LYN, and Fyn at 1 μM; inhibits B cell proliferation and activation in vitro and reduces tumor growth in a TMD8 mouse xenograft model
32818	ONO-4059 (hydrochlo	50 mg	≥98%	A BTK inhibitor (IC50 = 2.2 nM); selective for BTK over LCK, LYN, and Fyn at 1 μM; inhibits B cell proliferation and activation in vitro and reduces tumor growth in a TMD8 mouse xenograft model

32819	MLN120B	10 mg	≥98%	An IKKβ inhibitor (IC50 = 45 nM); selective for IKKβ over a panel of 30 tyrosine and serine/threonine kinases (IC50s = >50 μM for all); inhibits TPA-induced NF-κB activation (IC50 = 2.8 μM in a reporter assay); inhibits proliferation in a panel of six multiple myeloma cancer cell lines; reduces serum levels of soluble human IL-6 receptor in a SCID-hu mouse model of bone marrow-engrafted INA-6 multiple myeloma at 50 mg/kg; reduces paw swelling, as well as cartilage destruction and bone erosion in the inflamed joints, in a rat model of CFA-induced rheumatoid arthritis (MED = 12 mg/kg)
32819	MLN120B	25 mg	≥98%	An IKKβ inhibitor (IC50 = 45 nM); selective for IKKβ over a panel of 30 tyrosine and serine/threonine kinases (IC50s = >50 μM for all); inhibits TPA-induced NF-κB activation (IC50 = 2.8 μM in a reporter assay); inhibits proliferation in a panel of six multiple myeloma cancer cell lines; reduces serum levels of soluble human IL-6 receptor in a SCID-hu mouse model of bone marrow-engrafted INA-6 multiple myeloma at 50 mg/kg; reduces paw swelling, as well as cartilage destruction and bone erosion in the inflamed joints, in a rat model of CFA-induced rheumatoid arthritis (MED = 12 mg/kg)
32819	MLN120B	5 mg	≥98%	An IKKβ inhibitor (IC50 = 45 nM); selective for IKKβ over a panel of 30 tyrosine and serine/threonine kinases (IC50s = >50 μM for all); inhibits TPA-induced NF-κB activation (IC50 = 2.8 μM in a reporter assay); inhibits proliferation in a panel of six multiple myeloma cancer cell lines; reduces serum levels of soluble human IL-6 receptor in a SCID-hu mouse model of bone marrow-engrafted INA-6 multiple myeloma at 50 mg/kg; reduces paw swelling, as well as cartilage destruction and bone erosion in the inflamed joints, in a rat model of CFA-induced rheumatoid arthritis (MED = 12 mg/kg)
32819	MLN120B	50 mg	≥98%	An IKKβ inhibitor (IC50 = 45 nM); selective for IKKβ over a panel of 30 tyrosine and serine/threonine kinases (IC50s = >50 μM for all); inhibits TPA-induced NF-κB activation (IC50 = 2.8 μM in a reporter assay); inhibits proliferation in a panel of six multiple myeloma cancer cell lines; reduces serum levels of soluble human IL-6 receptor in a SCID-hu mouse model of bone marrow-engrafted INA-6 multiple myeloma at 50 mg/kg; reduces paw swelling, as well as cartilage destruction and bone erosion in the inflamed joints, in a rat model of CFA-induced rheumatoid arthritis (MED = 12 mg/kg)
32820	ZM 449829	10 mg	≥95%	An inhibitor of JAK3 (IC50 = 0.158 μM) and a degradation product of ZM 329923; selective for JAK3 over EGFR and JAK1 (IC50s = 10 and 19.95 μM, respectively) but does inhibit TGM2 and FXIIIa (IC50s = 0.005 and 0.006 μM, respectively); decreases the formation of CSC within MCF-7-derived mammospheres; decreases migration of, and colony formation by, MCF-7 cells at 10 μM; inhibits formation of replication vacuoles in C. burnetii-infected HeLa and THP-1 cells at 10 μM
32820	ZM 449829	25 mg	≥95%	An inhibitor of JAK3 (IC50 = 0.158 μM) and a degradation product of ZM 329923; selective for JAK3 over EGFR and JAK1 (IC50s = 10 and 19.95 μM, respectively) but does inhibit TGM2 and FXIIIa (IC50s = 0.005 and 0.006 μM, respectively); decreases the formation of CSC within MCF-7-derived mammospheres; decreases migration of, and colony formation by, MCF-7 cells at 10 μM; inhibits formation of replication vacuoles in C. burnetii-infected HeLa and THP-1 cells at 10 μM
32820	ZM 449829	5 mg	≥95%	An inhibitor of JAK3 (IC50 = 0.158 μM) and a degradation product of ZM 329923; selective for JAK3 over EGFR and JAK1 (IC50s = 10 and 19.95 μM, respectively) but does inhibit TGM2 and FXIIIa (IC50s = 0.005 and 0.006 μM, respectively); decreases the formation of CSC within MCF-7-derived mammospheres; decreases migration of, and colony formation by, MCF-7 cells at 10 μM; inhibits formation of replication vacuoles in C. burnetii-infected HeLa and THP-1 cells at 10 μM
32820	ZM 449829	50 mg	≥95%	An inhibitor of JAK3 (IC50 = 0.158 μM) and a degradation product of ZM 329923; selective for JAK3 over EGFR and JAK1 (IC50s = 10 and 19.95 μM, respectively) but does inhibit TGM2 and FXIIIa (IC50s = 0.005 and 0.006 μM, respectively); decreases the formation of CSC within MCF-7-derived mammospheres; decreases migration of, and colony formation by, MCF-7 cells at 10 μM; inhibits formation of replication vacuoles in C. burnetii-infected HeLa and THP-1 cells at 10 μM
32843	NSC 625987	1 mg	≥98%	A Cdk4/cyclin D1 complex inhibitor (IC50 = 0.2 μM); selective for the Cdk4/cyclin D1 complex over Cdk2/cyclin A, Cdk2/cyclin E, and Cdk1/cyclin A complexes (IC50s = >100 μM for all)
32843	NSC 625987	5 mg	≥98%	A Cdk4/cyclin D1 complex inhibitor (IC50 = 0.2 μM); selective for the Cdk4/cyclin D1 complex over Cdk2/cyclin A, Cdk2/cyclin E, and Cdk1/cyclin A complexes (IC50s = >100 μM for all)

32854	A-770041	1 mg	≥98%	An orally bioavailable LCK kinase inhibitor (IC50 = 0.147 µM); selective for LCK over Src, Fyn, Fgr, HCK, and Tie2 (IC50s = 9.05, 44.1, 14.1, 1.22, and >50 µM, respectively); inhibits IL-2 production induced by an anti-CD3 antibody and PMA in isolated human whole blood (EC50 = 80 nM) and by concanavalin A in rats; prevents acute rejection and increases graft survival in a rat model of heterotopic heart transplantation at 10 mg/kg; inhibits the growth of CTV-1 cells (IC50 = 224 nM) and sensitizes U2OSMR and KHOSR2 multidrug resistant human osteosarcoma cells to paclitaxel and doxorubicin
32854	A-770041	5 mg	≥98%	An orally bioavailable LCK kinase inhibitor (IC50 = 0.147 µM); selective for LCK over Src, Fyn, Fgr, HCK, and Tie2 (IC50s = 9.05, 44.1, 14.1, 1.22, and >50 µM, respectively); inhibits IL-2 production induced by an anti-CD3 antibody and PMA in isolated human whole blood (EC50 = 80 nM) and by concanavalin A in rats; prevents acute rejection and increases graft survival in a rat model of heterotopic heart transplantation at 10 mg/kg; inhibits the growth of CTV-1 cells (IC50 = 224 nM) and sensitizes U2OSMR and KHOSR2 multidrug resistant human osteosarcoma cells to paclitaxel and doxorubicin
32877	TGR-1202	100 mg	≥98%	A PI3K p110δ inhibitor (IC50 = 22 nM); selective for p110δ over p110α, p110β, and p110γ (IC50s = >10,000, 1,116, and 1,065 nM, respectively); induces apoptosis in patient-derived chronic lymphocytic leukemia lymphocytes from 0.1-25.6 µM; reduces tumor growth in a MOLT-4 T-ALL mouse xenograft model
32877	TGR-1202	25 mg	≥98%	A PI3K p110δ inhibitor (IC50 = 22 nM); selective for p110δ over p110α, p110β, and p110γ (IC50s = >10,000, 1,116, and 1,065 nM, respectively); induces apoptosis in patient-derived chronic lymphocytic leukemia lymphocytes from 0.1-25.6 µM; reduces tumor growth in a MOLT-4 T-ALL mouse xenograft model
32877	TGR-1202	5 mg	≥98%	A PI3K p110δ inhibitor (IC50 = 22 nM); selective for p110δ over p110α, p110β, and p110γ (IC50s = >10,000, 1,116, and 1,065 nM, respectively); induces apoptosis in patient-derived chronic lymphocytic leukemia lymphocytes from 0.1-25.6 µM; reduces tumor growth in a MOLT-4 T-ALL mouse xenograft model
32877	TGR-1202	50 mg	≥98%	A PI3K p110δ inhibitor (IC50 = 22 nM); selective for p110δ over p110α, p110β, and p110γ (IC50s = >10,000, 1,116, and 1,065 nM, respectively); induces apoptosis in patient-derived chronic lymphocytic leukemia lymphocytes from 0.1-25.6 µM; reduces tumor growth in a MOLT-4 T-ALL mouse xenograft model
32957	ONO-4059	10 mg	≥98%	A BTK inhibitor (IC50 = 2.2 nM); selective for BTK over LCK, LYN, and Fyn at 1 µM; inhibits B cell proliferation and activation in vitro and reduces tumor growth in a TMD8 mouse xenograft model
32957	ONO-4059	25 mg	≥98%	A BTK inhibitor (IC50 = 2.2 nM); selective for BTK over LCK, LYN, and Fyn at 1 µM; inhibits B cell proliferation and activation in vitro and reduces tumor growth in a TMD8 mouse xenograft model
32957	ONO-4059	5 mg	≥98%	A BTK inhibitor (IC50 = 2.2 nM); selective for BTK over LCK, LYN, and Fyn at 1 µM; inhibits B cell proliferation and activation in vitro and reduces tumor growth in a TMD8 mouse xenograft model
32957	ONO-4059	50 mg	≥98%	A BTK inhibitor (IC50 = 2.2 nM); selective for BTK over LCK, LYN, and Fyn at 1 µM; inhibits B cell proliferation and activation in vitro and reduces tumor growth in a TMD8 mouse xenograft model
32964	MK-2461	1 mg	≥98%	A c-MET inhibitor (IC50s = 0.4-2 nM for wild-type and mutant forms); selective for c-MET over a panel of 13 additional kinases (IC50s = 22-7,800 nM) but does inhibit Ron and FLT1 (IC50s = 7 and 10 nM, respectively); inhibits autophosphorylation of FGFR2 and PDGFRα in KATO III cells at 2 µM; reduces proliferation in a panel of cancer cell lines, including cells expressing constitutively active c-MET, FGFR2, or PDGFR (IC50s =≤ 1 µM for all); reduces tumor growth in a GTL-16 gastric cancer mouse xenograft model (10-200 mg/kg)
32964	MK-2461	10 mg	≥98%	A c-MET inhibitor (IC50s = 0.4-2 nM for wild-type and mutant forms); selective for c-MET over a panel of 13 additional kinases (IC50s = 22-7,800 nM) but does inhibit Ron and FLT1 (IC50s = 7 and 10 nM, respectively); inhibits autophosphorylation of FGFR2 and PDGFRα in KATO III cells at 2 µM; reduces proliferation in a panel of cancer cell lines, including cells expressing constitutively active c-MET, FGFR2, or PDGFR (IC50s =≤ 1 µM for all); reduces tumor growth in a GTL-16 gastric cancer mouse xenograft model (10-200 mg/kg)
32964	MK-2461	5 mg	≥98%	A c-MET inhibitor (IC50s = 0.4-2 nM for wild-type and mutant forms); selective for c-MET over a panel of 13 additional kinases (IC50s = 22-7,800 nM) but does inhibit Ron and FLT1 (IC50s = 7 and 10 nM, respectively); inhibits autophosphorylation of FGFR2 and PDGFRα in KATO III cells at 2 µM; reduces proliferation in a panel of cancer cell lines, including cells expressing constitutively active c-MET, FGFR2, or PDGFR (IC50s =≤ 1 µM for all); reduces tumor growth in a GTL-16 gastric cancer mouse xenograft model (10-200 mg/kg)

32988	SBP-7455	1 mg	≥98%	A dual inhibitor of ULK1 and ULK2 (IC50s = 13 and 476 nM, respectively, for the recombinant human enzymes in cell-free assays); inhibits increases in autophagic flux and induces apoptosis in serum-deprived MDA-MB-468 breast cancer cells at 10 µM; reduces the viability of MDA-MB-468 cells at 0.19 µM alone or in combination with olaparib
32988	SBP-7455	10 mg	≥98%	A dual inhibitor of ULK1 and ULK2 (IC50s = 13 and 476 nM, respectively, for the recombinant human enzymes in cell-free assays); inhibits increases in autophagic flux and induces apoptosis in serum-deprived MDA-MB-468 breast cancer cells at 10 µM; reduces the viability of MDA-MB-468 cells at 0.19 µM alone or in combination with olaparib
32988	SBP-7455	25 mg	≥98%	A dual inhibitor of ULK1 and ULK2 (IC50s = 13 and 476 nM, respectively, for the recombinant human enzymes in cell-free assays); inhibits increases in autophagic flux and induces apoptosis in serum-deprived MDA-MB-468 breast cancer cells at 10 µM; reduces the viability of MDA-MB-468 cells at 0.19 µM alone or in combination with olaparib
32988	SBP-7455	5 mg	≥98%	A dual inhibitor of ULK1 and ULK2 (IC50s = 13 and 476 nM, respectively, for the recombinant human enzymes in cell-free assays); inhibits increases in autophagic flux and induces apoptosis in serum-deprived MDA-MB-468 breast cancer cells at 10 µM; reduces the viability of MDA-MB-468 cells at 0.19 µM alone or in combination with olaparib
33073	Lyso-Monosialogangli	500 µg	≥98%	A ganglioside lacking the fatty acyl group; inhibits PKC in a cell-free assay (IC50 = 50 µM); gray matter levels are increased in postmortem brain samples from patients with Sandhoff disease or Tay-Sachs disease, as well as a mouse model of Sandhoff disease
33137	MDK34597	1 mg	≥98%	A PI3K p110α inhibitor (IC50 = 141.25 nM)
33137	MDK34597	10 mg	≥98%	A PI3K p110α inhibitor (IC50 = 141.25 nM)
33137	MDK34597	5 mg	≥98%	A PI3K p110α inhibitor (IC50 = 141.25 nM)
33180	Pachymic Acid	10 mg	≥98%	A triterpenoid with diverse biological activities; inhibits HK2 (IC50 = 5.01 µM); reduces glucose uptake and lactate production in SK-BR-3 breast cancer cells; inhibits IL-1β-induced cPLA2 activation and PGE2 production in, and inhibits the proliferation of, A549 lung cancer cells; decreases tumor growth in an NCI H23 lung cancer mouse xenograft model at 30 and 60 mg/kg; prevents increases in serum urea and creatinine levels in a mouse model of renal ischemia-reperfusion injury at 10 and 20 mg/kg
33180	Pachymic Acid	25 mg	≥98%	A triterpenoid with diverse biological activities; inhibits HK2 (IC50 = 5.01 µM); reduces glucose uptake and lactate production in SK-BR-3 breast cancer cells; inhibits IL-1β-induced cPLA2 activation and PGE2 production in, and inhibits the proliferation of, A549 lung cancer cells; decreases tumor growth in an NCI H23 lung cancer mouse xenograft model at 30 and 60 mg/kg; prevents increases in serum urea and creatinine levels in a mouse model of renal ischemia-reperfusion injury at 10 and 20 mg/kg
33180	Pachymic Acid	5 mg	≥98%	A triterpenoid with diverse biological activities; inhibits HK2 (IC50 = 5.01 µM); reduces glucose uptake and lactate production in SK-BR-3 breast cancer cells; inhibits IL-1β-induced cPLA2 activation and PGE2 production in, and inhibits the proliferation of, A549 lung cancer cells; decreases tumor growth in an NCI H23 lung cancer mouse xenograft model at 30 and 60 mg/kg; prevents increases in serum urea and creatinine levels in a mouse model of renal ischemia-reperfusion injury at 10 and 20 mg/kg
33213	Marein	1 mg	≥95%	A glucoside chalcone; scavenges DPPH radicals (IC50 = 48.35 µM); inhibits EGFR (IC50 = 19.94 µM); reduces fasting blood glucose and fasting serum insulin, triglycerides, LDL cholesterol, total cholesterol, IL-6, and CCL2 levels and renal IL-6 and CCL2 levels, as well as decreases fibrosis, in diabetic db/db mice at 50 mg/kg
33213	Marein	10 mg	≥95%	A glucoside chalcone; scavenges DPPH radicals (IC50 = 48.35 µM); inhibits EGFR (IC50 = 19.94 µM); reduces fasting blood glucose and fasting serum insulin, triglycerides, LDL cholesterol, total cholesterol, IL-6, and CCL2 levels and renal IL-6 and CCL2 levels, as well as decreases fibrosis, in diabetic db/db mice at 50 mg/kg
33213	Marein	5 mg	≥95%	A glucoside chalcone; scavenges DPPH radicals (IC50 = 48.35 µM); inhibits EGFR (IC50 = 19.94 µM); reduces fasting blood glucose and fasting serum insulin, triglycerides, LDL cholesterol, total cholesterol, IL-6, and CCL2 levels and renal IL-6 and CCL2 levels, as well as decreases fibrosis, in diabetic db/db mice at 50 mg/kg
33223	Olomoucine II	1 mg	≥98%	A CDK inhibitor (IC50s = 7.6, 0.1, 19.8, 0.45, and 0.06 µM for Cdk1, -2, -4, -7, and -9, respectively); selective for CDKs over 10 additional kinases (IC50s = >100 µM for all) but does inhibit ERK2 (IC50 = 32 µM) and ABCB1(IC50 = 6.4 µM); inhibits proliferation of a variety of cancer cells, including those expressing wild-type p53 or mutant p53 (mean IC50s = 7.4 and 10.1 µM, respectively); inhibits replication of HSV-1, HSV-2, vaccinia virus, Ad4, and human CMV (IC50s = 5, 4.7, 3.8, 2.4, 3.2 µM, respectively)

33229	SGC-GAK-1	10 mg	≥98%	A GAK inhibitor (Ki = 3.1 nM); >50-fold selective for GAK over a panel of 400 kinases at 1 µM but does bind to RIPK2 (IC50 = 360 nM in a BRET engagement assay); reduces the viability of LNCaP and 22Rv1 prostate cancer cells (IC50s = 0.65 and 0.17 µM, respectively); inhibits dengue virus infection in Huh7 cells (EC50 = 0.08 µM)
33229	SGC-GAK-1	25 mg	≥98%	A GAK inhibitor (Ki = 3.1 nM); >50-fold selective for GAK over a panel of 400 kinases at 1 µM but does bind to RIPK2 (IC50 = 360 nM in a BRET engagement assay); reduces the viability of LNCaP and 22Rv1 prostate cancer cells (IC50s = 0.65 and 0.17 µM, respectively); inhibits dengue virus infection in Huh7 cells (EC50 = 0.08 µM)
33229	SGC-GAK-1	5 mg	≥98%	A GAK inhibitor (Ki = 3.1 nM); >50-fold selective for GAK over a panel of 400 kinases at 1 µM but does bind to RIPK2 (IC50 = 360 nM in a BRET engagement assay); reduces the viability of LNCaP and 22Rv1 prostate cancer cells (IC50s = 0.65 and 0.17 µM, respectively); inhibits dengue virus infection in Huh7 cells (EC50 = 0.08 µM)
33229	SGC-GAK-1	50 mg	≥98%	A GAK inhibitor (Ki = 3.1 nM); >50-fold selective for GAK over a panel of 400 kinases at 1 µM but does bind to RIPK2 (IC50 = 360 nM in a BRET engagement assay); reduces the viability of LNCaP and 22Rv1 prostate cancer cells (IC50s = 0.65 and 0.17 µM, respectively); inhibits dengue virus infection in Huh7 cells (EC50 = 0.08 µM)
33258	ONO-7475	1 mg	≥98%	An inhibitor of Axl and Mer (IC50s = 0.7 and 1 nM, respectively); selective for Axl and Mer over FLT3 (IC50 = 147 nM); reduces viability of, and induces apoptosis in, MOLM-13 and MV4-11 leukemia cells at 10 nM; reduces leukemic burden and increases the median survival time in a MOLM-13 mouse xenograft model at 6 mg/kg
33258	ONO-7475	10 mg	≥98%	An inhibitor of Axl and Mer (IC50s = 0.7 and 1 nM, respectively); selective for Axl and Mer over FLT3 (IC50 = 147 nM); reduces viability of, and induces apoptosis in, MOLM-13 and MV4-11 leukemia cells at 10 nM; reduces leukemic burden and increases the median survival time in a MOLM-13 mouse xenograft model at 6 mg/kg
33258	ONO-7475	25 mg	≥98%	An inhibitor of Axl and Mer (IC50s = 0.7 and 1 nM, respectively); selective for Axl and Mer over FLT3 (IC50 = 147 nM); reduces viability of, and induces apoptosis in, MOLM-13 and MV4-11 leukemia cells at 10 nM; reduces leukemic burden and increases the median survival time in a MOLM-13 mouse xenograft model at 6 mg/kg
33258	ONO-7475	5 mg	≥98%	An inhibitor of Axl and Mer (IC50s = 0.7 and 1 nM, respectively); selective for Axl and Mer over FLT3 (IC50 = 147 nM); reduces viability of, and induces apoptosis in, MOLM-13 and MV4-11 leukemia cells at 10 nM; reduces leukemic burden and increases the median survival time in a MOLM-13 mouse xenograft model at 6 mg/kg
33260	Pemigatinib	1 mg	≥98%	An FGFR inhibitor (IC50s = 0.4, 0.5, and 1 nM for FGFR1, FGFR2, and FGFR3, respectively); selective for FGFR1, FGFR2, and FGFR3 over FGFR4 and KDR (IC50s = 30 and 70 nM, respectively), as well as over a panel of 56 tyrosine and serine/threonine kinases at 10 µM; reduces phosphorylation of FGFR, ERK1/2, and STAT5 in KG-1a acute myeloid leukemia cells in a concentration-dependent manner; inhibits growth in a panel of cancer cell lines expressing constitutively active FGFR (GI50s = 3-362 nM); reduces tumor growth in KATO III, KG-1, and RT-112 mouse xenograft model at 0.3 mg/kg
33260	Pemigatinib	10 mg	≥98%	An FGFR inhibitor (IC50s = 0.4, 0.5, and 1 nM for FGFR1, FGFR2, and FGFR3, respectively); selective for FGFR1, FGFR2, and FGFR3 over FGFR4 and KDR (IC50s = 30 and 70 nM, respectively), as well as over a panel of 56 tyrosine and serine/threonine kinases at 10 µM; reduces phosphorylation of FGFR, ERK1/2, and STAT5 in KG-1a acute myeloid leukemia cells in a concentration-dependent manner; inhibits growth in a panel of cancer cell lines expressing constitutively active FGFR (GI50s = 3-362 nM); reduces tumor growth in KATO III, KG-1, and RT-112 mouse xenograft model at 0.3 mg/kg
33260	Pemigatinib	25 mg	≥98%	An FGFR inhibitor (IC50s = 0.4, 0.5, and 1 nM for FGFR1, FGFR2, and FGFR3, respectively); selective for FGFR1, FGFR2, and FGFR3 over FGFR4 and KDR (IC50s = 30 and 70 nM, respectively), as well as over a panel of 56 tyrosine and serine/threonine kinases at 10 µM; reduces phosphorylation of FGFR, ERK1/2, and STAT5 in KG-1a acute myeloid leukemia cells in a concentration-dependent manner; inhibits growth in a panel of cancer cell lines expressing constitutively active FGFR (GI50s = 3-362 nM); reduces tumor growth in KATO III, KG-1, and RT-112 mouse xenograft model at 0.3 mg/kg

33260	Pemigatinib	5 mg	≥98%	An FGFR inhibitor (IC50s = 0.4, 0.5, and 1 nM for FGFR1, FGFR2, and FGFR3, respectively); selective for FGFR1, FGFR2, and FGFR3 over FGFR4 and KDR (IC50s = 30 and 70 nM, respectively), as well as over a panel of 56 tyrosine and serine/threonine kinases at 10 μM; reduces phosphorylation of FGFR, ERK1/2, and STAT5 in KG-1a acute myeloid leukemia cells in a concentration-dependent manner; inhibits growth in a panel of cancer cell lines expressing constitutively active FGFR (GI50s = 3-362 nM); reduces tumor growth in KATO III, KG-1, and RT-112 mouse xenograft model at 0.3 mg/kg
33267	IRAK Inhibitor 6	1 mg	≥98%	An IRAK4 inhibitor (IC50 = 160 nM)
33267	IRAK Inhibitor 6	10 mg	≥98%	An IRAK4 inhibitor (IC50 = 160 nM)
33267	IRAK Inhibitor 6	5 mg	≥98%	An IRAK4 inhibitor (IC50 = 160 nM)
33268	NCB-0846	1 mg	≥90%	A TNIK inhibitor (IC50 = 21 nM); selective for TNIK over a panel of 46 kinases but does inhibit FLT3, JAK3, PDGFRα, TrkA, Cdk2/CycA2, and HGK by >80% at 100 nM; inhibits phosphorylation of TCF4 and autophosphorylation of TNIK in cell-based assays at 3 μM; inhibits the growth and colony formation of HCT116 cells in two-dimensional growth and soft-agar assays, respectively, as well as reduces tumor growth in an HCT116 mouse xenograft model; reduces tumor growth in PDX mouse models of colon cancer at 50 and 100 mg/kg
33268	NCB-0846	25 mg	≥90%	A TNIK inhibitor (IC50 = 21 nM); selective for TNIK over a panel of 46 kinases but does inhibit FLT3, JAK3, PDGFRα, TrkA, Cdk2/CycA2, and HGK by >80% at 100 nM; inhibits phosphorylation of TCF4 and autophosphorylation of TNIK in cell-based assays at 3 μM; inhibits the growth and colony formation of HCT116 cells in two-dimensional growth and soft-agar assays, respectively, as well as reduces tumor growth in an HCT116 mouse xenograft model; reduces tumor growth in PDX mouse models of colon cancer at 50 and 100 mg/kg
33268	NCB-0846	5 mg	≥90%	A TNIK inhibitor (IC50 = 21 nM); selective for TNIK over a panel of 46 kinases but does inhibit FLT3, JAK3, PDGFRα, TrkA, Cdk2/CycA2, and HGK by >80% at 100 nM; inhibits phosphorylation of TCF4 and autophosphorylation of TNIK in cell-based assays at 3 μM; inhibits the growth and colony formation of HCT116 cells in two-dimensional growth and soft-agar assays, respectively, as well as reduces tumor growth in an HCT116 mouse xenograft model; reduces tumor growth in PDX mouse models of colon cancer at 50 and 100 mg/kg
33268	NCB-0846	50 mg	≥90%	A TNIK inhibitor (IC50 = 21 nM); selective for TNIK over a panel of 46 kinases but does inhibit FLT3, JAK3, PDGFRα, TrkA, Cdk2/CycA2, and HGK by >80% at 100 nM; inhibits phosphorylation of TCF4 and autophosphorylation of TNIK in cell-based assays at 3 μM; inhibits the growth and colony formation of HCT116 cells in two-dimensional growth and soft-agar assays, respectively, as well as reduces tumor growth in an HCT116 mouse xenograft model; reduces tumor growth in PDX mouse models of colon cancer at 50 and 100 mg/kg
33332	Savolitinib	1 mg	≥98%	An inhibitor of c-Met (IC50 = 5 nM); selectivity inhibits c-Met over 274 other kinases at 1 μM; inhibits c-Met autophosphorylation in NCI H441 human NSCLC cells (IC50 = 3 nM); inhibits HGF-induced growth of NCI H441 cells (IC50 = 6 nM); inhibits proliferation in a panel of gastric cancer cells with dysregulated c-Met (EC50s = 0.6-14.7 nM); inhibits intratumor c-Met autophosphorylation by 94% and reduces tumor growth in a Hs 746T human stomach cancer mouse xenograft model at 3 mg/kg
33332	Savolitinib	10 mg	≥98%	An inhibitor of c-Met (IC50 = 5 nM); selectivity inhibits c-Met over 274 other kinases at 1 μM; inhibits c-Met autophosphorylation in NCI H441 human NSCLC cells (IC50 = 3 nM); inhibits HGF-induced growth of NCI H441 cells (IC50 = 6 nM); inhibits proliferation in a panel of gastric cancer cells with dysregulated c-Met (EC50s = 0.6-14.7 nM); inhibits intratumor c-Met autophosphorylation by 94% and reduces tumor growth in a Hs 746T human stomach cancer mouse xenograft model at 3 mg/kg
33332	Savolitinib	25 mg	≥98%	An inhibitor of c-Met (IC50 = 5 nM); selectivity inhibits c-Met over 274 other kinases at 1 μM; inhibits c-Met autophosphorylation in NCI H441 human NSCLC cells (IC50 = 3 nM); inhibits HGF-induced growth of NCI H441 cells (IC50 = 6 nM); inhibits proliferation in a panel of gastric cancer cells with dysregulated c-Met (EC50s = 0.6-14.7 nM); inhibits intratumor c-Met autophosphorylation by 94% and reduces tumor growth in a Hs 746T human stomach cancer mouse xenograft model at 3 mg/kg
33332	Savolitinib	5 mg	≥98%	An inhibitor of c-Met (IC50 = 5 nM); selectivity inhibits c-Met over 274 other kinases at 1 μM; inhibits c-Met autophosphorylation in NCI H441 human NSCLC cells (IC50 = 3 nM); inhibits HGF-induced growth of NCI H441 cells (IC50 = 6 nM); inhibits proliferation in a panel of gastric cancer cells with dysregulated c-Met (EC50s = 0.6-14.7 nM); inhibits intratumor c-Met autophosphorylation by 94% and reduces tumor growth in a Hs 746T human stomach cancer mouse xenograft model at 3 mg/kg

33335	AG-556	10 mg	≥98%	An EGFR inhibitor (IC50 = 5 µM); selective for EGFR over HER2 (IC50 = >500 µM); inhibits EGF-induced growth of HER14 cells (IC50 = 3 µM); inhibits hydrogen peroxide-induced increases in intracellular calcium in HEK293 cells expressing TRPM2 (IC50 = 0.94 µM), as well as HEK293 cells expressing TRPA1 at 3 µM; reduces the incidence, severity, and duration of disease in a mouse model of EAE at 200 µg/animal per day; reduces edema, demyelination, and MPO activity in spinal cord tissue, as well as improves motor function in a mouse model of extradural compression-induced spinal cord injury at 10 mg/kg
33335	AG-556	25 mg	≥98%	An EGFR inhibitor (IC50 = 5 µM); selective for EGFR over HER2 (IC50 = >500 µM); inhibits EGF-induced growth of HER14 cells (IC50 = 3 µM); inhibits hydrogen peroxide-induced increases in intracellular calcium in HEK293 cells expressing TRPM2 (IC50 = 0.94 µM), as well as HEK293 cells expressing TRPA1 at 3 µM; reduces the incidence, severity, and duration of disease in a mouse model of EAE at 200 µg/animal per day; reduces edema, demyelination, and MPO activity in spinal cord tissue, as well as improves motor function in a mouse model of extradural compression-induced spinal cord injury at 10 mg/kg
33347	Edicotinib	1 mg	≥98%	A CSF1R inhibitor (IC50 = 3.2 nM); selective for CSF1R over KIT and FLT3 (IC50s = 20 and 190 nM, respectively); reduces CSF1-induced phosphorylation of CSF1R and ERK1/2 in N13 microglia at 0.1-1,000 nM; reduces spinal motor neuron degeneration and increases the latency to fall in the rotarod test in the P301S mouse model of tauopathy; reduces increases in the colonic weight to length ratio, as well as decreases colonic infiltration of macrophages, neutrophils, and CD3+ T cells, in an adoptive T cell transfer-induced mouse model of colitis at 15 mg/kg
33347	Edicotinib	10 mg	≥98%	A CSF1R inhibitor (IC50 = 3.2 nM); selective for CSF1R over KIT and FLT3 (IC50s = 20 and 190 nM, respectively); reduces CSF1-induced phosphorylation of CSF1R and ERK1/2 in N13 microglia at 0.1-1,000 nM; reduces spinal motor neuron degeneration and increases the latency to fall in the rotarod test in the P301S mouse model of tauopathy; reduces increases in the colonic weight to length ratio, as well as decreases colonic infiltration of macrophages, neutrophils, and CD3+ T cells, in an adoptive T cell transfer-induced mouse model of colitis at 15 mg/kg
33347	Edicotinib	25 mg	≥98%	A CSF1R inhibitor (IC50 = 3.2 nM); selective for CSF1R over KIT and FLT3 (IC50s = 20 and 190 nM, respectively); reduces CSF1-induced phosphorylation of CSF1R and ERK1/2 in N13 microglia at 0.1-1,000 nM; reduces spinal motor neuron degeneration and increases the latency to fall in the rotarod test in the P301S mouse model of tauopathy; reduces increases in the colonic weight to length ratio, as well as decreases colonic infiltration of macrophages, neutrophils, and CD3+ T cells, in an adoptive T cell transfer-induced mouse model of colitis at 15 mg/kg
33347	Edicotinib	5 mg	≥98%	A CSF1R inhibitor (IC50 = 3.2 nM); selective for CSF1R over KIT and FLT3 (IC50s = 20 and 190 nM, respectively); reduces CSF1-induced phosphorylation of CSF1R and ERK1/2 in N13 microglia at 0.1-1,000 nM; reduces spinal motor neuron degeneration and increases the latency to fall in the rotarod test in the P301S mouse model of tauopathy; reduces increases in the colonic weight to length ratio, as well as decreases colonic infiltration of macrophages, neutrophils, and CD3+ T cells, in an adoptive T cell transfer-induced mouse model of colitis at 15 mg/kg
33431	RIPA-56	10 mg	≥98%	A RIPK1 inhibitor (IC50 = 13 nM); selective for RIPK1 over RIPK3 at 10 µM, as well as over a panel of additional kinases at 2 µM; inhibits Z-VAD-FMK-induced necrosis in HT-29 cells (EC50 = 28 nM); reduces TNF-α-induced lethality and protects against TNF-α-induced organ damage in a mouse model of SIRS at 6 mg/kg; reduces spinal cord demyelination and BBB breakdown in a mouse model of EAE; reduces hepatic inflammatory cell infiltration and fibrosis, as well as body weight gain and total fat mass, in a mouse model of high-fat diet-induced NASH at 300 mg/kg
33431	RIPA-56	25 mg	≥98%	A RIPK1 inhibitor (IC50 = 13 nM); selective for RIPK1 over RIPK3 at 10 µM, as well as over a panel of additional kinases at 2 µM; inhibits Z-VAD-FMK-induced necrosis in HT-29 cells (EC50 = 28 nM); reduces TNF-α-induced lethality and protects against TNF-α-induced organ damage in a mouse model of SIRS at 6 mg/kg; reduces spinal cord demyelination and BBB breakdown in a mouse model of EAE; reduces hepatic inflammatory cell infiltration and fibrosis, as well as body weight gain and total fat mass, in a mouse model of high-fat diet-induced NASH at 300 mg/kg
33431	RIPA-56	5 mg	≥98%	A RIPK1 inhibitor (IC50 = 13 nM); selective for RIPK1 over RIPK3 at 10 µM, as well as over a panel of additional kinases at 2 µM; inhibits Z-VAD-FMK-induced necrosis in HT-29 cells (EC50 = 28 nM); reduces TNF-α-induced lethality and protects against TNF-α-induced organ damage in a mouse model of SIRS at 6 mg/kg; reduces spinal cord demyelination and BBB breakdown in a mouse model of EAE; reduces hepatic inflammatory cell infiltration and fibrosis, as well as body weight gain and total fat mass, in a mouse model of high-fat diet-induced NASH at 300 mg/kg
33431	RIPA-56	50 mg	≥98%	A RIPK1 inhibitor (IC50 = 13 nM); selective for RIPK1 over RIPK3 at 10 µM, as well as over a panel of additional kinases at 2 µM; inhibits Z-VAD-FMK-induced necrosis in HT-29 cells (EC50 = 28 nM); reduces TNF-α-induced lethality and protects against TNF-α-induced organ damage in a mouse model of SIRS at 6 mg/kg; reduces spinal cord demyelination and BBB breakdown in a mouse model of EAE; reduces hepatic inflammatory cell infiltration and fibrosis, as well as body weight gain and total fat mass, in a mouse model of high-fat diet-induced NASH at 300 mg/kg

33438	PNU 112455A	1 mg	≥95%	A Cdk2 and Cdk5 inhibitor (Ki = 2 µM for both); inhibits dexamethasone-induced hyperphosphorylation of tau and cell death in PC12 cells expressing human tau at 1 and 10 µM
33438	PNU 112455A	10 mg	≥95%	A Cdk2 and Cdk5 inhibitor (Ki = 2 µM for both); inhibits dexamethasone-induced hyperphosphorylation of tau and cell death in PC12 cells expressing human tau at 1 and 10 µM
33438	PNU 112455A	25 mg	≥95%	A Cdk2 and Cdk5 inhibitor (Ki = 2 µM for both); inhibits dexamethasone-induced hyperphosphorylation of tau and cell death in PC12 cells expressing human tau at 1 and 10 µM
33438	PNU 112455A	5 mg	≥95%	A Cdk2 and Cdk5 inhibitor (Ki = 2 µM for both); inhibits dexamethasone-induced hyperphosphorylation of tau and cell death in PC12 cells expressing human tau at 1 and 10 µM
33460	Ginkgotoxin	10 mg	≥98%	A pyridoxine antimetabolite; inhibits pyridoxal kinase (Ki = 3 µM); induces seizure-like behavior in zebrafish larvae at 200-1,000 µM
33460	Ginkgotoxin	25 mg	≥98%	A pyridoxine antimetabolite; inhibits pyridoxal kinase (Ki = 3 µM); induces seizure-like behavior in zebrafish larvae at 200-1,000 µM
33460	Ginkgotoxin	5 mg	≥98%	A pyridoxine antimetabolite; inhibits pyridoxal kinase (Ki = 3 µM); induces seizure-like behavior in zebrafish larvae at 200-1,000 µM
33460	Ginkgotoxin	50 mg	≥98%	A pyridoxine antimetabolite; inhibits pyridoxal kinase (Ki = 3 µM); induces seizure-like behavior in zebrafish larvae at 200-1,000 µM
33462	Branebrutinib	1 mg	≥98%	A covalent BTK inhibitor (IC50 = 0.1 nM); >5,000-fold selective for BTK over a panel of 240 kinases but does inhibit TEC, BMX, and TMX (IC50s = 0.9, 1.5, and 5.0 nM, respectively); inhibits BCR stimulation-induced calcium flux in Ramos B cells (IC50 = 7.2 nM), as well as BCR stimulation-induced proliferation of, and CD86 surface expression in, peripheral B cells (IC50s = 0.04 and 0.3 nM, respectively); inhibits Fcγ receptor stimulation-induced TNF-α production in human PBMCs (IC50 = 0.3 nM); completely protective against bone destruction in a mouse model of collagen-induced arthritis at 0.5 mg/kg; reduces proteinuria and glomerular IgG immune complex deposition and increases survival in an NZB/W lupus-prone mouse model
33462	Branebrutinib	10 mg	≥98%	A covalent BTK inhibitor (IC50 = 0.1 nM); >5,000-fold selective for BTK over a panel of 240 kinases but does inhibit TEC, BMX, and TMX (IC50s = 0.9, 1.5, and 5.0 nM, respectively); inhibits BCR stimulation-induced calcium flux in Ramos B cells (IC50 = 7.2 nM), as well as BCR stimulation-induced proliferation of, and CD86 surface expression in, peripheral B cells (IC50s = 0.04 and 0.3 nM, respectively); inhibits Fcγ receptor stimulation-induced TNF-α production in human PBMCs (IC50 = 0.3 nM); completely protective against bone destruction in a mouse model of collagen-induced arthritis at 0.5 mg/kg; reduces proteinuria and glomerular IgG immune complex deposition and increases survival in an NZB/W lupus-prone mouse model
33462	Branebrutinib	25 mg	≥98%	A covalent BTK inhibitor (IC50 = 0.1 nM); >5,000-fold selective for BTK over a panel of 240 kinases but does inhibit TEC, BMX, and TMX (IC50s = 0.9, 1.5, and 5.0 nM, respectively); inhibits BCR stimulation-induced calcium flux in Ramos B cells (IC50 = 7.2 nM), as well as BCR stimulation-induced proliferation of, and CD86 surface expression in, peripheral B cells (IC50s = 0.04 and 0.3 nM, respectively); inhibits Fcγ receptor stimulation-induced TNF-α production in human PBMCs (IC50 = 0.3 nM); completely protective against bone destruction in a mouse model of collagen-induced arthritis at 0.5 mg/kg; reduces proteinuria and glomerular IgG immune complex deposition and increases survival in an NZB/W lupus-prone mouse model
33462	Branebrutinib	5 mg	≥98%	A covalent BTK inhibitor (IC50 = 0.1 nM); >5,000-fold selective for BTK over a panel of 240 kinases but does inhibit TEC, BMX, and TMX (IC50s = 0.9, 1.5, and 5.0 nM, respectively); inhibits BCR stimulation-induced calcium flux in Ramos B cells (IC50 = 7.2 nM), as well as BCR stimulation-induced proliferation of, and CD86 surface expression in, peripheral B cells (IC50s = 0.04 and 0.3 nM, respectively); inhibits Fcγ receptor stimulation-induced TNF-α production in human PBMCs (IC50 = 0.3 nM); completely protective against bone destruction in a mouse model of collagen-induced arthritis at 0.5 mg/kg; reduces proteinuria and glomerular IgG immune complex deposition and increases survival in an NZB/W lupus-prone mouse model
33496	Trapidil	10 mg	≥98%	An inhibitor of PDGF-induced activity and an antiplatelet agent; inhibits PDGF-induced proliferation of U251MG glioma cells and isolated rat aortic smooth muscle cells; inhibits ADP-, arachidonic acid-, or U-46619-induced platelet aggregation in washed isolated human platelets at 1 mM; reduces increases in intimal thickness and prevents restenosis induced by balloon angioplasty in rabbits fed a high-cholesterol diet at 30 mg/kg
33496	Trapidil	25 mg	≥98%	An inhibitor of PDGF-induced activity and an antiplatelet agent; inhibits PDGF-induced proliferation of U251MG glioma cells and isolated rat aortic smooth muscle cells; inhibits ADP-, arachidonic acid-, or U-46619-induced platelet aggregation in washed isolated human platelets at 1 mM; reduces increases in intimal thickness and prevents restenosis induced by balloon angioplasty in rabbits fed a high-cholesterol diet at 30 mg/kg

33496	Trapidil	5 mg	≥98%	An inhibitor of PDGF-induced activity and an antiplatelet agent; inhibits PDGF-induced proliferation of U251MG glioma cells and isolated rat aortic smooth muscle cells; inhibits ADP-, arachidonic acid-, or U-46619-induced platelet aggregation in washed isolated human platelets at 1 mM; reduces increases in intimal thickness and prevents restenosis induced by balloon angioplasty in rabbits fed a high-cholesterol diet at 30 mg/kg
33496	Trapidil	50 mg	≥98%	An inhibitor of PDGF-induced activity and an antiplatelet agent; inhibits PDGF-induced proliferation of U251MG glioma cells and isolated rat aortic smooth muscle cells; inhibits ADP-, arachidonic acid-, or U-46619-induced platelet aggregation in washed isolated human platelets at 1 mM; reduces increases in intimal thickness and prevents restenosis induced by balloon angioplasty in rabbits fed a high-cholesterol diet at 30 mg/kg
33515	LOXO-292	10 mg	≥98%	A RET kinase inhibitor; inhibits phosphorylation of a KIF5B-RET fusion protein expressed in HEK293 cells (IC50 = 4 nM); selectively inhibits proliferation of cancer cells containing RET mutations or gene fusions, including RETM918T-containing MZ-CRC-1 medullary thyroid and CCDC6-RET gene fusion-positive TPC-1 thyroid cancer cells, by 20 to 1,700-fold; improves survival in a CCDC6-RET gene fusion positive orthotopic PDX mouse model of brain cancer at 30 mg/kg
33515	LOXO-292	25 mg	≥98%	A RET kinase inhibitor; inhibits phosphorylation of a KIF5B-RET fusion protein expressed in HEK293 cells (IC50 = 4 nM); selectively inhibits proliferation of cancer cells containing RET mutations or gene fusions, including RETM918T-containing MZ-CRC-1 medullary thyroid and CCDC6-RET gene fusion-positive TPC-1 thyroid cancer cells, by 20 to 1,700-fold; improves survival in a CCDC6-RET gene fusion positive orthotopic PDX mouse model of brain cancer at 30 mg/kg
33515	LOXO-292	5 mg	≥98%	A RET kinase inhibitor; inhibits phosphorylation of a KIF5B-RET fusion protein expressed in HEK293 cells (IC50 = 4 nM); selectively inhibits proliferation of cancer cells containing RET mutations or gene fusions, including RETM918T-containing MZ-CRC-1 medullary thyroid and CCDC6-RET gene fusion-positive TPC-1 thyroid cancer cells, by 20 to 1,700-fold; improves survival in a CCDC6-RET gene fusion positive orthotopic PDX mouse model of brain cancer at 30 mg/kg
33515	LOXO-292	50 mg	≥98%	A RET kinase inhibitor; inhibits phosphorylation of a KIF5B-RET fusion protein expressed in HEK293 cells (IC50 = 4 nM); selectively inhibits proliferation of cancer cells containing RET mutations or gene fusions, including RETM918T-containing MZ-CRC-1 medullary thyroid and CCDC6-RET gene fusion-positive TPC-1 thyroid cancer cells, by 20 to 1,700-fold; improves survival in a CCDC6-RET gene fusion positive orthotopic PDX mouse model of brain cancer at 30 mg/kg
33524	BMS 986165	1 mg	≥98%	An allosteric inhibitor of TYK2 (IC50 = 0.2 nM for the recombinant TYK2 pseudokinase domain); selective for TYK2 over a panel of 249 protein and lipid kinases at 1 μM but does inhibit the JAK1 pseudokinase domain and BMPR2 (IC50s = 1 and 193 nM, respectively); inhibits IFN-α-induced phosphorylation of STAT1, -2, -3, and -5 in PBMCs (IC50s = 1-6 nM); inhibits IL-12-induced production of IFN-γ in human PBMCs (IC50 = 11 nM) and IL-12-induced phosphorylation of STAT4 in NK-92 cells (IC50 = 5 nM); has anti-inflammatory effects in various mouse models
33524	BMS 986165	10 mg	≥98%	An allosteric inhibitor of TYK2 (IC50 = 0.2 nM for the recombinant TYK2 pseudokinase domain); selective for TYK2 over a panel of 249 protein and lipid kinases at 1 μM but does inhibit the JAK1 pseudokinase domain and BMPR2 (IC50s = 1 and 193 nM, respectively); inhibits IFN-α-induced phosphorylation of STAT1, -2, -3, and -5 in PBMCs (IC50s = 1-6 nM); inhibits IL-12-induced production of IFN-γ in human PBMCs (IC50 = 11 nM) and IL-12-induced phosphorylation of STAT4 in NK-92 cells (IC50 = 5 nM); has anti-inflammatory effects in various mouse models
33524	BMS 986165	25 mg	≥98%	An allosteric inhibitor of TYK2 (IC50 = 0.2 nM for the recombinant TYK2 pseudokinase domain); selective for TYK2 over a panel of 249 protein and lipid kinases at 1 μM but does inhibit the JAK1 pseudokinase domain and BMPR2 (IC50s = 1 and 193 nM, respectively); inhibits IFN-α-induced phosphorylation of STAT1, -2, -3, and -5 in PBMCs (IC50s = 1-6 nM); inhibits IL-12-induced production of IFN-γ in human PBMCs (IC50 = 11 nM) and IL-12-induced phosphorylation of STAT4 in NK-92 cells (IC50 = 5 nM); has anti-inflammatory effects in various mouse models
33524	BMS 986165	5 mg	≥98%	An allosteric inhibitor of TYK2 (IC50 = 0.2 nM for the recombinant TYK2 pseudokinase domain); selective for TYK2 over a panel of 249 protein and lipid kinases at 1 μM but does inhibit the JAK1 pseudokinase domain and BMPR2 (IC50s = 1 and 193 nM, respectively); inhibits IFN-α-induced phosphorylation of STAT1, -2, -3, and -5 in PBMCs (IC50s = 1-6 nM); inhibits IL-12-induced production of IFN-γ in human PBMCs (IC50 = 11 nM) and IL-12-induced phosphorylation of STAT4 in NK-92 cells (IC50 = 5 nM); has anti-inflammatory effects in various mouse models
33528	TAS 0728	1 mg	≥98%	A covalent HER2 inhibitor (IC50 = 36 nM); selective for HER2 over panels of 386 and 374 additional kinases, as well as a panel of 68 non-kinase enzymes, at 1 μM; inhibits HER2 autophosphorylation in HER2-overexpressing SK-BR-3 cells; inhibits the growth of six HER2-amplified cancer cell lines (GI50s = 1.6-31 nM); reduces tumor volume in NCI N87 and BT474 mouse xenograft models

33528	TAS 0728	10 mg	≥98%	A covalent HER2 inhibitor (IC50 = 36 nM); selective for HER2 over panels of 386 and 374 additional kinases, as well as a panel of 68 non-kinase enzymes, at 1 μM; inhibits HER2 autophosphorylation in HER2-overexpressing SK-BR-3 cells; inhibits the growth of six HER2-amplified cancer cell lines (GI50s = 1.6-31 nM); reduces tumor volume in NCI N87 and BT474 mouse xenograft models
33528	TAS 0728	25 mg	≥98%	A covalent HER2 inhibitor (IC50 = 36 nM); selective for HER2 over panels of 386 and 374 additional kinases, as well as a panel of 68 non-kinase enzymes, at 1 μM; inhibits HER2 autophosphorylation in HER2-overexpressing SK-BR-3 cells; inhibits the growth of six HER2-amplified cancer cell lines (GI50s = 1.6-31 nM); reduces tumor volume in NCI N87 and BT474 mouse xenograft models
33528	TAS 0728	5 mg	≥98%	A covalent HER2 inhibitor (IC50 = 36 nM); selective for HER2 over panels of 386 and 374 additional kinases, as well as a panel of 68 non-kinase enzymes, at 1 μM; inhibits HER2 autophosphorylation in HER2-overexpressing SK-BR-3 cells; inhibits the growth of six HER2-amplified cancer cell lines (GI50s = 1.6-31 nM); reduces tumor volume in NCI N87 and BT474 mouse xenograft models
33555	UNC0064-12	1 mg	≥98%	A multi-kinase inhibitor; has been used as an affinity ligand for proteomics-based kinome analyses of cancer cells
33555	UNC0064-12	10 mg	≥98%	A multi-kinase inhibitor; has been used as an affinity ligand for proteomics-based kinome analyses of cancer cells
33555	UNC0064-12	25 mg	≥98%	A multi-kinase inhibitor; has been used as an affinity ligand for proteomics-based kinome analyses of cancer cells
33555	UNC0064-12	5 mg	≥98%	A multi-kinase inhibitor; has been used as an affinity ligand for proteomics-based kinome analyses of cancer cells
33557	ASTX029	1 mg	≥98%	An ERK inhibitor (IC50 = 2.7 nM for ERK2); selective for ERK over a panel of 465 kinases; reduces RSK phosphorylation in mutant B-RAF-expressing A375 melanoma and mutant K-Ras-expressing HCT116 colorectal cancer cells (IC50s = 3.3 and 4 nM, respectively); inhibits proliferation in a panel of cancer cell lines, including melanoma, colorectal, and lung cancer cells; reduces tumor growth in A375, Calu-6, and COLO 205 mouse xenograft models
33557	ASTX029	10 mg	≥98%	An ERK inhibitor (IC50 = 2.7 nM for ERK2); selective for ERK over a panel of 465 kinases; reduces RSK phosphorylation in mutant B-RAF-expressing A375 melanoma and mutant K-Ras-expressing HCT116 colorectal cancer cells (IC50s = 3.3 and 4 nM, respectively); inhibits proliferation in a panel of cancer cell lines, including melanoma, colorectal, and lung cancer cells; reduces tumor growth in A375, Calu-6, and COLO 205 mouse xenograft models
33557	ASTX029	5 mg	≥98%	An ERK inhibitor (IC50 = 2.7 nM for ERK2); selective for ERK over a panel of 465 kinases; reduces RSK phosphorylation in mutant B-RAF-expressing A375 melanoma and mutant K-Ras-expressing HCT116 colorectal cancer cells (IC50s = 3.3 and 4 nM, respectively); inhibits proliferation in a panel of cancer cell lines, including melanoma, colorectal, and lung cancer cells; reduces tumor growth in A375, Calu-6, and COLO 205 mouse xenograft models
33557	ASTX029	500 µg	≥98%	An ERK inhibitor (IC50 = 2.7 nM for ERK2); selective for ERK over a panel of 465 kinases; reduces RSK phosphorylation in mutant B-RAF-expressing A375 melanoma and mutant K-Ras-expressing HCT116 colorectal cancer cells (IC50s = 3.3 and 4 nM, respectively); inhibits proliferation in a panel of cancer cell lines, including melanoma, colorectal, and lung cancer cells; reduces tumor growth in A375, Calu-6, and COLO 205 mouse xenograft models
33560	PCI 45227	1 mg	≥95% (mixture	An active metabolite of ibrutinib
33560	PCI 45227	10 mg	≥95% (mixture	An active metabolite of ibrutinib
33560	PCI 45227	5 mg	≥95% (mixture	An active metabolite of ibrutinib
33593	TAS 115 (methanesulf	1 mg	≥98%	A multi-kinase inhibitor; an inhibitor of PDGFRα and PDGFRβ (IC50s = 0.81 and 7.06 nM, respectively), c-FMS (IC50 = 15 nM), VEGFR2 and VEGFR1 (IC50s = 30 and 140 nM, respectively), Met (IC50 = 32 nM), and FGFR2 (IC50 = 340 nM); inhibits Axl, c-Kit, Src, and FLT1; inhibits VEGF-induced VEGFR2 phosphorylation in HUVECs and Met phosphorylation in Met-amplified MKN45 cells; inhibits VEGF-dependent growth of HUVECs (IC50 = 0.019 μM); inhibits growth of Met-amplified MKN45 cells (GI50 = 0.032 μM); reduces tumor growth in a MKN45 mouse xenograft model (ED50 = 8 mg/kg)
33593	TAS 115 (methanesulf	10 mg	≥98%	A multi-kinase inhibitor; an inhibitor of PDGFRα and PDGFRβ (IC50s = 0.81 and 7.06 nM, respectively), c-FMS (IC50 = 15 nM), VEGFR2 and VEGFR1 (IC50s = 30 and 140 nM, respectively), Met (IC50 = 32 nM), and FGFR2 (IC50 = 340 nM); inhibits Axl, c-Kit, Src, and FLT1; inhibits VEGF-induced VEGFR2 phosphorylation in HUVECs and Met phosphorylation in Met-amplified MKN45 cells; inhibits VEGF-dependent growth of HUVECs (IC50 = 0.019 μM); inhibits growth of Met-amplified MKN45 cells (GI50 = 0.032 μM); reduces tumor growth in a MKN45 mouse xenograft model (ED50 = 8 mg/kg)

33593	TAS 115 (methanesulf	25 mg	≥98%	A multi-kinase inhibitor; an inhibitor of PDGFRα and PDGFRβ (IC50s = 0.81 and 7.06 nM, respectively), c-FMS (IC50 = 15 nM), VEGFR2 and VEGFR1 (IC50s = 30 and 140 nM, respectively), Met (IC50 = 32 nM), and FGFR2 (IC50 = 340 nM); inhibits Axl, c-Kit, Src, and FLT1; inhibits VEGF-induced VEGFR2 phosphorylation in HUVECs and Met phosphorylation in Met-amplified MKN45 cells; inhibits VEGF-dependent growth of HUVECs (IC50 = 0.019 µM); inhibits growth of Met-amplified MKN45 cells (GI50 = 0.032 µM); reduces tumor growth in a MKN45 mouse xenograft model (ED50 = 8 mg/kg)
33593	TAS 115 (methanesulf	5 mg	≥98%	A multi-kinase inhibitor; an inhibitor of PDGFRα and PDGFRβ (IC50s = 0.81 and 7.06 nM, respectively), c-FMS (IC50 = 15 nM), VEGFR2 and VEGFR1 (IC50s = 30 and 140 nM, respectively), Met (IC50 = 32 nM), and FGFR2 (IC50 = 340 nM); inhibits Axl, c-Kit, Src, and FLT1; inhibits VEGF-induced VEGFR2 phosphorylation in HUVECs and Met phosphorylation in Met-amplified MKN45 cells; inhibits VEGF-dependent growth of HUVECs (IC50 = 0.019 µM); inhibits growth of Met-amplified MKN45 cells (GI50 = 0.032 µM); reduces tumor growth in a MKN45 mouse xenograft model (ED50 = 8 mg/kg)
33603	BAY-1895344	10 mg	≥98%	An ATR inhibitor (IC50 = 7 nM); selective for ATR over DNA-PK, ATM, and PI3Kβ (IC50s = 0.332, 1.42, and 3.27 µM, respectively); inhibits proliferation of HT-29 and LoVo colorectal cancer cells and SU-DHL-8 B lymphoma cells (IC50s = 0.16, 0.071, and 0.009 µM, respectively); reduces tumor growth in a mutant ATMK1964E-containing SU-DHL-8 and LoVo mouse xenograft models at 50 mg/kg; synergistic with carboplatin, olaparib, or radiation in various mouse xenograft models
33603	BAY-1895344	25 mg	≥98%	An ATR inhibitor (IC50 = 7 nM); selective for ATR over DNA-PK, ATM, and PI3Kβ (IC50s = 0.332, 1.42, and 3.27 µM, respectively); inhibits proliferation of HT-29 and LoVo colorectal cancer cells and SU-DHL-8 B lymphoma cells (IC50s = 0.16, 0.071, and 0.009 µM, respectively); reduces tumor growth in a mutant ATMK1964E-containing SU-DHL-8 and LoVo mouse xenograft models at 50 mg/kg; synergistic with carboplatin, olaparib, or radiation in various mouse xenograft models
33603	BAY-1895344	5 mg	≥98%	An ATR inhibitor (IC50 = 7 nM); selective for ATR over DNA-PK, ATM, and PI3Kβ (IC50s = 0.332, 1.42, and 3.27 µM, respectively); inhibits proliferation of HT-29 and LoVo colorectal cancer cells and SU-DHL-8 B lymphoma cells (IC50s = 0.16, 0.071, and 0.009 µM, respectively); reduces tumor growth in a mutant ATMK1964E-containing SU-DHL-8 and LoVo mouse xenograft models at 50 mg/kg; synergistic with carboplatin, olaparib, or radiation in various mouse xenograft models
33603	BAY-1895344	50 mg	≥98%	An ATR inhibitor (IC50 = 7 nM); selective for ATR over DNA-PK, ATM, and PI3Kβ (IC50s = 0.332, 1.42, and 3.27 µM, respectively); inhibits proliferation of HT-29 and LoVo colorectal cancer cells and SU-DHL-8 B lymphoma cells (IC50s = 0.16, 0.071, and 0.009 µM, respectively); reduces tumor growth in a mutant ATMK1964E-containing SU-DHL-8 and LoVo mouse xenograft models at 50 mg/kg; synergistic with carboplatin, olaparib, or radiation in various mouse xenograft models
33707	BPKDi	1 mg	≥98%	A PKD inhibitor (IC50s = 1, 9, and 1 nM for PKD1, PKD2, and PKD3, respectively); selective for PKD over PKCδ and PKCε, as well as over a panel of additional CaMK superfamily members, at 1 µM; inhibits phenylephrine-induced phosphorylation and nuclear export of HDAC4 and HDAC5 in, as well reduces phenylephrine-induced hypertrophy of, isolated neonatal rat ventricular myocytes at 1 µM.
33707	BPKDi	10 mg	≥98%	A PKD inhibitor (IC50s = 1, 9, and 1 nM for PKD1, PKD2, and PKD3, respectively); selective for PKD over PKCδ and PKCε, as well as over a panel of additional CaMK superfamily members, at 1 µM; inhibits phenylephrine-induced phosphorylation and nuclear export of HDAC4 and HDAC5 in, as well reduces phenylephrine-induced hypertrophy of, isolated neonatal rat ventricular myocytes at 1 µM.
33707	BPKDi	5 mg	≥98%	A PKD inhibitor (IC50s = 1, 9, and 1 nM for PKD1, PKD2, and PKD3, respectively); selective for PKD over PKCδ and PKCε, as well as over a panel of additional CaMK superfamily members, at 1 µM; inhibits phenylephrine-induced phosphorylation and nuclear export of HDAC4 and HDAC5 in, as well reduces phenylephrine-induced hypertrophy of, isolated neonatal rat ventricular myocytes at 1 µM.
33782	Ripretinib	10 mg	≥95%	A KIT and PDGFRα inhibitor (IC50s = 3 and 3.6 nM, respectively); selective for KIT and PDGFRα over a panel of 300 kinases (IC50s = >100 nM); inhibits DDR2, VEGFR2, PDGFRβ, and Tie2 (IC50s = V654A, KITT670I, KITD816H, KITD816V, and PDGFRαD842V (IC50s = 11, 9.2, 18, 25, and 36 nM, respectively); induces apoptosis in ROSA wild-type, and KITD816V- or KITK509I-expressing mast cells; reduces tumor growth and increases survival in an imatinib-resistant PDX mouse model of GISTs at 50 and 100 mg/kg
33782	Ripretinib	25 mg	≥95%	A KIT and PDGFRα inhibitor (IC50s = 3 and 3.6 nM, respectively); selective for KIT and PDGFRα over a panel of 300 kinases (IC50s = >100 nM); inhibits DDR2, VEGFR2, PDGFRβ, and Tie2 (IC50s = V654A, KITT670I, KITD816H, KITD816V, and PDGFRαD842V (IC50s = 11, 9.2, 18, 25, and 36 nM, respectively); induces apoptosis in ROSA wild-type, and KITD816V- or KITK509I-expressing mast cells; reduces tumor growth and increases survival in an imatinib-resistant PDX mouse model of GISTs at 50 and 100 mg/kg

33782	Ripretinib	5 mg	≥95%	A KIT and PDGFRα inhibitor (IC50s = 3 and 3.6 nM, respectively); selective for KIT and PDGFRα over a panel of 300 kinases (IC50s = >100 nM); inhibits DDR2, VEGFR2, PDGFRβ, and Tie2 (IC50s = V654A, KITT670I, KITD816H, KITD816V, and PDGFRαD842V (IC50s = 11, 9.2, 18, 25, and 36 nM, respectively); induces apoptosis in ROSA wild-type, and KITD816V- or KITK509I-expressing mast cells; reduces tumor growth and increases survival in an imatinib-resistant PDX mouse model of GISTs at 50 and 100 mg/kg
33782	Ripretinib	50 mg	≥95%	A KIT and PDGFRα inhibitor (IC50s = 3 and 3.6 nM, respectively); selective for KIT and PDGFRα over a panel of 300 kinases (IC50s = >100 nM); inhibits DDR2, VEGFR2, PDGFRβ, and Tie2 (IC50s = V654A, KITT670I, KITD816H, KITD816V, and PDGFRαD842V (IC50s = 11, 9.2, 18, 25, and 36 nM, respectively); induces apoptosis in ROSA wild-type, and KITD816V- or KITK509I-expressing mast cells; reduces tumor growth and increases survival in an imatinib-resistant PDX mouse model of GISTs at 50 and 100 mg/kg
33787	PRN-1371	1 mg	≥98%	An irreversible pan-FGFR inhibitor (IC50s = 0.7, 1.3, 4.4, and 19.3 nM for FGFR-1, -2, -3, and -4, respectively); selective for FGFR over VEGFR2 (IC50 = 705 nM) and a panel of 250 kinases (IC50s = >1 μM for all) but does inhibit CSF1R activity by >90% at 1 μM; inhibits proliferation in a panel of ten cancer cell lines containing various FGFR mutants (IC50s = 2-231 nM) and induces apoptosis in SNU-16 gastric and RT4 bladder cancer cells (EC50s = 15.9 and 11.8 nM, respectively); reduces tumor growth in an SNU-16 mouse xenograft model and a PDX mouse model of liver cancer at 15 mg/kg twice per day
33787	PRN-1371	10 mg	≥98%	An irreversible pan-FGFR inhibitor (IC50s = 0.7, 1.3, 4.4, and 19.3 nM for FGFR-1, -2, -3, and -4, respectively); selective for FGFR over VEGFR2 (IC50 = 705 nM) and a panel of 250 kinases (IC50s = >1 μM for all) but does inhibit CSF1R activity by >90% at 1 μM; inhibits proliferation in a panel of ten cancer cell lines containing various FGFR mutants (IC50s = 2-231 nM) and induces apoptosis in SNU-16 gastric and RT4 bladder cancer cells (EC50s = 15.9 and 11.8 nM, respectively); reduces tumor growth in an SNU-16 mouse xenograft model and a PDX mouse model of liver cancer at 15 mg/kg twice per day
33787	PRN-1371	25 mg	≥98%	An irreversible pan-FGFR inhibitor (IC50s = 0.7, 1.3, 4.4, and 19.3 nM for FGFR-1, -2, -3, and -4, respectively); selective for FGFR over VEGFR2 (IC50 = 705 nM) and a panel of 250 kinases (IC50s = >1 μM for all) but does inhibit CSF1R activity by >90% at 1 μM; inhibits proliferation in a panel of ten cancer cell lines containing various FGFR mutants (IC50s = 2-231 nM) and induces apoptosis in SNU-16 gastric and RT4 bladder cancer cells (EC50s = 15.9 and 11.8 nM, respectively); reduces tumor growth in an SNU-16 mouse xenograft model and a PDX mouse model of liver cancer at 15 mg/kg twice per day
33787	PRN-1371	5 mg	≥98%	An irreversible pan-FGFR inhibitor (IC50s = 0.7, 1.3, 4.4, and 19.3 nM for FGFR-1, -2, -3, and -4, respectively); selective for FGFR over VEGFR2 (IC50 = 705 nM) and a panel of 250 kinases (IC50s = >1 μM for all) but does inhibit CSF1R activity by >90% at 1 μM; inhibits proliferation in a panel of ten cancer cell lines containing various FGFR mutants (IC50s = 2-231 nM) and induces apoptosis in SNU-16 gastric and RT4 bladder cancer cells (EC50s = 15.9 and 11.8 nM, respectively); reduces tumor growth in an SNU-16 mouse xenograft model and a PDX mouse model of liver cancer at 15 mg/kg twice per day
33789	MW-150	1 mg	≥98%	An inhibitor of p38α MAPK (Ki = 101 nM); 6-, 10-, and 14-fold selective for p38α MAPK over NLK, p38β MAPK, and p38δ MAPK, respectively; selective for p38α MAPK over p38α MAPKT106M; inhibits p38α MAPK phosphorylation of MK2 in LPS-activated glia; improves spatial reference memory in the radial arm water maze in aged APP/PS1 mice
33789	MW-150	10 mg	≥98%	An inhibitor of p38α MAPK (Ki = 101 nM); 6-, 10-, and 14-fold selective for p38α MAPK over NLK, p38β MAPK, and p38δ MAPK, respectively; selective for p38α MAPK over p38α MAPKT106M; inhibits p38α MAPK phosphorylation of MK2 in LPS-activated glia; improves spatial reference memory in the radial arm water maze in aged APP/PS1 mice
33789	MW-150	25 mg	≥98%	An inhibitor of p38α MAPK (Ki = 101 nM); 6-, 10-, and 14-fold selective for p38α MAPK over NLK, p38β MAPK, and p38δ MAPK, respectively; selective for p38α MAPK over p38α MAPKT106M; inhibits p38α MAPK phosphorylation of MK2 in LPS-activated glia; improves spatial reference memory in the radial arm water maze in aged APP/PS1 mice
33789	MW-150	5 mg	≥98%	An inhibitor of p38α MAPK (Ki = 101 nM); 6-, 10-, and 14-fold selective for p38α MAPK over NLK, p38β MAPK, and p38δ MAPK, respectively; selective for p38α MAPK over p38α MAPKT106M; inhibits p38α MAPK phosphorylation of MK2 in LPS-activated glia; improves spatial reference memory in the radial arm water maze in aged APP/PS1 mice

33840	Gossypetin	1 mg	≥98%	A flavonoid with diverse biological activities; inhibits MKK3 and MKK6, as well as induces apoptosis and cell cycle arrest at the G2 phase in KYSE-450 and KYSE-510 esophageal cancer cells at 20 μM; scavenges DPPH radicals and inhibits copper-induced lipid peroxidation in cell-free assays; reduces high-fat diet-induced increases in serum cholesterol, triglycerides, and LDL-cholesterol levels, as well as decreases aortic extracellular lipid and foam cell deposits in a rabbit model of atherosclerosis at 10 mg/kg
33840	Gossypetin	10 mg	≥98%	A flavonoid with diverse biological activities; inhibits MKK3 and MKK6, as well as induces apoptosis and cell cycle arrest at the G2 phase in KYSE-450 and KYSE-510 esophageal cancer cells at 20 μM; scavenges DPPH radicals and inhibits copper-induced lipid peroxidation in cell-free assays; reduces high-fat diet-induced increases in serum cholesterol, triglycerides, and LDL-cholesterol levels, as well as decreases aortic extracellular lipid and foam cell deposits in a rabbit model of atherosclerosis at 10 mg/kg
33840	Gossypetin	25 mg	≥98%	A flavonoid with diverse biological activities; inhibits MKK3 and MKK6, as well as induces apoptosis and cell cycle arrest at the G2 phase in KYSE-450 and KYSE-510 esophageal cancer cells at 20 μM; scavenges DPPH radicals and inhibits copper-induced lipid peroxidation in cell-free assays; reduces high-fat diet-induced increases in serum cholesterol, triglycerides, and LDL-cholesterol levels, as well as decreases aortic extracellular lipid and foam cell deposits in a rabbit model of atherosclerosis at 10 mg/kg
33840	Gossypetin	5 mg	≥98%	A flavonoid with diverse biological activities; inhibits MKK3 and MKK6, as well as induces apoptosis and cell cycle arrest at the G2 phase in KYSE-450 and KYSE-510 esophageal cancer cells at 20 μM; scavenges DPPH radicals and inhibits copper-induced lipid peroxidation in cell-free assays; reduces high-fat diet-induced increases in serum cholesterol, triglycerides, and LDL-cholesterol levels, as well as decreases aortic extracellular lipid and foam cell deposits in a rabbit model of atherosclerosis at 10 mg/kg
33932	BDTX-189	1 mg	≥98%	An inhibitor of wild-type and mutant EGFR and HER2 (IC50s = ≤30-500 and ≤10-100 nM, respectively); reduces tumor growth in a CUTO14 NSCLC mouse xenograft model at 30 and 50 mg/kg, twice daily
33932	BDTX-189	10 mg	≥98%	An inhibitor of wild-type and mutant EGFR and HER2 (IC50s = ≤30-500 and ≤10-100 nM, respectively); reduces tumor growth in a CUTO14 NSCLC mouse xenograft model at 30 and 50 mg/kg, twice daily
33932	BDTX-189	25 mg	≥98%	An inhibitor of wild-type and mutant EGFR and HER2 (IC50s = ≤30-500 and ≤10-100 nM, respectively); reduces tumor growth in a CUTO14 NSCLC mouse xenograft model at 30 and 50 mg/kg, twice daily
33932	BDTX-189	5 mg	≥98%	An inhibitor of wild-type and mutant EGFR and HER2 (IC50s = ≤30-500 and ≤10-100 nM, respectively); reduces tumor growth in a CUTO14 NSCLC mouse xenograft model at 30 and 50 mg/kg, twice daily
33993	Brevilin A	1 mg	≥98%	A sesquiterpene lactone with anticancer activity; an inhibitor of STAT3 signaling (IC50 = 10.6 μM in A549R cells); inhibits the tyrosine kinase activity of the JAK1, JAK2, JAK3, and JAK4 JH1 subunit (IC50s = 11.2, 8.4, 10.2, and 11.9 μM, respectively); inhibits proliferation of a variety of cancer cells in a concentration-dependent manner; decreases the mitochondrial membrane potential, induces apoptosis, and increases ROS levels in CT26 cells; induces autophagosome formation in a PI3K-dependent manner; increases intratumor expression of LC3-II and reduces tumor growth in a murine CT26 colon cancer model at 5 mg/kg per day
33993	Brevilin A	10 mg	≥98%	A sesquiterpene lactone with anticancer activity; an inhibitor of STAT3 signaling (IC50 = 10.6 μM in A549R cells); inhibits the tyrosine kinase activity of the JAK1, JAK2, JAK3, and JAK4 JH1 subunit (IC50s = 11.2, 8.4, 10.2, and 11.9 μM, respectively); inhibits proliferation of a variety of cancer cells in a concentration-dependent manner; decreases the mitochondrial membrane potential, induces apoptosis, and increases ROS levels in CT26 cells; induces autophagosome formation in a PI3K-dependent manner; increases intratumor expression of LC3-II and reduces tumor growth in a murine CT26 colon cancer model at 5 mg/kg per day
33993	Brevilin A	25 mg	≥98%	A sesquiterpene lactone with anticancer activity; an inhibitor of STAT3 signaling (IC50 = 10.6 μM in A549R cells); inhibits the tyrosine kinase activity of the JAK1, JAK2, JAK3, and JAK4 JH1 subunit (IC50s = 11.2, 8.4, 10.2, and 11.9 μM, respectively); inhibits proliferation of a variety of cancer cells in a concentration-dependent manner; decreases the mitochondrial membrane potential, induces apoptosis, and increases ROS levels in CT26 cells; induces autophagosome formation in a PI3K-dependent manner; increases intratumor expression of LC3-II and reduces tumor growth in a murine CT26 colon cancer model at 5 mg/kg per day

33993	Brevilin A	5 mg	≥98%	A sesquiterpene lactone with anticancer activity; an inhibitor of STAT3 signaling (IC50 = 10.6 µM in A549R cells); inhibits the tyrosine kinase activity of the JAK1, JAK2, JAK3, and JAK4 JH1 subunit (IC50s = 11.2, 8.4, 10.2, and 11.9 µM, respectively); inhibits proliferation of a variety of cancer cells in a concentration-dependent manner; decreases the mitochondrial membrane potential, induces apoptosis, and increases ROS levels in CT26 cells; induces autophagosome formation in a PI3K-dependent manner; increases intratumor expression of LC3-II and reduces tumor growth in a murine CT26 colon cancer model at 5 mg/kg per day
34029	L-Norvaline	10 g	≥95%	An inhibitor of arginase and p70S6K1; inhibits arginase-mediated urea production in J774A.1 macrophage lysates at 10 mM; inhibits TNF-α-induced p70S6K1 activation in HUVECs at 20 mM; reduces microgliosis and the level of amyloid-β fibrils in the hippocampus, as well as improves learning and memory in the Morris water maze in the 3xTg mouse model of Alzheimer's disease
34029	L-Norvaline	100 g	≥95%	An inhibitor of arginase and p70S6K1; inhibits arginase-mediated urea production in J774A.1 macrophage lysates at 10 mM; inhibits TNF-α-induced p70S6K1 activation in HUVECs at 20 mM; reduces microgliosis and the level of amyloid-β fibrils in the hippocampus, as well as improves learning and memory in the Morris water maze in the 3xTg mouse model of Alzheimer's disease
34029	L-Norvaline	25 g	≥95%	An inhibitor of arginase and p70S6K1; inhibits arginase-mediated urea production in J774A.1 macrophage lysates at 10 mM; inhibits TNF-α-induced p70S6K1 activation in HUVECs at 20 mM; reduces microgliosis and the level of amyloid-β fibrils in the hippocampus, as well as improves learning and memory in the Morris water maze in the 3xTg mouse model of Alzheimer's disease
34029	L-Norvaline	5 g	≥95%	An inhibitor of arginase and p70S6K1; inhibits arginase-mediated urea production in J774A.1 macrophage lysates at 10 mM; inhibits TNF-α-induced p70S6K1 activation in HUVECs at 20 mM; reduces microgliosis and the level of amyloid-β fibrils in the hippocampus, as well as improves learning and memory in the Morris water maze in the 3xTg mouse model of Alzheimer's disease
34059	Tpl2 Kinase Inhibitor (	1 mg	≥98%	A Tpl2 inhibitor (IC50 = 0.05 µM); selective for Tpl2 over MEK, p38 MAPK, Src, MK2, and PKC (IC50s = >40, 180, >400, 110, and >400 µM, respectively); inhibits LPS-induced TNF-α production in isolated human monocytes and whole blood (IC50s = 0.7 and 8.5 µM, respectively); enhances differentiation induced by calcitriol in HL-60 and U937 cells at 5 µM; inhibits the proliferation of KG-1a leukemia cells at 5 µM
34059	Tpl2 Kinase Inhibitor (	10 mg	≥98%	A Tpl2 inhibitor (IC50 = 0.05 µM); selective for Tpl2 over MEK, p38 MAPK, Src, MK2, and PKC (IC50s = >40, 180, >400, 110, and >400 µM, respectively); inhibits LPS-induced TNF-α production in isolated human monocytes and whole blood (IC50s = 0.7 and 8.5 µM, respectively); enhances differentiation induced by calcitriol in HL-60 and U937 cells at 5 µM; inhibits the proliferation of KG-1a leukemia cells at 5 µM
34059	Tpl2 Kinase Inhibitor (	25 mg	≥98%	A Tpl2 inhibitor (IC50 = 0.05 µM); selective for Tpl2 over MEK, p38 MAPK, Src, MK2, and PKC (IC50s = >40, 180, >400, 110, and >400 µM, respectively); inhibits LPS-induced TNF-α production in isolated human monocytes and whole blood (IC50s = 0.7 and 8.5 µM, respectively); enhances differentiation induced by calcitriol in HL-60 and U937 cells at 5 µM; inhibits the proliferation of KG-1a leukemia cells at 5 µM
34059	Tpl2 Kinase Inhibitor (	5 mg	≥98%	A Tpl2 inhibitor (IC50 = 0.05 µM); selective for Tpl2 over MEK, p38 MAPK, Src, MK2, and PKC (IC50s = >40, 180, >400, 110, and >400 µM, respectively); inhibits LPS-induced TNF-α production in isolated human monocytes and whole blood (IC50s = 0.7 and 8.5 µM, respectively); enhances differentiation induced by calcitriol in HL-60 and U937 cells at 5 µM; inhibits the proliferation of KG-1a leukemia cells at 5 µM
34061	SM-16	1 mg	≥98%	An inhibitor of ALK5 (Ki = 44 nM); selective for ALK5 over a panel of 60 non-ALK kinases, as well as ALK1 and ALK6, at 10 µM; inhibits TGF-β1-induced reporter activity (IC50 = 64 nM) and SMAD2/3 phosphorylation (IC50s = 160-620 nM) in vitro; inhibits neointimal formation and luminal narrowing in a rat model of carotid injury at 15 and 30 mg/kg; inhibits tumor growth in an AB12 murine malignant mesothelioma model at 5 mg/kg
34061	SM-16	10 mg	≥98%	An inhibitor of ALK5 (Ki = 44 nM); selective for ALK5 over a panel of 60 non-ALK kinases, as well as ALK1 and ALK6, at 10 µM; inhibits TGF-β1-induced reporter activity (IC50 = 64 nM) and SMAD2/3 phosphorylation (IC50s = 160-620 nM) in vitro; inhibits neointimal formation and luminal narrowing in a rat model of carotid injury at 15 and 30 mg/kg; inhibits tumor growth in an AB12 murine malignant mesothelioma model at 5 mg/kg
34061	SM-16	25 mg	≥98%	An inhibitor of ALK5 (Ki = 44 nM); selective for ALK5 over a panel of 60 non-ALK kinases, as well as ALK1 and ALK6, at 10 µM; inhibits TGF-β1-induced reporter activity (IC50 = 64 nM) and SMAD2/3 phosphorylation (IC50s = 160-620 nM) in vitro; inhibits neointimal formation and luminal narrowing in a rat model of carotid injury at 15 and 30 mg/kg; inhibits tumor growth in an AB12 murine malignant mesothelioma model at 5 mg/kg
34061	SM-16	5 mg	≥98%	An inhibitor of ALK5 (Ki = 44 nM); selective for ALK5 over a panel of 60 non-ALK kinases, as well as ALK1 and ALK6, at 10 µM; inhibits TGF-β1-induced reporter activity (IC50 = 64 nM) and SMAD2/3 phosphorylation (IC50s = 160-620 nM) in vitro; inhibits neointimal formation and luminal narrowing in a rat model of carotid injury at 15 and 30 mg/kg; inhibits tumor growth in an AB12 murine malignant mesothelioma model at 5 mg/kg

34142	Gossypin	10 mg	≥95%	A flavonoid glycoside with diverse biological activities; inhibits RANKL-induced osteoclastogenesis in RAW 264.7 cells at 5 µM; inhibits Aurora B kinase (IC50 = 11.07 µM in a cell-free assay), as well as Aurora A kinase and RSK2 at 20 µM; induces cell cycle arrest at the G2/M phase and apoptosis in HGC-27 cells; decreases LDH release induced by D,L-buthionine (S,R)-sulfoximine in primary rat cortical cells (IC50 = 7.4 µg/ml); reduces acetic acid-induced writhing in mice
34142	Gossypin	100 mg	≥95%	A flavonoid glycoside with diverse biological activities; inhibits RANKL-induced osteoclastogenesis in RAW 264.7 cells at 5 µM; inhibits Aurora B kinase (IC50 = 11.07 µM in a cell-free assay), as well as Aurora A kinase and RSK2 at 20 µM; induces cell cycle arrest at the G2/M phase and apoptosis in HGC-27 cells; decreases LDH release induced by D,L-buthionine (S,R)-sulfoximine in primary rat cortical cells (IC50 = 7.4 µg/ml); reduces acetic acid-induced writhing in mice
34142	Gossypin	250 mg	≥95%	A flavonoid glycoside with diverse biological activities; inhibits RANKL-induced osteoclastogenesis in RAW 264.7 cells at 5 µM; inhibits Aurora B kinase (IC50 = 11.07 µM in a cell-free assay), as well as Aurora A kinase and RSK2 at 20 µM; induces cell cycle arrest at the G2/M phase and apoptosis in HGC-27 cells; decreases LDH release induced by D,L-buthionine (S,R)-sulfoximine in primary rat cortical cells (IC50 = 7.4 µg/ml); reduces acetic acid-induced writhing in mice
34142	Gossypin	50 mg	≥95%	A flavonoid glycoside with diverse biological activities; inhibits RANKL-induced osteoclastogenesis in RAW 264.7 cells at 5 µM; inhibits Aurora B kinase (IC50 = 11.07 µM in a cell-free assay), as well as Aurora A kinase and RSK2 at 20 µM; induces cell cycle arrest at the G2/M phase and apoptosis in HGC-27 cells; decreases LDH release induced by D,L-buthionine (S,R)-sulfoximine in primary rat cortical cells (IC50 = 7.4 µg/ml); reduces acetic acid-induced writhing in mice
34204	Ilorasertib	1 mg	≥98%	A multi-kinase inhibitor; inhibits Aurora C, VEGFR1, VEGFR2, FLT3, CSF-1R, and Aurora B (IC50s = 1, 1, 2, 1, 3, and 7 nM, respectively); inhibits PDGFRα, PDGFRβ, c-Kit, VEGFR3, and Aurora A (IC50s = 11, 13, 20, 43, and 120 nM, respectively); inhibits autophosphorylation of Aurora A, -B, and -C in HeLa cells (IC50s = 189, 13, and 13 nM, respectively); inhibits proliferation of a variety of cancer cells, including MV4-11, SUP-B15, and H1299 cells (IC50s = 0.3, 4, and 2 nM, respectively); decreases histone H3 phosphorylation in blood-borne tumor cells in an engrafted mouse model of leukemia at 25 mg/kg and reduces tumor growth in a variety of mouse xenograft models
34204	Ilorasertib	10 mg	≥98%	A multi-kinase inhibitor; inhibits Aurora C, VEGFR1, VEGFR2, FLT3, CSF-1R, and Aurora B (IC50s = 1, 1, 2, 1, 3, and 7 nM, respectively); inhibits PDGFRα, PDGFRβ, c-Kit, VEGFR3, and Aurora A (IC50s = 11, 13, 20, 43, and 120 nM, respectively); inhibits autophosphorylation of Aurora A, -B, and -C in HeLa cells (IC50s = 189, 13, and 13 nM, respectively); inhibits proliferation of a variety of cancer cells, including MV4-11, SUP-B15, and H1299 cells (IC50s = 0.3, 4, and 2 nM, respectively); decreases histone H3 phosphorylation in blood-borne tumor cells in an engrafted mouse model of leukemia at 25 mg/kg and reduces tumor growth in a variety of mouse xenograft models
34204	Ilorasertib	25 mg	≥98%	A multi-kinase inhibitor; inhibits Aurora C, VEGFR1, VEGFR2, FLT3, CSF-1R, and Aurora B (IC50s = 1, 1, 2, 1, 3, and 7 nM, respectively); inhibits PDGFRα, PDGFRβ, c-Kit, VEGFR3, and Aurora A (IC50s = 11, 13, 20, 43, and 120 nM, respectively); inhibits autophosphorylation of Aurora A, -B, and -C in HeLa cells (IC50s = 189, 13, and 13 nM, respectively); inhibits proliferation of a variety of cancer cells, including MV4-11, SUP-B15, and H1299 cells (IC50s = 0.3, 4, and 2 nM, respectively); decreases histone H3 phosphorylation in blood-borne tumor cells in an engrafted mouse model of leukemia at 25 mg/kg and reduces tumor growth in a variety of mouse xenograft models
34204	Ilorasertib	5 mg	≥98%	A multi-kinase inhibitor; inhibits Aurora C, VEGFR1, VEGFR2, FLT3, CSF-1R, and Aurora B (IC50s = 1, 1, 2, 1, 3, and 7 nM, respectively); inhibits PDGFRα, PDGFRβ, c-Kit, VEGFR3, and Aurora A (IC50s = 11, 13, 20, 43, and 120 nM, respectively); inhibits autophosphorylation of Aurora A, -B, and -C in HeLa cells (IC50s = 189, 13, and 13 nM, respectively); inhibits proliferation of a variety of cancer cells, including MV4-11, SUP-B15, and H1299 cells (IC50s = 0.3, 4, and 2 nM, respectively); decreases histone H3 phosphorylation in blood-borne tumor cells in an engrafted mouse model of leukemia at 25 mg/kg and reduces tumor growth in a variety of mouse xenograft models
34206	Sulfatinib	1 mg	≥98%	A multi-kinase inhibitor; inhibits VEGFR1, VEGFR2, VEGFR3, FGFR1, CSF1R, TrkB, and FLT3 (IC50s = 1-67 nM); selective for these kinases over a panel of 278 kinases (IC50s = >150 nM for all)
34206	Sulfatinib	10 mg	≥98%	A multi-kinase inhibitor; inhibits VEGFR1, VEGFR2, VEGFR3, FGFR1, CSF1R, TrkB, and FLT3 (IC50s = 1-67 nM); selective for these kinases over a panel of 278 kinases (IC50s = >150 nM for all)
34206	Sulfatinib	25 mg	≥98%	A multi-kinase inhibitor; inhibits VEGFR1, VEGFR2, VEGFR3, FGFR1, CSF1R, TrkB, and FLT3 (IC50s = 1-67 nM); selective for these kinases over a panel of 278 kinases (IC50s = >150 nM for all)

34206	Sulfatinib	5 mg	≥98%	A multi-kinase inhibitor; inhibits VEGFR1, VEGFR2, VEGFR3, FGFR1, CSF1R, TrkB, and FLT3 (IC50s = 1-67 nM); selective for these kinases over a panel of 278 kinases (IC50s = >150 nM for all)
34233	SR 318	1 mg	≥98%	A dual inhibitor of p38α and p38β MAPKs (IC50s = 5 and 32 nM, respectively); selective for p38α and p38β MAPKs over a panel of 468 kinases at 1 μM; inhibits LPS-induced TNF-α release in isolated human whole blood (IC50 = 0.283 μM)
34233	SR 318	10 mg	≥98%	A dual inhibitor of p38α and p38β MAPKs (IC50s = 5 and 32 nM, respectively); selective for p38α and p38β MAPKs over a panel of 468 kinases at 1 μM; inhibits LPS-induced TNF-α release in isolated human whole blood (IC50 = 0.283 μM)
34233	SR 318	25 mg	≥98%	A dual inhibitor of p38α and p38β MAPKs (IC50s = 5 and 32 nM, respectively); selective for p38α and p38β MAPKs over a panel of 468 kinases at 1 μM; inhibits LPS-induced TNF-α release in isolated human whole blood (IC50 = 0.283 μM)
34233	SR 318	5 mg	≥98%	A dual inhibitor of p38α and p38β MAPKs (IC50s = 5 and 32 nM, respectively); selective for p38α and p38β MAPKs over a panel of 468 kinases at 1 μM; inhibits LPS-induced TNF-α release in isolated human whole blood (IC50 = 0.283 μM)
34234	BAY-985	1 mg	≥98%	A dual inhibitor of TBK1 and IKKε (IC50 = 2 nM for both); selective for TBK1 and IKKε over FLT3, RSK4, DRAK1, and ULK1 (IC50s = 123, 276, 311, and 7,390 nM, respectively); inhibits phosphorylation of IRF3 in MDA-MB-231 cells expressing mouse IRF3 (IC50 = 74 nM); inhibits the proliferation of SK-MEL-2 cells in vitro (IC50 = 900 nM); reduces tumor weight in an SK-MEL-2 mouse xenograft model at 200 mg/kg
34234	BAY-985	10 mg	≥98%	A dual inhibitor of TBK1 and IKKε (IC50 = 2 nM for both); selective for TBK1 and IKKε over FLT3, RSK4, DRAK1, and ULK1 (IC50s = 123, 276, 311, and 7,390 nM, respectively); inhibits phosphorylation of IRF3 in MDA-MB-231 cells expressing mouse IRF3 (IC50 = 74 nM); inhibits the proliferation of SK-MEL-2 cells in vitro (IC50 = 900 nM); reduces tumor weight in an SK-MEL-2 mouse xenograft model at 200 mg/kg
34234	BAY-985	5 mg	≥98%	A dual inhibitor of TBK1 and IKKε (IC50 = 2 nM for both); selective for TBK1 and IKKε over FLT3, RSK4, DRAK1, and ULK1 (IC50s = 123, 276, 311, and 7,390 nM, respectively); inhibits phosphorylation of IRF3 in MDA-MB-231 cells expressing mouse IRF3 (IC50 = 74 nM); inhibits the proliferation of SK-MEL-2 cells in vitro (IC50 = 900 nM); reduces tumor weight in an SK-MEL-2 mouse xenograft model at 200 mg/kg
34234	BAY-985	500 μg	≥98%	A dual inhibitor of TBK1 and IKKε (IC50 = 2 nM for both); selective for TBK1 and IKKε over FLT3, RSK4, DRAK1, and ULK1 (IC50s = 123, 276, 311, and 7,390 nM, respectively); inhibits phosphorylation of IRF3 in MDA-MB-231 cells expressing mouse IRF3 (IC50 = 74 nM); inhibits the proliferation of SK-MEL-2 cells in vitro (IC50 = 900 nM); reduces tumor weight in an SK-MEL-2 mouse xenograft model at 200 mg/kg
34236	TH257	10 mg	≥98%	An inhibitor of LIMK1 and LIMK2 (IC50s = 84 and 39 nM, respectively)
34236	TH257	25 mg	≥98%	An inhibitor of LIMK1 and LIMK2 (IC50s = 84 and 39 nM, respectively)
34236	TH257	5 mg	≥98%	An inhibitor of LIMK1 and LIMK2 (IC50s = 84 and 39 nM, respectively)
34236	TH257	50 mg	≥98%	An inhibitor of LIMK1 and LIMK2 (IC50s = 84 and 39 nM, respectively)
34279	BAY-885	1 mg	≥98%	An ERK5 inhibitor (IC50 = 0.035 μM); inhibits ERK5-induced transcription in SN12C-MEF2 reporter cells (IC50 = 0.12 μM)
34279	BAY-885	10 mg	≥98%	An ERK5 inhibitor (IC50 = 0.035 μM); inhibits ERK5-induced transcription in SN12C-MEF2 reporter cells (IC50 = 0.12 μM)
34279	BAY-885	25 mg	≥98%	An ERK5 inhibitor (IC50 = 0.035 μM); inhibits ERK5-induced transcription in SN12C-MEF2 reporter cells (IC50 = 0.12 μM)
34279	BAY-885	5 mg	≥98%	An ERK5 inhibitor (IC50 = 0.035 μM); inhibits ERK5-induced transcription in SN12C-MEF2 reporter cells (IC50 = 0.12 μM)
34300	GDC-0575	1 mg	≥98%	A Chk1 inhibitor (IC50 = 1.2 nM); >30-fold selective for Chk1 over a panel of more than 450 wild-type and mutant kinases; enhances cytarabine-induced apoptosis in HL-60, KG-1, U937, and ML-1 AML cells; nearly completely eliminates tumor burden in AML PDX mouse models at 7.5 mg/kg in combination with cytarabine
34300	GDC-0575	10 mg	≥98%	A Chk1 inhibitor (IC50 = 1.2 nM); >30-fold selective for Chk1 over a panel of more than 450 wild-type and mutant kinases; enhances cytarabine-induced apoptosis in HL-60, KG-1, U937, and ML-1 AML cells; nearly completely eliminates tumor burden in AML PDX mouse models at 7.5 mg/kg in combination with cytarabine
34300	GDC-0575	25 mg	≥98%	A Chk1 inhibitor (IC50 = 1.2 nM); >30-fold selective for Chk1 over a panel of more than 450 wild-type and mutant kinases; enhances cytarabine-induced apoptosis in HL-60, KG-1, U937, and ML-1 AML cells; nearly completely eliminates tumor burden in AML PDX mouse models at 7.5 mg/kg in combination with cytarabine
34300	GDC-0575	5 mg	≥98%	A Chk1 inhibitor (IC50 = 1.2 nM); >30-fold selective for Chk1 over a panel of more than 450 wild-type and mutant kinases; enhances cytarabine-induced apoptosis in HL-60, KG-1, U937, and ML-1 AML cells; nearly completely eliminates tumor burden in AML PDX mouse models at 7.5 mg/kg in combination with cytarabine

34309	QLT0267	10 mg	≥98%	An ILK inhibitor (IC50 = 26 nM); greater than 10-fold selective for ILK over Cdk1, -2, and -5, as well as greater than 1,000-fold selective for ILK over CSK, DNA-PK, Pim-1, Akt, PKC, and CK2, at 10 mg/ml; inhibits the growth of NPA187 cells (IC50 = ~3 µM); induces apoptosis in NPA187, DRO, and K4 cancer cell lines; reduces tumor growth in a DRO mouse xenograft model at 100 mg/kg; reduces tumor volume and intratumoral blood vessel mass in a U87MG glioblastoma mouse xenograft model
34309	QLT0267	25 mg	≥98%	An ILK inhibitor (IC50 = 26 nM); greater than 10-fold selective for ILK over Cdk1, -2, and -5, as well as greater than 1,000-fold selective for ILK over CSK, DNA-PK, Pim-1, Akt, PKC, and CK2, at 10 mg/ml; inhibits the growth of NPA187 cells (IC50 = ~3 µM); induces apoptosis in NPA187, DRO, and K4 cancer cell lines; reduces tumor growth in a DRO mouse xenograft model at 100 mg/kg; reduces tumor volume and intratumoral blood vessel mass in a U87MG glioblastoma mouse xenograft model
34309	QLT0267	5 mg	≥98%	An ILK inhibitor (IC50 = 26 nM); greater than 10-fold selective for ILK over Cdk1, -2, and -5, as well as greater than 1,000-fold selective for ILK over CSK, DNA-PK, Pim-1, Akt, PKC, and CK2, at 10 mg/ml; inhibits the growth of NPA187 cells (IC50 = ~3 µM); induces apoptosis in NPA187, DRO, and K4 cancer cell lines; reduces tumor growth in a DRO mouse xenograft model at 100 mg/kg; reduces tumor volume and intratumoral blood vessel mass in a U87MG glioblastoma mouse xenograft model
34312	2-deoxy-D-Glucose-13	1 mg	≥95% (mixture	An internal standard for the quantification of 2-deoxy-D-glucose by GC- or LC-MS
34312	2-deoxy-D-Glucose-13	10 mg	≥95% (mixture	An internal standard for the quantification of 2-deoxy-D-glucose by GC- or LC-MS
34312	2-deoxy-D-Glucose-13	5 mg	≥95% (mixture	An internal standard for the quantification of 2-deoxy-D-glucose by GC- or LC-MS
34360	8(S)-HETE	100 µg	≥98%	A major LO product in PMA-treated murine epidermis
34360	8(S)-HETE	25 µg	≥98%	A major LO product in PMA-treated murine epidermis
34360	8(S)-HETE	50 µg	≥98%	A major LO product in PMA-treated murine epidermis
34389	Poliumoside	10 mg	≥95%	A phenylethanoid glycoside; scavenges DPPH and ABTS radicals (IC50s = 10.9 and 19.9 µM), as well as inhibits the activity of PKCα (IC50 = 24.4 µM), in cell-free assays); reduces LPS-induced production of TNF-α and IL-6 in RAW 264.7 cells from 12.5-100 µM; decreases glutamate-induced cytotoxicity in primary rat cortical neurons at 0.1, 1, or 10 µM
34389	Poliumoside	100 mg	≥95%	A phenylethanoid glycoside; scavenges DPPH and ABTS radicals (IC50s = 10.9 and 19.9 µM), as well as inhibits the activity of PKCα (IC50 = 24.4 µM), in cell-free assays); reduces LPS-induced production of TNF-α and IL-6 in RAW 264.7 cells from 12.5-100 µM; decreases glutamate-induced cytotoxicity in primary rat cortical neurons at 0.1, 1, or 10 µM
34389	Poliumoside	25 mg	≥95%	A phenylethanoid glycoside; scavenges DPPH and ABTS radicals (IC50s = 10.9 and 19.9 µM), as well as inhibits the activity of PKCα (IC50 = 24.4 µM), in cell-free assays); reduces LPS-induced production of TNF-α and IL-6 in RAW 264.7 cells from 12.5-100 µM; decreases glutamate-induced cytotoxicity in primary rat cortical neurons at 0.1, 1, or 10 µM
34389	Poliumoside	5 mg	≥95%	A phenylethanoid glycoside; scavenges DPPH and ABTS radicals (IC50s = 10.9 and 19.9 µM), as well as inhibits the activity of PKCα (IC50 = 24.4 µM), in cell-free assays); reduces LPS-induced production of TNF-α and IL-6 in RAW 264.7 cells from 12.5-100 µM; decreases glutamate-induced cytotoxicity in primary rat cortical neurons at 0.1, 1, or 10 µM
34422	SKLB1002	10 mg	≥98%	A VEGFR2 inhibitor (IC50 = 32 nM); selective for VEGFR2 over a panel of 16 additional kinases (IC50s = 619->10,000 nM); inhibits tube formation, migration, and VEGF-induced proliferation of HUVECs; induces tumor cell apoptosis, decreases tumor microvessel density, and reduces tumor growth in an SW620 mouse xenograft model at 50 or 100 mg/kg
34422	SKLB1002	25 mg	≥98%	A VEGFR2 inhibitor (IC50 = 32 nM); selective for VEGFR2 over a panel of 16 additional kinases (IC50s = 619->10,000 nM); inhibits tube formation, migration, and VEGF-induced proliferation of HUVECs; induces tumor cell apoptosis, decreases tumor microvessel density, and reduces tumor growth in an SW620 mouse xenograft model at 50 or 100 mg/kg
34422	SKLB1002	5 mg	≥98%	A VEGFR2 inhibitor (IC50 = 32 nM); selective for VEGFR2 over a panel of 16 additional kinases (IC50s = 619->10,000 nM); inhibits tube formation, migration, and VEGF-induced proliferation of HUVECs; induces tumor cell apoptosis, decreases tumor microvessel density, and reduces tumor growth in an SW620 mouse xenograft model at 50 or 100 mg/kg
34431	PKI (14-22) amide (my	1 mg	≥98%	A PKA inhibitor; inhibits PKA activity in mouse brain or spinal cord lysates at 75 µM; reduces IgG-dependent phagocytosis of heat-killed S. cerevisiae by isolated human neutrophils; inhibits replication of several strains of Zika virus, including IbH 30656, MR766, H/FP/2013, and PRVABC59, in HUVECs (IC50s = 17.75, 22.29, 34.09, and 19.19 µM, respectively); increases latency to tail withdrawal in the tail-flick test in morphine-tolerant mice at 2.5 nmol, i.c.v.

34431	PKI (14-22) amide (my	5 mg	≥98%	A PKA inhibitor; inhibits PKA activity in mouse brain or spinal cord lysates at 75 µM; reduces IgG-dependent phagocytosis of heat-killed S. cerevisiae by isolated human neutrophils; inhibits replication of several strains of Zika virus, including IbH 30656, MR766, H/FP/2013, and PRVABC59, in HUVECs (IC50s = 17.75, 22.29, 34.09, and 19.19 µM, respectively); increases latency to tail withdrawal in the tail-flick test in morphine-tolerant mice at 2.5 nmol, i.c.v.
34431	PKI (14-22) amide (my	500 µg	≥98%	A PKA inhibitor; inhibits PKA activity in mouse brain or spinal cord lysates at 75 µM; reduces IgG-dependent phagocytosis of heat-killed S. cerevisiae by isolated human neutrophils; inhibits replication of several strains of Zika virus, including IbH 30656, MR766, H/FP/2013, and PRVABC59, in HUVECs (IC50s = 17.75, 22.29, 34.09, and 19.19 µM, respectively); increases latency to tail withdrawal in the tail-flick test in morphine-tolerant mice at 2.5 nmol, i.c.v.
34445	Myr-ZIP	1 mg	≥95%	A PKMζ inhibitor (Ki = 0.076-2.11 µM); inhibits PKCα at 10 µM; prevents ionomycin-induced PKC translocation to the plasma membrane in HEK293 cells expressing AKAP79 at 5 µM; inhibits the conditioned place preference response to morphine in rats when administered intracranially into the nucleus accumbens core at doses of 10 and 30 nmol/0.5 µl per side
34445	Myr-ZIP	10 mg	≥95%	A PKMζ inhibitor (Ki = 0.076-2.11 µM); inhibits PKCα at 10 µM; prevents ionomycin-induced PKC translocation to the plasma membrane in HEK293 cells expressing AKAP79 at 5 µM; inhibits the conditioned place preference response to morphine in rats when administered intracranially into the nucleus accumbens core at doses of 10 and 30 nmol/0.5 µl per side
34445	Myr-ZIP	5 mg	≥95%	A PKMζ inhibitor (Ki = 0.076-2.11 µM); inhibits PKCα at 10 µM; prevents ionomycin-induced PKC translocation to the plasma membrane in HEK293 cells expressing AKAP79 at 5 µM; inhibits the conditioned place preference response to morphine in rats when administered intracranially into the nucleus accumbens core at doses of 10 and 30 nmol/0.5 µl per side
34485	GSK579289A	1 mg	≥98%	A Plk1 inhibitor (IC50 = 2 nM); selective for Plk1 over Plk3 (IC50 = 630 nM); inhibits proliferation of HCT116 cells (IC50 = 11 nM)
34485	GSK579289A	10 mg	≥98%	A Plk1 inhibitor (IC50 = 2 nM); selective for Plk1 over Plk3 (IC50 = 630 nM); inhibits proliferation of HCT116 cells (IC50 = 11 nM)
34485	GSK579289A	25 mg	≥98%	A Plk1 inhibitor (IC50 = 2 nM); selective for Plk1 over Plk3 (IC50 = 630 nM); inhibits proliferation of HCT116 cells (IC50 = 11 nM)
34485	GSK579289A	5 mg	≥98%	A Plk1 inhibitor (IC50 = 2 nM); selective for Plk1 over Plk3 (IC50 = 630 nM); inhibits proliferation of HCT116 cells (IC50 = 11 nM)
34487	Sorafenib-d3	1 mg	≥99% deutera	An internal standard for the quantification of sorafenib by GC- or LC-MS
34487	Sorafenib-d3	5 mg	≥99% deutera	An internal standard for the quantification of sorafenib by GC- or LC-MS
34495	NVP-BVU972	1 mg	≥98%	A Met kinase inhibitor (IC50 = 14 nM); selective for Met over a panel of 62 additional kinases (IC50s = >1 µM for all); inhibits proliferation of Met-amplified GTL-16 gastric, MKN45 gastric, and EBC-1 lung cancer cells (IC50s = 66, 32, and 82 nM, respectively); inhibits Met autophosphorylation in GTL-16 cells and HGF-induced Met phosphorylation in A549 cells (IC50s = 7.3 and 22 nM, respectively)
34495	NVP-BVU972	10 mg	≥98%	A Met kinase inhibitor (IC50 = 14 nM); selective for Met over a panel of 62 additional kinases (IC50s = >1 µM for all); inhibits proliferation of Met-amplified GTL-16 gastric, MKN45 gastric, and EBC-1 lung cancer cells (IC50s = 66, 32, and 82 nM, respectively); inhibits Met autophosphorylation in GTL-16 cells and HGF-induced Met phosphorylation in A549 cells (IC50s = 7.3 and 22 nM, respectively)
34495	NVP-BVU972	5 mg	≥98%	A Met kinase inhibitor (IC50 = 14 nM); selective for Met over a panel of 62 additional kinases (IC50s = >1 µM for all); inhibits proliferation of Met-amplified GTL-16 gastric, MKN45 gastric, and EBC-1 lung cancer cells (IC50s = 66, 32, and 82 nM, respectively); inhibits Met autophosphorylation in GTL-16 cells and HGF-induced Met phosphorylation in A549 cells (IC50s = 7.3 and 22 nM, respectively)
34502	GSK-A1	1 mg	≥98%	A PI4KIIIα inhibitor (IC50 = 3.16 nM); selective for PI4KIIIα over PI4KIIIβ, PI3Kα, PI3Kβ, and PI3Kδ (IC50s = >50 nM); inhibits PI3Kγ (IC50 = 15.8 nM); decreases the levels of PtdIns-(4)-P1 in HEK293 cells expressing the AT1 receptor (IC50 = 3 nM); inhibits HCV genotype 1a and 1b replication
34502	GSK-A1	10 mg	≥98%	A PI4KIIIα inhibitor (IC50 = 3.16 nM); selective for PI4KIIIα over PI4KIIIβ, PI3Kα, PI3Kβ, and PI3Kδ (IC50s = >50 nM); inhibits PI3Kγ (IC50 = 15.8 nM); decreases the levels of PtdIns-(4)-P1 in HEK293 cells expressing the AT1 receptor (IC50 = 3 nM); inhibits HCV genotype 1a and 1b replication
34502	GSK-A1	5 mg	≥98%	A PI4KIIIα inhibitor (IC50 = 3.16 nM); selective for PI4KIIIα over PI4KIIIβ, PI3Kα, PI3Kβ, and PI3Kδ (IC50s = >50 nM); inhibits PI3Kγ (IC50 = 15.8 nM); decreases the levels of PtdIns-(4)-P1 in HEK293 cells expressing the AT1 receptor (IC50 = 3 nM); inhibits HCV genotype 1a and 1b replication
34577	AMG 548	10 mg	≥98%	An inhibitor of p38α MAPK (Ki = 0.5 nM); selective for p38α over p38γ, p38δ, JNK1, JNK2, and JNK3 (Kis = 2,600, 4,100, 11,480, 39, and 61 nM, respectively) and is greater than 1,000-fold selective over a panel of 36 additional kinases but also inhibits p38β (Ki = 3.6 nM); inhibits LPS-induced production of TNF-α and IL-1β in isolated human whole blood (IC50s = 3 and 7 nM, respectively)

34577	AMG 548	100 mg	≥98%	An inhibitor of p38α MAPK (Ki = 0.5 nM); selective for p38α over p38γ, p38δ, JNK1, JNK2, and JNK3 (Kis = 2,600, 4,100, 11,480, 39, and 61 nM, respectively) and is greater than 1,000-fold selective over a panel of 36 additional kinases but also inhibits p38β (Ki = 3.6 nM); inhibits LPS-induced production of TNF-α and IL-1β in isolated human whole blood (IC50s = 3 and 7 nM, respectively)
34577	AMG 548	25 mg	≥98%	An inhibitor of p38α MAPK (Ki = 0.5 nM); selective for p38α over p38γ, p38δ, JNK1, JNK2, and JNK3 (Kis = 2,600, 4,100, 11,480, 39, and 61 nM, respectively) and is greater than 1,000-fold selective over a panel of 36 additional kinases but also inhibits p38β (Ki = 3.6 nM); inhibits LPS-induced production of TNF-α and IL-1β in isolated human whole blood (IC50s = 3 and 7 nM, respectively)
34577	AMG 548	50 mg	≥98%	An inhibitor of p38α MAPK (Ki = 0.5 nM); selective for p38α over p38γ, p38δ, JNK1, JNK2, and JNK3 (Kis = 2,600, 4,100, 11,480, 39, and 61 nM, respectively) and is greater than 1,000-fold selective over a panel of 36 additional kinases but also inhibits p38β (Ki = 3.6 nM); inhibits LPS-induced production of TNF-α and IL-1β in isolated human whole blood (IC50s = 3 and 7 nM, respectively)
34596	Apiin	1 mg	≥98%	A flavonoid glycoside with diverse biological activities; inhibits Aurora B kinase in a cell-free assay using the human enzyme (IC50 = 12.14 µM); inhibits LPS-induced increases in NO release and iNOS levels in J774.A1 macrophages at 10 and 50 µg/ml; scavenges DPPH, superoxide, and hydroxyl radicals (IC50s = 68, 390, and 48 µg/ml, respectively); increases SOD and catalase levels in mouse serum, brain, heart, liver, and kidney at 50 mg/kg
34596	Apiin	10 mg	≥98%	A flavonoid glycoside with diverse biological activities; inhibits Aurora B kinase in a cell-free assay using the human enzyme (IC50 = 12.14 µM); inhibits LPS-induced increases in NO release and iNOS levels in J774.A1 macrophages at 10 and 50 µg/ml; scavenges DPPH, superoxide, and hydroxyl radicals (IC50s = 68, 390, and 48 µg/ml, respectively); increases SOD and catalase levels in mouse serum, brain, heart, liver, and kidney at 50 mg/kg
34596	Apiin	25 mg	≥98%	A flavonoid glycoside with diverse biological activities; inhibits Aurora B kinase in a cell-free assay using the human enzyme (IC50 = 12.14 µM); inhibits LPS-induced increases in NO release and iNOS levels in J774.A1 macrophages at 10 and 50 µg/ml; scavenges DPPH, superoxide, and hydroxyl radicals (IC50s = 68, 390, and 48 µg/ml, respectively); increases SOD and catalase levels in mouse serum, brain, heart, liver, and kidney at 50 mg/kg
34596	Apiin	5 mg	≥98%	A flavonoid glycoside with diverse biological activities; inhibits Aurora B kinase in a cell-free assay using the human enzyme (IC50 = 12.14 µM); inhibits LPS-induced increases in NO release and iNOS levels in J774.A1 macrophages at 10 and 50 µg/ml; scavenges DPPH, superoxide, and hydroxyl radicals (IC50s = 68, 390, and 48 µg/ml, respectively); increases SOD and catalase levels in mouse serum, brain, heart, liver, and kidney at 50 mg/kg
34621	GSK626616	1 mg	≥98%	An inhibitor of DYRK3 (IC50 = 0.7 nM); enhances erythropoietin-induced erythropoiesis in isolated human bone marrow; increases hemoglobin levels in a mouse model of carboplatin- and radiation-induced anemia
34621	GSK626616	10 mg	≥98%	An inhibitor of DYRK3 (IC50 = 0.7 nM); enhances erythropoietin-induced erythropoiesis in isolated human bone marrow; increases hemoglobin levels in a mouse model of carboplatin- and radiation-induced anemia
34621	GSK626616	25 mg	≥98%	An inhibitor of DYRK3 (IC50 = 0.7 nM); enhances erythropoietin-induced erythropoiesis in isolated human bone marrow; increases hemoglobin levels in a mouse model of carboplatin- and radiation-induced anemia
34621	GSK626616	5 mg	≥98%	An inhibitor of DYRK3 (IC50 = 0.7 nM); enhances erythropoietin-induced erythropoiesis in isolated human bone marrow; increases hemoglobin levels in a mouse model of carboplatin- and radiation-induced anemia
34682	Chroman 1 (hydrochlo	1 mg	≥98%	A ROCK2 inhibitor (IC50 = 50s = 1,740 and 127 nM, respectively); inhibits phosphorylation of MLC in a cell-based assay (IC50 = <4 nM)
34682	Chroman 1 (hydrochlo	10 mg	≥98%	A ROCK2 inhibitor (IC50 = 50s = 1,740 and 127 nM, respectively); inhibits phosphorylation of MLC in a cell-based assay (IC50 = <4 nM)
34682	Chroman 1 (hydrochlo	5 mg	≥98%	A ROCK2 inhibitor (IC50 = 50s = 1,740 and 127 nM, respectively); inhibits phosphorylation of MLC in a cell-based assay (IC50 = <4 nM)
34684	EB 47 (hydrochloride)	1 mg	≥98%	A PARP1 and TNKS2 inhibitor (IC50 = 45 nM for both); an inhibitor of TNKS1 and PARP10 (IC50s = 410 and 1,179 nM, respectively); reduces infarct volume in a rat model of MCAO occlusion-induced ischemia-reperfusion injury at 10 mg/kg per hour
34684	EB 47 (hydrochloride)	10 mg	≥98%	A PARP1 and TNKS2 inhibitor (IC50 = 45 nM for both); an inhibitor of TNKS1 and PARP10 (IC50s = 410 and 1,179 nM, respectively); reduces infarct volume in a rat model of MCAO occlusion-induced ischemia-reperfusion injury at 10 mg/kg per hour
34684	EB 47 (hydrochloride)	5 mg	≥98%	A PARP1 and TNKS2 inhibitor (IC50 = 45 nM for both); an inhibitor of TNKS1 and PARP10 (IC50s = 410 and 1,179 nM, respectively); reduces infarct volume in a rat model of MCAO occlusion-induced ischemia-reperfusion injury at 10 mg/kg per hour

34725	NVP-2	1 mg	≥98%	A Cdk9/cyclin T1 complex inhibitor; selective for the Cdk9/cyclin T1 complex over nine additional Cdk complexes (IC50s = 0.584->10 μM), as well as over a panel of 468 kinases at 1 μM; inhibits the proliferation of, and induces apoptosis in, MOLT-4 human acute lymphoblastic leukemia cells at 250 nM
34725	NVP-2	10 mg	≥98%	A Cdk9/cyclin T1 complex inhibitor; selective for the Cdk9/cyclin T1 complex over nine additional Cdk complexes (IC50s = 0.584->10 μM), as well as over a panel of 468 kinases at 1 μM; inhibits the proliferation of, and induces apoptosis in, MOLT-4 human acute lymphoblastic leukemia cells at 250 nM
34725	NVP-2	25 mg	≥98%	A Cdk9/cyclin T1 complex inhibitor; selective for the Cdk9/cyclin T1 complex over nine additional Cdk complexes (IC50s = 0.584->10 μM), as well as over a panel of 468 kinases at 1 μM; inhibits the proliferation of, and induces apoptosis in, MOLT-4 human acute lymphoblastic leukemia cells at 250 nM
34725	NVP-2	5 mg	≥98%	A Cdk9/cyclin T1 complex inhibitor; selective for the Cdk9/cyclin T1 complex over nine additional Cdk complexes (IC50s = 0.584->10 μM), as well as over a panel of 468 kinases at 1 μM; inhibits the proliferation of, and induces apoptosis in, MOLT-4 human acute lymphoblastic leukemia cells at 250 nM
34766	AZ 7550	1 mg	≥98%	An active metabolite of AZ 9291; inhibits IGF-1R in a cell-free assay (IC50 = 1.6 μM); inhibits EGFR autophosphorylation in H1975 cells expressing EGFRT790M/L858R, PC-9 cells expressing EGFRExon19del, and LoVo cells expressing wild-type EGFR (IC50s = 0.045, 0.026, and 0.786 μM, respectively)
34766	AZ 7550	10 mg	≥98%	An active metabolite of AZ 9291; inhibits IGF-1R in a cell-free assay (IC50 = 1.6 μM); inhibits EGFR autophosphorylation in H1975 cells expressing EGFRT790M/L858R, PC-9 cells expressing EGFRExon19del, and LoVo cells expressing wild-type EGFR (IC50s = 0.045, 0.026, and 0.786 μM, respectively)
34766	AZ 7550	5 mg	≥98%	An active metabolite of AZ 9291; inhibits IGF-1R in a cell-free assay (IC50 = 1.6 μM); inhibits EGFR autophosphorylation in H1975 cells expressing EGFRT790M/L858R, PC-9 cells expressing EGFRExon19del, and LoVo cells expressing wild-type EGFR (IC50s = 0.045, 0.026, and 0.786 μM, respectively)
34850	JX06	10 mg	≥98%	An irreversible PDHK inhibitor (IC50s = 49, 101, and 313 nM for PDHK1, PDHK2, and PDHK3, respectively); selective for PDHK1-3 over PDHK4 (IC50 = >10 μM) and 322 other kinases at 10 μM but does inhibit FAK in a cell-free assay but not in a cell-based assay; increases ROS production and induces apoptosis in cancer cells with a high ECAR:OCR ratio; reduces the level of glycolysis metabolites in NCI H929 multiple myeloma cells at 0.25 μM; reduces tumor growth in an A549 mouse xenograft model
34850	JX06	25 mg	≥98%	An irreversible PDHK inhibitor (IC50s = 49, 101, and 313 nM for PDHK1, PDHK2, and PDHK3, respectively); selective for PDHK1-3 over PDHK4 (IC50 = >10 μM) and 322 other kinases at 10 μM but does inhibit FAK in a cell-free assay but not in a cell-based assay; increases ROS production and induces apoptosis in cancer cells with a high ECAR:OCR ratio; reduces the level of glycolysis metabolites in NCI H929 multiple myeloma cells at 0.25 μM; reduces tumor growth in an A549 mouse xenograft model
34850	JX06	5 mg	≥98%	An irreversible PDHK inhibitor (IC50s = 49, 101, and 313 nM for PDHK1, PDHK2, and PDHK3, respectively); selective for PDHK1-3 over PDHK4 (IC50 = >10 μM) and 322 other kinases at 10 μM but does inhibit FAK in a cell-free assay but not in a cell-based assay; increases ROS production and induces apoptosis in cancer cells with a high ECAR:OCR ratio; reduces the level of glycolysis metabolites in NCI H929 multiple myeloma cells at 0.25 μM; reduces tumor growth in an A549 mouse xenograft model
34850	JX06	50 mg	≥98%	An irreversible PDHK inhibitor (IC50s = 49, 101, and 313 nM for PDHK1, PDHK2, and PDHK3, respectively); selective for PDHK1-3 over PDHK4 (IC50 = >10 μM) and 322 other kinases at 10 μM but does inhibit FAK in a cell-free assay but not in a cell-based assay; increases ROS production and induces apoptosis in cancer cells with a high ECAR:OCR ratio; reduces the level of glycolysis metabolites in NCI H929 multiple myeloma cells at 0.25 μM; reduces tumor growth in an A549 mouse xenograft model
34869	Abrocitinib	1 mg	≥98%	A JAK1 inhibitor (IC50 = 0.029 μM); selective for JAK1 over JAK2, JAK3, and TYK2 (IC50s = 0.803, >10, and 1.253 μM, respectively) and a panel of 40 kinases at 1 μM; inhibits IFN-α-, IL-21-, or IL-27-induced phosphorylation of STAT3 (IC50s = 0.189, 0.511, and 0.271 μM, respectively) and IFN-γ-induced phosphorylation of STAT1 (IC50 = 0.163 μM) in isolated human whole blood; reduces paw edema in a rat model of adjuvant-induced arthritis at 1, 5, and 15 mg/kg

34869	Abrocitinib	10 mg	≥98%	A JAK1 inhibitor (IC50 = 0.029 µM); selective for JAK1 over JAK2, JAK3, and TYK2 (IC50s = 0.803, >10, and 1.253 µM, respectively) and a panel of 40 kinases at 1 µM; inhibits IFN-α-, IL-21-, or IL-27-induced phosphorylation of STAT3 (IC50s = 0.189, 0.511, and 0.271 µM, respectively) and IFN-γ-induced phosphorylation of STAT1 (IC50 = 0.163 µM) in isolated human whole blood; reduces paw edema in a rat model of adjuvant-induced arthritis at 1, 5, and 15 mg/kg
34869	Abrocitinib	25 mg	≥98%	A JAK1 inhibitor (IC50 = 0.029 µM); selective for JAK1 over JAK2, JAK3, and TYK2 (IC50s = 0.803, >10, and 1.253 µM, respectively) and a panel of 40 kinases at 1 µM; inhibits IFN-α-, IL-21-, or IL-27-induced phosphorylation of STAT3 (IC50s = 0.189, 0.511, and 0.271 µM, respectively) and IFN-γ-induced phosphorylation of STAT1 (IC50 = 0.163 µM) in isolated human whole blood; reduces paw edema in a rat model of adjuvant-induced arthritis at 1, 5, and 15 mg/kg
34869	Abrocitinib	5 mg	≥98%	A JAK1 inhibitor (IC50 = 0.029 µM); selective for JAK1 over JAK2, JAK3, and TYK2 (IC50s = 0.803, >10, and 1.253 µM, respectively) and a panel of 40 kinases at 1 µM; inhibits IFN-α-, IL-21-, or IL-27-induced phosphorylation of STAT3 (IC50s = 0.189, 0.511, and 0.271 µM, respectively) and IFN-γ-induced phosphorylation of STAT1 (IC50 = 0.163 µM) in isolated human whole blood; reduces paw edema in a rat model of adjuvant-induced arthritis at 1, 5, and 15 mg/kg
34871	U-0124	1 mg		An inactive analog of U-0126; has been used as a negative control for the kinase activity of MEK
34871	U-0124	500 µg		An inactive analog of U-0126; has been used as a negative control for the kinase activity of MEK
34872	CHIR98024	1 mg	≥95%	A GSK3 inhibitor (IC50 = 0.56 nM)
34872	CHIR98024	10 mg	≥95%	A GSK3 inhibitor (IC50 = 0.56 nM)
34872	CHIR98024	25 mg	≥95%	A GSK3 inhibitor (IC50 = 0.56 nM)
34872	CHIR98024	5 mg	≥95%	A GSK3 inhibitor (IC50 = 0.56 nM)
34880	LY2857785	1 mg	≥98%	A Cdk9 inhibitor (IC50 = 0.011 µM); inhibits Cdk8 and Cdk7 (IC50s = 0.016 and 0.246 µM, respectively), as well as five kinases in a panel of 114 kinases (IC50s = 50s = 0.22 and 0.197 µM, respectively); inhibits RNAP II phosphorylation in PBMCs isolated from patients with AML or CLL; reduces tumor growth in an MV4-11 rat xenograft model at 3, 6, and 9 mg/kg
34880	LY2857785	10 mg	≥98%	A Cdk9 inhibitor (IC50 = 0.011 µM); inhibits Cdk8 and Cdk7 (IC50s = 0.016 and 0.246 µM, respectively), as well as five kinases in a panel of 114 kinases (IC50s = 50s = 0.22 and 0.197 µM, respectively); inhibits RNAP II phosphorylation in PBMCs isolated from patients with AML or CLL; reduces tumor growth in an MV4-11 rat xenograft model at 3, 6, and 9 mg/kg
34880	LY2857785	25 mg	≥98%	A Cdk9 inhibitor (IC50 = 0.011 µM); inhibits Cdk8 and Cdk7 (IC50s = 0.016 and 0.246 µM, respectively), as well as five kinases in a panel of 114 kinases (IC50s = 50s = 0.22 and 0.197 µM, respectively); inhibits RNAP II phosphorylation in PBMCs isolated from patients with AML or CLL; reduces tumor growth in an MV4-11 rat xenograft model at 3, 6, and 9 mg/kg
34880	LY2857785	5 mg	≥98%	A Cdk9 inhibitor (IC50 = 0.011 µM); inhibits Cdk8 and Cdk7 (IC50s = 0.016 and 0.246 µM, respectively), as well as five kinases in a panel of 114 kinases (IC50s = 50s = 0.22 and 0.197 µM, respectively); inhibits RNAP II phosphorylation in PBMCs isolated from patients with AML or CLL; reduces tumor growth in an MV4-11 rat xenograft model at 3, 6, and 9 mg/kg
35027	RMM 46	1 mg	≥98%	An inhibitor of RSK2 (IC50s= 12 and T493M human enzymes, respectively); selective for RSK2 over Plk1 and NEK2 (IC50s = 2,200 and 530 nM, respectively) and a panel of 26 kinases at 1 µM; inhibits PMA-induced autophosphorylation of RSK2 and RSK3 in COS-7 cells expressing the human enzymes
35027	RMM 46	5 mg	≥98%	An inhibitor of RSK2 (IC50s= 12 and T493M human enzymes, respectively); selective for RSK2 over Plk1 and NEK2 (IC50s = 2,200 and 530 nM, respectively) and a panel of 26 kinases at 1 µM; inhibits PMA-induced autophosphorylation of RSK2 and RSK3 in COS-7 cells expressing the human enzymes
35027	RMM 46	500 µg	≥98%	An inhibitor of RSK2 (IC50s= 12 and T493M human enzymes, respectively); selective for RSK2 over Plk1 and NEK2 (IC50s = 2,200 and 530 nM, respectively) and a panel of 26 kinases at 1 µM; inhibits PMA-induced autophosphorylation of RSK2 and RSK3 in COS-7 cells expressing the human enzymes
35095	BAY-1816032	1 mg	≥98%	An inhibitor of BUB1 kinase (IC50 = 6.1 nM); selective for BUB1 over FLT3 (IC50 = 4.2 µM) and 15 other kinases (IC50s = >10 µM for all); inhibits proliferation of a variety of cancer cells (median IC50 = 1.4 µM); reduces tumor growth in a SUM149 mouse xenograft model at 25 mg/kg
35095	BAY-1816032	10 mg	≥98%	An inhibitor of BUB1 kinase (IC50 = 6.1 nM); selective for BUB1 over FLT3 (IC50 = 4.2 µM) and 15 other kinases (IC50s = >10 µM for all); inhibits proliferation of a variety of cancer cells (median IC50 = 1.4 µM); reduces tumor growth in a SUM149 mouse xenograft model at 25 mg/kg

35095	BAY-1816032	25 mg	≥98%	An inhibitor of BUB1 kinase (IC50 = 6.1 nM); selective for BUB1 over FLT3 (IC50 = 4.2 μM) and 15 other kinases (IC50s = >10 μM for all); inhibits proliferation of a variety of cancer cells (median IC50 = 1.4 μM); reduces tumor growth in a SUM149 mouse xenograft model at 25 mg/kg
35095	BAY-1816032	5 mg	≥98%	An inhibitor of BUB1 kinase (IC50 = 6.1 nM); selective for BUB1 over FLT3 (IC50 = 4.2 μM) and 15 other kinases (IC50s = >10 μM for all); inhibits proliferation of a variety of cancer cells (median IC50 = 1.4 μM); reduces tumor growth in a SUM149 mouse xenograft model at 25 mg/kg
35101	Regorafenib N-oxide	1 mg	≥95%	An active metabolite of regorafenib; formed from regorafenib by CYP3A4; inhibits VEGFR2, Tie2, c-Kit, and B-RAF in vitro; inhibits tumor growth in HT-29 and MDA-MB-231 mouse xenograft models at 1 mg/kg
35101	Regorafenib N-oxide	10 mg	≥95%	An active metabolite of regorafenib; formed from regorafenib by CYP3A4; inhibits VEGFR2, Tie2, c-Kit, and B-RAF in vitro; inhibits tumor growth in HT-29 and MDA-MB-231 mouse xenograft models at 1 mg/kg
35101	Regorafenib N-oxide	25 mg	≥95%	An active metabolite of regorafenib; formed from regorafenib by CYP3A4; inhibits VEGFR2, Tie2, c-Kit, and B-RAF in vitro; inhibits tumor growth in HT-29 and MDA-MB-231 mouse xenograft models at 1 mg/kg
35101	Regorafenib N-oxide	5 mg	≥95%	An active metabolite of regorafenib; formed from regorafenib by CYP3A4; inhibits VEGFR2, Tie2, c-Kit, and B-RAF in vitro; inhibits tumor growth in HT-29 and MDA-MB-231 mouse xenograft models at 1 mg/kg
35102	N-desmethyl Regorafe	1 mg	≥90%	An active metabolite of regorafenib; formed from regorafenib by CYP3A4; inhibits VEGFR2, Tie2, c-Kit, and B-RAF in vitro; inhibits tumor growth in HT-29 and MDA-MB-231 mouse xenograft models at 1 mg/kg
35102	N-desmethyl Regorafe	10 mg	≥90%	An active metabolite of regorafenib; formed from regorafenib by CYP3A4; inhibits VEGFR2, Tie2, c-Kit, and B-RAF in vitro; inhibits tumor growth in HT-29 and MDA-MB-231 mouse xenograft models at 1 mg/kg
35102	N-desmethyl Regorafe	25 mg	≥90%	An active metabolite of regorafenib; formed from regorafenib by CYP3A4; inhibits VEGFR2, Tie2, c-Kit, and B-RAF in vitro; inhibits tumor growth in HT-29 and MDA-MB-231 mouse xenograft models at 1 mg/kg
35102	N-desmethyl Regorafe	5 mg	≥90%	An active metabolite of regorafenib; formed from regorafenib by CYP3A4; inhibits VEGFR2, Tie2, c-Kit, and B-RAF in vitro; inhibits tumor growth in HT-29 and MDA-MB-231 mouse xenograft models at 1 mg/kg
35108	Y-33075	1 mg	≥98%	An inhibitor of ROCK2 (IC50 = 3.6 nM); selective for ROCK2 over PKC and CaMKII (IC50s = 420 and 810 nM, respectively); topical application reduces intraocular pressure in rabbit and cynomolgus monkeys at 0.05% v/v; increases axonal regeneration at the crush site in a cat model of surgically-induced optic nerve damage at 10 and 100 μM; inhibits demyelination and reduces the incidence of relapse episodes in a mouse model of chronic relapsing EAE
35108	Y-33075	10 mg	≥98%	An inhibitor of ROCK2 (IC50 = 3.6 nM); selective for ROCK2 over PKC and CaMKII (IC50s = 420 and 810 nM, respectively); topical application reduces intraocular pressure in rabbit and cynomolgus monkeys at 0.05% v/v; increases axonal regeneration at the crush site in a cat model of surgically-induced optic nerve damage at 10 and 100 μM; inhibits demyelination and reduces the incidence of relapse episodes in a mouse model of chronic relapsing EAE
35108	Y-33075	5 mg	≥98%	An inhibitor of ROCK2 (IC50 = 3.6 nM); selective for ROCK2 over PKC and CaMKII (IC50s = 420 and 810 nM, respectively); topical application reduces intraocular pressure in rabbit and cynomolgus monkeys at 0.05% v/v; increases axonal regeneration at the crush site in a cat model of surgically-induced optic nerve damage at 10 and 100 μM; inhibits demyelination and reduces the incidence of relapse episodes in a mouse model of chronic relapsing EAE
35117	SB-242235	10 mg	≥98%	A p38α MAPK inhibitor (IC50 = 0.019 μM); selective for p38α MAPK over a panel of 10 kinases, including ERK2, JNK1, EGFR, and C-RAF (IC50s = >10 μM for all); inhibits IL-1α-induced production of NO in bovine articular cartilage explants (IC50 = ~1 μM); inhibits increases in epidermal COX-2 levels and erythema in mice exposed to UVB irradiation at 100 mg/kg; reduces paw edema in a rat model of adjuvant-induced arthritis at 10, 30, and 60 mg/kg
35117	SB-242235	25 mg	≥98%	A p38α MAPK inhibitor (IC50 = 0.019 μM); selective for p38α MAPK over a panel of 10 kinases, including ERK2, JNK1, EGFR, and C-RAF (IC50s = >10 μM for all); inhibits IL-1α-induced production of NO in bovine articular cartilage explants (IC50 = ~1 μM); inhibits increases in epidermal COX-2 levels and erythema in mice exposed to UVB irradiation at 100 mg/kg; reduces paw edema in a rat model of adjuvant-induced arthritis at 10, 30, and 60 mg/kg

35117	SB-242235	5 mg	≥98%	A p38α MAPK inhibitor (IC50 = 0.019 μM); selective for p38α MAPK over a panel of 10 kinases, including ERK2, JNK1, EGFR, and C-RAF (IC50s = >10 μM for all); inhibits IL-1α-induced production of NO in bovine articular cartilage explants (IC50 = ~1 μM); inhibits increases in epidermal COX-2 levels and erythema in mice exposed to UVB irradiation at 100 mg/kg; reduces paw edema in a rat model of adjuvant-induced arthritis at 10, 30, and 60 mg/kg
35117	SB-242235	50 mg	≥98%	A p38α MAPK inhibitor (IC50 = 0.019 μM); selective for p38α MAPK over a panel of 10 kinases, including ERK2, JNK1, EGFR, and C-RAF (IC50s = >10 μM for all); inhibits IL-1α-induced production of NO in bovine articular cartilage explants (IC50 = ~1 μM); inhibits increases in epidermal COX-2 levels and erythema in mice exposed to UVB irradiation at 100 mg/kg; reduces paw edema in a rat model of adjuvant-induced arthritis at 10, 30, and 60 mg/kg
35388	7,4′-Di-O-methylapige	1 mg	≥98%	A flavonoid with diverse biological activities; inhibits MAO-B but not MAO-A (IC50s = 0.198 and >100 μM, respectively), as well as p38α MAPK but not JNK3 (IC50s = 27.8 and >100 μM, respectively); inhibits NO production in LPS-stimulated RAW 264.7 macrophages (IC50 = 24.5 μM); reduces the growth of C. albicans at 45 μg/ml; inhibits carrageenan-induced edema in rats (ED25 = 75 mg/kg)
35388	7,4′-Di-O-methylapige	10 mg	≥98%	A flavonoid with diverse biological activities; inhibits MAO-B but not MAO-A (IC50s = 0.198 and >100 μM, respectively), as well as p38α MAPK but not JNK3 (IC50s = 27.8 and >100 μM, respectively); inhibits NO production in LPS-stimulated RAW 264.7 macrophages (IC50 = 24.5 μM); reduces the growth of C. albicans at 45 μg/ml; inhibits carrageenan-induced edema in rats (ED25 = 75 mg/kg)
35388	7,4′-Di-O-methylapige	25 mg	≥98%	A flavonoid with diverse biological activities; inhibits MAO-B but not MAO-A (IC50s = 0.198 and >100 μM, respectively), as well as p38α MAPK but not JNK3 (IC50s = 27.8 and >100 μM, respectively); inhibits NO production in LPS-stimulated RAW 264.7 macrophages (IC50 = 24.5 μM); reduces the growth of C. albicans at 45 μg/ml; inhibits carrageenan-induced edema in rats (ED25 = 75 mg/kg)
35388	7,4′-Di-O-methylapige	5 mg	≥98%	A flavonoid with diverse biological activities; inhibits MAO-B but not MAO-A (IC50s = 0.198 and >100 μM, respectively), as well as p38α MAPK but not JNK3 (IC50s = 27.8 and >100 μM, respectively); inhibits NO production in LPS-stimulated RAW 264.7 macrophages (IC50 = 24.5 μM); reduces the growth of C. albicans at 45 μg/ml; inhibits carrageenan-induced edema in rats (ED25 = 75 mg/kg)
35391	Wee1 Inhibitor	1 mg	≥95%	An inhibitor of Wee1 (IC50 = 11 nM); selective for Wee1 over Chk1 (IC50 = 440 nM); inhibits the ATPase activity of LptB (IC50 = 25 μM for the E. coli enzyme)
35502	PF-06873600	1 mg	≥98%	An inhibitor of Cdk2, Cdk4, and Cdk6 (Kis = 0.13, 1.25, and 0.11 nM, respectively); selective for these CDKs over Cdk1 and Cdk9 (Kis = 4.5 and 19.6 nM, respectively); inhibits the phosphorylation of RB1 in, and the proliferation of, OVCAR-3 ovarian cancer cells (EC50s = 19 and 45 nM, respectively); reduces tumor volume in CTG-0464 and CTG-01912 NSCLC PDX mouse models at 30 mg/kg
35502	PF-06873600	10 mg	≥98%	An inhibitor of Cdk2, Cdk4, and Cdk6 (Kis = 0.13, 1.25, and 0.11 nM, respectively); selective for these CDKs over Cdk1 and Cdk9 (Kis = 4.5 and 19.6 nM, respectively); inhibits the phosphorylation of RB1 in, and the proliferation of, OVCAR-3 ovarian cancer cells (EC50s = 19 and 45 nM, respectively); reduces tumor volume in CTG-0464 and CTG-01912 NSCLC PDX mouse models at 30 mg/kg
35502	PF-06873600	25 mg	≥98%	An inhibitor of Cdk2, Cdk4, and Cdk6 (Kis = 0.13, 1.25, and 0.11 nM, respectively); selective for these CDKs over Cdk1 and Cdk9 (Kis = 4.5 and 19.6 nM, respectively); inhibits the phosphorylation of RB1 in, and the proliferation of, OVCAR-3 ovarian cancer cells (EC50s = 19 and 45 nM, respectively); reduces tumor volume in CTG-0464 and CTG-01912 NSCLC PDX mouse models at 30 mg/kg
35502	PF-06873600	5 mg	≥98%	An inhibitor of Cdk2, Cdk4, and Cdk6 (Kis = 0.13, 1.25, and 0.11 nM, respectively); selective for these CDKs over Cdk1 and Cdk9 (Kis = 4.5 and 19.6 nM, respectively); inhibits the phosphorylation of RB1 in, and the proliferation of, OVCAR-3 ovarian cancer cells (EC50s = 19 and 45 nM, respectively); reduces tumor volume in CTG-0464 and CTG-01912 NSCLC PDX mouse models at 30 mg/kg
35754	Takeda-6d	1 mg	≥95%	A dual inhibitor of RAF kinases and VEGFR2; inhibits wild-type B-RAF, mutant B-RAFV600E, and C-RAF (IC50s = 12, 7, and 1.5 nM, respectively), as well as VEGFR2 (IC50 = 2.8 nM); selective for these kinases over a panel of 19 additional kinases (IC50s = >1,000 nM) but does inhibit FGFR3, PDGFRα, and PDGFRβ (IC50s = 22, 12, and 5.5 nM, respectively); inhibits MEK and ERK1/2 phosphorylation in several colon cancer and melanoma cell lines expressing B-RAFV600E from 100-1,600 nM; inhibits VEGF-A-induced phosphorylation of VEGFR2 in VEGFR2-overexpressing KDR cells (IC50 = 0.53 nM); reduces tumor volume in an A375 melanoma mouse xenograft model at 10 mg/kg

35754	Takeda-6d	5 mg	≥95%	A dual inhibitor of RAF kinases and VEGFR2; inhibits wild-type B-RAF, mutant B-RAFV600E, and C-RAF (IC50s = 12, 7, and 1.5 nM, respectively), as well as VEGFR2 (IC50 = 2.8 nM); selective for these kinases over a panel of 19 additional kinases (IC50s = >1,000 nM) but does inhibit FGFR3, PDGFRα, and PDGFRβ (IC50s = 22, 12, and 5.5 nM, respectively); inhibits MEK and ERK1/2 phosphorylation in several colon cancer and melanoma cell lines expressing B-RAFV600E from 100-1,600 nM; inhibits VEGF-A-induced phosphorylation of VEGFR2 in VEGFR2-overexpressing KDR cells (IC50 = 0.53 nM); reduces tumor volume in an A375 melanoma mouse xenograft model at 10 mg/kg
36106	FLT3-IN-3	10 mg	≥98%	An FLT3 inhibitor; inhibits wild-type, FLT3D835Y, and FLT3-ITD (IC50s = 13, 8, and 3 nM, respectively); suppresses the growth of MV4-11 AML cells that express FLT3-ITD (GI50 = 7 nM); induces cell cycle arrest at the G1 phase and apoptosis in the same cells; reduces intratumor FLT3-ITD autophosphorylation in a MV4-11 mouse xenograft model at 10 mg/kg
36106	FLT3-IN-3	100 mg	≥98%	An FLT3 inhibitor; inhibits wild-type, FLT3D835Y, and FLT3-ITD (IC50s = 13, 8, and 3 nM, respectively); suppresses the growth of MV4-11 AML cells that express FLT3-ITD (GI50 = 7 nM); induces cell cycle arrest at the G1 phase and apoptosis in the same cells; reduces intratumor FLT3-ITD autophosphorylation in a MV4-11 mouse xenograft model at 10 mg/kg
36106	FLT3-IN-3	250 mg	≥98%	An FLT3 inhibitor; inhibits wild-type, FLT3D835Y, and FLT3-ITD (IC50s = 13, 8, and 3 nM, respectively); suppresses the growth of MV4-11 AML cells that express FLT3-ITD (GI50 = 7 nM); induces cell cycle arrest at the G1 phase and apoptosis in the same cells; reduces intratumor FLT3-ITD autophosphorylation in a MV4-11 mouse xenograft model at 10 mg/kg
36106	FLT3-IN-3	50 mg	≥98%	An FLT3 inhibitor; inhibits wild-type, FLT3D835Y, and FLT3-ITD (IC50s = 13, 8, and 3 nM, respectively); suppresses the growth of MV4-11 AML cells that express FLT3-ITD (GI50 = 7 nM); induces cell cycle arrest at the G1 phase and apoptosis in the same cells; reduces intratumor FLT3-ITD autophosphorylation in a MV4-11 mouse xenograft model at 10 mg/kg
36277	PLX5622 (hemifumara	1 mg	≥98%	A brain-penetrant CSF1R inhibitor (IC50 = 0.016 μM); selective for CSF1R over FLT3, Kit, Aurora C, and VEGFR2 (IC50s = 0.39, 0.86, 1, and 1.1 μM, respectively); greater than 100-fold selective for CSF1R over a panel of 230 kinases; reduces the number of Iba-1+ cells in the spinal cord dorsal horn in a mouse model of neuropathic pain induced by partial ligation of the sciatic nerve at 65 mg/kg; decreases macrophage levels of TNF-α and IL-1β and infiltration in the sciatic nerve and alleviates mechanical and cold allodynia in the same model; decreases the number of hippocampal microglia by 90%, as well as reduces the number and volume of retrosplenial and somatosensory cortical Aβ plaques in the 5XFAD mouse model of Alzheimer's disease at 1,200 ppm in the chow
36277	PLX5622 (hemifumara	10 mg	≥98%	A brain-penetrant CSF1R inhibitor (IC50 = 0.016 μM); selective for CSF1R over FLT3, Kit, Aurora C, and VEGFR2 (IC50s = 0.39, 0.86, 1, and 1.1 μM, respectively); greater than 100-fold selective for CSF1R over a panel of 230 kinases; reduces the number of Iba-1+ cells in the spinal cord dorsal horn in a mouse model of neuropathic pain induced by partial ligation of the sciatic nerve at 65 mg/kg; decreases macrophage levels of TNF-α and IL-1β and infiltration in the sciatic nerve and alleviates mechanical and cold allodynia in the same model; decreases the number of hippocampal microglia by 90%, as well as reduces the number and volume of retrosplenial and somatosensory cortical Aβ plaques in the 5XFAD mouse model of Alzheimer's disease at 1,200 ppm in the chow
36277	PLX5622 (hemifumara	25 mg	≥98%	A brain-penetrant CSF1R inhibitor (IC50 = 0.016 μM); selective for CSF1R over FLT3, Kit, Aurora C, and VEGFR2 (IC50s = 0.39, 0.86, 1, and 1.1 μM, respectively); greater than 100-fold selective for CSF1R over a panel of 230 kinases; reduces the number of Iba-1+ cells in the spinal cord dorsal horn in a mouse model of neuropathic pain induced by partial ligation of the sciatic nerve at 65 mg/kg; decreases macrophage levels of TNF-α and IL-1β and infiltration in the sciatic nerve and alleviates mechanical and cold allodynia in the same model; decreases the number of hippocampal microglia by 90%, as well as reduces the number and volume of retrosplenial and somatosensory cortical Aβ plaques in the 5XFAD mouse model of Alzheimer's disease at 1,200 ppm in the chow
36277	PLX5622 (hemifumara	5 mg	≥98%	A brain-penetrant CSF1R inhibitor (IC50 = 0.016 μM); selective for CSF1R over FLT3, Kit, Aurora C, and VEGFR2 (IC50s = 0.39, 0.86, 1, and 1.1 μM, respectively); greater than 100-fold selective for CSF1R over a panel of 230 kinases; reduces the number of Iba-1+ cells in the spinal cord dorsal horn in a mouse model of neuropathic pain induced by partial ligation of the sciatic nerve at 65 mg/kg; decreases macrophage levels of TNF-α and IL-1β and infiltration in the sciatic nerve and alleviates mechanical and cold allodynia in the same model; decreases the number of hippocampal microglia by 90%, as well as reduces the number and volume of retrosplenial and somatosensory cortical Aβ plaques in the 5XFAD mouse model of Alzheimer's disease at 1,200 ppm in the chow
36554	Gusacitinib	1 mg	≥98%	A dual inhibitor of JAKs (IC50s = 46, 4, and 11 nM for JAK1-3, respectively) and Syk family kinases (IC50s = 5 and 8 nM for SyK and TYK2, respectively)

36554	Gusacitinib	10 mg	≥98%	A dual inhibitor of JAKs (IC50s = 46, 4, and 11 nM for JAK1-3, respectively) and Syk family kinases (IC50s = 5 and 8 nM for SyK and TYK2, respectively)
36554	Gusacitinib	25 mg	≥98%	A dual inhibitor of JAKs (IC50s = 46, 4, and 11 nM for JAK1-3, respectively) and Syk family kinases (IC50s = 5 and 8 nM for SyK and TYK2, respectively)
36554	Gusacitinib	5 mg	≥98%	A dual inhibitor of JAKs (IC50s = 46, 4, and 11 nM for JAK1-3, respectively) and Syk family kinases (IC50s = 5 and 8 nM for SyK and TYK2, respectively)
36555	FIT-039	1 mg	≥98%	A Cdk9 inhibitor (IC50 = 5.8 µM for Cdk9/cyclin T1); selective for Cdk9/cyclin T1 over Cdk4/cyclin D3 at 30 µM and Cdk2/cyclin A2, Cdk2/cyclin E1, Cdk5/p25, Cdk6/cyclin D3, and Cdk7/cyclin/MAT1 at 10 µM; inhibits GSK3α, GSK3β, PKN1, haspin, p70S6K, DYRK1B, DYRK3, and IRR at 10 µM; inhibits DNA replication of HSV-1 in HeLa cells (IC50 = 0.69 µM); reduces skin lesions and improves survival in HSV-1-infected mice when applied topically at 1.25-10% w/w; reduces tumor growth in an HPV type 16-positive Ca Ski cervical cancer mouse xenograft model at 300 mg/kg
36555	FIT-039	10 mg	≥98%	A Cdk9 inhibitor (IC50 = 5.8 µM for Cdk9/cyclin T1); selective for Cdk9/cyclin T1 over Cdk4/cyclin D3 at 30 µM and Cdk2/cyclin A2, Cdk2/cyclin E1, Cdk5/p25, Cdk6/cyclin D3, and Cdk7/cyclin/MAT1 at 10 µM; inhibits GSK3α, GSK3β, PKN1, haspin, p70S6K, DYRK1B, DYRK3, and IRR at 10 µM; inhibits DNA replication of HSV-1 in HeLa cells (IC50 = 0.69 µM); reduces skin lesions and improves survival in HSV-1-infected mice when applied topically at 1.25-10% w/w; reduces tumor growth in an HPV type 16-positive Ca Ski cervical cancer mouse xenograft model at 300 mg/kg
36555	FIT-039	25 mg	≥98%	A Cdk9 inhibitor (IC50 = 5.8 µM for Cdk9/cyclin T1); selective for Cdk9/cyclin T1 over Cdk4/cyclin D3 at 30 µM and Cdk2/cyclin A2, Cdk2/cyclin E1, Cdk5/p25, Cdk6/cyclin D3, and Cdk7/cyclin/MAT1 at 10 µM; inhibits GSK3α, GSK3β, PKN1, haspin, p70S6K, DYRK1B, DYRK3, and IRR at 10 µM; inhibits DNA replication of HSV-1 in HeLa cells (IC50 = 0.69 µM); reduces skin lesions and improves survival in HSV-1-infected mice when applied topically at 1.25-10% w/w; reduces tumor growth in an HPV type 16-positive Ca Ski cervical cancer mouse xenograft model at 300 mg/kg
36555	FIT-039	5 mg	≥98%	A Cdk9 inhibitor (IC50 = 5.8 µM for Cdk9/cyclin T1); selective for Cdk9/cyclin T1 over Cdk4/cyclin D3 at 30 µM and Cdk2/cyclin A2, Cdk2/cyclin E1, Cdk5/p25, Cdk6/cyclin D3, and Cdk7/cyclin/MAT1 at 10 µM; inhibits GSK3α, GSK3β, PKN1, haspin, p70S6K, DYRK1B, DYRK3, and IRR at 10 µM; inhibits DNA replication of HSV-1 in HeLa cells (IC50 = 0.69 µM); reduces skin lesions and improves survival in HSV-1-infected mice when applied topically at 1.25-10% w/w; reduces tumor growth in an HPV type 16-positive Ca Ski cervical cancer mouse xenograft model at 300 mg/kg
44570	12(S)-HpETE	100 µg	≥98%	A monohydroperoxy PUFA produced from arachidonic acid by 12-LO
44570	12(S)-HpETE	25 µg	≥98%	A monohydroperoxy PUFA produced from arachidonic acid by 12-LO
44570	12(S)-HpETE	250 µg	≥98%	A monohydroperoxy PUFA produced from arachidonic acid by 12-LO
44570	12(S)-HpETE	50 µg	≥98%	A monohydroperoxy PUFA produced from arachidonic acid by 12-LO
60920	Hexadecyl Acetyl Glyc	10 mg	≥90%	An analog of DAG, which inhibits the activation of PKC by DAG
60920	Hexadecyl Acetyl Glyc	100 mg	≥90%	An analog of DAG, which inhibits the activation of PKC by DAG
60920	Hexadecyl Acetyl Glyc	5 mg	≥90%	An analog of DAG, which inhibits the activation of PKC by DAG
60920	Hexadecyl Acetyl Glyc	50 mg	≥90%	An analog of DAG, which inhibits the activation of PKC by DAG
60930	Hexadecyl Methyl Gly	10 mg	≥98%	An synthetic DAG that inhibits PKC
60930	Hexadecyl Methyl Gly	100 mg	≥98%	An synthetic DAG that inhibits PKC
60930	Hexadecyl Methyl Gly	50 mg	≥98%	An synthetic DAG that inhibits PKC
60972	D-myo-Inositol-1,3,4-	1 mg	≥98%	A member of the InsP family of small, soluble second messengers; inhibits Ins(3,4,5,6)P4 kinase activity to increase the cellular level of Ins(3,4,5,6)P4
60972	D-myo-Inositol-1,3,4-	100 µg	≥98%	A member of the InsP family of small, soluble second messengers; inhibits Ins(3,4,5,6)P4 kinase activity to increase the cellular level of Ins(3,4,5,6)P4
60972	D-myo-Inositol-1,3,4-	500 µg	≥98%	A member of the InsP family of small, soluble second messengers; inhibits Ins(3,4,5,6)P4 kinase activity to increase the cellular level of Ins(3,4,5,6)P4
62575	N,N-Dimethylsphingo	10 mg	≥98%	An SPHK inhibitor (Kis = 3.1, 6.8, and 2.3 µM in U937, PC12, and Swiss 3T3 cell extracts, respectively); selective for SPHK over PKC in PC12 cells at 10 µM
62575	N,N-Dimethylsphingo	25 mg	≥98%	An SPHK inhibitor (Kis = 3.1, 6.8, and 2.3 µM in U937, PC12, and Swiss 3T3 cell extracts, respectively); selective for SPHK over PKC in PC12 cells at 10 µM

62575	N,N-Dimethylsphingo	5 mg	≥98%	An SPHK inhibitor (Kis = 3.1, 6.8, and 2.3 μM in U937, PC12, and Swiss 3T3 cell extracts, respectively); selective for SPHK over PKC in PC12 cells at 10 μM
62575	N,N-Dimethylsphingo	50 mg	≥98%	An SPHK inhibitor (Kis = 3.1, 6.8, and 2.3 μM in U937, PC12, and Swiss 3T3 cell extracts, respectively); selective for SPHK over PKC in PC12 cells at 10 μM
70675	trans-Resveratrol	100 mg	≥98%	A polyphenol with diverse biological activities; inhibits the cyclooxygenase and hydroperoxidase activities of COX-1 (EC50s = 15 and 3.7 μM, respectively); inhibits ERK1, JNK1, Src, PKCα, aromatase/CYP19, and DNA polymerases α and δ (IC50s = 37, 50, 20, in vitro and/or ex vivo; exhibits anticancer, anti-inflammatory, and antiviral activities in mice
70675	trans-Resveratrol	250 mg	≥98%	A polyphenol with diverse biological activities; inhibits the cyclooxygenase and hydroperoxidase activities of COX-1 (EC50s = 15 and 3.7 μM, respectively); inhibits ERK1, JNK1, Src, PKCα, aromatase/CYP19, and DNA polymerases α and δ (IC50s = 37, 50, 20, in vitro and/or ex vivo; exhibits anticancer, anti-inflammatory, and antiviral activities in mice
70675	trans-Resveratrol	50 mg	≥98%	A polyphenol with diverse biological activities; inhibits the cyclooxygenase and hydroperoxidase activities of COX-1 (EC50s = 15 and 3.7 μM, respectively); inhibits ERK1, JNK1, Src, PKCα, aromatase/CYP19, and DNA polymerases α and δ (IC50s = 37, 50, 20, in vitro and/or ex vivo; exhibits anticancer, anti-inflammatory, and antiviral activities in mice
70675	trans-Resveratrol	500 mg	≥98%	A polyphenol with diverse biological activities; inhibits the cyclooxygenase and hydroperoxidase activities of COX-1 (EC50s = 15 and 3.7 μM, respectively); inhibits ERK1, JNK1, Src, PKCα, aromatase/CYP19, and DNA polymerases α and δ (IC50s = 37, 50, 20, in vitro and/or ex vivo; exhibits anticancer, anti-inflammatory, and antiviral activities in mice
70920	LY294002	10 mg	≥98%	A selective PI3K inhibitor with an IC50 value of 1.4 μM
70920	LY294002	25 mg	≥98%	A selective PI3K inhibitor with an IC50 value of 1.4 μM
70920	LY294002	5 mg	≥98%	A selective PI3K inhibitor with an IC50 value of 1.4 μM
70920	LY294002	50 mg	≥98%	A selective PI3K inhibitor with an IC50 value of 1.4 μM
70970	U-0126	1 mg	≥98%	A non ATP-competitive MEK inhibitor (IC50 = 72 and 58 nM for MEK1 and MEK2, respectively); an activator of AMPK (EC50 = 15 μM); increases the ratios of ADP:ATP and AMP:ATP
70970	U-0126	10 mg	≥98%	A non ATP-competitive MEK inhibitor (IC50 = 72 and 58 nM for MEK1 and MEK2, respectively); an activator of AMPK (EC50 = 15 μM); increases the ratios of ADP:ATP and AMP:ATP
70970	U-0126	25 mg	≥98%	A non ATP-competitive MEK inhibitor (IC50 = 72 and 58 nM for MEK1 and MEK2, respectively); an activator of AMPK (EC50 = 15 μM); increases the ratios of ADP:ATP and AMP:ATP
70970	U-0126	5 mg	≥98%	A non ATP-competitive MEK inhibitor (IC50 = 72 and 58 nM for MEK1 and MEK2, respectively); an activator of AMPK (EC50 = 15 μM); increases the ratios of ADP:ATP and AMP:ATP
81590	Staurosporine	1 mg	≥98%	A potent inhibitor of PKC (IC50 = 2.7 nM for the rat brain enzyme)
81590	Staurosporine	10 mg	≥98%	A potent inhibitor of PKC (IC50 = 2.7 nM for the rat brain enzyme)
81590	Staurosporine	5 mg	≥98%	A potent inhibitor of PKC (IC50 = 2.7 nM for the rat brain enzyme)
81590	Staurosporine	500 μg	≥98%	A potent inhibitor of PKC (IC50 = 2.7 nM for the rat brain enzyme)
9000059	(±)-Jasmonic Acid met	1 g	≥95% (mixture	A mixture of trans (3R/7R and 3S/7S) isomers; induces the synthesis of proteinase inhibitors in plant leaves; in cancer cells, suppresses proliferation and induces apoptosis; inhibits hexokinase that is bound to mitochondria; methyl jasmonate derivatives also have potential as anti-inflammatory agents.
9000059	(±)-Jasmonic Acid met	10 g	≥95% (mixture	A mixture of trans (3R/7R and 3S/7S) isomers; induces the synthesis of proteinase inhibitors in plant leaves; in cancer cells, suppresses proliferation and induces apoptosis; inhibits hexokinase that is bound to mitochondria; methyl jasmonate derivatives also have potential as anti-inflammatory agents.
9000059	(±)-Jasmonic Acid met	25 g	≥95% (mixture	A mixture of trans (3R/7R and 3S/7S) isomers; induces the synthesis of proteinase inhibitors in plant leaves; in cancer cells, suppresses proliferation and induces apoptosis; inhibits hexokinase that is bound to mitochondria; methyl jasmonate derivatives also have potential as anti-inflammatory agents.

9000059	(±)-Jasmonic Acid met	5 g	≥95% (mixture	A mixture of trans (3R/7R and 3S/7S) isomers; induces the synthesis of proteinase inhibitors in plant leaves; in cancer cells, suppresses proliferation and induces apoptosis; inhibits hexokinase that is bound to mitochondria; methyl jasmonate derivatives also have potential as anti-inflammatory agents.
9000887	FMK	1 mg	≥98%	An inhibitor of RSK2 (IC50 = 15 nM); inhibits EGF-induced phosphorylation of Ser386 in RSK2 in serum-starved COS-7 cells (EC50 = ~200 nM) reduces invasion of M4e, 212LN, and 37B human head and neck squamous cell carcinoma cells at 6 µM; induces apoptosis in OPM-1, LP-1, and KMS-18 human myeloma cells expressing the t(4;14) translocation mutation and FGFR3 at 10 µM
9000887	FMK	10 mg	≥98%	An inhibitor of RSK2 (IC50 = 15 nM); inhibits EGF-induced phosphorylation of Ser386 in RSK2 in serum-starved COS-7 cells (EC50 = ~200 nM) reduces invasion of M4e, 212LN, and 37B human head and neck squamous cell carcinoma cells at 6 µM; induces apoptosis in OPM-1, LP-1, and KMS-18 human myeloma cells expressing the t(4;14) translocation mutation and FGFR3 at 10 µM
9000887	FMK	5 mg	≥98%	An inhibitor of RSK2 (IC50 = 15 nM); inhibits EGF-induced phosphorylation of Ser386 in RSK2 in serum-starved COS-7 cells (EC50 = ~200 nM) reduces invasion of M4e, 212LN, and 37B human head and neck squamous cell carcinoma cells at 6 µM; induces apoptosis in OPM-1, LP-1, and KMS-18 human myeloma cells expressing the t(4;14) translocation mutation and FGFR3 at 10 µM
9000890	KN-92 (hydrochloride	1 mg	≥98%	An inactive derivative of KN-93, the selective inhibitor of CaMKII; ineffective at inhibiting CaMKII or arresting cell growth of NIH 3T3 fibroblasts at concentrations up to 25 µM
9000890	KN-92 (hydrochloride	10 mg	≥98%	An inactive derivative of KN-93, the selective inhibitor of CaMKII; ineffective at inhibiting CaMKII or arresting cell growth of NIH 3T3 fibroblasts at concentrations up to 25 µM
9000890	KN-92 (hydrochloride	5 mg	≥98%	An inactive derivative of KN-93, the selective inhibitor of CaMKII; ineffective at inhibiting CaMKII or arresting cell growth of NIH 3T3 fibroblasts at concentrations up to 25 µM
9000980	AS-605240 (potassium	1 mg	≥98%	An orally active inhibitor of PI3-kinase γ that suppresses joint inflammation in mouse models of rheumatoid arthritis; inhibits human recombinant PI3Kγ, α, β, and δ in an ATP-competitive manner with IC50 values of 8, 60, 270, and 300 nM, respectively
9000980	AS-605240 (potassium	10 mg	≥98%	An orally active inhibitor of PI3-kinase γ that suppresses joint inflammation in mouse models of rheumatoid arthritis; inhibits human recombinant PI3Kγ, α, β, and δ in an ATP-competitive manner with IC50 values of 8, 60, 270, and 300 nM, respectively
9000980	AS-605240 (potassium	25 mg	≥98%	An orally active inhibitor of PI3-kinase γ that suppresses joint inflammation in mouse models of rheumatoid arthritis; inhibits human recombinant PI3Kγ, α, β, and δ in an ATP-competitive manner with IC50 values of 8, 60, 270, and 300 nM, respectively
9000980	AS-605240 (potassium	5 mg	≥98%	An orally active inhibitor of PI3-kinase γ that suppresses joint inflammation in mouse models of rheumatoid arthritis; inhibits human recombinant PI3Kγ, α, β, and δ in an ATP-competitive manner with IC50 values of 8, 60, 270, and 300 nM, respectively
9000988	PD 166326	1 mg	≥95%	A pyridopyrimidine-type inhibitor of receptor tyrosine kinases that inhibits c-abl (IC50 = 8 nM) and Bcr/Abl-dependent cell growth (IC50 = 0.4 nM); also potently inhibits c-src (IC50 = 6 nM); effectively blocks Bcr/Abl kinase activity in vivo
9000988	PD 166326	10 mg	≥95%	A pyridopyrimidine-type inhibitor of receptor tyrosine kinases that inhibits c-abl (IC50 = 8 nM) and Bcr/Abl-dependent cell growth (IC50 = 0.4 nM); also potently inhibits c-src (IC50 = 6 nM); effectively blocks Bcr/Abl kinase activity in vivo
9000988	PD 166326	5 mg	≥95%	A pyridopyrimidine-type inhibitor of receptor tyrosine kinases that inhibits c-abl (IC50 = 8 nM) and Bcr/Abl-dependent cell growth (IC50 = 0.4 nM); also potently inhibits c-src (IC50 = 6 nM); effectively blocks Bcr/Abl kinase activity in vivo
9001589	APY0201	1 mg	≥98%	An inhibitor of PIKFYVE (IC50 = 5.2 nM); selectively inhibits IL-12 family inflammatory cytokine production (IC50s = 8, 99, and >10,000 nM for IL-12p70, IL-12p40, and TNF-α in stimulated human PBMCs); selective for PIKFYVE over a panel of 137 G protein-coupled receptors, enzymes, ion channels, and transporters, and other kinases only exhibiting >50% inhibition at LOK and ITPK1 at a concentration of 300 nM; inhibits Il-12p70 production ex vivo in murine plasma and reduces colonic inflammation in a mouse Il-10-/- cell transfer model of inflammatory bowel disease in a dose-dependent manner
9001589	APY0201	10 mg	≥98%	An inhibitor of PIKFYVE (IC50 = 5.2 nM); selectively inhibits IL-12 family inflammatory cytokine production (IC50s = 8, 99, and >10,000 nM for IL-12p70, IL-12p40, and TNF-α in stimulated human PBMCs); selective for PIKFYVE over a panel of 137 G protein-coupled receptors, enzymes, ion channels, and transporters, and other kinases only exhibiting >50% inhibition at LOK and ITPK1 at a concentration of 300 nM; inhibits Il-12p70 production ex vivo in murine plasma and reduces colonic inflammation in a mouse Il-10-/- cell transfer model of inflammatory bowel disease in a dose-dependent manner

9001589	APY0201	25 mg	≥98%	An inhibitor of PIKFYVE (IC50 = 5.2 nM); selectively inhibits IL-12 family inflammatory cytokine production (IC50s = 8, 99, and >10,000 nM for IL-12p70, IL-12p40, and TNF-α in stimulated human PBMCs); selective for PIKFYVE over a panel of 137 G protein-coupled receptors, enzymes, ion channels, and transporters, and other kinases only exhibiting >50% inhibition at LOK and ITPK1 at a concentration of 300 nM; inhibits Il-12p70 production ex vivo in murine plasma and reduces colonic inflammation in a mouse Il-10-/- cell transfer model of inflammatory bowel disease in a dose-dependent manner
9001589	APY0201	5 mg	≥98%	An inhibitor of PIKFYVE (IC50 = 5.2 nM); selectively inhibits IL-12 family inflammatory cytokine production (IC50s = 8, 99, and >10,000 nM for IL-12p70, IL-12p40, and TNF-α in stimulated human PBMCs); selective for PIKFYVE over a panel of 137 G protein-coupled receptors, enzymes, ion channels, and transporters, and other kinases only exhibiting >50% inhibition at LOK and ITPK1 at a concentration of 300 nM; inhibits Il-12p70 production ex vivo in murine plasma and reduces colonic inflammation in a mouse Il-10-/- cell transfer model of inflammatory bowel disease in a dose-dependent manner
9001799	A 83-01	1 mg	≥95%	An inhibitor of ALK5, ALK4, and ALK7 (IC50s = 12, 45, and 7.5 nM, respectively); blocks the phosphorylation of SMAD2/3 and inhibits TGF-β-induced epithelial-to-mesenchymal transition; used to reprogram fibroblasts into alternative lineages
9001799	A 83-01	10 mg	≥95%	An inhibitor of ALK5, ALK4, and ALK7 (IC50s = 12, 45, and 7.5 nM, respectively); blocks the phosphorylation of SMAD2/3 and inhibits TGF-β-induced epithelial-to-mesenchymal transition; used to reprogram fibroblasts into alternative lineages
9001799	A 83-01	25 mg	≥95%	An inhibitor of ALK5, ALK4, and ALK7 (IC50s = 12, 45, and 7.5 nM, respectively); blocks the phosphorylation of SMAD2/3 and inhibits TGF-β-induced epithelial-to-mesenchymal transition; used to reprogram fibroblasts into alternative lineages
9001799	A 83-01	5 mg	≥95%	An inhibitor of ALK5, ALK4, and ALK7 (IC50s = 12, 45, and 7.5 nM, respectively); blocks the phosphorylation of SMAD2/3 and inhibits TGF-β-induced epithelial-to-mesenchymal transition; used to reprogram fibroblasts into alternative lineages
9001879	PF-299804	1 mg	≥98%	An irreversible pan-ErbB receptor tyrosine kinase inhibitor (IC50s = 6, 45.7, and 73.7 nM for ErbB1, ErbB2, and ErbB4, respectively); demonstrates antitumor activity in various tumor xenograft models expressing either wild-type ErbB or mutant ErbB family members that show resistance to first generation ErbB kinase inhibitors
9001879	PF-299804	10 mg	≥98%	An irreversible pan-ErbB receptor tyrosine kinase inhibitor (IC50s = 6, 45.7, and 73.7 nM for ErbB1, ErbB2, and ErbB4, respectively); demonstrates antitumor activity in various tumor xenograft models expressing either wild-type ErbB or mutant ErbB family members that show resistance to first generation ErbB kinase inhibitors
9001879	PF-299804	5 mg	≥98%	An irreversible pan-ErbB receptor tyrosine kinase inhibitor (IC50s = 6, 45.7, and 73.7 nM for ErbB1, ErbB2, and ErbB4, respectively); demonstrates antitumor activity in various tumor xenograft models expressing either wild-type ErbB or mutant ErbB family members that show resistance to first generation ErbB kinase inhibitors
9001879	PF-299804	50 mg	≥98%	An irreversible pan-ErbB receptor tyrosine kinase inhibitor (IC50s = 6, 45.7, and 73.7 nM for ErbB1, ErbB2, and ErbB4, respectively); demonstrates antitumor activity in various tumor xenograft models expressing either wild-type ErbB or mutant ErbB family members that show resistance to first generation ErbB kinase inhibitors
9002067	WH-4-023	1 mg	≥98%	A selective inhibitor of the Src family of non-receptor tyrosine kinases (IC50s = 2 and 6 nM for Lck and Src, respectively); used in combination with PD 0325901, CHIR99021, and SB-590885 to support self-renewal of naïve human embryonic stem cells
9002067	WH-4-023	10 mg	≥98%	A selective inhibitor of the Src family of non-receptor tyrosine kinases (IC50s = 2 and 6 nM for Lck and Src, respectively); used in combination with PD 0325901, CHIR99021, and SB-590885 to support self-renewal of naïve human embryonic stem cells
9002067	WH-4-023	25 mg	≥98%	A selective inhibitor of the Src family of non-receptor tyrosine kinases (IC50s = 2 and 6 nM for Lck and Src, respectively); used in combination with PD 0325901, CHIR99021, and SB-590885 to support self-renewal of naïve human embryonic stem cells
9002067	WH-4-023	5 mg	≥98%	A selective inhibitor of the Src family of non-receptor tyrosine kinases (IC50s = 2 and 6 nM for Lck and Src, respectively); used in combination with PD 0325901, CHIR99021, and SB-590885 to support self-renewal of naïve human embryonic stem cells
9002215	THZ1	1 mg	≥95%	A covalent Cdk7 inhibitor (IC50s = 3.2-15.6 nM in vitro) that displays broad anti-proliferative activity against cancer cell lines, particularly T-ALL cell lines with characteristic misregulation of T cell lineage-specific transcription factors
9002215	THZ1	10 mg	≥95%	A covalent Cdk7 inhibitor (IC50s = 3.2-15.6 nM in vitro) that displays broad anti-proliferative activity against cancer cell lines, particularly T-ALL cell lines with characteristic misregulation of T cell lineage-specific transcription factors

9002215	THZ1	5 mg	≥95%	A covalent Cdk7 inhibitor (IC50s = 3.2-15.6 nM in vitro) that displays broad anti-proliferative activity against cancer cell lines, particularly T-ALL cell lines with characteristic misregulation of T cell lineage-specific transcription factors
9002215	THZ1	500 µg	≥95%	A covalent Cdk7 inhibitor (IC50s = 3.2-15.6 nM in vitro) that displays broad anti-proliferative activity against cancer cell lines, particularly T-ALL cell lines with characteristic misregulation of T cell lineage-specific transcription factors
9002394	PI-3065	1 mg	≥98%	A potent, selective inhibitor of p110δ (IC50 = 15 nM); suppresses tumor growth and metastasis in mouse xenograft models by inhibiting p110δ activity in regulatory T cells
9002394	PI-3065	10 mg	≥98%	A potent, selective inhibitor of p110δ (IC50 = 15 nM); suppresses tumor growth and metastasis in mouse xenograft models by inhibiting p110δ activity in regulatory T cells
9002394	PI-3065	25 mg	≥98%	A potent, selective inhibitor of p110δ (IC50 = 15 nM); suppresses tumor growth and metastasis in mouse xenograft models by inhibiting p110δ activity in regulatory T cells
9002394	PI-3065	5 mg	≥98%	A potent, selective inhibitor of p110δ (IC50 = 15 nM); suppresses tumor growth and metastasis in mouse xenograft models by inhibiting p110δ activity in regulatory T cells
9002596	Capsiate	10 mg	≥85% (mixture	A capsaicin analog with diverse biological activities; inhibits Src in, as well as VEGF-induced proliferation of and tube formation by, HUVECs from 5-25 µM; activates TRPV1 in HEK293 cells expressing the human channel (EC50 = 290 nM) and induces) nociceptive behaviors in mice; topical application reduces antigen-induced increases in ear thickness in a mouse model of passive cutaneous anaphylaxis and and decreases epidermal thickness and eosinophil and mast cell infiltration in a mouse model of atopic dermatitis; decreases body weight gain and perirenal fat weight, as well as increases oxygen consumption, fat oxidation, and carbohydrate oxidation, in a mouse model of ad libitum feeding-induced weight gain at 10 mg/kg
9002596	Capsiate	25 mg	≥85% (mixture	A capsaicin analog with diverse biological activities; inhibits Src in, as well as VEGF-induced proliferation of and tube formation by, HUVECs from 5-25 µM; activates TRPV1 in HEK293 cells expressing the human channel (EC50 = 290 nM) and induces) nociceptive behaviors in mice; topical application reduces antigen-induced increases in ear thickness in a mouse model of passive cutaneous anaphylaxis and and decreases epidermal thickness and eosinophil and mast cell infiltration in a mouse model of atopic dermatitis; decreases body weight gain and perirenal fat weight, as well as increases oxygen consumption, fat oxidation, and carbohydrate oxidation, in a mouse model of ad libitum feeding-induced weight gain at 10 mg/kg
9002596	Capsiate	50 mg	≥85% (mixture	A capsaicin analog with diverse biological activities; inhibits Src in, as well as VEGF-induced proliferation of and tube formation by, HUVECs from 5-25 µM; activates TRPV1 in HEK293 cells expressing the human channel (EC50 = 290 nM) and induces) nociceptive behaviors in mice; topical application reduces antigen-induced increases in ear thickness in a mouse model of passive cutaneous anaphylaxis and and decreases epidermal thickness and eosinophil and mast cell infiltration in a mouse model of atopic dermatitis; decreases body weight gain and perirenal fat weight, as well as increases oxygen consumption, fat oxidation, and carbohydrate oxidation, in a mouse model of ad libitum feeding-induced weight gain at 10 mg/kg
9003456	Palmitoylcholine (chlo	10 mg	≥95%	An acyl choline; inhibits protein kinase C activity at 100 µM; induces hemolysis in rat erythrocytes; plasma levels are decreased in female patients with ME/CFS
9003456	Palmitoylcholine (chlo	25 mg	≥95%	An acyl choline; inhibits protein kinase C activity at 100 µM; induces hemolysis in rat erythrocytes; plasma levels are decreased in female patients with ME/CFS
9003456	Palmitoylcholine (chlo	5 mg	≥95%	An acyl choline; inhibits protein kinase C activity at 100 µM; induces hemolysis in rat erythrocytes; plasma levels are decreased in female patients with ME/CFS
M1320	N,N-Dimethyl-D-eryth	1 mL	≥98%	N,N-Dimethylsphingosine is a potent and specific inhibitor of sphingosine kinase, the key enzyme in the phosphorylation of sphingosine to sphingosine-1-phosphate. It has also been reported to inhibit protein kinase C (another enzyme that is responsible for phosphorylating amino acids) in certain types of cells.1 It induces apoptosis (including in a number of cancer cell lines), possibly due to the inhibition of sphingosine-1-phosphate synthesis and the resulting increase in ceramides. It acts as a stereospecific enhancer for epidermal growth factor receptor kinase.2 At very low doses N,N-dimethylsphingosine protects the heart against ischemia/reperfusion injury due to its activating sphingosine kinase (via PKCε) which is critical for myocardial ischemic preconditioning.3 It can help prevent neointimal hyperplasia, which may be the result of inhibiting ERK-1/2 and Akt signalling, and modulation of smooth muscle growth.4

M1802	D-erythro-Sphingosin	25 mg	≥98%	Sphingosine is a characteristic structural unit of many sphingolipids such as ceramides, gangliosides, globosides, sulfatides, sphingomyelin, and others.1,2 It is most abundant in nervous tissue and cell membranes. Sphingosine with an 18-carbon chain and a double bond at carbon 4 is the most abundant sphingosine in animal tissues. Lysosphingolipids inhibit protein kinase C activity resulting in the pathogenesis of sphingolipidoses such as Krabbe's disease and Gaucher's disease.3 Sphingosine can be phosphorylated via two kinases to form sphingosine-1-phosphate, which has important signaling functions. While sphingosines and ceramides can induce apoptosis,4 sphingosine-1-phosphate can promote cell survival or proliferation. Sphingosine has been shown to cause an increase in the cytoplasmic calcium level of cells.
M1806	L-threo-Sphingosine	10 mg	≥98%	L-threo-Sphingosine is an inactive or less active isomer of the naturally occurring D-erythro-sphingosine. Natural sphingosine induces dephosphorylation of retinoblastoma gene products and inhibits cell growth while L-threo-sphingosine is less active. However, the L-threo-sphingosine is taken up by cells to the same extent as the natural sphingosine indicating that cellular uptake was not the factor influencing activity.1 L-threo-sphingosine, along with other sphingosine isomers, has been found to be an activator of 3-Phosphoinositide-dependent kinase-1.2 Natural D-erythro-sphingosine is a positive regulator of cell growth in fibroblasts whereas L-threo-sphingosine has no regulatory effect.3 However, non-natural stereoisomers of sphingosine are not always inactive; L-threo-sphingosine has been shown to inhibit protein kinase C a little more potently than D-erythro-sphingosine.4 Sphingosine is a characteristic structural unit of many sphingolipids such as ceramides, gangliosides, globosides, sulfatides, sphingomyelin, and others. It is most abundant in nervous tissue and cell membranes. Sphingosine with an 18-carbon chain and a double bond at carbon 4 is the most abundant sphingosine in animal tissues. Lysosphingolipids inhibit protein kinase C activity resulting in the pathogenesis of sphingolipidoses such as Krabbe's disease and Gaucher's disease. Sphingosine can be phosphorylated via two kinases to form sphingosine-1-phosphate, which has important signaling functions. While sphingosines and ceramides can induce apoptosis, sphingosine-1-phosphate can promote cell survival or proliferation. Sphingosine has been shown to cause an increase in the cytoplasmic calcium level of cells.
M1807	L-threo-Dihydrosphin	25 mg	≥98%	Safingol is a fully saturated, nonnatural analogue of sphingosine that has anticancer properties and is being investigated for its potential as an antitumor therapy. It has been shown to inhibit both protein kinase C (PKC) and sphingosine kinase. Safingol competitively interacts at the regulatory phorbol-binding domain of PKC, which is a kinase involved in tumorigenesis. Safingol has been shown to potentiate the effect of doxorubicin (DOX) in tumor-bearing animals.1 It has been reported that safingol is able to increase the activity of DOX and other chemotherapeutic agents, including mitomycin C, by generating the pro-apoptotic second messenger ceramide, even in tumor cell lines that were resistant to chemotherapy due to mutations.2 However, a study has recently claimed that safingol induces cell death of an exclusively autophagic character and lacking any of the hallmarks of apoptosis.3 Safingol inhibited the reactive oxygen intermediates (ROI) released from isolated neutrophils and phorbol ester-induced edema and neutrophil influx. Safingol also demonstrates anti-inflammatory activity. Safingol, like the natural sphinganine, is used as a biosynthetic precursor for all complex sphingolipids although the metabolism of the natural and the nonnatural compounds are different.4
M1807	L-threo-Dihydrosphin	5 mg	≥98%	Safingol is a fully saturated, nonnatural analogue of sphingosine that has anticancer properties and is being investigated for its potential as an antitumor therapy. It has been shown to inhibit both protein kinase C (PKC) and sphingosine kinase. Safingol competitively interacts at the regulatory phorbol-binding domain of PKC, which is a kinase involved in tumorigenesis. Safingol has been shown to potentiate the effect of doxorubicin (DOX) in tumor-bearing animals.1 It has been reported that safingol is able to increase the activity of DOX and other chemotherapeutic agents, including mitomycin C, by generating the pro-apoptotic second messenger ceramide, even in tumor cell lines that were resistant to chemotherapy due to mutations.2 However, a study has recently claimed that safingol induces cell death of an exclusively autophagic character and lacking any of the hallmarks of apoptosis.3 Safingol inhibited the reactive oxygen intermediates (ROI) released from isolated neutrophils and phorbol ester-induced edema and neutrophil influx. Safingol also demonstrates anti-inflammatory activity. Safingol, like the natural sphinganine, is used as a biosynthetic precursor for all complex sphingolipids although the metabolism of the natural and the nonnatural compounds are different.4

M1833	D-erythro-C14-Sphing	5 mg	≥98%	Sphingosine is a characteristic structural unit of many sphingolipids such as ceramides, gangliosides, globosides, sulfatides, sphingomyelin, and others.1 It is most abundant in nervous tissue and cell membranes. Sphingosine with an 18-carbon chain and a double bond at carbon 4 is the most abundant sphingosine in animal tissues but D-erythro-C14-sphingosine is the most common long chain base (LCB) in some organisms such as Drosophila. This shorter LCB is considerably less hydrophobic which could significantly change the process of signal transduction.2 D-erythro-C14-sphingosine has recently been found to act as a germination-accelerating factor in silkworms with much greater activity than its shorter or longer homologues.3 Lysosphingolipids inhibit protein kinase C activity resulting in the pathogenesis of sphingolipidoses such as Krabbe's disease and Gaucher's disease. Sphingosine can be phosphorylated via two kinases to form sphingosine-1-phosphate, which has important signaling functions. While sphingosines and ceramides can induce apoptosis,4 sphingosine-1-phosphate can promote cell survival or proliferation. Sphingosine has been shown to cause an increase in the cytoplasmic calcium level of cells.